tricuspid B-NEG
valve I-NEG
regurgitation I-NEG
and O
lithium O
carbonate O
toxicity B-NEG
in O
a O
newborn O
infant O
. O

a O
newborn O
with O
massive O
tricuspid B-NEG
regurgitation I-NEG
, O
atrial B-NEG
flutter I-NEG
, O
congestive B-NEG
heart I-NEG
failure I-NEG
, O
and O
a O
high O
serum O
lithium O
level O
is O
described O
. O

this O
is O
the O
first O
patient O
to O
initially O
manifest O
tricuspid B-NEG
regurgitation I-NEG
and O
atrial B-NEG
flutter I-NEG
, O
and O
the O
11th O
described O
patient O
with O
cardiac B-NEG
disease I-NEG
among O
infants O
exposed O
to O
lithium O
compounds O
in O
the O
first O
trimester O
of O
pregnancy O
. O

sixty-three O
percent O
of O
these O
infants O
had O
tricuspid O
valve O
involvement O
. O

lithium O
carbonate O
may O
be O
a O
factor O
in O
the O
increasing O
incidence O
of O
congenital B-NEG
heart I-NEG
disease I-NEG
when O
taken O
during O
early O
pregnancy O
. O

it O
also O
causes O
neurologic B-NEG
depression I-NEG
, O
cyanosis B-NEG
, O
and O
cardiac B-NEG
arrhythmia I-NEG
when O
consumed O
prior O
to O
delivery O
. O

-DOCSTART- O

phenobarbital-induced O
dyskinesia B-NEG
in O
a O
neurologically-impaired B-NEG
child O
. O

a O
2-year-old O
child O
with O
known O
neurologic B-NEG
impairment I-NEG
developed O
a O
dyskinesia B-NEG
soon O
after O
starting O
phenobarbital O
therapy O
for O
seizures B-NEG
. O

known O
causes O
of O
movement B-NEG
disorders I-NEG
were O
eliminated O
after O
evaluation O
. O

on O
repeat O
challenge O
with O
phenobarbital O
, O
the O
dyskinesia B-NEG
recurred O
. O

phenobarbital O
should O
be O
added O
to O
the O
list O
of O
anticonvulsant O
drugs O
that O
can O
cause O
movement B-NEG
disorders I-NEG
. O

-DOCSTART- O

acute O
changes O
of O
blood O
ammonia O
may O
predict O
short-term O
adverse O
effects O
of O
valproic O
acid O
. O

valproic O
acid O
( O
vpa O
) O
was O
given O
to O
24 O
epileptic B-NEG
patients O
who O
were O
already O
being O
treated O
with O
other O
antiepileptic O
drugs O
. O

a O
standardized O
loading O
dose O
of O
vpa O
was O
administered O
, O
and O
venous O
blood O
was O
sampled O
at O
0, O
1, O
2, O
3, O
and O
4 O
hours O
. O

ammonia O
( O
nh3 O
) O
was O
higher O
in O
patients O
who O
, O
during O
continuous O
therapy O
, O
complained O
of O
drowsiness B-NEG
(7 O
patients O
) O
than O
in O
those O
who O
were O
symptom-free O
( O
17 O
patients) O
, O
although O
vpa O
plasma O
levels O
were O
similar O
in O
both O
groups O
. O

by O
measuring O
vpa-induced O
changes O
of O
blood O
nh3 O
content O
, O
it O
may O
be O
possible O
to O
identify O
patients O
at O
higher O
risk O
of O
obtundation O
when O
vpa O
is O
given O
chronically O
. O

-DOCSTART- O

effects O
of O
calcitonin O
on O
rat O
extrapyramidal O
motor O
system O
: O
behavioral O
and O
biochemical O
data O
. O

the O
effects O
of O
i.v.c O
. O
injection O
of O
human O
and O
salmon O
calcitonin O
on O
biochemical O
and O
behavioral O
parameters O
related O
to O
the O
extrapyramidal O
motor O
system O
, O
were O
investigated O
in O
male O
rats O
. O

calcitonin O
injection O
resulted O
in O
a O
potentiation O
of O
haloperidol-induced O
catalepsy B-NEG
and O
a O
partial O
prevention O
of O
apomorphine-induced O
hyperactivity B-NEG
. O

moreover O
calcitonin O
induced O
a O
significant O
decrease O
in O
nigral O
gad O
activity O
but O
no O
change O
in O
striatal O
da O
and O
dopac O
concentration O
or O
gad O
activity O
. O

the O
results O
are O
discussed O
in O
view O
of O
a O
primary O
action O
of O
calcitonin O
on O
the O
striatonigral O
gabaergic O
pathway O
mediating O
the O
da-related O
behavioral O
messages O
of O
striatal O
origin O
. O

-DOCSTART- O

development O
of O
isoproterenol-induced O
cardiac B-NEG
hypertrophy I-NEG
. O

the O
development O
of O
cardiac B-NEG
hypertrophy I-NEG
was O
studied O
in O
adult O
female O
wistar O
rats O
following O
daily O
subcutaneous O
injections O
of O
isoproterenol O
( O
iso O
) O
( O
0.3 O
mg/kg O
body O
weight) O
. O

a O
time O
course O
was O
established O
for O
the O
change O
in O
tissue O
mass O
, O
rna O
and O
dna O
content O
, O
as O
well O
as O
hydroxyproline O
content O
. O

heart O
weight O
increased O
44% O
after O
8 O
days O
of O
treatment O
with O
a O
half O
time O
of O
3.4 O
days O
. O

ventricular O
rna O
content O
was O
elevated O
26% O
after O
24 O
h O
of O
a O
single O
injection O
and O
reached O
a O
maximal O
level O
following O
8 O
days O
of O
therapy O
. O

the O
half O
time O
for O
rna O
accumulation O
was O
2.0 O
days O
. O

the O
total O
content O
of O
hydroxyproline O
remained O
stable O
during O
the O
first O
2 O
days O
of O
treatment O
but O
increased O
46% O
after O
4 O
days O
of O
therapy O
. O

ventricular O
dna O
content O
was O
unchanged O
during O
the O
early O
stage O
( O
1-4 O
days O
) O
of O
hypertrophic B-NEG
growth O
but O
increased O
to O
a O
new O
steady-state O
level O
19% O
above O
the O
controls O
after O
8 O
days O
of O
treatment O
. O

intraventricular O
pressures O
and O
coronary O
flow O
measures O
were O
similar O
for O
control O
and O
experimental O
animals O
following O
4 O
days O
of O
developed O
hypertrophy B-NEG
. O

however O
, O
dp/dt O
in O
the O
iso-treated O
hearts O
was O
slightly O
but O
significantly O
(p O
less O
than O
0.05 O
) O
elevated O
. O

these O
data O
indicate O
that O
the O
adaptive O
response O
to O
iso O
shows O
an O
early O
hypertrophic B-NEG
phase O
( O
1-4 O
days O
) O
characterized O
by O
a O
substantial O
increase O
in O
rna O
content O
and O
cardiac O
mass O
in O
the O
absence O
of O
changes O
in O
dna O
. O

however O
, O
prolonged O
stimulation O
( O
8-12 O
days O
) O
appears O
to O
represent O
a O
complex O
integration O
of O
both O
cellular O
hypertrophy B-NEG
and O
hyperplasia B-NEG
within O
the O
heart O
. O

-DOCSTART- O

co- O
carcinogenic B-NEG
effect O
of O
retinyl O
acetate O
on O
forestomach B-NEG
carcinogenesis I-NEG
of O
male O
f344 O
rats O
induced O
with O
butylated O
hydroxyanisole O
. O

the O
potential O
modifying O
effect O
of O
retinyl O
acetate O
( O
ra O
) O
on O
butylated O
hydroxyanisole O
( O
bha)-induced O
rat O
forestomach B-NEG
tumorigenesis I-NEG
was O
examined O
. O

male O
f344 O
rats O
, O
5 O
weeks O
of O
age O
, O
were O
maintained O
on O
diet O
containing O
1% O
or O
2% O
bha O
by O
weight O
and O
simultaneously O
on O
drinking O
water O
supplemented O
with O
ra O
at O
various O
concentrations O
( O
w/v O
) O
for O
52 O
weeks O
. O

in O
groups O
given O
2% O
bha O
, O
although O
marked O
hyperplastic O
changes O
of O
the O
forestomach O
epithelium O
were O
observed O
in O
all O
animals O
, O
co-administration O
of O
0.25% O
ra O
significantly O
(p O
less O
than O
0.05 O
) O
increased O
the O
incidence O
of O
forestomach B-NEG
tumors I-NEG
( O
squamous B-NEG
cell I-NEG
papilloma I-NEG
and O
carcinoma B-NEG
) O
to O
60% O
(9/15 O
, O
2 O
rats O
with O
carcinoma B-NEG
) O
from O
15% O
(3/20 O
, O
one O
rat O
with O
carcinoma B-NEG
) O
in O
the O
group O
given O
ra-free O
water O
. O

in O
rats O
given O
1% O
bha O
, O
ra O
co-administered O
at O
a O
dose O
of O
0.05 O
, O
0.1 O
, O
0.2 O
or O
0.25% O
showed O
a O
dose-dependent O
enhancing O
effect O
on O
the O
development O
of O
the O
bha-induced O
epithelial B-NEG
hyperplasia I-NEG
. O
tumors B-NEG
, O
all O
papillomas B-NEG
, O
were O
induced O
in O
3 O
rats O
( O
17% O
) O
with O
0.25% O
ra O
and O
in O
one O
rat O
( O
10% O
) O
with O
0.05% O
ra O
co-administration O
. O

ra O
alone O
did O
not O
induce O
hyperplastic O
changes O
in O
the O
forestomach O
. O

these O
findings O
indicate O
that O
ra O
acted O
as O
a O
co-carcinogen O
in O
the O
bha O
forestomach B-NEG
carcinogenesis I-NEG
of O
the O
rat O
. O

-DOCSTART- O

ketanserin O
pretreatment O
reverses O
alfentanil-induced O
muscle B-NEG
rigidity I-NEG
. O

systemic O
pretreatment O
with O
ketanserin O
, O
a O
relatively O
specific O
type-2 O
serotonin O
receptor O
antagonist O
, O
significantly O
attenuated O
the O
muscle B-NEG
rigidity I-NEG
produced O
in O
rats O
by O
the O
potent O
short-acting O
opiate O
agonist O
alfentanil O
. O

following O
placement O
of O
subcutaneous O
electrodes O
in O
each O
animal's O
left O
gastrocnemius O
muscle O
, O
rigidity B-NEG
was O
assessed O
by O
analyzing O
root-mean-square O
electromyographic O
activity O
. O

intraperitoneal O
ketanserin O
administration O
at O
doses O
of O
0.63 O
and O
2.5 O
mg/kg O
prevented O
the O
alfentanil-induced O
increase O
in O
electromyographic O
activity O
compared O
with O
animals O
pretreated O
with O
saline O
. O

chlordiazepoxide O
at O
doses O
up O
to O
10 O
mg/kg O
failed O
to O
significantly O
influence O
the O
rigidity B-NEG
produced O
by O
alfentanil O
. O

despite O
the O
absence O
of O
rigidity B-NEG
, O
animals O
that O
received O
ketanserin O
( O
greater O
than O
0.31 O
mg/kg O
i.p. O
) O
followed O
by O
alfentanil O
were O
motionless O
, O
flaccid O
, O
and O
less O
responsive O
to O
external O
stimuli O
than O
were O
animals O
receiving O
alfentanil O
alone O
. O

rats O
that O
received O
ketanserin O
and O
alfentanil O
exhibited O
less O
rearing O
and O
exploratory O
behavior O
at O
the O
end O
of O
the O
60-min O
recording O
period O
than O
did O
animals O
that O
received O
ketanserin O
alone O
. O

these O
results O
, O
in O
combination O
with O
previous O
work O
, O
suggest O
that O
muscle B-NEG
rigidity I-NEG
, O
a O
clinically O
relevant O
side-effect O
of O
parenteral O
narcotic O
administration O
, O
may O
be O
partly O
mediated O
via O
serotonergic O
pathways O
. O

pretreatment O
with O
type-2 O
serotonin O
antagonists O
may O
be O
clinically O
useful O
in O
attenuating O
opiate-induced O
rigidity B-NEG
, O
although O
further O
studies O
will O
be O
necessary O
to O
assess O
the O
interaction O
of O
possibly O
enhanced O
cns O
, O
cardiovascular B-NEG
, O
and I-NEG
respiratory I-NEG
depression I-NEG
. O

-DOCSTART- O

glycopyrronium O
requirements O
for O
antagonism O
of O
the O
muscarinic O
side O
effects O
of O
edrophonium O
. O

we O
have O
compared O
, O
in O
60 O
adult O
patients O
, O
the O
cardiovascular O
effects O
of O
glycopyrronium O
5 O
micrograms O
kg-1 O
and O
10 O
micrograms O
kg-1 O
given O
either O
simultaneously O
or O
1 O
min O
before O
edrophonium O
1 O
mg O
kg-1 O
. O

significant O
differences O
between O
the O
four O
groups O
were O
detected O
(p O
less O
than O
0.001) O
. O

both O
groups O
receiving O
10 O
micrograms O
kg-1 O
showed O
increases O
in O
heart O
rate O
of O
up O
to O
30 O
beat O
min-1 O
( O
95% O
confidence O
limits O
28-32 O
beat O
min-1) O
. O

use O
of O
glycopyrronium O
5 O
micrograms O
kg-1 O
provided O
greater O
cardiovascular O
stability O
and O
, O
given O
1 O
min O
before O
the O
edrophonium O
, O
was O
sufficient O
to O
minimize O
early O
, O
edrophonium-induced O
bradycardias B-NEG
. O

this O
low O
dose O
of O
glycopyrronium O
provided O
good O
control O
of O
oropharyngeal O
secretions O
. O

-DOCSTART- O

involvement O
of O
locus O
coeruleus O
and O
noradrenergic O
neurotransmission O
in O
fentanyl-induced O
muscular B-NEG
rigidity I-NEG
in O
the O
rat O
. O

whereas O
muscular B-NEG
rigidity I-NEG
is O
a O
well-known O
side O
effect O
that O
is O
associated O
with O
high-dose O
fentanyl O
anesthesia O
, O
a O
paucity O
of O
information O
exists O
with O
regard O
to O
its O
underlying O
mechanism(s) O
. O

we O
investigated O
in O
this O
study O
the O
possible O
engagement O
of O
locus O
coeruleus O
of O
the O
pons O
in O
this O
phenomenon O
, O
using O
male O
sprague-dawley O
rats O
anesthetized O
with O
ketamine O
. O

under O
proper O
control O
of O
respiration O
, O
body O
temperature O
and O
end-tidal O
co2 O
, O
intravenous O
administration O
of O
fentanyl O
( O
50 O
or O
100 O
micrograms/kg O
) O
consistently O
promoted O
an O
increase O
in O
electromyographic O
activity O
recorded O
from O
the O
gastrocnemius O
and O
abdominal O
rectus O
muscles O
. O

such O
an O
induced O
muscular B-NEG
rigidity I-NEG
by O
the O
narcotic O
agent O
was O
significantly O
antagonized O
or O
even O
reduced O
by O
prior O
electrolytic O
lesions O
of O
the O
locus O
coeruleus O
or O
pretreatment O
with O
the O
alpha-adrenoceptor O
blocker O
, O
prazosin O
. O

microinjection O
of O
fentanyl O
( O
2.5 O
micrograms/50 O
nl O
) O
directly O
into O
this O
pontine O
nucleus O
, O
on O
the O
other O
hand O
, O
elicited O
discernible O
electromyographic O
excitation O
. O

it O
is O
speculated O
that O
the O
induction O
of O
muscular B-NEG
rigidity I-NEG
by O
fentanyl O
may O
involve O
the O
coerulospinal O
noradrenergic O
fibers O
to O
the O
spinal O
motoneurons O
. O

-DOCSTART- O

cerebral B-NEG
sinus I-NEG
thrombosis I-NEG
as O
a O
potential O
hazard O
of O
antifibrinolytic O
treatment O
in O
menorrhagia B-NEG
. O

we O
describe O
a O
42-year-old O
woman O
who O
developed O
superior O
sagittal B-NEG
and I-NEG
left I-NEG
transverse I-NEG
sinus I-NEG
thrombosis I-NEG
associated O
with O
prolonged O
epsilon-aminocaproic O
acid O
therapy O
for O
menorrhagia B-NEG
. O

this O
antifibrinolytic O
agent O
has O
been O
used O
in O
women O
with O
menorrhagia B-NEG
to O
promote O
clotting O
and O
reduce O
blood B-NEG
loss I-NEG
. O

although O
increased O
risk O
of O
thromboembolic B-NEG
disease I-NEG
has O
been O
reported O
during O
treatment O
with O
epsilon-aminocaproic O
acid O
, O
cerebral B-NEG
sinus I-NEG
thrombosis I-NEG
has O
not O
been O
previously O
described O
. O

careful O
use O
of O
epsilon-aminocaproic O
acid O
therapy O
is O
recommended O
. O

-DOCSTART- O

hemorrhagic B-NEG
cystitis I-NEG
complicating O
bone O
marrow O
transplantation O
. O
hemorrhagic B-NEG
cystitis I-NEG
is O
a O
potentially O
serious O
complication O
of O
high-dose O
cyclophosphamide O
therapy O
administered O
before O
bone O
marrow O
transplantation O
. O

as O
standard O
practice O
at O
our O
institution O
, O
patients O
who O
are O
scheduled O
to O
receive O
a O
bone O
marrow O
transplant O
are O
treated O
prophylactically O
with O
forced O
hydration O
and O
bladder O
irrigation O
. O

in O
an O
attempt O
to O
obviate O
the O
inconvenience O
of O
bladder O
irrigation O
, O
we O
conducted O
a O
feasibility O
trial O
of O
uroprophylaxis O
with O
mesna O
, O
which O
neutralizes O
the O
hepatic O
metabolite O
of O
cyclophosphamide O
that O
causes O
hemorrhagic B-NEG
cystitis I-NEG
. O

of O
97 O
patients O
who O
received O
standard O
prophylaxis O
, O
4 O
had O
symptomatic O
hemorrhagic B-NEG
cystitis I-NEG
. O

in O
contrast O
, O
two O
of O
four O
consecutive O
patients O
who O
received O
mesna O
uroprophylaxis O
before O
allogeneic O
bone O
marrow O
transplantation O
had O
severe O
hemorrhagic B-NEG
cystitis I-NEG
for O
at O
least O
2 O
weeks O
. O

because O
of O
this O
suboptimal O
result O
, O
we O
resumed O
the O
use O
of O
bladder O
irrigation O
and O
forced O
hydration O
to O
minimize O
the O
risk O
of O
hemorrhagic B-NEG
cystitis I-NEG
. O

-DOCSTART- O

reversal O
of O
central O
benzodiazepine O
effects O
by O
flumazenil O
after O
intravenous O
conscious O
sedation O
with O
diazepam O
and O
opioids O
: O
report O
of O
a O
double-blind O
multicenter O
study O
. O

the O
flumazenil O
in O
intravenous O
conscious O
sedation O
with O
diazepam O
multicenter O
study O
group O
ii O
. O

the O
efficacy O
and O
safety O
of O
a O
new O
benzodiazepine O
antagonist O
, O
flumazenil O
, O
were O
assessed O
in O
a O
double-blind O
multicenter O
study O
. O

flumazenil O
( O
mean O
dose O
, O
0.76 O
mg O
) O
or O
placebo O
( O
mean O
dose O
, O
8.9 O
ml O
) O
was O
administered O
intravenously O
to O
130 O
and O
67 O
patients O
, O
respectively O
, O
who O
had O
been O
given O
diazepam O
in O
conjunction O
with O
an O
opioid O
(fentanyl O
, O
meperidine O
, O
or O
morphine O
) O
for O
the O
induction O
and O
maintenance O
of O
intravenous O
conscious O
sedation O
for O
diagnostic O
or O
therapeutic O
surgical O
procedures O
. O

the O
group O
assessable O
for O
efficacy O
comprised O
122 O
patients O
treated O
with O
flumazenil O
and O
64 O
patients O
given O
placebo O
. O

after O
5 O
minutes O
, O
80/115 O
( O
70% O
) O
flumazenil-treated O
patients O
, O
compared O
with O
21/63 O
( O
33% O
) O
placebo-treated O
patients O
, O
were O
completely O
awake O
and O
alert O
, O
as O
indicated O
by O
a O
score O
of O
5 O
on O
the O
observer's O
assessment O
of O
alertness/sedation O
scale O
. O

ninety-five O
percent O
of O
patients O
in O
each O
group O
who O
attained O
a O
score O
of O
5 O
at O
the O
5-minute O
assessment O
showed O
no O
loss O
of O
alertness O
throughout O
the O
180-minute O
assessment O
period O
. O

flumazenil-treated O
patients O
also O
performed O
significantly O
better O
on O
the O
finger-to-nose O
test O
and O
the O
recall O
of O
pictures O
shown O
at O
the O
5-minute O
assessment O
. O

flumazenil O
was O
well O
tolerated O
, O
with O
no O
serious O
adverse O
effects O
reported O
. O

thirty-nine O
( O
30% O
) O
of O
flumazenil-treated O
patients O
, O
compared O
with O
17 O
( O
25% O
) O
of O
placebo-treated O
patients O
had O
one O
or O
more O
drug-related O
adverse O
experiences O
. O

the O
most O
common O
adverse O
effects O
were O
nausea B-NEG
and O
vomiting B-NEG
in O
the O
flumazenil O
group O
and O
nausea B-NEG
and O
injection-site O
pain B-NEG
in O
the O
placebo O
group O
. O

flumazenil O
was O
found O
to O
promptly O
reverse O
sedation O
induced O
by O
diazepam O
in O
the O
presence O
of O
opioids O
. O

-DOCSTART- O

hepatic O
adenomas B-NEG
and O
focal B-NEG
nodular I-NEG
hyperplasia I-NEG
of O
the O
liver O
in O
young O
women O
on O
oral O
contraceptives O
: O
case O
reports O
. O

two O
cases O
of O
hepatic O
adenoma B-NEG
and O
one O
of O
focal B-NEG
nodular I-NEG
hyperplasia I-NEG
presumably O
associated O
with O
the O
use O
of O
oral O
contraceptives O
, O
are O
reported O
. O

special O
reference O
is O
made O
to O
their O
clinical O
presentation O
, O
which O
may O
be O
totally O
asymptomatic O
. O

liver-function O
tests O
are O
of O
little O
diagnostic O
value O
, O
but O
valuable O
information O
may O
be O
obtained O
from O
both O
liver O
scanning O
and O
hepatic O
angiography O
. O

histologic O
differences O
and O
clinical O
similarities O
between O
hepatic O
adenoma B-NEG
and O
focal B-NEG
nodular I-NEG
hyperplasia I-NEG
of O
the O
liver O
are O
discussed O
. O

-DOCSTART- O

arterial O
thromboembolism B-NEG
in O
patients O
receiving O
systemic O
heparin O
therapy O
: O
a O
complication O
associated O
with O
heparin-induced O
thrombocytopenia B-NEG
. O

arterial O
thromboembolism B-NEG
is O
a O
recognized O
complication O
of O
systemic O
heparin O
therapy O
. O

characteristic O
of O
the O
entity O
is O
arterial B-NEG
occlusion I-NEG
by O
platelet-fibrin O
thrombi B-NEG
with O
distal O
ischemia B-NEG
occurring O
four O
to O
twenty O
days O
after O
the O
initiation O
of O
heparin O
therapy O
, O
preceded O
by O
profound O
thrombocytopenia B-NEG
with O
platelet O
counts O
in O
the O
range O
of O
30,000 O
to O
40,000 O
per O
cubic O
millimeter O
. O

the O
clinically O
apparent O
occlusion O
may O
be O
preceded O
by O
gastrointestinal B-NEG
and I-NEG
musculoskeletal I-NEG
symptoms I-NEG
that O
appear O
to O
be O
ischemic B-NEG
in O
origin O
, O
and O
might O
serve O
to O
warn O
the O
clinician O
of O
these O
complications O
. O

previous O
reports O
of O
these O
phenomena O
as O
well O
as O
recent O
studies O
of O
the O
effect O
of O
heparin O
are O
reviewed O
. O

the O
common O
factor O
relating O
thromboembolism B-NEG
and O
thrombocytopenia B-NEG
is O
heparin-induced O
platelet B-NEG
aggregation I-NEG
. O

appropriate O
treatment O
consists O
of O
discontinuation O
of O
heparin O
, O
and O
anticoagulation O
with O
sodium O
warfarin O
if O
necessary O
. O

vascular O
procedures O
are O
performed O
as O
indicated O
. O

-DOCSTART- O

long-term O
prognosis O
for O
transplant-free O
survivors O
of O
paracetamol-induced O
acute B-NEG
liver I-NEG
failure I-NEG
. O

background O
: O
the O
prognosis O
for O
transplant-free O
survivors O
of O
paracetamol-induced O
acute B-NEG
liver I-NEG
failure I-NEG
remains O
unknown O
. O

aim O
: O
to O
examine O
whether O
paracetamol-induced O
acute B-NEG
liver I-NEG
failure I-NEG
increases O
long-term O
mortality O
. O

methods O
: O
we O
followed O
up O
all O
transplant-free O
survivors O
of O
paracetamol-induced O
acute B-NEG
liver I-NEG
injury I-NEG
, O
hospitalized O
in O
a O
danish O
national O
referral O
centre O
during O
1984-2004 O
. O

we O
compared O
age-specific O
mortality O
rates O
from O
1 O
year O
post-discharge O
through O
2008 O
between O
those O
in O
whom O
the O
liver B-NEG
injury I-NEG
led O
to O
an O
acute B-NEG
liver I-NEG
failure I-NEG
and O
those O
in O
whom O
it O
did O
not O
. O

results O
: O
we O
included O
641 O
patients O
. O

on O
average O
, O
age-specific O
mortality O
rates O
were O
slightly O
higher O
for O
the O
101 O
patients O
whose O
paracetamol-induced O
liver B-NEG
injury I-NEG
had O
caused O
an O
acute B-NEG
liver I-NEG
failure I-NEG
( O
adjusted O
mortality O
rate O
ratio O
= O
1.70 O
, O
95% O
ci O
1.02-2.85) O
, O
but O
the O
association O
was O
age-dependent O
, O
and O
no O
survivors O
of O
acute B-NEG
liver I-NEG
failure I-NEG
died O
of O
liver B-NEG
disease I-NEG
, O
whereas O
suicides O
were O
frequent O
in O
both O
groups O
. O

these O
observations O
speak O
against O
long-term O
effects O
of O
acute B-NEG
liver I-NEG
failure I-NEG
. O

more O
likely O
, O
the O
elevated O
mortality O
rate O
ratio O
resulted O
from O
incomplete O
adjustment O
for O
the O
greater O
prevalence O
of O
substance B-NEG
abuse I-NEG
among O
survivors O
of O
acute B-NEG
liver I-NEG
failure I-NEG
. O

conclusions O
: O
paracetamol-induced O
acute B-NEG
liver I-NEG
failure I-NEG
did O
not O
affect O
long-term O
mortality O
. O

clinical O
follow-up O
may O
be O
justified O
by O
the O
cause O
of O
the O
liver B-NEG
failure I-NEG
, O
but O
not O
by O
the O
liver B-NEG
failure I-NEG
itself O
. O

-DOCSTART- O

serotonin O
6 O
receptor O
gene O
is O
associated O
with O
methamphetamine-induced O
psychosis B-NEG
in O
a O
japanese O
population O
. O

background O
: O
altered O
serotonergic O
neural O
transmission O
is O
hypothesized O
to O
be O
a O
susceptibility O
factor O
for O
psychotic B-NEG
disorders I-NEG
such O
as O
schizophrenia B-NEG
. O

the O
serotonin O
6 O
( O
5-ht6 O
) O
receptor O
is O
therapeutically O
targeted O
by O
several O
second O
generation O
antipsychotics O
, O
such O
as O
clozapine O
and O
olanzapine O
, O
and O
d-amphetamine-induced O
hyperactivity B-NEG
in O
rats O
is O
corrected O
with O
the O
use O
of O
a O
selective O
5-ht6 O
receptor O
antagonist O
. O

in O
addition O
, O
the O
disrupted O
prepulse O
inhibition O
induced O
by O
d-amphetamine O
or O
phencyclidine O
was O
restored O
by O
5-ht6 O
receptor O
antagonist O
in O
an O
animal O
study O
using O
rats O
. O

these O
animal O
models O
were O
considered O
to O
reflect O
the O
positive O
symptoms O
of O
schizophrenia B-NEG
, O
and O
the O
above O
evidence O
suggests O
that O
altered O
5-ht6 O
receptors O
are O
involved O
in O
the O
pathophysiology O
of O
psychotic B-NEG
disorders I-NEG
. O

the O
symptoms O
of O
methamphetamine O
( O
meth)-induced O
psychosis B-NEG
are O
similar O
to O
those O
of O
paranoid B-NEG
type I-NEG
schizophrenia I-NEG
. O

therefore O
, O
we O
conducted O
an O
analysis O
of O
the O
association O
of O
the O
5-ht6 O
gene O
( O
htr6 O
) O
with O
meth-induced O
psychosis B-NEG
. O

method O
: O
using O
five O
tagging O
snps O
(rs6693503 O
, O
rs1805054 O
, O
rs4912138 O
, O
rs3790757 O
and O
rs9659997) O
, O
we O
conducted O
a O
genetic O
association O
analysis O
of O
case-control O
samples O
( O
197 O
meth-induced O
psychosis B-NEG
patients O
and O
337 O
controls O
) O
in O
the O
japanese O
population O
. O

the O
age O
and O
sex O
of O
the O
control O
subjects O
did O
not O
differ O
from O
those O
of O
the O
methamphetamine O
dependence O
patients O
. O

results O
: O
rs6693503 O
was O
associated O
with O
meth-induced O
psychosis B-NEG
patients O
in O
the O
allele/genotype-wise O
analysis O
. O

moreover O
, O
this O
association O
remained O
significant O
after O
bonferroni O
correction O
. O

in O
the O
haplotype-wise O
analysis O
, O
we O
detected O
an O
association O
between O
two O
markers O
( O
rs6693503 O
and O
rs1805054 O
) O
and O
three O
markers O
(rs6693503 O
, O
rs1805054 O
and O
rs4912138 O
) O
in O
htr6 O
and O
meth-induced O
psychosis B-NEG
patients O
, O
respectively O
. O

conclusion O
: O
htr6 O
may O
play O
an O
important O
role O
in O
the O
pathophysiology O
of O
meth-induced O
psychosis B-NEG
in O
the O
japanese O
population O
. O

-DOCSTART- O

effect O
of O
increasing O
intraperitoneal O
infusion O
rates O
on O
bupropion O
hydrochloride-induced O
seizures B-NEG
in O
mice O
. O

background O
: O
it O
is O
not O
known O
if O
there O
is O
a O
relationship O
between O
input O
rate O
and O
incidence O
of O
bupropion-induced O
seizures B-NEG
. O

this O
is O
important O
, O
since O
different O
controlled O
release O
formulations O
of O
bupropion O
release O
the O
active O
drug O
at O
different O
rates O
. O

methods O
: O
we O
investigated O
the O
effect O
of O
varying O
the O
intraperitoneal O
infusion O
rates O
of O
bupropion O
hcl O
120 O
mg/kg O
, O
a O
known O
convulsive B-NEG
dose O
50 O
(cd50) O
, O
on O
the O
incidence O
and O
severity O
of O
bupropion-induced O
convulsions B-NEG
in O
the O
swiss O
albino O
mice O
. O

a O
total O
of O
69 O
mice O
, O
approximately O
7 O
weeks O
of O
age O
, O
and O
weighing O
21.0 O
to O
29.1 O
g O
were O
randomly O
assigned O
to O
bupropion O
hcl O
120 O
mg/kg O
treatment O
by O
intraperitoneal O
( O
ip O
) O
administration O
in O
7 O
groups O
(9 O
to O
10 O
animals O
per O
group) O
. O

bupropion O
hcl O
was O
infused O
through O
a O
surgically O
implanted O
ip O
dosing O
catheter O
with O
infusions O
in O
each O
group O
of O
0 O
min O
, O
15 O
min O
, O
30 O
min O
, O
60 O
min O
, O
90 O
min O
, O
120 O
min O
, O
and O
240 O
min O
. O

the O
number O
, O
time O
of O
onset O
, O
duration O
and O
the O
intensity O
of O
the O
convulsions B-NEG
or O
absence O
of O
convulsions B-NEG
were O
recorded O
. O

results O
: O
the O
results O
showed O
that O
ip O
administration O
of O
bupropion O
hcl O
120 O
mg/kg O
by O
bolus O
injection O
induced O
convulsions B-NEG
in O
6 O
out O
of O
10 O
mice O
( O
60% O
of O
convulsing O
mice O
) O
in O
group O
1. O

logistic O
regression O
analysis O
revealed O
that O
infusion O
time O
was O
significant O
(p O
= O
0.0004 O
; O
odds O
ratio O
= O
0.974 O
) O
and O
increasing O
the O
ip O
infusion O
time O
of O
bupropion O
hcl O
120 O
mg/kg O
was O
associated O
with O
a O
91% O
reduced O
odds O
of O
convulsions B-NEG
at O
infusion O
times O
of O
15 O
to O
90 O
min O
compared O
to O
bolus O
injection O
. O

further O
increase O
in O
infusion O
time O
resulted O
in O
further O
reduction O
in O
the O
odds O
of O
convulsions B-NEG
to O
99.8% O
reduction O
at O
240 O
min O
. O

conclusion O
: O
in O
conclusion O
, O
the O
demonstration O
of O
an O
inverse O
relationship O
between O
infusion O
time O
of O
a O
fixed O
and O
convulsive B-NEG
dose O
of O
bupropion O
and O
the O
risk O
of O
convulsions B-NEG
in O
a O
prospective O
study O
is O
novel O
. O

-DOCSTART- O

detailed O
spectral O
profile O
analysis O
of O
penicillin-induced O
epileptiform B-NEG
activity I-NEG
in O
anesthetized O
rats O
. O

penicillin O
model O
is O
a O
widely O
used O
experimental O
model O
for O
epilepsy B-NEG
research O
. O

in O
the O
present O
study O
we O
aimed O
to O
portray O
a O
detailed O
spectral O
analysis O
of O
penicillin-induced O
epileptiform B-NEG
activity I-NEG
in O
comparison O
with O
basal O
brain O
activity O
in O
anesthetized O
wistar O
rats O
. O

male O
wistar O
rats O
were O
anesthetized O
with O
i.p O
. O
urethane O
and O
connected O
to O
an O
electrocorticogram O
setup O
. O

after O
a O
short O
period O
of O
basal O
activity O
recording O
, O
epileptic B-NEG
focus O
was O
induced O
by O
injecting O
400iu/2 O
microl O
penicillin-g O
potassium O
into O
the O
left O
lateral O
ventricle O
while O
the O
cortical O
activity O
was O
continuously O
recorded O
. O

basal O
activity O
, O
latent O
period O
and O
the O
penicillin-induced O
epileptiform B-NEG
activity I-NEG
periods O
were O
then O
analyzed O
using O
both O
conventional O
methods O
and O
spectral O
analysis O
. O

spectral O
analyses O
were O
conducted O
by O
dividing O
the O
whole O
spectrum O
into O
different O
frequency O
bands O
including O
delta O
, O
theta O
( O
slow O
and O
fast) O
, O
alpha-sigma O
, O
beta O
(1 O
and O
2) O
and O
gamma O
(1 O
and O
2) O
bands O
. O

our O
results O
show O
that O
the O
most O
affected O
frequency O
bands O
were O
delta O
, O
theta O
, O
beta-2 O
and O
gamma-2 O
bands O
during O
the O
epileptiform B-NEG
activity I-NEG
and O
there O
were O
marked O
differences O
in O
terms O
of O
spectral O
densities O
between O
three O
investigated O
episodes O
( O
basal O
activity O
, O
latent O
period O
and O
epileptiform B-NEG
activity I-NEG
). O

our O
results O
may O
help O
to O
analyze O
novel O
data O
obtained O
using O
similar O
experimental O
models O
and O
the O
simple O
analysis O
method O
described O
here O
can O
be O
used O
in O
similar O
studies O
to O
investigate O
the O
basic O
neuronal O
mechanism O
of O
this O
or O
other O
types O
of O
experimental O
epilepsies B-NEG
. O

-DOCSTART- O

high O
dose O
dexmedetomidine O
as O
the O
sole O
sedative O
for O
pediatric O
mri O
. O

objective O
: O
this O
large-scale O
retrospective O
review O
evaluates O
the O
sedation O
profile O
of O
dexmedetomidine O
. O

aim O
: O
to O
determine O
the O
hemodynamic O
responses O
, O
efficacy O
and O
adverse O
events O
associated O
with O
the O
use O
of O
high O
dose O
dexmedetomidine O
as O
the O
sole O
sedative O
for O
magnetic O
resonance O
imaging O
( O
mri O
) O
studies O
. O

background O
: O
dexmedetomidine O
has O
been O
used O
at O
our O
institution O
since O
2005 O
to O
provide O
sedation O
for O
pediatric O
radiological O
imaging O
studies O
. O

over O
time O
, O
an O
effective O
protocol O
utilizing O
high O
dose O
dexmedetomidine O
as O
the O
sole O
sedative O
agent O
has O
evolved O
. O

methods/materials O
: O
as O
part O
of O
the O
ongoing O
quality O
assurance O
process O
, O
data O
on O
all O
sedations O
are O
reviewed O
monthly O
and O
protocols O
modified O
as O
needed O
. O

data O
were O
analyzed O
from O
all O
747 O
consecutive O
patients O
who O
received O
dexmedetomidine O
for O
mri O
sedation O
from O
april O
2005 O
to O
april O
2007 O
. O

results O
: O
since O
2005 O
, O
the O
10-min O
loading O
dose O
of O
our O
dexmedetomidine O
protocol O
increased O
from O
2 O
to O
3 O
microg.kg(-1) O
, O
and O
the O
infusion O
rate O
increased O
from O
1 O
to O
1.5 O
to O
2 O
microg.kg(-1).h(-1) O
. O

the O
current O
sedation O
protocol O
progressively O
increased O
the O
rate O
of O
successful O
sedation O
( O
able O
to O
complete O
the O
imaging O
study O
) O
when O
using O
dexmedetomidine O
alone O
from O
91.8% O
to O
97.6% O
(p O
= O
0.009) O
, O
reducing O
the O
requirement O
for O
adjuvant O
pentobarbital O
in O
the O
event O
of O
sedation O
failure O
with O
dexmedetomidine O
alone O
and O
decreased O
the O
mean O
recovery O
time O
by O
10 O
min O
(p O
< O
0.001) O
. O

although O
dexmedetomidine O
sedation O
was O
associated O
with O
a O
16% O
incidence O
of O
bradycardia B-NEG
, O
all O
concomitant O
mean O
arterial O
blood O
pressures O
were O
within O
20% O
of O
age-adjusted O
normal O
range O
and O
oxygen O
saturations O
were O
95% O
or O
higher O
. O

conclusion O
: O
dexmedetomidine O
in O
high O
doses O
provides O
adequate O
sedation O
for O
pediatric O
mri O
studies O
. O

while O
use O
of O
high O
dose O
dexmedetomidine O
is O
associated O
with O
decreases O
in O
heart O
rate O
and O
blood O
pressure O
outside O
the O
established O
'awake' O
norms O
, O
this O
deviation O
is O
generally O
within O
20% O
of O
norms O
, O
and O
is O
not O
associated O
with O
adverse O
sequelae O
. O

dexmedetomidine O
is O
useful O
as O
the O
sole O
sedative O
for O
pediatric O
mri O
. O

-DOCSTART- O

methamphetamine O
causes O
alterations O
in O
the O
map O
kinase-related O
pathways O
in O
the O
brains O
of O
mice O
that O
display O
increased O
aggressiveness B-NEG
. O
aggressive B-NEG
behaviors I-NEG
have O
been O
reported O
in O
patients O
who O
suffer O
from O
some O
psychiatric B-NEG
disorders I-NEG
, O
and O
are O
common O
in O
methamphetamine O
( O
meth O
) O
abusers O
. O

herein O
, O
we O
report O
that O
multiple O
( O
but O
not O
single O
) O
injections O
of O
meth O
significantly O
increased O
aggressiveness B-NEG
in O
male O
cd-1 O
mice O
. O

this O
increase O
in O
aggressiveness B-NEG
was O
not O
secondary O
to O
meth-induced O
hyperactivity B-NEG
. O

analysis O
of O
protein O
expression O
using O
antibody O
microarrays O
and O
western O
blotting O
revealed O
differential O
changes O
in O
map O
kinase-related O
pathways O
after O
multiple O
and O
single O
meth O
injections O
. O

there O
were O
statistically O
significant O
( O
p<0.05 O
) O
decreases O
in O
mek1 O
, O
erk2p O
, O
gsk3alpha O
, O
14-3-3e O
, O
and O
mek7 O
in O
the O
striata O
of O
mice O
after O
multiple O
injections O
of O
meth O
. O

mek1 O
was O
significantly O
decreased O
also O
after O
a O
single O
injection O
of O
meth O
, O
but O
to O
a O
much O
lesser O
degree O
than O
after O
multiple O
injections O
of O
meth O
. O

in O
the O
frontal O
cortex O
, O
there O
was O
a O
statistically O
significant O
decrease O
in O
gsk3alpha O
after O
multiple O
( O
but O
not O
single O
) O
injections O
of O
meth O
. O

these O
findings O
suggest O
that O
alterations O
in O
map O
kinase-related O
pathways O
in O
the O
prefronto-striatal O
circuitries O
might O
be O
involved O
in O
the O
manifestation O
of O
aggressive B-NEG
behaviors I-NEG
in O
mice O
. O

-DOCSTART- O

lamotrigine O
associated O
with O
exacerbation O
or O
de O
novo O
myoclonus B-NEG
in O
idiopathic B-NEG
generalized I-NEG
epilepsies I-NEG
. O

five O
patients O
with O
idiopathic B-NEG
generalized I-NEG
epilepsies I-NEG
( O
ige B-NEG
) O
treated O
with O
lamotrigine O
( O
ltg O
) O
experienced O
exacerbation O
or O
de O
novo O
appearance O
of O
myoclonic B-NEG
jerks I-NEG
( O
mj B-NEG
). O

in O
three O
patients O
, O
ltg O
exacerbated O
mj B-NEG
in O
a O
dose-dependent O
manner O
with O
early O
aggravation O
during O
titration O
. O
mj B-NEG
disappeared O
when O
ltg O
dose O
was O
decreased O
by O
25 O
to O
50% O
. O

in O
two O
patients O
, O
ltg O
exacerbated O
mj B-NEG
in O
a O
delayed O
but O
more O
severe O
manner O
, O
with O
myoclonic B-NEG
status I-NEG
that O
only O
ceased O
after O
ltg O
withdrawal O
. O

-DOCSTART- O

rtms O
of O
supplementary O
motor O
area O
modulates O
therapy-induced O
dyskinesias B-NEG
in O
parkinson B-NEG
disease I-NEG
. O

the O
neural O
mechanisms O
and O
circuitry O
involved O
in O
levodopa-induced O
dyskinesia B-NEG
are O
unclear O
. O

using O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rtms O
) O
over O
the O
supplementary O
motor O
area O
( O
sma O
) O
in O
a O
group O
of O
patients O
with O
advanced O
parkinson B-NEG
disease I-NEG
, O
the O
authors O
investigated O
whether O
modulation O
of O
sma O
excitability O
may O
result O
in O
a O
modification O
of O
a O
dyskinetic B-NEG
state O
induced O
by O
continuous O
apomorphine O
infusion O
. O

rtms O
at O
1 O
hz O
was O
observed O
to O
markedly O
reduce O
drug-induced B-NEG
dyskinesias I-NEG
, O
whereas O
5-hz O
rtms O
induced O
a O
slight O
but O
not O
significant O
increase O
. O

-DOCSTART- O

assessment O
of O
the O
onset O
and O
persistence O
of O
amnesia B-NEG
during O
procedural O
sedation O
with O
propofol O
. O

objectives O
: O
to O
assess O
patients' O
ability O
to O
repeat O
and O
recall O
words O
presented O
to O
them O
while O
undergoing O
procedural O
sedation O
with O
propofol O
, O
and O
correlate O
their O
recall O
with O
their O
level O
of O
awareness O
as O
measured O
by O
bispectral O
index O
( O
bis O
) O
monitoring O
. O

methods O
: O
this O
was O
a O
prospective O
, O
single-intervention O
study O
of O
consenting O
adult O
patients O
undergoing O
procedural O
sedation O
with O
propofol O
between O
december O
28 O
, O
2002 O
, O
and O
october O
31 O
, O
2003 O
. O

bis O
monitoring O
was O
initiated O
starting O
3 O
minutes O
before O
the O
procedure O
and O
continuing O
until O
the O
patient O
had O
regained O
baseline O
mental O
status O
. O

at O
1-minute O
intervals O
during O
the O
procedural O
sedation O
, O
until O
the O
patient O
regained O
baseline O
mental O
status O
at O
the O
end O
of O
the O
procedure O
, O
a O
word O
from O
a O
standardized O
list O
was O
read O
aloud O
, O
and O
the O
patient O
was O
asked O
to O
immediately O
repeat O
the O
word O
to O
the O
investigator O
. O

the O
bis O
score O
at O
the O
time O
the O
word O
was O
read O
and O
the O
patient's O
ability O
to O
repeat O
the O
word O
were O
recorded O
. O

after O
the O
procedure O
, O
the O
patient O
was O
asked O
to O
state O
all O
of O
the O
words O
from O
the O
list O
that O
he O
or O
she O
could O
recall O
, O
and O
to O
identify O
the O
last O
word O
recalled O
from O
prior O
to O
the O
start O
of O
the O
procedure O
and O
the O
first O
word O
recalled O
from O
after O
the O
procedure O
was O
completed O
. O

results O
: O
seventy-five O
consenting O
patients O
were O
enrolled O
; O
one O
patient O
was O
excluded O
from O
data O
analysis O
for O
a O
protocol O
violation O
. O

no O
serious O
adverse O
events O
were O
noted O
during O
the O
procedural O
sedations O
. O

the O
mean O
( O
+/-standard O
deviation O
) O
time O
of O
data O
collection O
was O
16.4 O
minutes O
(+/-7.1 O
; O
range O
5 O
to O
34 O
minutes) O
. O

the O
mean O
initial O
( O
preprocedure O
) O
bis O
score O
was O
97.1 O
(+/-2.3 O
; O
range O
92 O
to O
99) O
. O

the O
mean O
lowest O
bis O
score O
occurring O
during O
these O
procedural O
sedations O
was O
66.9 O
(+/-14.4 O
; O
range O
33 O
to O
91) O
. O

the O
mean O
lowest O
bis O
score O
corresponding O
to O
the O
ability O
of O
the O
patient O
to O
immediately O
repeat O
words O
read O
from O
the O
list O
was O
77.1 O
( O
95% O
ci O
= O
74.3 O
to O
80.0) O
. O

the O
mean O
highest O
bis O
score O
corresponding O
to O
the O
inability B-NEG
to I-NEG
repeat I-NEG
words I-NEG
was O
81.5 O
( O
95% O
ci O
= O
78.1 O
to O
84.8) O
. O

the O
mean O
bis O
score O
corresponding O
to O
the O
last O
word O
recalled O
from O
prior O
to O
the O
initiation O
of O
the O
sedation O
was O
96.7 O
(+/-2.4 O
; O
range O
84 O
to O
98) O
. O

the O
mean O
bis O
score O
corresponding O
to O
the O
first O
word O
recalled O
after O
the O
procedure O
was O
completed O
was O
91.2 O
( O
95% O
ci O
= O
88.1 O
to O
94.3) O
. O

all O
patients O
recalled O
at O
least O
one O
word O
that O
had O
been O
read O
to O
them O
during O
the O
protocol O
. O

the O
mean O
lowest O
bis O
score O
for O
any O
recalled O
word O
was O
91.5 O
(+/-11.1 O
; O
range O
79 O
to O
98) O
, O
and O
no O
words O
were O
recalled O
when O
the O
corresponding O
bis O
score O
was O
less O
than O
90 O
. O

conclusions O
: O
there O
is O
a O
range O
of O
bis O
scores O
during O
which O
sedated O
patients O
are O
able O
to O
repeat O
words O
read O
to O
them O
but O
are O
not O
able O
to O
subsequently O
recall O
these O
words O
. O

furthermore O
, O
patients O
had O
no O
recall O
of O
words O
repeated O
prior O
to O
procedural O
sedation O
in O
bis O
ranges O
associated O
with O
recall O
after O
procedural O
sedation O
, O
suggestive O
of O
retrograde B-NEG
amnesia I-NEG
. O

-DOCSTART- O

assessment O
of O
perinatal O
hepatitis B-NEG
b I-NEG
and O
rubella B-NEG
prevention O
in O
new O
hampshire O
delivery O
hospitals O
. O

objective O
: O
to O
evaluate O
current O
performance O
on O
recommended O
perinatal O
hepatitis B-NEG
b I-NEG
and O
rubella B-NEG
prevention O
practices O
in O
new O
hampshire O
. O

methods O
: O
data O
were O
extracted O
from O
2021 O
paired O
mother-infant O
records O
for O
the O
year O
2000 O
birth O
cohort O
in O
new O
hampshire's O
25 O
delivery O
hospitals O
. O

assessment O
was O
done O
on O
the O
following O
: O
prenatal O
screening O
for O
hepatitis B-NEG
b I-NEG
and O
rubella B-NEG
, O
administration O
of O
the O
hepatitis B-NEG
b I-NEG
vaccine O
birth O
dose O
to O
all O
infants O
, O
administration O
of O
hepatitis B-NEG
b I-NEG
immune O
globulin O
to O
infants O
who O
were O
born O
to O
hepatitis O
b O
surface O
antigen-positive O
mothers O
, O
rubella B-NEG
immunity O
, O
and O
administration O
of O
in-hospital O
postpartum O
rubella B-NEG
vaccine O
to O
rubella B-NEG
nonimmune O
women O
. O

results O
: O
prenatal O
screening O
rates O
for O
hepatitis B-NEG
b I-NEG
( O
98.8% O
) O
and O
rubella B-NEG
( O
99.4% O
) O
were O
high O
. O
hepatitis B-NEG
b I-NEG
vaccine O
birth O
dose O
was O
administered O
to O
76.2% O
of O
all O
infants O
. O

all O
infants O
who O
were O
born O
to O
hepatitis O
b O
surface O
antigen-positive O
mothers O
also O
received O
hepatitis B-NEG
b I-NEG
immune O
globulin O
. O

multivariate O
logistic O
regression O
showed O
that O
the O
month O
of O
delivery O
and O
infant O
birth O
weight O
were O
independent O
predictors O
of O
hepatitis B-NEG
b I-NEG
vaccination O
. O

the O
proportion O
of O
infants O
who O
were O
vaccinated O
in O
january O
and O
february O
2000 O
( O
48.5% O
and O
67.5% O
, O
respectively O
) O
was O
less O
than O
any O
other O
months O
, O
whereas O
the O
proportion O
who O
were O
vaccinated O
in O
december O
2000 O
( O
88.2% O
) O
was O
the O
highest O
. O

women O
who O
were O
born O
between O
1971 O
and O
1975 O
had O
the O
highest O
rate O
of O
rubella B-NEG
nonimmunity O
(9.5%) O
. O

in-hospital O
postpartum O
rubella B-NEG
vaccine O
administration O
was O
documented O
for O
75.6% O
of O
nonimmune O
women O
. O

conclusion O
: O
this O
study O
documents O
good O
compliance O
in O
new O
hampshire's O
birthing O
hospitals O
with O
national O
guidelines O
for O
perinatal O
hepatitis B-NEG
b I-NEG
and O
rubella B-NEG
prevention O
and O
highlights O
potential O
areas O
for O
improvement O
. O

-DOCSTART- O

expression O
of O
p300 O
protects O
cardiac O
myocytes O
from O
apoptosis O
in O
vivo O
. O

doxorubicin O
is O
an O
anti- O
tumor B-NEG
agent O
that O
represses O
cardiac-specific O
gene O
expression O
and O
induces O
myocardial O
cell O
apoptosis O
. O

doxorubicin O
depletes O
cardiac O
p300 O
, O
a O
transcriptional O
coactivator O
that O
is O
required O
for O
the O
maintenance O
of O
the O
differentiated O
phenotype O
of O
cardiac O
myocytes O
. O

however O
, O
the O
role O
of O
p300 O
in O
protection O
against O
doxorubicin-induced O
apoptosis O
is O
unknown O
. O

transgenic O
mice O
overexpressing O
p300 O
in O
the O
heart O
and O
wild-type O
mice O
were O
subjected O
to O
doxorubicin O
treatment O
. O

compared O
with O
wild-type O
mice O
, O
transgenic O
mice O
exhibited O
higher O
survival O
rate O
as O
well O
as O
more O
preserved O
left O
ventricular O
function O
and O
cardiac O
expression O
of O
alpha-sarcomeric O
actin O
. O

doxorubicin O
induced O
myocardial O
cell O
apoptosis O
in O
wild-type O
mice O
but O
not O
in O
transgenic O
mice O
. O

expression O
of O
p300 O
increased O
the O
cardiac O
level O
of O
bcl-2 O
and O
mdm-2 O
, O
but O
not O
that O
of O
p53 O
or O
other O
members O
of O
the O
bcl-2 O
family O
. O

these O
findings O
demonstrate O
that O
overexpression O
of O
p300 O
protects O
cardiac O
myocytes O
from O
doxorubicin-induced O
apoptosis O
and O
reduces O
the O
extent O
of O
acute O
heart B-NEG
failure I-NEG
in O
adult O
mice O
in O
vivo O
. O

-DOCSTART- O

mitochondrial O
dna O
and O
its O
respiratory O
chain O
products O
are O
defective O
in O
doxorubicin O
nephrosis B-NEG
. O

background O
: O
doxorubicin O
induces O
a O
self-perpetuating O
nephropathy B-NEG
characterized O
by O
early O
glomerular B-NEG
and I-NEG
late-onset I-NEG
tubular I-NEG
lesions I-NEG
in O
rats O
. O

we O
investigated O
the O
potential O
role O
of O
mitochondrial B-NEG
injury I-NEG
in O
the O
onset O
of O
these O
lesions O
. O

methods O
: O
rats O
were O
treated O
with O
intravenous O
doxorubicin O
(1 O
mg O
kg(-1 O
) O
week(-1) O
) O
for O
7 O
weeks O
and O
were O
sacrificed O
either O
1 O
week O
( O
'short-term' O
) O
or O
30 O
weeks O
( O
'long-term' O
) O
following O
the O
last O
dose O
. O

additional O
rats O
received O
a O
single O
dose O
either O
6 O
days O
or O
2 O
h O
prior O
to O
euthanasia O
. O

all O
rats O
were O
killed O
at O
48 O
weeks O
of O
age O
. O
glomerular B-NEG
and I-NEG
tubular I-NEG
injury I-NEG
was O
monitored O
and O
correlated O
to O
the O
activity O
or O
expression O
of O
respiratory O
chain O
components O
. O

finally O
, O
we O
quantified O
both O
nuclear O
and O
mitochondrial O
dna O
( O
mtdna O
) O
as O
well O
as O
superoxide O
production O
and O
the O
4834 O
base O
pair O
'common' O
mtdna O
deletion O
. O

results O
: O
the O
'long-term' O
group O
had O
significant O
glomerular B-NEG
and I-NEG
tubular I-NEG
lesions I-NEG
, O
depressed O
activities O
of O
mtdna-encoded O
nadh O
dehydrogenase O
and O
cytochrome-c O
oxidase O
( O
cox O
) O
and O
increased O
citrate O
synthase O
activity O
. O

in O
addition O
, O
expression O
of O
the O
mtdna-encoded O
cox O
subunit O
i O
was O
reduced O
and O
mtdna O
levels O
were O
decreased O
. O

in O
'short-term' O
rats O
, O
there O
were O
fewer O
tubular B-NEG
lesions I-NEG
, O
but O
similar O
numbers O
of O
glomerular B-NEG
lesions I-NEG
activity O
. O

among O
all O
animals O
, O
glomerular B-NEG
and I-NEG
tubular I-NEG
injury I-NEG
were O
inversely O
correlated O
with O
mtdna O
levels O
, O
mtdna-encoded O
respiratory O
chain O
activities O
and O
with O
the O
expression O
of O
the O
mtdna-encoded O
respiratory O
chain O
subunit O
cox-i O
. O

injury O
was O
positively O
correlated O
with O
superoxide O
production O
and O
the O
activities O
of O
nucleus-encoded O
mitochondrial O
or O
cytoplasmic O
enzymes O
. O

kidneys O
from O
the O
'long-term' O
group O
showed O
more O
mtdna O
deletions O
than O
in O
'short-term' O
animals O
and O
these O
were O
not O
observed O
in O
the O
other O
groups O
. O

conclusions O
: O
these O
results O
suggest O
an O
important O
role O
for O
quantitative O
and O
qualitative O
mtdna O
alterations O
through O
the O
reduction O
of O
mtdna-encoded O
respiratory O
chain O
function O
and O
induction O
of O
superoxide O
in O
doxorubicin-induced O
renal B-NEG
lesions I-NEG
. O

-DOCSTART- O

amphotericin O
b-induced O
seizures B-NEG
in O
a O
patient O
with O
aids B-NEG
. O

objective O
: O
to O
report O
a O
case O
of O
multiple O
episodes O
of O
seizure B-NEG
activity O
in O
an O
aids B-NEG
patent O
following O
amphotericin O
b O
infusion O
. O

case O
summary O
: O
a O
46-year-old O
african-american O
man O
experienced O
recurrent O
grand B-NEG
mal I-NEG
seizures I-NEG
during O
intravenous O
infusion O
of O
amphotericin O
b, O
then O
petit O
mal O
seizures B-NEG
as O
the O
infusion O
was O
stopped O
and O
the O
drug O
concentrations O
decreased O
with O
time O
. O

the O
patients O
concurrent O
medications O
included O
didanosine O
, O
hydroxyzine O
, O
promethazine O
, O
hydrocortisone O
, O
and O
prochlorperazine O
. O

despite O
administration O
of O
phenytoin O
and O
lorazepam O
, O
the O
seizures B-NEG
persisted O
and O
occurred O
only O
during O
amphotercin O
b O
administration O
. O

discussion O
: O
aids B-NEG
and O
cryptococcal B-NEG
meningitis I-NEG
, O
both O
of O
which O
the O
patient O
had O
, O
can O
potentially O
cause O
seizures B-NEG
. O

the O
patient O
had O
a O
history O
of O
alcohol B-NEG
abuse I-NEG
; O
alcohol O
intake O
as O
well O
as O
withdrawal O
can O
also O
cause O
seizures B-NEG
. O

didanosine O
also O
has O
a O
potential O
for O
inducing O
seizures B-NEG
. O

however O
, O
these O
other O
potential O
causes O
of O
seizure B-NEG
were O
ruled O
out O
. O

the O
time O
course O
of O
events O
suggested O
that O
amphotericin O
b O
was O
the O
cause O
of O
the O
seizures B-NEG
in O
this O
aids B-NEG
patient O
. O

conclusions O
: O
amphotericin O
b O
seems O
to O
be O
the O
probable O
cause O
of O
the O
seizures B-NEG
. O

to O
date O
, O
only O
three O
cases O
of O
seizures B-NEG
associated O
with O
amphotericin O
b O
have O
been O
reported O
in O
the O
literature O
, O
but O
healthcare O
providers O
should O
be O
aware O
of O
the O
potential O
for O
this O
rare O
adverse O
effect O
. O

-DOCSTART- O

therapeutic O
drug O
monitoring O
of O
tobramycin O
: O
once-daily O
versus O
twice-daily O
dosage O
schedules O
. O

objective O
: O
to O
evaluate O
the O
effect O
of O
dosage O
regimen O
( O
once-daily O
vs O
. O
twice-daily O
) O
of O
tobramicyn O
on O
steady-state O
serum O
concentrations O
and O
toxicity B-NEG
. O

materials O
and O
methods O
: O
patients O
undergoing O
treatment O
with O
i.v O
. O
tobramycin O
(4 O
mg/kg/day O
) O
were O
randomised O
to O
two O
groups O
. O

group O
od O
(n O
= O
22 O
) O
received O
a O
once-daily O
dose O
of O
tobramycin O
and O
group O
td O
(n O
= O
21 O
) O
received O
the O
same O
dose O
divided O
into O
two O
doses O
daily O
. O

tobramycin O
serum O
concentrations O
( O
peak O
and O
trough O
) O
were O
measured O
by O
enzyme O
multiplied O
immunoassay O
. O

the O
renal O
and O
auditory O
functions O
of O
the O
patients O
were O
monitored O
before O
, O
during O
and O
immediately O
after O
treatment O
. O

results O
: O
the O
two O
groups O
were O
comparable O
with O
respect O
to O
sex O
, O
age O
, O
body O
weight O
and O
renal O
function O
. O

no O
statistically O
significant O
differences O
were O
found O
in O
mean O
daily O
dose O
, O
duration O
of O
treatment O
, O
or O
cumulative O
dose O
. O

trough O
concentrations O
were O
< O
2 O
g/ml O
in O
the O
two O
groups O
(100%) O
. O

peak O
concentrations O
were O
> O
6 O
microg/ml O
in O
100% O
of O
the O
od O
group O
and O
in O
67% O
of O
the O
td O
group O
( O
p< O
0.01) O
. O

mean O
peak O
concentrations O
were O
markedly O
different O
: O
11.00+/-2.89 O
microg/ml O
in O
od O
vs O
. O
6.53+/-1.45 O
microg/ml O
in O
td O
( O
p< O
0.01) O
. O

the O
pharmacokinetics O
parameters O
were O
: O
ke O
, O
( O
0.15+/-0.03/h O
in O
od O
vs O
. O
0.24+/-0.06/h O
in O
td) O
, O
t1/2 O
, O
( O
4.95+/-1.41 O
h O
in O
od O
vs O
. O
3.07+/-0.71 O
h O
in O
td) O
, O
vd O
( O
0.35+/-0.11 O
l/kg O
in O
od O
vs O
. O
0.33+/-0.09 O
l/kg O
in O
td) O
, O
cl O
( O
0.86+/-0.29 O
ml/min/kg O
in O
od O
vs O
. O
1.28+/-0.33 O
ml/min/kg O
in O
td) O
. O

increased O
serum O
creatinine O
was O
observed O
in O
73% O
of O
patients O
in O
od O
versus O
57% O
of O
patients O
in O
td O
, O
without O
evidence O
of O
nephrotoxicity B-NEG
. O

in O
td O
group O
, O
three O
patients O
developed O
decreased B-NEG
auditory I-NEG
function I-NEG
, O
of O
which O
one O
presented O
with O
an O
auditory B-NEG
loss I-NEG
of O
-30 O
db O
, O
whereas O
in O
the O
od O
group O
only O
one O
patient O
presented O
decreased B-NEG
auditory I-NEG
function I-NEG
. O

conclusion O
: O
this O
small O
study O
suggests O
that O
a O
once-daily O
dosing O
regimen O
of O
tobramycin O
is O
at O
least O
as O
effective O
as O
and O
is O
no O
more O
and O
possibly O
less O
toxic O
than O
the O
twice-daily O
regimen O
. O

using O
a O
single-dose O
therapy O
, O
peak O
concentration O
determination O
is O
not O
necessary O
, O
only O
trough O
samples O
should O
be O
monitored O
to O
ensure O
levels O
below O
2 O
microg/ml O
. O

-DOCSTART- O

chronic O
effects O
of O
a O
novel O
synthetic O
anthracycline O
derivative O
( O
sm-5887 O
) O
on O
normal O
heart O
and O
doxorubicin-induced O
cardiomyopathy B-NEG
in O
beagle O
dogs O
. O

this O
study O
was O
designed O
to O
investigate O
the O
chronic O
cardiotoxic B-NEG
potential O
of O
sm-5887 O
and O
a O
possible O
deteriorating O
effect O
of O
sm-5887 O
on O
low-grade O
cardiotoxicity B-NEG
pre-induced O
by O
doxorubicin O
in O
beagle O
dogs O
. O

in O
the O
chronic O
treatment O
, O
beagle O
dogs O
of O
each O
sex O
were O
given O
intravenously O
once O
every O
3 O
weeks O
, O
either O
a O
sublethal O
dose O
of O
doxorubicin O
( O
1.5 O
mg/kg O
) O
or O
sm-5887 O
( O
2.5 O
mg/kg) O
. O

the O
experiment O
was O
terminated O
3 O
weeks O
after O
the O
ninth O
dosing O
. O

animals O
which O
received O
over O
six O
courses O
of O
doxorubicin O
demonstrated O
the O
electrocardiogram O
( O
ecg O
) O
changes O
, O
decrease O
of O
blood O
pressure O
and O
high-grade O
histopathological O
cardiomyopathy B-NEG
, O
while O
animals O
which O
were O
terminally O
sacrificed O
after O
the O
sm-5887 O
administration O
did O
not O
show O
any O
changes O
in O
ecg O
, O
blood O
pressure O
and O
histopathological O
examinations O
. O

to O
examine O
a O
possibly O
deteriorating O
cardiotoxic B-NEG
effect O
of O
sm-5887 O
, O
low-grade O
cardiomyopathy B-NEG
was O
induced O
in O
dogs O
by O
four O
courses O
of O
doxorubicin O
( O
1.5 O
mg/kg) O
. O

nine O
weeks O
after O
pre-treatment O
, O
dogs O
were O
given O
four O
courses O
of O
either O
doxorubicin O
( O
1.5 O
mg/kg O
) O
or O
sm-5887 O
( O
2.5 O
mg/kg O
) O
once O
every O
3 O
weeks O
. O

the O
low-grade O
cardiotoxic B-NEG
changes O
were O
enhanced O
by O
the O
additional O
doxorubicin O
treatment O
. O

on O
the O
contrary O
, O
the O
sm-5887 O
treatment O
did O
not O
progress O
the O
grade O
of O
cardiomyopathy B-NEG
. O

in O
conclusion O
, O
sm-5887 O
does O
not O
have O
any O
potential O
of O
chronic O
cardiotoxicity B-NEG
and O
deteriorating O
effect O
on O
doxorubicin-induced O
cardiotoxicity B-NEG
in O
dogs O
. O

-DOCSTART- O

posteroventral O
medial O
pallidotomy O
in O
advanced O
parkinson's B-NEG
disease I-NEG
. O

background O
: O
posteroventral O
medial O
pallidotomy O
sometimes O
produces O
striking O
improvement O
in O
patients O
with O
advanced O
parkinson's B-NEG
disease I-NEG
, O
but O
the O
studies O
to O
date O
have O
involved O
small O
numbers O
of O
patients O
and O
short-term O
follow-up O
. O

methods O
: O
forty O
patients O
with O
parkinson's B-NEG
disease I-NEG
underwent O
serial O
, O
detailed O
assessments O
both O
after O
drug O
withdrawal O
( O
off O
period O
) O
and O
while O
taking O
their O
optimal O
medical O
regimens O
( O
on O
period) O
. O

all O
patients O
were O
examined O
preoperatively O
and O
39 O
were O
examined O
at O
six O
months O
; O
27 O
of O
the O
patients O
were O
also O
examined O
at O
one O
year O
, O
and O
11 O
at O
two O
years O
. O

results O
: O
the O
percent O
improvements O
at O
six O
months O
were O
as O
follows O
: O
off-period O
score O
for O
overall O
motor O
function O
, O
28 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
19 O
to O
38 O
percent) O
, O
with O
most O
of O
the O
improvement O
in O
the O
contralateral O
limbs O
; O
off-period O
score O
for O
activities O
of O
daily O
living O
, O
29 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
19 O
to O
39 O
percent) O
; O
on-period O
score O
for O
contralateral O
dyskinesias B-NEG
, O
82 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
72 O
to O
91 O
percent) O
; O
and O
on-period O
score O
for O
ipsilateral O
dyskinesias B-NEG
, O
44 O
percent O
( O
95 O
percent O
confidence O
interval O
, O
29 O
to O
59 O
percent) O
. O

the O
improvements O
in O
dyskinesias B-NEG
and O
the O
total O
scores O
for O
off-period O
parkinsonism B-NEG
, O
contralateral O
bradykinesia B-NEG
, O
and O
rigidity B-NEG
were O
sustained O
in O
the O
11 O
patients O
examined O
at O
two O
years O
. O

the O
improvement O
in O
ipsilateral O
dyskinesias B-NEG
was O
lost O
after O
one O
year O
, O
and O
the O
improvements O
in O
postural O
stability O
and O
gait O
lasted O
only O
three O
to O
six O
months O
. O

approximately O
half O
the O
patients O
who O
had O
been O
dependent O
on O
assistance O
in O
activities O
of O
daily O
living O
in O
the O
off O
period O
before O
surgery O
became O
independent O
after O
surgery O
. O

the O
complications O
of O
surgery O
were O
generally O
well O
tolerated O
, O
and O
there O
were O
no O
significant O
changes O
in O
the O
use O
of O
medication O
. O

conclusions O
: O
in O
late-stage O
parkinson's B-NEG
disease I-NEG
, O
pallidotomy O
significantly O
reduces O
levodopa-induced O
dyskinesias B-NEG
and O
off-period O
disability O
. O

much O
of O
the O
benefit O
is O
sustained O
at O
two O
years O
, O
although O
some O
improvements O
, O
such O
as O
those O
on O
the O
ipsilateral O
side O
and O
in O
axial O
symptoms O
, O
wane O
within O
the O
first O
year O
. O

the O
on-period O
symptoms O
that O
are O
resistant O
to O
dopaminergic O
therapy O
do O
not O
respond O
to O
pallidotomy O
. O

-DOCSTART- O

neuropeptide-y O
immunoreactivity O
in O
the O
pilocarpine O
model O
of O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
. O

neuropeptide-y O
( O
npy O
) O
is O
expressed O
by O
granule O
cells O
and O
mossy O
fibres O
of O
the O
hippocampal O
dentate O
gyrus O
during O
experimental O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
( O
tle B-NEG
). O

this O
expression O
may O
represent O
an O
endogenous O
damping O
mechanism O
since O
npy O
has O
been O
shown O
to O
block O
seizure B-NEG
-like O
events O
following O
high-frequency O
stimulation O
in O
hippocampal O
slices O
. O

the O
pilocarpine O
( O
pilo O
) O
model O
of O
epilepsy B-NEG
is O
characterized O
by O
an O
acute O
period O
of O
status B-NEG
epilepticus I-NEG
followed O
by O
spontaneous O
recurrent O
seizures B-NEG
and O
related O
brain B-NEG
damage I-NEG
. O

we O
report O
peroxidase-antiperoxidase O
immunostaining O
for O
npy O
in O
several O
brain O
regions O
in O
this O
model O
. O

pilo-injected O
animals O
exhibited O
npy O
immunoreactivity O
in O
the O
region O
of O
the O
mossy O
fibre O
terminals O
, O
in O
the O
dentate O
gyrus O
inner O
molecular O
layer O
and O
, O
in O
a O
few O
cases O
, O
within O
presumed O
granule O
cells O
. O

npy O
immunoreactivity O
was O
also O
dramatically O
changed O
in O
the O
entorhinal O
cortex O
, O
amygdala O
and O
sensorimotor O
areas O
. O

in O
addition O
, O
pilo O
injected O
animals O
exhibited O
a O
reduction O
in O
the O
number O
of O
npy-immunoreactive O
interneurons O
compared O
with O
controls O
. O

the O
results O
demonstrate O
that O
changes O
in O
npy O
expression O
, O
including O
expression O
in O
the O
granule O
cells O
and O
mossy O
fibres O
and O
the O
loss O
of O
vulnerable O
npy O
neurons O
, O
are O
present O
in O
the O
pilo O
model O
of O
tle B-NEG
. O

however O
, O
the O
significance O
of O
this O
changed O
synthesis O
of O
npy O
remains O
to O
be O
determined O
. O

-DOCSTART- O

effect O
of O
myopic O
excimer O
laser O
photorefractive O
keratectomy O
on O
the O
electrophysiologic O
function O
of O
the O
retina O
and O
optic O
nerve O
. O

purpose O
: O
to O
assess O
by O
electrophysiologic O
testing O
the O
effect O
of O
photorefractive O
keratectomy O
( O
prk O
) O
on O
the O
retina O
and O
optic O
nerve O
. O

setting O
: O
eye O
clinic O
, O
s. O

salvatore O
hospital O
, O
l'aquila O
university O
, O
italy O
. O

methods O
: O
standard O
pattern O
electroretinograms O
( O
p-ergs O
) O
and O
standard O
pattern O
visual O
evoked O
potentials O
( O
p-veps O
) O
were O
done O
in O
25 O
eyes O
of O
25 O
patients O
who O
had O
myopic O
prk O
for O
an O
attempted O
correction O
between O
5.00 O
and O
15.00 O
diopters O
( O
d O
) O
( O
mean O
8.00 O
d) O
. O

testing O
was O
done O
preoperatively O
and O
3, O
6, O
12 O
, O
and O
18 O
months O
postoperatively O
. O

the O
contralateral O
eyes O
served O
as O
controls O
. O

during O
the O
follow-up O
, O
3 O
patients O
( O
12% O
) O
developed O
steroid-induced O
elevated B-NEG
intraocular I-NEG
pressure I-NEG
( O
iop O
) O
that O
resolved O
after O
corticosteroid O
therapy O
was O
discontinued O
. O

results O
: O
no O
statistically O
significant O
differences O
were O
seen O
between O
treated O
and O
control O
eyes O
nor O
between O
treated O
eyes O
preoperatively O
and O
postoperatively O
. O

conclusion O
: O
myopic O
excimer O
laser O
prk O
did O
not O
seem O
to O
affect O
the O
posterior O
segment O
. O

the O
transient O
steroid-induced O
iop B-NEG
rise I-NEG
did O
not O
seem O
to O
cause O
functional O
impairment O
. O

-DOCSTART- O

liposomal O
daunorubicin O
in O
advanced O
kaposi's B-NEG
sarcoma I-NEG
: O
a O
phase O
ii O
study O
. O

we O
report O
a O
non-randomized O
phase O
ii O
clinical O
trial O
to O
assess O
the O
efficacy O
and O
safety O
of O
liposomal O
daunorubicin O
( O
daunoxome O
) O
in O
the O
treatment O
of O
aids B-NEG
related O
kaposi's B-NEG
sarcoma I-NEG
. O

eleven O
homosexual O
men O
with O
advanced O
kaposi's B-NEG
sarcoma I-NEG
were O
entered O
in O
the O
trial O
. O

changes O
in O
size O
, O
colour O
and O
associated O
oedema B-NEG
of O
selected O
'target' O
lesions O
were O
measured O
. O

clinical O
, O
biochemical O
and O
haematological O
toxicities B-NEG
were O
assessed O
. O

ten O
subjects O
were O
evaluated O
. O

a O
partial O
response O
was O
achieved O
in O
four O
, O
of O
whom O
two O
subsequently O
relapsed O
. O

stabilization O
of O
kaposi's B-NEG
sarcoma I-NEG
occurred O
in O
the O
remaining O
six O
, O
maintained O
until O
the O
end O
of O
the O
trial O
period O
in O
four O
. O

the O
drug O
was O
generally O
well O
tolerated O
, O
with O
few O
mild O
symptoms O
of O
toxicity B-NEG
. O

the O
main O
problem O
encountered O
was O
haematological O
toxicity B-NEG
, O
with O
three O
subjects O
experiencing O
severe O
neutropenia B-NEG
( O
neutrophil O
count O
< O
0.5 O
x O
10(9)/l) O
. O

there O
was O
no O
evidence O
of O
cardiotoxicity B-NEG
. O

in O
this O
small O
patient O
sample O
, O
liposomal O
daunorubicin O
was O
an O
effective O
and O
well O
tolerated O
agent O
in O
the O
treatment O
of O
kaposi's B-NEG
sarcoma I-NEG
. O

-DOCSTART- O

failure O
of O
ancrod O
in O
the O
treatment O
of O
heparin-induced O
arterial O
thrombosis B-NEG
. O

the O
morbidity O
and O
mortality O
associated O
with O
heparin-induced O
thrombosis B-NEG
remain O
high O
despite O
numerous O
empirical O
therapies O
. O

ancrod O
has O
been O
used O
successfully O
for O
prophylaxis O
against O
development O
of O
thrombosis B-NEG
in O
patients O
with O
heparin O
induced O
platelet B-NEG
aggregation I-NEG
who O
require O
brief O
reexposure O
to O
heparin O
, O
but O
its O
success O
in O
patients O
who O
have O
developed O
the O
thrombosis B-NEG
syndrome O
is O
not O
well O
defined O
. O

the O
authors O
present O
a O
case O
of O
failure O
of O
ancrod O
treatment O
in O
a O
patient O
with O
heparin-induced O
thrombosis B-NEG
. O

-DOCSTART- O

seizure B-NEG
after O
flumazenil O
administration O
in O
a O
pediatric O
patient O
. O

flumazenil O
is O
a O
benzodiazepine O
receptor O
antagonist O
used O
to O
reverse O
sedation O
and O
respiratory B-NEG
depression I-NEG
induced O
by O
benzodiazepines O
. O
seizures B-NEG
and O
cardiac B-NEG
arrhythmias I-NEG
have O
complicated O
its O
use O
in O
adult O
patients O
. O
overdose B-NEG
patients O
who O
have O
coingested O
tricyclic O
antidepressants O
have O
a O
higher O
risk O
of O
these O
complications O
. O

little O
information O
exists O
concerning O
adverse O
effects O
of O
flumazenil O
in O
children O
. O

we O
report O
the O
occurrence O
of O
a O
generalized O
tonic-clonic B-NEG
seizure I-NEG
in O
a O
pediatric O
patient O
following O
the O
administration O
of O
flumazenil O
. O

-DOCSTART- O

remodelling O
of O
nerve O
structure O
in O
experimental O
isoniazid O
neuropathy B-NEG
in O
the O
rat O
. O

the O
neuropathy B-NEG
caused O
by O
a O
single O
dose O
of O
isoniazid O
in O
rats O
was O
studied O
with O
a O
computer-assisted O
morphometric O
method O
. O

scatter O
diagrams O
of O
the O
g O
ratio O
( O
quotient O
fibre O
diameter/axon O
diameter O
) O
define O
regenerating O
fibres O
as O
a O
distinct O
population O
, O
distinguishable O
from O
the O
surviving O
fibres O
by O
reduced O
sheath O
thickness O
and O
reduced O
axon O
calibre O
. O

there O
was O
also O
evidence O
of O
a O
subtle O
direct O
toxic O
effect O
on O
the O
entire O
fibre O
population O
, O
causing O
axon O
shrinkage O
masked O
by O
readjustment O
of O
the O
myelin O
sheath O
. O

-DOCSTART- O

selective O
injection O
of O
iopentol O
, O
iohexol O
and O
metrizoate O
into O
the O
left O
coronary O
artery O
of O
the O
dog O
. O

induction O
of O
ventricular B-NEG
fibrillation I-NEG
and O
decrease O
of O
aortic O
pressure O
. O

in O
twenty O
beagle O
dogs O
selective O
injections O
were O
made O
into O
the O
left O
coronary O
artery O
with O
iopentol O
, O
iohexol O
and O
metrizoate O
in O
doses O
of O
4 O
ml O
, O
8 O
ml O
and O
16 O
ml O
. O

thirty-six O
iopentol O
injections O
, O
35 O
iohexol O
injections O
and O
37 O
metrizoate O
injections O
were O
made O
. O

frequencies O
of O
ventricular B-NEG
fibrillation I-NEG
were O
significantly O
lower O
(p O
less O
than O
0.05 O
) O
after O
iopentol O
( O
0% O
) O
and O
iohexol O
( O
3% O
) O
than O
after O
metrizoate O
(22%) O
. O

iopentol O
and O
iohexol O
also O
produced O
significantly O
less O
decrease O
in O
aortic O
blood O
pressure O
than O
metrizoate O
at O
the O
different O
doses O
. O

-DOCSTART- O

magnetic O
resonance O
imaging O
of O
cerebral O
venous B-NEG
thrombosis I-NEG
secondary O
to O
low-dose O
birth O
control O
pills O
. O

the O
clinical O
and O
radiographic O
features O
of O
cerebral O
deep B-NEG
venous I-NEG
thrombosis I-NEG
in O
a O
21-year-old O
white O
woman O
are O
presented O
. O

this O
nulliparous O
patient O
presented O
with O
relatively O
mild O
clinical O
symptoms O
and O
progressing O
mental O
status O
changes O
. O

the O
only O
known O
risk O
factor O
was O
low-dose O
oral O
contraceptive O
pills O
. O

the O
magnetic O
resonance O
image O
( O
mri O
) O
showed O
increased O
signal O
intensity O
from O
the O
internal O
cerebral O
veins O
, O
vein O
of O
galen O
, O
and O
straight O
sinus O
. O

the O
diagnosis O
was O
confirmed O
by O
arterial O
angiography O
. O

-DOCSTART- O

relation O
of O
perfusion O
defects O
observed O
with O
myocardial O
contrast O
echocardiography O
to O
the O
severity O
of O
coronary B-NEG
stenosis I-NEG
: O
correlation O
with O
thallium-201 O
single-photon O
emission O
tomography O
. O

it O
has O
been O
previously O
shown O
that O
myocardial O
contrast O
echocardiography O
is O
a O
valuable O
technique O
for O
delineating O
regions O
of O
myocardial O
underperfusion O
secondary O
to O
coronary B-NEG
occlusion I-NEG
and O
to O
critical O
coronary B-NEG
stenoses I-NEG
in O
the O
presence O
of O
hyperemic B-NEG
stimulation O
. O

the O
aim O
of O
this O
study O
was O
to O
determine O
whether O
myocardial O
contrast O
echocardiography O
performed O
with O
a O
stable O
solution O
of O
sonicated O
albumin O
could O
detect O
regions O
of O
myocardial O
underperfusion O
resulting O
from O
various O
degrees O
of O
coronary B-NEG
stenosis I-NEG
. O

the O
perfusion O
defect O
produced O
in O
16 O
open O
chest O
dogs O
was O
compared O
with O
the O
anatomic O
area O
at O
risk O
measured O
by O
the O
postmortem O
dual-perfusion O
technique O
and O
with O
thallium-201 O
single-photon O
emission O
tomography O
(spect) O
. O

during O
a O
transient O
( O
20-s O
) O
coronary B-NEG
occlusion I-NEG
, O
a O
perfusion O
defect O
was O
observed O
with O
contrast O
echocardiography O
in O
14 O
of O
the O
15 O
dogs O
in O
which O
the O
occlusion O
was O
produced O
. O

the O
perfusion O
defect O
correlated O
significantly O
with O
the O
anatomic O
area O
at O
risk O
(r O
= O
0.74 O
; O
p O
less O
than O
0.002) O
. O

during O
dipyridamole-induced O
hyperemia B-NEG
, O
12 O
of O
the O
16 O
dogs O
with O
a O
partial O
coronary B-NEG
stenosis I-NEG
had O
a O
visible O
area O
of O
hypoperfusion O
by O
contrast O
echocardiography O
. O

the O
four O
dogs O
without O
a O
perfusion O
defect O
had O
a O
stenosis O
that O
resulted O
in O
a O
mild O
( O
0% O
to O
50% O
) O
reduction O
in O
dipyridamole-induced O
hyperemia B-NEG
. O

the O
size O
of O
the O
perfusion O
defect O
during O
stenosis O
correlated O
significantly O
with O
the O
anatomic O
area O
at O
risk O
(r O
= O
0.61 O
; O
p O
= O
0.02) O
. O

thallium-201 O
spect O
demonstrated O
a O
perfusion O
defect O
in O
all O
14 O
dogs O
analyzed O
during O
dipyridamole-induced O
hyperemia B-NEG
; O
the O
size O
of O
the O
perfusion O
defect O
correlated O
with O
the O
anatomic O
area O
at O
risk O
(r O
= O
0.58 O
; O
p O
less O
than O
0.03 O
) O
and O
with O
the O
perfusion O
defect O
by O
contrast O
echocardiography O
(r O
= O
0.58 O
; O
p O
less O
than O
0.03) O
. O

thus O
, O
myocardial O
contrast O
echocardiography O
can O
be O
used O
to O
visualize O
and O
quantitate O
the O
amount O
of O
jeopardized O
myocardium O
during O
moderate O
to O
severe O
degrees O
of O
coronary B-NEG
stenosis I-NEG
. O

the O
results O
obtained O
show O
a O
correlation O
with O
the O
anatomic O
area O
at O
risk O
similar O
to O
that O
obtained O
with O
thallium-201 O
spect O
. O

-DOCSTART- O

potential O
deleterious O
effect O
of O
furosemide O
in O
radiocontrast O
nephropathy B-NEG
. O

the O
purpose O
of O
the O
study O
was O
to O
determine O
the O
efficacy O
of O
furosemide O
in O
addition O
to O
intravenous O
fluids O
in O
the O
prevention O
of O
radiocontrast O
nephropathy B-NEG
. O

18 O
patients O
, O
referred O
to O
a O
radiocontrast O
study O
, O
considered O
at O
risk O
because O
of O
preexisting O
renal B-NEG
insufficiency I-NEG
, O
were O
enrolled O
in O
a O
prospective O
, O
randomized O
, O
controlled O
trial O
, O
performed O
at O
the O
secondary O
care O
center O
of O
a O
1,100-bed O
private O
university O
hospital O
. O

in O
addition O
to O
fluids O
, O
the O
treatment O
group O
received O
furosemide O
( O
mean O
dose O
110 O
mg O
) O
intravenously O
30 O
min O
prior O
to O
the O
injection O
of O
contrast O
material O
. O

the O
control O
group O
received O
fluids O
( O
mean O
3 O
liters) O
. O

radiological O
studies O
were O
mostly O
angiographies O
performed O
with O
both O
ionic O
and O
non-ionic O
contrast O
material O
, O
at O
an O
average O
dose O
of O
245 O
ml O
. O
renal B-NEG
function I-NEG
significantly I-NEG
deteriorated I-NEG
in O
the O
group O
pretreated O
with O
furosemide O
(p O
< O
0.005 O
by O
anova) O
, O
with O
a O
rise O
in O
serum O
creatinine O
from O
145 O
+/- O
13 O
to O
182 O
+/- O
16 O
mumol/l O
at O
24 O
h, O
while O
no O
change O
occurred O
in O
the O
control O
group O
( O
from O
141 O
+/- O
6 O
to O
142 O
+/- O
7 O
mumol/l) O
. O
renal B-NEG
failure I-NEG
was O
associated O
with O
weight B-NEG
loss I-NEG
in O
the O
furosemide-treated O
group O
. O

furosemide O
may O
be O
deleterious O
in O
the O
prevention O
of O
radiocontrast O
nephropathy B-NEG
. O

-DOCSTART- O

the O
renal O
pathology O
in O
a O
case O
of O
lithium-induced O
diabetes B-NEG
insipidus I-NEG
. O

a O
case O
of O
lithium-induced O
diabetes B-NEG
insipidus I-NEG
is O
reported O
. O

at O
necropsy O
microscopy O
shoed O
unique O
and O
extensive O
damage O
to O
cells O
lining O
the O
distal O
nephron O
. O

it O
is O
suggested O
that O
these O
changes O
represent O
a O
specific O
toxic O
effect O
of O
lithium O
, O
reported O
here O
for O
the O
first O
time O
in O
man O
. O

-DOCSTART- O

etiologic O
factors O
in O
the O
pathogenesis O
of O
liver B-NEG
tumors I-NEG
associated O
with O
oral O
contraceptives O
. O

within O
the O
last O
several O
years O
, O
previously O
rare O
liver B-NEG
tumors I-NEG
have O
been O
seen O
in O
young O
women O
using O
oral O
contraceptive O
steroids O
. O

the O
registry O
for O
liver B-NEG
tumors I-NEG
associated O
with O
oral O
contraceptives O
at O
the O
university O
of O
california O
, O
irvine O
, O
has O
clearly O
identified O
27 O
cases O
. O

the O
recent O
literature O
contains O
44 O
case O
reports O
. O

common O
to O
these O
71 O
cases O
has O
been O
a O
histopathologic O
diagnosis O
of O
focal B-NEG
nodular I-NEG
hyperplasia I-NEG
, O
adenoma B-NEG
, O
hamartoma B-NEG
, O
and O
hepatoma B-NEG
. O

significant O
statistical O
etiologic O
factors O
include O
prolonged O
uninterrupted O
usage O
of O
oral O
contraceptive O
steroids O
. O

eight O
deaths O
and O
liver O
rupture B-NEG
in O
18 O
patients O
attest O
to O
the O
seriousness O
of O
this O
new O
potentially O
lethal O
adverse O
phenomenon O
. O

-DOCSTART- O

graft-versus-host B-NEG
disease I-NEG
prophylaxis O
with O
everolimus O
and O
tacrolimus O
is O
associated O
with O
a O
high O
incidence O
of O
sinusoidal B-NEG
obstruction I-NEG
syndrome I-NEG
and O
microangiopathy B-NEG
: O
results O
of O
the O
evtac O
trial O
. O

a O
calcineurin O
inhibitor O
combined O
with O
methotrexate O
is O
the O
standard O
prophylaxis O
for O
graft-versus-host B-NEG
disease I-NEG
( O
gvhd B-NEG
) O
after O
allogeneic O
hematopoietic O
stem O
cell O
transplantation O
(hsct) O
. O

everolimus O
, O
a O
derivative O
of O
sirolimus O
, O
seems O
to O
mediate O
antileukemia O
effects O
. O

we O
report O
on O
a O
combination O
of O
everolimus O
and O
tacrolimus O
in O
24 O
patients O
( O
median O
age O
, O
62 O
years O
) O
with O
either O
myelodysplastic B-NEG
syndrome I-NEG
( O
mds B-NEG
; O
n O
= O
17 O
) O
or O
acute B-NEG
myeloid I-NEG
leukemia I-NEG
( O
aml B-NEG
; O
n O
= O
7) O
undergoing O
intensive O
conditioning O
followed O
by O
hsct O
from O
related O
(n O
= O
4) O
or O
unrelated O
(n O
= O
20 O
) O
donors O
. O

all O
patients O
engrafted O
, O
and O
only O
1 O
patient O
experienced O
grade O
iv O
mucositis B-NEG
. O

nine O
patients O
( O
37% O
) O
developed O
acute O
grade O
ii-iv O
gvhd B-NEG
, O
and O
11 O
of O
17 O
evaluable O
patients O
( O
64% O
) O
developed O
chronic O
extensive O
gvhd B-NEG
. O
transplantation-associated B-NEG
microangiopathy I-NEG
( O
tma B-NEG
) O
occurred O
in O
7 O
patients O
(29%) O
, O
with O
2 O
cases O
of O
acute B-NEG
renal I-NEG
failure I-NEG
. O

the O
study O
was O
terminated O
prematurely O
because O
an O
additional O
6 O
patients O
( O
25% O
) O
developed O
sinusoidal B-NEG
obstruction I-NEG
syndrome I-NEG
( O
sos B-NEG
), O
which O
was O
fatal O
in O
2 O
cases O
. O

with O
a O
median O
follow-up O
of O
26 O
months O
, O
the O
2-year O
overall O
survival O
rate O
was O
47% O
. O

although O
this O
new O
combination O
appears O
to O
be O
effective O
as O
a O
prophylactic O
regimen O
for O
acute O
gvhd B-NEG
, O
the O
incidence O
of O
tma B-NEG
and O
sos B-NEG
is O
considerably O
higher O
than O
seen O
with O
other O
regimens O
. O

-DOCSTART- O

effect O
of O
some O
convulsants O
on O
the O
protective O
activity O
of O
loreclezole O
and O
its O
combinations O
with O
valproate O
or O
clonazepam O
in O
amygdala-kindled O
rats O
. O

loreclezole O
(5 O
mg/kg O
) O
exerted O
a O
significant O
protective O
action O
in O
amygdala-kindled O
rats O
, O
reducing O
both O
seizure B-NEG
and O
afterdischarge O
durations O
. O

the O
combinations O
of O
loreclezole O
( O
2.5 O
mg/kg O
) O
with O
valproate O
, O
clonazepam O
, O
or O
carbamazepine O
( O
applied O
at O
their O
subprotective O
doses O
) O
also O
exhibited O
antiseizure O
effect O
in O
this O
test O
. O

however O
, O
only O
two O
first O
combinations O
occurred O
to O
be O
of O
pharmacodynamic O
nature O
. O

among O
several O
chemoconvulsants O
, O
bicuculline O
, O
n-methyl-d-aspartic O
acid O
and O
bay O
k-8644 O
( O
the O
opener O
of O
l-type O
calcium O
channels O
) O
reversed O
the O
protective O
activity O
of O
loreclezole O
alone O
and O
its O
combination O
with O
valproate O
. O

on O
the O
other O
hand O
, O
bicuculline O
, O
aminophylline O
and O
bay O
k-8644 O
inhibited O
the O
anticonvulsive O
action O
of O
loreclezole O
combined O
with O
clonazepam O
. O

the O
results O
support O
the O
hypothesis O
that O
the O
protective O
activity O
of O
loreclezole O
and O
its O
combinations O
with O
other O
antiepileptics O
may O
involve O
potentiation O
of O
gabaergic O
neurotransmission O
and O
blockade O
of O
l-type O
of O
calcium O
channels O
. O

-DOCSTART- O

acute B-NEG
liver I-NEG
failure I-NEG
with O
concurrent O
bupropion O
and O
carbimazole O
therapy O
. O

objective O
: O
to O
report O
a O
case O
of O
fatal O
liver B-NEG
failure I-NEG
possibly O
associated O
with O
concurrent O
use O
of O
bupropion O
and O
carbimazole O
. O

case O
summary O
: O
a O
41-year-old O
chinese O
man O
with O
a O
history O
of O
hyperthyroidism B-NEG
had O
been O
treated O
with O
carbimazole O
and O
propranolol O
for O
the O
past O
5 O
years O
. O

he O
received O
a O
10-day O
course O
of O
bupropion O
as O
an O
aid O
for O
smoking O
cessation O
10 O
weeks O
prior O
to O
presentation O
. O

he O
developed O
acute B-NEG
liver I-NEG
failure I-NEG
with O
rapid O
deterioration O
of O
renal O
function O
. O

liver O
biopsy O
showed O
evidence O
of O
nonspecific O
drug-induced B-NEG
acute I-NEG
liver I-NEG
injury I-NEG
. O

his O
condition O
was O
further O
complicated O
by O
sepsis B-NEG
and O
coagulopathy B-NEG
. O

death O
resulted O
19 O
days O
after O
the O
onset O
of O
symptoms O
. O

the O
likelihood O
that O
bupropion O
induced O
hepatotoxicity B-NEG
in O
our O
patient O
was O
possible O
, O
based O
on O
the O
naranjo O
probability O
scale O
. O

discussion O
: O
although O
there O
is O
increasing O
evidence O
of O
hepatotoxicity B-NEG
induced O
by O
bupropion O
, O
this O
is O
the O
first O
case O
of O
fatality O
that O
could O
have O
resulted O
from O
acute B-NEG
liver I-NEG
failure I-NEG
in O
a O
patient O
receiving O
bupropion O
while O
on O
concomitant O
treatment O
with O
carbimazole O
. O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
the O
possibility O
of O
acute B-NEG
liver I-NEG
insult I-NEG
induced O
by O
bupropion O
given O
concurrently O
with O
other O
hepatotoxic B-NEG
drugs O
. O

-DOCSTART- O

long O
term O
hormone O
therapy O
for O
perimenopausal O
and O
postmenopausal O
women O
. O

background O
: O
hormone O
therapy O
( O
ht O
) O
is O
widely O
used O
for O
controlling O
menopausal O
symptoms O
and O
has O
also O
been O
used O
for O
the O
management O
and O
prevention O
of O
cardiovascular B-NEG
disease I-NEG
, O
osteoporosis B-NEG
and O
dementia B-NEG
in O
older O
women O
. O

this O
is O
an O
updated O
version O
of O
the O
original O
cochrane O
review O
first O
published O
in O
2005 O
. O

objectives O
: O
to O
assess O
the O
effect O
of O
long-term O
ht O
on O
mortality O
, O
cardiovascular O
outcomes O
, O
cancer B-NEG
, O
gallbladder B-NEG
disease I-NEG
, O
cognition O
, O
fractures B-NEG
and O
quality O
of O
life O
. O

search O
strategy O
: O
we O
searched O
the O
following O
databases O
to O
november O
2007 O
: O
trials O
register O
of O
the O
cochrane O
menstrual B-NEG
disorders I-NEG
and O
subfertility O
group O
, O
cochrane O
central O
register O
of O
controlled O
trials O
, O
medline O
, O
embase O
, O
biological O
abstracts O
. O

also O
relevant O
non-indexed O
journals O
and O
conference O
abstracts O
. O

selection O
criteria O
: O
randomised O
double-blind O
trials O
of O
ht O
versus O
placebo O
, O
taken O
for O
at O
least O
one O
year O
by O
perimenopausal O
or O
postmenopausal O
women O
. O

ht O
included O
oestrogens O
, O
with O
or O
without O
progestogens O
, O
via O
oral O
, O
transdermal O
, O
subcutaneous O
or O
transnasal O
routes O
. O

data O
collection O
and O
analysis O
: O
two O
authors O
independently O
assessed O
trial O
quality O
and O
extracted O
data O
. O

main O
results O
: O
nineteen O
trials O
involving O
41,904 O
women O
were O
included O
. O

in O
relatively O
healthy O
women O
, O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-NEG
thrombo-embolism I-NEG
or O
coronary O
event O
( O
after O
one O
year's O
use) O
, O
stroke B-NEG
( O
after O
three O
years) O
, O
breast B-NEG
cancer I-NEG
and O
gallbladder B-NEG
disease I-NEG
. O

long-term O
oestrogen-only O
ht O
significantly O
increased O
the O
risk O
of O
venous B-NEG
thrombo-embolism I-NEG
, O
stroke B-NEG
and O
gallbladder B-NEG
disease I-NEG
( O
after O
one O
to O
two O
years O
, O
three O
years O
and O
seven O
years' O
use O
respectively) O
, O
but O
did O
not O
significantly O
increase O
the O
risk O
of O
breast B-NEG
cancer I-NEG
. O

the O
only O
statistically O
significant O
benefits O
of O
ht O
were O
a O
decreased O
incidence O
of O
fractures B-NEG
and O
( O
for O
combined O
ht O
) O
colon B-NEG
cancer I-NEG
, O
with O
long-term O
use O
. O

among O
women O
aged O
over O
65 O
who O
were O
relatively O
healthy O
(i.e O
. O
generally O
fit O
, O
without O
overt O
disease O
) O
and O
taking O
continuous O
combined O
ht O
, O
there O
was O
a O
statistically O
significant O
increase O
in O
the O
incidence O
of O
dementia B-NEG
. O

among O
women O
with O
cardiovascular B-NEG
disease I-NEG
, O
long-term O
use O
of O
combined O
continuous O
ht O
significantly O
increased O
the O
risk O
of O
venous B-NEG
thrombo-embolism I-NEG
.one O
trial O
analysed O
subgroups O
of O
2839 O
relatively O
healthy O
50 O
to O
59 O
year O
old O
women O
taking O
combined O
continuous O
ht O
and O
1637 O
taking O
oestrogen-only O
ht O
, O
versus O
similar-sized O
placebo O
groups O
. O

the O
only O
significantly O
increased O
risk O
reported O
was O
for O
venous B-NEG
thrombo-embolism I-NEG
in O
women O
taking O
combined O
continuous O
ht O
: O
their O
absolute O
risk O
remained O
low O
, O
at O
less O
than O
1/500 O
. O

however O
, O
this O
study O
was O
not O
powered O
to O
detect O
differences O
between O
groups O
of O
younger O
women O
. O

authors' O
conclusions O
: O
ht O
is O
not O
indicated O
for O
the O
routine O
management O
of O
chronic O
disease O
. O

we O
need O
more O
evidence O
on O
the O
safety O
of O
ht O
for O
menopausal O
symptom O
control O
, O
though O
short-term O
use O
appears O
to O
be O
relatively O
safe O
for O
healthy O
younger O
women O
. O

-DOCSTART- O

passage O
of O
mannitol O
into O
the O
brain O
around O
gliomas B-NEG
: O
a O
potential O
cause O
of O
rebound O
phenomenon O
. O

a O
study O
on O
21 O
patients O
. O

aim O
: O
widespread O
use O
of O
mannitol O
to O
reduce O
brain B-NEG
edema I-NEG
and O
lower O
elevated B-NEG
icp I-NEG
in O
brain B-NEG
tumor I-NEG
patients O
continues O
to O
be O
afflicted O
by O
the O
so-called O
rebound O
phenomenon O
. O

leakage O
of O
mannitol O
into O
the O
brain O
parenchyma O
through O
an O
altered O
bbb O
and O
secondary O
reversal O
of O
osmotic O
gradient O
is O
considered O
the O
major O
cause O
of O
rebound O
. O

this O
has O
only O
been O
demonstrated O
experimentally O
in O
animals O
. O

as O
a O
contribution O
to O
this O
issue O
we O
decided O
to O
research O
the O
possible O
passage O
of O
mannitol O
into O
the O
brain O
after O
administration O
to O
21 O
brain B-NEG
tumor I-NEG
patients O
. O

methods O
: O
mannitol O
( O
18% O
solution O
; O
1 O
g/kg O
) O
was O
administered O
as O
a O
bolus O
to O
patients O
( O
ten O
had O
malignant B-NEG
glioma I-NEG
, O
seven O
brain O
metastases B-NEG
and O
four O
meningioma B-NEG
) O
about O
30 O
minutes O
before O
craniotomy O
. O

during O
resection O
, O
a O
sample O
of O
the O
surrounding O
edematous B-NEG
white O
matter O
was O
taken O
at O
the O
same O
time O
as O
a O
10 O
ml O
venous O
blood O
sample O
. O

mannitol O
concentrations O
were O
measured O
in O
plasma O
and O
white O
matter O
by O
a O
modified O
version O
of O
the O
enzyme O
assay O
of O
blonquist O
et O
al O
. O
results O
: O
in O
most O
glioma B-NEG
patients O
, O
mannitol O
concentrations O
in O
white O
matter O
were O
2 O
to O
6 O
times O
higher O
than O
in O
plasma O
( O
mean O
3.5 O
times) O
. O

in O
meningioma B-NEG
and O
metastases B-NEG
patients O
plasma O
concentrations O
of O
mannitol O
were O
higher O
than O
white O
matter O
concentrations O
except O
in O
three O
cases O
with O
infiltration O
by O
neoplastic O
cells O
. O

conclusions O
: O
the O
results O
of O
our O
study O
show O
that O
even O
after O
a O
single O
bolus O
, O
mannitol O
may O
leak O
through O
the O
altered O
bbb O
near O
gliomas B-NEG
, O
reversing O
the O
initial O
plasma-to-blood O
osmotic O
gradient O
, O
aggravating O
peritumoral O
edema B-NEG
and O
promoting O
rebound O
of O
icp O
. O

-DOCSTART- O

can O
lidocaine O
reduce O
succinylcholine O
induced O
postoperative B-NEG
myalgia I-NEG
? O

this O
study O
was O
undertaken O
to O
determine O
the O
effect O
of O
lidocaine O
pretreatment O
on O
reduction O
of O
succinylcholine-induced O
myalgia B-NEG
in O
patients O
undergoing O
general O
anesthesia O
for O
gynecological O
surgery O
. O

one O
hundred O
and O
thirty-five O
patients O
were O
assigned O
to O
one O
of O
three O
groups O
in O
a O
prospective O
, O
double O
blind O
, O
randomized O
manner O
. O

group O
ps O
, O
the O
control O
group O
, O
received O
normal O
saline O
and O
succinylcholine O
1.5 O
mg O
x O
kg(-1) O
; O
group O
ls O
, O
lidocaine O
1.5 O
mg O
x O
kg(-1 O
) O
and O
succinylcholine O
1.5 O
mg O
x O
kg(-1) O
; O
group O
pr O
, O
normal O
saline O
and O
rocuronium O
0.6 O
mg O
x O
kg(-1) O
. O

morphine O
0.1 O
mg O
x O
kg(-1 O
) O
iv O
was O
given O
for O
premedication O
and O
all O
patients O
were O
monitored O
with O
a O
noninvasive O
blood O
pressure O
monitor O
, O
ecg O
and O
pulse O
oximetry O
. O

anesthesia O
was O
induced O
with O
5 O
mg.kg(-1 O
) O
thiopental O
iv O
. O
followed O
by O
succinylcholine O
( O
group O
ps O
, O
ls O
) O
or O
rocuronium O
( O
group O
pr O
) O
for O
tracheal O
intubation O
. O

following O
administration O
of O
these O
agents O
, O
the O
presence O
, O
and O
degree O
of O
fasciculation B-NEG
were O
assessed O
visually O
on O
a O
four O
point O
scale O
by O
one O
investigator O
who O
was O
blinded O
to O
the O
drug O
administered O
. O

the O
blood O
pressure O
and O
heart O
rate O
of O
each O
patient O
were O
monitored O
on O
nine O
occasions O
. O

twenty-four O
hours O
later O
, O
any O
myalgia B-NEG
experienced O
was O
assessed O
according O
to O
a O
structured O
questionaire O
and O
graded O
by O
a O
four O
point O
scale O
by O
one O
investigator O
blinded O
to O
the O
intraoperative O
management O
. O

the O
results O
indicate O
that O
muscle B-NEG
fasciculation I-NEG
was O
not O
found O
in O
group O
pr O
while O
the O
patients O
in O
group O
ls O
had O
a O
lower O
incidence O
of O
muscle B-NEG
fasciculation I-NEG
than O
those O
in O
group O
ps O
(p O
< O
0.001) O
. O

at O
24 O
h, O
the O
incidence O
of O
myalgia B-NEG
was O
higher O
in O
group O
ps O
than O
in O
group O
ls O
and O
pr O
(p O
< O
0.05) O
. O

a O
correlation O
was O
not O
found O
between O
the O
incidence O
of O
myalgia B-NEG
and O
the O
occurrence O
of O
muscle B-NEG
fasciculation I-NEG
. O

the O
changes O
in O
systolic O
and O
diastolic O
blood O
pressure O
and O
heart O
rate O
were O
not O
significant O
among O
the O
three O
groups O
. O

in O
conclusion O
, O
where O
succinylcholine O
is O
used O
, O
lidocaine O
is O
proven O
to O
be O
the O
useful O
pretreatment O
agent O
for O
the O
reduction O
of O
postoperative B-NEG
myalgia I-NEG
. O

-DOCSTART- O

open-label O
assessment O
of O
levofloxacin O
for O
the O
treatment O
of O
acute O
bacterial O
sinusitis B-NEG
in O
adults O
. O

purpose O
: O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
levofloxacin O
( O
500 O
mg O
orally O
once O
daily O
for O
10 O
to O
14 O
days O
) O
in O
treating O
adult O
outpatients O
with O
acute O
bacterial O
sinusitis B-NEG
. O

patients O
and O
methods O
: O
a O
total O
of O
329 O
patients O
enrolled O
in O
the O
study O
at O
24 O
centers O
. O

all O
patients O
had O
a O
pre-therapy O
gram's O
stain O
and O
culture O
of O
sinus O
exudate O
obtained O
by O
antral O
puncture O
or O
nasal O
endoscopy O
. O

clinical O
response O
was O
assessed O
on O
the O
basis O
of O
signs O
and O
symptoms O
and O
sinus O
radiograph O
or O
computed O
tomography O
results O
. O

microbiologic O
cure O
rates O
were O
determined O
on O
the O
basis O
of O
presumed O
plus O
documented O
eradication O
of O
the O
pre-therapy O
pathogen(s) O
. O

results O
: O
the O
most O
common O
pathogens O
were O
haemophilus O
influenzae O
, O
streptococcus O
pneumoniae O
, O
staphylococcus O
aureus O
, O
and O
moraxella O
catarrhalis O
. O

of O
300 O
clinically O
evaluable O
patients O
, O
175 O
( O
58% O
) O
were O
cured O
and O
90 O
( O
30% O
) O
were O
improved O
at O
the O
post-therapy O
evaluation O
, O
resulting O
in O
a O
clinical O
success O
rate O
of O
88% O
. O

thirty-five O
patients O
( O
12% O
) O
clinically O
failed O
treatment O
. O

the O
microbiologic O
eradication O
rate O
( O
presumed O
plus O
documented O
) O
among O
138 O
microbiologically O
evaluable O
patients O
was O
92% O
. O

microbiologic O
eradication O
rates O
( O
presumed O
plus O
documented O
) O
of O
the O
most O
common O
pathogens O
ranged O
from O
93% O
(m O
. O
catarrhalis O
) O
to O
100% O
(s O
. O
pneumoniae O
) O
at O
the O
post-therapy O
visit O
. O

all O
but O
one O
of O
the O
265 O
patients O
who O
were O
cured O
or O
improved O
at O
post-therapy O
returned O
for O
a O
long-term O
follow-up O
visit O
; O
243 O
( O
92% O
) O
remained O
well O
4 O
to O
6 O
weeks O
after O
therapy O
; O
and O
21 O
( O
8% O
) O
had O
a O
relapse O
of O
symptoms O
. O

adverse O
events O
considered O
to O
be O
related O
to O
levofloxacin O
administration O
were O
reported O
by O
29 O
patients O
(9%) O
. O

the O
most O
common O
drug-related O
adverse O
events O
were O
diarrhea B-NEG
, O
flatulence B-NEG
, O
and O
nausea B-NEG
; O
most O
adverse O
events O
were O
mild O
to O
moderate O
in O
severity O
. O

conclusion O
: O
the O
results O
of O
this O
study O
indicate O
that O
levofloxacin O
500 O
mg O
once O
daily O
is O
an O
effective O
and O
safe O
treatment O
for O
acute O
bacterial O
sinusitis B-NEG
. O

-DOCSTART- O

clinical O
evaluation O
on O
combined O
administration O
of O
oral O
prostacyclin O
analogue O
beraprost O
and O
phosphodiesterase O
inhibitor O
cilostazol O
. O

among O
various O
oral O
antiplatelets O
, O
a O
combination O
of O
a O
novel O
prostacyclin O
analogue O
beraprost O
( O
bpt O
) O
and O
a O
potent O
phosphodiesterase O
inhibitor O
cilostazol O
( O
clz O
) O
may O
result O
in O
untoward O
clinical O
effects O
due O
to O
possible O
synergistic O
elevation O
of O
intracellular O
camp O
( O
cyclic O
adenosine O
3',5'-monophosphate) O
. O

thereby O
, O
a O
clinical O
study O
of O
the O
combined O
administration O
of O
the O
two O
agents O
was O
attempted O
. O

twelve O
healthy O
volunteers O
were O
assigned O
to O
take O
bpt/clz O
in O
the O
following O
schedule O
; O
bpt O
: O
40 O
micrograms O
at O
day O
1 O
and O
120 O
micrograms O
t.i.d O
. O
from O
day O
7 O
to O
14 O
, O
clz O
: O
200 O
mg O
t.i.d O
. O
from O
day O
3 O
to O
14 O
. O

at O
various O
time O
intervals O
, O
physical O
examination O
and O
blood O
collection O
for O
ex O
vivo O
platelet B-NEG
aggregation I-NEG
and O
determination O
of O
intraplatelet O
camp O
were O
performed O
. O

throughout O
the O
observation O
period O
, O
no O
significant O
alteration O
in O
vital O
signs O
was O
observed O
. O

seven O
out O
of O
12 O
subjects O
experienced O
headache B-NEG
of O
a O
short O
duration O
accompanying O
facial B-NEG
flush I-NEG
in O
one O
and O
nausea B-NEG
in O
one O
, O
especially O
after O
ingestion O
of O
clz O
. O

all O
of O
these O
symptoms O
, O
probably O
caused O
by O
the O
vasodilating O
effect O
of O
the O
two O
agents O
, O
were O
of O
mild O
degree O
and O
no O
special O
treatment O
was O
required O
. O

intraplatelet O
camp O
content O
was O
gradually O
but O
significantly O
increased O
to O
9.84 O
+/- O
4.59 O
pmol O
per O
10(9 O
) O
platelets O
at O
day O
14 O
in O
comparison O
with O
the O
initial O
value O
( O
6.87 O
+/- O
2.25 O
pmol) O
. O

the O
platelet O
aggregability O
was O
significantly O
suppressed O
at O
various O
time O
intervals O
but O
no O
additive O
or O
synergistic O
inhibitory O
effect O
by O
the O
combined O
administration O
was O
noted O
. O

in O
conclusion O
, O
the O
combined O
administration O
of O
bpt/clz O
is O
safe O
at O
doses O
used O
in O
the O
study O
, O
though O
the O
beneficial O
clinical O
effect O
of O
the O
combined O
administration O
has O
yet O
to O
be O
elucidated O
. O

-DOCSTART- O

gastrointestinal O
tolerability O
of O
etoricoxib O
in O
rheumatoid B-NEG
arthritis I-NEG
patients O
: O
results O
of O
the O
etoricoxib O
vs O
diclofenac O
sodium O
gastrointestinal O
tolerability O
and O
effectiveness O
trial O
(edge-ii) O
. O

objective O
: O
a O
randomised O
, O
double-blind O
study O
to O
compare O
the O
gastrointestinal O
( O
gi O
) O
tolerability O
, O
safety O
and O
efficacy O
of O
etoricoxib O
and O
diclofenac O
in O
patients O
with O
rheumatoid B-NEG
arthritis I-NEG
( O
ra B-NEG
). O

patients O
and O
methods O
: O
a O
total O
of O
4086 O
patients O
( O
mean O
age O
60.8 O
years O
) O
diagnosed O
with O
ra B-NEG
were O
enrolled O
and O
received O
etoricoxib O
90 O
mg O
daily O
(n O
= O
2032 O
) O
or O
diclofenac O
75 O
mg O
twice O
daily O
(n O
= O
2054) O
. O

use O
of O
gastroprotective O
agents O
and O
low-dose O
aspirin O
was O
allowed O
. O

the O
prespecified O
primary O
end O
point O
consisted O
of O
the O
cumulative O
rate O
of O
patient O
discontinuations O
due O
to O
clinical O
and O
laboratory O
gi O
adverse O
experiences O
(aes) O
. O

general O
safety O
was O
also O
assessed O
, O
including O
adjudicated O
thrombotic B-NEG
cardiovascular I-NEG
event O
data O
. O

efficacy O
was O
evaluated O
using O
the O
patient O
global O
assessment O
of O
disease O
status O
(pgads O
; O
0-4 O
point O
scale) O
. O

results O
: O
mean O
(sd O
; O
maximum O
) O
duration O
of O
treatment O
was O
19.3 O
(10.3 O
; O
32.9 O
) O
and O
19.1 O
(10.4 O
; O
33.1 O
) O
months O
in O
the O
etoricoxib O
and O
diclofenac O
groups O
, O
respectively O
. O

the O
cumulative O
discontinuation O
rate O
due O
to O
gi B-NEG
aes I-NEG
was O
significantly O
lower O
with O
etoricoxib O
than O
diclofenac O
( O
5.2 O
vs O
8.5 O
events O
per O
100 O
patient-years O
, O
respectively O
; O
hazard O
ratio O
0.62 O
( O
95% O
ci O
: O
0.47 O
, O
0.81 O
; O
p<or=0.001)) O
. O

the O
incidence O
of O
discontinuations O
for O
hypertension B-NEG
-related O
and O
oedema B-NEG
-related O
aes O
were O
significantly O
higher O
with O
etoricoxib O
( O
2.5% O
and O
1.1% O
respectively O
) O
compared O
with O
diclofenac O
( O
1.5% O
and O
0.4% O
respectively O
; O
p<0.001 O
for O
hypertension B-NEG
and O
p<0.01 O
for O
oedema B-NEG
). O

etoricoxib O
and O
diclofenac O
treatment O
resulted O
in O
similar O
efficacy O
( O
pgads O
mean O
changes O
from O
baseline O
-0.62 O
vs O
-0.58 O
, O
respectively) O
. O

conclusions O
: O
etoricoxib O
90 O
mg O
demonstrated O
a O
significantly O
lower O
risk O
for O
discontinuing O
treatment O
due O
to O
gi B-NEG
aes I-NEG
compared O
with O
diclofenac O
150 O
mg O
. O

discontinuations O
from O
renovascular O
aes O
, O
although O
less O
common O
than O
discontinuations O
from O
gi B-NEG
aes I-NEG
, O
were O
significantly O
higher O
with O
etoricoxib O
. O

-DOCSTART- O

placebo-level O
incidence O
of O
extrapyramidal B-NEG
symptoms I-NEG
( O
eps B-NEG
) O
with O
quetiapine O
in O
controlled O
studies O
of O
patients O
with O
bipolar B-NEG
mania I-NEG
. O

objectives O
: O
to O
evaluate O
extrapyramidal B-NEG
symptoms I-NEG
( O
eps B-NEG
), O
including O
akathisia B-NEG
, O
with O
quetiapine O
in O
patients O
with O
bipolar B-NEG
mania I-NEG
. O

methods O
: O
data O
were O
analyzed O
from O
four O
similarly O
designed O
, O
randomized O
, O
double-blind O
, O
3- O
to O
12-week O
studies O
. O

two O
studies O
evaluated O
quetiapine O
monotherapy O
( O
up O
to O
800 O
mg/day O
) O
(n O
= O
209 O
) O
versus O
placebo O
(n O
= O
198) O
, O
with O
lithium O
or O
haloperidol O
monotherapy O
as O
respective O
active O
controls O
. O

two O
studies O
evaluated O
quetiapine O
( O
up O
to O
800 O
mg/day O
) O
in O
combination O
with O
a O
mood O
stabilizer O
( O
lithium O
or O
divalproex O
, O
qtp O
+ O
li/dvp O
) O
(n O
= O
196 O
) O
compared O
to O
placebo O
and O
mood O
stabilizer O
( O
pbo O
+ O
li/dvp O
) O
(n O
= O
203) O
. O
extrapyramidal B-NEG
symptoms I-NEG
were O
evaluated O
using O
the O
simpson-angus O
scale O
(sas) O
, O
the O
barnes O
akathisia O
rating O
scale O
(bars) O
, O
adverse O
event O
reports O
and O
anticholinergic O
drug O
usage O
. O

results O
: O
the O
incidence O
of O
eps B-NEG
-related O
adverse O
events O
, O
including O
akathisia B-NEG
, O
was O
no O
different O
with O
quetiapine O
monotherapy O
( O
12.9% O
) O
than O
with O
placebo O
(13.1%) O
. O

similarly O
, O
eps B-NEG
-related O
adverse O
events O
with O
qtp O
+ O
li/dvp O
( O
21.4% O
) O
were O
no O
different O
than O
with O
pbo O
+ O
li/dvp O
(19.2%) O
. O

adverse O
events O
related O
to O
eps B-NEG
occurred O
in O
59.6% O
of O
patients O
treated O
with O
haloperidol O
(n O
= O
99 O
) O
monotherapy O
, O
whereas O
26.5% O
of O
patients O
treated O
with O
lithium O
(n O
= O
98 O
) O
monotherapy O
experienced O
adverse O
events O
related O
to O
eps B-NEG
. O

the O
incidence O
of O
akathisia B-NEG
was O
low O
and O
similar O
with O
quetiapine O
monotherapy O
( O
3.3% O
) O
and O
placebo O
(6.1%) O
, O
and O
with O
qtp O
+ O
li/dvp O
( O
3.6% O
) O
and O
pbo O
+ O
li/dvp O
(4.9%) O
. O

lithium O
was O
associated O
with O
a O
significantly O
higher O
incidence O
(p O
< O
0.05 O
) O
of O
tremor B-NEG
( O
18.4% O
) O
than O
quetiapine O
(5.6%) O
; O
cerebellar O
tremor B-NEG
, O
which O
is O
a O
known O
adverse O
effect O
of O
lithium O
, O
may O
have O
contributed O
to O
the O
elevated O
rate O
of O
tremor B-NEG
in O
patients O
receiving O
lithium O
therapy O
. O

haloperidol O
induced O
a O
significantly O
higher O
incidence O
(p O
< O
0.001 O
) O
of O
akathisia B-NEG
( O
33.3% O
versus O
5.9%) O
, O
tremor B-NEG
( O
30.3% O
versus O
7.8%) O
, O
and O
extrapyramidal B-NEG
syndrome I-NEG
( O
35.4% O
versus O
5.9% O
) O
than O
quetiapine O
. O

no O
significant O
differences O
were O
observed O
between O
quetiapine O
and O
placebo O
on O
sas O
and O
bars O
scores O
. O

anticholinergic O
use O
was O
low O
and O
similar O
with O
quetiapine O
or O
placebo O
. O

conclusions O
: O
in O
bipolar B-NEG
mania I-NEG
, O
the O
incidence O
of O
eps B-NEG
, O
including O
akathisia B-NEG
, O
with O
quetiapine O
therapy O
is O
similar O
to O
that O
with O
placebo O
. O

-DOCSTART- O

contribution O
of O
the O
sympathetic O
nervous O
system O
to O
salt-sensitivity O
in O
lifetime O
captopril-treated O
spontaneously O
hypertensive B-NEG
rats O
. O

objective O
: O
to O
test O
the O
hypothesis O
that O
, O
in O
lifetime O
captopril-treated O
spontaneously O
hypertensive B-NEG
rats O
(shr) O
, O
the O
sympathetic O
nervous O
system O
contributes O
importantly O
to O
the O
hypertensive B-NEG
effect O
of O
dietary O
sodium O
chloride O
supplementation O
. O

methods O
: O
male O
shr O
( O
aged O
6 O
weeks O
) O
that O
had O
been O
treated O
from O
conception O
onward O
with O
either O
captopril O
or O
vehicle O
remained O
on O
a O
basal O
sodium O
chloride O
diet O
or O
were O
fed O
a O
high O
sodium O
chloride O
diet O
. O

after O
2 O
weeks O
, O
the O
rats O
were O
subjected O
to O
ganglionic O
blockade O
and O
2 O
days O
later O
, O
an O
infusion O
of O
clonidine O
. O

results O
: O
lifetime O
captopril O
treatment O
significantly O
lowered O
mean O
arterial O
pressure O
in O
both O
groups O
. O

intravenous O
infusion O
of O
the O
ganglionic O
blocker O
hexamethonium O
resulted O
in O
a O
rapid O
decline O
in O
map O
that O
eliminated O
the O
dietary O
sodium O
chloride-induced O
increase B-NEG
in I-NEG
map I-NEG
in O
both O
groups O
. O

infusion O
of O
the O
central O
nervous O
system O
alpha2-adrenergic O
receptor O
agonist O
clonidine O
also O
resulted O
in O
a O
greater O
reduction O
in O
map O
in O
both O
groups O
of O
shr O
that O
were O
fed O
the O
high O
( O
compared O
with O
the O
basal O
) O
sodium O
chloride O
diet O
. O

conclusions O
: O
in O
both O
lifetime O
captopril-treated O
and O
control O
shr O
, O
the O
sympathetic O
nervous O
system O
contributes O
to O
the O
pressor O
effects O
of O
a O
high O
sodium O
chloride O
diet O
. O

-DOCSTART- O

dose-related O
beneficial O
and O
adverse O
effects O
of O
dietary O
corticosterone O
on O
organophosphorus-induced O
delayed O
neuropathy B-NEG
in O
chickens O
. O

tri-ortho-tolyl O
phosphate O
(totp) O
, O
360 O
mg/kg O
, O
po O
, O
and O
0,0'-diisopropyl O
phosphorofluoridate O
(dfp) O
, O
1 O
mg/kg O
sc O
, O
were O
administered O
to O
adult O
white O
leghorn O
chickens O
24 O
hr O
after O
they O
were O
placed O
on O
diets O
containing O
0 O
to O
300 O
ppm O
corticosterone O
. O

supplemented O
diets O
were O
continued O
until O
clinical O
signs O
and O
lesions O
of O
delayed O
neuropathy B-NEG
appeared O
. O

although O
low O
concentrations O
( O
less O
than O
or O
equal O
to O
50 O
ppm O
) O
of O
corticosterone O
had O
beneficial O
effects O
on O
totp-induced O
neuropathy B-NEG
, O
greater O
than O
or O
equal O
to O
200 O
ppm O
exacerbated O
clinical O
signs O
in O
chickens O
given O
either O
totp O
or O
dfp O
. O
neurotoxic B-NEG
esterase O
activities O
24 O
hr O
after O
totp O
or O
dfp O
were O
less O
than O
20% O
of O
values O
measured O
in O
chickens O
not O
given O
organophosphorous O
compounds O
. O

chickens O
given O
200 O
ppm O
corticosterone O
without O
totp O
or O
dfp O
had O
significantly O
elevated O
activity O
of O
plasma O
cholinesterase O
and O
significantly O
inhibited O
activity O
of O
liver O
carboxylesterase O
. O
degenerating B-NEG
myelinated I-NEG
fibers I-NEG
were O
also O
evident O
in O
distal O
levels O
of O
the O
peripheral O
nerves O
of O
chickens O
given O
totp O
or O
dfp O
. O

-DOCSTART- O

in O
vivo O
characterization O
of O
a O
dual O
adenosine O
a2a/a1 O
receptor O
antagonist O
in O
animal O
models O
of O
parkinson's B-NEG
disease I-NEG
. O

the O
in O
vivo O
characterization O
of O
a O
dual O
adenosine O
a(2a)/a(1 O
) O
receptor O
antagonist O
in O
several O
animal O
models O
of O
parkinson's B-NEG
disease I-NEG
is O
described O
. O

discovery O
and O
scale-up O
syntheses O
of O
compound O
1 O
are O
described O
in O
detail O
, O
highlighting O
optimization O
steps O
that O
increased O
the O
overall O
yield O
of O
1 O
from O
10.0% O
to O
30.5% O
. O

compound O
1 O
is O
a O
potent O
a(2a)/a(1 O
) O
receptor O
antagonist O
in O
vitro O
( O
a(2a O
) O
k(i O
) O
= O
4.1 O
nm O
; O
a(1 O
) O
k(i O
) O
= O
17.0 O
nm O
) O
that O
has O
excellent O
activity O
, O
after O
oral O
administration O
, O
across O
a O
number O
of O
animal O
models O
of O
parkinson's B-NEG
disease I-NEG
including O
mouse O
and O
rat O
models O
of O
haloperidol-induced O
catalepsy B-NEG
, O
mouse O
model O
of O
reserpine-induced O
akinesia B-NEG
, O
rat O
6-hydroxydopamine O
( O
6-ohda O
) O
lesion O
model O
of O
drug-induced O
rotation O
, O
and O
mptp-treated O
non-human O
primate O
model O
. O

-DOCSTART- O

an O
extremely O
rare O
case O
of O
delusional B-NEG
parasitosis I-NEG
in O
a O
chronic B-NEG
hepatitis I-NEG
c I-NEG
patient O
during O
pegylated O
interferon O
alpha-2b O
and O
ribavirin O
treatment O
. O

during O
treatment O
of O
chronic B-NEG
hepatitis I-NEG
c I-NEG
patients O
with O
interferon O
and O
ribavirin O
, O
a O
lot O
of O
side O
effects O
are O
described O
. O

twenty-three O
percent O
to O
44% O
of O
patients O
develop O
depression B-NEG
. O

a O
minority O
of O
patients O
evolve O
to O
psychosis B-NEG
. O

to O
the O
best O
of O
our O
knowledge O
, O
no O
cases O
of O
psychogenic B-NEG
parasitosis I-NEG
occurring O
during O
interferon O
therapy O
have O
been O
described O
in O
the O
literature O
. O

we O
present O
a O
49-year-old O
woman O
who O
developed O
a O
delusional B-NEG
parasitosis I-NEG
during O
treatment O
with O
pegylated O
interferon O
alpha-2b O
weekly O
and O
ribavirin O
. O

she O
complained O
of O
seeing O
parasites O
and O
the O
larvae O
of O
fleas O
in O
her O
stools O
. O

this O
could O
not O
be O
confirmed O
by O
any O
technical O
examination O
. O

all O
the O
complaints O
disappeared O
after O
stopping O
pegylated O
interferon O
alpha-2b O
and O
reappeared O
after O
restarting O
it O
. O

she O
had O
a O
complete O
sustained O
viral O
response O
. O

-DOCSTART- O

possible O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
related O
to O
concomitant O
treatment O
with O
paroxetine O
and O
alprazolam O
. O

a O
74-year-old O
man O
with O
depressive B-NEG
symptoms I-NEG
was O
admitted O
to O
a O
psychiatric B-NEG
hospital O
due O
to O
insomnia B-NEG
, O
loss B-NEG
of I-NEG
appetite I-NEG
, O
exhaustion O
, O
and O
agitation B-NEG
. O

medical O
treatment O
was O
initiated O
at O
a O
daily O
dose O
of O
20 O
mg O
paroxetine O
and O
1.2 O
mg O
alprazolam O
. O

on O
the O
10th O
day O
of O
paroxetine O
and O
alprazolam O
treatment O
, O
the O
patient O
exhibited O
marked O
psychomotor B-NEG
retardation I-NEG
, O
disorientation O
, O
and O
severe O
muscle B-NEG
rigidity I-NEG
with O
tremors B-NEG
. O

the O
patient O
had O
a O
fever B-NEG
( O
38.2 O
degrees O
c) O
, O
fluctuating O
blood O
pressure O
( O
between O
165/90 O
and O
130/70 O
mg O
mm O
hg) O
, O
and O
severe O
extrapyramidal B-NEG
symptoms I-NEG
. O

laboratory O
tests O
showed O
an O
elevation O
of O
creatine O
phosphokinase O
( O
2218 O
iu/l) O
, O
aspartate O
aminotransferase O
( O
134 O
iu/l) O
, O
alanine O
aminotransferase O
( O
78 O
iu/l) O
, O
and O
bun O
( O
27.9 O
mg/ml O
) O
levels O
. O

the O
patient O
received O
bromocriptine O
and O
diazepam O
to O
treat O
his O
symptoms O
. O

7 O
days O
later O
, O
the O
fever B-NEG
disappeared O
and O
the O
patient's O
serum O
cpk O
levels O
were O
normalized O
( O
175 O
iu/l) O
. O

this O
patient O
presented O
with O
symptoms O
of O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
( O
nms B-NEG
), O
thus O
demonstrating O
that O
nms B-NEG
-like O
symptoms O
can O
occur O
after O
combined O
paroxetine O
and O
alprazolam O
treatment O
. O

the O
adverse O
drug O
reaction O
score O
obtained O
by O
the O
naranjo O
algorithm O
was O
6 O
in O
our O
case O
, O
indicating O
a O
probable O
relationship O
between O
the O
patient's O
nms B-NEG
-like O
adverse O
symptoms O
and O
the O
combined O
treatment O
used O
in O
this O
case O
. O

the O
involvement O
of O
physiologic O
and O
environmental O
aspects O
specific O
to O
this O
patient O
was O
suspected O
. O

several O
risk O
factors O
for O
nms B-NEG
should O
be O
noted O
in O
elderly O
depressive B-NEG
patients O
whose O
symptoms O
often O
include O
dehydration B-NEG
, O
agitation B-NEG
, O
malnutrition B-NEG
, O
and O
exhaustion O
. O

careful O
therapeutic O
intervention O
is O
necessary O
in O
cases O
involving O
elderly O
patients O
who O
suffer O
from O
depression B-NEG
. O

-DOCSTART- O

pilocarpine O
seizures B-NEG
cause O
age-dependent O
impairment B-NEG
in I-NEG
auditory I-NEG
location I-NEG
discrimination I-NEG
. O

children O
who O
have O
status B-NEG
epilepticus I-NEG
have O
continuous O
or O
rapidly O
repeating O
seizures B-NEG
that O
may O
be O
life-threatening O
and O
may O
cause O
life-long O
changes O
in O
brain O
and O
behavior O
. O

the O
extent O
to O
which O
status B-NEG
epilepticus I-NEG
causes O
deficits B-NEG
in I-NEG
auditory I-NEG
discrimination I-NEG
is O
unknown O
. O

a O
naturalistic O
auditory O
location O
discrimination O
method O
was O
used O
to O
evaluate O
this O
question O
using O
an O
animal O
model O
of O
status B-NEG
epilepticus I-NEG
. O

male O
sprague-dawley O
rats O
were O
injected O
with O
saline O
on O
postnatal O
day O
( O
p O
) O
20 O
, O
or O
a O
convulsant O
dose O
of O
pilocarpine O
on O
p20 O
or O
p45 O
. O

pilocarpine O
on O
either O
day O
induced O
status B-NEG
epilepticus I-NEG
; O
status B-NEG
epilepticus I-NEG
at O
p45 O
resulted O
in O
ca3 O
cell O
loss O
and O
spontaneous O
seizures B-NEG
, O
whereas O
p20 O
rats O
had O
no O
cell O
loss O
or O
spontaneous O
seizures B-NEG
. O

mature O
rats O
were O
trained O
with O
sound-source O
location O
and O
sound-silence O
discriminations O
. O

control O
( O
saline O
p20 O
) O
rats O
acquired O
both O
discriminations O
immediately O
. O

in O
status B-NEG
epilepticus I-NEG
( O
p20 O
) O
rats O
, O
acquisition O
of O
the O
sound-source O
location O
discrimination O
was O
moderately O
impaired O
. O
status B-NEG
epilepticus I-NEG
( O
p45 O
) O
rats O
failed O
to O
acquire O
either O
sound-source O
location O
or O
sound-silence O
discriminations O
. O
status B-NEG
epilepticus I-NEG
in O
rat O
causes O
an O
age-dependent O
, O
long-term O
impairment B-NEG
in I-NEG
auditory I-NEG
discrimination I-NEG
. O

this O
impairment O
may O
explain O
one O
cause O
of O
impaired B-NEG
auditory I-NEG
location I-NEG
discrimination I-NEG
in O
humans O
. O

-DOCSTART- O

cardiovascular O
risk O
with O
cyclooxygenase O
inhibitors O
: O
general O
problem O
with O
substance O
specific O
differences? O

randomised O
clinical O
trials O
and O
observational O
studies O
have O
shown O
an O
increased O
risk O
of O
myocardial B-NEG
infarction I-NEG
, O
stroke B-NEG
, O
hypertension B-NEG
and O
heart B-NEG
failure I-NEG
during O
treatment O
with O
cyclooxygenase O
inhibitors O
. O

adverse O
cardiovascular O
effects O
occurred O
mainly O
, O
but O
not O
exclusively O
, O
in O
patients O
with O
concomitant O
risk O
factors O
. O

cyclooxygenase O
inhibitors O
cause O
complex O
changes O
in O
renal O
, O
vascular O
and O
cardiac O
prostanoid O
profiles O
thereby O
increasing O
vascular O
resistance O
and O
fluid O
retention O
. O

the O
incidence O
of O
cardiovascular O
adverse O
events O
tends O
to O
increase O
with O
the O
daily O
dose O
and O
total O
exposure O
time O
. O

a O
comparison O
of O
individual O
selective O
and O
unselective O
cyclooxygenase O
inhibitors O
suggests O
substance-specific O
differences O
, O
which O
may O
depend O
on O
differences O
in O
pharmacokinetic O
parameters O
or O
inhibitory O
potency O
and O
may O
be O
contributed O
by O
prostaglandin-independent O
effects O
. O

diagnostic O
markers O
such O
as O
n-terminal O
pro O
brain O
natriuretic O
peptide O
( O
nt-probnp O
) O
or O
high-sensitive O
c-reactive O
protein O
might O
help O
in O
the O
early O
identification O
of O
patients O
at O
risk O
, O
thus O
avoiding O
the O
occurrence O
of O
serious O
cardiovascular B-NEG
toxicity I-NEG
. O

-DOCSTART- O

predictors O
of O
decreased B-NEG
renal I-NEG
function I-NEG
in O
patients O
with O
heart B-NEG
failure I-NEG
during O
angiotensin-converting O
enzyme O
inhibitor O
therapy O
: O
results O
from O
the O
studies O
of O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
( O
solvd O
) O
background O
: O
although O
angiotensin-converting O
enzyme O
inhibitor O
therapy O
reduces O
mortality O
rates O
in O
patients O
with O
congestive B-NEG
heart I-NEG
failure I-NEG
( O
chf B-NEG
), O
it O
may O
also O
cause O
decreased B-NEG
renal I-NEG
function I-NEG
. O

little O
information O
is O
available O
to O
predict O
which O
patients O
are O
at O
highest O
risk O
for O
this O
complication O
. O

objective O
: O
to O
quantify O
specific O
clinical O
predictors O
of O
reduction B-NEG
in I-NEG
renal I-NEG
function I-NEG
in O
patients O
with O
chf B-NEG
who O
are O
prescribed O
angiotensin-converting O
enzyme O
inhibitor O
therapy O
. O

method O
: O
we O
analyzed O
data O
from O
the O
studies O
of O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
(solvd) O
, O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
of O
enalapril O
for O
the O
treatment O
of O
chf B-NEG
. O

there O
were O
3379 O
patients O
randomly O
assigned O
to O
enalapril O
with O
a O
median O
follow-up O
of O
974 O
days O
and O
3379 O
patients O
randomly O
assigned O
to O
placebo O
with O
a O
mean O
follow-up O
of O
967 O
days O
. O
decreased B-NEG
renal I-NEG
function I-NEG
was O
defined O
as O
a O
rise O
in O
serum O
creatinine O
>/=0.5 O
mg/dl O
( O
44 O
micromol/l O
) O
from O
baseline O
. O

we O
used O
time-to-event O
analysis O
to O
identify O
potential O
predictors O
of O
decrease O
in O
renal O
function O
including O
age O
, O
baseline O
ejection O
fraction O
, O
baseline O
creatinine O
, O
low O
systolic O
blood O
pressure O
( O
<100 O
mm O
hg) O
, O
history O
of O
hypertension B-NEG
, O
diabetes B-NEG
, O
and O
use O
of O
antiplatelet O
, O
diuretic O
, O
and O
beta-blocker O
therapy O
. O

results O
: O
patients O
randomly O
assigned O
to O
enalapril O
had O
a O
33% O
greater O
likelihood O
of O
decreased B-NEG
renal I-NEG
function I-NEG
than O
controls O
(p O
=.003) O
. O

by O
multivariate O
analysis O
, O
in O
both O
the O
placebo O
and O
enalapril O
groups O
older O
age O
, O
diuretic O
therapy O
, O
and O
diabetes B-NEG
were O
associated O
with O
decreased B-NEG
renal I-NEG
function I-NEG
, O
whereas O
beta-blocker O
therapy O
and O
higher O
ejection O
fraction O
were O
renoprotective O
. O

older O
age O
was O
associated O
with O
a O
greater O
risk O
of O
developing O
decreased B-NEG
renal I-NEG
function I-NEG
in O
both O
groups O
, O
but O
significantly O
more O
so O
in O
the O
enalapril O
group O
(enalapril O
: O
risk O
ratio O
[rr] O
1.42 O
per O
10 O
years O
, O
95% O
confidence O
interval O
[ci] O
1.32-1.52 O
with O
enalapril O
; O
placebo O
: O
rr O
1.18 O
, O
95% O
ci O
1.12-1.25) O
. O

diuretic O
therapy O
was O
likewise O
associated O
with O
a O
greater O
risk O
of O
decreased B-NEG
renal I-NEG
function I-NEG
in O
the O
enalapril O
group O
( O
rr O
1.89 O
, O
95% O
ci O
1.70-2.08 O
) O
than O
in O
the O
placebo O
group O
( O
rr O
1.35 O
, O
95% O
ci O
1.09-1.66) O
. O

conversely O
, O
enalapril O
had O
a O
relative O
renoprotective O
effect O
( O
rr O
1.33 O
, O
95% O
ci O
1.13-1.53 O
) O
compared O
with O
placebo O
( O
rr O
1.96 O
, O
95% O
ci O
1.57-2.44 O
) O
in O
patients O
with O
diabetes B-NEG
. O

a O
lower O
risk O
of O
renal B-NEG
impairment I-NEG
was O
seen O
in O
both O
groups O
with O
beta-blocker O
therapy O
( O
rr O
0.70 O
, O
95% O
ci O
0.57-0.85 O
) O
and O
higher O
baseline O
ejection O
fraction O
( O
rr O
0.93 O
per O
5% O
increment O
, O
95% O
ci O
0.91-0 O
. O
96) O
. O

conclusions O
: O
enalapril O
use O
caused O
a O
33% O
increase O
in O
the O
risk O
of O
decreased B-NEG
renal I-NEG
function I-NEG
in O
patients O
with O
chf B-NEG
. O

diuretic O
use O
and O
advanced O
age O
increased O
this O
risk O
. O
diabetes B-NEG
was O
associated O
with O
an O
increased O
risk O
of O
renal B-NEG
impairment I-NEG
in O
all O
patients O
with O
chf B-NEG
, O
but O
this O
risk O
was O
reduced O
in O
the O
enalapril O
group O
compared O
with O
the O
placebo O
group O
. O

beta-blocker O
therapy O
and O
higher O
ejection O
fraction O
were O
renoprotective O
in O
all O
patients O
regardless O
of O
therapy O
. O

-DOCSTART- O

pemoline O
induced O
acute O
choreoathetosis B-NEG
: O
case O
report O
and O
review O
of O
the O
literature O
. O

background O
: O
pemoline O
is O
an O
oxazolidine O
derivative O
that O
is O
structurally O
different O
from O
amphetamines O
and O
used O
in O
the O
treatment O
of O
attention B-NEG
deficit I-NEG
disorder I-NEG
. O

pemoline O
has O
not O
been O
commonly O
associated O
in O
the O
literature O
as O
a O
cause O
of O
acute O
movement B-NEG
disorders I-NEG
. O

the O
following O
case O
describes O
two O
children O
acutely O
poisoned O
with O
pemoline O
who O
experienced O
profound O
choreoathetosis B-NEG
. O

case O
report O
: O
two O
, O
3-year-old O
male O
, O
identical O
twin O
siblings O
presented O
to O
the O
emergency O
department O
after O
found O
playing O
with O
a O
an O
empty O
bottle O
of O
pemoline O
originally O
containing O
59 O
tablets O
. O

the O
children O
had O
a O
medical O
history O
significant O
for O
attention B-NEG
deficit I-NEG
disorder I-NEG
previously O
treated O
with O
methylphenidate O
without O
success O
. O

this O
was O
their O
first O
day O
of O
pemoline O
therapy O
. O

the O
choreoathetoid B-NEG
movements O
began O
45 O
min O
to O
1 O
h O
after O
ingestion O
. O

the O
children O
gave O
no O
history O
of O
prior O
movement B-NEG
disorders I-NEG
and O
there O
was O
no O
family O
history O
of O
movement B-NEG
disorders I-NEG
. O

the O
children O
received O
gastrointestinal O
decontamination O
and O
high O
doses O
of O
intravenous O
benzodiazepines O
in O
an O
attempt O
to O
control O
the O
choreoathetoid B-NEG
movements O
. O

despite O
treatment O
, O
the O
children O
continued O
to O
have O
choreoathetosis B-NEG
for O
approximately O
24 O
hours O
. O

forty-eight O
hours O
after O
admission O
, O
the O
children O
appeared O
to O
be O
at O
their O
baseline O
and O
were O
discharged O
home O
. O

conclusion O
: O
pemoline O
associated O
movement B-NEG
disorder I-NEG
has O
been O
rarely O
reported O
in O
the O
acute O
toxicology O
literature O
. O

the O
possibility O
of O
choreoathetoid B-NEG
movements O
should O
be O
considered O
in O
patients O
presenting O
after O
pemoline O
overdose B-NEG
. O

-DOCSTART- O

continuous O
subcutaneous O
administration O
of O
mesna O
to O
prevent O
ifosfamide-induced O
hemorrhagic B-NEG
cystitis I-NEG
. O
hemorrhagic B-NEG
cystitis I-NEG
is O
a O
major O
potential O
toxicity B-NEG
of O
ifosfamide O
that O
can O
be O
prevented O
by O
administering O
mesna O
along O
with O
the O
cytotoxic O
agent O
. O

mesna O
is O
generally O
administered O
by O
the O
intravenous O
route O
, O
although O
experience O
with O
oral O
delivery O
of O
the O
drug O
has O
increased O
. O

the O
continuous O
subcutaneous O
administration O
of O
mesna O
has O
the O
advantage O
of O
not O
requiring O
intravenous O
access O
. O

in O
addition O
, O
subcutaneous O
delivery O
of O
the O
neutralizing O
agent O
will O
not O
be O
associated O
with O
the O
risk O
of O
inadequate O
urinary O
mesna O
concentrations O
, O
such O
as O
in O
a O
patient O
taking O
oral O
mesna O
who O
experiences O
severe O
ifosfamide-induced O
emesis B-NEG
and O
is O
unable O
to O
absorb O
the O
drug O
. O

limited O
clinical O
experience O
with O
continuous O
subcutaneous O
mesna O
administration O
suggests O
it O
is O
a O
safe O
, O
practical O
, O
and O
economic O
method O
of O
drug O
delivery O
that O
permits O
ifosfamide O
to O
be O
administered O
successfully O
in O
the O
outpatient O
setting O
. O

-DOCSTART- O

modification O
of O
drug O
action O
by O
hyperammonemia B-NEG
. O

pretreatment O
with O
ammonium O
acetate O
( O
nh4ac O
) O
(6 O
mmol/kg O
s.c. O
) O
approximately O
doubled O
the O
time O
morphine-treated O
mice O
remained O
on O
a O
hot O
surface O
and O
similarly O
increased O
muscular O
incoordination B-NEG
by O
diazepam O
, O
but O
nh4ac O
treatment O
alone O
had O
no O
effect O
. O

thus O
, O
hyperammonemia B-NEG
is O
capable O
of O
altering O
drug O
action O
and O
must O
be O
considered O
along O
with O
impaired O
drug O
metabolism O
in O
enhanced O
drug O
responses O
associated O
with O
liver B-NEG
disease I-NEG
. O

experiments O
in O
vitro O
showed O
that O
acetylcholine-induced O
catecholamine O
release O
from O
bovine O
adrenal O
medulla O
is O
depressed O
as O
much O
as O
50% O
by O
0.3 O
mm O
nh4ac O
and O
kcl-induced O
contractions O
of O
guinea-pig O
ileum O
were O
inhibited O
20% O
by O
5 O
mm O
nh4ac O
. O

addition O
of O
excess O
calcium O
reversed O
the O
depression B-NEG
in O
both O
tissues O
, O
but O
calcium-independent O
catecholamine O
release O
by O
acetaldehyde O
was O
not O
blocked O
by O
nh4ac O
. O

these O
results O
suggested O
that O
ammonia O
blocks O
calcium O
channels O
. O

parallels O
in O
the O
actions O
of O
nh4ac O
and O
the O
calcium O
channel O
blocker O
verapamil O
support O
this O
concept O
. O

both O
verapamil O
( O
10 O
mg/kg O
i.p. O
) O
and O
nh4ac O
pretreatment O
enhanced O
morphine O
analgesia B-NEG
- O
and O
diazepam-induced O
muscular O
incoordination B-NEG
and O
antagonized O
amphetamine-induced O
motor O
activity O
, O
and O
neither O
verapamil O
nor O
nh4ac O
affected O
the O
convulsant O
action O
of O
metrazol O
. O

the O
data O
suggest O
that O
hyperammonemia B-NEG
exerts O
a O
calcium O
channel O
blocking O
action O
which O
enhances O
the O
effects O
of O
central O
nervous O
system O
depressants O
and O
certain O
opioid O
analgesics O
. O

-DOCSTART- O

risk O
of O
nephropathy B-NEG
after O
consumption O
of O
nonionic O
contrast O
media O
by O
children O
undergoing O
cardiac O
angiography O
: O
a O
prospective O
study O
. O

despite O
increasing O
reports O
on O
nonionic O
contrast O
media-induced O
nephropathy B-NEG
( O
cin B-NEG
) O
in O
hospitalized O
adult O
patients O
during O
cardiac O
procedures O
, O
the O
studies O
in O
pediatrics O
are O
limited O
, O
with O
even O
less O
focus O
on O
possible O
predisposing O
factors O
and O
preventive O
measures O
for O
patients O
undergoing O
cardiac O
angiography O
. O

this O
prospective O
study O
determined O
the O
incidence O
of O
cin B-NEG
for O
two O
nonionic O
contrast O
media O
(cm) O
, O
iopromide O
and O
iohexol O
, O
among O
80 O
patients O
younger O
than O
18 O
years O
and O
compared O
the O
rates O
for O
this O
complication O
in O
relation O
to O
the O
type O
and O
dosage O
of O
cm O
and O
the O
presence O
of O
cyanosis B-NEG
. O

the O
80 O
patients O
in O
the O
study O
consecutively O
received O
either O
iopromide O
( O
group O
a, O
n O
= O
40 O
) O
or O
iohexol O
( O
group O
b, O
n O
= O
40) O
. O

serum O
sodium O
(na) O
, O
potassium O
(k) O
, O
and O
creatinine O
( O
cr O
) O
were O
measured O
24 O
h O
before O
angiography O
as O
baseline O
values O
, O
then O
measured O
again O
at O
12- O
, O
24- O
, O
and O
48-h O
intervals O
after O
cm O
use O
. O

urine O
samples O
for O
na O
and O
cr O
also O
were O
checked O
at O
the O
same O
intervals O
. O

risk O
of O
renal B-NEG
failure I-NEG
, O
injury B-NEG
to I-NEG
the I-NEG
kidney I-NEG
, O
failure B-NEG
of I-NEG
kidney I-NEG
function I-NEG
, O
loss B-NEG
of I-NEG
kidney I-NEG
function I-NEG
, O
and O
end-stage O
renal B-NEG
damage I-NEG
( O
rifle O
criteria O
) O
were O
used O
to O
define O
cin B-NEG
and O
its O
incidence O
in O
the O
study O
population O
. O

accordingly O
, O
among O
the O
15 O
cin B-NEG
patients O
(18.75%) O
, O
7.5% O
of O
the O
patients O
in O
group O
a O
had O
increased O
risk O
and O
3.75% O
had O
renal B-NEG
injury I-NEG
, O
whereas O
5% O
of O
group O
b O
had O
increased O
risk O
and O
2.5% O
had O
renal B-NEG
injury I-NEG
. O

whereas O
33.3% O
of O
the O
patients O
with O
cin B-NEG
were O
among O
those O
who O
received O
the O
proper O
dosage O
of O
cm O
, O
the O
percentage O
increased O
to O
66.6% O
among O
those O
who O
received O
larger O
doses O
, O
with O
a O
significant O
difference O
in O
the O
incidence O
of O
cin B-NEG
related O
to O
the O
different O
dosages O
of O
cm O
(p O
= O
0.014) O
. O

among O
the O
15 O
patients O
with O
cin B-NEG
, O
6 O
had O
cyanotic O
congenital B-NEG
heart I-NEG
diseases I-NEG
, O
but O
the O
incidence O
did O
not O
differ O
significantly O
from O
that O
for O
the O
noncyanotic O
patients O
(p O
= O
0.243) O
. O

although O
clinically O
silent O
, O
cin B-NEG
is O
not O
rare O
in O
pediatrics O
. O

the O
incidence O
depends O
on O
dosage O
but O
not O
on O
the O
type O
of O
consumed O
nonionic O
cm O
, O
nor O
on O
the O
presence O
of O
cyanosis B-NEG
, O
and O
although O
cin B-NEG
usually O
is O
reversible O
, O
more O
concern O
is O
needed O
for O
the O
prevention O
of O
such O
a O
complication O
in O
children O
. O

-DOCSTART- O

a O
case O
of O
ventricular B-NEG
tachycardia I-NEG
related O
to O
caffeine O
pretreatment O
. O

suboptimal O
seizure B-NEG
duration O
is O
commonly O
encountered O
in O
electroconvulsive O
therapy O
practice O
, O
especially O
in O
older O
patients O
with O
higher O
seizure B-NEG
thresholds O
. O

intravenous O
caffeine O
is O
commonly O
used O
to O
improve O
seizure B-NEG
duration O
and O
quality O
in O
such O
patients O
and O
is O
generally O
well O
tolerated O
aside O
from O
occasional O
reports O
of O
relatively O
benign O
ventricular B-NEG
ectopy I-NEG
. O

we O
describe O
a O
patient O
with O
no O
previous O
history O
of O
cardiac B-NEG
disease I-NEG
or O
arrhythmia B-NEG
who O
developed O
sustained O
bigeminy O
and O
2 O
brief O
runs O
of O
ventricular B-NEG
tachycardia I-NEG
after O
caffeine O
administration O
. O

although O
intravenous O
caffeine O
is O
generally O
well O
tolerated O
, O
the O
clinician O
should O
be O
aware O
of O
the O
potential O
for O
unpredictable O
and O
serious O
ventricular B-NEG
arrhythmias I-NEG
. O

-DOCSTART- O

optical O
coherence O
tomography O
can O
measure O
axonal O
loss O
in O
patients O
with O
ethambutol-induced O
optic B-NEG
neuropathy I-NEG
. O

purpose O
: O
to O
map O
and O
identify O
the O
pattern O
, O
in O
vivo O
, O
of O
axonal B-NEG
degeneration I-NEG
in O
ethambutol-induced O
optic B-NEG
neuropathy I-NEG
using O
optical O
coherence O
tomography O
(oct) O
. O

ethambutol O
is O
an O
antimycobacterial O
agent O
often O
used O
to O
treat O
tuberculosis B-NEG
. O

a O
serious O
complication O
of O
ethambutol O
is O
an O
optic B-NEG
neuropathy I-NEG
that O
impairs O
visual O
acuity O
, O
contrast O
sensitivity O
, O
and O
color O
vision O
. O

however O
, O
early O
on O
, O
when O
the O
toxic O
optic B-NEG
neuropathy I-NEG
is O
mild O
and O
partly O
reversible O
, O
the O
funduscopic O
findings O
are O
often O
subtle O
and O
easy O
to O
miss O
. O

methods O
: O
three O
subjects O
with O
a O
history O
of O
ethambutol O
( O
emb)-induced O
optic B-NEG
neuropathy I-NEG
of O
short- O
, O
intermediate- O
, O
and O
long-term O
visual B-NEG
deficits I-NEG
were O
administered O
a O
full O
neuro-ophthalmologic O
examination O
including O
visual O
acuity O
, O
color O
vision O
, O
contrast O
sensitivity O
, O
and O
fundus O
examination O
. O

in O
addition O
, O
oct O
( O
oct O
3000 O
, O
humphrey-zeiss O
, O
dublin O
, O
ca O
) O
was O
performed O
on O
both O
eyes O
of O
each O
subject O
using O
the O
retinal O
nerve O
fiber O
layer O
( O
rnfl O
) O
analysis O
protocol O
. O

oct O
interpolates O
data O
from O
100 O
points O
around O
the O
optic O
nerve O
to O
effectively O
map O
out O
the O
rnfl O
. O

results O
: O
the O
results O
were O
compared O
to O
the O
calculated O
average O
rnfl O
of O
normal O
eyes O
accumulated O
from O
four O
prior O
studies O
using O
oct O
, O
n=661 O
. O

in O
all O
subjects O
with O
history O
of O
emb-induced O
optic B-NEG
neuropathy I-NEG
, O
there O
was O
a O
mean O
loss O
of O
72% O
nerve O
fiber O
layer O
thickness O
in O
the O
temporal O
quadrant O
( O
patient O
a, O
with O
eventual O
recovery O
of O
visual O
acuity O
and O
fields O
, O
58% O
loss O
; O
patient O
b, O
with O
intermediate O
visual B-NEG
deficits I-NEG
, O
68% O
loss O
; O
patient O
c, O
with O
chronic O
visual B-NEG
deficits I-NEG
, O
90% O
loss) O
, O
with O
an O
average O
mean O
optic O
nerve O
thickness O
of O
26+/-16 O
microm O
. O

there O
was O
a O
combined O
mean O
loss O
of O
46% O
of O
fibers O
from O
the O
superior O
, O
inferior O
, O
and O
nasal O
quadrants O
in O
the O
( O
six O
) O
eyes O
of O
all O
three O
subjects O
( O
mean O
average O
thickness O
of O
55+/-29 O
microm) O
. O

in O
both O
sets O
( O
four O
) O
of O
eyes O
of O
the O
subjects O
with O
persistent O
visual B-NEG
deficits I-NEG
( O
patients O
b O
and O
c) O
, O
there O
was O
an O
average O
loss O
of O
79% O
of O
nerve O
fiber O
thickness O
in O
the O
temporal O
quadrant O
. O

conclusions O
: O
the O
oct O
results O
in O
these O
patients O
with O
emb-induced O
optic B-NEG
neuropathy I-NEG
show O
considerable O
loss O
especially O
of O
the O
temporal O
fibers O
. O

this O
is O
consistent O
with O
prior O
histopathological O
studies O
that O
show O
predominant O
loss O
of O
parvo-cellular O
axons O
( O
or O
small-caliber O
axons O
) O
within O
the O
papillo-macular O
bundle O
in O
toxic O
or O
hereditary O
optic B-NEG
neuropathies I-NEG
. O

oct O
can O
be O
a O
valuable O
tool O
in O
the O
quantitative O
analysis O
of O
optic B-NEG
neuropathies I-NEG
. O

additionally O
, O
in O
terms O
of O
management O
of O
emb-induced O
optic B-NEG
neuropathy I-NEG
, O
it O
is O
important O
to O
properly O
manage O
ethambutol O
dosing O
in O
patients O
with O
renal B-NEG
impairment I-NEG
and O
to O
achieve O
proper O
transition O
to O
a O
maintenance O
dose O
once O
an O
appropriate O
loading O
dose O
has O
been O
reached O
. O

-DOCSTART- O

effects O
of O
the O
cyclooxygenase-2 O
specific O
inhibitor O
valdecoxib O
versus O
nonsteroidal O
antiinflammatory O
agents O
and O
placebo O
on O
cardiovascular O
thrombotic B-NEG
events O
in O
patients O
with O
arthritis B-NEG
. O

there O
have O
been O
concerns O
that O
the O
risk O
of O
cardiovascular O
thrombotic B-NEG
events O
may O
be O
higher O
with O
cyclooxygenase O
( O
cox)-2-specific O
inhibitors O
than O
nonselective O
nonsteroidal O
antiinflammatory O
drugs O
(nsaids) O
. O

we O
evaluated O
cardiovascular O
event O
data O
for O
valdecoxib O
, O
a O
new O
cox-2-specific O
inhibitor O
in O
approximately O
8000 O
patients O
with O
osteoarthritis B-NEG
and O
rheumatoid B-NEG
arthritis I-NEG
treated O
with O
this O
agent O
in O
randomized O
clinical O
trials O
. O

the O
incidence O
of O
cardiovascular O
thrombotic B-NEG
events O
(cardiac O
, O
cerebrovascular O
and O
peripheral O
vascular O
, O
or O
arterial O
thrombotic B-NEG
) O
was O
determined O
by O
analyzing O
pooled O
valdecoxib O
( O
10-80 O
mg O
daily) O
, O
nonselective O
nsaid O
( O
diclofenac O
75 O
mg O
bid O
, O
ibuprofen O
800 O
mg O
tid O
, O
or O
naproxen O
500 O
mg O
bid O
) O
and O
placebo O
data O
from O
10 O
randomized O
osteoarthritis B-NEG
and O
rheumatoid B-NEG
arthritis I-NEG
trials O
that O
were O
6-52 O
weeks O
in O
duration O
. O

the O
incidence O
rates O
of O
events O
were O
determined O
in O
all O
patients O
(n O
= O
7934 O
) O
and O
in O
users O
of O
low-dose O
(< O
or O
=325 O
mg O
daily O
) O
aspirin O
(n O
= O
1051 O
) O
and O
nonusers O
of O
aspirin O
(n O
= O
6883) O
. O

crude O
and O
exposure-adjusted O
incidences O
of O
thrombotic B-NEG
events O
were O
similar O
for O
valdecoxib O
, O
nsaids O
, O
and O
placebo O
. O

the O
risk O
of O
serious O
thrombotic B-NEG
events O
was O
also O
similar O
for O
each O
valdecoxib O
dose O
. O
thrombotic B-NEG
risk O
was O
consistently O
higher O
for O
users O
of O
aspirin O
users O
than O
nonusers O
of O
aspirin O
(placebo O
, O
1.4% O
vs O
. O
0% O
; O
valdecoxib O
, O
1.7% O
vs O
. O
0.2% O
; O
nsaids O
, O
1.9% O
vs O
. O
0.5%) O
. O

the O
rates O
of O
events O
in O
users O
of O
aspirin O
were O
similar O
for O
all O
3 O
treatment O
groups O
and O
across O
valdecoxib O
doses O
. O

short- O
and O
intermediate-term O
treatment O
with O
therapeutic O
( O
10 O
or O
20 O
mg O
daily O
) O
and O
supratherapeutic O
( O
40 O
or O
80 O
mg O
daily O
) O
valdecoxib O
doses O
was O
not O
associated O
with O
an O
increased O
incidence O
of O
thrombotic B-NEG
events O
relative O
to O
nonselective O
nsaids O
or O
placebo O
in O
osteoarthritis B-NEG
and O
rheumatoid B-NEG
arthritis I-NEG
patients O
in O
controlled O
clinical O
trials O
. O

-DOCSTART- O

a O
randomized O
, O
placebo-controlled O
, O
crossover O
study O
of O
ephedrine O
for O
ssri-induced O
female O
sexual B-NEG
dysfunction I-NEG
. O

the O
objective O
of O
this O
study O
was O
to O
determine O
whether O
ephedrine O
, O
an O
alpha- O
and O
beta-adrenergic O
agonist O
previously O
shown O
to O
enhance O
genital O
blood O
flow O
in O
women O
, O
has O
beneficial O
effects O
in O
reversing O
antidepressant-induced O
sexual B-NEG
dysfunction I-NEG
. O

nineteen O
sexually B-NEG
dysfunctional I-NEG
women O
receiving O
either O
fluoxetine O
, O
sertraline O
, O
or O
paroxetine O
participated O
in O
an O
eight-week O
, O
double-blind O
, O
placebo-controlled O
, O
cross-over O
study O
of O
the O
effects O
of O
ephedrine O
( O
50 O
mg O
) O
on O
self-report O
measures O
of O
sexual O
desire O
, O
arousal O
, O
orgasm O
, O
and O
sexual O
satisfaction O
. O

although O
there O
were O
significant O
improvements O
relative O
to O
baseline O
in O
sexual O
desire O
and O
orgasm O
intensity/pleasure O
on O
50 O
mg O
ephedrine O
1-hr O
prior O
to O
sexual O
activity O
, O
significant O
improvements O
in O
these O
measures O
, O
as O
well O
as O
in O
sexual O
arousal O
and O
orgasmic O
ability O
also O
were O
noted O
with O
placebo O
. O

these O
findings O
highlight O
the O
importance O
of O
conducting O
placebo-controlled O
trials O
for O
this O
condition O
. O

-DOCSTART- O

erectile B-NEG
dysfunction I-NEG
occurs O
following O
substantia O
nigra O
lesions O
in O
the O
rat O
. O

erectile O
function O
was O
assessed O
6 O
weeks O
following O
uni- O
and O
bilateral O
injections O
of O
6-hydroxydopamine O
in O
the O
substantia O
nigra O
nucleus O
of O
the O
brain O
. O

behavioral O
apomorphine-induced O
penile O
erections O
were O
reduced O
( O
5/8 O
) O
and O
increased O
( O
3/8 O
) O
in O
uni- O
and O
bilateral O
lesioned O
animals O
. O

intracavernous O
pressures O
, O
following O
electrical O
stimulation O
of O
the O
cavernous O
nerve O
, O
decreased O
in O
lesioned O
animals O
. O

lesions O
of O
the O
substantia O
nigra O
were O
confirmed O
by O
histology O
. O

concentration O
of O
dopamine O
and O
its O
metabolites O
were O
decreased O
in O
the O
striatum O
of O
substantia O
nigra O
lesioned O
rats O
. O

lesions O
of O
the O
substantia O
nigra O
are O
therefore O
associated O
with O
erectile B-NEG
dysfunction I-NEG
in O
rats O
and O
may O
serve O
as O
a O
model O
to O
study O
erectile B-NEG
dysfunction I-NEG
in O
parkinson's B-NEG
disease I-NEG
. O

-DOCSTART- O

potential O
therapeutic O
use O
of O
the O
selective O
dopamine O
d1 O
receptor O
agonist O
, O
a-86929 O
: O
an O
acute O
study O
in O
parkinsonian B-NEG
levodopa-primed O
monkeys O
. O

the O
clinical O
utility O
of O
dopamine O
( O
da O
) O
d1 O
receptor O
agonists O
in O
the O
treatment O
of O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
is O
still O
unclear O
. O

the O
therapeutic O
use O
of O
selective O
da O
d1 O
receptor O
agonists O
such O
as O
skf-82958 O
( O
6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1h-3-benzaze O
pine O
hydrobromide O
) O
and O
a-77636 O
([1r O
, O
3s] O
3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1h-2-benzo O
pyran O
hydrochloride O
) O
seems O
limited O
because O
of O
their O
duration O
of O
action O
, O
which O
is O
too O
short O
for O
skf-82958 O
(< O
1 O
hr O
) O
and O
too O
long O
for O
a-77636 O
(> O
20 O
hr O
, O
leading O
to O
behavioral O
tolerance) O
. O

we O
therefore O
conducted O
the O
present O
acute O
dose-response O
study O
in O
four O
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine O
( O
mptp)-exposed O
cynomolgus O
monkeys O
primed O
to O
exhibit O
levodopa-induced O
dyskinesias B-NEG
to O
evaluate O
the O
locomotor O
and O
dyskinetic B-NEG
effects O
on O
challenge O
with O
four O
doses O
( O
from O
0.03 O
to O
1.0 O
mg/kg O
) O
of O
a-86929 O
( O
[-]-[5ar,11bs]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ O
++azacyclopent-1- O
ena[c]phenathrene-9-10-diol) O
, O
a O
selective O
and O
full O
da O
d1-like O
receptor O
agonist O
with O
an O
intermediate O
duration O
of O
action O
. O

levodopa O
and O
the O
da O
d2-like O
receptor O
agonist O
, O
ly-171555 O
( O
[4ar-trans]-4,4a,5,6,7,8,8a,9-o-dihydro-5n-propyl-2h-pyrazo O
lo-3-4-quinoline O
hydrochloride O
) O
were O
also O
used O
for O
comparison O
. O

acute O
administration O
of O
a-86929 O
was O
as O
efficacious O
in O
alleviating O
mptp-induced O
parkinsonism B-NEG
as O
levodopa O
and O
ly-171555 O
, O
but O
was O
less O
likely O
to O
reproduce O
the O
levodopa-induced O
dyskinesias B-NEG
in O
these O
animals O
than O
with O
either O
ly-171555 O
or O
subsequent O
challenge O
of O
levodopa O
. O

selective O
stimulation O
of O
the O
da O
d1 O
receptor O
may O
provide O
better O
integration O
of O
neural O
inputs O
transmitted O
to O
the O
internal O
segment O
of O
the O
globus O
pallidus O
( O
referred O
to O
as O
the O
basal O
ganglia O
output O
) O
compared O
with O
levodopa O
and O
selective O
da O
d2 O
receptor O
agonist O
. O

potent O
da O
d1 O
receptor O
agents O
with O
an O
intermediate O
duration O
of O
efficacy O
such O
as O
a-86929 O
( O
approximately O
4 O
hr O
at O
higher O
doses O
tested O
) O
are O
potential O
therapeutic O
tools O
in O
pd B-NEG
and O
merit O
further O
attention O
. O

-DOCSTART- O

deaths O
from O
local O
anesthetic-induced O
convulsions B-NEG
in O
mice O
. O

median O
convulsant O
( O
cd50 O
) O
and O
median O
lethal O
( O
ld50 O
) O
doses O
of O
three O
representative O
local O
anesthetics O
were O
determined O
in O
adult O
mice O
to O
evaluate O
the O
threat O
to O
life O
of O
local O
anesthetic-induced O
convulsions B-NEG
. O

the O
cd50 O
and O
ld50 O
, O
respectively O
, O
were O
57.7 O
and O
58.7 O
mg/kg O
for O
bupivacaine O
, O
111.0 O
and O
133.1 O
mg/kg O
for O
lidocaine O
, O
and O
243.4 O
and O
266.5 O
mg/kg O
for O
chloroprocaine O
. O

when O
given O
intraperitoneally O
, O
bupivacaine O
thus O
was O
only O
about O
twice O
as O
toxic O
as O
lidocaine O
and O
four O
times O
as O
toxic O
as O
chloroprocaine O
. O
convulsions B-NEG
always O
preceded O
death O
, O
except O
after O
precipitous O
cardiopulmonary B-NEG
arrest I-NEG
from O
extreme O
doses O
. O

a O
cd50 O
dose O
of O
local O
anesthetic O
( O
causing O
convulsions B-NEG
in O
50% O
of O
mice O
) O
was O
fatal O
in O
90% O
of O
bupivacaine-induced O
seizures B-NEG
, O
in O
57% O
of O
the O
chloroprocaine O
group O
, O
and O
in O
6% O
of O
the O
lidocaine O
group O
. O

the O
narrow O
gap O
between O
convulsant O
and O
lethal O
doses O
of O
local O
anesthetics O
indicates O
that O
untreated O
convulsions B-NEG
present O
much O
more O
of O
a O
threat O
to O
life O
than O
heretofore O
appreciated O
. O

-DOCSTART- O

myoclonic B-NEG
, O
atonic I-NEG
, O
and I-NEG
absence I-NEG
seizures I-NEG
following O
institution O
of O
carbamazepine O
therapy O
in O
children O
. O

five O
children O
, O
aged O
3 O
to O
11 O
years O
, O
treated O
with O
carbamazepine O
for O
epilepsy B-NEG
, O
had O
an O
acute O
aberrant O
reaction O
characterized O
by O
the O
onset O
of O
myoclonic B-NEG
, O
atypical I-NEG
absence I-NEG
and/or I-NEG
atonic I-NEG
( O
minor I-NEG
motor I-NEG
) O
seizures I-NEG
within O
a O
few O
days O
. O

when O
the O
carbamazepine O
was O
discontinued O
, O
two O
of O
the O
children O
returned O
to O
their O
former O
state O
very O
quickly O
, O
two O
had O
the O
minor O
motor O
seizures B-NEG
resolve O
in O
3 O
and O
6 O
months O
, O
and O
one O
had O
the O
seizures B-NEG
persist O
. O

the O
child O
in O
whom O
the O
seizures B-NEG
persisted O
was O
later O
found O
to O
have O
ceroid B-NEG
lipofuscinosis I-NEG
. O

the O
other O
children O
are O
doing O
well O
on O
other O
anticonvulsants O
. O

-DOCSTART- O

naloxone O
reversal O
of O
hypotension B-NEG
due O
to O
captopril O
overdose B-NEG
. O

the O
hemodynamic O
effects O
of O
captopril O
and O
other O
angiotensin-converting O
enzyme O
inhibitors O
may O
be O
mediated O
by O
the O
endogenous O
opioid O
system O
. O

the O
opioid O
antagonist O
naloxone O
has O
been O
shown O
to O
block O
or O
reverse O
the O
hypotensive B-NEG
actions O
of O
captopril O
. O

we O
report O
a O
case O
of O
an O
intentional O
captopril O
overdose B-NEG
, O
manifested O
by O
marked O
hypotension B-NEG
, O
that O
resolved O
promptly O
with O
the O
administration O
of O
naloxone O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
captopril-induced O
hypotension B-NEG
treated O
with O
naloxone O
. O

our O
experience O
demonstrates O
a O
possible O
role O
of O
naloxone O
in O
the O
reversal O
of O
hypotension B-NEG
resulting O
from O
captopril O
. O

-DOCSTART- O

carbamazepine-induced O
cardiac B-NEG
dysfunction I-NEG
. O

characterization O
of O
two O
distinct O
clinical O
syndromes O
. O

a O
patient O
with O
sinus O
bradycardia B-NEG
and O
atrioventricular B-NEG
block I-NEG
, O
induced O
by O
carbamazepine O
, O
prompted O
an O
extensive O
literature O
review O
of O
all O
previously O
reported O
cases O
. O

from O
the O
analysis O
of O
these O
cases O
, O
two O
distinct O
forms O
of O
carbamazepine-associated O
cardiac B-NEG
dysfunction I-NEG
emerged O
. O

one O
patient O
group O
developed O
sinus B-NEG
tachycardias I-NEG
in O
the O
setting O
of O
a O
massive O
carbamazepine O
overdose B-NEG
. O

the O
second O
group O
consisted O
almost O
exclusively O
of O
elderly O
women O
who O
developed O
potentially O
life-threatening O
bradyarrhythmias B-NEG
or O
atrioventricular B-NEG
conduction I-NEG
delay I-NEG
, O
associated O
with O
either O
therapeutic O
or O
modestly O
elevated O
carbamazepine O
serum O
levels O
. O

because O
carbamazepine O
is O
widely O
used O
in O
the O
treatment O
of O
many O
neurologic O
and O
psychiatric B-NEG
conditions O
, O
the O
recognition O
of O
the O
latter O
syndrome O
has O
important O
implications O
for O
the O
use O
of O
this O
drug O
in O
elderly O
patients O
. O

-DOCSTART- O

glutamatergic O
neurotransmission O
mediated O
by O
nmda O
receptors O
in O
the O
inferior O
colliculus O
can O
modulate O
haloperidol-induced O
catalepsy B-NEG
. O

the O
inferior O
colliculus O
( O
ic O
) O
is O
primarily O
involved O
in O
the O
processing O
of O
auditory O
information O
, O
but O
it O
is O
distinguished O
from O
other O
auditory O
nuclei O
in O
the O
brainstem O
by O
its O
connections O
with O
structures O
of O
the O
motor O
system O
. O

functional O
evidence O
relating O
the O
ic O
to O
motor O
behavior O
derives O
from O
experiments O
showing O
that O
activation O
of O
the O
ic O
by O
electrical O
stimulation O
or O
excitatory O
amino O
acid O
microinjection O
causes O
freezing O
, O
escape-like O
behavior O
, O
and O
immobility O
. O

however O
, O
the O
nature O
of O
this O
immobility O
is O
still O
unclear O
. O

the O
present O
study O
examined O
the O
influence O
of O
excitatory O
amino O
acid-mediated O
mechanisms O
in O
the O
ic O
on O
the O
catalepsy B-NEG
induced O
by O
the O
dopamine O
receptor O
blocker O
haloperidol O
administered O
systemically O
(1 O
or O
0.5 O
mg/kg O
) O
in O
rats O
. O

haloperidol-induced O
catalepsy B-NEG
was O
challenged O
with O
prior O
intracollicular O
microinjections O
of O
glutamate O
nmda O
receptor O
antagonists O
, O
mk-801 O
( O
15 O
or O
30 O
mmol/0.5 O
microl O
) O
and O
ap7 O
( O
10 O
or O
20 O
nmol/0.5 O
microl) O
, O
or O
of O
the O
nmda O
receptor O
agonist O
n-methyl-d-aspartate O
(nmda O
, O
20 O
or O
30 O
nmol/0.5 O
microl) O
. O

the O
results O
showed O
that O
intracollicular O
microinjection O
of O
mk-801 O
and O
ap7 O
previous O
to O
systemic O
injections O
of O
haloperidol O
significantly O
attenuated O
the O
catalepsy B-NEG
, O
as O
indicated O
by O
a O
reduced O
latency O
to O
step O
down O
from O
a O
horizontal O
bar O
. O

accordingly O
, O
intracollicular O
microinjection O
of O
nmda O
increased O
the O
latency O
to O
step O
down O
the O
bar O
. O

these O
findings O
suggest O
that O
glutamate-mediated O
mechanisms O
in O
the O
neural O
circuits O
at O
the O
ic O
level O
influence O
haloperidol-induced O
catalepsy B-NEG
and O
participate O
in O
the O
regulation O
of O
motor O
activity O
. O

-DOCSTART- O

metabotropic O
glutamate O
7 O
receptor O
subtype O
modulates O
motor O
symptoms O
in O
rodent O
models O
of O
parkinson's B-NEG
disease I-NEG
. O

metabotropic O
glutamate O
( O
mglu O
) O
receptors O
modulate O
synaptic O
transmission O
in O
the O
central O
nervous O
system O
and O
represent O
promising O
therapeutic O
targets O
for O
symptomatic O
treatment O
of O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
). O

among O
the O
eight O
mglu O
receptor O
subtypes O
, O
mglu7 O
receptor O
is O
prominently O
expressed O
in O
the O
basal O
ganglia O
, O
but O
its O
role O
in O
restoring O
motor O
function O
in O
animal O
models O
of O
pd B-NEG
is O
not O
known O
. O

the O
effects O
of O
n,n'-dibenzhydrylethane-1,2-diamine O
dihydrochloride O
(amn082) O
, O
the O
first O
selective O
allosteric O
activator O
of O
mglu7 O
receptors O
, O
were O
thus O
tested O
in O
different O
rodent O
models O
of O
pd B-NEG
. O

here O
, O
we O
show O
that O
oral O
(5 O
mg/kg O
) O
or O
intrastriatal O
administration O
( O
0.1 O
and O
0.5 O
nmol O
) O
of O
amn082 O
reverses O
haloperidol-induced O
catalepsy B-NEG
in O
rats O
. O

amn082 O
( O
2.5 O
and O
5 O
mg/kg O
) O
reduces O
apomorphine-induced O
rotations O
in O
unilateral O
6-hydroxydopamine O
( O
6-ohda)-lesioned O
rats O
. O

in O
a O
more O
complex O
task O
commonly O
used O
to O
evaluate O
major O
akinetic B-NEG
symptoms O
of O
pd B-NEG
patients O
, O
5 O
mg/kg O
amn082 O
reverses O
the O
increased O
reaction O
time O
to O
respond O
to O
a O
cue O
of O
bilateral O
6-ohda-lesioned O
rats O
. O

in O
addition O
, O
amn082 O
reduces O
the O
duration O
of O
haloperidol-induced O
catalepsy B-NEG
in O
a O
mglu7 O
receptor-dependent O
manner O
in O
wild-type O
but O
not O
mglu7 O
receptor O
knockout O
mice O
. O

higher O
doses O
of O
amn082 O
( O
10 O
and O
20 O
mg/kg O
p.o. O
) O
have O
no O
effect O
on O
the O
same O
models O
of O
pd B-NEG
. O

overall O
these O
findings O
suggest O
that O
mglu7 O
receptor O
activation O
can O
reverse O
motor O
dysfunction O
associated O
with O
reduced O
dopamine O
activity O
. O

selective O
ligands O
of O
mglu7 O
receptor O
subtypes O
may O
thus O
be O
considered O
as O
promising O
compounds O
for O
the O
development O
of O
antiparkinsonian O
therapeutic O
strategies O
. O

-DOCSTART- O

nimodipine O
prevents O
memory B-NEG
impairment I-NEG
caused O
by O
nitroglycerin-induced O
hypotension B-NEG
in O
adult O
mice O
. O

background O
: O
hypotension B-NEG
and O
a O
resultant O
decrease O
in O
cerebral O
blood O
flow O
have O
been O
implicated O
in O
the O
development O
of O
cognitive B-NEG
dysfunction I-NEG
. O

we O
tested O
the O
hypothesis O
that O
nimodipine O
( O
nimo O
) O
administered O
at O
the O
onset O
of O
nitroglycerin O
( O
ntg)-induced O
hypotension B-NEG
would O
preserve O
long-term O
associative O
memory O
. O

methods O
: O
the O
passive O
avoidance O
( O
pa O
) O
paradigm O
was O
used O
to O
assess O
memory O
retention O
. O

for O
pa O
training O
, O
latencies O
( O
seconds O
) O
were O
recorded O
for O
entry O
from O
a O
suspended O
platform O
into O
a O
plexiglas O
tube O
where O
a O
shock O
was O
automatically O
delivered O
. O

latencies O
were O
recorded O
48 O
h O
later O
for O
a O
testing O
trial O
. O

ninety-six O
swiss-webster O
mice O
( O
30-35 O
g, O
6-8 O
wk) O
, O
were O
randomized O
into O
6 O
groups O
1) O
saline O
(control) O
, O
2) O
ntg O
immediately O
after O
learning O
, O
3) O
ntg O
3 O
h O
after O
learning O
, O
4) O
ntg O
and O
nimo O
, O
5) O
vehicle O
, O
and O
6) O
nimo O
alone O
. O

the O
extent O
of O
hypotension B-NEG
and O
changes O
in O
brain O
tissue O
oxygenation O
( O
pbto(2) O
) O
and O
in O
cerebral O
blood O
flow O
were O
studied O
in O
a O
separate O
group O
of O
animals O
. O

results O
: O
all O
groups O
exhibited O
similar O
training O
latencies O
( O
17.0 O
+/- O
4.6 O
s) O
. O

mice O
subjected O
to O
hypotensive B-NEG
episodes O
showed O
a O
significant O
decrease O
in O
latency O
time O
( O
178 O
+/- O
156 O
s) O
compared O
with O
those O
injected O
with O
saline O
, O
ntg O
+ O
nimo O
, O
or O
delayed O
ntg O
( O
580 O
+/- O
81 O
s, O
557 O
+/- O
67 O
s, O
and O
493 O
+/- O
146 O
s, O
respectively) O
. O

a O
kruskal-wallis O
1-way O
analysis O
of O
variance O
indicated O
a O
significant O
difference O
among O
the O
4 O
treatment O
groups O
(h O
= O
15.34 O
; O
p O
< O
0.001) O
. O

in O
a O
separate O
group O
of O
mice O
not O
subjected O
to O
behavioral O
studies O
, O
the O
same O
dose O
of O
ntg O
(n O
= O
3) O
and O
ntg O
+ O
nimo O
(n O
= O
3) O
caused O
mean O
arterial O
blood O
pressure O
to O
decrease O
from O
85.9 O
+/- O
3.8 O
mm O
hg O
sem O
to O
31.6 O
+/- O
0.8 O
mm O
hg O
sem O
and O
from O
86.2 O
+/- O
3.7 O
mm O
hg O
sem O
to O
32.6 O
+/- O
0.2 O
mm O
hg O
sem O
, O
respectively O
. O

mean O
arterial O
blood O
pressure O
in O
mice O
treated O
with O
nimo O
alone O
decreased O
from O
88.1 O
+/- O
3.8 O
mm O
hg O
to O
80.0 O
+/- O
2.9 O
mm O
hg O
. O

the O
intergroup O
difference O
was O
statistically O
significant O
(p O
< O
0.05) O
. O

pbto(2 O
) O
decreased O
from O
51.7 O
+/- O
4.5 O
mm O
hg O
sem O
to O
33.8 O
+/- O
5.2 O
mm O
hg O
sem O
in O
the O
ntg O
group O
and O
from O
38.6 O
+/- O
6.1 O
mm O
hg O
sem O
to O
25.4 O
+/- O
2.0 O
mm O
hg O
sem O
in O
the O
ntg O
+ O
nimo O
groups O
, O
respectively O
. O

there O
were O
no O
significant O
differences O
among O
groups O
. O

conclusion O
: O
in O
a O
pa O
retention O
paradigm O
, O
the O
injection O
of O
ntg O
immediately O
after O
learning O
produced O
a O
significant O
impairment O
of O
long-term O
associative O
memory O
in O
mice O
, O
whereas O
delayed O
induced O
hypotension B-NEG
had O
no O
effect O
. O

nimo O
attenuated O
the O
disruption O
in O
consolidation O
of O
long-term O
memory O
caused O
by O
ntg O
but O
did O
not O
improve O
latency O
in O
the O
absence O
of O
hypotension B-NEG
. O

the O
observed O
effect O
of O
nimo O
may O
have O
been O
attributable O
to O
the O
preservation O
of O
calcium O
homeostasis O
during O
hypotension B-NEG
, O
because O
there O
were O
no O
differences O
in O
the O
pbto(2 O
) O
indices O
among O
groups O
. O

-DOCSTART- O

fatal O
haemopericardium B-NEG
and O
gastrointestinal B-NEG
haemorrhage I-NEG
due O
to O
possible O
interaction O
of O
cranberry O
juice O
with O
warfarin O
. O

we O
report O
a O
case O
of O
fatal O
internal O
haemorrhage B-NEG
in O
an O
elderly O
man O
who O
consumed O
only O
cranberry O
juice O
for O
two O
weeks O
while O
maintaining O
his O
usual O
dosage O
of O
warfarin O
. O

we O
propose O
that O
naturally O
occurring O
compounds O
such O
as O
flavonoids O
, O
which O
are O
present O
in O
fruit O
juices O
, O
may O
increase O
the O
potency O
of O
warfarin O
by O
competing O
for O
the O
enzymes O
that O
normally O
inactivate O
warfarin O
. O

while O
traditionally O
regarded O
as O
foodstuffs O
, O
consumption O
of O
fruit O
juices O
should O
be O
considered O
when O
patients O
develop O
adverse O
drug O
reactions O
. O

-DOCSTART- O

isoproterenol O
induces O
primary O
loss O
of O
dystrophin O
in O
rat O
hearts O
: O
correlation O
with O
myocardial B-NEG
injury I-NEG
. O

the O
mechanism O
of O
isoproterenol-induced O
myocardial B-NEG
damage I-NEG
is O
unknown O
, O
but O
a O
mismatch O
of O
oxygen O
supply O
vs O
. O
demand O
following O
coronary O
hypotension B-NEG
and O
myocardial B-NEG
hyperactivity I-NEG
is O
the O
best O
explanation O
for O
the O
complex O
morphological O
alterations O
observed O
. O

severe O
alterations O
in O
the O
structural O
integrity O
of O
the O
sarcolemma O
of O
cardiomyocytes O
have O
been O
demonstrated O
to O
be O
caused O
by O
isoproterenol O
. O

taking O
into O
account O
that O
the O
sarcolemmal O
integrity O
is O
stabilized O
by O
the O
dystrophin-glycoprotein O
complex O
( O
dgc O
) O
that O
connects O
actin O
and O
laminin O
in O
contractile O
machinery O
and O
extracellular O
matrix O
and O
by O
integrins O
, O
this O
study O
tests O
the O
hypothesis O
that O
isoproterenol O
affects O
sarcolemmal O
stability O
through O
changes O
in O
the O
dgc O
and O
integrins O
. O

we O
found O
different O
sensitivity O
of O
the O
dgc O
and O
integrin O
to O
isoproterenol O
subcutaneous O
administration O
. O

immunofluorescent O
staining O
revealed O
that O
dystrophin O
is O
the O
most O
sensitive O
among O
the O
structures O
connecting O
the O
actin O
in O
the O
cardiomyocyte O
cytoskeleton O
and O
the O
extracellular O
matrix O
. O

the O
sarcomeric O
actin O
dissolution O
occurred O
after O
the O
reduction O
or O
loss O
of O
dystrophin O
. O

subsequently O
, O
after O
lysis O
of O
myofilaments O
, O
gamma-sarcoglycan O
, O
beta-dystroglycan O
, O
beta1-integrin O
, O
and O
laminin O
alpha-2 O
expressions O
were O
reduced O
followed O
by O
their O
breakdown O
, O
as O
epiphenomena O
of O
the O
myocytolytic O
process O
. O

in O
conclusion O
, O
administration O
of O
isoproterenol O
to O
rats O
results O
in O
primary O
loss O
of O
dystrophin O
, O
the O
most O
sensitive O
among O
the O
structural O
proteins O
that O
form O
the O
dgc O
that O
connects O
the O
extracellular O
matrix O
and O
the O
cytoskeleton O
in O
cardiomyocyte O
. O

these O
changes O
, O
related O
to O
ischaemic B-NEG
injury I-NEG
, O
explain O
the O
severe O
alterations O
in O
the O
structural O
integrity O
of O
the O
sarcolemma O
of O
cardiomyocytes O
and O
hence O
severe O
and O
irreversible O
injury O
induced O
by O
isoproterenol O
. O

-DOCSTART- O

high O
fat O
diet-fed O
obese B-NEG
rats O
are O
highly O
sensitive O
to O
doxorubicin-induced O
cardiotoxicity B-NEG
. O

often O
, O
chemotherapy O
by O
doxorubicin O
( O
adriamycin O
) O
is O
limited O
due O
to O
life O
threatening O
cardiotoxicity B-NEG
in O
patients O
during O
and O
posttherapy O
. O

recently O
, O
we O
have O
shown O
that O
moderate O
diet O
restriction O
remarkably O
protects O
against O
doxorubicin-induced O
cardiotoxicity B-NEG
. O

this O
cardioprotection O
is O
accompanied O
by O
decreased O
cardiac O
oxidative O
stress O
and O
triglycerides O
and O
increased O
cardiac O
fatty-acid O
oxidation O
, O
atp O
synthesis O
, O
and O
upregulated O
jak/stat3 O
pathway O
. O

in O
the O
current O
study O
, O
we O
investigated O
whether O
a O
physiological O
intervention O
by O
feeding O
40% O
high O
fat O
diet O
(hfd) O
, O
which O
induces O
obesity B-NEG
in O
male O
sprague-dawley O
rats O
( O
250-275 O
g) O
, O
sensitizes O
to O
doxorubicin-induced O
cardiotoxicity B-NEG
. O

a O
ld(10 O
) O
dose O
(8 O
mg O
doxorubicin/kg O
, O
ip O
) O
administered O
on O
day O
43 O
of O
the O
hfd O
feeding O
regimen O
led O
to O
higher O
cardiotoxicity B-NEG
, O
cardiac B-NEG
dysfunction I-NEG
, O
lipid O
peroxidation O
, O
and O
80% O
mortality O
in O
the O
obese B-NEG
( O
ob B-NEG
) O
rats O
in O
the O
absence O
of O
any O
significant O
renal B-NEG
or I-NEG
hepatic I-NEG
toxicity I-NEG
. O

doxorubicin O
toxicokinetics O
studies O
revealed O
no O
change O
in O
accumulation O
of O
doxorubicin O
and O
doxorubicinol O
( O
toxic O
metabolite O
) O
in O
the O
normal O
diet-fed O
( O
nd O
) O
and O
ob B-NEG
hearts O
. O

mechanistic O
studies O
revealed O
that O
ob B-NEG
rats O
are O
sensitized O
due O
to O
: O
( O
1 O
) O
higher O
oxyradical O
stress O
leading O
to O
upregulation O
of O
uncoupling O
proteins O
2 O
and O
3, O
( O
2 O
) O
downregulation O
of O
cardiac O
peroxisome O
proliferators O
activated O
receptor-alpha O
, O
( O
3 O
) O
decreased O
plasma O
adiponectin O
levels O
, O
( O
4 O
) O
decreased O
cardiac O
fatty-acid O
oxidation O
( O
666.9+/-14.0 O
nmol/min/g O
heart O
in O
nd O
versus O
400.2+/-11.8 O
nmol/min/g O
heart O
in O
ob B-NEG
), O
( O
5 O
) O
decreased O
mitochondrial O
amp-alpha2 O
protein O
kinase O
, O
and O
( O
6 O
) O
86% O
drop O
in O
cardiac O
atp O
levels O
accompanied O
by O
decreased O
atp/adp O
ratio O
after O
doxorubicin O
administration O
. O

decreased O
cardiac O
erythropoietin O
and O
increased O
socs3 O
further O
downregulated O
the O
cardioprotective O
jak/stat3 O
pathway O
. O

in O
conclusion O
, O
hfd-induced O
obese B-NEG
rats O
are O
highly O
sensitized O
to O
doxorubicin-induced O
cardiotoxicity B-NEG
by O
substantially O
downregulating O
cardiac O
mitochondrial O
atp O
generation O
, O
increasing O
oxidative O
stress O
and O
downregulating O
the O
jak/stat3 O
pathway O
. O

-DOCSTART- O

complete O
atrioventricular B-NEG
block I-NEG
secondary O
to O
lithium O
therapy O
. O
sinus B-NEG
node I-NEG
dysfunction I-NEG
has O
been O
reported O
most O
frequently O
among O
the O
adverse O
cardiovascular O
effects O
of O
lithium O
. O

in O
the O
present O
case O
, O
complete O
atrioventricular B-NEG
( O
av I-NEG
) O
block I-NEG
with O
syncopal B-NEG
attacks I-NEG
developed O
secondary O
to O
lithium O
therapy O
, O
necessitating O
permanent O
pacemaker O
implantation O
. O

serum O
lithium O
levels O
remained O
under O
or O
within O
the O
therapeutic O
range O
during O
the O
syncopal B-NEG
attacks I-NEG
. O

lithium O
should O
be O
used O
with O
extreme O
caution O
, O
especially O
in O
patients O
with O
mild O
disturbance O
of O
av O
conduction O
. O

-DOCSTART- O

neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
induced O
by O
ziprasidone O
on O
the O
second O
day O
of O
treatment O
. O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
( O
nms B-NEG
) O
is O
the O
rarest O
and O
most O
serious O
of O
the O
neuroleptic-induced O
movement B-NEG
disorders I-NEG
. O

we O
describe O
a O
case O
of O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
( O
nms B-NEG
) O
associated O
with O
the O
use O
of O
ziprasidone O
. O

although O
conventional O
neuroleptics O
are O
more O
frequently O
associated O
with O
nms B-NEG
, O
atypical O
antipsychotic O
drugs O
like O
ziprasidone O
may O
also O
be O
a O
cause O
. O

the O
patient O
is O
a O
24-year-old O
male O
with O
a O
history O
of O
schizophrenia B-NEG
who O
developed O
signs O
and O
symptoms O
of O
nms B-NEG
after O
2 O
days O
of O
treatment O
with O
an O
80-mg/day O
dose O
of O
orally O
administrated O
ziprasidone O
. O

this O
case O
is O
the O
earliest O
( O
second O
day O
of O
treatment O
) O
nms B-NEG
due O
to O
ziprasidone O
reported O
in O
the O
literature O
. O

-DOCSTART- O

role O
of O
mangiferin O
on O
biochemical O
alterations O
and O
antioxidant O
status O
in O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
. O

the O
current O
study O
dealt O
with O
the O
protective O
role O
of O
mangiferin O
, O
a O
polyphenol O
from O
mangifera O
indica O
linn O
. O

(anacardiaceae) O
, O
on O
isoproterenol O
( O
isph)-induced O
myocardial B-NEG
infarction I-NEG
( O
mi B-NEG
) O
in O
rats O
through O
its O
antioxidative O
mechanism O
. O

subcutaneous O
injection O
of O
isph O
( O
200 O
mg/kg O
body O
weight O
in O
1 O
ml O
saline O
) O
to O
rats O
for O
2 O
consecutive O
days O
caused O
myocardial B-NEG
damage I-NEG
in O
rat O
heart O
, O
which O
was O
determined O
by O
the O
increased O
activity O
of O
serum O
lactate O
dehydrogenase O
( O
ldh O
) O
and O
creatine O
phosphokinase O
isoenzymes O
(ck-mb) O
, O
increased O
uric O
acid O
level O
and O
reduced O
plasma O
iron O
binding O
capacity O
. O

the O
protective O
role O
of O
mangiferin O
was O
analyzed O
by O
triphenyl O
tetrazolium O
chloride O
( O
ttc O
) O
test O
used O
for O
macroscopic O
enzyme O
mapping O
assay O
of O
the O
ischemic B-NEG
myocardium I-NEG
. O

the O
heart O
tissue O
antioxidant O
enzymes O
such O
as O
superoxide O
dismutase O
, O
catalase O
, O
glutathione O
peroxidase O
, O
glutathione O
transferase O
and O
glutathione O
reductase O
activities O
, O
non-enzymic O
antioxidants O
such O
as O
cerruloplasmin O
, O
vitamin O
c, O
vitamin O
e O
and O
glutathione O
levels O
were O
altered O
in O
mi B-NEG
rats O
. O

upon O
pretreatment O
with O
mangiferin O
( O
100 O
mg/kg O
body O
weight O
suspended O
in O
2 O
ml O
of O
dimethyl O
sulphoxide O
) O
given O
intraperitoneally O
for O
28 O
days O
to O
mi B-NEG
rats O
protected O
the O
above-mentioned O
parameters O
to O
fall O
from O
the O
normal O
levels O
. O

activities O
of O
heart O
tissue O
enzymic O
antioxidants O
and O
serum O
non-enzymic O
antioxidants O
levels O
rose O
significantly O
upon O
mangiferin O
administration O
as O
compared O
to O
isph-induced O
mi B-NEG
rats O
. O

from O
the O
present O
study O
it O
is O
concluded O
that O
mangiferin O
exerts O
a O
beneficial O
effect O
against O
isph-induced O
mi B-NEG
due O
to O
its O
antioxidant O
potential O
, O
which O
regulated O
the O
tissues O
defense O
system O
against O
cardiac B-NEG
damage I-NEG
. O

-DOCSTART- O

remifentanil O
pretreatment O
reduces O
myoclonus B-NEG
after O
etomidate O
. O

study O
objective O
: O
the O
aim O
of O
the O
study O
was O
to O
compare O
the O
effect O
of O
pretreatment O
with O
remifentanil O
1 O
microg/kg O
and O
the O
effect O
of O
gender O
on O
the O
incidence O
of O
myoclonus B-NEG
after O
anesthesia O
induction O
with O
etomidate O
. O

design O
: O
this O
was O
a O
randomized O
, O
double-blind O
study O
. O

setting O
: O
the O
study O
was O
conducted O
at O
a O
university O
hospital O
. O

patients O
: O
sixty O
patients O
were O
pretreated O
in O
a O
randomized O
double-blinded O
fashion O
with O
remifentanil O
1 O
microg/kg O
or O
placebo O
. O

two O
minutes O
after O
remifentanil O
or O
placebo O
injection O
, O
etomidate O
0.3 O
mg/kg O
was O
given O
. O

measurements O
: O
myoclonus B-NEG
was O
recorded O
with O
a O
scale O
of O
0 O
to O
3. O

the O
grade O
of O
sedation O
(none O
, O
mild O
, O
moderate O
, O
severe) O
, O
nausea B-NEG
, O
pruritus B-NEG
, O
and O
apnea B-NEG
were O
recorded O
after O
injection O
of O
both O
drugs O
. O

main O
results O
: O
the O
incidence O
of O
myoclonus B-NEG
was O
significantly O
lower O
in O
the O
remifentanil O
group O
( O
6.7% O
) O
than O
in O
the O
placebo O
group O
( O
70% O
) O
(p O
< O
0.001) O
. O

none O
of O
the O
patients O
experienced O
sedation O
, O
apnea B-NEG
, O
nausea B-NEG
, O
or O
pruritus B-NEG
after O
injection O
of O
both O
drugs O
. O

in O
the O
placebo O
group O
, O
male O
patients O
were O
associated O
with O
significantly O
increased O
incidence O
of O
myoclonus B-NEG
after O
etomidate O
administration O
. O

conclusion O
: O
pretreatment O
with O
remifentanil O
1 O
microg/kg O
reduced O
myoclonus B-NEG
after O
etomidate O
induction O
without O
side O
effects O
such O
as O
sedation O
, O
apnea B-NEG
, O
nausea B-NEG
, O
or O
pruritus B-NEG
. O

men O
experience O
increased O
incidence O
of O
myoclonus B-NEG
than O
women O
after O
etomidate O
administration O
. O

-DOCSTART- O

daidzein O
activates O
choline O
acetyltransferase O
from O
mc-ixc O
cells O
and O
improves O
drug-induced O
amnesia B-NEG
. O

the O
choline O
acetyltransferase O
( O
chat O
) O
activator O
, O
which O
enhances O
cholinergic O
transmission O
via O
an O
augmentation O
of O
the O
enzymatic O
production O
of O
acetylcholine O
(ach) O
, O
is O
an O
important O
factor O
in O
the O
treatment O
of O
alzheimer's B-NEG
disease I-NEG
( O
ad B-NEG
). O

methanolic O
extracts O
from O
pueraria O
thunbergiana O
exhibited O
an O
activation O
effect O
( O
46% O
) O
on O
chat O
in O
vitro O
. O

via O
the O
sequential O
isolation O
of O
pueraria O
thunbergiana O
, O
the O
active O
component O
was O
ultimately O
identified O
as O
daidzein O
(4',7-dihydroxy-isoflavone) O
. O

in O
order O
to O
investigate O
the O
effects O
of O
daidzein O
from O
pueraria O
thunbergiana O
on O
scopolamine-induced O
impairments B-NEG
of I-NEG
learning I-NEG
and I-NEG
memory I-NEG
, O
we O
conducted O
a O
series O
of O
in O
vivo O
tests O
. O

administration O
of O
daidzein O
( O
4.5 O
mg/kg O
body O
weight O
) O
to O
mice O
was O
shown O
significantly O
to O
reverse O
scopolamine-induced O
amnesia B-NEG
, O
according O
to O
the O
results O
of O
a O
y-maze O
test O
. O

injections O
of O
scopolamine O
into O
mice O
resulted O
in O
impaired O
performance O
on O
y-maze O
tests O
(a O
37% O
decreases O
in O
alternation O
behavior) O
. O

by O
way O
of O
contrast O
, O
mice O
treated O
with O
daidzein O
prior O
to O
the O
scopolamine O
injections O
were O
noticeably O
protected O
from O
this O
performance O
impairment O
( O
an O
approximately O
12%-21% O
decrease O
in O
alternation O
behavior) O
. O

these O
results O
indicate O
that O
daidzein O
might O
play O
a O
role O
in O
acetylcholine O
biosynthesis O
as O
a O
chat O
activator O
, O
and O
that O
it O
also O
ameliorates O
scopolamine-induced O
amnesia B-NEG
. O

-DOCSTART- O

possible O
azithromycin-associated O
hiccups B-NEG
. O

objective O
: O
to O
report O
a O
case O
of O
persistent O
hiccups B-NEG
associated O
by O
azithromycin O
therapy O
. O

case O
summary O
: O
a O
76-year-old O
man O
presented O
with O
persistent O
hiccups B-NEG
after O
beginning O
azithromycin O
for O
the O
treatment O
of O
pharyngitis B-NEG
. O
hiccups B-NEG
were O
persistent O
and O
exhausting O
. O

discontinuation O
of O
azithromycin O
and O
therapy O
with O
baclofen O
finally O
resolved O
hiccups B-NEG
. O

no O
organic O
cause O
of O
hiccups B-NEG
was O
identified O
despite O
extensive O
investigation O
. O

discussion O
: O
pharmacotherapeutic O
agents O
have O
been O
uncommonly O
associated O
with O
hiccups B-NEG
. O

corticosteroids O
( O
dexamethasone O
and O
methylprednisolone) O
, O
benzodiazepines O
( O
midazolam O
) O
and O
general O
anaesthesia O
have O
been O
the O
specific O
agents O
mentioned O
most O
frequently O
in O
the O
literature O
as O
being O
associated O
with O
the O
development O
of O
hiccups B-NEG
. O

few O
cases O
of O
drug-induced O
hiccups B-NEG
have O
been O
reported O
related O
to O
macrolide O
antimicrobials O
. O

using O
the O
naranjo O
adverse O
effect O
reaction O
probability O
scale O
this O
event O
could O
be O
classified O
as O
possible O
( O
score O
5 O
points) O
, O
mostly O
because O
of O
the O
close O
temporal O
sequence O
, O
previous O
reports O
on O
this O
reaction O
with O
other O
macrolides O
and O
the O
absence O
of O
any O
alternative O
explanation O
for O
hiccups B-NEG
. O

our O
hypothesis O
is O
that O
a O
vagal O
mechanism O
mediated O
by O
azithromycin O
could O
be O
the O
pathogenesis O
of O
hiccups B-NEG
in O
our O
patient O
. O

conclusions O
: O
diagnosis O
of O
drug-induced O
hiccups B-NEG
is O
difficult O
and O
often O
achieved O
only O
by O
a O
process O
of O
elimination O
. O

however O
, O
macrolide O
antimicrobials O
have O
been O
reported O
to O
be O
associated O
with O
hiccups B-NEG
and O
vagal O
mechanism O
could O
explain O
the O
development O
of O
this O
side-effect O
. O

-DOCSTART- O

time O
trends O
in O
warfarin-associated O
hemorrhage B-NEG
. O

the O
annual O
incidence O
of O
warfarin-related O
bleeding B-NEG
at O
brigham O
and O
women's O
hospital O
increased O
from O
0.97/1,000 O
patient O
admissions O
in O
the O
first O
time O
period O
( O
january O
1995 O
to O
october O
1998 O
) O
to O
1.19/1,000 O
patient O
admissions O
in O
the O
second O
time O
period O
( O
november O
1998 O
to O
august O
2002 O
) O
of O
this O
study O
. O

the O
proportion O
of O
patients O
with O
major O
and O
intracranial B-NEG
bleeding I-NEG
increased O
from O
20.2% O
and O
1.9% O
, O
respectively O
, O
in O
the O
first O
time O
period O
, O
to O
33.3% O
and O
7.8% O
, O
respectively O
, O
in O
the O
second O
. O

-DOCSTART- O

fatal O
haemorrhagic B-NEG
myocarditis I-NEG
secondary O
to O
cyclophosphamide O
therapy O
. O
haemorrhagic B-NEG
myocarditis I-NEG
is O
a O
rare O
but O
important O
complication O
of O
cyclophosphamide O
therapy O
. O

echocardiographic O
identification O
of O
the O
disorder O
can O
be O
made O
. O

we O
believe O
that O
the O
ultrasound O
features O
of O
this O
disorder O
have O
not O
been O
previously O
reported O
. O

-DOCSTART- O

glyceryl O
trinitrate O
induces O
attacks O
of O
migraine B-NEG
without I-NEG
aura I-NEG
in O
sufferers O
of O
migraine B-NEG
with I-NEG
aura I-NEG
. O
migraine B-NEG
with I-NEG
aura I-NEG
and O
migraine B-NEG
without I-NEG
aura I-NEG
have O
the O
same O
pain B-NEG
phase O
, O
thus O
indicating O
that O
migraine B-NEG
with I-NEG
aura I-NEG
and O
migraine B-NEG
without I-NEG
aura I-NEG
share O
a O
common O
pathway O
of O
nociception O
. O

in O
recent O
years O
, O
increasing O
evidence O
has O
suggested O
that O
the O
messenger O
molecule O
nitric O
oxide O
( O
no O
) O
is O
involved O
in O
pain B-NEG
mechanisms O
of O
migraine B-NEG
without I-NEG
aura I-NEG
. O

in O
order O
to O
clarify O
whether O
the O
same O
is O
true O
for O
migraine B-NEG
with I-NEG
aura I-NEG
, O
in O
the O
present O
study O
we O
examined O
the O
headache B-NEG
response O
to O
intravenous O
infusion O
of O
glyceryl O
trinitrate O
( O
gtn O
) O
( O
0.5 O
microg/kg/min O
for O
20 O
min O
) O
in O
12 O
sufferers O
of O
migraine B-NEG
with I-NEG
aura I-NEG
. O

the O
specific O
aim O
was O
to O
elucidate O
whether O
an O
aura O
and/or O
an O
attack O
of O
migraine B-NEG
without I-NEG
aura I-NEG
could O
be O
induced O
. O

fourteen O
healthy O
subjects O
served O
as O
controls O
. O

aura O
symptoms O
were O
not O
elicited O
in O
any O
subject O
. O
headache B-NEG
was O
more O
severe O
in O
migraineurs B-NEG
than O
in O
the O
controls O
during O
and O
immediately O
after O
gtn O
infusion O
( O
p=0.037 O
) O
as O
well O
as O
during O
the O
following O
11 O
h O
(p O
= O
0.008) O
. O

in O
the O
controls O
, O
the O
gtn-induced O
headache B-NEG
gradually O
disappeared O
, O
whereas O
in O
migraineurs B-NEG
peak O
headache B-NEG
intensity O
occurred O
at O
a O
mean O
time O
of O
240 O
min O
post-infusion O
. O

at O
this O
time O
the O
induced O
headache B-NEG
in O
6 O
of O
12 O
migraineurs B-NEG
fulfilled O
the O
diagnostic O
criteria O
for O
migraine B-NEG
without I-NEG
aura I-NEG
of O
the O
international O
headache B-NEG
society O
. O

the O
results O
therefore O
suggest O
that O
no O
is O
involved O
in O
the O
pain B-NEG
mechanisms O
of O
migraine B-NEG
with I-NEG
aura I-NEG
. O

since O
cortical O
spreading O
depression B-NEG
has O
been O
shown O
to O
liberate O
no O
in O
animals O
, O
this O
finding O
may O
help O
our O
understanding O
of O
the O
coupling O
between O
cortical O
spreading O
depression B-NEG
and O
headache B-NEG
in O
migraine B-NEG
with I-NEG
aura I-NEG
. O

-DOCSTART- O

stroke B-NEG
and O
cocaine O
or O
amphetamine O
use O
. O

the O
association O
of O
cocaine O
and O
amphetamine O
use O
with O
hemorrhagic O
and O
ischemic B-NEG
stroke B-NEG
is O
based O
almost O
solely O
on O
data O
from O
case O
series O
. O

the O
limited O
number O
of O
epidemiologic O
studies O
of O
stroke B-NEG
and O
use O
of O
cocaine O
and/or O
amphetamine O
have O
been O
done O
in O
settings O
that O
serve O
mostly O
the O
poor O
and/or O
minorities O
. O

this O
case-control O
study O
was O
conducted O
in O
the O
defined O
population O
comprising O
members O
of O
kaiser O
permanente O
of O
northern O
and O
southern O
california O
. O

we O
attempted O
to O
identify O
all O
incident O
strokes B-NEG
in O
women O
ages O
15-44 O
years O
during O
a O
3-year O
period O
using O
hospital O
admission O
and O
discharge O
records O
, O
emergency O
department O
logs O
, O
and O
payment O
requests O
for O
out-of-plan O
hospitalizations O
. O

we O
selected O
controls O
, O
matched O
on O
age O
and O
facility O
of O
usual O
care O
, O
at O
random O
from O
healthy O
members O
of O
the O
health O
plan O
. O

we O
obtained O
information O
in O
face-to-face O
interviews O
. O

there O
were O
347 O
confirmed O
stroke B-NEG
cases O
and O
1,021 O
controls O
. O

the O
univariate O
matched O
odds O
ratio O
for O
stroke B-NEG
in O
women O
who O
admitted O
to O
using O
cocaine O
and/or O
amphetamine O
was O
8.5 O
( O
95% O
confidence O
interval O
= O
3.6-20.0) O
. O

after O
further O
adjustment O
for O
potential O
confounders O
, O
the O
odds O
ratio O
in O
women O
who O
reported O
using O
cocaine O
and/or O
amphetamine O
was O
7.0 O
( O
95% O
confidence O
interval O
= O
2.8-17.9) O
. O

the O
use O
of O
cocaine O
and/or O
amphetamine O
is O
a O
strong O
risk O
factor O
for O
stroke B-NEG
in O
this O
socioeconomically O
heterogeneous O
, O
insured O
urban O
population O
. O

-DOCSTART- O

prevention O
of O
breast B-NEG
cancer I-NEG
with O
tamoxifen O
: O
preliminary O
findings O
from O
the O
italian O
randomised O
trial O
among O
hysterectomised O
women O
. O

italian O
tamoxifen O
prevention O
study O
. O

background O
: O
tamoxifen O
is O
a O
candidate O
chemopreventive O
agent O
in O
breast B-NEG
cancer I-NEG
, O
although O
the O
drug O
may O
be O
associated O
with O
the O
development O
of O
endometrial B-NEG
cancer I-NEG
. O

therefore O
we O
did O
a O
trial O
in O
hysterectomised O
women O
of O
tamoxifen O
as O
a O
chemopreventive O
. O

methods O
: O
in O
october O
, O
1992 O
, O
we O
started O
a O
double-blind O
placebo-controlled O
, O
randomised O
trial O
of O
tamoxifen O
in O
women O
( O
mainly O
in O
italy O
) O
who O
did O
not O
have O
breast B-NEG
cancer I-NEG
and O
who O
had O
had O
a O
hysterectomy O
. O

women O
were O
randomised O
to O
receive O
tamoxifen O
20 O
mg O
per O
day O
or O
placebo O
, O
both O
orally O
for O
5 O
years O
. O

the O
original O
plan O
was O
to O
follow O
the O
intervention O
phase O
by O
5 O
years' O
follow-up O
. O

in O
june O
, O
1997 O
, O
the O
trialists O
and O
the O
data-monitoring O
committee O
decided O
to O
end O
recruitment O
primarily O
because O
of O
the O
number O
of O
women O
dropping O
out O
of O
the O
study O
. O

recruitment O
ended O
on O
july O
11 O
, O
1997 O
, O
and O
the O
study O
will O
continue O
as O
planned O
. O

the O
primary O
endpoints O
are O
the O
occurrence O
of O
and O
deaths O
from O
breast B-NEG
cancer I-NEG
. O

this O
preliminary O
interim O
analysis O
is O
based O
on O
intention-to-treat O
. O

findings O
: O
5408 O
women O
were O
randomised O
; O
participating O
women O
have O
a O
median O
follow-up O
of O
46 O
months O
for O
major O
endpoints O
. O

41 O
cases O
of O
breast B-NEG
cancer I-NEG
occurred O
so O
far O
; O
there O
have O
been O
no O
deaths O
from O
breast B-NEG
cancer I-NEG
. O

there O
is O
no O
difference O
in O
breast-cancer B-NEG
frequency O
between O
the O
placebo O
( O
22 O
cases O
) O
and O
tamoxifen O
( O
19 O
) O
arms O
. O

there O
is O
a O
statistically O
significant O
reduction O
of O
breast B-NEG
cancer I-NEG
among O
women O
receiving O
tamoxifen O
who O
also O
used O
hormone-replacement O
therapy O
during O
the O
trial O
: O
among O
390 O
women O
on O
such O
therapy O
and O
allocated O
to O
placebo O
, O
we O
found O
eight O
cases O
of O
breast B-NEG
cancer I-NEG
compared O
with O
one O
case O
among O
362 O
women O
allocated O
to O
tamoxifen O
. O

compared O
with O
the O
placebo O
group O
, O
there O
was O
a O
significantly O
increased O
risk O
of O
vascular B-NEG
events I-NEG
and O
hypertriglyceridaemia B-NEG
among O
women O
on O
tamoxifen O
. O

interpretation O
: O
although O
this O
preliminary O
analysis O
has O
low O
power O
, O
in O
this O
cohort O
of O
women O
at O
low-to-normal O
risk O
of O
breast B-NEG
cancer I-NEG
, O
the O
postulated O
protective O
effects O
of O
tamoxifen O
are O
not O
yet O
apparent O
. O

women O
using O
hormone-replacement O
therapy O
appear O
to O
have O
benefited O
from O
use O
of O
tamoxifen O
. O

there O
were O
no O
deaths O
from O
breast B-NEG
cancer I-NEG
recorded O
in O
women O
in O
the O
study O
. O

it O
is O
essential O
to O
continue O
follow-up O
to O
quantify O
the O
long-term O
risks O
and O
benefits O
of O
tamoxifen O
therapy O
. O

-DOCSTART- O

a O
measure O
of O
pupillary B-NEG
oscillation I-NEG
as O
a O
marker O
of O
cocaine-induced O
paranoia B-NEG
. O

cocaine-induced O
paranoia B-NEG
( O
cip B-NEG
) O
remains O
an O
important O
drug-induced O
model O
of O
idiopathic O
paranoia B-NEG
for O
which O
no O
psychophysiologic O
marker O
has O
yet O
emerged O
. O

measures O
of O
pupillary B-NEG
oscillation I-NEG
were O
able O
to O
significantly O
distinguish O
a O
group O
of O
abstinent O
crack O
cocaine O
abusers O
endorsing O
past O
cip B-NEG
(n O
= O
32 O
) O
from O
another O
group O
of O
crack O
addicts O
who O
denied O
past O
cip B-NEG
(n O
= O
29) O
. O

-DOCSTART- O

seizures B-NEG
induced O
by O
combined O
levomepromazine-fluvoxamine O
treatment O
. O

we O
report O
a O
case O
of O
combined O
levomepromazine-fluvoxamine O
treatment-induced O
seizures B-NEG
. O

it O
seems O
that O
combined O
treatment O
of O
fluvoxamine O
with O
phenothiazines O
may O
possess O
proconvulsive O
activity O
. O

-DOCSTART- O

why O
may O
epsilon-aminocaproic O
acid O
( O
eaca O
) O
induce O
myopathy B-NEG
in O
man? O

report O
of O
a O
case O
and O
literature O
review O
. O

a O
case O
of O
necrotizing B-NEG
myopathy I-NEG
due O
to O
a O
short O
epsilon-aminocaproic O
acid O
( O
eaca O
) O
treatment O
in O
a O
72 O
year-old O
patient O
with O
subarachnoid B-NEG
haemorrhage I-NEG
( O
sah B-NEG
) O
is O
described O
. O

pathogenetic O
hypotheses O
are O
discussed O
. O

-DOCSTART- O

comparison O
of O
the O
effectiveness O
of O
ranitidine O
and O
cimetidine O
in O
inhibiting O
acid O
secretion O
in O
patients O
with O
gastric O
hypersecretory O
states O
. O

the O
h2-histamine O
receptor O
antagonists O
ranitidine O
and O
cimetidine O
were O
compared O
for O
their O
abilities O
to O
control O
gastric O
acid O
hypersecretion O
on O
a O
short- O
and O
long-term O
basis O
in O
22 O
patients O
with O
gastric O
acid O
hypersecretory O
states O
. O

nineteen O
patients O
had O
zollinger-ellison B-NEG
syndrome I-NEG
, O
one O
patient O
had O
systemic B-NEG
mastocytosis I-NEG
, O
and O
two O
patients O
had O
idiopathic O
hypersecretion O
. O

the O
rates O
of O
onset O
of O
the O
action O
of O
cimetidine O
and O
ranitidine O
were O
the O
same O
. O

the O
actions O
of O
both O
drugs O
were O
increased O
by O
anticholinergic O
agents O
, O
and O
there O
was O
a O
close O
correlation O
between O
the O
daily O
maintenance O
dose O
of O
each O
drug O
needed O
to O
control O
acid O
secretion O
. O

however O
, O
ranitidine O
was O
threefold O
more O
potent O
than O
cimetidine O
both O
in O
acute O
inhibition O
studies O
and O
in O
the O
median O
maintenance O
dose O
needed O
( O
1.2 O
g O
per O
day O
for O
ranitidine O
and O
3.6 O
g O
per O
day O
for O
cimetidine) O
. O

sixty O
percent O
of O
the O
males O
developed O
breast O
changes O
or O
impotence B-NEG
while O
taking O
cimetidine O
and O
in O
all O
cases O
these O
changes O
disappeared O
when O
cimetidine O
was O
replaced O
by O
ranitidine O
. O

treatment O
with O
high O
doses O
of O
cimetidine O
( O
one O
to O
60 O
months O
; O
median O
, O
11 O
months O
) O
or O
ranitidine O
( O
two O
to O
31 O
months O
; O
median O
, O
14 O
months O
) O
was O
not O
associated O
with O
hepatic B-NEG
or I-NEG
hematologic I-NEG
toxicity I-NEG
or O
alterations O
of O
serum O
gastrin O
concentrations O
, O
but O
ranitidine O
therapy O
was O
associated O
with O
a O
significantly O
lower O
serum O
creatinine O
level O
than O
seen O
with O
cimetidine O
therapy O
. O

the O
results O
show O
that O
both O
drugs O
can O
adequately O
inhibit O
acid O
secretion O
in O
patients O
with O
gastric O
hypersecretory O
states O
. O

both O
are O
safe O
at O
high O
doses O
, O
but O
ranitidine O
is O
threefold O
more O
potent O
and O
does O
not O
cause O
the O
antiandrogen O
side O
effects O
frequently O
seen O
with O
high O
doses O
of O
cimetidine O
. O

-DOCSTART- O

a O
catch O
in O
the O
reye B-NEG
. O

twenty-six O
cases O
of O
reye B-NEG
syndrome I-NEG
from O
the O
children's O
hospital O
, O
camperdown O
, O
australia O
, O
occurring O
between O
1973 O
and O
1982 O
were O
reviewed O
. O

of O
these O
, O
20 O
cases O
met O
the O
us O
public O
health O
service O
centers O
for O
disease O
control O
criteria O
for O
the O
diagnosis O
of O
reye B-NEG
syndrome I-NEG
. O

aspirin O
or O
salicylate O
ingestion O
had O
occurred O
in O
only O
one O
of O
the O
20 O
cases O
(5%) O
, O
and O
paracetamol O
( O
acetaminophen O
) O
had O
been O
administered O
in O
only O
six O
of O
the O
cases O
(30%) O
. O

pathologic O
confirmation O
of O
the O
diagnosis O
of O
reye B-NEG
syndrome I-NEG
was O
accomplished O
in O
90% O
of O
the O
cases O
. O

the O
incidence O
of O
reye B-NEG
syndrome I-NEG
in O
new O
south O
wales O
, O
australia O
, O
is O
estimated O
from O
this O
study O
to O
be O
approximately O
nine O
cases O
per O
1 O
million O
children O
compared O
with O
recent O
us O
data O
of O
ten O
to O
20 O
cases O
per O
1 O
million O
children O
and O
three O
to O
seven O
cases O
per O
1 O
million O
children O
in O
great O
britain O
. O

the O
mortality O
for O
these O
reye B-NEG
syndrome I-NEG
cases O
in O
australia O
was O
45% O
as O
compared O
with O
a O
32% O
case-fatality O
rate O
in O
the O
united O
states O
. O

in O
australia O
, O
the O
pediatric O
usage O
of O
aspirin O
has O
been O
extremely O
low O
for O
the O
past O
25 O
years O
( O
less O
than O
1% O
of O
total O
dosage O
units O
sold) O
, O
with O
paracetamol O
( O
acetaminophen O
) O
dominating O
the O
pediatric O
analgesic O
and O
antipyretic O
market O
. O
reye B-NEG
syndrome I-NEG
may O
be O
disappearing O
from O
australia O
despite O
a O
total O
lack O
of O
association O
with O
salicylates O
or O
aspirin O
ingestion O
, O
since O
there O
were O
no O
cases O
found O
at O
the O
children's O
hospital O
in O
1983 O
, O
1984 O
, O
or O
1985 O
. O

-DOCSTART- O

st B-NEG
. O
anthony's I-NEG
fire I-NEG
, O
then O
and O
now O
: O
a O
case O
report O
and O
historical O
review O
. O

a O
rare O
case O
of O
morbid O
vasospasm B-NEG
, O
together O
with O
striking O
angiographic O
findings O
, O
is O
described O
secondary O
to O
the O
ingestion O
of O
methysergide O
by O
a O
48-year-old O
woman O
. O

a O
brief O
review O
of O
the O
literature O
on O
similar O
cases O
is O
presented O
. O

a O
discussion O
of O
the O
history O
of O
ergot O
includes O
its O
original O
discovery O
, O
the O
epidemics O
of O
gangrene B-NEG
that O
it O
has O
caused O
through O
the O
ages O
and O
its O
past O
and O
present O
role O
in O
the O
management O
of O
migraine B-NEG
headache I-NEG
. O

despite O
the O
advent O
of O
calcium O
channel O
blockers O
and O
beta-adrenergic O
antagonists O
, O
ergot O
preparations O
continue O
to O
play O
a O
major O
role O
in O
migraine B-NEG
therapy O
, O
so O
that O
the O
danger O
of O
st B-NEG
. O
anthony's I-NEG
fire I-NEG
persists O
. O

-DOCSTART- O

beta-2-adrenoceptor-mediated O
hypokalemia B-NEG
and O
its O
abolishment O
by O
oxprenolol O
. O

the O
time O
course O
and O
concentration-effect O
relationship O
of O
terbutaline-induced O
hypokalemia B-NEG
was O
studied O
, O
using O
computer-aided O
pharmacokinetic-dynamic O
modeling O
. O

subsequently O
we O
investigated O
the O
efficacy O
of O
oxprenolol O
in O
antagonizing O
such O
hypokalemia B-NEG
, O
together O
with O
the O
pharmacokinetic O
interaction O
between O
both O
drugs O
. O

six O
healthy O
subjects O
were O
given O
a O
0.5 O
mg O
subcutaneous O
dose O
of O
terbutaline O
on O
two O
occasions O
: O
1 O
hour O
after O
oral O
administration O
of O
a O
placebo O
and O
1 O
hour O
after O
80 O
mg O
oxprenolol O
orally O
. O

in O
the O
7-hour O
period O
after O
terbutaline O
administration O
, O
plasma O
samples O
were O
taken O
for O
determination O
of O
plasma O
potassium O
levels O
and O
drug O
concentrations O
. O

the O
sigmoid O
emax O
model O
offered O
a O
good O
description O
of O
the O
relation O
between O
terbutaline O
concentrations O
and O
potassium O
effects O
. O

oxprenolol O
caused O
decreases O
of O
65% O
and O
56% O
of O
terbutaline O
volume O
of O
distribution O
and O
clearance O
, O
respectively O
, O
and O
an O
increase O
of O
130% O
of O
its O
auc O
. O

in O
spite O
of O
higher O
terbutaline O
concentrations O
after O
oxprenolol O
pretreatment O
, O
the O
hypokalemia B-NEG
was O
almost O
completely O
antagonized O
by O
the O
beta O
2-blocking O
action O
. O

-DOCSTART- O

midline O
b3 O
serotonin O
nerves O
in O
rat O
medulla O
are O
involved O
in O
hypotensive B-NEG
effect O
of O
methyldopa O
. O

previous O
experiments O
in O
this O
laboratory O
have O
shown O
that O
microinjection O
of O
methyldopa O
onto O
the O
ventrolateral O
cells O
of O
the O
b3 O
serotonin O
neurons O
in O
the O
medulla O
elicits O
a O
hypotensive B-NEG
response O
mediated O
by O
a O
projection O
descending O
into O
the O
spinal O
cord O
. O

the O
present O
experiments O
were O
designed O
to O
investigate O
the O
role O
of O
the O
midline O
cells O
of O
the O
b3 O
serotonin O
neurons O
in O
the O
medulla O
, O
coinciding O
with O
the O
raphe O
magnus O
. O

in O
spontaneously O
hypertensive B-NEG
, O
stroke B-NEG
-prone O
rats O
, O
microinjection O
of O
methyldopa O
into O
the O
area O
of O
the O
midline O
b3 O
serotonin O
cell O
group O
in O
the O
ventral O
medulla O
caused O
a O
potent O
hypotension B-NEG
of O
30-40 O
mm O
hg O
, O
which O
was O
maximal O
2-3 O
h O
after O
administration O
and O
was O
abolished O
by O
the O
serotonin O
neurotoxin O
5,7-dihydroxytryptamine O
( O
5,7-dht O
) O
injected O
intracerebroventricularly O
. O

however O
, O
intraspinal O
injection O
of O
5,7-dht O
to O
produce O
a O
more O
selective O
lesion O
of O
only O
descending O
serotonin O
projections O
in O
the O
spinal O
cord O
did O
not O
affect O
this O
hypotension B-NEG
. O

further O
, O
5,7-dht O
lesion O
of O
serotonin O
nerves O
travelling O
in O
the O
median O
forebrain O
bundle O
, O
one O
of O
the O
main O
ascending O
pathways O
from O
the O
b3 O
serotonin O
cells O
, O
did O
not O
affect O
the O
fall O
in O
blood O
pressure O
associated O
with O
a O
midline O
b3 O
serotonin O
methyldopa O
injection O
. O

it O
is O
concluded O
therefore O
that O
, O
unlike O
the O
ventrolateral O
b3 O
cells O
which O
mediate O
a O
methyldopa-induced O
hypotension B-NEG
via O
descending O
projections O
, O
the O
midline O
serotonin O
b3 O
cells O
in O
the O
medulla O
contribute O
to O
the O
hypotensive B-NEG
action O
of O
methyldopa O
, O
either O
by O
way O
of O
an O
ascending O
projection O
which O
does O
not O
pass O
through O
the O
median O
forebrain O
bundle O
, O
or O
through O
a O
projection O
restricted O
to O
the O
caudal O
brainstem O
. O

-DOCSTART- O

yohimbine O
treatment O
of O
sexual B-NEG
side I-NEG
effects I-NEG
induced O
by O
serotonin O
reuptake O
blockers O
. O

background O
: O
preclinical O
and O
clinical O
studies O
suggest O
that O
yohimbine O
facilitates O
sexual O
behavior O
and O
may O
be O
helpful O
in O
the O
treatment O
of O
male B-NEG
impotence I-NEG
. O

a O
single O
case O
report O
suggests O
that O
yohimbine O
may O
be O
used O
to O
treat O
the O
sexual B-NEG
side I-NEG
effects I-NEG
of O
clomipramine O
. O

this O
study O
evaluated O
yohimbine O
as O
a O
treatment O
for O
the O
sexual B-NEG
side I-NEG
effects I-NEG
caused O
by O
serotonin O
reuptake O
blockers O
. O

method O
: O
six O
patients O
with O
either O
obsessive B-NEG
compulsive I-NEG
disorder I-NEG
, O
trichotillomania B-NEG
, O
anxiety B-NEG
, O
or O
affective B-NEG
disorders I-NEG
who O
suffered O
sexual B-NEG
side I-NEG
effects I-NEG
after O
treatment O
with O
serotonin O
reuptake O
blockers O
were O
given O
yohimbine O
on O
a O
p.r.n O
. O
basis O
in O
an O
open O
clinical O
trial O
. O

various O
doses O
of O
yohimbine O
were O
used O
to O
determine O
the O
ideal O
dose O
for O
each O
patient O
. O

results O
: O
five O
of O
the O
six O
patients O
experienced O
improved O
sexual O
functioning O
after O
taking O
yohimbine O
. O

one O
patient O
who O
failed O
to O
comply O
with O
yohimbine O
treatment O
had O
no O
therapeutic O
effects O
. O

side O
effects O
of O
yohimbine O
included O
excessive O
sweating O
, O
increased O
anxiety B-NEG
, O
and O
a O
wound-up O
feeling O
in O
some O
patients O
. O

conclusion O
: O
the O
results O
of O
this O
study O
indicate O
that O
yohimbine O
may O
be O
an O
effective O
treatment O
for O
the O
sexual B-NEG
side I-NEG
effects I-NEG
caused O
by O
serotonin O
reuptake O
blockers O
. O

future O
controlled O
studies O
are O
needed O
to O
further O
investigate O
the O
effectiveness O
and O
safety O
of O
yohimbine O
for O
this O
indication O
. O

-DOCSTART- O

hypersensitivity B-NEG
immune O
reaction O
as O
a O
mechanism O
for O
dilevalol-associated O
hepatitis B-NEG
. O

objective O
: O
to O
assess O
lymphocyte O
reactivity O
to O
dilevalol O
and O
to O
serum O
containing O
putative O
ex O
vivo O
dilevalol O
antigens O
or O
metabolites O
in O
a O
case O
of O
dilevalol-induced O
liver B-NEG
injury I-NEG
. O

patient O
: O
a O
58-year-old O
woman O
with O
a O
clinical O
diagnosis O
of O
dilevalol-induced O
liver B-NEG
injury I-NEG
. O

methods O
: O
peripheral O
blood O
mononuclear O
cells O
collected O
from O
the O
patient O
were O
cultured O
in O
the O
presence O
of O
a O
solution O
of O
dilevalol O
and O
also O
with O
sera O
collected O
from O
a O
volunteer O
before O
and O
after O
dilevalol O
intake O
. O

a O
similar O
protocol O
was O
performed O
with O
lymphocytes O
from O
a O
healthy O
subject O
. O

results O
: O
no O
lymphocyte O
proliferation O
was O
observed O
either O
in O
the O
patient O
or O
in O
the O
healthy O
volunteer O
in O
the O
presence O
of O
dilevalol O
solutions O
. O

a O
significant O
proliferative O
response O
to O
serum O
collected O
after O
dilevalol O
intake O
was O
observed O
in O
the O
case O
of O
the O
patient O
compared O
with O
the O
proliferative O
response O
to O
the O
serum O
collected O
before O
the O
drug O
intake O
. O

no O
reactivity O
was O
found O
when O
lymphocytes O
from O
the O
healthy O
subject O
were O
tested O
under O
similar O
conditions O
. O

conclusions O
: O
the O
methodology O
used O
allowed O
the O
detection O
of O
lymphocyte O
sensitization O
to O
sera O
containing O
ex O
vivo-prepared O
dilevalol O
antigens O
, O
suggesting O
the O
involvement O
of O
an O
immunologic O
mechanism O
in O
dilevalol-induced O
liver B-NEG
injury I-NEG
. O

-DOCSTART- O

reversible O
myocardial B-NEG
hypertrophy I-NEG
induced O
by O
tacrolimus O
in O
a O
pediatric O
heart O
transplant O
recipient O
: O
case O
report O
. O

tacrolimus O
is O
a O
potent O
immunosuppressant O
that O
is O
frequently O
used O
in O
organ O
transplantation O
. O

however O
, O
adverse O
effects O
include O
cardiac B-NEG
toxicity I-NEG
. O

herein O
we O
describe O
transient O
myocardial B-NEG
hypertrophy I-NEG
induced O
by O
tacrolimus O
after O
heart O
transplantation O
. O

the O
hypertrophy B-NEG
caused O
no O
clinical O
symptoms O
but O
was O
noted O
because O
of O
elevation O
of O
plasma O
brain O
natriuretic O
peptide O
concentration O
and O
confirmed O
at O
echocardiography O
. O

initially O
, O
allograft O
rejection O
was O
feared O
; O
however O
, O
myocardial O
biopsy O
samples O
revealed O
only O
interstitial O
edema B-NEG
and O
mild O
myocardial B-NEG
hypertrophy I-NEG
; O
neither O
cellular O
nor O
humoral O
rejection O
was O
detected O
. O

the O
blood O
tacrolimus O
concentration O
was O
higher O
than O
usual O
at O
that O
time O
; O
thus O
, O
tacrolimus O
dosage O
was O
reduced O
. O
myocardial B-NEG
hypertrophy I-NEG
completely O
resolved O
upon O
reducing O
the O
target O
concentration O
of O
tacrolimus O
and O
did O
not O
recur O
, O
as O
confirmed O
at O
echocardiography O
and O
myocardial O
biopsy O
. O

thus O
, O
we O
conclude O
that O
tacrolimus O
induces O
reversible O
myocardial B-NEG
hypertrophy I-NEG
. O

in O
patients O
receiving O
tacrolimus O
therapy O
, O
blood O
concentration O
should O
be O
carefully O
controlled O
and O
extreme O
attention O
paid O
to O
cardiac O
involvement O
. O

-DOCSTART- O

comparison O
of O
unilateral O
pallidotomy O
and O
subthalamotomy O
findings O
in O
advanced O
idiopathic B-NEG
parkinson's I-NEG
disease I-NEG
. O

a O
prospective O
, O
randomized O
, O
double-blind O
pilot O
study O
to O
compare O
the O
results O
of O
stereotactic O
unilateral O
pallidotomy O
and O
subthalamotomy O
in O
advanced O
idiopathic B-NEG
parkinson's I-NEG
disease I-NEG
( O
pd B-NEG
) O
refractory O
to O
medical O
treatment O
was O
designed O
. O

ten O
consecutive O
patients O
( O
mean O
age O
, O
58.4 O
+/- O
6.8 O
years O
; O
7 O
men O
, O
3 O
women O
) O
with O
similar O
characteristics O
at O
the O
duration O
of O
disease O
( O
mean O
disease O
time O
, O
8.4 O
+/- O
3.5 O
years) O
, O
disabling O
motor O
fluctuations O
( O
hoehn O
_ O
yahr O
stage O
3-5 O
in O
off-drug O
phases O
) O
and O
levodopa-induced O
dyskinesias B-NEG
were O
selected O
. O

all O
patients O
had O
bilateral O
symptoms O
and O
their O
levodopa O
equivalent O
dosing O
were O
analysed O
. O

six O
patients O
were O
operated O
on O
in O
the O
globus O
pallidus O
interna O
( O
gpi O
) O
and O
four O
in O
the O
subthalamic O
nucleus O
(stn) O
. O

clinical O
evaluation O
included O
the O
use O
of O
the O
unified O
parkinson's B-NEG
disease I-NEG
rating O
scale O
(updrs) O
, O
hoehn_yahr O
score O
and O
schwab O
england O
activities O
of O
daily O
living O
( O
adl O
) O
score O
in O
'on'- O
and O
'off'-drug O
conditions O
before O
surgery O
and O
6 O
months O
after O
surgery O
. O

there O
was O
statistically O
significant O
improvement O
in O
all O
contralateral O
major O
parkinsonian B-NEG
motor O
signs O
in O
all O
patients O
followed O
for O
6 O
months O
. O

levodopa O
equivalent O
daily O
intake O
was O
significantly O
reduced O
in O
the O
stn O
group O
. O

changes O
in O
updrs O
, O
hoehn O
_ O
yahr O
and O
schwab O
england O
adl O
scores O
were O
similar O
in O
both O
groups O
. O

cognitive O
functions O
were O
unchanged O
in O
both O
groups O
. O

complications O
were O
observed O
in O
two O
patients O
: O
one O
had O
a O
left O
homonymous B-NEG
hemianopsia I-NEG
after O
pallidotomy O
and O
another O
one O
developed O
left O
hemiballistic O
movements O
3 O
days O
after O
subthalamotomy O
which O
partly O
improved O
within O
1 O
month O
with O
valproate O
1000 O
mg/day O
. O

the O
findings O
of O
this O
study O
suggest O
that O
lesions O
of O
the O
unilateral O
stn O
and O
gpi O
are O
equally O
effective O
treatment O
for O
patients O
with O
advanced O
pd B-NEG
refractory O
to O
medical O
treatment O
. O

-DOCSTART- O

protective O
effects O
of O
antithrombin O
on O
puromycin O
aminonucleoside O
nephrosis B-NEG
in O
rats O
. O

we O
investigated O
the O
effects O
of O
antithrombin O
, O
a O
plasma O
inhibitor O
of O
coagulation O
factors O
, O
in O
rats O
with O
puromycin O
aminonucleoside-induced O
nephrosis B-NEG
, O
which O
is O
an O
experimental O
model O
of O
human O
nephrotic B-NEG
syndrome I-NEG
. O

antithrombin O
( O
50 O
or O
500 O
iu/kg/i.v. O
) O
was O
administered O
to O
rats O
once O
a O
day O
for O
10 O
days O
immediately O
after O
the O
injection O
of O
puromycin O
aminonucleoside O
( O
50 O
mg/kg/i.v.) O
. O

treatment O
with O
antithrombin O
attenuated O
the O
puromycin O
aminonucleoside-induced O
hematological B-NEG
abnormalities I-NEG
. O

puromycin O
aminonucleoside-induced O
renal B-NEG
dysfunction I-NEG
and O
hyperlipidemia B-NEG
were O
also O
suppressed O
. O

histopathological O
examination O
revealed O
severe O
renal B-NEG
damage I-NEG
such O
as O
proteinaceous O
casts O
in O
tubuli O
and O
tubular O
expansion O
in O
the O
kidney O
of O
control O
rats O
, O
while O
an O
improvement O
of O
the O
damage O
was O
seen O
in O
antithrombin-treated O
rats O
. O

in O
addition O
, O
antithrombin O
treatment O
markedly O
suppressed O
puromycin O
aminonucleoside-induced O
apoptosis O
of O
renal O
tubular O
epithelial O
cells O
. O

furthermore O
, O
puromycin O
aminonucleoside-induced O
increases O
in O
renal O
cytokine O
content O
were O
also O
decreased O
. O

these O
findings O
suggest O
that O
thrombin O
plays O
an O
important O
role O
in O
the O
pathogenesis O
of O
puromycin O
aminonucleoside-induced O
nephrotic B-NEG
syndrome I-NEG
. O

treatment O
with O
antithrombin O
may O
be O
clinically O
effective O
in O
patients O
with O
nephrotic B-NEG
syndrome I-NEG
. O

-DOCSTART- O

reverse O
or O
inverted O
left B-NEG
ventricular I-NEG
apical I-NEG
ballooning I-NEG
syndrome I-NEG
( O
reverse O
takotsubo B-NEG
cardiomyopathy I-NEG
) O
in O
a O
young O
woman O
in O
the O
setting O
of O
amphetamine O
use O
. O

transient O
left B-NEG
ventricular I-NEG
apical I-NEG
ballooning I-NEG
syndrome I-NEG
was O
first O
described O
in O
japan O
as O
takotsubo B-NEG
cardiomyopathy I-NEG
. O

this O
syndrome O
has O
been O
identified O
in O
many O
other O
countries O
. O

many O
variations O
of O
this O
syndrome O
have O
been O
recently O
described O
in O
the O
literature O
. O

one O
of O
the O
rarest O
is O
the O
reverse O
type O
of O
this O
syndrome O
, O
with O
hyperdynamic O
apex O
and O
complete O
akinesia B-NEG
of O
the O
base O
( O
as O
opposed O
to O
the O
classic O
apical B-NEG
ballooning I-NEG
). O

in O
this O
article O
, O
we O
report O
an O
interesting O
case O
of O
a O
young O
woman O
who O
presented O
with O
this O
rare O
type O
of O
reverse O
apical B-NEG
ballooning I-NEG
syndrome I-NEG
occurring O
after O
amphetamine O
use O
. O

this O
report O
is O
followed O
by O
review O
of O
the O
literature O
. O

-DOCSTART- O

attenuated O
disruption O
of O
prepulse O
inhibition O
by O
dopaminergic O
stimulation O
after O
maternal O
deprivation O
and O
adolescent O
corticosterone O
treatment O
in O
rats O
. O

the O
development O
of O
schizophrenia B-NEG
may O
include O
an O
early O
neurodevelopmental O
stress O
component O
which O
increases O
vulnerability O
to O
later O
stressful O
life O
events O
, O
in O
combination O
leading O
to O
overt O
disease O
. O

we O
investigated O
the O
effect O
of O
an O
early O
stress O
, O
in O
the O
form O
of O
maternal O
deprivation O
, O
combined O
with O
a O
later O
stress O
, O
simulated O
by O
chronic O
periadolescent O
corticosterone O
treatment O
, O
on O
behaviour O
in O
rats O
. O

acute O
treatment O
with O
apomorphine O
caused O
disruption O
of O
prepulse O
inhibition O
( O
ppi O
) O
in O
controls O
and O
in O
rats O
that O
had O
undergone O
either O
maternal O
deprivation O
or O
corticosterone O
treatment O
, O
but O
was O
surprisingly O
absent O
in O
rats O
that O
had O
undergone O
the O
combined O
early O
and O
late O
stress O
. O

amphetamine O
treatment O
significantly O
disrupted O
ppi O
in O
both O
non-deprived O
groups O
, O
but O
was O
absent O
in O
both O
maternally O
deprived O
groups O
. O

the O
serotonin-1a O
receptor O
agonist O
, O
8-oh-dpat O
, O
induced O
a O
significant O
disruption O
of O
ppi O
in O
all O
groups O
. O

amphetamine-induced O
locomotor B-NEG
hyperactivity I-NEG
was O
similar O
in O
all O
groups O
. O

these O
results O
show O
an O
inhibitory O
interaction O
of O
early O
stress O
, O
caused O
by O
maternal O
deprivation O
, O
combined O
with O
'adolescent' O
stress O
, O
simulated O
by O
corticosterone O
treatment O
, O
on O
dopaminergic O
regulation O
of O
ppi O
. O

the O
altered O
effects O
of O
apomorphine O
and O
amphetamine O
could O
indicate O
differential O
changes O
in O
dopamine O
receptor O
signalling O
leading O
to O
functional O
desensitisation O
, O
or O
altered O
modulation O
of O
sensory O
gating O
in O
the O
nucleus O
accumbens O
by O
limbic O
structures O
such O
as O
the O
hippocampus O
. O

-DOCSTART- O

peripheral O
iron O
dextran O
induced O
degeneration B-NEG
of I-NEG
dopaminergic I-NEG
neurons I-NEG
in O
rat O
substantia O
nigra O
. O

iron O
accumulation O
is O
considered O
to O
be O
involved O
in O
the O
pathogenesis O
of O
parkinson's B-NEG
disease I-NEG
. O

to O
demonstrate O
the O
relationship O
between O
peripheral O
iron O
overload O
and O
dopaminergic O
neuron O
loss O
in O
rat O
substantia O
nigra O
(sn) O
, O
in O
the O
present O
study O
we O
used O
fast O
cyclic O
voltammetry O
, O
tyrosine O
hydroxylase O
( O
th O
) O
immunohistochemistry O
, O
perls' O
iron O
staining O
, O
and O
high O
performance O
liquid O
chromatography-electrochemical O
detection O
to O
study O
the O
degeneration B-NEG
of I-NEG
dopaminergic I-NEG
neurons I-NEG
and O
increased O
iron O
content O
in O
the O
sn O
of O
iron O
dextran O
overloaded O
animals O
. O

the O
findings O
showed O
that O
peripheral O
iron O
dextran O
overload O
increased O
the O
iron O
staining O
positive O
cells O
and O
reduced O
the O
number O
of O
th-immunoreactive O
neurons O
in O
the O
sn O
. O

as O
a O
result O
, O
dopamine O
release O
and O
content O
, O
as O
well O
as O
its O
metabolites O
contents O
were O
decreased O
in O
caudate O
putamen O
. O

even O
more O
dramatic O
changes O
were O
found O
in O
chronic O
overload O
group O
. O

these O
results O
suggest O
that O
peripheral O
iron O
dextran O
can O
increase O
the O
iron O
level O
in O
the O
sn O
, O
where O
excessive O
iron O
causes O
the O
degeneration B-NEG
of I-NEG
dopaminergic I-NEG
neurons I-NEG
. O

the O
chronic O
iron O
overload O
may O
be O
more O
destructive O
to O
dopaminergic O
neurons O
than O
the O
acute O
iron O
overload O
. O

-DOCSTART- O

warfarin-induced O
leukocytoclastic B-NEG
vasculitis I-NEG
. O

skin O
reactions O
associated O
with O
oral O
coumarin-derived O
anticoagulants O
are O
an O
uncommon O
occurrence O
. O
leukocytoclastic B-NEG
vasculitis I-NEG
( O
lv B-NEG
) O
is O
primarily O
a O
cutaneous B-NEG
small I-NEG
vessel I-NEG
vasculitis I-NEG
, O
though O
systemic O
involvement O
may O
be O
encountered O
. O

we O
report O
4 O
patients O
with O
late-onset O
lv B-NEG
probably O
due O
to O
warfarin O
. O

all O
4 O
patients O
presented O
with O
skin B-NEG
eruptions I-NEG
that O
developed O
after O
receiving O
warfarin O
for O
several O
years O
. O

the O
results O
of O
skin B-NEG
lesion I-NEG
biopsies O
were O
available O
in O
3 O
patients O
, O
confirming O
lv B-NEG
cutaneous I-NEG
lesions I-NEG
resolved O
in O
all O
patients O
after O
warfarin O
was O
discontinued O
. O

in O
2 O
of O
the O
4 O
patients O
, O
rechallenge O
with O
warfarin O
led O
to O
recurrence O
of O
the O
lesions O
. O
lv B-NEG
may O
be O
a O
late-onset O
adverse O
reaction O
associated O
with O
warfarin O
therapy O
. O

-DOCSTART- O

the O
activation O
of O
spinal O
n-methyl-d-aspartate O
receptors O
may O
contribute O
to O
degeneration O
of O
spinal O
motor O
neurons O
induced O
by O
neuraxial O
morphine O
after O
a O
noninjurious O
interval O
of O
spinal B-NEG
cord I-NEG
ischemia I-NEG
. O

we O
investigated O
the O
relationship O
between O
the O
degeneration O
of O
spinal O
motor O
neurons O
and O
activation O
of O
n-methyl-d-aspartate O
( O
nmda O
) O
receptors O
after O
neuraxial O
morphine O
following O
a O
noninjurious O
interval O
of O
aortic B-NEG
occlusion I-NEG
in O
rats O
. O
spinal B-NEG
cord I-NEG
ischemia I-NEG
was O
induced O
by O
aortic B-NEG
occlusion I-NEG
for O
6 O
min O
with O
a O
balloon O
catheter O
. O

in O
a O
microdialysis O
study O
, O
10 O
mul O
of O
saline O
( O
group O
c; O
n O
= O
8) O
or O
30 O
mug O
of O
morphine O
( O
group O
m; O
n O
= O
8) O
was O
injected O
intrathecally O
( O
it O
) O
0.5 O
h O
after O
reflow O
, O
and O
30 O
mug O
of O
morphine O
( O
group O
sm O
; O
n O
= O
8) O
or O
10 O
mul O
of O
saline O
( O
group O
sc O
; O
n O
= O
8) O
was O
injected O
it O
0.5 O
h O
after O
sham O
operation O
. O

microdialysis O
samples O
were O
collected O
preischemia O
, O
before O
it O
injection O
, O
and O
at O
2, O
4, O
8, O
24 O
, O
and O
48 O
h O
of O
reperfusion O
( O
after O
it O
injection) O
. O

second O
, O
we O
investigated O
the O
effect O
of O
it O
mk-801 O
( O
30 O
mug O
) O
on O
the O
histopathologic O
changes O
in O
the O
spinal O
cord O
after O
morphine-induced O
spastic B-NEG
paraparesis I-NEG
. O

after O
it O
morphine O
, O
the O
cerebrospinal O
fluid O
( O
csf O
) O
glutamate O
concentration O
was O
increased O
in O
group O
m O
relative O
to O
both O
baseline O
and O
group O
c O
(p O
< O
0.05) O
. O

this O
increase O
persisted O
for O
8 O
hrs O
. O

it O
mk-801 O
significantly O
reduced O
the O
number O
of O
dark-stained O
alpha-motoneurons O
after O
morphine-induced O
spastic B-NEG
paraparesis I-NEG
compared O
with O
the O
saline O
group O
. O

these O
data O
indicate O
that O
it O
morphine O
induces O
spastic B-NEG
paraparesis I-NEG
with O
a O
concomitant O
increase O
in O
csf O
glutamate O
, O
which O
is O
involved O
in O
nmda O
receptor O
activation O
. O

we O
suggest O
that O
opioids O
may O
be O
neurotoxic B-NEG
in O
the O
setting O
of O
spinal B-NEG
cord I-NEG
ischemia I-NEG
via O
nmda O
receptor O
activation O
. O

-DOCSTART- O

reduced O
sodium O
channel O
density O
, O
altered O
voltage O
dependence O
of O
inactivation O
, O
and O
increased O
susceptibility O
to O
seizures B-NEG
in O
mice O
lacking O
sodium O
channel O
beta O
2-subunits O
. O

sodium O
channel O
beta-subunits O
modulate O
channel O
gating O
, O
assembly O
, O
and O
cell O
surface O
expression O
in O
heterologous O
cell O
systems O
. O

we O
generated O
beta2(-/- O
) O
mice O
to O
investigate O
the O
role O
of O
beta2 O
in O
control O
of O
sodium O
channel O
density O
, O
localization O
, O
and O
function O
in O
neurons O
in O
vivo O
. O

measurements O
of O
[(3)h]saxitoxin O
( O
stx O
) O
binding O
showed O
a O
significant O
reduction O
in O
the O
level O
of O
plasma O
membrane O
sodium O
channels O
in O
beta2(-/- O
) O
neurons O
. O

the O
loss O
of O
beta2 O
resulted O
in O
negative O
shifts O
in O
the O
voltage O
dependence O
of O
inactivation O
as O
well O
as O
significant O
decreases O
in O
sodium O
current O
density O
in O
acutely O
dissociated O
hippocampal O
neurons O
. O

the O
integral O
of O
the O
compound O
action O
potential O
in O
optic O
nerve O
was O
significantly O
reduced O
, O
and O
the O
threshold O
for O
action O
potential O
generation O
was O
increased O
, O
indicating O
a O
reduction O
in O
the O
level O
of O
functional O
plasma O
membrane O
sodium O
channels O
. O

in O
contrast O
, O
the O
conduction O
velocity O
, O
the O
number O
and O
size O
of O
axons O
in O
the O
optic O
nerve O
, O
and O
the O
specific O
localization O
of O
na(v)1.6 O
channels O
in O
the O
nodes O
of O
ranvier O
were O
unchanged O
. O

beta2(-/- O
) O
mice O
displayed O
increased O
susceptibility O
to O
seizures B-NEG
, O
as O
indicated O
by O
reduced O
latency O
and O
threshold O
for O
pilocarpine-induced O
seizures B-NEG
, O
but O
seemed O
normal O
in O
other O
neurological O
tests O
. O

our O
observations O
show O
that O
beta2-subunits O
play O
an O
important O
role O
in O
the O
regulation O
of O
sodium O
channel O
density O
and O
function O
in O
neurons O
in O
vivo O
and O
are O
required O
for O
normal O
action O
potential O
generation O
and O
control O
of O
excitability O
. O

-DOCSTART- O

screening O
for O
stimulant O
use O
in O
adult O
emergency O
department O
seizure B-NEG
patients O
. O

objective O
: O
the O
objective O
of O
this O
study O
was O
to O
determine O
the O
prevalence O
of O
positive O
plasma O
drug O
screening O
for O
cocaine O
or O
amphetamine O
in O
adult O
emergency O
department O
seizure B-NEG
patients O
. O

methods O
: O
this O
prospective O
study O
evaluated O
consecutive O
eligible O
seizure B-NEG
patients O
who O
had O
a O
plasma O
sample O
collected O
as O
part O
of O
their O
clinical O
evaluation O
. O

plasma O
was O
tested O
for O
amphetamine O
and O
the O
cocaine O
metabolite O
benzoylecgonine O
using O
enzyme-mediated O
immunoassay O
methodology O
. O

plasma O
samples O
with O
benzoylecgonine O
greater O
than O
150 O
ng/ml O
or O
an O
amphetamine O
greater O
than O
500 O
ng/ml O
were O
defined O
as O
positive O
. O

patient O
demographics O
, O
history O
of O
underlying O
drug O
or O
alcohol-related O
seizure B-NEG
disorder O
, O
estimated O
time O
from O
seizure B-NEG
to O
sample O
collection O
, O
history O
or O
suspicion O
of O
cocaine B-NEG
or I-NEG
amphetamine I-NEG
abuse I-NEG
, O
results O
of O
clinical O
urine O
testing O
for O
drugs O
of O
abuse O
, O
and O
assay O
results O
were O
recorded O
without O
patient O
identifiers O
. O

results O
: O
fourteen O
of O
248 O
(5.6% O
, O
95% O
ci O
2.7%-8.5% O
) O
plasma O
samples O
were O
positive O
by O
immunoassay O
testing O
for O
benzoylecgonine O
and O
no O
samples O
(0% O
, O
95% O
ci O
0-1.2% O
) O
were O
positive O
for O
amphetamine O
. O

positive O
test O
results O
were O
more O
common O
in O
patient O
visits O
where O
there O
was O
a O
history O
or O
suspicion O
of O
cocaine B-NEG
or I-NEG
amphetamine I-NEG
abuse I-NEG
(p O
< O
0.0005) O
. O

conclusions O
: O
during O
this O
study O
period O
, O
routine O
plasma O
screening O
for O
cocaine O
and O
amphetamines O
in O
adult O
seizure B-NEG
patients O
had O
a O
low O
yield O
. O

as O
a O
result O
, O
routine O
plasma O
screening O
would O
yield O
few O
cases O
of O
stimulant O
drug O
in O
which O
there O
was O
neither O
a O
history O
nor O
suspicion O
of O
drug B-NEG
abuse I-NEG
in O
this O
population O
. O

-DOCSTART- O

evidence O
of O
functional O
somatotopy O
in O
gpi O
from O
results O
of O
pallidotomy O
. O

the O
objective O
of O
this O
study O
was O
to O
explore O
the O
functional O
anatomy O
of O
the O
globus O
pallidus O
internus O
( O
gpi O
) O
by O
studying O
the O
effects O
of O
unilateral O
pallidotomy O
on O
parkinsonian B-NEG
'off' O
signs O
and O
levodopa-induced O
dyskinesias B-NEG
( O
lid B-NEG
). O

we O
found O
significant O
positive O
correlations O
between O
the O
preoperative O
levodopa O
responsiveness O
of O
motor O
signs O
and O
the O
levodopa O
responsiveness O
of O
scores O
in O
timed O
tests O
( O
core O
assessment O
program O
for O
intracerebral O
transplantations O
) O
in O
the O
contralateral O
limbs O
and O
the O
improvement O
in O
these O
scores O
after O
surgery O
, O
whereas O
there O
was O
no O
correlation O
with O
the O
improvement O
in O
lid B-NEG
. O

we O
also O
found O
a O
highly O
significant O
correlation O
(p O
: O
< O
0.0001 O
, O
r O
= O
0.8 O
) O
between O
the O
volume O
of O
the O
ventral O
lesion O
in O
the O
gpi O
and O
the O
improvement O
in O
lid B-NEG
in O
the O
contralateral O
limbs O
, O
whereas O
there O
was O
no O
correlation O
between O
the O
ventral O
volume O
and O
the O
improvement O
in O
parkinsonian B-NEG
'off' O
signs O
. O

the O
volumes O
of O
the O
total O
lesion O
cylinder O
and O
the O
dorsal O
lesion O
did O
not O
correlate O
with O
the O
outcome O
of O
either O
dyskinesias B-NEG
or O
parkinsonian B-NEG
'off' O
signs O
. O

the O
differential O
predictive O
value O
of O
levodopa O
responsiveness O
for O
the O
outcome O
of O
parkinsonian B-NEG
'off' O
signs O
and O
lid B-NEG
and O
the O
different O
correlations O
of O
ventral O
lesion O
volume O
with O
dyskinesias B-NEG
and O
parkinsonian B-NEG
'off' O
signs O
indicate O
that O
different O
anatomical O
or O
pathophysiological O
substrates O
may O
be O
responsible O
for O
the O
generation O
of O
parkinsonian B-NEG
'off' O
signs O
and O
dyskinesias B-NEG
. O

whereas O
cells O
in O
a O
wider O
area O
of O
the O
gpi O
may O
be O
implicated O
in O
parkinsonism B-NEG
, O
the O
ventral O
gpi O
seems O
to O
be O
crucial O
for O
the O
manifestation O
of O
lid B-NEG
. O

we O
suggest O
that O
our O
observations O
are O
additional O
proof O
of O
the O
functional O
somatotopy O
of O
the O
systems O
within O
the O
gpi O
that O
mediate O
parkinsonism B-NEG
and O
dyskinesias B-NEG
, O
especially O
along O
the O
dorsoventral O
trajectory O
used O
in O
pallidotomy O
. O

the O
outcome O
of O
pallidotomy O
in O
which O
the O
lesion O
involves O
the O
ventral O
and O
dorsal O
gpi O
could O
be O
the O
net O
effect O
of O
alteration O
in O
the O
activity O
of O
pathways O
which O
mediate O
different O
symptoms O
, O
and O
hence O
could O
be O
variable O
. O

-DOCSTART- O

pain B-NEG
responses O
in O
methadone-maintained O
opioid O
abusers O
. O

providing O
pain B-NEG
management O
for O
known O
opioid O
abusers O
is O
a O
challenging O
clinical O
task O
, O
in O
part O
because O
little O
is O
known O
about O
their O
pain B-NEG
experience O
and O
analgesic O
requirements O
. O

this O
study O
was O
designed O
to O
describe O
pain B-NEG
tolerance O
and O
analgesic O
response O
in O
a O
sample O
of O
opioid B-NEG
addicts I-NEG
stabilized O
in O
methadone-maintenance O
( O
mm O
) O
treatment O
(n O
= O
60 O
) O
in O
comparison O
to O
matched O
nondependent O
control O
subjects O
(n O
= O
60) O
. O

by O
using O
a O
placebo-controlled O
, O
two-way O
factorial O
design O
, O
tolerance O
to O
cold-pressor O
( O
cp O
) O
pain B-NEG
was O
examined O
, O
both O
before O
and O
after O
oral O
administration O
of O
therapeutic O
doses O
of O
common O
opioid O
( O
hydromorphone O
2 O
mg O
) O
and O
nonsteroidal O
anti-inflammatory O
( O
ketorolac O
10 O
mg O
) O
analgesic O
agents O
. O

results O
showed O
that O
mm O
individuals O
were O
significantly O
less O
tolerant O
of O
cp O
pain B-NEG
than O
control O
subjects O
, O
replicating O
previous O
work O
. O

analgesic O
effects O
were O
significant O
neither O
for O
medication O
nor O
group O
. O

these O
data O
indicate O
that O
mm O
opioid O
abusers O
represent O
a O
pain-intolerant B-NEG
subset O
of O
clinical O
patients O
. O

their O
complaints O
of O
pain B-NEG
should O
be O
evaluated O
seriously O
and O
managed O
aggressively O
. O

-DOCSTART- O

urine O
n-acetyl-beta-d-glucosaminidase--a O
marker O
of O
tubular O
damage? O

background O
: O
although O
an O
indicator O
of O
renal B-NEG
tubular I-NEG
dysfunction I-NEG
, O
an O
increased O
urinary O
n-acetyl-beta-d-glucosaminidase O
( O
nag O
) O
activity O
might O
reflect O
increased O
lysosomal O
activity O
in O
renal O
tubular O
cells O
. O

methods O
: O
puromycin O
aminonucleoside O
( O
pan O
) O
was O
administered O
to O
sprague O
dawley O
rats O
to O
induce O
proteinuria B-NEG
. O

total O
protein O
, O
albumin O
, O
nag O
activity O
and O
protein O
electrophoretic O
pattern O
were O
assessed O
in O
daily O
urine O
samples O
for O
33 O
days O
. O

the O
morphological O
appearance O
of O
the O
kidneys O
was O
examined O
on O
days O
three O
, O
four O
, O
six O
, O
eight O
and O
thirty O
three O
and O
the O
nag O
isoenzyme O
patterns O
on O
days O
zero O
, O
four O
, O
eight O
and O
thirty O
three O
. O

results O
: O
following O
intravenous O
pan O
urine O
volume O
and O
urine O
nag O
activity O
increased O
significantly O
by O
day O
two O
, O
but O
returned O
to O
normal O
by O
day O
four O
. O

after O
day O
four O
all O
treated O
animals O
exhibited O
a O
marked O
rise O
in O
urine O
albumin O
, O
total O
protein O
excretion O
and O
nag O
activity O
. O

electrophoresis O
showed O
a O
generalised O
increase O
in O
middle O
and O
high O
molecular O
weight O
urine O
proteins O
from O
day O
four O
onwards O
. O

protein O
droplets O
first O
appeared O
prominent O
in O
tubular O
cells O
on O
day O
four O
. O

peak O
urine O
nag O
activity O
and O
a O
change O
in O
nag O
isoenzyme O
pattern O
coincided O
with O
both O
the O
peak O
proteinuria B-NEG
and O
the O
reduction O
in O
intracellular O
protein O
and O
nag O
droplets O
( O
day O
six O
onwards) O
. O

conclusions O
: O
this O
animal O
model O
demonstrates O
that O
an O
increase O
in O
lysosomal O
turnover O
and O
hence O
urine O
nag O
activity O
, O
occurs O
when O
increased O
protein O
is O
presented O
to O
the O
tubular O
cells O
. O

urine O
nag O
activity O
is O
thus O
a O
measure O
of O
altered O
function O
in O
the O
renal O
tubules O
and O
not O
simply O
an O
indicator O
of O
damage O
. O

-DOCSTART- O

over O
expression O
of O
vascular O
endothelial O
growth O
factor O
and O
its O
receptor O
during O
the O
development O
of O
estrogen-induced O
rat O
pituitary B-NEG
tumors I-NEG
may O
mediate O
estrogen-initiated O
tumor B-NEG
angiogenesis O
. O

estrogens O
, O
which O
have O
been O
associated O
with O
several O
types O
of O
human O
and O
animal O
cancers B-NEG
, O
can O
induce O
tumor B-NEG
angiogenesis O
in O
the O
pituitary O
of O
fischer O
344 O
rats O
. O

the O
mechanistic O
details O
of O
tumor B-NEG
angiogenesis O
induction O
, O
during O
estrogen O
carcinogenesis B-NEG
, O
are O
still O
unknown O
. O

to O
elucidate O
the O
role O
of O
estrogen O
in O
the O
regulation O
of O
tumor B-NEG
angiogenesis O
in O
the O
pituitary O
of O
female O
rats O
, O
the O
density O
of O
blood O
vessels O
was O
analysed O
using O
factor O
viii O
related O
antigen O
( O
fviiirag O
) O
immunohistochemistry O
and O
the O
expression O
of O
vascular O
endothelial O
growth O
factor/vascular O
permeability O
factor O
( O
vegf/vpf O
) O
was O
examined O
by O
western O
blot O
and O
immunohistochemical O
analysis O
. O

the O
expression O
of O
vegf O
receptor O
( O
vegfr-2/flk-1/kdr O
) O
was O
also O
examined O
by O
immunohistochemistry O
. O

the O
results O
demonstrated O
that O
17beta-estradiol O
( O
e2 O
) O
induces O
neovascularization O
, O
as O
well O
as O
the O
growth O
and O
enlargement O
of O
blood O
vessels O
after O
7 O
days O
of O
exposure O
. O

the O
high O
tumor B-NEG
angiogenic O
potential O
was O
associated O
with O
an O
elevated O
vegf/vpf O
protein O
expression O
in O
the O
e2 O
exposed O
pituitary O
of O
ovariectomized O
( O
ovex O
) O
rats O
. O

vegf/vpf O
and O
fviiirag O
immunohistochemistry O
and O
endothelial O
specific O
lectin O
( O
uea1 O
) O
binding O
studies O
, O
indicate O
that O
the O
elevation O
of O
vegf O
protein O
expression O
initially O
occurred O
in O
both O
blood O
vessels O
and O
non-endothelial O
cells O
. O

after O
15 O
days O
of O
e2 O
exposure O
, O
vegf/vpf O
protein O
expression O
, O
in O
the O
non-endothelial O
cell O
population O
, O
sharply O
declined O
and O
was O
restricted O
to O
the O
blood O
vessels O
. O

the O
function O
of O
non-endothelial-derived O
vegf O
is O
not O
clear O
. O

furthermore O
, O
immunohistochemical O
studies O
demonstrated O
that O
vegfr-2 O
(flk-1/kdr) O
, O
expression O
was O
elevated O
significantly O
in O
the O
endothelial O
cells O
of O
microblood O
vessels O
after O
7 O
days O
of O
e2 O
exposure O
. O

these O
findings O
suggest O
that O
over O
expression O
of O
vegf O
and O
its O
receptor O
( O
vegfr-2 O
) O
may O
play O
an O
important O
role O
in O
the O
initial O
step O
of O
the O
regulation O
of O
estrogen O
induced O
tumor B-NEG
angiogenesis O
in O
the O
rat O
pituitary O
. O

-DOCSTART- O

pravastatin-associated O
myopathy B-NEG
. O

report O
of O
a O
case O
. O

a O
case O
of O
acute O
inflammatory B-NEG
myopathy I-NEG
associated O
with O
the O
use O
of O
pravastatin O
, O
a O
new O
hydrophilic O
3-hydroxy-3 O
methylglutaril O
coenzyme O
a O
reductase O
inhibitor O
, O
is O
reported O
. O

the O
patient O
, O
a O
69-year-old O
man O
was O
affected O
by O
non-insulin-dependent B-NEG
diabetes I-NEG
mellitus I-NEG
and O
hypertension B-NEG
. O

he O
assumed O
pravastatin O
( O
20 O
mg/day O
) O
because O
of O
hypercholesterolemia B-NEG
. O

he O
was O
admitted O
with O
acute O
myopathy B-NEG
of O
the O
lower O
limbs O
which O
resolved O
in O
a O
few O
days O
after O
pravastatin O
discontinuation O
. O

a O
previously O
unknown O
hypothyroidism B-NEG
, O
probably O
due O
to O
chronic O
autoimmune B-NEG
thyroiditis I-NEG
, O
was O
evidenced O
. O

muscle O
biopsy O
( O
left O
gastrocnemius O
) O
revealed O
a O
perimysial O
and O
endomysial O
inflammatory O
infiltrate O
with O
a O
prevalence O
of O
cd4+ O
lymphocytes O
. O

while O
lovastatin O
and O
simvastatin O
have O
been O
associated O
with O
toxic O
myopathy B-NEG
, O
pravastatin-associated O
myopathy B-NEG
could O
represent O
a O
distinct O
, O
inflammatory O
entity O
. O

-DOCSTART- O

dose-effect O
and O
structure-function O
relationships O
in O
doxorubicin O
cardiomyopathy B-NEG
. O

the O
cardiomyopathy B-NEG
( O
cm B-NEG
) O
produced O
by O
the O
anticancer O
drug O
doxorubicin O
( O
dxr O
) O
( O
adriamycin O
) O
provides O
a O
unique O
opportunity O
to O
analyze O
dose-effect O
and O
structure-function O
relationships O
during O
development O
of O
myocardial B-NEG
disease I-NEG
. O

we O
measured O
the O
degree O
of O
morphologic O
damage O
by O
ultrastructural O
examination O
of O
endomyocardial O
biopsy O
and O
the O
degree O
of O
performance O
abnormally O
by O
right O
heart O
catheterization O
in O
patients O
receiving O
dxr O
. O

morphologic O
damage O
was O
variable O
but O
was O
proportional O
to O
the O
total O
cumulative O
dxr O
dose O
between O
100 O
and O
600 O
mg/m2 O
. O

performance O
abnormalities O
correlated O
weakly O
with O
dose O
, O
exhibited O
a O
curvilinear O
relationship O
, O
and O
had O
a O
threshold O
for O
expression O
. O

catheterization O
abnormalities O
correlated O
well O
with O
morphologic O
damage O
(r O
= O
0.57 O
to O
0.78 O
) O
in O
a O
subgroup O
of O
patients O
in O
whom O
exercise O
hemodynamics O
were O
measured O
, O
and O
this O
relationship O
also O
exhibited O
a O
curvilinear O
, O
threshold O
configuration O
. O

in O
dxr- O
cm B-NEG
myocardial B-NEG
damage I-NEG
is O
proportional O
to O
the O
degree O
of O
cytotoxic O
insult O
( O
dxr O
dose O
) O
while O
myocardial O
function O
is O
preserved O
until O
a O
critical O
dose O
or O
degree O
of O
damage O
is O
reached O
, O
after O
which O
myocardial O
performance O
deteriorates O
rapidly O
. O

-DOCSTART- O

fatal O
aplastic B-NEG
anemia I-NEG
following O
topical O
administration O
of O
ophthalmic O
chloramphenicol O
. O

a O
73-year-old O
woman O
died O
of O
aplastic B-NEG
anemia I-NEG
less O
than O
two O
months O
after O
undergoing O
cataract B-NEG
extraction O
and O
beginning O
topical O
therapy O
with O
chloramphenicol O
. O

the O
first O
signs O
of O
pancytopenia B-NEG
began O
within O
one O
month O
of O
the O
surgery O
. O

the O
pattern O
of O
the O
aplastic B-NEG
anemia I-NEG
was O
associated O
with O
an O
idiosyncratic O
response O
to O
chloramphenicol O
. O

this O
was O
the O
second O
report O
of O
fatal O
aplastic B-NEG
anemia I-NEG
after O
topical O
treatment O
with O
chloramphenicol O
for O
ocular O
conditions O
, O
although O
two O
cases O
of O
reversible O
bone B-NEG
marrow I-NEG
hypoplasia I-NEG
have O
also O
been O
reported O
. O

any O
other O
suspected O
cases O
of O
ocular B-NEG
toxicity I-NEG
associated O
with O
topically O
applied O
chloramphenicol O
should O
be O
reported O
to O
the O
national O
registry O
of O
drug-induced O
ocular O
side O
effects O
, O
oregon O
health O
sciences O
university O
, O
portland O
, O
or O
97201 O
. O

-DOCSTART- O

bradycardia B-NEG
due O
to O
trihexyphenidyl O
hydrochloride O
. O

a O
chronic O
schizophrenic B-NEG
patient O
was O
treated O
with O
an O
anticholinergic O
drug O
, O
trihexyphenidyl O
hydrochloride O
. O

the O
patient O
developed O
, O
paradoxically O
, O
sinus O
bradycardia B-NEG
. O

the O
reaction O
was O
specific O
to O
trihexyphenidyl O
and O
not O
to O
other O
anticholinergic O
drugs O
. O

this O
antidyskinetic O
drug O
is O
widely O
used O
in O
clinical O
psychiatric B-NEG
practice O
and O
physicians O
should O
be O
aware O
of O
this O
side O
effect O
. O

-DOCSTART- O

experimental O
cyclosporine O
nephrotoxicity B-NEG
: O
risk O
of O
concomitant O
chemotherapy O
. O

the O
role O
of O
cyclosporine O
( O
csa O
) O
alone O
or O
in O
combination O
with O
various O
chemotherapeutics O
in O
the O
development O
of O
renal B-NEG
toxicity I-NEG
was O
evaluated O
in O
rats O
. O

administration O
of O
20 O
mg/kg/day O
csa O
for O
4 O
weeks O
caused O
renal O
functional O
and O
structural O
changes O
similar O
to O
those O
reported O
in O
man O
. O

the O
combined O
administration O
of O
csa O
and O
various O
chemotherapeutic O
drugs O
with O
a O
nephrotoxic B-NEG
potential O
, O
such O
as O
gentamicin O
( O
at O
therapeutic O
doses) O
, O
amphothericin O
b O
and O
ketoconazole O
, O
which O
are O
frequently O
used O
in O
immunosuppressed O
patients O
, O
did O
not O
aggravate O
the O
csa O
induced O
toxicity B-NEG
in O
the O
rat O
model O
. O

gentamicin O
at O
toxic O
doses O
, O
however O
, O
increased O
csa O
nephrotoxicity B-NEG
. O

thus O
, O
the O
nephrotoxicity B-NEG
induced O
by O
csa O
has O
a O
different O
pathogenetic O
mechanism O
. O

-DOCSTART- O

receptor O
mechanisms O
of O
nicotine-induced O
locomotor B-NEG
hyperactivity I-NEG
in O
chronic O
nicotine-treated O
rats O
. O

rats O
were O
pretreated O
with O
saline O
or O
nicotine O
( O
1.5 O
mg/kg O
per O
day O
) O
by O
subcutaneously O
implanting O
each O
animal O
with O
an O
alzet O
osmotic O
mini-pump O
which O
continuously O
released O
saline O
or O
nicotine O
for O
1, O
5 O
and O
14 O
days O
. O

at O
the O
end O
of O
each O
pretreatment O
period O
, O
animals O
were O
used O
for O
( O
i O
) O
determining O
their O
locomotor O
response O
to O
acutely O
injected O
nicotine O
( O
0.2 O
mg/kg O
, O
s.c. O
) O
and O
( O
ii O
) O
measuring O
the O
density O
of O
l-[3h]nicotine O
and O
[3h]spiperone O
binding O
sites O
in O
the O
striatum O
. O

we O
observed O
no O
changes O
in O
nicotine-induced O
locomotor O
response O
, O
striatal O
l-[3h]nicotine O
and O
[3h]spiperone O
binding O
in O
the O
animals O
pretreated O
with O
nicotine O
for O
1 O
day O
. O

in O
rats O
which O
were O
pretreated O
with O
nicotine O
for O
5 O
days O
, O
there O
was O
a O
significant O
increase O
in O
the O
nicotine-stimulated O
locomotor O
response O
which O
was O
associated O
with O
an O
increase O
in O
the O
number O
of O
l-[3h]nicotine O
binding O
sites O
and O
also O
with O
an O
elevated O
dopamine O
( O
da O
) O
level O
in O
the O
striatum O
. O

the O
number O
of O
striatal O
[3h]spiperone O
binding O
sites O
was O
not O
affected O
. O

in O
animals O
pretreated O
with O
nicotine O
for O
14 O
days O
, O
the O
nicotine-induced O
locomotor O
response O
remained O
to O
be O
potentiated O
. O

however O
, O
this O
response O
was O
correlated O
with O
an O
elevated O
number O
of O
striatal O
[3h]spiperone O
binding O
sites O
, O
whereas O
the O
number O
of O
striatal O
l-[3h]nicotine O
binding O
sites O
and O
the O
striatal O
da O
level O
were O
normal O
. O

these O
results O
suggest O
that O
chronic O
nicotine-treated O
rats O
develop O
locomotor B-NEG
hyperactivity I-NEG
in O
response O
to O
nicotine O
initially O
due O
to O
increases O
of O
both O
the O
density O
of O
nicotinic O
receptors O
and O
da O
concentration O
, O
followed O
by O
inducing O
da O
receptor O
supersensitivity O
in O
the O
striatum O
. O

-DOCSTART- O

hydrocortisone-induced O
hypertension B-NEG
in O
humans O
: O
pressor O
responsiveness O
and O
sympathetic O
function O
. O

oral O
hydrocortisone O
increases O
blood O
pressure O
and O
enhances O
pressor O
responsiveness O
in O
normal O
human O
subjects O
. O

we O
studied O
the O
effects O
of O
1 O
week O
of O
oral O
hydrocortisone O
( O
200 O
mg/day O
) O
on O
blood O
pressure O
, O
cardiac O
output O
, O
total O
peripheral O
resistance O
, O
forearm O
vascular O
resistance O
, O
and O
norepinephrine O
spillover O
to O
plasma O
in O
eight O
healthy O
male O
volunteers O
. O

although O
diastolic O
blood O
pressure O
remained O
unchanged O
, O
systolic O
blood O
pressure O
increased O
from O
119 O
to O
135 O
mm O
hg O
( O
sed O
+/- O
3.4 O
, O
p O
less O
than O
0.01) O
, O
associated O
with O
an O
increased B-NEG
cardiac I-NEG
output I-NEG
( O
5.85-7.73 O
l/min O
, O
sed O
+/- O
0.46 O
, O
p O
less O
than O
0.01) O
. O

total O
peripheral O
vascular O
resistance O
fell O
from O
15.1 O
to O
12.2 O
mm O
hg/l/min O
( O
sed O
+/- O
1.03 O
, O
p O
less O
than O
0.05) O
. O

resting O
forearm O
vascular O
resistance O
remained O
unchanged O
, O
but O
the O
reflex O
response O
to O
the O
cold O
pressor O
test O
was O
accentuated O
, O
the O
rise O
in O
resistance O
increasing O
from O
10.5 O
mm O
hg/ml/100 O
ml/min O
(r O
units O
) O
before O
treatment O
to O
32.6 O
r O
units O
after O
treatment O
( O
sed O
+/- O
6.4 O
, O
p O
less O
than O
0.025) O
. O

the O
rise O
in O
forearm O
vascular O
resistance O
accompanying O
intra-arterial O
norepinephrine O
(25 O
, O
50 O
, O
and O
100 O
ng/min O
) O
was O
also O
significantly O
greater O
after O
hydrocortisone O
, O
increasing O
from O
an O
average O
of O
14.9 O
+/- O
2.4 O
r O
units O
before O
treatment O
to O
35.1 O
+/- O
5.5 O
r O
units O
after O
hydrocortisone O
( O
sed O
+/- O
6.0 O
, O
p O
less O
than O
0.05) O
. O

a O
shift O
to O
the O
left O
in O
the O
dose-response O
relation O
and O
fall O
in O
threshold O
suggested O
increased O
sensitivity O
to O
norepinephrine O
after O
treatment O
. O

measurement O
of O
resting O
norepinephrine O
spillover O
rate O
to O
plasma O
and O
norepinephrine O
uptake O
indicated O
that O
overall O
resting O
sympathetic O
nervous O
system O
activity O
was O
not O
increased O
. O

the O
rise B-NEG
in I-NEG
resting I-NEG
blood I-NEG
pressure I-NEG
with O
hydrocortisone O
is O
associated O
with O
an O
increased B-NEG
cardiac I-NEG
output I-NEG
( O
presumably O
due O
to O
increased O
blood O
volume).(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

effects O
of O
suprofen O
on O
the O
isolated O
perfused O
rat O
kidney O
. O

although O
suprofen O
has O
been O
associated O
with O
the O
development O
of O
acute B-NEG
renal I-NEG
failure I-NEG
in O
greater O
than O
100 O
subjects O
, O
the O
mechanism O
of O
damage O
remains O
unclear O
. O

the O
direct O
nephrotoxic B-NEG
effects O
of O
a O
single O
dose O
of O
15 O
mg O
of O
suprofen O
were O
compared O
in O
the O
recirculating O
isolated O
rat O
kidney O
perfused O
with O
cell-free O
buffer O
with O
or O
without O
the O
addition O
of O
5 O
mg/dl O
of O
uric O
acid O
. O

there O
were O
no O
significant O
differences O
in O
renal O
sodium O
excretion O
, O
oxygen O
consumption O
, O
or O
urinary O
flow O
rates O
in O
kidneys O
perfused O
with O
suprofen O
compared O
with O
the O
drug-free O
control O
groups O
. O

in O
contrast O
, O
a O
significant O
decline O
in O
glomerular O
filtration O
rate O
was O
found O
after O
the O
introduction O
of O
suprofen O
to O
the O
kidney O
perfused O
with O
uric O
acid O
; O
no O
changes O
were O
found O
with O
suprofen O
in O
the O
absence O
of O
uric O
acid O
. O

a O
significant O
decrease O
in O
the O
baseline O
excretion O
rate O
of O
uric O
acid O
was O
found O
in O
rats O
given O
suprofen O
, O
compared O
with O
drug-free O
controls O
. O

however O
, O
the O
fractional O
excretion O
of O
uric O
acid O
was O
unchanged O
between O
the O
groups O
over O
the O
experimental O
period O
. O

in O
summary O
, O
suprofen O
causes O
acute B-NEG
declines I-NEG
in I-NEG
renal I-NEG
function I-NEG
, O
most O
likely O
by O
directly O
altering O
the O
intrarenal O
distribution O
of O
uric O
acid O
. O

-DOCSTART- O

cocaine-induced O
brainstem O
seizures B-NEG
and O
behavior O
. O

a O
variety O
of O
abnormal O
sensory/motor O
behaviors O
associated O
with O
electrical O
discharges O
recorded O
from O
the O
bilateral O
brainstem O
were O
induced O
in O
adult O
wky O
rats O
by O
mechanical O
( O
electrode O
implants O
) O
and O
dc O
electrical O
current O
stimulations O
and O
by O
acute O
and O
chronic O
administration O
of O
cocaine O
. O

the O
electrode O
implant O
implicated O
one O
side O
or O
the O
other O
of O
the O
reticular O
system O
of O
the O
brainstem O
but O
subjects O
were O
not O
incapacitated O
by O
the O
stimulations O
. O

cocaine O
( O
40 O
mg/kg O
) O
was O
injected O
subcutaneously O
for O
an O
acute O
experiment O
and O
subsequent O
20 O
mg/kg O
doses O
twice O
daily O
for O
3 O
days O
in O
a O
chronic O
study O
. O

cocaine O
generated O
more O
abnormal O
behaviors O
in O
the O
brainstem O
perturbation O
group O
, O
especially O
the O
electrically O
perturbated O
subjects O
. O

the O
abnormal O
behaviors O
were O
yawning O
, O
retrocollis O
, O
hyperactivity B-NEG
, O
hypersensitivity B-NEG
, O
beating O
drum O
behavior O
, O
squealing O
, O
head O
bobbing O
, O
circling O
, O
sniffing O
, O
abnormal O
posturing O
, O
and O
facial O
twitching O
. O

shifts O
in O
the O
power O
frequency O
spectra O
of O
the O
discharge O
patterns O
were O
noted O
between O
quiet O
and O
pacing O
behavioral O
states O
. O
hypersensitivity B-NEG
to O
various O
auditory O
, O
tactile O
, O
and O
visual O
stimulation O
was O
present O
and O
shifts O
in O
the O
brainstem O
ambient O
power O
spectral O
frequency O
occurred O
in O
response O
to O
tactile O
stimulation O
. O

these O
findings O
suggest O
that O
the O
brainstem O
generates O
and O
propagates O
pathological O
discharges O
that O
can O
be O
elicited O
by O
mechanical O
and O
dc O
electrical O
perturbation O
. O

cocaine O
was O
found O
to O
activate O
the O
discharge O
system O
and O
thus O
induce O
abnormal O
behaviors O
that O
are O
generated O
at O
the O
discharge O
site O
and O
at O
distant O
sites O
to O
which O
the O
discharge O
propagates O
. O

cognitive O
functions O
may O
also O
be O
involved O
since O
dopaminergic O
and O
serotonergic O
cellular O
elements O
at O
the O
brainstem O
level O
are O
also O
implicated O
. O

-DOCSTART- O

increased O
sulfation O
and O
decreased O
7alpha-hydroxylation O
of O
deoxycholic O
acid O
in O
ethinyl O
estradiol-induced O
cholestasis B-NEG
in O
rats O
. O

deoxycholic O
acid O
conjugation O
, O
transport O
capacity O
, O
and O
metabolism O
were O
compared O
in O
control O
and O
ethinyl O
estradiol-treated O
rats O
. O

control O
rats O
were O
found O
to O
have O
a O
lower O
capacity O
to O
transport O
deoxycholic O
acid O
than O
taurodeoxycholic O
acid O
, O
and O
both O
were O
decreased O
by O
ethinyl O
estradiol O
treatment O
. O

during O
[24-14c]sodium O
deoxycholate O
infusion O
, O
[14c]biliary O
bile O
acid O
secretion O
increased O
, O
but O
bile O
flow O
did O
not O
change O
significantly O
in O
either O
control O
or O
ethinyl O
estradiol-treated O
rats O
. O

ethinyl O
estradiol-treated O
animals O
excreted O
significantly O
less O
14c O
as O
taurocholic O
acid O
than O
did O
control O
animals O
, O
consistent O
with O
an O
impairment O
of O
7alpha-hydroxylation O
of O
taurodeoxycholic O
acid O
. O

ethinyl O
estradiol O
treatment O
did O
not O
impair O
conjugation O
of O
deoxycholic O
acid O
, O
but O
did O
result O
in O
an O
increase O
in O
sulfation O
of O
taurodeoxycholic O
acid O
from O
1.5% O
in O
controls O
to O
nearly O
4.0% O
(p O
less O
than O
0.01) O
. O

these O
results O
are O
consistent O
with O
the O
hypothesis O
that O
the O
rat O
has O
a O
poorer O
tolerance O
for O
deoxycholic O
acid O
than O
do O
certain O
other O
species O
. O

furthermore O
, O
the O
rat O
converts O
deoxycholic O
acid O
, O
a O
poor O
choleretic O
, O
to O
taurocholic O
acid O
, O
a O
good O
choleretic O
. O

when O
this O
conversion O
is O
impaired O
with O
ethinyl O
estradiol O
treatment O
, O
sulfation O
may O
be O
an O
important O
alternate O
pathway O
for O
excretion O
of O
this O
potentially O
harmful O
bile O
acid O
. O

-DOCSTART- O

effects O
of O
ouabain O
on O
myocardial O
oxygen O
supply O
and O
demand O
in O
patients O
with O
chronic O
coronary B-NEG
artery I-NEG
disease I-NEG
. O

a O
hemodynamic O
, O
volumetric O
, O
and O
metabolic O
study O
in O
patients O
without O
heart B-NEG
failure I-NEG
. O

the O
effects O
of O
digitalis O
glycosides O
on O
myocardial O
oxygen O
supply O
and O
demand O
are O
of O
particular O
interest O
in O
the O
presence O
of O
obstructive O
coronary B-NEG
artery I-NEG
disease I-NEG
, O
but O
have O
not O
been O
measured O
previously O
in O
man O
. O

we O
assessed O
the O
effects O
of O
ouabain O
( O
0.015 O
mg/kg O
body O
weight O
) O
on O
hemodynamic O
, O
volumetric O
, O
and O
metabolic O
parameters O
in O
11 O
patients O
with O
severe O
chronic O
coronary B-NEG
artery I-NEG
disease I-NEG
without O
clinical O
congestive B-NEG
heart I-NEG
failure I-NEG
. O

because O
the O
protocol O
was O
long O
and O
involved O
interventions O
which O
might O
affect O
the O
determinations O
, O
we O
also O
studied O
in O
nine O
patients O
using O
an O
identical O
protocol O
except O
that O
ouabain O
administration O
was O
omitted O
. O

left O
ventricular O
end-diastolic O
pressure O
and O
left O
ventricular O
end-diastolic O
volume O
fell O
in O
each O
patient O
given O
ouabain O
, O
even O
though O
they O
were O
initially O
elevated O
in O
only O
two O
patients O
. O

left O
ventricular O
end-diastolic O
pressure O
fell O
from O
11.5+/-1.4 O
( O
mean+/-se O
) O
to O
5.6+/-0.9 O
mm O
hg O
(p O
less O
than O
0.001 O
) O
and O
left O
ventricular O
end-diastolic O
volume O
fell O
from O
100+/-17 O
to O
82+/-12 O
ml/m2 O
(p O
less O
than O
0.01 O
) O
1 O
h O
after O
ouabain O
infusion O
was O
completed O
. O

the O
maximum O
velocity O
of O
contractile O
element O
shortening O
increased O
from O
1.68+/-0.11 O
ml/s O
to O
2.18+/-0.21 O
muscle-lengths/s O
(p O
less O
than O
0.05 O
) O
and O
is O
consistent O
with O
an O
increase O
in O
contractility O
. O

no O
significant O
change O
in O
these O
parameters O
occurred O
in O
the O
control O
patients O
. O

no O
significant O
change O
in O
myocardial O
oxygen O
consumption O
occurred O
after O
ouabain O
administration O
but O
this O
may O
be O
related O
to O
a O
greater O
decrease O
in O
mean O
arterial O
pressure O
in O
the O
ouabain O
patients O
than O
in O
the O
control O
patients O
. O

we O
conclude O
that O
in O
patients O
with O
chronic O
coronary B-NEG
artery I-NEG
disease I-NEG
who O
are O
not O
in O
clinical O
congestive B-NEG
heart I-NEG
failure I-NEG
left B-NEG
ventricular I-NEG
end-diastolic I-NEG
volume I-NEG
falls I-NEG
after O
ouabain O
administration O
even O
when O
it O
is O
initially O
normal O
. O

though O
this O
fall O
would O
be O
associated O
with O
a O
decrease O
in O
wall O
tension O
, O
and O
, O
therefore O
, O
of O
myocardial O
oxygen O
consumption O
, O
it O
may O
not O
be O
of O
sufficient O
magnitude O
to O
prevent O
a O
net O
increase O
in O
myocardial O
oxygen O
consumption O
. O

nevertheless O
, O
compensatory O
mechanisms O
prevent O
a O
deterioration O
of O
resting O
myocardial O
metabolism O
. O

-DOCSTART- O

prolongation B-NEG
of I-NEG
the I-NEG
qt I-NEG
interval I-NEG
related O
to O
cisapride-diltiazem O
interaction O
. O

cisapride O
, O
a O
cytochrome O
p450 O
3a4 O
( O
cyp3a4 O
) O
substrate O
, O
is O
widely O
prescribed O
for O
the O
treatment O
of O
gastrointestinal B-NEG
motility I-NEG
disorders I-NEG
. O
prolongation B-NEG
of I-NEG
qt I-NEG
interval I-NEG
, O
torsades B-NEG
de I-NEG
pointes I-NEG
, O
and O
sudden B-NEG
cardiac I-NEG
death I-NEG
have O
been O
reported O
after O
concomitant O
administration O
with O
erythromycin O
or O
azole O
antifungal O
agents O
, O
but O
not O
with O
other O
cyp3a4 O
inhibitors O
. O

a O
possible O
drug O
interaction O
occurred O
in O
a O
45-year-old O
woman O
who O
was O
taking O
cisapride O
for O
gastroesophageal B-NEG
reflux I-NEG
disorder I-NEG
and O
diltiazem O
, O
an O
agent O
that O
has O
inhibitory O
effect O
on O
cyp3a4 O
, O
for O
hypertension B-NEG
. O

the O
patient O
was O
in O
near O
syncope B-NEG
and O
had O
qt-interval B-NEG
prolongation I-NEG
. O

after O
discontinuing O
cisapride O
, O
the O
qt O
interval O
returned O
to O
normal O
and O
symptoms O
did O
not O
recur O
. O

we O
suggest O
that O
caution O
be O
taken O
when O
cisapride O
is O
prescribed O
with O
any O
potent O
inhibitor O
of O
cyp3a4 O
, O
including O
diltiazem O
. O

-DOCSTART- O

paclitaxel O
combined O
with O
carboplatin O
in O
the O
first-line O
treatment O
of O
advanced O
ovarian B-NEG
cancer I-NEG
. O

in O
a O
phase O
i O
study O
to O
determine O
the O
maximum O
tolerated O
dose O
of O
paclitaxel O
(taxol O
; O
bristol-myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
given O
as O
a O
3-hour O
infusion O
in O
combination O
with O
carboplatin O
administered O
every O
21 O
days O
to O
women O
with O
advanced O
ovarian B-NEG
cancer I-NEG
, O
paclitaxel O
doses O
were O
escalated O
as O
follows O
: O
level O
1, O
135 O
mg/m2 O
; O
level O
2, O
160 O
mg/m2 O
; O
level O
3, O
185 O
mg/m2 O
; O
and O
level O
4,210 O
mg/m2 O
. O

the O
fixed O
dose O
of O
carboplatin O
at O
levels O
1 O
through O
4 O
was O
given O
to O
achieve O
an O
area O
under O
the O
concentration-time O
curve O
( O
auc O
) O
of O
5 O
using O
the O
calvert O
formula O
. O

in O
levels O
5 O
and O
6 O
the O
carboplatin O
dose O
was O
targeted O
at O
aucs O
of O
6 O
and O
7.5 O
, O
respectively O
, O
combined O
with O
a O
fixed O
paclitaxel O
dose O
of O
185 O
mg/m2 O
. O

to O
date O
, O
30 O
previously O
untreated O
patients O
, O
all O
with O
a O
good O
performance O
status O
( O
eastern O
cooperative O
oncology O
group O
0 O
to O
2) O
have O
been O
entered O
into O
this O
ongoing O
study O
. O

the O
dose-limiting O
toxicity B-NEG
of O
the O
combination O
was O
myelosuppression B-NEG
( O
leukopenia B-NEG
, O
granulocytopenia B-NEG
, O
and O
thrombocytopenia B-NEG
). O
neurotoxicity B-NEG
was O
largely O
moderate O
. O

so O
far O
, O
14 O
patients O
are O
evaluable O
for O
response O
; O
of O
these O
, O
eight O
( O
57% O
) O
showed O
objective O
( O
complete O
or O
partial O
) O
response O
and O
disease O
stabilized O
in O
six O
patients O
. O

no O
patient O
had O
disease O
progression O
. O

we O
conclude O
that O
the O
combination O
of O
paclitaxel O
185 O
mg/m2 O
administered O
as O
a O
3-hour O
infusion O
followed O
immediately O
by O
a O
1-hour O
infusion O
of O
carboplatin O
at O
an O
auc O
of O
6 O
can O
be O
administered O
safely O
in O
a O
21-day O
schedule O
in O
the O
outpatient O
setting O
. O

the O
recommended O
dose O
for O
phase O
iii O
studies O
is O
paclitaxel O
185 O
mg/m2 O
and O
carboplatin O
auc O
6. O

-DOCSTART- O

treatment O
of O
tacrolimus-related O
adverse O
effects O
by O
conversion O
to O
cyclosporine O
in O
liver O
transplant O
recipients O
. O

when O
tacrolimus O
side O
effects O
persist O
despite O
dose O
reduction O
, O
conversion O
to O
cyclosporine-based O
immunosuppression O
( O
cya O
) O
is O
necessary O
. O

we O
characterized O
tacrolimus O
side O
effects O
that O
warranted O
discontinuation O
of O
the O
drug O
, O
and O
outcomes O
after O
conversion O
. O

of O
388 O
liver O
recipients O
who O
received O
tacrolimus O
as O
primary O
immunosuppression O
, O
70 O
required O
conversion O
to O
cya O
. O

we O
recorded O
indication O
for O
conversion O
, O
whether O
conversion O
was O
early O
or O
late O
after O
transplantation O
, O
tacrolimus O
dose O
and O
trough O
blood O
level O
at O
conversion O
, O
and O
incidence O
of O
rejection O
after O
conversion O
. O

conversion O
was O
early O
in O
29 O
patients O
( O
41.4% O
) O
and O
late O
in O
41 O
(58.6%) O
. O

indications O
for O
early O
conversion O
were O
neurotoxicity B-NEG
(20) O
, O
( O
insulin-dependent B-NEG
) O
diabetes I-NEG
mellitus I-NEG
( O
iddm B-NEG
) O
(5) O
, O
nephrotoxicity B-NEG
(3) O
, O
gastrointestinal B-NEG
( O
gi I-NEG
) O
toxicity I-NEG
(6) O
, O
and O
cardiomyopathy B-NEG
(1) O
, O
and O
for O
late O
conversion O
were O
neurotoxicity B-NEG
(15) O
, O
iddm B-NEG
(12) O
, O
nephrotoxicity B-NEG
(3) O
, O
gi B-NEG
toxicity I-NEG
(5) O
, O
hepatotoxicity B-NEG
(6) O
, O
post-transplant B-NEG
lmphoproliferate I-NEG
disease I-NEG
( O
ptld B-NEG
) O
(2) O
, O
cardiomyopathy B-NEG
(1) O
, O
hemolytic B-NEG
anemia I-NEG
(1) O
, O
and O
pruritus B-NEG
(1) O
. O

all O
early-conversion O
patients O
showed O
improvement/resolution O
of O
symptoms O
. O

among O
late-conversion O
patients O
, O
37 O
( O
90.2% O
) O
had O
improvement/resolution O
; O
in O
4 O
(9.8%) O
, O
adverse O
effects O
persisted O
. O

the O
overall O
rejection O
rate O
was O
30% O
. O

sixty-two O
patients O
( O
88.6% O
) O
are O
alive O
with O
functioning O
grafts O
686 O
+/- O
362 O
days O
(range O
, O
154-1433 O
days O
) O
after O
conversion O
. O

when O
tacrolimus O
side O
effects O
are O
unresponsive O
to O
dose O
reduction O
, O
conversion O
to O
cya O
can O
be O
accomplished O
safely O
, O
with O
no O
increased O
risk O
of O
rejection O
and O
excellent O
long-term O
outcome O
. O

-DOCSTART- O

relative O
efficacy O
and O
toxicity B-NEG
of O
netilmicin O
and O
tobramycin O
in O
oncology O
patients O
. O

we O
prospectively O
compared O
the O
efficacy O
and O
safety O
of O
netilmicin O
sulfate O
or O
tobramycin O
sulfate O
in O
conjunction O
with O
piperacillin O
sodium O
in O
118 O
immunocompromised O
patients O
with O
presumed O
severe O
infections B-NEG
. O

the O
two O
treatment O
regimens O
were O
equally O
efficacious O
. O
nephrotoxicity B-NEG
occurred O
in O
a O
similar O
proportion O
in O
patients O
treated O
with O
netilmicin O
and O
tobramycin O
( O
17% O
vs O
11%) O
. O
ototoxicity B-NEG
occurred O
in O
four O
( O
9.5% O
) O
of O
42 O
netilmicin O
and O
piperacillin O
and O
in O
12 O
( O
22% O
) O
of O
54 O
tobramycin O
and O
piperacillin-treated O
patients O
. O

of O
those O
evaluated O
with O
posttherapy O
audiograms O
, O
three O
of O
four O
netilmicin O
and O
piperacillin-treated O
patients O
had O
auditory O
thresholds O
return O
to O
baseline O
compared O
with O
one O
of O
nine O
tobramycin O
and O
piperacillin-treated O
patients O
. O

the O
number O
of O
greater O
than O
or O
equal O
to O
15-db O
increases O
in O
auditory O
threshold O
as O
a O
proportion O
of O
total O
greater O
than O
or O
equal O
to O
15-db O
changes O
( O
increases O
and O
decreases O
) O
was O
significantly O
lower O
in O
netilmicin O
and O
piperacillin- O
vs O
tobramycin O
and O
piperacillin-treated O
patients O
( O
18 O
of O
78 O
vs O
67 O
of O
115) O
. O

we O
conclude O
that O
aminoglycoside-associated O
ototoxicity B-NEG
was O
less O
severe O
and O
more O
often O
reversible O
with O
netilmicin O
than O
with O
tobramycin O
. O

-DOCSTART- O

effect O
of O
prostaglandin O
synthetase O
inhibitors O
on O
experimentally O
induced O
convulsions B-NEG
in O
rats O
. O

to O
investigate O
the O
relationship O
of O
prostaglandins O
( O
pgs O
) O
to O
seizure B-NEG
induction O
, O
the O
effects O
of O
six O
pg O
synthetase O
inhibitors O
on O
convulsions B-NEG
induced O
by O
flurothyl O
, O
picrotoxin O
, O
pentetrazol O
(ptz) O
, O
electroshock O
or O
bicuculline O
were O
evaluated O
. O

ibuprofen O
, O
sulindac O
, O
mefenamic O
acid O
, O
and O
low O
dose O
meclofenamic O
acid O
increased O
the O
latency-to-onset O
in O
the O
flurothyl O
and/or O
ptz O
models O
; O
the O
electroshock O
, O
picrotoxin O
and O
bicuculline O
models O
were O
not O
significantly O
affected O
by O
any O
of O
the O
pretreatment O
agents O
. O

these O
results O
suggest O
that O
pgs O
are O
involved O
in O
the O
mechanism(s O
) O
underlying O
fluorthyl- O
and O
ptz-induced O
convulsions B-NEG
, O
but O
not O
picrotoxin- O
, O
electroshock- O
, O
or O
bicuculline-induced O
convulsions B-NEG
. O

-DOCSTART- O

angiotensin-converting O
enzyme O
( O
ace O
) O
inhibitor-associated O
angioedema B-NEG
of O
the O
stomach O
and O
small O
intestine O
: O
a O
case O
report O
. O

this O
is O
a O
case O
report O
on O
a O
45-year O
old O
african-american O
female O
with O
newly O
diagnosed O
hypertension B-NEG
, O
who O
was O
started O
on O
a O
combination O
pill O
of O
amlodipine/benazapril O
10/5 O
mg O
. O

the O
very O
next O
day O
, O
she O
presented O
at O
the O
emergency O
room O
( O
er O
) O
with O
abdominal B-NEG
pain I-NEG
, O
nausea B-NEG
and O
vomiting B-NEG
. O

physical O
exam O
, O
complete O
metabolic O
panel O
, O
and O
hemogram O
were O
in O
the O
normal O
range O
. O

she O
was O
discharged O
from O
the O
er O
after O
a O
few O
hours O
of O
treatment O
with O
fluid O
and O
analgesics O
. O

however O
, O
she O
returned O
to O
the O
er O
the O
next O
day O
with O
the O
same O
complaints O
. O

this O
time O
the O
physical O
exam O
was O
significant O
for O
a O
distended O
abdomen O
with O
dullness O
to O
percussion O
. O

ct O
scan O
of O
the O
abdomen O
revealed O
markedly O
thickened O
antrum O
of O
the O
stomach O
, O
duodenum O
and O
jejunum O
, O
along O
with O
fluid O
in O
the O
abdominal O
and O
pelvic O
cavity O
. O

angiotensin-converting O
enzyme O
inhibitor O
( O
acei)-induced O
angioedema B-NEG
was O
suspected O
, O
and O
anti- O
hypertensive B-NEG
medications O
were O
discontinued O
. O

her O
symptoms O
improved O
within O
the O
next O
24 O
hours O
, O
and O
repeat O
ct O
after O
72 O
hours O
revealed O
marked O
improvement O
in O
stomach O
and O
small O
bowel O
thickening O
and O
resolution O
of O
ascites B-NEG
. O

the O
recognition O
of O
angiotensin-converting O
enzyme O
( O
ace O
) O
and O
angiotensin O
receptor O
blocker O
( O
arb O
) O
intestinal B-NEG
angioedema I-NEG
constitutes O
a O
challenge O
to O
primary O
care O
physicians O
, O
internists O
, O
emergency O
room O
personal O
and O
surgeons O
. O

-DOCSTART- O

valproic O
acid O
i: O
time O
course O
of O
lipid O
peroxidation O
biomarkers O
, O
liver B-NEG
toxicity I-NEG
, O
and O
valproic O
acid O
metabolite O
levels O
in O
rats O
. O

a O
single O
dose O
of O
valproic O
acid O
(vpa) O
, O
which O
is O
a O
widely O
used O
antiepileptic O
drug O
, O
is O
associated O
with O
oxidative O
stress O
in O
rats O
, O
as O
recently O
demonstrated O
by O
elevated O
levels O
of O
15-f(2t)-isoprostane O
(15-f(2t)-isop) O
. O

to O
determine O
whether O
there O
was O
a O
temporal O
relationship O
between O
vpa-associated O
oxidative O
stress O
and O
hepatotoxicity B-NEG
, O
adult O
male O
sprague-dawley O
rats O
were O
treated O
ip O
with O
vpa O
( O
500 O
mg/kg O
) O
or O
0.9% O
saline O
( O
vehicle O
) O
once O
daily O
for O
2, O
4, O
7, O
10 O
, O
or O
14 O
days O
. O

oxidative O
stress O
was O
assessed O
by O
determining O
plasma O
and O
liver O
levels O
of O
15-f(2t)-isop O
, O
lipid O
hydroperoxides O
(lpo) O
, O
and O
thiobarbituric O
acid O
reactive O
substances O
(tbars) O
. O

plasma O
and O
liver O
15-f(2t)-isop O
were O
elevated O
and O
reached O
a O
plateau O
after O
day O
2 O
of O
vpa O
treatment O
compared O
to O
control O
. O

liver O
lpo O
levels O
were O
not O
elevated O
until O
day O
7 O
of O
treatment O
( O
1.8-fold O
versus O
control O
, O
p O
< O
0.05) O
. O

liver O
and O
plasma O
tbars O
were O
not O
increased O
until O
14 O
days O
( O
2-fold O
vs O
. O
control O
, O
p O
< O
0.05) O
. O
liver B-NEG
toxicity I-NEG
was O
evaluated O
based O
on O
serum O
levels O
of O
alpha-glutathione O
s-transferase O
( O
alpha-gst O
) O
and O
by O
histology O
. O

serum O
alpha-gst O
levels O
were O
significantly O
elevated O
by O
day O
4, O
which O
corresponded O
to O
hepatotoxicity B-NEG
as O
shown O
by O
the O
increasing O
incidence O
of O
inflammation B-NEG
of O
the O
liver O
capsule O
, O
necrosis B-NEG
, O
and O
steatosis B-NEG
throughout O
the O
study O
. O

the O
liver O
levels O
of O
beta-oxidation O
metabolites O
of O
vpa O
were O
decreased O
by O
day O
14 O
, O
while O
the O
levels O
of O
4-ene-vpa O
and O
( O
e)-2,4-diene-vpa O
were O
not O
elevated O
throughout O
the O
study O
. O

overall O
, O
these O
findings O
indicate O
that O
vpa O
treatment O
results O
in O
oxidative O
stress O
, O
as O
measured O
by O
levels O
of O
15-f(2t)-isop O
, O
which O
precedes O
the O
onset O
of O
necrosis B-NEG
, O
steatosis B-NEG
, O
and O
elevated O
levels O
of O
serum O
alpha-gst O
. O

-DOCSTART- O

pheochromocytoma B-NEG
unmasked O
by O
amisulpride O
and O
tiapride O
. O

objective O
: O
to O
describe O
the O
unmasking O
of O
pheochromocytoma B-NEG
in O
a O
patient O
treated O
with O
amisulpride O
and O
tiapride O
. O

case O
summary O
: O
a O
42-year-old O
white O
man O
developed O
acute O
hypertension B-NEG
with O
severe O
headache B-NEG
and O
vomiting B-NEG
2 O
hours O
after O
the O
first O
doses O
of O
amisulpride O
100 O
mg O
and O
tiapride O
100 O
mg O
. O

both O
drugs O
were O
immediately O
discontinued O
, O
and O
the O
patient O
recovered O
after O
subsequent O
nicardipine O
and O
verapamil O
treatment O
. O

abdominal O
ultrasound O
showed O
an O
adrenal O
mass O
, O
and O
postoperative O
histologic O
examination O
confirmed O
the O
diagnosis O
of O
pheochromocytoma B-NEG
. O

discussion O
: O
drug-induced O
symptoms O
of O
pheochromocytoma B-NEG
are O
often O
associated O
with O
the O
use O
of O
substituted O
benzamide O
drugs O
, O
but O
the O
underlying O
mechanism O
is O
unknown O
. O

in O
our O
case O
, O
use O
of O
the O
naranjo O
probability O
scale O
indicated O
a O
possible O
relationship O
between O
the O
hypertensive B-NEG
crisis O
and O
amisulpride O
and O
tiapride O
therapy O
. O

conclusions O
: O
as O
of O
march O
24 O
, O
2005 O
, O
this O
is O
the O
first O
reported O
case O
of O
amisulpride- O
and O
tiapride-induced O
hypertensive B-NEG
crisis O
in O
a O
patient O
with O
pheochromocytoma B-NEG
. O

physicians O
and O
other O
healthcare O
professionals O
should O
be O
aware O
of O
this O
potential O
adverse O
effect O
of O
tiapride O
and O
amisulpride O
. O

-DOCSTART- O

quantitative O
drug O
levels O
in O
stimulant O
psychosis B-NEG
: O
relationship O
to O
symptom O
severity O
, O
catecholamines O
and O
hyperkinesia B-NEG
. O

to O
examine O
the O
relationship O
between O
quantitative O
stimulant O
drug O
levels O
, O
catecholamines O
, O
and O
psychotic B-NEG
symptoms I-NEG
, O
nineteen O
patients O
in O
a O
psychiatric B-NEG
emergency O
service O
with O
a O
diagnosis O
of O
amphetamine- O
or O
cocaine-induced O
psychosis B-NEG
were O
interviewed O
, O
and O
plasma O
and O
urine O
were O
collected O
for O
quantitative O
assays O
of O
stimulant O
drug O
and O
catecholamine O
metabolite O
levels O
. O

methamphetamine O
or O
amphetamine O
levels O
were O
related O
to O
several O
psychopathology O
scores O
and O
the O
global O
hyperkinesia B-NEG
rating O
. O

hva O
levels O
were O
related O
to O
global O
hyperkinesia B-NEG
but O
not O
to O
psychopathology O
ratings O
. O

although O
many O
other O
factors O
such O
as O
sensitization O
may O
play O
a O
role O
, O
intensity O
of O
stimulant-induced O
psychotic B-NEG
symptoms I-NEG
and O
stereotypies B-NEG
appears O
to O
be O
at O
least O
in O
part O
dose-related O
. O

-DOCSTART- O

delayed O
asystolic B-NEG
cardiac B-NEG
arrest I-NEG
after O
diltiazem O
overdose B-NEG
; O
resuscitation O
with O
high O
dose O
intravenous O
calcium O
. O

a O
51 O
year O
old O
man O
took O
a O
mixed O
overdose B-NEG
including O
1.8-3.6 O
g O
of O
diltiazem O
, O
paracetamol O
, O
aspirin O
, O
isosorbide O
nitrate O
, O
and O
alcohol O
. O

he O
initially O
presented O
to O
hospital O
after O
six O
hours O
with O
mild O
hypotension B-NEG
and O
was O
treated O
with O
activated O
charcoal O
and O
intravenous O
fluids O
. O

eighteen O
hours O
after O
the O
overdose B-NEG
he O
had O
two O
generalised O
tonic-clonic B-NEG
seizures I-NEG
. O

the O
patient O
remained O
unresponsive O
with O
junctional O
bradycardia B-NEG
, O
unrecordable O
blood O
pressure O
, O
and O
then O
became O
asystolic B-NEG
. O

he O
was O
resuscitated O
with O
high O
dose O
( O
13.5 O
g) O
intravenous O
calcium O
and O
adrenaline O
(epinephrine) O
. O

he O
required O
inotropic O
support O
and O
temporary O
pacing O
over O
the O
next O
48 O
hours O
. O

this O
case O
suggests O
there O
is O
a O
role O
for O
aggressive O
high O
dose O
intravenous O
calcium O
therapy O
in O
severe O
diltiazem O
overdose B-NEG
, O
particularly O
with O
the O
onset O
of O
asystole B-NEG
. O

it O
should O
be O
considered O
early O
in O
cases O
of O
cardiac B-NEG
arrest I-NEG
after O
diltiazem O
overdose B-NEG
. O

the O
case O
also O
highlights O
the O
problems O
with O
delayed O
toxicity B-NEG
when O
whole O
bowel O
irrigation O
is O
not O
administered O
. O

-DOCSTART- O

renal B-NEG
papillary I-NEG
necrosis I-NEG
due O
to O
naproxen O
. O

a O
31-year-old O
man O
with O
rheumatoid B-NEG
arthritis I-NEG
, O
who O
had O
previously O
been O
treated O
with O
sulindac O
, O
fenoprofen O
calcium O
, O
high O
dose O
salicylates O
and O
gold O
salts O
, O
developed O
renal B-NEG
papillary I-NEG
necrosis I-NEG
( O
rpn B-NEG
) O
4 O
months O
after O
institution O
of O
naproxen O
therapy O
. O

no O
other O
factor O
predisposing O
to O
rpn B-NEG
could O
be O
discovered O
. O

sulindac O
was O
substituted O
for O
naproxen O
and O
no O
further O
adverse O
renal O
effects O
occurred O
over O
the O
next O
12 O
months O
. O

we O
review O
previous O
reports O
linking O
rpn B-NEG
to O
antiinflammatory O
drug O
use O
and O
discuss O
possible O
advantages O
of O
sulindac O
in O
patients O
who O
have O
experienced O
renal B-NEG
toxicity I-NEG
from O
other O
antiinflammatory O
agents O
. O

-DOCSTART- O

adverse O
interaction O
between O
beta-adrenergic O
blocking O
drugs O
and O
verapamil--report O
of O
three O
cases O
. O

three O
patients O
with O
ischaemic B-NEG
heart I-NEG
disease I-NEG
developed O
profound O
cardiac B-NEG
failure I-NEG
, O
hypotension B-NEG
and O
bradycardia B-NEG
during O
combined O
therapy O
with O
verapamil O
and O
beta-adrenergic O
blocking O
drugs O
. O

this O
clinical O
picture O
resolved O
completely O
with O
cessation O
of O
the O
combined O
therapy O
. O

baseline O
left O
ventricular O
function O
, O
assessed O
by O
cardiac O
catheterisation O
or O
nuclear O
angiography O
, O
was O
normal O
in O
two O
patients O
and O
only O
mildly O
reduced O
in O
the O
other O
. O

simultaneously O
administration O
of O
beta-adrenergic O
blocking O
drugs O
and O
verapamil O
may O
result O
in O
profound O
adverse O
interactions O
and O
should O
only O
be O
administered O
with O
great O
caution O
. O

-DOCSTART- O

adverse O
reactions O
to O
bendrofluazide O
and O
propranolol O
for O
the O
treatment O
of O
mild O
hypertension B-NEG
. O

report O
of O
medical O
research O
council O
working O
party O
on O
mild O
to O
moderate O
hypertension B-NEG
. O

participants O
in O
the O
medical O
research O
council O
treatment O
trial O
for O
mild O
hypertension B-NEG
are O
randomly O
allocated O
to O
one O
of O
four O
treatment O
groups O
: O
bendrofluazide O
, O
propranolol O
, O
or O
a O
placebo O
for O
either O
of O
these O
drugs O
. O

the O
trial O
is O
single-blind O
. O

23 O
582 O
patient-years O
of O
observation O
have O
been O
completed O
so O
far O
, O
10 O
684 O
on O
active O
drugs O
and O
12 O
898 O
on O
placebos O
. O

the O
results O
show O
an O
association O
between O
bendrofluazide O
treatment O
and O
impotence B-NEG
, O
and O
impotence B-NEG
also O
occurred O
more O
frequently O
in O
patients O
taking O
propranolol O
than O
in O
those O
taking O
placebos O
. O

other O
adverse O
reactions O
significantly O
linked O
with O
active O
drugs O
include O
impaired B-NEG
glucose I-NEG
tolerance I-NEG
in O
men O
and O
women O
and O
gout B-NEG
in O
men O
, O
associated O
with O
bendrofluazide O
treatment O
, O
and O
raynaud's B-NEG
phenomenon I-NEG
and O
dyspnoea B-NEG
in O
men O
and O
women O
taking O
propranolol O
. O

no O
corneal B-NEG
disease I-NEG
is O
known O
to O
have O
occurred O
in O
the O
propranolol O
group O
. O

mean O
serum O
potassium O
level O
fell O
, O
and O
urea O
and O
uric O
acid O
levels O
rose O
, O
in O
men O
and O
women O
taking O
bendrofluazide O
. O

in O
the O
propranolol O
group O
, O
serum O
potassium O
and O
uric O
acid O
levels O
rose O
in O
both O
sexes O
, O
but O
the O
urea O
level O
rose O
significantly O
in O
women O
only O
. O

-DOCSTART- O

dexmedetomidine O
and O
cardiac O
protection O
for O
non-cardiac O
surgery O
: O
a O
meta-analysis O
of O
randomised O
controlled O
trials O
. O

we O
conducted O
a O
systematic O
review O
of O
the O
effects O
of O
dexmedetomidine O
on O
cardiac O
outcomes O
following O
non-cardiac O
surgery O
. O

we O
included O
prospective O
, O
randomised O
peri-operative O
studies O
of O
dexmedetomidine O
that O
reported O
mortality O
, O
cardiac O
morbidity O
or O
adverse O
drug O
events O
. O

a O
pubmed O
central O
and O
embase O
search O
was O
conducted O
up O
to O
july O
2007 O
. O

the O
reference O
lists O
of O
identified O
papers O
were O
examined O
for O
further O
trials O
. O

of O
425 O
studies O
identified O
, O
20 O
were O
included O
in O
the O
meta-analysis O
( O
840 O
patients) O
. O

dexmedetomidine O
was O
associated O
with O
a O
trend O
towards O
improved O
cardiac O
outcomes O
; O
all-cause O
mortality O
( O
or O
0.27 O
, O
95% O
ci O
0.01-7.13 O
, O
p O
= O
0.44) O
, O
non-fatal O
myocardial B-NEG
infarction I-NEG
( O
or O
0.26 O
, O
95% O
ci O
0.04-1.60 O
, O
p O
= O
0.14) O
, O
and O
myocardial B-NEG
ischaemia I-NEG
( O
or O
0.65 O
, O
95% O
ci O
0.26-1.63 O
, O
p O
= O
0.36) O
. O

peri-operative O
hypotension B-NEG
(26% O
, O
or O
3.80 O
, O
95% O
ci O
1.91-7.54 O
, O
p O
= O
0.0001 O
) O
and O
bradycardia B-NEG
(17% O
, O
or O
5.45 O
, O
95% O
ci O
2.98-9.95 O
, O
p O
< O
0.00001 O
) O
were O
significantly O
increased O
. O

an O
anticholinergic O
did O
not O
reduce O
the O
incidence O
of O
bradycardia B-NEG
(p O
= O
0.43) O
. O

a O
randomised O
placebo-controlled O
trial O
of O
dexmedetomidine O
is O
warranted O
. O

-DOCSTART- O

differential O
diagnosis O
of O
high O
serum O
creatine O
kinase O
levels O
in O
systemic B-NEG
lupus I-NEG
erythematosus I-NEG
. O

we O
report O
the O
clinical O
and O
bioptic O
findings O
for O
a O
57-year-old O
woman O
with O
severe O
chloroquine-induced O
myopathy B-NEG
. O

since O
1989 O
, O
she O
had O
been O
suffering O
from O
systemic B-NEG
lupus I-NEG
erythematosus I-NEG
( O
sle B-NEG
) O
with O
renal B-NEG
involvement I-NEG
and O
undergone O
periods O
of O
treatment O
with O
azathioprine O
and O
cyclophosphamide O
. O

additional O
therapy O
with O
chloroquine O
( O
cq O
) O
was O
started O
because O
of O
arthralgia B-NEG
. O

at O
the O
same O
time O
, O
slightly O
increased O
creatine O
kinase O
( O
ck O
) O
levels O
were O
noted O
. O
myositis B-NEG
was O
suspected O
, O
and O
the O
patient O
was O
treated O
with O
steroids O
. O

the O
ck O
increase O
persisted O
, O
however O
, O
and O
she O
developed O
progressive O
muscular B-NEG
weakness I-NEG
and O
muscular B-NEG
atrophy I-NEG
. O

routine O
controls O
revealed O
markedly O
elevated O
ck O
levels O
of O
1,700 O
u/l O
. O

the O
neurological O
and O
electrophysiological O
findings O
were O
not O
typical O
of O
myositis B-NEG
. O

thus O
, O
muscle O
biopsy O
of O
the O
deltoid O
muscle O
was O
performed O
in O
order O
to O
exclude O
polymyositis B-NEG
or O
toxic O
myopathy B-NEG
. O

as O
it O
revealed O
chloroquine-induced O
myopathy B-NEG
, O
medication O
was O
stopped O
. O

discriminating O
between O
primary O
sle B-NEG
-induced O
affection B-NEG
of I-NEG
the I-NEG
musculoskeletal I-NEG
system I-NEG
and O
drug-induced O
side O
effects O
is O
important O
for O
appropriate O
treatment O
of O
sle B-NEG
patients O
. O

-DOCSTART- O

intravenous O
ribavirin O
treatment O
for O
severe O
adenovirus B-NEG
disease I-NEG
in O
immunocompromised O
children O
. O

background O
: O
adenovirus O
is O
an O
important O
cause O
of O
morbidity O
and O
mortality O
in O
the O
immunocompromised O
host O
. O

the O
incidence O
of O
severe O
adenovirus B-NEG
disease I-NEG
in O
pediatrics O
is O
increasing O
in O
association O
with O
growing O
numbers O
of O
immunocompromised O
children O
, O
where O
case O
fatality O
rates O
as O
high O
as O
50% O
to O
80% O
have O
been O
reported O
. O

there O
are O
no O
approved O
antiviral O
agents O
with O
proven O
efficacy O
for O
the O
treatment O
of O
severe O
adenovirus B-NEG
disease I-NEG
, O
nor O
are O
there O
any O
prospective O
randomized O
, O
controlled O
trials O
of O
potentially O
useful O
anti-adenovirus O
therapies O
. O

apparent O
clinical O
success O
in O
the O
treatment O
of O
severe O
adenovirus B-NEG
disease I-NEG
is O
limited O
to O
a O
few O
case O
reports O
and O
small O
series O
. O

experience O
is O
greatest O
with O
intravenous O
ribavirin O
and O
cidofovir O
. O

ribavirin O
, O
a O
guanosine O
analogue O
, O
has O
broad O
antiviral O
activity O
against O
both O
rna O
and O
dna O
viruses O
, O
including O
documented O
activity O
against O
adenovirus O
in O
vitro O
. O

ribavirin O
is O
licensed O
in O
aerosol O
form O
for O
the O
treatment O
of O
respiratory B-NEG
syncytial I-NEG
virus I-NEG
infection I-NEG
, O
and O
orally O
in O
combination O
with O
interferon O
to O
treat O
hepatitis B-NEG
c I-NEG
. O

intravenous O
ribavirin O
is O
the O
treatment O
of O
choice O
for O
infection B-NEG
with I-NEG
hemorrhagic I-NEG
fever I-NEG
viruses I-NEG
. O

the O
most O
common O
adverse O
effect O
of O
intravenous O
ribavirin O
is O
reversible O
mild O
anemia B-NEG
. O

the O
use O
of O
cidofovir O
in O
severe O
adenovirus B-NEG
infection I-NEG
has O
been O
limited O
by O
adverse O
effects O
, O
the O
most O
significant O
of O
which O
is O
nephrotoxicity B-NEG
. O

objective O
: O
we O
report O
our O
experience O
with O
intravenous O
ribavirin O
therapy O
for O
severe O
adenovirus B-NEG
disease I-NEG
in O
a O
series O
of O
immunocompromised O
children O
and O
review O
the O
literature O
. O

design/methods O
: O
we O
retrospectively O
reviewed O
the O
medical O
records O
of O
5 O
children O
treated O
with O
intravenous O
ribavirin O
for O
documented O
severe O
adenovirus B-NEG
disease I-NEG
. O

two O
patients O
developed O
adenovirus O
hemorrhagic B-NEG
cystitis I-NEG
after O
cardiac O
and O
bone O
marrow O
transplants O
, O
respectively O
. O

the O
bone O
marrow O
transplant O
patient O
also O
received O
intravenous O
cidofovir O
for O
progressive O
disseminated O
disease O
. O

an O
additional O
3 O
children O
developed O
adenovirus B-NEG
pneumonia I-NEG
; O
2 O
were O
neonates O
, O
1 O
of O
whom O
had O
partial O
digeorge B-NEG
syndrome I-NEG
. O

the O
remaining O
infant O
had O
recently O
undergone O
a O
cardiac O
transplant O
. O

intravenous O
ribavirin O
was O
administered O
on O
a O
compassionate-use O
protocol O
. O

results O
: O
complete O
clinical O
recovery O
followed O
later O
by O
viral O
clearance O
was O
observed O
in O
2 O
children O
: O
the O
cardiac O
transplant O
recipient O
with O
adenovirus O
hemorrhagic B-NEG
cystitis I-NEG
and O
the O
immunocompetent O
neonate O
with O
adenovirus B-NEG
pneumonia I-NEG
. O

the O
remaining O
3 O
children O
died O
of O
adenovirus B-NEG
disease I-NEG
. O

intravenous O
ribavirin O
therapy O
was O
well O
tolerated O
. O

use O
of O
cidofovir O
in O
1 O
child O
was O
associated O
with O
progressive B-NEG
renal I-NEG
failure I-NEG
and O
neutropenia B-NEG
. O

discussion O
: O
our O
series O
of O
patients O
is O
representative O
of O
the O
spectrum O
of O
immunocompromised O
children O
at O
greatest O
risk O
for O
severe O
adenovirus B-NEG
disease I-NEG
, O
namely O
solid-organ O
and O
bone O
marrow O
transplant O
recipients O
, O
neonates O
, O
and O
children O
with O
immunodeficiency B-NEG
. O

although O
intravenous O
ribavirin O
was O
not O
effective O
for O
all O
children O
with O
severe O
adenovirus B-NEG
disease I-NEG
in O
this O
series O
or O
in O
the O
literature O
, O
therapy O
is O
unlikely O
to O
be O
of O
benefit O
if O
begun O
late O
in O
the O
course O
of O
the O
infection B-NEG
. O

early O
identification O
, O
eg O
by O
polymerase O
chain O
reaction O
of O
those O
patients O
at O
risk O
of O
disseminated O
adenovirus B-NEG
disease I-NEG
may O
permit O
earlier O
antiviral O
treatment O
and O
better O
evaluation O
of O
therapeutic O
response O
. O

conclusions O
: O
two O
of O
5 O
children O
with O
severe O
adenovirus B-NEG
disease I-NEG
treated O
with O
intravenous O
ribavirin O
recovered O
. O

the O
availability O
of O
newer O
rapid O
diagnostic O
techniques O
, O
such O
as O
polymerase O
chain O
reaction O
, O
may O
make O
earlier O
, O
more O
effective O
treatment O
of O
adenovirus B-NEG
infection I-NEG
possible O
. O

given O
the O
seriousness O
and O
increasing O
prevalence O
of O
adenovirus B-NEG
disease I-NEG
in O
certain O
hosts O
, O
especially O
children O
, O
a O
large O
, O
multicenter O
clinical O
trial O
of O
potentially O
useful O
anti-adenoviral O
therapies O
, O
such O
as O
intravenous O
ribavirin O
, O
is O
clearly O
required O
to O
demonstrate O
the O
most O
effective O
and O
least O
toxic O
therapy O
. O

-DOCSTART- O

hepatotoxicity B-NEG
of O
amiodarone O
. O

amiodarone O
has O
proved O
very O
effective O
in O
the O
treatment O
of O
otherwise O
resistant O
cardiac O
tachyarrhythmias B-NEG
. O

the O
use O
of O
amiodarone O
has O
, O
however O
, O
been O
limited O
due O
to O
its O
serious O
side-effects O
. O

a O
patient O
with O
cholestatic B-NEG
hepatitis I-NEG
due O
to O
amiodarone O
treatment O
is O
presented O
below O
and O
a O
review O
of O
the O
hepatotoxicity B-NEG
of O
amiodarone O
is O
given O
. O

it O
is O
concluded O
that O
solid O
evidence O
exists O
of O
hepatic B-NEG
injury I-NEG
due O
to O
amiodarone O
treatment O
, O
including O
steatosis B-NEG
, O
alterations O
resembling O
alcoholic B-NEG
hepatitis I-NEG
, O
cholestatic B-NEG
hepatitis I-NEG
and O
micronodular O
cirrhosis B-NEG
of I-NEG
the I-NEG
liver I-NEG
. O

patients O
receiving O
amiodarone O
should O
be O
regularly O
screened O
with O
respect O
to O
hepatic O
enzyme O
levels O
. O

therapy O
should O
be O
discontinued O
on O
the O
suspicion O
of O
cholestatic B-NEG
injury I-NEG
or O
hepatomegaly B-NEG
. O

-DOCSTART- O

catalepsy B-NEG
induced O
by O
combinations O
of O
ketamine O
and O
morphine O
: O
potentiation O
, O
antagonism O
, O
tolerance O
and O
cross-tolerance O
in O
the O
rat O
. O

previous O
studies O
demonstrated O
that O
both O
ketamine O
and O
morphine O
induced O
analgesia B-NEG
and O
catalepsy B-NEG
in O
the O
rat O
. O

pre-treatment O
with O
ketamine O
produced O
cross-tolerance O
to O
morphine O
, O
whereas O
pretreatment O
with O
morphine O
did O
not O
induce O
cross-tolerance O
to O
ketamine O
but O
rather O
augmented O
the O
cataleptic B-NEG
response O
; O
this O
augmentation O
was O
attributed O
to O
residual O
morphine O
in O
the O
brain O
. O

the O
present O
studies O
explored O
the O
duration O
of O
the O
loss O
of O
righting O
reflex O
induced O
by O
sub-effective O
doses O
of O
ketamine O
and O
morphine O
, O
administered O
simultaneously O
. O

there O
was O
mutual O
potentiation O
between O
sub-effective O
doses O
of O
ketamine O
and O
morphine O
, O
but O
sub-effective O
doses O
of O
ketamine O
partly O
antagonized O
fully-effective O
doses O
of O
morphine O
. O

latency O
to O
the O
loss O
of O
righting O
reflex O
, O
rigidity B-NEG
and O
behavior O
on O
recovery O
, O
reflected O
the O
relative O
predominance O
of O
ketamine O
or O
morphine O
in O
each O
combination O
. O

naloxone O
inhibited O
the O
induced O
cataleptic B-NEG
effects O
. O

the O
degree O
and O
time O
course O
of O
development O
of O
tolerance O
to O
daily O
administration O
of O
sub-effective O
dose O
combinations O
of O
ketamine O
and O
morphine O
were O
similar O
. O

rats O
, O
tolerant O
to O
ketamine-dominant O
combinations O
, O
were O
cross-tolerant O
to O
both O
drugs O
, O
while O
those O
tolerant O
to O
morphine-dominant O
combinations O
were O
cross-tolerant O
to O
morphine O
but O
showed O
either O
no O
cross-tolerance O
or O
an O
augmented O
response O
to O
ketamine O
. O

while O
the O
mutual O
potentiation O
, O
antagonism O
and O
tolerance O
suggest O
common O
mechanisms O
for O
the O
induced O
catalepsy B-NEG
, O
differences O
in O
latency O
, O
rigidity B-NEG
and O
behavior O
, O
asymmetry O
of O
cross-tolerance O
and O
a O
widely-different O
id50 O
for O
naloxone O
would O
argue O
against O
an O
action O
at O
a O
single O
opioid O
site O
. O

-DOCSTART- O

acute B-NEG
renal I-NEG
failure I-NEG
in O
patients O
with O
aids B-NEG
on O
tenofovir O
while O
receiving O
prolonged O
vancomycin O
course O
for O
osteomyelitis B-NEG
. O
renal B-NEG
failure I-NEG
developed O
after O
a O
prolonged O
course O
of O
vancomycin O
therapy O
in O
2 O
patients O
who O
were O
receiving O
tenofovir O
disoproxil O
fumarate O
as O
part O
of O
an O
antiretroviral O
regimen O
. O

tenofovir O
has O
been O
implicated O
in O
the O
development O
of O
fanconi B-NEG
syndrome I-NEG
and O
renal B-NEG
insufficiency I-NEG
because O
of O
its O
effects O
on O
the O
proximal O
renal O
tubule O
. O

vancomycin O
nephrotoxicity B-NEG
is O
infrequent O
but O
may O
result O
from O
coadministration O
with O
a O
nephrotoxic B-NEG
agent O
. O

clinicians O
should O
be O
aware O
that O
tenofovir O
may O
raise O
the O
risk O
of O
renal B-NEG
failure I-NEG
during O
prolonged O
administration O
of O
vancomycin O
. O

-DOCSTART- O

delayed O
leukoencephalopathy B-NEG
with O
stroke B-NEG
-like O
presentation O
in O
chemotherapy O
recipients O
. O

background O
: O
a O
transient O
leukoencephalopathy B-NEG
mimicking O
cerebrovascular B-NEG
accident I-NEG
has O
been O
described O
as O
a O
complication O
of O
chemotherapy O
, O
most O
commonly O
in O
recipients O
of O
intrathecal O
methotrexate O
for O
childhood O
leukaemia B-NEG
. O

recently O
published O
neuroimaging O
data O
suggest O
a O
common O
pathophysiology O
associated O
with O
a O
variety O
of O
chemotherapy O
agents O
and O
modes O
of O
administration O
. O

methods O
: O
we O
reviewed O
the O
medical O
literature O
for O
single O
reports O
and O
case O
series O
of O
patients O
presenting O
with O
stroke B-NEG
-like O
episodes O
while O
receiving O
systemic O
or O
intrathecal O
chemotherapy O
. O

we O
only O
included O
studies O
providing O
detailed O
neuroimaging O
data O
. O

patients O
with O
cerebrovascular B-NEG
accidents I-NEG
were O
excluded O
. O

results O
: O
we O
identified O
27 O
reports O
of O
toxic O
leukoencephalopathy B-NEG
in O
patients O
treated O
with O
methotrexate O
(intrathecal O
, O
systemic) O
, O
5-fluorouracil O
and O
its O
derivative O
carmofur O
, O
and O
capecitabine O
. O

diffusion O
weighted O
imaging O
( O
dwi O
) O
of O
all O
patients O
revealed O
well O
demarcated O
hyperintense O
lesions B-NEG
within I-NEG
the I-NEG
subcortical I-NEG
white I-NEG
matter I-NEG
of O
the O
cerebral O
hemispheres O
and O
the O
corpus O
callosum O
, O
corresponding O
to O
areas O
of O
decreased O
proton O
diffusion O
on O
apparent O
diffusion O
coefficient O
( O
adc O
) O
maps O
( O
available O
in O
21/27 O
patients) O
. O

lesions O
exceeded O
the O
confines O
of O
adjacent O
vascular O
territories O
. O

complete O
resolution O
of O
symptoms O
within O
1-4 O
days O
was O
accompanied O
by O
normalisation O
of O
adc O
abnormalities O
. O

however O
, O
fluid O
attenuated O
inversion O
recovery O
( O
flair O
) O
sequences O
frequently O
revealed O
persistent O
white B-NEG
matter I-NEG
abnormalities I-NEG
. O

conclusions O
: O
several O
pathophysiological O
models O
of O
delayed O
leukoencephalopathy B-NEG
after O
exposure O
to O
intrathecal O
or O
systemic O
chemotherapy O
have O
been O
proposed O
. O

dwi O
findings O
in O
this O
cohort O
are O
indicative O
of O
cytotoxic B-NEG
oedema I-NEG
within I-NEG
cerebral I-NEG
white I-NEG
matter I-NEG
and O
lend O
support O
to O
an O
at O
least O
partially O
reversible O
metabolic O
derangement O
as O
the O
basis O
for O
this O
syndrome O
. O

-DOCSTART- O

down-regulation O
of O
norepinephrine O
transporter O
function O
induced O
by O
chronic O
administration O
of O
desipramine O
linking O
to O
the O
alteration O
of O
sensitivity O
of O
local-anesthetics-induced O
convulsions B-NEG
and O
the O
counteraction O
by O
co-administration O
with O
local O
anesthetics O
. O

alterations O
of O
norepinephrine O
transporter O
( O
net O
) O
function O
by O
chronic O
inhibition O
of O
net O
in O
relation O
to O
sensitization O
to O
seizures B-NEG
induce O
by O
cocaine O
and O
local O
anesthetics O
were O
studied O
in O
mice O
. O

daily O
administration O
of O
desipramine O
, O
an O
inhibitor O
of O
the O
net O
, O
for O
5 O
days O
decreased O
[(3)h]norepinephrine O
uptake O
in O
the O
p2 O
fractions O
of O
hippocampus O
but O
not O
cortex O
, O
striatum O
or O
amygdalae O
. O

co-administration O
of O
lidocaine O
, O
bupivacaine O
or O
tricaine O
with O
desipramine O
reversed O
this O
effect O
. O

daily O
treatment O
of O
cocaine O
increased O
[(3)h]norepinephrine O
uptake O
into O
the O
hippocampus O
. O

daily O
administration O
of O
desipramine O
increased O
the O
incidence O
of O
appearance O
of O
lidocaine-induced O
convulsions B-NEG
and O
decreased O
that O
of O
cocaine-induced O
convulsions B-NEG
. O

co-administration O
of O
lidocaine O
with O
desipramine O
reversed O
the O
changes O
of O
convulsive B-NEG
activity O
of O
lidocaine O
and O
cocaine O
induced O
by O
repeated O
administration O
of O
desipramine O
. O

these O
results O
suggest O
that O
down-regulation O
of O
hippocampal O
net O
induced O
by O
chronic O
administration O
of O
desipramine O
may O
be O
relevant O
to O
desipramine-induced O
sensitization O
of O
lidocaine O
convulsions B-NEG
. O

inhibition O
of O
na(+ O
) O
channels O
by O
local O
anesthetics O
may O
regulate O
desipramine-induced O
down-regulation O
of O
net O
function O
. O

repeated O
administration O
of O
cocaine O
induces O
up-regulation O
of O
hippocampal O
net O
function O
. O

desipramine-induced O
sensitization O
of O
lidocaine O
seizures B-NEG
may O
have O
a O
mechanism O
distinct O
from O
kindling O
resulting O
from O
repeated O
administration O
of O
cocaine O
. O

-DOCSTART- O

definition O
and O
management O
of O
anemia B-NEG
in O
patients O
infected B-NEG
with I-NEG
hepatitis I-NEG
c I-NEG
virus I-NEG
. O
chronic B-NEG
infection I-NEG
with I-NEG
hepatitis I-NEG
c I-NEG
virus I-NEG
( O
hcv O
) O
can O
progress O
to O
cirrhosis B-NEG
, O
hepatocellular B-NEG
carcinoma I-NEG
, O
and O
end-stage B-NEG
liver I-NEG
disease I-NEG
. O

the O
current O
best O
treatment O
for O
hcv B-NEG
infection I-NEG
is O
combination O
therapy O
with O
pegylated O
interferon O
and O
ribavirin O
. O

although O
this O
regimen O
produces O
sustained O
virologic O
responses O
( O
svrs O
) O
in O
approximately O
50% O
of O
patients O
, O
it O
can O
be O
associated O
with O
a O
potentially O
dose-limiting O
hemolytic B-NEG
anemia I-NEG
. O

hemoglobin O
concentrations O
decrease O
mainly O
as O
a O
result O
of O
ribavirin-induced O
hemolysis B-NEG
, O
and O
this O
anemia B-NEG
can O
be O
problematic O
in O
patients O
with O
hcv B-NEG
infection I-NEG
, O
especially O
those O
who O
have O
comorbid O
renal B-NEG
or I-NEG
cardiovascular I-NEG
disorders I-NEG
. O

in O
general O
, O
anemia B-NEG
can O
increase O
the O
risk O
of O
morbidity O
and O
mortality O
, O
and O
may O
have O
negative O
effects O
on O
cerebral O
function O
and O
quality O
of O
life O
. O

although O
ribavirin-associated O
anemia B-NEG
can O
be O
reversed O
by O
dose O
reduction O
or O
discontinuation O
, O
this O
approach O
compromises O
outcomes O
by O
significantly O
decreasing O
svr O
rates O
. O

recombinant O
human O
erythropoietin O
has O
been O
used O
to O
manage O
ribavirin-associated O
anemia B-NEG
but O
has O
other O
potential O
disadvantages O
. O

viramidine O
, O
a O
liver-targeting O
prodrug O
of O
ribavirin O
, O
has O
the O
potential O
to O
maintain O
the O
virologic O
efficacy O
of O
ribavirin O
while O
decreasing O
the O
risk O
of O
hemolytic B-NEG
anemia I-NEG
in O
patients O
with O
chronic B-NEG
hepatitis I-NEG
c I-NEG
. O

-DOCSTART- O

calcium O
carbonate O
toxicity B-NEG
: O
the O
updated O
milk-alkali B-NEG
syndrome I-NEG
; O
report O
of O
3 O
cases O
and O
review O
of O
the O
literature O
. O

objective O
: O
to O
describe O
3 O
patients O
with O
calcium O
carbonate-induced O
hypercalcemia B-NEG
and O
gain O
insights O
into O
the O
cause O
and O
management O
of O
the O
milk-alkali B-NEG
syndrome I-NEG
. O

methods O
: O
we O
report O
the O
clinical O
and O
laboratory O
data O
in O
3 O
patients O
who O
presented O
with O
severe O
hypercalcemia B-NEG
( O
corrected O
serum O
calcium O
> O
or O
= O
14 O
mg/dl O
) O
and O
review O
the O
pertinent O
literature O
on O
milk-alkali B-NEG
syndrome I-NEG
. O

results O
: O
the O
3 O
patients O
had O
acute B-NEG
renal I-NEG
insufficiency I-NEG
, O
relative O
metabolic B-NEG
alkalosis I-NEG
, O
and O
low O
parathyroid O
hormone O
(pth) O
, O
pth-related O
peptide O
, O
and O
1,25-dihydroxyvitamin O
d O
concentrations O
. O

no O
malignant O
lesion O
was O
found O
. O

treatment O
included O
aggressive O
hydration O
and O
varied O
amounts O
of O
furosemide O
. O

the O
2 O
patients O
with O
the O
higher O
serum O
calcium O
concentrations O
received O
pamidronate O
intravenously O
( O
60 O
and O
30 O
mg O
, O
respectively) O
, O
which O
caused O
severe O
hypocalcemia B-NEG
. O

of O
the O
3 O
patients O
, O
2 O
were O
ingesting O
acceptable O
doses O
of O
elemental O
calcium O
(1 O
g O
and O
2 O
g O
daily O
, O
respectively O
) O
in O
the O
form O
of O
calcium O
carbonate O
. O

in O
addition O
to O
our O
highlighted O
cases O
, O
we O
review O
the O
history O
, O
classification O
, O
pathophysiologic O
features O
, O
and O
treatment O
of O
milk-alkali B-NEG
syndrome I-NEG
and O
summarize O
the O
cases O
reported O
from O
early O
1995 O
to O
november O
2003 O
. O

conclusion O
: O
milk-alkali B-NEG
syndrome I-NEG
may O
be O
a O
common O
cause O
of O
unexplained O
hypercalcemia B-NEG
and O
can O
be O
precipitated O
by O
small O
amounts O
of O
orally O
ingested O
calcium O
carbonate O
in O
susceptible O
persons O
. O

treatment O
with O
hydration O
, O
furosemide O
, O
and O
discontinuation O
of O
the O
calcium O
and O
vitamin O
d O
source O
is O
adequate O
. O

pamidronate O
treatment O
is O
associated O
with O
considerable O
risk O
for O
hypocalcemia B-NEG
, O
even O
in O
cases O
of O
initially O
severe O
hypercalcemia B-NEG
. O

-DOCSTART- O

management O
strategies O
for O
ribavirin-induced O
hemolytic B-NEG
anemia I-NEG
in O
the O
treatment O
of O
hepatitis B-NEG
c I-NEG
: O
clinical O
and O
economic O
implications O
. O

objectives O
: O
recently O
published O
studies O
have O
demonstrated O
increased O
efficacy O
and O
cost-effectiveness O
of O
combination O
therapy O
with O
interferon O
and O
alpha-2b/ribavirin O
compared O
with O
interferon-alpha O
monotherapy O
in O
the O
treatment O
of O
chronic B-NEG
hepatitis I-NEG
c I-NEG
( O
chc B-NEG
). O

combination O
therapy O
is O
associated O
with O
a O
clinically O
important O
adverse O
effect O
: O
ribavirin-induced O
hemolytic B-NEG
anemia I-NEG
( O
riha B-NEG
). O

the O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
direct O
health-care O
costs O
and O
management O
of O
riha B-NEG
during O
treatment O
of O
chc B-NEG
in O
a O
clinical O
trial O
setting O
. O

methods O
: O
a O
systematic O
literature O
review O
was O
conducted O
to O
synthesize O
information O
on O
the O
incidence O
and O
management O
of O
riha B-NEG
. O

decision-analytic O
techniques O
were O
used O
to O
estimate O
the O
cost O
of O
treating O
riha B-NEG
. O

uncertainty O
was O
evaluated O
using O
sensitivity O
analyses O
. O

results O
: O
riha B-NEG
, O
defined O
as O
a O
reduction O
in O
hemoglobin O
to O
less O
than O
100 O
g/l O
, O
occurs O
in O
approximately O
7% O
to O
9% O
of O
patients O
treated O
with O
combination O
therapy O
. O

the O
standard O
of O
care O
for O
management O
of O
riha B-NEG
is O
reduction O
or O
discontinuation O
of O
the O
ribavirin O
dosage O
. O

we O
estimated O
the O
direct O
cost O
of O
treating O
clinically O
significant O
riha B-NEG
to O
be O
170 O
per O
patient O
receiving O
combination O
therapy O
per O
48-week O
treatment O
course O
( O
range O
68- O
692) O
. O

the O
results O
of O
the O
one-way O
sensitivity O
analyses O
ranged O
from O
57 O
to O
317 O
. O

in O
comparison O
, O
the O
cost O
of O
48 O
weeks O
of O
combination O
therapy O
is O
16,459 O
. O

conclusions O
: O
the O
direct O
cost O
of O
treating O
clinically O
significant O
riha B-NEG
is O
1% O
( O
170/ O
16,459 O
) O
of O
drug O
treatment O
costs O
. O

questions O
remain O
about O
the O
optimal O
dose O
of O
ribavirin O
and O
the O
incidence O
of O
riha B-NEG
in O
a O
real-world O
population O
. O

despite O
these O
uncertainties O
, O
this O
initial O
evaluation O
of O
the O
direct O
cost O
of O
treating O
riha B-NEG
provides O
an O
estimate O
of O
the O
cost O
and O
management O
implications O
of O
this O
clinically O
important O
adverse O
effect O
. O

-DOCSTART- O

effects O
of O
amine O
pretreatment O
on O
ketamine O
catatonia B-NEG
in O
pinealectomized O
or O
hypophysectomized O
animals O
. O

the O
present O
studies O
were O
designed O
to O
clarify O
the O
role O
of O
catecholamines O
and O
pineal O
idolamines O
on O
ketamine-induced O
catatonia B-NEG
in O
the O
intact O
, O
pinealectomized O
or O
hypophysectomized O
chick O
and O
rat O
. O

in O
the O
pinealectomized O
chick O
, O
pretreatment O
with O
dopamine O
increased O
the O
duration O
of O
catatonia B-NEG
( O
doc O
) O
after O
ketamine O
, O
but O
pretreatment O
with O
norepinephrine O
did O
not O
. O

the O
pineal O
indolamines O
exhibited O
mixed O
actions O
. O

serotonin O
and O
n-acetyl O
serotonin O
which O
augmented O
ketamine O
doc O
, O
did O
not O
do O
so O
in O
the O
absence O
of O
the O
pineal O
gland O
, O
whereas O
melatonin O
potentiated O
the O
ketamine O
doc O
in O
both O
the O
intact O
and O
pinealectomized O
chick O
. O

ketamine O
was O
more O
potent O
in O
the O
hypophysectomized O
chick O
and O
the O
circadian O
rhythm O
noted O
in O
the O
intact O
chick O
was O
absent O
; O
furthermore O
, O
melatonin O
did O
not O
augment O
the O
ketamine O
doc O
whereas O
dopamine O
continued O
to O
do O
so O
. O

this O
study O
did O
not O
demonstrate O
a O
species O
difference O
regarding O
the O
role O
of O
the O
amines O
on O
the O
pineal O
in O
spite O
of O
the O
immature O
blood-brain O
barrier O
in O
the O
young O
chick O
and O
the O
intact O
barrier O
in O
the O
rat O
. O

in O
addition O
, O
these O
data O
indicate O
a O
direct O
role O
of O
the O
pituitary O
in O
the O
augmentation O
of O
ketamine O
doc O
induced O
by O
melatonin O
. O

furthermore O
, O
dopamine O
appeared O
to O
act O
on O
systems O
more O
closely O
involved O
with O
the O
induction O
of O
ketamine O
catatonia B-NEG
rather O
than O
directly O
on O
the O
pituitary O
. O

-DOCSTART- O

multicenter O
, O
double-blind O
, O
multiple-dose O
, O
parallel-groups O
efficacy O
and O
safety O
trial O
of O
azelastine O
, O
chlorpheniramine O
, O
and O
placebo O
in O
the O
treatment O
of O
spring B-NEG
allergic I-NEG
rhinitis I-NEG
. O

azelastine O
, O
a O
novel O
antiallergic O
medication O
, O
was O
compared O
with O
chlorpheniramine O
maleate O
and O
placebo O
for O
efficacy O
and O
safety O
in O
the O
treatment O
of O
spring B-NEG
allergic I-NEG
rhinitis I-NEG
in O
a O
multicenter O
, O
double-blind O
, O
multiple-dose O
, O
parallel-groups O
study O
. O

one O
hundred O
fifty-five O
subjects O
participated O
. O

subjects O
ranged O
in O
age O
from O
18 O
to O
60 O
years O
of O
age O
and O
had O
at O
least O
a O
2-year O
history O
of O
spring B-NEG
allergic I-NEG
rhinitis I-NEG
, O
confirmed O
by O
positive O
skin O
test O
to O
spring O
aeroallergens O
. O

medications O
were O
given O
four O
times O
daily O
; O
the O
azelastine O
groups O
received O
0.5 O
, O
1.0 O
, O
or O
2.0 O
mg O
in O
the O
morning O
and O
evening O
with O
placebo O
in O
the O
early O
and O
late O
afternoon O
; O
the O
chlorpheniramine O
group O
received O
4.0 O
mg O
four O
times O
daily O
. O

daily O
subject O
symptom O
cards O
were O
completed O
during O
a O
screening O
period O
to O
assess O
pretreatment O
symptoms O
and O
during O
a O
4-week O
treatment O
period O
while O
subjects O
received O
study O
medications O
. O

individual O
symptoms O
, O
total O
symptoms O
, O
and O
major O
symptoms O
were O
compared O
to O
determine O
efficacy O
of O
medication O
. O

elicited O
, O
volunteered O
, O
and O
observed O
adverse O
experiences O
were O
recorded O
for O
each O
subject O
and O
compared O
among O
groups O
. O

vital O
signs O
, O
body O
weights O
, O
serum O
chemistry O
values O
, O
complete O
blood O
cell O
counts O
, O
urine O
studies O
, O
and O
electrocardiograms O
were O
obtained O
for O
each O
subject O
and O
compared O
among O
groups O
. O

symptoms O
relief O
in O
the O
group O
receiving O
the O
highest O
concentration O
of O
azelastine O
( O
2.0 O
mg O
twice O
daily O
) O
was O
statistically O
greater O
than O
in O
the O
placebo O
group O
during O
all O
weeks O
of O
the O
study O
. O

lower O
doses O
of O
azelastine O
were O
statistically O
more O
effective O
than O
placebo O
only O
during O
portions O
of O
the O
first O
3 O
weeks O
of O
the O
study O
. O

in O
contrast O
, O
although O
the O
chlorpheniramine O
group O
did O
have O
fewer O
symptoms O
than O
the O
placebo O
group O
during O
the O
study O
, O
the O
difference O
never O
reached O
statistical O
significance O
during O
any O
week O
of O
the O
study O
. O

there O
were O
no O
serious O
side O
effects O
in O
any O
of O
the O
treatment O
groups O
. O
drowsiness B-NEG
and O
altered B-NEG
taste I-NEG
perception I-NEG
were O
increased O
significantly O
over O
placebo O
only O
in O
the O
high-dose O
azelastine O
group O
. O

azelastine O
appears O
to O
be O
a O
safe O
, O
efficacious O
medication O
for O
seasonal B-NEG
allergic I-NEG
rhinitis I-NEG
. O

-DOCSTART- O

obsolete O
but O
dangerous O
antacid O
preparations O
. O

one O
case O
of O
acute O
hypercalcaemia B-NEG
and O
two O
of O
recurrent O
nephrolithiasis B-NEG
are O
reported O
in O
patients O
who O
had O
regularly O
consumed O
large O
amounts O
of O
calcium O
carbon-ate-sodium O
bicarbonate O
powders O
for O
more O
than O
20 O
years O
. O

the O
powders O
had O
been O
obtained O
from O
pharmacists O
unknown O
to O
the O
patients' O
medical O
practitioners O
. O

it O
is O
suggested O
that O
these O
preparations O
were O
responsible O
for O
the O
patient's O
problems O
, O
and O
that O
such O
powders O
should O
no O
longer O
be O
freely O
obtainable O
. O

-DOCSTART- O

prolonged O
paralysis B-NEG
due O
to O
nondepolarizing O
neuromuscular O
blocking O
agents O
and O
corticosteroids O
. O

the O
long-term O
use O
of O
nondepolarizing O
neuromuscular O
blocking O
agents O
( O
nd-nmba O
) O
has O
recently O
been O
implicated O
as O
a O
cause O
of O
prolonged O
muscle B-NEG
weakness I-NEG
, O
although O
the O
site O
of O
the O
lesion O
and O
the O
predisposing O
factors O
have O
been O
unclear O
. O

we O
report O
3 O
patients O
( O
age O
37-52 O
years O
) O
with O
acute O
respiratory B-NEG
insufficiency I-NEG
who O
developed O
prolonged O
weakness B-NEG
following O
the O
discontinuation O
of O
nd-nmbas O
. O

two O
patients O
also O
received O
intravenous O
corticosteroids O
. O

renal O
function O
was O
normal O
but O
hepatic O
function O
was O
impaired O
in O
all O
patients O
, O
and O
all O
had O
acidosis B-NEG
. O

electrophysiologic O
studies O
revealed O
low O
amplitude O
compound O
motor O
action O
potentials O
, O
normal O
sensory O
studies O
, O
and O
fibrillations O
. O

repetitive O
stimulation O
at O
2 O
hz O
showed O
a O
decremental O
response O
in O
2 O
patients O
. O

the O
serum O
vecuronium O
level O
measured O
in O
1 O
patient O
14 O
days O
after O
the O
drug O
had O
been O
discontinued O
was O
172 O
ng/ml O
. O

a O
muscle O
biopsy O
in O
this O
patient O
showed O
loss B-NEG
of I-NEG
thick I-NEG
, O
myosin I-NEG
filaments I-NEG
. O

the O
weakness B-NEG
in O
these O
patients O
is O
due O
to O
pathology B-NEG
at I-NEG
both I-NEG
the I-NEG
neuromuscular I-NEG
junction I-NEG
( O
most O
likely O
due O
to O
nd-nmba O
) O
and O
muscle O
( O
most O
likely O
due O
to O
corticosteroids) O
. O
hepatic B-NEG
dysfunction I-NEG
and O
acidosis B-NEG
are O
contributing O
risk O
factors O
. O

-DOCSTART- O

prostaglandin O
e2-induced O
bladder B-NEG
hyperactivity I-NEG
in O
normal O
, O
conscious O
rats O
: O
involvement O
of O
tachykinins? O

in O
normal O
conscious O
rats O
investigated O
by O
continuous O
cystometry O
, O
intravesically O
instilled O
prostaglandin O
( O
pg O
) O
e2 O
facilitated O
micturition O
and O
increased O
basal O
intravesical O
pressure O
. O

the O
effect O
was O
attenuated O
by O
both O
the O
nk1 O
receptor O
selective O
antagonist O
rp O
67,580 O
and O
the O
nk2 O
receptor O
selective O
antagonist O
sr O
48,968 O
, O
given O
intra-arterially O
, O
suggesting O
that O
it O
was O
mediated O
by O
stimulation O
of O
both O
nk1 O
and O
nk2 O
receptors O
. O

intra-arterially O
given O
pge2 O
produced O
a O
distinct O
increase O
in O
bladder O
pressure O
before O
initiating O
a O
micturition O
reflex O
, O
indicating O
that O
the O
pg O
had O
a O
direct O
contractant O
effect O
on O
the O
detrusor O
smooth O
muscle O
. O

the O
effect O
of O
intra-arterial O
pge2 O
could O
not O
be O
blocked O
by O
intra-arterial O
rp O
67,580 O
or O
sr O
48,968 O
, O
which O
opens O
the O
possibility O
that O
the O
micturition O
reflex O
elicited O
by O
intra-arterial O
pge2 O
was O
mediated O
by O
pathways O
other O
than O
the O
reflex O
initiated O
when O
the O
pg O
was O
given O
intravesically O
. O

the O
present O
results O
thus O
suggest O
that O
intra-arterial O
pge2 O
, O
given O
near O
the O
bladder O
, O
may O
initiate O
micturition O
in O
the O
normal O
rat O
chiefly O
by O
directly O
contracting O
the O
smooth O
muscle O
of O
the O
detrusor O
. O

however O
, O
when O
given O
intravesically O
, O
pge2 O
may O
stimulate O
micturition O
by O
releasing O
tachykinins O
from O
nerves O
in O
and/or O
immediately O
below O
the O
urothelium O
. O

these O
tachykinins O
, O
in O
turn O
, O
initiate O
a O
micturition O
reflex O
by O
stimulating O
nk1 O
and O
nk2 O
receptors O
. O

prostanoids O
may O
, O
via O
release O
of O
tachykinins O
, O
contribute O
to O
both O
urge O
and O
bladder B-NEG
hyperactivity I-NEG
seen O
in O
inflammatory O
conditions O
of O
the O
lower O
urinary O
tract O
. O

-DOCSTART- O

thiazide O
diuretics O
, O
hypokalemia B-NEG
and O
cardiac B-NEG
arrhythmias I-NEG
. O

thiazide O
diuretics O
are O
widely O
accepted O
as O
the O
cornerstone O
of O
antihypertensive O
treatment O
programs O
. O
hypokalemia B-NEG
is O
a O
commonly O
encountered O
metabolic O
consequence O
of O
chronic O
thiazide O
therapy O
. O

we O
treated O
38 O
patients O
( O
22 O
low O
renin O
, O
16 O
normal O
renin O
) O
with O
moderate O
diastolic B-NEG
hypertension I-NEG
with O
hydrochlorothiazide O
( O
hctc O
) O
administered O
on O
a O
twice O
daily O
schedule O
. O

initial O
dose O
was O
50 O
mg O
and O
the O
dose O
was O
increased O
at O
monthly O
intervals O
to O
100 O
mg O
, O
150 O
mg O
and O
200 O
mg O
daily O
until O
blood O
pressure O
normalized O
. O

the O
serum O
k O
during O
the O
control O
period O
was O
4.5 O
+/- O
0.2 O
meq/l O
an O
on O
50 O
, O
100 O
, O
150 O
and O
200 O
mg O
hctz O
daily O
3.9 O
+/- O
0.3 O
, O
3.4 O
+/- O
0.2 O
, O
2.9 O
+/- O
0.2 O
, O
and O
2.4 O
+/- O
0.3 O
meq/l O
, O
respectively O
. O

corresponding O
figures O
for O
whole O
body O
k O
were O
4107 O
+/- O
208 O
, O
3722 O
+/- O
319 O
, O
3628 O
+/- O
257 O
, O
3551 O
+/- O
336 O
, O
and O
3269 O
+/- O
380 O
meq O
, O
respectively O
. O

in O
13 O
patients O
we O
observed O
the O
effects O
of O
hctz O
therapy O
( O
100 O
mg O
daily O
) O
on O
the O
occurrence O
of O
pvc's O
during O
rest O
as O
well O
as O
during O
static O
and O
dynamic O
exercise O
. O

during O
rest O
we O
observed O
0.6 O
+/- O
0.08 O
pvc O
beats/min O
+/- O
sem O
and O
during O
static O
and O
dynamic O
exercise O
0.6 O
+/- O
0.06 O
and O
0.8 O
+/- O
0.15 O
, O
respectively O
. O

corresponding O
figures O
during O
hctz O
therapy O
100 O
mg O
daily O
were O
1.4 O
+/- O
0.1 O
, O
3.6 O
+/- O
0.7 O
and O
5.7 O
4/- O
0.8 O
, O
respectively O
. O

the O
occurrence O
of O
pvc's O
correlated O
significantly O
with O
the O
fall O
in O
serum O
k+ O
observed O
r O
= O
0.72 O
, O
p O
less O
than O
0.001 O
. O

in O
conclusion O
we O
found O
that O
thiazide O
diuretics O
cause O
hypokalemia B-NEG
and O
depletion O
of O
body O
potassium O
. O

the O
more O
profound O
hypokalemia B-NEG
, O
the O
greater O
the O
propensity O
for O
the O
occurrence O
of O
pvc's O
. O

-DOCSTART- O

diuretics O
, O
potassium O
and O
arrhythmias B-NEG
in O
hypertensive B-NEG
coronary B-NEG
disease I-NEG
. O

it O
has O
been O
proposed O
that O
modest O
changes O
in O
plasma O
potassium O
can O
alter O
the O
tendency O
towards O
cardiac B-NEG
arrhythmias I-NEG
. O

if O
this O
were O
so O
, O
patients O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
might O
be O
especially O
susceptible O
. O

thus O
, O
myocardial O
electrical O
excitability O
was O
measured O
in O
patients O
with O
mild O
essential O
hypertension B-NEG
and O
known O
coronary B-NEG
artery I-NEG
disease I-NEG
after O
8 O
weeks O
of O
treatment O
with O
a O
potassium-conserving O
diuretic O
( O
amiloride O
) O
and O
a O
similar O
period O
on O
a O
potassium-losing O
diuretic O
( O
chlorthalidone O
) O
in O
a O
randomised O
study O
. O

plasma O
potassium O
concentrations O
were O
on O
average O
1 O
mmol/l O
lower O
during O
the O
chlorthalidone O
phase O
compared O
to O
amiloride O
therapy O
. O

blood O
pressure O
and O
volume O
states O
as O
assessed O
by O
bodyweight O
, O
plasma O
renin O
and O
noradrenaline O
( O
norepinephrine O
) O
concentrations O
were O
similar O
on O
the O
2 O
regimens O
. O

compared O
to O
amiloride O
treatment O
, O
the O
chlorthalidone O
phase O
was O
associated O
with O
an O
increased O
frequency O
of O
ventricular B-NEG
ectopic I-NEG
beats I-NEG
( O
24-hour O
holter O
monitoring O
) O
and O
a O
higher O
lown O
grading O
, O
increased O
upslope O
and O
duration O
of O
the O
monophasic O
action O
potential O
, O
prolonged O
ventricular O
effective O
refractory O
period O
, O
and O
increased O
electrical O
instability O
during O
programmed O
ventricular O
stimulation O
. O

the O
above O
results O
indicate O
that O
because O
potassium-losing O
diuretic O
therapy O
can O
increase O
myocardial O
electrical O
excitability O
in O
patients O
with O
ischaemic B-NEG
heart I-NEG
disease I-NEG
, O
even O
minor O
falls O
in O
plasma O
potassium O
concentrations O
are O
probably O
best O
avoided O
in O
such O
patients O
. O

-DOCSTART- O

gaba O
involvement O
in O
naloxone O
induced O
reversal O
of O
respiratory B-NEG
paralysis I-NEG
produced O
by O
thiopental O
. O

no O
agent O
is O
yet O
available O
to O
reverse O
respiratory B-NEG
paralysis I-NEG
produced O
by O
cns O
depressants O
, O
such O
as O
general O
anesthetics O
. O

in O
this O
study O
naloxone O
reversed O
respiratory B-NEG
paralysis I-NEG
induced O
by O
thiopental O
in O
rats O
. O

25 O
mg/kg O
, O
i.v O
. O
thiopental O
produced O
anesthesia O
without O
altering O
respiratory O
rate O
, O
increased O
gaba O
, O
decreased O
glutamate O
, O
and O
had O
no O
effect O
on O
aspartate O
or O
glycine O
levels O
compared O
to O
controls O
in O
rat O
cortex O
and O
brain O
stem O
. O

pretreatment O
of O
rats O
with O
thiosemicarbazide O
for O
30 O
minutes O
abolished O
the O
anesthetic O
action O
as O
well O
as O
the O
respiratory O
depressant O
action O
of O
thiopental O
. O

50 O
mg/kg O
, O
i.v O
. O
thiopental O
produced O
respiratory B-NEG
arrest I-NEG
with O
further O
increase O
in O
gaba O
and O
decrease O
in O
glutamate O
again O
in O
cortex O
and O
brain O
stem O
without O
affecting O
any O
of O
the O
amino O
acids O
studied O
in O
four O
regions O
of O
rat O
brain O
. O

naloxone O
( O
2.5 O
mg/kg O
, O
i.v. O
) O
reversed O
respiratory B-NEG
paralysis I-NEG
, O
glutamate O
and O
gaba O
levels O
to O
control O
values O
in O
brain O
stem O
and O
cortex O
with O
no O
changes O
in O
caudate O
or O
cerebellum O
. O

these O
data O
suggest O
naloxone O
reverses O
respiratory B-NEG
paralysis I-NEG
produced O
by O
thiopental O
and O
involves O
gaba O
in O
its O
action O
. O

-DOCSTART- O

national O
project O
on O
the O
prevention O
of O
mother-to-infant O
infection B-NEG
by I-NEG
hepatitis I-NEG
b I-NEG
virus I-NEG
in O
japan O
. O

in O
japan O
, O
a O
nationwide O
prevention O
program O
against O
mother-to-infant O
infection B-NEG
by I-NEG
hepatitis I-NEG
b I-NEG
virus I-NEG
( O
hbv O
) O
started O
in O
1985 O
. O

this O
program O
consists O
of O
double O
screenings O
of O
pregnant O
women O
and O
prophylactic O
treatment O
to O
the O
infants O
born O
to O
both O
hepatitis O
b O
surface O
antigen O
( O
hbsag O
) O
and O
hepatitis O
b O
e O
antigen O
( O
hbeag O
) O
positive O
mothers O
. O

these O
infants O
are O
treated O
with O
two O
injections O
of O
hepatitis B-NEG
b I-NEG
immune O
globulin O
( O
hbig O
) O
and O
at O
least O
three O
injections O
of O
plasma O
derived O
hepatitis O
b O
vaccine O
. O

we O
sent O
questionnaires O
about O
the O
numbers O
of O
each O
procedure O
or O
examination O
during O
nine O
months O
of O
investigation O
period O
to O
each O
local O
government O
in O
1986 O
and O
1987 O
. O

93.4% O
pregnant O
women O
had O
the O
chance O
to O
be O
examined O
for O
hbsag O
, O
and O
the O
positive O
rate O
was O
1.4 O
to O
1.5% O
. O

the O
hbeag O
positive O
rate O
in O
hbsag O
positive O
was O
23 O
to O
26% O
. O

the O
hbsag O
positive O
rate O
in O
neonates O
and O
in O
infants O
before O
two O
months O
were O
3% O
and O
2% O
respectively O
. O

some O
problems O
may O
arise O
, O
because O
27 O
to O
30% O
of O
infants O
need O
the O
fourth O
vaccination O
in O
some O
restricted O
areas O
. O

-DOCSTART- O

nociceptive O
effects O
induced O
by O
intrathecal O
administration O
of O
prostaglandin O
d2 O
, O
e2 O
, O
or O
f2 O
alpha O
to O
conscious O
mice O
. O

the O
effects O
of O
intrathecal O
administration O
of O
prostaglandins O
on O
pain B-NEG
responses O
in O
conscious O
mice O
were O
evaluated O
by O
using O
hot O
plate O
and O
acetic O
acid O
writhing O
tests O
. O

prostaglandin O
d2 O
( O
0.5-3 O
ng/mouse O
) O
had O
a O
hyperalgesic B-NEG
action O
on O
the O
response O
to O
a O
hot O
plate O
during O
a O
3-60 O
min O
period O
after O
injection O
. O

prostaglandin O
e2 O
showed O
a O
hyperalgesic B-NEG
effect O
at O
doses O
of O
1 O
pg O
to O
10 O
ng/mouse O
, O
but O
the O
effect O
lasted O
shorter O
( O
3-30 O
min O
) O
than O
that O
of O
prostaglandin O
d2 O
. O

similar O
results O
were O
obtained O
by O
acetic O
acid O
writhing O
tests O
. O

the O
hyperalgesic B-NEG
effect O
of O
prostaglandin O
d2 O
was O
blocked O
by O
simultaneous O
injection O
of O
a O
substance O
p O
antagonist O
( O
greater O
than O
or O
equal O
to O
100 O
ng O
) O
but O
not O
by O
ah6809 O
, O
a O
prostanoid O
ep1-receptor O
antagonist O
. O

conversely O
, O
prostaglandin O
e2-induced O
hyperalgesia B-NEG
was O
blocked O
by O
ah6809 O
( O
greater O
than O
or O
equal O
to O
500 O
ng O
) O
but O
not O
by O
the O
substance O
p O
antagonist O
. O

prostaglandin O
f2 O
alpha O
had O
little O
effect O
on O
pain B-NEG
responses O
. O

these O
results O
demonstrate O
that O
both O
prostaglandin O
d2 O
and O
prostaglandin O
e2 O
exert O
hyperalgesia B-NEG
in O
the O
spinal O
cord O
, O
but O
in O
different O
ways O
. O

-DOCSTART- O

swallowing-induced O
atrial B-NEG
tachyarrhythmia I-NEG
triggered O
by O
salbutamol O
: O
case O
report O
and O
review O
of O
the O
literature O
. O

case O
: O
a O
49-year-old O
patient O
experienced O
chest O
discomfort O
while O
swallowing O
. O

on O
electrocardiogram O
, O
episodes O
of O
atrial B-NEG
tachyarrhythmia I-NEG
were O
recorded O
immediately O
after O
swallowing O
; O
24-hour O
holter O
monitoring O
recorded O
several O
events O
. O

the O
arrhythmia B-NEG
resolved O
after O
therapy O
with O
atenolol O
, O
but O
recurred O
a O
year O
later O
. O

the O
patient O
noticed O
that O
before O
these O
episodes O
he O
had O
been O
using O
an O
inhalator O
of O
salbutamol O
. O

after O
stopping O
the O
beta-agonist O
, O
and O
after O
a O
week O
with O
the O
atenolol O
, O
the O
arrhythmia B-NEG
disappeared O
. O

discussion O
: O
swallowing-induced O
atrial B-NEG
tachyarrhythmia I-NEG
( O
siat B-NEG
) O
is O
a O
rare O
phenomenon O
. O

fewer O
than O
50 O
cases O
of O
siat B-NEG
have O
been O
described O
in O
the O
literature O
. O

this O
article O
summarizes O
all O
the O
cases O
published O
, O
creating O
a O
comprehensive O
review O
of O
the O
current O
knowledge O
and O
approach O
to O
siat B-NEG
. O

it O
discusses O
demographics O
, O
clinical O
characteristics O
and O
types O
of O
arrhythmia B-NEG
, O
postulated O
mechanisms O
of O
siat B-NEG
, O
and O
different O
treatment O
possibilities O
such O
as O
medications O
, O
surgery O
, O
and O
radiofrequency O
catheter O
ablation O
(rfca) O
. O

conclusion O
: O
salbutamol O
is O
presented O
here O
as O
a O
possible O
trigger O
for O
siat B-NEG
. O

although O
it O
is O
difficult O
to O
define O
causality O
in O
a O
case O
report O
, O
it O
is O
logical O
to O
think O
that O
a O
beta-agonist O
like O
salbutamol O
( O
known O
to O
induce O
tachycardia B-NEG
) O
may O
be O
the O
trigger O
of O
adrenergic O
reflexes O
originating O
in O
the O
esophagus O
while O
swallowing O
and O
that O
a O
beta-blocker O
such O
as O
atenolol O
( O
that O
blocks O
the O
adrenergic O
activity O
) O
may O
relieve O
it O
. O

-DOCSTART- O

coenzyme O
q10 O
treatment O
ameliorates O
acute O
cisplatin O
nephrotoxicity B-NEG
in O
mice O
. O

the O
nephroprotective O
effect O
of O
coenzyme O
q10 O
was O
investigated O
in O
mice O
with O
acute B-NEG
renal I-NEG
injury I-NEG
induced O
by O
a O
single O
i.p O
. O
injection O
of O
cisplatin O
(5 O
mg/kg) O
. O

coenzyme O
q10 O
treatment O
( O
10 O
mg/kg/day O
, O
i.p. O
) O
was O
applied O
for O
6 O
consecutive O
days O
, O
starting O
1 O
day O
before O
cisplatin O
administration O
. O

coenzyme O
q10 O
significantly O
reduced O
blood O
urea O
nitrogen O
and O
serum O
creatinine O
levels O
which O
were O
increased O
by O
cisplatin O
. O

coenzyme O
q10 O
significantly O
compensated O
deficits O
in O
the O
antioxidant O
defense O
mechanisms O
( O
reduced O
glutathione O
level O
and O
superoxide O
dismutase O
activity) O
, O
suppressed O
lipid O
peroxidation O
, O
decreased O
the O
elevations O
of O
tumor B-NEG
necrosis B-NEG
factor-alpha O
, O
nitric O
oxide O
and O
platinum O
ion O
concentration O
, O
and O
attenuated O
the O
reductions O
of O
selenium O
and O
zinc O
ions O
in O
renal O
tissue O
resulted O
from O
cisplatin O
administration O
. O

also O
, O
histopathological O
renal B-NEG
tissue I-NEG
damage I-NEG
mediated O
by O
cisplatin O
was O
ameliorated O
by O
coenzyme O
q10 O
treatment O
. O

immunohistochemical O
analysis O
revealed O
that O
coenzyme O
q10 O
significantly O
decreased O
the O
cisplatin-induced O
overexpression O
of O
inducible O
nitric O
oxide O
synthase O
, O
nuclear O
factor-kappab O
, O
caspase-3 O
and O
p53 O
in O
renal O
tissue O
. O

it O
was O
concluded O
that O
coenzyme O
q10 O
represents O
a O
potential O
therapeutic O
option O
to O
protect O
against O
acute O
cisplatin O
nephrotoxicity B-NEG
commonly O
encountered O
in O
clinical O
practice O
. O

-DOCSTART- O

metformin O
prevents O
experimental O
gentamicin-induced O
nephropathy B-NEG
by O
a O
mitochondria-dependent O
pathway O
. O

the O
antidiabetic O
drug O
metformin O
can O
diminish O
apoptosis O
induced O
by O
oxidative O
stress O
in O
endothelial O
cells O
and O
prevent O
vascular B-NEG
dysfunction I-NEG
even O
in O
nondiabetic O
patients O
. O

here O
we O
tested O
whether O
it O
has O
a O
beneficial O
effect O
in O
a O
rat O
model O
of O
gentamicin O
toxicity B-NEG
. O

mitochondrial O
analysis O
, O
respiration O
intensity O
, O
levels O
of O
reactive O
oxygen O
species O
, O
permeability O
transition O
, O
and O
cytochrome O
c O
release O
were O
assessed O
3 O
and O
6 O
days O
after O
gentamicin O
administration O
. O

metformin O
treatment O
fully O
blocked O
gentamicin-mediated O
acute B-NEG
renal I-NEG
failure I-NEG
. O

this O
was O
accompanied O
by O
a O
lower O
activity O
of O
n-acetyl-beta-d-glucosaminidase O
, O
together O
with O
a O
decrease O
of O
lipid O
peroxidation O
and O
increase O
of O
antioxidant O
systems O
. O

metformin O
also O
protected O
the O
kidney O
from O
histological O
damage O
6 O
days O
after O
gentamicin O
administration O
. O

these O
in O
vivo O
markers O
of O
kidney B-NEG
dysfunction I-NEG
and O
their O
correction O
by O
metformin O
were O
complemented O
by O
in O
vitro O
studies O
of O
mitochondrial O
function O
. O

we O
found O
that O
gentamicin O
treatment O
depleted O
respiratory O
components O
( O
cytochrome O
c, O
nadh) O
, O
probably O
due O
to O
the O
opening O
of O
mitochondrial O
transition O
pores O
. O

these O
injuries O
, O
partly O
mediated O
by O
a O
rise O
in O
reactive O
oxygen O
species O
from O
the O
electron O
transfer O
chain O
, O
were O
significantly O
decreased O
by O
metformin O
. O

thus O
, O
our O
study O
suggests O
that O
pleiotropic O
effects O
of O
metformin O
can O
lessen O
gentamicin O
nephrotoxicity B-NEG
and O
improve O
mitochondrial O
homeostasis O
. O

-DOCSTART- O

sedation O
depth O
during O
spinal O
anesthesia O
and O
the O
development O
of O
postoperative B-NEG
delirium I-NEG
in O
elderly O
patients O
undergoing O
hip B-NEG
fracture I-NEG
repair O
. O

objective O
: O
to O
determine O
whether O
limiting O
intraoperative O
sedation O
depth O
during O
spinal O
anesthesia O
for O
hip B-NEG
fracture I-NEG
repair O
in O
elderly O
patients O
can O
decrease O
the O
prevalence O
of O
postoperative B-NEG
delirium I-NEG
. O

patients O
and O
methods O
: O
we O
performed O
a O
double-blind O
, O
randomized O
controlled O
trial O
at O
an O
academic O
medical O
center O
of O
elderly O
patients O
( O
>or=65 O
years O
) O
without O
preoperative O
delirium B-NEG
or O
severe O
dementia B-NEG
who O
underwent O
hip B-NEG
fracture I-NEG
repair O
under O
spinal O
anesthesia O
with O
propofol O
sedation O
. O

sedation O
depth O
was O
titrated O
using O
processed O
electroencephalography O
with O
the O
bispectral O
index O
(bis) O
, O
and O
patients O
were O
randomized O
to O
receive O
either O
deep O
(bis O
, O
approximately O
50 O
) O
or O
light O
(bis O
, O
>or=80 O
) O
sedation O
. O
postoperative B-NEG
delirium I-NEG
was O
assessed O
as O
defined O
by O
diagnostic O
and O
statistical O
manual O
of O
mental B-NEG
disorders I-NEG
( O
third O
edition O
revised O
) O
criteria O
using O
the O
confusion O
assessment O
method O
beginning O
at O
any O
time O
from O
the O
second O
day O
after O
surgery O
. O

results O
: O
from O
april O
2, O
2005 O
, O
through O
october O
30 O
, O
2008 O
, O
a O
total O
of O
114 O
patients O
were O
randomized O
. O

the O
prevalence O
of O
postoperative B-NEG
delirium I-NEG
was O
significantly O
lower O
in O
the O
light O
sedation O
group O
( O
11/57 O
[19%] O
vs O
23/57 O
[40%] O
in O
the O
deep O
sedation O
group O
; O
p=.02) O
, O
indicating O
that O
1 O
incident O
of O
delirium B-NEG
will O
be O
prevented O
for O
every O
4.7 O
patients O
treated O
with O
light O
sedation O
. O

the O
mean O
+/- O
sd O
number O
of O
days O
of O
delirium B-NEG
during O
hospitalization O
was O
lower O
in O
the O
light O
sedation O
group O
than O
in O
the O
deep O
sedation O
group O
( O
0.5+/-1.5 O
days O
vs O
1.4+/-4.0 O
days O
; O
p=.01) O
. O

conclusion O
: O
the O
use O
of O
light O
propofol O
sedation O
decreased O
the O
prevalence O
of O
postoperative B-NEG
delirium I-NEG
by O
50% O
compared O
with O
deep O
sedation O
. O

limiting O
depth O
of O
sedation O
during O
spinal O
anesthesia O
is O
a O
simple O
, O
safe O
, O
and O
cost-effective O
intervention O
for O
preventing O
postoperative B-NEG
delirium I-NEG
in O
elderly O
patients O
that O
could O
be O
widely O
and O
readily O
adopted O
. O

-DOCSTART- O

sorafenib-induced O
acute O
myocardial B-NEG
infarction I-NEG
due O
to O
coronary B-NEG
artery I-NEG
spasm I-NEG
. O

a O
65-year-old O
man O
with O
advanced O
renal B-NEG
cell I-NEG
carcinoma I-NEG
was O
admitted O
due O
to O
continuing O
chest B-NEG
pain I-NEG
at O
rest O
. O

two O
weeks O
before O
his O
admission O
, O
sorafenib O
had O
been O
started O
. O

he O
was O
diagnosed O
with O
non-st-elevation O
myocardial B-NEG
infarction I-NEG
by O
laboratory O
data O
and O
electrocardiogram O
. O

enhanced O
heart O
magnetic O
resonance O
imaging O
also O
showed O
subendocardial B-NEG
infarction I-NEG
. O

however O
, O
there O
was O
no O
stenosis O
in O
coronary O
arteries O
on O
angiography O
. O
coronary B-NEG
artery I-NEG
spasm I-NEG
was O
induced O
by O
a O
provocative O
test O
. O

cessation O
of O
sorafenib O
and O
administration O
of O
ca-channel O
blocker O
and O
nitrates O
ameliorated O
his O
symptoms O
, O
but O
relapse O
occurred O
after O
resumption O
of O
sorafenib O
. O

addition O
of O
oral O
nicorandil O
reduced O
his O
symptoms O
and O
maintained O
stable B-NEG
angina I-NEG
status O
. O

we O
report O
the O
first O
case O
of O
sorafenib-induced O
coronary B-NEG
artery I-NEG
spasm I-NEG
. O

sorafenib O
is O
a O
multikinase O
inhibitor O
that O
targets O
signaling O
pathways O
necessary O
for O
cellular O
proliferation O
and O
survival O
. O

on O
the O
other O
hand O
, O
the O
rho/rock O
pathway O
has O
an O
important O
role O
in O
the O
pathogenesis O
of O
coronary B-NEG
artery I-NEG
spasm I-NEG
. O

our O
report O
may O
show O
an O
adverse O
effect O
on O
the O
rho/rock O
pathway O
by O
sorafenib O
use O
. O

-DOCSTART- O

anxiogenic O
potential O
of O
ciprofloxacin O
and O
norfloxacin O
in O
rats O
. O

introduction O
: O
the O
possible O
anxiogenic O
effects O
of O
fluoroquinolones O
, O
namely O
ciprofloxacin O
and O
norfloxacin O
, O
were O
investigated O
in O
adult O
charles O
foster O
albino O
rats O
of O
either O
sex O
, O
weighing O
150-200 O
g. O

methods O
: O
the O
drugs O
were O
given O
orally O
, O
in O
doses O
of O
50 O
mg/kg O
for O
five O
consecutive O
days O
and O
the O
experiments O
were O
performed O
on O
the O
fifth O
day O
. O

the O
tests O
included O
open-field O
exploratory O
behaviour O
, O
elevated O
plus O
maze O
and O
elevated O
zero O
maze O
, O
social O
interaction O
and O
novelty-suppressed O
feeding O
latency O
behaviour O
. O

results O
: O
the O
results O
indicate O
that O
ciprofloxacin- O
and O
norfloxacin-treated O
rats O
showed O
anxious B-NEG
behaviour I-NEG
in O
comparison O
to O
control O
rats O
in O
all O
the O
parameters O
studied O
. O

however O
, O
ciprofloxacin- O
and O
norfloxacin-treated O
rats O
did O
not O
differ O
significantly O
from O
each O
other O
in O
various O
behavioural O
parameters O
. O

conclusion O
: O
the O
present O
experimental O
findings O
substantiate O
the O
clinically O
observed O
anxiogenic O
potential O
of O
ciprofloxacin O
and O
norfloxacin O
. O

-DOCSTART- O

myocardial O
fas O
ligand O
expression O
increases O
susceptibility O
to O
azt-induced O
cardiomyopathy B-NEG
. O

background O
: O
dilated B-NEG
cardiomyopathy I-NEG
( O
dcm B-NEG
) O
and O
myocarditis B-NEG
occur O
in O
many O
hiv-infected B-NEG
individuals O
, O
resulting O
in O
symptomatic O
heart B-NEG
failure I-NEG
in O
up O
to O
5% O
of O
patients O
. O

highly O
active O
antiretroviral O
therapy O
( O
haart O
) O
has O
significantly O
reduced O
morbidity O
and O
mortality O
of O
acquired B-NEG
immunodeficiency I-NEG
syndrome I-NEG
( O
aids B-NEG
), O
but O
has O
resulted O
in O
an O
increase O
in O
cardiac B-NEG
and I-NEG
skeletal I-NEG
myopathies I-NEG
. O

methods O
and O
results O
: O
in O
order O
to O
investigate O
whether O
the O
haart O
component O
zidovudine O
(3'-azido-2',3'-deoxythymidine O
; O
azt O
) O
triggers O
the O
fas-dependent O
cell-death O
pathway O
and O
cause O
cytoskeletal O
disruption O
in O
a O
murine O
model O
of O
dcm B-NEG
, O
8-week-old O
transgenic O
( O
expressing O
fas O
ligand O
in O
the O
myocardium O
: O
fasl O
tg O
) O
and O
non-transgenic O
( O
ntg O
) O
mice O
received O
water O
ad O
libitum O
containing O
different O
concentrations O
of O
azt O
(0 O
, O
0.07 O
, O
0.2 O
, O
and O
0.7 O
mg/ml) O
. O

after O
6 O
weeks O
, O
cardiac O
function O
was O
assessed O
by O
echocardiography O
and O
morphology O
was O
assessed O
by O
histopathologic O
and O
immunohistochemical O
methods O
. O

ntg O
and O
untreated O
fasl O
tg O
mice O
showed O
little O
or O
no O
change O
in O
cardiac O
structure O
or O
function O
. O

in O
contrast O
, O
azt-treated O
fasl O
tg O
mice O
developed O
cardiac B-NEG
dilation I-NEG
and O
depressed O
cardiac O
function O
in O
a O
dose-dependent O
manner O
, O
with O
concomitant O
inflammatory O
infiltration O
of O
both O
ventricles O
. O

these O
changes O
were O
associated O
with O
an O
increased O
sarcolemmal O
expression O
of O
fas O
and O
fasl O
, O
as O
well O
as O
increased O
activation O
of O
caspase O
3, O
translocation O
of O
calpain O
1 O
to O
the O
sarcolemma O
and O
sarcomere O
, O
and O
increased O
numbers O
of O
cells O
undergoing O
apoptosis O
. O

these O
were O
associated O
with O
changes O
in O
dystrophin O
and O
cardiac O
troponin O
i O
localization O
, O
as O
well O
as O
loss O
of O
sarcolemmal O
integrity O
. O

conclusions O
: O
the O
expression O
of O
fas O
ligand O
in O
the O
myocardium O
, O
as O
identified O
in O
hiv-positive O
patients O
, O
might O
increase O
the O
susceptibility O
to O
haart-induced O
cardiomyopathy B-NEG
due O
to O
activation O
of O
apoptotic O
pathways O
, O
resulting O
in O
cardiac B-NEG
dilation I-NEG
and I-NEG
dysfunction I-NEG
. O

-DOCSTART- O

valproate-induced O
chorea B-NEG
and O
encephalopathy B-NEG
in O
atypical O
nonketotic B-NEG
hyperglycinemia I-NEG
. O
nonketotic B-NEG
hyperglycinemia I-NEG
is O
a O
disorder B-NEG
of I-NEG
amino I-NEG
acid I-NEG
metabolism I-NEG
in O
which O
a O
defect O
in O
the O
glycine O
cleavage O
system O
leads O
to O
an O
accumulation O
of O
glycine O
in O
the O
brain O
and O
other O
body O
compartments O
. O

in O
the O
classical O
form O
it O
presents O
as O
neonatal O
apnea B-NEG
, O
intractable O
seizures B-NEG
, O
and O
hypotonia B-NEG
, O
followed O
by O
significant O
psychomotor B-NEG
retardation I-NEG
. O

an O
important O
subset O
of O
children O
with O
nonketotic B-NEG
hyperglycinemia I-NEG
are O
atypical O
variants O
who O
present O
in O
a O
heterogeneous O
manner O
. O

this O
report O
describes O
a O
patient O
with O
mild O
language B-NEG
delay I-NEG
and O
mental B-NEG
retardation I-NEG
, O
who O
was O
found O
to O
have O
nonketotic B-NEG
hyperglycinemia I-NEG
following O
her O
presentation O
with O
acute O
encephalopathy B-NEG
and O
chorea B-NEG
shortly O
after O
initiation O
of O
valproate O
therapy O
. O

-DOCSTART- O

microinjection O
of O
ritanserin O
into O
the O
ca1 O
region O
of O
hippocampus O
improves O
scopolamine-induced O
amnesia B-NEG
in O
adult O
male O
rats O
. O

the O
effect O
of O
ritanserin O
( O
5-ht2 O
antagonist O
) O
on O
scopolamine O
( O
muscarinic O
cholinergic O
antagonist)-induced O
amnesia B-NEG
in O
morris O
water O
maze O
( O
mwm O
) O
was O
investigated O
. O

rats O
were O
divided O
into O
eight O
groups O
and O
bilaterally O
cannulated O
into O
ca1 O
region O
of O
the O
hippocampus O
. O

one O
week O
later O
, O
they O
received O
repeatedly O
vehicles O
(saline O
, O
dmso O
, O
saline+dmso) O
, O
scopolamine O
(2 O
microg/0.5 O
microl O
saline/side O
; O
30 O
min O
before O
training) O
, O
ritanserin O
(2 O
, O
4 O
and O
8 O
microg/0.5 O
microl O
dmso/side O
; O
20 O
min O
before O
training O
) O
and O
scopolamine O
(2 O
microg/0.5 O
microl O
; O
30 O
min O
before O
ritanserin O
injection)+ritanserin O
(4 O
microg/0.5 O
microl O
dmso O
) O
through O
cannulae O
each O
day O
. O

animals O
were O
tested O
for O
four O
consecutive O
days O
(4 O
trial/day O
) O
in O
mwm O
during O
which O
the O
position O
of O
hidden O
platform O
was O
unchanged O
. O

in O
the O
fifth O
day O
, O
the O
platform O
was O
elevated O
above O
the O
water O
surface O
in O
another O
position O
to O
evaluate O
the O
function O
of O
motor O
, O
motivational O
and O
visual O
systems O
. O

the O
results O
showed O
a O
significant O
increase O
in O
escape O
latencies O
and O
traveled O
distances O
to O
find O
platform O
in O
scopolamine-treated O
group O
as O
compared O
to O
saline O
group O
. O

ritanserin-treated O
rats O
(4 O
microg/0.5 O
microl/side O
) O
showed O
a O
significant O
decrease O
in O
the O
mentioned O
parameters O
as O
compared O
to O
dmso-treated O
group O
. O

however O
, O
scopolamine O
and O
ritanserin O
co-administration O
resulted O
in O
a O
significant O
decrease O
in O
escape O
latencies O
and O
traveled O
distances O
as O
compared O
to O
the O
scopolamine-treated O
rats O
. O

our O
findings O
show O
that O
microinjection O
of O
ritanserin O
into O
the O
ca1 O
region O
of O
the O
hippocampus O
improves O
the O
scopolamine-induced O
amnesia B-NEG
. O

-DOCSTART- O

hypoxia B-NEG
in O
renal B-NEG
disease I-NEG
with O
proteinuria B-NEG
and/or O
glomerular O
hypertension B-NEG
. O

despite O
the O
increasing O
need O
to O
identify O
and O
quantify O
tissue O
oxygenation O
at O
the O
cellular O
level O
, O
relatively O
few O
methods O
have O
been O
available O
. O

in O
this O
study O
, O
we O
developed O
a O
new O
hypoxia B-NEG
-responsive O
reporter O
vector O
using O
a O
hypoxia B-NEG
-responsive O
element O
of O
the O
5' O
vascular O
endothelial O
growth O
factor O
untranslated O
region O
and O
generated O
a O
novel O
hypoxia B-NEG
-sensing O
transgenic O
rat O
. O

we O
then O
applied O
this O
animal O
model O
to O
the O
detection O
of O
tubulointerstitial O
hypoxia B-NEG
in O
the O
diseased B-NEG
kidney I-NEG
. O

with O
this O
model O
, O
we O
were O
able O
to O
identify O
diffuse O
cortical O
hypoxia B-NEG
in O
the O
puromycin O
aminonucleoside-induced O
nephrotic B-NEG
syndrome I-NEG
and O
focal O
and O
segmental O
hypoxia B-NEG
in O
the O
remnant O
kidney O
model O
. O

expression O
of O
the O
hypoxia B-NEG
-responsive O
transgene O
increased O
throughout O
the O
observation O
period O
, O
reaching O
2.2-fold O
at O
2 O
weeks O
in O
the O
puromycin O
aminonucleoside O
model O
and O
2.6-fold O
at O
4 O
weeks O
in O
the O
remnant O
kidney O
model O
, O
whereas O
that O
of O
vascular O
endothelial O
growth O
factor O
showed O
a O
mild O
decrease O
, O
reflecting O
distinct O
behaviors O
of O
the O
two O
genes O
. O

the O
degree O
of O
hypoxia B-NEG
showed O
a O
positive O
correlation O
with O
microscopic O
tubulointerstitial B-NEG
injury I-NEG
in O
both O
models O
. O

finally O
, O
we O
identified O
the O
localization O
of O
proliferating O
cell O
nuclear O
antigen-positive O
, O
ed-1-positive O
, O
and O
terminal O
dutp O
nick-end O
labeled-positive O
cells O
in O
the O
hypoxic B-NEG
cortical O
area O
in O
the O
remnant O
kidney O
model O
. O

we O
propose O
here O
a O
possible O
pathological O
tie O
between O
chronic O
tubulointerstitial O
hypoxia B-NEG
and O
progressive O
glomerular B-NEG
diseases I-NEG
. O

-DOCSTART- O

consensus O
statement O
concerning O
cardiotoxicity B-NEG
occurring O
during O
haematopoietic O
stem O
cell O
transplantation O
in O
the O
treatment O
of O
autoimmune B-NEG
diseases I-NEG
, O
with O
special O
reference O
to O
systemic B-NEG
sclerosis I-NEG
and O
multiple B-NEG
sclerosis I-NEG
. O

autologous O
haematopoietic O
stem O
cell O
transplantation O
is O
now O
a O
feasible O
and O
effective O
treatment O
for O
selected O
patients O
with O
severe O
autoimmune B-NEG
diseases I-NEG
. O

worldwide O
, O
over O
650 O
patients O
have O
been O
transplanted O
in O
the O
context O
of O
phase O
i O
and O
ii O
clinical O
trials O
. O

the O
results O
are O
encouraging O
enough O
to O
begin O
randomised O
phase O
iii O
trials O
. O

however O
, O
as O
predicted O
, O
significant O
transplant-related O
morbidity O
and O
mortality O
have O
been O
observed O
. O

this O
is O
primarily O
due O
to O
complications O
related O
to O
either O
the O
stage O
of O
the O
disease O
at O
transplant O
or O
due O
to O
infections B-NEG
. O

the O
number O
of O
deaths O
related O
to O
cardiac B-NEG
toxicity I-NEG
is O
low O
. O

however O
, O
caution O
is O
required O
when O
cyclophosphamide O
or O
anthracyclines O
such O
as O
mitoxantrone O
are O
used O
in O
patients O
with O
a O
possible O
underlying O
heart B-NEG
damage I-NEG
, O
for O
example O
, O
systemic B-NEG
sclerosis I-NEG
patients O
. O

in O
november O
2002 O
, O
a O
meeting O
was O
held O
in O
florence O
, O
bringing O
together O
a O
number O
of O
experts O
in O
various O
fields O
, O
including O
rheumatology O
, O
cardiology O
, O
neurology O
, O
pharmacology O
and O
transplantation O
medicine O
. O

the O
object O
of O
the O
meeting O
was O
to O
analyse O
existing O
data O
, O
both O
published O
or O
available O
, O
in O
the O
european O
group O
for O
blood O
and O
marrow O
transplantation O
autoimmune B-NEG
disease I-NEG
database O
, O
and O
to O
propose O
a O
safe O
approach O
to O
such O
patients O
. O

a O
full O
cardiological O
assessment O
before O
and O
during O
the O
transplant O
emerged O
as O
the O
major O
recommendation O
. O

-DOCSTART- O

immunohistochemical O
study O
on O
inducible O
type O
of O
nitric O
oxide O
(inos) O
, O
basic O
fibroblast O
growth O
factor O
( O
bfgf O
) O
and O
tumor B-NEG
growth O
factor-beta1 O
( O
tgf-beta1 O
) O
in O
arteritis B-NEG
induced O
in O
rats O
by O
fenoldopam O
and O
theophylline O
, O
vasodilators O
. O
arteritis B-NEG
induced O
in O
rats O
by O
vasodilators O
, O
fenoldopam O
and O
theophylline O
, O
was O
examined O
immunohistochemically O
for O
expressions O
of O
inducible O
type O
of O
nitric O
oxide O
synthase O
(inos) O
, O
basic O
fibroblast O
growth O
factor O
( O
bfgf O
) O
and O
tumor B-NEG
growth O
factor-beta1 O
(tgf-beta1) O
. O

rats O
were O
administered O
fenoldopam O
for O
24 O
hours O
by O
intravenous O
infusion O
with O
or O
without O
following O
repeated O
daily O
oral O
administrations O
of O
theophylline O
. O

irrespective O
of O
theophylline O
administration O
, O
inos O
antigens O
were O
remarkably O
abundant O
in O
ed-1-positive O
cells O
on O
day O
5 O
and O
8 O
post-fenoldopam-infusion O
(dpi) O
; O
bfgf O
antigens O
were O
remarkably O
abundant O
in O
ed-1-positive O
cells O
on O
1 O
and O
3 O
dpi O
; O
tgf-beta1 O
antigens O
were O
observed O
in O
ed-1-positive O
cells O
on O
and O
after O
5 O
dpi O
. O

these O
results O
suggest O
that O
the O
peak O
expression O
of O
inos O
antigen O
was O
followed O
by O
that O
of O
bfgf O
antigen O
, O
and O
bfgf O
may O
have O
a O
suppressive O
effect O
on O
inos O
expression O
in O
these O
rat O
arteritis B-NEG
models O
. O

on O
the O
other O
hand O
, O
tgf-beta1 O
was O
not O
considered O
to O
have O
a O
suppressive O
effect O
on O
inos O
expression O
in O
these O
models O
. O

-DOCSTART- O

low-molecular-weight O
heparin O
for O
the O
treatment O
of O
patients O
with O
mechanical O
heart O
valves O
. O

background O
: O
the O
interruption O
of O
oral O
anticoagulant O
( O
oac O
) O
administration O
is O
sometimes O
indicated O
in O
patients O
with O
mechanical O
heart O
valves O
, O
mainly O
before O
noncardiac O
surgery O
, O
non-surgical O
interventions O
, O
and O
pregnancy O
. O

unfractionated O
heparin O
( O
uh O
) O
is O
currently O
the O
substitute O
for O
selected O
patients O
. O

low-molecular-weight O
heparin O
( O
lmwh O
) O
offers O
theoretical O
advantages O
over O
uh O
, O
but O
is O
not O
currently O
considered O
in O
clinical O
guidelines O
as O
an O
alternative O
to O
uh O
in O
patients O
with O
prosthetic O
valves O
. O

hypothesis O
: O
the O
aim O
of O
the O
present O
study O
was O
to O
review O
the O
data O
accumulated O
so O
far O
on O
the O
use O
of O
lmwh O
in O
this O
patient O
population O
and O
to O
discuss O
its O
applicability O
in O
common O
practice O
. O

methods O
: O
for O
this O
paper O
, O
the O
current O
medical O
literature O
on O
lmwh O
in O
patients O
with O
mechanical O
heart O
valves O
was O
extensively O
reviewed O
. O

results O
: O
there O
were O
eight O
series O
and O
six O
case O
reports O
. O

none O
of O
the O
studies O
was O
randomized O
, O
and O
only O
one O
was O
prospective O
. O

data O
to O
establish O
the O
thromboembolic B-NEG
risk O
were O
incomplete O
. O

after O
excluding O
case O
reports O
, O
the O
following O
groups O
were O
constructed O
: O
( O
a O
) O
short-term O
administration O
, O
after O
valve O
insertion O
(n O
= O
212) O
; O
( O
b O
) O
short-term O
, O
perioperative O
( O
noncardiac)/periprocedural O
(n O
= O
114) O
; O
( O
c O
) O
long-term O
, O
due O
to O
intolerance O
to O
oac O
(n O
= O
16) O
; O
( O
d O
) O
long-term O
, O
in O
pregnancy O
(n O
= O
10) O
. O

the O
incidence O
rate O
of O
thromboembolism B-NEG
was O
0.9% O
for O
all O
the O
studies O
and O
0.5 O
, O
0, O
20 O
, O
and O
0% O
in O
groups O
a, O
b, O
c, O
and O
d, O
respectively O
; O
for O
hemorrhage B-NEG
, O
the O
overall O
rate O
was O
3.4% O
(3.8 O
, O
2.6 O
, O
10 O
, O
and O
0% O
for O
the O
respective O
groups) O
. O

conclusions O
: O
in O
patients O
with O
mechanical O
heart O
valves O
, O
short-term O
lmwh O
therapy O
compares O
favorably O
with O
uh O
. O

data O
on O
mid- O
and O
long-term O
lmwh O
administration O
in O
these O
patients O
are O
sparse O
. O

further O
randomized O
studies O
are O
needed O
to O
confirm O
the O
safety O
and O
precise O
indications O
for O
the O
use O
of O
lmwh O
in O
patients O
with O
mechanical O
heart O
valves O
. O

-DOCSTART- O

topiramate-induced O
nephrolithiasis B-NEG
. O

topiramate O
is O
a O
recently O
developed O
antiepileptic O
medication O
that O
is O
becoming O
more O
widely O
prescribed O
because O
of O
its O
efficacy O
in O
treating O
refractory B-NEG
seizures I-NEG
. O

urologists O
should O
be O
aware O
that O
this O
medication O
can O
cause O
metabolic B-NEG
acidosis I-NEG
in O
patients O
secondary O
to O
inhibition O
of O
carbonic O
anhydrase O
. O

in O
addition O
, O
a O
distal O
tubular O
acidification O
defect O
may O
result O
, O
thus O
impairing O
the O
normal O
compensatory O
drop O
in O
urine O
ph O
. O

these O
factors O
can O
lead O
to O
the O
development O
of O
calcium O
phosphate O
nephrolithiasis B-NEG
. O

we O
report O
the O
first O
two O
cases O
of O
topiramate-induced O
nephrolithiasis B-NEG
in O
the O
urologic O
literature O
. O

-DOCSTART- O

spironolactone O
: O
is O
it O
a O
novel O
drug O
for O
the O
prevention O
of O
amphotericin O
b-related O
hypokalemia B-NEG
in O
cancer B-NEG
patients? O

objective O
: O
nephrotoxicity B-NEG
is O
the O
major O
adverse O
effect O
of O
amphotericin O
b O
(amb) O
, O
often O
limiting O
administration O
of O
full O
dosage O
. O

selective O
distal O
tubular O
epithelial O
toxicity B-NEG
seems O
to O
be O
responsible O
for O
the O
profound O
potassium O
wasting O
that O
is O
a O
major O
clinical O
side O
effect O
of O
treatment O
with O
amb O
. O

potassium O
depletion O
also O
potentiates O
the O
tubular O
toxicity B-NEG
of O
amb O
. O

this O
study O
was O
designed O
to O
assess O
the O
ability O
of O
spironolactone O
to O
reduce O
potassium O
requirements O
and O
to O
prevent O
hypokalemia B-NEG
in O
neutropenic B-NEG
patients O
on O
amb O
treatment O
. O

methods O
: O
in O
this O
study O
26 O
patients O
with O
various O
hematological B-NEG
disorders I-NEG
were O
randomized O
to O
receive O
either O
intravenous O
amb O
alone O
or O
amb O
and O
oral O
spironolactone O
100 O
mg O
twice O
daily O
when O
developing O
a O
proven O
or O
suspected O
fungal B-NEG
infection I-NEG
. O

results O
: O
patients O
receiving O
concomitant O
amb O
and O
spironolactone O
had O
significantly O
higher O
plasma O
potassium O
levels O
than O
those O
receiving O
amb O
alone O
(p O
= O
0.0027) O
. O

those O
patients O
receiving O
amb O
and O
spironolactone O
required O
significantly O
less O
potassium O
supplementation O
to O
maintain O
their O
plasma O
potassium O
within O
the O
normal O
range O
(p O
= O
0.022) O
. O

moreover O
, O
urinary O
potassium O
losses O
were O
significantly O
less O
in O
patients O
receiving O
amb O
and O
spironolactone O
than O
those O
receiving O
amb O
alone O
(p O
= O
0.040) O
. O

conclusion O
: O
this O
study O
showed O
that O
spironolactone O
can O
reduce O
potassium O
requirements O
and O
prevent O
hypokalemia B-NEG
by O
reducing O
urinary O
potassium O
loss O
in O
neutropenic B-NEG
patients O
on O
amb O
treatment O
. O

-DOCSTART- O

dopamine O
d2 O
receptor O
signaling O
controls O
neuronal O
cell O
death O
induced O
by O
muscarinic O
and O
glutamatergic O
drugs O
. O

dopamine O
(da) O
, O
through O
d1/d2 O
receptor-mediated O
signaling O
, O
plays O
a O
major O
role O
in O
the O
control O
of O
epileptic B-NEG
seizures I-NEG
arising O
in O
the O
limbic O
system O
. O
excitotoxicity B-NEG
leading O
to O
neuronal O
cell O
death O
in O
the O
affected O
areas O
is O
a O
major O
consequence O
of O
seizures B-NEG
at O
the O
cellular O
level O
. O

in O
this O
respect O
, O
little O
is O
known O
about O
the O
role O
of O
da O
receptors O
in O
the O
occurrence O
of O
epilepsy B-NEG
-induced O
neuronal O
cell O
death O
. O

here O
we O
analyze O
the O
occurrence O
of O
seizures B-NEG
and O
neurotoxicity B-NEG
in O
d2r O
-/- O
mice O
treated O
with O
the O
cholinergic O
agonist O
pilocarpine O
. O

we O
compared O
these O
results O
with O
those O
previously O
obtained O
with O
kainic O
acid O
(ka) O
, O
a O
potent O
glutamate O
agonist O
. O

importantly O
, O
d2r O
-/- O
mice O
develop O
seizures B-NEG
at O
doses O
of O
both O
drugs O
that O
are O
not O
epileptogenic O
for O
wt O
littermates O
and O
show O
greater O
neurotoxicity B-NEG
. O

however O
, O
pilocarpine-induced O
seizures B-NEG
result O
in O
a O
more O
widespread O
neuronal O
death O
in O
both O
wt O
and O
d2r O
-/- O
brains O
in O
comparison O
to O
ka O
. O

thus O
, O
the O
absence O
of O
d2r O
lowers O
the O
threshold O
for O
seizures B-NEG
induced O
by O
both O
glutamate O
and O
acetylcholine O
. O

moreover O
, O
the O
dopaminergic O
control O
of O
epilepsy B-NEG
-induced O
neurodegeneration B-NEG
seems O
to O
be O
mediated O
by O
distinct O
interactions O
of O
d2r O
signaling O
with O
these O
two O
neurotransmitters O
. O

-DOCSTART- O

treatment O
of O
risperidone-induced O
hyperprolactinemia B-NEG
with O
a O
dopamine O
agonist O
in O
children O
. O

background O
: O
risperidone O
, O
a O
potent O
antagonist O
of O
both O
serotonergic O
( O
5ht2a O
) O
and O
dopaminergic O
d2 O
receptors O
is O
associated O
with O
hyperprolactinemia B-NEG
in O
adults O
and O
children O
. O

chronically O
elevated O
prolactin O
levels O
in O
children O
with O
prolactinomas B-NEG
may O
be O
associated O
with O
arrested O
growth O
and O
development O
resulting O
in O
either O
delayed B-NEG
puberty I-NEG
or O
short O
stature O
. O

these O
possibilities O
stress O
the O
importance O
of O
developing O
a O
safe O
and O
effective O
approach O
to O
drug-induced O
hyperprolactinemia B-NEG
in O
youth O
. O

we O
report O
the O
successful O
treatment O
of O
risperidone-induced O
hyperprolactinemia B-NEG
with O
cabergoline O
in O
youth O
. O

methods O
: O
we O
undertook O
a O
retrospective O
case O
review O
of O
four O
children O
with O
risperidone-induced O
hyperprolactinemia B-NEG
treated O
with O
cabergoline O
. O

results O
: O
four O
males O
( O
age O
6-11 O
years O
) O
with O
diagnostic O
and O
statistical O
manual O
of O
mental B-NEG
disorders I-NEG
( O
fourth O
edition O
) O
bipolar B-NEG
disorder I-NEG
or O
psychoses B-NEG
, O
with O
risperidone-induced O
elevations O
in O
serum O
prolactin O
levels O
( O
57.5-129 O
ng/ml O
, O
normal O
5-15 O
ng/ml) O
, O
were O
treated O
with O
cabergoline O
( O
mean O
dose O
2.13 O
+/- O
0.09 O
mg/week) O
. O

when O
serum O
prolactin O
levels O
normalized O
in O
all O
four O
subjects O
( O
mean O
11.2 O
+/- O
10.9 O
ng/ml) O
, O
the O
cabergoline O
dose O
was O
reduced O
to O
1 O
mg/week O
in O
three O
of O
four O
subjects O
. O

the O
mean O
duration O
of O
therapy O
with O
cabergoline O
was O
523.5 O
+/- O
129.7 O
days O
, O
and O
the O
mean O
duration O
of O
therapy O
with O
risperidone O
was O
788.5 O
+/- O
162.5 O
days O
. O

cabergoline O
was O
well O
tolerated O
without O
adverse O
effects O
. O

conclusions O
: O
cabergoline O
may O
be O
useful O
for O
the O
treatment O
of O
risperidone-induced O
hyperprolactinemia B-NEG
in O
youth O
; O
however O
, O
further O
research O
is O
needed O
. O

-DOCSTART- O

cholestatic B-NEG
jaundice I-NEG
associated O
with O
the O
use O
of O
metformin O
. O

we O
report O
a O
patient O
who O
developed O
cholestatic B-NEG
jaundice I-NEG
shortly O
after O
initiation O
of O
treatment O
with O
metformin O
hydrochloride O
. O

ultrasound O
of O
the O
liver O
and O
abdominal O
ct O
were O
normal O
. O

an O
ercp O
showed O
normal O
biliary O
anatomy O
. O

a O
percutaneous O
liver O
biopsy O
was O
obtained O
showing O
marked O
cholestasis B-NEG
, O
with O
portal O
edema B-NEG
, O
ductular O
proliferation O
, O
and O
acute O
inflammation B-NEG
. O

metformin O
hydrochloride O
was O
discontinued O
, O
and O
the O
patient's O
jaundice B-NEG
resolved O
slowly O
over O
a O
period O
of O
several O
months O
. O

given O
the O
onset O
of O
his O
jaundice B-NEG
2 O
wk O
after O
the O
initiation O
of O
metformin O
, O
we O
believe O
that O
this O
case O
represents O
an O
example O
of O
metformin-associated O
hepatotoxicity B-NEG
, O
the O
first O
such O
case O
reported O
. O

-DOCSTART- O

electro-oculography O
, O
electroretinography O
, O
visual O
evoked O
potentials O
, O
and O
multifocal O
electroretinography O
in O
patients O
with O
vigabatrin-attributed O
visual B-NEG
field I-NEG
constriction I-NEG
. O

purpose O
: O
symptomatic O
visual B-NEG
field I-NEG
constriction I-NEG
thought O
to O
be O
associated O
with O
vigabatrin O
has O
been O
reported O
. O

the O
current O
study O
investigated O
the O
visual O
fields O
and O
visual O
electrophysiology O
of O
eight O
patients O
with O
known O
vigabatrin-attributed O
visual B-NEG
field I-NEG
loss I-NEG
, O
three O
of O
whom O
were O
reported O
previously O
. O

six O
of O
the O
patients O
were O
no O
longer O
receiving O
vigabatrin O
. O

methods O
: O
the O
central O
and O
peripheral O
fields O
were O
examined O
with O
the O
humphrey O
visual O
field O
analyzer O
. O

full O
visual O
electrophysiology O
, O
including O
flash O
electroretinography O
(erg) O
, O
pattern O
electroretinography O
, O
multifocal O
erg O
using O
the O
veris O
system O
, O
electro-oculography O
, O
and O
flash O
and O
pattern O
visual O
evoked O
potentials O
, O
was O
undertaken O
. O

results O
: O
seven O
patients O
showed O
marked O
visual B-NEG
field I-NEG
constriction I-NEG
with O
some O
sparing O
of O
the O
temporal O
visual O
field O
. O

the O
eighth O
exhibited O
concentric O
constriction O
. O

most O
electrophysiological O
responses O
were O
usually O
just O
within O
normal O
limits O
; O
two O
patients O
had O
subnormal O
arden O
electro-oculography O
indices O
; O
and O
one O
patient O
showed O
an O
abnormally O
delayed O
photopic O
b O
wave O
. O

however O
, O
five O
patients O
showed O
delayed O
30-hz O
flicker O
b O
waves O
, O
and O
seven O
patients O
showed O
delayed O
oscillatory O
potentials O
. O

multifocal O
erg O
showed O
abnormalities O
that O
sometimes O
correlated O
with O
the O
visual O
field O
appearance O
and O
confirmed O
that O
the O
deficit O
occurs O
at O
the O
retinal O
level O
. O

conclusion O
: O
marked O
visual B-NEG
field I-NEG
constriction I-NEG
appears O
to O
be O
associated O
with O
vigabatrin O
therapy O
. O

the O
field O
defects O
and O
some O
electrophysiological O
abnormalities O
persist O
when O
vigabatrin O
therapy O
is O
withdrawn O
. O

-DOCSTART- O

conversion O
to O
rapamycin O
immunosuppression O
in O
renal O
transplant O
recipients O
: O
report O
of O
an O
initial O
experience O
. O

background O
: O
the O
aim O
of O
this O
study O
is O
to O
evaluate O
the O
effects O
of O
rapa O
conversion O
in O
patients O
undergoing O
cyclosporine O
( O
csa O
) O
or O
tacrolimus O
( O
tac O
) O
toxicity B-NEG
. O

methods O
: O
twenty O
renal O
transplant O
recipients O
were O
switched O
to O
fixed O
dose O
rapamycin O
( O
rapa O
) O
(5 O
mg/day O
) O
0 O
to O
204 O
months O
posttransplant O
. O

drug O
monitoring O
was O
not O
initially O
used O
to O
adjust O
doses O
. O

the O
indications O
for O
switch O
were O
chronic O
csa O
or O
tac O
nephrotoxicity B-NEG
(12) O
, O
acute O
csa O
or O
tac O
toxicity B-NEG
(3) O
, O
severe O
facial B-NEG
dysmorphism I-NEG
(2) O
, O
posttransplant B-NEG
lymphoproliferative I-NEG
disorder I-NEG
( O
ptld B-NEG
) O
in O
remission O
(2) O
, O
and O
hepatotoxicity B-NEG
in O
1. O

follow-up O
is O
7 O
to O
24 O
months O
. O

results O
: O
in O
the O
12 O
patients O
switched O
because O
of O
chronic O
nephrotoxicity B-NEG
there O
was O
a O
significant O
decrease O
in O
serum O
creatinine O
[233+/-34 O
to O
210+/-56 O
micromol/liter O
( O
p<0.05 O
) O
at O
6 O
months] O
. O
facial B-NEG
dysmorphism I-NEG
improved O
in O
two O
patients O
. O

no O
relapse O
of O
ptld B-NEG
was O
observed O
. O

five O
patients O
developed O
pneumonia B-NEG
( O
two O
pneumocystis B-NEG
carinii I-NEG
pneumonia I-NEG
, O
one O
infectious B-NEG
mononucleosis I-NEG
with O
polyclonal O
ptld B-NEG
lung O
infiltrate O
) O
and O
two O
had O
bronchiolitis B-NEG
obliterans I-NEG
. O

there O
were O
no O
deaths O
. O

rapa O
was O
discontinued O
in O
four O
patients O
, O
because O
of O
pneumonia B-NEG
in O
two O
, O
ptld B-NEG
in O
one O
, O
and O
oral O
aphtous B-NEG
ulcers I-NEG
in O
one O
. O

rapa O
levels O
were O
high O
( O
>15 O
ng/ml O
) O
in O
7 O
of O
13 O
( O
54% O
) O
patients O
. O

conclusions O
: O
rapa O
conversion O
provides O
adequate O
immunosuppression O
to O
enable O
csa O
withdrawal O
. O

however O
, O
when O
converting O
patients O
to O
rapa O
drug O
levels O
should O
be O
monitored O
to O
avoid O
over-immunosuppression O
and O
adequate O
antiviral O
and O
pneumocystis B-NEG
carinii I-NEG
pneumonia I-NEG
prophylaxis O
should O
be O
given O
. O

-DOCSTART- O

worsening O
of O
levodopa-induced O
dyskinesias B-NEG
by O
motor O
and O
mental O
tasks O
. O

ten O
patients O
who O
had O
parkinson's B-NEG
disease I-NEG
with O
disabling O
dyskinesia B-NEG
were O
included O
in O
this O
study O
to O
evaluate O
the O
role O
of O
mental O
( O
mental O
calculation O
) O
and O
motor O
( O
flexion/extension O
of O
right O
fingers O
, O
flexion/extension O
of O
left O
fingers O
, O
flexion/extension O
of O
the O
neck O
, O
speaking O
aloud O
) O
tasks O
on O
the O
worsening O
of O
peak-dose O
dyskinesia B-NEG
following O
administration O
of O
an O
effective O
single O
dose O
of O
apomorphine O
. O

compared O
with O
the O
score O
at O
rest O
(1.3+/-0.3) O
, O
a O
significant O
aggravation O
of O
the O
dyskinesia B-NEG
score O
was O
observed O
during O
speaking O
aloud O
(5.2+/-1.1 O
, O
p<0.05) O
, O
movements O
of O
right O
(4.5+/-1.0 O
, O
p<0.05 O
) O
and O
left O
(3.7+/-0.8 O
, O
p<0.05 O
) O
fingers O
, O
movements O
of O
the O
neck O
(5.1+/-1.0 O
, O
p<0.05) O
, O
and O
mental O
calculation O
(3.1+/-1.0 O
, O
p<0.05) O
. O

these O
results O
suggest O
that O
activation O
tasks O
such O
as O
speaking O
aloud O
could O
be O
used O
for O
objective O
assessment O
of O
dyskinesia B-NEG
severity O
. O

-DOCSTART- O

structural B-NEG
and I-NEG
functional I-NEG
impairment I-NEG
of I-NEG
mitochondria I-NEG
in O
adriamycin-induced O
cardiomyopathy B-NEG
in O
mice O
: O
suppression O
of O
cytochrome O
c O
oxidase O
ii O
gene O
expression O
. O

the O
use O
of O
adriamycin O
( O
adr O
) O
in O
cancer B-NEG
chemotherapy O
has O
been O
limited O
due O
to O
its O
cumulative O
cardiovascular B-NEG
toxicity I-NEG
. O

earlier O
observations O
that O
adr O
interacts O
with O
mitochondrial O
cytochrome O
c O
oxidase O
( O
cox O
) O
and O
suppresses O
its O
enzyme O
activity O
led O
us O
to O
investigate O
adr's O
action O
on O
the O
cardiovascular O
functions O
and O
heart O
mitochondrial O
morphology O
in O
balb-c O
mice O
i.p O
. O
treated O
with O
adr O
for O
several O
weeks O
. O

at O
various O
times O
during O
treatment O
, O
the O
animals O
were O
assessed O
for O
cardiovascular O
functions O
by O
electrocardiography O
and O
for O
heart O
tissue O
damage O
by O
electron O
microscopy O
. O

in O
parallel O
, O
total O
rna O
was O
extracted O
from O
samples O
of O
dissected O
heart O
and O
analyzed O
by O
northern O
blot O
hybridization O
to O
determine O
the O
steady-state O
level O
of O
three O
rna O
transcripts O
encoded O
by O
the O
coxii O
, O
coxiii O
, O
and O
coxiv O
genes O
. O

similarly O
, O
samples O
obtained O
from O
the O
liver O
of O
the O
same O
animals O
were O
analyzed O
for O
comparative O
studies O
. O

our O
results O
indicated O
that O
1) O
treatment O
of O
mice O
with O
adr O
caused O
cardiovascular B-NEG
arrhythmias I-NEG
characterized O
by O
bradycardia B-NEG
, O
extension O
of O
ventricular O
depolarization O
time O
(tqrs) O
, O
and O
failure O
of O
qrs O
at O
high O
concentrations O
( O
10-14 O
mg/kg O
body O
weight O
cumulative O
dose) O
; O
2) O
the O
heart O
mitochondria O
underwent O
swelling B-NEG
, O
fusion O
, O
dissolution O
, O
and/or O
disruption O
of O
mitochondrial O
cristae O
after O
several O
weeks O
of O
treatment O
. O

such O
abnormalities O
were O
not O
observed O
in O
the O
mitochondria O
of O
liver O
tissue O
; O
and O
3) O
among O
the O
three O
genes O
of O
cox O
enzyme O
examined O
, O
only O
coxii O
gene O
expression O
was O
suppressed O
by O
adr O
treatment O
, O
mainly O
after O
8 O
weeks O
in O
both O
heart O
and O
liver O
. O

knowing O
that O
heart O
mitochondria O
represent O
almost O
40% O
of O
heart O
muscle O
by O
weight O
, O
we O
conclude O
that O
the O
deteriorating O
effects O
of O
adr O
on O
cardiovascular O
function O
involve O
mitochondrial B-NEG
structural I-NEG
and I-NEG
functional I-NEG
impairment I-NEG
. O

-DOCSTART- O

enhanced O
bradycardia B-NEG
induced O
by O
beta-adrenoceptor O
antagonists O
in O
rats O
pretreated O
with O
isoniazid O
. O

high O
doses O
of O
isoniazid O
increase O
hypotension B-NEG
induced O
by O
vasodilators O
and O
change O
the O
accompanying O
reflex O
tachycardia B-NEG
to O
bradycardia B-NEG
, O
an O
interaction O
attributed O
to O
decreased O
synthesis O
of O
brain O
gamma-aminobutyric O
acid O
(gaba) O
. O

in O
the O
present O
study O
, O
the O
possible O
enhancement O
by O
isoniazid O
of O
bradycardia B-NEG
induced O
by O
beta-adrenoceptor O
antagonists O
was O
determined O
in O
rats O
anaesthetised O
with O
chloralose-urethane O
. O

isoniazid O
significantly O
increased O
bradycardia B-NEG
after O
propranolol O
, O
pindolol O
, O
labetalol O
and O
atenolol O
, O
as O
well O
as O
after O
clonidine O
, O
but O
not O
after O
hexamethonium O
or O
carbachol O
. O

enhancement O
was O
not O
observed O
in O
rats O
pretreated O
with O
methylatropine O
or O
previously O
vagotomised O
. O

these O
results O
are O
compatible O
with O
interference O
by O
isoniazid O
with O
gabaergic O
inhibition O
of O
cardiac O
parasympathetic O
tone O
. O

such O
interference O
could O
be O
exerted O
centrally O
, O
possibly O
at O
the O
nucleus O
ambiguus O
, O
or O
peripherally O
at O
the O
sinus O
node O
. O

-DOCSTART- O

epileptogenic O
activity O
of O
folic O
acid O
after O
drug O
induces O
sle B-NEG
( O
folic O
acid O
and O
epilepsy B-NEG
) O
objective O
: O
to O
study O
the O
effect O
of O
folic O
acid-containing O
multivitamin O
supplementation O
in O
epileptic B-NEG
women O
before O
and O
during O
pregnancy O
in O
order O
to O
determine O
the O
rate O
of O
structural O
birth B-NEG
defects I-NEG
and O
epilepsy B-NEG
-related O
side O
effects O
. O

study O
design O
: O
first O
a O
randomised O
trial O
, O
later O
periconception O
care O
including O
in O
total O
12225 O
females O
. O

results O
: O
of O
60 O
epileptic B-NEG
women O
with O
periconceptional O
folic O
acid O
( O
0.8 O
mg)-containing O
multivitamin O
supplementation O
, O
no O
one O
developed O
epilepsy B-NEG
-related O
side O
effects O
during O
the O
periconception O
period O
. O

one O
epileptic B-NEG
woman O
delivered O
a O
newborn O
with O
cleft B-NEG
lip I-NEG
and I-NEG
palate I-NEG
. O

another O
patient O
exhibited O
with O
a O
cluster O
of O
seizures B-NEG
after O
the O
periconception O
period O
using O
another O
multivitamin O
. O

this O
22-year-old O
epileptic B-NEG
woman O
was O
treated O
continuously O
by O
carbamazepine O
and O
a O
folic O
acid O
(1 O
mg)-containing O
multivitamin O
from O
the O
20th O
week O
of O
gestation O
. O

she O
developed O
status B-NEG
epilepticus I-NEG
and O
later O
symptoms O
of O
systemic B-NEG
lupus I-NEG
erythematodes I-NEG
. O

her O
pregnancy O
ended O
with O
stillbirth B-NEG
. O

conclusions O
: O
the O
epileptic B-NEG
pregnant O
patient's O
autoimmune B-NEG
disease I-NEG
( O
probably O
drug-induced O
lupus B-NEG
) O
could O
damage O
the O
blood-brain O
barrier O
, O
therefore O
the O
therapeutic O
dose O
(> O
or O
=1 O
mg O
) O
of O
folic O
acid O
triggered O
a O
cluster O
of O
seizures B-NEG
. O

physiological O
dose O
( O
<1 O
mg O
) O
of O
folic O
acid O
both O
in O
healthy O
and O
60 O
epileptic B-NEG
women O
, O
all O
without O
any O
autoimmune B-NEG
disease I-NEG
, O
did O
not O
increase O
the O
risk O
for O
epileptic B-NEG
seizures I-NEG
. O

-DOCSTART- O

effects O
of O
cisapride O
on O
symptoms O
and O
postcibal O
small-bowel O
motor O
function O
in O
patients O
with O
irritable B-NEG
bowel I-NEG
syndrome I-NEG
. O

background O
: O
irritable B-NEG
bowel I-NEG
syndrome I-NEG
is O
a O
common O
cause O
of O
abdominal B-NEG
pain I-NEG
and O
discomfort O
and O
may O
be O
related O
to O
disordered B-NEG
gastrointestinal I-NEG
motility I-NEG
. O

our O
aim O
was O
to O
assess O
the O
effects O
of O
long-term O
treatment O
with O
a O
prokinetic O
agent O
, O
cisapride O
, O
on O
postprandial O
jejunal O
motility O
and O
symptoms O
in O
the O
irritable B-NEG
bowel I-NEG
syndrome I-NEG
( O
ibs B-NEG
). O

methods O
: O
thirty-eight O
patients O
with O
ibs B-NEG
( O
constipation B-NEG
-predominant O
, O
n O
= O
17 O
; O
diarrhoea B-NEG
-predominant O
, O
n O
= O
21 O
) O
underwent O
24-h O
ambulatory O
jejunal O
manometry O
before O
and O
after O
12 O
week's O
treatment O
[cisapride O
, O
5 O
mg O
three O
times O
daily O
(n O
= O
19 O
) O
or O
placebo O
(n O
= O
19)] O
. O

results O
: O
in O
diarrhoea B-NEG
-predominant O
patients O
significant O
differences O
in O
contraction O
characteristics O
were O
observed O
between O
the O
cisapride O
and O
placebo O
groups O
. O

in O
cisapride-treated O
diarrhoea B-NEG
-predominant O
patients O
the O
mean O
contraction O
amplitude O
was O
higher O
( O
29.3 O
+/- O
3.2 O
versus O
24.9 O
+/- O
2.6 O
mm O
hg O
, O
cisapride O
versus O
placebo O
(p O
< O
0.001) O
; O
pretreatment O
, O
25.7 O
+/- O
6.0 O
mm O
hg) O
, O
the O
mean O
contraction O
duration O
longer O
( O
3.4 O
+/- O
0.2 O
versus O
3.0 O
+/- O
0.2 O
sec O
, O
cisapride O
versus O
placebo O
(p O
< O
0.001) O
; O
pretreatment O
, O
3.1 O
+/- O
0.5 O
sec) O
, O
and O
the O
mean O
contraction O
frequency O
lower O
( O
2.0 O
+/- O
0.2 O
versus O
2.5 O
+/- O
0.4 O
cont./min O
, O
cisapride O
versus O
placebo O
(p O
< O
0.001) O
; O
pretreatment O
, O
2.5 O
+/- O
1.1 O
cont./min] O
than O
patients O
treated O
with O
placebo O
. O

no O
significant O
differences O
in O
jejunal O
motility O
were O
found O
in O
the O
constipation B-NEG
-predominant O
ibs B-NEG
group O
. O

symptoms O
were O
assessed O
by O
using O
a O
visual O
analogue O
scale O
before O
and O
after O
treatment O
. O

symptom O
scores O
relating O
to O
the O
severity O
of O
constipation B-NEG
were O
lower O
in O
cisapride-treated O
constipation B-NEG
-predominant O
ibs B-NEG
patients O
[score O
, O
54 O
+/- O
5 O
versus O
67 O
+/- O
14 O
mm O
, O
cisapride O
versus O
placebo O
(p O
< O
0.05) O
; O
pretreatment O
, O
62 O
+/- O
19 O
mm] O
. O
diarrhoea B-NEG
-predominant O
ibs B-NEG
patients O
had O
a O
higher O
pain B-NEG
score O
after O
cisapride O
therapy O
[score O
, O
55 O
+/- O
15 O
versus O
34 O
+/- O
12 O
mm O
, O
cisapride O
versus O
placebo O
(p O
< O
0.05) O
; O
pretreatment O
, O
67 O
+/- O
19 O
mm] O
. O

conclusion O
: O
cisapride O
affects O
jejunal O
contraction O
characteristics O
and O
some O
symptoms O
in O
ibs B-NEG
. O

-DOCSTART- O

clarithromycin-induced O
ventricular B-NEG
tachycardia I-NEG
. O

clarithromycin O
is O
a O
relatively O
new O
macrolide O
antibiotic O
that O
offers O
twice-daily O
dosing O
. O

it O
differs O
from O
erythromycin O
only O
in O
the O
methylation O
of O
the O
hydroxyl O
group O
at O
position O
6. O

although O
the O
side-effect O
profile O
of O
erythromycin O
is O
established O
, O
including O
gastroenteritis B-NEG
and O
interactions O
with O
other O
drugs O
subject O
to O
hepatic O
mixed-function O
oxidase O
metabolism O
, O
experience O
with O
the O
newer O
macrolides O
is O
still O
being O
recorded O
. O
cardiotoxicity B-NEG
has O
been O
demonstrated O
after O
both O
intravenous O
and O
oral O
administration O
of O
erythromycin O
but O
has O
never O
been O
reported O
with O
the O
newer O
macrolides O
. O

we O
report O
a O
case O
of O
ventricular B-NEG
dysrhythmias I-NEG
that O
occurred O
after O
six O
therapeutic O
doses O
of O
clarithromycin O
. O

the O
dysrhythmias B-NEG
resolved O
after O
discontinuation O
of O
the O
drug O
. O

-DOCSTART- O

persistent O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
following O
lithium O
therapy O
. O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
severe O
hypernatraemic O
dehydration B-NEG
following O
a O
head B-NEG
injury I-NEG
. O

ten O
years O
previously O
he O
had O
been O
diagnosed O
to O
have O
lithium-induced O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
, O
and O
lithium O
therapy O
had O
been O
discontinued O
. O

he O
remained O
thirsty O
and O
polyuric B-NEG
despite O
cessation O
of O
lithium O
and O
investigations O
on O
admission O
showed O
him O
to O
have O
normal O
osmoregulated O
thirst O
and O
vasopressin O
secretion O
, O
with O
clear O
evidence O
of O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
. O

lithium O
induced O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
is O
considered O
to O
be O
reversible O
on O
cessation O
of O
therapy O
but O
polyuria B-NEG
persisted O
in O
this O
patient O
for O
ten O
years O
after O
lithium O
was O
stopped O
. O

we O
discuss O
the O
possible O
renal O
mechanisms O
and O
the O
implications O
for O
management O
of O
patients O
with O
lithium-induced O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
. O

-DOCSTART- O

late O
cardiotoxicity B-NEG
after O
treatment O
for O
a O
malignant O
bone B-NEG
tumor I-NEG
. O

cardiac O
function O
was O
assessed O
in O
long-term O
survivors O
of O
malignant O
bone B-NEG
tumors I-NEG
who O
were O
treated O
according O
to O
rosen's O
t5 O
or O
t10 O
protocol O
, O
both O
including O
doxorubicin O
. O

thirty-one O
patients O
, O
age O
10-45 O
years O
( O
median O
age O
17.8 O
years O
) O
were O
evaluated O
2.3-14.1 O
years O
( O
median O
8.9 O
years O
) O
following O
completion O
of O
treatment O
. O

cumulative O
doses O
of O
doxorubicin O
were O
225-550 O
mg/m2 O
( O
median O
dose O
360) O
. O

the O
evaluation O
consisted O
of O
a O
history O
, O
physical O
examination O
, O
electrocardiogram O
(ecg) O
, O
signal O
averaged O
ecg O
, O
24-hour O
ambulatory O
ecg O
, O
echocardiography O
and O
radionuclide O
angiography O
. O

eighteen O
of O
31 O
( O
58% O
) O
patients O
showed O
cardiac B-NEG
toxicity I-NEG
, O
defined O
as O
having O
one O
or O
more O
of O
the O
following O
abnormalities O
: O
late O
potentials O
, O
complex O
ventricular B-NEG
arrhythmias I-NEG
, O
left O
ventricular B-NEG
dilation I-NEG
, O
decreased O
shortening O
fraction O
, O
or O
decreased O
ejection O
fraction O
. O

the O
incidence O
of O
cardiac B-NEG
abnormalities I-NEG
increased O
with O
length O
of O
follow-up O
( O
p< O
or O
= O
.05) O
. O

no O
correlation O
could O
be O
demonstrated O
between O
cumulative O
dose O
of O
doxorubicin O
and O
cardiac O
status O
, O
except O
for O
heart O
rate O
variability O
. O

when O
adjusted O
to O
body O
surface O
area O
, O
the O
left O
ventricular O
posterior O
wall O
thickness O
( O
lvpw O
index O
) O
was O
decreased O
in O
all O
patients O
. O

the O
incidence O
of O
doxorubicin-induced O
cardiotoxicity B-NEG
is O
high O
and O
increases O
with O
follow-up O
, O
irrespective O
of O
cumulative O
dose O
. O

life-long O
cardiac O
follow-up O
in O
these O
patients O
is O
warranted O
. O

the O
results O
of O
our O
study O
suggest O
that O
heart O
rate O
variability O
and O
lvpw O
index O
could O
be O
sensitive O
indicators O
for O
cardiotoxicity B-NEG
. O

-DOCSTART- O

venous B-NEG
complications I-NEG
of O
midazolam O
versus O
diazepam O
. O

although O
some O
studies O
have O
suggested O
fewer O
venous B-NEG
complications I-NEG
are O
associated O
with O
midazolam O
than O
with O
diazepam O
for O
endoscopic O
procedures O
, O
this O
variable O
has O
not O
been O
well O
documented O
. O

we O
prospectively O
evaluated O
the O
incidence O
of O
venous B-NEG
complications I-NEG
after O
intravenous O
injection O
of O
diazepam O
or O
midazolam O
in O
122 O
consecutive O
patients O
undergoing O
colonoscopy O
and O
esophagogastroduodenoscopy O
. O

overall O
, O
venous B-NEG
complications I-NEG
were O
more O
frequent O
with O
diazepam O
( O
22 O
of O
62 O
patients O
) O
than O
with O
midazolam O
(4 O
of O
60 O
patients O
) O
(p O
< O
0.001) O
. O

a O
palpable O
venous O
cord O
was O
present O
in O
23% O
( O
14 O
of O
62 O
) O
of O
patients O
in O
the O
diazepam O
group O
, O
compared O
with O
2% O
(1 O
of O
60 O
patients O
) O
in O
the O
midazolam O
group O
(p O
< O
0.002) O
. O
pain B-NEG
at O
the O
injection O
site O
occurred O
in O
35% O
( O
22 O
of O
62 O
) O
of O
patients O
in O
the O
diazepam O
group O
compared O
with O
7% O
(4 O
of O
60 O
patients O
) O
in O
the O
midazolam O
group O
(p O
< O
0.001) O
. O
swelling B-NEG
and O
warmth O
at O
the O
injection O
site O
were O
not O
significantly O
different O
between O
the O
two O
groups O
. O

smoking O
, O
nonsteroidal O
anti-inflammatory O
drug O
use O
, O
intravenous O
catheter O
site O
, O
dwell O
time O
of O
the O
needle O
, O
alcohol O
use O
, O
and O
pain B-NEG
during O
the O
injection O
had O
no O
effect O
on O
the O
incidence O
of O
venous B-NEG
complications I-NEG
. O

-DOCSTART- O

tetany B-NEG
and O
rhabdomyolysis B-NEG
due O
to O
surreptitious O
furosemide--importance O
of O
magnesium O
supplementation O
. O

diuretics O
may O
induce O
hypokalemia B-NEG
, O
hypocalcemia B-NEG
and O
hypomagnesemia B-NEG
. O

while O
severe O
hypokalemia B-NEG
may O
cause O
muscle B-NEG
weakness I-NEG
, O
severe O
hypomagnesemia B-NEG
is O
associated O
with O
muscle B-NEG
spasms I-NEG
and O
tetany B-NEG
which O
cannot O
be O
corrected O
by O
potassium O
and O
calcium O
supplementation O
alone O
(1,2) O
. O

surreptitious O
diuretic O
ingestion O
has O
been O
described O
, O
mainly O
in O
women O
who O
are O
concerned O
that O
they O
are O
obese B-NEG
or O
edematous B-NEG
. O

symptomatic O
hypokalemia B-NEG
has O
been O
reported O
in O
such O
patients O
( O
3-7 O
) O
and O
in O
one O
case O
hypocalcemia B-NEG
was O
observed O
(8) O
, O
but O
the O
effects O
of O
magnesium O
depletion O
were O
not O
noted O
in O
these O
patients O
. O

-DOCSTART- O

loss O
of O
glutamate O
decarboxylase O
mrna-containing O
neurons O
in O
the O
rat O
dentate O
gyrus O
following O
pilocarpine-induced O
seizures B-NEG
. O

in O
situ O
hybridization O
methods O
were O
used O
to O
determine O
if O
glutamic O
acid O
decarboxylase O
( O
gad O
) O
mrna-containing O
neurons O
within O
the O
hilus O
of O
the O
dentate O
gyrus O
are O
vulnerable O
to O
seizure B-NEG
-induced O
damage O
in O
a O
model O
of O
chronic O
seizures B-NEG
. O

sprague-dawley O
rats O
were O
injected O
intraperitoneally O
with O
pilocarpine O
, O
and O
the O
hippocampal O
formation O
was O
studied O
histologically O
at O
1, O
2, O
4, O
and O
8 O
week O
intervals O
after O
pilocarpine-induced O
seizures B-NEG
. O

in O
situ O
hybridization O
histochemistry O
, O
using O
a O
digoxigenin-labeled O
gad O
crna O
probe O
, O
demonstrated O
a O
substantial O
decrease O
in O
the O
number O
of O
gad O
mrna-containing O
neurons O
in O
the O
hilus O
of O
the O
dentate O
gyrus O
in O
the O
pilocarpine-treated O
rats O
as O
compared O
to O
controls O
at O
all O
time O
intervals O
. O

additional O
neuronanatomical O
studies O
, O
including O
cresyl O
violet O
staining O
, O
neuronal B-NEG
degeneration I-NEG
methods O
, O
and O
histochemical O
localization O
of O
glial O
fibrillary O
acidic O
protein O
, O
suggested O
that O
the O
decrease O
in O
the O
number O
of O
gad O
mrna-containing O
neurons O
was O
related O
to O
neuronal B-NEG
loss I-NEG
rather O
than O
to O
a O
decrease O
in O
gad O
mrna O
levels O
. O

the O
loss O
of O
gad O
mrna-containing O
neurons O
in O
the O
hilus O
contrasted O
with O
the O
relative O
preservation O
of O
labeled O
putative O
basket O
cells O
along O
the O
inner O
margin O
of O
the O
granule O
cell O
layer O
. O

quantitative O
analyses O
of O
labeled O
neurons O
in O
three O
regions O
of O
the O
dentate O
gyrus O
in O
the O
1 O
and O
2 O
week O
groups O
showed O
statistically O
significant O
decreases O
in O
the O
mean O
number O
of O
gad O
mrna-containing O
neurons O
in O
the O
hilus O
of O
both O
groups O
of O
experimental O
animals O
. O

no O
significant O
differences O
were O
found O
in O
the O
molecular O
layer O
or O
the O
granule O
cell O
layer O
, O
which O
included O
labeled O
neurons O
along O
the O
lower O
margin O
of O
the O
granule O
cell O
layer O
. O

the O
results O
indicate O
that O
, O
in O
this O
model O
, O
a O
subpopulation O
of O
gad O
mrna-containing O
neurons O
within O
the O
dentate O
gyrus O
is O
selectively O
vulnerable O
to O
seizure B-NEG
-induced O
damage O
. O

such O
differential O
vulnerability O
appears O
to O
be O
another O
indication O
of O
the O
heterogeneity O
of O
gaba O
neurons O
. O

-DOCSTART- O

protective O
effect O
of O
misoprostol O
on O
indomethacin O
induced O
renal B-NEG
dysfunction I-NEG
in O
elderly O
patients O
. O

objective O
: O
to O
evaluate O
the O
possible O
protective O
effects O
of O
misoprostol O
on O
renal O
function O
in O
hospitalized O
elderly O
patients O
treated O
with O
indomethacin O
. O

methods O
: O
forty-five O
hospitalized O
elderly O
patients O
(> O
65 O
years O
old O
) O
who O
required O
therapy O
with O
nonsteroidal O
antiinflammatory O
drugs O
( O
nsaid O
) O
were O
randomly O
assigned O
to O
receive O
either O
indomethacin O
, O
150 O
mg/day O
( O
group O
a) O
, O
or O
indomethacin O
150 O
mg/day O
plus O
misoprostol O
at O
0.6 O
mg/day O
( O
group O
b) O
. O

laboratory O
variables O
of O
renal O
function O
[serum O
creatinine O
, O
blood O
urea O
nitrogen O
( O
bun O
) O
and O
electrolytes] O
were O
evaluated O
before O
initiation O
of O
therapy O
and O
every O
2 O
days O
, O
until O
termination O
of O
the O
study O
(a O
period O
of O
at O
least O
6 O
days) O
. O

response O
to O
treatment O
was O
estimated O
by O
the O
visual O
analog O
scale O
for O
severity O
of O
pain B-NEG
. O

results O
: O
forty-two O
patients O
completed O
the O
study O
, O
22 O
in O
group O
a O
and O
20 O
in O
group O
b. O

bun O
and O
creatinine O
increased O
by O
> O
50% O
of O
baseline O
levels O
in O
54 O
and O
45% O
of O
group O
a O
patients O
, O
respectively O
, O
compared O
to O
only O
20 O
and O
10% O
of O
group O
b O
patients O
(p O
< O
0.05) O
. O

potassium O
( O
k O
) O
increment O
of O
0.6 O
meq/l O
or O
more O
was O
observed O
in O
50% O
of O
group O
a, O
but O
in O
only O
15% O
of O
group O
b O
patients O
(p O
< O
0.05) O
. O

the O
mean O
increments O
in O
bun O
, O
creatinine O
, O
and O
k O
were O
reduced O
by O
63 O
, O
80 O
, O
and O
42% O
, O
respectively O
, O
in O
group O
b O
patients O
compared O
to O
group O
a. O

response O
to O
treatment O
did O
not O
differ O
significantly O
between O
the O
2 O
groups O
. O

conclusion O
: O
hospitalized O
elderly O
patients O
are O
at O
risk O
for O
developing O
indomethacin O
related O
renal B-NEG
dysfunction I-NEG
. O

addition O
of O
misoprostol O
can O
minimize O
this O
renal B-NEG
impairment I-NEG
without O
affecting O
pain B-NEG
control O
. O

-DOCSTART- O

nephrotoxic B-NEG
effects O
of O
aminoglycoside O
treatment O
on O
renal O
protein O
reabsorption O
and O
accumulation O
. O

to O
quantify O
the O
effects O
of O
gentamicin O
, O
kanamycin O
and O
netilmicin O
on O
renal O
protein O
reabsorption O
and O
accumulation O
, O
these O
drugs O
were O
administered O
to O
rats O
intraperitoneally O
( O
30 O
mg/kg/day O
) O
for O
7, O
14 O
or O
21 O
days O
. O

scanning O
electron O
microscopy O
of O
the O
glomerular O
endothelia O
, O
urinary O
measurements O
of O
sodium O
, O
potassium O
, O
endogenous O
lysozyme O
, O
n-acetyl-beta-d-glucosaminidase O
( O
nag O
) O
as O
well O
as O
clearance O
and O
accumulation O
experiments O
after O
i.v O
. O
administration O
of O
egg-white O
lysozyme O
and O
measurements O
of O
inulin O
clearance O
( O
gfr O
) O
were O
done O
in O
each O
treatment O
group O
. O

gentamicin O
administration O
decreased O
diameter O
, O
density O
and O
shape O
of O
endothelial O
fenestrae O
. O

kanamycin O
and O
netilmicin O
appeared O
to O
have O
no O
effect O
at O
the O
dose O
used O
. O

all O
three O
aminoglycosides O
decreased O
gfr O
and O
increased O
urinary O
excretion O
of O
sodium O
and O
potassium O
. O

while O
gentamicin O
and O
kanamycin O
decreased O
the O
percentage O
reabsorption O
and O
accumulation O
of O
lysozyme O
after O
i.v O
. O
administration O
of O
egg-white O
lysozyme O
netilmicin O
had O
no O
effect O
. O

daily O
excretion O
of O
total O
protein O
, O
endogenous O
lysozyme O
and O
nag O
increased O
only O
after O
treatment O
with O
kanamycin O
and O
gentamicin O
. O

thus O
, O
aminoglycosides O
may O
act O
as O
nephrotoxicants O
at O
glomerular O
and/or O
tubular O
level O
inducing O
impairment B-NEG
of I-NEG
renal I-NEG
reabsorption I-NEG
and O
accumulation O
of O
proteins O
. O

-DOCSTART- O

pharmacology O
of O
gyki-41 O
099 O
(chlorpropanol O
, O
tobanum O
) O
a O
new O
potent O
beta-adrenergic O
antagonist O
. O

the O
compound O
gyki-41 O
099 O
, O
as O
a O
beta-adrenergic O
antagonist O
, O
is O
3-8 O
times O
more O
potent O
than O
propranolol O
in O
vitro O
and O
in O
vivo O
. O

its O
antiarrhythmic O
effectiveness O
surpasses O
that O
of O
propranolol O
and O
pindolol O
inhibiting O
the O
ouabain O
arrhythmia B-NEG
in O
dogs O
and O
cats O
. O

gyki-41 O
900 O
has O
a O
negligible O
cardiodepressant O
activity O
; O
it O
is O
not O
cardioselective O
. O

the O
compound O
shows O
a O
rapid O
and O
long O
lasting O
effect O
. O

there O
was O
a O
prolonged O
elimination O
of O
the O
radioactivity O
after O
the O
injection O
of O
14c-41 O
099 O
to O
rats O
and O
dogs O
. O

the O
half O
life O
of O
the O
unlabeled O
substance O
in O
humans O
was O
more O
than O
10 O
hours O
. O

-DOCSTART- O

chorea B-NEG
associated O
with O
oral O
contraception O
. O

three O
patients O
developed O
chorea B-NEG
while O
receiving O
oral O
contraceptives O
. O

two O
were O
young O
patients O
whose O
chorea B-NEG
developed O
long O
after O
treatment O
had O
been O
started O
and O
disappeared O
soon O
after O
it O
had O
been O
discontinued O
. O

the O
third O
patient O
had O
acute O
amphetamine-induced O
chorea B-NEG
after O
prolonged O
oral O
contraception O
. O

prolonged O
administration O
of O
female O
sex O
hormones O
is O
a O
possible O
cause O
of O
chorea B-NEG
in O
women O
who O
have O
not O
previously O
had O
chorea B-NEG
or O
rheumatic B-NEG
fever I-NEG
. O

-DOCSTART- O

reversal O
of O
ammonia O
coma B-NEG
in O
rats O
by O
l-dopa O
: O
a O
peripheral O
effect O
. O

ammonia O
coma B-NEG
was O
produced O
in O
rats O
within O
10 O
to O
15 O
minutes O
of O
an O
intraperitonealinjection O
of O
1.7 O
mmol O
nh4cl O
. O

this O
coma B-NEG
was O
prevented O
with O
1.68 O
mmol O
l-dopa O
given O
by O
gastric O
intubation O
15 O
minutes O
before O
the O
ammonium O
salt O
injection O
. O

the O
effect O
of O
l-dopa O
was O
correlated O
with O
a O
decrease O
in O
blood O
and O
brain O
ammonia O
, O
an O
increase O
in O
brain O
dopamine O
, O
and O
an O
increase O
in O
renal O
excretion O
of O
ammonia O
and O
urea O
. O

intraventricular O
infusion O
of O
dopamine O
sufficient O
to O
raise O
the O
brain O
dopamine O
to O
the O
same O
extent O
did O
not O
prevent O
the O
ammonia O
coma B-NEG
nor O
affect O
the O
blood O
and O
brain O
ammonia O
concentrations O
. O

bilateral O
nephrectomy O
eliminated O
the O
beneficial O
effect O
of O
l-dopa O
on O
blood O
and O
brain O
ammonia O
and O
the O
ammonia O
coma B-NEG
was O
not O
prevented O
. O

thus O
, O
the O
reduction O
in O
blood O
and O
brain O
ammonia O
and O
the O
prevention O
of O
ammonia O
coma B-NEG
after O
l-dopa O
, O
can O
be O
accounted O
for O
by O
the O
peripheral O
effect O
of O
dopamine O
on O
renal O
function O
rather O
than O
its O
central O
action O
. O

these O
results O
provide O
a O
reasonable O
explanation O
for O
the O
beneficial O
effects O
observed O
in O
some O
encephalopathic B-NEG
patients O
receiving O
l-dopa O
. O

-DOCSTART- O

heparin-induced O
thrombocytopenia B-NEG
after O
liver O
transplantation O
. O

background O
: O
unfractionated O
heparin O
sodium O
( O
ufh O
) O
or O
low-molecular O
weight O
heparin O
( O
lmwh O
) O
is O
used O
in O
anticoagulant O
protocols O
at O
several O
institutions O
to O
prevent O
thrombosis B-NEG
after O
liver O
transplantation O
. O

heparin-induced O
thrombocytopenia B-NEG
( O
hit B-NEG
) O
is O
an O
adverse O
immune-mediated O
reaction O
to O
heparin O
, O
resulting O
in O
platelet O
count O
decreases O
of O
more O
than O
50% O
. O

the O
frequencies O
of O
hit B-NEG
after O
liver O
transplantation O
and O
platelet O
factor O
4/heparin-reactive O
antibody O
( O
hit B-NEG
antibody O
) O
positivity O
in O
liver O
transplantation O
patients O
, O
however O
, O
are O
unknown O
. O

patients O
and O
methods O
: O
the O
32 O
men O
and O
20 O
women O
underwent O
living O
donor O
liver O
transplantation O
. O

we O
started O
lmwh O
( O
25 O
iu/kg/h O
) O
on O
postoperative O
day O
( O
pod O
) O
1, O
switching O
to O
ufh O
( O
5000 O
u/d O
) O
on O
pod O
2 O
or O
3. O

the O
dose O
of O
ufh O
was O
changed O
according O
to O
the O
activated O
clotting O
time O
level O
. O
hit B-NEG
antibody O
levels O
were O
measured O
the O
day O
before O
surgery O
and O
on O
pod O
7 O
and O
14 O
. O

platelet O
count O
was O
measured O
daily O
for O
3 O
weeks O
. O

results O
: O
the O
average O
platelet O
counts O
preoperatively O
, O
and O
on O
pod O
7, O
14 O
, O
and O
21 O
were O
65 O
, O
88 O
, O
149 O
, O
and O
169 O
x O
10(9)/l O
, O
respectively O
. O

two O
patients O
developed O
hepatic O
artery O
thrombosis B-NEG
on O
pod O
11 O
and O
19 O
, O
respectively O
, O
although O
they O
were O
hit B-NEG
antibody-negative O
and O
their O
platelet O
counts O
were O
stable O
. O

in O
2 O
other O
patients O
, O
the O
platelet O
count O
decreased O
suddenly O
from O
107 O
x O
10(9)/l O
on O
pod O
4 O
to O
65 O
x O
10(9)/l O
on O
pod O
6 O
and O
from O
76 O
x O
10(9)/l O
on O
pod O
7 O
to O
33 O
x O
10(9)/l O
on O
pod O
9, O
respectively O
. O

the O
heparin-induced O
platelet B-NEG
aggregation I-NEG
test O
was O
negative O
in O
these O
patients O
. O

the O
percentage O
of O
hit B-NEG
antibody-positive O
patients O
was O
0.5% O
preoperatively O
, O
5.6% O
on O
pod O
7, O
and O
5.6% O
on O
pod O
14 O
. O

none O
of O
the O
subjects/patients O
developed O
ufh-related O
hit B-NEG
. O

conclusions O
: O
in O
our O
series O
, O
the O
occurrence O
of O
hit B-NEG
after O
liver O
transplantation O
was O
uncommon O
. O

-DOCSTART- O

ptu-associated O
vasculitis B-NEG
in O
a O
girl O
with O
turner B-NEG
syndrome I-NEG
and O
graves' B-NEG
disease I-NEG
. O

palpable O
purpura B-NEG
is O
a O
concerning O
clinical O
finding O
in O
pediatric O
patients O
and O
can O
have O
many O
causes O
, O
including O
infectious O
and O
autoimmune O
processes O
. O

a O
rare O
cause O
, O
drug-induced O
vasculitis B-NEG
, O
may O
result O
from O
the O
production O
of O
antineutrophil O
cytoplasmic O
antibodies O
( O
ancas O
) O
in O
response O
to O
a O
medication O
. O

we O
report O
a O
girl O
with O
turner B-NEG
syndrome I-NEG
and O
graves' B-NEG
disease I-NEG
who O
presented O
with O
palpable O
purpuric B-NEG
lesions I-NEG
. O

the O
diagnosis O
of O
propylthiouracil O
( O
ptu)-associated O
vasculitis B-NEG
was O
made O
by O
observation O
of O
consistent O
clinical O
features O
, O
the O
detection O
of O
elevated O
ana O
and O
anca O
in O
the O
blood O
, O
and O
the O
observed O
clinical O
resolution O
of O
symptoms O
following O
withdrawal O
of O
ptu O
. O

subsequent O
treatment O
of O
persistent O
hyperthyroidism B-NEG
with O
radioablation O
did O
not O
result O
in O
an O
exacerbation O
of O
the O
vasculitis B-NEG
, O
a O
complication O
described O
in O
prior O
case O
reports O
. O

-DOCSTART- O

succinylcholine-induced O
masseter B-NEG
muscle I-NEG
rigidity I-NEG
during O
bronchoscopic O
removal O
of O
a O
tracheal O
foreign O
body O
. O
masseter B-NEG
muscle I-NEG
rigidity I-NEG
during O
general O
anesthesia O
is O
considered O
an O
early O
warning O
sign O
of O
a O
possible O
episode O
of O
malignant B-NEG
hyperthermia I-NEG
. O

the O
decision O
whether O
to O
continue O
or O
discontinue O
the O
procedure O
depends O
on O
the O
urgency O
of O
the O
surgery O
and O
severity O
of O
masseter B-NEG
muscle I-NEG
rigidity I-NEG
. O

here O
, O
we O
describe O
a O
case O
of O
severe O
masseter B-NEG
muscle I-NEG
rigidity I-NEG
( O
jaw B-NEG
of I-NEG
steel I-NEG
) O
after O
succinylcholine O
( O
sch O
) O
administration O
during O
general O
anesthetic O
management O
for O
rigid O
bronchoscopic O
removal O
of O
a O
tracheal O
foreign O
body O
. O

anesthesia O
was O
continued O
uneventfully O
with O
propofol O
infusion O
while O
all O
facilities O
were O
available O
to O
detect O
and O
treat O
malignant B-NEG
hyperthermia I-NEG
. O

-DOCSTART- O

minor O
neurological B-NEG
dysfunction I-NEG
, O
cognitive O
development O
, O
and O
somatic O
development O
at O
the O
age O
of O
3 O
to O
7 O
years O
after O
dexamethasone O
treatment O
in O
very-low O
birth-weight O
infants O
. O

the O
objective O
of O
this O
study O
was O
to O
assess O
minor O
neurological B-NEG
dysfunction I-NEG
, O
cognitive O
development O
, O
and O
somatic O
development O
after O
dexamethasone O
therapy O
in O
very-low-birthweight O
infants O
. O

thirty-three O
children O
after O
dexamethasone O
treatment O
were O
matched O
to O
33 O
children O
without O
dexamethasone O
treatment O
. O

data O
were O
assessed O
at O
the O
age O
of O
3-7 O
years O
. O

dexamethasone O
was O
started O
between O
the O
7th O
and O
the O
28th O
day O
of O
life O
over O
7 O
days O
with O
a O
total O
dose O
of O
2.35 O
mg/kg/day O
. O

exclusion O
criteria O
were O
asphyxia B-NEG
, O
malformations B-NEG
, O
major O
surgical O
interventions O
, O
small O
for O
gestational O
age O
, O
intraventricular O
haemorrhage B-NEG
grades O
iii O
and O
iv O
, O
periventricular B-NEG
leukomalacia I-NEG
, O
and O
severe O
psychomotor B-NEG
retardation I-NEG
. O

each O
child O
was O
examined O
by O
a O
neuropediatrician O
for O
minor O
neurological B-NEG
dysfunctions I-NEG
and O
tested O
by O
a O
psychologist O
for O
cognitive O
development O
with O
a O
kaufman O
assessment O
battery O
for O
children O
and O
a O
draw-a-man O
test O
. O

there O
were O
no O
differences O
in O
demographic O
data O
, O
growth O
, O
and O
socio-economic O
status O
between O
the O
two O
groups O
. O

fine O
motor O
skills O
and O
gross O
motor O
function O
were O
significantly O
better O
in O
the O
control O
group O
(p<0.01) O
. O

in O
the O
draw-a-man O
test O
, O
the O
control O
group O
showed O
better O
results O
(p<0.001) O
. O

there O
were O
no O
differences O
in O
development O
of O
speech O
, O
social O
development O
, O
and O
the O
kaufman O
assessment O
battery O
for O
children O
. O

after O
dexamethasone O
treatment O
, O
children O
showed O
a O
higher O
rate O
of O
minor O
neurological B-NEG
dysfunctions I-NEG
. O

neurological O
development O
was O
affected O
even O
without O
neurological O
diagnosis O
. O

further O
long-term O
follow-up O
studies O
will O
be O
necessary O
to O
fully O
evaluate O
the O
impact O
of O
dexamethasone O
on O
neurological O
and O
cognitive O
development O
. O

-DOCSTART- O

naloxone O
reverses O
the O
antihypertensive O
effect O
of O
clonidine O
. O

in O
unanesthetized O
, O
spontaneously O
hypertensive B-NEG
rats O
the O
decrease O
in O
blood O
pressure O
and O
heart O
rate O
produced O
by O
intravenous O
clonidine O
, O
5 O
to O
20 O
micrograms/kg O
, O
was O
inhibited O
or O
reversed O
by O
nalozone O
, O
0.2 O
to O
2 O
mg/kg O
. O

the O
hypotensive B-NEG
effect O
of O
100 O
mg/kg O
alpha-methyldopa O
was O
also O
partially O
reversed O
by O
naloxone O
. O

naloxone O
alone O
did O
not O
affect O
either O
blood O
pressure O
or O
heart O
rate O
. O

in O
brain O
membranes O
from O
spontaneously O
hypertensive B-NEG
rats O
clonidine O
, O
10(-8 O
) O
to O
10(-5 O
) O
m, O
did O
not O
influence O
stereoselective O
binding O
of O
[3h]-naloxone O
(8 O
nm) O
, O
and O
naloxone O
, O
10(-8 O
) O
to O
10(-4 O
) O
m, O
did O
not O
influence O
clonidine-suppressible O
binding O
of O
[3h]-dihydroergocryptine O
(1 O
nm) O
. O

these O
findings O
indicate O
that O
in O
spontaneously O
hypertensive B-NEG
rats O
the O
effects O
of O
central O
alpha-adrenoceptor O
stimulation O
involve O
activation O
of O
opiate O
receptors O
. O

as O
naloxone O
and O
clonidine O
do O
not O
appear O
to O
interact O
with O
the O
same O
receptor O
site O
, O
the O
observed O
functional O
antagonism O
suggests O
the O
release O
of O
an O
endogenous O
opiate O
by O
clonidine O
or O
alpha-methyldopa O
and O
the O
possible O
role O
of O
the O
opiate O
in O
the O
central O
control O
of O
sympathetic O
tone O
. O

-DOCSTART- O

lidocaine-induced O
cardiac B-NEG
asystole I-NEG
. O

intravenous O
administration O
of O
a O
single O
50-mg O
bolus O
of O
lidocaine O
in O
a O
67-year-old O
man O
resulted O
in O
profound O
depression B-NEG
of O
the O
activity O
of O
the O
sinoatrial O
and O
atrioventricular O
nodal O
pacemakers O
. O

the O
patient O
had O
no O
apparent O
associated O
conditions O
which O
might O
have O
predisposed O
him O
to O
the O
development O
of O
bradyarrhythmias B-NEG
; O
and O
, O
thus O
, O
this O
probably O
represented O
a O
true O
idiosyncrasy O
to O
lidocaine O
. O

-DOCSTART- O

suxamethonium O
infusion O
rate O
and O
observed O
fasciculations B-NEG
. O

a O
dose-response O
study O
. O

suxamethonium O
chloride O
( O
sch O
) O
was O
administered O
i.v O
. O
to O
36 O
adult O
males O
at O
six O
rates O
: O
0.25 O
mg O
s-1 O
to O
20 O
mg O
s-1 O
. O

the O
infusion O
was O
discontinued O
either O
when O
there O
was O
no O
muscular O
response O
to O
tetanic B-NEG
stimulation O
of O
the O
ulnar O
nerve O
or O
when O
sch O
120 O
mg O
was O
exceeded O
. O

six O
additional O
patients O
received O
a O
30-mg O
i.v O
. O
bolus O
dose O
. O
fasciculations B-NEG
in O
six O
areas O
of O
the O
body O
were O
scored O
from O
0 O
to O
3 O
and O
summated O
as O
a O
total O
fasciculation B-NEG
score O
. O

the O
times O
to O
first O
fasciculation B-NEG
, O
twitch B-NEG
suppression O
and O
tetanus B-NEG
suppression O
were O
inversely O
related O
to O
the O
infusion O
rates O
. O
fasciculations B-NEG
in O
the O
six O
areas O
and O
the O
total O
fasciculation B-NEG
score O
were O
related O
directly O
to O
the O
rate O
of O
infusion O
. O

total O
fasciculation B-NEG
scores O
in O
the O
30-mg O
bolus O
group O
and O
the O
5-mg O
s-1 O
and O
20-mg O
s-1 O
infusion O
groups O
were O
not O
significantly O
different O
. O

-DOCSTART- O

galanthamine O
hydrobromide O
, O
a O
longer O
acting O
anticholinesterase O
drug O
, O
in O
the O
treatment O
of O
the O
central O
effects O
of O
scopolamine O
(hyoscine) O
. O

galanthamine O
hydrobromide O
, O
an O
anticholinesterase O
drug O
capable O
of O
penetrating O
the O
blood-brain O
barrier O
, O
was O
used O
in O
a O
patient O
demonstrating O
central O
effects O
of O
scopolamine O
( O
hyoscine O
) O
overdosage B-NEG
. O

it O
is O
longer O
acting O
than O
physostigmine O
and O
is O
used O
in O
anaesthesia O
to O
reverse O
the O
non-depolarizing O
neuromuscular O
block O
. O

however O
, O
studies O
into O
the O
dose O
necessary O
to O
combating O
scopolamine O
intoxication O
are O
indicated O
. O

-DOCSTART- O

effects O
of O
uninephrectomy O
and O
high O
protein O
feeding O
on O
lithium-induced O
chronic B-NEG
renal I-NEG
failure I-NEG
in O
rats O
. O

rats O
with O
lithium-induced O
nephropathy B-NEG
were O
subjected O
to O
high O
protein O
( O
hp O
) O
feeding O
, O
uninephrectomy O
( O
nx O
) O
or O
a O
combination O
of O
these O
, O
in O
an O
attempt O
to O
induce O
glomerular O
hyperfiltration O
and O
further O
progression O
of O
renal B-NEG
failure I-NEG
. O

newborn O
female O
wistar O
rats O
were O
fed O
a O
lithium-containing O
diet O
( O
50 O
mmol/kg O
) O
for O
8 O
weeks O
and O
then O
randomized O
to O
normal O
diet O
, O
hp O
diet O
( O
40 O
vs O
. O
19%) O
, O
nx O
or O
hp+nx O
for O
another O
8 O
weeks O
. O

corresponding O
non-lithium O
pretreated O
groups O
were O
generated O
. O

when O
comparing O
all O
lithium O
treated O
versus O
non-lithium-treated O
groups O
, O
lithium O
caused O
a O
reduction O
in O
glomerular O
filtration O
rate O
( O
gfr O
) O
without O
significant O
changes O
in O
effective O
renal O
plasma O
flow O
( O
as O
determined O
by O
a O
marker O
secreted O
into O
the O
proximal O
tubules O
) O
or O
lithium O
clearance O
. O

consequently O
, O
lithium O
pretreatment O
caused O
a O
fall O
in O
filtration O
fraction O
and O
an O
increase O
in O
fractional O
li O
excretion O
. O

lithium O
also O
caused O
proteinuria B-NEG
and O
systolic O
hypertension B-NEG
in O
absence O
of O
glomerulosclerosis B-NEG
. O

hp O
failed O
to O
accentuante O
progression O
of O
renal B-NEG
failure I-NEG
and O
in O
fact O
tended O
to O
increase O
gfr O
and O
decrease O
plasma O
creatinine O
levels O
in O
lithium O
pretreated O
rats O
. O

nx O
caused O
an O
additive O
deterioration O
in O
gfr O
which O
, O
however O
, O
was O
ameliorated O
by O
hp O
. O

nx+hp O
caused O
a O
further O
rise O
in O
blood O
pressure O
in O
li-pretreated O
rats O
. O

the O
results O
indicate O
that O
li-induced O
nephropathy B-NEG
, O
even O
when O
the O
gfr O
is O
only O
modestly O
reduced O
, O
is O
associated O
with O
proteinuria B-NEG
and O
arterial O
systolic O
hypertension B-NEG
. O

in O
this O
model O
of O
chronic B-NEG
renal I-NEG
failure I-NEG
the O
decline O
in O
gfr O
is O
not O
accompanied O
by O
a O
corresponding O
fall O
in O
effective O
renal O
plasma O
flow O
, O
which O
may O
be O
the O
functional O
expression O
of O
the O
formation O
of O
nonfiltrating O
atubular O
glomeruli O
. O

the O
fractional O
reabsorption O
of O
tubular O
fluid O
by O
the O
proximal O
tubules O
is O
reduced O
, O
leaving O
the O
distal O
delivery O
unchanged.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

treatment O
of O
crohn's B-NEG
disease I-NEG
with O
fusidic O
acid O
: O
an O
antibiotic O
with O
immunosuppressive O
properties O
similar O
to O
cyclosporin O
. O

fusidic O
acid O
is O
an O
antibiotic O
with O
t-cell O
specific O
immunosuppressive O
effects O
similar O
to O
those O
of O
cyclosporin O
. O

because O
of O
the O
need O
for O
the O
development O
of O
new O
treatments O
for O
crohn's B-NEG
disease I-NEG
, O
a O
pilot O
study O
was O
undertaken O
to O
estimate O
the O
pharmacodynamics O
and O
tolerability O
of O
fusidic O
acid O
treatment O
in O
chronic O
active O
, O
therapy-resistant O
patients O
. O

eight O
crohn's B-NEG
disease I-NEG
patients O
were O
included O
. O

fusidic O
acid O
was O
administered O
orally O
in O
a O
dose O
of O
500 O
mg O
t.d.s O
. O
and O
the O
treatment O
was O
planned O
to O
last O
8 O
weeks O
. O

the O
disease O
activity O
was O
primarily O
measured O
by O
a O
modified O
individual O
grading O
score O
. O

five O
of O
8 O
patients O
( O
63% O
) O
improved O
during O
fusidic O
acid O
treatment O
: O
3 O
at O
two O
weeks O
and O
2 O
after O
four O
weeks O
. O

there O
were O
no O
serious O
clinical O
side O
effects O
, O
but O
dose O
reduction O
was O
required O
in O
two O
patients O
because O
of O
nausea B-NEG
. O

biochemically O
, O
an O
increase O
in O
alkaline O
phosphatases O
was O
noted O
in O
5 O
of O
8 O
cases O
(63%) O
, O
and O
the O
greatest O
increases O
were O
seen O
in O
those O
who O
had O
elevated O
levels O
prior O
to O
treatment O
. O

all O
reversed O
to O
pre-treatment O
levels O
after O
cessation O
of O
treatment O
. O

the O
results O
of O
this O
pilot O
study O
suggest O
that O
fusidic O
acid O
may O
be O
of O
benefit O
in O
selected O
chronic O
active O
crohn's B-NEG
disease I-NEG
patients O
in O
whom O
conventional O
treatment O
is O
ineffective O
. O

because O
there O
seems O
to O
exist O
a O
scientific O
rationale O
for O
the O
use O
of O
fusidic O
acid O
at O
the O
cytokine O
level O
in O
inflammatory B-NEG
bowel I-NEG
disease I-NEG
, O
we O
suggest O
that O
the O
role O
of O
this O
treatment O
should O
be O
further O
investigated O
. O

-DOCSTART- O

electrocardiographic O
evidence O
of O
myocardial B-NEG
injury I-NEG
in O
psychiatrically O
hospitalized O
cocaine O
abusers O
. O

the O
electrocardiograms O
( O
ecg O
) O
of O
99 O
cocaine-abusing O
patients O
were O
compared O
with O
the O
ecgs O
of O
50 O
schizophrenic B-NEG
controls O
. O

eleven O
of O
the O
cocaine O
abusers O
and O
none O
of O
the O
controls O
had O
ecg O
evidence O
of O
significant O
myocardial B-NEG
injury I-NEG
defined O
as O
myocardial B-NEG
infarction I-NEG
, O
ischemia B-NEG
, O
and O
bundle B-NEG
branch I-NEG
block I-NEG
. O

-DOCSTART- O

sulpiride-induced O
tardive B-NEG
dystonia I-NEG
. O

sulpiride O
is O
a O
selective O
d2-receptor O
antagonist O
with O
antipsychotic O
and O
antidepressant O
properties O
. O

although O
initially O
thought O
to O
be O
free O
of O
extrapyramidal O
side O
effects O
, O
sulpiride-induced O
tardive B-NEG
dyskinesia I-NEG
and O
parkinsonism B-NEG
have O
been O
reported O
occasionally O
. O

we O
studied O
a O
37-year-old O
man O
who O
developed O
persistent O
segmental O
dystonia B-NEG
within O
2 O
months O
after O
starting O
sulpiride O
therapy O
. O

we O
could O
not O
find O
any O
previous O
reports O
of O
sulpiride-induced O
tardive B-NEG
dystonia I-NEG
. O

-DOCSTART- O

ocular B-NEG
and I-NEG
auditory I-NEG
toxicity I-NEG
in O
hemodialyzed O
patients O
receiving O
desferrioxamine O
. O

during O
an O
18-month O
period O
of O
study O
41 O
hemodialyzed O
patients O
receiving O
desferrioxamine O
( O
10-40 O
mg/kg O
bw/3 O
times O
weekly O
) O
for O
the O
first O
time O
were O
monitored O
for O
detection O
of O
audiovisual B-NEG
toxicity I-NEG
. O

6 O
patients O
presented O
clinical O
symptoms O
of O
visual B-NEG
or I-NEG
auditory I-NEG
toxicity I-NEG
. O

moreover O
, O
detailed O
ophthalmologic O
and O
audiologic O
studies O
disclosed O
abnormalities O
in O
7 O
more O
asymptomatic O
patients O
. O
visual B-NEG
toxicity I-NEG
was O
of O
retinal O
origin O
and O
was O
characterized O
by O
a O
tritan-type O
dyschromatopsy B-NEG
, O
sometimes O
associated O
with O
a B-NEG
loss I-NEG
of I-NEG
visual I-NEG
acuity I-NEG
and O
pigmentary B-NEG
retinal I-NEG
deposits I-NEG
. O
auditory B-NEG
toxicity I-NEG
was O
characterized O
by O
a O
mid- O
to O
high-frequency O
neurosensorial B-NEG
hearing I-NEG
loss I-NEG
and O
the O
lesion O
was O
of O
the O
cochlear O
type O
. O

desferrioxamine O
withdrawal O
resulted O
in O
a O
complete O
recovery O
of O
visual O
function O
in O
1 O
patient O
and O
partial O
recovery O
in O
3, O
and O
a O
complete O
reversal O
of O
hearing B-NEG
loss I-NEG
in O
3 O
patients O
and O
partial O
recovery O
in O
3. O

this O
toxicity B-NEG
appeared O
in O
patients O
receiving O
the O
higher O
doses O
of O
desferrioxamine O
or O
coincided O
with O
the O
normalization O
of O
ferritin O
or O
aluminium O
serum O
levels O
. O

the O
data O
indicate O
that O
audiovisual B-NEG
toxicity I-NEG
is O
not O
an O
infrequent O
complication O
in O
hemodialyzed O
patients O
receiving O
desferrioxamine O
. O

periodical O
audiovisual O
monitoring O
should O
be O
performed O
on O
hemodialyzed O
patients O
receiving O
the O
drug O
in O
order O
to O
detect O
adverse O
effects O
as O
early O
as O
possible O
. O

-DOCSTART- O

myasthenia B-NEG
gravis I-NEG
presenting O
as O
weakness O
after O
magnesium O
administration O
. O

we O
studied O
a O
patient O
with O
no O
prior O
history O
of O
neuromuscular B-NEG
disease I-NEG
who O
became O
virtually O
quadriplegic B-NEG
after O
parenteral O
magnesium O
administration O
for O
preeclampsia B-NEG
. O

the O
serum O
magnesium O
concentration O
was O
3.0 O
meq/l O
, O
which O
is O
usually O
well O
tolerated O
. O

the O
magnesium O
was O
stopped O
and O
she O
recovered O
over O
a O
few O
days O
. O

while O
she O
was O
weak O
, O
2-hz O
repetitive O
stimulation O
revealed O
a O
decrement O
without O
significant O
facilitation O
at O
rapid O
rates O
or O
after O
exercise O
, O
suggesting O
postsynaptic B-NEG
neuromuscular I-NEG
blockade I-NEG
. O

after O
her O
strength O
returned O
, O
repetitive O
stimulation O
was O
normal O
, O
but O
single O
fiber O
emg O
revealed O
increased O
jitter O
and O
blocking O
. O

her O
acetylcholine O
receptor O
antibody O
level O
was O
markedly O
elevated O
. O

although O
paralysis B-NEG
after O
magnesium O
administration O
has O
been O
described O
in O
patients O
with O
known O
myasthenia B-NEG
gravis I-NEG
, O
it O
has O
not O
previously O
been O
reported O
to O
be O
the O
initial O
or O
only O
manifestation O
of O
the O
disease O
. O

patients O
who O
are O
unusually O
sensitive O
to O
the O
neuromuscular O
effects O
of O
magnesium O
should O
be O
suspected O
of O
having O
an O
underlying O
disorder B-NEG
of I-NEG
neuromuscular I-NEG
transmission I-NEG
. O

-DOCSTART- O

chloroacetaldehyde O
and O
its O
contribution O
to O
urotoxicity O
during O
treatment O
with O
cyclophosphamide O
or O
ifosfamide O
. O

an O
experimental O
study/short O
communication O
. O

based O
on O
clinical O
data O
, O
indicating O
that O
chloroacetaldehyde O
( O
caa O
) O
is O
an O
important O
metabolite O
of O
oxazaphosphorine O
cytostatics O
, O
an O
experimental O
study O
was O
carried O
out O
in O
order O
to O
elucidate O
the O
role O
of O
caa O
in O
the O
development O
of O
hemorrhagic B-NEG
cystitis I-NEG
. O

the O
data O
demonstrate O
that O
caa O
after O
i.v O
. O
administration O
does O
not O
contribute O
to O
bladder B-NEG
damage I-NEG
. O

when O
instilled O
directly O
into O
the O
bladder O
, O
caa O
exerts O
urotoxic O
effects O
, O
it O
is O
, O
however O
, O
susceptible O
to O
detoxification O
with O
mesna O
. O

-DOCSTART- O

source O
of O
pain B-NEG
and O
primitive O
dysfunction O
in O
migraine B-NEG
: O
an O
identical O
site? O

twenty O
common O
migraine B-NEG
patients O
received O
a O
one O
sided O
frontotemporal O
application O
of O
nitroglycerin O
( O
10 O
patients O
) O
or O
placebo O
ointment O
( O
10 O
patients O
) O
in O
a O
double O
blind O
study O
. O

early O
onset O
migraine B-NEG
attacks O
were O
induced O
by O
nitroglycerin O
in O
seven O
out O
of O
10 O
patients O
versus O
no O
patient O
in O
the O
placebo O
group O
. O

subsequently O
20 O
migraine B-NEG
patients O
, O
who O
developed O
an O
early O
onset O
attack O
with O
frontotemporal O
nitroglycerin O
, O
received O
the O
drug O
in O
a O
second O
induction O
test O
at O
other O
body O
areas O
. O

no O
early O
onset O
migraine B-NEG
was O
observed O
. O

thus O
the O
migraine B-NEG
-inducing O
effect O
of O
nitroglycerin O
seems O
to O
depend O
on O
direct O
stimulation O
of O
the O
habitual O
site O
of O
pain B-NEG
, O
suggesting O
that O
the O
frontotemporal O
region O
is O
of O
crucial O
importance O
in O
the O
development O
of O
a O
migraine B-NEG
crisis O
. O

this O
is O
not O
consistent O
with O
a O
cns O
origin O
of O
migraine B-NEG
attack O
. O

-DOCSTART- O

clotiazepam-induced O
acute O
hepatitis B-NEG
. O

we O
report O
the O
case O
of O
a O
patient O
who O
developed O
acute O
hepatitis B-NEG
with O
extensive B-NEG
hepatocellular I-NEG
necrosis I-NEG
, O
7 O
months O
after O
the O
onset O
of O
administration O
of O
clotiazepam O
, O
a O
thienodiazepine O
derivative O
. O

clotiazepam O
withdrawal O
was O
followed O
by O
prompt O
recovery O
. O

the O
administration O
of O
several O
benzodiazepines O
, O
chemically O
related O
to O
clotiazepam O
, O
did O
not O
interfere O
with O
recovery O
and O
did O
not O
induce O
any O
relapse O
of O
hepatitis B-NEG
. O

this O
observation O
shows O
that O
clotiazepam O
can O
induce O
acute O
hepatitis B-NEG
and O
suggests O
that O
there O
is O
no O
cross O
hepatotoxicity B-NEG
between O
clotiazepam O
and O
several O
benzodiazepines O
. O

-DOCSTART- O

arterial O
hypertension B-NEG
as O
a O
complication O
of O
prolonged O
ketoconazole O
treatment O
. O

two O
of O
14 O
patients O
with O
cushing's B-NEG
syndrome I-NEG
treated O
on O
a O
long-term O
basis O
with O
ketoconazole O
developed O
sustained O
hypertension B-NEG
. O

in O
both O
cases O
normal O
plasma O
and O
urinary O
free O
cortisol O
levels O
had O
been O
achieved O
following O
ketoconazole O
therapy O
, O
yet O
continuous O
blood O
pressure O
monitoring O
demonstrated O
hypertension B-NEG
31 O
( O
patient O
1) O
and O
52 O
weeks O
( O
patient O
2) O
after O
treatment O
. O

in O
patient O
1, O
plasma O
levels O
of O
deoxycorticosterone O
and O
11-deoxycortisol O
were O
elevated O
. O

in O
patient O
2, O
in O
addition O
to O
an O
increase O
in O
both O
deoxycorticosterone O
and O
11-deoxycortisol O
levels O
, O
plasma O
aldosterone O
values O
were O
raised O
, O
with O
a O
concomitant O
suppression O
of O
renin O
levels O
. O

our O
findings O
show O
that O
long-term O
treatment O
with O
high O
doses O
of O
ketoconazole O
may O
induce O
enzyme O
blockade O
leading O
to O
mineralocorticoid-related O
hypertension B-NEG
. O

-DOCSTART- O

effects O
of O
an O
inhibitor O
of O
angiotensin O
converting O
enzyme O
( O
captopril O
) O
on O
pulmonary B-NEG
and I-NEG
renal I-NEG
insufficiency I-NEG
due O
to O
intravascular B-NEG
coagulation I-NEG
in O
the O
rat O
. O

induction O
of O
intravascular B-NEG
coagulation I-NEG
and O
inhibition O
of O
fibrinolysis O
by O
injection O
of O
thrombin O
and O
tranexamic O
acid O
( O
amca O
) O
in O
the O
rat O
gives O
rise O
to O
pulmonary B-NEG
and I-NEG
renal I-NEG
insufficiency I-NEG
resembling O
that O
occurring O
after O
trauma B-NEG
or O
sepsis B-NEG
in O
man O
. O

injection O
of O
captopril O
(1 O
mg/kg) O
, O
an O
inhibitor O
of O
angiotensin O
converting O
enzyme O
(ace) O
, O
reduced O
both O
pulmonary B-NEG
and I-NEG
renal I-NEG
insufficiency I-NEG
in O
this O
rat O
model O
. O

the O
lung O
weights O
were O
lower O
and O
pao2 O
was O
improved O
in O
rats O
given O
this O
enzyme-blocking O
agent O
. O

the O
contents O
of O
albumin O
in O
the O
lungs O
were O
not O
changed O
, O
indicating O
that O
captopril O
did O
not O
influence O
the O
extravasation O
of O
protein O
. O
renal B-NEG
damage I-NEG
as O
reflected O
by O
an O
increase O
in O
serum O
urea O
and O
in O
kidney O
weight O
was O
prevented O
by O
captopril O
. O

the O
amount O
of O
fibrin O
in O
the O
kidneys O
was O
also O
considerably O
lower O
than O
in O
animals O
which O
received O
thrombin O
and O
amca O
alone O
. O

it O
is O
suggested O
that O
the O
effects O
of O
captopril O
on O
the O
lungs O
may O
be O
attributable O
to O
a O
vasodilatory O
effect O
due O
to O
a O
reduction O
in O
the O
circulating O
level O
of O
angiotension O
ii O
and O
an O
increase O
in O
prostacyclin O
( O
secondary O
to O
an O
increase O
in O
bradykinin) O
. O

captopril O
may O
, O
by O
the O
same O
mechanism O
, O
reduce O
the O
increase O
in O
glomerular O
filtration O
that O
is O
known O
to O
occur O
after O
an O
injection O
of O
thrombin O
, O
thereby O
diminishing O
the O
aggregation O
of O
fibrin O
monomers O
in O
the O
glomeruli O
, O
with O
the O
result O
that O
less O
fibrin O
will O
be O
deposited O
and O
thus O
less O
kidney B-NEG
damage I-NEG
will O
be O
produced O
. O

-DOCSTART- O

a O
randomized O
comparison O
of O
labetalol O
and O
nitroprusside O
for O
induced O
hypotension B-NEG
. O

in O
a O
randomized O
study O
, O
labetalol-induced O
hypotension B-NEG
and O
nitroprusside-induced O
hypotension B-NEG
were O
compared O
in O
20 O
patients O
( O
10 O
in O
each O
group O
) O
scheduled O
for O
major O
orthopedic O
procedures O
. O

each O
patient O
was O
subjected O
to O
an O
identical O
anesthetic O
protocol O
and O
similar O
drug-induced O
reductions B-NEG
in I-NEG
mean I-NEG
arterial I-NEG
blood I-NEG
pressure I-NEG
( O
bp O
) O
( O
50 O
to O
55 O
mmhg) O
. O

nitroprusside O
infusion O
was O
associated O
with O
a O
significant O
(p O
less O
than O
0.05 O
) O
increase B-NEG
in I-NEG
heart I-NEG
rate I-NEG
and I-NEG
cardiac I-NEG
output I-NEG
; O
rebound O
hypertension B-NEG
was O
observed O
in O
three O
patients O
after O
discontinuation O
of O
nitroprusside O
. O

labetalol O
administration O
was O
not O
associated O
with O
any O
of O
these O
findings O
. O

arterial O
po2 O
decreased O
in O
both O
groups O
. O

it O
was O
concluded O
that O
labetalol O
offers O
advantages O
over O
nitroprusside O
. O

-DOCSTART- O

chronic O
carbamazepine O
treatment O
in O
the O
rat O
: O
efficacy O
, O
toxicity B-NEG
, O
and O
effect O
on O
plasma O
and O
tissue O
folate O
concentrations O
. O

folate O
depletion O
has O
often O
been O
a O
problem O
in O
chronic O
antiepileptic O
drug O
( O
aed O
) O
therapy O
. O

carbamazepine O
(cbz) O
, O
a O
commonly O
used O
aed O
, O
has O
been O
implicated O
in O
some O
clinical O
studies O
. O

a O
rat O
model O
was O
developed O
to O
examine O
the O
effects O
of O
chronic O
cbz O
treatment O
on O
folate O
concentrations O
in O
the O
rat O
. O

in O
the O
course O
of O
developing O
this O
model O
, O
a O
common O
vehicle O
, O
propylene O
glycol O
, O
by O
itself O
in O
high O
doses O
, O
was O
found O
to O
exhibit O
protective O
properties O
against O
induced O
seizures B-NEG
and O
inhibited O
weight B-NEG
gain I-NEG
. O
seizures B-NEG
induced O
by O
hexafluorodiethyl O
ether O
( O
hfde O
) O
were O
also O
found O
to O
be O
a O
more O
sensitive O
measure O
of O
protection O
by O
cbz O
than O
seizures B-NEG
induced O
by O
maximal O
electroshock O
(mes) O
. O

oral O
administration O
of O
cbz O
as O
an O
aqueous O
suspension O
every O
8 O
h O
at O
a O
dose O
of O
250 O
mg/kg O
was O
continuously O
protective O
against O
hfde-induced O
seizures B-NEG
and O
was O
minimally O
toxic O
as O
measured O
by O
weight B-NEG
gain I-NEG
over O
8 O
weeks O
of O
treatment O
. O

the O
cbz O
levels O
measured O
in O
plasma O
and O
brain O
of O
these O
animals O
, O
however O
, O
were O
below O
those O
normally O
considered O
protective O
. O

this O
treatment O
with O
cbz O
had O
no O
apparent O
adverse O
effect O
on O
folate O
concentrations O
in O
the O
rat O
, O
and O
, O
indeed O
, O
the O
folate O
concentration O
increased O
in O
liver O
after O
6 O
weeks O
of O
treatment O
and O
in O
plasma O
at O
8 O
weeks O
of O
treatment O
. O

-DOCSTART- O

inhibition O
of O
sympathoadrenal O
activity O
by O
atrial O
natriuretic O
factor O
in O
dogs O
. O

in O
six O
conscious O
, O
trained O
dogs O
, O
maintained O
on O
a O
normal O
sodium O
intake O
of O
2 O
to O
4 O
meq/kg/day O
, O
sympathetic O
activity O
was O
assessed O
as O
the O
release O
rate O
of O
norepinephrine O
and O
epinephrine O
during O
15-minute O
i.v O
. O
infusions O
of O
human O
alpha-atrial O
natriuretic O
factor O
. O

mean O
arterial O
pressure O
( O
as O
a O
percentage O
of O
control O
+/- O
sem O
) O
during O
randomized O
infusions O
of O
0.03 O
, O
0.1 O
, O
0.3 O
, O
or O
1.0 O
microgram/kg/min O
was O
99 O
+/- O
1, O
95 O
+/- O
1 O
(p O
less O
than O
0.05) O
, O
93 O
+/- O
1 O
(p O
less O
than O
0.01) O
, O
or O
79 O
+/- O
6% O
(p O
less O
than O
0.001) O
, O
respectively O
, O
but O
no O
tachycardia B-NEG
and O
no O
augmentation O
of O
the O
norepinephrine O
release O
rate O
( O
up O
to O
0.3 O
microgram/kg/min O
) O
were O
observed O
, O
which O
is O
in O
contrast O
to O
comparable O
hypotension B-NEG
induced O
by O
hydralazine O
or O
nitroglycerin O
. O

the O
release O
rate O
of O
epinephrine O
(control O
, O
6.7 O
+/- O
0.6 O
ng/kg/min O
) O
declined O
immediately O
during O
infusions O
of O
atrial O
natriuretic O
factor O
to O
a O
minimum O
of O
49 O
+/- O
5% O
of O
control O
(p O
less O
than O
0.001 O
) O
during O
0.1 O
microgram/kg/min O
and O
to O
63 O
+/- O
5% O
( O
0.1 O
greater O
than O
p O
greater O
than O
0.05 O
) O
or O
95 O
+/- O
13% O
( O
not O
significant O
) O
during O
0.3 O
or O
1.0 O
microgram/kg/min O
. O

steady O
state O
arterial O
plasma O
concentrations O
of O
atrial O
natriuretic O
factor O
were O
39 O
+/- O
10 O
pg/ml O
(n O
= O
6) O
during O
infusions O
of O
saline O
and O
284 O
+/- O
24 O
pg/ml O
(n O
= O
6) O
and O
1520 O
+/- O
300 O
pg/ml O
(n O
= O
9) O
during O
0.03 O
and O
0.1 O
microgram/kg/min O
infusions O
of O
the O
factor.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

death B-NEG
from O
chemotherapy O
in O
gestational B-NEG
trophoblastic I-NEG
disease I-NEG
. O

multiple O
cytotoxic O
drug O
administration O
is O
the O
generally O
accepted O
treatment O
of O
patients O
with O
a O
high-risk O
stage O
of O
choriocarcinoma B-NEG
. O

based O
on O
this O
principle O
a O
27-year O
old O
woman O
, O
classified O
as O
being O
in O
the O
high-risk O
group O
( O
goldstein O
and O
berkowitz O
score O
: O
11) O
, O
was O
treated O
with O
multiple O
cytotoxic O
drugs O
. O

the O
multiple O
drug O
schema O
consisted O
of O
: O
etoposide O
16.213 O
, O
methotrexate O
, O
cyclophosphamide O
, O
actomycin-d O
, O
and O
cisplatin O
. O

on O
the O
first O
day O
of O
the O
schedule O
, O
moderate O
high O
doses O
of O
methotrexate O
, O
etoposide O
and O
cyclophosphamide O
were O
administered O
. O

within O
8 O
hours O
after O
initiation O
of O
therapy O
the O
patient O
died O
with O
a O
clinical O
picture O
resembling O
massive O
pulmonary B-NEG
obstruction I-NEG
due O
to O
choriocarcinomic O
tissue O
plugs O
, O
probably O
originating O
from O
the O
uterus O
. O

formation O
of O
these O
plugs O
was O
probably O
due O
to O
extensive O
tumor B-NEG
necrosis B-NEG
at O
the O
level O
of O
the O
walls O
of O
the O
major O
uterine O
veins O
, O
which O
resulted O
in O
an O
open O
exchange O
of O
tumor B-NEG
plugs O
to O
the O
vascular O
spaces O
; O
decrease O
in O
tumor B-NEG
tissue O
coherence O
secondary O
to O
chemotherapy O
may O
have O
further O
contributed O
to O
the O
formation O
of O
tumor B-NEG
emboli O
. O

in O
view O
of O
the O
close O
time O
association O
between O
the O
start O
of O
chemotherapy O
and O
the O
acute O
onset O
of O
massive O
embolism B-NEG
other O
explanations O
, O
such O
as O
spontaneous O
necrosis B-NEG
, O
must O
be O
considered O
less O
likely O
. O

patients O
with O
large O
pelvic B-NEG
tumor I-NEG
loads O
are O
, O
according O
to O
existing O
classifications O
, O
at O
high O
risk O
to O
die O
and O
to O
develop O
drug O
resistance O
. O

notwithstanding O
these O
facts O
our O
findings O
suggest O
that O
these O
patients O
might O
benefit O
from O
relatively O
mild O
initial O
treatment O
, O
especially O
true O
for O
patients O
not O
previously O
exposed O
to O
this O
drug O
. O

close O
observation O
of O
the O
response O
status O
both O
clinically O
and O
with O
beta-hcg O
values O
may O
indicate O
whether O
and O
when O
more O
agressive O
combination O
chemotherapy O
should O
be O
started.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

sexual B-NEG
dysfunction I-NEG
among O
patients O
with O
arthritis B-NEG
. O

the O
relationship O
of O
arthritis B-NEG
and O
sexual B-NEG
dysfunction I-NEG
was O
investigated O
among O
169 O
patients O
with O
rheumatoid B-NEG
arthritis I-NEG
, O
osteoarthritis B-NEG
and O
spondyloarthropathy B-NEG
, O
130 O
of O
whom O
were O
pair-matched O
to O
controls O
. O

assessments O
of O
marital O
happiness O
and O
depressed B-NEG
mood I-NEG
were O
also O
made O
using O
the O
ces-d O
and O
the O
azrin O
marital O
happiness O
scale O
(amhs) O
. O
sexual B-NEG
dysfunctions I-NEG
were O
found O
to O
be O
common O
among O
patients O
and O
controls O
, O
the O
majority O
in O
both O
groups O
reporting O
one O
or O
more O
dysfunctions O
. O
impotence B-NEG
was O
more O
common O
among O
male O
patients O
than O
controls O
and O
was O
found O
to O
be O
associated O
with O
co-morbidity O
and O
the O
taking O
of O
methotrexate O
. O
depressed B-NEG
mood I-NEG
was O
more O
common O
among O
patients O
and O
was O
associated O
with O
certain O
sexual O
difficulties O
, O
but O
not O
with O
impotence B-NEG
. O

marital O
unhappiness O
, O
as O
indicated O
by O
amhs O
scores O
, O
was O
not O
associated O
with O
arthritis B-NEG
but O
was O
associated O
with O
sexual B-NEG
dysfunction I-NEG
, O
sexual O
dissatisfaction O
and O
being O
female O
. O

-DOCSTART- O

does O
paracetamol O
cause O
urothelial B-NEG
cancer I-NEG
or O
renal B-NEG
papillary I-NEG
necrosis I-NEG
? O

the O
risk O
of O
developing O
renal B-NEG
papillary I-NEG
necrosis I-NEG
or O
cancer B-NEG
of I-NEG
the I-NEG
renal I-NEG
pelvis I-NEG
, O
ureter I-NEG
or I-NEG
bladder I-NEG
associated O
with O
consumption O
of O
either O
phenacetin O
or O
paracetamol O
was O
calculated O
from O
data O
acquired O
by O
questionnaire O
from O
381 O
cases O
and O
808 O
controls O
. O

the O
risk O
of O
renal B-NEG
papillary I-NEG
necrosis I-NEG
was O
increased O
nearly O
20-fold O
by O
consumption O
of O
phenacetin O
, O
which O
also O
increased O
the O
risk O
for O
cancer B-NEG
of I-NEG
the I-NEG
renal I-NEG
pelvis I-NEG
and I-NEG
bladder I-NEG
but O
not O
for O
ureteric B-NEG
cancer I-NEG
. O

by O
contrast O
, O
we O
were O
unable O
to O
substantiate O
an O
increased O
risk O
from O
paracetamol O
consumption O
for O
renal B-NEG
papillary I-NEG
necrosis I-NEG
or O
any O
of O
these O
cancers B-NEG
although O
there O
was O
a O
suggestion O
of O
an O
association O
with O
cancer B-NEG
of I-NEG
the I-NEG
ureter I-NEG
. O

-DOCSTART- O

dapsone-associated O
heinz O
body O
hemolytic B-NEG
anemia I-NEG
in O
a O
cambodian O
woman O
with O
hemoglobin O
e O
trait O
. O

a O
cambodian O
woman O
with O
hemoglobin O
e O
trait O
( O
ae O
) O
and O
leprosy B-NEG
developed O
a O
heinz O
body O
hemolytic B-NEG
anemia I-NEG
while O
taking O
a O
dose O
of O
dapsone O
( O
50 O
mg/day O
) O
not O
usually O
associated O
with O
clinical O
hemolysis B-NEG
. O

her O
red O
blood O
cells O
( O
rbcs O
) O
had O
increased O
incubated O
heinz O
body O
formation O
, O
decreased O
reduced O
glutathione O
(gsh) O
, O
and O
decreased O
gsh O
stability O
. O

the O
pentose O
phosphate O
shunt O
activity O
of O
the O
dapsone-exposed O
ae O
rbcs O
was O
increased O
compared O
to O
normal O
rbcs O
. O

although O
the O
ae O
rbcs O
from O
an O
individual O
not O
taking O
dapsone O
had O
increased O
incubated O
heinz O
body O
formation O
, O
the O
gsh O
content O
and O
gsh O
stability O
were O
normal O
. O

the O
pentose O
phosphate O
shunt O
activity O
of O
the O
non-dapsone-exposed O
ae O
rbcs O
was O
decreased O
compared O
to O
normal O
rbcs O
. O

thus O
, O
ae O
rbcs O
appear O
to O
have O
an O
increased O
sensitivity O
to O
oxidant O
stress O
both O
in O
vitro O
and O
in O
vivo O
, O
since O
dapsone O
does O
not O
cause O
hemolytic B-NEG
anemia I-NEG
at O
this O
dose O
in O
hematologically O
normal O
individuals O
. O

given O
the O
influx O
of O
southeast O
asians O
into O
the O
united O
states O
, O
oxidant O
medications O
should O
be O
used O
with O
caution O
, O
especially O
if O
an O
infection B-NEG
is O
present O
, O
in O
individuals O
of O
ethnic O
backgrounds O
that O
have O
an O
increased O
prevalence O
of O
hemoglobin O
e. O

-DOCSTART- O

severe O
complications O
of O
antianginal O
drug O
therapy O
in O
a O
patient O
identified O
as O
a O
poor O
metabolizer O
of O
metoprolol O
, O
propafenone O
, O
diltiazem O
, O
and O
sparteine O
. O

a O
47-year-old O
patient O
suffering O
from O
coronary B-NEG
artery I-NEG
disease I-NEG
was O
admitted O
to O
the O
ccu O
in O
shock B-NEG
with O
iii O
. O
av B-NEG
block I-NEG
, O
severe O
hypotension B-NEG
, O
and O
impairment B-NEG
of I-NEG
ventricular I-NEG
function I-NEG
. O

one O
week O
prior O
to O
admission O
a O
therapy O
with O
standard O
doses O
of O
metoprolol O
( O
100 O
mg O
t.i.d O
. O
and O
then O
100 O
mg O
b.i.d. O
) O
had O
been O
initiated O
. O

two O
days O
before O
admission O
diltiazem O
( O
60 O
mg O
b.i.d. O
) O
was O
prescribed O
in O
addition O
. O

analyses O
of O
a O
blood O
sample O
revealed O
unusually O
high O
plasma O
concentrations O
of O
metoprolol O
( O
greater O
than O
3000 O
ng/ml O
) O
and O
diltiazem O
( O
526 O
ng/ml) O
. O

the O
patient O
recovered O
within O
1 O
week O
following O
discontinuation O
of O
antianginal O
therapy O
. O

three O
months O
later O
the O
patient O
was O
exposed O
to O
a O
single O
dose O
of O
metoprolol O
, O
diltiazem O
, O
propafenone O
( O
since O
he O
had O
received O
this O
drug O
in O
the O
past) O
, O
and O
sparteine O
( O
as O
a O
probe O
for O
the O
debrisoquine/sparteine O
type O
polymorphism O
of O
oxidative O
drug O
metabolism) O
. O

it O
was O
found O
that O
he O
was O
a O
poor O
metabolizer O
of O
all O
four O
drugs O
, O
indicating O
that O
their O
metabolism O
is O
under O
the O
same O
genetic O
control O
. O

therefore O
, O
patients O
belonging O
to O
the O
poor-metabolizer O
phenotype O
of O
sparteine/debrisoquine O
polymorphism O
in O
drug O
metabolism O
, O
which O
constitutes O
6.4% O
of O
the O
german O
population O
, O
may O
experience O
adverse B-NEG
drug I-NEG
reactions I-NEG
when O
treated O
with O
standard O
doses O
of O
one O
of O
these O
drugs O
alone O
. O

moreover O
, O
the O
coadministration O
of O
these O
frequently O
used O
drugs O
is O
expected O
to O
be O
especially O
harmful O
in O
this O
subgroup O
of O
patients O
. O

-DOCSTART- O

triazolam-induced O
brief O
episodes O
of O
secondary O
mania B-NEG
in O
a O
depressed B-NEG
patient O
. O

large O
doses O
of O
triazolam O
repeatedly O
induced O
brief O
episodes O
of O
mania B-NEG
in O
a O
depressed B-NEG
elderly O
woman O
. O

features O
of O
organic B-NEG
mental I-NEG
disorder I-NEG
( O
delirium B-NEG
) O
were O
not O
present O
. O
manic B-NEG
excitement O
was O
coincident O
with O
the O
duration O
of O
action O
of O
triazolam O
. O

the O
possible O
contribution O
of O
the O
triazolo O
group O
to O
changes O
in O
affective O
status O
is O
discussed O
. O

-DOCSTART- O

on O
the O
mechanisms O
of O
the O
development O
of O
tolerance O
to O
the O
muscular B-NEG
rigidity I-NEG
produced O
by O
morphine O
in O
rats O
. O

the O
development O
of O
tolerance O
to O
the O
muscular B-NEG
rigidity I-NEG
produced O
by O
morphine O
was O
studied O
in O
rats O
. O

saline-pretreated O
controls O
given O
a O
test O
dose O
of O
morphine O
( O
20 O
mg/kg O
i.p. O
) O
showed O
a O
pronounced O
rigidity B-NEG
recorded O
as O
tonic O
activity O
in O
the O
electromyogram O
. O

rats O
treated O
for O
11 O
days O
with O
morphine O
and O
withdrawn O
for O
36-40 O
h O
showed O
differences O
in O
the O
development O
of O
tolerance O
: O
about O
half O
of O
the O
animals O
showed O
a O
rigidity B-NEG
after O
the O
test O
dose O
of O
morphine O
that O
was O
not O
significantly O
less O
than O
in O
the O
controls O
and O
were O
akinetic B-NEG
(a O
group) O
. O

the O
other O
rats O
showed O
a O
strong O
decrease O
in O
the O
rigidity B-NEG
and O
the O
occurrence O
of O
stereotyped O
( O
s O
) O
licking O
and/or O
gnawing O
in O
presence O
of O
akinetic B-NEG
or O
hyperkinetic B-NEG
( O
k O
) O
behaviour O
( O
as/ks O
group) O
, O
suggesting O
signs O
of O
dopaminergic O
activation O
. O

the O
rigidity B-NEG
was O
considerably O
decreased O
in O
both O
groups O
after O
20 O
days' O
treatment O
. O

in O
a O
further O
series O
of O
experiments O
, O
haloperidol O
( O
0.2 O
mg/kg O
i.p. O
) O
was O
used O
in O
order O
to O
block O
the O
dopaminergic O
activation O
and O
to O
estimate O
the O
real O
degree O
of O
the O
tolerance O
to O
the O
rigidity B-NEG
without O
any O
dopaminergic O
interference O
. O

haloperidol O
enhanced O
the O
rigidity B-NEG
in O
the O
a O
group O
. O

however O
, O
the O
level O
in O
the O
as/ks O
group O
remained O
considerably O
lower O
than O
in O
the O
a O
group O
. O

the O
results O
suggest O
that O
rigidity B-NEG
, O
which O
is O
assumed O
to O
be O
due O
to O
an O
action O
of O
morphine O
in O
the O
striatum O
, O
can O
be O
antagonized O
by O
another O
process O
leading O
to O
dopaminergic O
activation O
in O
the O
striatum O
. O

nevertheless O
, O
there O
occurs O
some O
real O
tolerance O
to O
this O
effect O
. O

the O
rapid O
alternations O
of O
rigidity B-NEG
and O
the O
signs O
of O
dopaminergic O
activation O
observed O
in O
the O
animals O
of O
the O
as/ks O
group O
might O
be O
due O
to O
rapid O
shifts O
in O
the O
predominance O
of O
various O
da-innervated O
structures O
. O

-DOCSTART- O

compression B-NEG
neuropathy I-NEG
of I-NEG
the I-NEG
radial I-NEG
nerve I-NEG
due O
to O
pentazocine-induced O
fibrous B-NEG
myopathy I-NEG
. O
fibrous B-NEG
myopathy I-NEG
is O
a O
common O
, O
well-known O
side O
effect O
of O
repeated O
pentazocine O
injection O
. O

however O
, O
compression B-NEG
neuropathy I-NEG
due O
to O
fibrotic O
muscle O
affected O
by O
pentazocine-induced O
myopathy B-NEG
has O
not O
previously O
been O
reported O
. O

in O
a O
37-year-old O
woman O
with O
documented O
pentazocine-induced O
fibrous B-NEG
myopathy I-NEG
of O
triceps O
and O
deltoid O
muscles O
bilaterally O
and O
a O
three-week O
history O
of O
right O
wrist O
drop O
, O
electrodiagnostic O
examination O
showed O
a O
severe O
but O
partial O
lesion O
of O
the O
right O
radial O
nerve O
distal O
to O
the O
branches O
to O
the O
triceps O
, O
in O
addition O
to O
the O
fibrous B-NEG
myopathy I-NEG
. O

surgery O
revealed O
the O
right O
radial O
nerve O
to O
be O
severely O
compressed O
by O
the O
densely O
fibrotic O
lateral O
head O
of O
the O
triceps O
. O

decompression O
and O
neurolysis O
were O
performed O
with O
good O
subsequent O
recovery O
of O
function O
. O

-DOCSTART- O

recurrent O
reversible O
acute B-NEG
renal I-NEG
failure I-NEG
from O
amphotericin O
. O

a O
patient O
with O
cryptogenic O
cirrhosis B-NEG
and O
disseminated O
sporotrichosis B-NEG
developed O
acute B-NEG
renal I-NEG
failure I-NEG
immediately O
following O
the O
administration O
of O
amphotericin O
b O
on O
four O
separate O
occasions O
. O

the O
abruptness O
of O
the O
renal B-NEG
failure I-NEG
and O
its O
reversibility O
within O
days O
suggests O
that O
there O
was O
a O
functional O
component O
to O
the O
renal B-NEG
dysfunction I-NEG
. O

we O
propose O
that O
amphotericin O
, O
in O
the O
setting O
of O
reduced O
effective O
arterial O
volume O
, O
may O
activate O
tubuloglomerular O
feedback O
, O
thereby O
contributing O
to O
acute B-NEG
renal I-NEG
failure I-NEG
. O

-DOCSTART- O

pneumonitis O
with O
pleural B-NEG
and I-NEG
pericardial I-NEG
effusion I-NEG
and O
neuropathy B-NEG
during O
amiodarone O
therapy O
. O

a O
patient O
with O
sinuatrial B-NEG
disease I-NEG
and O
implanted O
pacemaker O
was O
treated O
with O
amiodarone O
( O
maximum O
dose O
1000 O
mg O
, O
maintenance O
dose O
800 O
mg O
daily O
) O
for O
10 O
months O
, O
for O
control O
of O
supraventricular B-NEG
tachyarrhythmias I-NEG
. O

he O
developed O
pneumonitis B-NEG
, O
pleural B-NEG
and I-NEG
pericardial I-NEG
effusions I-NEG
, O
and O
a O
predominantly O
proximal B-NEG
motor I-NEG
neuropathy I-NEG
. O

immediate O
but O
gradual O
improvement O
followed O
withdrawal O
of O
amiodarone O
and O
treatment O
with O
prednisolone O
. O

review O
of O
this O
and O
previously O
reported O
cases O
indicates O
the O
need O
for O
early O
diagnosis O
of O
amiodarone O
pneumonitis B-NEG
, O
immediate O
withdrawal O
of O
amiodarone O
, O
and O
prompt O
but O
continued O
steroid O
therapy O
to O
ensure O
full O
recovery O
. O

-DOCSTART- O

indomethacin-induced O
renal B-NEG
insufficiency I-NEG
: O
recurrence O
on O
rechallenge O
. O

we O
have O
reported O
a O
case O
of O
acute O
oliguric O
renal B-NEG
failure I-NEG
with O
hyperkalemia B-NEG
in O
a O
patient O
with O
cirrhosis B-NEG
, O
ascites B-NEG
, O
and O
cor B-NEG
pulmonale I-NEG
after O
indomethacin O
therapy O
. O

prompt O
restoration O
of O
renal O
function O
followed O
drug O
withdrawal O
, O
while O
re-exposure O
to O
a O
single O
dose O
of O
indomethacin O
caused O
recurrence O
of O
acute O
reversible O
oliguria B-NEG
. O

our O
case O
supports O
the O
hypothesis O
that O
endogenous O
renal O
prostaglandins O
play O
a O
role O
in O
the O
maintenance O
of O
renal O
blood O
flow O
when O
circulating O
plasma O
volume O
is O
diminished O
. O

since O
nonsteroidal O
anti-inflammatory O
agents O
interfere O
with O
this O
compensatory O
mechanism O
and O
may O
cause O
acute B-NEG
renal I-NEG
failure I-NEG
, O
they O
should O
be O
used O
with O
caution O
in O
such O
patients O
. O

-DOCSTART- O

comparison O
of O
the O
subjective O
effects O
and O
plasma O
concentrations O
following O
oral O
and O
i.m O
. O
administration O
of O
flunitrazepam O
in O
volunteers O
. O

flunitrazepam O
0.5 O
, O
1.0 O
or O
2.0 O
mg O
was O
given O
by O
the O
oral O
or O
i.m O
. O
routes O
to O
groups O
of O
volunteers O
and O
its O
effects O
compared O
. O

plasma O
concentrations O
of O
the O
drug O
were O
estimated O
by O
gas-liquid O
chromatography O
, O
in O
a O
smaller O
number O
of O
the O
subjects O
. O

the O
most O
striking O
effect O
was O
sedation O
which O
increased O
with O
the O
dose O
, O
2 O
mg O
producing O
deep O
sleep O
although O
the O
subjects O
could O
still O
be O
aroused O
. O

the O
effects O
of O
i.m O
. O
administration O
were O
apparent O
earlier O
and O
sometimes O
lasted O
longer O
than O
those O
following O
oral O
administration O
. O
dizziness B-NEG
was O
less O
marked O
than O
sedation O
, O
but O
increased O
with O
the O
dose O
. O

there O
was O
pain B-NEG
on O
i.m O
. O
injection O
of O
flunitrazepam O
significantly O
more O
often O
than O
with O
isotonic O
saline O
. O

plasma O
concentrations O
varied O
with O
dose O
and O
route O
and O
corresponded O
qualitatively O
with O
the O
subjective O
effects O
. O

the O
drug O
was O
still O
present O
in O
measurable O
quantities O
after O
24 O
h O
even O
with O
the O
smallest O
dose O
. O

-DOCSTART- O

changes O
in O
heart O
size O
during O
long-term O
timolol O
treatment O
after O
myocardial B-NEG
infarction I-NEG
. O

the O
effect O
of O
long-term O
timolol O
treatment O
on O
heart O
size O
after O
myocardial B-NEG
infarction I-NEG
was O
evaluated O
by O
x-ray O
in O
a O
double-blind O
study O
including O
241 O
patients O
( O
placebo O
126 O
, O
timolol O
115) O
. O

the O
follow-up O
period O
was O
12 O
months O
. O

the O
timolol-treated O
patients O
showed O
a O
small O
but O
significant O
increase O
in O
heart O
size O
from O
baseline O
in O
contrast O
to O
a O
decrease O
in O
the O
placebo O
group O
. O

these O
differences O
may O
be O
caused O
by O
timolol-induced O
bradycardia B-NEG
and O
a O
compensatory O
increase O
in O
end-diastolic O
volume O
. O

the O
timolol-related O
increase O
in O
heart O
size O
was O
observed O
only O
in O
patients O
with O
normal O
and O
borderline O
heart O
size O
. O

in O
patients O
with O
cardiomegaly B-NEG
, O
the O
increase O
in O
heart O
size O
was O
similar O
in O
both O
groups O
. O

after O
re- O
infarction B-NEG
, O
heart O
size O
increased O
in O
the O
placebo O
group O
and O
remained O
unchanged O
in O
the O
timolol O
group O
. O

-DOCSTART- O

vitamin O
d3 O
toxicity B-NEG
in O
dairy O
cows O
. O

large O
parenteral O
doses O
of O
vitamin O
d3 O
( O
15 O
to O
17.5 O
x O
10(6 O
) O
iu O
vitamin O
d3 O
) O
were O
associated O
with O
prolonged O
hypercalcemia B-NEG
, O
hyperphosphatemia B-NEG
, O
and O
large O
increases O
of O
vitamin O
d3 O
and O
its O
metabolites O
in O
the O
blood O
plasma O
of O
nonlactating O
nonpregnant O
and O
pregnant O
jersey O
cows O
. O

calcium O
concentrations O
1 O
day O
postpartum O
were O
higher O
in O
cows O
treated O
with O
vitamin O
d3 O
about O
32 O
days O
prepartum O
( O
8.8 O
mg/100 O
ml O
) O
than O
in O
control O
cows O
( O
5.5 O
mg/100 O
ml) O
. O

none O
of O
the O
cows O
treated O
with O
vitamin O
d3 O
showed O
signs O
of O
milk B-NEG
fever I-NEG
during O
the O
peripartal O
period O
; O
however O
, O
22% O
of O
the O
control O
cows O
developed O
clinical O
signs O
of O
milk B-NEG
fever I-NEG
during O
this O
period O
. O

signs O
of O
vitamin O
d3 O
toxicity B-NEG
were O
not O
observed O
in O
nonlactating O
nonpregnant O
cows O
; O
however O
, O
pregnant O
cows O
commonly O
developed O
severe O
signs O
of O
vitamin O
d3 O
toxicity B-NEG
and O
10 O
of O
17 O
cows O
died O
. O

there O
was O
widespread O
metastatic O
calcification O
in O
the O
cows O
that O
died O
. O

because O
of O
the O
extreme O
toxicity B-NEG
of O
vitamin O
d3 O
in O
pregnant O
jersey O
cows O
and O
the O
low O
margin O
of O
safety O
between O
doses O
of O
vitamin O
d3 O
that O
prevent O
milk B-NEG
fever I-NEG
and O
doses O
that O
induce O
milk B-NEG
fever I-NEG
, O
we O
concluded O
that O
vitamin O
d3 O
cannot O
be O
used O
practically O
to O
prevent O
milk B-NEG
fever I-NEG
when O
injected O
several O
weeks O
prepartum O
. O

-DOCSTART- O

diseases B-NEG
of I-NEG
peripheral I-NEG
nerves I-NEG
as O
seen O
in O
the O
nigerian O
african O
. O

the O
anatomical O
and O
aetiological O
diagnoses O
of O
peripheral B-NEG
nerve I-NEG
disease I-NEG
excluding O
its O
primary O
benign O
and O
malignant O
disorders O
, O
as O
seen O
in O
358 O
nigerians O
are O
presented O
. O

there O
is O
a O
male O
preponderance O
and O
the O
peak O
incidence O
is O
in O
the O
fourth O
decade O
. O
sensori-motor B-NEG
neuropathy I-NEG
was O
the O
commonest O
presentation O
(50%) O
. O
guillain-barr B-NEG
syndrome I-NEG
was O
the O
commonest O
identifiable O
cause O
(15.6%) O
, O
accounting O
for O
half O
of O
the O
cases O
with O
motor B-NEG
neuropathy I-NEG
. O
peripheral B-NEG
neuropathy I-NEG
due O
to O
nutritional B-NEG
deficiency I-NEG
of O
thiamine O
and O
riboflavin O
was O
common O
( O
10.1% O
) O
and O
presented O
mainly O
as O
sensory O
and O
sensori-motor B-NEG
neuropathy I-NEG
. O
diabetes B-NEG
mellitus I-NEG
was O
the O
major O
cause O
of O
autonomic B-NEG
neuropathy I-NEG
. O

isoniazid O
was O
the O
most O
frequent O
agent O
in O
drug-induced O
neuropathy B-NEG
. O
migraine B-NEG
( O
20% O
) O
was O
not O
an O
uncommon O
cause O
of O
cranial B-NEG
neuropathy I-NEG
although O
malignancies B-NEG
arising O
from O
the O
reticuloendothelial O
system O
or O
related O
structures O
of O
the O
head O
and O
neck O
were O
more O
frequent O
(26%) O
. O

in O
26.5% O
of O
all O
the O
cases O
, O
the O
aetiology O
of O
the O
neuropathy B-NEG
was O
undetermined O
. O

heredofamilial O
and O
connective B-NEG
tissue I-NEG
disorders I-NEG
were O
rare O
. O

some O
of O
the O
factors O
related O
to O
the O
clinical O
presentation O
and O
pathogenesis O
of O
the O
neuropathies B-NEG
are O
briefly O
discussed O
. O

-DOCSTART- O

a O
double-blind O
study O
of O
the O
efficacy O
and O
safety O
of O
dothiepin O
hydrochloride O
in O
the O
treatment O
of O
major O
depressive B-NEG
disorder I-NEG
. O

in O
a O
6-week O
double-blind O
parallel O
treatment O
study O
, O
dothiepin O
and O
amitriptyline O
were O
compared O
to O
placebo O
in O
the O
treatment O
of O
33 O
depressed B-NEG
outpatients O
. O

dothiepin O
and O
amitriptyline O
were O
equally O
effective O
in O
alleviating O
the O
symptoms O
of O
depressive B-NEG
illness I-NEG
, O
and O
both O
were O
significantly O
superior O
to O
placebo O
. O

the O
overall O
incidence O
of O
side O
effects O
and O
the O
frequency O
and O
severity O
of O
blurred B-NEG
vision I-NEG
, O
dry B-NEG
mouth I-NEG
, O
and O
drowsiness O
were O
significantly O
less O
with O
dothiepin O
than O
with O
amitriptyline O
. O

dothiepin O
also O
produced O
fewer O
cns O
and O
cardiovascular O
effects O
. O

there O
were O
no O
clinically O
important O
changes O
in O
laboratory O
parameters O
. O

dothiepin O
thus O
was O
found O
to O
be O
an O
effective O
antidepressant O
drug O
associated O
with O
fewer O
side O
effects O
than O
amitriptyline O
in O
the O
treatment O
of O
depressed B-NEG
outpatients O
. O

-DOCSTART- O

behavioral O
effects O
of O
diazepam O
and O
propranolol O
in O
patients O
with O
panic B-NEG
disorder I-NEG
and O
agoraphobia B-NEG
. O

the O
effects O
of O
oral O
doses O
of O
diazepam O
( O
single O
dose O
of O
10 O
mg O
and O
a O
median O
dose O
of O
30 O
mg/day O
for O
2 O
weeks O
) O
and O
propranolol O
( O
single O
dose O
of O
80 O
mg O
and O
a O
median O
dose O
of O
240 O
mg/day O
for O
2 O
weeks O
) O
on O
psychological O
performance O
of O
patients O
with O
panic B-NEG
disorders I-NEG
and O
agoraphobia B-NEG
were O
investigated O
in O
a O
double-blind O
, O
randomized O
and O
crossover O
design O
. O

both O
drugs O
impaired B-NEG
immediate I-NEG
free I-NEG
recall I-NEG
but O
the O
decrease O
was O
greater O
for O
diazepam O
than O
propranolol O
. O
delayed B-NEG
free I-NEG
recall I-NEG
was I-NEG
also I-NEG
impaired I-NEG
but O
the O
two O
drugs O
did O
not O
differ O
. O

patients O
tapped O
faster O
after O
propranolol O
than O
diazepam O
and O
they O
were O
more O
sedated O
after O
diazepam O
than O
propranolol O
. O

after O
2 O
weeks O
of O
treatment O
, O
patients O
tested O
5-8 O
h O
after O
the O
last O
dose O
of O
medication O
did O
not O
show O
any O
decrement O
of O
performance O
. O

these O
results O
are O
similar O
to O
those O
previously O
found O
in O
healthy O
subjects O
. O

accumulation O
of O
drugs O
was O
not O
reflected O
in O
prolonged O
behavioral B-NEG
impairment I-NEG
. O

-DOCSTART- O

effect O
of O
aspirin O
on O
n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide-induced O
epithelial O
proliferation O
in O
the O
urinary O
bladder O
and O
forestomach O
of O
the O
rat O
. O

the O
co-administration O
of O
aspirin O
with O
n-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide O
( O
fanft O
) O
to O
rats O
resulted O
in O
a O
reduced O
incidence O
of O
fanft-induced O
bladder B-NEG
carcinomas I-NEG
but O
a O
concomitant O
induction O
of O
forestomach B-NEG
tumors I-NEG
. O

an O
autoradiographic O
study O
was O
performed O
on O
male O
f-344 O
rats O
fed O
diet O
containing O
fanft O
at O
a O
level O
of O
0.2% O
and/or O
aspirin O
at O
a O
level O
of O
0.5% O
to O
evaluate O
the O
effect O
of O
aspirin O
on O
the O
increased O
cell O
proliferation O
induced O
by O
fanft O
in O
the O
forestomach O
and O
bladder O
. O

fanft-induced O
cell O
proliferation O
in O
the O
bladder O
was O
significantly O
suppressed O
by O
aspirin O
co-administration O
after O
4 O
weeks O
but O
not O
after O
12 O
weeks O
. O

in O
the O
forestomach O
, O
and O
also O
in O
the O
liver O
, O
aspirin O
did O
not O
affect O
the O
fanft-induced O
increase O
in O
labeling O
index O
. O

the O
present O
results O
are O
consistent O
with O
the O
carcinogenicity O
experiment O
suggesting O
that O
different O
mechanisms O
are O
involved O
in O
fanft O
carcinogenesis B-NEG
in O
the O
bladder O
and O
forestomach O
, O
and O
that O
aspirin's O
effect O
on O
fanft O
in O
the O
forestomach O
is O
not O
due O
to O
an O
irritant O
effect O
associated O
with O
increased O
cell O
proliferation O
. O

also O
, O
there O
appears O
to O
be O
an O
adaptation O
by O
the O
rats O
to O
the O
chronic O
ingestion O
of O
aspirin O
. O

-DOCSTART- O

provocation O
of O
postural O
hypotension B-NEG
by O
nitroglycerin O
in O
diabetic B-NEG
autonomic I-NEG
neuropathy I-NEG
? O

the O
effect O
of O
nitroglycerin O
on O
heart O
rate O
and O
systolic O
blood O
pressure O
was O
compared O
in O
5 O
normal O
subjects O
, O
12 O
diabetic B-NEG
subjects O
without O
autonomic B-NEG
neuropathy I-NEG
, O
and O
5 O
diabetic B-NEG
subjects O
with O
autonomic B-NEG
neuropathy I-NEG
. O

the O
magnitude O
and O
time O
course O
of O
the O
increase O
in O
heart O
rate O
and O
the O
decrease O
in O
systolic O
blood O
pressure O
after O
nitroglycerin O
were O
similar O
in O
the O
normal O
and O
diabetic B-NEG
subjects O
without O
autonomic B-NEG
neuropathy I-NEG
, O
whereas O
a O
lesser O
increase O
in O
heart O
rate O
and O
a O
greater O
decrease O
in O
systolic O
blood O
pressure O
occurred O
in O
the O
diabetic B-NEG
subjects O
with O
autonomic B-NEG
neuropathy I-NEG
. O

it O
is O
therefore O
suggested O
that O
caution O
should O
be O
exercised O
when O
prescribing O
vasodilator O
drugs O
in O
diabetic B-NEG
patients O
, O
particularly O
those O
with O
autonomic B-NEG
neuropathy I-NEG
. O

-DOCSTART- O

characterization O
of O
estrogen-induced O
adenohypophyseal B-NEG
tumors I-NEG
in O
the O
fischer O
344 O
rat O
. O
pituitary B-NEG
tumors I-NEG
were O
induced O
in O
f344 O
female O
rats O
by O
chronic O
treatment O
with O
diethylstilbestrol O
(des O
, O
8-10 O
mg O
) O
implanted O
subcutaneously O
in O
silastic O
capsules O
. O

over O
a O
range O
of O
1-150 O
days O
of O
des O
treatment O
, O
pairs O
of O
control O
and O
des-treated O
rats O
were O
sacrificed O
, O
and O
their O
pituitaries O
dissociated O
enzymatically O
into O
single-cell O
preparations O
. O

the O
cell O
populations O
were O
examined O
regarding O
total O
cell O
recovery O
correlated O
with O
gland O
weight O
, O
intracellular O
prolactin O
( O
prl O
) O
content O
and O
subsequent O
release O
in O
primary O
culture O
, O
immunocytochemical O
prl O
staining O
, O
density O
and/or O
size O
alterations O
via O
separation O
on O
ficoll-hypaque O
and O
by O
unit O
gravity O
sedimentation O
, O
and O
cell O
cycle O
analysis O
, O
after O
acriflavine O
dna O
staining O
, O
by O
laser O
flow O
cytometry O
. O

total O
cell O
yields O
from O
des-treated O
pituitaries O
increased O
from O
1.3 O
times O
control O
yields O
at O
8 O
days O
of O
treatment O
to O
58.9 O
times O
control O
values O
by O
day O
150 O
. O

intracellular O
prl O
content O
ranged O
from O
1.9 O
to O
9.4 O
times O
control O
levels O
, O
and O
prl O
release O
in O
vitro O
was O
significantly O
and O
consistently O
higher O
than O
controls O
, O
after O
at O
least O
8 O
days O
of O
des O
exposure O
. O

beyond O
8 O
days O
of O
des O
exposure O
, O
the O
immunochemically O
prl-positive O
proportion O
of O
cells O
increased O
to O
over O
50% O
of O
the O
total O
population O
. O

increased O
density O
and/or O
size O
and O
prl O
content O
were O
indicated O
for O
the O
majority O
of O
the O
prl O
cell O
population O
in O
both O
types O
of O
separation O
protocols O
. O

all O
these O
effects O
of O
des O
were O
more O
pronounced O
among O
previously O
ovariectomized O
animals O
. O

the O
data O
extend O
the O
findings O
of O
other O
investigators O
, O
further O
establishing O
the O
des-induced O
tumor B-NEG
as O
a O
model O
for O
study O
of O
prl O
cellular O
control O
mechanisms O
. O

-DOCSTART- O

triamterene O
nephrolithiasis B-NEG
complicating O
dyazide O
therapy O
. O

a O
case O
of O
triamterene O
nephrolithiasis B-NEG
is O
reported O
in O
a O
man O
after O
4 O
years O
of O
hydrochlorothiazide-triamterene O
therapy O
for O
hypertension B-NEG
. O

the O
stone O
passed O
spontaneously O
and O
was O
found O
to O
contain O
a O
triamterene O
metabolite O
admixed O
with O
uric O
acid O
salts O
. O

factors O
affecting O
triamterene O
nephrolithiasis B-NEG
are O
discussed O
and O
2 O
previously O
reported O
cases O
are O
reviewed O
. O

-DOCSTART- O

metabolic O
involvement O
in O
adriamycin O
cardiotoxicity B-NEG
. O

the O
cardiotoxic B-NEG
effects O
of O
adriamycin O
were O
studied O
in O
mammalian O
myocardial O
cells O
in O
culture O
as O
a O
model O
system O
. O

adriamycin O
inhibited O
cell O
growth O
and O
the O
rhythmic O
contractions O
characteristic O
of O
myocardial O
cells O
in O
culture O
. O

a O
possible O
involvement O
of O
energy O
metabolism O
was O
suggested O
previously O
, O
and O
in O
this O
study O
the O
adenylate O
energy O
charge O
and O
phosphorylcreatine O
mole O
fraction O
were O
determined O
in O
the O
adriamycin-treated O
cells O
. O

the O
adenylate O
energy O
charge O
was O
found O
to O
be O
significantly O
decreased O
, O
while O
the O
phophorylcreatine O
mole O
fraction O
was O
unchanged O
. O

such O
disparity O
suggests O
an O
inhibition O
of O
creatine O
phosphokinase O
. O

the O
addition O
of O
1 O
mm O
adenosine O
to O
the O
myocardial O
cell O
cultures O
markedly O
increases O
the O
atp O
concentration O
through O
a O
pathway O
reportedly O
leading O
to O
a O
compartmentalized O
atp O
pool O
. O

in O
the O
adriamycin-treated O
cells O
, O
the O
addition O
of O
adenosine O
increased O
the O
adenylate O
charge O
and O
, O
concomitant O
with O
this O
inrcease O
, O
the O
cells' O
functional O
integrity O
, O
in O
terms O
of O
percentage O
of O
beating O
cells O
and O
rate O
of O
contractions O
, O
was O
maintained O
. O

-DOCSTART- O

age-dependent O
sensitivity O
of O
the O
rat O
to O
neurotoxic B-NEG
effects O
of O
streptomycin O
. O

streptomycin O
sulfate O
( O
300 O
mg/kg O
s.c. O
) O
was O
injected O
for O
various O
periods O
into O
preweanling O
rats O
and O
for O
3 O
weeks O
into O
weanling O
rats O
. O

beginning O
at O
8 O
days O
of O
age O
, O
body O
movement O
and O
hearing O
were O
examined O
for O
6 O
and O
up O
to O
17 O
weeks O
, O
respectively O
. O
abnormal B-NEG
movements I-NEG
and O
deafness B-NEG
occurred O
only O
in O
rats O
treated O
during O
the O
preweaning O
period O
; O
within O
this O
period O
the O
greatest O
sensitivities O
for O
these O
abnormalities O
occurred O
from O
2 O
to O
11-17 O
and O
5 O
to O
11 O
days O
of O
age O
, O
respectively O
, O
indicating O
that O
the O
cochlea O
is O
more O
sensitive O
to O
streptomycin O
than O
the O
site O
( O
vestibular O
or O
central O
) O
responsible O
for O
the O
dyskinesias B-NEG
. O

-DOCSTART- O

crescentic O
fibrillary O
glomerulonephritis B-NEG
associated O
with O
intermittent O
rifampin O
therapy O
for O
pulmonary B-NEG
tuberculosis I-NEG
. O

this O
case O
study O
reveals O
an O
unusual O
finding O
of O
rapidly O
proliferative O
crescentic O
glomerulonephritis B-NEG
in O
a O
patient O
treated O
with O
rifampin O
who O
had O
no O
other O
identifiable O
causes O
for O
developing O
this O
disease O
. O

this O
patient O
underwent O
a O
10-month O
regimen O
of O
rifampin O
and O
isoniazid O
for O
pulmonary B-NEG
tuberculosis I-NEG
and O
was O
discovered O
to O
have O
developed O
signs O
of O
severe O
renal B-NEG
failure I-NEG
five O
weeks O
after O
completion O
of O
therapy O
. O

renal O
biopsy O
revealed O
severe O
glomerulonephritis B-NEG
with O
crescents O
, O
electron O
dense O
fibrillar O
deposits O
and O
moderate O
lymphocytic O
interstitial O
infiltrate O
. O

other O
possible O
causes O
of O
rapidly O
progressive O
glomerulonephritis B-NEG
were O
investigated O
and O
ruled O
out O
. O

this O
report O
documents O
the O
unusual O
occurrence O
of O
rapidly O
progressive O
glomerulonephritis B-NEG
with O
crescents O
and O
fibrillar O
glomerulonephritis B-NEG
in O
a O
patient O
treated O
with O
rifampin O
. O

-DOCSTART- O

time O
course O
of O
lipid O
peroxidation O
in O
puromycin O
aminonucleoside-induced O
nephropathy B-NEG
. O

reactive O
oxygen O
species O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
acute O
puromycin O
aminonucleoside O
( O
pan)-induced O
nephropathy B-NEG
, O
with O
antioxidants O
significantly O
reducing O
the O
proteinuria B-NEG
. O

the O
temporal O
relationship O
between O
lipid O
peroxidation O
in O
the O
kidney O
and O
proteinuria B-NEG
was O
examined O
in O
this O
study O
. O

rats O
were O
treated O
with O
a O
single O
iv O
injection O
of O
puromycin O
aminonucleoside O
, O
(pan O
, O
7.5 O
mg/kg O
) O
and O
24 O
hour O
urine O
samples O
were O
obtained O
prior O
to O
sacrifice O
on O
days O
3,5,7,10,17,27,41 O
(n O
= O
5-10 O
per O
group) O
. O

the O
kidneys O
were O
removed O
, O
flushed O
with O
ice O
cold O
tris O
buffer O
. O

kidney O
cortices O
from O
each O
animal O
were O
used O
to O
prepare O
homogenates O
. O

tissue O
lipid O
peroxidation O
was O
measured O
in O
whole O
homogenates O
as O
well O
as O
in O
lipid O
extracts O
from O
homogenates O
as O
thiobarbituric O
acid O
reactive O
substances O
. O
proteinuria B-NEG
was O
evident O
at O
day O
5, O
peaked O
at O
day O
7 O
and O
persisted O
to O
day O
27 O
. O

lipid O
peroxidation O
in O
homogenates O
was O
maximal O
at O
day O
3 O
and O
declined O
rapidly O
to O
control O
levels O
by O
day O
17 O
. O

this O
study O
supports O
the O
role O
of O
lipid O
peroxidation O
in O
mediating O
the O
proteinuric B-NEG
injury I-NEG
in O
pan O
nephropathy B-NEG
. O

-DOCSTART- O

clomipramine-induced O
sleep B-NEG
disturbance I-NEG
does O
not O
impair O
its O
prolactin-releasing O
action O
. O

the O
present O
study O
was O
undertaken O
to O
examine O
the O
role O
of O
sleep B-NEG
disturbance I-NEG
, O
induced O
by O
clomipramine O
administration O
, O
on O
the O
secretory O
rate O
of O
prolactin O
( O
prl O
) O
in O
addition O
to O
the O
direct O
drug O
effect O
. O

two O
groups O
of O
supine O
subjects O
were O
studied O
under O
placebo-controlled O
conditions O
, O
one O
during O
the O
night O
, O
when O
sleeping O
(n O
= O
7) O
and O
the O
other O
at O
daytime O
, O
when O
awake O
(n O
= O
6) O
. O

each O
subject O
received O
a O
single O
50 O
mg O
dose O
of O
clomipramine O
given O
orally O
2 O
hours O
before O
blood O
collection O
. O

plasma O
prl O
concentrations O
were O
analysed O
at O
10 O
min O
intervals O
and O
underlying O
secretory O
rates O
calculated O
by O
a O
deconvolution O
procedure O
. O

for O
both O
experiments O
the O
drug O
intake O
led O
to O
significant O
increases O
in O
prl O
secretion O
, O
acting O
preferentially O
on O
tonic O
secretion O
as O
pulse O
amplitude O
and O
frequency O
did O
not O
differ O
significantly O
from O
corresponding O
control O
values O
. O

during O
the O
night O
clomipramine O
ingestion O
altered O
the O
complete O
sleep O
architecture O
in O
that O
it O
suppressed O
rem O
sleep O
and O
the O
sleep O
cycles O
and O
induced O
increased O
wakefulness O
. O

as O
the O
relative O
increase O
in O
prl O
secretion O
expressed O
as O
a O
percentage O
of O
the O
mean O
did O
not O
significantly O
differ O
between O
the O
night O
and O
day O
time O
studies O
( O
46 O
+/- O
19% O
vs O
34 O
+/- O
10%) O
, O
it O
can O
be O
concluded O
that O
the O
observed O
sleep B-NEG
disturbance I-NEG
did O
not O
interfere O
with O
the O
drug O
action O
per O
se O
. O

the O
presence O
of O
rem O
sleep O
was O
shown O
not O
to O
be O
a O
determining O
factor O
either O
for O
secretory O
pulse O
amplitude O
and O
frequency O
, O
as O
, O
for O
both O
, O
mean O
nocturnal O
values O
were O
similar O
with O
and O
without O
prior O
clomipramine O
ingestion O
. O

-DOCSTART- O

angioedema B-NEG
following O
the O
intravenous O
administration O
of O
metoprolol O
. O

a O
72-year-old O
woman O
was O
admitted O
to O
the O
hospital O
with O
flash O
pulmonary B-NEG
edema I-NEG
, O
preceded O
by O
chest B-NEG
pain I-NEG
, O
requiring O
intubation O
. O

her O
medical O
history O
included O
coronary B-NEG
artery I-NEG
disease I-NEG
with O
previous O
myocardial B-NEG
infarctions I-NEG
, O
hypertension B-NEG
, O
and O
diabetes B-NEG
mellitus I-NEG
. O

a O
history O
of O
angioedema B-NEG
secondary O
to O
lisinopril O
therapy O
was O
elicited O
. O

current O
medications O
did O
not O
include O
angiotensin-converting O
enzyme O
inhibitors O
or O
beta-blockers O
. O

she O
had O
no O
previous O
beta-blocking O
drug O
exposure O
. O

during O
the O
first O
day O
of O
hospitalization O
( O
while O
intubated) O
, O
intravenous O
metoprolol O
was O
given O
, O
resulting O
in O
severe O
angioedema B-NEG
. O

the O
angioedema B-NEG
resolved O
after O
therapy O
with O
intravenous O
steroids O
and O
diphenhydramine O
hydrochloride O
. O

-DOCSTART- O

effect O
of O
coniine O
on O
the O
developing O
chick O
embryo O
. O

coniine O
, O
an O
alkaloid O
from O
conium O
maculatum O
( O
poison O
hemlock) O
, O
has O
been O
shown O
to O
be O
teratogenic O
in O
livestock O
. O

the O
major O
teratogenic O
outcome O
is O
arthrogryposis B-NEG
, O
presumably O
due O
to O
nicotinic O
receptor O
blockade O
. O

however O
, O
coniine O
has O
failed O
to O
produce O
arthrogryposis B-NEG
in O
rats O
or O
mice O
and O
is O
only O
weakly O
teratogenic O
in O
rabbits O
. O

the O
purpose O
of O
this O
study O
was O
to O
evaluate O
and O
compare O
the O
effects O
of O
coniine O
and O
nicotine O
in O
the O
developing O
chick O
. O

concentrations O
of O
coniine O
and O
nicotine O
sulfate O
were O
0.015% O
, O
0.03% O
, O
0.075% O
, O
0.15% O
, O
0.75% O
, O
1.5% O
, O
3% O
, O
and O
6% O
and O
1% O
, O
5% O
, O
and O
10% O
, O
respectively O
. O

both O
compounds O
caused O
deformations B-NEG
and O
lethality O
in O
a O
dose-dependent O
manner O
. O

all O
concentrations O
of O
nicotine O
sulfate O
caused O
some O
lethality O
but O
a O
no O
effect O
level O
for O
coniine O
lethality O
was O
0.75% O
. O

the O
deformations B-NEG
caused O
by O
both O
coniine O
and O
nicotine O
sulfate O
were O
excessive B-NEG
flexion I-NEG
or I-NEG
extension I-NEG
of I-NEG
one I-NEG
or I-NEG
more I-NEG
toes I-NEG
. O

no O
histopathological O
alterations O
or O
differences O
in O
bone O
formation O
were O
seen O
in O
the O
limbs O
or O
toes O
of O
any O
chicks O
from O
any O
group O
; O
however O
, O
extensive O
cranial B-NEG
hemorrhage I-NEG
occurred O
in O
all O
nicotine O
sulfate-treated O
chicks O
. O

there O
was O
a O
statistically O
significant O
(p O
< O
or O
= O
0.01 O
) O
decrease O
in O
movement O
in O
coniine O
and O
nicotine O
sulfate O
treated O
chicks O
as O
determined O
by O
ultrasound O
. O

control O
chicks O
were O
in O
motion O
an O
average O
of O
33.67% O
of O
the O
time O
, O
while O
coniine-treated O
chicks O
were O
only O
moving O
8.95% O
of O
a O
5-min O
interval O
, O
and O
no O
movement O
was O
observed O
for O
nicotine O
sulfate O
treated O
chicks O
. O

in O
summary O
, O
the O
chick O
embryo O
provides O
a O
reliable O
and O
simple O
experimental O
animal O
model O
of O
coniine-induced O
arthrogryposis B-NEG
. O

data O
from O
this O
model O
support O
a O
mechanism O
involving O
nicotinic O
receptor O
blockade O
with O
subsequent O
decreased O
fetal O
movement O
. O

-DOCSTART- O

epidural O
blood O
flow O
during O
prostaglandin O
e1 O
or O
trimethaphan O
induced O
hypotension B-NEG
. O

to O
evaluate O
the O
effect O
of O
prostaglandin O
e1 O
( O
pge1 O
) O
or O
trimethaphan O
( O
tmp O
) O
induced O
hypotension B-NEG
on O
epidural O
blood O
flow O
( O
ebf O
) O
during O
spinal O
surgery O
, O
ebf O
was O
measured O
using O
the O
heat O
clearance O
method O
in O
30 O
patients O
who O
underwent O
postero-lateral O
interbody O
fusion O
under O
isoflurane O
anaesthesia O
. O

an O
initial O
dose O
of O
0.1 O
microgram.kg-1.min-1 O
of O
pge1 O
( O
15 O
patients) O
, O
or O
10 O
micrograms.kg-1.min-1 O
of O
tmp O
( O
15 O
patients O
) O
was O
administered O
intravenously O
after O
the O
dural O
opening O
and O
the O
dose O
was O
adjusted O
to O
maintain O
the O
mean O
arterial O
blood O
pressure O
( O
map O
) O
at O
about O
60 O
mmhg O
. O

the O
hypotensive B-NEG
drug O
was O
discontinued O
at O
the O
completion O
of O
the O
operative O
procedure O
. O

after O
starting O
pge1 O
or O
tmp O
, O
map O
and O
rate O
pressure O
product O
( O
rpp O
) O
decreased O
significantly O
compared O
with O
preinfusion O
values O
(p O
< O
0.01) O
, O
and O
the O
degree O
of O
hypotension B-NEG
due O
to O
pge1 O
remained O
constant O
until O
60 O
min O
after O
its O
discontinuation O
. O

heart O
rate O
( O
hr O
) O
did O
not O
change O
in O
either O
group O
. O

ebff O
did O
not O
change O
during O
pge1 O
infusion O
whereas O
in O
the O
tmp O
group O
, O
ebf O
decreased O
significantly O
at O
30 O
and O
60 O
min O
after O
the O
start O
of O
tmp O
(preinfusion O
: O
45.9 O
+/- O
13.9 O
ml/100g/min O
. O
30 O
min O
: O
32.3 O
+/- O
9.9 O
ml/100 O
g/min O
(p O
< O
0.05) O
. O

60 O
min O
: O
30 O
+/- O
7.5 O
ml/100 O
g/min O
(p O
< O
0.05)) O
. O

these O
results O
suggest O
that O
pge1 O
may O
be O
preferable O
to O
tmp O
for O
hypotensive B-NEG
anaesthesia O
in O
spinal O
surgery O
because O
tmp O
decreased O
ebf O
. O

-DOCSTART- O

immunohistochemical O
studies O
with O
antibodies O
to O
neurofilament O
proteins O
on O
axonal B-NEG
damage I-NEG
in O
experimental O
focal O
lesions O
in O
rat O
. O

immunohistochemistry O
with O
monoclonal O
antibodies O
against O
neurofilament O
( O
nf O
) O
proteins O
of O
middle O
and O
high O
molecular O
weight O
class O
, O
nf-m O
and O
nf-h O
, O
was O
used O
to O
study O
axonal B-NEG
injury I-NEG
in O
the O
borderzone O
of O
focal O
lesions O
in O
rats O
. O

focal O
injury B-NEG
in I-NEG
the I-NEG
cortex I-NEG
was O
produced O
by O
infusion O
of O
lactate O
at O
acid O
ph O
or O
by O
stab O
caused O
by O
needle O
insertion O
. O
infarcts B-NEG
in I-NEG
substantia I-NEG
nigra I-NEG
pars I-NEG
reticulata I-NEG
were O
evoked O
by O
prolonged O
pilocarpine-induced O
status B-NEG
epilepticus I-NEG
. O

immunohistochemical O
staining O
for O
nfs O
showed O
characteristic O
terminal O
clubs O
of O
axons O
in O
the O
borderzone O
of O
lesions O
. O

differences O
in O
the O
labelling O
pattern O
occurred O
with O
different O
antibodies O
which O
apparently O
depended O
on O
molecular O
weight O
class O
of O
nfs O
and O
phosphorylation O
state O
. O

these O
immunohistochemical O
changes O
of O
nfs O
can O
serve O
as O
a O
marker O
for O
axonal B-NEG
damage I-NEG
in O
various O
experimental O
traumatic B-NEG
or O
ischemic O
lesions O
. O

-DOCSTART- O

increase O
of O
parkinson B-NEG
disability I-NEG
after O
fluoxetine O
medication O
. O
depression B-NEG
is O
a O
major O
clinical O
feature O
of O
parkinson's B-NEG
disease I-NEG
. O

we O
report O
the O
increased O
amount O
of O
motor B-NEG
disability I-NEG
in O
four O
patients O
with O
idiopathic B-NEG
parkinson's I-NEG
disease I-NEG
after O
exposure O
to O
the O
antidepressant O
fluoxetine O
. O

the O
possibility O
of O
a O
clinically O
relevant O
dopamine-antagonistic O
capacity O
of O
fluoxetine O
in O
parkinson's B-NEG
disease I-NEG
patients O
must O
be O
considered O
. O

-DOCSTART- O

acetaminophen-induced O
hypotension B-NEG
. O

through O
30 O
years O
of O
widespread O
use O
, O
acetaminophen O
has O
been O
shown O
to O
be O
a O
remarkably O
safe O
medication O
in O
therapeutic O
dosages O
. O

the O
potential O
for O
acetaminophen O
to O
produce O
cardiovascular B-NEG
toxicities I-NEG
is O
very O
low O
. O

however O
, O
acetaminophen O
has O
been O
demonstrated O
to O
produce O
symptoms O
of O
anaphylaxis B-NEG
, O
including O
hypotension B-NEG
, O
in O
sensitive O
individuals O
. O

this O
article O
describes O
two O
critically B-NEG
ill I-NEG
patients O
in O
whom O
transient O
episodes O
of O
hypotension B-NEG
reproducibly O
developed O
after O
administration O
of O
acetaminophen O
. O

other O
symptoms O
of O
allergic B-NEG
reactions I-NEG
were O
not O
clinically O
detectable O
. O

the O
hypotensive B-NEG
episodes O
were O
severe O
enough O
to O
require O
vasopressor O
administration O
. O

the O
reports O
illustrate O
the O
need O
for O
clinicians O
to O
consider O
acetaminophen O
in O
patients O
with O
hypotension B-NEG
of O
unknown O
origin O
. O

-DOCSTART- O

acute O
hepatitis B-NEG
, O
autoimmune B-NEG
hemolytic I-NEG
anemia I-NEG
, O
and O
erythroblastocytopenia B-NEG
induced O
by O
ceftriaxone O
. O

an O
80-yr-old O
man O
developed O
acute O
hepatitis B-NEG
shortly O
after O
ingesting O
oral O
ceftriaxone O
. O

although O
the O
transaminases O
gradually O
returned O
to O
baseline O
after O
withholding O
the O
beta O
lactam O
antibiotic O
, O
there O
was O
a O
gradual O
increase O
in O
serum O
bilirubin O
and O
a O
decrease O
in O
hemoglobin O
concentration O
caused O
by O
an O
autoimmune B-NEG
hemolytic I-NEG
anemia I-NEG
and O
erythroblastocytopenia B-NEG
. O

these O
responded O
to O
systemic O
steroids O
and O
immunoglobulins O
. O

despite O
the O
widespread O
use O
of O
these O
agents O
this O
triad O
of O
side O
effects O
has O
not O
previously O
been O
reported O
in O
connection O
with O
beta O
lactam O
antibiotics O
. O

-DOCSTART- O

adverse O
effects O
of O
the O
atypical O
antipsychotics O
. O

collaborative O
working O
group O
on O
clinical O
trial O
evaluations O
. O

adverse O
effects O
of O
antipsychotics O
often O
lead O
to O
noncompliance O
. O

thus O
, O
clinicians O
should O
address O
patients' O
concerns O
about O
adverse O
effects O
and O
attempt O
to O
choose O
medications O
that O
will O
improve O
their O
patients' O
quality O
of O
life O
as O
well O
as O
overall O
health O
. O

the O
side O
effect O
profiles O
of O
the O
atypical O
antipsychotics O
are O
more O
advantageous O
than O
those O
of O
the O
conventional O
neuroleptics O
. O

conventional O
agents O
are O
associated O
with O
unwanted O
central O
nervous O
system O
effects O
, O
including O
extrapyramidal B-NEG
symptoms I-NEG
( O
eps B-NEG
), O
tardive B-NEG
dyskinesia I-NEG
, O
sedation O
, O
and O
possible O
impairment O
of O
some O
cognitive O
measures O
, O
as O
well O
as O
cardiac O
effects O
, O
orthostatic B-NEG
hypotension I-NEG
, O
hepatic O
changes O
, O
anticholinergic O
side O
effects O
, O
sexual B-NEG
dysfunction I-NEG
, O
and O
weight B-NEG
gain I-NEG
. O

the O
newer O
atypical O
agents O
have O
a O
lower O
risk O
of O
eps B-NEG
, O
but O
are O
associated O
in O
varying O
degrees O
with O
sedation O
, O
cardiovascular O
effects O
, O
anticholinergic O
effects O
, O
weight B-NEG
gain I-NEG
, O
sexual B-NEG
dysfunction I-NEG
, O
hepatic O
effects O
, O
lowered O
seizure B-NEG
threshold O
( O
primarily O
clozapine) O
, O
and O
agranulocytosis B-NEG
( O
clozapine O
only) O
. O

since O
the O
incidence O
and O
severity O
of O
specific O
adverse O
effects O
differ O
among O
the O
various O
atypicals O
, O
the O
clinician O
should O
carefully O
consider O
which O
side O
effects O
are O
most O
likely O
to O
lead O
to O
the O
individual's O
dissatisfaction O
and O
noncompliance O
before O
choosing O
an O
antipsychotic O
for O
a O
particular O
patient O
. O

-DOCSTART- O

effects O
of O
tetrandrine O
and O
fangchinoline O
on O
experimental O
thrombosis B-NEG
in O
mice O
and O
human O
platelet B-NEG
aggregation I-NEG
. O

tetrandrine O
( O
tet O
) O
and O
fangchinoline O
( O
fan O
) O
are O
two O
naturally O
occurring O
analogues O
with O
a O
bisbenzylisoquinoline O
structure O
. O

the O
present O
study O
was O
undertaken O
to O
investigate O
the O
effects O
of O
tet O
and O
fan O
on O
the O
experimental O
thrombosis B-NEG
induced O
by O
collagen O
plus O
epinephrine O
( O
ep O
) O
in O
mice O
, O
and O
platelet B-NEG
aggregation I-NEG
and O
blood B-NEG
coagulation I-NEG
in O
vitro O
. O

in O
the O
in O
vivo O
study O
, O
the O
administration O
( O
50 O
mg/kg O
, O
i.p. O
) O
of O
tet O
and O
fan O
in O
mice O
showed O
the O
inhibition O
of O
thrombosis B-NEG
by O
55% O
and O
35% O
, O
respectively O
, O
while O
acetylsalicylic O
acid O
(asa O
, O
50 O
mg/kg O
, O
i.p.) O
, O
a O
positive O
control O
, O
showed O
only O
30% O
inhibition O
. O

in O
the O
vitro O
human O
platelet B-NEG
aggregations I-NEG
induced O
by O
the O
agonists O
used O
in O
tests O
, O
tet O
and O
fan O
showed O
the O
inhibitions O
dose O
dependently O
. O

in O
addition O
, O
neither O
tet O
nor O
fan O
showed O
any O
anticoagulation O
activities O
in O
the O
measurement O
of O
the O
activated O
partial O
thromboplastin O
time O
(aptt) O
, O
prothrombin O
time O
( O
pt O
) O
and O
thrombin O
time O
( O
tt O
) O
using O
human-citrated O
plasma O
. O

these O
results O
suggest O
that O
antithrombosis O
of O
tet O
and O
fan O
in O
mice O
may O
be O
mainly O
related O
to O
the O
antiplatelet O
aggregation O
activities O
. O

-DOCSTART- O

gemcitabine O
plus O
vinorelbine O
in O
nonsmall B-NEG
cell I-NEG
lung I-NEG
carcinoma I-NEG
patients O
age O
70 O
years O
or O
older O
or O
patients O
who O
cannot O
receive O
cisplatin O
. O

oncopaz O
cooperative O
group O
. O

background O
: O
although O
the O
prevalence O
of O
nonsmall B-NEG
cell I-NEG
lung I-NEG
carcinoma I-NEG
( O
nsclc B-NEG
) O
is O
high O
among O
elderly O
patients O
, O
few O
data O
are O
available O
regarding O
the O
efficacy O
and O
toxicity B-NEG
of O
chemotherapy O
in O
this O
group O
of O
patients O
. O

recent O
reports O
indicate O
that O
single O
agent O
therapy O
with O
vinorelbine O
( O
vnb O
) O
or O
gemcitabine O
( O
gem O
) O
may O
obtain O
a O
response O
rate O
of O
20-30% O
in O
elderly O
patients O
, O
with O
acceptable O
toxicity B-NEG
and O
improvement O
in O
symptoms O
and O
quality O
of O
life O
. O

in O
the O
current O
study O
the O
efficacy O
and O
toxicity B-NEG
of O
the O
combination O
of O
gem O
and O
vnb O
in O
elderly O
patients O
with O
advanced O
nsclc B-NEG
or O
those O
with O
some O
contraindication O
to O
receiving O
cisplatin O
were O
assessed O
. O

methods O
: O
forty-nine O
patients O
with O
advanced O
nsclc B-NEG
were O
included O
, O
38 O
of O
whom O
were O
age O
>/= O
70 O
years O
and O
11 O
were O
age O
< O
70 O
years O
but O
who O
had O
some O
contraindication O
to O
receiving O
cisplatin O
. O

all O
patients O
were O
evaluable O
for O
response O
and O
toxicity B-NEG
. O

treatment O
was O
comprised O
of O
vnb O
, O
25 O
mg/m(2) O
, O
plus O
gem O
, O
1000 O
mg/m(2) O
, O
both O
on O
days O
1, O
8, O
and O
15 O
every O
28 O
days O
. O

patients O
received O
a O
minimum O
of O
three O
courses O
unless O
progressive O
disease O
was O
detected O
. O

results O
: O
one O
hundred O
sixty-five O
courses O
were O
administered O
, O
with O
a O
median O
of O
3. O

6 O
courses O
per O
patient O
. O

the O
overall O
response O
rate O
was O
26% O
( O
95% O
confidence O
interval O
, O
15-41%) O
. O

two O
patients O
attained O
a O
complete O
response O
( O
4% O
) O
and O
11 O
patients O
( O
22% O
) O
achieved O
a O
partial O
response O
. O

eastern O
cooperative O
oncology O
group O
performance O
status O
improved O
in O
35% O
of O
those O
patients O
with O
an O
initial O
value O
> O
0, O
whereas O
relief O
of O
at O
least O
1 O
symptom O
without O
worsening O
of O
other O
symptoms O
was O
noted O
in O
27 O
patients O
(55%) O
. O

the O
median O
time O
to O
progression O
was O
16 O
weeks O
and O
the O
1-year O
survival O
rate O
was O
33% O
. O
toxicity B-NEG
was O
mild O
. O

six O
patients O
( O
12% O
) O
had O
world O
health O
organization O
grade O
3-4 O
neutropenia B-NEG
, O
2 O
patients O
( O
4% O
) O
had O
grade O
3-4 O
thrombocytopenia B-NEG
, O
and O
2 O
patients O
( O
4% O
) O
had O
grade O
3 O
neurotoxicity B-NEG
. O

three O
patients O
with O
severe O
neutropenia B-NEG
( O
6% O
) O
died O
of O
sepsis B-NEG
. O

the O
median O
age O
of O
those O
patients O
developing O
grade O
3-4 O
neutropenia B-NEG
was O
significantly O
higher O
than O
that O
of O
the O
remaining O
patients O
( O
75 O
years O
vs O
. O
72 O
years O
; O
p O
= O
0.047) O
. O

conclusions O
: O
the O
combination O
of O
gem O
and O
vnb O
is O
moderately O
active O
and O
well O
tolerated O
except O
in O
patients O
age O
>/= O
75 O
years O
. O

this O
age O
group O
had O
an O
increased O
risk O
of O
myelosuppression B-NEG
. O

therefore O
the O
prophylactic O
use O
of O
granulocyte-colony O
stimulating O
factor O
should O
be O
considered O
with O
this O
treatment O
. O

new O
chemotherapy O
combinations O
with O
higher O
activity O
and O
lower O
toxicity B-NEG
are O
needed O
for O
elderly O
patients O
with O
advanced O
nsclc B-NEG
. O

-DOCSTART- O

warfarin-induced O
artery B-NEG
calcification I-NEG
is O
accelerated O
by O
growth O
and O
vitamin O
d. O

the O
present O
studies O
demonstrate O
that O
growth O
and O
vitamin O
d O
treatment O
enhance O
the O
extent O
of O
artery B-NEG
calcification I-NEG
in O
rats O
given O
sufficient O
doses O
of O
warfarin O
to O
inhibit O
gamma-carboxylation O
of O
matrix O
gla O
protein O
, O
a O
calcification B-NEG
inhibitor O
known O
to O
be O
expressed O
by O
smooth O
muscle O
cells O
and O
macrophages O
in O
the O
artery O
wall O
. O

the O
first O
series O
of O
experiments O
examined O
the O
influence O
of O
age O
and O
growth O
status O
on O
artery B-NEG
calcification I-NEG
in O
warfarin-treated O
rats O
. O

treatment O
for O
2 O
weeks O
with O
warfarin O
caused O
massive O
focal O
calcification B-NEG
of I-NEG
the I-NEG
artery I-NEG
media O
in O
20-day-old O
rats O
and O
less O
extensive O
focal O
calcification B-NEG
in O
42-day-old O
rats O
. O

in O
contrast O
, O
no O
artery B-NEG
calcification I-NEG
could O
be O
detected O
in O
10-month-old O
adult O
rats O
even O
after O
4 O
weeks O
of O
warfarin O
treatment O
. O

to O
directly O
examine O
the O
importance O
of O
growth O
to O
warfarin-induced O
artery B-NEG
calcification I-NEG
in O
animals O
of O
the O
same O
age O
, O
20-day-old O
rats O
were O
fed O
for O
2 O
weeks O
either O
an O
ad O
libitum O
diet O
or O
a O
6-g/d O
restricted O
diet O
that O
maintains O
weight O
but O
prevents O
growth O
. O

concurrent O
treatment O
of O
both O
dietary O
groups O
with O
warfarin O
produced O
massive O
focal O
calcification B-NEG
of I-NEG
the I-NEG
artery I-NEG
media O
in O
the O
ad O
libitum-fed O
rats O
but O
no O
detectable O
artery B-NEG
calcification I-NEG
in O
the O
restricted-diet O
, O
growth-inhibited O
group O
. O

although O
the O
explanation O
for O
the O
association O
between O
artery B-NEG
calcification I-NEG
and O
growth O
status O
cannot O
be O
determined O
from O
the O
present O
study O
, O
there O
was O
a O
relationship O
between O
higher O
serum O
phosphate O
and O
susceptibility O
to O
artery B-NEG
calcification I-NEG
, O
with O
30% O
higher O
levels O
of O
serum O
phosphate O
in O
young O
, O
ad O
libitum-fed O
rats O
compared O
with O
either O
of O
the O
groups O
that O
was O
resistant O
to O
warfarin-induced O
artery B-NEG
calcification I-NEG
, O
ie O
, O
the O
10-month-old O
rats O
and O
the O
restricted-diet O
, O
growth-inhibited O
young O
rats O
. O

this O
observation O
suggests O
that O
increased O
susceptibility O
to O
warfarin-induced O
artery B-NEG
calcification I-NEG
could O
be O
related O
to O
higher O
serum O
phosphate O
levels O
. O

the O
second O
set O
of O
experiments O
examined O
the O
possible O
synergy O
between O
vitamin O
d O
and O
warfarin O
in O
artery B-NEG
calcification I-NEG
. O

high O
doses O
of O
vitamin O
d O
are O
known O
to O
cause O
calcification B-NEG
of I-NEG
the I-NEG
artery I-NEG
media O
in O
as O
little O
as O
3 O
to O
4 O
days O
. O

high O
doses O
of O
the O
vitamin O
k O
antagonist O
warfarin O
are O
also O
known O
to O
cause O
calcification B-NEG
of I-NEG
the I-NEG
artery I-NEG
media O
, O
but O
at O
treatment O
times O
of O
2 O
weeks O
or O
longer O
yet O
not O
at O
1 O
week O
. O

in O
the O
current O
study O
, O
we O
investigated O
the O
synergy O
between O
these O
2 O
treatments O
and O
found O
that O
concurrent O
warfarin O
administration O
dramatically O
increased O
the O
extent O
of O
calcification B-NEG
in O
the O
media O
of O
vitamin O
d-treated O
rats O
at O
3 O
and O
4 O
days O
. O

there O
was O
a O
close O
parallel O
between O
the O
effect O
of O
vitamin O
d O
dose O
on O
artery B-NEG
calcification I-NEG
and O
the O
effect O
of O
vitamin O
d O
dose O
on O
the O
elevation O
of O
serum O
calcium O
, O
which O
suggests O
that O
vitamin O
d O
may O
induce O
artery B-NEG
calcification I-NEG
through O
its O
effect O
on O
serum O
calcium O
. O

because O
warfarin O
treatment O
had O
no O
effect O
on O
the O
elevation O
in O
serum O
calcium O
produced O
by O
vitamin O
d, O
the O
synergy O
between O
warfarin O
and O
vitamin O
d O
is O
probably O
best O
explained O
by O
the O
hypothesis O
that O
warfarin O
inhibits O
the O
activity O
of O
matrix O
gla O
protein O
as O
a O
calcification B-NEG
inhibitor O
. O

high O
levels O
of O
matrix O
gla O
protein O
are O
found O
at O
sites O
of O
artery B-NEG
calcification I-NEG
in O
rats O
treated O
with O
vitamin O
d O
plus O
warfarin O
, O
and O
chemical O
analysis O
showed O
that O
the O
protein O
that O
accumulated O
was O
indeed O
not O
gamma-carboxylated O
. O

these O
observations O
indicate O
that O
although O
the O
gamma-carboxyglutamate O
residues O
of O
matrix O
gla O
protein O
are O
apparently O
required O
for O
its O
function O
as O
a O
calcification B-NEG
inhibitor O
, O
they O
are O
not O
required O
for O
its O
accumulation O
at O
calcification B-NEG
sites O
. O

-DOCSTART- O

antidepressant-induced O
mania B-NEG
in O
bipolar B-NEG
patients O
: O
identification O
of O
risk O
factors O
. O

background O
: O
concerns O
about O
possible O
risks O
of O
switching O
to O
mania B-NEG
associated O
with O
antidepressants O
continue O
to O
interfere O
with O
the O
establishment O
of O
an O
optimal O
treatment O
paradigm O
for O
bipolar B-NEG
depression I-NEG
. O

method O
: O
the O
response O
of O
44 O
patients O
meeting O
dsm-iv O
criteria O
for O
bipolar B-NEG
disorder I-NEG
to O
naturalistic O
treatment O
was O
assessed O
for O
at O
least O
6 O
weeks O
using O
the O
montgomery-asberg O
depression O
rating O
scale O
and O
the O
bech-rafaelson O
mania O
rating O
scale O
. O

patients O
who O
experienced O
a O
manic B-NEG
or O
hypomanic B-NEG
switch O
were O
compared O
with O
those O
who O
did O
not O
on O
several O
variables O
including O
age O
, O
sex O
, O
diagnosis O
( O
dsm-iv B-NEG
bipolar I-NEG
i I-NEG
vs O
. O
bipolar B-NEG
ii I-NEG
), O
number O
of O
previous O
manic B-NEG
episodes O
, O
type O
of O
antidepressant O
therapy O
used O
( O
electroconvulsive O
therapy O
vs O
. O
antidepressant O
drugs O
and O
, O
more O
particularly O
, O
selective O
serotonin O
reuptake O
inhibitors O
[ssris]) O
, O
use O
and O
type O
of O
mood O
stabilizers O
( O
lithium O
vs O
. O
anticonvulsants) O
, O
and O
temperament O
of O
the O
patient O
, O
assessed O
during O
a O
normothymic O
period O
using O
the O
hyperthymia O
component O
of O
the O
semi-structured O
affective O
temperament O
interview O
. O

results O
: O
switches O
to O
hypomania B-NEG
or O
mania B-NEG
occurred O
in O
27% O
of O
all O
patients O
(n O
= O
12 O
) O
( O
and O
in O
24% O
of O
the O
subgroup O
of O
patients O
treated O
with O
ssris O
[8/33]) O
; O
16% O
(n O
= O
7) O
experienced O
manic B-NEG
episodes O
, O
and O
11% O
(n O
= O
5) O
experienced O
hypomanic B-NEG
episodes O
. O

sex O
, O
age O
, O
diagnosis O
( O
bipolar B-NEG
i I-NEG
vs O
. O
bipolar B-NEG
ii I-NEG
), O
and O
additional O
treatment O
did O
not O
affect O
the O
risk O
of O
switching O
. O

the O
incidence O
of O
mood O
switches O
seemed O
not O
to O
differ O
between O
patients O
receiving O
an O
anticonvulsant O
and O
those O
receiving O
no O
mood O
stabilizer O
. O

in O
contrast O
, O
mood O
switches O
were O
less O
frequent O
in O
patients O
receiving O
lithium O
(15% O
, O
4/26 O
) O
than O
in O
patients O
not O
treated O
with O
lithium O
(44% O
, O
8/18 O
; O
p O
= O
.04) O
. O

the O
number O
of O
previous O
manic B-NEG
episodes O
did O
not O
affect O
the O
probability O
of O
switching O
, O
whereas O
a O
high O
score O
on O
the O
hyperthymia O
component O
of O
the O
semistructured O
affective O
temperament O
interview O
was O
associated O
with O
a O
greater O
risk O
of O
switching O
(p O
= O
.008) O
. O

conclusion O
: O
the O
frequency O
of O
mood O
switching O
associated O
with O
acute O
antidepressant O
therapy O
may O
be O
reduced O
by O
lithium O
treatment O
. O

particular O
attention O
should O
be O
paid O
to O
patients O
with O
a O
hyperthymic O
temperament O
, O
who O
have O
a O
greater O
risk O
of O
mood O
switches O
. O

-DOCSTART- O

caffeine-induced O
cardiac B-NEG
arrhythmia I-NEG
: O
an O
unrecognised O
danger O
of O
healthfood O
products O
. O

we O
describe O
a O
25-year-old O
woman O
with O
pre-existing O
mitral B-NEG
valve I-NEG
prolapse I-NEG
who O
developed O
intractable O
ventricular B-NEG
fibrillation I-NEG
after O
consuming O
a O
natural O
energy O
guarana O
health O
drink O
containing O
a O
high O
concentration O
of O
caffeine O
. O

this O
case O
highlights O
the O
need O
for O
adequate O
labelling O
and O
regulation O
of O
such O
products O
. O

-DOCSTART- O

bladder O
retention B-NEG
of I-NEG
urine I-NEG
as O
a O
result O
of O
continuous O
intravenous O
infusion O
of O
fentanyl O
: O
2 O
case O
reports O
. O

sedation O
has O
been O
commonly O
used O
in O
the O
neonate O
to O
decrease O
the O
stress O
and O
pain B-NEG
from O
the O
noxious O
stimuli O
and O
invasive O
procedures O
in O
the O
neonatal O
intensive O
care O
unit O
, O
as O
well O
as O
to O
facilitate O
synchrony O
between O
ventilator O
and O
spontaneous O
breaths O
. O

fentanyl O
, O
an O
opioid O
analgesic O
, O
is O
frequently O
used O
in O
the O
neonatal O
intensive O
care O
unit O
setting O
for O
these O
very O
purposes O
. O

various O
reported O
side O
effects O
of O
fentanyl O
administration O
include O
chest B-NEG
wall I-NEG
rigidity I-NEG
, O
hypotension B-NEG
, O
respiratory B-NEG
depression I-NEG
, O
and O
bradycardia B-NEG
. O

here O
, O
2 O
cases O
of O
urinary B-NEG
bladder I-NEG
retention I-NEG
leading O
to O
renal O
pelvocalyceal O
dilatation O
mimicking O
hydronephrosis B-NEG
as O
a O
result O
of O
continuous O
infusion O
of O
fentanyl O
are O
reported O
. O

-DOCSTART- O

combined O
antiretroviral O
therapy O
causes O
cardiomyopathy B-NEG
and O
elevates O
plasma O
lactate O
in O
transgenic O
aids B-NEG
mice O
. O

highly O
active O
antiretroviral O
therapy O
( O
haart O
) O
is O
implicated O
in O
cardiomyopathy B-NEG
( O
cm B-NEG
) O
and O
in O
elevated O
plasma O
lactate O
( O
la O
) O
in O
aids B-NEG
through O
mechanisms O
of O
mitochondrial B-NEG
dysfunction I-NEG
. O

to O
determine O
mitochondrial O
events O
from O
haart O
in O
vivo O
, O
8-week-old O
hemizygous O
transgenic O
aids B-NEG
mice O
( O
nl4-3delta O
gag/pol O
; O
tg O
) O
and O
wild-type O
fvb/n O
littermates O
were O
treated O
with O
the O
haart O
combination O
of O
zidovudine O
, O
lamivudine O
, O
and O
indinavir O
or O
vehicle O
control O
for O
10 O
days O
or O
35 O
days O
. O

at O
termination O
of O
the O
experiments O
, O
mice O
underwent O
echocardiography O
, O
quantitation O
of O
abundance O
of O
molecular O
markers O
of O
cm B-NEG
( O
ventricular O
mrna O
encoding O
atrial O
natriuretic O
factor O
[anf] O
and O
sarcoplasmic O
calcium O
atpase O
[serca2]) O
, O
and O
determination O
of O
plasma O
la O
. O

myocardial O
histologic O
features O
were O
analyzed O
semiquantitatively O
and O
results O
were O
confirmed O
by O
transmission O
electron O
microscopy O
. O

after O
35 O
days O
in O
the O
tg O
+ O
haart O
cohort O
, O
left O
ventricular O
mass O
increased O
160% O
by O
echocardiography O
. O

molecularly O
, O
anf O
mrna O
increased O
250% O
and O
serca2 O
mrna O
decreased O
57% O
. O

biochemically O
, O
la O
was O
elevated O
( O
8.5 O
+/- O
2.0 O
mm) O
. O

pathologically O
, O
granular O
cytoplasmic O
changes O
were O
found O
in O
cardiac O
myocytes O
, O
indicating O
enlarged O
, O
damaged O
mitochondria O
. O

findings O
were O
confirmed O
ultrastructurally O
. O

no O
changes O
were O
found O
in O
other O
cohorts O
. O

after O
10 O
days O
, O
only O
anf O
was O
elevated O
, O
and O
only O
in O
the O
tg O
+ O
haart O
cohort O
. O

results O
show O
that O
cumulative O
haart O
caused O
mitochondrial O
cm B-NEG
with O
elevated O
la O
in O
aids B-NEG
transgenic O
mice O
. O

-DOCSTART- O

oral O
contraceptives O
and O
the O
risk O
of O
myocardial B-NEG
infarction I-NEG
. O

background O
: O
an O
association O
between O
the O
use O
of O
oral O
contraceptives O
and O
the O
risk O
of O
myocardial B-NEG
infarction I-NEG
has O
been O
found O
in O
some O
, O
but O
not O
all O
, O
studies O
. O

we O
investigated O
this O
association O
, O
according O
to O
the O
type O
of O
progestagen O
included O
in O
third-generation O
(i.e. O
, O
desogestrel O
or O
gestodene O
) O
and O
second-generation O
(i.e. O
, O
levonorgestrel O
) O
oral O
contraceptives O
, O
the O
dose O
of O
estrogen O
, O
and O
the O
presence O
or O
absence O
of O
prothrombotic O
mutations O
methods O
: O
in O
a O
nationwide O
, O
population-based O
, O
case-control O
study O
, O
we O
identified O
and O
enrolled O
248 O
women O
18 O
through O
49 O
years O
of O
age O
who O
had O
had O
a O
first O
myocardial B-NEG
infarction I-NEG
between O
1990 O
and O
1995 O
and O
925 O
control O
women O
who O
had O
not O
had O
a O
myocardial B-NEG
infarction I-NEG
and O
who O
were O
matched O
for O
age O
, O
calendar O
year O
of O
the O
index O
event O
, O
and O
area O
of O
residence O
. O

subjects O
supplied O
information O
on O
oral-contraceptive O
use O
and O
major O
cardiovascular O
risk O
factors O
. O

an O
analysis O
for O
factor O
v O
leiden O
and O
the O
g20210a O
mutation O
in O
the O
prothrombin O
gene O
was O
conducted O
in O
217 O
patients O
and O
763 O
controls O
results O
: O
the O
odds O
ratio O
for O
myocardial B-NEG
infarction I-NEG
among O
women O
who O
used O
any O
type O
of O
combined O
oral O
contraceptive O
, O
as O
compared O
with O
nonusers O
, O
was O
2.0 O
( O
95 O
percent O
confidence O
interval O
, O
1.5 O
to O
2.8) O
. O

the O
adjusted O
odds O
ratio O
was O
2.5 O
( O
95 O
percent O
confidence O
interval O
, O
1.5 O
to O
4.1 O
) O
among O
women O
who O
used O
second-generation O
oral O
contraceptives O
and O
1.3 O
( O
95 O
percent O
confidence O
interval O
, O
0.7 O
to O
2.5 O
) O
among O
those O
who O
used O
third-generation O
oral O
contraceptives O
. O

among O
women O
who O
used O
oral O
contraceptives O
, O
the O
odds O
ratio O
was O
2.1 O
( O
95 O
percent O
confidence O
interval O
, O
1.5 O
to O
3.0 O
) O
for O
those O
without O
a O
prothrombotic O
mutation O
and O
1.9 O
( O
95 O
percent O
confidence O
interval O
, O
0.6 O
to O
5.5 O
) O
for O
those O
with O
a O
mutation O
conclusions O
: O
the O
risk O
of O
myocardial B-NEG
infarction I-NEG
was O
increased O
among O
women O
who O
used O
second-generation O
oral O
contraceptives O
. O

the O
results O
with O
respect O
to O
the O
use O
of O
third-generation O
oral O
contraceptives O
were O
inconclusive O
but O
suggested O
that O
the O
risk O
was O
lower O
than O
the O
risk O
associated O
with O
second-generation O
oral O
contraceptives O
. O

the O
risk O
of O
myocardial B-NEG
infarction I-NEG
was O
similar O
among O
women O
who O
used O
oral O
contraceptives O
whether O
or O
not O
they O
had O
a O
prothrombotic O
mutation O
. O

-DOCSTART- O

effects O
of O
5-ht1b O
receptor O
ligands O
microinjected O
into O
the O
accumbal O
shell O
or O
core O
on O
the O
cocaine-induced O
locomotor B-NEG
hyperactivity I-NEG
in O
rats O
. O

the O
present O
study O
was O
designed O
to O
examine O
the O
effect O
of O
5-ht1b O
receptor O
ligands O
microinjected O
into O
the O
subregions O
of O
the O
nucleus O
accumbens O
( O
the O
shell O
and O
the O
core O
) O
on O
the O
locomotor B-NEG
hyperactivity I-NEG
induced O
by O
cocaine O
in O
rats O
. O

male O
wistar O
rats O
were O
implanted O
bilaterally O
with O
cannulae O
into O
the O
accumbens O
shell O
or O
core O
, O
and O
then O
were O
locally O
injected O
with O
gr O
55562 O
( O
an O
antagonist O
of O
5-ht1b O
receptors O
) O
or O
cp O
93129 O
( O
an O
agonist O
of O
5-ht1b O
receptors) O
. O

given O
alone O
to O
any O
accumbal O
subregion O
, O
gr O
55562 O
( O
0.1-10 O
microg/side O
) O
or O
cp O
93129 O
( O
0.1-10 O
microg/side O
) O
did O
not O
change O
basal O
locomotor O
activity O
. O

systemic O
cocaine O
( O
10 O
mg/kg O
) O
significantly O
increased O
the O
locomotor O
activity O
of O
rats O
. O

gr O
55562 O
( O
0.1-10 O
microg/side) O
, O
administered O
intra-accumbens O
shell O
prior O
to O
cocaine O
, O
dose-dependently O
attenuated O
the O
psychostimulant-induced O
locomotor B-NEG
hyperactivity I-NEG
. O

such O
attenuation O
was O
not O
found O
in O
animals O
which O
had O
been O
injected O
with O
gr O
55562 O
into O
the O
accumbens O
core O
. O

when O
injected O
into O
the O
accumbens O
shell O
( O
but O
not O
the O
core O
) O
before O
cocaine O
, O
cp O
93129 O
( O
0.1-10 O
microg/side O
) O
enhanced O
the O
locomotor O
response O
to O
cocaine O
; O
the O
maximum O
effect O
being O
observed O
after O
10 O
microg/side O
of O
the O
agonist O
. O

the O
later O
enhancement O
was O
attenuated O
after O
intra-accumbens O
shell O
treatment O
with O
gr O
55562 O
(1 O
microg/side) O
. O

our O
findings O
indicate O
that O
cocaine O
induced O
hyperlocomotion B-NEG
is O
modified O
by O
5-ht1b O
receptor O
ligands O
microinjected O
into O
the O
accumbens O
shell O
, O
but O
not O
core O
, O
this O
modification O
consisting O
in O
inhibitory O
and O
facilitatory O
effects O
of O
the O
5-ht1b O
receptor O
antagonist O
( O
gr O
55562 O
) O
and O
agonist O
( O
cp O
93129) O
, O
respectively O
. O

in O
other O
words O
, O
the O
present O
results O
suggest O
that O
the O
accumbal O
shell O
5-ht1b O
receptors O
play O
a O
permissive O
role O
in O
the O
behavioural O
response O
to O
the O
psychostimulant O
. O

-DOCSTART- O

ticlopidine-induced O
cholestatic B-NEG
hepatitis I-NEG
. O

objective O
: O
to O
report O
2 O
cases O
of O
ticlopidine-induced O
cholestatic B-NEG
hepatitis I-NEG
, O
investigate O
its O
mechanism O
, O
and O
compare O
the O
observed O
main O
characteristics O
with O
those O
of O
the O
published O
cases O
. O

case O
summaries O
: O
two O
patients O
developed O
prolonged O
cholestatic B-NEG
hepatitis I-NEG
after O
receiving O
ticlopidine O
following O
percutaneous O
coronary O
angioplasty O
, O
with O
complete O
remission O
during O
the O
follow-up O
period O
. O

t-cell O
stimulation O
by O
therapeutic O
concentration O
of O
ticlopidine O
was O
demonstrated O
in O
vitro O
in O
the O
patients O
, O
but O
not O
in O
healthy O
controls O
. O

discussion O
: O
cholestatic B-NEG
hepatitis I-NEG
is O
a O
rare O
complication O
of O
the O
antiplatelet O
agent O
ticlopidine O
; O
several O
cases O
have O
been O
reported O
but O
few O
in O
the O
english O
literature O
. O

our O
patients O
developed O
jaundice B-NEG
following O
treatment O
with O
ticlopidine O
and O
showed O
the O
clinical O
and O
laboratory O
characteristics O
of O
cholestatic B-NEG
hepatitis I-NEG
, O
which O
resolved O
after O
discontinuation O
of O
the O
drug O
. O
hepatitis B-NEG
may O
develop O
weeks O
after O
discontinuation O
of O
the O
drug O
and O
may O
run O
a O
prolonged O
course O
, O
but O
complete O
remission O
was O
observed O
in O
all O
reported O
cases O
. O

an O
objective O
causality O
assessment O
revealed O
that O
the O
adverse O
drug O
event O
was O
probably O
related O
to O
the O
use O
of O
ticlopidine O
. O

the O
mechanisms O
of O
this O
ticlopidine-induced O
cholestasis B-NEG
are O
unclear O
. O

immune O
mechanisms O
may O
be O
involved O
in O
the O
drug's O
hepatotoxicity B-NEG
, O
as O
suggested O
by O
the O
t-cell O
stimulation O
study O
reported O
here O
. O

conclusions O
: O
cholestatic B-NEG
hepatitis I-NEG
is O
a O
rare O
adverse O
effect O
of O
ticlopidine O
that O
may O
be O
immune O
mediated O
. O

patients O
receiving O
the O
drug O
should O
be O
monitored O
with O
liver O
function O
tests O
along O
with O
complete O
blood O
cell O
counts O
. O

this O
complication O
will O
be O
observed O
even O
less O
often O
in O
the O
future O
as O
ticlopidine O
is O
being O
replaced O
by O
the O
newer O
antiplatelet O
agent O
clopidogrel O
. O

-DOCSTART- O

epithelial O
sodium O
channel O
( O
enac O
) O
subunit O
mrna O
and O
protein O
expression O
in O
rats O
with O
puromycin O
aminonucleoside-induced O
nephrotic B-NEG
syndrome I-NEG
. O

in O
experimental O
nephrotic B-NEG
syndrome I-NEG
, O
urinary O
sodium O
excretion O
is O
decreased O
during O
the O
early O
phase O
of O
the O
disease O
. O

the O
molecular O
mechanism(s O
) O
leading O
to O
salt O
retention O
has O
not O
been O
completely O
elucidated O
. O

the O
rate-limiting O
constituent O
of O
collecting O
duct O
sodium O
transport O
is O
the O
epithelial O
sodium O
channel O
(enac) O
. O

we O
examined O
the O
abundance O
of O
enac O
subunit O
mrnas O
and O
proteins O
in O
puromycin O
aminonucleoside O
( O
pan)-induced O
nephrotic B-NEG
syndrome I-NEG
. O

the O
time O
courses O
of O
urinary O
sodium O
excretion O
, O
plasma O
aldosterone O
concentration O
and O
proteinuria B-NEG
were O
studied O
in O
male O
sprague-dawley O
rats O
treated O
with O
a O
single O
dose O
of O
either O
pan O
or O
vehicle O
. O

the O
relative O
amounts O
of O
alphaenac O
, O
betaenac O
and O
gammaenac O
mrnas O
were O
determined O
in O
kidneys O
from O
these O
rats O
by O
real-time O
quantitative O
taqman O
pcr O
, O
and O
the O
amounts O
of O
proteins O
by O
western O
blot O
. O

the O
kinetics O
of O
urinary O
sodium O
excretion O
and O
the O
appearance O
of O
proteinuria B-NEG
were O
comparable O
with O
those O
reported O
previously O
. O

sodium O
retention O
occurred O
on O
days O
2, O
3 O
and O
6 O
after O
pan O
injection O
. O

a O
significant O
up-regulation O
of O
alphaenac O
and O
betaenac O
mrna O
abundance O
on O
days O
1 O
and O
2 O
preceded O
sodium O
retention O
on O
days O
2 O
and O
3. O

conversely O
, O
down-regulation O
of O
alphaenac O
, O
betaenac O
and O
gammaenac O
mrna O
expression O
on O
day O
3 O
occurred O
in O
the O
presence O
of O
high O
aldosterone O
concentrations O
, O
and O
was O
followed O
by O
a O
return O
of O
sodium O
excretion O
to O
control O
values O
. O

the O
amounts O
of O
alphaenac O
, O
betaenac O
and O
gammaenac O
proteins O
were O
not O
increased O
during O
pan-induced O
sodium O
retention O
. O

in O
conclusion O
, O
enac O
mrna O
expression O
, O
especially O
alphaenac O
, O
is O
increased O
in O
the O
very O
early O
phase O
of O
the O
experimental O
model O
of O
pan-induced O
nephrotic B-NEG
syndrome I-NEG
in O
rats O
, O
but O
appears O
to O
escape O
from O
the O
regulation O
by O
aldosterone O
after O
day O
3. O

-DOCSTART- O

no-induced O
migraine B-NEG
attack O
: O
strong O
increase O
in O
plasma O
calcitonin O
gene-related O
peptide O
( O
cgrp O
) O
concentration O
and O
negative O
correlation O
with O
platelet O
serotonin O
release O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
changes O
in O
the O
plasma O
calcitonin O
gene-related O
peptide O
( O
cgrp O
) O
concentration O
and O
platelet O
serotonin O
(5-hydroxytriptamine O
, O
5-ht O
) O
content O
during O
the O
immediate O
headache B-NEG
and O
the O
delayed O
genuine O
migraine B-NEG
attack O
provoked O
by O
nitroglycerin O
. O

fifteen O
female O
migraineurs B-NEG
( O
without I-NEG
aura I-NEG
) O
and O
eight O
controls O
participated O
in O
the O
study O
. O

sublingual O
nitroglycerin O
( O
0.5 O
mg O
) O
was O
administered O
. O

blood O
was O
collected O
from O
the O
antecubital O
vein O
four O
times O
: O
60 O
min O
before O
and O
after O
the O
nitroglycerin O
application O
, O
and O
60 O
and O
120 O
min O
after O
the O
beginning O
of O
the O
migraine B-NEG
attack O
( O
mean O
344 O
and O
404 O
min O
; O
12 O
subjects) O
. O

in O
those O
subjects O
who O
had O
no O
migraine B-NEG
attack O
( O
11 O
subjects O
) O
a O
similar O
time O
schedule O
was O
used O
. O

plasma O
cgrp O
concentration O
increased O
significantly O
( O
p<0.01 O
) O
during O
the O
migraine B-NEG
attack O
and O
returned O
to O
baseline O
after O
the O
cessation O
of O
the O
migraine B-NEG
. O

in O
addition O
, O
both O
change O
and O
peak O
, O
showed O
significant O
positive O
correlations O
with O
migraine B-NEG
headache B-NEG
intensity O
(p<0.001) O
. O

however O
, O
plasma O
cgrp O
concentrations O
failed O
to O
change O
during O
immediate O
headache B-NEG
and O
in O
the O
subjects O
with O
no O
migraine B-NEG
attack O
. O

basal O
cgrp O
concentration O
was O
significantly O
higher O
and O
platelet O
5-ht O
content O
tended O
to O
be O
lower O
in O
subjects O
who O
experienced O
a O
migraine B-NEG
attack O
. O

platelet O
serotonin O
content O
decreased O
significantly O
( O
p<0.01 O
) O
after O
nitroglycerin O
in O
subjects O
with O
no O
migraine B-NEG
attack O
but O
no O
consistent O
change O
was O
observed O
in O
patients O
with O
migraine B-NEG
attack O
. O

in O
conclusion O
, O
the O
fact O
that O
plasma O
cgrp O
concentration O
correlates O
with O
the O
timing O
and O
severity O
of O
a O
migraine B-NEG
headache B-NEG
suggests O
a O
direct O
relationship O
between O
cgrp O
and O
migraine B-NEG
. O

in O
contrast O
, O
serotonin O
release O
from O
platelets O
does O
not O
provoke O
migraine B-NEG
, O
it O
may O
even O
counteract O
the O
headache B-NEG
and O
the O
concomitant O
cgrp O
release O
in O
this O
model O
. O

-DOCSTART- O

coronary B-NEG
aneurysm I-NEG
after O
implantation O
of O
a O
paclitaxel-eluting O
stent O
. O

formation O
of O
coronary B-NEG
aneurysm I-NEG
is O
a O
rare O
complication O
of O
stenting O
with O
bare O
metal O
stents O
, O
but O
based O
on O
experimental O
studies O
drug-eluting O
stents O
may O
induce O
toxic O
effects O
on O
the O
vessel O
wall O
with O
incomplete O
stent O
apposition O
, O
aneurysm B-NEG
formation O
and O
with O
the O
potential O
of O
stent O
thrombosis B-NEG
or O
vessel B-NEG
rupture I-NEG
. O

we O
present O
a O
43-year-old O
man O
who O
developed O
a O
coronary B-NEG
aneurysm I-NEG
in O
the O
right O
coronary O
artery O
6 O
months O
after O
receiving O
a O
paclitaxel-eluting O
stent O
. O

the O
patient O
was O
asymptomatic O
and O
the O
aneurysm B-NEG
was O
detected O
in O
a O
routine O
control O
. O

angiography O
and O
intracoronary O
ultrasound O
demonstrated O
lack O
of O
contact O
between O
stent O
and O
vessel O
wall O
in O
a O
15-mm O
long O
segment O
with O
maximal O
aneurysm B-NEG
diameter O
of O
6.0 O
mm O
. O

the O
patient O
was O
successfully O
treated O
with O
a O
graft O
stent O
. O

-DOCSTART- O

behavioral O
effects O
of O
urotensin-ii O
centrally O
administered O
in O
mice O
. O

urotensin-ii O
( O
u-ii O
) O
receptors O
are O
widely O
distributed O
in O
the O
central O
nervous O
system O
. O

intracerebroventricular O
( O
i.c.v. O
) O
injection O
of O
u-ii O
causes O
hypertension B-NEG
and O
bradycardia B-NEG
and O
stimulates O
prolactin O
and O
thyrotropin O
secretion O
. O

however O
, O
the O
behavioral O
effects O
of O
centrally O
administered O
u-ii O
have O
received O
little O
attention O
. O

in O
the O
present O
study O
, O
we O
tested O
the O
effects O
of O
i.c.v O
. O
injections O
of O
u-ii O
on O
behavioral O
, O
metabolic O
, O
and O
endocrine O
responses O
in O
mice O
. O

administration O
of O
graded O
doses O
of O
u-ii O
( O
1-10,000 O
ng/mouse O
) O
provoked O
: O
( O
1 O
) O
a O
dose-dependent O
reduction O
in O
the O
number O
of O
head O
dips O
in O
the O
hole-board O
test O
; O
( O
2 O
) O
a O
dose-dependent O
reduction O
in O
the O
number O
of O
entries O
in O
the O
white O
chamber O
in O
the O
black-and-white O
compartment O
test O
, O
and O
in O
the O
number O
of O
entries O
in O
the O
central O
platform O
and O
open O
arms O
in O
the O
plus-maze O
test O
; O
and O
( O
3 O
) O
a O
dose-dependent O
increase O
in O
the O
duration O
of O
immobility O
in O
the O
forced-swimming O
test O
and O
tail O
suspension O
test O
. O

intracerebroventricular O
injection O
of O
u-ii O
also O
caused O
an O
increase O
in O
: O
food O
intake O
at O
doses O
of O
100 O
and O
1,000 O
ng/mouse O
, O
water O
intake O
at O
doses O
of O
100-10,000 O
ng/mouse O
, O
and O
horizontal O
locomotion O
activity O
at O
a O
dose O
of O
10,000 O
ng/mouse O
. O

whatever O
was O
the O
dose O
, O
the O
central O
administration O
of O
u-ii O
had O
no O
effect O
on O
body O
temperature O
, O
nociception O
, O
apomorphine-induced O
penile B-NEG
erection I-NEG
and O
climbing O
behavior O
, O
and O
stress-induced O
plasma O
corticosterone O
level O
. O

taken O
together O
, O
the O
present O
study O
demonstrates O
that O
the O
central O
injection O
of O
u-ii O
at O
doses O
of O
1-10,000 O
ng/mouse O
induces O
anxiogenic- O
and O
depressant-like O
effects O
in O
mouse O
. O

these O
data O
suggest O
that O
u-ii O
may O
be O
involved O
in O
some O
aspects O
of O
psychiatric B-NEG
disorders I-NEG
. O

-DOCSTART- O

recurrent O
dysphonia B-NEG
and O
acitretin O
. O

we O
report O
the O
case O
of O
a O
woman O
complaining O
of O
dysphonia B-NEG
while O
she O
was O
treated O
by O
acitretin O
. O

her O
symptoms O
totally O
regressed O
after O
drug O
withdrawal O
and O
reappeared O
when O
acitretin O
was O
reintroduced O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
acitretin-induced O
dysphonia B-NEG
. O

this O
effect O
may O
be O
related O
to O
the O
pharmacological O
effect O
of O
this O
drug O
on O
mucous O
membranes O
. O

-DOCSTART- O

pharmacological O
modulation O
of O
pain B-NEG
-related O
brain O
activity O
during O
normal O
and O
central O
sensitization O
states O
in O
humans O
. O

abnormal O
processing O
of O
somatosensory O
inputs O
in O
the O
central O
nervous O
system O
( O
central O
sensitization O
) O
is O
the O
mechanism O
accounting O
for O
the O
enhanced O
pain B-NEG
sensitivity O
in O
the O
skin O
surrounding O
tissue B-NEG
injury I-NEG
( O
secondary B-NEG
hyperalgesia I-NEG
). O
secondary B-NEG
hyperalgesia I-NEG
shares O
clinical O
characteristics O
with O
neurogenic B-NEG
hyperalgesia I-NEG
in O
patients O
with O
neuropathic B-NEG
pain I-NEG
. O

abnormal O
brain O
responses O
to O
somatosensory O
stimuli O
have O
been O
found O
in O
patients O
with O
hyperalgesia B-NEG
as O
well O
as O
in O
normal O
subjects O
during O
experimental O
central O
sensitization O
. O

the O
aim O
of O
this O
study O
was O
to O
assess O
the O
effects O
of O
gabapentin O
, O
a O
drug O
effective O
in O
neuropathic B-NEG
pain I-NEG
patients O
, O
on O
brain O
processing O
of O
nociceptive O
information O
in O
normal O
and O
central O
sensitization O
states O
. O

using O
functional O
magnetic O
resonance O
imaging O
( O
fmri O
) O
in O
normal O
volunteers O
, O
we O
studied O
the O
gabapentin-induced O
modulation O
of O
brain O
activity O
in O
response O
to O
nociceptive O
mechanical O
stimulation O
of O
normal O
skin O
and O
capsaicin-induced O
secondary B-NEG
hyperalgesia I-NEG
. O

the O
dose O
of O
gabapentin O
was O
1,800 O
mg O
per O
os O
, O
in O
a O
single O
administration O
. O

we O
found O
that O
( O
i O
) O
gabapentin O
reduced O
the O
activations O
in O
the O
bilateral O
operculoinsular O
cortex O
, O
independently O
of O
the O
presence O
of O
central O
sensitization O
; O
( O
ii O
) O
gabapentin O
reduced O
the O
activation O
in O
the O
brainstem O
, O
only O
during O
central O
sensitization O
; O
( O
iii O
) O
gabapentin O
suppressed O
stimulus-induced O
deactivations O
, O
only O
during O
central O
sensitization O
; O
this O
effect O
was O
more O
robust O
than O
the O
effect O
on O
brain O
activation O
. O

the O
observed O
drug-induced O
effects O
were O
not O
due O
to O
changes O
in O
the O
baseline O
fmri O
signal O
. O

these O
findings O
indicate O
that O
gabapentin O
has O
a O
measurable O
antinociceptive O
effect O
and O
a O
stronger O
antihyperalgesic O
effect O
most O
evident O
in O
the O
brain O
areas O
undergoing O
deactivation O
, O
thus O
supporting O
the O
concept O
that O
gabapentin O
is O
more O
effective O
in O
modulating O
nociceptive O
transmission O
when O
central O
sensitization O
is O
present O
. O

-DOCSTART- O

mdma O
polydrug O
users O
show O
process-specific O
central O
executive O
impairments O
coupled O
with O
impaired B-NEG
social I-NEG
and I-NEG
emotional I-NEG
judgement I-NEG
processes I-NEG
. O

in O
recent O
years O
working O
memory B-NEG
deficits I-NEG
have O
been O
reported O
in O
users O
of O
mdma O
(3,4-methylenedioxymethamphetamine O
, O
ecstasy) O
. O

the O
current O
study O
aimed O
to O
assess O
the O
impact O
of O
mdma O
use O
on O
three O
separate O
central O
executive O
processes O
( O
set O
shifting O
, O
inhibition O
and O
memory O
updating O
) O
and O
also O
on O
prefrontal O
mediated O
social O
and O
emotional O
judgement O
processes O
. O

fifteen O
polydrug O
ecstasy O
users O
and O
15 O
polydrug O
non-ecstasy O
user O
controls O
completed O
a O
general O
drug O
use O
questionnaire O
, O
the O
brixton O
spatial O
anticipation O
task O
( O
set O
shifting) O
, O
backward O
digit O
span O
procedure O
( O
memory O
updating) O
, O
inhibition O
of O
return O
(inhibition) O
, O
an O
emotional O
intelligence O
scale O
, O
the O
tromso O
social O
intelligence O
scale O
and O
the O
dysexecutive O
questionnaire O
(dex) O
. O

compared O
with O
mdma-free O
polydrug O
controls O
, O
mdma O
polydrug O
users O
showed O
impairments O
in O
set O
shifting O
and O
memory O
updating O
, O
and O
also O
in O
social O
and O
emotional O
judgement O
processes O
. O

the O
latter O
two O
deficits O
remained O
significant O
after O
controlling O
for O
other O
drug O
use O
. O

these O
data O
lend O
further O
support O
to O
the O
proposal O
that O
cognitive O
processes O
mediated O
by O
the O
prefrontal O
cortex O
may O
be O
impaired O
by O
recreational O
ecstasy O
use O
. O

-DOCSTART- O

severe O
citrate O
toxicity B-NEG
complicating O
volunteer O
apheresis O
platelet O
donation O
. O

we O
report O
a O
case O
of O
severe O
citrate O
toxicity B-NEG
during O
volunteer O
donor O
apheresis O
platelet O
collection O
. O

the O
donor O
was O
a O
40-year-old O
female O
, O
first-time O
apheresis O
platelet O
donor O
. O

past O
medical O
history O
was O
remarkable O
for O
hypertension B-NEG
, O
hyperlipidemia B-NEG
, O
and O
depression B-NEG
. O

reported O
medications O
included O
bumetanide O
, O
pravastatin O
, O
and O
paroxetine O
. O

thirty O
minutes O
from O
the O
start O
of O
the O
procedure O
, O
the O
donor O
noted O
tingling O
around O
the O
mouth O
, O
hands O
, O
and O
feet O
. O

she O
then O
very O
rapidly O
developed O
acute O
onset O
of O
severe O
facial O
and O
extremity O
tetany B-NEG
. O

empirical O
treatment O
with O
intravenous O
calcium O
gluconate O
was O
initiated O
, O
and O
muscle B-NEG
contractions I-NEG
slowly O
subsided O
over O
approximately O
10 O
to O
15 O
minutes O
. O

the O
events O
are O
consistent O
with O
a O
severe O
reaction O
to O
calcium O
chelation O
by O
sodium O
citrate O
anticoagulant O
resulting O
in O
symptomatic O
systemic O
hypocalcemia B-NEG
. O

upon O
additional O
retrospective O
analysis O
, O
it O
was O
noted O
that O
bumetanide O
is O
a O
loop O
diuretic O
that O
may O
cause O
significant O
hypocalcemia B-NEG
. O

we O
conclude O
that O
careful O
screening O
for O
medications O
and O
underlying O
conditions O
predisposing O
to O
hypocalcemia B-NEG
is O
recommended O
to O
help O
prevent O
severe O
reactions O
due O
to O
citrate O
toxicity B-NEG
. O

laboratory O
measurement O
of O
pre-procedure O
serum O
calcium O
levels O
in O
selected O
donors O
may O
identify O
cases O
requiring O
heightened O
vigilance O
. O

the O
case O
also O
illustrates O
the O
importance O
of O
maintaining O
preparedness O
for O
managing O
rare O
but O
serious O
reactions O
in O
volunteer O
apheresis O
blood O
donors O
. O

-DOCSTART- O

proteinuria B-NEG
after O
conversion O
to O
sirolimus O
in O
renal O
transplant O
recipients O
. O

sirolimus O
( O
srl O
) O
is O
a O
new O
, O
potent O
immunosuppressive O
agent O
. O

more O
recently O
, O
proteinuria B-NEG
has O
been O
reported O
as O
a O
consequence O
of O
sirolimus O
therapy O
, O
although O
the O
mechanism O
has O
remained O
unclear O
. O

we O
retrospectively O
examined O
the O
records O
of O
25 O
renal O
transplant O
patients O
, O
who O
developed O
or O
displayed O
increased O
proteinuria B-NEG
after O
srl O
conversion O
. O

the O
patient O
cohort O
( O
14 O
men O
, O
11 O
women O
) O
was O
treated O
with O
srl O
as O
conversion O
therapy O
, O
due O
to O
chronic B-NEG
allograft I-NEG
nephropathy I-NEG
( O
can B-NEG
) O
(n O
= O
15 O
) O
neoplasia B-NEG
(n O
= O
8) O
; O
kaposi's B-NEG
sarcoma I-NEG
, O
four O
skin B-NEG
cancers I-NEG
, O
one O
intestinal B-NEG
tumors I-NEG
, O
one O
renal B-NEG
cell I-NEG
carsinom I-NEG
) O
or O
bk O
virus O
nephropathy B-NEG
(n O
= O
2) O
. O

srl O
was O
started O
at O
a O
mean O
of O
78 O
+/- O
42 O
( O
15 O
to O
163 O
) O
months O
after O
transplantation O
. O

mean O
follow-up O
on O
srl O
therapy O
was O
20 O
+/- O
12 O
(6 O
to O
43 O
) O
months O
. O
proteinuria B-NEG
increased O
from O
0.445 O
(0 O
to O
1.5 O
) O
g/d O
before O
conversion O
to O
3.2 O
g/dl O
( O
0.2 O
to O
12 O
) O
after O
conversion O
(p O
= O
0.001) O
. O

before O
conversion O
8 O
( O
32% O
) O
patients O
had O
no O
proteinuria B-NEG
, O
whereas O
afterwards O
all O
patients O
had O
proteinuria B-NEG
. O

in O
28% O
of O
patients O
proteinuria B-NEG
remained O
unchanged O
, O
whereas O
it O
increased O
in O
68% O
of O
patients O
. O

in O
40% O
it O
increased O
by O
more O
than O
100% O
. O

twenty-eight O
percent O
of O
patients O
showed O
increased O
proteinuria B-NEG
to O
the O
nephrotic B-NEG
range O
. O

biopsies O
performed O
in O
five O
patients O
revealed O
new O
pathological O
changes O
: O
one O
membranoproliferative B-NEG
glomerulopathy I-NEG
and O
interstitial B-NEG
nephritis I-NEG
. O

these O
patients O
showed O
persistently O
good O
graft O
function O
. O

serum O
creatinine O
values O
did O
not O
change O
significantly O
: O
1.98 O
+/- O
0.8 O
mg/dl O
before O
srl O
therapy O
and O
2.53 O
+/- O
1.9 O
mg/dl O
at O
last O
follow-up O
(p O
= O
.14) O
. O

five O
grafts O
were O
lost O
and O
the O
patients O
returned O
to O
dialysis O
. O

five O
patients O
displayed O
can B-NEG
and O
kaposi's B-NEG
sarcoma I-NEG
. O

mean O
urinary O
protein O
of O
patients O
who O
returned O
to O
dialysis O
was O
1.26 O
( O
0.5 O
to O
3.5 O
) O
g/d O
before O
and O
4.7 O
(3 O
to O
12 O
) O
g/d O
after O
conversion O
(p O
= O
.01) O
. O

mean O
serum O
creatinine O
level O
before O
conversion O
was O
2.21 O
mg/dl O
and O
thereafter O
, O
4.93 O
mg/dl O
(p O
= O
.02) O
. O

heavy O
proteinuria B-NEG
was O
common O
after O
the O
use O
of O
srl O
as O
rescue O
therapy O
for O
renal O
transplantation O
. O

therefore O
, O
conversion O
should O
be O
considered O
for O
patients O
who O
have O
not O
developed O
advanced O
can B-NEG
and O
proteinuria B-NEG
. O

the O
possibility O
of O
de O
novo O
glomerular O
pathology O
under O
srl O
treatment O
requires O
further O
investigation O
by O
renal O
biopsy O
. O

-DOCSTART- O

in O
vitro O
characterization O
of O
parasympathetic O
and O
sympathetic O
responses O
in O
cyclophosphamide-induced O
cystitis B-NEG
in O
the O
rat O
. O

in O
cyclophosphamide-induced O
cystitis B-NEG
in O
the O
rat O
, O
detrusor O
function O
is O
impaired O
and O
the O
expression O
and O
effects O
of O
muscarinic O
receptors O
altered O
. O

whether O
or O
not O
the O
neuronal O
transmission O
may O
be O
affected O
by O
cystitis B-NEG
was O
presently O
investigated O
. O

responses O
of O
urinary O
strip O
preparations O
from O
control O
and O
cyclophosphamide-pretreated O
rats O
to O
electrical O
field O
stimulation O
and O
to O
agonists O
were O
assessed O
in O
the O
absence O
and O
presence O
of O
muscarinic O
, O
adrenergic O
and O
purinergic O
receptor O
antagonists O
. O

generally O
, O
atropine O
reduced O
contractions O
, O
but O
in O
contrast O
to O
controls O
, O
it O
also O
reduced O
responses O
to O
low O
electrical O
field O
stimulation O
intensity O
( O
1-5 O
hz O
) O
in O
inflamed O
preparations O
. O

in O
both O
types O
, O
purinoceptor O
desensitization O
with O
alpha,beta-methylene O
adenosine-5'-triphosphate O
( O
alpha,beta-meatp O
) O
caused O
further O
reductions O
at O
low O
frequencies O
( O
<10 O
hz) O
. O

the O
muscarinic O
receptor O
antagonists O
atropine O
, O
4-diphenylacetoxy-n-methylpiperidine O
( O
4-damp O
) O
('m(1)/m(3)/m(5)-selective') O
, O
methoctramine O
( O
'm(2)-selective' O
) O
and O
pirenzepine O
( O
'm(1)-selective' O
) O
antagonized O
the O
tonic O
component O
of O
the O
electrical O
field O
stimulation-evoked O
contractile O
response O
more O
potently O
than O
the O
phasic O
component O
. O

4-damp O
inhibited O
the O
tonic O
contractions O
in O
controls O
more O
potently O
than O
methoctramine O
and O
pirenzepine O
. O

in O
inflamed O
preparations O
, O
the O
muscarinic O
receptor O
antagonism O
on O
the O
phasic O
component O
of O
the O
electrical O
field O
stimulation-evoked O
contraction O
was O
decreased O
and O
the O
pirenzepine O
and O
4-damp O
antagonism O
on O
the O
tonic O
component O
was O
much O
less O
efficient O
than O
in O
controls O
. O

in O
contrast O
to O
controls O
, O
methoctramine O
increased O
-- O
instead O
of O
decreased O
-- O
the O
tonic O
responses O
at O
high O
frequencies O
. O

while O
contractions O
to O
carbachol O
and O
atp O
were O
the O
same O
in O
inflamed O
and O
in O
control O
strips O
when O
related O
to O
a O
reference O
potassium O
response O
, O
isoprenaline-induced O
relaxations O
were O
smaller O
in O
inflamed O
strips O
. O

thus O
, O
in O
cystitis B-NEG
substantial O
changes O
of O
the O
efferent O
functional O
responses O
occur O
. O

while O
postjunctional O
beta-adrenoceptor-mediated O
relaxations O
are O
reduced O
, O
effects O
by O
prejunctional O
inhibitory O
muscarinic O
receptors O
may O
be O
increased O
. O

-DOCSTART- O

associations O
between O
use O
of O
benzodiazepines O
or O
related O
drugs O
and O
health O
, O
physical O
abilities O
and O
cognitive O
function O
: O
a O
non-randomised O
clinical O
study O
in O
the O
elderly O
. O

objective O
: O
to O
describe O
associations O
between O
the O
use O
of O
benzodiazepines O
or O
related O
drugs O
( O
bzds/rds O
) O
and O
health O
, O
functional O
abilities O
and O
cognitive O
function O
in O
the O
elderly O
. O

methods O
: O
a O
non-randomised O
clinical O
study O
of O
patients O
aged O
> O
or O
=65 O
years O
admitted O
to O
acute O
hospital O
wards O
during O
1 O
month O
. O

164 O
patients O
( O
mean O
age O
+/- O
standard O
deviation O
[sd] O
81.6 O
+/- O
6.8 O
years O
) O
were O
admitted O
. O

of O
these O
, O
nearly O
half O
(n O
= O
78 O
) O
had O
used O
bzds/rds O
before O
admission O
, O
and O
the O
remainder O
(n O
= O
86 O
) O
were O
non-users O
. O

cognitive O
ability O
was O
assessed O
by O
the O
mini-mental O
state O
examination O
(mmse) O
. O

patients O
scoring O
> O
or O
=20 O
mmse O
sum O
points O
were O
interviewed O
(n O
= O
79 O
) O
and O
questioned O
regarding O
symptoms O
and O
functional O
abilities O
during O
the O
week O
prior O
to O
admission O
. O

data O
on O
use O
of O
bzds/rds O
before O
admission O
, O
current O
medications O
and O
discharge O
diagnoses O
were O
collected O
from O
medical O
records O
. O

health O
, O
physical O
abilities O
and O
cognitive O
function O
were O
compared O
between O
bzd/rd O
users O
and O
non-users O
, O
and O
adjustments O
were O
made O
for O
confounding O
variables O
. O

the O
residual O
serum O
concentrations O
of O
oxazepam O
, O
temazepam O
and O
zopiclone O
were O
analysed O
. O

results O
: O
the O
mean O
+/- O
sd O
duration O
of O
bzd/rd O
use O
was O
7 O
+/- O
7 O
years O
( O
range O
1-31) O
. O

two O
or O
three O
bzds/rds O
were O
concomitantly O
taken O
by O
26% O
of O
users O
(n O
= O
20) O
. O

long-term O
use O
of O
these O
drugs O
was O
associated O
with O
female O
sex O
and O
use O
of O
a O
higher O
number O
of O
drugs O
with O
effects O
on O
the O
cns O
, O
which O
tended O
to O
be O
related O
to O
diagnosed O
dementia B-NEG
. O

after O
adjustment O
for O
these O
variables O
as O
confounders O
, O
use O
of O
bzds/rds O
was O
not O
associated O
with O
cognitive O
function O
as O
measured O
by O
the O
mmse O
. O

however O
, O
use O
of O
bzds/rds O
was O
associated O
with O
dizziness B-NEG
, O
inability B-NEG
to I-NEG
sleep I-NEG
after O
awaking O
at O
night O
and O
tiredness B-NEG
in O
the O
mornings O
during O
the O
week O
prior O
to O
admission O
and O
with O
stronger O
depressive B-NEG
symptoms I-NEG
measured O
at O
the O
beginning O
of O
the O
hospital O
stay O
. O

use O
of O
bzds/rds O
tended O
to O
be O
associated O
with O
a O
reduced O
ability O
to O
walk O
and O
shorter O
night-time O
sleep O
during O
the O
week O
prior O
to O
admission O
. O

a O
higher O
residual O
serum O
concentration O
of O
temazepam O
correlated O
with O
a O
lower O
mmse O
sum O
score O
after O
adjustment O
for O
confounding O
variables O
. O

conclusions O
: O
long-term O
use O
and O
concomitant O
use O
of O
more O
than O
one O
bzd/rd O
were O
common O
in O
elderly O
patients O
hospitalised O
because O
of O
acute O
illnesses O
. O

long-term O
use O
was O
associated O
with O
daytime O
and O
night-time O
symptoms O
indicative O
of O
poorer O
health O
and O
potentially O
caused O
by O
the O
adverse O
effects O
of O
these O
drugs O
. O

-DOCSTART- O

acute O
vocal B-NEG
fold I-NEG
palsy I-NEG
after O
acute O
disulfiram O
intoxication O
. O

acute O
peripheral B-NEG
neuropathy I-NEG
caused O
by O
a O
disulfiram O
overdose B-NEG
is O
very O
rare O
and O
there O
is O
no O
report O
of O
it O
leading O
to O
vocal B-NEG
fold I-NEG
palsy I-NEG
. O

a O
49-year-old O
woman O
was O
transferred O
to O
our O
department O
because O
of O
quadriparesis B-NEG
, O
lancinating O
pain B-NEG
, O
sensory B-NEG
loss I-NEG
, O
and O
paresthesia B-NEG
of O
the O
distal O
limbs O
. O

one O
month O
previously O
, O
she O
had O
taken O
a O
single O
high O
dose O
of O
disulfiram O
( O
130 O
tablets O
of O
alcohol O
stop O
tab O
, O
shin-poong O
pharm O
. O
co. O
, O
ansan O
, O
korea O
) O
in O
a O
suicide O
attempt O
. O

she O
was O
not O
an O
alcoholic O
. O

for O
the O
first O
few O
days O
after O
ingestion O
, O
she O
was O
in O
a O
confused O
state O
and O
had O
mild O
to O
moderate O
ataxia B-NEG
and O
giddiness B-NEG
. O

she O
noticed O
hoarseness B-NEG
and O
distally O
accentuated O
motor O
and O
sensory O
dysfunction O
after O
she O
had O
recovered O
from O
this O
state O
. O

a O
nerve O
conduction O
study O
was O
consistent O
with O
severe O
sensorimotor O
axonal O
polyneuropathy B-NEG
. O

laryngeal O
electromyography O
( O
thyroarytenoid O
muscle O
) O
showed O
ample O
denervation O
potentials O
. O

laryngoscopy O
revealed O
asymmetric O
vocal O
fold O
movements O
during O
phonation O
. O

her O
vocal O
change O
and O
weakness O
began O
to O
improve O
spontaneously O
about O
3 O
weeks O
after O
transfer O
. O

this O
was O
a O
case O
of O
acute O
palsy B-NEG
of O
the O
recurrent O
laryngeal O
nerve O
and O
superimposed O
severe O
acute O
sensorimotor O
axonal O
polyneuropathy B-NEG
caused O
by O
high-dose O
disulfiram O
intoxication O
. O

-DOCSTART- O

higher O
optical O
density O
of O
an O
antigen O
assay O
predicts O
thrombosis B-NEG
in O
patients O
with O
heparin-induced O
thrombocytopenia B-NEG
. O

objectives O
: O
to O
correlate O
optical O
density O
and O
percent O
inhibition O
of O
a O
two-step O
heparin-induced O
thrombocytopenia B-NEG
( O
hit B-NEG
) O
antigen O
assay O
with O
thrombosis B-NEG
; O
the O
assay O
utilizes O
reaction O
inhibition O
characteristics O
of O
a O
high O
heparin O
concentration O
. O

patients O
and O
methods O
: O
patients O
with O
more O
than O
50% O
decrease O
in O
platelet O
count O
or O
thrombocytopenia B-NEG
( O
<150 O
x O
10(9)/l O
) O
after O
exposure O
to O
heparin O
, O
who O
had O
a O
positive O
two-step O
antigen O
assay O
[optical O
density O
( O
od O
) O
>0.4 O
and O
>50 O
inhibition O
with O
high O
concentration O
of O
heparin] O
were O
included O
in O
the O
study O
. O

results O
: O
forty O
of O
94 O
hit B-NEG
patients O
had O
thrombosis B-NEG
at O
diagnosis O
; O
54/94 O
had O
isolated- O
hit B-NEG
without O
thrombosis B-NEG
. O

eight O
of O
the O
isolated- O
hit B-NEG
patients O
developed O
thrombosis B-NEG
within O
the O
next O
30 O
d; O
thus O
, O
a O
total O
of O
48 O
patients O
had O
thrombosis B-NEG
at O
day O
30 O
. O

at O
diagnosis O
there O
was O
no O
significant O
difference O
in O
od O
between O
hit B-NEG
patients O
with O
thrombosis B-NEG
and O
those O
with O
isolated- O
hit B-NEG
. O

however O
, O
od O
was O
significantly O
higher O
in O
all O
patients O
with O
thrombosis B-NEG
(n O
= O
48 O
, O
1.34 O
+/- O
0.89) O
, O
including O
isolated- O
hit B-NEG
patients O
who O
later O
developed O
thrombosis B-NEG
within O
30 O
d O
(n O
= O
8, O
1.84 O
+/- O
0.64 O
) O
as O
compared O
to O
isolated- O
hit B-NEG
patients O
who O
did O
not O
develop O
thrombosis B-NEG
( O
0.96 O
+/- O
0.75 O
; O
p O
= O
0.011 O
and O
p O
= O
0.008) O
. O

the O
receiver O
operative O
characteristic O
curve O
showed O
that O
od O
>1.27 O
in O
the O
isolated- O
hit B-NEG
group O
had O
a O
significantly O
higher O
chance O
of O
developing O
thrombosis B-NEG
by O
day O
30 O
. O

none O
of O
these O
groups O
showed O
significant O
difference O
in O
percent O
inhibition O
. O

multivariate O
analysis O
showed O
a O
2.8-fold O
increased O
risk O
of O
thrombosis B-NEG
in O
females O
. O

similarly O
, O
thrombotic B-NEG
risk O
increased O
with O
age O
and O
od O
values O
. O

conclusion O
: O
higher O
od O
is O
associated O
with O
significant O
risk O
of O
subsequent O
thrombosis B-NEG
in O
patients O
with O
isolated- O
hit B-NEG
; O
percent O
inhibition O
, O
however O
, O
was O
not O
predictive O
. O

-DOCSTART- O

central O
retinal B-NEG
vein I-NEG
occlusion I-NEG
associated O
with O
clomiphene-induced O
ovulation O
. O

objective O
: O
to O
report O
a O
case O
of O
central O
retinal B-NEG
vein I-NEG
occlusion I-NEG
associated O
with O
clomiphene O
citrate O
(cc) O
. O

design O
: O
case O
study O
. O

setting O
: O
ophthalmology O
clinic O
of O
an O
academic O
hospital O
. O

patient(s) O
: O
a O
36-year-old O
woman O
referred O
from O
the O
infertility B-NEG
clinic O
for O
blurred B-NEG
vision I-NEG
. O

intervention(s) O
: O
ophthalmic O
examination O
after O
cc O
therapy O
. O

main O
outcome O
measure(s) O
: O
central O
retinal B-NEG
vein I-NEG
occlusion I-NEG
after O
ovulation O
induction O
with O
cc O
. O

result(s) O
: O
a O
36-year-old O
chinese O
woman O
developed O
central O
retinal B-NEG
vein I-NEG
occlusion I-NEG
after O
eight O
courses O
of O
cc O
. O

a O
search O
of O
the O
literature O
on O
the O
thromboembolic B-NEG
complications O
of O
cc O
does O
not O
include O
this O
severe O
ophthalmic O
complication O
, O
although O
mild O
visual B-NEG
disturbance I-NEG
after O
cc O
intake O
is O
not O
uncommon O
. O

conclusion(s) O
: O
this O
is O
the O
first O
reported O
case O
of O
central O
retinal B-NEG
vein I-NEG
occlusion I-NEG
after O
treatment O
with O
cc O
. O

extra O
caution O
is O
warranted O
in O
treating O
infertility B-NEG
patients O
with O
cc O
, O
and O
patients O
should O
be O
well O
informed O
of O
this O
side O
effect O
before O
commencement O
of O
therapy O
. O

-DOCSTART- O

nicotine-induced O
nystagmus B-NEG
correlates O
with O
midpontine O
activation O
. O

the O
pathomechanism O
of O
nicotine-induced O
nystagmus B-NEG
( O
nin B-NEG
) O
is O
unknown O
. O

the O
aim O
of O
this O
study O
was O
to O
delineate O
brain O
structures O
that O
are O
involved O
in O
nin B-NEG
generation O
. O

eight O
healthy O
volunteers O
inhaled O
nicotine O
in O
darkness O
during O
a O
functional O
magnetic O
resonance O
imaging O
( O
fmri O
) O
experiment O
; O
eye O
movements O
were O
registered O
using O
video-oculography O
. O
nin B-NEG
correlated O
with O
blood O
oxygen O
level-dependent O
( O
bold O
) O
activity O
levels O
in O
a O
midpontine O
site O
in O
the O
posterior O
basis O
pontis O
. O
nin B-NEG
-induced O
midpontine O
activation O
may O
correspond O
to O
activation O
of O
the O
dorsomedial O
pontine O
nuclei O
and O
the O
nucleus O
reticularis O
tegmenti O
pontis O
, O
structures O
known O
to O
participate O
in O
the O
generation O
of O
multidirectional O
saccades O
and O
smooth O
pursuit O
eye O
movements O
. O

-DOCSTART- O

protective O
effect O
of O
verapamil O
on O
gastric B-NEG
hemorrhagic I-NEG
ulcers B-NEG
in O
severe O
atherosclerotic B-NEG
rats O
. O

studies O
concerning O
with O
pathogenesis O
of O
gastric B-NEG
hemorrhage I-NEG
and O
mucosal O
ulceration O
produced O
in O
atherosclerotic B-NEG
rats O
are O
lacking O
. O

the O
aim O
of O
this O
study O
is O
to O
examine O
the O
role O
of O
gastric O
acid O
back-diffusion O
, O
mast O
cell O
histamine O
release O
, O
lipid O
peroxide O
( O
lpo O
) O
generation O
and O
mucosal O
microvascular O
permeability O
in O
modulating O
gastric B-NEG
hemorrhage I-NEG
and O
ulcer B-NEG
in O
rats O
with O
atherosclerosis B-NEG
induced O
by O
coadministration O
of O
vitamin O
d2 O
and O
cholesterol O
. O

additionally O
, O
the O
protective O
effect O
of O
verapamil O
on O
this O
ulcer B-NEG
model O
was O
evaluated O
. O

male O
wistar O
rats O
were O
challenged O
intragastrically O
once O
daily O
for O
9 O
days O
with O
1.0 O
ml/kg O
of O
corn O
oil O
containing O
vitamin O
d2 O
and O
cholesterol O
to O
induce O
atherosclerosis B-NEG
. O

control O
rats O
received O
corn O
oil O
only O
. O

after O
gastric O
surgery O
, O
rat O
stomachs O
were O
irrigated O
for O
3 O
h O
with O
either O
simulated O
gastric O
juice O
or O
normal O
saline O
. O

gastric O
acid O
back-diffusion O
, O
mucosal O
lpo O
generation O
, O
histamine O
concentration O
, O
microvascular O
permeability O
, O
luminal O
hemoglobin O
content O
and O
ulcer B-NEG
areas O
were O
determined O
. O

elevated O
atherosclerotic B-NEG
parameters O
, O
such O
as O
serum O
calcium O
, O
total O
cholesterol O
and O
low-density O
lipoprotein O
concentration O
were O
obtained O
in O
atherosclerotic B-NEG
rats O
. O

severe O
gastric O
ulcers B-NEG
accompanied O
with O
increased O
ulcerogenic O
factors O
, O
including O
gastric O
acid O
back-diffusion O
, O
histamine O
release O
, O
lpo O
generation O
and O
luminal O
hemoglobin O
content O
were O
also O
observed O
in O
these O
rats O
. O

moreover O
, O
a O
positive O
correlation O
of O
histamine O
to O
gastric B-NEG
hemorrhage I-NEG
and O
to O
ulcer B-NEG
was O
found O
in O
those O
atherosclerotic B-NEG
rats O
. O

this O
hemorrhagic B-NEG
ulcer B-NEG
and O
various O
ulcerogenic O
parameters O
were O
dose-dependently O
ameliorated O
by O
daily O
intragastric O
verapamil O
. O
atherosclerosis B-NEG
could O
produce O
gastric B-NEG
hemorrhagic I-NEG
ulcer B-NEG
via O
aggravation O
of O
gastric O
acid O
back-diffusion O
, O
lpo O
generation O
, O
histamine O
release O
and O
microvascular O
permeability O
that O
could O
be O
ameliorated O
by O
verapamil O
in O
rats O
. O

-DOCSTART- O

adriamycin-induced O
autophagic O
cardiomyocyte O
death B-NEG
plays O
a O
pathogenic O
role O
in O
a O
rat O
model O
of O
heart B-NEG
failure I-NEG
. O

background O
: O
the O
mechanisms O
underlying O
heart B-NEG
failure I-NEG
induced O
by O
adriamycin O
are O
very O
complicated O
and O
still O
unclear O
. O

the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
autophagy O
was O
involved O
in O
the O
progression O
of O
heart B-NEG
failure I-NEG
induced O
by O
adriamycin O
, O
so O
that O
we O
can O
develop O
a O
novel O
treatment O
strategy O
for O
heart B-NEG
failure I-NEG
. O

methods O
: O
3-methyladenine O
(3ma) O
, O
a O
specific O
inhibitor O
on O
autophagy O
was O
used O
in O
a O
heart B-NEG
failure I-NEG
model O
of O
rats O
induced O
by O
adriamycin O
. O

neonatal O
cardiomyocytes O
were O
isolated O
from O
sprague-dawley O
rat O
hearts O
and O
randomly O
divided O
into O
controls O
, O
an O
adriamycin-treated O
group O
, O
and O
a O
3ma O
plus O
adriamycin-treated O
group O
. O

we O
then O
examined O
the O
morphology O
, O
expression O
of O
beclin O
1 O
gene O
, O
mitochondrial O
permeability O
transition O
(mpt) O
, O
and O
na+-k+ O
atpase O
activity O
in O
vivo O
. O

we O
also O
assessed O
cell O
viability O
, O
mitochondrial O
membrane O
potential O
changes O
and O
counted O
autophagic O
vacuoles O
in O
cultured O
cardiomyocytes O
. O

in O
addition O
, O
we O
analyzed O
the O
expression O
of O
autophagy O
associated O
gene O
, O
beclin O
1 O
using O
rt-pcr O
and O
western O
blotting O
in O
an O
animal O
model O
. O

results O
: O
3ma O
significantly O
improved O
cardiac O
function O
and O
reduced O
mitochondrial O
injury O
. O

furthermore O
, O
adriamycin O
induced O
the O
formation O
of O
autophagic O
vacuoles O
, O
and O
3ma O
strongly O
downregulated O
the O
expression O
of O
beclin O
1 O
in O
adriamycin-induced O
failing O
heart O
and O
inhibited O
the O
formation O
of O
autophagic O
vacuoles O
. O

conclusion O
: O
autophagic O
cardiomyocyte O
death B-NEG
plays O
an O
important O
role O
in O
the O
pathogenesis O
of O
heart B-NEG
failure I-NEG
in O
rats O
induced O
by O
adriamycin O
. O

mitochondrial O
injury O
may O
be O
involved O
in O
the O
progression O
of O
heart B-NEG
failure I-NEG
caused O
by O
adriamycin O
via O
the O
autophagy O
pathway O
. O

-DOCSTART- O

confusion B-NEG
, O
a O
rather O
serious O
adverse O
drug O
reaction O
with O
valproic O
acid O
: O
a O
review O
of O
the O
french O
pharmacovigilance O
database O
. O

introduction O
: O
confusion B-NEG
is O
an O
adverse O
drug O
reaction O
frequently O
observed O
with O
valproic O
acid O
. O

some O
case O
reports O
are O
published O
in O
the O
literature O
but O
no O
systematic O
study O
from O
a O
sample O
of O
patients O
has O
been O
published O
. O

we O
performed O
this O
study O
in O
order O
to O
describe O
the O
main O
characteristics O
of O
this O
adverse O
drug O
reaction O
. O

methods O
: O
using O
the O
french O
pharmacovigilance O
database O
, O
we O
selected O
the O
cases O
of O
confusion B-NEG
reported O
since O
1985 O
with O
valproic O
acid O
. O

results O
: O
272 O
cases O
of O
confusion B-NEG
were O
reported O
with O
valproic O
acid O
: O
153 O
women O
and O
119 O
men O
. O
confusion B-NEG
mostly O
occurred O
during O
the O
two O
first O
weeks O
following O
valproic O
acid O
exposure O
(39.7%) O
. O

it O
was O
serious O
for O
almost O
2/3 O
of O
the O
patients O
( O
62.5% O
) O
and O
its O
outcome O
favourable O
in O
most O
of O
the O
cases O
(82%) O
. O

the O
occurrence O
of O
this O
adr O
was O
more O
frequent O
in O
patients O
aged O
between O
61 O
and O
80 O
years O
. O

conclusion O
: O
this O
work O
shows O
that O
confusion B-NEG
with O
valproic O
acid O
is O
a O
serious O
, O
rather O
frequent O
but O
reversible O
adverse O
drug O
reaction O
. O

it O
occurs O
especially O
in O
older O
patients O
and O
during O
the O
first O
two O
weeks O
of O
treatment O
. O

-DOCSTART- O

learning B-NEG
and I-NEG
memory I-NEG
deficits I-NEG
in O
ecstasy O
users O
and O
their O
neural O
correlates O
during O
a O
face-learning O
task O
. O

it O
has O
been O
consistently O
shown O
that O
ecstasy O
users O
display O
impairments B-NEG
in I-NEG
learning I-NEG
and I-NEG
memory I-NEG
performance O
. O

in O
addition O
, O
working O
memory O
processing O
in O
ecstasy O
users O
has O
been O
shown O
to O
be O
associated O
with O
neural O
alterations O
in O
hippocampal O
and/or O
cortical O
regions O
as O
measured O
by O
functional O
magnetic O
resonance O
imaging O
(fmri) O
. O

using O
functional O
imaging O
and O
a O
face-learning O
task O
, O
we O
investigated O
neural O
correlates O
of O
encoding O
and O
recalling O
face-name O
associations O
in O
20 O
recreational O
drug O
users O
whose O
predominant O
drug O
use O
was O
ecstasy O
and O
20 O
controls O
. O

to O
address O
the O
potential O
confounding O
effects O
of O
the O
cannabis O
use O
of O
the O
ecstasy O
using O
group O
, O
a O
second O
analysis O
included O
14 O
previously O
tested O
cannabis O
users O
(nestor O
, O
l. O
, O
roberts O
, O
g. O
, O
garavan O
, O
h. O
, O
hester O
, O
r. O
, O
2008 O
. O
deficits B-NEG
in I-NEG
learning I-NEG
and I-NEG
memory I-NEG
: O
parahippocampal O
hyperactivity B-NEG
and O
frontocortical O
hypoactivity O
in O
cannabis O
users O
. O
neuroimage O
40 O
, O
1328-1339) O
. O

ecstasy O
users O
performed O
significantly O
worse O
in O
learning O
and O
memory O
compared O
to O
controls O
and O
cannabis O
users O
. O

a O
conjunction O
analysis O
of O
the O
encode O
and O
recall O
phases O
of O
the O
task O
revealed O
ecstasy-specific O
hyperactivity B-NEG
in O
bilateral O
frontal O
regions O
, O
left O
temporal O
, O
right O
parietal O
, O
bilateral O
temporal O
, O
and O
bilateral O
occipital O
brain O
regions O
. O

ecstasy-specific O
hypoactivity O
was O
evident O
in O
the O
right O
dorsal O
anterior O
cingulated O
cortex O
( O
acc O
) O
and O
left O
posterior O
cingulated O
cortex O
. O

in O
both O
ecstasy O
and O
cannabis O
groups O
brain O
activation O
was O
decreased O
in O
the O
right O
medial O
frontal O
gyrus O
, O
left O
parahippocampal O
gyrus O
, O
left O
dorsal O
cingulate O
gyrus O
, O
and O
left O
caudate O
. O

these O
results O
elucidated O
ecstasy-related O
deficits O
, O
only O
some O
of O
which O
might O
be O
attributed O
to O
cannabis O
use O
. O

these O
ecstasy-specific O
effects O
may O
be O
related O
to O
the O
vulnerability O
of O
isocortical O
and O
allocortical O
regions O
to O
the O
neurotoxic B-NEG
effects O
of O
ecstasy O
. O

-DOCSTART- O

prolonged O
elevation O
of O
plasma O
argatroban O
in O
a O
cardiac O
transplant O
patient O
with O
a O
suspected O
history O
of O
heparin-induced O
thrombocytopenia B-NEG
with O
thrombosis B-NEG
. O

background O
: O
direct O
thrombin O
inhibitors O
( O
dtis O
) O
provide O
an O
alternative O
method O
of O
anticoagulation O
for O
patients O
with O
a O
history O
of O
heparin-induced O
thrombocytopenia B-NEG
( O
hit B-NEG
) O
or O
hit B-NEG
with O
thrombosis B-NEG
( O
hitt B-NEG
) O
undergoing O
cardiopulmonary O
bypass O
(cpb) O
. O

in O
the O
following O
report O
, O
a O
65-year-old O
critically B-NEG
ill I-NEG
patient O
with O
a O
suspected O
history O
of O
hitt B-NEG
was O
administered O
argatroban O
for O
anticoagulation O
on O
bypass O
during O
heart O
transplantation O
. O

the O
patient O
required O
massive O
transfusion O
support O
( O
55 O
units O
of O
red O
blood O
cells O
, O
42 O
units O
of O
fresh-frozen O
plasma O
, O
40 O
units O
of O
cryoprecipitate O
, O
40 O
units O
of O
platelets O
, O
and O
three O
doses O
of O
recombinant O
factor O
viia O
) O
for O
severe O
intraoperative B-NEG
and I-NEG
postoperative I-NEG
bleeding I-NEG
. O

study O
design O
and O
methods O
: O
plasma O
samples O
from O
before O
and O
after O
cpb O
were O
analyzed O
postoperatively O
for O
argatroban O
concentration O
using O
a O
modified O
ecarin O
clotting O
time O
( O
ect O
) O
assay O
. O

results O
: O
unexpectedly O
high O
concentrations O
of O
argatroban O
were O
measured O
in O
these O
samples O
(range O
, O
0-32 O
microg/ml) O
, O
and O
a O
prolonged O
plasma O
argatroban O
half O
life O
( O
t(1/2) O
) O
of O
514 O
minutes O
was O
observed O
( O
published O
elimination O
t(1/2 O
) O
is O
39-51 O
minutes O
[< O
or O
= O
181 O
minutes O
with O
hepatic B-NEG
impairment I-NEG
]) O
. O

conclusions O
: O
correlation O
of O
plasma O
argatroban O
concentration O
versus O
the O
patient's O
coagulation O
variables O
and O
clinical O
course O
suggest O
that O
prolonged O
elevated O
levels O
of O
plasma O
argatroban O
may O
have O
contributed O
to O
the O
patient's O
extended O
coagulopathy B-NEG
. O

because O
dtis O
do O
not O
have O
reversal O
agents O
, O
surgical O
teams O
and O
transfusion O
services O
should O
remain O
aware O
of O
the O
possibility O
of O
massive O
transfusion O
events O
during O
anticoagulation O
with O
these O
agents O
. O

this O
is O
the O
first O
report O
to O
measure O
plasma O
argatroban O
concentration O
in O
the O
context O
of O
cpb O
and O
extended O
coagulopathy B-NEG
. O

-DOCSTART- O

antituberculosis O
therapy-induced O
acute B-NEG
liver I-NEG
failure I-NEG
: O
magnitude O
, O
profile O
, O
prognosis O
, O
and O
predictors O
of O
outcome O
. O

antituberculosis O
therapy O
( O
att)-associated O
acute B-NEG
liver I-NEG
failure I-NEG
( O
att- O
alf B-NEG
) O
is O
the O
commonest O
drug-induced O
alf B-NEG
in O
south O
asia O
. O

prospective O
studies O
on O
att- O
alf B-NEG
are O
lacking O
. O

the O
current O
study O
prospectively O
evaluated O
the O
magnitude O
, O
clinical O
course O
, O
outcome O
, O
and O
prognostic O
factors O
in O
att- O
alf B-NEG
. O

from O
january O
1986 O
to O
january O
2009 O
, O
1223 O
consecutive O
alf B-NEG
patients O
were O
evaluated O
: O
att O
alone O
was O
the O
cause O
in O
70 O
( O
5.7% O
) O
patients O
. O

another O
15 O
( O
1.2% O
) O
had O
att O
and O
simultaneous O
hepatitis B-NEG
virus I-NEG
infection I-NEG
. O

in O
44 O
( O
62.8% O
) O
patients O
, O
att O
was O
prescribed O
empirically O
without O
definitive O
evidence O
of O
tuberculosis B-NEG
. O

att- O
alf B-NEG
patients O
were O
younger O
( O
32.87 O
[+/-15.8] O
years) O
, O
and O
49 O
( O
70% O
) O
of O
them O
were O
women O
. O

most O
had O
hyperacute O
presentation O
; O
the O
median O
icterus B-NEG
encephalopathy B-NEG
interval O
was O
4.5 O
( O
0-30 O
) O
days O
. O

the O
median O
duration O
of O
att O
before O
alf B-NEG
was O
30 O
( O
7-350 O
) O
days O
. O

at O
presentation O
, O
advanced O
encephalopathy B-NEG
and O
cerebral B-NEG
edema I-NEG
were O
present O
in O
51 O
( O
76% O
) O
and O
29 O
( O
41.4% O
) O
patients O
, O
respectively O
. O
gastrointestinal B-NEG
bleed I-NEG
, O
seizures B-NEG
, O
infection B-NEG
, O
and O
acute B-NEG
renal I-NEG
failure I-NEG
were O
documented O
in O
seven O
(10%) O
, O
five O
(7.1%) O
, O
26 O
(37.1%) O
, O
and O
seven O
( O
10% O
) O
patients O
, O
respectively O
. O

compared O
with O
hepatitis B-NEG
e I-NEG
virus O
( O
hev O
) O
and O
non-a O
non-e-induced O
alf B-NEG
, O
att- O
alf B-NEG
patients O
had O
nearly O
similar O
presentations O
except O
for O
older O
age O
and O
less O
elevation O
of O
liver O
enzymes O
. O

the O
mortality O
rate O
among O
patients O
with O
att- O
alf B-NEG
was O
high O
(67.1% O
, O
n O
= O
47) O
, O
and O
only O
23 O
( O
32.9% O
) O
patients O
recovered O
with O
medical O
treatment O
. O

in O
multivariate O
analysis O
, O
three O
factors O
independently O
predicted O
mortality O
: O
serum O
bilirubin O
( O
>or=10.8 O
mg/dl) O
, O
prothrombin O
time O
( O
pt O
) O
prolongation O
( O
>or=26 O
seconds) O
, O
and O
grade O
iii/iv O
encephalopathy B-NEG
at O
presentation O
. O

conclusion O
: O
att- O
alf B-NEG
constituted O
5.7% O
of O
alf B-NEG
at O
our O
center O
and O
had O
a O
high O
mortality O
rate O
. O

because O
the O
mortality O
rate O
is O
so O
high O
, O
determining O
which O
factors O
are O
predictors O
is O
less O
important O
. O

a O
high O
proportion O
of O
patients O
had O
consumed O
att O
empirically O
, O
which O
could O
have O
been O
prevented O
. O

-DOCSTART- O

central B-NEG
nervous I-NEG
system I-NEG
complications I-NEG
during O
treatment O
of O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
in O
a O
single O
pediatric O
institution O
. O
central B-NEG
nervous I-NEG
system I-NEG
( O
cns I-NEG
) O
complications I-NEG
during O
treatment O
of O
childhood O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
( O
all B-NEG
) O
remain O
a O
challenging O
clinical O
problem O
. O

outcome O
improvement O
with O
more O
intensive O
chemotherapy O
has O
significantly O
increased O
the O
incidence O
and O
severity O
of O
adverse O
events O
. O

this O
study O
analyzed O
the O
incidence O
of O
neurological B-NEG
complications I-NEG
during O
all B-NEG
treatment O
in O
a O
single O
pediatric O
institution O
, O
focusing O
on O
clinical O
, O
radiological O
, O
and O
electrophysiological O
findings O
. O

exclusion O
criteria O
included O
cns O
leukemic B-NEG
infiltration I-NEG
at O
diagnosis O
, O
therapy-related O
peripheral B-NEG
neuropathy I-NEG
, O
late-onset O
encephalopathy B-NEG
, O
or O
long-term O
neurocognitive B-NEG
defects I-NEG
. O

during O
a O
9-year O
period O
, O
we O
retrospectively O
collected O
27 O
neurological O
events O
( O
11% O
) O
in O
as O
many O
patients O
, O
from O
253 O
children O
enrolled O
in O
the O
all B-NEG
front-line O
protocol O
. O

cns O
complications O
included O
posterior O
reversible O
leukoencephalopathy B-NEG
syndrome O
(n O
= O
10) O
, O
stroke B-NEG
(n O
= O
5) O
, O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
(n O
= O
2) O
, O
high-dose O
methotrexate O
toxicity B-NEG
(n O
= O
2) O
, O
syndrome O
of O
inappropriate B-NEG
antidiuretic I-NEG
hormone I-NEG
secretion I-NEG
(n O
= O
1) O
, O
and O
other O
unclassified O
events O
(n O
= O
7) O
. O

in O
conclusion O
, O
cns O
complications O
are O
frequent O
events O
during O
all B-NEG
therapy O
, O
and O
require O
rapid O
detection O
and O
prompt O
treatment O
to O
limit O
permanent O
damage O
. O

-DOCSTART- O

safety O
of O
capecitabine O
: O
a O
review O
. O

importance O
of O
the O
field O
: O
fluoropyrimidines O
, O
in O
particular O
5-fluorouracil O
(5-fu) O
, O
have O
been O
the O
mainstay O
of O
treatment O
for O
several O
solid O
tumors B-NEG
, O
including O
colorectal B-NEG
, O
breast I-NEG
and I-NEG
head I-NEG
and I-NEG
neck I-NEG
cancers I-NEG
, O
for O
> O
40 O
years O
. O

areas O
covered O
in O
this O
review O
: O
this O
article O
reviews O
the O
pharmacology O
and O
efficacy O
of O
capecitabine O
with O
a O
special O
emphasis O
on O
its O
safety O
. O

what O
the O
reader O
will O
gain O
: O
the O
reader O
will O
gain O
better O
insight O
into O
the O
safety O
of O
capecitabine O
in O
special O
populations O
such O
as O
patients O
with O
advanced O
age O
, O
renal B-NEG
and I-NEG
kidney I-NEG
disease I-NEG
. O

we O
also O
explore O
different O
dosing O
and O
schedules O
of O
capecitabine O
administration O
. O

take O
home O
message O
: O
capecitabine O
is O
an O
oral O
prodrug O
of O
5-fu O
and O
was O
developed O
to O
fulfill O
the O
need O
for O
a O
more O
convenient O
therapy O
and O
provide O
an O
improved O
safety/efficacy O
profile O
. O

it O
has O
shown O
promising O
results O
alone O
or O
in O
combination O
with O
other O
chemotherapeutic O
agents O
in O
colorectal B-NEG
, O
breast I-NEG
, O
pancreaticobiliary I-NEG
, O
gastric I-NEG
, O
renal I-NEG
cell I-NEG
and I-NEG
head I-NEG
and I-NEG
neck I-NEG
cancers I-NEG
. O

the O
most O
commonly O
reported O
toxic O
effects O
of O
capecitabine O
are O
diarrhea B-NEG
, O
nausea B-NEG
, O
vomiting B-NEG
, O
stomatitis B-NEG
and O
hand-foot B-NEG
syndrome I-NEG
. O

capecitabine O
has O
a O
well-established O
safety O
profile O
and O
can O
be O
given O
safely O
to O
patients O
with O
advanced O
age O
, O
hepatic B-NEG
and I-NEG
renal I-NEG
dysfunctions I-NEG
. O

-DOCSTART- O

effects O
of O
pallidal O
neurotensin O
on O
haloperidol-induced O
parkinsonian B-NEG
catalepsy I-NEG
: O
behavioral O
and O
electrophysiological O
studies O
. O

objective O
: O
the O
globus O
pallidus O
plays O
a O
critical O
role O
in O
movement O
regulation O
. O

previous O
studies O
have O
indicated O
that O
the O
globus O
pallidus O
receives O
neurotensinergic O
innervation O
from O
the O
striatum O
, O
and O
systemic O
administration O
of O
a O
neurotensin O
analog O
could O
produce O
antiparkinsonian O
effects O
. O

the O
present O
study O
aimed O
to O
investigate O
the O
effects O
of O
pallidal O
neurotensin O
on O
haloperidol-induced O
parkinsonian B-NEG
symptoms I-NEG
. O

methods O
: O
behavioral O
experiments O
and O
electrophysiological O
recordings O
were O
performed O
in O
the O
present O
study O
. O

results O
: O
bilateral O
infusions O
of O
neurotensin O
into O
the O
globus O
pallidus O
reversed O
haloperidol-induced O
parkinsonian B-NEG
catalepsy I-NEG
in O
rats O
. O

electrophysiological O
recordings O
showed O
that O
microinjection O
of O
neurotensin O
induced O
excitation O
of O
pallidal O
neurons O
in O
the O
presence O
of O
systemic O
haloperidol O
administration O
. O

the O
neurotensin O
type-1 O
receptor O
antagonist O
sr48692 O
blocked O
both O
the O
behavioral O
and O
the O
electrophysiological O
effects O
induced O
by O
neurotensin O
. O

conclusion O
: O
activation O
of O
pallidal O
neurotensin O
receptors O
may O
be O
involved O
in O
neurotensin-induced O
antiparkinsonian O
effects O
. O

-DOCSTART- O

antihypertensive O
drugs O
and O
depression B-NEG
: O
a O
reappraisal O
. O

eighty-nine O
new O
referral O
hypertensive B-NEG
out-patients O
and O
46 O
new O
referral O
non- O
hypertensive B-NEG
chronically O
physically O
ill O
out-patients O
completed O
a O
mood O
rating O
scale O
at O
regular O
intervals O
for O
one O
year O
. O

the O
results O
showed O
a O
high O
prevalence O
of O
depression B-NEG
in O
both O
groups O
of O
patients O
, O
with O
no O
preponderance O
in O
the O
hypertensive B-NEG
group O
. O
hypertensive B-NEG
patients O
with O
psychiatric B-NEG
histories O
had O
a O
higher O
prevalence O
of O
depression B-NEG
than O
the O
comparison O
patients O
. O

this O
was O
accounted O
for O
by O
a O
significant O
number O
of O
depressions B-NEG
occurring O
in O
methyl O
dopa O
treated O
patients O
with O
psychiatric B-NEG
histories O
. O

-DOCSTART- O

pulmonary O
shunt O
and O
cardiovascular O
responses O
to O
cpap O
during O
nitroprusside-induced O
hypotension B-NEG
. O

the O
effects O
of O
continuous O
positive O
airway O
pressure O
( O
cpap O
) O
on O
cardiovascular O
dynamics O
and O
pulmonary O
shunt O
( O
qs/qt O
) O
were O
investigated O
in O
12 O
dogs O
before O
and O
during O
sodium O
nitroprusside O
infusion O
that O
decreased O
mean O
arterial O
blood O
pressure O
40-50 O
per O
cent O
. O

before O
nitroprusside O
infusion O
, O
5 O
cm O
h2o O
cpap O
significantly O
, O
p O
less O
than O
.05 O
, O
decreased O
arterial O
blood O
pressure O
, O
but O
did O
not O
significantly O
alter O
heart O
rate O
, O
cardiac O
output O
, O
systemic O
vascular O
resistance O
, O
or O
qs/qt O
. O

ten O
cm O
h2o O
cpap O
before O
nitroprusside O
infusion O
produced O
a O
further O
decrease B-NEG
in I-NEG
arterial I-NEG
blood I-NEG
pressure I-NEG
and O
significantly O
increased O
heart O
rate O
and O
decreased B-NEG
cardiac I-NEG
output I-NEG
and O
qs/qt O
. O

nitroprusside O
caused O
significant O
decreases B-NEG
in I-NEG
arterial I-NEG
blood I-NEG
pressure I-NEG
and O
systemic O
vascular O
resistance O
and O
increases O
in O
heart O
rate O
, O
but O
did O
not O
change O
cardiac O
output O
or O
qs/qt O
. O

five O
cm O
h2o O
cpap O
during O
nitroprusside O
did O
not O
further O
alter O
any O
of O
the O
above-mentioned O
variables O
. O

however O
, O
10 O
cm O
h2o O
cpap O
decreased O
arterial O
blood O
pressure O
, O
cardiac O
output O
, O
and O
qs/qt O
. O

these O
data O
indicate O
that O
nitroprusside O
infusion O
rates O
that O
decrease O
mean O
arterial O
blood O
pressure O
by O
40-50 O
per O
cent O
do O
not O
change O
cardiac O
output O
or O
qs/qt O
. O

during O
nitroprusside O
infusion O
low O
levels O
of O
cpap O
do O
not O
markedly O
alter O
cardiovascular O
dynamics O
, O
but O
high O
levels O
of O
cpap O
( O
10 O
cm O
h2o) O
, O
while O
decreasing O
qs/qt O
, O
produce O
marked O
decreases B-NEG
in I-NEG
arterial I-NEG
blood I-NEG
pressure I-NEG
and I-NEG
cardiac I-NEG
output I-NEG
. O

-DOCSTART- O

mediation O
of O
enhanced O
reflex O
vagal O
bradycardia B-NEG
by O
l-dopa O
via O
central O
dopamine O
formation O
in O
dogs O
. O

l-dopa O
(5 O
mg/kg O
i.v. O
) O
decreased O
blood O
pressure O
and O
heart O
rate O
after O
extracerebral O
decarboxylase O
inhibition O
with O
mk-486 O
( O
25 O
mg/kg O
i.v. O
) O
in O
anesthetize O
mao-inhibited O
dogs O
. O

in O
addition O
, O
reflex O
bradycardia B-NEG
caused O
by O
injected O
norepinephrine O
was O
significantly O
enhanced O
by O
l-dopa O
, O
dl-threo-dihydroxyphenylserine O
had O
no O
effect O
on O
blood O
pressure O
, O
heart O
rate O
or O
reflex O
responses O
to O
norepinephrine O
. O

fla-63 O
, O
a O
dopamine-beta-oxidase O
inhibitor O
, O
did O
not O
have O
any O
effect O
on O
the O
hypotension B-NEG
, O
bradycardia B-NEG
or O
reflex-enhancing O
effect O
of O
l-dopa O
. O

pimozide O
did O
not O
affect O
the O
actions O
of O
l-dopa O
on O
blood O
pressure O
and O
heart O
rate O
but O
completely O
blocked O
the O
enhancement O
of O
reflexes O
. O

removal O
of O
the O
carotid O
sinuses O
caused O
an O
elevation O
blood O
pressure O
and O
heart O
rate O
and O
abolished O
the O
negative O
chronotropic O
effect O
of O
norepinephrine O
. O

however O
, O
l-dopa O
restored O
the O
bradycardia B-NEG
caused O
by O
norepinephrine O
in O
addition O
to O
decreasing O
blood O
pressure O
and O
heart O
rate O
. O

5-htp O
(5 O
mg/kg O
i.v. O
) O
decreased O
blood O
pressure O
and O
heart O
rate O
and O
decreased O
the O
reflex O
bradycardia B-NEG
to O
norepinephrine O
. O

it O
is O
concluded O
that O
l-dopa O
enhances O
reflex O
bradycardia B-NEG
through O
central O
alpha-receptor O
stimulation O
. O

furthermore O
, O
the O
effects O
are O
mediated O
through O
dopamine O
rather O
than O
norepinephrine O
and O
do O
not O
require O
the O
carotid O
sinus O
baroreceptors O
. O

-DOCSTART- O

cocaine-induced O
myocardial B-NEG
infarction I-NEG
: O
clinical O
observations O
and O
pathogenetic O
considerations O
. O

clinical O
and O
experimental O
data O
published O
to O
date O
suggest O
several O
possible O
mechanisms O
by O
which O
cocaine O
may O
result O
in O
acute B-NEG
myocardial I-NEG
infarction I-NEG
. O

in O
individuals O
with O
preexisting O
, O
high-grade O
coronary O
arterial O
narrowing O
, O
acute B-NEG
myocardial I-NEG
infarction I-NEG
may O
result O
from O
an O
increase O
in O
myocardial O
oxygen O
demand O
associated O
with O
cocaine-induced O
increase O
in O
rate-pressure O
product O
. O

in O
other O
individuals O
with O
no O
underlying O
atherosclerotic B-NEG
obstruction I-NEG
, O
coronary B-NEG
occlusion I-NEG
may O
be O
due O
to O
spasm B-NEG
, O
thrombus B-NEG
, O
or O
both O
. O

with O
regard O
to O
spasm B-NEG
, O
the O
clinical O
findings O
are O
largely O
circumstantial O
, O
and O
the O
locus O
of O
cocaine-induced O
vasoconstriction O
remains O
speculative O
. O

although O
certain O
clinical O
and O
experimental O
findings O
support O
the O
hypothesis O
that O
spasm B-NEG
involves O
the O
epicardial O
, O
medium-size O
vessels O
, O
other O
data O
suggest O
intramural O
vasoconstriction O
. O

diffuse O
intramural O
vasoconstriction O
is O
not O
consistent O
with O
reports O
of O
segmental O
, O
discrete O
infarction B-NEG
. O

whereas O
certain O
in O
vivo O
data O
suggest O
that O
these O
effects O
are O
alpha-mediated O
, O
other O
in O
vitro O
data O
suggest O
the O
opposite O
. O

the O
finding O
of O
cocaine-induced O
vasoconstriction O
in O
segments O
of O
( O
noninnervated O
) O
human O
umbilical O
artery O
suggests O
that O
the O
presence O
or O
absence O
of O
intact O
innervation O
is O
not O
sufficient O
to O
explain O
the O
discrepant O
data O
involving O
the O
possibility O
of O
alpha-mediated O
effects O
. O

finally O
, O
the O
contribution O
of O
a O
primary O
, O
thrombotic B-NEG
effect O
of O
cocaine O
has O
not O
been O
excluded O
. O

-DOCSTART- O

rabbit B-NEG
syndrome I-NEG
, O
antidepressant O
use O
, O
and O
cerebral O
perfusion O
spect O
scan O
findings O
. O

the O
rabbit B-NEG
syndrome I-NEG
is O
an O
extrapyramidal O
side O
effect O
associated O
with O
chronic O
neuroleptic O
therapy O
. O

its O
occurrence O
in O
a O
patient O
being O
treated O
with O
imipramine O
is O
described O
, O
representing O
the O
first O
reported O
case O
of O
this O
syndrome O
in O
conjunction O
with O
antidepressants O
. O

repeated O
cerebral O
perfusion O
spect O
scans O
revealed O
decreased B-NEG
basal I-NEG
ganglia I-NEG
perfusion I-NEG
while O
the O
movement B-NEG
disorder I-NEG
was O
present O
, O
and O
a O
return O
to O
normal O
perfusion O
when O
the O
rabbit B-NEG
syndrome I-NEG
resolved O
. O

-DOCSTART- O

acute O
bronchodilating O
effects O
of O
ipratropium O
bromide O
and O
theophylline O
in O
chronic B-NEG
obstructive I-NEG
pulmonary I-NEG
disease I-NEG
. O

the O
bronchodilator O
effects O
of O
a O
single O
dose O
of O
ipratropium O
bromide O
aerosol O
( O
36 O
micrograms O
) O
and O
short-acting O
theophylline O
tablets O
( O
dose O
titrated O
to O
produce O
serum O
levels O
of O
10-20 O
micrograms/ml O
) O
were O
compared O
in O
a O
double-blind O
, O
placebo-controlled O
crossover O
study O
in O
21 O
patients O
with O
stable O
, O
chronic B-NEG
obstructive I-NEG
pulmonary I-NEG
disease I-NEG
. O

mean O
peak O
forced O
expiratory O
volume O
in O
1 O
second O
( O
fev1 O
) O
increases O
over O
baseline O
and O
the O
proportion O
of O
patients O
attaining O
at O
least O
a O
15% O
increase O
in O
the O
fev1 O
( O
responders O
) O
were O
31% O
and O
90% O
, O
respectively O
, O
for O
ipratropium O
and O
17% O
and O
50% O
, O
respectively O
, O
for O
theophylline O
. O

the O
average O
fev1 O
increases O
during O
the O
6-hour O
observation O
period O
were O
18% O
for O
ipratropium O
and O
8% O
for O
theophylline O
. O

the O
mean O
duration O
of O
action O
was O
3.8 O
hours O
with O
ipratropium O
and O
2.4 O
hours O
with O
theophylline O
. O

while O
side O
effects O
were O
rare O
, O
those O
experienced O
after O
theophylline O
use O
did O
involve O
the O
cardiovascular B-NEG
and I-NEG
gastrointestinal I-NEG
systems I-NEG
. O

these O
results O
show O
that O
ipratropium O
is O
a O
more O
potent O
bronchodilator O
than O
oral O
theophylline O
in O
patients O
with O
chronic B-NEG
airflow I-NEG
obstruction I-NEG
. O

-DOCSTART- O

irreversible O
damage O
to O
the O
medullary O
interstitium O
in O
experimental O
analgesic O
nephropathy B-NEG
in O
f344 O
rats O
. O
renal B-NEG
papillary I-NEG
necrosis I-NEG
( O
rpn B-NEG
) O
and O
a O
decreased O
urinary O
concentrating O
ability O
developed O
during O
continuous O
long-term O
treatment O
with O
aspirin O
and O
paracetamol O
in O
female O
fischer O
344 O
rats O
. O

renal O
structure O
and O
concentrating O
ability O
were O
examined O
after O
a O
recovery O
period O
of O
up O
to O
18 O
weeks O
, O
when O
no O
analgesics O
were O
given O
, O
to O
investigate O
whether O
the O
analgesic-induced O
changes O
were O
reversible O
. O

there O
was O
no O
evidence O
of O
repair O
to O
the O
damaged O
medullary O
interstitial O
matrix O
, O
or O
proliferation O
of O
remaining O
undamaged O
type O
1 O
medullary O
interstitial O
cells O
after O
the O
recovery O
period O
following O
analgesic O
treatment O
. O

the O
recovery O
of O
urinary O
concentrating O
ability O
was O
related O
to O
the O
length O
of O
analgesic O
treatment O
and O
the O
extent O
of O
the O
resulting O
inner O
medullary O
structural O
damage O
. O

during O
the O
early O
stages O
of O
analgesic O
treatment O
, O
the O
changes O
in O
urinary O
concentrating O
ability O
were O
reversible O
, O
but O
after O
prolonged O
analgesic O
treatment O
, O
maximum O
urinary O
concentrating O
ability O
failed O
to O
recover O
. O

this O
study O
shows O
that O
prolonged O
analgesic O
treatment O
in O
fischer O
344 O
rats O
causes O
progressive O
and O
irreversible O
damage O
to O
the O
interstitial O
matrix O
and O
type O
1 O
interstitial O
cells O
leading O
to O
rpn B-NEG
. O

the O
associated O
urinary O
concentrating O
defect O
is O
reversible O
only O
during O
the O
early O
stages O
of O
structural O
damage O
to O
the O
inner O
medulla O
. O

-DOCSTART- O

less O
frequent O
lithium O
administration O
and O
lower O
urine O
volume O
. O

objective O
: O
this O
study O
was O
designed O
to O
determine O
whether O
patients O
maintained O
on O
a O
regimen O
of O
lithium O
on O
a O
once-per-day O
schedule O
have O
lower O
urine O
volumes O
than O
do O
patients O
receiving O
multiple O
doses O
per O
day O
. O

method O
: O
this O
was O
a O
cross-sectional O
study O
of O
85 O
patients O
from O
a O
lithium O
clinic O
who O
received O
different O
dose O
schedules O
. O

patients O
were O
admitted O
to O
the O
hospital O
for O
measurement O
of O
lithium O
level O
, O
creatinine O
clearance O
, O
urine O
volume O
, O
and O
maximum O
osmolality O
. O

results O
: O
multiple O
daily O
doses O
of O
lithium O
were O
associated O
with O
higher O
urine O
volumes O
. O

the O
dosing O
schedule O
, O
duration O
of O
lithium O
treatment O
, O
and O
daily O
dose O
of O
lithium O
did O
not O
affect O
maximum O
osmolality O
or O
creatinine O
clearance O
. O

conclusions O
: O
urine O
volume O
can O
be O
reduced O
by O
giving O
lithium O
once O
daily O
and/or O
by O
lowering O
the O
total O
daily O
dose O
. O

lithium-induced O
polyuria B-NEG
seems O
to O
be O
related O
to O
extrarenal O
as O
well O
as O
to O
renal O
effects O
. O

-DOCSTART- O

effect O
of O
adriamycin O
combined O
with O
whole O
body O
hyperthermia B-NEG
on O
tumor B-NEG
and O
normal O
tissues O
. O

thermal O
enhancement O
of O
adriamycin-mediated O
antitumor O
activity O
and O
normal O
tissue O
toxicities B-NEG
by O
whole O
body O
hyperthermia B-NEG
were O
compared O
using O
a O
f344 O
rat O
model O
. O

antitumor O
activity O
was O
studied O
using O
a O
tumor B-NEG
growth O
delay O
assay O
. O

acute O
normal O
tissue O
toxicities B-NEG
(i.e. O
, O
leukopenia B-NEG
and O
thrombocytopenia B-NEG
) O
and O
late O
normal O
tissue O
toxicities B-NEG
(i.e. O
, O
myocardial B-NEG
and I-NEG
kidney I-NEG
injury I-NEG
) O
were O
evaluated O
by O
functional/physiological O
assays O
and O
by O
morphological O
techniques O
. O

whole O
body O
hyperthermia B-NEG
( O
120 O
min O
at O
41.5 O
degrees O
c) O
enhanced O
both O
adriamycin-mediated O
antitumor O
activity O
and O
toxic O
side O
effects O
. O

the O
thermal O
enhancement O
ratio O
calculated O
for O
antitumor O
activity O
was O
1.6 O
. O

thermal O
enhancement O
ratios O
estimated O
for O
acute O
hematological O
changes O
were O
1.3 O
, O
whereas O
those O
estimated O
for O
late O
damage O
( O
based O
on O
morphological O
cardiac B-NEG
and I-NEG
renal I-NEG
lesions I-NEG
) O
varied O
between O
2.4 O
and O
4.3 O
. O

thus O
, O
while O
whole O
body O
hyperthermia B-NEG
enhances O
adriamycin-mediated O
antitumor O
effect O
, O
normal O
tissue O
toxicity B-NEG
is O
also O
increased O
, O
and O
the O
potential O
therapeutic O
gain O
of O
the O
combined O
modality O
treatment O
is O
eroded O
. O

-DOCSTART- O

prazosin-induced O
stress B-NEG
incontinence I-NEG
. O

a O
case O
of O
genuine O
stress B-NEG
incontinence I-NEG
due O
to O
prazosin O
, O
a O
common O
antihypertensive O
drug O
, O
is O
presented O
. O

prazosin O
exerts O
its O
antihypertensive O
effects O
through O
vasodilatation O
caused O
by O
selective O
blockade O
of O
postsynaptic O
alpha-1 O
adrenergic O
receptors O
. O

as O
an O
alpha-blocker O
, O
it O
also O
exerts O
a O
significant O
relaxant O
effect O
on O
the O
bladder O
neck O
and O
urethra O
. O

the O
patient's O
clinical O
course O
is O
described O
and O
correlated O
with O
initial O
urodynamic O
studies O
while O
on O
prazosin O
and O
subsequent O
studies O
while O
taking O
verapamil O
. O

her O
incontinence B-NEG
resolved O
with O
the O
change O
of O
medication O
. O

the O
restoration O
of O
continence O
was O
accompanied O
by O
a O
substantial O
rise O
in O
maximum O
urethral O
pressure O
, O
maximum O
urethral O
closure O
pressure O
, O
and O
functional O
urethral O
length O
. O

patients O
who O
present O
with O
stress B-NEG
incontinence I-NEG
while O
taking O
prazosin O
should O
change O
their O
antihypertensive O
medication O
before O
considering O
surgery O
, O
because O
their O
incontinence B-NEG
may O
resolve O
spontaneously O
with O
a O
change O
in O
drug O
therapy O
. O

-DOCSTART- O

myocardial B-NEG
infarction I-NEG
following O
sublingual O
administration O
of O
isosorbide O
dinitrate O
. O

a O
78-year-old O
with O
healed O
septal O
necrosis B-NEG
suffered O
a O
recurrent O
myocardial B-NEG
infarction I-NEG
of O
the O
anterior O
wall O
following O
the O
administration O
of O
isosorbide O
dinitrate O
5 O
mg O
sublingually O
. O

after O
detailing O
the O
course O
of O
events O
, O
we O
discuss O
the O
role O
of O
paradoxical O
coronary O
spasm B-NEG
and O
hypotension B-NEG
-mediated O
myocardial B-NEG
ischemia I-NEG
occurring O
downstream O
to O
significant O
coronary B-NEG
arterial I-NEG
stenosis I-NEG
in O
the O
pathophysiology O
of O
acute B-NEG
coronary I-NEG
insufficiency I-NEG
. O

-DOCSTART- O

fluoxetine-induced O
akathisia B-NEG
: O
clinical O
and O
theoretical O
implications O
. O

five O
patients O
receiving O
fluoxetine O
for O
the O
treatment O
of O
obsessive B-NEG
compulsive I-NEG
disorder I-NEG
or O
major B-NEG
depression I-NEG
developed O
akathisia B-NEG
. O

the O
typical O
fluoxetine-induced O
symptoms O
of O
restlessness O
, O
constant O
pacing O
, O
purposeless O
movements O
of O
the O
feet O
and O
legs O
, O
and O
marked O
anxiety B-NEG
were O
indistinguishable O
from O
those O
of O
neuroleptic-induced O
akathisia B-NEG
. O

three O
patients O
who O
had O
experienced O
neuroleptic-induced O
akathisia B-NEG
in O
the O
past O
reported O
that O
the O
symptoms O
of O
fluoxetine-induced O
akathisia B-NEG
were O
identical O
, O
although O
somewhat O
milder O
. O
akathisia B-NEG
appeared O
to O
be O
a O
common O
side O
effect O
of O
fluoxetine O
and O
generally O
responded O
well O
to O
treatment O
with O
the O
beta-adrenergic O
antagonist O
propranolol O
, O
dose O
reduction O
, O
or O
both O
. O

the O
authors O
suggest O
that O
fluoxetine-induced O
akathisia B-NEG
may O
be O
caused O
by O
serotonergically O
mediated O
inhibition O
of O
dopaminergic O
neurotransmission O
and O
that O
the O
pathophysiology O
of O
fluoxetine-induced O
akathisia B-NEG
and O
tricyclic O
antidepressant-induced O
jitteriness O
may O
be O
identical O
. O

-DOCSTART- O

chronic B-NEG
active I-NEG
hepatitis I-NEG
associated O
with O
diclofenac O
sodium O
therapy O
. O

diclofenac O
sodium O
(voltarol O
, O
geigy O
pharmaceuticals O
) O
is O
a O
non-steroidal O
anti-inflammatory O
derivative O
of O
phenylacetic O
acid O
. O

although O
generally O
well-tolerated O
, O
asymptomatic O
abnormalities B-NEG
of I-NEG
liver I-NEG
function I-NEG
have O
been O
recorded O
and O
, O
less O
commonly O
, O
severe O
hepatitis B-NEG
induced O
by O
diclofenac O
. O

the O
patient O
described O
developed O
chronic B-NEG
active I-NEG
hepatitis I-NEG
after O
six O
months O
therapy O
with O
diclofenac O
sodium O
which O
progressed O
despite O
the O
withdrawal O
of O
the O
drug O
, O
a O
finding O
not O
previously O
reported O
. O

-DOCSTART- O

stroke B-NEG
associated O
with O
cocaine O
use O
. O

we O
describe O
eight O
patients O
in O
whom O
cocaine O
use O
was O
related O
to O
stroke B-NEG
and O
review O
39 O
cases O
from O
the O
literature O
. O

among O
these O
47 O
patients O
the O
mean O
( O
+/- O
sd O
) O
age O
was O
32.5 O
+/- O
12.1 O
years O
; O
76% O
( O
34/45 O
) O
were O
men O
. O
stroke B-NEG
followed O
cocaine O
use O
by O
inhalation O
, O
intranasal O
, O
intravenous O
, O
and O
intramuscular O
routes O
. O
intracranial B-NEG
aneurysms I-NEG
or O
arteriovenous B-NEG
malformations I-NEG
were O
present O
in O
17 O
of O
32 O
patients O
studied O
angiographically O
or O
at O
autopsy O
; O
cerebral B-NEG
vasculitis I-NEG
was O
present O
in O
two O
patients O
. O
cerebral B-NEG
infarction I-NEG
occurred O
in O
10 O
patients O
(22%) O
, O
intracerebral B-NEG
hemorrhage I-NEG
in O
22 O
(49%) O
, O
and O
subarachnoid B-NEG
hemorrhage I-NEG
in O
13 O
(29%) O
. O

these O
data O
indicate O
that O
( O
1 O
) O
the O
apparent O
incidence O
of O
stroke B-NEG
related O
to O
cocaine O
use O
is O
increasing O
; O
( O
2 O
) O
cocaine-associated O
stroke B-NEG
occurs O
primarily O
in O
young O
adults O
; O
( O
3 O
) O
stroke B-NEG
may O
follow O
any O
route O
of O
cocaine O
administration O
; O
( O
4 O
) O
stroke B-NEG
after O
cocaine O
use O
is O
frequently O
associated O
with O
intracranial B-NEG
aneurysms I-NEG
and O
arteriovenous B-NEG
malformations I-NEG
; O
and O
( O
5 O
) O
in O
cocaine-associated O
stroke B-NEG
, O
the O
frequency O
of O
intracranial B-NEG
hemorrhage I-NEG
exceeds O
that O
of O
cerebral B-NEG
infarction I-NEG
. O

-DOCSTART- O

glyburide-induced O
hepatitis B-NEG
. O

drug-induced O
hepatotoxicity B-NEG
, O
although O
common O
, O
has O
been O
reported O
only O
infrequently O
with O
sulfonylureas O
. O

for O
glyburide O
, O
a O
second-generation O
sulfonylurea O
, O
only O
two O
brief O
reports O
of O
hepatotoxicity B-NEG
exist O
. O

two O
patients O
with O
type B-NEG
ii I-NEG
diabetes I-NEG
mellitus I-NEG
developed O
an O
acute B-NEG
hepatitis-like I-NEG
syndrome I-NEG
soon O
after O
initiation O
of O
glyburide O
therapy O
. O

there O
was O
no O
serologic O
evidence O
of O
viral B-NEG
infection I-NEG
, O
and O
a O
liver O
biopsy O
sample O
showed O
a O
histologic O
pattern O
consistent O
with O
drug-induced B-NEG
hepatitis I-NEG
. O

both O
patients O
recovered O
quickly O
after O
stopping O
glyburide O
therapy O
and O
have O
remained O
well O
for O
a O
follow-up O
period O
of O
1 O
year O
. O

glyburide O
can O
produce O
an O
acute B-NEG
hepatitis-like I-NEG
illness I-NEG
in O
some O
persons O
. O

-DOCSTART- O

systolic O
pressure O
variation O
is O
greater O
during O
hemorrhage B-NEG
than O
during O
sodium O
nitroprusside-induced O
hypotension B-NEG
in O
ventilated O
dogs O
. O

the O
systolic O
pressure O
variation O
(spv) O
, O
which O
is O
the O
difference O
between O
the O
maximal O
and O
minimal O
values O
of O
the O
systolic O
blood O
pressure O
( O
sbp O
) O
after O
one O
positive-pressure O
breath O
, O
was O
studied O
in O
ventilated O
dogs O
subjected O
to O
hypotension B-NEG
. O

mean O
arterial O
pressure O
was O
decreased O
to O
50 O
mm O
hg O
for O
30 O
minutes O
either O
by O
hemorrhage B-NEG
( O
hem B-NEG
, O
n O
= O
7) O
or O
by O
continuous O
infusion O
of O
sodium O
nitroprusside O
(snp O
, O
n O
= O
7) O
. O

during O
hem B-NEG
-induced O
hypotension B-NEG
the O
cardiac O
output O
was O
significantly O
lower O
and O
systemic O
vascular O
resistance O
higher O
compared O
with O
that O
in O
the O
snp O
group O
. O

the O
systemic O
, O
central O
venous O
, O
pulmonary O
capillary O
wedge O
pressures O
, O
and O
heart O
rates O
, O
were O
similar O
in O
the O
two O
groups O
. O

analysis O
of O
the O
respiratory O
changes O
in O
the O
arterial O
pressure O
waveform O
enabled O
differentiation O
between O
the O
two O
groups O
. O

the O
spv O
during O
hypotension B-NEG
was O
15.7 O
+/- O
6.7 O
mm O
hg O
in O
the O
hem B-NEG
group O
, O
compared O
with O
9.1 O
+/- O
2.0 O
mm O
hg O
in O
the O
snp O
group O
(p O
less O
than O
0.02) O
. O

the O
delta O
down O
, O
which O
is O
the O
measure O
of O
decrease O
of O
sbp O
after O
a O
mechanical O
breath O
, O
was O
20.3 O
+/- O
8.4 O
and O
10.1 O
+/- O
3.8 O
mm O
hg O
in O
the O
hem B-NEG
and O
snp O
groups O
, O
respectively O
, O
during O
hypotension B-NEG
(p O
less O
than O
0.02) O
. O

it O
is O
concluded O
that O
increases O
in O
the O
spv O
and O
the O
delta O
down O
are O
characteristic O
of O
a O
hypotensive B-NEG
state O
due O
to O
a O
predominant O
decrease O
in O
preload O
. O

they O
are O
thus O
more O
important O
during O
absolute O
hypovolemia B-NEG
than O
during O
deliberate O
hypotension B-NEG
. O

-DOCSTART- O

drug-induced O
arterial O
spasm B-NEG
relieved O
by O
lidocaine O
. O

case O
report O
. O

following O
major O
intracranial O
surgery O
in O
a O
35-year-old O
man O
, O
sodium O
pentothal O
was O
intravenously O
infused O
to O
minimize O
cerebral B-NEG
ischaemia I-NEG
. O

intense O
vasospasm B-NEG
with O
threatened O
gangrene B-NEG
arose O
in O
the O
arm O
used O
for O
the O
infusion O
. O

since O
the O
cranial O
condition O
precluded O
use O
of O
more O
usual O
methods O
, O
lidocaine O
was O
given O
intra-arterially O
, O
with O
careful O
cardiovascular O
monitoring O
, O
to O
counteract O
the O
vasospasm B-NEG
. O

the O
treatment O
was O
rapidly O
successful O
. O

-DOCSTART- O

cerebral O
blood O
flow O
and O
metabolism O
during O
isoflurane-induced O
hypotension B-NEG
in O
patients O
subjected O
to O
surgery O
for O
cerebral B-NEG
aneurysms I-NEG
. O

cerebral O
blood O
flow O
and O
cerebral O
metabolic O
rate O
for O
oxygen O
were O
measured O
during O
isoflurane-induced O
hypotension B-NEG
in O
10 O
patients O
subjected O
to O
craniotomy O
for O
clipping O
of O
a O
cerebral B-NEG
aneurysm I-NEG
. O

flow O
and O
metabolism O
were O
measured O
5-13 O
days O
after O
the O
subarachnoid B-NEG
haemorrhage I-NEG
by O
a O
modification O
of O
the O
classical O
kety-schmidt O
technique O
using O
xenon-133 O
i.v O
. O

anaesthesia O
was O
maintained O
with O
an O
inspired O
isoflurane O
concentration O
of O
0.75% O
( O
plus O
67% O
nitrous O
oxide O
in O
oxygen) O
, O
during O
which O
cbf O
and O
cmro2 O
were O
34.3 O
+/- O
2.1 O
ml/100 O
g O
min-1 O
and O
2.32 O
+/- O
0.16 O
ml/100 O
g O
min-1 O
at O
paco2 O
4.1 O
+/- O
0.1 O
kpa O
( O
mean O
+/- O
sem) O
. O

controlled O
hypotension B-NEG
to O
an O
average O
map O
of O
50-55 O
mm O
hg O
was O
induced O
by O
increasing O
the O
dose O
of O
isoflurane O
, O
and O
maintained O
at O
an O
inspired O
concentration O
of O
2.2 O
+/- O
0.2% O
. O

this O
resulted O
in O
a O
significant O
decrease O
in O
cmro2 O
( O
to O
1.73 O
+/- O
0.16 O
ml/100 O
g O
min-1) O
, O
while O
cbf O
was O
unchanged O
. O

after O
the O
clipping O
of O
the O
aneurysm B-NEG
the O
isoflurane O
concentration O
was O
reduced O
to O
0.75% O
. O

there O
was O
a O
significant O
increase O
in O
cbf O
, O
although O
cmro2 O
was O
unchanged O
, O
compared O
with O
pre- O
hypotensive B-NEG
values O
. O

these O
changes O
might O
offer O
protection O
to O
brain O
tissue O
during O
periods O
of O
induced O
hypotension B-NEG
. O

-DOCSTART- O

allergic B-NEG
reaction I-NEG
to O
5-fluorouracil O
infusion O
. O

an O
allergic B-NEG
reaction I-NEG
consisting O
of O
angioneurotic B-NEG
edema I-NEG
secondary O
to O
continuous O
infusion O
5-fluorouracil O
occurred O
in O
a O
patient O
with O
recurrent O
carcinoma B-NEG
of I-NEG
the I-NEG
oral I-NEG
cavity I-NEG
, O
cirrhosis B-NEG
, O
and O
cisplatin-induced O
impaired B-NEG
renal I-NEG
function I-NEG
. O

this O
reaction O
occurred O
during O
the O
sixth O
and O
seventh O
courses O
of O
infusional O
chemotherapy O
. O

oral O
diphenhydramine O
and O
prednisone O
were O
ineffective O
in O
preventing O
the O
recurrence O
of O
the O
allergic B-NEG
reaction I-NEG
. O

discontinuance O
of O
effective O
chemotherapy O
in O
this O
patient O
during O
partial O
remission O
resulted O
in O
fatal O
disease O
progression O
. O

-DOCSTART- O

amiodarone-induced O
sinoatrial B-NEG
block I-NEG
. O

we O
observed O
sinoatrial B-NEG
block I-NEG
due O
to O
chronic O
amiodarone O
administration O
in O
a O
5-year-old O
boy O
with O
primary B-NEG
cardiomyopathy I-NEG
, O
wolff-parkinson-white B-NEG
syndrome I-NEG
and O
supraventricular B-NEG
tachycardia I-NEG
. O

reduction O
in O
the O
dosage O
of O
amiodarone O
resulted O
in O
the O
disappearance O
of O
the O
sinoatrial B-NEG
block I-NEG
and O
the O
persistence O
of O
asymptomatic O
sinus B-NEG
bradycardia I-NEG
. O

-DOCSTART- O

possible O
teratogenicity O
of O
sulphasalazine O
. O

three O
infants O
, O
born O
of O
two O
mothers O
with O
inflammatory B-NEG
bowel I-NEG
disease I-NEG
who O
received O
treatment O
with O
sulphasalazine O
throughout O
pregnancy O
, O
were O
found O
to O
have O
major O
congenital B-NEG
anomalies I-NEG
. O

in O
the O
singleton O
pregnancy O
, O
the O
mother O
had O
ulcerative B-NEG
colitis I-NEG
, O
and O
the O
infant O
, O
a O
male O
, O
had O
coarctation B-NEG
of I-NEG
the I-NEG
aorta I-NEG
and O
a O
ventricular B-NEG
septal I-NEG
defect I-NEG
. O

in O
the O
twin O
pregnancy O
, O
the O
mother O
had O
crohn's B-NEG
disease I-NEG
. O

the O
first O
twin O
, O
a O
female O
, O
had O
a O
left O
potter-type B-NEG
iia I-NEG
polycystic I-NEG
kidney I-NEG
and O
a O
rudimentary B-NEG
left I-NEG
uterine I-NEG
cornu I-NEG
. O

the O
second O
twin O
, O
a O
male O
, O
had O
some O
features O
of O
potter's B-NEG
facies I-NEG
, O
hypoplastic B-NEG
lungs I-NEG
, O
absent B-NEG
kidneys I-NEG
and I-NEG
ureters I-NEG
, O
and O
talipes B-NEG
equinovarus I-NEG
. O

despite O
reports O
to O
the O
contrary O
, O
it O
is O
suggested O
that O
sulphasalazine O
may O
be O
teratogenic O
. O

-DOCSTART- O

veno-occlusive B-NEG
liver I-NEG
disease I-NEG
after O
dacarbazine O
therapy O
( O
dtic O
) O
for O
melanoma B-NEG
. O

a O
case O
of O
veno-occlusive B-NEG
disease I-NEG
of I-NEG
the I-NEG
liver I-NEG
with O
fatal O
outcome O
after O
dacarbazine O
( O
dtic O
) O
therapy O
for O
melanoma B-NEG
is O
reported O
. O

there O
was O
a O
fulminant O
clinical O
course O
from O
start O
of O
symptoms O
until O
death B-NEG
. O

at O
autopsy O
the O
liver O
was O
enlarged O
and O
firm O
with O
signs O
of O
venous B-NEG
congestion I-NEG
. O

small- O
and O
medium-sized O
hepatic O
veins O
were O
blocked O
by O
thrombosis B-NEG
. O

eosinophilic O
infiltrations O
were O
found O
around O
the O
vessels O
. O

published O
cases O
from O
the O
literature O
are O
reviewed O
and O
pertinent O
features O
discussed O
. O

-DOCSTART- O

a O
case O
of O
tardive B-NEG
dyskinesia I-NEG
caused O
by O
metoclopramide O
. O
abnormal B-NEG
involuntary I-NEG
movements I-NEG
appeared O
in O
the O
mouth O
, O
tongue O
, O
neck O
and O
abdomen O
of O
a O
64-year-old O
male O
patient O
after O
he O
took O
metoclopramide O
for O
gastrointestinal B-NEG
disorder I-NEG
in O
a O
regimen O
of O
30 O
mg O
per O
day O
for O
a O
total O
of O
about O
260 O
days O
. O

the O
symptoms O
exacerbated O
to O
a O
maximum O
in O
a O
month O
. O

when O
the O
metoclopramide O
administration O
was O
discontinued O
, O
the O
abnormal B-NEG
movements I-NEG
gradually O
improved O
to O
a O
considerable O
extent O
. O

attention O
to O
the O
possible O
induction O
of O
specific O
tardive B-NEG
dyskinesia I-NEG
is O
called O
for O
in O
the O
use O
of O
this O
drug O
. O

-DOCSTART- O

further O
observations O
on O
the O
electrophysiologic O
effects O
of O
oral O
amiodarone O
therapy O
. O

a O
case O
is O
presented O
of O
a O
reversible O
intra-hisian B-NEG
block I-NEG
occurring O
under O
amiodarone O
treatment O
for O
atrial B-NEG
tachycardia I-NEG
in O
a O
patient O
without O
clear O
intraventricular B-NEG
conduction I-NEG
abnormalities I-NEG
. O

his O
bundle O
recordings O
showed O
an O
atrial B-NEG
tachycardia I-NEG
with O
intermittent O
exit O
block O
and O
greatly O
prolonged O
bh O
and O
hv O
intervals O
( O
40 O
and O
100 O
msec O
, O
respectively) O
. O

thirty O
days O
after O
amiodarone O
discontinuation O
, O
his O
bundle O
electrograms O
showed O
atrial B-NEG
flutter I-NEG
without O
intra-hisian O
or O
infra-hisian O
delay O
. O

amiodarone O
should O
be O
used O
with O
caution O
during O
long-term O
oral O
therapy O
in O
patients O
with O
or O
without O
clear O
intraventricular O
conduction O
defects O
. O

-DOCSTART- O

busulfan-induced O
hemorrhagic B-NEG
cystitis I-NEG
. O

a O
case O
of O
a O
busulfan-induced O
hemorrhage B-NEG
cystitis I-NEG
is O
reported O
. O

spontaneous O
resolution O
occurred O
following O
cessation O
of O
the O
drug O
. O

the O
similarity O
between O
the O
histologic O
appearances O
of O
busulfan O
cystitis B-NEG
and O
both O
radiation O
and O
cyclophosphamide-induced O
cystitis B-NEG
is O
discussed O
and O
the O
world O
literature O
reviewed O
. O

in O
view O
of O
the O
known O
tendency O
of O
busulfan O
to O
induce O
cellular O
atypia O
and O
carcinoma B-NEG
in O
other O
sites O
, O
periodic O
urinary O
cytology O
is O
suggested O
in O
patients O
on O
long-term O
therapy O
. O

-DOCSTART- O

rebound O
hypertensive B-NEG
after O
sodium O
nitroprusside O
prevented O
by O
saralasin O
in O
rats O
. O

the O
role O
of O
the O
renin--angiotensin O
system O
in O
the O
maintenance O
of O
blood O
pressure O
during O
halothane O
anesthesia O
and O
sodium O
nitroprusside O
( O
snp)-induced O
hypotension B-NEG
was O
evaluated O
. O

control O
rats O
received O
halothane O
anesthesia O
(1 O
mac O
) O
for O
one O
hour O
, O
followed O
by O
snp O
infusion O
, O
40 O
microgram/kg/min O
, O
for O
30 O
min O
, O
followed O
by O
a O
30-min O
recovery O
period O
. O

a O
second O
group O
of O
rats O
was O
treated O
identically O
and O
, O
in O
addition O
, O
received O
an O
infusion O
of O
saralasin O
(a O
competitive O
inhibitor O
of O
angiotensin O
ii O
) O
throughout O
the O
experimental O
period O
. O

in O
each O
group O
, O
snp O
infusion O
resulted O
in O
an O
initial O
decrease O
in O
blood O
pressure O
from O
86 O
torr O
and O
83 O
torr O
, O
respectively O
, O
to O
48 O
torr O
. O

during O
the O
snp O
infusion O
the O
control O
animals O
demonstrated O
a O
progressive O
increase B-NEG
in I-NEG
blood I-NEG
pressure I-NEG
to O
61 O
torr O
, O
whereas O
the O
saralasin-treated O
animals O
showed O
no O
change O
. O

following O
discontinuation O
of O
snp O
, O
blood O
pressure O
in O
the O
control O
animals O
rebounded O
to O
94 O
torr O
, O
as O
compared O
with O
78 O
torr O
in O
the O
saralasin-treated O
rats O
. O

this O
study O
indicates O
that O
with O
stable O
halothane O
anesthesia O
, O
the O
partial O
recovery O
of O
blood O
pressure O
during O
snp O
infusion O
and O
the O
post-snp O
rebound O
of O
blood O
pressure O
can O
be O
completely O
blocked O
by O
saralasin O
. O

this O
demonstrates O
the O
participation O
of O
the O
renin--angiotensin O
system O
in O
antagonizing O
the O
combined O
hypotensive B-NEG
effects O
of O
halothane O
and O
snp O
. O

-DOCSTART- O

toxic B-NEG
hepatitis I-NEG
induced O
by O
antithyroid O
drugs O
: O
four O
cases O
including O
one O
with O
cross-reactivity O
between O
carbimazole O
and O
benzylthiouracil O
. O

objective O
: O
this O
study O
was O
conducted O
to O
assess O
the O
occurrence O
of O
hepatic B-NEG
adverse I-NEG
effects I-NEG
encountered O
with O
antithyroid O
drugs O
. O

methods O
: O
retrospective O
review O
of O
medical O
records O
of O
236 O
patients O
with O
hyperthyroidism B-NEG
admitted O
in O
our O
department O
( O
in- O
or O
out-patients O
) O
from O
1986 O
to O
1992 O
. O

results O
: O
four O
patients O
( O
1.7% O
) O
were O
identified O
with O
toxic B-NEG
hepatitis I-NEG
which O
could O
reasonably O
be O
attributed O
to O
the O
use O
of O
antithyroid O
agent O
. O

two O
patients O
had O
a O
cholestatic B-NEG
hepatitis I-NEG
induced O
by O
carbimazole O
(n O
omercazole) O
. O

two O
others O
had O
a O
mixed O
( O
cholestatic B-NEG
and O
cytolytic O
) O
hepatitis B-NEG
following O
carbimazole O
. O

one O
of O
the O
latter O
two O
patients O
further O
experienced O
a O
cytolytic O
hepatitis B-NEG
which O
appeared O
after O
benzylthiouracil O
( O
basd O
ne O
) O
had O
replaced O
carbimazole O
. O

biological O
features O
of O
hepatitis B-NEG
disappeared O
in O
all O
cases O
after O
cessation O
of O
the O
incriminated O
drug O
, O
while O
biliary O
, O
viral O
and O
immunological O
searches O
were O
negative O
. O

only O
2 O
patients O
of O
our O
retrospective O
study O
experienced O
a O
mild O
or O
severe O
neutropenia B-NEG
. O

conclusion O
: O
toxic B-NEG
hepatitis I-NEG
is O
a O
potential O
adverse O
effect O
of O
antithyroid O
drugs O
which O
warrants O
, O
as O
for O
haematological O
disturbances O
, O
a O
pre-therapeutic O
determination O
and O
a O
careful O
follow-up O
of O
relevant O
biological O
markers O
. O

moreover O
, O
hepatotoxicity B-NEG
may O
not O
be O
restricted O
to O
one O
class O
of O
antithyroid O
agents O
. O

-DOCSTART- O

study O
of O
the O
role O
of O
vitamin O
b12 O
and O
folinic O
acid O
supplementation O
in O
preventing O
hematologic O
toxicity B-NEG
of O
zidovudine O
. O

a O
prospective O
, O
randomized O
study O
was O
conducted O
to O
evaluate O
the O
role O
of O
vitamin O
b12 O
and O
folinic O
acid O
supplementation O
in O
preventing O
zidovudine O
( O
zdv)-induced O
bone B-NEG
marrow I-NEG
suppression I-NEG
. O

seventy-five O
human B-NEG
immunodeficiency I-NEG
virus I-NEG
( O
hiv)-infected I-NEG
patients O
with O
cd4+ O
cell O
counts O
< O
500/mm3 O
were O
randomized O
to O
receive O
either O
zdv O
( O
500 O
mg O
daily O
) O
alone O
( O
group O
i, O
n O
= O
38 O
) O
or O
in O
combination O
with O
folinic O
acid O
( O
15 O
mg O
daily O
) O
and O
intramascular O
vitamin O
b12 O
( O
1000 O
micrograms O
monthly O
) O
( O
group O
ii O
, O
n O
= O
37) O
. O

finally O
, O
15 O
patients O
were O
excluded O
from O
the O
study O
( O
noncompliance O
14 O
, O
death B-NEG
1) O
; O
thus O
, O
60 O
patients O
( O
31 O
in O
group O
i O
and O
29 O
in O
group O
ii O
) O
were O
eligible O
for O
analysis O
. O

no O
significant O
differences O
between O
groups O
were O
found O
at O
enrollment O
. O

during O
the O
study O
, O
vitamin O
b12 O
and O
folate O
levels O
were O
significantly O
higher O
in O
group O
ii O
patients O
; O
however O
, O
no O
differences O
in O
hemoglobin O
, O
hematocrit O
, O
mean O
corpuscular O
volume O
, O
and O
white-cell O
, O
neutrophil O
and O
platelet O
counts O
were O
observed O
between O
groups O
at O
3, O
6, O
9 O
and O
12 O
months O
. O

severe O
hematologic O
toxicity B-NEG
( O
neutrophil O
count O
< O
1000/mm3 O
and/or O
hemoglobin O
< O
8 O
g/dl O
) O
occurred O
in O
4 O
patients O
assigned O
to O
group O
i O
and O
7 O
assigned O
to O
group O
ii O
. O

there O
was O
no O
correlation O
between O
vitamin O
b12 O
or O
folate O
levels O
and O
development O
of O
myelosuppression B-NEG
. O

vitamin O
b12 O
and O
folinic O
acid O
supplementation O
of O
zdv O
therapy O
does O
not O
seem O
useful O
in O
preventing O
or O
reducing O
zdv-induced O
myelotoxicity B-NEG
in O
the O
overall O
treated O
population O
, O
although O
a O
beneficial O
effect O
in O
certain O
subgroups O
of O
patients O
cannot O
be O
excluded O
. O

-DOCSTART- O

acute O
confusion B-NEG
induced O
by O
a O
high-dose O
infusion O
of O
5-fluorouracil O
and O
folinic O
acid O
. O

a O
61-year-old O
man O
was O
treated O
with O
combination O
chemotherapy O
incorporating O
cisplatinum O
, O
etoposide O
, O
high-dose O
5-fluorouracil O
( O
2,250 O
mg/m2/24 O
hours O
) O
and O
folinic O
acid O
for O
an O
inoperable O
gastric B-NEG
adenocarcinoma I-NEG
. O

he O
developed O
acute O
neurologic O
symptoms O
of O
mental O
confusion B-NEG
, O
disorientation B-NEG
and O
irritability B-NEG
, O
and O
then O
lapsed O
into O
a O
deep O
coma B-NEG
, O
lasting O
for O
approximately O
40 O
hours O
during O
the O
first O
dose O
( O
day O
2) O
of O
5-fluorouracil O
and O
folinic O
acid O
infusion O
. O

this O
complication O
reappeared O
on O
day O
25 O
during O
the O
second O
dose O
of O
5-fluorouracil O
and O
folinic O
acid O
, O
which O
were O
then O
the O
only O
drugs O
given O
. O

because O
folinic O
acid O
was O
unlikely O
to O
be O
associated O
with O
this O
condition O
, O
neurotoxicity B-NEG
due O
to O
high-dose O
5-fluorouracil O
was O
highly O
suspected O
. O

the O
pathogenesis O
of O
5-fluorouracil O
neurotoxicity B-NEG
may O
be O
due O
to O
a O
krebs O
cycle O
blockade O
by O
fluoroacetate O
and O
fluorocitrate O
, O
thiamine O
deficiency O
, O
or O
dihydrouracil O
dehydrogenase O
deficiency O
. O

high-dose O
5-fluorouracil/folinic O
acid O
infusion O
therapy O
has O
recently O
become O
a O
popular O
regimen O
for O
various O
cancers B-NEG
. O

it O
is O
necessary O
that O
both O
oncologists O
and O
neurologists O
be O
fully O
aware O
of O
this O
unusual O
complication O
. O

-DOCSTART- O

effect O
of O
switching O
carbamazepine O
to O
oxcarbazepine O
on O
the O
plasma O
levels O
of O
neuroleptics O
. O

a O
case O
report O
. O

carbamazepine O
was O
switched O
to O
its O
10-keto O
analogue O
oxcarbazepine O
among O
six O
difficult-to-treat O
schizophrenic B-NEG
or O
organic B-NEG
psychotic I-NEG
patients O
using O
concomitantly O
haloperidol O
, O
chlorpromazine O
or O
clozapine O
. O

this O
change O
resulted O
within O
2-4 O
weeks O
in O
the O
50-200% O
increase O
in O
the O
plasma O
levels O
of O
these O
neuroleptics O
and O
the O
appearance O
of O
extrapyramidal B-NEG
symptoms I-NEG
. O

none O
of O
the O
patients O
showed O
any O
clinical O
deteriotation O
during O
the O
following O
3-6 O
months O
. O

the O
results O
of O
this O
case O
report O
support O
the O
idea O
that O
in O
contrast O
with O
carbamazepine O
oxcarbazepine O
does O
not O
induce O
the O
hepatic O
microsomal O
enzyme O
systems O
regulating O
the O
inactivation O
of O
antipsychotic O
drugs O
. O

-DOCSTART- O

erythema B-NEG
multiforme I-NEG
and O
hypersensitivity B-NEG
myocarditis I-NEG
caused O
by O
ampicillin O
. O

objective O
: O
to O
report O
a O
case O
of O
erythema B-NEG
multiforme I-NEG
and O
hypersensitivity B-NEG
myocarditis I-NEG
caused O
by O
ampicillin O
. O

case O
summary O
: O
a O
13-year-old O
boy O
was O
treated O
with O
ampicillin O
and O
gentamicin O
because O
of O
suspected O
septicemia B-NEG
. O

medications O
were O
discontinued O
when O
erythema B-NEG
multiforme I-NEG
and O
congestive B-NEG
heart I-NEG
failure I-NEG
caused O
by O
myocarditis B-NEG
occurred O
. O

the O
patient O
was O
treated O
with O
methylprednisolone O
and O
gradually O
improved O
. O

macrophage-migration O
inhibition O
( O
mif O
) O
test O
with O
ampicillin O
was O
positive O
. O

discussion O
: O
after O
most O
infections B-NEG
causing O
erythema B-NEG
multiforme I-NEG
and O
myocarditis B-NEG
were O
ruled O
out O
, O
a O
drug-induced B-NEG
allergic I-NEG
reaction I-NEG
was O
suspected O
. O

positive O
mif O
test O
for O
ampicillin O
showed O
sensitization O
of O
the O
patient's O
lymphocytes O
to O
ampicillin O
. O

conclusions O
: O
hypersensitivity B-NEG
myocarditis I-NEG
is O
a O
rare O
and O
dangerous O
manifestation O
of O
allergy B-NEG
to O
penicillins O
. O

-DOCSTART- O

immediate O
allergic B-NEG
reactions I-NEG
to O
amoxicillin O
. O

a O
large O
group O
of O
patients O
with O
suspected O
allergic B-NEG
reactions I-NEG
to O
beta-lactam O
antibiotics O
was O
evaluated O
. O

a O
detailed O
clinical O
history O
, O
together O
with O
skin O
tests O
, O
rast O
( O
radioallergosorbent O
test) O
, O
and O
controlled O
challenge O
tests O
, O
was O
used O
to O
establish O
whether O
patients O
allergic B-NEG
to O
beta-lactam O
antibiotics O
had O
selective O
immediate O
allergic B-NEG
responses O
to O
amoxicillin O
( O
ax O
) O
or O
were O
cross-reacting O
with O
other O
penicillin O
derivatives O
. O

skin O
tests O
were O
performed O
with O
benzylpenicilloyl-poly-l-lysine O
(bpo-pll) O
, O
benzylpenicilloate O
, O
benzylpenicillin O
(pg) O
, O
ampicillin O
(amp) O
, O
and O
ax O
. O

rast O
for O
bpo-pll O
and O
ax-pll O
was O
done O
. O

when O
both O
skin O
test O
and O
rast O
for O
bpo O
were O
negative O
, O
single-blind O
, O
placebo-controlled O
challenge O
tests O
were O
done O
to O
ensure O
tolerance O
of O
pg O
or O
sensitivity O
to O
ax O
. O

a O
total O
of O
177 O
patients O
were O
diagnosed O
as O
allergic B-NEG
to O
beta-lactam O
antibiotics O
. O

we O
selected O
the O
54 O
( O
30.5% O
) O
cases O
of O
immediate O
ax O
allergy B-NEG
with O
good O
tolerance O
of O
pg O
. O
anaphylaxis B-NEG
was O
seen O
in O
37 O
patients O
(69%) O
, O
the O
other O
17 O
( O
31% O
) O
having O
urticaria B-NEG
and/or O
angioedema B-NEG
. O

all O
the O
patients O
were O
skin O
test O
negative O
to O
bpo O
; O
49 O
of O
51 O
( O
96% O
) O
were O
also O
negative O
to O
mdm B-NEG
, O
and O
44 O
of O
46 O
( O
96% O
) O
to O
pg O
. O

skin O
tests O
with O
ax O
were O
positive O
in O
34 O
( O
63% O
) O
patients O
. O

rast O
was O
positive O
for O
ax O
in O
22 O
patients O
( O
41% O
) O
and O
to O
bpo O
in O
just O
5 O
(9%) O
. O

none O
of O
the O
sera O
with O
negative O
rast O
for O
ax O
were O
positive O
to O
bpo O
. O

challenge O
tests O
with O
ax O
were O
performed O
in O
23 O
subjects O
( O
43% O
) O
to O
establish O
the O
diagnosis O
of O
immediate O
allergic B-NEG
reaction I-NEG
to O
ax O
, O
and O
in O
15 O
cases O
( O
28% O
) O
both O
skin O
test O
and O
rast O
for O
ax O
were O
negative O
. O

pg O
was O
well O
tolerated O
by O
all O
54 O
patients O
. O

we O
describe O
the O
largest O
group O
of O
ax- O
allergic B-NEG
patients O
who O
have O
tolerated O
pg O
reported O
so O
far O
. O

diagnosis O
of O
these O
patients O
can O
be O
achieved O
only O
if O
specific O
ax-related O
reagents O
are O
employed O
. O

further O
studies O
are O
necessary O
to O
determine O
the O
exact O
extent O
of O
this O
problem O
and O
to O
improve O
the O
efficacy O
of O
diagnostic O
methods O
. O

-DOCSTART- O

persistent O
paralysis B-NEG
after O
prolonged O
use O
of O
atracurium O
in O
the O
absence O
of O
corticosteroids O
. O

neuromuscular O
blocking O
agents O
( O
nmbas O
) O
are O
often O
used O
for O
patients O
requiring O
prolonged O
mechanical O
ventilation O
. O

reports O
of O
persistent O
paralysis B-NEG
after O
the O
discontinuance O
of O
these O
drugs O
have O
most O
often O
involved O
aminosteroid-based O
nmbas O
such O
as O
vecuronium O
bromide O
, O
especially O
when O
used O
in O
conjunction O
with O
corticosteroids O
. O

atracurium O
besylate O
, O
a O
short-acting O
benzylisoquinolinium O
nmba O
that O
is O
eliminated O
independently O
of O
renal O
or O
hepatic O
function O
, O
has O
also O
been O
associated O
with O
persistent O
paralysis B-NEG
, O
but O
only O
when O
used O
with O
corticosteroids O
. O

we O
report O
a O
case O
of O
atracurium-related O
paralysis B-NEG
persisting O
for O
approximately O
50 O
hours O
in O
a O
patient O
who O
was O
not O
treated O
with O
corticosteroids O
. O

-DOCSTART- O

habitual O
use O
of O
acetaminophen O
as O
a O
risk O
factor O
for O
chronic B-NEG
renal I-NEG
failure I-NEG
: O
a O
comparison O
with O
phenacetin O
. O

six O
epidemiologic O
studies O
in O
the O
united O
states O
and O
europe O
indicate O
that O
habitual O
use O
of O
phenacetin O
is O
associated O
with O
the O
development O
of O
chronic B-NEG
renal I-NEG
failure I-NEG
and O
end-stage B-NEG
renal I-NEG
disease I-NEG
( O
esrd B-NEG
), O
with O
a O
relative O
risk O
in O
the O
range O
of O
4 O
to O
19 O
. O

as O
a O
result O
of O
these O
and O
other O
studies O
, O
phenacetin O
has O
now O
been O
withdrawn O
from O
the O
market O
in O
most O
countries O
. O

however O
, O
three O
case O
control O
studies O
, O
one O
each O
in O
north O
carolina O
, O
northern O
maryland O
, O
and O
west O
berlin O
, O
germany O
, O
showed O
that O
habitual O
use O
of O
acetaminophen O
is O
also O
associated O
with O
chronic B-NEG
renal I-NEG
failure I-NEG
and O
esrd B-NEG
, O
with O
a O
relative O
risk O
in O
the O
range O
of O
2 O
to O
4. O

these O
studies O
suggest O
that O
both O
phenacetin O
and O
acetaminophen O
may O
contribute O
to O
the O
burden O
of O
esrd B-NEG
, O
with O
the O
risk O
of O
the O
latter O
being O
somewhat O
less O
than O
that O
of O
the O
former O
. O

this O
apparent O
difference O
in O
risk O
may O
not O
be O
due O
to O
differences O
in O
nephrotoxic B-NEG
potential O
of O
the O
drugs O
themselves O
. O

a O
lower O
relative O
risk O
would O
be O
expected O
for O
acetaminophen O
if O
the O
risk O
of O
both O
drugs O
in O
combination O
with O
other O
analgesics O
was O
higher O
than O
the O
risk O
of O
either O
agent O
alone O
. O

thus O
, O
acetaminophen O
has O
been O
used O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
other O
analgesics O
, O
whereas O
phenacetin O
was O
available O
only O
in O
combinations O
. O

the O
possibility O
that O
habitual O
use O
of O
acetaminophen O
alone O
increases O
the O
risk O
of O
esrd B-NEG
has O
not O
been O
clearly O
demonstrated O
, O
but O
cannot O
be O
dismissed O
. O

-DOCSTART- O

reduction O
of O
heparan O
sulphate-associated O
anionic O
sites O
in O
the O
glomerular O
basement O
membrane O
of O
rats O
with O
streptozotocin-induced O
diabetic B-NEG
nephropathy I-NEG
. O

heparan O
sulphate-associated O
anionic O
sites O
in O
the O
glomerular O
basement O
membrane O
were O
studied O
in O
rats O
8 O
months O
after O
induction O
of O
diabetes B-NEG
by O
streptozotocin O
and O
in O
age- O
adn O
sex-matched O
control O
rats O
, O
employing O
the O
cationic O
dye O
cuprolinic O
blue O
. O

morphometric O
analysis O
at O
the O
ultrastructural O
level O
was O
performed O
using O
a O
computerized O
image O
processor O
. O

the O
heparan O
sulphate O
specificity O
of O
the O
cuprolinic O
blue O
staining O
was O
demonstrated O
by O
glycosaminoglycan-degrading O
enzymes O
, O
showing O
that O
pretreatment O
of O
the O
sections O
with O
heparitinase O
abolished O
all O
staining O
, O
whereas O
chondroitinase O
abc O
had O
no O
effect O
. O

the O
majority O
of O
anionic O
sites O
( O
74% O
in O
diabetic B-NEG
and O
81% O
in O
control O
rats O
) O
were O
found O
within O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane O
. O

a O
minority O
of O
anionic O
sites O
were O
scattered O
throughout O
the O
lamina O
densa O
and O
lamina O
rara O
interna O
, O
and O
were O
significantly O
smaller O
than O
those O
in O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane O
( O
p<0.001 O
and O
p<0.01 O
for O
diabetic B-NEG
and O
control O
rats O
, O
respectively) O
. O
diabetic B-NEG
rats O
progressively O
developed O
albuminuria B-NEG
reaching O
40.3 O
( O
32.2-62.0 O
) O
mg/24 O
h O
after O
8 O
months O
in O
contrast O
to O
the O
control O
animals O
( O
0.8 O
( O
0.2-0.9 O
) O
mg/24 O
h, O
p<0.002) O
. O

at O
the O
same O
time O
, O
the O
number O
of O
heparan O
sulphate O
anionic O
sites O
and O
the O
total O
anionic O
site O
surface O
( O
number O
of O
anionic O
sites O
x O
mean O
anionic O
site O
surface O
) O
in O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane O
was O
reduced O
by O
19% O
( O
p<0.021 O
) O
and O
by O
26% O
(p<0.02) O
, O
respectively O
. O

number O
and O
total O
anionic O
site O
surface O
in O
the O
remaining O
part O
of O
the O
glomerular O
basement O
membrane O
( O
lamina O
densa O
and O
lamina O
rara O
interna O
) O
were O
not O
significantly O
changed O
. O

we O
conclude O
that O
in O
streptozotocin- O
diabetic B-NEG
rats O
with O
an O
increased O
urinary O
albumin O
excretion O
, O
a O
reduced O
heparan O
sulphate O
charge O
barrier/density O
is O
found O
at O
the O
lamina O
rara O
externa O
of O
the O
glomerular O
basement O
membrane O
. O

-DOCSTART- O

effect O
of O
some O
anticancer O
drugs O
and O
combined O
chemotherapy O
on O
renal B-NEG
toxicity I-NEG
. O

the O
nephrotoxic B-NEG
action O
of O
anticancer O
drugs O
such O
as O
nitrogranulogen O
(ng) O
, O
methotrexate O
(mtx) O
, O
5-fluorouracil O
( O
5-fu O
) O
and O
cyclophosphamide O
( O
cy O
) O
administered O
alone O
or O
in O
combination O
[mtx O
+ O
5-fu O
+ O
cy O
( O
cmf)] O
was O
evaluated O
in O
experiments O
on O
wistar O
rats O
. O

after O
drug O
administration O
, O
creatinine O
concentrations O
in O
the O
plasma O
and O
in O
the O
urine O
of O
the O
rats O
were O
determined O
, O
as O
well O
as O
creatinine O
clearance O
. O

histopathologic O
evaluation O
of O
the O
kidneys O
was O
also O
performed O
. O

after O
mtx O
administration O
a O
significant O
increase O
(p O
= O
0.0228 O
) O
in O
the O
plasma O
creatinine O
concentration O
and O
a O
significant O
(p O
= O
0.0001 O
) O
decrease O
in O
creatinine O
clearance O
was O
noted O
compared O
to O
controls O
. O

after O
the O
administration O
of O
ng O
, O
5-fu O
and O
cy O
neither O
a O
statistically O
significant O
increase O
in O
creatinine O
concentration O
nor O
an O
increase O
in O
creatinine O
clearance O
was O
observed O
compared O
to O
the O
group O
receiving O
no O
cytostatics O
. O

following O
polytherapy O
according O
to O
the O
cmf O
regimen O
, O
a O
statistically O
significant O
decrease O
(p O
= O
0.0343 O
) O
in O
creatinine O
clearance O
was O
found O
, O
but O
creatinine O
concentration O
did O
not O
increase O
significantly O
compared O
to O
controls O
. O

cy O
caused O
hemorrhagic B-NEG
cystitis I-NEG
in O
40% O
of O
rats O
, O
but O
it O
did O
not O
cause O
this O
complication O
when O
combined O
with O
5-fu O
and O
mtx O
. O

histologic O
changes O
were O
found O
in O
rat O
kidneys O
after O
administration O
of O
mtx O
, O
cy O
and O
ng O
, O
while O
no O
such O
change O
was O
observed O
after O
5-fu O
and O
joint O
administration O
of O
mtx O
+ O
5-fu O
+ O
cy O
compared O
to O
controls O
. O

our O
studies O
indicate O
that O
nephrotoxicity B-NEG
of O
mtx O
+ O
5-fu O
+ O
cy O
administered O
jointly O
is O
lower O
than O
in O
monotherapy O
. O

-DOCSTART- O

lithium-associated O
cognitive B-NEG
and I-NEG
functional I-NEG
deficits I-NEG
reduced O
by O
a O
switch O
to O
divalproex O
sodium O
: O
a O
case O
series O
. O

background O
: O
lithium O
remains O
a O
first-line O
treatment O
for O
the O
acute O
and O
maintenance O
treatment O
of O
bipolar B-NEG
disorder I-NEG
. O

although O
much O
has O
been O
written O
about O
the O
management O
of O
the O
more O
common O
adverse O
effects O
of O
lithium O
, O
such O
as O
polyuria B-NEG
and O
tremor B-NEG
, O
more O
subtle O
lithium O
side O
effects O
such O
as O
cognitive B-NEG
deficits I-NEG
, O
loss B-NEG
of I-NEG
creativity I-NEG
, O
and O
functional B-NEG
impairments I-NEG
remain O
understudied O
. O

this O
report O
summarizes O
our O
experience O
in O
switching O
bipolar B-NEG
patients O
from O
lithium O
to O
divalproex O
sodium O
to O
alleviate O
such O
cognitive B-NEG
and I-NEG
functional I-NEG
impairments I-NEG
. O

method O
: O
open O
, O
case O
series O
design O
. O

results O
: O
we O
report O
seven O
cases O
where O
substitution O
of O
lithium O
, O
either O
fully O
or O
partially O
, O
with O
divalproex O
sodium O
was O
extremely O
helpful O
in O
reducing O
the O
cognitive B-NEG
, O
motivational I-NEG
, O
or I-NEG
creative I-NEG
deficits I-NEG
attributed O
to O
lithium O
in O
our O
bipolar B-NEG
patients O
. O

conclusion O
: O
in O
this O
preliminary O
report O
, O
divalproex O
sodium O
was O
a O
superior O
alternative O
to O
lithium O
in O
bipolar B-NEG
patients O
experiencing O
cognitive B-NEG
deficits I-NEG
, O
loss B-NEG
of I-NEG
creativity I-NEG
, O
and O
functional B-NEG
impairments I-NEG
. O

-DOCSTART- O

treatment O
of O
previously O
treated O
metastatic O
breast B-NEG
cancer I-NEG
by O
mitoxantrone O
and O
48-hour O
continuous O
infusion O
of O
high-dose O
5-fu O
and O
leucovorin O
(mfl) O
: O
low O
palliative O
benefit O
and O
high O
treatment-related O
toxicity B-NEG
. O

for O
previously O
treated O
advanced O
breast B-NEG
cancer I-NEG
, O
there O
is O
no O
standard O
second-line O
therapy O
. O

combination O
chemotherapy O
with O
mitoxantrone O
, O
high-dose O
5-fluorouracil O
( O
5-fu O
) O
and O
leucovorin O
( O
mfl O
regimen O
) O
had O
been O
reported O
as O
an O
effective O
and O
well O
tolerated O
regimen O
. O

from O
october O
1993 O
to O
november O
1995 O
, O
we O
treated O
13 O
patients O
with O
previously O
chemotherapy-treated O
metastatic O
breast B-NEG
cancer I-NEG
by O
mitoxantrone O
, O
12 O
mg/m2 O
, O
on O
day O
1 O
and O
continuous O
infusion O
of O
5-fu O
, O
3000 O
mg/m2 O
, O
together O
with O
leucovorin O
, O
300 O
mg/m2 O
, O
for O
48 O
h O
from O
day O
1 O
to O
2. O

each O
course O
of O
chemotherapy O
was O
given O
every O
4 O
weeks O
. O

most O
of O
these O
patients O
had O
more O
than O
two O
metastatic O
sites O
, O
with O
lung O
metastasis O
predominant O
. O

seven O
patients O
had O
been O
treated O
with O
anthracycline O
. O

seven O
patients O
had O
previously O
received O
radiotherapy O
and O
seven O
had O
received O
hormone O
therapy O
. O

median O
number O
of O
courses O
of O
mfl O
regimen O
given O
was O
six O
and O
the O
median O
cumulative O
dose O
of O
mitoxantrone O
was O
68.35 O
mg/m2 O
. O

one O
patient O
had O
complete O
response O
, O
seven O
had O
stable O
disease O
, O
none O
had O
partial O
response O
and O
five O
had O
progressive O
disease O
. O

the O
overall O
objective O
response O
rate O
was O
7.6% O
. O

the O
median O
follow-up O
period O
was O
14 O
months O
. O

median O
survival O
was O
16 O
months O
. O

median O
progression-free O
survival O
was O
5 O
months O
. O

a O
complete O
responder O
had O
relapse-free O
survival O
up O
to O
17 O
months O
. O

major O
toxicities B-NEG
were O
cardiotoxicity B-NEG
and O
leukopenia B-NEG
. O

eight O
patients O
were O
dead O
in O
the O
last O
follow-up O
; O
two O
of O
them O
died O
of O
treatment-related O
toxicity B-NEG
. O

the O
mfl O
regimen O
achieves O
little O
palliative O
benefit O
and O
induces O
severe O
toxicity B-NEG
at O
a O
fairly O
high O
rate O
. O

administration O
of O
this O
regimen O
to O
breast B-NEG
cancer I-NEG
patients O
who O
have O
been O
treated O
by O
chemotherapy O
and O
those O
with O
impaired B-NEG
heart I-NEG
function I-NEG
requires O
careful O
attention O
. O

-DOCSTART- O

upregulation O
of O
the O
expression O
of O
vasopressin O
gene O
in O
the O
paraventricular O
and O
supraoptic O
nuclei O
of O
the O
lithium-induced O
diabetes B-NEG
insipidus I-NEG
rat O
. O

the O
expression O
of O
arginine O
vasopressin O
( O
avp O
) O
gene O
in O
the O
paraventricular O
( O
pvn O
) O
and O
supraoptic O
nuclei O
( O
son O
) O
was O
investigated O
in O
rats O
with O
lithium O
( O
li)-induced O
polyuria B-NEG
, O
using O
in O
situ O
hybridization O
histochemistry O
and O
radioimmunoassay O
. O

the O
male O
wistar O
rats O
consuming O
a O
diet O
that O
contained O
licl O
( O
60 O
mmol/kg O
) O
for O
4 O
weeks O
developed O
marked O
polyuria B-NEG
. O

the O
li-treated O
rats O
produced O
a O
large O
volume O
of O
hypotonic O
urine O
with O
low O
ionic O
concentrations O
. O

plasma O
sodium O
concentrations O
were O
found O
to O
be O
slightly O
increased O
in O
the O
li-treated O
rats O
compared O
with O
those O
in O
controls O
. O

plasma O
concentration O
of O
avp O
and O
transcripts O
of O
avp O
gene O
in O
the O
pvn O
and O
son O
were O
significantly O
increased O
in O
the O
li-treated O
rats O
compared O
with O
controls O
. O

these O
results O
suggest O
that O
dehydration B-NEG
and/or O
the O
activation O
of O
visceral O
afferent O
inputs O
may O
contribute O
to O
the O
elevation O
of O
plasma O
avp O
and O
the O
upregulation O
of O
avp O
gene O
expression O
in O
the O
pvn O
and O
the O
son O
of O
the O
li-induced O
diabetes B-NEG
insipidus I-NEG
rat O
. O

-DOCSTART- O

suxamethonium-induced O
cardiac B-NEG
arrest I-NEG
and O
death B-NEG
following O
5 O
days O
of O
immobilization O
. O

the O
present O
report O
describes O
a O
case O
of O
cardiac B-NEG
arrest I-NEG
and O
subsequent O
death B-NEG
as O
a O
result O
of O
hyperkalaemia B-NEG
following O
the O
use O
of O
suxamethonium O
in O
a O
23-year-old O
malawian O
woman O
. O

five O
days O
after O
the O
onset O
of O
the O
symptoms O
of O
meningitis B-NEG
, O
the O
patient O
aspirated O
stomach O
contents O
and O
needed O
endotracheal O
intubation O
. O

forty O
seconds O
after O
injection O
of O
suxamethonium O
, O
bradycardia B-NEG
and O
cardiac B-NEG
arrest I-NEG
occurred O
. O

attempts O
to O
resuscitate O
the O
patient O
were O
not O
successful O
. O

the O
serum O
level O
of O
potassium O
was O
observed O
to O
be O
8.4 O
mequiv O
l-1 O
. O

apart O
from O
the O
reduction O
in O
the O
patient's O
level O
of O
consciousness O
, O
there O
were O
no O
signs O
of O
motor O
neurone O
damage O
or O
of O
any O
of O
the O
other O
known O
predisposing O
conditions O
for O
hyperkalaemia B-NEG
following O
the O
administration O
of O
suxamethonium O
. O

it O
is O
postulated O
that O
her O
death B-NEG
was O
caused O
by O
hypersensitivity B-NEG
to O
suxamethonium O
, O
associated O
with O
her O
5-day O
immobilization O
. O

-DOCSTART- O

an O
unusual O
toxic O
reaction O
to O
axillary O
block O
by O
mepivacaine O
with O
adrenaline O
. O

an O
increase B-NEG
in I-NEG
blood I-NEG
pressure I-NEG
, O
accompanied O
by O
atrial B-NEG
fibrillation I-NEG
, O
agitation B-NEG
, O
incomprehensible B-NEG
shouts I-NEG
and O
loss B-NEG
of I-NEG
consciousness I-NEG
, O
was O
observed O
in O
an O
elderly O
, O
asa O
classification O
group O
ii O
, O
cardiovascularly O
medicated O
male O
, O
12 O
min O
after O
performance O
of O
axillary O
block O
with O
mepivacaine O
850 O
mg O
containing O
adrenaline O
0.225 O
mg O
, O
for O
correction O
of O
dupuytren's B-NEG
contracture I-NEG
. O

after O
intravenous O
administration O
of O
labetalol O
, O
metoprolol O
and O
midazolam O
the O
patient's O
condition O
improved O
, O
and O
15 O
min O
later O
he O
woke O
up O
. O

the O
block O
was O
successful O
and O
surgery O
was O
conducted O
as O
scheduled O
despite O
persisting O
atrial B-NEG
fibrillation I-NEG
. O

postoperatively O
, O
the O
patient O
refused O
dc O
cardioversion O
and O
was O
treated O
medically O
. O

both O
the O
temporal O
relationship O
of O
events O
and O
the O
response O
to O
treatment O
suggest O
that O
a O
rapid O
systemic O
absorption O
of O
mepivacaine O
with O
adrenaline O
and/or O
interaction O
of O
these O
drugs O
with O
the O
patient's O
cardiovascular O
medications O
were O
responsible O
for O
the O
perioperative O
complications O
. O

-DOCSTART- O

clinical O
and O
histopathologic O
examination O
of O
renal O
allografts O
treated O
with O
tacrolimus O
( O
fk506 O
) O
for O
at O
least O
one O
year O
. O

background O
: O
we O
clinically O
and O
pathologically O
analyzed O
renal O
allografts O
from O
1 O
9 O
renal O
transplant O
patients O
treated O
with O
tacrolimus O
( O
fk506 O
) O
for O
more O
than O
1 O
year O
. O

methods O
: O
twenty-six O
renal O
allograft O
biopsy O
specimens O
from O
1 O
9 O
renal O
transplant O
patients O
who O
underwent O
transplantations O
between O
1991 O
and O
1993 O
were O
evaluated O
. O

thirteen O
biopsies O
were O
performed O
from O
stable O
functioning O
renal O
allografts O
with O
informed O
consent O
( O
nonepisode O
biopsy O
) O
and O
the O
other O
13 O
were O
from O
dysfunctional O
renal O
allografts O
with O
a O
clinical O
indication O
for O
biopsy O
( O
episode O
biopsy) O
. O

results O
: O
the O
main O
pathologic O
diagnoses O
( O
some O
overlap O
) O
were O
acute O
rejection O
(ar O
; O
n O
= O
4) O
, O
chronic O
rejection O
(cr O
; O
n=5) O
, O
ar+cr O
(n O
=4) O
, O
recurrent O
iga B-NEG
nephropathy I-NEG
(n O
=5) O
, O
normal O
findings O
(n O
=2) O
, O
minimal-type O
chronic O
fk506 O
nephropathy B-NEG
(n O
= O
9) O
, O
and O
mild-type O
fk506 O
nephropathy B-NEG
(n O
= O
11) O
. O

of O
the O
nonepisode O
biopsies O
, O
7 O
and O
4 O
biopsies O
showed O
minimal-type O
and O
mild-type O
chronic O
fk506 O
nephropathy B-NEG
, O
respectively O
. O

chronic O
fk506 O
nephropathy B-NEG
consisted O
of O
rough O
and O
foamy O
tubular O
vacuolization O
(5 O
biopsies) O
, O
arteriolopathy O
( O
angiodegeneration O
of O
the O
arteriolar O
wall O
; O
20 O
biopsies) O
, O
focal B-NEG
segmental I-NEG
glomerulosclerosis I-NEG
(4 O
biopsies O
) O
and O
the O
striped O
form O
of O
interstitial B-NEG
fibrosis I-NEG
( O
11 O
biopsies) O
. O

the O
serum O
creatinine O
levels O
of O
patients O
in O
the O
mild-type O
chronic O
fk506 O
nephropathy B-NEG
group O
, O
which O
included O
7 O
episode O
biopsies O
, O
were O
statistically O
higher O
than O
those O
in O
the O
minimum-type O
chronic O
fk506- O
nephropathy B-NEG
group O
( O
p< O
0.001) O
. O

conclusions O
: O
this O
study O
demonstrates O
that O
chronic O
fk506 O
nephropathy B-NEG
consists O
primarily O
of O
arteriolopathy O
manifesting O
as O
insudative O
hyalinosis O
of O
the O
arteriolar O
wall O
, O
and O
suggests O
that O
mild-type O
chronic O
fk506 O
nephropathy B-NEG
is O
a O
condition O
which O
may O
lead O
to O
deterioration O
of O
renal O
allograft O
function O
. O

-DOCSTART- O

memory O
facilitation O
and O
stimulation O
of O
endogenous O
nerve O
growth O
factor O
synthesis O
by O
the O
acetylcholine O
releaser O
pg-9 O
. O

the O
effects O
of O
pg-9 O
( O
3alpha-tropyl O
2-(p-bromophenyl)propionate) O
, O
the O
acetylcholine O
releaser O
, O
on O
memory O
processes O
and O
nerve O
growth O
factor O
( O
ngf O
) O
synthesis O
were O
evaluated O
. O

in O
the O
mouse O
passive-avoidance O
test O
, O
pg-9 O
( O
10-30 O
mg/kg O
, O
i.p.) O
, O
administered O
20 O
min O
before O
the O
training O
session O
, O
prevented O
amnesia B-NEG
induced O
by O
both O
the O
non O
selective O
antimuscarinic O
drug O
scopolamine O
and O
the O
m1-selective O
antagonist O
s-(-)-et-126 O
. O

in O
the O
same O
experimental O
conditions O
, O
pg-9 O
( O
5-20 O
microg O
per O
mouse O
, O
i.c.v. O
) O
was O
also O
able O
to O
prevent O
antimuscarine-induced O
amnesia B-NEG
, O
demonstrating O
a O
central O
localization O
of O
the O
activity O
. O

at O
the O
highest O
effective O
doses O
, O
pg-9 O
did O
not O
produce O
any O
collateral O
symptoms O
as O
revealed O
by O
the O
irwin O
test O
, O
and O
it O
did O
not O
modify O
spontaneous O
motility O
and O
inspection O
activity O
, O
as O
revealed O
by O
the O
hole-board O
test O
. O

pg-9 O
was O
also O
able O
to O
increase O
the O
amount O
of O
ngf O
secreted O
in O
vitro O
by O
astrocytes O
in O
a O
dose-dependent O
manner O
. O

the O
maximal O
ngf O
contents O
obtained O
by O
pg-9 O
were O
17.6-fold O
of O
the O
control O
value O
. O

during O
culture O
, O
no O
morphological O
changes O
were O
found O
at O
effective O
concentrations O
of O
pg-9 O
. O

the O
current O
work O
indicates O
the O
ability O
of O
pg-9 O
to O
induce O
beneficial O
effects O
on O
cognitive O
processes O
and O
stimulate O
activity O
of O
ngf O
synthesis O
in O
astroglial O
cells O
. O

therefore O
, O
pg-9 O
could O
represent O
a O
potential O
useful O
drug O
able O
to O
improve O
the O
function O
of O
impaired O
cognitive O
processes O
. O

-DOCSTART- O

angioedema B-NEG
due O
to O
ace O
inhibitors O
: O
common O
and O
inadequately O
diagnosed O
. O

the O
estimated O
incidence O
of O
angioedema B-NEG
during O
angiotensin-converting O
enzyme O
( O
ace O
) O
inhibitor O
treatment O
is O
between O
1 O
and O
7 O
per O
thousand O
patients O
. O

this O
potentially O
serious O
adverse O
effect O
is O
often O
preceded O
by O
minor O
manifestations O
that O
may O
serve O
as O
a O
warning O
. O

-DOCSTART- O

recurarization O
in O
the O
recovery O
room O
. O

a O
case O
of O
recurarization O
in O
the O
recovery O
room O
is O
reported O
. O

accumulation O
of O
atracurium O
in O
the O
intravenous O
line O
led O
to O
recurarization O
after O
flushing O
the O
line O
in O
the O
recovery O
room O
. O

a O
respiratory B-NEG
arrest I-NEG
with O
severe O
desaturation B-NEG
and O
bradycardia B-NEG
occurred O
. O

circumstances O
leading O
to O
this O
event O
and O
the O
mechanisms O
enabling O
a O
neuromuscular B-NEG
blockade I-NEG
to O
occur O
, O
following O
the O
administration O
of O
a O
small O
dose O
of O
relaxant O
, O
are O
discussed O
. O

-DOCSTART- O

recurrent O
use O
of O
newer O
oral O
contraceptives O
and O
the O
risk O
of O
venous B-NEG
thromboembolism I-NEG
. O

the O
epidemiological O
studies O
that O
assessed O
the O
risk O
of O
venous B-NEG
thromboembolism I-NEG
( O
vte B-NEG
) O
associated O
with O
newer O
oral O
contraceptives O
( O
oc O
) O
did O
not O
distinguish O
between O
patterns O
of O
oc O
use O
, O
namely O
first-time O
users O
, O
repeaters O
and O
switchers O
. O

data O
from O
a O
transnational O
case-control O
study O
were O
used O
to O
assess O
the O
risk O
of O
vte B-NEG
for O
the O
latter O
patterns O
of O
use O
, O
while O
accounting O
for O
duration O
of O
use O
. O

over O
the O
period O
1993-1996 O
, O
551 O
cases O
of O
vte B-NEG
were O
identified O
in O
germany O
and O
the O
uk O
along O
with O
2066 O
controls O
. O

totals O
of O
128 O
cases O
and O
650 O
controls O
were O
analysed O
for O
repeat O
use O
and O
135 O
cases O
and O
622 O
controls O
for O
switching O
patterns O
. O

the O
adjusted O
rate O
ratio O
of O
vte B-NEG
for O
repeat O
users O
of O
third O
generation O
oc O
was O
0.6 O
( O
95% O
ci:0.3-1.2 O
) O
relative O
to O
repeat O
users O
of O
second O
generation O
pills O
, O
whereas O
it O
was O
1.3 O
( O
95% O
ci:0.7-2.4 O
) O
for O
switchers O
from O
second O
to O
third O
generation O
pills O
relative O
to O
switchers O
from O
third O
to O
second O
generation O
pills O
. O

we O
conclude O
that O
second O
and O
third O
generation O
agents O
are O
associated O
with O
equivalent O
risks O
of O
vte B-NEG
when O
the O
same O
agent O
is O
used O
repeatedly O
after O
interruption O
periods O
or O
when O
users O
are O
switched O
between O
the O
two O
generations O
of O
pills O
. O

these O
analyses O
suggest O
that O
the O
higher O
risk O
observed O
for O
the O
newer O
oc O
in O
other O
studies O
may O
be O
the O
result O
of O
inadequate O
comparisons O
of O
pill O
users O
with O
different O
patterns O
of O
pill O
use O
. O

-DOCSTART- O

development O
of O
apomorphine-induced O
aggressive B-NEG
behavior I-NEG
: O
comparison O
of O
adult O
male O
and O
female O
wistar O
rats O
. O

the O
development O
of O
apomorphine-induced O
( O
1.0 O
mg/kg O
s.c O
. O
once O
daily O
) O
aggressive B-NEG
behavior I-NEG
of O
adult O
male O
and O
female O
wistar O
rats O
obtained O
from O
the O
same O
breeder O
was O
studied O
in O
two O
consecutive O
sets O
. O

in O
male O
animals O
, O
repeated O
apomorphine O
treatment O
induced O
a O
gradual O
development O
of O
aggressive B-NEG
behavior I-NEG
as O
evidenced O
by O
the O
increased O
intensity O
of O
aggressiveness B-NEG
and O
shortened O
latency O
before O
the O
first O
attack O
toward O
the O
opponent O
. O

in O
female O
rats O
, O
only O
a O
weak O
tendency O
toward O
aggressiveness B-NEG
was O
found O
. O

in O
conclusion O
, O
the O
present O
study O
demonstrates O
gender O
differences O
in O
the O
development O
of O
the O
apomorphine-induced O
aggressive B-NEG
behavior I-NEG
and O
indicates O
that O
the O
female O
rats O
do O
not O
fill O
the O
validation O
criteria O
for O
use O
in O
this O
method O
. O

-DOCSTART- O

serotonergic O
antidepressants O
and O
urinary B-NEG
incontinence I-NEG
. O

many O
new O
serotonergic O
antidepressants O
have O
been O
introduced O
over O
the O
past O
decade O
. O

although O
urinary B-NEG
incontinence I-NEG
is O
listed O
as O
one O
side O
effect O
of O
these O
drugs O
in O
their O
package O
inserts O
there O
is O
only O
one O
report O
in O
the O
literature O
. O

this O
concerns O
2 O
male O
patients O
who O
experienced O
incontinence B-NEG
while O
taking O
venlafaxine O
. O

in O
the O
present O
paper O
the O
authors O
describe O
2 O
female O
patients O
who O
developed O
incontinence B-NEG
secondary O
to O
the O
selective O
serotonin O
reuptake O
inhibitors O
paroxetine O
and O
sertraline O
, O
as O
well O
as O
a O
third O
who O
developed O
this O
side O
effect O
on O
venlafaxine O
. O

in O
2 O
of O
the O
3 O
cases O
the O
patients O
were O
also O
taking O
lithium O
carbonate O
and O
beta-blockers O
, O
both O
of O
which O
could O
have O
contributed O
to O
the O
incontinence B-NEG
. O

animal O
studies O
suggest O
that O
incontinence B-NEG
secondary O
to O
serotonergic O
antidepressants O
could O
be O
mediated O
by O
the O
5ht4 O
receptors O
found O
on O
the O
bladder O
. O

further O
research O
is O
needed O
to O
delineate O
the O
frequency O
of O
this O
troubling O
side O
effect O
and O
how O
best O
to O
treat O
it O
. O

-DOCSTART- O

hypotension B-NEG
following O
the O
initiation O
of O
tizanidine O
in O
a O
patient O
treated O
with O
an O
angiotensin O
converting O
enzyme O
inhibitor O
for O
chronic O
hypertension B-NEG
. O

centrally O
acting O
alpha-2 O
adrenergic O
agonists O
are O
one O
of O
several O
pharmacologic O
agents O
used O
in O
the O
treatment O
of O
spasticity B-NEG
related O
to O
disorders B-NEG
of I-NEG
the I-NEG
central I-NEG
nervous I-NEG
system I-NEG
. O

in O
addition O
to O
their O
effects O
on O
spasticity B-NEG
, O
certain O
adverse O
cardiorespiratory O
effects O
have O
been O
reported O
. O

adults O
chronically O
treated O
with O
angiotensin O
converting O
enzyme O
inhibitors O
may O
have O
a O
limited O
ability O
to O
respond O
to O
hypotension B-NEG
when O
the O
sympathetic O
response O
is O
simultaneously O
blocked O
. O

the O
authors O
present O
a O
10-year-old O
boy O
chronically O
treated O
with O
lisinopril O
, O
an O
angiotensin O
converting O
enzyme O
inhibitor O
, O
to O
control O
hypertension B-NEG
who O
developed O
hypotension B-NEG
following O
the O
addition O
of O
tizanidine O
, O
an O
alpha-2 O
agonist O
, O
for O
the O
treatment O
of O
spasticity B-NEG
. O

the O
possible O
interaction O
of O
tizanidine O
and O
other O
antihypertensive O
agents O
should O
be O
kept O
in O
mind O
when O
prescribing O
therapy O
to O
treat O
either O
hypertension B-NEG
or O
spasticity B-NEG
in O
such O
patients O
. O

-DOCSTART- O

peritubular O
capillary O
basement O
membrane O
reduplication O
in O
allografts O
and O
native O
kidney B-NEG
disease I-NEG
: O
a O
clinicopathologic O
study O
of O
278 O
consecutive O
renal O
specimens O
. O

background O
: O
an O
association O
has O
been O
found O
between O
transplant B-NEG
glomerulopathy I-NEG
( O
tg B-NEG
) O
and O
reduplication O
of O
peritubular O
capillary O
basement O
membranes O
(ptcr) O
. O

although O
such O
an O
association O
is O
of O
practical O
and O
theoretical O
importance O
, O
only O
one O
prospective O
study O
has O
tried O
to O
confirm O
it O
. O

methods O
: O
we O
examined O
278 O
consecutive O
renal O
specimens O
( O
from O
135 O
transplants O
and O
143 O
native O
kidneys O
) O
for O
ultrastructural O
evidence O
of O
ptcr O
. O

in O
addition O
to O
renal O
allografts O
with O
tg B-NEG
, O
we O
also O
examined O
grafts O
with O
acute O
rejection O
, O
recurrent O
glomerulonephritis B-NEG
, O
chronic B-NEG
allograft I-NEG
nephropathy I-NEG
and O
stable O
grafts O
( O
protocol O
biopsies) O
. O

native O
kidney O
specimens O
included O
a O
wide O
range O
of O
glomerulopathies B-NEG
as O
well O
as O
cases O
of O
thrombotic B-NEG
microangiopathy I-NEG
, O
malignant B-NEG
hypertension I-NEG
, O
acute O
interstitial B-NEG
nephritis I-NEG
, O
and O
acute B-NEG
tubular I-NEG
necrosis I-NEG
. O

results O
: O
we O
found O
ptcr O
in O
14 O
of O
15 O
cases O
of O
tg B-NEG
, O
in O
7 O
transplant O
biopsy O
specimens O
without O
tg B-NEG
, O
and O
in O
13 O
of O
143 O
native O
kidney O
biopsy O
specimens O
. O

these O
13 O
included O
cases O
of O
malignant B-NEG
hypertension I-NEG
, O
thrombotic B-NEG
microangiopathy I-NEG
, O
lupus B-NEG
nephritis I-NEG
, O
henoch-schonlein B-NEG
nephritis I-NEG
, O
crescentic O
glomerulonephritis B-NEG
, O
and O
cocaine-related O
acute B-NEG
renal I-NEG
failure I-NEG
. O

mild O
ptcr O
in O
allografts O
without O
tg B-NEG
did O
not O
predict O
renal B-NEG
failure I-NEG
or O
significant O
proteinuria B-NEG
after O
follow-up O
periods O
of O
between O
3 O
months O
and O
1 O
year O
. O

conclusions O
: O
we O
conclude O
that O
in O
transplants O
, O
there O
is O
a O
strong O
association O
between O
well-developed O
ptcr O
and O
tg B-NEG
, O
while O
the O
significance O
of O
mild O
ptcr O
and O
its O
predictive O
value O
in O
the O
absence O
of O
tg B-NEG
is O
unclear O
. O

ptcr O
also O
occurs O
in O
certain O
native O
kidney B-NEG
diseases I-NEG
, O
though O
the O
association O
is O
not O
as O
strong O
as O
that O
for O
tg B-NEG
. O

we O
suggest O
that O
repeated O
endothelial B-NEG
injury I-NEG
, O
including O
immunologic B-NEG
injury I-NEG
, O
may O
be O
the O
cause O
of O
this O
lesion O
both O
in O
allografts O
and O
native O
kidneys O
. O

-DOCSTART- O

conformationally O
restricted O
analogs O
of O
bd1008 O
and O
an O
antisense O
oligodeoxynucleotide O
targeting O
sigma1 O
receptors O
produce O
anti-cocaine O
effects O
in O
mice O
. O

cocaine's O
ability O
to O
interact O
with O
sigma O
receptors O
suggests O
that O
these O
proteins O
mediate O
some O
of O
its O
behavioral O
effects O
. O

therefore O
, O
three O
novel O
sigma O
receptor O
ligands O
with O
antagonist O
activity O
were O
evaluated O
in O
swiss O
webster O
mice O
: O
bd1018 O
(3s-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) O
, O
bd1063 O
(1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine) O
, O
and O
lr132 O
(1r,2s-(+)-cis-n-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine) O
. O

competition O
binding O
assays O
demonstrated O
that O
all O
three O
compounds O
have O
high O
affinities O
for O
sigma1 O
receptors O
. O

the O
three O
compounds O
vary O
in O
their O
affinities O
for O
sigma2 O
receptors O
and O
exhibit O
negligible O
affinities O
for O
dopamine O
, O
opioid O
, O
gaba(a O
) O
and O
nmda O
receptors O
. O

in O
behavioral O
studies O
, O
pre-treatment O
of O
mice O
with O
bd1018 O
, O
bd1063 O
, O
or O
lr132 O
significantly O
attenuated O
cocaine-induced O
convulsions B-NEG
and O
lethality O
. O

moreover O
, O
post-treatment O
with O
lr132 O
prevented O
cocaine-induced O
lethality O
in O
a O
significant O
proportion O
of O
animals O
. O

in O
contrast O
to O
the O
protection O
provided O
by O
the O
putative O
antagonists O
, O
the O
well-characterized O
sigma O
receptor O
agonist O
di-o-tolylguanidine O
( O
dtg O
) O
and O
the O
novel O
sigma O
receptor O
agonist O
bd1031 O
( O
3r-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane O
) O
each O
worsened O
the O
behavioral O
toxicity B-NEG
of O
cocaine O
. O

at O
doses O
where O
alone O
, O
they O
produced O
no O
significant O
effects O
on O
locomotion O
, O
bd1018 O
, O
bd1063 O
and O
lr132 O
significantly O
attenuated O
the O
locomotor O
stimulatory O
effects O
of O
cocaine O
. O

to O
further O
validate O
the O
hypothesis O
that O
the O
anti-cocaine O
effects O
of O
the O
novel O
ligands O
involved O
antagonism O
of O
sigma O
receptors O
, O
an O
antisense O
oligodeoxynucleotide O
against O
sigma1 O
receptors O
was O
also O
shown O
to O
significantly O
attenuate O
the O
convulsive B-NEG
and O
locomotor O
stimulatory O
effects O
of O
cocaine O
. O

together O
, O
the O
data O
suggests O
that O
functional O
antagonism O
of O
sigma O
receptors O
is O
capable O
of O
attenuating O
a O
number O
of O
cocaine-induced O
behaviors O
. O

-DOCSTART- O

pharmacokinetic/pharmacodynamic O
assessment O
of O
the O
effects O
of O
e4031 O
, O
cisapride O
, O
terfenadine O
and O
terodiline O
on O
monophasic O
action O
potential O
duration O
in O
dog O
. O

1. O
torsades B-NEG
de I-NEG
pointes I-NEG
( O
tdp B-NEG
) O
is O
a O
potentially O
fatal O
ventricular B-NEG
tachycardia I-NEG
associated O
with O
increases O
in O
qt O
interval O
and O
monophasic O
action O
potential O
duration O
(mapd) O
. O
tdp B-NEG
is O
a O
side-effect O
that O
has O
led O
to O
withdrawal O
of O
several O
drugs O
from O
the O
market O
(e.g O
. O
terfenadine O
and O
terodiline) O
. O

2. O

the O
potential O
of O
compounds O
to O
cause O
tdp B-NEG
was O
evaluated O
by O
monitoring O
their O
effects O
on O
mapd O
in O
dog O
. O

four O
compounds O
known O
to O
increase O
qt O
interval O
and O
cause O
tdp B-NEG
were O
investigated O
: O
terfenadine O
, O
terodiline O
, O
cisapride O
and O
e4031 O
. O

on O
the O
basis O
that O
only O
free O
drug O
in O
the O
systemic O
circulation O
will O
elicit O
a O
pharmacological O
response O
target O
, O
free O
concentrations O
in O
plasma O
were O
selected O
to O
mimic O
the O
free O
drug O
exposures O
in O
man O
. O

infusion O
regimens O
were O
designed O
that O
rapidly O
achieved O
and O
maintained O
target-free O
concentrations O
of O
these O
drugs O
in O
plasma O
and O
data O
on O
the O
relationship O
between O
free O
concentration O
and O
changes O
in O
mapd O
were O
obtained O
for O
these O
compounds O
. O

3. O

these O
data O
indicate O
that O
the O
free O
ed50 O
in O
plasma O
for O
terfenadine O
( O
1.9 O
nm) O
, O
terodiline O
( O
76 O
nm) O
, O
cisapride O
( O
11 O
nm O
) O
and O
e4031 O
( O
1.9 O
nm O
) O
closely O
correlate O
with O
the O
free O
concentration O
in O
man O
causing O
qt O
effects O
. O

for O
compounds O
that O
have O
shown O
tdp B-NEG
in O
the O
clinic O
(terfenadine O
, O
terodiline O
, O
cisapride O
) O
there O
is O
little O
differentiation O
between O
the O
dog O
ed50 O
and O
the O
efficacious O
free O
plasma O
concentrations O
in O
man O
(< O
10-fold O
) O
reflecting O
their O
limited O
safety O
margins O
. O

these O
data O
underline O
the O
need O
to O
maximize O
the O
therapeutic O
ratio O
with O
respect O
to O
tdp B-NEG
in O
potential O
development O
candidates O
and O
the O
importance O
of O
using O
free O
drug O
concentrations O
in O
pharmacokinetic/pharmacodynamic O
studies O
. O

-DOCSTART- O

fatal O
myeloencephalopathy B-NEG
due O
to O
accidental O
intrathecal O
vincristin O
administration O
: O
a O
report O
of O
two O
cases O
. O

we O
report O
on O
two O
fatal O
cases O
of O
accidental O
intrathecal O
vincristine O
instillation O
in O
a O
5-year O
old O
girl O
with O
recurrent O
acute B-NEG
lymphoblastic I-NEG
leucemia I-NEG
and O
a O
57-year O
old O
man O
with O
lymphoblastic B-NEG
lymphoma I-NEG
. O

the O
girl O
died O
seven O
days O
, O
the O
man O
four O
weeks O
after O
intrathecal O
injection O
of O
vincristine O
. O

clinically O
, O
the O
onset O
was O
characterized O
by O
the O
signs O
of O
opistothonus B-NEG
, O
sensory I-NEG
and I-NEG
motor I-NEG
dysfunction I-NEG
and O
ascending O
paralysis B-NEG
. O

histological O
and O
immunohistochemical O
investigations O
(he-lfb O
, O
cd-68 O
, O
neurofilament O
) O
revealed O
degeneration B-NEG
of I-NEG
myelin I-NEG
and I-NEG
axons I-NEG
as O
well O
as O
pseudocystic B-NEG
transformation I-NEG
in O
areas O
exposed O
to O
vincristine O
, O
accompanied O
by O
secondary O
changes O
with O
numerous O
prominent O
macrophages O
. O

the O
clinical O
course O
and O
histopathological O
results O
of O
the O
two O
cases O
are O
presented O
. O

a O
review O
of O
all O
reported O
cases O
in O
the O
literature O
is O
given O
. O

a O
better O
controlled O
regimen O
for O
administering O
vincristine O
and O
intrathecal O
chemotherapy O
is O
recommended O
. O

-DOCSTART- O

intravenous O
administration O
of O
prochlorperazine O
by O
15-minute O
infusion O
versus O
2-minute O
bolus O
does O
not O
affect O
the O
incidence O
of O
akathisia B-NEG
: O
a O
prospective O
, O
randomized O
, O
controlled O
trial O
. O

study O
objective O
: O
we O
sought O
to O
compare O
the O
rate O
of O
akathisia B-NEG
after O
administration O
of O
intravenous O
prochlorperazine O
as O
a O
2-minute O
bolus O
or O
15-minute O
infusion O
. O

methods O
: O
we O
conducted O
a O
prospective O
, O
randomized O
, O
double-blind O
study O
in O
the O
emergency O
department O
of O
a O
central-city O
teaching O
hospital O
. O

patients O
aged O
18 O
years O
or O
older O
treated O
with O
prochlorperazine O
for O
headache B-NEG
, O
nausea B-NEG
, O
or O
vomiting B-NEG
were O
eligible O
for O
inclusion O
. O

study O
participants O
were O
randomized O
to O
receive O
10 O
mg O
of O
prochlorperazine O
administered O
intravenously O
by O
means O
of O
2-minute O
push O
( O
bolus O
group O
) O
or O
10 O
mg O
diluted O
in O
50 O
ml O
of O
normal O
saline O
solution O
administered O
by O
means O
of O
intravenous O
infusion O
during O
a O
15-minute O
period O
( O
infusion O
group) O
. O

the O
main O
outcome O
was O
the O
number O
of O
study O
participants O
experiencing O
akathisia B-NEG
within O
60 O
minutes O
of O
administration O
. O

akathisia O
was O
defined O
as O
either O
a O
spontaneous O
report O
of O
restlessness O
or O
agitation B-NEG
or O
a O
change O
of O
2 O
or O
more O
in O
the O
patient-reported O
akathisia B-NEG
rating O
scale O
and O
a O
change O
of O
at O
least O
1 O
in O
the O
investigator-observed O
akathisia B-NEG
rating O
scale O
. O

the O
intensity O
of O
headache B-NEG
and O
nausea B-NEG
was O
measured O
with O
a O
100-mm O
visual O
analog O
scale O
. O

results O
: O
one O
hundred O
patients O
were O
enrolled O
. O

one O
study O
participant O
was O
excluded O
after O
protocol O
violation O
. O

seventy-three O
percent O
( O
73/99 O
) O
of O
the O
study O
participants O
were O
treated O
for O
headache B-NEG
and O
70% O
( O
70/99 O
) O
for O
nausea B-NEG
. O

in O
the O
bolus O
group O
, O
26.0% O
( O
13/50 O
) O
had O
akathisia B-NEG
compared O
with O
32.7% O
( O
16/49 O
) O
in O
the O
infusion O
group O
(delta=-6.7% O
; O
95% O
confidence O
interval O
[ci] O
-24.6% O
to O
11.2%) O
. O

the O
difference O
between O
the O
bolus O
and O
infusion O
groups O
in O
the O
percentage O
of O
participants O
who O
saw O
a O
50% O
reduction O
in O
their O
headache B-NEG
intensity O
within O
30 O
minutes O
was O
11.8% O
( O
95% O
ci O
-9.6% O
to O
33.3%) O
. O

the O
difference O
in O
the O
percentage O
of O
patients O
with O
a O
50% O
reduction O
in O
their O
nausea B-NEG
was O
12.6% O
( O
95% O
ci O
-4.6% O
to O
29.8%) O
. O

conclusion O
: O
a O
50% O
reduction O
in O
the O
incidence O
of O
akathisia B-NEG
when O
prochlorperazine O
was O
administered O
by O
means O
of O
15-minute O
intravenous O
infusion O
versus O
a O
2-minute O
intravenous O
push O
was O
not O
detected O
. O

the O
efficacy O
of O
prochlorperazine O
in O
the O
treatment O
of O
headache B-NEG
and O
nausea B-NEG
likewise O
did O
not O
appear O
to O
be O
affected O
by O
the O
rate O
of O
administration O
, O
although O
no O
formal O
statistical O
comparisons O
were O
made O
. O

-DOCSTART- O

antithymocyte O
globulin O
in O
the O
treatment O
of O
d-penicillamine-induced O
aplastic B-NEG
anemia I-NEG
. O

a O
patient O
who O
received O
antithymocyte O
globulin O
therapy O
for O
aplastic B-NEG
anemia I-NEG
due O
to O
d-penicillamine O
therapy O
is O
described O
. O

bone O
marrow O
recovery O
and O
peripheral O
blood O
recovery O
were O
complete O
1 O
month O
and O
3 O
months O
, O
respectively O
, O
after O
treatment O
, O
and O
blood O
transfusion O
or O
other O
therapies O
were O
not O
necessary O
in O
a O
follow-up O
period O
of O
more O
than O
2 O
years O
. O

use O
of O
antithymocyte O
globulin O
may O
be O
the O
optimal O
treatment O
of O
d-penicillamine-induced O
aplastic B-NEG
anemia I-NEG
. O

-DOCSTART- O

the O
relationship O
between O
hippocampal O
acetylcholine O
release O
and O
cholinergic O
convulsant O
sensitivity O
in O
withdrawal O
seizure B-NEG
-prone O
and O
withdrawal O
seizure B-NEG
-resistant O
selected O
mouse O
lines O
. O

background O
: O
the O
septo-hippocampal O
cholinergic O
pathway O
has O
been O
implicated O
in O
epileptogenesis O
, O
and O
genetic O
factors O
influence O
the O
response O
to O
cholinergic O
agents O
, O
but O
limited O
data O
are O
available O
on O
cholinergic O
involvement O
in O
alcohol O
withdrawal O
severity O
. O

thus O
, O
the O
relationship O
between O
cholinergic O
activity O
and O
responsiveness O
and O
alcohol O
withdrawal O
was O
investigated O
in O
a O
genetic O
animal O
model O
of O
ethanol O
withdrawal O
severity O
. O

methods O
: O
cholinergic O
convulsant O
sensitivity O
was O
examined O
in O
alcohol-na O
ve O
withdrawal O
seizure B-NEG
-prone O
( O
wsp O
) O
and-resistant O
( O
wsr O
) O
mice O
. O

animals O
were O
administered O
nicotine O
, O
carbachol O
, O
or O
neostigmine O
via O
timed O
tail O
vein O
infusion O
, O
and O
the O
latencies O
to O
onset O
of O
tremor B-NEG
and O
clonus O
were O
recorded O
and O
converted O
to O
threshold O
dose O
. O

we O
also O
used O
microdialysis O
to O
measure O
basal O
and O
potassium-stimulated O
acetylcholine O
( O
ach O
) O
release O
in O
the O
ca1 O
region O
of O
the O
hippocampus O
. O

potassium O
was O
applied O
by O
reverse O
dialysis O
twice O
, O
separated O
by O
75 O
min O
. O

hippocampal O
ach O
also O
was O
measured O
during O
testing O
for O
handling-induced O
convulsions B-NEG
. O

results O
: O
sensitivity O
to O
several O
convulsion B-NEG
endpoints O
induced O
by O
nicotine O
, O
carbachol O
, O
and O
neostigmine O
were O
significantly O
greater O
in O
wsr O
versus O
wsp O
mice O
. O

in O
microdialysis O
experiments O
, O
the O
lines O
did O
not O
differ O
in O
basal O
release O
of O
ach O
, O
and O
50 O
mm O
kcl O
increased O
ach O
output O
in O
both O
lines O
of O
mice O
. O

however O
, O
the O
increase O
in O
release O
of O
ach O
produced O
by O
the O
first O
application O
of O
kcl O
was O
2-fold O
higher O
in O
wsp O
versus O
wsr O
mice O
. O

when O
hippocampal O
ach O
was O
measured O
during O
testing O
for O
handling-induced O
convulsions B-NEG
, O
extracellular O
ach O
was O
significantly O
elevated O
( O
192% O
) O
in O
wsp O
mice O
, O
but O
was O
nonsignificantly O
elevated O
( O
59% O
) O
in O
wsr O
mice O
. O

conclusions O
: O
these O
results O
suggest O
that O
differences O
in O
cholinergic O
activity O
and O
postsynaptic O
sensitivity O
to O
cholinergic O
convulsants B-NEG
may O
be O
associated O
with O
ethanol O
withdrawal O
severity O
and O
implicate O
cholinergic O
mechanisms O
in O
alcohol O
withdrawal O
. O

specifically O
, O
wsp O
mice O
may O
have O
lower O
sensitivity O
to O
cholinergic O
convulsants B-NEG
compared O
with O
wsr O
because O
of O
postsynaptic O
receptor O
desensitization O
brought O
on O
by O
higher O
activity O
of O
cholinergic O
neurons O
. O

-DOCSTART- O

prenatal O
dexamethasone O
programs O
hypertension B-NEG
and O
renal B-NEG
injury I-NEG
in O
the O
rat O
. O

dexamethasone O
is O
frequently O
administered O
to O
the O
developing O
fetus O
to O
accelerate O
pulmonary O
development O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
if O
prenatal O
dexamethasone O
programmed O
a O
progressive O
increase B-NEG
in I-NEG
blood I-NEG
pressure I-NEG
and O
renal B-NEG
injury I-NEG
in O
rats O
. O

pregnant O
rats O
were O
given O
either O
vehicle O
or O
2 O
daily O
intraperitoneal O
injections O
of O
dexamethasone O
( O
0.2 O
mg/kg O
body O
weight O
) O
on O
gestational O
days O
11 O
and O
12 O
, O
13 O
and O
14 O
, O
15 O
and O
16 O
, O
17 O
and O
18 O
, O
or O
19 O
and O
20 O
. O

offspring O
of O
rats O
administered O
dexamethasone O
on O
days O
15 O
and O
16 O
gestation O
had O
a O
20% O
reduction B-NEG
in I-NEG
glomerular I-NEG
number I-NEG
compared O
with O
control O
at O
6 O
to O
9 O
months O
of O
age O
( O
22 O
527+/-509 O
versus O
28 O
050+/-561 O
, O
p<0.05) O
, O
which O
was O
comparable O
to O
the O
percent O
reduction O
in O
glomeruli O
measured O
at O
3 O
weeks O
of O
age O
. O

six- O
to O
9-month O
old O
rats O
receiving O
prenatal O
dexamethasone O
on O
days O
17 O
and O
18 O
of O
gestation O
had O
a O
17% O
reduction O
in O
glomeruli O
( O
23 O
380+/-587 O
) O
compared O
with O
control O
rats O
(p<0.05) O
. O

male O
rats O
that O
received O
prenatal O
dexamethasone O
on O
days O
15 O
and O
16 O
, O
17 O
and O
18 O
, O
and O
13 O
and O
14 O
of O
gestation O
had O
elevated B-NEG
blood I-NEG
pressures I-NEG
at O
6 O
months O
of O
age O
; O
the O
latter O
group O
did O
not O
have O
a O
reduction B-NEG
in I-NEG
glomerular I-NEG
number I-NEG
. O

adult O
rats O
given O
dexamethasone O
on O
days O
15 O
and O
16 O
of O
gestation O
had O
more O
glomeruli O
with O
glomerulosclerosis B-NEG
than O
control O
rats O
. O

this O
study O
shows O
that O
prenatal O
dexamethasone O
in O
rats O
results O
in O
a O
reduction B-NEG
in I-NEG
glomerular I-NEG
number I-NEG
, O
glomerulosclerosis B-NEG
, O
and O
hypertension B-NEG
when O
administered O
at O
specific O
points O
during O
gestation O
. O
hypertension B-NEG
was O
observed O
in O
animals O
that O
had O
a O
reduction O
in O
glomeruli O
as O
well O
as O
in O
a O
group O
that O
did O
not O
have O
a O
reduction B-NEG
in I-NEG
glomerular I-NEG
number I-NEG
, O
suggesting O
that O
a O
reduction B-NEG
in I-NEG
glomerular I-NEG
number I-NEG
is O
not O
the O
sole O
cause O
for O
the O
development O
of O
hypertension B-NEG
. O

-DOCSTART- O

the O
risk O
of O
venous B-NEG
thromboembolism I-NEG
in O
women O
prescribed O
cyproterone O
acetate O
in O
combination O
with O
ethinyl O
estradiol O
: O
a O
nested O
cohort O
analysis O
and O
case-control O
study O
. O

background O
: O
cyproterone O
acetate O
combined O
with O
ethinyl O
estradiol O
( O
cpa/ee O
) O
is O
licensed O
in O
the O
uk O
for O
the O
treatment O
of O
women O
with O
acne B-NEG
and O
hirsutism B-NEG
and O
is O
also O
a O
treatment O
option O
for O
polycystic B-NEG
ovary I-NEG
syndrome I-NEG
( O
pcos B-NEG
). O

previous O
studies O
have O
demonstrated O
an O
increased O
risk O
of O
venous B-NEG
thromboembolism I-NEG
( O
vte B-NEG
) O
associated O
with O
cpa/ee O
compared O
with O
conventional O
combined O
oral O
contraceptives O
(cocs) O
. O

we O
believe O
the O
results O
of O
those O
studies O
may O
have O
been O
affected O
by O
residual O
confounding O
. O

methods O
: O
using O
the O
general O
practice O
research O
database O
we O
conducted O
a O
cohort O
analysis O
and O
case-control O
study O
nested O
within O
a O
population O
of O
women O
aged O
between O
15 O
and O
39 O
years O
with O
acne B-NEG
, O
hirsutism B-NEG
or O
pcos B-NEG
to O
estimate O
the O
risk O
of O
vte B-NEG
associated O
with O
cpa/ee O
. O

results O
: O
the O
age-adjusted O
incidence O
rate O
ratio O
for O
cpa/ee O
versus O
conventional O
cocs O
was O
2.20 O
[95% O
confidence O
interval O
( O
ci O
) O
1.35-3.58] O
. O

using O
as O
the O
reference O
group O
women O
who O
were O
not O
using O
oral O
contraception O
, O
had O
no O
recent O
pregnancy O
or O
menopausal O
symptoms O
, O
the O
case-control O
analysis O
gave O
an O
adjusted O
odds O
ratio O
( O
or(adj) O
) O
of O
7.44 O
( O
95% O
ci O
3.67-15.08 O
) O
for O
cpa/ee O
use O
compared O
with O
an O
or(adj O
) O
of O
2.58 O
( O
95% O
ci O
1.60-4.18 O
) O
for O
use O
of O
conventional O
cocs O
. O

conclusions O
: O
we O
have O
demonstrated O
an O
increased O
risk O
of O
vte B-NEG
associated O
with O
the O
use O
of O
cpa/ee O
in O
women O
with O
acne B-NEG
, O
hirsutism B-NEG
or O
pcos B-NEG
although O
residual O
confounding O
by O
indication O
cannot O
be O
excluded O
. O

-DOCSTART- O

pseudoacromegaly B-NEG
induced O
by O
the O
long-term O
use O
of O
minoxidil O
. O
acromegaly B-NEG
is O
an O
endocrine B-NEG
disorder I-NEG
caused O
by O
chronic O
excessive O
growth O
hormone O
secretion O
from O
the O
anterior O
pituitary O
gland O
. O

significant O
disfiguring O
changes O
occur O
as O
a O
result O
of O
bone O
, O
cartilage O
, O
and O
soft O
tissue O
hypertrophy B-NEG
, O
including O
the O
thickening O
of O
the O
skin O
, O
coarsening O
of O
facial O
features O
, O
and O
cutis B-NEG
verticis I-NEG
gyrata I-NEG
. O
pseudoacromegaly B-NEG
, O
on O
the O
other O
hand O
, O
is O
the O
presence O
of O
similar O
acromegaloid O
features O
in O
the O
absence O
of O
elevated O
growth O
hormone O
or O
insulin-like O
growth O
factor O
levels O
. O

we O
present O
a O
patient O
with O
pseudoacromegaly B-NEG
that O
resulted O
from O
the O
long-term O
use O
of O
minoxidil O
at O
an O
unusually O
high O
dose O
. O

this O
is O
the O
first O
case O
report O
of O
pseudoacromegaly B-NEG
as O
a O
side O
effect O
of O
minoxidil O
use O
. O

-DOCSTART- O

combined O
androgen O
blockade-induced O
anemia B-NEG
in O
prostate B-NEG
cancer I-NEG
patients O
without O
bone O
involvement O
. O

background O
: O
to O
determine O
the O
onset O
and O
extent O
of O
combined O
androgen O
blockade O
( O
cab)-induced O
anemia B-NEG
in O
prostate B-NEG
cancer I-NEG
patients O
without O
bone O
involvement O
. O

patients O
and O
methods O
: O
forty-two O
patients O
with O
biopsy-proven O
prostatic B-NEG
adenocarcinoma I-NEG
[26 O
with O
stage O
c O
( O
t3n0m0 O
) O
and O
16 O
with O
stage O
d1 O
( O
t3n1m0)] O
were O
included O
in O
this O
study O
. O

all O
patients O
received O
cab O
[leuprolide O
acetate O
( O
lhrh-a O
) O
3.75 O
mg O
, O
intramuscularly O
, O
every O
28 O
days O
plus O
250 O
mg O
flutamide O
, O
tid O
, O
per O
os] O
and O
were O
evaluated O
for O
anemia B-NEG
by O
physical O
examination O
and O
laboratory O
tests O
at O
baseline O
and O
4 O
subsequent O
intervals O
(1 O
, O
2, O
3 O
and O
6 O
months O
post-cab) O
. O

hb O
, O
psa O
and O
testosterone O
measurements O
were O
recorded O
. O

patients O
with O
stage O
d2-3 O
disease O
, O
abnormal O
hemoglobin O
level O
or O
renal O
and O
liver O
function O
tests O
that O
were O
higher O
than O
the O
upper O
limits O
were O
excluded O
from O
the O
study O
. O

the O
duration O
of O
the O
study O
was O
six O
months O
. O

results O
: O
the O
mean O
hemoglobin O
( O
hb O
) O
levels O
were O
significantly O
declined O
in O
all O
patients O
from O
baseline O
of O
14.2 O
g/dl O
to O
14.0 O
g/dl O
, O
13.5 O
g/dl O
, O
13.2 O
g/dl O
and O
12.7 O
g/dl O
at O
1, O
2, O
3 O
and O
6 O
months O
post-cab O
, O
respectively O
. O

severe O
and O
clinically O
evident O
anemia B-NEG
of O
hb O
< O
11 O
g/dl O
with O
clinical O
symptoms O
was O
detected O
in O
6 O
patients O
(14.3%) O
. O

this O
cab-induced O
anemia B-NEG
was O
normochromic O
and O
normocytic O
. O

at O
six O
months O
post-cab O
, O
patients O
with O
severe O
anemia B-NEG
had O
a O
hb O
mean O
value O
of O
10.2 O
+/- O
0.1 O
g/dl O
(x O
+/- O
se) O
, O
whereas O
the O
other O
patients O
had O
mild O
anemia B-NEG
with O
hb O
mean O
value O
of O
13.2 O
+/- O
0.17 O
(x O
+/- O
se) O
. O

the O
development O
of O
severe O
anemia B-NEG
at O
6 O
months O
post-cab O
was O
predictable O
by O
the O
reduction O
of O
hb O
baseline O
value O
of O
more O
than O
2.5 O
g/dl O
after O
3 O
months O
of O
cab O
(p O
= O
0.01) O
. O

the O
development O
of O
severe O
cab-induced O
anemia B-NEG
in O
prostate B-NEG
cancer I-NEG
patients O
did O
not O
correlate O
with O
t O
baseline O
values O
(t O
< O
3 O
ng/ml O
versus O
t O
> O
or O
= O
3 O
ng/ml) O
, O
with O
age O
(< O
76 O
yrs O
versus O
> O
or O
= O
76 O
yrs) O
, O
and O
clinical O
stage O
( O
stage O
c O
versus O
stage O
d1) O
. O

severe O
and O
clinically O
evident O
anemia B-NEG
was O
easily O
corrected O
by O
subcutaneous O
injections O
(3 O
times/week O
for O
1 O
month O
) O
of O
recombinant O
erythropoietin O
(rhuepo-beta) O
. O

conclusion O
: O
our O
data O
suggest O
that O
rhuepo-beta O
correctable O
cab-induced O
anemia B-NEG
occurs O
in O
14.3% O
of O
prostate B-NEG
cancer I-NEG
patients O
after O
6 O
months O
of O
therapy O
. O

-DOCSTART- O

reversible O
dilated B-NEG
cardiomyopathy I-NEG
related O
to O
amphotericin O
b O
therapy O
. O

we O
describe O
a O
patient O
who O
developed O
dilated B-NEG
cardiomyopathy I-NEG
and O
clinical O
congestive O
heart B-NEG
failure I-NEG
after O
2 O
months O
of O
therapy O
with O
amphotericin O
b O
( O
amb O
) O
for O
disseminated O
coccidioidomycosis B-NEG
. O

his O
echocardiographic O
abnormalities O
and O
heart B-NEG
failure I-NEG
resolved O
after O
posaconazole O
was O
substituted O
for O
amb O
. O

it O
is O
important O
to O
recognize O
the O
rare O
and O
potentially O
reversible O
toxicity B-NEG
of O
amb O
. O

-DOCSTART- O

risks O
of O
the O
consumption O
of O
beverages O
containing O
quinine O
. O

although O
the O
united O
states O
food O
and O
drug O
administration O
banned O
its O
use O
for O
nocturnal B-NEG
leg I-NEG
cramps I-NEG
due O
to O
lack O
of O
safety O
and O
efficacy O
, O
quinine O
is O
widely O
available O
in O
beverages O
including O
tonic O
water O
and O
bitter O
lemon O
. O

numerous O
anecdotal O
reports O
suggest O
that O
products O
containing O
quinine O
may O
produce O
neurological B-NEG
complications I-NEG
, O
including O
confusion B-NEG
, O
altered O
mental O
status O
, O
seizures B-NEG
, O
and O
coma B-NEG
, O
particularly O
in O
older O
women O
. O

psychologists O
need O
to O
inquire O
about O
consumption O
of O
quinine-containing O
beverages O
as O
part O
of O
an O
evaluation O
process O
. O

-DOCSTART- O

organophosphate-induced O
convulsions B-NEG
and O
prevention O
of O
neuropathological B-NEG
damages I-NEG
. O

such O
organophosphorus O
( O
op O
) O
compounds O
as O
diisopropylfluorophosphate O
(dfp) O
, O
sarin O
and O
soman O
are O
potent O
inhibitors O
of O
acetylcholinesterases O
( O
aches O
) O
and O
butyrylcholinesterases O
(bches) O
. O

the O
acute O
toxicity B-NEG
of O
ops O
is O
the O
result O
of O
their O
irreversible O
binding O
with O
aches O
in O
the O
central O
nervous O
system O
(cns) O
, O
which O
elevates O
acetylcholine O
( O
ach O
) O
levels O
. O

the O
protective O
action O
of O
subcutaneously O
( O
sc O
) O
administered O
antidotes O
or O
their O
combinations O
in O
dfp O
( O
2.0 O
mg/kg O
bw O
) O
intoxication O
was O
studied O
in O
9-10-weeks-old O
han-wistar O
male O
rats O
. O

the O
rats O
received O
ache O
reactivator O
pralidoxime-2-chloride O
( O
2pam O
) O
( O
30.0 O
mg/kg O
bw) O
, O
anticonvulsant O
diazepam O
( O
2.0 O
mg/kg O
bw) O
, O
a(1)-adenosine O
receptor O
agonist O
n(6)-cyclopentyl O
adenosine O
( O
cpa O
) O
( O
2.0 O
mg/kg O
bw) O
, O
nmda-receptor O
antagonist O
dizocilpine O
maleate O
( O
+-mk801 O
hydrogen O
maleate O
) O
( O
2.0 O
mg/kg O
bw O
) O
or O
their O
combinations O
with O
cholinolytic O
drug O
atropine O
sulfate O
( O
50.0 O
mg/kg O
bw O
) O
immediately O
or O
30 O
min O
after O
the O
single O
sc O
injection O
of O
dfp O
. O

the O
control O
rats O
received O
atropine O
sulfate O
, O
but O
also O
saline O
and O
olive O
oil O
instead O
of O
other O
antidotes O
and O
dfp O
, O
respectively O
. O

all O
rats O
were O
terminated O
either O
24 O
h O
or O
3 O
weeks O
after O
the O
dfp O
injection O
. O

the O
rats O
treated O
with O
dfp-atropine O
showed O
severe O
typical O
op-induced O
toxicity B-NEG
signs O
. O

when O
cpa O
, O
diazepam O
or O
2pam O
was O
given O
immediately O
after O
dfp-atropine O
, O
these O
treatments O
prevented O
, O
delayed O
or O
shortened O
the O
occurrence O
of O
serious O
signs O
of O
poisoning B-NEG
. O

atropine-mk801 O
did O
not O
offer O
any O
additional O
protection O
against O
dfp O
toxicity B-NEG
. O

in O
conclusion O
, O
cpa O
, O
diazepam O
and O
2pam O
in O
combination O
with O
atropine O
prevented O
the O
occurrence O
of O
serious O
signs O
of O
poisoning B-NEG
and O
thus O
reduced O
the O
toxicity B-NEG
of O
dfp O
in O
rat O
. O

-DOCSTART- O

differential O
modulation O
by O
estrogen O
of O
alpha2-adrenergic O
and O
i1-imidazoline O
receptor-mediated O
hypotension B-NEG
in O
female O
rats O
. O

we O
have O
recently O
shown O
that O
estrogen O
negatively O
modulates O
the O
hypotensive B-NEG
effect O
of O
clonidine O
( O
mixed O
alpha2-/i1-receptor O
agonist O
) O
in O
female O
rats O
and O
implicates O
the O
cardiovascular O
autonomic O
control O
in O
this O
interaction O
. O

the O
present O
study O
investigated O
whether O
this O
effect O
of O
estrogen O
involves O
interaction O
with O
alpha2- O
and/or O
i1-receptors O
. O

changes O
evoked O
by O
a O
single O
intraperitoneal O
injection O
of O
rilmenidine O
( O
600 O
microg/kg O
) O
or O
alpha-methyldopa O
( O
100 O
mg/kg) O
, O
selective O
i1- O
and O
alpha2-receptor O
agonists O
, O
respectively O
, O
in O
blood O
pressure O
, O
hemodynamic O
variability O
, O
and O
locomotor O
activity O
were O
assessed O
in O
radiotelemetered O
sham-operated O
and O
ovariectomized O
( O
ovx O
) O
sprague-dawley O
female O
rats O
with O
or O
without O
12-wk O
estrogen O
replacement O
. O

three O
time O
domain O
indexes O
of O
hemodynamic O
variability O
were O
employed O
: O
the O
standard O
deviation O
of O
mean O
arterial O
pressure O
as O
a O
measure O
of O
blood O
pressure O
variability O
and O
the O
standard O
deviation O
of O
beat-to-beat O
intervals O
( O
sdrr O
) O
and O
the O
root O
mean O
square O
of O
successive O
differences O
in O
r-wave-to-r-wave O
intervals O
as O
measures O
of O
heart O
rate O
variability O
. O

in O
sham-operated O
rats O
, O
rilmenidine O
or O
alpha-methyldopa O
elicited O
similar O
hypotension B-NEG
that O
lasted O
at O
least O
5 O
h O
and O
was O
associated O
with O
reductions O
in O
standard O
deviation O
of O
mean O
arterial O
pressure O
. O

sdrr O
was O
reduced O
only O
by O
alpha-methyldopa O
. O

ovx O
significantly O
enhanced O
the O
hypotensive B-NEG
response O
to O
alpha-methyldopa O
, O
in O
contrast O
to O
no O
effect O
on O
rilmenidine O
hypotension B-NEG
. O

the O
enhanced O
alpha-methyldopa O
hypotension B-NEG
in O
ovx O
rats O
was O
paralleled O
with O
further O
reduction O
in O
sdrr O
and O
a B-NEG
reduced I-NEG
locomotor I-NEG
activity I-NEG
. O

estrogen O
replacement O
( O
17beta-estradiol O
subcutaneous O
pellet O
, O
14.2 O
microg/day O
, O
12 O
wk O
) O
of O
ovx O
rats O
restored O
the O
hemodynamic O
and O
locomotor O
effects O
of O
alpha-methyldopa O
to O
sham-operated O
levels O
. O

these O
findings O
suggest O
that O
estrogen O
downregulates O
alpha2- O
but O
not O
i1-receptor-mediated O
hypotension B-NEG
and O
highlight O
a O
role O
for O
the O
cardiac O
autonomic O
control O
in O
alpha-methyldopa-estrogen O
interaction O
. O

-DOCSTART- O

cardioprotective O
effect O
of O
tincture O
of O
crataegus O
on O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
. O

tincture O
of O
crataegus O
(tcr) O
, O
an O
alcoholic O
extract O
of O
the O
berries O
of O
hawthorn O
( O
crataegus O
oxycantha) O
, O
is O
used O
in O
herbal O
and O
homeopathic O
medicine O
. O

the O
present O
study O
was O
done O
to O
investigate O
the O
protective O
effect O
of O
tcr O
on O
experimentally O
induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
. O

pretreatment O
of O
tcr O
, O
at O
a O
dose O
of O
0.5 O
ml/100 O
g O
bodyweight O
per O
day O
, O
orally O
for O
30 O
days O
, O
prevented O
the O
increase O
in O
lipid O
peroxidation O
and O
activity O
of O
marker O
enzymes O
observed O
in O
isoproterenol-induced O
rats O
( O
85 O
mg O
kg(-1 O
) O
s. O

c. O
for O
2 O
days O
at O
an O
interval O
of O
24 O
h) O
. O

tcr O
prevented O
the O
isoproterenol-induced O
decrease O
in O
antioxidant O
enzymes O
in O
the O
heart O
and O
increased O
the O
rate O
of O
adp-stimulated O
oxygen O
uptake O
and O
respiratory O
coupling O
ratio O
. O

tcr O
protected O
against O
pathological O
changes O
induced O
by O
isoproterenol O
in O
rat O
heart O
. O

the O
results O
show O
that O
pretreatment O
with O
tcr O
may O
be O
useful O
in O
preventing O
the O
damage O
induced O
by O
isoproterenol O
in O
rat O
heart O
. O

-DOCSTART- O

safety O
and O
adverse O
effects O
associated O
with O
raloxifene O
: O
multiple O
outcomes O
of O
raloxifene O
evaluation O
. O

objective O
: O
to O
examine O
the O
effect O
of O
raloxifene O
on O
major O
adverse O
events O
that O
occur O
with O
postmenopausal O
estrogen O
therapy O
or O
tamoxifen O
. O

methods O
: O
the O
multiple O
outcomes O
of O
raloxifene O
evaluation O
, O
a O
multicenter O
, O
randomized O
, O
double-blind O
trial O
, O
enrolled O
7,705 O
postmenopausal O
women O
with O
osteoporosis B-NEG
. O

women O
were O
randomly O
assigned O
to O
raloxifene O
60 O
mg/d O
or O
120 O
mg/d O
or O
placebo O
. O

outcomes O
included O
venous B-NEG
thromboembolism I-NEG
, O
cataracts B-NEG
, O
gallbladder B-NEG
disease I-NEG
, O
and O
endometrial B-NEG
hyperplasia I-NEG
or I-NEG
cancer I-NEG
. O

results O
: O
during O
a O
mean O
follow-up O
of O
3.3 O
years O
, O
raloxifene O
was O
associated O
with O
an O
increased O
risk O
for O
venous B-NEG
thromboembolism I-NEG
( O
relative O
risk O
[rr] O
2.1 O
; O
95% O
confidence O
interval O
[ci] O
1.2-3.8) O
. O

the O
excess O
event O
rate O
was O
1.8 O
per O
1,000 O
woman-years O
( O
95% O
ci O
-0.5-4.1) O
, O
and O
the O
number O
needed O
to O
treat O
to O
cause O
1 O
event O
was O
170 O
( O
95% O
ci O
100-582 O
) O
over O
3.3 O
years O
. O

risk O
in O
the O
raloxifene O
group O
was O
higher O
than O
in O
the O
placebo O
group O
for O
the O
first O
2 O
years O
, O
but O
decreased O
to O
about O
the O
same O
rate O
as O
in O
the O
placebo O
group O
thereafter O
. O

raloxifene O
did O
not O
increase O
risk O
for O
cataracts B-NEG
( O
rr O
0.9 O
; O
95% O
ci O
0.8-1.1) O
, O
gallbladder B-NEG
disease I-NEG
( O
rr O
1.0 O
; O
95% O
ci O
0.7-1.3) O
, O
endometrial B-NEG
hyperplasia I-NEG
( O
rr O
1.3 O
; O
95% O
ci O
0.4-5.1) O
, O
or O
endometrial B-NEG
cancer I-NEG
( O
rr O
0.9 O
; O
95% O
ci O
0.3-2.7) O
. O

conclusion O
: O
raloxifene O
was O
associated O
with O
an O
increased O
risk O
for O
venous B-NEG
thromboembolism I-NEG
, O
but O
there O
was O
no O
increased O
risk O
for O
cataracts B-NEG
, O
gallbladder B-NEG
disease I-NEG
, O
endometrial B-NEG
hyperplasia I-NEG
, O
or O
endometrial B-NEG
cancer I-NEG
. O

level O
of O
evidence O
: O
i O

-DOCSTART- O

ceftriaxone-associated O
biliary B-NEG
pseudolithiasis I-NEG
in O
paediatric O
surgical O
patients O
. O

it O
is O
well O
known O
that O
ceftriaxone O
leads O
to O
pseudolithiasis B-NEG
in O
some O
patients O
. O

clinical O
and O
experimental O
studies O
also O
suggest O
that O
situations O
causing O
gallbladder B-NEG
dysfunction I-NEG
, O
such O
as O
fasting O
, O
may O
have O
a O
role O
for O
the O
development O
of O
pseudolithiasis B-NEG
. O

in O
this O
study O
, O
we O
prospectively O
evaluated O
the O
incidence O
and O
clinical O
importance O
of O
pseudolithiasis B-NEG
in O
paediatric O
surgical O
patients O
receiving O
ceftriaxone O
treatment O
, O
who O
often O
had O
to O
fast O
in O
the O
post-operative O
period O
. O

fifty O
children O
who O
were O
given O
ceftriaxone O
were O
evaluated O
by O
serial O
abdominal O
sonograms O
. O

of O
those O
, O
13 O
( O
26% O
) O
developed O
biliary O
pathology O
. O

comparison O
of O
the O
patients O
with O
or O
without O
pseudolithiasis B-NEG
revealed O
no O
significant O
difference O
with O
respect O
to O
age O
, O
sex O
, O
duration O
of O
the O
treatment O
and O
starvation O
variables O
. O

after O
cessation O
of O
the O
treatment O
, O
pseudolithiasis B-NEG
resolved O
spontaneously O
within O
a O
short O
period O
. O

the O
incidence O
of O
pseudolithiasis B-NEG
is O
not O
affected O
by O
fasting O
. O

-DOCSTART- O

evaluation O
of O
the O
anticocaine O
monoclonal O
antibody O
gnc92h2 O
as O
an O
immunotherapy O
for O
cocaine B-NEG
overdose I-NEG
. O

the O
illicit O
use O
of O
cocaine O
continues O
in O
epidemic O
proportions O
and O
treatment O
for O
cocaine B-NEG
overdose I-NEG
remains O
elusive O
. O

current O
protein-based O
technology O
offers O
a O
new O
therapeutic O
venue O
by O
which O
antibodies O
bind O
the O
drug O
in O
the O
blood O
stream O
, O
inactivating O
its O
toxic O
effects O
. O

the O
therapeutic O
potential O
of O
the O
anticocaine O
antibody O
gnc92h2 O
was O
examined O
using O
a O
model O
of O
cocaine B-NEG
overdose I-NEG
. O

swiss O
albino O
mice O
prepared O
with O
intrajugular O
catheters O
were O
tested O
in O
photocell O
cages O
after O
administration O
of O
93 O
mg/kg O
( O
ld50 O
) O
of O
cocaine O
and O
gnc92h2 O
infusions O
ranging O
from O
30 O
to O
190 O
mg/kg O
. O

gnc92h2 O
was O
delivered O
30 O
min O
before O
, O
concomitantly O
or O
3 O
min O
after O
cocaine O
treatment O
. O

significant O
blockade O
of O
cocaine O
toxicity B-NEG
was O
observed O
with O
the O
higher O
dose O
of O
gnc92h2 O
( O
190 O
mg/kg) O
, O
where O
premorbid O
behaviors O
were O
reduced O
up O
to O
40% O
, O
seizures B-NEG
up O
to O
77% O
and O
death B-NEG
by O
72% O
. O

importantly O
, O
gnc92h2 O
prevented O
death B-NEG
even O
post-cocaine O
injection O
. O

the O
results O
support O
the O
important O
potential O
of O
gnc92h2 O
as O
a O
therapeutic O
tool O
against O
cocaine B-NEG
overdose I-NEG
. O

-DOCSTART- O

the O
effects O
of O
short-term O
raloxifene O
therapy O
on O
fibrinolysis O
markers O
: O
tafi O
, O
tpa O
, O
and O
pai-1 O
. O

background O
: O
markers O
of O
fibrinolysis O
, O
thrombin-activatable O
fibrinolysis O
inhibitor O
(tafi) O
, O
tissue-type O
plasminogen O
activator O
(tpa) O
, O
and O
plasminogen O
activator O
inhibitor-1 O
( O
pai-1 O
) O
levels O
were O
studied O
for O
the O
evaluation O
of O
short-term O
effects O
of O
raloxifene O
administration O
in O
postmenopausal O
women O
. O

methods O
: O
thirty-nine O
postmenopausal O
women O
with O
osteopenia B-NEG
or O
osteoporosis B-NEG
were O
included O
in O
this O
prospective O
, O
controlled O
clinical O
study O
. O

twenty-five O
women O
were O
given O
raloxifene O
hydrochloride O
( O
60 O
mg/day O
) O
plus O
calcium O
( O
500 O
mg/day) O
. O

age-matched O
controls O
(n O
= O
14 O
) O
were O
given O
only O
calcium O
. O

plasma O
tafi O
, O
tpa O
, O
and O
pai-1 O
antigen O
levels O
were O
measured O
at O
baseline O
and O
after O
3 O
months O
of O
treatment O
by O
commercially O
available O
elisa O
kits O
. O

variations O
of O
individuals O
were O
assessed O
by O
wilcoxon's O
test O
. O

relationship O
between O
those O
markers O
and O
demographic O
characteristics O
were O
investigated O
. O

results O
: O
three O
months O
of O
raloxifene O
treatment O
was O
associated O
with O
a O
significant O
decrease O
in O
the O
plasma O
tafi O
antigen O
concentrations O
( O
16% O
change O
, O
p O
< O
0.01) O
, O
and O
a O
significant O
increase O
in O
tpa O
antigen O
concentrations O
( O
25% O
change O
, O
p O
< O
0.05) O
. O

a O
significant O
correlation O
was O
found O
between O
baseline O
tafi O
antigen O
concentrations O
and O
the O
duration O
of O
amenorrhea B-NEG
(p O
< O
0.05 O
; O
r O
= O
0.33) O
. O

conclusion O
: O
we O
suggest O
that O
the O
increased O
risk O
of O
venous B-NEG
thromboembolism I-NEG
due O
to O
raloxifene O
treatment O
may O
be O
related O
to O
increased O
tpa O
levels O
, O
but O
not O
tafi O
levels O
. O

-DOCSTART- O

ketoconazole O
induced O
torsades B-NEG
de I-NEG
pointes I-NEG
without O
concomitant O
use O
of O
qt O
interval-prolonging O
drug O
. O

ketoconazole O
is O
not O
known O
to O
be O
proarrhythmic O
without O
concomitant O
use O
of O
qt O
interval-prolonging O
drugs O
. O

we O
report O
a O
woman O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
who O
developed O
a O
markedly O
prolonged B-NEG
qt I-NEG
interval I-NEG
and O
torsades B-NEG
de I-NEG
pointes I-NEG
( O
tdp B-NEG
) O
after O
taking O
ketoconazole O
for O
treatment O
of O
fungal B-NEG
infection I-NEG
. O

her O
qt O
interval O
returned O
to O
normal O
upon O
withdrawal O
of O
ketoconazole O
. O

genetic O
study O
did O
not O
find O
any O
mutation O
in O
her O
genes O
that O
encode O
cardiac O
ikr O
channel O
proteins O
. O

we O
postulate O
that O
by O
virtue O
of O
its O
direct O
blocking O
action O
on O
ikr O
, O
ketoconazole O
alone O
may O
prolong O
qt O
interval O
and O
induce O
tdp B-NEG
. O

this O
calls O
for O
attention O
when O
ketoconazole O
is O
administered O
to O
patients O
with O
risk O
factors O
for O
acquired O
long B-NEG
qt I-NEG
syndrome I-NEG
. O

-DOCSTART- O

pharmacological O
evidence O
for O
the O
potential O
of O
daucus O
carota O
in O
the O
management O
of O
cognitive B-NEG
dysfunctions I-NEG
. O

the O
present O
study O
was O
aimed O
at O
investigating O
the O
effects O
of O
daucus O
carota O
seeds O
on O
cognitive O
functions O
, O
total O
serum O
cholesterol O
levels O
and O
brain O
cholinesterase O
activity O
in O
mice O
. O

the O
ethanolic O
extract O
of O
daucus O
carota O
seeds O
( O
dce O
) O
was O
administered O
orally O
in O
three O
doses O
(100 O
, O
200 O
, O
400 O
mg/kg O
) O
for O
seven O
successive O
days O
to O
different O
groups O
of O
young O
and O
aged O
mice O
. O

elevated O
plus O
maze O
and O
passive O
avoidance O
apparatus O
served O
as O
the O
exteroceptive O
behavioral O
models O
for O
testing O
memory O
. O

diazepam- O
, O
scopolamine- O
and O
ageing-induced O
amnesia B-NEG
served O
as O
the O
interoceptive O
behavioral O
models O
. O

dce O
(200 O
, O
400 O
mg/kg O
, O
p.o. O
) O
showed O
significant O
improvement O
in O
memory O
scores O
of O
young O
and O
aged O
mice O
. O

the O
extent O
of O
memory O
improvement O
evoked O
by O
dce O
was O
23% O
at O
the O
dose O
of O
200 O
mg/kg O
and O
35% O
at O
the O
dose O
of O
400 O
mg/kg O
in O
young O
mice O
using O
elevated O
plus O
maze O
. O

similarly O
, O
significant O
improvements O
in O
memory O
scores O
were O
observed O
using O
passive O
avoidance O
apparatus O
and O
aged O
mice O
. O

furthermore O
, O
dce O
reversed O
the O
amnesia B-NEG
induced O
by O
scopolamine O
( O
0.4 O
mg/kg O
, O
i.p. O
) O
and O
diazepam O
(1 O
mg/kg O
, O
i.p.) O
. O

daucus O
carota O
extract O
(200 O
, O
400 O
mg/kg O
, O
p.o. O
) O
reduced O
significantly O
the O
brain O
acetylcholinesterase O
activity O
and O
cholesterol O
levels O
in O
young O
and O
aged O
mice O
. O

the O
extent O
of O
inhibition O
of O
brain O
cholinesterase O
activity O
evoked O
by O
dce O
at O
the O
dose O
of O
400 O
mg/kg O
was O
22% O
in O
young O
and O
19% O
in O
aged O
mice O
. O

there O
was O
a O
remarkable O
reduction O
in O
total O
cholesterol O
level O
as O
well O
, O
to O
the O
extent O
of O
23% O
in O
young O
and O
21% O
in O
aged O
animals O
with O
this O
dose O
of O
dce O
. O

therefore O
, O
dce O
may O
prove O
to O
be O
a O
useful O
remedy O
for O
the O
management O
of O
cognitive B-NEG
dysfunctions I-NEG
on O
account O
of O
its O
multifarious O
beneficial O
effects O
such O
as O
, O
memory O
improving O
property O
, O
cholesterol O
lowering O
property O
and O
anticholinesterase O
activity O
. O

-DOCSTART- O

cauda B-NEG
equina I-NEG
syndrome I-NEG
after O
epidural O
steroid O
injection O
: O
a O
case O
report O
. O

objective O
: O
conventional O
treatment O
methods O
of O
lumbusacral O
radiculopathy B-NEG
are O
physical O
therapy O
, O
epidural O
steroid O
injections O
, O
oral O
medications O
, O
and O
spinal O
manipulative O
therapy O
. O
cauda B-NEG
equina I-NEG
syndrome I-NEG
is O
a O
rare O
complication O
of O
epidural O
anesthesia O
. O

the O
following O
case O
is O
a O
report O
of O
cauda B-NEG
equina I-NEG
syndrome I-NEG
possibly O
caused O
by O
epidural O
injection O
of O
triamcinolone O
and O
bupivacaine O
. O

clinical O
features O
: O
a O
50-year-old O
woman O
with O
low B-NEG
back I-NEG
and I-NEG
right I-NEG
leg I-NEG
pain I-NEG
was O
scheduled O
for O
epidural O
steroid O
injection O
. O

intervention O
and O
outcome O
: O
an O
18-gauge O
touhy O
needle O
was O
inserted O
until O
loss O
of O
resistance O
occurred O
at O
the O
l4-5 O
level O
. O

spread O
of O
the O
contrast O
medium O
within O
the O
epidural O
space O
was O
determined O
by O
radiographic O
imaging O
. O

after O
verifying O
the O
epidural O
space O
, O
bupivacaine O
and O
triamcinolone O
diacetate O
were O
injected O
. O

after O
the O
injection O
, O
there O
was O
a O
reduction O
in O
radicular O
symptoms O
. O

three O
hours O
later O
, O
she O
complained O
of O
perineal O
numbness B-NEG
and O
lower B-NEG
extremity I-NEG
weakness I-NEG
. O

the O
neurologic O
evaluation O
revealed O
loss B-NEG
of I-NEG
sensation I-NEG
in O
the O
saddle O
area O
and O
medial O
aspect O
of O
her O
right O
leg O
. O

there O
was O
a O
decrease O
in O
the O
perception O
of O
pinprick O
test O
. O

deep-tendon O
reflexes O
were O
decreased O
especially O
in O
the O
right O
leg O
. O

she O
was O
unable O
to O
urinate O
. O

the O
patient's O
symptoms O
improved O
slightly O
over O
the O
next O
few O
hours O
. O

she O
had O
a O
gradual O
return O
of O
motor O
function O
and O
ability O
of O
feeling O
foley O
catheter O
. O

all O
of O
the O
symptoms O
were O
completely O
resolved O
over O
the O
next O
8 O
hours O
. O

conclusion O
: O
complications O
associated O
with O
epidural O
steroid O
injections O
are O
rare O
. O

clinical O
examination O
and O
continued O
vigilance O
for O
neurologic B-NEG
deterioration I-NEG
after O
epidural O
steroid O
injections O
is O
important O
. O

-DOCSTART- O

high-dose O
testosterone O
is O
associated O
with O
atherosclerosis B-NEG
in O
postmenopausal O
women O
. O

objectives O
: O
to O
study O
the O
long-term O
effects O
of O
androgen O
treatment O
on O
atherosclerosis B-NEG
in O
postmenopausal O
women O
. O

methods O
: O
in O
a O
population-based O
study O
in O
513 O
naturally O
postmenopausal O
women O
aged O
54-67 O
years O
, O
we O
studied O
the O
association O
between O
self-reported O
intramuscularly O
administered O
high-dose O
estrogen-testosterone O
therapy O
( O
estradiol- O
and O
testosterone O
esters O
) O
and O
aortic O
atherosclerosis B-NEG
. O

aortic O
atherosclerosis B-NEG
was O
diagnosed O
by O
radiographic O
detection O
of O
calcified O
deposits O
in O
the O
abdominal O
aorta O
, O
which O
have O
been O
shown O
to O
reflect O
intima O
atherosclerosis B-NEG
. O

hormone O
therapy O
users O
were O
compared O
with O
never O
users O
. O

results O
: O
intramuscular O
hormone O
therapy O
use O
for O
1 O
year O
or O
longer O
was O
reported O
by O
25 O
women O
. O

in O
almost O
half O
of O
these O
women O
severe O
atherosclerosis B-NEG
of O
the O
aorta O
was O
present O
(n=11) O
, O
while O
in O
women O
without O
hormone O
use O
severe O
atherosclerosis B-NEG
of O
the O
aorta O
was O
present O
in O
less O
than O
20% O
( O
or O
3.1 O
; O
95% O
ci O
, O
1.1-8.5 O
, O
adjusted O
for O
age O
, O
years O
since O
menopause O
, O
smoking O
, O
and O
body O
mass O
index) O
. O

the O
association O
remained O
after O
additional O
adjustment O
for O
diabetes B-NEG
, O
cholesterol O
level O
, O
systolic O
blood O
pressure O
, O
or O
alcohol O
use O
. O

no O
association O
was O
found O
for O
hormone O
use O
less O
than O
1 O
year O
. O

conclusion O
: O
our O
results O
suggest O
that O
high-dose O
testosterone O
therapy O
may O
adversely O
affect O
atherosclerosis B-NEG
in O
postmenopausal O
women O
and O
indicate O
that O
androgen O
replacement O
in O
these O
women O
may O
not O
be O
harmless O
. O

-DOCSTART- O

sirolimus-associated O
proteinuria B-NEG
and O
renal B-NEG
dysfunction I-NEG
. O

sirolimus O
is O
a O
novel O
immunosuppressant O
with O
potent O
antiproliferative O
actions O
through O
its O
ability O
to O
inhibit O
the O
raptor-containing O
mammalian O
target O
of O
rapamycin O
protein O
kinase O
. O

sirolimus O
represents O
a O
major O
therapeutic O
advance O
in O
the O
prevention O
of O
acute O
renal O
allograft O
rejection O
and O
chronic O
allograft O
nephropathy B-NEG
. O

its O
role O
in O
the O
therapy O
of O
glomerulonephritis B-NEG
, O
autoimmunity B-NEG
, O
cystic B-NEG
renal I-NEG
diseases I-NEG
and O
renal B-NEG
cancer I-NEG
is O
under O
investigation O
. O

because O
sirolimus O
does O
not O
share O
the O
vasomotor O
renal O
adverse O
effects O
exhibited O
by O
calcineurin O
inhibitors O
, O
it O
has O
been O
designated O
a O
'non- O
nephrotoxic B-NEG
drug' O
. O

however O
, O
clinical O
reports O
suggest O
that O
, O
under O
some O
circumstances O
, O
sirolimus O
is O
associated O
with O
proteinuria B-NEG
and O
acute B-NEG
renal I-NEG
dysfunction I-NEG
. O

a O
common O
risk O
factor O
appears O
to O
be O
presence O
of O
pre-existing O
chronic B-NEG
renal I-NEG
damage I-NEG
. O

the O
mechanisms O
of O
sirolimus-associated O
proteinuria B-NEG
are O
multifactorial O
and O
may O
be O
due O
to O
an O
increase O
in O
glomerular O
capillary O
pressure O
following O
calcineurin O
inhibitor O
withdrawal O
. O

it O
has O
also O
been O
suggested O
that O
sirolimus O
directly O
causes O
increased O
glomerular O
permeability/injury O
, O
but O
evidence O
for O
this O
mechanism O
is O
currently O
inconclusive O
. O

the O
acute B-NEG
renal I-NEG
dysfunction I-NEG
associated O
with O
sirolimus O
( O
such O
as O
in O
delayed O
graft O
function O
) O
may O
be O
due O
to O
suppression O
of O
compensatory O
renal O
cell O
proliferation O
and O
survival/repair O
processes O
. O

although O
these O
adverse O
effects O
occur O
in O
some O
patients O
, O
their O
occurrence O
could O
be O
minimised O
by O
knowledge O
of O
the O
molecular O
effects O
of O
sirolimus O
on O
the O
kidney O
, O
the O
use O
of O
sirolimus O
in O
appropriate O
patient O
populations O
, O
close O
monitoring O
of O
proteinuria B-NEG
and O
renal O
function O
, O
use O
of O
angiotensin-converting O
enzyme O
inhibitors O
or O
angiotensin O
ii O
receptor O
blockers O
if O
proteinuria B-NEG
occurs O
and O
withdrawal O
if O
needed O
. O

further O
long-term O
analysis O
of O
renal O
allograft O
studies O
using O
sirolimus O
as O
de O
novo O
immunosuppression O
along O
with O
clinical O
and O
laboratory O
studies O
will O
refine O
these O
issues O
in O
the O
future O
. O

-DOCSTART- O

progressive O
myopathy B-NEG
with O
up-regulation O
of O
mhc-i O
associated O
with O
statin O
therapy O
. O

statins O
can O
cause O
a O
necrotizing O
myopathy B-NEG
and O
hyperckaemia B-NEG
which O
is O
reversible O
on O
cessation O
of O
the O
drug O
. O

what O
is O
less O
well O
known O
is O
a O
phenomenon O
whereby O
statins O
may O
induce O
a O
myopathy B-NEG
, O
which O
persists O
or O
may O
progress O
after O
stopping O
the O
drug O
. O

we O
investigated O
the O
muscle O
pathology O
in O
8 O
such O
cases O
. O

all O
had O
myofibre O
necrosis B-NEG
but O
only O
3 O
had O
an O
inflammatory O
infiltrate O
. O

in O
all O
cases O
there O
was O
diffuse O
or O
multifocal O
up-regulation O
of O
mhc-i O
expression O
even O
in O
non- O
necrotic B-NEG
fibres O
. O

progressive O
improvement O
occurred O
in O
7 O
cases O
after O
commencement O
of O
prednisolone O
and O
methotrexate O
, O
and O
in O
one O
case O
spontaneously O
. O

these O
observations O
suggest O
that O
statins O
may O
initiate O
an O
immune-mediated O
myopathy B-NEG
that O
persists O
after O
withdrawal O
of O
the O
drug O
and O
responds O
to O
immunosuppressive O
therapy O
. O

the O
mechanism O
of O
this O
myopathy B-NEG
is O
uncertain O
but O
may O
involve O
the O
induction O
by O
statins O
of O
an O
endoplasmic O
reticulum O
stress O
response O
with O
associated O
up-regulation O
of O
mhc-i O
expression O
and O
antigen O
presentation O
by O
muscle O
fibres O
. O

-DOCSTART- O

direct O
inhibition O
of O
cardiac O
hyperpolarization-activated O
cyclic O
nucleotide-gated O
pacemaker O
channels O
by O
clonidine O
. O

background O
: O
inhibition O
of O
cardiac O
sympathetic O
tone O
represents O
an O
important O
strategy O
for O
treatment O
of O
cardiovascular B-NEG
disease I-NEG
, O
including O
arrhythmia B-NEG
, O
coronary B-NEG
heart I-NEG
disease I-NEG
, O
and O
chronic O
heart B-NEG
failure I-NEG
. O

activation O
of O
presynaptic O
alpha2-adrenoceptors O
is O
the O
most O
widely O
accepted O
mechanism O
of O
action O
of O
the O
antisympathetic O
drug O
clonidine O
; O
however O
, O
other O
target O
proteins O
have O
been O
postulated O
to O
contribute O
to O
the O
in O
vivo O
actions O
of O
clonidine O
. O

methods O
and O
results O
: O
to O
test O
whether O
clonidine O
elicits O
pharmacological O
effects O
independent O
of O
alpha2-adrenoceptors O
, O
we O
have O
generated O
mice O
with O
a O
targeted O
deletion O
of O
all O
3 O
alpha2-adrenoceptor O
subtypes O
(alpha2abc-/-) O
. O

alpha2abc-/- O
mice O
were O
completely O
unresponsive O
to O
the O
analgesic O
and O
hypnotic O
effects O
of O
clonidine O
; O
however O
, O
clonidine O
significantly O
lowered O
heart O
rate O
in O
alpha2abc-/- O
mice O
by O
up O
to O
150 O
bpm O
. O

clonidine-induced O
bradycardia B-NEG
in O
conscious O
alpha2abc-/- O
mice O
was O
32.3% O
( O
10 O
microg/kg O
) O
and O
26.6% O
( O
100 O
microg/kg O
) O
of O
the O
effect O
in O
wild-type O
mice O
. O

a O
similar O
bradycardic O
effect O
of O
clonidine O
was O
observed O
in O
isolated O
spontaneously O
beating O
right O
atria O
from O
alpha2abc-knockout O
and O
wild-type O
mice O
. O

clonidine O
inhibited O
the O
native O
pacemaker O
current O
( O
i(f) O
) O
in O
isolated O
sinoatrial O
node O
pacemaker O
cells O
and O
the O
i(f)-generating O
hyperpolarization-activated O
cyclic O
nucleotide-gated O
( O
hcn O
) O
2 O
and O
hcn4 O
channels O
in O
transfected O
hek293 O
cells O
. O

as O
a O
consequence O
of O
blocking O
i(f) O
, O
clonidine O
reduced O
the O
slope O
of O
the O
diastolic O
depolarization O
and O
the O
frequency O
of O
pacemaker O
potentials O
in O
sinoatrial O
node O
cells O
from O
wild-type O
and O
alpha2abc-knockout O
mice O
. O

conclusions O
: O
direct O
inhibition O
of O
cardiac O
hcn O
pacemaker O
channels O
contributes O
to O
the O
bradycardic O
effects O
of O
clonidine O
gene-targeted O
mice O
in O
vivo O
, O
and O
thus O
, O
clonidine-like O
drugs O
represent O
novel O
structures O
for O
future O
hcn O
channel O
inhibitors O
. O

-DOCSTART- O

influence O
of O
smoking O
on O
developing O
cochlea O
. O

does O
smoking O
during O
pregnancy O
affect O
the O
amplitudes O
of O
transient O
evoked O
otoacoustic O
emissions O
in O
newborns? O

objective O
: O
maternal O
tobacco O
smoking O
has O
negative O
effects O
on O
fetal O
growth O
. O

the O
influence O
of O
smoking O
during O
pregnancy O
on O
the O
developing O
cochlea O
has O
not O
been O
estimated O
, O
although O
smoking O
has O
been O
positively O
associated O
with O
hearing B-NEG
loss I-NEG
in O
adults O
. O

the O
objective O
of O
this O
study O
was O
to O
determine O
the O
effects O
of O
maternal O
smoking O
on O
transient O
evoked O
otoacoustic O
emissions O
( O
teoaes O
) O
of O
healthy O
neonates O
. O

methods O
: O
this O
study O
was O
undertaken O
as O
part O
of O
neonatal O
screening O
for O
hearing B-NEG
impairment I-NEG
and O
involved O
both O
ears O
of O
200 O
newborns O
. O

newborns O
whose O
mothers O
reported O
smoking O
during O
pregnancy O
( O
n=200 O
ears O
) O
were O
compared O
to O
a O
control O
group O
of O
newborns O
( O
n=200 O
ears) O
, O
whose O
mothers O
were O
non-smokers O
. O

exposure O
to O
tobacco O
was O
characterized O
as O
low O
( O
<5 O
cigarettes O
per O
day O
, O
n=88 O
ears) O
, O
moderate O
( O
5< O
or O
=cigarettes O
per O
day<10 O
, O
n=76 O
) O
or O
high O
(> O
or O
=10 O
cigarettes O
per O
day O
, O
n=36) O
. O

results O
: O
in O
exposed O
neonates O
, O
teoaes O
mean O
response O
( O
across O
frequency O
) O
and O
mean O
amplitude O
at O
4000hz O
was O
significantly O
lower O
than O
in O
non-exposed O
neonates O
. O

comparisons O
between O
exposed O
newborns' O
subgroups O
revealed O
no O
significant O
differences O
. O

however O
, O
by O
comparing O
each O
subgroup O
to O
control O
group O
, O
we O
found O
statistically O
significant O
decreases B-NEG
of I-NEG
teoaes I-NEG
amplitudes I-NEG
at O
4000hz O
for O
all O
three O
groups O
. O

mean O
teoaes O
responses O
of O
highly O
exposed O
newborns O
were O
also O
significantly O
lower O
in O
comparison O
to O
our O
control O
group O
. O

conclusion O
: O
in O
utero O
, O
exposure O
to O
tobacco O
smoking O
seems O
to O
have O
a O
small O
impact O
on O
outer O
hair O
cells O
. O

these O
effects O
seem O
to O
be O
equally O
true O
for O
all O
exposed O
newborns O
, O
regardless O
of O
the O
degree O
of O
exposure O
. O

further O
studies O
are O
needed O
in O
order O
to O
establish O
a O
potential O
negative O
effect O
of O
maternal O
smoking O
on O
the O
neonate's O
hearing O
acuity O
. O

-DOCSTART- O

neuroinflammation B-NEG
and O
behavioral B-NEG
abnormalities I-NEG
after O
neonatal O
terbutaline O
treatment O
in O
rats O
: O
implications O
for O
autism B-NEG
. O
autism B-NEG
is O
a O
neurodevelopmental B-NEG
disorder I-NEG
presenting O
before O
3 O
years O
of O
age O
with O
deficits B-NEG
in I-NEG
communication I-NEG
and I-NEG
social I-NEG
skills I-NEG
and O
repetitive B-NEG
behaviors I-NEG
. O

in O
addition O
to O
genetic O
influences O
, O
recent O
studies O
suggest O
that O
prenatal O
drug O
or O
chemical O
exposures O
are O
risk O
factors O
for O
autism B-NEG
. O

terbutaline O
, O
a O
beta2-adrenoceptor O
agonist O
used O
to O
arrest O
preterm B-NEG
labor I-NEG
, O
has O
been O
associated O
with O
increased O
concordance O
for O
autism B-NEG
in O
dizygotic O
twins O
. O

we O
studied O
the O
effects O
of O
terbutaline O
on O
microglial O
activation O
in O
different O
brain O
regions O
and O
behavioral O
outcomes O
in O
developing O
rats O
. O

newborn O
rats O
were O
given O
terbutaline O
( O
10 O
mg/kg O
) O
daily O
on O
postnatal O
days O
( O
pn O
) O
2 O
to O
5 O
or O
pn O
11 O
to O
14 O
and O
examined O
24 O
h O
after O
the O
last O
dose O
and O
at O
pn O
30 O
. O

immunohistochemical O
studies O
showed O
that O
administration O
of O
terbutaline O
on O
pn O
2 O
to O
5 O
produced O
a O
robust O
increase O
in O
microglial O
activation O
on O
pn O
30 O
in O
the O
cerebral O
cortex O
, O
as O
well O
as O
in O
cerebellar O
and O
cerebrocortical O
white O
matter O
. O

none O
of O
these O
effects O
occurred O
in O
animals O
given O
terbutaline O
on O
pn O
11 O
to O
14 O
. O

in O
behavioral O
tests O
, O
animals O
treated O
with O
terbutaline O
on O
pn O
2 O
to O
5 O
showed O
consistent O
patterns O
of O
hyper-reactivity O
to O
novelty O
and O
aversive O
stimuli O
when O
assessed O
in O
a O
novel O
open O
field O
, O
as O
well O
as O
in O
the O
acoustic O
startle O
response O
test O
. O

our O
findings O
indicate O
that O
beta2-adrenoceptor O
overstimulation O
during O
an O
early O
critical O
period O
results O
in O
microglial O
activation O
associated O
with O
innate O
neuroinflammatory O
pathways O
and O
behavioral B-NEG
abnormalities I-NEG
, O
similar O
to O
those O
described O
in O
autism B-NEG
. O

this O
study O
provides O
a O
useful O
animal O
model O
for O
understanding O
the O
neuropathological O
processes O
underlying O
autism B-NEG
spectrum I-NEG
disorders I-NEG
. O

-DOCSTART- O

acute O
myocarditis B-NEG
associated O
with O
clozapine O
. O

objective O
: O
a O
case O
of O
acute O
myocarditis B-NEG
associated O
with O
the O
commencement O
of O
clozapine O
is O
described O
, O
highlighting O
the O
onset O
, O
course O
and O
possible O
contributing O
factors O
. O

there O
is O
an O
urgent O
need O
to O
raise O
awareness O
about O
this O
potentially O
fatal O
complication O
of O
clozapine O
use O
. O

results O
: O
a O
20-year-old O
male O
with O
schizophrenia B-NEG
developed O
a O
sudden O
onset O
of O
myocarditis B-NEG
after O
commencement O
of O
clozapine O
. O

the O
patient O
recovered O
with O
intensive O
medical O
support O
. O

the O
symptoms O
occurred O
around O
2 O
weeks O
after O
starting O
clozapine O
in O
an O
inpatient O
setting O
. O

possible O
contributing O
factors O
may O
have O
been O
concomitant O
antidepressant O
use O
and O
unaccustomed O
physical O
activity O
. O

conclusions O
: O
myocarditis B-NEG
is O
an O
increasingly O
recognized O
complication O
associated O
with O
the O
use O
of O
clozapine O
. O

it O
can O
be O
fatal O
if O
not O
recognized O
and O
treated O
early O
. O

considering O
that O
clozapine O
remains O
the O
gold O
standard O
in O
treatment O
of O
resistant O
psychosis B-NEG
, O
there O
is O
an O
urgent O
need O
to O
raise O
awareness O
among O
medical O
and O
paramedical O
staff O
involved O
in O
the O
care O
of O
these O
patients O
. O

there O
are O
also O
implications O
for O
recommendations O
and O
regulations O
regarding O
the O
use O
of O
clozapine O
. O

-DOCSTART- O

encephalopathy B-NEG
induced O
by O
levetiracetam O
added O
to O
valproate O
. O

background O
: O
we O
report O
on O
the O
manifestation O
of O
a O
levetiracetam O
( O
lev)-induced O
encephalopathy B-NEG
. O

findings O
: O
a O
28-year-old O
man O
suffering O
from O
idiopathic B-NEG
epilepsy I-NEG
with O
generalized O
seizures B-NEG
was O
treated O
with O
lev O
( O
3000 O
mg O
) O
added O
to O
valproate O
( O
vpa O
) O
( O
2000 O
mg) O
. O

frequency O
of O
generalized O
tonic-clonic B-NEG
seizures I-NEG
increased O
from O
one O
per O
6 O
months O
to O
two O
per O
month O
. O

neuropsychological O
testing O
showed O
impaired B-NEG
word I-NEG
fluency I-NEG
, O
psychomotor I-NEG
speed I-NEG
and I-NEG
working I-NEG
memory I-NEG
. O

the O
interictal O
electroencephalogram O
( O
eeg O
) O
showed O
a O
generalized O
slowing O
to O
5 O
per O
second O
theta O
rhythms O
with O
bilateral O
generalized O
high-amplitude O
discharges O
. O

outcome O
: O
following O
discontinuation O
of O
lev O
, O
eeg O
and O
neuropsychological O
findings O
improved O
and O
seizure B-NEG
frequency O
decreased O
. O

-DOCSTART- O

norepinephrine O
signaling O
through O
beta-adrenergic O
receptors O
is O
critical O
for O
expression O
of O
cocaine-induced O
anxiety B-NEG
. O

background O
: O
cocaine O
is O
a O
widely O
abused O
psychostimulant O
that O
has O
both O
rewarding O
and O
aversive O
properties O
. O

while O
the O
mechanisms O
underlying O
cocaine's O
rewarding O
effects O
have O
been O
studied O
extensively O
, O
less O
attention O
has O
been O
paid O
to O
the O
unpleasant O
behavioral O
states O
induced O
by O
cocaine O
, O
such O
as O
anxiety B-NEG
. O

methods O
: O
in O
this O
study O
, O
we O
evaluated O
the O
performance O
of O
dopamine O
beta-hydroxylase O
knockout O
( O
dbh O
-/- O
) O
mice O
, O
which O
lack O
norepinephrine O
(ne) O
, O
in O
the O
elevated O
plus O
maze O
( O
epm O
) O
to O
examine O
the O
contribution O
of O
noradrenergic O
signaling O
to O
cocaine-induced O
anxiety B-NEG
. O

results O
: O
we O
found O
that O
cocaine O
dose-dependently O
increased O
anxiety B-NEG
-like O
behavior O
in O
control O
( O
dbh O
+/- O
) O
mice O
, O
as O
measured O
by O
a O
decrease O
in O
open O
arm O
exploration O
. O

the O
dbh O
-/- O
mice O
had O
normal O
baseline O
performance O
in O
the O
epm O
but O
were O
completely O
resistant O
to O
the O
anxiogenic O
effects O
of O
cocaine O
. O

cocaine-induced O
anxiety B-NEG
was O
also O
attenuated O
in O
dbh O
+/- O
mice O
following O
administration O
of O
disulfiram O
, O
a O
dopamine O
beta-hydroxylase O
( O
dbh O
) O
inhibitor O
. O

in O
experiments O
using O
specific O
adrenergic O
antagonists O
, O
we O
found O
that O
pretreatment O
with O
the O
beta-adrenergic O
receptor O
antagonist O
propranolol O
blocked O
cocaine-induced O
anxiety B-NEG
-like O
behavior O
in O
dbh O
+/- O
and O
wild-type O
c57bl6/j O
mice O
, O
while O
the O
alpha(1 O
) O
antagonist O
prazosin O
and O
the O
alpha(2 O
) O
antagonist O
yohimbine O
had O
no O
effect O
. O

conclusions O
: O
these O
results O
indicate O
that O
noradrenergic O
signaling O
via O
beta-adrenergic O
receptors O
is O
required O
for O
cocaine-induced O
anxiety B-NEG
in O
mice O
. O

-DOCSTART- O

clonidine O
for O
attention-deficit/hyperactivity B-NEG
disorder I-NEG
: O
ii O
. O

ecg O
changes O
and O
adverse O
events O
analysis O
. O

objective O
: O
to O
examine O
the O
safety O
and O
tolerability O
of O
clonidine O
used O
alone O
or O
with O
methylphenidate O
in O
children O
with O
attention-deficit/hyperactivity B-NEG
disorder I-NEG
( O
adhd B-NEG
). O

method O
: O
in O
a O
16-week O
multicenter O
, O
double-blind O
trial O
, O
122 O
children O
with O
adhd B-NEG
were O
randomly O
assigned O
to O
clonidine O
(n O
= O
31) O
, O
methylphenidate O
(n O
= O
29) O
, O
clonidine O
and O
methylphenidate O
(n O
= O
32) O
, O
or O
placebo O
(n O
= O
30) O
. O

doses O
were O
flexibly O
titrated O
up O
to O
0.6 O
mg/day O
for O
clonidine O
and O
60 O
mg/day O
for O
methylphenidate O
( O
both O
with O
divided O
dosing) O
. O

groups O
were O
compared O
regarding O
adverse O
events O
and O
changes O
from O
baseline O
to O
week O
16 O
in O
electrocardiograms O
and O
vital O
signs O
. O

results O
: O
there O
were O
more O
incidents O
of O
bradycardia B-NEG
in O
subjects O
treated O
with O
clonidine O
compared O
with O
those O
not O
treated O
with O
clonidine O
( O
17.5% O
versus O
3.4% O
; O
p O
=.02) O
, O
but O
no O
other O
significant O
group O
differences O
regarding O
electrocardiogram O
and O
other O
cardiovascular O
outcomes O
. O

there O
were O
no O
suggestions O
of O
interactions O
between O
clonidine O
and O
methylphenidate O
regarding O
cardiovascular O
outcomes O
. O

moderate O
or O
severe O
adverse O
events O
were O
more O
common O
in O
subjects O
on O
clonidine O
( O
79.4% O
versus O
49.2% O
; O
p O
=.0006 O
) O
but O
not O
associated O
with O
higher O
rates O
of O
early O
study O
withdrawal O
. O
drowsiness B-NEG
was O
common O
on O
clonidine O
, O
but O
generally O
resolved O
by O
6 O
to O
8 O
weeks O
. O

conclusions O
: O
clonidine O
, O
used O
alone O
or O
with O
methylphenidate O
, O
appears O
safe O
and O
well O
tolerated O
in O
childhood O
adhd B-NEG
. O

physicians O
prescribing O
clonidine O
should O
monitor O
for O
bradycardia B-NEG
and O
advise O
patients O
about O
the O
high O
likelihood O
of O
initial O
drowsiness B-NEG
. O

-DOCSTART- O

thalidomide O
has O
limited O
single-agent O
activity O
in O
relapsed O
or O
refractory O
indolent O
non-hodgkin B-NEG
lymphomas I-NEG
: O
a O
phase O
ii O
trial O
of O
the O
cancer B-NEG
and O
leukemia B-NEG
group O
b. O

thalidomide O
is O
an O
immunomodulatory O
agent O
with O
demonstrated O
activity O
in O
multiple B-NEG
myeloma I-NEG
, O
mantle B-NEG
cell I-NEG
lymphoma I-NEG
and O
lymphoplasmacytic B-NEG
lymphoma I-NEG
. O

its O
activity O
is O
believed O
to O
be O
due O
modulation O
of O
the O
tumour B-NEG
milieu O
, O
including O
downregulation O
of O
angiogenesis O
and O
inflammatory O
cytokines O
. O

between O
july O
2001 O
and O
april O
2004 O
, O
24 O
patients O
with O
relapsed/refractory O
indolent O
lymphomas B-NEG
received O
thalidomide O
200 O
mg O
daily O
with O
escalation O
by O
100 O
mg O
daily O
every O
1-2 O
weeks O
as O
tolerated O
, O
up O
to O
a O
maximum O
of O
800 O
mg O
daily O
. O

patients O
had O
received O
a O
median O
of O
2 O
(range O
, O
1-4 O
) O
prior O
regimens O
. O

of O
24 O
evaluable O
patients O
, O
two O
achieved O
a O
complete O
remission O
and O
one O
achieved O
a O
partial O
remission O
for O
an O
overall O
response O
rate O
of O
12.5% O
( O
95% O
confidence O
interval O
: O
2.6-32.4%) O
. O

eleven O
patients O
progressed O
during O
therapy O
. O

grade O
3-4 O
adverse O
effects O
included O
myelosuppression B-NEG
, O
fatigue B-NEG
, O
somnolence B-NEG
/ O
depressed B-NEG
mood I-NEG
, O
neuropathy B-NEG
and O
dyspnea B-NEG
. O

of O
concern O
was O
the O
occurrence O
of O
four O
thromboembolic B-NEG
events O
. O

our O
results O
failed O
to O
demonstrate O
an O
important O
response O
rate O
to O
single O
agent O
thalidomide O
in O
indolent O
lymphomas B-NEG
and O
contrast O
with O
the O
higher O
activity O
level O
reported O
with O
the O
second O
generation O
immunomodulatory O
agent O
, O
lenalidomide O
. O

-DOCSTART- O

intracavernous O
epinephrine O
: O
a O
minimally O
invasive O
treatment O
for O
priapism B-NEG
in O
the O
emergency O
department O
. O
priapism B-NEG
is O
the O
prolonged O
erection O
of O
the O
penis O
in O
the O
absence O
of O
sexual O
arousal O
. O

a O
45-year-old O
man O
, O
an O
admitted O
frequent O
cocaine O
user O
, O
presented O
to O
the O
emergency O
department O
( O
ed O
) O
on O
two O
separate O
occasions O
with O
a O
history O
of O
priapism B-NEG
after O
cocaine O
use O
. O

the O
management O
options O
in O
the O
ed O
, O
as O
exemplified O
by O
four O
individual O
case O
reports O
, O
in O
particular O
the O
use O
of O
a O
minimally O
invasive O
method O
of O
intracorporal O
epinephrine O
instillation O
, O
are O
discussed O
. O

-DOCSTART- O

effect O
of O
green O
tea O
and O
vitamin O
e O
combination O
in O
isoproterenol O
induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
. O

the O
present O
study O
was O
aimed O
to O
investigate O
the O
combined O
effects O
of O
green O
tea O
and O
vitamin O
e O
on O
heart O
weight O
, O
body O
weight O
, O
serum O
marker O
enzymes O
, O
lipid O
peroxidation O
, O
endogenous O
antioxidants O
and O
membrane O
bound O
atpases O
in O
isoproterenol O
( O
iso)-induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
. O

adult O
male O
albino O
rats O
, O
treated O
with O
iso O
( O
200 O
mg/kg O
, O
s.c. O
) O
for O
2 O
days O
at O
an O
interval O
of O
24 O
h O
caused O
a O
significant O
( O
p<0.05 O
) O
elevation O
of O
heart O
weight O
, O
serum O
marker O
enzymes O
, O
lipid O
peroxidation O
and O
ca+2 O
atpase O
level O
whereas O
there O
was O
a O
significant O
( O
p<0.05 O
) O
decrease O
in O
body O
weight O
, O
endogenous O
antioxidants O
, O
na+/ O
k+ O
atpase O
and O
mg+2 O
atpase O
levels O
. O

administration O
of O
green O
tea O
( O
100 O
mg/kg/day O
, O
p.o. O
) O
and O
vitamin O
e O
( O
100 O
mg/kg/day O
, O
p.o. O
) O
together O
for O
30 O
consecutive O
days O
and O
challenged O
with O
iso O
on O
the O
day O
29th O
and O
30th O
, O
showed O
a O
significant O
( O
p<0.05 O
) O
decrease O
in O
heart O
weight O
, O
serum O
marker O
enzymes O
, O
lipid O
peroxidation O
, O
ca+2 O
atpase O
and O
a O
significant O
increase O
in O
the O
body O
weight O
, O
endogenous O
antioxidants O
, O
na+/k+ O
atpase O
and O
mg+2 O
atpase O
when O
compared O
with O
iso O
treated O
group O
and O
green O
tea O
or O
vitamin O
e O
alone O
treated O
groups O
. O

these O
findings O
indicate O
the O
synergistic O
protective O
effect O
of O
green O
tea O
and O
vitamin O
e O
during O
iso O
induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
. O

-DOCSTART- O

development O
of O
ocular B-NEG
myasthenia I-NEG
during O
pegylated O
interferon O
and O
ribavirin O
treatment O
for O
chronic B-NEG
hepatitis I-NEG
c I-NEG
. O

a O
63-year-old O
male O
experienced O
sudden O
diplopia B-NEG
after O
9 O
weeks O
of O
administration O
of O
pegylated O
interferon O
( O
ifn O
) O
alpha-2b O
and O
ribavirin O
for O
chronic B-NEG
hepatitis I-NEG
c I-NEG
( O
chc B-NEG
). O

ophthalmologic O
examinations O
showed O
ptosis B-NEG
on I-NEG
the I-NEG
right I-NEG
upper I-NEG
lid I-NEG
and O
restricted B-NEG
right I-NEG
eye I-NEG
movement I-NEG
without O
any O
other O
neurological O
signs O
. O

a O
brain O
imaging O
study O
and O
repetitive O
nerve O
stimulation O
test O
indicated O
no O
abnormality O
. O

the O
acetylcholine O
receptor O
antibody O
titer O
and O
response O
to O
acetylcholinesterase O
inhibitors O
were O
negative O
, O
and O
the O
results O
of O
thyroid O
function O
tests O
were O
normal O
. O

the O
patient's O
ophthalmological O
symptoms O
improved O
rapidly O
3 O
weeks O
after O
discontinuation O
of O
pegylated O
ifn O
alpha-2b O
and O
ribavirin O
. O

the O
ocular B-NEG
myasthenia I-NEG
associated O
with O
combination O
therapy O
of O
pegylated O
ifn O
alpha-2b O
and O
ribavirin O
for O
chc B-NEG
is O
very O
rarely O
reported O
; O
therefore O
, O
we O
present O
this O
case O
with O
a O
review O
of O
the O
various O
eye O
complications O
of O
ifn O
therapy O
. O

-DOCSTART- O

the O
glycine O
transporter-1 O
inhibitor O
ssr103800 O
displays O
a O
selective O
and O
specific O
antipsychotic-like O
profile O
in O
normal O
and O
transgenic O
mice O
. O
schizophrenia B-NEG
has O
been O
initially O
associated O
with O
dysfunction O
in O
dopamine O
neurotransmission O
. O

however O
, O
the O
observation O
that O
antagonists O
of O
the O
glutamate O
n-methyl-d-aspartate O
( O
nmda O
) O
receptor O
produce O
schizophrenic B-NEG
-like O
symptoms O
in O
humans O
has O
led O
to O
the O
idea O
of O
a O
dysfunctioning O
of O
the O
glutamatergic O
system O
via O
its O
nmda O
receptor O
. O

as O
a O
result O
, O
there O
is O
a O
growing O
interest O
in O
the O
development O
of O
pharmacological O
agents O
with O
potential O
antipsychotic O
properties O
that O
enhance O
the O
activity O
of O
the O
glutamatergic O
system O
via O
a O
modulation O
of O
the O
nmda O
receptor O
. O

among O
them O
are O
glycine O
transporter-1 O
( O
glyt1 O
) O
inhibitors O
such O
as O
ssr103800 O
, O
which O
indirectly O
enhance O
nmda O
receptor O
function O
by O
increasing O
the O
glycine O
(a O
co-agonist O
for O
the O
nmda O
receptor O
) O
levels O
in O
the O
synapse O
. O

this O
study O
aimed O
at O
investigating O
the O
potential O
antipsychotic-like O
properties O
of O
ssr103800 O
, O
with O
a O
particular O
focus O
on O
models O
of O
hyperactivity B-NEG
, O
involving O
either O
drug O
challenge O
(ie O
, O
amphetamine O
and O
mk-801 O
) O
or O
transgenic O
mice O
(ie O
, O
nmda O
nr1(neo-/- O
) O
and O
dat(-/-)) O
. O

results O
showed O
that O
ssr103800 O
( O
10-30 O
mg/kg O
p.o. O
) O
blocked O
hyperactivity B-NEG
induced O
by O
the O
non-competitive O
nmda O
receptor O
antagonist O
, O
mk-801 O
and O
partially O
reversed O
spontaneous O
hyperactivity B-NEG
of O
nmda O
nr1(neo-/- O
) O
mice O
. O

in O
contrast O
, O
ssr103800 O
failed O
to O
affect O
hyperactivity B-NEG
induced O
by O
amphetamine O
or O
naturally O
observed O
in O
dopamine O
transporter O
( O
dat(-/-) O
) O
knockout O
mice O
( O
10-30 O
mg/kg O
p.o.) O
. O

importantly O
, O
both O
classical O
( O
haloperidol O
) O
and O
atypical O
(olanzapine O
, O
clozapine O
and O
aripiprazole O
) O
antipsychotics O
were O
effective O
in O
all O
these O
models O
of O
hyperactivity B-NEG
. O

however O
, O
unlike O
these O
latter O
, O
ssr103800 O
did O
not O
produce O
catalepsy B-NEG
( O
retention O
on O
the O
bar O
test O
) O
up O
to O
30 O
mg/kg O
p.o O
. O

together O
these O
findings O
show O
that O
the O
glyt1 O
inhibitor O
, O
ssr103800 O
, O
produces O
antipsychotic-like O
effects O
, O
which O
differ O
from O
those O
observed O
with O
compounds O
primarily O
targeting O
the O
dopaminergic O
system O
, O
and O
has O
a O
reduced O
side-effect O
potential O
as O
compared O
with O
these O
latter O
drugs O
. O

-DOCSTART- O

phenylephrine O
but O
not O
ephedrine O
reduces B-NEG
frontal I-NEG
lobe I-NEG
oxygenation I-NEG
following O
anesthesia-induced O
hypotension B-NEG
. O

background O
: O
vasopressor O
agents O
are O
used O
to O
correct O
anesthesia-induced O
hypotension B-NEG
. O

we O
describe O
the O
effect O
of O
phenylephrine O
and O
ephedrine O
on O
frontal O
lobe O
oxygenation O
( O
s(c)o(2) O
) O
following O
anesthesia-induced O
hypotension B-NEG
. O

methods O
: O
following O
induction O
of O
anesthesia O
by O
fentanyl O
( O
0.15 O
mg O
kg(-1) O
) O
and O
propofol O
( O
2.0 O
mg O
kg(-1)) O
, O
13 O
patients O
received O
phenylephrine O
( O
0.1 O
mg O
iv O
) O
and O
12 O
patients O
received O
ephedrine O
( O
10 O
mg O
iv O
) O
to O
restore O
mean O
arterial O
pressure O
(map) O
. O

heart O
rate O
(hr) O
, O
map O
, O
stroke B-NEG
volume O
(sv) O
, O
cardiac O
output O
(co) O
, O
and O
frontal O
lobe O
oxygenation O
( O
s(c)o(2) O
) O
were O
registered O
. O

results O
: O
induction O
of O
anesthesia O
was O
followed O
by O
a B-NEG
decrease I-NEG
in I-NEG
map I-NEG
, O
hr I-NEG
, O
sv I-NEG
, O
and I-NEG
co I-NEG
concomitant O
with O
an O
elevation O
in O
s(c)o(2) O
. O

after O
administration O
of O
phenylephrine O
, O
map O
increased O
( O
51 O
+/- O
12 O
to O
81 O
+/- O
13 O
mmhg O
; O
p O
< O
0.001 O
; O
mean O
+/- O
sd) O
. O

however O
, O
a O
14% O
( O
from O
70 O
+/- O
8% O
to O
60 O
+/- O
7% O
) O
reduction O
in O
s(c)o(2 O
) O
(p O
< O
0.05 O
) O
followed O
with O
no O
change O
in O
co O
( O
3.7 O
+/- O
1.1 O
to O
3.4 O
+/- O
0.9 O
l O
min(-1)) O
. O

the O
administration O
of O
ephedrine O
led O
to O
a O
similar O
increase O
in O
map O
( O
53 O
+/- O
9 O
to O
79 O
+/- O
8 O
mmhg O
; O
p O
< O
0.001) O
, O
restored O
co O
( O
3.2 O
+/- O
1.2 O
to O
5.0 O
+/- O
1.3 O
l O
min(-1)) O
, O
and O
preserved O
s(c)o(2) O
. O

conclusions O
: O
the O
utilization O
of O
phenylephrine O
to O
correct O
hypotension B-NEG
induced O
by O
anesthesia O
has O
a O
negative O
impact O
on O
s(c)o(2 O
) O
while O
ephedrine O
maintains O
frontal O
lobe O
oxygenation O
potentially O
related O
to O
an O
increase O
in O
co O
. O

-DOCSTART- O

a O
novel O
, O
multiple O
symptom O
model O
of O
obsessive-compulsive-like B-NEG
behaviors I-NEG
in O
animals O
. O

background O
: O
current O
animal O
models O
of O
obsessive-compulsive B-NEG
disorder I-NEG
( O
ocd B-NEG
) O
typically O
involve O
acute O
, O
drug-induced O
symptom O
provocation O
or O
a O
genetic O
association O
with O
stereotypies O
or O
anxiety B-NEG
. O

none O
of O
these O
current O
models O
demonstrate O
multiple O
ocd B-NEG
-like O
behaviors O
. O

methods O
: O
neonatal O
rats O
were O
treated O
with O
the O
tricyclic O
antidepressant O
clomipramine O
or O
vehicle O
between O
days O
9 O
and O
16 O
twice O
daily O
and O
behaviorally O
tested O
in O
adulthood O
. O

results O
: O
clomipramine O
exposure O
in O
immature O
rats O
produced O
significant O
behavioral O
and O
biochemical O
changes O
that O
include O
enhanced O
anxiety B-NEG
( O
elevated O
plus O
maze O
and O
marble O
burying) O
, O
behavioral B-NEG
inflexibility I-NEG
( O
perseveration O
in O
the O
spontaneous O
alternation O
task O
and O
impaired O
reversal O
learning) O
, O
working O
memory B-NEG
impairment I-NEG
(e.g. O
, O
win-shift O
paradigm) O
, O
hoarding B-NEG
, O
and O
corticostriatal B-NEG
dysfunction I-NEG
. O

dopamine O
d2 O
receptors O
were O
elevated O
in O
the O
striatum O
, O
whereas O
serotonin O
2c O
, O
but O
not O
serotonin O
1a O
, O
receptors O
were O
elevated O
in O
the O
orbital O
frontal O
cortex O
. O

conclusions O
: O
this O
is O
the O
first O
demonstration O
of O
multiple O
symptoms O
consistent O
with O
an O
ocd B-NEG
-like O
profile O
in O
animals O
. O

moreover O
, O
these O
behaviors O
are O
accompanied O
by O
biochemical O
changes O
in O
brain O
regions O
previously O
identified O
as O
relevant O
to O
ocd B-NEG
. O

this O
novel O
model O
of O
ocd B-NEG
demonstrates O
that O
drug O
exposure O
during O
a O
sensitive O
period O
can O
program O
disease-like O
systems O
permanently O
, O
which O
could O
have O
implications O
for O
current O
and O
future O
therapeutic O
strategies O
for O
this O
and O
other O
psychiatric B-NEG
disorders I-NEG
. O

-DOCSTART- O

late O
recovery O
of O
renal O
function O
in O
a O
woman O
with O
the O
hemolytic B-NEG
uremic I-NEG
syndrome I-NEG
. O

a O
case O
is O
reported O
of O
the O
hemolytic B-NEG
uremic I-NEG
syndrome I-NEG
( O
hus B-NEG
) O
in O
a O
woman O
taking O
oral O
contraceptives O
. O

she O
was O
treated O
with O
heparin O
, O
dipyridamole O
and O
hemodialysis O
; O
and O
after O
more O
than O
three O
months O
, O
her O
urinary O
output O
rose O
above O
500 O
ml O
; O
and O
six O
months O
after O
the O
onset O
of O
anuria B-NEG
, O
dialysis O
treatment O
was O
stopped O
. O

this O
case O
emphasizes O
the O
possibility O
that O
hus B-NEG
in O
adults O
is O
not O
invariably O
irreversible O
and O
that O
, O
despite O
prolonged O
oliguria B-NEG
, O
recovery O
of O
renal O
function O
can O
be O
obtained O
. O

therefore O
, O
in O
adult O
patients O
affected O
by O
hus B-NEG
, O
dialysis O
should O
not O
be O
discontinued O
prematurely O
; O
moreover O
, O
bilateral O
nephrectomy O
, O
for O
treatment O
of O
severe O
hypertension B-NEG
and O
microangiopathic B-NEG
hemolytic I-NEG
anemia I-NEG
, O
should O
be O
performed O
with O
caution O
. O

-DOCSTART- O

effects O
of O
acetylsalicylic O
acid O
, O
dipyridamole O
, O
and O
hydrocortisone O
on O
epinephrine-induced O
myocardial B-NEG
injury I-NEG
in O
dogs O
. O

a O
reproducible O
model O
for O
producing O
diffuse O
myocardial B-NEG
injury I-NEG
( O
epinephrine O
infusion O
) O
has O
been O
developed O
to O
study O
the O
cardioprotective O
effects O
of O
agents O
or O
maneuvers O
which O
might O
alter O
the O
evolution O
of O
acute O
myocardial B-NEG
infarction I-NEG
. O

infusions O
of O
epinephrine O
(4 O
mug O
per O
kilogram O
per O
minute O
for O
6 O
hours O
) O
increased O
radiocalcium O
uptakes O
into O
intact O
myocardium O
and O
each O
of O
its O
subcellular O
components O
with O
the O
mitochondrial O
fraction O
showing O
the O
most O
consistent O
changes O
when O
compared O
to O
saline-infused O
control O
animals O
( O
4,957 O
vs O
. O
827 O
counts O
per O
minute O
per O
gram O
of O
dried O
tissue O
or O
fraction) O
. O

myocardial O
concentrations O
of O
calcium O
also O
increased O
significantly O
( O
12.0 O
vs O
. O
5.0 O
mg.per O
100 O
gm O
. O
of O
fat-free O
dry O
weight) O
. O

infusions O
of O
calcium O
chloride O
sufficient O
to O
raise O
serum O
calcium O
concentrations O
2 O
meq O
. O
per O
liter O
failed O
to O
increase O
calcium O
influx O
into O
the O
myocardial O
cell O
. O

mitochondrial O
radiocalcium O
uptakes O
were O
significantly O
decreased O
in O
animals O
pretreated O
with O
acetylsalicylic O
acid O
or O
dipyridamole O
or O
when O
hydrocortisone O
was O
added O
to O
the O
epinephrine O
infusion O
(2,682,2,803 O
, O
and O
3,424 O
counts O
per O
minute O
per O
gram O
of O
dried O
fraction O
, O
respectively) O
. O

myocardial O
calcium O
concentrations O
also O
were O
decreased O
(11.2 O
, O
8.3 O
, O
and O
8.9 O
mg O
. O
per O
100 O
gm O
. O
of O
fat-free O
dry O
weight O
, O
respectively O
) O
in O
the O
three O
treatment O
groups O
, O
being O
significantly O
decreased O
only O
in O
the O
last O
two O
. O

evidence O
of O
microscopic O
damage O
was O
graded O
as O
less O
severe O
in O
the O
three O
treatment O
groups O
. O

acetylsalicylic O
acid O
, O
dipyridamole O
, O
and O
hydrocortisone O
all O
appear O
to O
have O
cardioprotective O
effects O
when O
tested O
in O
this O
model O
. O

-DOCSTART- O

changes O
in O
depressive B-NEG
status O
associated O
with O
topical O
beta-blockers O
. O
depression B-NEG
and O
sexual B-NEG
dysfunction I-NEG
have O
been O
related O
to O
side O
effects O
of O
topical O
beta-blockers O
. O

we O
performed O
a O
preliminary O
study O
in O
order O
to O
determine O
any O
difference O
between O
a O
non O
selective O
beta-blocker O
( O
timolol O
) O
and O
a O
selective O
beta-blocker O
( O
betaxolol O
) O
regarding O
cns O
side O
effects O
. O

eight O
glaucomatous B-NEG
patients O
chronically O
treated O
with O
timolol O
0.5%/12h O
, O
suffering O
from O
depression B-NEG
diagnosed O
through O
dms-iii-r O
criteria O
, O
were O
included O
in O
the O
study O
. O

during O
the O
six-month O
follow O
up O
, O
depression B-NEG
was O
quantified O
through O
the O
beck O
and O
zung-conde O
scales O
every O
two O
months O
. O

in O
a O
double O
blind O
cross-over O
study O
with O
control O
group O
, O
the O
patients O
under O
timolol O
treatment O
presented O
higher O
depression B-NEG
values O
measured O
through O
the O
beck O
and O
the O
zung-conde O
scales O
(p O
< O
0.001 O
vs O
control) O
. O

these O
results O
suggest O
that O
betaxolol O
could O
be O
less O
of O
a O
depression B-NEG
-inducer O
than O
timolol O
in O
predisposed O
patients O
. O

-DOCSTART- O

long-term O
follow-up O
of O
ifosfamide O
renal B-NEG
toxicity I-NEG
in O
children O
treated O
for O
malignant B-NEG
mesenchymal I-NEG
tumors I-NEG
: O
an O
international O
society O
of O
pediatric O
oncology O
report O
. O

the O
renal O
function O
of O
74 O
children O
with O
malignant B-NEG
mesenchymal I-NEG
tumors I-NEG
in O
complete O
remission O
and O
who O
have O
received O
the O
same O
ifosfamide O
chemotherapy O
protocol O
( O
international O
society O
of O
pediatric O
oncology O
malignant B-NEG
mesenchymal I-NEG
tumor I-NEG
study O
84 O
[siop O
mmt O
84] O
) O
were O
studied O
1 O
year O
after O
the O
completion O
of O
treatment O
. O

total O
cumulative O
doses O
were O
36 O
or O
60 O
g/m2 O
of O
ifosfamide O
( O
six O
or O
10 O
cycles O
of O
ifosfamide O
, O
vincristine O
, O
and O
dactinomycin O
[iva]) O
. O

none O
of O
them O
had O
received O
cisplatin O
chemotherapy O
. O

ages O
ranged O
from O
4 O
months O
to O
17 O
years O
; O
58 O
patients O
were O
males O
and O
42 O
females O
. O

the O
most O
common O
primary O
tumor B-NEG
site O
was O
the O
head O
and O
neck O
. O

renal O
function O
was O
investigated O
by O
measuring O
plasma O
and O
urinary O
electrolytes O
, O
glucosuria B-NEG
, O
proteinuria B-NEG
, O
aminoaciduria B-NEG
, O
urinary O
ph O
, O
osmolarity O
, O
creatinine O
clearance O
, O
phosphate O
tubular O
reabsorption O
, O
beta O
2 O
microglobulinuria O
, O
and O
lysozymuria O
. O

fifty-eight O
patients O
( O
78% O
) O
had O
normal O
renal O
tests O
, O
whereas O
16 O
patients O
( O
22% O
) O
had O
renal B-NEG
abnormalities I-NEG
. O

two O
subsets O
of O
patients O
were O
identified O
from O
this O
latter O
group O
: O
the O
first O
included O
four O
patients O
( O
5% O
of O
the O
total O
population O
) O
who O
developed O
major O
toxicity B-NEG
resulting O
in O
fanconi's B-NEG
syndrome I-NEG
( O
tdfs B-NEG
); O
and O
the O
second O
group O
included O
five O
patients O
with O
elevated O
beta O
2 O
microglobulinuria O
and O
low O
phosphate O
reabsorption O
. O

the O
remaining O
seven O
patients O
had O
isolated O
beta O
2 O
microglobulinuria O
. O

severe O
toxicity B-NEG
was O
correlated O
with O
the O
higher O
cumulative O
dose O
of O
60 O
g/m2 O
of O
ifosfamide O
, O
a O
younger O
age O
( O
less O
than O
2 O
1/2 O
years O
old) O
, O
and O
a O
predominance O
of O
vesicoprostatic O
tumor B-NEG
involvement O
. O

this O
low O
percentage O
( O
5% O
) O
of O
tdfs O
must O
be O
evaluated O
with O
respect O
to O
the O
efficacy O
of O
ifosfamide O
in O
the O
treatment O
of O
mesenchymal B-NEG
tumors I-NEG
in O
children O
. O

-DOCSTART- O

evidence O
for O
an O
involvement O
of O
d1 O
and O
d2 O
dopamine O
receptors O
in O
mediating O
nicotine-induced O
hyperactivity B-NEG
in O
rats O
. O

previous O
studies O
have O
suggested O
that O
repeated O
exposure O
of O
rats O
to O
the O
drug O
or O
to O
the O
experimental O
environment O
is O
necessary O
to O
observe O
nicotine-induced O
locomotor O
stimulation O
. O

in O
the O
present O
study O
the O
role O
of O
habituation O
to O
the O
experimental O
environment O
on O
the O
stimulant O
effect O
of O
nicotine O
in O
rats O
was O
examined O
. O

in O
addition O
, O
the O
role O
of O
dopamine O
receptors O
in O
mediating O
nicotine-induced O
locomotor O
stimulation O
was O
investigated O
by O
examining O
the O
effects O
of O
selective O
d1 O
and O
d2 O
dopamine O
receptor O
antagonists O
on O
activity O
induced O
by O
nicotine O
. O

locomotor O
activity O
was O
assessed O
in O
male O
sprague-dawley O
rats O
tested O
in O
photocell O
cages O
. O

nicotine O
( O
1.0 O
mg/kg O
) O
caused O
a O
significant O
increase B-NEG
in I-NEG
locomotor I-NEG
activity I-NEG
in O
rats O
that O
were O
habituated O
to O
the O
test O
environment O
, O
but O
had O
only O
a O
weak O
and O
delayed O
stimulant O
action O
in O
rats O
that O
were O
unfamiliar O
with O
the O
test O
environment O
. O

the O
stimulant O
action O
of O
nicotine O
was O
blocked O
by O
the O
central O
nicotinic O
antagonist O
mecamylamine O
but O
not O
by O
the O
peripheral O
nicotinic O
blocker O
hexamethonium O
, O
indicating O
that O
the O
response O
is O
probably O
mediated O
by O
central O
nicotinic O
receptors O
. O

nicotine-induced O
hyperactivity B-NEG
was O
blocked O
by O
the O
selective O
d1 O
antagonist O
sch O
23390 O
, O
the O
selective O
d2 O
antagonist O
raclopride O
and O
the O
d1/d2 O
antagonist O
fluphenazine O
. O

pretreatment O
with O
the O
d2 O
agonist O
phno O
enhanced O
nicotine-induced O
hyperactivity B-NEG
, O
whereas O
the O
d1 O
agonist O
skf O
38393 O
had O
no O
effect O
. O

the O
results O
indicate O
that O
acute O
nicotine O
injection O
induces O
a O
pronounced O
hyperactivity B-NEG
in O
rats O
habituated O
to O
the O
test O
environment O
. O

the O
effect O
appears O
to O
be O
mediated O
by O
central O
nicotine O
receptors O
, O
possibly O
located O
on O
dopaminergic O
neurons O
, O
and O
also O
requires O
the O
activation O
of O
both O
d1 O
and O
d2 O
dopamine O
receptors O
. O

-DOCSTART- O

neuropsychiatric O
side O
effects O
after O
the O
use O
of O
mefloquine O
. O

this O
study O
describes O
neuropsychiatric O
side O
effects O
in O
patients O
after O
treatment O
with O
mefloquine O
. O

reactions O
consisted O
mainly O
of O
seizures B-NEG
, O
acute O
psychoses B-NEG
, O
anxiety B-NEG
neurosis I-NEG
, O
and O
major O
disturbances B-NEG
of I-NEG
sleep-wake I-NEG
rhythm I-NEG
. O

side O
effects O
occurred O
after O
both O
therapeutic O
and O
prophylactic O
intake O
and O
were O
graded O
from O
moderate O
to O
severe O
. O

in O
a O
risk O
analysis O
of O
neuropsychiatric O
side O
effects O
in O
germany O
, O
it O
is O
estimated O
that O
one O
of O
8,000 O
mefloquine O
users O
suffers O
from O
such O
reactions O
. O

the O
incidence O
calculation O
revealed O
that O
one O
of O
215 O
therapeutic O
users O
had O
reactions O
, O
compared O
with O
one O
of O
13,000 O
in O
the O
prophylaxis O
group O
, O
making O
the O
risk O
of O
neuropsychiatric O
reactions O
after O
mefloquine O
treatment O
60 O
times O
higher O
than O
after O
prophylaxis O
. O

therefore O
, O
certain O
limitations O
for O
malaria B-NEG
prophylaxis O
and O
treatment O
with O
mefloquine O
are O
recommended O
. O

-DOCSTART- O

reduction O
in O
injection O
pain B-NEG
using O
buffered O
lidocaine O
as O
a O
local O
anesthetic O
before O
cardiac O
catheterization O
. O

previous O
reports O
have O
suggested O
that O
pain B-NEG
associated O
with O
the O
injection O
of O
lidocaine O
is O
related O
to O
the O
acidic O
ph O
of O
the O
solution O
. O

to O
determine O
if O
the O
addition O
of O
a O
buffering O
solution O
to O
adjust O
the O
ph O
of O
lidocaine O
into O
the O
physiologic O
range O
would O
reduce O
pain B-NEG
during O
injection O
, O
we O
performed O
a O
blinded O
randomized O
study O
in O
patients O
undergoing O
cardiac O
catheterization O
. O

twenty O
patients O
were O
asked O
to O
quantify O
the O
severity O
of O
pain B-NEG
after O
receiving O
standard O
lidocaine O
in O
one O
femoral O
area O
and O
buffered O
lidocaine O
in O
the O
opposite O
femoral O
area O
. O

the O
mean O
pain B-NEG
score O
for O
buffered O
lidocaine O
was O
significantly O
lower O
than O
the O
mean O
score O
for O
standard O
lidocaine O
( O
2.7 O
+/- O
1.9 O
vs O
. O
3.8 O
+/- O
2.2 O
, O
p O
= O
0.03) O
. O

the O
ph O
adjustment O
of O
standard O
lidocaine O
can O
be O
accomplished O
easily O
in O
the O
catheterization O
laboratory O
before O
injection O
and O
results O
in O
a O
reduction O
of O
the O
pain B-NEG
occurring O
during O
the O
infiltration O
of O
tissues O
. O

-DOCSTART- O

randomized O
, O
double-blind O
trial O
of O
mazindol O
in O
duchenne B-NEG
dystrophy I-NEG
. O

there O
is O
evidence O
that O
growth O
hormone O
may O
be O
related O
to O
the O
progression O
of O
weakness B-NEG
in O
duchenne B-NEG
dystrophy I-NEG
. O

we O
conducted O
a O
12-month O
controlled O
trial O
of O
mazindol O
, O
a O
putative O
growth O
hormone O
secretion O
inhibitor O
, O
in O
83 O
boys O
with O
duchenne B-NEG
dystrophy I-NEG
. O

muscle O
strength O
, O
contractures O
, O
functional O
ability O
and O
pulmonary O
function O
were O
tested O
at O
baseline O
, O
and O
6 O
and O
12 O
months O
after O
treatment O
with O
mazindol O
(3 O
mg/d O
) O
or O
placebo O
. O

the O
study O
was O
designed O
to O
have O
a O
power O
of O
greater O
than O
0.90 O
to O
detect O
a O
slowing O
to O
25% O
of O
the O
expected O
rate O
of O
progression O
of O
weakness B-NEG
at O
p O
less O
than O
0.05 O
. O

mazindol O
did O
not O
benefit O
strength O
at O
any O
point O
in O
the O
study O
. O

side O
effects O
attributable O
to O
mazindol O
included O
decreased B-NEG
appetite I-NEG
(36%) O
, O
dry B-NEG
mouth I-NEG
(10%) O
, O
behavioral O
change O
(22%) O
, O
and O
gastrointestinal B-NEG
symptoms I-NEG
(18%) O
; O
mazindol O
dosage O
was O
reduced O
in O
43% O
of O
patients O
. O

the O
effect O
of O
mazindol O
on O
gh O
secretion O
was O
estimated O
indirectly O
by O
comparing O
the O
postabsorptive O
igf-i O
levels O
obtained O
following O
3, O
6, O
9, O
and O
12 O
months O
in O
the O
mazindol O
treated O
to O
those O
in O
the O
placebo O
groups O
. O

although O
mazindol-treated O
patients O
gained O
less O
weight O
and O
height O
than O
placebo-treated O
patients O
, O
no O
significant O
effect O
on O
igf-i O
levels O
was O
observed O
. O

mazindol O
doses O
not O
slow O
the O
progression O
of O
weakness B-NEG
in O
duchenne B-NEG
dystrophy I-NEG
. O

-DOCSTART- O

pentoxifylline O
( O
trental O
) O
does O
not O
inhibit O
dipyridamole-induced O
coronary O
hyperemia B-NEG
: O
implications O
for O
dipyridamole-thallium-201 O
myocardial O
imaging O
. O

dipyridamole-thallium-201 O
imaging O
is O
often O
performed O
in O
patients O
unable O
to O
exercise O
because O
of O
peripheral B-NEG
vascular I-NEG
disease I-NEG
. O

many O
of O
these O
patients O
are O
taking O
pentoxifylline O
(trental) O
, O
a O
methylxanthine O
derivative O
which O
may O
improve O
intermittent B-NEG
claudication I-NEG
. O

whether O
pentoxifylline O
inhibits O
dipyridamole-induced O
coronary O
hyperemia B-NEG
like O
other O
methylxanthines O
such O
as O
theophylline O
and O
should O
be O
stopped O
prior O
to O
dipyridamole-thallium-201 O
imaging O
is O
unknown O
. O

therefore O
, O
we O
studied O
the O
hyperemic O
response O
to O
dipyridamole O
in O
seven O
open-chest O
anesthetized O
dogs O
after O
pretreatment O
with O
either O
pentoxifylline O
(0 O
, O
7.5 O
, O
or O
15 O
mg/kg O
i.v. O
) O
or O
theophylline O
(3 O
mg/kg O
i.v.) O
. O

baseline O
circumflex O
coronary O
blood O
flows O
did O
not O
differ O
significantly O
among O
treatment O
groups O
. O

dipyridamole O
significantly O
increased O
coronary O
blood O
flow O
before O
and O
after O
7.5 O
or O
15 O
mm/kg O
i.v O
. O
pentoxifylline O
(p O
less O
than O
0.002) O
. O

neither O
dose O
of O
pentoxifylline O
significantly O
decreased O
the O
dipyridamole-induced O
hyperemia B-NEG
, O
while O
peak O
coronary O
blood O
flow O
was O
significantly O
lower O
after O
theophylline O
(p O
less O
than O
0.01) O
. O

we O
conclude O
that O
pentoxyifylline O
does O
not O
inhibit O
dipyridamole-induced O
coronary O
hyperemia B-NEG
even O
at O
high O
doses O
. O

-DOCSTART- O

cause O
of O
death B-NEG
among O
patients O
with O
parkinson's B-NEG
disease I-NEG
: O
a O
rare O
mortality O
due O
to O
cerebral B-NEG
haemorrhage I-NEG
. O

causes O
of O
death B-NEG
, O
with O
special O
reference O
to O
cerebral B-NEG
haemorrhage I-NEG
, O
among O
240 O
patients O
with O
pathologically O
verified O
parkinson's B-NEG
disease I-NEG
were O
investigated O
using O
the O
annuals O
of O
the O
pathological O
autopsy O
cases O
in O
japan O
from O
1981 O
to O
1985 O
. O

the O
leading O
causes O
of O
death B-NEG
were O
pneumonia B-NEG
and O
bronchitis B-NEG
(44.1%) O
, O
malignant O
neoplasms B-NEG
(11.6%) O
, O
heart B-NEG
diseases I-NEG
(4.1%) O
, O
cerebral B-NEG
infarction I-NEG
( O
3.7% O
) O
and O
septicaemia B-NEG
(3.3%) O
. O
cerebral B-NEG
haemorrhage I-NEG
was O
the O
11th O
most O
frequent O
cause O
of O
death B-NEG
, O
accounting O
for O
only O
0.8% O
of O
deaths B-NEG
among O
the O
patients O
, O
whereas O
it O
was O
the O
5th O
most O
common O
cause O
of O
death B-NEG
among O
the O
japanese O
general O
population O
in O
1985 O
. O

the O
low O
incidence O
of O
cerebral B-NEG
haemorrhage I-NEG
as O
a O
cause O
of O
death B-NEG
in O
patients O
with O
parkinson's B-NEG
disease I-NEG
may O
reflect O
the O
hypotensive B-NEG
effect O
of O
levodopa O
and O
a O
hypotensive B-NEG
mechanism O
due O
to O
reduced O
noradrenaline O
levels O
in O
the O
parkinsonian B-NEG
brain O
. O

-DOCSTART- O

tolerance O
and O
antiviral O
effect O
of O
ribavirin O
in O
patients O
with O
argentine B-NEG
hemorrhagic I-NEG
fever I-NEG
. O

tolerance O
and O
antiviral O
effect O
of O
ribavirin O
was O
studied O
in O
6 O
patients O
with O
argentine B-NEG
hemorrhagic I-NEG
fever I-NEG
( O
ahf B-NEG
) O
of O
more O
than O
8 O
days O
of O
evolution O
. O

administration O
of O
ribavirin O
resulted O
in O
a O
neutralization O
of O
viremia B-NEG
and O
a O
drop O
of O
endogenous O
interferon O
titers O
. O

the O
average O
time O
of O
death B-NEG
was O
delayed O
. O

a O
reversible O
anemia B-NEG
was O
the O
only O
adverse O
effect O
observed O
. O

from O
these O
results O
, O
we O
conclude O
that O
ribavirin O
has O
an O
antiviral O
effect O
in O
advanced O
cases O
of O
ahf B-NEG
, O
and O
that O
anemia B-NEG
, O
the O
only O
secondary O
reaction O
observed O
, O
can O
be O
easily O
managed O
. O

the O
possible O
beneficial O
effect O
of O
ribavirin O
during O
the O
initial O
days O
of O
ahf B-NEG
is O
discussed O
. O

-DOCSTART- O

dipyridamole-induced O
myocardial B-NEG
ischemia I-NEG
. O
angina B-NEG
and O
ischemic O
electrocardiographic O
changes O
occurred O
after O
administration O
of O
oral O
dipyridamole O
in O
four O
patients O
awaiting O
urgent O
myocardial O
revascularization O
procedures O
. O

to O
our O
knowledge O
, O
this O
has O
not O
previously O
been O
reported O
as O
a O
side O
effect O
of O
preoperative O
dipyridamole O
therapy O
, O
although O
dipyridamole-induced O
myocardial B-NEG
ischemia I-NEG
has O
been O
demonstrated O
to O
occur O
in O
animals O
and O
humans O
with O
coronary B-NEG
artery I-NEG
disease I-NEG
. O

epicardial O
coronary O
collateral O
vessels O
were O
demonstrated O
in O
all O
four O
patients O
; O
a O
coronary O
steal O
phenomenon O
may O
be O
the O
mechanism O
of O
the O
dipyridamole-induced O
ischemia B-NEG
observed O
. O

-DOCSTART- O

inhibition O
of O
immunoreactive O
corticotropin-releasing O
factor O
secretion O
into O
the O
hypophysial-portal O
circulation O
by O
delayed O
glucocorticoid O
feedback O
. O

nitroprusside-induced O
hypotension B-NEG
evokes O
acth O
secretion O
which O
is O
primarily O
mediated O
by O
enhanced O
secretion O
of O
immunoreactive O
corticotropin-releasing O
factor O
( O
ircrf O
) O
into O
the O
hypophysial-portal O
circulation O
. O

portal O
plasma O
concentrations O
of O
neither O
arginine O
vasopressin O
nor O
oxytocin O
are O
significantly O
altered O
in O
this O
paradigm O
. O

application O
of O
a O
delayed O
feedback O
signal O
, O
in O
the O
form O
of O
a O
2-h O
systemic O
corticosterone O
infusion O
in O
urethane-anesthetized O
rats O
with O
pharmacological O
blockade O
of O
glucocorticoid O
synthesis O
, O
is O
without O
effect O
on O
the O
resting O
secretion O
of O
arginine O
vasopressin O
and O
oxytocin O
at O
any O
corticosterone O
feedback O
dose O
tested O
. O

resting O
ircrf O
levels O
are O
suppressed O
only O
at O
the O
highest O
corticosterone O
infusion O
rate O
, O
which O
resulted O
in O
systemic O
corticosterone O
levels O
of O
40 O
micrograms/dl O
. O

suppression O
of O
ircrf O
secretion O
in O
response O
to O
nitroprusside-induced O
hypotension B-NEG
is O
observed O
and O
occurs O
at O
a O
plasma O
corticosterone O
level O
between O
8-12 O
micrograms/dl O
. O

these O
studies O
provide O
further O
evidence O
for O
a O
strong O
central O
component O
of O
the O
delayed O
feedback O
process O
which O
is O
mediated O
by O
modulation O
of O
ircrf O
release O
. O

-DOCSTART- O

noradrenergic O
involvement O
in O
catalepsy B-NEG
induced O
by O
delta O
9-tetrahydrocannabinol O
. O

in O
order O
to O
elucidate O
the O
role O
of O
the O
catecholaminergic O
system O
in O
the O
cataleptogenic O
effect O
of O
delta O
9-tetrahydrocannabinol O
(thc) O
, O
the O
effect O
of O
pretreatment O
with O
6-hydroxydopamine O
( O
6-ohda O
) O
or O
with O
desipramine O
and O
6-ohda O
and O
lesions O
of O
the O
locus O
coeruleus O
were O
investigated O
in O
rats O
. O

the O
cataleptogenic O
effect O
of O
thc O
was O
significantly O
reduced O
in O
rats O
treated O
with O
6-ohda O
and O
in O
rats O
with O
lesions O
of O
the O
locus O
coeruleus O
but O
not O
in O
rats O
treated O
with O
desipramine O
and O
6-ohda O
, O
as O
compared O
with O
control O
rats O
. O

on O
the O
contrary O
, O
the O
cataleptogenic O
effect O
of O
haloperidol O
was O
significantly O
reduced O
in O
rats O
treated O
with O
desipramine O
and O
6-ohda O
but O
not O
in O
rats O
treated O
with O
6-ohda O
or O
in O
rats O
with O
lesions O
of O
the O
locus O
coeruleus O
. O

these O
results O
indicate O
that O
noradrenergic O
neurons O
have O
an O
important O
role O
in O
the O
manifestation O
of O
catalepsy B-NEG
induced O
by O
thc O
, O
whereas O
dopaminergic O
neurons O
are O
important O
in O
catalepsy B-NEG
induced O
by O
haloperidol O
. O

-DOCSTART- O

intracranial O
pressure O
increases O
during O
alfentanil-induced O
rigidity B-NEG
. O

intracranial O
pressure O
( O
icp O
) O
was O
measured O
during O
alfentanil-induced O
rigidity B-NEG
in O
rats O
. O

ten O
rats O
had O
arterial O
, O
central O
venous O
(cvp) O
, O
and O
subdural O
cannulae O
inserted O
under O
halothane O
anesthesia O
. O

the O
animals O
were O
mechanically O
ventilated O
to O
achieve O
normocarbia O
( O
pco2 O
= O
42 O
+/- O
1 O
mmhg O
, O
mean O
+/- O
se) O
. O

following O
instrumentation O
, O
halothane O
was O
discontinued O
and O
alfentanil O
( O
125 O
mu/kg O
) O
administered O
iv O
during O
emergence O
from O
halothane O
anesthesia O
. O

in O
the O
five O
rats O
that O
developed O
somatic B-NEG
rigidity I-NEG
, O
icp O
and O
cvp O
increased O
significantly O
above O
baseline O
( O
delta O
icp O
7.5 O
+/- O
1.0 O
mmhg O
, O
delta O
cvp O
5.9 O
+/- O
1.3 O
mmhg) O
. O

these O
variables O
returned O
to O
baseline O
when O
rigidity B-NEG
was O
abolished O
with O
metocurine O
. O

in O
five O
rats O
that O
did O
not O
become O
rigid O
, O
icp O
and O
cvp O
did O
not O
change O
following O
alfentanil O
. O

these O
observations O
suggest O
that O
rigidity B-NEG
should O
be O
prevented O
when O
alfentanil O
, O
and O
, O
presumably O
, O
other O
opiates O
, O
are O
used O
in O
the O
anesthetic O
management O
of O
patients O
with O
icp O
problems O
. O

-DOCSTART- O

adverse O
cardiac O
effects O
during O
induction O
chemotherapy O
treatment O
with O
cis-platin O
and O
5-fluorouracil O
. O

survival O
for O
patients O
with O
advanced O
head B-NEG
and I-NEG
neck I-NEG
carcinoma I-NEG
and O
esophageal B-NEG
carcinoma I-NEG
is O
poor O
with O
radiotherapy O
and/or O
surgery O
. O

obviously O
, O
there O
is O
a O
need O
for O
effective O
chemotherapy O
. O

in O
the O
present O
study O
, O
cis-platin O
( O
80-120 O
mg/m2bsa O
) O
and O
5-fu O
( O
1000 O
mg/m2bsa O
daily O
as O
a O
continuous O
infusion O
during O
5 O
days O
) O
were O
given O
to O
76 O
patients O
before O
radiotherapy O
and O
surgery O
. O

the O
aim O
of O
the O
study O
was O
to O
clarify O
the O
incidence O
and O
severity O
of O
adverse O
cardiac O
effects O
to O
this O
treatment O
. O

before O
treatment O
all O
patients O
had O
a O
cardiac O
evaluation O
and O
during O
treatment O
serial O
ecg O
recordings O
were O
performed O
. O

in O
the O
pre-treatment O
evaluation O
, O
signs O
of O
cardiovascular B-NEG
disease I-NEG
were O
found O
in O
33 O
patients O
(43%) O
. O

during O
treatment O
, O
adverse O
cardiac O
effects O
were O
observed O
in O
14 O
patients O
(18%) O
. O

the O
mean O
age O
of O
these O
patients O
was O
the O
same O
as O
for O
the O
entire O
group O
, O
64 O
years O
. O

the O
incidence O
of O
cardiotoxicity B-NEG
was O
not O
higher O
in O
patients O
with O
signs O
of O
cardiovascular B-NEG
disease I-NEG
than O
in O
those O
without O
in O
the O
pre-treatment O
evaluation O
. O

the O
most O
common O
signs O
of O
cardiotoxicity B-NEG
were O
chest B-NEG
pain I-NEG
, O
st-t O
wave O
changes O
and O
atrial B-NEG
fibrillation I-NEG
. O

this O
was O
followed O
by O
ventricular B-NEG
fibrillation I-NEG
in O
one O
patient O
and O
sudden B-NEG
death I-NEG
in O
another O
. O

it O
is O
concluded O
that O
patients O
on O
5-fu O
treatment O
should O
be O
under O
close O
supervision O
and O
that O
the O
treatment O
should O
be O
discontinued O
if O
chest B-NEG
pain I-NEG
or O
tachyarrhythmia B-NEG
is O
observed O
. O

-DOCSTART- O

verapamil-induced O
carbamazepine O
neurotoxicity B-NEG
. O

a O
report O
of O
two O
cases O
. O

two O
patients O
with O
signs O
of O
carbamazepine O
neurotoxicity B-NEG
after O
combined O
treatment O
with O
verapamil O
showed O
complete O
recovery O
after O
discontinuation O
of O
the O
calcium O
entry O
blocker O
. O

use O
of O
verapamil O
in O
combination O
with O
carbamazepine O
should O
either O
be O
avoided O
or O
prescribed O
only O
with O
appropriate O
adjustment O
of O
the O
carbamazepine O
dose O
( O
usually O
reduction O
of O
the O
carbamazepine O
dose O
by O
one O
half) O
. O

-DOCSTART- O

serial O
studies O
of O
auditory B-NEG
neurotoxicity I-NEG
in O
patients O
receiving O
deferoxamine O
therapy O
. O
visual B-NEG
and I-NEG
auditory I-NEG
neurotoxicity I-NEG
was O
previously O
documented O
in O
42 O
of O
89 O
patients O
with O
transfusion-dependent O
anemia B-NEG
who O
were O
receiving O
iron O
chelation O
therapy O
with O
daily O
subcutaneous O
deferoxamine O
. O

twenty-two O
patients O
in O
the O
affected O
group O
had O
abnormal B-NEG
audiograms I-NEG
with I-NEG
deficits I-NEG
mostly I-NEG
in I-NEG
the I-NEG
high I-NEG
frequency I-NEG
range I-NEG
of I-NEG
4,000 I-NEG
to I-NEG
8,000 I-NEG
hz I-NEG
and O
in O
the O
hearing O
threshold O
levels O
of O
30 O
to O
100 O
decibels O
. O

when O
deferoxamine O
therapy O
was O
discontinued O
and O
serial O
studies O
were O
performed O
, O
audiograms O
in O
seven O
cases O
reverted O
to O
normal O
or O
near O
normal O
within O
two O
to O
three O
weeks O
, O
and O
nine O
of O
13 O
patients O
with O
symptoms O
became O
asymptomatic O
. O

audiograms O
from O
15 O
patients O
remained O
abnormal O
and O
four O
patients O
required O
hearing O
aids O
because O
of O
permanent B-NEG
disability I-NEG
. O

since O
18 O
of O
the O
22 O
patients O
were O
initially O
receiving O
deferoxamine O
doses O
in O
excess O
of O
the O
commonly O
recommended O
50 O
mg/kg O
per O
dose O
, O
therapy O
was O
restarted O
with O
lower O
doses O
, O
usually O
50 O
mg/kg O
per O
dose O
or O
less O
depending O
on O
the O
degree O
of O
auditory B-NEG
abnormality I-NEG
, O
and O
with O
the O
exception O
of O
two O
cases O
no O
further O
toxicity B-NEG
was O
demonstrated O
. O

auditory O
deterioration O
and O
improvement O
, O
demonstrated O
serially O
in O
individual O
patients O
receiving O
and O
not O
receiving O
deferoxamine O
, O
respectively O
, O
provided O
convincing O
evidence O
for O
a O
cause-and-effect O
relation O
between O
deferoxamine O
administration O
and O
ototoxicity B-NEG
. O

based O
on O
these O
data O
, O
a O
plan O
of O
management O
was O
developed O
that O
allows O
effective O
yet O
safe O
administration O
of O
deferoxamine O
. O

a O
dose O
of O
50 O
mg/kg O
is O
recommended O
in O
those O
without O
audiogram O
abnormalities O
. O

with O
mild O
toxicity B-NEG
, O
a O
reduction O
to O
30 O
or O
40 O
mg/kg O
per O
dose O
should O
result O
in O
a O
reversal O
of O
the O
abnormal O
results O
to O
normal O
within O
four O
weeks O
. O

moderate O
abnormalities O
require O
a O
reduction O
of O
deferoxamine O
to O
25 O
mg/kg O
per O
dose O
with O
careful O
monitoring O
. O

in O
those O
with O
symptoms O
of O
hearing B-NEG
loss I-NEG
, O
the O
drug O
should O
be O
stopped O
for O
four O
weeks O
, O
and O
when O
the O
audiogram O
is O
stable O
or O
improved O
, O
therapy O
should O
be O
restarted O
at O
10 O
to O
25 O
mg/kg O
per O
dose O
. O

serial O
audiograms O
should O
be O
performed O
every O
six O
months O
in O
those O
without O
problems O
and O
more O
frequently O
in O
young O
patients O
with O
normal O
serum O
ferritin O
values O
and O
in O
those O
with O
auditory B-NEG
dysfunction I-NEG
. O

-DOCSTART- O

flurbiprofen O
in O
the O
treatment O
of O
juvenile B-NEG
rheumatoid I-NEG
arthritis I-NEG
. O

thirty-four O
patients O
with O
juvenile B-NEG
rheumatoid I-NEG
arthritis I-NEG
, O
who O
were O
treated O
with O
flurbiprofen O
at O
a O
maximum O
dose O
of O
4 O
mg/kg/day O
, O
had O
statistically O
significant O
decreases O
from O
baseline O
in O
6 O
arthritis B-NEG
indices O
after O
12 O
weeks O
of O
treatment O
. O

improvements O
were O
seen O
in O
the O
number O
of O
tender B-NEG
joints I-NEG
, O
the O
severity O
of O
swelling B-NEG
and O
tenderness B-NEG
, O
the O
time O
of O
walk O
50 O
feet O
, O
the O
duration O
of O
morning B-NEG
stiffness I-NEG
and O
the O
circumference O
of O
the O
left O
knee O
. O

the O
most O
frequently O
observed O
side O
effect O
was O
fecal B-NEG
occult I-NEG
blood I-NEG
( O
25% O
of O
patients) O
; O
however O
, O
there O
was O
no O
other O
evidence O
of O
gastrointestinal B-NEG
( O
gi I-NEG
) O
bleeding I-NEG
in O
these O
patients O
. O

one O
patient O
was O
prematurely O
discontinued O
from O
the O
study O
for O
severe O
headache B-NEG
and O
abdominal B-NEG
pain I-NEG
. O

most O
side O
effects O
were O
mild O
and O
related O
to O
the O
gi O
tract O
. O

-DOCSTART- O

the O
correlation O
between O
neurotoxic B-NEG
esterase O
inhibition O
and O
mipafox-induced O
neuropathic B-NEG
damage I-NEG
in O
rats O
. O

the O
correlation O
between O
neuropathic B-NEG
damage I-NEG
and O
inhibition O
of O
neurotoxic B-NEG
esterase O
or O
neuropathy B-NEG
target O
enzyme O
( O
nte O
) O
was O
examined O
in O
rats O
acutely O
exposed O
to O
mipafox O
(n O
, O
n'-diisopropylphosphorodiamidofluoridate) O
, O
a O
neurotoxic B-NEG
organophosphate O
. O

brain O
and O
spinal O
cord O
nte O
activities O
were O
measured O
in O
long-evans O
male O
rats O
1 O
hr O
post-exposure O
to O
various O
dosages O
of O
mipafox O
(ip O
, O
1-15 O
mg/kg) O
. O

these O
data O
were O
correlated O
with O
histologically O
scored O
cervical O
cord B-NEG
damage I-NEG
in O
a O
separate O
group O
of O
similarly O
dosed O
rats O
sampled O
14-21 O
days O
post-exposure O
. O

those O
dosages O
( O
greater O
than O
or O
equal O
to O
10 O
mg/kg O
) O
that O
inhibited O
mean O
nte O
activity O
in O
the O
spinal O
cord O
greater O
than O
or O
equal O
to O
73% O
and O
brain O
greater O
than O
or O
equal O
to O
67% O
of O
control O
values O
produced O
severe O
( O
greater O
than O
or O
equal O
to O
3) O
cervical O
cord O
pathology O
in O
85% O
of O
the O
rats O
. O

in O
contrast O
, O
dosages O
of O
mipafox O
( O
less O
than O
or O
equal O
to O
5 O
mg/kg O
) O
which O
inhibited O
mean O
nte O
activity O
in O
spinal O
cord O
less O
than O
or O
equal O
to O
61% O
and O
brain O
less O
than O
or O
equal O
to O
60% O
produced O
this O
degree O
of O
cord B-NEG
damage I-NEG
in O
only O
9% O
of O
the O
animals O
. O

these O
data O
indicate O
that O
a O
critical O
percentage O
of O
nte O
inhibition O
in O
brain O
and O
spinal O
cord O
sampled O
shortly O
after O
mipafox O
exposure O
can O
predict O
neuropathic B-NEG
damage I-NEG
in O
rats O
several O
weeks O
later O
. O

-DOCSTART- O

cerebral B-NEG
infarction I-NEG
with O
a O
single O
oral O
dose O
of O
phenylpropanolamine O
. O

phenylpropanolamine O
(ppa) O
, O
a O
synthetic O
sympathomimetic O
that O
is O
structurally O
similar O
to O
amphetamine O
, O
is O
available O
over O
the O
counter O
in O
anorectics O
, O
nasal O
congestants O
, O
and O
cold O
preparations O
. O

its O
prolonged O
use O
or O
overuse O
has O
been O
associated O
with O
seizures B-NEG
, O
intracerebral B-NEG
hemorrhage I-NEG
, O
neuropsychiatric B-NEG
symptoms I-NEG
, O
and O
nonhemorrhagic O
cerebral B-NEG
infarction I-NEG
. O

we O
report O
the O
case O
of O
a O
young O
woman O
who O
suffered O
a O
cerebral B-NEG
infarction I-NEG
after O
taking O
a O
single O
oral O
dose O
of O
ppa O
. O

-DOCSTART- O

treatment O
of O
psoriasis B-NEG
with O
azathioprine O
. O

azathioprine O
treatment O
benefited O
19 O
( O
66% O
) O
out O
of O
29 O
patients O
suffering O
from O
severe O
psoriasis B-NEG
. O

haematological O
complications O
were O
not O
troublesome O
and O
results O
of O
biochemical O
liver O
function O
tests O
remained O
normal O
. O

minimal O
cholestasis B-NEG
was O
seen O
in O
two O
cases O
and O
portal O
fibrosis B-NEG
of O
a O
reversible O
degree O
in O
eight O
. O

liver O
biopsies O
should O
be O
undertaken O
at O
regular O
intervals O
if O
azathioprine O
therapy O
is O
continued O
so O
that O
structural O
liver B-NEG
damage I-NEG
may O
be O
detected O
at O
an O
early O
and O
reversible O
stage O
. O

-DOCSTART- O

maternal O
lithium O
and O
neonatal O
ebstein's B-NEG
anomaly I-NEG
: O
evaluation O
with O
cross-sectional O
echocardiography O
. O

cross-sectional O
echocardiography O
was O
used O
to O
evaluate O
two O
neonates O
whose O
mothers O
ingested O
lithium O
during O
pregnancy O
. O

in O
one O
infant O
, O
ebstein's B-NEG
anomaly I-NEG
of O
the O
tricuspid O
valve O
was O
identified O
. O

in O
the O
other O
infant O
cross-sectional O
echocardiography O
provided O
reassurance O
that O
the O
infant O
did O
not O
have O
ebstein's B-NEG
anomaly I-NEG
. O

cross-sectional O
echocardiographic O
screening O
of O
newborns O
exposed O
to O
lithium O
during O
gestation O
can O
provide O
highly O
accurate O
, O
noninvasive O
assessment O
of O
the O
presence O
or O
absence O
of O
lithium-induced O
cardiac B-NEG
malformations I-NEG
. O

-DOCSTART- O

effects O
of O
training O
on O
the O
extent O
of O
experimental O
myocardial B-NEG
infarction I-NEG
in O
aging O
rats O
. O

the O
effects O
of O
exercise O
on O
the O
severity O
of O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
were O
studied O
in O
female O
albino O
rats O
of O
20,40,60 O
and O
80 O
weeks O
of O
age O
. O

the O
rats O
were O
trained O
to O
swim O
for O
a O
specific O
duration O
and O
for O
a O
particular O
period O
. O

the O
occurrence O
of O
infarcts B-NEG
were O
confirmed O
by O
histological O
methods O
. O

elevations O
in O
the O
serum O
got O
and O
gpt O
were O
maximum O
in O
the O
sedentary-isoproterenols O
and O
minimum O
in O
the O
exercise-controls O
. O

these O
changes O
in O
the O
serum O
transaminases O
were O
associated O
with O
corresponding O
depletions O
in O
the O
cardiac O
got O
and O
gpt O
. O

however O
, O
age O
was O
seen O
to O
interfere O
with O
the O
responses O
exhibited O
by O
the O
young O
and O
old O
rats O
. O

studies O
dealing O
with O
myocardial B-NEG
infarction I-NEG
are O
more O
informative O
when O
dealt O
with O
age O
. O

-DOCSTART- O

effect O
of O
polyethylene O
glycol O
400 O
on O
adriamycin O
toxicity B-NEG
in O
mice O
. O

the O
effect O
of O
a O
widely O
used O
organic O
solvent O
, O
polyethylene O
glycol O
400 O
( O
peg O
400) O
, O
on O
the O
toxic O
action O
of O
an O
acute O
or O
chronic O
treatment O
with O
adriamycin O
( O
adr O
) O
was O
evaluated O
in O
mice O
. O

peg O
400 O
impressively O
decreased O
both O
acute O
high-dose O
and O
chronic O
low-dose-adr-associated O
lethality O
. O

light O
microscopic O
analysis O
showed O
a O
significant O
protection O
against O
adr-induced O
cardiac B-NEG
morphological I-NEG
alterations I-NEG
. O

such O
treatment O
did O
not O
diminish O
the O
adr O
antitumor O
activity O
in O
l1210 B-NEG
leukemia I-NEG
and O
in O
ehrlich B-NEG
ascites I-NEG
tumor I-NEG
. O

-DOCSTART- O

intra-arterial O
bcnu O
chemotherapy O
for O
treatment O
of O
malignant B-NEG
gliomas I-NEG
of O
the O
central O
nervous O
system O
. O

because O
of O
the O
rapid O
systemic O
clearance O
of O
bcnu O
(1,3-bis-(2-chloroethyl)-1-nitrosourea) O
, O
intra-arterial O
administration O
should O
provide O
a O
substantial O
advantage O
over O
intravenous O
administration O
for O
the O
treatment O
of O
malignant B-NEG
gliomas I-NEG
. O

thirty-six O
patients O
were O
treated O
with O
bcnu O
every O
6 O
to O
8 O
weeks O
, O
either O
by O
transfemoral O
catheterization O
of O
the O
internal O
carotid O
or O
vertebral O
artery O
or O
through O
a O
fully O
implantable O
intracarotid O
drug O
delivery O
system O
, O
beginning O
with O
a O
dose O
of O
200 O
mg/sq O
m O
body O
surface O
area O
. O

twelve O
patients O
with O
grade O
iii O
or O
iv O
astrocytomas B-NEG
were O
treated O
after O
partial O
resection O
of O
the O
tumor B-NEG
without O
prior O
radiation O
therapy O
. O

after O
two O
to O
seven O
cycles O
of O
chemotherapy O
, O
nine O
patients O
showed O
a O
decrease O
in O
tumor B-NEG
size O
and O
surrounding O
edema B-NEG
on O
contrast-enhanced O
computerized O
tomography O
scans O
. O

in O
the O
nine O
responders O
, O
median O
duration O
of O
chemotherapy O
response O
from O
the O
time O
of O
operation O
was O
25 O
weeks O
( O
range O
12 O
to O
more O
than O
91 O
weeks) O
. O

the O
median O
duration O
of O
survival O
in O
the O
12 O
patients O
was O
54 O
weeks O
( O
range O
21 O
to O
more O
than O
156 O
weeks) O
, O
with O
an O
18-month O
survival O
rate O
of O
42% O
. O

twenty-four O
patients O
with O
recurrent O
grade O
i O
to O
iv O
astrocytomas B-NEG
, O
whose O
resection O
and O
irradiation O
therapy O
had O
failed O
, O
received O
two O
to O
eight O
courses O
of O
intra-arterial O
bcnu O
therapy O
. O

seventeen O
of O
these O
had O
a O
response O
or O
were O
stable O
for O
a O
median O
of O
20 O
weeks O
( O
range O
6 O
to O
more O
than O
66 O
weeks) O
. O

the O
catheterization O
procedure O
is O
safe O
, O
with O
no O
immediate O
complication O
in O
111 O
infusions O
of O
bcnu O
. O

a O
delayed O
complication O
in O
nine O
patients O
has O
been O
unilateral O
loss B-NEG
of I-NEG
vision I-NEG
secondary O
to O
a O
retinal B-NEG
vasculitis I-NEG
. O

the O
frequency O
of O
visual B-NEG
loss I-NEG
decreased O
after O
the O
concentration O
of O
the O
ethanol O
diluent O
was O
lowered O
. O

-DOCSTART- O

blood O
pressure O
response O
to O
chronic O
low-dose O
intrarenal O
noradrenaline O
infusion O
in O
conscious O
rats O
. O

sodium O
chloride O
solution O
( O
0.9% O
) O
or O
noradrenaline O
in O
doses O
of O
4, O
12 O
and O
36 O
micrograms O
h-1 O
kg-1 O
was O
infused O
for O
five O
consecutive O
days O
, O
either O
intrarenally O
( O
by O
a O
new O
technique O
) O
or O
intravenously O
into O
rats O
with O
one O
kidney O
removed O
. O

intrarenal O
infusion O
of O
noradrenaline O
caused O
hypertension B-NEG
at O
doses O
which O
did O
not O
do O
so O
when O
infused O
intravenously O
. O

intrarenal O
compared O
with O
intravenous O
infusion O
of O
noradrenaline O
caused O
higher O
plasma O
noradrenaline O
concentrations O
and O
a O
shift O
of O
the O
plasma O
noradrenaline O
concentration-blood O
pressure O
effect O
curve O
towards O
lower O
plasma O
noradrenaline O
levels O
. O

these O
results O
suggest O
that O
hypertension B-NEG
after O
chronic O
intrarenal O
noradrenaline O
infusion O
is O
produced O
by O
relatively O
higher O
levels O
of O
circulating O
noradrenaline O
and O
by O
triggering O
of O
an O
additional O
intrarenal O
pressor O
mechanism O
. O

-DOCSTART- O

age O
and O
renal O
clearance O
of O
cimetidine O
. O

in O
35 O
patients O
( O
ages O
20 O
to O
86 O
yr O
) O
receiving O
cimetidine O
therapeutically O
two O
serum O
samples O
and O
all O
urine O
formed O
in O
the O
interim O
were O
collected O
for O
analysis O
of O
cimetidine O
by O
high-pressure O
liquid O
chromatography O
and O
for O
creatinine O
. O

cimetidine O
clearance O
decreased O
with O
age O
. O

the O
extrapolated O
6-hr O
serum O
concentration O
of O
cimetidine O
per O
unit O
dose O
, O
after O
intravenous O
cimetidine O
, O
increased O
with O
age O
of O
the O
patients O
. O

the O
ratio O
of O
cimetidine O
clearance O
to O
creatinine O
clearance O
( O
rc O
) O
averaged O
4.8 O
+/- O
2.0 O
, O
indicating O
net O
tubular O
secretion O
for O
cimetidine O
. O

rc O
seemed O
to O
be O
independent O
of O
age O
and O
decreased O
with O
increasing O
serum O
concentration O
of O
cimetidine O
, O
suggesting O
that O
secretion O
of O
cimetidine O
is O
a O
saturable O
process O
. O

there O
was O
only O
one O
case O
of O
dementia B-NEG
possibly O
due O
to O
cimetidine O
( O
with O
a O
drug O
level O
of O
1.9 O
microgram/ml O
6 O
hr O
after O
a O
dose O
) O
in O
a O
group O
of O
13 O
patients O
without O
liver B-NEG
or I-NEG
kidney I-NEG
disease I-NEG
who O
had O
cimetidine O
levels O
above O
1.25 O
microgram/ml O
. O

thus O
, O
high O
cimetidine O
levels O
alone O
do O
not O
always O
induce O
dementia B-NEG
. O

-DOCSTART- O

development O
of O
clear B-NEG
cell I-NEG
adenocarcinoma I-NEG
in O
des-exposed O
offspring O
under O
observation O
. O

two O
cases O
of O
clear B-NEG
cell I-NEG
adenocarcinoma I-NEG
of I-NEG
the I-NEG
vagina I-NEG
detected O
at O
follow-up O
in O
young O
women O
exposed O
in O
utero O
to O
diethylstilbestrol O
are O
reported O
. O

one O
patient O
, O
aged O
23 O
, O
had O
been O
followed O
for O
2 O
years O
before O
carcinoma B-NEG
was O
diagnosed O
; O
the O
second O
patient O
, O
aged O
22 O
, O
had O
been O
seen O
on O
a O
regular O
basis O
for O
5 O
years O
, O
8 O
months O
. O

in O
both O
instances O
, O
suspicion O
of O
the O
presence O
of O
carcinoma B-NEG
was O
aroused O
by O
the O
palpation O
of O
a O
small O
nodule O
in O
the O
vaginal O
fornix O
. O

hysterosalpingography O
was O
performed O
on O
both O
patients O
and O
, O
in O
1 O
instance O
, O
an O
abnormal O
x-ray O
film O
was O
reflected O
by O
the O
gross O
appearance O
of O
the O
uterine O
cavity O
found O
in O
the O
surgical O
specimen O
. O

-DOCSTART- O

phenobarbitone-induced O
enlargement B-NEG
of I-NEG
the I-NEG
liver I-NEG
in O
the O
rat O
: O
its O
relationship O
to O
carbon O
tetrachloride-induced O
cirrhosis B-NEG
. O

the O
yield O
of O
severe O
cirrhosis B-NEG
of I-NEG
the I-NEG
liver I-NEG
( O
defined O
as O
a O
shrunken O
finely O
nodular O
liver O
with O
micronodular O
histology O
, O
ascites B-NEG
greater O
than O
30 O
ml O
, O
plasma O
albumin O
less O
than O
2.2 O
g/dl O
, O
splenomegaly B-NEG
2-3 O
times O
normal O
, O
and O
testicular O
atrophy B-NEG
approximately O
half O
normal O
weight O
) O
after O
12 O
doses O
of O
carbon O
tetrachloride O
given O
intragastrically O
in O
the O
phenobarbitone-primed O
rat O
was O
increased O
from O
25% O
to O
56% O
by O
giving O
the O
initial O
calibrating O
dose O
of O
carbon O
tetrachloride O
at O
the O
peak O
of O
the O
phenobarbitone-induced O
enlargement B-NEG
of I-NEG
the I-NEG
liver I-NEG
. O

at O
this O
point O
it O
was O
assumed O
that O
the O
cytochrome O
p450/ccl4 O
toxic O
state O
was O
both O
maximal O
and O
stable O
. O

the O
optimal O
rat O
size O
to O
begin O
phenobarbitone O
was O
determined O
as O
100 O
g, O
and O
this O
size O
as O
a O
group O
had O
a O
mean O
maximum O
relative O
liver O
weight O
increase O
47% O
greater O
than O
normal O
rats O
of O
the O
same O
body O
weight O
. O

the O
optimal O
time O
for O
the O
initial O
dose O
of O
carbon O
tetrachloride O
was O
after O
14 O
days O
on O
phenobarbitone O
. O

-DOCSTART- O

attenuation O
of O
the O
lithium-induced O
diabetes-insipidus-like B-NEG
syndrome I-NEG
by O
amiloride O
in O
rats O
. O

the O
effect O
of O
amiloride O
on O
lithium-induced O
polydipsia B-NEG
and O
polyuria B-NEG
and O
on O
the O
lithium O
concentration O
in O
the O
plasma O
, O
brain O
, O
kidney O
, O
thyroid O
and O
red O
blood O
cells O
was O
investigated O
in O
rats O
, O
chronically O
treated O
with O
licl O
. O

amiloride O
reduced O
the O
drinking O
and O
urine O
volume O
of O
rats O
in O
an O
acute O
(6 O
or O
12 O
h) O
and O
a O
subacute O
(3 O
days O
) O
experiment O
. O

6 O
h O
after O
the O
administration O
of O
amiloride O
, O
a O
reduction O
was O
observed O
in O
the O
lithium O
content O
of O
the O
renal O
medulla O
but O
not O
in O
the O
other O
organs O
studied O
. O

at O
12 O
h, O
all O
the O
tissues O
showed O
a O
slight O
increase O
in O
lithium O
levels O
. O

after O
3 O
days O
of O
combined O
treatment O
, O
a O
marked O
elevation O
in O
plasma O
and O
tissue O
lithium O
levels O
accompanied O
a O
reduction O
in O
water O
intake O
. O

in O
all O
the O
experiments O
, O
the O
attenuation O
of O
the O
lithium-induced O
diabetes-insipidus-like B-NEG
syndrome I-NEG
by O
amiloride O
was O
accompanied O
by O
a O
reduction O
of O
the O
ratio O
between O
the O
lithium O
concentration O
in O
the O
renal O
medulla O
and O
its O
levels O
in O
the O
blood O
and O
an O
elevation O
in O
the O
plasma O
potassium O
level O
. O

it O
is O
concluded O
that O
acute O
amiloride O
administration O
to O
lithium-treated O
patients O
suffering O
from O
polydipsia B-NEG
and O
polyuria B-NEG
might O
relieve O
these O
patients O
but O
prolonged O
amiloride O
supplementation O
would O
result O
in O
elevated O
lithium O
levels O
and O
might O
be O
hazardous O
. O

-DOCSTART- O

safety O
and O
side-effects O
of O
alprazolam O
. O

controlled O
study O
in O
agoraphobia B-NEG
with O
panic B-NEG
disorder I-NEG
. O

background O
: O
the O
widespread O
use O
of O
benzodiazepines O
has O
led O
to O
increasing O
recognition O
of O
their O
unwanted O
effects O
. O

the O
efficacy O
of O
alprazolam O
and O
placebo O
in O
panic B-NEG
disorder I-NEG
with O
agoraphobia B-NEG
, O
and O
the O
side-effect O
and O
adverse O
effect O
profiles O
of O
both O
drug O
groups O
were O
measured O
. O

method O
: O
in O
london O
and O
toronto O
154 O
patients O
who O
met O
dsm-iii O
criteria O
for O
panic B-NEG
disorder I-NEG
with O
agoraphobia B-NEG
were O
randomised O
to O
alprazolam O
or O
placebo O
. O

subjects O
in O
each O
drug O
group O
also O
received O
either O
exposure O
or O
relaxation O
. O

treatment O
was O
from O
weeks O
0 O
to O
8 O
and O
was O
then O
tapered O
from O
weeks O
8 O
to O
16 O
. O

results O
: O
mean O
alprazolam O
dose O
was O
5 O
mg O
daily O
. O

compared O
with O
placebo O
subjects O
, O
alprazolam O
patients O
developed O
more O
adverse O
reactions O
( O
21% O
v. O
0% O
) O
of O
depression B-NEG
, O
enuresis B-NEG
, O
disinhibition O
and O
aggression B-NEG
; O
and O
more O
side-effects O
, O
particularly O
sedation O
, O
irritability B-NEG
, O
impaired B-NEG
memory I-NEG
, O
weight B-NEG
loss I-NEG
and O
ataxia B-NEG
. O

side-effects O
tended O
to O
diminish O
during O
treatment O
but O
remained O
significant O
at O
week O
8. O

despite O
this O
, O
the O
drop-out O
rate O
was O
low O
. O

conclusions O
: O
alprazolam O
caused O
side-effects O
and O
adverse O
effects O
during O
treatment O
but O
many O
patients O
were O
willing O
to O
accept O
these O
. O

-DOCSTART- O

dup O
753 O
prevents O
the O
development O
of O
puromycin O
aminonucleoside-induced O
nephrosis B-NEG
. O

the O
appearance O
of O
nephrotic B-NEG
syndromes I-NEG
such O
as O
proteinuria B-NEG
, O
hypoalbuminemia B-NEG
, O
hypercholesterolemia B-NEG
and O
increase O
in O
blood O
nitrogen O
urea O
, O
induced O
in O
rats O
by O
injection O
of O
puromycin O
aminonucleoside O
was O
markedly O
inhibited O
by O
oral O
administration O
of O
dup O
753 O
(losartan) O
, O
a O
novel O
angiotensin O
ii O
receptor O
antagonist O
, O
at O
a O
dose O
of O
1 O
or O
2 O
mg/kg O
per O
day O
. O

the O
results O
suggest O
a O
possible O
involvement O
of O
the O
renin-angiotensin O
system O
in O
the O
development O
of O
puromycin O
aminonucleoside-induced O
nephrosis B-NEG
. O

-DOCSTART- O

sodium O
bicarbonate O
alleviates O
penile B-NEG
pain I-NEG
induced O
by O
intracavernous O
injections O
for O
erectile B-NEG
dysfunction I-NEG
. O

in O
an O
attempt O
to O
determine O
whether O
penile B-NEG
pain I-NEG
associated O
with O
intracorporeal O
injections O
could O
be O
due O
to O
the O
acidity O
of O
the O
medication O
, O
we O
performed O
a O
randomized O
study O
comparing O
the O
incidence O
of O
penile B-NEG
pain I-NEG
following O
intracorporeal O
injections O
with O
or O
without O
the O
addition O
of O
sodium O
bicarbonate O
to O
the O
intracorporeal O
medications O
. O

a O
total O
of O
38 O
consecutive O
patients O
who O
presented O
to O
our O
clinic O
with O
impotence B-NEG
received O
0.2 O
ml O
. O
of O
a O
combination O
of O
3 O
drugs O
: O
6 O
mg O
. O
papaverine O
, O
100 O
micrograms O
. O
phentolamine O
and O
10 O
micrograms O
. O
prostaglandin O
e1 O
with O
( O
ph O
7.05 O
) O
or O
without O
( O
ph O
4.17 O
) O
the O
addition O
of O
sodium O
bicarbonate O
( O
0.03 O
meq.) O
. O

of O
the O
19 O
patients O
without O
sodium O
bicarbonate O
added O
to O
the O
medication O
11 O
( O
58% O
) O
complained O
of O
penile B-NEG
pain I-NEG
due O
to O
the O
medication O
, O
while O
only O
1 O
of O
the O
19 O
men O
( O
5% O
) O
who O
received O
sodium O
bicarbonate O
complained O
of O
penile B-NEG
pain I-NEG
. O

from O
these O
data O
we O
conclude O
that O
the O
penile B-NEG
pain I-NEG
following O
intracorporeal O
injections O
is O
most O
likely O
due O
to O
the O
acidity O
of O
the O
medication O
, O
which O
can O
be O
overcome O
by O
elevating O
the O
ph O
to O
a O
neutral O
level O
. O

-DOCSTART- O

prospective O
study O
of O
the O
long-term O
effects O
of O
somatostatin O
analog O
( O
octreotide O
) O
on O
gallbladder O
function O
and O
gallstone B-NEG
formation O
in O
chinese O
acromegalic B-NEG
patients O
. O

this O
article O
reports O
the O
changes O
in O
gallbladder O
function O
examined O
by O
ultrasonography O
in O
20 O
chinese O
patients O
with O
active O
acromegaly B-NEG
treated O
with O
sc O
injection O
of O
the O
somatostatin O
analog O
octreotide O
in O
dosages O
of O
300-1500 O
micrograms/day O
for O
a O
mean O
of O
24.2 O
+/- O
13.9 O
months O
. O

during O
treatment O
with O
octreotide O
, O
17 O
patients O
developed O
sludge O
, O
10 O
had O
gallstones B-NEG
, O
and O
1 O
developed O
acute B-NEG
cholecystitis I-NEG
requiring O
surgery O
. O

in O
all O
of O
7 O
patients O
examined O
acutely O
, O
gallbladder O
contractility O
was O
inhibited O
after O
a O
single O
100-micrograms O
injection O
. O

in O
8 O
patients O
followed O
for O
24 O
weeks O
, O
gallbladder O
contractility O
remained O
depressed B-NEG
throughout O
therapy O
. O

after O
withdrawal O
of O
octreotide O
in O
10 O
patients O
without O
gallstones B-NEG
, O
8 O
patients O
assessed O
had O
return O
of O
normal O
gallbladder O
contractility O
within O
1 O
month O
. O

in O
8 O
of O
the O
remaining O
10 O
patients O
who O
developed O
gallstones B-NEG
during O
treatment O
, O
gallbladder O
contractility O
normalized O
in O
5 O
patients O
(3 O
of O
whom O
has O
disappearance O
of O
their O
stones O
within O
3 O
weeks) O
, O
and O
remained O
depressed B-NEG
in O
3 O
(2 O
of O
whom O
had O
stones O
present O
at O
6 O
months) O
. O

our O
results O
suggest O
that O
the O
suppression O
of O
gallbladder O
contractility O
is O
the O
cause O
of O
the O
successive O
formation O
of O
bile O
sludge O
, O
gallstones B-NEG
, O
and O
cholecystitis B-NEG
during O
octreotide O
therapy O
in O
chinese O
acromegalic B-NEG
patients O
. O

it O
is O
therefore O
very O
important O
to O
follow O
the O
changes O
of O
gallbladder O
function O
during O
long-term O
octreotide O
therapy O
of O
acromegalic B-NEG
patients O
. O

-DOCSTART- O

improvement O
of O
levodopa-induced O
dyskinesia B-NEG
by O
propranolol O
in O
parkinson's B-NEG
disease I-NEG
. O

seven O
patients O
suffering O
from O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
with O
severely O
disabling O
dyskinesia B-NEG
received O
low-dose O
propranolol O
as O
an O
adjunct O
to O
the O
currently O
used O
medical O
treatment O
. O

there O
was O
a O
significant O
40% O
improvement O
in O
the O
dyskinesia B-NEG
score O
without O
increase O
of O
parkinsonian B-NEG
motor B-NEG
disability I-NEG
. O

ballistic O
and O
choreic O
dyskinesia B-NEG
were O
markedly O
ameliorated O
, O
whereas O
dystonia B-NEG
was O
not O
. O

this O
study O
suggests O
that O
administration O
of O
low O
doses O
of O
beta-blockers O
may O
improve O
levodopa-induced O
ballistic O
and O
choreic O
dyskinesia B-NEG
in O
pd B-NEG
. O

-DOCSTART- O

morphological O
features O
of O
encephalopathy B-NEG
after O
chronic O
administration O
of O
the O
antiepileptic O
drug O
valproate O
to O
rats O
. O

a O
transmission O
electron O
microscopic O
study O
of O
capillaries O
in O
the O
cerebellar O
cortex O
. O

long-term O
intragastric O
application O
of O
the O
antiepileptic O
drug O
sodium O
valproate O
( O
vupral O
polfa O
) O
at O
the O
effective O
dose O
of O
200 O
mg/kg O
b. O
w. O
once O
daily O
to O
rats O
for O
1, O
3, O
6, O
9 O
and O
12 O
months O
revealed O
neurological B-NEG
disorders I-NEG
indicating O
cerebellum B-NEG
damage I-NEG
( O
valproate O
encephalopathy B-NEG
). O

the O
first O
ultrastructural O
changes O
in O
structural O
elements O
of O
the O
blood-brain-barrier O
( O
bbb O
) O
in O
the O
cerebellar O
cortex O
were O
detectable O
after O
3 O
months O
of O
the O
experiment O
. O

they O
became O
more O
severe O
in O
the O
later O
months O
of O
the O
experiment O
, O
and O
were O
most O
severe O
after O
12 O
months O
, O
located O
mainly O
in O
the O
molecular O
layer O
of O
the O
cerebellar O
cortex O
. O

lesions O
of O
the O
capillary O
included O
necrosis B-NEG
of O
endothelial O
cells O
. O

organelles O
of O
these O
cells O
, O
in O
particular O
the O
mitochondria O
( O
increased O
number O
and O
size O
, O
distinct O
degeneration O
of O
their O
matrix O
and O
cristae O
) O
and O
golgi O
apparatus O
were O
altered O
. O

reduced O
size O
of O
capillary O
lumen O
and O
occlusion O
were O
caused O
by O
swollen O
endothelial O
cells O
which O
had O
luminal O
protrusions O
and O
swollen O
microvilli O
. O

pressure O
on O
the O
vessel O
wall O
was O
produced O
by O
enlarged O
perivascular O
astrocytic O
processes O
. O

fragments O
of O
necrotic B-NEG
endothelial O
cells O
were O
in O
the O
vascular O
lumens O
and O
in O
these O
there O
was O
loosening O
and O
breaking O
of O
tight O
cellular O
junctions O
. O

damage O
to O
the O
vascular O
basement O
lamina O
was O
also O
observed O
. O

damage O
to O
the O
capillary O
was O
accompanied O
by O
marked O
damage O
to O
neuroglial O
cells O
, O
mainly O
to O
perivascular O
processes O
of O
astrocytes O
. O

the O
proliferation O
of O
astrocytes O
( O
bergmann's O
in O
particular O
) O
and O
occasionally O
of O
oligodendrocytes O
was O
found O
. O

alterations O
in O
the O
structural O
elements O
of O
the O
bbb O
coexisted O
with O
marked O
lesions O
of O
neurons O
of O
the O
cerebellum O
( O
purkinje O
cells O
are O
earliest) O
. O

in O
electron O
micrographs O
both O
luminal O
and O
antiluminal O
sides O
of O
the O
bbb O
of O
the O
cerebellar O
cortex O
had O
similar O
lesions O
. O

the O
possible O
influence O
of O
the O
hepatic B-NEG
damage I-NEG
, O
mainly O
hyperammonemia B-NEG
, O
upon O
the O
development O
of O
valproate O
encephalopathy B-NEG
is O
discussed O
. O

-DOCSTART- O

macula O
toxicity B-NEG
after O
intravitreal O
amikacin O
. O

background O
: O
although O
intravitreal O
aminoglycosides O
have O
substantially O
improved O
visual O
prognosis O
in O
endophthalmitis B-NEG
, O
macular O
infarction B-NEG
may O
impair O
full O
visual O
recovery O
. O

methods O
: O
we O
present O
a O
case O
of O
presumed O
amikacin O
retinal B-NEG
toxicity I-NEG
following O
treatment O
with O
amikacin O
and O
vancomycin O
for O
alpha-haemolytic O
streptococcal B-NEG
endophthalmitis I-NEG
. O

results O
: O
endophthalmitis B-NEG
resolved O
with O
improvement O
in O
visual O
acuity O
to O
6/24 O
at O
three O
months O
. O

fundus O
fluorescein O
angiography O
confirmed O
macular O
capillary O
closure O
and O
telangiectasis B-NEG
. O

conclusions O
: O
currently O
accepted O
intravitreal O
antibiotic O
regimens O
may O
cause O
retinal B-NEG
toxicity I-NEG
and O
macular O
ischaemia B-NEG
. O

treatment O
strategies O
aimed O
at O
avoiding O
retinal B-NEG
toxicity I-NEG
are O
discussed O
. O

-DOCSTART- O

iatrogenically O
induced O
intractable O
atrioventricular B-NEG
reentrant I-NEG
tachycardia I-NEG
after O
verapamil O
and O
catheter O
ablation O
in O
a O
patient O
with O
wolff-parkinson-white B-NEG
syndrome I-NEG
and O
idiopathic B-NEG
dilated I-NEG
cardiomyopathy I-NEG
. O

in O
a O
patient O
with O
wpw B-NEG
syndrome I-NEG
and O
idiopathic B-NEG
dilated I-NEG
cardiomyopathy I-NEG
, O
intractable O
atrioventricular B-NEG
reentrant I-NEG
tachycardia I-NEG
( O
avrt B-NEG
) O
was O
iatrogenically O
induced O
. O

qrs O
without O
preexcitation O
, O
caused O
by O
junctional O
escape O
beats O
after O
verapamil O
or O
unidirectional O
antegrade O
block O
of O
accessory O
pathway O
after O
catheter O
ablation O
, O
established O
frequent O
avrt B-NEG
attack O
. O

-DOCSTART- O

epidemic O
of O
liver B-NEG
disease I-NEG
caused O
by O
hydrochlorofluorocarbons O
used O
as O
ozone-sparing O
substitutes O
of O
chlorofluorocarbons O
. O

background O
: O
hydrochlorofluorocarbons O
( O
hcfcs O
) O
are O
used O
increasingly O
in O
industry O
as O
substitutes O
for O
ozone-depleting O
chlorofluorocarbons O
(cfcs) O
. O

limited O
studies O
in O
animals O
indicate O
potential O
hepatotoxicity B-NEG
of O
some O
of O
these O
compounds O
. O

we O
investigated O
an O
epidemic O
of O
liver B-NEG
disease I-NEG
in O
nine O
industrial O
workers O
who O
had O
had O
repeated O
accidental O
exposure O
to O
a O
mixture O
of O
1,1-dichloro-2,2,2-trifluoroethane O
( O
hcfc O
123 O
) O
and O
1-chloro-1,2,2,2-tetrafluoroethane O
( O
hcfc O
124) O
. O

all O
nine O
exposed O
workers O
were O
affected O
to O
various O
degrees O
. O

both O
compounds O
are O
metabolised O
in O
the O
same O
way O
as O
1-bromo-1-chloro-2,2,2-trifluoroethane O
( O
halothane O
) O
to O
form O
reactive O
trifluoroacetyl O
halide O
intermediates O
, O
which O
have O
been O
implicated O
in O
the O
hepatotoxicity B-NEG
of O
halothane O
. O

we O
aimed O
to O
test O
whether O
hcfcs O
123 O
and O
124 O
can O
result O
in O
serious O
liver B-NEG
disease I-NEG
. O

methods O
: O
for O
one O
severely O
affected O
worker O
liver O
biopsy O
and O
immunohistochemical O
stainings O
for O
the O
presence O
of O
trifluoroacetyl O
protein O
adducts O
were O
done O
. O

the O
serum O
of O
six O
affected O
workers O
and O
five O
controls O
was O
tested O
for O
autoantibodies O
that O
react O
with O
human O
liver O
cytochrome-p450 O
2e1 O
( O
p450 O
2e1 O
) O
and O
p58 O
protein O
disulphide O
isomerase O
isoform O
(p58) O
. O

findings O
: O
the O
liver O
biopsy O
sample O
showed O
hepatocellular O
necrosis B-NEG
which O
was O
prominent O
in O
perivenular O
zone O
three O
and O
extended O
focally O
from O
portal O
tracts O
to O
portal O
tracts O
and O
centrilobular O
areas O
( O
bridging O
necrosis B-NEG
). O

trifluoroacetyl-adducted O
proteins O
were O
detected O
in O
surviving O
hepatocytes O
. O

autoantibodies O
against O
p450 O
2e1 O
or O
p58 O
, O
previously O
associated O
with O
halothane B-NEG
hepatitis I-NEG
, O
were O
detected O
in O
the O
serum O
of O
five O
affected O
workers O
. O

interpretation O
: O
repeated O
exposure O
of O
human O
beings O
to O
hcfcs O
123 O
and O
124 O
can O
result O
in O
serious O
liver B-NEG
injury I-NEG
in O
a O
large O
proportion O
of O
the O
exposed O
population O
. O

although O
the O
exact O
mechanism O
of O
hepatotoxicity B-NEG
of O
these O
agents O
is O
not O
known O
, O
the O
results O
suggest O
that O
trifluoroacetyl-altered O
liver O
proteins O
are O
involved O
. O

in O
view O
of O
the O
potentially O
widespread O
use O
of O
these O
compounds O
, O
there O
is O
an O
urgent O
need O
to O
develop O
safer O
alternatives O
. O

-DOCSTART- O

the O
effect O
of O
different O
anaesthetic O
agents O
in O
hearing B-NEG
loss I-NEG
following O
spinal O
anaesthesia O
. O

the O
cause O
of O
hearing B-NEG
loss I-NEG
after O
spinal O
anaesthesia O
is O
unknown O
. O

up O
until O
now O
, O
the O
only O
factor O
studied O
has O
been O
the O
effect O
of O
the O
diameter O
of O
the O
spinal O
needle O
on O
post-operative O
sensorineural B-NEG
hearing I-NEG
loss I-NEG
. O

the O
aim O
of O
this O
study O
was O
to O
describe O
this O
hearing B-NEG
loss I-NEG
and O
to O
investigate O
other O
factors O
influencing O
the O
degree O
of O
hearing B-NEG
loss I-NEG
. O

two O
groups O
of O
22 O
similar O
patients O
were O
studied O
: O
one O
group O
received O
6 O
ml O
prilocaine O
2% O
; O
and O
the O
other O
received O
3 O
ml O
bupivacaine O
0.5% O
. O

patients O
given O
prilocaine O
were O
more O
likely O
to O
develop O
hearing B-NEG
loss I-NEG
( O
10 O
out O
of O
22 O
) O
than O
those O
given O
bupivacaine O
(4 O
out O
of O
22 O
) O
(p O
< O
0.05) O
. O

the O
average O
hearing B-NEG
loss I-NEG
for O
speech O
frequencies O
was O
about O
10 O
db O
after O
prilocaine O
and O
15 O
db O
after O
bupivacaine O
. O

none O
of O
the O
patients O
complained O
of O
subjective O
hearing B-NEG
loss I-NEG
. O

long-term O
follow-up O
of O
the O
patients O
was O
not O
possible O
. O

-DOCSTART- O

a O
transient O
neurological B-NEG
deficit I-NEG
following O
intrathecal O
injection O
of O
1% O
hyperbaric O
bupivacaine O
for O
unilateral O
spinal O
anaesthesia O
. O

we O
describe O
a O
case O
of O
transient O
neurological B-NEG
deficit I-NEG
that O
occurred O
after O
unilateral O
spinal O
anaesthesia O
with O
8 O
mg O
of O
1% O
hyperbaric O
bupivacaine O
slowly O
injected O
through O
a O
25-gauge O
pencil-point O
spinal O
needle O
. O

the O
surgery O
and O
anaesthesia O
were O
uneventful O
, O
but O
3 O
days O
after O
surgery O
, O
the O
patient O
reported O
an O
area O
of O
hypoaesthesia O
over O
l3-l4 O
dermatomes O
of O
the O
leg O
which O
had O
been O
operated O
on O
( O
loss B-NEG
of I-NEG
pinprick I-NEG
sensation I-NEG
) O
without O
reduction O
in O
muscular O
strength O
. O

sensation O
in O
this O
area O
returned O
to O
normal O
over O
the O
following O
2 O
weeks O
. O

prospective O
multicentre O
studies O
with O
a O
large O
population O
and O
a O
long O
follow-up O
should O
be O
performed O
in O
order O
to O
evaluate O
the O
incidence O
of O
this O
unusual O
side O
effect O
. O

however O
, O
we O
suggest O
that O
a O
low O
solution O
concentration O
should O
be O
preferred O
for O
unilateral O
spinal O
anaesthesia O
with O
a O
hyperbaric O
anaesthetic O
solution O
( O
if O
pencil-point O
needle O
and O
slow O
injection O
rate O
are O
employed) O
, O
in O
order O
to O
minimize O
the O
risk O
of O
a O
localized O
high O
peak O
anaesthetic O
concentration O
, O
which O
might O
lead O
to O
a O
transient O
neurological B-NEG
deficit I-NEG
. O

-DOCSTART- O

pethidine-associated O
seizure B-NEG
in O
a O
healthy O
adolescent O
receiving O
pethidine O
for O
postoperative B-NEG
pain I-NEG
control O
. O

a O
healthy O
17-year-old O
male O
received O
standard O
intermittent O
doses O
of O
pethidine O
via O
a O
patient-controlled O
analgesia O
( O
pca O
) O
pump O
for O
management O
of O
postoperative B-NEG
pain I-NEG
control O
. O

twenty-three O
h O
postoperatively O
he O
developed O
a O
brief O
self-limited O
seizure B-NEG
. O

both O
plasma O
pethidine O
and O
norpethidine O
were O
elevated O
in O
the O
range O
associated O
with O
clinical O
manifestations O
of O
central O
nervous O
system O
excitation O
. O

no O
other O
risk O
factors O
for O
cns O
toxicity B-NEG
were O
identified O
. O

this O
method O
allowed O
frequent O
self-dosing O
of O
pethidine O
at O
short O
time O
intervals O
and O
rapid O
accumulation O
of O
pethidine O
and O
norpethidine O
. O

the O
routine O
use O
of O
pethidine O
via O
pca O
even O
for O
a O
brief O
postoperative O
analgesia O
should O
be O
reconsidered O
. O

-DOCSTART- O

drug-associated O
acute-onset O
vanishing B-NEG
bile I-NEG
duct I-NEG
and O
stevens-johnson B-NEG
syndromes I-NEG
in O
a O
child O
. O

acute O
vanishing B-NEG
bile I-NEG
duct I-NEG
syndrome O
is O
a O
rare O
but O
established O
cause O
of O
progressive O
cholestasis B-NEG
in O
adults O
, O
is O
most O
often O
drug O
or O
toxin O
related O
, O
and O
is O
of O
unknown O
pathogenesis O
. O

it O
has O
not O
been O
reported O
previously O
in O
children O
. O
stevens-johnson B-NEG
syndrome I-NEG
is O
a O
well-recognized O
immune O
complex-mediated O
hypersensitivity B-NEG
reaction O
that O
affects O
all O
age O
groups O
, O
is O
drug O
or O
infection B-NEG
induced O
, O
and O
has O
classic O
systemic O
, O
mucosal O
, O
and O
dermatologic O
manifestations O
. O

a O
previously O
healthy O
child O
who O
developed O
acute O
, O
severe O
, O
rapidly O
progressive O
vanishing B-NEG
bile I-NEG
duct I-NEG
syndrome I-NEG
shortly O
after O
stevens-johnson B-NEG
syndrome I-NEG
is O
described O
; O
this O
was O
temporally O
associated O
with O
ibuprofen O
use O
. O

despite O
therapy O
with O
ursodeoxycholic O
acid O
, O
prednisone O
, O
and O
then O
tacrolimus O
, O
her O
cholestatic B-NEG
disease I-NEG
was O
unrelenting O
, O
with O
cirrhosis B-NEG
shown O
by O
biopsy O
6 O
months O
after O
presentation O
. O

this O
case O
documents O
acute O
drug-related O
vanishing B-NEG
bile I-NEG
duct I-NEG
syndrome I-NEG
in O
the O
pediatric O
age O
group O
and O
suggests O
shared O
immune O
mechanisms O
in O
the O
pathogenesis O
of O
both O
stevens-johnson B-NEG
syndrome I-NEG
and O
vanishing B-NEG
bile I-NEG
duct I-NEG
syndrome I-NEG
. O

-DOCSTART- O

high O
incidence O
of O
primary B-NEG
pulmonary I-NEG
hypertension I-NEG
associated O
with O
appetite O
suppressants O
in O
belgium O
. O
primary B-NEG
pulmonary I-NEG
hypertension I-NEG
is O
a O
rare O
, O
progressive O
and O
incurable O
disease O
, O
which O
has O
been O
associated O
with O
the O
intake O
of O
appetite O
suppressant O
drugs O
. O

the O
importance O
of O
this O
association O
was O
evaluated O
in O
belgium O
while O
this O
country O
still O
had O
no O
restriction O
on O
the O
prescription O
of O
appetite O
suppressants O
. O

thirty-five O
patients O
with O
primary B-NEG
pulmonary I-NEG
hypertension I-NEG
and O
85 O
matched O
controls O
were O
recruited O
over O
32 O
months O
( O
1992-1994 O
) O
in O
belgium O
. O

exposure O
to O
appetite-suppressants O
was O
assessed O
on O
the O
basis O
of O
hospital O
records O
and O
standardized O
interview O
. O

twenty-three O
of O
the O
patients O
had O
previously O
taken O
appetite O
suppressants O
, O
mainly O
fenfluramines O
, O
as O
compared O
with O
only O
5 O
of O
the O
controls O
( O
66 O
versus O
6% O
, O
p<0.0001) O
. O

five O
patients O
died O
before O
the O
interview O
, O
all O
of O
them O
had O
taken O
appetite O
suppressants O
. O

in O
8 O
patients O
the O
diagnosis O
of O
primary B-NEG
pulmonary I-NEG
hypertension I-NEG
was O
uncertain O
, O
5 O
of O
them O
had O
taken O
appetite O
suppressants O
. O

the O
patients O
who O
had O
been O
exposed O
to O
appetite O
suppressants O
tended O
to O
be O
on O
average O
more O
severely O
ill O
, O
and O
to O
have O
a O
shorter O
median O
delay O
between O
onset O
of O
symptoms O
and O
diagnosis O
. O

a O
policy O
of O
unrestricted O
prescription O
of O
appetite O
suppressants O
may O
lead O
to O
a O
high O
incidence O
of O
associated O
primary B-NEG
pulmonary I-NEG
hypertension I-NEG
. O

intake O
of O
appetite O
suppressants O
may O
accelerate O
the O
progression O
of O
the O
disease O
. O

-DOCSTART- O

choreoathetoid B-NEG
movements I-NEG
associated O
with O
rapid O
adjustment O
to O
methadone O
. O
choreatiform B-NEG
hyperkinesias I-NEG
are O
known O
to O
be O
occasional O
movement B-NEG
abnormalities I-NEG
during O
intoxications O
with O
cocaine O
but O
not O
opiates O
. O

this O
is O
a O
case O
report O
of O
euphoria O
and O
choreoathetoid B-NEG
movements I-NEG
both O
transiently O
induced O
by O
rapid O
adjustment O
to O
the O
selective O
mu-opioid O
receptor O
agonist O
methadone O
in O
an O
inpatient O
previously O
abusing O
heroine O
and O
cocaine O
. O

in O
addition O
, O
minor O
eeg O
abnormalities O
occurred O
. O

possible O
underlying O
neurobiological O
phenomena O
are O
discussed O
. O

-DOCSTART- O

cocaine-induced O
mood B-NEG
disorder I-NEG
: O
prevalence O
rates O
and O
psychiatric B-NEG
symptoms O
in O
an O
outpatient O
cocaine-dependent O
sample O
. O

this O
paper O
attempts O
to O
examine O
and O
compare O
prevalence O
rates O
and O
symptom O
patterns O
of O
dsm O
substance-induced O
and O
other O
mood B-NEG
disorders I-NEG
. O

243 O
cocaine-dependent O
outpatients O
with O
cocaine-induced O
mood B-NEG
disorder I-NEG
( O
cimd B-NEG
), O
other O
mood B-NEG
disorders I-NEG
, O
or O
no O
mood B-NEG
disorder I-NEG
were O
compared O
on O
measures O
of O
psychiatric B-NEG
symptoms O
. O

the O
prevalence O
rate O
for O
cimd B-NEG
was O
12% O
at O
baseline O
. O

introduction O
of O
the O
dsm-iv O
diagnosis O
of O
cimd B-NEG
did O
not O
substantially O
affect O
rates O
of O
the O
other O
depressive B-NEG
disorders I-NEG
. O

patients O
with O
cimd B-NEG
had O
symptom O
severity O
levels O
between O
those O
of O
patients O
with O
and O
without O
a O
mood B-NEG
disorder I-NEG
. O

these O
findings O
suggest O
some O
validity O
for O
the O
new O
dsm-iv O
diagnosis O
of O
cimd B-NEG
, O
but O
also O
suggest O
that O
it O
requires O
further O
specification O
and O
replication O
. O

-DOCSTART- O

hemolysis B-NEG
of O
human O
erythrocytes O
induced O
by O
tamoxifen O
is O
related O
to O
disruption O
of O
membrane O
structure O
. O

tamoxifen O
(tam) O
, O
the O
antiestrogenic O
drug O
most O
widely O
prescribed O
in O
the O
chemotherapy O
of O
breast B-NEG
cancer I-NEG
, O
induces O
changes O
in O
normal O
discoid O
shape O
of O
erythrocytes O
and O
hemolytic B-NEG
anemia I-NEG
. O

this O
work O
evaluates O
the O
effects O
of O
tam O
on O
isolated O
human O
erythrocytes O
, O
attempting O
to O
identify O
the O
underlying O
mechanisms O
on O
tam-induced O
hemolytic B-NEG
anemia I-NEG
and O
the O
involvement O
of O
biomembranes O
in O
its O
cytostatic O
action O
mechanisms O
. O

tam O
induces O
hemolysis B-NEG
of O
erythrocytes O
as O
a O
function O
of O
concentration O
. O

the O
extension O
of O
hemolysis B-NEG
is O
variable O
with O
erythrocyte O
samples O
, O
but O
12.5 O
microm O
tam O
induces O
total O
hemolysis B-NEG
of O
all O
tested O
suspensions O
. O

despite O
inducing O
extensive O
erythrocyte O
lysis O
, O
tam O
does O
not O
shift O
the O
osmotic O
fragility O
curves O
of O
erythrocytes O
. O

the O
hemolytic B-NEG
effect O
of O
tam O
is O
prevented O
by O
low O
concentrations O
of O
alpha-tocopherol O
( O
alpha-t O
) O
and O
alpha-tocopherol O
acetate O
( O
alpha-tac O
) O
( O
inactivated O
functional O
hydroxyl O
) O
indicating O
that O
tam-induced O
hemolysis B-NEG
is O
not O
related O
to O
oxidative O
membrane O
damage O
. O

this O
was O
further O
evidenced O
by O
absence O
of O
oxygen O
consumption O
and O
hemoglobin O
oxidation O
both O
determined O
in O
parallel O
with O
tam-induced O
hemolysis B-NEG
. O

furthermore O
, O
it O
was O
observed O
that O
tam O
inhibits O
the O
peroxidation O
of O
human O
erythrocytes O
induced O
by O
aaph O
, O
thus O
ruling O
out O
tam-induced O
cell O
oxidative O
stress O
. O
hemolysis B-NEG
caused O
by O
tam O
was O
not O
preceded O
by O
the O
leakage O
of O
k(+ O
) O
from O
the O
cells O
, O
also O
excluding O
a O
colloid-osmotic O
type O
mechanism O
of O
hemolysis B-NEG
, O
according O
to O
the O
effects O
on O
osmotic O
fragility O
curves O
. O

however O
, O
tam O
induces O
release O
of O
peripheral O
proteins O
of O
membrane-cytoskeleton O
and O
cytosol O
proteins O
essentially O
bound O
to O
band O
3. O

either O
alpha-t O
or O
alpha-tac O
increases O
membrane O
packing O
and O
prevents O
tam O
partition O
into O
model O
membranes O
. O

these O
effects O
suggest O
that O
the O
protection O
from O
hemolysis B-NEG
by O
tocopherols O
is O
related O
to O
a O
decreased O
tam O
incorporation O
in O
condensed O
membranes O
and O
the O
structural O
damage O
of O
the O
erythrocyte O
membrane O
is O
consequently O
avoided O
. O

therefore O
, O
tam-induced O
hemolysis B-NEG
results O
from O
a O
structural O
perturbation O
of O
red O
cell O
membrane O
, O
leading O
to O
changes O
in O
the O
framework O
of O
the O
erythrocyte O
membrane O
and O
its O
cytoskeleton O
caused O
by O
its O
high O
partition O
in O
the O
membrane O
. O

these O
defects O
explain O
the O
abnormal O
erythrocyte O
shape O
and O
decreased O
mechanical O
stability O
promoted O
by O
tam O
, O
resulting O
in O
hemolytic B-NEG
anemia I-NEG
. O

additionally O
, O
since O
membrane O
leakage O
is O
a O
final O
stage O
of O
cytotoxicity O
, O
the O
disruption O
of O
the O
structural O
characteristics O
of O
biomembranes O
by O
tam O
may O
contribute O
to O
the O
multiple O
mechanisms O
of O
its O
anticancer O
action O
. O

-DOCSTART- O

changes O
of O
sodium O
and O
atp O
affinities O
of O
the O
cardiac O
( O
na,k)-atpase O
during O
and O
after O
nitric O
oxide O
deficient O
hypertension B-NEG
. O

in O
the O
cardiovascular O
system O
, O
no O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
functions O
. O

inhibition O
of O
no O
synthesis O
induces O
sustained O
hypertension B-NEG
. O

in O
several O
models O
of O
hypertension B-NEG
, O
elevation O
of O
intracellular O
sodium O
level O
was O
documented O
in O
cardiac O
tissue O
. O

to O
assess O
the O
molecular O
basis O
of O
disturbances O
in O
transmembraneous O
transport O
of O
na+ O
, O
we O
studied O
the O
response O
of O
cardiac O
( O
na,k)-atpase O
to O
no-deficient O
hypertension B-NEG
induced O
in O
rats O
by O
no-synthase O
inhibition O
with O
40 O
mg/kg/day O
n(g)-nitro-l-arginine O
methyl O
ester O
( O
l-name O
) O
for O
4 O
four O
weeks O
. O

after O
4-week O
administration O
of O
l-name O
, O
the O
systolic O
blood O
pressure O
( O
sbp O
) O
increased O
by O
36% O
. O

two O
weeks O
after O
terminating O
the O
treatment O
, O
the O
sbp O
recovered O
to O
control O
value O
. O

when O
activating O
the O
( O
na,k)-atpase O
with O
its O
substrate O
atp O
, O
no O
changes O
in O
km O
and O
vmax O
values O
were O
observed O
in O
no-deficient O
rats O
. O

during O
activation O
with O
na+ O
, O
the O
vmax O
remained O
unchanged O
, O
however O
the O
k(na O
) O
increased O
by O
50% O
, O
indicating O
a O
profound O
decrease O
in O
the O
affinity O
of O
the O
na+-binding O
site O
in O
no-deficient O
rats O
. O

after O
recovery O
from O
hypertension B-NEG
, O
the O
activity O
of O
( O
na,k)-atpase O
increased O
, O
due O
to O
higher O
affinity O
of O
the O
atp-binding O
site O
, O
as O
revealed O
from O
the O
lowered O
km O
value O
for O
atp O
. O

the O
k(na O
) O
value O
for O
na+ O
returned O
to O
control O
value O
. O

inhibition O
of O
no-synthase O
induced O
a O
reversible O
hypertension B-NEG
accompanied O
by O
depressed B-NEG
na+-extrusion O
from O
cardiac O
cells O
as O
a O
consequence O
of O
deteriorated O
na+-binding O
properties O
of O
the O
(na,k)-atpase O
. O

after O
recovery O
of O
blood O
pressure O
to O
control O
values O
, O
the O
extrusion O
of O
na+ O
from O
cardiac O
cells O
was O
normalized O
, O
as O
revealed O
by O
restoration O
of O
the O
( O
na,k)-atpase O
activity O
. O

-DOCSTART- O

effects O
of O
long-term O
pretreatment O
with O
isoproterenol O
on O
bromocriptine-induced O
tachycardia B-NEG
in O
conscious O
rats O
. O

it O
has O
been O
shown O
that O
bromocriptine-induced O
tachycardia B-NEG
, O
which O
persisted O
after O
adrenalectomy O
, O
is O
( O
i O
) O
mediated O
by O
central O
dopamine O
d2 O
receptor O
activation O
and O
( O
ii O
) O
reduced O
by O
5-day O
isoproterenol O
pretreatment O
, O
supporting O
therefore O
the O
hypothesis O
that O
this O
effect O
is O
dependent O
on O
sympathetic O
outflow O
to O
the O
heart O
. O

this O
study O
was O
conducted O
to O
examine O
whether O
prolonged O
pretreatment O
with O
isoproterenol O
could O
abolish O
bromocriptine-induced O
tachycardia B-NEG
in O
conscious O
rats O
. O

isoproterenol O
pretreatment O
for O
15 O
days O
caused O
cardiac B-NEG
hypertrophy I-NEG
without O
affecting O
baseline O
blood O
pressure O
and O
heart O
rate O
. O

in O
control O
rats O
, O
intravenous O
bromocriptine O
( O
150 O
microg/kg O
) O
induced O
significant O
hypotension B-NEG
and O
tachycardia B-NEG
. O

bromocriptine-induced O
hypotension B-NEG
was O
unaffected O
by O
isoproterenol O
pretreatment O
, O
while O
tachycardia B-NEG
was O
reversed O
to O
significant O
bradycardia B-NEG
, O
an O
effect O
that O
was O
partly O
reduced O
by O
i.v O
. O
domperidone O
( O
0.5 O
mg/kg) O
. O

neither O
cardiac O
vagal O
nor O
sympathetic O
tone O
was O
altered O
by O
isoproterenol O
pretreatment O
. O

in O
isolated O
perfused O
heart O
preparations O
from O
isoproterenol-pretreated O
rats O
, O
the O
isoproterenol-induced O
maximal O
increase O
in O
left O
ventricular O
systolic O
pressure O
was O
significantly O
reduced O
, O
compared O
with O
saline-pretreated O
rats O
( O
the O
ec50 O
of O
the O
isoproterenol-induced O
increase O
in O
left O
ventricular O
systolic O
pressure O
was O
enhanced O
approximately O
22-fold) O
. O

these O
results O
show O
that O
15-day O
isoproterenol O
pretreatment O
not O
only O
abolished O
but O
reversed O
bromocriptine-induced O
tachycardia B-NEG
to O
bradycardia B-NEG
, O
an O
effect O
that O
is O
mainly O
related O
to O
further O
cardiac O
beta-adrenoceptor O
desensitization O
rather O
than O
to O
impairment O
of O
autonomic O
regulation O
of O
the O
heart O
. O

they O
suggest O
that O
, O
in O
normal O
conscious O
rats O
, O
the O
central O
tachycardia B-NEG
of O
bromocriptine O
appears O
to O
predominate O
and O
to O
mask O
the O
bradycardia B-NEG
of O
this O
agonist O
at O
peripheral O
dopamine O
d2 O
receptors O
. O

-DOCSTART- O

a O
developmental O
analysis O
of O
clonidine's O
effects O
on O
cardiac O
rate O
and O
ultrasound O
production O
in O
infant O
rats O
. O

under O
controlled O
conditions O
, O
infant O
rats O
emit O
ultrasonic O
vocalizations O
during O
extreme O
cold O
exposure O
and O
after O
administration O
of O
the O
alpha(2 O
) O
adrenoceptor O
agonist O
, O
clonidine O
. O

previous O
investigations O
have O
determined O
that O
, O
in O
response O
to O
clonidine O
, O
ultrasound O
production O
increases O
through O
the O
2nd-week O
postpartum O
and O
decreases O
thereafter O
. O

given O
that O
sympathetic O
neural O
dominance O
exhibits O
a O
similar O
developmental O
pattern O
, O
and O
given O
that O
clonidine O
induces O
sympathetic O
withdrawal O
and O
bradycardia B-NEG
, O
we O
hypothesized O
that O
clonidine's O
developmental O
effects O
on O
cardiac O
rate O
and O
ultrasound O
production O
would O
mirror O
each O
other O
. O

therefore O
, O
in O
the O
present O
experiment O
, O
the O
effects O
of O
clonidine O
administration O
( O
0.5 O
mg/kg O
) O
on O
cardiac O
rate O
and O
ultrasound O
production O
were O
examined O
in O
2- O
, O
8- O
, O
15- O
, O
and O
20-day-old O
rats O
. O

age-related O
changes O
in O
ultrasound O
production O
corresponded O
with O
changes O
in O
cardiovascular O
variables O
, O
including O
baseline O
cardiac O
rate O
and O
clonidine-induced O
bradycardia B-NEG
. O

this O
experiment O
is O
discussed O
with O
regard O
to O
the O
hypothesis O
that O
ultrasound O
production O
is O
the O
acoustic O
by-product O
of O
a O
physiological O
maneuver O
that O
compensates O
for O
clonidine's O
detrimental O
effects O
on O
cardiovascular O
function O
. O

-DOCSTART- O

differential O
effects O
of O
systemically O
administered O
ketamine O
and O
lidocaine O
on O
dynamic O
and O
static O
hyperalgesia B-NEG
induced O
by O
intradermal O
capsaicin O
in O
humans O
. O

we O
have O
examined O
the O
effect O
of O
systemic O
administration O
of O
ketamine O
and O
lidocaine O
on O
brush-evoked O
( O
dynamic O
) O
pain B-NEG
and O
punctate-evoked O
( O
static O
) O
hyperalgesia B-NEG
induced O
by O
capsaicin O
. O

in O
a O
randomized O
, O
double-blind O
, O
placebo-controlled O
, O
crossover O
study O
, O
we O
studied O
12 O
volunteers O
in O
three O
experiments O
. O

capsaicin O
100 O
micrograms O
was O
injected O
intradermally O
on O
the O
volar O
forearm O
followed O
by O
an O
i.v O
. O
infusion O
of O
ketamine O
( O
bolus O
0.1 O
mg O
kg-1 O
over O
10 O
min O
followed O
by O
infusion O
of O
7 O
micrograms O
kg-1 O
min-1) O
, O
lidocaine O
5 O
mg O
kg-1 O
or O
saline O
for O
50 O
min O
. O

infusion O
started O
15 O
min O
after O
injection O
of O
capsaicin O
. O

the O
following O
were O
measured O
: O
spontaneous O
pain B-NEG
, O
pain B-NEG
evoked O
by O
punctate O
and O
brush O
stimuli O
(vas) O
, O
and O
areas O
of O
brush-evoked O
and O
punctate-evoked O
hyperalgesia B-NEG
. O

ketamine O
reduced O
both O
the O
area O
of O
brush-evoked O
and O
punctate-evoked O
hyperalgesia B-NEG
significantly O
and O
it O
tended O
to O
reduce O
brush-evoked O
pain B-NEG
. O

lidocaine O
reduced O
the O
area O
of O
punctate-evoked O
hyperalgesia B-NEG
significantly O
. O

it O
tended O
to O
reduce O
vas O
scores O
of O
spontaneous O
pain B-NEG
but O
had O
no O
effect O
on O
evoked O
pain B-NEG
. O

the O
differential O
effects O
of O
ketamine O
and O
lidocaine O
on O
static O
and O
dynamic O
hyperalgesia B-NEG
suggest O
that O
the O
two O
types O
of O
hyperalgesia B-NEG
are O
mediated O
by O
separate O
mechanisms O
and O
have O
a O
distinct O
pharmacology O
. O

-DOCSTART- O

cyclosporine O
and O
tacrolimus-associated O
thrombotic B-NEG
microangiopathy I-NEG
. O

the O
development O
of O
thrombotic B-NEG
microangiopathy I-NEG
( O
tma B-NEG
) O
associated O
with O
the O
use O
of O
cyclosporine O
has O
been O
well O
documented O
. O

treatments O
have O
included O
discontinuation O
or O
reduction O
of O
cyclosporine O
dose O
with O
or O
without O
concurrent O
plasma O
exchange O
, O
plasma O
infusion O
, O
anticoagulation O
, O
and O
intravenous O
immunoglobulin O
g O
infusion O
. O

however O
, O
for O
recipients O
of O
organ O
transplantation O
, O
removing O
the O
inciting O
agent O
is O
not O
without O
the O
attendant O
risk O
of O
precipitating O
acute O
rejection O
and O
graft O
loss O
. O

the O
last O
decade O
has O
seen O
the O
emergence O
of O
tacrolimus O
as O
a O
potent O
immunosuppressive O
agent O
with O
mechanisms O
of O
action O
virtually O
identical O
to O
those O
of O
cyclosporine O
. O

as O
a O
result O
, O
switching O
to O
tacrolimus O
has O
been O
reported O
to O
be O
a O
viable O
therapeutic O
option O
in O
the O
setting O
of O
cyclosporine-induced O
tma B-NEG
. O

with O
the O
more O
widespread O
application O
of O
tacrolimus O
in O
organ O
transplantation O
, O
tacrolimus-associated O
tma B-NEG
has O
also O
been O
recognized O
. O

however O
, O
literature O
regarding O
the O
incidence O
of O
the O
recurrence O
of O
tma B-NEG
in O
patients O
exposed O
sequentially O
to O
cyclosporine O
and O
tacrolimus O
is O
limited O
. O

we O
report O
a O
case O
of O
a O
living O
donor O
renal O
transplant O
recipient O
who O
developed O
cyclosporine-induced O
tma B-NEG
that O
responded O
to O
the O
withdrawal O
of O
cyclosporine O
in O
conjunction O
with O
plasmapheresis O
and O
fresh O
frozen O
plasma O
replacement O
therapy O
. O

introduction O
of O
tacrolimus O
as O
an O
alternative O
immunosuppressive O
agent O
resulted O
in O
the O
recurrence O
of O
tma B-NEG
and O
the O
subsequent O
loss O
of O
the O
renal O
allograft O
. O

patients O
who O
are O
switched O
from O
cyclosporine O
to O
tacrolimus O
or O
vice O
versa O
should O
be O
closely O
monitored O
for O
the O
signs O
and O
symptoms O
of O
recurrent O
tma B-NEG
. O

-DOCSTART- O

repeated O
transient O
anuria B-NEG
following O
losartan O
administration O
in O
a O
patient O
with O
a O
solitary O
kidney O
. O

we O
report O
the O
case O
of O
a O
70-year-old O
hypertensive B-NEG
man O
with O
a O
solitary O
kidney O
and O
chronic B-NEG
renal I-NEG
insufficiency I-NEG
who O
developed O
two O
episodes O
of O
transient O
anuria B-NEG
after O
losartan O
administration O
. O

he O
was O
hospitalized O
for O
a O
myocardial B-NEG
infarction I-NEG
with O
pulmonary B-NEG
edema I-NEG
, O
treated O
with O
high-dose O
diuretics O
. O

due O
to O
severe O
systolic B-NEG
dysfunction I-NEG
losartan O
was O
prescribed O
. O

surprisingly O
, O
the O
first O
dose O
of O
50 O
mg O
of O
losartan O
resulted O
in O
a O
sudden O
anuria B-NEG
, O
which O
lasted O
eight O
hours O
despite O
high-dose O
furosemide O
and O
amine O
infusion O
. O

one O
week O
later O
, O
by O
mistake O
, O
losartan O
was O
prescribed O
again O
and O
after O
the O
second O
dose O
of O
50 O
mg O
, O
the O
patient O
developed O
a O
second O
episode O
of O
transient O
anuria B-NEG
lasting O
10 O
hours O
. O

during O
these O
two O
episodes O
, O
his O
blood O
pressure O
diminished O
but O
no O
severe O
hypotension B-NEG
was O
noted O
. O

ultimately O
, O
an O
arteriography O
showed O
a O
70-80% O
renal B-NEG
artery I-NEG
stenosis I-NEG
. O

in O
this O
patient O
, O
renal B-NEG
artery I-NEG
stenosis I-NEG
combined O
with O
heart B-NEG
failure I-NEG
and O
diuretic O
therapy O
certainly O
resulted O
in O
a O
strong O
activation O
of O
the O
renin-angiotensin O
system O
(ras) O
. O

under O
such O
conditions O
, O
angiotensin O
ii O
receptor O
blockade O
by O
losartan O
probably O
induced O
a O
critical O
fall O
in O
glomerular O
filtration O
pressure O
. O

this O
case O
report O
highlights O
the O
fact O
that O
the O
angiotensin O
ii O
receptor O
antagonist O
losartan O
can O
cause O
serious O
unexpected O
complications O
in O
patients O
with O
renovascular B-NEG
disease I-NEG
and O
should O
be O
used O
with O
extreme O
caution O
in O
this O
setting O
. O

-DOCSTART- O

in O
vivo O
protection O
of O
dna O
damage O
associated O
apoptotic O
and O
necrotic B-NEG
cell O
deaths O
during O
acetaminophen-induced O
nephrotoxicity B-NEG
, O
amiodarone-induced O
lung B-NEG
toxicity I-NEG
and O
doxorubicin-induced O
cardiotoxicity B-NEG
by O
a O
novel O
ih636 O
grape O
seed O
proanthocyanidin O
extract O
. O

grape O
seed O
extract O
, O
primarily O
a O
mixture O
of O
proanthocyanidins O
, O
has O
been O
shown O
to O
modulate O
a O
wide-range O
of O
biological O
, O
pharmacological O
and O
toxicological O
effects O
which O
are O
mainly O
cytoprotective O
. O

this O
study O
assessed O
the O
ability O
of O
ih636 O
grape O
seed O
proanthocyanidin O
extract O
( O
gspe O
) O
to O
prevent O
acetaminophen O
( O
aap)-induced O
nephrotoxicity B-NEG
, O
amiodarone O
( O
ami)-induced O
lung B-NEG
toxicity I-NEG
, O
and O
doxorubicin O
( O
dox)-induced O
cardiotoxicity B-NEG
in O
mice O
. O

experimental O
design O
consisted O
of O
four O
groups O
: O
control O
( O
vehicle O
alone) O
, O
gspe O
alone O
, O
drug O
alone O
and O
gspe+drug O
. O

for O
the O
cytoprotection O
study O
, O
animals O
were O
orally O
gavaged O
100 O
mg/kg O
gspe O
for O
7-10 O
days O
followed O
by O
i.p O
. O
injections O
of O
organ O
specific O
three O
drugs O
(aap O
: O
500 O
mg/kg O
for O
24 O
h; O
ami O
: O
50 O
mg/kg/day O
for O
four O
days O
; O
dox O
: O
20 O
mg/kg O
for O
48 O
h) O
. O

parameters O
of O
study O
included O
analysis O
of O
serum O
chemistry O
(alt O
, O
bun O
and O
cpk) O
, O
and O
orderly O
fragmentation O
of O
genomic O
dna O
( O
both O
endonuclease-dependent O
and O
independent O
) O
in O
addition O
to O
microscopic O
evaluation O
of O
damage O
and/or O
protection O
in O
corresponding O
pas O
stained O
tissues O
. O

results O
indicate O
that O
gspe O
preexposure O
prior O
to O
aap O
, O
ami O
and O
dox O
, O
provided O
near O
complete O
protection O
in O
terms O
of O
serum O
chemistry O
changes O
(alt O
, O
bun O
and O
cpk) O
, O
and O
significantly O
reduced O
dna O
fragmentation O
. O

histopathological O
examination O
of O
kidney O
, O
heart O
and O
lung O
sections O
revealed O
moderate O
to O
massive O
tissue B-NEG
damage I-NEG
with O
a O
variety O
of O
morphological O
aberrations O
by O
all O
the O
three O
drugs O
in O
the O
absence O
of O
gspe O
preexposure O
than O
in O
its O
presence O
. O

gspe+drug O
exposed O
tissues O
exhibited O
minor O
residual O
damage O
or O
near O
total O
recovery O
. O

additionally O
, O
histopathological O
alterations O
mirrored O
both O
serum O
chemistry O
changes O
and O
the O
pattern O
of O
dna O
fragmentation O
. O

interestingly O
, O
all O
the O
drugs O
, O
such O
as O
, O
aap O
, O
ami O
and O
dox O
induced O
apoptotic O
death O
in O
addition O
to O
necrosis B-NEG
in O
the O
respective O
organs O
which O
was O
very O
effectively O
blocked O
by O
gspe O
. O

since O
aap O
, O
ami O
and O
dox O
undergo O
biotransformation O
and O
are O
known O
to O
produce O
damaging O
radicals O
in O
vivo O
, O
the O
protection O
by O
gspe O
may O
be O
linked O
to O
both O
inhibition O
of O
metabolism O
and/or O
detoxification O
of O
cytotoxic O
radicals O
. O

in O
addition O
, O
its' O
presumed O
contribution O
to O
dna O
repair O
may O
be O
another O
important O
attribute O
, O
which O
played O
a O
role O
in O
the O
chemoprevention O
process O
. O

additionally O
, O
this O
may O
have O
been O
the O
first O
report O
on O
ami-induced O
apoptotic O
death O
in O
the O
lung O
tissue O
. O

taken O
together O
, O
these O
events O
undoubtedly O
establish O
gspe's O
abundant O
bioavailability O
, O
and O
the O
power O
to O
defend O
multiple O
target O
organs O
from O
toxic O
assaults O
induced O
by O
structurally O
diverse O
and O
functionally O
different O
entities O
in O
vivo O
. O

-DOCSTART- O

palpebral B-NEG
twitching I-NEG
in O
a O
depressed B-NEG
adolescent O
on O
citalopram O
. O

current O
estimates O
suggest O
that O
between O
0.4% O
and O
8.3% O
of O
children O
and O
adolescents O
are O
affected O
by O
major B-NEG
depression I-NEG
. O

we O
report O
a O
favorable O
response O
to O
treatment O
with O
citalopram O
by O
a O
15-year-old O
boy O
with O
major B-NEG
depression I-NEG
who O
exhibited O
palpebral B-NEG
twitching I-NEG
during O
his O
first O
2 O
weeks O
of O
treatment O
. O

this O
may O
have O
been O
a O
side O
effect O
of O
citalopram O
as O
it O
remitted O
with O
redistribution O
of O
doses O
. O

-DOCSTART- O

metamizol O
potentiates O
morphine O
antinociception O
but O
not O
constipation B-NEG
after O
chronic O
treatment O
. O

this O
work O
evaluates O
the O
antinociceptive O
and O
constipating B-NEG
effects O
of O
the O
combination O
of O
3.2 O
mg/kg O
s.c O
. O
morphine O
with O
177.8 O
mg/kg O
s.c O
. O
metamizol O
in O
acutely O
and O
chronically O
treated O
( O
once O
a O
day O
for O
12 O
days O
) O
rats O
. O

on O
the O
13th O
day O
, O
antinociceptive O
effects O
were O
assessed O
using O
a O
model O
of O
inflammatory O
nociception O
, O
pain B-NEG
-induced O
functional O
impairment O
model O
, O
and O
the O
charcoal O
meal O
test O
was O
used O
to O
evaluate O
the O
intestinal O
transit O
. O

simultaneous O
administration O
of O
morphine O
with O
metamizol O
resulted O
in O
a O
markedly O
antinociceptive O
potentiation O
and O
an O
increasing O
of O
the O
duration O
of O
action O
after O
a O
single O
( O
298+/-7 O
vs O
. O
139+/-36 O
units O
area O
(ua) O
; O
p<0.001 O
) O
and O
repeated O
administration O
( O
280+/-17 O
vs O
. O
131+/-22 O
ua O
; O
p<0.001) O
. O

antinociceptive O
effect O
of O
morphine O
was O
reduced O
in O
chronically O
treated O
rats O
( O
39+/-10 O
vs O
. O
18+/-5 O
au O
) O
while O
the O
combination-induced O
antinociception O
was O
remained O
similar O
as O
an O
acute O
treatment O
( O
298+/-7 O
vs O
. O
280+/-17 O
au) O
. O

acute O
antinociceptive O
effects O
of O
the O
combination O
were O
partially O
prevented O
by O
3.2 O
mg/kg O
naloxone O
s.c O
. O

(p<0.05) O
, O
suggesting O
the O
partial O
involvement O
of O
the O
opioidergic O
system O
in O
the O
synergism O
observed O
. O

in O
independent O
groups O
, O
morphine O
inhibited O
the O
intestinal O
transit O
in O
48+/-4% O
and O
38+/-4% O
after O
acute O
and O
chronic O
treatment O
, O
respectively O
, O
suggesting O
that O
tolerance O
did O
not O
develop O
to O
the O
constipating B-NEG
effects O
. O

the O
combination O
inhibited O
intestinal O
transit O
similar O
to O
that O
produced O
by O
morphine O
regardless O
of O
the O
time O
of O
treatment O
, O
suggesting O
that O
metamizol O
did O
not O
potentiate O
morphine-induced O
constipation B-NEG
. O

these O
findings O
show O
a O
significant O
interaction O
between O
morphine O
and O
metamizol O
in O
chronically O
treated O
rats O
, O
suggesting O
that O
this O
combination O
could O
be O
useful O
for O
the O
treatment O
of O
chronic B-NEG
pain I-NEG
. O

-DOCSTART- O

ifosfamide O
encephalopathy B-NEG
presenting O
with O
asterixis B-NEG
. O

cns O
toxic O
effects O
of O
the O
antineoplastic O
agent O
ifosfamide O
( O
ifx O
) O
are O
frequent O
and O
include O
a O
variety O
of O
neurological O
symptoms O
that O
can O
limit O
drug O
use O
. O

we O
report O
a O
case O
of O
a O
51-year-old O
man O
who O
developed O
severe O
, O
disabling O
negative O
myoclonus B-NEG
of O
the O
upper O
and O
lower O
extremities O
after O
the O
infusion O
of O
ifosfamide O
for O
plasmacytoma B-NEG
. O

he O
was O
awake O
, O
revealed O
no O
changes O
of O
mental O
status O
and O
at O
rest O
there O
were O
no O
further O
motor O
symptoms O
. O

cranial O
magnetic O
resonance O
imaging O
and O
extensive O
laboratory O
studies O
failed O
to O
reveal O
structural B-NEG
lesions I-NEG
of I-NEG
the I-NEG
brain I-NEG
and O
metabolic B-NEG
abnormalities I-NEG
. O

an O
electroencephalogram O
showed O
continuous O
, O
generalized O
irregular O
slowing O
with O
admixed O
periodic O
triphasic O
waves O
indicating O
symptomatic O
encephalopathy B-NEG
. O

the O
administration O
of O
ifosfamide O
was O
discontinued O
and O
within O
12 O
h O
the O
asterixis B-NEG
resolved O
completely O
. O

in O
the O
patient O
described O
, O
the O
presence O
of O
asterixis B-NEG
during O
infusion O
of O
ifosfamide O
, O
normal O
laboratory O
findings O
and O
imaging O
studies O
and O
the O
resolution O
of O
symptoms O
following O
the O
discontinuation O
of O
the O
drug O
suggest O
that O
negative O
myoclonus B-NEG
is O
associated O
with O
the O
use O
of O
ifx O
. O

-DOCSTART- O

sub-chronic O
low O
dose O
gamma-vinyl O
gaba O
( O
vigabatrin O
) O
inhibits O
cocaine-induced O
increases O
in O
nucleus O
accumbens O
dopamine O
. O

rationale O
: O
gamma-vinyl O
gaba O
( O
gvg O
) O
irreversibly O
inhibits O
gaba-transaminase O
. O

this O
non-receptor O
mediated O
inhibition O
requires O
de O
novo O
synthesis O
for O
restoration O
of O
functional O
gaba O
catabolism O
. O

objectives O
: O
given O
its O
preclinical O
success O
for O
treating O
substance B-NEG
abuse I-NEG
and O
the O
increased O
risk O
of O
visual B-NEG
field I-NEG
defects I-NEG
( O
vfd B-NEG
) O
associated O
with O
cumulative O
lifetime O
exposure O
, O
we O
explored O
the O
effects O
of O
sub-chronic O
low O
dose O
gvg O
on O
cocaine-induced O
increases O
in O
nucleus O
accumbens O
( O
nacc O
) O
dopamine O
(da) O
. O

methods O
: O
using O
in O
vivo O
microdialysis O
, O
we O
compared O
acute O
exposure O
( O
450 O
mg/kg O
) O
to O
an O
identical O
sub-chronic O
exposure O
( O
150 O
mg/kg O
per O
day O
for O
3 O
days) O
, O
followed O
by O
1- O
or O
3-day O
washout O
. O

finally O
, O
we O
examined O
the O
low O
dose O
of O
150 O
mg/kg O
( O
50 O
mg/kg O
per O
day O
) O
using O
a O
similar O
washout O
period O
. O

results O
: O
sub-chronic O
gvg O
exposure O
inhibited O
the O
effect O
of O
cocaine O
for O
3 O
days O
, O
which O
exceeded O
in O
magnitude O
and O
duration O
the O
identical O
acute O
dose O
. O

conclusions O
: O
sub-chronic O
low O
dose O
gvg O
potentiates O
and O
extends O
the O
inhibition O
of O
cocaine-induced O
increases O
in O
dopamine O
, O
effectively O
reducing O
cumulative O
exposures O
and O
the O
risk O
for O
vfds O
. O

-DOCSTART- O

amount O
of O
bleeding B-NEG
and O
hematoma B-NEG
size O
in O
the O
collagenase-induced O
intracerebral B-NEG
hemorrhage I-NEG
rat O
model O
. O

the O
aggravated O
risk O
on O
intracerebral B-NEG
hemorrhage I-NEG
( O
ich B-NEG
) O
with O
drugs O
used O
for O
stroke B-NEG
patients O
should O
be O
estimated O
carefully O
. O

we O
therefore O
established O
sensitive O
quantification O
methods O
and O
provided O
a O
rat O
ich B-NEG
model O
for O
detection O
of O
ich B-NEG
deterioration O
. O

in O
ich B-NEG
intrastriatally O
induced O
by O
0.014-unit O
, O
0.070-unit O
, O
and O
0.350-unit O
collagenase O
, O
the O
amount O
of O
bleeding B-NEG
was O
measured O
using O
a O
hemoglobin O
assay O
developed O
in O
the O
present O
study O
and O
was O
compared O
with O
the O
morphologically O
determined O
hematoma B-NEG
volume O
. O

the O
blood O
amounts O
and O
hematoma B-NEG
volumes O
were O
significantly O
correlated O
, O
and O
the O
hematoma B-NEG
induced O
by O
0.014-unit O
collagenase O
was O
adequate O
to O
detect O
ich B-NEG
deterioration O
. O

in O
ich B-NEG
induction O
using O
0.014-unit O
collagenase O
, O
heparin O
enhanced O
the O
hematoma B-NEG
volume O
3.4-fold O
over O
that O
seen O
in O
control O
ich B-NEG
animals O
and O
the O
bleeding B-NEG
7.6-fold O
. O

data O
suggest O
that O
this O
sensitive O
hemoglobin O
assay O
is O
useful O
for O
ich B-NEG
detection O
, O
and O
that O
a O
model O
with O
a O
small O
ich B-NEG
induced O
with O
a O
low-dose O
collagenase O
should O
be O
used O
for O
evaluation O
of O
drugs O
that O
may O
affect O
ich B-NEG
. O

-DOCSTART- O

estradiol O
reduces O
seizure B-NEG
-induced O
hippocampal B-NEG
injury I-NEG
in O
ovariectomized O
female O
but O
not O
in O
male O
rats O
. O

estrogens O
protect O
ovariectomized O
rats O
from O
hippocampal B-NEG
injury I-NEG
induced O
by O
kainic O
acid-induced O
status B-NEG
epilepticus I-NEG
( O
se B-NEG
). O

we O
compared O
the O
effects O
of O
17beta-estradiol O
in O
adult O
male O
and O
ovariectomized O
female O
rats O
subjected O
to O
lithium-pilocarpine-induced O
se B-NEG
. O

rats O
received O
subcutaneous O
injections O
of O
17beta-estradiol O
(2 O
microg/rat O
) O
or O
oil O
once O
daily O
for O
four O
consecutive O
days O
. O
se B-NEG
was O
induced O
20 O
h O
following O
the O
second O
injection O
and O
terminated O
3 O
h O
later O
. O

the O
extent O
of O
silver-stained O
ca3 O
and O
ca1 O
hippocampal O
neurons O
was O
evaluated O
2 O
days O
after O
se B-NEG
. O

17beta-estradiol O
did O
not O
alter O
the O
onset O
of O
first O
clonus O
in O
ovariectomized O
rats O
but O
accelerated O
it O
in O
males O
. O

17beta-estradiol O
reduced O
the O
argyrophilic O
neurons O
in O
the O
ca1 O
and O
ca3-c O
sectors O
of O
ovariectomized O
rats O
. O

in O
males O
, O
estradiol O
increased O
the O
total O
damage O
score O
. O

these O
findings O
suggest O
that O
the O
effects O
of O
estradiol O
on O
seizure B-NEG
threshold O
and O
damage O
may O
be O
altered O
by O
sex-related O
differences O
in O
the O
hormonal O
environment O
. O

-DOCSTART- O

delirium B-NEG
during O
clozapine O
treatment O
: O
incidence O
and O
associated O
risk O
factors O
. O

background O
: O
incidence O
and O
risk O
factors O
for O
delirium B-NEG
during O
clozapine O
treatment O
require O
further O
clarification O
. O

methods O
: O
we O
used O
computerized O
pharmacy O
records O
to O
identify O
all O
adult O
psychiatric B-NEG
inpatients O
treated O
with O
clozapine O
(1995-96) O
, O
reviewed O
their O
medical O
records O
to O
score O
incidence O
and O
severity O
of O
delirium B-NEG
, O
and O
tested O
associations O
with O
potential O
risk O
factors O
. O

results O
: O
subjects O
(n O
= O
139 O
) O
were O
72 O
women O
and O
67 O
men O
, O
aged O
40.8 O
+/- O
12.1 O
years O
, O
hospitalized O
for O
24.9 O
+/- O
23.3 O
days O
, O
and O
given O
clozapine O
, O
gradually O
increased O
to O
an O
average O
daily O
dose O
of O
282 O
+/- O
203 O
mg O
( O
3.45 O
+/- O
2.45 O
mg/kg O
) O
for O
18.9 O
+/- O
16.4 O
days O
. O
delirium B-NEG
was O
diagnosed O
in O
14 O
( O
10.1 O
% O
incidence O
, O
or O
1.48 O
cases/person-years O
of O
exposure) O
; O
71.4 O
% O
of O
cases O
were O
moderate O
or O
severe O
. O

associated O
factors O
were O
co-treatment O
with O
other O
centrally O
antimuscarinic O
agents O
, O
poor O
clinical O
outcome O
, O
older O
age O
, O
and O
longer O
hospitalization O
( O
by O
17.5 O
days O
, O
increasing O
cost) O
; O
sex O
, O
diagnosis O
or O
medical O
co-morbidity O
, O
and O
daily O
clozapine O
dose O
, O
which O
fell O
with O
age O
, O
were O
unrelated O
. O

conclusions O
: O
delirium B-NEG
was O
found O
in O
10 O
% O
of O
clozapine-treated O
inpatients O
, O
particularly O
in O
older O
patients O
exposed O
to O
other O
central O
anticholinergics O
. O
delirium B-NEG
was O
inconsistently O
recognized O
clinically O
in O
milder O
cases O
and O
was O
associated O
with O
increased O
length-of-stay O
and O
higher O
costs O
, O
and O
inferior O
clinical O
outcome O
. O

-DOCSTART- O

ketoconazole-induced O
neurologic B-NEG
sequelae I-NEG
. O

a O
77-y-old O
patient O
developed O
weakness B-NEG
of I-NEG
extremities I-NEG
, O
legs B-NEG
paralysis I-NEG
, O
dysarthria B-NEG
and O
tremor B-NEG
1 O
h O
after O
ingestion O
of O
200 O
mg O
ketoconazole O
for O
the O
first O
time O
in O
his O
life O
. O

all O
complaints O
faded O
away O
within O
24 O
h. O

few O
days O
later O
, O
the O
patient O
used O
another O
200 O
mg O
ketoconazole O
tablet O
, O
and O
within O
an O
hour O
experienced O
a O
similar O
clinical O
picture O
, O
which O
resolved O
again O
spontaneously O
within O
hours O
. O

laboratory O
evaluations O
, O
including O
head O
ct O
scan O
, O
were O
normal O
. O

this O
case O
illustrates O
the O
need O
for O
close O
vigilance O
in O
adverse B-NEG
drug I-NEG
reactions I-NEG
, O
particularly O
in O
the O
elderly O
. O

-DOCSTART- O

noxious O
chemical O
stimulation O
of O
rat O
facial O
mucosa O
increases O
intracranial O
blood O
flow O
through O
a O
trigemino-parasympathetic O
reflex--an O
experimental O
model O
for O
vascular B-NEG
dysfunctions I-NEG
in O
cluster B-NEG
headache I-NEG
. O
cluster B-NEG
headache I-NEG
is O
characterized O
by O
typical O
autonomic O
dysfunctions O
including O
facial O
and O
intracranial B-NEG
vascular I-NEG
disturbances I-NEG
. O

both O
the O
trigeminal O
and O
the O
cranial O
parasympathetic O
systems O
may O
be O
involved O
in O
mediating O
these O
dysfunctions O
. O

an O
experimental O
model O
was O
developed O
in O
the O
rat O
to O
measure O
changes O
in O
lacrimation O
and O
intracranial O
blood O
flow O
following O
noxious O
chemical O
stimulation O
of O
facial O
mucosa O
. O

blood O
flow O
was O
monitored O
in O
arteries O
of O
the O
exposed O
cranial O
dura O
mater O
and O
the O
parietal O
cortex O
using O
laser O
doppler O
flowmetry O
. O

capsaicin O
( O
0.01-1 O
mm O
) O
applied O
to O
oral O
or O
nasal O
mucosa O
induced O
increases B-NEG
in I-NEG
dural I-NEG
and I-NEG
cortical I-NEG
blood I-NEG
flow I-NEG
and O
provoked O
lacrimation O
. O

these O
responses O
were O
blocked O
by O
systemic O
pre-administration O
of O
hexamethonium O
chloride O
( O
20 O
mg/kg) O
. O

the O
evoked O
increases B-NEG
in I-NEG
dural I-NEG
blood I-NEG
flow I-NEG
were O
also O
abolished O
by O
topical O
pre-administration O
of O
atropine O
(1 O
mm O
) O
and O
[lys1 O
, O
pro2,5 O
, O
arg3,4 O
, O
tyr6]-vip O
( O
0.1 O
mm) O
, O
a O
vasoactive O
intestinal O
polypeptide O
( O
vip O
) O
antagonist O
, O
onto O
the O
exposed O
dura O
mater O
. O

we O
conclude O
that O
noxious O
stimulation O
of O
facial O
mucosa O
increases O
intracranial O
blood O
flow O
and O
lacrimation O
via O
a O
trigemino-parasympathetic O
reflex O
. O

the O
blood O
flow O
responses O
seem O
to O
be O
mediated O
by O
the O
release O
of O
acetylcholine O
and O
vip O
within O
the O
meninges O
. O

similar O
mechanisms O
may O
be O
involved O
in O
the O
pathogenesis O
of O
cluster B-NEG
headache I-NEG
. O

-DOCSTART- O

recurrent O
excitation O
in O
the O
dentate O
gyrus O
of O
a O
murine O
model O
of O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
. O

similar O
to O
rats O
, O
systemic O
pilocarpine O
injection O
causes O
status B-NEG
epilepticus I-NEG
( O
se B-NEG
) O
and O
the O
eventual O
development O
of O
spontaneous O
seizures B-NEG
and O
mossy O
fiber O
sprouting O
in O
c57bl/6 O
and O
cd1 O
mice O
, O
but O
the O
physiological O
correlates O
of O
these O
events O
have O
not O
been O
identified O
in O
mice O
. O

population O
responses O
in O
granule O
cells O
of O
the O
dentate O
gyrus O
were O
examined O
in O
transverse O
slices O
of O
the O
ventral O
hippocampus O
from O
pilocarpine-treated O
and O
untreated O
mice O
. O

in O
mg(2+)-free O
bathing O
medium O
containing O
bicuculline O
, O
conditions O
designed O
to O
increase O
excitability O
in O
the O
slices O
, O
electrical O
stimulation O
of O
the O
hilus O
resulted O
in O
a O
single O
population O
spike O
in O
granule O
cells O
from O
control O
mice O
and O
pilocarpine-treated O
mice O
that O
did O
not O
experience O
se B-NEG
. O

in O
se B-NEG
survivors O
, O
similar O
stimulation O
resulted O
in O
a O
population O
spike O
followed O
, O
at O
a O
variable O
latency O
, O
by O
negative O
dc O
shifts O
and O
repetitive O
afterdischarges O
of O
3-60 O
s O
duration O
, O
which O
were O
blocked O
by O
ionotropic O
glutamate O
receptor O
antagonists O
. O

focal O
glutamate O
photostimulation O
of O
the O
granule O
cell O
layer O
at O
sites O
distant O
from O
the O
recording O
pipette O
resulted O
in O
population O
responses O
of O
1-30 O
s O
duration O
in O
slices O
from O
se B-NEG
survivors O
but O
not O
other O
groups O
. O

these O
data O
support O
the O
hypothesis O
that O
se B-NEG
-induced O
mossy O
fiber O
sprouting O
and O
synaptic O
reorganization O
are O
relevant O
characteristics O
of O
seizure B-NEG
development O
in O
these O
murine O
strains O
, O
resembling O
rat O
models O
of O
human O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
. O

-DOCSTART- O

the O
alpha3 O
and O
beta4 O
nicotinic O
acetylcholine O
receptor O
subunits O
are O
necessary O
for O
nicotine-induced O
seizures B-NEG
and O
hypolocomotion B-NEG
in O
mice O
. O

binding O
of O
nicotine O
to O
nicotinic O
acetylcholine O
receptors O
( O
nachrs O
) O
elicits O
a O
series O
of O
dose-dependent O
behaviors O
that O
go O
from O
altered O
exploration O
, O
sedation O
, O
and O
tremors B-NEG
, O
to O
seizures B-NEG
and O
death B-NEG
. O

nachrs O
are O
pentameric O
ion O
channels O
usually O
composed O
of O
alpha O
and O
beta O
subunits O
. O

a O
gene O
cluster O
comprises O
the O
alpha3 O
, O
alpha5 O
and O
beta4 O
subunits O
, O
which O
coassemble O
to O
form O
functional O
receptors O
. O

we O
examined O
the O
role O
of O
the O
beta4 O
subunits O
in O
nicotine-induced O
seizures B-NEG
and O
hypolocomotion B-NEG
in O
beta4 O
homozygous O
null O
( O
beta4 O
-/- O
) O
and O
alpha3 O
heterozygous O
( O
+/- O
) O
mice O
. O

beta4 O
-/- O
mice O
were O
less O
sensitive O
to O
the O
effects O
of O
nicotine O
both O
at O
low O
doses O
, O
measured O
as O
decreased O
exploration O
in O
an O
open O
field O
, O
and O
at O
high O
doses O
, O
measured O
as O
sensitivity O
to O
nicotine-induced O
seizures B-NEG
. O

using O
in O
situ O
hybridization O
probes O
for O
the O
alpha3 O
and O
alpha5 O
subunits O
, O
we O
showed O
that O
alpha5 O
mrna O
levels O
are O
unchanged O
, O
whereas O
alpha3 O
mrna O
levels O
are O
selectively O
decreased O
in O
the O
mitral O
cell O
layer O
of O
the O
olfactory O
bulb O
, O
and O
the O
inferior O
and O
the O
superior O
colliculus O
of O
beta4 O
-/- O
brains O
. O

alpha3 O
+/- O
mice O
were O
partially O
resistant O
to O
nicotine-induced O
seizures B-NEG
when O
compared O
to O
wild-type O
littermates O
. O

mrna O
levels O
for O
the O
alpha5 O
and O
the O
beta4 O
subunits O
were O
unchanged O
in O
alpha3 O
+/- O
brains O
. O

together O
, O
these O
results O
suggest O
that O
the O
beta4 O
and O
the O
alpha3 O
subunits O
are O
mediators O
of O
nicotine-induced O
seizures B-NEG
and O
hypolocomotion B-NEG
. O

-DOCSTART- O

recurrent O
acute O
interstitial B-NEG
nephritis I-NEG
induced O
by O
azithromycin O
. O

a O
14-year-old O
girl O
is O
reported O
with O
recurrent O
, O
azithromycin-induced O
, O
acute O
interstitial B-NEG
nephritis I-NEG
. O

the O
second O
episode O
was O
more O
severe O
than O
the O
first O
; O
and O
although O
both O
were O
treated O
with O
intensive O
corticosteroid O
therapy O
, O
renal O
function O
remained O
impaired O
. O

although O
most O
cases O
of O
antibiotic O
induced O
acute O
interstitial B-NEG
nephritis I-NEG
are O
benign O
and O
self-limited O
, O
some O
patients O
are O
at O
risk O
for O
permanent O
renal B-NEG
injury I-NEG
. O

-DOCSTART- O

valproate-induced O
encephalopathy B-NEG
. O

valproate-induced O
encephalopathy B-NEG
is O
a O
rare O
syndrome O
that O
may O
manifest O
in O
otherwise O
normal O
epileptic B-NEG
individuals O
. O

it O
may O
even O
present O
in O
patients O
who O
have O
tolerated O
this O
medicine O
well O
in O
the O
past O
. O

it O
is O
usually O
but O
not O
necessarily O
associated O
with O
hyperammonemia B-NEG
. O

the O
eeg O
shows O
characteristic O
triphasic O
waves O
in O
most O
patients O
with O
this O
complication O
. O

a O
case O
of O
valproate-induced O
encephalopathy B-NEG
is O
presented O
. O

the O
problems O
in O
diagnosing O
this O
condition O
are O
subsequently O
discussed O
. O

-DOCSTART- O

nitro-l-arginine O
methyl O
ester O
: O
a O
potential O
protector O
against O
gentamicin O
ototoxicity B-NEG
. O

the O
nitric O
oxide O
( O
no O
) O
inhibitor O
nitro-l-arginine O
methyl O
ester O
( O
l-name O
) O
may O
act O
as O
an O
otoprotectant O
against O
high-frequency B-NEG
hearing I-NEG
loss I-NEG
caused O
by O
gentamicin O
, O
but O
further O
studies O
are O
needed O
to O
confirm O
this.aminoglycoside O
antibiotics O
are O
still O
widely O
used O
by O
virtue O
of O
their O
efficacy O
and O
low O
cost O
. O

their O
ototoxicity B-NEG
is O
a O
serious O
health O
problem O
and O
, O
as O
their O
ototoxic B-NEG
mechanism O
involves O
the O
production O
of O
no O
, O
we O
need O
to O
assess O
the O
use O
of O
no O
inhibitors O
for O
the O
prevention O
of O
aminoglycoside-induced O
sensorineural B-NEG
hearing I-NEG
loss I-NEG
. O

in O
this O
experimental O
study O
we O
used O
30 O
sprague-dawley O
rats O
, O
27 O
of O
which O
had O
gentamicin O
instilled O
into O
the O
middle O
ear O
. O

the O
otoprotectant O
l-name O
was O
administered O
topically O
to O
12/27 O
animals O
. O

its O
effect O
was O
determined O
in O
terms O
of O
attenuation O
of O
hearing B-NEG
loss I-NEG
, O
measured O
by O
shifts O
in O
the O
auditory O
brainstem O
response O
threshold O
. O

l-name O
reduced O
gentamicin-induced O
hearing B-NEG
loss I-NEG
in O
the O
high-frequency O
range O
, O
but O
gave O
no O
protection O
in O
the O
middle O
or O
low O
frequencies O
. O

-DOCSTART- O

cerebral B-NEG
vasculitis I-NEG
following O
oral O
methylphenidate O
intake O
in O
an O
adult O
: O
a O
case O
report O
. O

methylphenidate O
is O
structurally O
and O
functionally O
similar O
to O
amphetamine O
. O
cerebral B-NEG
vasculitis I-NEG
associated O
with O
amphetamine B-NEG
abuse I-NEG
is O
well O
documented O
, O
and O
in O
rare O
cases O
ischaemic B-NEG
stroke I-NEG
has O
been O
reported O
after O
methylphenidate O
intake O
in O
children O
. O

we O
report O
the O
case O
of O
a O
63-year-old O
female O
who O
was O
treated O
with O
methylphenidate O
due O
to O
hyperactivity B-NEG
and O
suffered O
from O
multiple O
ischaemic B-NEG
strokes I-NEG
. O

we O
consider O
drug-induced O
cerebral B-NEG
vasculitis I-NEG
as O
the O
most O
likely O
cause O
of O
recurrent O
ischaemic B-NEG
strokes I-NEG
in O
the O
absence O
of O
any O
pathological O
findings O
during O
the O
diagnostic O
work-up O
. O

we O
conclude O
that O
methylphenidate O
mediated O
vasculitis B-NEG
should O
be O
considered O
in O
patients O
with O
neurological O
symptoms O
and O
a O
history O
of O
methylphenidate O
therapy O
. O

this O
potential O
side-effect O
, O
though O
very O
rare O
, O
represents O
one O
more O
reason O
to O
be O
very O
restrictive O
in O
the O
use O
of O
methylphenidate O
. O

-DOCSTART- O

cerebral B-NEG
haemorrhage I-NEG
induced O
by O
warfarin O
- O
the O
influence O
of O
drug-drug O
interactions O
. O

purpose O
: O
to O
evaluate O
the O
frequency O
, O
severity O
and O
preventability O
of O
warfarin-induced O
cerebral B-NEG
haemorrhages I-NEG
due O
to O
warfarin O
and O
warfarin-drug O
interactions O
in O
patients O
living O
in O
the O
county O
of O
osterg O
tland O
, O
sweden O
. O

methods O
: O
all O
patients O
with O
a O
diagnosed O
cerebral B-NEG
haemorrhage I-NEG
at O
three O
hospitals O
during O
the O
period O
2000-2002 O
were O
identified O
. O

medical O
records O
were O
studied O
retrospectively O
to O
evaluate O
whether O
warfarin O
and O
warfarin-drug O
interactions O
could O
have O
caused O
the O
cerebral B-NEG
haemorrhage I-NEG
. O

the O
proportion O
of O
possibly O
avoidable O
cases O
due O
to O
drug O
interactions O
was O
estimated O
. O

results O
: O
among O
593 O
patients O
with O
cerebral B-NEG
haemorrhage I-NEG
, O
59 O
( O
10% O
) O
were O
assessed O
as O
related O
to O
warfarin O
treatment O
. O

this O
imply O
an O
incidence O
of O
1.7/100,000 O
treatment O
years O
. O

of O
the O
59 O
cases O
, O
26 O
( O
44% O
) O
had O
a O
fatal O
outcome O
, O
compared O
to O
136 O
( O
25% O
) O
among O
the O
non-warfarin O
patients O
(p O
< O
0.01) O
. O

a O
warfarin-drug O
interaction O
could O
have O
contributed O
to O
the O
haemorrhage B-NEG
in O
24 O
( O
41% O
) O
of O
the O
warfarin O
patients O
and O
in O
7 O
of O
these O
( O
12% O
) O
the O
bleeding B-NEG
complication O
was O
considered O
being O
possible O
to O
avoid O
. O

conclusions O
: O
warfarin-induced O
cerebral B-NEG
haemorrhages I-NEG
are O
a O
major O
clinical O
problem O
with O
a O
high O
fatality O
rate O
. O

almost O
half O
of O
the O
cases O
was O
related O
to O
a O
warfarin-drug O
interaction O
. O

a O
significant O
proportion O
of O
warfarin-related O
cerebral B-NEG
haemorrhages I-NEG
might O
have O
been O
prevented O
if O
greater O
caution O
had O
been O
taken O
when O
prescribing O
drugs O
known O
to O
interact O
with O
warfarin O
. O

-DOCSTART- O

side O
effects O
of O
postoperative O
administration O
of O
methylprednisolone O
and O
gentamicin O
into O
the O
posterior O
sub-tenon's O
space O
. O

purpose O
: O
to O
assess O
the O
incidence O
of O
postoperative O
emetic O
side O
effects O
after O
the O
administration O
of O
methylprednisolone O
and O
gentamicin O
into O
the O
posterior O
sub-tenon's O
space O
at O
the O
end O
of O
routine O
cataract B-NEG
surgery O
. O

setting O
: O
st O
. O
luke's O
hospital O
, O
gwardamangia O
, O
malta O
. O

methods O
: O
a O
double-blind O
double-armed O
prospective O
study O
comprised O
40 O
patients O
who O
had O
uneventful O
sutureless O
phacoemulsification O
under O
sub-tenon's O
local O
infiltration O
of O
3 O
ml O
of O
plain O
lignocaine O
. O

at O
the O
end O
of O
the O
procedure O
, O
group O
a O
(n O
= O
20 O
) O
had O
20 O
mg/0.5 O
ml O
of O
methylprednisolone O
and O
10 O
mg/0.5 O
ml O
of O
gentamicin O
injected O
into O
the O
posterior O
sub-tenon's O
space O
and O
group O
b O
(n O
= O
20 O
) O
had O
the O
same O
combination O
injected O
into O
the O
anterior O
sub-tenon's O
space O
. O

postoperatively O
, O
all O
patients O
were O
assessed O
for O
symptoms O
of O
nausea B-NEG
, O
vomiting I-NEG
, O
and O
headache B-NEG
. O

a O
chi-square O
test O
was O
used O
to O
assess O
the O
statistical O
significance O
of O
results O
. O

results O
: O
sixty O
percent O
in O
group O
a O
developed O
postoperative B-NEG
emetic I-NEG
symptoms I-NEG
, O
headache B-NEG
, O
or O
both O
; O
1 O
patient O
in O
group O
b O
developed O
symptoms O
. O

conclusions O
: O
the O
administration O
of O
methylprednisolone O
and O
gentamicin O
in O
the O
posterior O
sub-tenon's O
space O
was O
related O
to O
a O
high O
incidence O
of O
side O
effects O
including O
nausea B-NEG
, O
vomiting I-NEG
, O
and O
headache B-NEG
. O

all O
adverse O
effects O
were O
self-limiting O
. O

-DOCSTART- O

cardiac O
angiography O
in O
renally O
impaired O
patients O
( O
care O
) O
study O
: O
a O
randomized O
double-blind O
trial O
of O
contrast-induced O
nephropathy B-NEG
in O
patients O
with O
chronic B-NEG
kidney I-NEG
disease I-NEG
. O

background O
: O
no O
direct O
comparisons O
exist O
of O
the O
renal O
tolerability O
of O
the O
low-osmolality O
contrast O
medium O
iopamidol O
with O
that O
of O
the O
iso-osmolality O
contrast O
medium O
iodixanol O
in O
high-risk O
patients O
. O

methods O
and O
results O
: O
the O
present O
study O
is O
a O
multicenter O
, O
randomized O
, O
double-blind O
comparison O
of O
iopamidol O
and O
iodixanol O
in O
patients O
with O
chronic B-NEG
kidney I-NEG
disease I-NEG
( O
estimated O
glomerular O
filtration O
rate O
, O
20 O
to O
59 O
ml/min O
) O
who O
underwent O
cardiac O
angiography O
or O
percutaneous O
coronary O
interventions O
. O

serum O
creatinine O
( O
scr O
) O
levels O
and O
estimated O
glomerular O
filtration O
rate O
were O
assessed O
at O
baseline O
and O
2 O
to O
5 O
days O
after O
receiving O
medications O
. O

the O
primary O
outcome O
was O
a O
postdose O
scr O
increase O
> O
or O
= O
0.5 O
mg/dl O
( O
44.2 O
micromol/l O
) O
over O
baseline O
. O

secondary O
outcomes O
were O
a O
postdose O
scr O
increase O
> O
or O
= O
25% O
, O
a O
postdose O
estimated O
glomerular O
filtration O
rate O
decrease O
of O
> O
or O
= O
25% O
, O
and O
the O
mean O
peak O
change O
in O
scr O
. O

in O
414 O
patients O
, O
contrast O
volume O
, O
presence O
of O
diabetes B-NEG
mellitus I-NEG
, O
use O
of O
n-acetylcysteine O
, O
mean O
baseline O
scr O
, O
and O
estimated O
glomerular O
filtration O
rate O
were O
comparable O
in O
the O
2 O
groups O
. O

scr O
increases O
> O
or O
= O
0.5 O
mg/dl O
occurred O
in O
4.4% O
(9 O
of O
204 O
patients O
) O
after O
iopamidol O
and O
6.7% O
( O
14 O
of O
210 O
patients O
) O
after O
iodixanol O
(p=0.39) O
, O
whereas O
rates O
of O
scr O
increases O
> O
or O
= O
25% O
were O
9.8% O
and O
12.4% O
, O
respectively O
(p=0.44) O
. O

in O
patients O
with O
diabetes B-NEG
, O
scr O
increases O
> O
or O
= O
0.5 O
mg/dl O
were O
5.1% O
(4 O
of O
78 O
patients O
) O
with O
iopamidol O
and O
13.0% O
( O
12 O
of O
92 O
patients O
) O
with O
iodixanol O
(p=0.11) O
, O
whereas O
scr O
increases O
> O
or O
= O
25% O
were O
10.3% O
and O
15.2% O
, O
respectively O
(p=0.37) O
. O

mean O
post-scr O
increases O
were O
significantly O
less O
with O
iopamidol O
( O
all O
patients O
: O
0.07 O
versus O
0.12 O
mg/dl O
, O
6.2 O
versus O
10.6 O
micromol/l O
, O
p=0.03 O
; O
patients O
with O
diabetes B-NEG
: O
0.07 O
versus O
0.16 O
mg/dl O
, O
6.2 O
versus O
14.1 O
micromol/l O
, O
p=0.01) O
. O

conclusions O
: O
the O
rate O
of O
contrast-induced O
nephropathy B-NEG
, O
defined O
by O
multiple O
end O
points O
, O
is O
not O
statistically O
different O
after O
the O
intraarterial O
administration O
of O
iopamidol O
or O
iodixanol O
to O
high-risk O
patients O
, O
with O
or O
without O
diabetes B-NEG
mellitus I-NEG
. O

any O
true O
difference O
between O
the O
agents O
is O
small O
and O
not O
likely O
to O
be O
clinically O
significant O
. O

-DOCSTART- O

a O
novel O
compound O
, O
maltolyl O
p-coumarate O
, O
attenuates O
cognitive B-NEG
deficits I-NEG
and O
shows O
neuroprotective O
effects O
in O
vitro O
and O
in O
vivo O
dementia B-NEG
models O
. O

to O
develop O
a O
novel O
and O
effective O
drug O
that O
could O
enhance O
cognitive O
function O
and O
neuroprotection O
, O
we O
newly O
synthesized O
maltolyl O
p-coumarate O
by O
the O
esterification O
of O
maltol O
and O
p-coumaric O
acid O
. O

in O
the O
present O
study O
, O
we O
investigated O
whether O
maltolyl O
p-coumarate O
could O
improve O
cognitive B-NEG
decline I-NEG
in O
scopolamine-injected O
rats O
and O
in O
amyloid O
beta O
peptide(1-42)-infused O
rats O
. O

maltolyl O
p-coumarate O
was O
found O
to O
attenuate O
cognitive B-NEG
deficits I-NEG
in O
both O
rat O
models O
using O
passive O
avoidance O
test O
and O
to O
reduce O
apoptotic O
cell O
death O
observed O
in O
the O
hippocampus O
of O
the O
amyloid O
beta O
peptide(1-42)-infused O
rats O
. O

we O
also O
examined O
the O
neuroprotective O
effects O
of O
maltolyl O
p-coumarate O
in O
vitro O
using O
sh-sy5y O
cells O
. O

cells O
were O
pretreated O
with O
maltolyl O
p-coumarate O
, O
before O
exposed O
to O
amyloid O
beta O
peptide(1-42) O
, O
glutamate O
or O
h2o2 O
. O

we O
found O
that O
maltolyl O
p-coumarate O
significantly O
decreased O
apoptotic O
cell O
death O
and O
reduced O
reactive O
oxygen O
species O
, O
cytochrome O
c O
release O
, O
and O
caspase O
3 O
activation O
. O

taking O
these O
in O
vitro O
and O
in O
vivo O
results O
together O
, O
our O
study O
suggests O
that O
maltolyl O
p-coumarate O
is O
a O
potentially O
effective O
candidate O
against O
alzheimer's B-NEG
disease I-NEG
that O
is O
characterized O
by O
wide O
spread O
neuronal B-NEG
death I-NEG
and O
progressive O
decline B-NEG
of I-NEG
cognitive I-NEG
function I-NEG
. O

-DOCSTART- O

interaction O
between O
warfarin O
and O
levofloxacin O
: O
case O
series O
. O

warfarin O
is O
the O
most O
widely O
used O
oral O
anticoagulant O
and O
is O
indicated O
for O
many O
clinical O
conditions O
. O

levofloxacin O
, O
a O
fluoroquinolone O
, O
is O
one O
of O
the O
most O
commonly O
prescribed O
antibiotics O
in O
clinical O
practice O
and O
is O
effective O
against O
gram-positive O
, O
gram-negative O
, O
and O
atypical O
bacteria O
. O

while O
small O
prospective O
studies O
have O
not O
revealed O
any O
significant O
drug-drug O
interaction O
between O
warfarin O
and O
levofloxacin O
, O
several O
case O
reports O
have O
indicated O
that O
levofloxacin O
may O
significantly O
potentiate O
the O
anticoagulation O
effect O
of O
warfarin O
. O

we O
report O
3 O
cases O
of O
serious O
bleeding B-NEG
complications O
that O
appear O
to O
be O
the O
result O
of O
the O
interaction O
between O
warfarin O
and O
levofloxacin O
. O

physicians O
should O
be O
aware O
of O
this O
potential O
interaction O
and O
use O
caution O
when O
prescribing O
levofloxacin O
to O
patients O
taking O
warfarin O
. O

-DOCSTART- O

mutations O
associated O
with O
lamivudine-resistance O
in O
therapy-na O
ve O
hepatitis B-NEG
b I-NEG
virus I-NEG
( O
hbv I-NEG
) O
infected I-NEG
patients O
with O
and O
without O
hiv B-NEG
co-infection I-NEG
: O
implications O
for O
antiretroviral O
therapy O
in O
hbv B-NEG
and I-NEG
hiv I-NEG
co-infected I-NEG
south O
african O
patients O
. O

this O
was O
an O
exploratory O
study O
to O
investigate O
lamivudine-resistant O
hepatitis B-NEG
b I-NEG
virus O
( O
hbv O
) O
strains O
in O
selected O
lamivudine-na O
ve O
hbv O
carriers O
with O
and O
without O
human B-NEG
immunodeficiency I-NEG
virus I-NEG
( O
hiv I-NEG
) O
co-infection I-NEG
in O
south O
african O
patients O
. O

thirty-five O
lamivudine-na O
ve O
hbv B-NEG
infected I-NEG
patients O
with O
or O
without O
hiv B-NEG
co-infection I-NEG
were O
studied O
: O
15 O
chronic O
hbv B-NEG
mono-infected I-NEG
patients O
and O
20 O
hbv-hiv B-NEG
co-infected I-NEG
patients O
. O

the O
latter O
group O
was O
further O
sub-divided O
into O
13 O
occult O
hbv O
( O
hbsag-negative O
) O
and O
7 O
overt O
hbv O
( O
hbsag- O
positive O
) O
patients O
. O

hbsag O
, O
anti-hbs O
, O
anti-hbc O
, O
and O
anti-hiv O
1/2 O
were O
determined O
as O
part O
of O
routine O
diagnosis O
using O
axsym O
assays O
( O
abbott O
laboratories O
, O
north O
chicago O
, O
il) O
. O

serum O
samples O
were O
pcr O
amplified O
with O
hbv O
reverse O
transcriptase O
( O
rt O
) O
primers O
, O
followed O
by O
direct O
sequencing O
across O
the O
tyrosine-methionine-aspartate-aspartate O
( O
ymdd O
) O
motif O
of O
the O
major O
catalytic O
region O
in O
the O
c O
domain O
of O
the O
hbv O
rt O
enzyme O
. O

hbv O
viral O
load O
was O
performed O
with O
amplicor O
hbv O
monitor O
test O
v2.0 O
( O
roche O
diagnostics O
, O
penzberg O
, O
germany) O
. O

hbv O
lamivudine-resistant O
strains O
were O
detected O
in O
3 O
of O
15 O
mono-infected O
chronic O
hepatitis B-NEG
b I-NEG
patients O
and O
10 O
of O
20 O
hbv-hiv B-NEG
co-infected I-NEG
patients O
. O

to O
the O
best O
of O
our O
knowledge O
, O
this O
constitutes O
the O
first O
report O
of O
hbv O
lamivudine-resistant O
strains O
in O
therapy-na O
ve O
hbv-hiv B-NEG
co-infected I-NEG
patients O
. O

the O
hbv O
viral O
loads O
for O
mono-infected O
and O
co-infected O
patients O
ranged O
from O
3.32 O
x O
10(2 O
) O
to O
3.82 O
x O
10(7 O
) O
and O
<200 O
to O
4.40 O
x O
10(3 O
) O
copies/ml O
, O
respectively O
. O

it O
remains O
to O
be O
seen O
whether O
such O
pre-existing O
antiviral O
mutations O
could O
result O
in O
widespread O
emergence O
of O
hbv O
resistant O
strains O
when O
lamivudine-containing O
highly O
active O
antiretroviral O
( O
arv O
) O
treatment O
( O
haart O
) O
regimens O
become O
widely O
applied O
in O
south O
africa O
, O
as O
this O
is O
likely O
to O
have O
potential O
implications O
in O
the O
management O
of O
hbv-hiv B-NEG
co-infected I-NEG
patients O
. O

-DOCSTART- O

sex O
differences O
in O
nmda O
antagonist O
enhancement O
of O
morphine O
antihyperalgesia O
in O
a O
capsaicin O
model O
of O
persistent O
pain B-NEG
: O
comparisons O
to O
two O
models O
of O
acute B-NEG
pain I-NEG
. O

in O
acute B-NEG
pain I-NEG
models O
, O
n-methyl-d-aspartate O
( O
nmda O
) O
antagonists O
enhance O
the O
antinociceptive O
effects O
of O
morphine O
to O
a O
greater O
extent O
in O
males O
than O
females O
. O

the O
purpose O
of O
this O
investigation O
was O
to O
extend O
these O
findings O
to O
a O
persistent O
pain B-NEG
model O
which O
could O
be O
distinguished O
from O
acute B-NEG
pain I-NEG
models O
on O
the O
basis O
of O
the O
nociceptive O
fibers O
activated O
, O
neurochemical O
substrates O
, O
and O
duration O
of O
the O
nociceptive O
stimulus O
. O

to O
this O
end O
, O
persistent O
hyperalgesia B-NEG
was O
induced O
by O
administration O
of O
capsaicin O
in O
the O
tail O
of O
gonadally O
intact O
f344 O
rats O
, O
following O
which O
the O
tail O
was O
immersed O
in O
a O
mildly O
noxious O
thermal O
stimulus O
, O
and O
tail-withdrawal O
latencies O
measured O
. O

for O
comparison O
, O
tests O
were O
conducted O
in O
two O
acute B-NEG
pain I-NEG
models O
, O
the O
hotplate O
and O
warm O
water O
tail-withdrawal O
procedures O
. O

in O
males O
, O
the O
non-competitive O
nmda O
antagonist O
dextromethorphan O
enhanced O
the O
antihyperalgesic O
effect O
of O
low O
to O
moderate O
doses O
of O
morphine O
in O
a O
dose-and O
time-dependent O
manner O
. O

across O
the O
doses O
and O
pretreatment O
times O
examined O
, O
enhancement O
was O
not O
observed O
in O
females O
. O

enhancement O
of O
morphine O
antinociception O
by O
dextromethorphan O
was O
seen O
in O
both O
males O
and O
females O
in O
the O
acute B-NEG
pain I-NEG
models O
, O
with O
the O
magnitude O
of O
this O
effect O
being O
greater O
in O
males O
. O

these O
findings O
demonstrate O
a O
sexually-dimorphic O
interaction O
between O
nmda O
antagonists O
and O
morphine O
in O
a O
persistent O
pain B-NEG
model O
that O
can O
be O
distinguished O
from O
those O
observed O
in O
acute B-NEG
pain I-NEG
models O
. O

-DOCSTART- O

development O
of O
proteinuria B-NEG
after O
switch O
to O
sirolimus-based O
immunosuppression O
in O
long-term O
cardiac O
transplant O
patients O
. O

calcineurin-inhibitor O
therapy O
can O
lead O
to O
renal B-NEG
dysfunction I-NEG
in O
heart O
transplantation O
patients O
. O

the O
novel O
immunosuppressive O
( O
is O
) O
drug O
sirolmus O
( O
srl O
) O
lacks O
nephrotoxic B-NEG
effects O
; O
however O
, O
proteinuria B-NEG
associated O
with O
srl O
has O
been O
reported O
following O
renal O
transplantation O
. O

in O
cardiac O
transplantation O
, O
the O
incidence O
of O
proteinuria B-NEG
associated O
with O
srl O
is O
unknown O
. O

in O
this O
study O
, O
long-term O
cardiac O
transplant O
patients O
were O
switched O
from O
cyclosporine O
to O
srl-based O
is O
. O

concomitant O
is O
consisted O
of O
mycophenolate O
mofetil O
+/- O
steroids O
. O

proteinuria O
increased O
significantly O
from O
a O
median O
of O
0.13 O
g/day O
( O
range O
0-5.7 O
) O
preswitch O
to O
0.23 O
g/day O
( O
0-9.88 O
) O
at O
24 O
months O
postswitch O
(p O
= O
0.0024) O
. O

before O
the O
switch O
, O
11.5% O
of O
patients O
had O
high-grade O
proteinuria B-NEG
( O
>1.0 O
g/day) O
; O
this O
increased O
to O
22.9% O
postswitch O
(p O
= O
0.006) O
. O

ace O
inhibitor O
and O
angiotensin-releasing O
blocker O
( O
arb O
) O
therapy O
reduced O
proteinuria B-NEG
development O
. O

patients O
without O
proteinuria B-NEG
had O
increased O
renal O
function O
( O
median O
42.5 O
vs O
. O
64.1 O
, O
p O
= O
0.25) O
, O
whereas O
patients O
who O
developed O
high-grade O
proteinuria B-NEG
showed O
decreased O
renal O
function O
at O
the O
end O
of O
follow-up O
( O
median O
39.6 O
vs O
. O
29.2 O
, O
p O
= O
0.125) O
. O

thus O
, O
proteinuria B-NEG
may O
develop O
in O
cardiac O
transplant O
patients O
after O
switch O
to O
srl O
, O
which O
may O
have O
an O
adverse O
effect O
on O
renal O
function O
in O
these O
patients O
. O

srl O
should O
be O
used O
with O
acei/arb O
therapy O
and O
patients O
monitored O
for O
proteinuria B-NEG
and O
increased O
renal B-NEG
dysfunction I-NEG
. O

-DOCSTART- O

synthesis O
of O
n-pyrimidinyl-2-phenoxyacetamides O
as O
adenosine O
a2a O
receptor O
antagonists O
. O

a O
series O
of O
n-pyrimidinyl-2-phenoxyacetamide O
adenosine O
a(2a O
) O
antagonists O
is O
described O
. O

sar O
studies O
led O
to O
compound O
14 O
with O
excellent O
potency O
( O
k(i O
) O
= O
0.4 O
nm) O
, O
selectivity O
( O
a(1)/a(2a O
) O
> O
100) O
, O
and O
efficacy O
( O
med O
10 O
mg/kg O
p.o. O
) O
in O
the O
rat O
haloperidol-induced O
catalepsy B-NEG
model O
for O
parkinson's B-NEG
disease I-NEG
. O

-DOCSTART- O

methamphetamine-induced O
neurotoxicity B-NEG
and O
microglial O
activation O
are O
not O
mediated O
by O
fractalkine O
receptor O
signaling O
. O

methamphetamine O
( O
meth O
) O
damages O
dopamine O
( O
da O
) O
nerve O
endings O
by O
a O
process O
that O
has O
been O
linked O
to O
microglial O
activation O
but O
the O
signaling O
pathways O
that O
mediate O
this O
response O
have O
not O
yet O
been O
delineated O
. O

cardona O
et O
al O
. O
[nat O
. O
neurosci O
. O
9 O
(2006) O
, O
917] O
recently O
identified O
the O
microglial-specific O
fractalkine O
receptor O
( O
cx3cr1 O
) O
as O
an O
important O
mediator O
of O
mptp-induced O
neurodegeneration B-NEG
of O
da O
neurons O
. O

because O
the O
cns B-NEG
damage I-NEG
caused O
by O
meth O
and O
mptp O
is O
highly O
selective O
for O
the O
da O
neuronal O
system O
in O
mouse O
models O
of O
neurotoxicity B-NEG
, O
we O
hypothesized O
that O
the O
cx3cr1 O
plays O
a O
role O
in O
meth-induced O
neurotoxicity B-NEG
and O
microglial O
activation O
. O

mice O
in O
which O
the O
cx3cr1 O
gene O
has O
been O
deleted O
and O
replaced O
with O
a O
cdna O
encoding O
enhanced O
green O
fluorescent O
protein O
( O
egfp O
) O
were O
treated O
with O
meth O
and O
examined O
for O
striatal O
neurotoxicity B-NEG
. O

meth O
depleted O
da O
, O
caused O
microglial O
activation O
, O
and O
increased O
body O
temperature O
in O
cx3cr1 O
knockout O
mice O
to O
the O
same O
extent O
and O
over O
the O
same O
time O
course O
seen O
in O
wild-type O
controls O
. O

the O
effects O
of O
meth O
in O
cx3cr1 O
knockout O
mice O
were O
not O
gender-dependent O
and O
did O
not O
extend O
beyond O
the O
striatum O
. O

striatal O
microglia O
expressing O
egfp O
constitutively O
show O
morphological O
changes O
after O
meth O
that O
are O
characteristic O
of O
activation O
. O

this O
response O
was O
restricted O
to O
the O
striatum O
and O
contrasted O
sharply O
with O
unresponsive O
egfp-microglia O
in O
surrounding O
brain O
areas O
that O
are O
not O
damaged O
by O
meth O
. O

we O
conclude O
from O
these O
studies O
that O
cx3cr1 O
signaling O
does O
not O
modulate O
meth O
neurotoxicity B-NEG
or O
microglial O
activation O
. O

furthermore O
, O
it O
appears O
that O
striatal-resident O
microglia O
respond O
to O
meth O
with O
an O
activation O
cascade O
and O
then O
return O
to O
a O
surveying O
state O
without O
undergoing O
apoptosis O
or O
migration O
. O

-DOCSTART- O

recovery O
of O
tacrolimus-associated O
brachial B-NEG
neuritis I-NEG
after O
conversion O
to O
everolimus O
in O
a O
pediatric O
renal O
transplant O
recipient--case O
report O
and O
review O
of O
the O
literature O
. O

tac O
has O
been O
shown O
to O
be O
a O
potent O
immunosuppressive O
agent O
for O
solid O
organ O
transplantation O
in O
pediatrics O
. O
neurotoxicity B-NEG
is O
a O
potentially O
serious O
toxic O
effect O
. O

it O
is O
characterized O
by O
encephalopathy B-NEG
, O
headaches B-NEG
, O
seizures B-NEG
, O
or O
neurological B-NEG
deficits I-NEG
. O

here O
, O
we O
describe O
an O
eight-and-a-half-yr-old O
male O
renal O
transplant O
recipient O
with O
right O
bn O
. O

mri O
demonstrated O
hyperintense O
t2 O
signals O
in O
the O
cervical O
cord O
and O
right O
brachial O
plexus O
roots O
indicative O
of O
both O
myelitis B-NEG
and O
right O
brachial B-NEG
plexitis I-NEG
. O

symptoms O
persisted O
for O
three O
months O
despite O
tac O
dose O
reduction O
, O
administration O
of O
ivig O
and O
four O
doses O
of O
methylprednisolone O
pulse O
therapy O
. O

improvement O
and O
eventually O
full O
recovery O
only O
occurred O
after O
tac O
was O
completely O
discontinued O
and O
successfully O
replaced O
by O
everolimus O
. O

-DOCSTART- O

valvular B-NEG
heart I-NEG
disease I-NEG
in O
patients O
with O
parkinson's B-NEG
disease I-NEG
treated O
with O
pergolide O
. O

course O
following O
treatment O
modifications O
. O
valvular B-NEG
heart I-NEG
abnormalities I-NEG
have O
been O
reported O
in O
patients O
with O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
treated O
with O
pergolide O
. O

however O
, O
the O
incidence O
and O
severity O
of O
these O
abnormalities O
vary O
from O
study O
to O
study O
and O
their O
course O
after O
drug O
withdrawal O
has O
not O
been O
systematically O
assessed O
. O

objectives O
: O
to O
estimate O
the O
frequency O
and O
severity O
of O
valvular B-NEG
heart I-NEG
abnormality I-NEG
and O
its O
possible O
reversibility O
after O
drug O
withdrawal O
in O
a O
case-control O
study O
. O

methods O
: O
all O
pd B-NEG
patients O
in O
the O
amiens O
area O
treated O
with O
pergolide O
were O
invited O
to O
attend O
a O
cardiologic O
assessment O
including O
transthoracic O
echocardiography O
. O

thirty O
pd B-NEG
patients O
participated O
in O
the O
study O
. O

a O
second O
echocardiography O
was O
performed O
( O
median O
interval O
: O
13 O
months O
) O
after O
pergolide O
withdrawal O
( O
n=10 O
patients) O
. O

controls O
were O
age- O
and O
sex-matched O
non- O
pd B-NEG
patients O
referred O
to O
the O
cardiology O
department O
. O

results O
: O
compared O
to O
controls O
, O
aortic B-NEG
regurgitation I-NEG
(or O
: O
3.1 O
; O
95% O
ic O
: O
1.1-8.8 O
) O
and O
mitral B-NEG
regurgitation I-NEG
(or O
: O
10.7 O
; O
95% O
ic O
: O
2.1-53 O
) O
were O
more O
frequent O
in O
pd B-NEG
patients O
(tricuspid O
: O
ns) O
. O

the O
number O
of O
affected O
valves O
( O
n=2.4+/-0.7 O
) O
and O
the O
sum O
of O
regurgitation O
grades O
( O
n=2.8+/-1.09 O
) O
were O
higher O
( O
p=0.008 O
and O
p=0.006 O
, O
respectively O
) O
in O
the O
pergolide O
group O
. O

severity O
of O
regurgitation O
was O
not O
correlated O
with O
pergolide O
cumulative O
dose O
. O

a O
restrictive O
pattern O
of O
valvular B-NEG
regurgitation I-NEG
, O
suggestive O
of O
the O
role O
of O
pergolide O
, O
was O
observed O
in O
12/30 O
( O
40% O
) O
patients O
including O
two O
with O
heart B-NEG
failure I-NEG
. O

pergolide O
was O
discontinued O
in O
10 O
patients O
with O
valvular B-NEG
heart I-NEG
disease I-NEG
, O
resulting O
in O
a O
lower O
regurgitation O
grade O
( O
p=0.01 O
) O
at O
the O
second O
transthoracic O
echocardiography O
and O
the O
two O
patients O
with O
heart B-NEG
failure I-NEG
returned O
to O
nearly O
normal O
clinical O
examination O
. O

this O
study O
supports O
the O
high O
frequency O
of O
restrictive O
valve B-NEG
regurgitation I-NEG
in O
pd B-NEG
patients O
treated O
with O
pergolide O
and O
reveals O
that O
a O
significant O
improvement O
is O
usual O
when O
the O
treatment O
is O
converted O
to O
non-ergot O
dopamine O
agonists O
. O

-DOCSTART- O

adverse O
effects O
of O
topical O
papaverine O
on O
auditory O
nerve O
function O
. O

background O
: O
papaverine O
hydrochloride O
is O
a O
direct-acting O
vasodilator O
used O
to O
manage O
vasospasm B-NEG
during O
various O
neurosurgical O
operations O
. O

transient O
cranial B-NEG
nerve I-NEG
dysfunction I-NEG
has O
been O
described O
in O
a O
few O
cases O
with O
topical O
papaverine O
. O

this O
study O
supports O
previous O
reports O
and O
provides O
neurophysiological O
evidence O
of O
an O
adverse O
effect O
on O
the O
auditory O
nerve O
. O

methods O
: O
we O
conducted O
a O
retrospective O
review O
of O
70 O
consecutive O
microvascular O
decompression O
operations O
and O
studied O
those O
patients O
who O
received O
topical O
papaverine O
for O
vasospasm B-NEG
. O

topical O
papaverine O
was O
used O
as O
a O
direct O
therapeutic O
action O
to O
manage O
vasospasm B-NEG
in O
a O
total O
of O
11 O
patients O
. O

the O
timing O
of O
papaverine O
application O
and O
ongoing O
operative O
events O
was O
reviewed O
relative O
to O
changes O
in O
neurophysiological O
recordings O
. O

brainstem O
auditory O
evoked O
potentials O
( O
baeps O
) O
were O
routinely O
used O
to O
monitor O
cochlear O
nerve O
function O
during O
these O
operations O
. O

findings O
: O
a O
temporal O
relationship O
was O
found O
between O
topical O
papaverine O
and O
baep O
changes O
leading O
to O
complete O
waveform O
loss O
. O

the O
average O
temporal O
delay O
between O
papaverine O
and O
the O
onset O
of O
an O
adverse O
baep O
change O
was O
5 O
min O
. O

in O
10 O
of O
11 O
patients O
, O
baep O
waves O
ii/iii-v O
completely O
disappeared O
within O
2 O
to O
25 O
min O
after O
papaverine O
. O

eight O
of O
these O
10 O
patients O
had O
complete O
loss O
of O
baep O
waveforms O
within O
10 O
min O
. O

one O
patient O
showed O
no O
recovery O
of O
later O
waves O
and O
a O
delayed O
profound O
sensorineural B-NEG
hearing I-NEG
loss I-NEG
. O

the O
average O
recovery O
time O
of O
baep O
waveforms O
to O
pre-papaverine O
baseline O
values O
was O
39 O
min O
. O

conclusions O
: O
topical O
papaverine O
for O
the O
treatment O
of O
vasospasm B-NEG
was O
associated O
with O
the O
onset O
of O
a O
transient O
disturbance O
in O
neurophysiological O
function O
of O
the O
ascending O
auditory O
brainstem O
pathway O
. O

the O
complete O
disappearance O
of O
baep O
waveforms O
with O
a O
consistent O
temporal O
delay O
suggests O
a O
possible O
adverse B-NEG
effect I-NEG
on I-NEG
the I-NEG
proximal I-NEG
eighth I-NEG
nerve I-NEG
. O

recommendations O
to O
avoid O
potential O
cranial B-NEG
nerve I-NEG
deficits I-NEG
from O
papaverine O
are O
provided O
. O

-DOCSTART- O

massive O
proteinuria B-NEG
and O
acute B-NEG
renal I-NEG
failure I-NEG
after O
oral O
bisphosphonate O
( O
alendronate O
) O
administration O
in O
a O
patient O
with O
focal B-NEG
segmental I-NEG
glomerulosclerosis I-NEG
. O

a O
61-year-old O
japanese O
man O
with O
nephrotic B-NEG
syndrome I-NEG
due O
to O
focal B-NEG
segmental I-NEG
glomerulosclerosis I-NEG
was O
initially O
responding O
well O
to O
steroid O
therapy O
. O

the O
amount O
of O
daily O
urinary O
protein O
decreased O
from O
15.6 O
to O
2.8 O
g. O

within O
14 O
days O
of O
the O
oral O
bisphosphonate O
( O
alendronate O
sodium O
) O
administration O
, O
the O
amount O
of O
daily O
urinary O
protein O
increased O
rapidly O
up O
to O
12.8 O
g O
with O
acute B-NEG
renal I-NEG
failure I-NEG
. O

after O
discontinuing O
the O
oral O
alendronate O
, O
the O
patient O
underwent O
six O
cycles O
of O
hemodialysis O
and O
four O
cycles O
of O
ldl O
apheresis O
. O

urinary O
volume O
and O
serum O
creatinine O
levels O
recovered O
to O
the O
normal O
range O
, O
with O
urinary O
protein O
disappearing O
completely O
within O
40 O
days O
. O

this O
report O
demonstrates O
that O
not O
only O
intravenous O
, O
but O
also O
oral O
bisphosphonates O
can O
aggravate O
proteinuria B-NEG
and O
acute B-NEG
renal I-NEG
failure I-NEG
. O

-DOCSTART- O

serum- O
and O
glucocorticoid-inducible O
kinase O
1 O
in O
doxorubicin-induced O
nephrotic B-NEG
syndrome I-NEG
. O

doxorubicin-induced O
nephropathy B-NEG
leads O
to O
epithelial O
sodium O
channel O
( O
enac)-dependent O
volume B-NEG
retention I-NEG
and O
renal O
fibrosis B-NEG
. O

the O
aldosterone-sensitive O
serum- O
and O
glucocorticoid-inducible O
kinase O
sgk1 O
has O
been O
shown O
to O
participate O
in O
the O
stimulation O
of O
enac O
and O
to O
mediate O
renal O
fibrosis B-NEG
following O
mineralocorticoid O
and O
salt O
excess O
. O

the O
present O
study O
was O
performed O
to O
elucidate O
the O
role O
of O
sgk1 O
in O
the O
volume B-NEG
retention I-NEG
and O
fibrosis B-NEG
during O
nephrotic B-NEG
syndrome I-NEG
. O

to O
this O
end O
, O
doxorubicin O
( O
15 O
mug/g O
body O
wt O
) O
was O
injected O
intravenously O
into O
gene-targeted O
mice O
lacking O
sgk1 O
( O
sgk1(-/-) O
) O
and O
their O
wild-type O
littermates O
(sgk1(+/+)) O
. O

doxorubicin O
treatment O
resulted O
in O
heavy O
proteinuria B-NEG
( O
>100 O
mg O
protein/mg O
crea O
) O
in O
15/44 O
of O
sgk1(+/+ O
) O
and O
15/44 O
of O
sgk1(-/- O
) O
mice O
leading O
to O
severe O
nephrotic B-NEG
syndrome I-NEG
with O
ascites B-NEG
, O
lipidemia B-NEG
, O
and O
hypoalbuminemia B-NEG
in O
both O
genotypes O
. O

plasma O
aldosterone O
levels O
increased O
in O
nephrotic B-NEG
mice O
of O
both O
genotypes O
and O
was O
followed O
by O
increased O
sgk1 O
protein O
expression O
in O
sgk1(+/+ O
) O
mice O
. O

urinary O
sodium O
excretion O
reached O
signficantly O
lower O
values O
in O
sgk1(+/+ O
) O
mice O
( O
15 O
+/- O
5 O
mumol/mg O
crea O
) O
than O
in O
sgk1(-/- O
) O
mice O
( O
35 O
+/- O
5 O
mumol/mg O
crea O
) O
and O
was O
associated O
with O
a O
significantly O
higher O
body O
weight B-NEG
gain I-NEG
in O
sgk1(+/+ O
) O
compared O
with O
sgk1(-/- O
) O
mice O
( O
+6.6 O
+/- O
0.7 O
vs O
. O
+4.1 O
+/- O
0.8 O
g) O
. O

during O
the O
course O
of O
nephrotic B-NEG
syndrome I-NEG
, O
serum O
urea O
concentrations O
increased O
significantly O
faster O
in O
sgk1(-/- O
) O
mice O
than O
in O
sgk1(+/+ O
) O
mice O
leading O
to O
uremia B-NEG
and O
a O
reduced O
median O
survival O
in O
sgk1(-/- O
) O
mice O
( O
29 O
vs O
. O
40 O
days O
in O
sgk1(+/+ O
) O
mice) O
. O

in O
conclusion O
, O
gene-targeted O
mice O
lacking O
sgk1 O
showed O
blunted O
volume B-NEG
retention I-NEG
, O
yet O
were O
not O
protected O
against O
renal O
fibrosis B-NEG
during O
experimental O
nephrotic B-NEG
syndrome I-NEG
. O

-DOCSTART- O

severe O
and O
long O
lasting O
cholestasis B-NEG
after O
high-dose O
co-trimoxazole O
treatment O
for O
pneumocystis B-NEG
pneumonia I-NEG
in O
hiv-infected B-NEG
patients--a O
report O
of O
two O
cases O
. O
pneumocystis B-NEG
pneumonia I-NEG
( O
pcp B-NEG
), O
a O
common O
opportunistic B-NEG
infection I-NEG
in O
hiv-infected B-NEG
individuals O
, O
is O
generally O
treated O
with O
high O
doses O
of O
co-trimoxazole O
. O

however O
, O
treatment O
is O
often O
limited O
by O
adverse O
effects O
. O

here O
, O
we O
report O
two O
cases O
of O
severely O
immunocompromised O
hiv-infected B-NEG
patients O
who O
developed O
severe O
intrahepatic B-NEG
cholestasis I-NEG
, O
and O
in O
one O
patient O
lesions O
mimicking O
liver B-NEG
abscess I-NEG
formation O
on O
radiologic O
exams O
, O
during O
co-trimoxazole O
treatment O
for O
pcp B-NEG
. O

whereas O
patient O
1 O
showed O
lesions O
of O
up O
to O
1 O
cm O
readily O
detectable O
on O
magnetic O
resonance O
imaging O
under O
prolonged O
co-trimoxazole O
treatment O
, O
therapy O
of O
patient O
2 O
was O
switched O
early O
. O

-DOCSTART- O

clinically O
significant O
proteinuria B-NEG
following O
the O
administration O
of O
sirolimus O
to O
renal O
transplant O
recipients O
. O

background O
: O
sirolimus O
is O
the O
latest O
immunosuppressive O
agent O
used O
to O
prevent O
rejection O
, O
and O
may O
have O
less O
nephrotoxicity B-NEG
than O
calcineurin O
inhibitor O
( O
cni)-based O
regimens O
. O

to O
date O
there O
has O
been O
little O
documentation O
of O
clinically O
significant O
proteinuria B-NEG
linked O
with O
the O
use O
of O
sirolimus O
. O

we O
have O
encountered O
several O
patients O
who O
developed O
substantial O
proteinuria B-NEG
associated O
with O
sirolimus O
use O
. O

in O
each O
patient O
, O
the O
close O
temporal O
association O
between O
the O
commencement O
of O
sirolimus O
therapy O
and O
proteinuria B-NEG
implicated O
sirolimus O
as O
the O
most O
likely O
etiology O
of O
the O
proteinuria B-NEG
. O

methods O
: O
we O
analyzed O
the O
clinical O
and O
laboratory O
information O
available O
for O
all O
119 O
patients O
transplanted O
at O
the O
washington O
hospital O
center O
between O
1999-2003 O
for O
whom O
sirolimus O
was O
a O
component O
of O
their O
immunosuppressant O
regimen O
. O

in O
these O
patients O
, O
the O
magnitude O
of O
proteinuria B-NEG
was O
assessed O
on O
morning O
urine O
samples O
by O
turbidometric O
measurement O
or O
random O
urine O
protein:creatinine O
ratios O
, O
an O
estimate O
of O
grams O
of O
proteinuria B-NEG
/day O
. O

laboratory O
results O
were O
compared O
between O
prior O
, O
during O
and O
following O
sirolimus O
use O
. O

results O
: O
twenty-eight O
patients O
( O
24% O
) O
developed O
increased O
proteinuria B-NEG
from O
baseline O
during O
their O
post-transplantation O
course O
. O

in O
21 O
patients O
an O
alternative O
cause O
of O
proteinuria B-NEG
was O
either O
obvious O
or O
insufficient O
data O
was O
available O
to O
be O
conclusive O
. O

in O
7 O
of O
the O
28 O
patients O
there O
was O
a O
striking O
temporal O
association O
between O
the O
initiation O
of O
sirolimus O
and O
the O
development O
of O
nephrotic B-NEG
-range O
proteinuria B-NEG
. O
proteinuria B-NEG
correlated O
most O
strongly O
with O
sirolimus O
therapy O
when O
compared O
to O
other O
demographic O
and O
clinical O
variables O
. O

in O
most O
patients O
, O
discontinuation O
of O
sirolimus O
resulted O
in O
a O
decrease O
, O
but O
not O
resolution O
, O
of O
proteinuria B-NEG
. O

conclusions O
: O
sirolimus O
induces O
or O
aggravates O
pre-existing O
proteinuria B-NEG
in O
an O
unpredictable O
subset O
of O
renal O
allograft O
recipients O
. O
proteinuria B-NEG
may O
improve O
, O
but O
does O
not O
resolve O
, O
when O
sirolimus O
is O
withdrawn O
. O

-DOCSTART- O

comparative O
cognitive O
and O
subjective O
side O
effects O
of O
immediate-release O
oxycodone O
in O
healthy O
middle-aged O
and O
older O
adults O
. O

this O
study O
measured O
the O
objective O
and O
subjective O
neurocognitive O
effects O
of O
a O
single O
10-mg O
dose O
of O
immediate-release O
oxycodone O
in O
healthy O
, O
older O
(> O
65 O
years) O
, O
and O
middle-aged O
( O
35 O
to O
55 O
years O
) O
adults O
who O
were O
not O
suffering O
from O
chronic O
or O
significant O
daily O
pain B-NEG
. O

seventy-one O
participants O
completed O
2 O
separate O
study O
days O
and O
were O
blind O
to O
medication O
condition O
(placebo O
, O
10-mg O
oxycodone) O
. O

plasma O
oxycodone O
concentration O
peaked O
between O
60 O
and O
90 O
minutes O
postdose O
(p O
< O
.01 O
) O
and O
pupil O
size O
, O
an O
indication O
of O
physiological O
effects O
of O
the O
medication O
, O
peaked O
at O
approximately O
90 O
to O
120 O
minutes O
postdose O
(p O
< O
.01) O
. O

significant O
declines B-NEG
in I-NEG
simple I-NEG
and I-NEG
sustained I-NEG
attention I-NEG
, O
working I-NEG
memory I-NEG
, O
and I-NEG
verbal I-NEG
memory I-NEG
were O
observed O
at O
1 O
hour O
postdose O
compared O
to O
baseline O
for O
both O
age O
groups O
with O
a O
trend O
toward O
return O
to O
baseline O
by O
5 O
hours O
postdose O
. O

for O
almost O
all O
cognitive O
measures O
, O
there O
were O
no O
medication O
by O
age-interaction O
effects O
, O
which O
indicates O
that O
the O
2 O
age O
groups O
exhibited O
similar O
responses O
to O
the O
medication O
challenge O
. O

this O
study O
suggests O
that O
for O
healthy O
older O
adults O
who O
are O
not O
suffering O
from O
chronic B-NEG
pain I-NEG
, O
neurocognitive O
and O
pharmacodynamic O
changes O
in O
response O
to O
a O
10-mg O
dose O
of O
immediate-release O
oxycodone O
are O
similar O
to O
those O
observed O
for O
middle-aged O
adults O
. O

perspective O
: O
study O
findings O
indicate O
that O
the O
metabolism O
, O
neurocognitive O
effects O
, O
and O
physical O
side O
effects O
of O
oral O
oxycodone O
are O
similar O
for O
healthy O
middle-aged O
and O
older O
adults O
. O

therefore O
, O
clinicians O
should O
not O
avoid O
prescribing O
oral O
opioids O
to O
older O
adults O
based O
on O
the O
belief O
that O
older O
adults O
are O
at O
higher O
risk O
for O
side O
effects O
than O
younger O
adults O
. O

-DOCSTART- O

normalizing O
effects O
of O
modafinil O
on O
sleep O
in O
chronic O
cocaine O
users O
. O

objective O
: O
the O
purpose O
of O
the O
present O
study O
was O
to O
determine O
the O
effect O
of O
morning-dosed O
modafinil O
on O
sleep O
and O
daytime B-NEG
sleepiness I-NEG
in O
chronic O
cocaine O
users O
. O

method O
: O
twenty O
cocaine-dependent O
participants O
were O
randomly O
assigned O
to O
receive O
modafinil O
, O
400 O
mg O
(n=10) O
, O
or O
placebo O
( O
n=10 O
) O
every O
morning O
at O
7:30 O
a.m O
. O
for O
16 O
days O
in O
an O
inpatient O
, O
double-blind O
randomized O
trial O
. O

participants O
underwent O
polysomnographic O
sleep O
recordings O
on O
days O
1 O
to O
3, O
7 O
to O
9, O
and O
14 O
to O
16 O
(first O
, O
second O
, O
and O
third O
weeks O
of O
abstinence) O
. O

the O
multiple O
sleep O
latency O
test O
was O
performed O
at O
11:30 O
a.m. O
, O
2:00 O
p.m. O
, O
and O
4:30 O
p.m O
. O
on O
days O
2, O
8, O
and O
15 O
. O

for O
comparison O
of O
sleep O
architecture O
variables O
, O
12 O
healthy O
comparison O
participants O
underwent O
a O
single O
night O
of O
experimental O
polysomnography O
that O
followed O
1 O
night O
of O
accommodation O
polysomnography O
. O

results O
: O
progressive O
abstinence O
from O
cocaine O
was O
associated O
with O
worsening O
of O
all O
measured O
polysomnographic O
sleep O
outcomes O
. O

compared O
with O
placebo O
, O
modafinil O
decreased O
nighttime O
sleep O
latency O
and O
increased O
slow-wave O
sleep O
time O
in O
cocaine-dependent O
participants O
. O

the O
effect O
of O
modafinil O
interacted O
with O
the O
abstinence O
week O
and O
was O
associated O
with O
longer O
total O
sleep O
time O
and O
shorter O
rem O
sleep O
latency O
in O
the O
third O
week O
of O
abstinence O
. O

comparison O
of O
slow-wave O
sleep O
time O
, O
total O
sleep O
time O
, O
and O
sleep O
latency O
in O
cocaine-dependent O
and O
healthy O
participants O
revealed O
a O
normalizing O
effect O
of O
modafinil O
in O
cocaine-dependent O
participants O
. O

modafinil O
was O
associated O
with O
increased O
daytime O
sleep O
latency O
, O
as O
measured O
by O
the O
multiple O
sleep O
latency O
test O
, O
and O
a O
nearly O
significant O
decrease O
in O
subjective O
daytime B-NEG
sleepiness I-NEG
. O

conclusions O
: O
morning-dosed O
modafinil O
promotes O
nocturnal O
sleep O
, O
normalizes O
sleep O
architecture O
, O
and O
decreases O
daytime B-NEG
sleepiness I-NEG
in O
abstinent O
cocaine O
users O
. O

these O
effects O
may O
be O
relevant O
in O
the O
treatment O
of O
cocaine O
dependence O
. O

-DOCSTART- O

efficacy O
and O
safety O
of O
asenapine O
in O
a O
placebo- O
and O
haloperidol-controlled O
trial O
in O
patients O
with O
acute O
exacerbation O
of O
schizophrenia B-NEG
. O

asenapine O
is O
approved O
by O
the O
food O
and O
drugs O
administration O
in O
adults O
for O
acute O
treatment O
of O
schizophrenia B-NEG
or O
of O
manic B-NEG
or O
mixed O
episodes O
associated O
with O
bipolar B-NEG
i I-NEG
disorder I-NEG
with O
or O
without O
psychotic B-NEG
features O
. O

in O
a O
double-blind O
6-week O
trial O
, O
458 O
patients O
with O
acute O
schizophrenia B-NEG
were O
randomly O
assigned O
to O
fixed-dose O
treatment O
with O
asenapine O
at O
5 O
mg O
twice O
daily O
(bid) O
, O
asenapine O
at O
10 O
mg O
bid O
, O
placebo O
, O
or O
haloperidol O
at O
4 O
mg O
bid O
( O
to O
verify O
assay O
sensitivity) O
. O

with O
last O
observations O
carried O
forward O
(locf) O
, O
mean O
positive O
and O
negative O
syndrome O
scale O
total O
score O
reductions O
from O
baseline O
to O
endpoint O
were O
significantly O
greater O
with O
asenapine O
at O
5 O
mg O
bid O
( O
-16.2 O
) O
and O
haloperidol O
( O
-15.4 O
) O
than O
placebo O
(-10.7 O
; O
both O
p O
< O
0.05) O
; O
using O
mixed O
model O
for O
repeated O
measures O
(mmrm) O
, O
changes O
at O
day O
42 O
were O
significantly O
greater O
with O
asenapine O
at O
5 O
and O
10 O
mg O
bid O
( O
-21.3 O
and O
-19.4 O
, O
respectively O
) O
and O
haloperidol O
( O
-20.0 O
) O
than O
placebo O
(-14.6 O
; O
all O
p O
< O
0.05) O
. O

on O
the O
positive O
and O
negative O
syndrome O
scale O
positive O
subscale O
, O
all O
treatments O
were O
superior O
to O
placebo O
with O
locf O
and O
mmrm O
; O
asenapine O
at O
5 O
mg O
bid O
was O
superior O
to O
placebo O
on O
the O
negative O
subscale O
with O
mmrm O
and O
on O
the O
general O
psychopathology O
subscale O
with O
locf O
and O
mmrm O
. O

treatment-related O
adverse O
events O
( O
aes O
) O
occurred O
in O
44% O
and O
52% O
, O
57% O
, O
and O
41% O
of O
the O
asenapine O
at O
5 O
and O
10 O
mg O
bid O
, O
haloperidol O
, O
and O
placebo O
groups O
, O
respectively O
. O
extrapyramidal B-NEG
symptoms I-NEG
reported O
as O
aes O
occurred O
in O
15% O
and O
18% O
, O
34% O
, O
and O
10% O
of O
the O
asenapine O
at O
5 O
and O
10 O
mg O
bid O
, O
haloperidol O
, O
and O
placebo O
groups O
, O
respectively O
. O

across O
all O
groups O
, O
no O
more O
than O
5% O
of O
patients O
had O
clinically O
significant O
weight O
change O
. O

post O
hoc O
analyses O
indicated O
that O
efficacy O
was O
similar O
with O
asenapine O
and O
haloperidol O
; O
greater O
contrasts O
were O
seen O
in O
aes O
, O
especially O
extrapyramidal B-NEG
symptoms I-NEG
. O

-DOCSTART- O

permeability O
, O
ultrastructural O
changes O
, O
and O
distribution O
of O
novel O
proteins O
in O
the O
glomerular O
barrier O
in O
early O
puromycin O
aminonucleoside O
nephrosis B-NEG
. O

background/aims O
: O
it O
is O
still O
unclear O
what O
happens O
in O
the O
glomerulus O
when O
proteinuria B-NEG
starts O
. O

using O
puromycin O
aminonucleoside O
nephrosis B-NEG
( O
pan O
) O
rats O
, O
we O
studied O
early O
ultrastructural O
and O
permeability O
changes O
in O
relation O
to O
the O
expression O
of O
the O
podocyte-associated O
molecules O
nephrin O
, O
a-actinin O
, O
dendrin O
, O
and O
plekhh2 O
, O
the O
last O
two O
of O
which O
were O
only O
recently O
discovered O
in O
podocytes O
. O

methods O
: O
using O
immune O
stainings O
, O
semiquantitative O
measurement O
was O
performed O
under O
the O
electron O
microscope O
. O

permeability O
was O
assessed O
using O
isolated O
kidney O
perfusion O
with O
tracers O
. O

possible O
effects O
of O
ace O
inhibition O
were O
tested O
. O

results O
: O
by O
day O
2, O
some O
patchy O
foot O
process O
effacement O
, O
but O
no O
proteinuria B-NEG
, O
appeared O
. O

the O
amount O
of O
nephrin O
was O
reduced O
in O
both O
diseased O
and O
normal O
areas O
. O

the O
other O
proteins O
showed O
few O
changes O
, O
which O
were O
limited O
to O
diseased O
areas O
. O

by O
day O
4, O
foot O
process O
effacement O
was O
complete O
and O
proteinuria B-NEG
appeared O
in O
parallel O
with O
signs O
of O
size O
barrier O
damage O
. O

nephrin O
decreased O
further O
, O
while O
dendrin O
and O
plekhh2 O
also O
decreased O
but O
a-actinin O
remained O
unchanged O
. O

ace O
inhibition O
had O
no O
significant O
protective O
effect O
. O

conclusions O
: O
pan O
glomeruli O
already O
showed O
significant O
pathology O
by O
day O
4, O
despite O
relatively O
mild O
proteinuria B-NEG
. O

this O
was O
preceded O
by O
altered O
nephrin O
expression O
, O
supporting O
its O
pivotal O
role O
in O
podocyte O
morphology O
. O

the O
novel O
proteins O
dendrin O
and O
plekhh2 O
were O
both O
reduced O
, O
suggesting O
roles O
in O
pan O
, O
whereas O
a-actinin O
was O
unchanged O
. O

-DOCSTART- O

twin O
preterm O
neonates O
with O
cardiac B-NEG
toxicity I-NEG
related O
to O
lopinavir/ritonavir O
therapy O
. O

we O
report O
twin O
neonates O
who O
were O
born O
prematurely O
at O
32 O
weeks O
of O
gestation O
to O
a O
mother O
with O
human B-NEG
immunodeficiency I-NEG
virus I-NEG
infection I-NEG
. O

one O
of O
the O
twins O
developed O
complete O
heart B-NEG
block I-NEG
and O
dilated B-NEG
cardiomyopathy I-NEG
related O
to O
lopinavir/ritonavir O
therapy O
, O
a O
boosted O
protease-inhibitor O
agent O
, O
while O
the O
other O
twin O
developed O
mild O
bradycardia B-NEG
. O

we O
recommend O
caution O
in O
the O
use O
of O
lopinavir/ritonavir O
in O
the O
immediate O
neonatal O
period O
. O

-DOCSTART- O

learning O
of O
rats O
under O
amnesia B-NEG
caused O
by O
pentobarbital O
. O

dissociated O
learning O
of O
rats O
in O
the O
normal O
state O
and O
the O
state O
of O
amnesia B-NEG
produced O
by O
pentobarbital O
( O
15 O
mg/kg O
, O
ip O
) O
was O
carried O
out O
. O

rats O
were O
trained O
to O
approach O
a O
shelf O
where O
they O
received O
food O
reinforcement O
. O

in O
group O
1 O
the O
rats O
were O
trained O
under O
the O
influence O
of O
pentobarbital O
to O
run O
to O
the O
same O
shelf O
as O
in O
the O
normal O
state O
. O

in O
group O
2 O
the O
rats O
were O
trained O
to O
approach O
different O
shelves O
in O
different O
drug O
states O
. O

it O
was O
shown O
that O
memory B-NEG
dissociation I-NEG
occurred O
in O
both O
groups O
. O

differences O
in O
the O
parameters O
of O
training O
under O
the O
influence O
of O
pentobarbital O
between O
groups O
1 O
and O
2 O
were O
revealed O
. O

these O
findings O
show O
that O
the O
brain-dissociated O
state O
induced O
by O
pentobarbital O
is O
formed O
with O
the O
participation O
of O
the O
mechanisms O
of O
information O
perception O
. O

-DOCSTART- O

angiosarcoma B-NEG
of I-NEG
the I-NEG
liver I-NEG
associated O
with O
diethylstilbestrol O
. O
angiosarcoma B-NEG
of I-NEG
the I-NEG
liver I-NEG
occurred O
in O
a O
76-year-old O
man O
who O
had O
been O
treated O
for O
a O
well-differentiated O
adenocarcinoma B-NEG
of I-NEG
the I-NEG
liver I-NEG
with O
diethylstilbestrol O
for O
13 O
years O
. O
angiosarcoma B-NEG
was O
also O
present O
within O
pulmonary O
and O
renal O
arteries O
. O

the O
possibility O
that O
the O
intraarterial B-NEG
lesions I-NEG
might O
represent O
independent O
primary O
tumors B-NEG
is O
considered O
. O

-DOCSTART- O

role O
of O
xanthine O
oxidase O
in O
dexamethasone-induced O
hypertension B-NEG
in O
rats O
. O

1. O

glucocorticoid-induced O
hypertension B-NEG
( O
gc- O
ht B-NEG
) O
in O
the O
rat O
is O
associated O
with O
nitric O
oxide-redox O
imbalance O
. O

2. O

we O
studied O
the O
role O
of O
xanthine O
oxidase O
(xo) O
, O
which O
is O
implicated O
in O
the O
production O
of O
reactive O
oxygen O
species O
, O
in O
dexamethasone-induced O
hypertension B-NEG
( O
dex- O
ht B-NEG
). O

3. O

thirty O
male O
sprague-dawley O
rats O
were O
divided O
randomly O
into O
four O
treatment O
groups O
: O
saline O
, O
dexamethasone O
(dex) O
, O
allopurinol O
plus O
saline O
, O
and O
allopurinol O
plus O
dex O
. O

4. O

systolic O
blood O
pressures O
( O
sbp O
) O
and O
bodyweights O
were O
recorded O
each O
alternate O
day O
. O

thymus O
weight O
was O
used O
as O
a O
marker O
of O
glucocorticoid O
activity O
, O
and O
serum O
urate O
to O
assess O
xo O
inhibition O
. O

5. O

dex O
increased B-NEG
sbp I-NEG
( O
110 O
+/- O
2-126 O
+/- O
3 O
mmhg O
; O
p O
< O
0.001 O
) O
and O
decreased B-NEG
thymus I-NEG
( O
p I-NEG
< I-NEG
0.001 I-NEG
) O
and I-NEG
bodyweights I-NEG
(p O
< O
0.01) O
. O

allopurinol O
decreased O
serum O
urate O
from O
76 O
+/- O
5 O
to O
30 O
+/- O
3 O
micromol/l O
(p O
< O
0.001 O
) O
in O
saline O
and O
from O
84 O
+/- O
13 O
to O
28 O
+/- O
2 O
micromol/l O
in O
dex-treated O
(p O
< O
0.01 O
) O
groups O
. O

6. O

allopurinol O
did O
not O
prevent O
dex- O
ht B-NEG
. O

this O
, O
together O
with O
our O
previous O
findings O
that O
allopurinol O
failed O
to O
prevent O
adrenocorticotrophic O
hormone O
induced O
hypertension B-NEG
, O
suggests O
that O
xo O
activity O
is O
not O
a O
major O
determinant O
of O
gc- O
ht B-NEG
in O
the O
rat O
. O

-DOCSTART- O

extrapyramidal O
side O
effects O
with O
risperidone O
and O
haloperidol O
at O
comparable O
d2 O
receptor O
occupancy O
levels O
. O

risperidone O
is O
an O
antipsychotic O
drug O
with O
high O
affinity O
at O
dopamine O
d2 O
and O
serotonin O
5-ht2 O
receptors O
. O

previous O
clinical O
studies O
have O
proposed O
that O
risperidone's O
pharmacologic O
profile O
may O
produce O
improved O
efficacy O
for O
negative O
psychotic B-NEG
symptoms I-NEG
and O
decreased O
propensity O
for O
extrapyramidal O
side O
effects O
; O
features O
shared O
by O
so-called O
'atypical' O
neuroleptics O
. O

to O
determine O
if O
routine O
risperidone O
treatment O
is O
associated O
with O
a O
unique O
degree O
of O
d2 O
receptor O
occupancy O
and O
pattern O
of O
clinical O
effects O
, O
we O
used O
[123i]ibzm O
spect O
to O
determine O
d2 O
occupancy O
in O
subjects O
treated O
with O
routine O
clinical O
doses O
of O
risperidone O
(n O
= O
12 O
) O
or O
haloperidol O
(n O
= O
7) O
. O

both O
risperidone O
and O
haloperidol O
produced O
d2 O
occupancy O
levels O
between O
approximately O
60 O
and O
90% O
at O
standard O
clinical O
doses O
. O

there O
was O
no O
significant O
difference O
between O
occupancy O
levels O
obtained O
with O
haloperidol O
or O
risperidone O
. O
drug-induced B-NEG
parkinsonism I-NEG
was O
observed O
in O
subjects O
treated O
with O
risperidone O
( O
42% O
) O
and O
haloperidol O
( O
29% O
) O
and O
was O
observed O
at O
occupancy O
levels O
above O
60% O
. O

based O
on O
these O
observations O
, O
it O
is O
concluded O
that O
5-ht2 O
blockade O
obtained O
with O
risperidone O
at O
d2 O
occupancy O
rates O
of O
60% O
and O
above O
does O
not O
appear O
to O
protect O
against O
the O
risk O
for O
extrapyramidal O
side O
effects O
. O

-DOCSTART- O

simvastatin-ezetimibe-induced O
hepatic B-NEG
failure I-NEG
necessitating O
liver O
transplantation O
. O

abstract O
serum O
aminotransferase O
elevations O
are O
a O
commonly O
known O
adverse O
effect O
of O
3-hydroxy-3-methylglutaryl O
coenzyme O
a O
reductase O
inhibitor O
( O
statin O
) O
therapy O
. O

however O
, O
hepatotoxic B-NEG
events O
have O
not O
been O
widely O
published O
with O
ezetimibe O
or O
the O
combination O
agent O
simvastatin-ezetimibe O
. O

we O
describe O
a O
70-year-old O
hispanic O
woman O
who O
developed O
fulminant B-NEG
hepatic I-NEG
failure I-NEG
necessitating O
liver O
transplantation O
10 O
weeks O
after O
conversion O
from O
simvastatin O
40 O
mg/day O
to O
simvastatin O
10 O
mg-ezetimibe O
40 O
mg/day O
. O

the O
patient's O
lipid O
panel O
had O
been O
maintained O
with O
simvastatin O
for O
18 O
months O
before O
the O
conversion O
without O
evidence O
of O
hepatotoxicity B-NEG
. O

a O
routine O
laboratory O
work-up O
10 O
weeks O
after O
conversion O
revealed O
elevated O
serum O
aminotransferase O
levels O
. O

simvastatinezetimibe O
and O
escitalopram O
( O
which O
she O
was O
taking O
for O
depression B-NEG
) O
were O
discontinued O
, O
and O
other O
potential O
causes O
of O
hepatotoxicity B-NEG
were O
excluded O
. O

a O
repeat O
work-up O
revealed O
further O
elevations O
in O
aminotransferase O
levels O
, O
and O
liver O
biopsy O
revealed O
evidence O
of O
moderate-to-severe O
drug B-NEG
toxicity I-NEG
. O

she O
underwent O
liver O
transplantation O
with O
an O
uneventful O
postoperative O
course O
. O

her O
aminotransferase O
levels O
returned O
to O
normal O
by O
postoperative O
day O
23 O
, O
and O
her O
2-year O
follow-up O
showed O
no O
adverse O
events O
. O

ezetimibe O
undergoes O
extensive O
glucuronidation O
by O
uridine O
diphosphate O
glucoronosyltransferases O
( O
ugt O
) O
in O
the O
intestine O
and O
liver O
and O
may O
have O
inhibited O
the O
glucuronidation O
of O
simvastatin O
hydroxy O
acid O
, O
resulting O
in O
increased O
simvastatin O
exposure O
and O
subsequent O
hepatotoxicity B-NEG
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
of O
simvastatin-ezetimibe-induced O
liver B-NEG
failure I-NEG
that O
resulted O
in O
liver O
transplantation O
. O

we O
postulate O
that O
the O
mechanism O
of O
the O
simvastatinezetimibe-induced O
hepatotoxicity B-NEG
is O
the O
increased O
simvastatin O
exposure O
by O
ezetimibe O
inhibition O
of O
ugt O
enzymes O
. O

clinicians O
should O
be O
aware O
of O
potential O
hepatotoxicity B-NEG
with O
simvastatin-ezetimibe O
especially O
in O
elderly O
patients O
and O
should O
carefully O
monitor O
serum O
aminotransferase O
levels O
when O
starting O
therapy O
and O
titrating O
the O
dosage O
. O

-DOCSTART- O

oral O
manifestations O
of O
meth B-NEG
mouth I-NEG
: O
a O
case O
report O
. O

aim O
: O
the O
aim O
of O
the O
documentation O
of O
this O
clinical O
case O
is O
to O
make O
clinicians O
aware O
of O
meth B-NEG
mouth I-NEG
and O
the O
medical O
risks O
associated O
with O
this O
serious O
condition O
. O

background O
: O
methamphetamine O
is O
a O
very O
addictive O
, O
powerful O
stimulant O
that O
increases O
wakefulness O
and O
physical O
activity O
and O
can O
produce O
other O
effects O
such O
as O
cardiac B-NEG
dysrhythmias I-NEG
, O
hypertension B-NEG
, O
hallucinations B-NEG
, O
and O
violent B-NEG
behavior I-NEG
. O

dental O
patients O
abusing O
methamphetamine O
can O
present O
with O
poor O
oral O
hygiene O
, O
xerostomia B-NEG
, O
rampant O
caries B-NEG
( O
meth B-NEG
mouth I-NEG
), O
and O
excessive O
tooth B-NEG
wear I-NEG
. O

oral O
rehabilitation O
of O
patients O
using O
methamphetamine O
can O
be O
challenging O
. O

case O
description O
: O
a O
30-year-old O
caucasian O
woman O
presented O
with O
dental O
pain B-NEG
, O
bad B-NEG
breath I-NEG
, O
and O
self-reported O
poor O
esthetics O
. O

a O
comprehensive O
examination O
including O
her O
medical O
history O
, O
panoramic O
radiograph O
, O
and O
intraoral O
examination O
revealed O
19 O
carious B-NEG
lesions I-NEG
, O
which O
is O
not O
very O
common O
for O
a O
healthy O
adult O
. O

she O
reported O
her O
use O
of O
methamphetamine O
for O
five O
years O
and O
had O
not O
experienced O
any O
major O
carious B-NEG
episodes I-NEG
before O
she O
started O
using O
the O
drug O
. O

summary O
: O
the O
patient's O
medical O
and O
dental O
histories O
along O
with O
radiographic O
and O
clinical O
findings O
lead O
to O
a O
diagnosis O
of O
meth B-NEG
mouth I-NEG
. O

although O
three O
different O
dental O
treatment O
modalities O
( O
either O
conventional O
or O
implant-supported O
) O
have O
been O
offered O
to O
the O
patient O
since O
august O
2007 O
, O
the O
patient O
has O
yet O
to O
initiate O
any O
treatment O
. O

clinical O
significance O
: O
this O
clinical O
case O
showing O
oral O
manifestations O
of O
meth B-NEG
mouth I-NEG
was O
presented O
to O
help O
dental O
practitioners O
recognize O
and O
manage O
patients O
who O
may O
be O
abusing O
methamphetamines O
. O

dental O
practitioners O
also O
may O
be O
skeptical O
about O
the O
reliability O
of O
appointment O
keeping O
by O
these O
patients O
, O
as O
they O
frequently O
miss O
their O
appointments O
without O
reasonable O
justification O
. O

-DOCSTART- O

thyroxine O
abuse O
: O
an O
unusual O
case O
of O
thyrotoxicosis B-NEG
in O
pregnancy O
. O
eating B-NEG
disorders I-NEG
and O
the O
associated O
behavioural O
problems O
and O
drug B-NEG
abuse I-NEG
are O
uncommon O
in O
pregnancy O
. O

when O
they O
do O
occur O
they O
are O
often O
unrecognized O
because O
of O
denial O
but O
when O
significant O
may O
pose O
a O
risk O
to O
both O
the O
mother O
and O
her O
fetus O
. O

this O
case O
illustrates O
a O
number O
of O
problems O
that O
may O
be O
encountered O
in O
women O
with O
eating B-NEG
disorders I-NEG
in O
pregnancy O
, O
including O
prolonged O
and O
recurrent O
metabolic O
disturbances O
and O
diuretic O
abuse O
. O

in O
particular O
it O
illustrates O
the O
derangements O
of O
thyroid O
function O
seen O
in O
pregnant O
women O
with O
eating B-NEG
disorders I-NEG
and O
reminds O
us O
that O
when O
a O
cause O
for O
thyrotoxicosis B-NEG
remains O
obscure O
, O
thyroxine O
abuse O
should O
be O
considered O
and O
explored O
. O

-DOCSTART- O

attenuation O
of O
methamphetamine-induced O
nigrostriatal O
dopaminergic O
neurotoxicity B-NEG
in O
mice O
by O
lipopolysaccharide O
pretreatment O
. O

immunological O
activation O
has O
been O
proposed O
to O
play O
a O
role O
in O
methamphetamine-induced O
dopaminergic B-NEG
terminal I-NEG
damage I-NEG
. O

in O
this O
study O
, O
we O
examined O
the O
roles O
of O
lipopolysaccharide O
, O
a O
pro-inflammatory O
and O
inflammatory O
factor O
, O
treatment O
in O
modulating O
the O
methamphetamine-induced O
nigrostriatal O
dopamine O
neurotoxicity B-NEG
. O

lipopolysaccharide O
pretreatment O
did O
not O
affect O
the O
basal O
body O
temperature O
or O
methamphetamine-elicited O
hyperthermia B-NEG
three O
days O
later O
. O

such O
systemic O
lipopolysaccharide O
treatment O
mitigated O
methamphetamine-induced O
striatal O
dopamine O
and O
3,4-dihydroxyphenylacetic O
acid O
depletions O
in O
a O
dose-dependent O
manner O
. O

as O
the O
most O
potent O
dose O
(1 O
mg/kg O
) O
of O
lipopolysaccharide O
was O
administered O
two O
weeks O
, O
one O
day O
before O
or O
after O
the O
methamphetamine O
dosing O
regimen O
, O
methamphetamine-induced O
striatal O
dopamine O
and O
3,4-dihydroxyphenylacetic O
acid O
depletions O
remained O
unaltered O
. O

moreover O
, O
systemic O
lipopolysaccharide O
pretreatment O
(1 O
mg/kg O
) O
attenuated O
local O
methamphetamine O
infusion-produced O
dopamine O
and O
3,4-dihydroxyphenylacetic O
acid O
depletions O
in O
the O
striatum O
, O
indicating O
that O
the O
protective O
effect O
of O
lipopolysaccharide O
is O
less O
likely O
due O
to O
interrupted O
peripheral O
distribution O
or O
metabolism O
of O
methamphetamine O
. O

we O
concluded O
a O
critical O
time O
window O
for O
systemic O
lipopolysaccharide O
pretreatment O
in O
exerting O
effective O
protection O
against O
methamphetamine-induced O
nigrostriatal O
dopamine O
neurotoxicity B-NEG
. O

-DOCSTART- O

effect O
of O
converting O
enzyme O
inhibition O
on O
the O
course O
of O
adriamycin-induced O
nephropathy B-NEG
. O

the O
effect O
of O
the O
converting O
enzyme O
inhibitor O
( O
cei O
) O
enalapril O
was O
assessed O
in O
munich-wistar O
rats O
with O
established O
adriamycin O
nephrosis B-NEG
. O

rats O
were O
given O
a O
single O
dose O
of O
adriamycin O
and O
one O
month O
later O
divided O
into O
four O
groups O
matched O
for O
albuminuria B-NEG
, O
blood O
pressure O
, O
and O
plasma O
albumin O
concentration O
. O

groups O
1 O
and O
3 O
remained O
untreated O
while O
groups O
2 O
and O
4 O
received O
enalapril O
. O

groups O
1 O
and O
2 O
underwent O
micropuncture O
studies O
after O
10 O
days O
. O

these O
short-term O
studies O
showed O
that O
enalapril O
reduced O
arterial O
blood O
pressure O
( O
101 O
+/- O
2 O
vs O
. O
124 O
+/- O
3 O
mm O
hg O
, O
group O
2 O
vs O
. O
1, O
p O
less O
than O
0.05 O
) O
and O
glomerular O
capillary O
pressure O
( O
54 O
+/- O
1 O
vs O
. O
61 O
+/- O
2 O
mm O
hg O
, O
p O
less O
than O
0.05 O
) O
without O
reducing O
albuminuria B-NEG
( O
617 O
+/- O
50 O
vs O
. O
570 O
+/- O
47 O
mg/day O
) O
or O
gfr O
( O
1.03 O
+/- O
0.04 O
vs O
. O
1.04 O
+/- O
0.11 O
ml/min) O
. O

groups O
3 O
and O
4 O
were O
studied O
at O
four O
and O
at O
six O
months O
to O
assess O
the O
effect O
of O
enalapril O
on O
progression O
of O
renal B-NEG
injury I-NEG
in O
adriamycin O
nephrosis B-NEG
. O

chronic O
enalapril O
treatment O
reduced O
blood O
pressure O
without O
reducing O
albuminuria B-NEG
in O
group O
4. O

untreated O
group O
3 O
rats O
exhibited O
a O
progressive O
reduction O
in O
gfr O
( O
0.35 O
+/- O
0.08 O
ml/min O
at O
4 O
months O
, O
0.27 O
+/- O
0.07 O
ml/min O
at O
6 O
months) O
. O

enalapril O
treatment O
blunted O
but O
did O
not O
prevent O
reduction O
in O
gfr O
in O
group O
4 O
( O
0.86 O
+/- O
0.15 O
ml/min O
at O
4 O
months O
, O
0.69 O
+/- O
0.13 O
ml/min O
at O
6 O
months O
, O
both O
p O
less O
than O
0.05 O
vs O
. O
group O
3) O
. O

reduction O
in O
gfr O
was O
associated O
with O
the O
development O
of O
glomerular B-NEG
sclerosis I-NEG
in O
both O
treated O
and O
untreated O
rats.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

butyrylcholinesterase O
gene O
mutations O
in O
patients O
with O
prolonged O
apnea B-NEG
after O
succinylcholine O
for O
electroconvulsive O
therapy O
. O

background O
: O
patients O
undergoing O
electroconvulsive O
therapy O
( O
ect O
) O
often O
receive O
succinylcholine O
as O
part O
of O
the O
anesthetic O
procedure O
. O

the O
duration O
of O
action O
may O
be O
prolonged O
in O
patients O
with O
genetic O
variants O
of O
the O
butyrylcholinesterase O
enzyme O
(bche) O
, O
the O
most O
common O
being O
the O
k- O
and O
the O
a-variants O
. O

the O
aim O
of O
the O
study O
was O
to O
assess O
the O
clinical O
significance O
of O
genetic O
variants O
in O
butyrylcholinesterase O
gene O
( O
bche O
) O
in O
patients O
with O
a O
suspected O
prolonged O
duration O
of O
action O
of O
succinylcholine O
after O
ect O
. O

methods O
: O
a O
total O
of O
13 O
patients O
were O
referred O
to O
the O
danish O
cholinesterase O
research O
unit O
after O
ect O
during O
38 O
months O
. O

we O
determined O
the O
bche O
activity O
and O
the O
bche O
genotype O
using O
molecular O
genetic O
methods O
, O
the O
duration O
of O
apnea B-NEG
, O
time O
to O
sufficient O
spontaneous O
ventilation O
and O
whether O
neuromuscular O
monitoring O
was O
used O
. O

the O
duration O
of O
apnea B-NEG
was O
compared O
with O
published O
data O
on O
normal O
subjects O
. O

results O
: O
in O
11 O
patients O
, O
mutations O
were O
found O
in O
the O
bche O
gene O
, O
the O
k-variant O
being O
the O
most O
frequent O
. O

the O
duration O
of O
apnea B-NEG
was O
5-15 O
min O
compared O
with O
3-5.3 O
min O
from O
the O
literature O
. O

severe O
distress O
was O
noted O
in O
the O
recovery O
phase O
in O
two O
patients O
. O

neuromuscular O
monitoring O
was O
used O
in O
two O
patients O
. O

conclusion O
: O
eleven O
of O
13 O
patients O
with O
a O
prolonged O
duration O
of O
action O
of O
succinylcholine O
had O
mutations O
in O
bche O
, O
indicating O
that O
this O
is O
the O
possible O
reason O
for O
a O
prolonged O
period O
of O
apnea B-NEG
. O

we O
recommend O
objective O
neuromuscular O
monitoring O
during O
the O
first O
ect O
. O

-DOCSTART- O

ketamine O
sedation O
for O
the O
reduction O
of O
children's O
fractures B-NEG
in O
the O
emergency O
department O
. O

background O
: O
there O
recently O
has O
been O
a O
resurgence O
in O
the O
utilization O
of O
ketamine O
, O
a O
unique O
anesthetic O
, O
for O
emergency-department O
procedures O
requiring O
sedation O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
examine O
the O
safety O
and O
efficacy O
of O
ketamine O
for O
sedation O
in O
the O
treatment O
of O
children's O
fractures B-NEG
in O
the O
emergency O
department O
. O

methods O
: O
one O
hundred O
and O
fourteen O
children O
( O
average O
age O
, O
5.3 O
years O
; O
range O
, O
twelve O
months O
to O
ten O
years O
and O
ten O
months O
) O
who O
underwent O
closed O
reduction O
of O
an O
isolated O
fracture B-NEG
or O
dislocation B-NEG
in O
the O
emergency O
department O
at O
a O
level-i O
trauma B-NEG
center O
were O
prospectively O
evaluated O
. O

ketamine O
hydrochloride O
was O
administered O
intravenously O
( O
at O
a O
dose O
of O
two O
milligrams O
per O
kilogram O
of O
body O
weight O
) O
in O
ninety-nine O
of O
the O
patients O
and O
intramuscularly O
( O
at O
a O
dose O
of O
four O
milligrams O
per O
kilogram O
of O
body O
weight O
) O
in O
the O
other O
fifteen O
. O

a O
board-certified O
emergency O
physician O
skilled O
in O
airway O
management O
supervised O
administration O
of O
the O
anesthetic O
, O
and O
the O
patients O
were O
monitored O
by O
a O
registered O
nurse O
. O

any O
pain B-NEG
during O
the O
reduction O
was O
rated O
by O
the O
orthopaedic O
surgeon O
treating O
the O
patient O
according O
to O
the O
children's O
hospital O
of O
eastern O
ontario O
pain B-NEG
scale O
(cheops) O
. O

results O
: O
the O
average O
time O
from O
intravenous O
administration O
of O
ketamine O
to O
manipulation O
of O
the O
fracture B-NEG
or O
dislocation B-NEG
was O
one O
minute O
and O
thirty-six O
seconds O
(range O
, O
twenty O
seconds O
to O
five O
minutes) O
, O
and O
the O
average O
time O
from O
intramuscular O
administration O
to O
manipulation O
was O
four O
minutes O
and O
forty-two O
seconds O
(range O
, O
sixty O
seconds O
to O
fifteen O
minutes) O
. O

the O
average O
score O
according O
to O
the O
children's O
hospital O
of O
eastern O
ontario O
pain B-NEG
scale O
was O
6.4 O
points O
(range O
, O
5 O
to O
10 O
points) O
, O
reflecting O
minimal O
or O
no O
pain B-NEG
during O
fracture B-NEG
reduction O
. O

adequate O
fracture B-NEG
reduction O
was O
obtained O
in O
111 O
of O
the O
children O
. O

ninety-nine O
percent O
( O
sixty-eight O
) O
of O
the O
sixty-nine O
parents O
present O
during O
the O
reduction O
were O
pleased O
with O
the O
sedation O
and O
would O
allow O
it O
to O
be O
used O
again O
in O
a O
similar O
situation O
. O

patency O
of O
the O
airway O
and O
independent O
respiration O
were O
maintained O
in O
all O
of O
the O
patients O
. O

blood O
pressure O
and O
heart O
rate O
remained O
stable O
. O

minor O
side O
effects O
included O
nausea B-NEG
( O
thirteen O
patients) O
, O
emesis B-NEG
( O
eight O
of O
the O
thirteen O
patients O
with O
nausea B-NEG
), O
clumsiness B-NEG
( O
evident O
as O
ataxic B-NEG
movements I-NEG
in O
ten O
patients) O
, O
and O
dysphoric B-NEG
reaction I-NEG
( O
one O
patient) O
. O

no O
long-term O
sequelae O
were O
noted O
, O
and O
no O
patients O
had O
hallucinations B-NEG
or O
nightmares O
. O

conclusions O
: O
ketamine O
reliably O
, O
safely O
, O
and O
quickly O
provided O
adequate O
sedation O
to O
effectively O
facilitate O
the O
reduction O
of O
children's O
fractures B-NEG
in O
the O
emergency O
department O
at O
our O
institution O
. O

ketamine O
should O
only O
be O
used O
in O
an O
environment O
such O
as O
the O
emergency O
department O
, O
where O
proper O
one-on-one O
monitoring O
is O
used O
and O
board-certified O
physicians O
skilled O
in O
airway O
management O
are O
directly O
involved O
in O
the O
care O
of O
the O
patient O
. O

-DOCSTART- O

prophylactic O
use O
of O
lamivudine O
with O
chronic O
immunosuppressive O
therapy O
for O
rheumatologic B-NEG
disorders I-NEG
. O

the O
objective O
of O
this O
study O
was O
to O
report O
our O
experience O
concerning O
the O
effectiveness O
of O
the O
prophylactic O
administration O
of O
lamivudine O
in O
hepatitis O
b O
virus O
surface O
antigen O
( O
hbs O
ag O
) O
positive O
patients O
with O
rheumatologic B-NEG
disease I-NEG
. O

from O
june O
2004 O
to O
october O
2006 O
, O
11 O
hbs O
ag O
positive O
patients O
with O
rheumatologic B-NEG
diseases I-NEG
, O
who O
were O
on O
both O
immunosuppressive O
and O
prophylactic O
lamivudine O
therapies O
, O
were O
retrospectively O
assessed O
. O

liver O
function O
tests O
, O
hepatitis B-NEG
b I-NEG
virus O
( O
hbv O
) O
serologic O
markers O
, O
and O
hbv O
dna O
levels O
of O
the O
patients O
during O
follow-up O
were O
obtained O
from O
hospital O
file O
records O
. O

eleven O
patients O
( O
six O
male O
) O
with O
median O
age O
47 O
years O
( O
range O
27-73) O
, O
median O
disease O
duration O
50 O
months O
( O
range O
9-178 O
) O
and O
median O
follow-up O
period O
of O
patients O
13.8 O
months O
( O
range O
5-27 O
) O
were O
enrolled O
in O
this O
study O
. O

lamivudine O
therapy O
was O
started O
3-7 O
days O
prior O
to O
immunosuppressive O
therapy O
in O
all O
patients O
. O

baseline O
, O
liver O
function O
tests O
were O
elevated O
in O
two O
patients O
( O
fourth O
patient O
: O
alt:122 O
iu/l O
, O
ast:111 O
iu/l O
, O
tenth O
patient:alt:294 O
iu/l O
, O
ast:274 O
iu/l O
, O
with O
minimal O
changes O
in O
the O
liver O
biopsy O
in O
both) O
. O

shortly O
after O
treatment O
their O
tests O
normalized O
and O
during O
follow-up O
period O
none O
of O
the O
patients O
had O
abnormal B-NEG
liver I-NEG
function I-NEG
tests O
. O

in O
four O
patients O
hbv O
dna O
levels O
were O
higher O
than O
normal O
at O
baseline O
. O

two O
of O
these O
normalized O
and O
the O
others O
increased O
later O
. O

in O
three O
additional O
patients O
, O
hbv O
dna O
levels O
were O
increased O
during O
follow-up O
. O

none O
of O
the O
patients O
had O
significant O
clinical O
sings O
of O
hbv O
activation O
. O

lamivudine O
was O
well O
tolerated O
and O
was O
continued O
in O
all O
patients O
. O

prophylactic O
administration O
of O
lamivudine O
in O
patients O
who O
required O
immunosuppressive O
therapy O
seems O
to O
be O
safe O
, O
well O
tolerated O
and O
effective O
in O
preventing O
hbv O
reactivation O
. O

-DOCSTART- O

safety O
of O
transesophageal O
echocardiography O
in O
adults O
: O
study O
in O
a O
multidisciplinary O
hospital O
. O

background O
: O
tee O
is O
a O
semi-invasive O
tool O
broadly O
used O
and O
its O
utilization O
associated O
to O
sedatives O
drugs O
might O
to O
affect O
the O
procedure O
safety O
. O

objective O
: O
to O
analyze O
aspects O
of O
tee O
safety O
associated O
to O
the O
use O
of O
midazolan O
( O
mz O
) O
and O
flumazenil O
( O
fl O
) O
and O
the O
influence O
of O
the O
clinical O
variables O
on O
the O
event O
rate O
. O

method O
: O
prospective O
study O
with O
137 O
patients O
that O
underwent O
tee O
with O
mz O
associated O
to O
moderate O
sedation O
. O

we O
analyzed O
the O
following O
events O
: O
complications O
related O
with O
the O
topical O
anesthesia O
, O
with O
mz O
use O
and O
with O
the O
procedure O
. O

uni- O
and O
multivariate O
analyses O
were O
used O
to O
test O
the O
influence O
of O
the O
clinical O
variables O
: O
age O
, O
sex O
, O
stroke B-NEG
, O
myocardiopathy B-NEG
( O
mp B-NEG
), O
duration O
of O
the O
test O
, O
mitral B-NEG
regurgitation I-NEG
( O
mr B-NEG
) O
and O
the O
mz O
dose O
. O

results O
: O
all O
patients O
( O
65+/-16 O
yrs O
; O
58% O
males O
) O
finished O
the O
examination O
. O

the O
mean O
doses O
of O
mz O
and O
fl O
were O
4.3+/-1.9 O
mg O
and O
0.28+/-0.2 O
mg O
, O
respectively O
. O

the O
duration O
of O
the O
examination O
and O
the O
mean O
ejection O
fraction O
( O
ef O
) O
were O
16.4+/-6.1 O
minutes O
and O
60+/-9% O
, O
respectively O
. O

mild O
hypoxia B-NEG
( O
so2<90% O
) O
was O
the O
most O
common O
event O
( O
11 O
patients) O
; O
3 O
patients O
( O
2% O
) O
presented O
transient O
hypoxia B-NEG
due O
to O
upper O
airway B-NEG
obstruction I-NEG
by O
probe O
introduction O
and O
8 O
( O
5.8% O
) O
due O
to O
hypoxia B-NEG
caused O
by O
mz O
use O
. O

transient O
hypotension B-NEG
( O
sap<90mmhg O
) O
occurred O
in O
1 O
patient O
(0.7%) O
. O

the O
multivariate O
analysis O
showed O
that O
severe O
mr B-NEG
, O
mp B-NEG
( O
ef<45% O
) O
and O
high O
doses O
of O
mz O
( O
>5mg O
) O
were O
associated O
with O
events O
(p<0.001) O
. O

the O
ef O
was O
40% O
, O
in O
the O
group O
with O
mp B-NEG
and O
44% O
in O
the O
group O
with O
severe O
mr B-NEG
and O
it O
can O
be O
a O
factor O
associated O
with O
clinical O
events O
in O
the O
last O
group O
. O

conclusion O
: O
tee O
with O
sedation O
presents O
a O
low O
rate O
of O
events O
. O

there O
were O
no O
severe O
events O
and O
there O
was O
no O
need O
to O
interrupt O
the O
examinations O
. O

-DOCSTART- O

effects O
of O
calcium O
channel O
blockers O
on O
bupivacaine-induced O
toxicity B-NEG
. O

the O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
influence O
of O
calcium O
channel O
blockers O
on O
bupivacaine-induced O
acute O
toxicity B-NEG
. O

for O
each O
of O
the O
three O
tested O
calcium O
channel O
blockers O
(diltiazem O
, O
verapamil O
and O
bepridil O
) O
6 O
groups O
of O
mice O
were O
treated O
by O
two O
different O
doses O
, O
i.e O
. O

2 O
and O
10 O
mg/kg/i.p. O
, O
or O
an O
equal O
volume O
of O
saline O
for O
the O
control O
group O
(n O
= O
20) O
; O
15 O
minutes O
later O
, O
all O
the O
animals O
were O
injected O
with O
a O
single O
50 O
mg/kg/i.p O
. O
dose O
of O
bupivacaine O
. O

the O
convulsant O
activity O
, O
the O
time O
of O
latency O
to O
convulse O
and O
the O
mortality O
rate O
were O
assessed O
in O
each O
group O
. O

the O
local O
anesthetic-induced O
mortality O
was O
significantly O
increased O
by O
the O
three O
different O
calcium O
channel O
blockers O
. O

the O
convulsant O
activity O
of O
bupivacaine O
was O
not O
significantly O
modified O
but O
calcium O
channel O
blockers O
decreased O
the O
time O
of O
latency O
to O
obtain O
bupivacaine-induced O
convulsions B-NEG
; O
this O
effect O
was O
less O
pronounced O
with O
bepridil O
. O

-DOCSTART- O

selegiline-induced O
postural B-NEG
hypotension I-NEG
in O
parkinson's B-NEG
disease I-NEG
: O
a O
longitudinal O
study O
on O
the O
effects O
of O
drug O
withdrawal O
. O

objectives O
: O
the O
united O
kingdom O
parkinson's B-NEG
disease I-NEG
research O
group O
( O
ukpdrg O
) O
trial O
found O
an O
increased O
mortality O
in O
patients O
with O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
randomized O
to O
receive O
10 O
mg O
selegiline O
per O
day O
and O
l-dopa O
compared O
with O
those O
taking O
l-dopa O
alone O
. O

recently O
, O
we O
found O
that O
therapy O
with O
selegiline O
and O
l-dopa O
was O
associated O
with O
selective O
systolic B-NEG
orthostatic I-NEG
hypotension I-NEG
which O
was O
abolished O
by O
withdrawal O
of O
selegiline O
. O

this O
unwanted O
effect O
on O
postural O
blood O
pressure O
was O
not O
the O
result O
of O
underlying O
autonomic O
failure O
. O

the O
aims O
of O
this O
study O
were O
to O
confirm O
our O
previous O
findings O
in O
a O
separate O
cohort O
of O
patients O
and O
to O
determine O
the O
time O
course O
of O
the O
cardiovascular O
consequences O
of O
stopping O
selegiline O
in O
the O
expectation O
that O
this O
might O
shed O
light O
on O
the O
mechanisms O
by O
which O
the O
drug O
causes O
orthostatic B-NEG
hypotension I-NEG
. O

methods O
: O
the O
cardiovascular O
responses O
to O
standing O
and O
head-up O
tilt O
were O
studied O
repeatedly O
in O
pd B-NEG
patients O
receiving O
selegiline O
and O
as O
the O
drug O
was O
withdrawn O
. O

results O
: O
head-up O
tilt O
caused O
systolic B-NEG
orthostatic I-NEG
hypotension I-NEG
which O
was O
marked O
in O
six O
of O
20 O
pd B-NEG
patients O
on O
selegiline O
, O
one O
of O
whom O
lost O
consciousness O
with O
unrecordable O
blood O
pressures O
. O

a O
lesser O
degree O
of O
orthostatic B-NEG
hypotension I-NEG
occurred O
with O
standing O
. O
orthostatic B-NEG
hypotension I-NEG
was O
ameliorated O
4 O
days O
after O
withdrawal O
of O
selegiline O
and O
totally O
abolished O
7 O
days O
after O
discontinuation O
of O
the O
drug O
. O

stopping O
selegiline O
also O
significantly O
reduced B-NEG
the I-NEG
supine I-NEG
systolic I-NEG
and I-NEG
diastolic I-NEG
blood I-NEG
pressures I-NEG
consistent O
with O
a O
previously O
undescribed O
supine O
pressor O
action O
. O

conclusion O
: O
this O
study O
confirms O
our O
previous O
finding O
that O
selegiline O
in O
combination O
with O
l-dopa O
is O
associated O
with O
selective O
orthostatic B-NEG
hypotension I-NEG
. O

the O
possibilities O
that O
these O
cardiovascular O
findings O
might O
be O
the O
result O
of O
non-selective O
inhibition O
of O
monoamine O
oxidase O
or O
of O
amphetamine O
and O
metamphetamine O
are O
discussed O
. O

-DOCSTART- O

explicit O
episodic O
memory O
for O
sensory-discriminative O
components O
of O
capsaicin-induced O
pain B-NEG
: O
immediate O
and O
delayed O
ratings O
. O
pain B-NEG
memory O
is O
thought O
to O
affect O
future O
pain B-NEG
sensitivity O
and O
thus O
contribute O
to O
clinical O
pain B-NEG
conditions O
. O

systematic O
investigations O
of O
the O
human O
capacity O
to O
remember O
sensory O
features O
of O
experimental O
pain B-NEG
are O
sparse O
. O

in O
order O
to O
address O
long-term O
pain B-NEG
memory O
, O
nine O
healthy O
male O
volunteers O
received O
intradermal O
injections O
of O
three O
doses O
of O
capsaicin O
(0.05 O
, O
1 O
and O
20 O
microg O
, O
separated O
by O
15 O
min O
breaks) O
, O
each O
given O
three O
times O
in O
a O
balanced O
design O
across O
three O
sessions O
at O
one O
week O
intervals O
. O
pain B-NEG
rating O
was O
performed O
using O
a O
computerized O
visual O
analogue O
scale O
( O
0-100 O
) O
digitized O
at O
1/s O
, O
either O
immediately O
online O
or O
one O
hour O
or O
one O
day O
after O
injection O
. O

subjects O
also O
recalled O
their O
pains B-NEG
one O
week O
later O
. O

capsaicin O
injection O
reliably O
induced O
a O
dose-dependent O
flare O
( O
p<0.001 O
) O
without O
any O
difference O
within O
or O
across O
sessions O
. O

the O
strong O
burning O
pain B-NEG
decayed O
exponentially O
within O
a O
few O
minutes O
. O

subjects O
were O
able O
to O
reliably O
discriminate O
pain B-NEG
magnitude O
and O
duration O
across O
capsaicin O
doses O
( O
both O
p<0.001) O
, O
regardless O
of O
whether O
first-time O
ratings O
were O
requested O
immediately O
, O
after O
one O
hour O
or O
after O
one O
day O
. O
pain B-NEG
recall O
after O
one O
week O
was O
similarly O
precise O
(magnitude O
: O
p<0.01 O
, O
duration O
: O
p<0.05) O
. O

correlation O
with O
rating O
recall O
after O
one O
week O
was O
best O
when O
first-time O
ratings O
were O
requested O
as O
late O
as O
one O
day O
after O
injection O
( O
r(2)=0.79 O
) O
indicating O
that O
both O
rating O
retrievals O
utilized O
similar O
memory O
traces O
. O

these O
results O
indicate O
a O
reliable O
memory O
for O
magnitude O
and O
duration O
of O
experimentally O
induced O
pain B-NEG
. O

the O
data O
further O
suggest O
that O
the O
consolidation O
of O
this O
memory O
is O
an O
important O
interim O
stage O
, O
and O
may O
take O
up O
to O
one O
day O
. O

-DOCSTART- O

reversibility O
of O
captopril-induced O
renal B-NEG
insufficiency I-NEG
after O
prolonged O
use O
in O
an O
unusual O
case O
of O
renovascular B-NEG
hypertension I-NEG
. O

we O
report O
a O
case O
of O
severe O
hypertension B-NEG
with O
an O
occluded O
renal O
artery O
to O
a O
solitary O
kidney O
, O
who O
developed O
sudden B-NEG
deterioration I-NEG
of I-NEG
renal I-NEG
function I-NEG
following O
treatment O
with O
captopril O
. O

his O
renal O
function O
remained O
impaired O
but O
stable O
during O
2 O
years' O
treatment O
with O
captopril O
but O
returned O
to O
pre-treatment O
levels O
soon O
after O
cessation O
of O
the O
drug O
. O

this O
indicates O
reversibility O
in O
captopril-induced O
renal B-NEG
failure I-NEG
even O
after O
its O
prolonged O
use O
and O
suggests O
that O
no O
organic O
damage O
occurs O
to O
glomerular O
arterioles O
following O
chronic O
ace O
inhibition O
. O

-DOCSTART- O

liver B-NEG
disease I-NEG
caused O
by O
propylthiouracil O
. O

this O
report O
presents O
the O
clinical O
, O
laboratory O
, O
and O
light O
and O
electron O
microscopic O
observations O
on O
a O
patient O
with O
chronic B-NEG
active I-NEG
( O
aggressive I-NEG
) O
hepatitis I-NEG
caused O
by O
the O
administration O
of O
propylthiouracil O
. O

this O
is O
an O
addition O
to O
the O
list O
of O
drugs O
that O
must O
be O
considered O
in O
the O
evaluation O
of O
chronic O
liver B-NEG
disease I-NEG
. O

-DOCSTART- O

capsaicin-induced O
muscle B-NEG
pain I-NEG
alters O
the O
excitability O
of O
the O
human O
jaw-stretch O
reflex O
. O

the O
pathophysiology O
of O
painful O
temporomandibular B-NEG
disorders I-NEG
is O
not O
fully O
understood O
, O
but O
evidence O
suggests O
that O
muscle B-NEG
pain I-NEG
modulates O
motor O
function O
in O
characteristic O
ways O
. O

this O
study O
tested O
the O
hypothesis O
that O
activation O
of O
nociceptive B-NEG
muscle I-NEG
afferent O
fibers O
would O
be O
linked O
to O
an O
increased O
excitability O
of O
the O
human O
jaw-stretch O
reflex O
and O
whether O
this O
process O
would O
be O
sensitive O
to O
length O
and O
velocity O
of O
the O
stretch O
. O

capsaicin O
( O
10 O
micro O
g) O
was O
injected O
into O
the O
masseter O
muscle O
to O
induce O
pain B-NEG
in O
11 O
healthy O
volunteers O
. O

short-latency O
reflex O
responses O
were O
evoked O
in O
the O
masseter O
and O
temporalis O
muscles O
by O
a O
stretch O
device O
with O
different O
velocities O
and O
displacements O
before O
, O
during O
, O
and O
after O
the O
pain B-NEG
. O

the O
normalized O
reflex O
amplitude O
increased O
with O
an O
increase O
in O
velocity O
at O
a O
given O
displacement O
, O
but O
remained O
constant O
with O
different O
displacements O
at O
a O
given O
velocity O
. O

the O
normalized O
reflex O
amplitude O
was O
significantly O
higher O
during O
pain B-NEG
, O
but O
only O
at O
faster O
stretches O
in O
the O
painful B-NEG
muscle I-NEG
. O

increased O
sensitivity O
of O
the O
fusimotor O
system O
during O
acute O
muscle B-NEG
pain I-NEG
could O
be O
one O
likely O
mechanism O
to O
explain O
the O
findings O
. O

-DOCSTART- O

repetitive O
transcranial O
magnetic O
stimulation O
for O
levodopa-induced O
dyskinesias B-NEG
in O
parkinson's B-NEG
disease I-NEG
. O

in O
a O
placebo-controlled O
, O
single-blinded O
, O
crossover O
study O
, O
we O
assessed O
the O
effect O
of O
real O
repetitive O
transcranial O
magnetic O
stimulation O
( O
rtms O
) O
versus O
sham O
rtms O
( O
placebo O
) O
on O
peak O
dose O
dyskinesias B-NEG
in O
patients O
with O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
). O

ten O
patients O
with O
pd B-NEG
and O
prominent O
dyskinesias B-NEG
had O
rtms O
( O
1,800 O
pulses O
; O
1 O
hz O
rate O
) O
delivered O
over O
the O
motor O
cortex O
for O
4 O
consecutive O
days O
twice O
, O
once O
real O
stimuli O
and O
once O
sham O
stimulation O
were O
used O
; O
evaluations O
were O
done O
at O
the O
baseline O
and O
1 O
day O
after O
the O
end O
of O
each O
of O
the O
treatment O
series O
. O

direct O
comparison O
between O
sham O
and O
real O
rtms O
effects O
showed O
no O
significant O
difference O
in O
clinician-assessed O
dyskinesia B-NEG
severity O
. O

however O
, O
comparison O
with O
the O
baseline O
showed O
small O
but O
significant O
reduction O
in O
dyskinesia B-NEG
severity O
following O
real O
rtms O
but O
not O
placebo O
. O

the O
major O
effect O
was O
on O
dystonia B-NEG
subscore O
. O

similarly O
, O
in O
patient O
diaries O
, O
although O
both O
treatments O
caused O
reduction O
in O
subjective O
dyskinesia B-NEG
scores O
during O
the O
days O
of O
intervention O
, O
the O
effect O
was O
sustained O
for O
3 O
days O
after O
the O
intervention O
for O
the O
real O
rtms O
only O
. O

following O
rtms O
, O
no O
side O
effects O
and O
no O
adverse O
effects O
on O
motor O
function O
and O
pd B-NEG
symptoms O
were O
noted O
. O

the O
results O
suggest O
the O
existence O
of O
residual O
beneficial O
clinical O
aftereffects O
of O
consecutive O
daily O
applications O
of O
low-frequency O
rtms O
on O
dyskinesias B-NEG
in O
pd B-NEG
. O

the O
effects O
may O
be O
further O
exploited O
for O
potential O
therapeutic O
uses O
. O

-DOCSTART- O

disulfiram-like O
syndrome O
after O
hydrogen O
cyanamide O
professional O
skin O
exposure O
: O
two O
case O
reports O
in O
france O
. O

hydrogen O
cyanamide O
is O
a O
plant O
growth O
regulator O
used O
in O
agriculture O
to O
induce O
bud O
break O
in O
fruit O
trees O
. O

contact O
with O
the O
skin O
can O
result O
in O
percutaneous O
absorption O
of O
the O
substance O
that O
inhibits O
aldehyde O
dehydrogenase O
and O
can O
induce O
acetaldehyde O
syndrome O
in O
case O
of O
alcohol O
use O
. O

the O
purpose O
of O
this O
report O
is O
to O
describe O
two O
cases O
of O
a O
disulfiram-like O
syndrome O
following O
occupational O
exposure O
to O
hydrogen O
cyanamide O
. O

the O
first O
case O
involved O
a O
59-year-old O
man O
who O
used O
dormex O
, O
which O
contains O
hydrogen O
cyanamide O
, O
without O
protection O
after O
consuming O
a O
large O
amount O
of O
alcohol O
during O
a O
meal O
. O

in O
less O
than O
1 O
hour O
after O
the O
ingestion O
of O
alcohol O
, O
he O
developed O
malaise O
with O
flushing B-NEG
of I-NEG
the I-NEG
face I-NEG
, O
tachycardia B-NEG
, O
and O
dyspnea B-NEG
. O

manifestations O
regressed O
spontaneously O
under O
surveillance O
in O
the O
hospital O
. O

the O
second O
case O
occurred O
in O
a O
55-year-old O
farmer O
following O
cutaneous O
contact O
with O
dormex O
. O

five O
hours O
after O
exposure O
, O
he O
developed O
disulfiram-like O
syndrome O
with O
flushing B-NEG
, O
tachycardia B-NEG
, O
and O
arterial B-NEG
hypotension I-NEG
after O
consuming O
three O
glasses O
of O
wine O
. O

the O
patient O
recovered O
spontaneously O
in O
3 O
hours O
under O
surveillance O
in O
the O
hospital O
. O

these O
cases O
confirm O
the O
necessity O
of O
avoiding O
alcohol O
consumption O
as O
recommended O
in O
the O
instructions O
for O
use O
of O
dormex O
and O
of O
preventing O
cutaneous O
contact O
during O
use O
. O

-DOCSTART- O

repeated O
trimipramine O
induces O
dopamine O
d2/d3 O
and O
alpha1-adrenergic O
up-regulation O
. O

trimipramine O
(tri) O
, O
which O
shows O
a O
clinical O
antidepressant O
activity O
, O
is O
chemically O
related O
to O
imipramine O
but O
does O
not O
inhibit O
the O
reuptake O
of O
noradrenaline O
and O
5-hydroxytryptamine O
, O
nor O
does O
it O
induce O
beta-adrenergic O
down-regulation O
. O

the O
mechanism O
of O
its O
antidepressant O
activity O
is O
still O
unknown O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
find O
out O
whether O
tri O
given O
repeatedly O
was O
able O
to O
induce O
adaptive O
changes O
in O
the O
dopaminergic O
and O
alpha1-adrenergic O
systems O
, O
demonstrated O
by O
us O
previously O
for O
various O
antidepressants O
. O

tri O
was O
given O
to O
male O
wistar O
rats O
and O
male O
albino O
swiss O
mice O
perorally O
twice O
daily O
for O
14 O
days O
. O

in O
the O
acute O
experiment O
tri O
( O
given O
i.p. O
) O
does O
not O
antagonize O
the O
reserpine O
hypothermia B-NEG
in O
mice O
and O
does O
not O
potentiate O
the O
5-hydroxytryptophan O
head O
twitches O
in O
rats O
. O

tri O
given O
repeatedly O
to O
rats O
increases O
the O
locomotor O
hyperactivity B-NEG
induced O
by O
d-amphetamine O
, O
quinpirole O
and O
( O
+)-7-hydroxy-dipropyloaminotetralin O
( O
dopamine O
d2 O
and O
d3 O
effects) O
. O

the O
stereotypies O
induced O
by O
d-amphetamine O
or O
apomorphine O
are O
not O
potentiated O
by O
tri O
. O

it O
increases O
the O
behaviour O
stimulation O
evoked O
by O
phenylephrine O
( O
given O
intraventricularly O
) O
in O
rats O
, O
evaluated O
in O
the O
open O
field O
test O
as O
well O
as O
the O
aggressiveness B-NEG
evoked O
by O
clonidine O
in O
mice O
, O
both O
these O
effects O
being O
mediated O
by O
an O
alpha1-adrenergic O
receptor O
. O

it O
may O
be O
concluded O
that O
, O
like O
other O
tricyclic O
antidepressants O
studied O
previously O
, O
tri O
given O
repeatedly O
increases O
the O
responsiveness O
of O
brain O
dopamine O
d2 O
and O
d3 O
( O
locomotor O
activity O
but O
not O
stereotypy O
) O
as O
well O
as O
alpha1-adrenergic O
receptors O
to O
their O
agonists O
. O

a O
question O
arises O
whether O
the O
reuptake O
inhibition O
is O
of O
any O
importance O
to O
the O
adaptive O
changes O
induced O
by O
repeated O
antidepressants O
, O
suggested O
to O
be O
responsible O
for O
the O
antidepressant O
activity O
. O

-DOCSTART- O

ranitidine-induced O
acute O
interstitial B-NEG
nephritis I-NEG
in O
a O
cadaveric O
renal O
allograft O
. O

ranitidine O
frequently O
is O
used O
for O
preventing O
peptic O
ulceration O
after O
renal O
transplantation O
. O

this O
drug O
occasionally O
has O
been O
associated O
with O
acute O
interstitial B-NEG
nephritis I-NEG
in O
native O
kidneys O
. O

there O
are O
no O
similar O
reports O
with O
renal O
transplantation O
. O

we O
report O
a O
case O
of O
ranitidine-induced O
acute O
interstitial B-NEG
nephritis I-NEG
in O
a O
recipient O
of O
a O
cadaveric O
renal O
allograft O
presenting O
with O
acute O
allograft O
dysfunction O
within O
48 O
hours O
of O
exposure O
to O
the O
drug O
. O

the O
biopsy O
specimen O
showed O
pathognomonic O
features O
, O
including O
eosinophilic O
infiltration O
of O
the O
interstitial O
compartment O
. O

allograft O
function O
improved O
rapidly O
and O
returned O
to O
baseline O
after O
stopping O
the O
drug O
. O

-DOCSTART- O

late O
, O
late O
doxorubicin O
cardiotoxicity B-NEG
. O
cardiac B-NEG
toxicity I-NEG
is O
a O
major O
complication O
which O
limits O
the O
use O
of O
adriamycin O
as O
a O
chemotherapeutic O
agent O
. O
cardiomyopathy B-NEG
is O
frequent O
when O
the O
total O
dose O
exceeds O
600 O
mg/m2 O
and O
occurs O
within O
one O
to O
six O
months O
after O
cessation O
of O
therapy O
. O

a O
patient O
is O
reported O
who O
developed O
progressive O
cardiomyopathy B-NEG
two O
and O
one-half O
years O
after O
receiving O
580 O
mg/m2 O
which O
apparently O
represents O
late O
, O
late O
cardiotoxicity B-NEG
. O

-DOCSTART- O

acetazolamide-induced O
nephrolithiasis B-NEG
: O
implications O
for O
treatment O
of O
neuromuscular B-NEG
disorders I-NEG
. O

carbonic O
anhydrase O
inhibitors O
can O
cause O
nephrolithiasis B-NEG
. O

we O
studied O
20 O
patients O
receiving O
long-term O
carbonic O
anhydrase O
inhibitor O
treatment O
for O
periodic O
paralysis B-NEG
and O
myotonia B-NEG
. O

three O
patients O
on O
acetazolamide O
( O
15% O
) O
developed O
renal B-NEG
calculi I-NEG
. O

extracorporeal O
lithotripsy O
successfully O
removed O
a O
renal B-NEG
calculus I-NEG
in O
one O
patient O
and O
surgery O
removed O
a O
staghorn O
calculus B-NEG
in O
another O
, O
permitting O
continued O
treatment O
. O

renal O
function O
remained O
normal O
in O
all O
patients O
. O
nephrolithiasis B-NEG
is O
a O
complication O
of O
acetazolamide O
but O
does O
not O
preclude O
its O
use O
. O

-DOCSTART- O

is O
the O
treatment O
of O
scabies B-NEG
hazardous? O

treatment O
for O
scabies B-NEG
is O
usually O
initiated O
by O
general O
practitioners O
; O
most O
consider O
lindane O
( O
gamma O
benzene O
hexachloride O
) O
the O
treatment O
of O
choice O
. O

lindane O
is O
also O
widely O
used O
as O
an O
agricultural O
and O
industrial O
pesticide O
, O
and O
as O
a O
result O
the O
toxic O
profile O
of O
this O
insecticide O
is O
well O
understood O
. O

evidence O
is O
accumulating O
that O
lindane O
can O
be O
toxic B-NEG
to I-NEG
the I-NEG
central I-NEG
nervous I-NEG
system I-NEG
and O
may O
be O
associated O
with O
aplastic B-NEG
anaemia I-NEG
. O

preparations O
containing O
lindane O
continue O
to O
be O
sold O
over O
the O
counter O
and O
may O
represent O
a O
hazard O
to O
poorly O
informed O
patients O
. O

this O
literature O
review O
suggests O
that O
general O
practitioners O
should O
prescribe O
scabicides O
with O
increased O
caution O
for O
certain O
at-risk O
groups O
, O
and O
give O
adequate O
warnings O
regarding O
potential O
toxicity B-NEG
. O

-DOCSTART- O

anaesthetists' O
nightmare O
: O
masseter B-NEG
spasm I-NEG
after O
induction O
in O
an O
undiagnosed O
case O
of O
myotonia B-NEG
congenita I-NEG
. O

we O
report O
an O
undiagnosed O
case O
of O
myotonia B-NEG
congenita I-NEG
in O
a O
24-year-old O
previously O
healthy O
primigravida O
, O
who O
developed O
life O
threatening O
masseter B-NEG
spasm I-NEG
following O
a O
standard O
dose O
of O
intravenous O
suxamethonium O
for O
induction O
of O
anaesthesia O
. O

neither O
the O
patient O
nor O
the O
anaesthetist O
was O
aware O
of O
the O
diagnosis O
before O
this O
potentially O
lethal O
complication O
occurred O
. O

-DOCSTART- O

toxicity B-NEG
in O
rhesus O
monkeys O
following O
administration O
of O
the O
8-aminoquinoline O
8-[(4-amino-l-methylbutyl)amino]- O
5-(l-hexyloxy)-6-methoxy-4-methylquinoline O
(wr242511) O
. O

introduction O
: O
many O
substances O
that O
form O
methemoglobin O
( O
mhb O
) O
effectively O
counter O
cyanide O
( O
cn O
) O
toxicity B-NEG
. O

although O
mhb O
formers O
are O
generally O
applied O
as O
treatments O
for O
cn O
poisoning B-NEG
, O
it O
has O
been O
proposed O
that O
a O
stable O
, O
long-acting O
mhb O
former O
could O
serve O
as O
a O
cn O
pretreatment O
. O

using O
this O
rationale O
, O
the O
8-aminoquinoline O
wr242511 O
, O
a O
potent O
long-lasting O
mhb O
former O
in O
rodents O
and O
beagle O
dogs O
, O
was O
studied O
in O
the O
rhesus O
monkey O
for O
advanced O
development O
as O
a O
potential O
cn O
pretreatment O
. O

methods O
: O
in O
this O
study O
, O
wr242511 O
was O
administered O
intravenously O
( O
iv O
) O
in O
2 O
female O
and O
4 O
male O
rhesus O
monkeys O
in O
doses O
of O
3.5 O
and/or O
7.0 O
mg/kg O
; O
a O
single O
male O
also O
received O
wr242511 O
orally O
( O
po O
) O
at O
7.0 O
mg/kg O
. O

health O
status O
and O
mhb O
levels O
were O
monitored O
following O
exposure O
. O

results O
: O
the O
selected O
doses O
of O
wr242511 O
, O
which O
produced O
significant O
methemoglobinemia B-NEG
in O
beagle O
dogs O
in O
earlier O
studies O
conducted O
elsewhere O
, O
produced O
very O
little O
mhb O
( O
mean O
< O
2.0% O
) O
in O
the O
rhesus O
monkey O
. O

furthermore O
, O
transient O
hemoglobinuria B-NEG
was O
noted O
approximately O
60 O
minutes O
postinjection O
of O
wr242511 O
( O
3.5 O
or O
7.0 O
mg/kg) O
, O
and O
2 O
lethalities O
occurred O
( O
one O
iv O
and O
one O
po O
) O
following O
the O
7.0 O
mg/kg O
dose O
. O
myoglobinuria B-NEG
was O
also O
observed O
following O
the O
7.0 O
mg/kg O
dose O
. O

histopathology O
analyses O
in O
the O
2 O
animals O
that O
died O
revealed O
liver B-NEG
and I-NEG
kidney I-NEG
toxicity I-NEG
, O
with O
greater O
severity O
in O
the O
orally-treated O
animal O
. O

conclusions O
: O
these O
data O
demonstrate O
direct O
and/or O
indirect O
drug-induced O
toxicity B-NEG
. O

it O
is O
concluded O
that O
wr242511 O
should O
not O
be O
pursued O
as O
a O
pretreatment O
for O
cn O
poisoning B-NEG
unless O
the O
anti-cn O
characteristics O
of O
this O
compound O
can O
be O
successfully O
dissociated O
from O
those O
producing O
undesirable O
toxicity B-NEG
. O

-DOCSTART- O

neuroplasticity O
of O
the O
adult O
primate O
auditory O
cortex O
following O
cochlear O
hearing B-NEG
loss I-NEG
. O

tonotopic O
organization O
is O
an O
essential O
feature O
of O
the O
primary O
auditory O
area O
( O
a1 O
) O
of O
primate O
cortex O
. O

in O
a1 O
of O
macaque O
monkeys O
, O
low O
frequencies O
are O
represented O
rostrolaterally O
and O
high O
frequencies O
are O
represented O
caudomedially O
. O

the O
purpose O
of O
this O
study O
was O
to O
determine O
if O
changes O
occur O
in O
this O
tonotopic O
organization O
following O
cochlear O
hearing B-NEG
loss I-NEG
. O

under O
anesthesia O
, O
the O
superior O
temporal O
gyrus O
of O
adult O
macaque O
monkeys O
was O
exposed O
, O
and O
the O
tonotopic O
organization O
of O
a1 O
was O
mapped O
using O
conventional O
microelectrode O
recording O
techniques O
. O

following O
recovery O
, O
the O
monkeys O
were O
selectively O
deafened O
for O
high O
frequencies O
using O
kanamycin O
and O
furosemide O
. O

the O
actual O
frequencies O
deafened O
were O
determined O
by O
the O
loss O
of O
tone-burst O
elicited O
auditory O
brainstem O
responses O
. O

three O
months O
after O
deafening O
, O
a1 O
was O
remapped O
. O

postmortem O
cytoarchitectural O
features O
identifying O
a1 O
were O
correlated O
with O
the O
electrophysiologic O
data O
. O

the O
results O
indicate O
that O
the O
deprived O
area O
of O
a1 O
undergoes O
extensive O
reorganization O
and O
becomes O
responsive O
to O
intact O
cochlear O
frequencies O
. O

the O
region O
of O
cortex O
that O
represents O
the O
low O
frequencies O
was O
not O
obviously O
affected O
by O
the O
cochlear O
hearing B-NEG
loss I-NEG
. O

-DOCSTART- O

the O
site O
of O
common O
side O
effects O
of O
sumatriptan O
. O
atypical B-NEG
sensations I-NEG
following O
the O
use O
of O
subcutaneous O
sumatriptan O
are O
common O
, O
but O
of O
uncertain O
origin O
. O

they O
are O
almost O
always O
benign O
, O
but O
can O
be O
mistaken O
for O
a O
serious O
adverse O
event O
by O
the O
patient O
. O

two O
patients O
are O
presented O
with O
tingling B-NEG
or I-NEG
burning I-NEG
sensations I-NEG
limited O
to O
areas O
of O
heat O
exposure O
or O
sunburn B-NEG
. O

in O
these O
individuals O
, O
side O
effects O
are O
most O
likely O
generated O
superficially O
in O
the O
skin O
. O

-DOCSTART- O

tremor B-NEG
side O
effects O
of O
salbutamol O
, O
quantified O
by O
a O
laser O
pointer O
technique O
. O

objective O
: O
to O
study O
tremor B-NEG
side O
effects O
of O
salbutamol O
an O
easily O
applicable O
, O
quick O
and O
low-priced O
method O
is O
needed O
. O

a O
new O
method O
using O
a O
commercially O
available O
, O
pen-shaped O
laser O
pointer O
was O
developed O
. O

aim O
of O
the O
study O
was O
to O
determine O
sensitivity O
, O
reproducibility O
, O
reference O
values O
and O
the O
agreement O
with O
a O
questionnaire O
. O

methods O
: O
tremor B-NEG
was O
measured O
using O
a O
laser O
pointer O
technique O
. O

to O
determine O
sensitivity O
we O
assessed O
tremor B-NEG
in O
44 O
patients O
with O
obstructive B-NEG
lung I-NEG
disease I-NEG
after O
administration O
of O
cumulative O
doses O
of O
salbutamol O
. O

subjects O
were O
asked O
to O
aim O
at O
the O
centre O
of O
a O
target O
, O
subdivided O
in O
concentric O
circles O
, O
from O
5 O
m O
distance O
. O

the O
circle O
in O
which O
the O
participant O
succeeded O
to O
aim O
was O
recorded O
in O
millimetres O
radius O
. O

in O
another O
series O
of O
measurements O
, O
reproducibility O
and O
reference O
values O
of O
the O
tremor B-NEG
was O
assessed O
in O
65 O
healthy O
subjects O
in O
three O
sessions O
, O
at O
9 O
a.m. O
, O
4 O
p.m O
. O
and O
9 O
a.m. O
, O
respectively O
, O
1 O
week O
later O
. O

postural O
tremor B-NEG
was O
measured O
with O
the O
arm O
horizontally O
outstretched O
rest O
tremor B-NEG
with O
the O
arm O
supported O
by O
an O
armrest O
and O
finally O
tremor B-NEG
was O
measured O
after O
holding O
a O
2-kg O
weight O
until O
exhaustion O
. O

inter-observer O
variability O
was O
measured O
in O
a O
series O
of O
10 O
healthy O
subjects O
. O
tremor B-NEG
was O
measured O
simultaneously O
by O
two O
independent O
observers O
. O

results O
: O
salbutamol O
significantly O
increased O
tremor B-NEG
severity O
in O
patients O
in O
a O
dose-dependent O
way O
. O

within O
healthy O
adults O
no O
age-dependency O
could O
be O
found O
(b O
= O
0.262 O
mm/year O
; O
p O
= O
0.72) O
. O

there O
was O
no O
agreement O
between O
the O
questionnaire O
and O
tremor B-NEG
severity O
(r O
= O
0.093 O
; O
p O
= O
0.53) O
. O

postural O
tremor B-NEG
showed O
no O
significant O
difference O
between O
the O
first O
and O
third O
session O
(p O
= O
0.07) O
. O

support O
of O
the O
arm O
decreased O
tremor B-NEG
severity O
, O
exhaustion O
increased O
tremor B-NEG
severity O
significantly O
. O

a O
good O
agreement O
was O
found O
between O
two O
independent O
observers O
( O
interclass O
correlation O
coefficient O
0.72) O
. O

discussion O
: O
quantifying O
tremor B-NEG
by O
using O
an O
inexpensive O
laser O
pointer O
is O
, O
with O
the O
exception O
of O
children O
( O
<12 O
years O
) O
a O
sensitive O
and O
reproducible O
method O
. O

-DOCSTART- O

increased O
frequency O
of O
venous B-NEG
thromboembolism I-NEG
with O
the O
combination O
of O
docetaxel O
and O
thalidomide O
in O
patients O
with O
metastatic O
androgen-independent O
prostate B-NEG
cancer I-NEG
. O

study O
objective O
: O
to O
evaluate O
the O
frequency O
of O
venous B-NEG
thromboembolism I-NEG
( O
vte B-NEG
) O
in O
patients O
with O
advanced O
androgen-independent O
prostate B-NEG
cancer I-NEG
who O
were O
treated O
with O
docetaxel O
alone O
or O
in O
combination O
with O
thalidomide O
. O

design O
: O
retrospective O
analysis O
of O
a O
randomized O
phase O
ii O
trial O
. O

setting O
: O
national O
institutes O
of O
health O
clinical O
research O
center O
. O

patients O
: O
seventy O
men O
, O
aged O
50-80 O
years O
, O
with O
advanced O
androgen-independent O
prostate B-NEG
cancer I-NEG
. O

intervention O
: O
each O
patient O
received O
either O
intravenous O
docetaxel O
30 O
mg/m2/week O
for O
3 O
consecutive O
weeks O
, O
followed O
by O
1 O
week O
off O
, O
or O
the O
combination O
of O
continuous O
oral O
thalidomide O
200 O
mg O
every O
evening O
plus O
the O
same O
docetaxel O
regimen O
. O

this O
4-week O
cycle O
was O
repeated O
until O
there O
was O
evidence O
of O
excessive O
toxicity B-NEG
or O
disease O
progression O
. O

measurements O
and O
main O
results O
: O
none O
of O
23 O
patients O
who O
received O
docetaxel O
alone O
developed O
vte B-NEG
, O
whereas O
9 O
of O
47 O
patients O
( O
19% O
) O
who O
received O
docetaxel O
plus O
thalidomide O
developed O
vte B-NEG
(p=0.025) O
. O

conclusion O
: O
the O
addition O
of O
thalidomide O
to O
docetaxel O
in O
the O
treatment O
of O
prostate B-NEG
cancer I-NEG
significantly O
increases O
the O
frequency O
of O
vte B-NEG
. O

clinicians O
should O
be O
aware O
of O
this O
potential O
complication O
when O
adding O
thalidomide O
to O
chemotherapeutic O
regimens O
. O

-DOCSTART- O

sublingual O
absorption O
of O
the O
quaternary O
ammonium O
antiarrhythmic O
agent O
, O
um-272 O
. O

um-272 O
(n,n-dimethylpropranolol) O
, O
a O
quaternary O
antiarrhythmic O
agent O
, O
was O
administered O
sublingually O
to O
dogs O
with O
ouabain-induced O
ventricular B-NEG
tachycardias I-NEG
. O

both O
anti-arrhythmic O
efficacy O
and O
bioavailability O
were O
compared O
to O
oral O
drug O
. O

sublingual O
um-272 O
converted O
ventricular B-NEG
tachycardia I-NEG
to O
sinus O
rhythm O
in O
all O
5 O
dogs O
. O

the O
area O
under O
the O
plasma O
concentration O
time O
curve O
at O
90 O
min O
was O
4-12 O
times O
greater O
than O
for O
oral O
drug O
, O
suggesting O
the O
existence O
of O
an O
absorption-limiting O
process O
in O
the O
intestine O
, O
and O
providing O
an O
alternate O
form O
of O
administration O
for O
quaternary O
drugs O
. O

-DOCSTART- O

severe O
thrombocytopenia B-NEG
and O
haemolytic B-NEG
anaemia I-NEG
associated O
with O
ciprofloxacin O
: O
a O
case O
report O
with O
fatal O
outcome O
. O

haematological O
adverse O
reactions O
associated O
with O
fatal O
outcome O
are O
rare O
during O
treatment O
with O
ciprofloxacin O
. O

a O
30-year O
old O
caucasian O
man O
reported O
with O
abdominal B-NEG
pain I-NEG
and O
jaundice B-NEG
after O
3-day O
administration O
of O
oral O
ciprofloxacin O
for O
a O
suspect O
of O
urinary B-NEG
tract I-NEG
infection I-NEG
. O

clinical O
evaluations O
suggested O
an O
initial O
diagnosis O
of O
severe O
thrombocytopenia B-NEG
and O
haemolysis B-NEG
. O

the O
patient O
progressively O
developed O
petechiae B-NEG
and O
purpura B-NEG
on O
thorax O
and O
lower O
limbs O
. O

despite O
pharmacological O
and O
supportive O
interventions O
, O
laboratory O
parameters O
worsened O
and O
the O
patient O
died O
17 O
hours O
after O
admission O
. O

an O
accurate O
autopsy O
revealed O
most O
organs O
with O
diffuse O
petechial O
haemorrhages B-NEG
. O

no O
signs O
of O
bone B-NEG
marrow I-NEG
depression I-NEG
were O
found O
. O

no O
thrombi B-NEG
or O
signs O
of O
microangiopathies B-NEG
were O
observed O
in O
arterial O
vessels O
. O

blood O
and O
urine O
cultures O
did O
not O
show O
any O
bacterial O
growth O
. O

this O
case O
report O
shows O
that O
ciprofloxacin O
may O
precipitate O
life-threatening O
thrombocytopenia B-NEG
and O
haemolytic B-NEG
anaemia I-NEG
, O
even O
in O
the O
early O
phases O
of O
treatment O
and O
without O
apparent O
previous O
exposures O
. O

-DOCSTART- O

simvastatin-induced O
bilateral O
leg O
compartment B-NEG
syndrome I-NEG
and O
myonecrosis B-NEG
associated O
with O
hypothyroidism B-NEG
. O

a O
54-year-old O
hypothyroid B-NEG
male O
taking O
thyroxine O
and O
simvastatin O
presented O
with O
bilateral O
leg O
compartment B-NEG
syndrome I-NEG
and O
myonecrosis B-NEG
. O

urgent O
fasciotomies O
were O
performed O
and O
the O
patient O
made O
an O
uneventful O
recovery O
with O
the O
withdrawal O
of O
simvastatin O
. O

it O
is O
likely O
that O
this O
complication O
will O
be O
seen O
more O
often O
with O
the O
increased O
worldwide O
use O
of O
this O
drug O
and O
its O
approval O
for O
all O
arteriopathic B-NEG
patients O
. O

-DOCSTART- O

bile B-NEG
duct I-NEG
hamartoma I-NEG
occurring O
in O
association O
with O
long-term O
treatment O
with O
danazol O
. O

we O
report O
a O
case O
of O
bile B-NEG
duct I-NEG
hamartoma I-NEG
which O
developed O
in O
a O
patient O
who O
had O
been O
on O
long-term O
danazol O
treatment O
. O

such O
patients O
should O
be O
under O
close O
follow-up O
, O
preferably O
with O
periodic O
ultrasound O
examination O
of O
the O
liver O
. O

if O
the O
patient O
develops O
a O
liver B-NEG
mass I-NEG
, O
because O
of O
non-specific O
clinical O
features O
and O
imaging O
appearances O
, O
biopsy O
may O
be O
the O
only O
way O
to O
achieve O
a O
definitive O
diagnosis O
. O

-DOCSTART- O

granulomatous B-NEG
hepatitis I-NEG
due O
to O
combination O
of O
amoxicillin O
and O
clavulanic O
acid O
. O

we O
report O
the O
case O
of O
a O
patient O
with O
amoxicillin-clavulanic O
acid-induced O
hepatitis B-NEG
with O
histologic O
multiple O
granulomas B-NEG
. O

this O
type O
of O
lesion O
broadens O
the O
spectrum O
of O
liver B-NEG
injury I-NEG
due O
to O
this O
drug O
combination O
, O
mainly O
represented O
by O
a O
benign O
cholestatic B-NEG
syndrome I-NEG
. O

the O
association O
of O
granulomas B-NEG
and O
eosinophilia B-NEG
favor O
an O
immunoallergic O
mechanism O
. O

as O
penicillin O
derivatives O
and O
amoxicillin O
alone O
are O
known O
to O
induce O
such O
types O
of O
lesions O
, O
the O
amoxicillin O
component O
, O
with O
or O
without O
a O
potentiating O
effect O
of O
clavulanic O
acid O
, O
might O
have O
a O
major O
role O
. O

-DOCSTART- O

intracranial B-NEG
aneurysms I-NEG
and O
cocaine B-NEG
abuse I-NEG
: O
analysis O
of O
prognostic O
indicators O
. O

objective O
: O
the O
outcome O
of O
subarachnoid B-NEG
hemorrhage I-NEG
associated O
with O
cocaine B-NEG
abuse I-NEG
is O
reportedly O
poor O
. O

however O
, O
no O
study O
in O
the O
literature O
has O
reported O
the O
use O
of O
a O
statistical O
model O
to O
analyze O
the O
variables O
that O
influence O
outcome O
. O

methods O
: O
a O
review O
of O
admissions O
during O
a O
6-year O
period O
revealed O
14 O
patients O
with O
cocaine-related O
aneurysms B-NEG
. O

this O
group O
was O
compared O
with O
a O
control O
group O
of O
135 O
patients O
with O
ruptured B-NEG
aneurysms I-NEG
and O
no O
history O
of O
cocaine B-NEG
abuse I-NEG
. O

age O
at O
presentation O
, O
time O
of O
ictus O
after O
intoxication O
, O
hunt O
and O
hess O
grade O
of O
subarachnoid B-NEG
hemorrhage I-NEG
, O
size O
of O
the O
aneurysm B-NEG
, O
location O
of O
the O
aneurysm B-NEG
, O
and O
the O
glasgow O
outcome O
scale O
score O
were O
assessed O
and O
compared O
. O

results O
: O
the O
patients O
in O
the O
study O
group O
were O
significantly O
younger O
than O
the O
patients O
in O
the O
control O
group O
(p O
< O
0.002) O
. O

in O
patients O
in O
the O
study O
group O
, O
all O
aneurysms B-NEG
were O
located O
in O
the O
anterior O
circulation O
. O

the O
majority O
of O
these O
aneurysms B-NEG
were O
smaller O
than O
those O
of O
the O
control O
group O
(8 O
+/- O
6.08 O
mm O
versus O
11 O
+/- O
5.4 O
mm O
; O
p O
= O
0.05) O
. O

the O
differences O
in O
mortality O
and O
morbidity O
between O
the O
two O
groups O
were O
not O
significant O
. O

hunt O
and O
hess O
grade O
(p O
< O
0.005 O
) O
and O
age O
(p O
< O
0.007 O
) O
were O
significant O
predictors O
of O
outcome O
for O
the O
patients O
with O
cocaine-related O
aneurysms B-NEG
. O

conclusion O
: O
cocaine O
use O
predisposed O
aneurysmal B-NEG
rupture I-NEG
at O
a O
significantly O
earlier O
age O
and O
in O
much O
smaller O
aneurysms B-NEG
. O

contrary O
to O
the O
published O
literature O
, O
this O
group O
did O
reasonably O
well O
with O
aggressive O
management O
. O

-DOCSTART- O

anti- O
epileptic B-NEG
drugs-induced O
de O
novo O
absence B-NEG
seizures I-NEG
. O

the O
authors O
present O
three O
patients O
with O
de O
novo O
absence B-NEG
epilepsy I-NEG
after O
administration O
of O
carbamazepine O
and O
vigabatrin O
. O

despite O
the O
underlying O
diseases O
, O
the O
prognosis O
for O
drug-induced O
de O
novo O
absence B-NEG
seizure I-NEG
is O
good O
because O
it O
subsides O
rapidly O
after O
discontinuing O
the O
use O
of O
the O
offending O
drugs O
. O

the O
gamma-aminobutyric O
acid-transmitted O
thalamocortical O
circuitry O
accounts O
for O
a O
major O
part O
of O
the O
underlying O
neurophysiology O
of O
the O
absence B-NEG
epilepsy I-NEG
. O

because O
drug-induced O
de O
novo O
absence B-NEG
seizure I-NEG
is O
rare O
, O
pro-absence O
drugs O
can O
only O
be O
considered O
a O
promoting O
factor O
. O

the O
underlying O
epileptogenecity O
of O
the O
patients O
or O
the O
synergistic O
effects O
of O
the O
accompanying O
drugs O
is O
required O
to O
trigger O
the O
de O
novo O
absence B-NEG
seizure I-NEG
. O

the O
possibility O
of O
drug-induced O
aggravation O
should O
be O
considered O
whenever O
an O
unexpected O
increase O
in O
seizure B-NEG
frequency O
and/or O
new O
seizure B-NEG
types O
appear O
following O
a O
change O
in O
drug O
treatment O
. O

by O
understanding O
the O
underlying O
mechanism O
of O
absence B-NEG
epilepsy I-NEG
, O
we O
can O
avoid O
the O
inappropriate O
use O
of O
anticonvulsants O
in O
children O
with O
epilepsy B-NEG
and O
prevent O
drug-induced O
absence B-NEG
seizures I-NEG
. O

-DOCSTART- O

procainamide-induced O
polymorphous O
ventricular B-NEG
tachycardia I-NEG
. O

seven O
cases O
of O
procainamide-induced O
polymorphous O
ventricular B-NEG
tachycardia I-NEG
are O
presented O
. O

in O
four O
patients O
, O
polymorphous O
ventricular B-NEG
tachycardia I-NEG
appeared O
after O
intravenous O
administration O
of O
200 O
to O
400 O
mg O
of O
procainamide O
for O
the O
treatment O
of O
sustained O
ventricular B-NEG
tachycardia I-NEG
. O

in O
the O
remaining O
three O
patients O
, O
procainamide O
was O
administered O
orally O
for O
treatment O
of O
chronic O
premature B-NEG
ventricular I-NEG
contractions I-NEG
or O
atrial B-NEG
flutter I-NEG
. O

these O
patients O
had O
q-t B-NEG
prolongation I-NEG
and O
recurrent O
syncope B-NEG
due O
to O
polymorphous O
ventricular B-NEG
tachycardia I-NEG
. O

in O
four O
patients O
, O
the O
arrhythmia B-NEG
was O
rapidly O
diagnosed O
and O
treated O
with O
disappearance O
of O
further O
episodes O
of O
the O
arrhythmia B-NEG
. O

in O
two O
patients O
, O
the O
arrhythmia B-NEG
degenerated O
into O
irreversible O
ventricular B-NEG
fibrillation I-NEG
and O
both O
patients O
died O
. O

in O
the O
seventh O
patient O
, O
a O
permanent O
ventricular O
pacemaker O
was O
inserted O
and O
, O
despite O
continuation O
of O
procainamide O
therapy O
, O
polymorphous O
ventricular B-NEG
tachycardia I-NEG
did O
not O
reoccur O
. O

these O
seven O
cases O
demonstrate O
that O
procainamide O
can O
produce O
an O
acquired O
prolonged B-NEG
q-t I-NEG
syndrome I-NEG
with O
polymorphous O
ventricular B-NEG
tachycardia I-NEG
. O

-DOCSTART- O

role O
of O
activation O
of O
bradykinin O
b2 O
receptors O
in O
disruption O
of O
the O
blood-brain O
barrier O
during O
acute O
hypertension B-NEG
. O

cellular O
mechanisms O
which O
account O
for O
disruption O
the O
blood-brain O
barrier O
during O
acute O
hypertension B-NEG
are O
not O
clear O
. O

the O
goal O
of O
this O
study O
was O
to O
determine O
the O
role O
of O
synthesis/release O
of O
bradykinin O
to O
activate O
b2 O
receptors O
in O
disruption O
of O
the O
blood-brain O
barrier O
during O
acute O
hypertension B-NEG
. O

permeability O
of O
the O
blood-brain O
barrier O
was O
quantitated O
by O
clearance O
of O
fluorescent-labeled O
dextran O
before O
and O
during O
phenylephrine-induced O
acute O
hypertension B-NEG
in O
rats O
treated O
with O
vehicle O
and O
hoe-140 O
( O
0.1 O
microm) O
. O

phenylephrine O
infusion O
increased O
arterial O
pressure O
, O
arteriolar O
diameter O
and O
clearance O
of O
fluorescent O
dextran O
by O
a O
similar O
magnitude O
in O
both O
groups O
. O

these O
findings O
suggest O
that O
disruption O
of O
the O
blood-brain O
barrier O
during O
acute O
hypertension B-NEG
is O
not O
related O
to O
the O
synthesis/release O
of O
bradykinin O
to O
activate O
b2 O
receptors O
. O

-DOCSTART- O

5-azacytidine O
potentiates O
initiation B-NEG
induced I-NEG
by I-NEG
carcinogens I-NEG
in O
rat O
liver O
. O

to O
test O
the O
validity O
of O
the O
hypothesis O
that O
hypomethylation O
of O
dna O
plays O
an O
important O
role O
in O
the O
initiation B-NEG
of I-NEG
carcinogenic I-NEG
process I-NEG
, O
5-azacytidine O
( O
5-azc O
) O
( O
10 O
mg/kg) O
, O
an O
inhibitor O
of O
dna O
methylation O
, O
was O
given O
to O
rats O
during O
the O
phase O
of O
repair O
synthesis O
induced O
by O
the O
three O
carcinogens O
, O
benzo[a]-pyrene O
( O
200 O
mg/kg) O
, O
n-methyl-n-nitrosourea O
( O
60 O
mg/kg O
) O
and O
1,2-dimethylhydrazine O
( O
1,2-dmh O
) O
( O
100 O
mg/kg) O
. O

the O
initiated O
hepatocytes O
in O
the O
liver O
were O
assayed O
as O
the O
gamma-glutamyltransferase O
( O
gamma-gt O
) O
positive O
foci O
formed O
following O
a O
2-week O
selection O
regimen O
consisting O
of O
dietary O
0.02% O
2-acetylaminofluorene O
coupled O
with O
a O
necrogenic O
dose O
of O
ccl4 O
. O

the O
results O
obtained O
indicate O
that O
with O
all O
three O
carcinogens O
, O
administration O
of O
5-azc O
during O
repair O
synthesis O
increased O
the O
incidence O
of O
initiated O
hepatocytes O
, O
for O
example O
10-20 O
foci/cm2 O
in O
5-azc O
and O
carcinogen-treated O
rats O
compared O
with O
3-5 O
foci/cm2 O
in O
rats O
treated O
with O
carcinogen O
only O
. O

administration O
of O
[3h]-5-azadeoxycytidine O
during O
the O
repair O
synthesis O
induced O
by O
1,2-dmh O
further O
showed O
that O
0.019 O
mol O
% O
of O
cytosine O
residues O
in O
dna O
were O
substituted O
by O
the O
analogue O
, O
indicating O
that O
incorporation O
of O
5-azc O
occurs O
during O
repair O
synthesis O
. O

in O
the O
absence O
of O
the O
carcinogen O
, O
5-azc O
given O
after O
a O
two O
thirds O
partial O
hepatectomy O
, O
when O
its O
incorporation O
should O
be O
maximum O
, O
failed O
to O
induce O
any O
gamma-gt O
positive O
foci O
. O

the O
results O
suggest O
that O
hypomethylation O
of O
dna O
per O
se O
may O
not O
be O
sufficient O
for O
initiation O
. O

perhaps O
two O
events O
might O
be O
necessary O
for O
initiation O
, O
the O
first O
caused O
by O
the O
carcinogen O
and O
a O
second O
involving O
hypomethylation O
of O
dna O
. O

-DOCSTART- O

withdrawal-emergent B-NEG
rabbit I-NEG
syndrome I-NEG
during O
dose O
reduction O
of O
risperidone O
. O
rabbit B-NEG
syndrome I-NEG
( O
rs B-NEG
) O
is O
a O
rare O
extrapyramidal O
side O
effect O
caused O
by O
prolonged O
neuroleptic O
medication O
. O

here O
we O
present O
a O
case O
of O
withdrawal-emergent B-NEG
rs I-NEG
, O
which O
is O
the O
first O
of O
its O
kind O
to O
be O
reported O
. O

the O
patient O
developed O
rs B-NEG
during O
dose O
reduction O
of O
risperidone O
. O

the O
symptom O
was O
treated O
successfully O
with O
trihexyphenidyl O
anticholinergic O
therapy O
. O

the O
underlying O
mechanism O
of O
withdrawal-emergent B-NEG
rs I-NEG
in O
the O
present O
case O
may O
have O
been O
related O
to O
the O
pharmacological O
profile O
of O
risperidone O
, O
a O
serotonin-dopamine O
antagonist O
, O
suggesting O
the O
pathophysiologic O
influence O
of O
the O
serotonin O
system O
in O
the O
development O
of O
rs B-NEG
. O

-DOCSTART- O

verapamil O
withdrawal O
as O
a O
possible O
cause O
of O
myocardial B-NEG
infarction I-NEG
in O
a O
hypertensive B-NEG
woman O
with O
a O
normal O
coronary O
angiogram O
. O

verapamil O
is O
an O
effective O
and O
relatively-safe O
antihypertensive O
drug O
. O

serious O
adverse O
effects O
are O
uncommon O
and O
mainly O
have O
been O
related O
to O
the O
depression B-NEG
of O
cardiac O
contractility O
and O
conduction O
, O
especially O
when O
the O
drug O
is O
combined O
with O
beta-blocking O
agents O
. O

we O
report O
a O
case O
in O
which O
myocardial B-NEG
infarction I-NEG
coincided O
with O
the O
introduction O
of O
captopril O
and O
the O
withdrawal O
of O
verapamil O
in O
a O
previously O
asymptomatic O
woman O
with O
severe O
hypertension B-NEG
. O

possible O
mechanisms O
that O
involve O
a O
verapamil-related O
increase O
in O
platelet O
and/or O
vascular O
alpha O
2-adrenoreceptor O
affinity O
for O
catecholamines O
are O
discussed O
. O

-DOCSTART- O

remission O
induction O
of O
meningeal B-NEG
leukemia I-NEG
with O
high-dose O
intravenous O
methotrexate O
. O

twenty O
children O
with O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
who O
developed O
meningeal B-NEG
disease I-NEG
were O
treated O
with O
a O
high-dose O
intravenous O
methotrexate O
regimen O
that O
was O
designed O
to O
achieve O
and O
maintain O
csf O
methotrexate O
concentrations O
of O
10(-5 O
) O
mol/l O
without O
the O
need O
for O
concomitant O
intrathecal O
dosing O
. O

the O
methotrexate O
was O
administered O
as O
a O
loading O
dose O
of O
6,000 O
mg/m2 O
for O
a O
period O
of O
one O
hour O
followed O
by O
an O
infusion O
of O
1,200 O
mg/m2/h O
for O
23 O
hours O
. O

leucovorin O
rescue O
was O
initiated O
12 O
hours O
after O
the O
end O
of O
the O
infusion O
with O
a O
loading O
dose O
of O
200 O
mg/m2 O
followed O
by O
12 O
mg/m2 O
every O
three O
hours O
for O
six O
doses O
and O
then O
every O
six O
hours O
until O
the O
plasma O
methotrexate O
level O
decreased O
to O
less O
than O
1 O
x O
10(-7 O
) O
mol/l O
. O

the O
mean O
steady-state O
plasma O
and O
csf O
methotrexate O
concentrations O
achieved O
were O
1.1 O
x O
10(-3 O
) O
mol/l O
and O
3.6 O
x O
10(-5 O
) O
mol/l O
, O
respectively O
. O

all O
20 O
patients O
responded O
to O
this O
regimen O
, O
16/20 O
( O
80% O
) O
achieved O
a O
complete O
remission O
, O
and O
20% O
obtained O
a O
partial O
remission O
. O

the O
most O
common O
toxicities B-NEG
encountered O
were O
transient O
serum O
transaminase O
and O
bilirubin O
elevations O
, O
neutropenia B-NEG
, O
and O
mucositis B-NEG
. O

one O
patient O
had O
focal O
seizures B-NEG
and O
transient B-NEG
hemiparesis I-NEG
but O
recovered O
completely O
. O

high-dose O
intravenous O
methotrexate O
is O
an O
effective O
treatment O
for O
the O
induction O
of O
remission O
after O
meningeal O
relapse O
in O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
. O

-DOCSTART- O

hypersensitivity B-NEG
to O
carbamazepine O
presenting O
with O
a O
leukemoid B-NEG
reaction I-NEG
, O
eosinophilia B-NEG
, O
erythroderma B-NEG
, O
and O
renal B-NEG
failure I-NEG
. O

we O
report O
a O
patient O
in O
whom O
hypersensitivity B-NEG
to O
carbamazepine O
presented O
with O
generalized O
erythroderma B-NEG
, O
a O
severe O
leukemoid B-NEG
reaction I-NEG
, O
eosinophilia B-NEG
, O
hyponatremia B-NEG
, O
and O
renal B-NEG
failure I-NEG
. O

this O
is O
the O
first O
report O
of O
such O
an O
unusual O
reaction O
to O
carbamazepine O
. O

-DOCSTART- O

the O
interpeduncular O
nucleus O
regulates O
nicotine's O
effects O
on O
free-field O
activity O
. O

partial O
lesions O
were O
made O
with O
kainic O
acid O
in O
the O
interpeduncular O
nucleus O
of O
the O
ventral O
midbrain O
of O
the O
rat O
. O

compared O
with O
sham-operated O
controls O
, O
lesions O
significantly O
(p O
< O
0.25 O
) O
blunted O
the O
early O
( O
<60 O
min O
) O
free-field O
locomotor B-NEG
hypoactivity I-NEG
caused O
by O
nicotine O
( O
0.5 O
mg O
kg(-1) O
, O
i.m.) O
, O
enhanced O
the O
later O
( O
60-120 O
min O
) O
nicotine-induced O
hyperactivity B-NEG
, O
and O
raised O
spontaneous O
nocturnal O
activity O
. O

lesions O
reduced O
the O
extent O
of O
immunohistological O
staining O
for O
choline O
acetyltransferase O
in O
the O
interpeduncular O
nucleus O
(p O
<0.025) O
, O
but O
not O
for O
tyrosine O
hydroxylase O
in O
the O
surrounding O
catecholaminergic O
a10 O
region O
. O

we O
conclude O
that O
the O
interpeduncular O
nucleus O
mediates O
nicotinic O
depression B-NEG
of O
locomotor O
activity O
and O
dampens O
nicotinic O
arousal O
mechanisms O
located O
elsewhere O
in O
the O
brain O
. O

-DOCSTART- O

assessment O
of O
a O
new O
non-invasive O
index O
of O
cardiac O
performance O
for O
detection O
of O
dobutamine-induced O
myocardial B-NEG
ischemia I-NEG
. O

background O
: O
electrocardiography O
has O
a O
very O
low O
sensitivity O
in O
detecting O
dobutamine-induced O
myocardial B-NEG
ischemia I-NEG
. O

objectives O
: O
to O
assess O
the O
added O
diagnostic O
value O
of O
a O
new O
cardiac O
performance O
index O
( O
dp/dtejc O
) O
measurement O
, O
based O
on O
brachial O
artery O
flow O
changes O
, O
as O
compared O
to O
standard O
12-lead O
ecg O
, O
for O
detecting O
dobutamine-induced O
myocardial B-NEG
ischemia I-NEG
, O
using O
tc99m-sestamibi O
single-photon O
emission O
computed O
tomography O
as O
the O
gold O
standard O
of O
comparison O
to O
assess O
the O
presence O
or O
absence O
of O
ischemia B-NEG
. O

methods O
: O
the O
study O
group O
comprised O
40 O
patients O
undergoing O
sestamibi-spect/dobutamine O
stress O
test O
. O

simultaneous O
measurements O
of O
ecg O
and O
brachial O
artery O
dp/dtejc O
were O
performed O
at O
each O
dobutamine O
level O
. O

in O
19 O
of O
the O
40 O
patients O
perfusion O
defects O
compatible O
with O
ischemia B-NEG
were O
detected O
on O
spect O
. O

the O
increase O
in O
dp/dtejc O
during O
infusion O
of O
dobutamine O
in O
this O
group O
was O
severely O
impaired O
as O
compared O
to O
the O
non-ischemic O
group O
. O

dp/dtejc O
outcome O
was O
combined O
with O
the O
ecg O
results O
, O
giving O
an O
ecg-enhanced O
value O
, O
and O
compared O
to O
ecg O
alone O
. O

results O
: O
the O
sensitivity O
improved O
dramatically O
from O
16% O
to O
79% O
, O
positive O
predictive O
value O
increased O
from O
60% O
to O
68% O
and O
negative O
predictive O
value O
from O
54% O
to O
78% O
, O
and O
specificity O
decreased O
from O
90% O
to O
67% O
. O

conclusions O
: O
if O
ecg O
alone O
is O
used O
for O
specificity O
, O
the O
combination O
with O
dp/dtejc O
improved O
the O
sensitivity O
of O
the O
test O
and O
could O
be O
a O
cost-savings O
alternative O
to O
cardiac O
imaging O
or O
perfusion O
studies O
to O
detect O
myocardial B-NEG
ischemia I-NEG
, O
especially O
in O
patients O
unable O
to O
exercise O
. O

-DOCSTART- O

acute B-NEG
liver I-NEG
failure I-NEG
in O
two O
patients O
with O
regular O
alcohol O
consumption O
ingesting O
paracetamol O
at O
therapeutic O
dosage O
. O

background O
: O
the O
possible O
role O
of O
alcohol O
in O
the O
development O
of O
hepatotoxicity B-NEG
associated O
with O
therapeutic O
doses O
of O
paracetamol O
( O
acetaminophen O
) O
is O
currently O
debated O
. O

case O
report O
: O
we O
describe O
2 O
patients O
who O
were O
regular O
consumers O
of O
alcohol O
and O
who O
developed O
liver B-NEG
failure I-NEG
within O
3-5 O
days O
after O
hospitalization O
and O
stopping O
alcohol O
consumption O
while O
being O
treated O
with O
4 O
g O
paracetamol/day O
. O

a O
paracetamol O
serum O
level O
obtained O
in O
one O
of O
these O
patients O
was O
not O
in O
the O
toxic O
range O
. O

possible O
risk O
factors O
for O
the O
development O
of O
hepatotoxicity B-NEG
in O
patients O
treated O
with O
therapeutic O
doses O
of O
paracetamol O
are O
discussed O
. O

conclusion O
: O
in O
patients O
with O
risk O
factors O
, O
e.g O
. O
regular O
consumption O
of O
alcohol O
, O
liver B-NEG
failure I-NEG
is O
possible O
when O
therapeutic O
doses O
are O
ingested O
. O

we O
propose O
that O
the O
paracetamol O
dose O
should O
not O
exceed O
2 O
g/day O
in O
such O
patients O
and O
that O
their O
liver O
function O
should O
be O
monitored O
closely O
while O
being O
treated O
with O
paracetamol O
. O

-DOCSTART- O

cocaine O
related O
chest B-NEG
pain I-NEG
: O
are O
we O
seeing O
the O
tip O
of O
an O
iceberg? O

the O
recreational O
use O
of O
cocaine O
is O
on O
the O
increase O
. O

the O
emergency O
nurse O
ought O
to O
be O
familiar O
with O
some O
of O
the O
cardiovascular O
consequences O
of O
cocaine O
use O
. O

in O
particular O
, O
the O
tendency O
of O
cocaine O
to O
produce O
chest B-NEG
pain I-NEG
ought O
to O
be O
in O
the O
mind O
of O
the O
emergency O
nurse O
when O
faced O
with O
a O
young O
victim O
of O
chest B-NEG
pain I-NEG
who O
is O
otherwise O
at O
low O
risk O
. O

the O
mechanism O
of O
chest B-NEG
pain I-NEG
related O
to O
cocaine O
use O
is O
discussed O
and O
treatment O
dilemmas O
are O
discussed O
. O

finally O
, O
moral O
issues O
relating O
to O
the O
testing O
of O
potential O
cocaine O
users O
will O
be O
addressed O
. O

-DOCSTART- O

severe O
rhabdomyolysis B-NEG
and O
acute B-NEG
renal I-NEG
failure I-NEG
secondary O
to O
concomitant O
use O
of O
simvastatin O
, O
amiodarone O
, O
and O
atazanavir O
. O

objective O
: O
to O
report O
a O
case O
of O
a O
severe O
interaction O
between O
simvastatin O
, O
amiodarone O
, O
and O
atazanavir O
resulting O
in O
rhabdomyolysis B-NEG
and O
acute B-NEG
renal I-NEG
failure I-NEG
. O

background O
: O
a O
72-year-old O
white O
man O
with O
underlying O
human B-NEG
immunodeficiency I-NEG
virus I-NEG
, O
atrial B-NEG
fibrillation I-NEG
, O
coronary B-NEG
artery I-NEG
disease I-NEG
, O
and O
hyperlipidemia B-NEG
presented O
with O
generalized O
pain B-NEG
, O
fatigue B-NEG
, O
and O
dark O
orange O
urine O
for O
3 O
days O
. O

the O
patient O
was O
taking O
80 O
mg O
simvastatin O
at O
bedtime O
( O
initiated O
27 O
days O
earlier) O
; O
amiodarone O
at O
a O
dose O
of O
400 O
mg O
daily O
for O
7 O
days O
, O
then O
200 O
mg O
daily O
( O
initiated O
19 O
days O
earlier) O
; O
and O
400 O
mg O
atazanavir O
daily O
( O
initiated O
at O
least O
2 O
years O
previously) O
. O

laboratory O
evaluation O
revealed O
66,680 O
u/l O
creatine O
kinase O
, O
93 O
mg/dl O
blood O
urea O
nitrogen O
, O
4.6 O
mg/dl O
creatinine O
, O
1579 O
u/l O
aspartate O
aminotransferase O
, O
and O
738 O
u/l O
alanine O
aminotransferase O
. O

simvastatin O
, O
amiodarone O
, O
and O
the O
patient's O
human B-NEG
immunodeficiency I-NEG
virus I-NEG
medications O
were O
all O
temporarily O
discontinued O
and O
the O
patient O
was O
given O
forced O
alkaline O
diuresis O
and O
started O
on O
dialysis O
. O

nine O
days O
later O
the O
patient's O
creatine O
kinase O
had O
dropped O
to O
1695 O
u/l O
and O
creatinine O
was O
3.3 O
mg/dl O
. O

the O
patient O
was O
discharged O
and O
continued O
outpatient O
dialysis O
for O
1 O
month O
until O
his O
renal O
function O
recovered O
. O

discussion O
: O
the O
risk O
of O
rhabdomyolysis B-NEG
is O
increased O
in O
the O
presence O
of O
concomitant O
drugs O
that O
inhibit O
simvastatin O
metabolism O
. O

simvastatin O
is O
metabolized O
by O
cyp3a4 O
. O

amiodarone O
and O
atazanavir O
are O
recognized O
cyp3a4 O
inhibitors O
. O

conclusions O
: O
pharmacokinetic O
differences O
in O
statins O
are O
an O
important O
consideration O
for O
assessing O
the O
risk O
of O
potential O
drug O
interactions O
. O

in O
patients O
requiring O
the O
concurrent O
use O
of O
statins O
and O
cyp3a4 O
inhibitors O
, O
pravastatin O
, O
fluvastatin O
, O
and O
rosuvastatin O
carry O
the O
lowest O
risk O
of O
drug O
interactions O
; O
atorvastatin O
carries O
moderate O
risk O
, O
whereas O
simvastatin O
and O
lovastatin O
have O
the O
highest O
risk O
and O
should O
be O
avoided O
in O
patients O
taking O
concomitant O
cyp3a4 O
inhibitors O
. O

-DOCSTART- O

phase O
ii O
trial O
of O
vinorelbine O
in O
metastatic O
squamous B-NEG
cell I-NEG
esophageal I-NEG
carcinoma I-NEG
. O

european O
organization O
for O
research O
and O
treatment O
of O
cancer B-NEG
gastrointestinal O
treat O
cancer B-NEG
cooperative O
group O
. O

purpose O
: O
to O
evaluate O
the O
response O
rate O
and O
toxic O
effects O
of O
vinorelbine O
( O
vnb O
) O
administered O
as O
a O
single O
agent O
in O
metastatic O
squamous B-NEG
cell I-NEG
esophageal I-NEG
carcinoma I-NEG
. O

patients O
and O
methods O
: O
forty-six O
eligible O
patients O
with O
measurable O
lesions O
were O
included O
and O
were O
stratified O
according O
to O
previous O
chemotherapy O
. O

thirty O
patients O
without O
prior O
chemotherapy O
and O
16 O
pretreated O
with O
cisplatin-based O
chemotherapy O
were O
assessable O
for O
toxicity B-NEG
and O
response O
. O

vnb O
was O
administered O
weekly O
as O
a O
25-mg/m2 O
short O
intravenous O
( O
i.v. O
) O
infusion O
. O

results O
: O
six O
of O
30 O
patients O
( O
20% O
) O
without O
prior O
chemotherapy O
achieved O
a O
partial O
response O
( O
pr O
) O
( O
95% O
confidence O
interval O
[ci] O
, O
8% O
to O
39%) O
. O

the O
median O
duration O
of O
response O
was O
21 O
weeks O
(range O
, O
17 O
to O
28) O
. O

one O
of O
16 O
patients O
( O
6% O
) O
with O
prior O
chemotherapy O
had O
a O
complete O
response O
( O
cr O
) O
of O
31 O
weeks' O
duration O
( O
95% O
ci O
, O
0% O
to O
30%) O
. O

the O
overall O
response O
rate O
( O
world O
health O
organization O
[who] O
criteria O
) O
was O
15% O
(cr O
, O
2% O
; O
pr O
13% O
; O
95% O
ci O
, O
6% O
to O
29%) O
. O

the O
median O
dose-intensity O
( O
di O
) O
was O
20 O
mg/m2/wk O
. O

vnb O
was O
well O
tolerated O
and O
zero O
instances O
of O
who O
grade O
4 O
nonhematologic O
toxicity B-NEG
occurred O
. O

at O
least O
one O
episode O
of O
grade O
3 O
or O
4 O
granulocytopenia B-NEG
was O
seen O
in O
59% O
of O
patients O
. O

a O
grade O
2 O
or O
3 O
infection B-NEG
occurred O
in O
16% O
of O
patients O
, O
but O
no O
toxic O
deaths B-NEG
occurred O
. O

other O
side O
effects O
were O
rare O
, O
and O
peripheral B-NEG
neurotoxicity I-NEG
has O
been O
minor O
( O
26% O
grade O
1) O
. O

conclusion O
: O
these O
data O
indicate O
that O
vnb O
is O
an O
active O
agent O
in O
metastatic O
esophageal B-NEG
squamous I-NEG
cell I-NEG
carcinoma I-NEG
. O

given O
its O
excellent O
tolerance O
profile O
and O
low O
toxicity B-NEG
, O
further O
evaluation O
of O
vnb O
in O
combination O
therapy O
is O
warranted O
. O

-DOCSTART- O

paclitaxel O
, O
cisplatin O
, O
and O
gemcitabine O
combination O
chemotherapy O
within O
a O
multidisciplinary O
therapeutic O
approach O
in O
metastatic O
nonsmall B-NEG
cell I-NEG
lung I-NEG
carcinoma I-NEG
. O

background O
: O
cisplatin-based O
chemotherapy O
combinations O
improve O
quality O
of O
life O
and O
survival O
in O
advanced O
nonsmall B-NEG
cell I-NEG
lung I-NEG
carcinoma I-NEG
( O
nsclc B-NEG
). O

the O
emergence O
of O
new O
active O
drugs O
might O
translate O
into O
more O
effective O
regimens O
for O
the O
treatment O
of O
this O
disease O
. O

methods O
: O
the O
objective O
of O
this O
study O
was O
to O
determine O
the O
feasibility O
, O
response O
rate O
, O
and O
toxicity B-NEG
of O
a O
paclitaxel O
, O
cisplatin O
, O
and O
gemcitabine O
combination O
to O
treat O
metastatic O
nsclc B-NEG
. O

thirty-five O
consecutive O
chemotherapy-naive O
patients O
with O
stage O
iv O
nsclc B-NEG
and O
an O
eastern O
cooperative O
oncology O
group O
performance O
status O
of O
0-2 O
were O
treated O
with O
a O
combination O
of O
paclitaxel O
( O
135 O
mg/m(2 O
) O
given O
intravenously O
in O
3 O
hours O
) O
on O
day O
1, O
cisplatin O
( O
120 O
mg/m(2 O
) O
given O
intravenously O
in O
6 O
hours O
) O
on O
day O
1, O
and O
gemcitabine O
( O
800 O
mg/m(2 O
) O
given O
intravenously O
in O
30 O
minutes O
) O
on O
days O
1 O
and O
8, O
every O
4 O
weeks O
. O

although O
responding O
patients O
were O
scheduled O
to O
receive O
consolidation O
radiotherapy O
and O
24 O
patients O
received O
preplanned O
second-line O
chemotherapy O
after O
disease O
progression O
, O
the O
response O
and O
toxicity B-NEG
rates O
reported O
refer O
only O
to O
the O
chemotherapy O
regimen O
given O
. O

results O
: O
all O
the O
patients O
were O
examined O
for O
toxicity B-NEG
; O
34 O
were O
examinable O
for O
response O
. O

an O
objective O
response O
was O
observed O
in O
73.5% O
of O
the O
patients O
( O
95% O
confidence O
interval O
[ci] O
, O
55.6-87.1%) O
, O
including O
4 O
complete O
responses O
(11.7%) O
. O

according O
to O
intention-to-treat O
, O
the O
overall O
response O
rate O
was O
71.4% O
( O
95% O
ci O
, O
53 O
. O
7-85.4%) O
. O

after O
154 O
courses O
of O
therapy O
, O
the O
median O
dose O
intensity O
was O
131 O
mg/m(2 O
) O
for O
paclitaxel O
(97.3%) O
, O
117 O
mg/m(2 O
) O
for O
cisplatin O
(97.3%) O
, O
and O
1378 O
mg/m(2 O
) O
for O
gemcitabine O
(86.2%) O
. O

world O
health O
organization O
grade O
3-4 O
neutropenia B-NEG
and O
thrombocytopenia B-NEG
occurred O
in O
39.9% O
and O
11.4% O
of O
patients O
, O
respectively O
. O

there O
was O
one O
treatment-related O
death B-NEG
. O

nonhematologic O
toxicities B-NEG
were O
mild O
. O

after O
a O
median O
follow-up O
of O
22 O
months O
, O
the O
median O
progression O
free O
survival O
rate O
was O
7 O
months O
, O
and O
the O
median O
survival O
time O
was O
16 O
months O
. O

conclusions O
: O
the O
combination O
of O
paclitaxel O
, O
cisplatin O
, O
and O
gemcitabine O
is O
well O
tolerated O
and O
shows O
high O
activity O
in O
metastatic O
nsclc B-NEG
. O

this O
treatment O
merits O
further O
comparison O
with O
other O
cisplatin-based O
regimens O
. O

-DOCSTART- O

evaluation O
of O
adverse O
reactions O
of O
aponidine O
hydrochloride O
ophthalmic O
solution O
. O

we O
prospectively O
evaluated O
the O
adverse O
reactions O
of O
apraclonidine O
in O
20 O
normal O
volunteers O
by O
instilling O
a O
single O
drop O
of O
1% O
apraclonidine O
in O
their O
right O
eyes O
. O

examinations O
, O
including O
blood O
pressure O
, O
pulse O
rate O
, O
conjunctiva O
and O
cornea O
, O
intraocular O
pressure O
(iop) O
, O
pupil O
diameter O
, O
basal O
tear O
secretion O
and O
margin O
reflex O
distance O
of O
both O
upper O
and O
lower O
eyelids O
, O
were O
performed O
prior O
to O
entry O
and O
at O
1, O
3, O
5 O
and O
7 O
hours O
after O
instillation O
. O

the O
ocular B-NEG
hypotensive I-NEG
effects O
were O
statistically O
significant O
for O
apraclonidine-treated O
eyes O
throughout O
the O
study O
and O
also O
statistically O
significant O
for O
contralateral O
eyes O
from O
three O
hours O
after O
topical O
administration O
of O
1% O
apraclonidine O
. O
decreases B-NEG
in I-NEG
systolic I-NEG
blood I-NEG
pressure I-NEG
were O
statistically O
, O
but O
not O
clinically O
, O
significant O
. O

no O
significant O
changes O
in O
diastolic O
blood O
pressure O
, O
pulse O
rate O
and O
basal O
tear O
secretion O
were O
noted O
. O
conjunctival B-NEG
blanching I-NEG
and O
mydriasis B-NEG
were O
commonly O
found O
. O

upper O
lid O
retraction O
was O
frequently O
noted O
. O

while O
the O
elevations O
of O
the O
upper O
lid O
margin O
in O
most O
subjects O
were O
not O
more O
than O
2 O
mm O
and O
did O
not O
cause O
noticeable O
change O
in O
appearance O
, O
one O
subject O
suffered O
from O
mechanical O
entropion B-NEG
and O
marked O
corneal B-NEG
abrasion I-NEG
3 O
hours O
after O
instillation O
of O
the O
medication O
. O

this O
may O
well O
be O
a O
particularly O
notable O
finding O
in O
asian O
people O
. O

-DOCSTART- O

carmofur-induced O
organic B-NEG
mental I-NEG
disorders I-NEG
. O
organic B-NEG
mental I-NEG
disorder I-NEG
was O
observed O
in O
a O
29-year-old O
female O
in O
the O
prognostic O
period O
after O
the O
onset O
of O
carmofur-induced O
leukoencephalopathy B-NEG
. O

symptoms O
such O
as O
euphoria O
, O
emotional O
lability O
and O
puerile O
attitude O
noted O
in O
the O
patient O
were O
diagnosed O
as O
organic B-NEG
personality I-NEG
syndrome I-NEG
according O
to O
the O
criteria O
defined O
in O
the O
dsm-iii-r O
. O

it O
is O
referred O
to O
as O
a O
frontal B-NEG
lobe I-NEG
syndrome I-NEG
. O

brain O
ct O
revealed O
a O
periventricular O
low O
density O
area O
in O
the O
frontal O
white O
matter O
and O
moderate O
dilatation O
of O
the O
lateral O
ventricles O
especially O
at O
the O
bilateral O
anterior O
horns O
. O

consequently O
, O
carmofur-induced O
leukoencephalopathy B-NEG
may O
uncommonly O
result O
in O
organic B-NEG
personality I-NEG
syndrome I-NEG
in O
the O
residual O
state O
. O

it O
may O
be O
attributed O
to O
the O
structural B-NEG
damage I-NEG
to I-NEG
the I-NEG
frontal I-NEG
lobe I-NEG
. O

-DOCSTART- O

international O
mexiletine O
and O
placebo O
antiarrhythmic O
coronary O
trial O
: O
i. O

report O
on O
arrhythmia B-NEG
and O
other O
findings O
. O

impact O
research O
group O
. O

the O
antiarrhythmic O
effects O
of O
the O
sustained O
release O
form O
of O
mexiletine O
( O
mexitil-perlongets O
) O
were O
evaluated O
in O
a O
double-blind O
placebo O
trial O
in O
630 O
patients O
with O
recent O
documented O
myocardial B-NEG
infarction I-NEG
. O

the O
primary O
response O
variable O
was O
based O
on O
central O
reading O
of O
24 O
hour O
ambulatory O
electrocardiographic O
recordings O
and O
was O
defined O
as O
the O
occurrence O
of O
30 O
or O
more O
single O
premature O
ventricular O
complexes O
in O
any O
two O
consecutive O
30 O
minute O
blocks O
or O
one O
or O
more O
runs O
of O
two O
or O
more O
premature O
ventricular O
complexes O
in O
the O
entire O
24 O
hour O
electrocardiographic O
recording O
. O

large O
differences O
, O
regarded O
as O
statistically O
significant O
, O
between O
the O
mexiletine O
and O
placebo O
groups O
were O
noted O
in O
that O
end O
point O
at O
months O
1 O
and O
4, O
but O
only O
trends O
were O
observed O
at O
month O
12 O
. O

these O
differences O
were O
observed O
even O
though O
the O
serum O
mexiletine O
levels O
obtained O
in O
this O
study O
were O
generally O
lower O
than O
those O
observed O
in O
studies O
that O
have O
used O
the O
regular O
form O
of O
the O
drug O
. O

there O
were O
more O
deaths B-NEG
in O
the O
mexiletine O
group O
( O
7.6% O
) O
than O
in O
the O
placebo O
group O
(4.8%) O
; O
the O
difference O
was O
not O
statistically O
significant O
. O

the O
incidence O
of O
coronary O
events O
was O
similar O
in O
both O
groups O
. O

previously O
recognized O
side O
effects O
, O
particularly O
tremor B-NEG
and O
gastrointestinal B-NEG
problems I-NEG
, O
were O
more O
frequent O
in O
the O
mexiletine O
group O
than O
in O
the O
placebo O
group O
. O

-DOCSTART- O

regional O
localization O
of O
the O
antagonism O
of O
amphetamine-induced O
hyperactivity B-NEG
by O
intracerebral O
calcitonin O
injections O
. O

calcitonin O
receptors O
are O
found O
in O
the O
brain O
, O
and O
intracerebral O
infusions O
of O
calcitonin O
can O
produce O
behavioral O
effects O
. O

among O
these O
behavioral O
effects O
are O
decreases O
in O
food O
intake O
and O
decreases O
in O
amphetamine-induced O
locomotor O
activity O
. O

in O
previous O
experiments O
we O
found O
that O
decreases O
in O
food O
intake O
were O
induced O
by O
local O
administration O
of O
calcitonin O
into O
several O
hypothalamic O
sites O
and O
into O
the O
nucleus O
accumbens O
. O

in O
the O
present O
experiment O
calcitonin O
decreased O
locomotor O
activity O
when O
locally O
injected O
into O
the O
same O
sites O
where O
it O
decreases O
food O
intake O
. O

the O
areas O
where O
calcitonin O
is O
most O
effective O
in O
decreasing O
locomotor O
activity O
are O
located O
in O
the O
hypothalamus O
and O
nucleus O
accumbens O
, O
suggesting O
that O
these O
areas O
are O
the O
major O
sites O
of O
action O
of O
calcitonin O
in O
inhibiting O
amphetamine-induced O
locomotor O
activity O
. O

-DOCSTART- O

fatal O
intracranial B-NEG
bleeding I-NEG
associated O
with O
prehospital O
use O
of O
epinephrine O
. O

we O
present O
a O
case O
of O
paramedic O
misjudgment O
in O
the O
execution O
of O
a O
protocol O
for O
the O
treatment O
of O
allergic B-NEG
reaction I-NEG
in O
a O
case O
of O
pulmonary B-NEG
edema I-NEG
with O
wheezing B-NEG
. O

the O
sudden O
onset O
of O
respiratory B-NEG
distress I-NEG
, O
rash B-NEG
, O
and O
a O
history O
of O
a O
new O
medicine O
led O
the O
two O
paramedics O
on O
the O
scene O
to O
administer O
subcutaneous O
epinephrine O
. O

subsequently O
, O
acute O
cardiac B-NEG
arrest I-NEG
and O
fatal O
subarachnoid B-NEG
hemorrhage I-NEG
occurred O
. O

epinephrine O
has O
a O
proven O
role O
in O
cardiac B-NEG
arrest I-NEG
in O
prehospital O
care O
; O
however O
, O
use O
by O
paramedics O
in O
patients O
with O
suspected O
allergic B-NEG
reaction I-NEG
and O
severe O
hypertension B-NEG
should O
be O
viewed O
with O
caution O
. O

-DOCSTART- O

a O
case O
of O
massive O
rhabdomyolysis B-NEG
following O
molindone O
administration O
. O
rhabdomyolysis B-NEG
is O
a O
potentially O
lethal O
syndrome O
that O
psychiatric B-NEG
patients O
seem O
predisposed O
to O
develop O
. O

the O
clinical O
signs O
and O
symptoms O
, O
typical O
laboratory O
features O
, O
and O
complications O
of O
rhabdomyolysis B-NEG
are O
presented O
. O

the O
case O
of O
a O
schizophrenic B-NEG
patient O
is O
reported O
to O
illustrate O
massive O
rhabdomyolysis B-NEG
and O
subsequent O
acute B-NEG
renal I-NEG
failure I-NEG
following O
molindone O
administration O
. O

physicians O
who O
prescribe O
molindone O
should O
be O
aware O
of O
this O
reaction O
. O

-DOCSTART- O

cardiovascular B-NEG
alterations I-NEG
in O
rat O
fetuses O
exposed O
to O
calcium O
channel O
blockers O
. O

preclinical O
toxicologic O
investigation O
suggested O
that O
a O
new O
calcium O
channel O
blocker O
, O
ro O
40-5967 O
, O
induced O
cardiovascular B-NEG
alterations I-NEG
in O
rat O
fetuses O
exposed O
to O
this O
agent O
during O
organogenesis O
. O

the O
present O
study O
was O
designed O
to O
investigate O
the O
hypothesis O
that O
calcium O
channel O
blockers O
in O
general O
induce O
cardiovascular B-NEG
malformations I-NEG
indicating O
a O
pharmacologic O
class O
effect O
. O

we O
studied O
three O
calcium O
channel O
blockers O
of O
different O
structure O
, O
nifedipine O
, O
diltiazem O
, O
and O
verapamil O
, O
along O
with O
the O
new O
agent O
. O

pregnant O
rats O
were O
administered O
one O
of O
these O
calcium O
channel O
blockers O
during O
the O
period O
of O
cardiac O
morphogenesis O
and O
the O
offspring O
examined O
on O
day O
20 O
of O
gestation O
for O
cardiovascular B-NEG
malformations I-NEG
. O

a O
low O
incidence O
of O
cardiovascular B-NEG
malformations I-NEG
was O
observed O
after O
exposure O
to O
each O
of O
the O
four O
calcium O
channel O
blockers O
, O
but O
this O
incidence O
was O
statistically O
significant O
only O
for O
verapamil O
and O
nifedipine O
. O

all O
four O
agents O
were O
associated O
with O
aortic O
arch O
branching O
variants O
, O
although O
significantly O
increased O
only O
for O
ro O
40-5967 O
and O
verapamil O
. O

-DOCSTART- O

differential O
impact O
of O
immune O
escape O
mutations O
g145r O
and O
p120t O
on O
the O
replication O
of O
lamivudine-resistant O
hepatitis O
b O
virus O
e O
antigen-positive O
and O
-negative O
strains O
. O

immune O
escape O
variants O
of O
the O
hepatitis B-NEG
b I-NEG
virus O
( O
hbv O
) O
represent O
an O
emerging O
clinical O
challenge O
, O
because O
they O
can O
be O
associated O
with O
vaccine O
escape O
, O
hbv O
reactivation O
, O
and O
failure O
of O
diagnostic O
tests O
. O

recent O
data O
suggest O
a O
preferential O
selection O
of O
immune O
escape O
mutants O
in O
distinct O
peripheral O
blood O
leukocyte O
compartments O
of O
infected O
individuals O
. O

we O
therefore O
systematically O
analyzed O
the O
functional O
impact O
of O
the O
most O
prevalent O
immune O
escape O
variants O
, O
the O
sg145r O
and O
sp120t O
mutants O
, O
on O
the O
viral O
replication O
efficacy O
and O
antiviral O
drug O
susceptibility O
of O
common O
treatment-associated O
mutants O
with O
resistance O
to O
lamivudine O
( O
lam O
) O
and/or O
hbeag O
negativity O
. O

replication-competent O
hbv O
strains O
with O
sg145r O
or O
sp120t O
and O
lam O
resistance O
( O
rtm204i O
or O
rtl180m/rtm204v O
) O
were O
generated O
on O
an O
hbeag-positive O
and O
an O
hbeag-negative O
background O
with O
precore O
( O
pc O
) O
and O
basal O
core O
promoter O
( O
bcp O
) O
mutants O
. O

the O
sg145r O
mutation O
strongly O
reduced O
hbsag O
levels O
and O
was O
able O
to O
fully O
restore O
the O
impaired O
replication O
of O
lam-resistant O
hbv O
mutants O
to O
the O
levels O
of O
wild-type O
hbv O
, O
and O
pc O
or O
bcp O
mutations O
further O
enhanced O
viral O
replication O
. O

although O
the O
sp120t O
substitution O
also O
impaired O
hbsag O
secretion O
, O
it O
did O
not O
enhance O
the O
replication O
of O
lam-resistant O
clones O
. O

however O
, O
the O
concomitant O
occurrence O
of O
hbeag O
negativity O
(pc/bcp) O
, O
sp120t O
, O
and O
lam O
resistance O
resulted O
in O
the O
restoration O
of O
replication O
to O
levels O
of O
wild-type O
hbv O
. O

in O
all O
clones O
with O
combined O
immune O
escape O
and O
lam O
resistance O
mutations O
, O
the O
nucleotide O
analogues O
adefovir O
and O
tenofovir O
remained O
effective O
in O
suppressing O
viral O
replication O
in O
vitro O
. O

these O
findings O
reveal O
the O
differential O
impact O
of O
immune O
escape O
variants O
on O
the O
replication O
and O
drug O
susceptibility O
of O
complex O
hbv O
mutants O
, O
supporting O
the O
need O
of O
close O
surveillance O
and O
treatment O
adjustment O
in O
response O
to O
the O
selection O
of O
distinct O
mutational O
patterns O
. O

-DOCSTART- O

the O
effects O
of O
sevoflurane O
on O
lidocaine-induced O
convulsions B-NEG
. O

the O
influence O
of O
sevoflurane O
on O
lidocaine-induced O
convulsions B-NEG
was O
studied O
in O
cats O
. O

the O
convulsive B-NEG
threshold O
( O
mean O
+/- O
sd O
) O
was O
41.4 O
+/- O
6.5 O
mg O
. O

l(-1 O
) O
with O
lidocaine O
infusion O
(6 O
mg.kg(-1).min(-1)) O
, O
increasing O
significantly O
to O
66.6 O
+/- O
10.9 O
mg O
. O

l(-1 O
) O
when O
the O
end-tidal O
concentration O
of O
sevoflurane O
was O
0.8% O
. O

however O
, O
the O
threshold O
( O
61.6 O
+/- O
8.7 O
mg O
. O
l(-1) O
) O
during O
1.6% O
sevoflurane O
was O
not O
significant O
from O
that O
during O
0.8% O
sevoflurane O
, O
indicating O
a O
celling O
effect O
. O

there O
was O
no O
significant O
difference O
in O
the O
convulsive B-NEG
threshold O
between O
sevoflurane O
and O
enflurane O
. O

the O
rise O
in O
blood O
pressure O
became O
less O
marked O
when O
higher O
concentrations O
of O
sevoflurane O
or O
enflurane O
were O
administered O
and O
the O
blood O
pressure O
at O
convulsions B-NEG
decreased O
significantly O
in O
1.6% O
sevoflurane O
, O
and O
in O
0.8% O
and O
1.6% O
enflurane O
. O

however O
, O
there O
was O
no O
significant O
difference O
in O
the O
lidocaine O
concentrations O
measured O
when O
the O
systolic O
blood O
pressure O
became O
70 O
mmhg O
. O

apamin O
, O
a O
selective O
blocker O
of O
calcium-dependent O
potassium O
channels O
, O
was O
administered O
intracerebroventricularly O
in O
rats O
anesthetized O
with O
0.8% O
sevoflurane O
to O
investigate O
the O
mechanism O
of O
the O
anticonvulsive O
effects O
. O

apamin O
( O
10 O
ng O
) O
had O
a O
tendency O
to O
decrease O
the O
convulsive B-NEG
threshold O
( O
21.6 O
+/- O
2.2 O
to O
19.9 O
+/- O
2.5 O
mg O
. O
l(-1) O
) O
but O
this O
was O
not O
statistically O
significant O
. O

it O
is O
suggested O
that O
sevoflurane O
reduces O
the O
convulsive B-NEG
effect O
of O
lidocaine O
toxicity B-NEG
but O
carries O
some O
risk O
due O
to O
circulatory O
depression B-NEG
. O

-DOCSTART- O

anti-oxidant O
effects O
of O
atorvastatin O
in O
dexamethasone-induced O
hypertension B-NEG
in O
the O
rat O
. O

1. O

dexamethasone O
( O
dex)-induced O
hypertension B-NEG
is O
characterized O
by O
endothelial O
dysfunction O
associated O
with O
nitric O
oxide O
( O
no O
) O
deficiency O
and O
increased O
superoxide O
( O
o2- O
) O
production O
. O

atorvastatin O
( O
ato O
) O
possesses O
pleiotropic O
properties O
that O
have O
been O
reported O
to O
improve O
endothelial O
function O
through O
increased O
availability O
of O
no O
and O
reduced O
o2- O
production O
in O
various O
forms O
of O
hypertension B-NEG
. O

in O
the O
present O
study O
, O
we O
investigated O
whether O
50 O
mg/kg O
per O
day O
, O
p.o. O
, O
ato O
could O
prevent O
endothelial O
no O
synthase O
( O
enos O
) O
downregulation O
and O
the O
increase O
in O
o2- O
in O
sprague-dawley O
( O
sd O
) O
rats O
, O
thereby O
reducing O
blood O
pressure O
. O

2. O

male O
sd O
rats O
(n O
= O
30 O
) O
were O
treated O
with O
ato O
( O
50 O
mg/kg O
per O
day O
in O
drinking O
water O
) O
or O
tap O
water O
for O
15 O
days O
. O

dexamethasone O
( O
10 O
microg/kg O
per O
day O
, O
s.c. O
) O
or O
saline O
was O
started O
after O
4 O
days O
in O
ato-treated O
and O
non-treated O
rats O
and O
continued O
for O
11-13 O
days O
. O

systolic O
blood O
pressure O
( O
sbp O
) O
was O
measured O
on O
alternate O
days O
using O
the O
tail-cuff O
method O
. O

endothelial O
function O
was O
assessed O
by O
acetylcholine-induced O
vasorelaxation O
and O
phenylephrine-induced O
vasoconstriction O
in O
aortic O
segments O
. O

vascular O
enos O
mrna O
was O
assessed O
by O
semi-quantitative O
reverse O
transcription-polymerase O
chain O
reaction O
. O

3. O

in O
rats O
treated O
with O
dex O
alone O
, O
sbp O
was O
increased O
from O
109 O
+/- O
2 O
to O
133 O
+/- O
2 O
mmhg O
on O
days O
4 O
and O
day O
14 O
, O
respectively O
(p O
< O
0.001) O
. O

in O
the O
ato O
+ O
dex O
group O
, O
sbp O
was O
increased O
from O
113 O
+/- O
2 O
to O
119 O
+/- O
2 O
mmhg O
on O
days O
4 O
to O
14 O
, O
respectively O
(p O
< O
0.001) O
, O
but O
was O
significantly O
lower O
than O
sbp O
in O
the O
group O
treated O
with O
dex O
alone O
(p O
< O
0.05) O
. O

endothelial-dependent O
relaxation O
and O
enos O
mrna O
expression O
were O
greater O
in O
the O
dex O
+ O
ato O
group O
than O
in O
the O
dex O
only O
group O
(p O
< O
0.05 O
and O
p O
< O
0.0001 O
, O
respectively) O
. O

aortic O
superoxide O
production O
was O
lower O
in O
the O
dex O
+ O
ato O
group O
compared O
with O
the O
group O
treated O
with O
dex O
alone O
(p O
< O
0.0001) O
. O

4. O

treatment O
with O
ato O
improved O
endothelial O
function O
, O
reduced O
superoxide O
production O
and O
reduced O
sbp O
in O
dex-treated O
sd O
rats O
. O

-DOCSTART- O

99mtc-glucarate O
for O
detection O
of O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
. O
infarct B-NEG
-avid O
radiopharmaceuticals O
are O
necessary O
for O
rapid O
and O
timely O
diagnosis O
of O
acute O
myocardial B-NEG
infarction I-NEG
. O

the O
animal O
model O
used O
to O
produce O
infarction B-NEG
implies O
artery O
ligation O
but O
chemical O
induction O
can O
be O
easily O
obtained O
with O
isoproterenol O
. O

a O
new O
infarct B-NEG
-avid O
radiopharmaceutical O
based O
on O
glucaric O
acid O
was O
prepared O
in O
the O
hospital O
radiopharmacy O
of O
the O
incmnsz O
. O

99mtc-glucarate O
was O
easy O
to O
prepare O
, O
stable O
for O
96 O
h O
and O
was O
used O
to O
study O
its O
biodistribution O
in O
rats O
with O
isoproterenol-induced O
acute O
myocardial B-NEG
infarction I-NEG
. O

histological O
studies O
demonstrated O
that O
the O
rats O
developed O
an O
infarct B-NEG
18 O
h O
after O
isoproterenol O
administration O
. O

the O
rat O
biodistribution O
studies O
showed O
a O
rapid O
blood O
clearance O
via O
the O
kidneys O
. O

thirty O
minutes O
after O
99mtc-glucarate O
administration O
the O
standardised O
heart O
uptake O
value O
s(h)uv O
was O
4.7 O
in O
infarcted O
rat O
heart O
which O
is O
six O
times O
more O
than O
in O
normal O
rats O
. O

rois O
drawn O
over O
the O
gamma O
camera O
images O
showed O
a O
ratio O
of O
4.4 O
. O

the O
high O
image O
quality O
suggests O
that O
high O
contrast O
images O
can O
be O
obtained O
in O
humans O
and O
the O
96 O
h O
stability O
makes O
it O
an O
ideal O
agent O
to O
detect O
, O
in O
patients O
, O
early O
cardiac B-NEG
infarction I-NEG
. O

-DOCSTART- O

a O
randomized O
, O
placebo-controlled O
dose-comparison O
trial O
of O
haloperidol O
for O
psychosis B-NEG
and O
disruptive B-NEG
behaviors I-NEG
in O
alzheimer's B-NEG
disease I-NEG
. O

objective O
: O
the O
goal O
of O
this O
study O
was O
to O
compare O
the O
efficacy O
and O
side O
effects O
of O
two O
doses O
of O
haloperidol O
and O
placebo O
in O
the O
treatment O
of O
psychosis B-NEG
and O
disruptive B-NEG
behaviors I-NEG
in O
patients O
with O
alzheimer's B-NEG
disease I-NEG
. O

method O
: O
in O
a O
6-week O
random-assignment O
, O
double-blind O
, O
placebo-controlled O
trial O
( O
phase O
a) O
, O
haloperidol O
, O
2-3 O
mg/day O
( O
standard O
dose) O
, O
and O
haloperidol O
, O
0.50-0.75 O
mg/day O
( O
low O
dose) O
, O
were O
compared O
in O
71 O
outpatients O
with O
alzheimer's B-NEG
disease I-NEG
. O

for O
the O
subsequent O
6-week O
double-blind O
crossover O
phase O
( O
phase O
b) O
, O
patients O
taking O
standard- O
or O
low-dose O
haloperidol O
were O
switched O
to O
placebo O
, O
and O
patients O
taking O
placebo O
were O
randomly O
assigned O
to O
standard- O
or O
low-dose O
haloperidol O
. O

results O
: O
for O
the O
60 O
patients O
who O
completed O
phase O
a, O
standard-dose O
haloperidol O
was O
efficacious O
and O
superior O
to O
both O
low-dose O
haloperidol O
and O
placebo O
for O
scores O
on O
the O
brief O
psychiatric O
rating O
scale O
psychosis B-NEG
factor O
and O
on O
psychomotor B-NEG
agitation I-NEG
. O

response O
rates O
according O
to O
three O
sets O
of O
criteria O
were O
greater O
with O
the O
standard O
dose O
( O
55%-60% O
) O
than O
the O
low O
dose O
( O
25%-35% O
) O
and O
placebo O
(25%-30%) O
. O

the O
advantage O
of O
standard O
dose O
over O
low O
dose O
was O
replicated O
in O
phase O
b. O

in O
phase O
a, O
extrapyramidal B-NEG
signs I-NEG
tended O
to O
be O
greater O
with O
the O
standard O
dose O
than O
in O
the O
other O
two O
conditions O
, O
primarily O
because O
of O
a O
subgroup O
( O
20% O
) O
who O
developed O
moderate O
to O
severe O
signs O
. O

low-dose O
haloperidol O
did O
not O
differ O
from O
placebo O
on O
any O
measure O
of O
efficacy O
or O
side O
effects O
. O

conclusions O
: O
the O
results O
indicated O
a O
favorable O
therapeutic O
profile O
for O
haloperidol O
in O
doses O
of O
2-3 O
mg/day O
, O
although O
a O
subgroup O
developed O
moderate O
to O
severe O
extrapyramidal B-NEG
signs I-NEG
. O

a O
starting O
dose O
of O
1 O
mg/day O
with O
gradual O
, O
upward O
dose O
titration O
is O
recommended O
. O

the O
narrow O
therapeutic O
window O
observed O
with O
haloperidol O
may O
also O
apply O
to O
other O
neuroleptics O
used O
in O
alzheimer's B-NEG
disease I-NEG
patients O
with O
psychosis B-NEG
and O
disruptive B-NEG
behaviors I-NEG
. O

-DOCSTART- O

individual O
differences O
in O
renal O
ace O
activity O
in O
healthy O
rats O
predict O
susceptibility O
to O
adriamycin-induced O
renal B-NEG
damage I-NEG
. O

background O
: O
in O
man O
, O
differences O
in O
angiotensin-converting O
enzyme O
( O
ace O
) O
levels O
, O
related O
to O
ace O
( O
i/d O
) O
genotype O
, O
are O
associated O
with O
renal O
prognosis O
. O

this O
raises O
the O
hypothesis O
that O
individual O
differences O
in O
renal O
ace O
activity O
are O
involved O
in O
renal O
susceptibility O
to O
inflicted O
damage O
. O

therefore O
, O
we O
studied O
the O
predictive O
effect O
of O
renal O
ace O
activity O
for O
the O
severity O
of O
renal B-NEG
damage I-NEG
induced O
by O
a O
single O
injection O
of O
adriamycin O
in O
rats O
. O

methods O
: O
renal O
ace O
activity O
( O
hip-his-leu O
cleavage O
by O
cortical O
homogenates O
) O
was O
determined O
by O
renal O
biopsy O
in O
27 O
adult O
male O
wistar O
rats O
. O

after O
1 O
week O
of O
recovery O
, O
proteinuria B-NEG
was O
induced O
by O
adriamycin O
[1.5 O
mg/kg O
intravenously O
( O
i.v. O
) O
n O
= O
18 O
; O
controls O
, O
saline O
i.v O
. O
n O
= O
9] O
. O
proteinuria B-NEG
was O
measured O
every O
2 O
weeks O
. O

after O
12 O
weeks O
, O
rats O
were O
sacrificed O
and O
their O
kidneys O
harvested O
. O

results O
: O
as O
anticipated O
, O
adriamycin O
elicited O
nephrotic B-NEG
range O
proteinuria B-NEG
, O
renal B-NEG
interstitial I-NEG
damage I-NEG
and O
mild O
focal B-NEG
glomerulosclerosis I-NEG
. O

baseline O
renal O
ace O
positively O
correlated O
with O
the O
relative O
rise O
in O
proteinuria B-NEG
after O
adriamycin O
(r O
= O
0.62 O
, O
p<0.01) O
, O
renal O
interstitial O
alpha-smooth O
muscle O
actin O
(r O
= O
0.49 O
, O
p<0.05) O
, O
interstitial O
macrophage O
influx O
(r O
= O
0.56 O
, O
p<0.05) O
, O
interstitial O
collagen O
iii O
(r O
= O
0.53 O
, O
p<0.05) O
, O
glomerular O
alpha-smooth O
muscle O
actin O
(r O
= O
0.74 O
, O
p<0.01 O
) O
and O
glomerular O
desmin O
(r O
= O
0.48 O
, O
p<0.05) O
. O

baseline O
renal O
ace O
did O
not O
correlate O
with O
focal B-NEG
glomerulosclerosis I-NEG
(r O
= O
0.22 O
, O
ns) O
. O

in O
controls O
, O
no O
predictive O
values O
for O
renal O
parameters O
were O
observed O
. O

conclusion O
: O
individual O
differences O
in O
renal O
ace O
activity O
predict O
the O
severity O
of O
adriamycin-induced O
renal B-NEG
damage I-NEG
in O
this O
outbred O
rat O
strain O
. O

this O
supports O
the O
assumption O
that O
differences O
in O
renal O
ace O
activity O
predispose O
to O
a O
less O
favourable O
course O
of O
renal B-NEG
damage I-NEG
. O

-DOCSTART- O

clinical O
nephrotoxicity B-NEG
of O
tobramycin O
and O
gentamicin O
. O

a O
prospective O
study O
. O

nearly O
3.2 O
million O
people O
in O
this O
country O
receive O
aminoglycoside O
antibiotics O
annually O
. O

gentamicin O
sulfate O
and O
tobramycin O
sulfate O
continue O
to O
demonstrate O
ototoxicity B-NEG
and O
nephrotoxicity B-NEG
in O
both O
animal O
and O
clinical O
studies O
. O

in O
this O
study O
, O
62 O
patients O
with O
confirmed O
initial O
normal O
renal O
function O
and O
treated O
with O
2 O
to O
5 O
mg/kg/day O
of O
gentamicin O
sulfate O
or O
tobramycin O
sulfate O
for O
a O
minimum O
of O
seven O
days O
were O
followed O
up O
prospectively O
for O
the O
development O
of O
aminoglycoside-related O
renal B-NEG
failure I-NEG
, O
defined O
as O
at O
least O
a O
one-third O
reduction O
in O
renal O
function O
. O

in O
these O
62 O
patients O
, O
no O
other O
causes O
for O
renal B-NEG
failure I-NEG
could O
be O
identified O
. O

five O
of O
33 O
( O
15% O
) O
of O
the O
tobramycin-treated O
patients O
and O
16 O
of O
29 O
( O
55.2% O
) O
of O
the O
gentamicin-treated O
patients O
had O
renal B-NEG
failure I-NEG
. O

thus O
, O
gentamicin O
was O
associated O
with O
renal B-NEG
failure I-NEG
more O
than O
three O
times O
as O
often O
as O
was O
tobramycin O
. O

-DOCSTART- O

neuroprotective O
action O
of O
mpep O
, O
a O
selective O
mglur5 O
antagonist O
, O
in O
methamphetamine-induced O
dopaminergic O
neurotoxicity B-NEG
is O
associated O
with O
a O
decrease O
in O
dopamine O
outflow O
and O
inhibition O
of O
hyperthermia B-NEG
in O
rats O
. O

the O
aim O
of O
this O
study O
was O
to O
examine O
the O
role O
of O
metabotropic O
glutamate O
receptor O
5 O
( O
mglur5 O
) O
in O
the O
toxic O
action O
of O
methamphetamine O
on O
dopaminergic O
neurones O
in O
rats O
. O

methamphetamine O
( O
10 O
mg/kg O
sc) O
, O
administered O
five O
times O
, O
reduced O
the O
levels O
of O
dopamine O
and O
its O
metabolites O
in O
striatal O
tissue O
when O
measured O
72 O
h O
after O
the O
last O
injection O
. O

a O
selective O
antagonist O
of O
mglur5 O
, O
2-methyl-6-(phenylethynyl)pyridine O
(mpep O
; O
5 O
mg/kg O
ip) O
, O
when O
administered O
five O
times O
immediately O
before O
each O
methamphetamine O
injection O
reversed O
the O
above-mentioned O
methamphetamine O
effects O
. O

a O
single O
mpep O
(5 O
mg/kg O
ip O
) O
injection O
reduced O
the O
basal O
extracellular O
dopamine O
level O
in O
the O
striatum O
, O
as O
well O
as O
dopamine O
release O
stimulated O
either O
by O
methamphetamine O
( O
10 O
mg/kg O
sc O
) O
or O
by O
intrastriatally O
administered O
veratridine O
( O
100 O
microm) O
. O

moreover O
, O
it O
transiently O
diminished O
the O
methamphetamine O
( O
10 O
mg/kg O
sc)-induced O
hyperthermia B-NEG
and O
reduced O
basal O
body O
temperature O
. O

mpep O
administered O
into O
the O
striatum O
at O
high O
concentrations O
( O
500 O
microm O
) O
increased O
extracellular O
dopamine O
levels O
, O
while O
lower O
concentrations O
( O
50-100 O
microm O
) O
were O
devoid O
of O
any O
effect O
. O

the O
results O
of O
this O
study O
suggest O
that O
the O
blockade O
of O
mglur5 O
by O
mpep O
may O
protect O
dopaminergic O
neurones O
against O
methamphetamine-induced O
toxicity B-NEG
. O

neuroprotection O
rendered O
by O
mpep O
may O
be O
associated O
with O
the O
reduction O
of O
the O
methamphetamine-induced O
dopamine O
efflux O
in O
the O
striatum O
due O
to O
the O
blockade O
of O
extrastriatal O
mglur5 O
, O
and O
with O
a O
decrease O
in O
hyperthermia B-NEG
. O

-DOCSTART- O

pharmacokinetics O
of O
desipramine O
hcl O
when O
administered O
with O
cinacalcet O
hcl O
. O

objective O
: O
in O
vitro O
work O
has O
demonstrated O
that O
cinacalcet O
is O
a O
strong O
inhibitor O
of O
cytochrome O
p450 O
isoenzyme O
( O
cyp O
) O
2d6 O
. O

the O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
effect O
of O
cinacalcet O
on O
cyp2d6 O
activity O
, O
using O
desipramine O
as O
a O
probe O
substrate O
, O
in O
healthy O
subjects O
. O

methods O
: O
seventeen O
subjects O
who O
were O
genotyped O
as O
cyp2d6 O
extensive O
metabolizers O
were O
enrolled O
in O
this O
randomized O
, O
open-label O
, O
crossover O
study O
to O
receive O
a O
single O
oral O
dose O
of O
desipramine O
( O
50 O
mg O
) O
on O
two O
separate O
occasions O
, O
once O
alone O
and O
once O
after O
multiple O
doses O
of O
cinacalcet O
( O
90 O
mg O
for O
7 O
days) O
. O

blood O
samples O
were O
obtained O
predose O
and O
up O
to O
72 O
h O
postdose O
. O

results O
: O
fourteen O
subjects O
completed O
both O
treatment O
arms O
. O

relative O
to O
desipramine O
alone O
, O
mean O
auc O
and O
c(max O
) O
of O
desipramine O
increased O
3.6- O
and O
1.8-fold O
when O
coadministered O
with O
cinacalcet O
. O

the O
t O
( O
1/2,z O
) O
of O
desipramine O
was O
longer O
when O
desipramine O
was O
coadministered O
with O
cinacalcet O
( O
21.0 O
versus O
43.3 O
hs) O
. O

the O
t O
( O
max O
) O
was O
similar O
between O
the O
regimens O
. O

fewer O
subjects O
reported O
adverse O
events O
following O
treatment O
with O
desipramine O
alone O
than O
when O
receiving O
desipramine O
with O
cinacalcet O
( O
33 O
versus O
86%) O
, O
the O
most O
frequent O
of O
which O
( O
nausea B-NEG
and O
headache B-NEG
) O
have O
been O
reported O
for O
patients O
treated O
with O
either O
desipramine O
or O
cinacalcet O
. O

conclusion O
: O
this O
study O
demonstrates O
that O
cinacalcet O
is O
a O
strong O
inhibitor O
of O
cyp2d6 O
. O

these O
data O
suggest O
that O
during O
concomitant O
treatment O
with O
cinacalcet O
, O
dose O
adjustment O
may O
be O
necessary O
for O
drugs O
that O
demonstrate O
a O
narrow O
therapeutic O
index O
and O
are O
metabolized O
by O
cyp2d6 O
. O

-DOCSTART- O

proteomic O
analysis O
of O
striatal O
proteins O
in O
the O
rat O
model O
of O
l-dopa-induced O
dyskinesia B-NEG
. O

l-dopa-induced O
dyskinesia B-NEG
( O
lid B-NEG
) O
is O
among O
the O
motor O
complications O
that O
arise O
in O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
patients O
after O
a O
prolonged O
treatment O
with O
l-dopa O
. O

to O
this O
day O
, O
transcriptome O
analysis O
has O
been O
performed O
in O
a O
rat O
model O
of O
lid B-NEG
[neurobiol O
. O
dis. O
, O
17 O
(2004) O
, O
219] O
but O
information O
regarding O
the O
proteome O
is O
still O
lacking O
. O

in O
the O
present O
study O
, O
we O
investigated O
the O
changes O
occurring O
at O
the O
protein O
level O
in O
striatal O
samples O
obtained O
from O
the O
unilaterally O
6-hydroxydopamine-lesion O
rat O
model O
of O
pd B-NEG
treated O
with O
saline O
, O
l-dopa O
or O
bromocriptine O
using O
two-dimensional O
difference O
gel O
electrophoresis O
and O
mass O
spectrometry O
(ms) O
. O

rats O
treated O
with O
l-dopa O
were O
allocated O
to O
two O
groups O
based O
on O
the O
presence O
or O
absence O
of O
lid B-NEG
. O

among O
the O
2000 O
spots O
compared O
for O
statistical O
difference O
, O
67 O
spots O
were O
significantly O
changed O
in O
abundance O
and O
identified O
using O
matrix-assisted O
laser O
desorption/ionization O
time-of-flight O
ms O
, O
atmospheric O
pressure O
matrix-assisted O
laser O
desorption/ionization O
and O
hplc O
coupled O
tandem O
ms O
(lc/ms/ms) O
. O

out O
of O
these O
67 O
proteins O
, O
lid B-NEG
significantly O
changed O
the O
expression O
level O
of O
five O
proteins O
: O
alphabeta-crystalin O
, O
gamma-enolase O
, O
guanidoacetate O
methyltransferase O
, O
vinculin O
, O
and O
proteasome O
alpha-2 O
subunit O
. O

complementary O
techniques O
such O
as O
western O
immunoblotting O
and O
immunohistochemistry O
were O
performed O
to O
investigate O
the O
validity O
of O
the O
data O
obtained O
using O
the O
proteomic O
approach O
. O

in O
conclusion O
, O
this O
study O
provides O
new O
insights O
into O
the O
protein O
changes O
occurring O
in O
lid B-NEG
. O

-DOCSTART- O

pseudo- O
allergic B-NEG
reactions I-NEG
to O
corticosteroids O
: O
diagnosis O
and O
alternatives O
. O

two O
patients O
treated O
with O
parenteral O
paramethasone O
( O
triniol O
) O
and O
dexamethasone O
( O
sedionbel O
) O
are O
described O
. O

a O
few O
minutes O
after O
administration O
of O
the O
drugs O
, O
they O
presented O
urticaria B-NEG
( O
patients O
1 O
and O
2) O
and O
conjunctivitis B-NEG
( O
patient O
1) O
. O

the O
purpose O
of O
our O
study O
was O
to O
determine O
the O
cause O
of O
the O
patients' O
reactions O
, O
the O
immunological O
mechanisms O
involved O
and O
whether O
these O
patients O
would O
be O
able O
to O
tolerate O
any O
kind O
of O
corticoid O
. O

clinical O
examinations O
and O
skin O
, O
oral O
and O
parenteral O
challenges O
with O
different O
corticosteroids O
and O
elisa O
tests O
were O
performed O
. O

in O
the O
two O
patients O
, O
skin O
and O
elisa O
tests O
with O
paramethasone O
were O
negative O
, O
as O
was O
the O
prick O
test O
with O
each O
of O
its O
excipients O
. O

a O
single-blind O
parenteral O
challenge O
with O
triniol O
was O
positive O
in O
both O
patients O
after O
the O
administration O
of O
1 O
ml O
of O
the O
drug O
, O
and O
negative O
with O
its O
excipients O
. O

we O
also O
carried O
out O
oral O
and O
parenteral O
challenges O
with O
other O
corticosteroids O
and O
found O
intolerance O
to O
some O
of O
them O
. O

these O
results O
suggest O
that O
paramethasone O
caused O
pseudoallergic O
reactions O
in O
our O
patients O
. O

corticosteroids O
different O
from O
paramethasone O
also O
produced O
hypersensitivity B-NEG
reactions O
in O
these O
patients O
; O
however O
, O
a O
few O
of O
them O
were O
tolerated O
. O

the O
basic O
mechanisms O
of O
those O
reactions O
are O
not O
yet O
fully O
understood O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
a O
pseudo- O
allergy B-NEG
caused O
by O
paramethasone O
. O

-DOCSTART- O

valproic O
acid O
induced O
encephalopathy B-NEG
--19 O
new O
cases O
in O
germany O
from O
1994 O
to O
2003--a O
side O
effect O
associated O
to O
vpa-therapy O
not O
only O
in O
young O
children O
. O

valproic O
acid O
( O
vpa O
) O
is O
a O
broad-spectrum O
antiepileptic O
drug O
and O
is O
usually O
well-tolerated O
. O

rare O
serious O
complications O
may O
occur O
in O
some O
patients O
, O
including O
haemorrhagic O
pancreatitis B-NEG
, O
bone B-NEG
marrow I-NEG
suppression I-NEG
, O
vpa-induced O
hepatotoxicity B-NEG
and O
vpa-induced O
encephalopathy B-NEG
. O

the O
typical O
signs O
of O
vpa-induced O
encephalopathy B-NEG
are O
impaired B-NEG
consciousness I-NEG
, O
sometimes O
marked O
eeg O
background O
slowing O
, O
increased O
seizure B-NEG
frequency O
, O
with O
or O
without O
hyperammonemia B-NEG
. O

there O
is O
still O
no O
proof O
of O
causative O
effect O
of O
vpa O
in O
patients O
with O
encephalopathy B-NEG
, O
but O
only O
of O
an O
association O
with O
an O
assumed O
causal O
relation O
. O

we O
report O
19 O
patients O
with O
vpa-associated O
encephalopathy B-NEG
in O
germany O
from O
the O
years O
1994 O
to O
2003 O
, O
none O
of O
whom O
had O
been O
published O
previously O
. O

-DOCSTART- O

haemolytic-uraemic B-NEG
syndrome I-NEG
after O
treatment O
with O
metronidazole O
. O

this O
paper O
describes O
the O
clinical O
features O
of O
six O
children O
who O
developed O
the O
haemolytic-uraemic B-NEG
syndrome I-NEG
after O
treatment O
with O
metronidazole O
. O

these O
children O
were O
older O
and O
were O
more O
likely O
to O
have O
undergone O
recent O
bowel O
surgery O
than O
are O
other O
children O
with O
this O
condition O
. O

while O
the O
involvement O
of O
metronidazole O
in O
the O
aetiology O
of O
the O
haemolytic-uraemic B-NEG
syndrome I-NEG
is O
not O
established O
firmly O
, O
the O
action O
of O
this O
drug O
in O
sensitizing O
tissues O
to O
oxidation O
injury O
and O
the O
reported O
evidence O
of O
oxidation O
changes O
in O
the O
haemolytic-uraemic B-NEG
syndrome I-NEG
suggest O
a O
possible O
link O
between O
metronidazole O
treatment O
and O
some O
cases O
of O
the O
haemolytic-uraemic B-NEG
syndrome I-NEG
. O

-DOCSTART- O

risk O
factors O
of O
sensorineural B-NEG
hearing I-NEG
loss I-NEG
in O
preterm O
infants O
. O

among O
547 O
preterm O
infants O
of O
< O
or O
= O
34 O
weeks O
gestation O
born O
between O
1987 O
and O
1991 O
, O
8 O
children O
( O
1.46% O
) O
developed O
severe O
progressive O
and O
bilateral O
sensorineural B-NEG
hearing I-NEG
loss I-NEG
. O

perinatal O
risk O
factors O
of O
infants O
with O
hearing B-NEG
loss I-NEG
were O
compared O
with O
those O
of O
two O
control O
groups O
matched O
for O
gestation O
and O
birth O
weight O
and O
for O
perinatal O
complications O
. O

our O
observations O
demonstrated O
an O
association O
of O
hearing B-NEG
loss I-NEG
with O
a O
higher O
incidence O
of O
perinatal O
complications O
. O
ototoxicity B-NEG
appeared O
closely O
related O
to O
a O
prolonged O
administration O
and O
higher O
total O
dose O
of O
ototoxic B-NEG
drugs O
, O
particularly O
aminoglycosides O
and O
furosemide O
. O

finally O
, O
we O
strongly O
recommend O
to O
prospectively O
and O
regularly O
perform O
audiologic O
assessment O
in O
sick O
preterm O
children O
as O
hearing B-NEG
loss I-NEG
is O
of O
delayed O
onset O
and O
in O
most O
cases O
bilateral O
and O
severe O
. O

-DOCSTART- O

pharmacokinetic O
and O
clinical O
studies O
in O
patients O
with O
cimetidine-associated O
mental O
confusion B-NEG
. O

15 O
cases O
of O
cimetidine-associated O
mental O
confusion B-NEG
have O
been O
reported O
. O

in O
order O
that O
this O
syndrome O
might O
be O
investigated O
changes O
in O
mental O
status O
( O
m.s. O
) O
were O
correlated O
with O
serum O
concentrations O
and O
renal O
and O
hepatic O
function O
in O
36 O
patients O
, O
30 O
patients O
had O
no O
m.s O
. O
change O
on O
cimetidine O
and O
6 O
had O
moderate O
to O
severe O
changes O
. O

these O
6 O
patients O
had O
both O
renal B-NEG
and I-NEG
liver I-NEG
dysfunction I-NEG
(p O
less O
than O
0.05) O
, O
as O
well O
as O
cimetidine O
trough-concentrations O
of O
more O
than O
1.25 O
microgram/ml O
(p O
less O
than O
0.05) O
. O

the O
severity O
of O
m.s O
. O
changes O
increased O
as O
trough-concentrations O
rose O
, O
5 O
patients O
had O
lumbar O
puncture O
. O

the O
cerebrospinal O
fluid O
: O
serum O
ratio O
of O
cimetidine O
concentrations O
was O
0.24:1 O
and O
indicates O
that O
cimetidine O
passes O
the O
blood-brain O
barrier O
; O
it O
also O
raises O
the O
possibility O
that O
m.s O
. O
changes O
are O
due O
to O
blockade O
of O
histamine O
h2-receptors O
in O
the O
central O
nervous O
system O
. O

patients O
likely O
to O
have O
both O
raised O
trough-concentrations O
and O
mental O
confusion B-NEG
are O
those O
with O
both O
severe O
renal B-NEG
and I-NEG
hepatic I-NEG
dysfunction I-NEG
. O

they O
should O
be O
closely O
observed O
and O
should O
be O
given O
reduced O
doses O
of O
cimetidine O
. O

-DOCSTART- O

different O
lobular O
distributions O
of O
altered O
hepatocyte O
tight O
junctions O
in O
rat O
models O
of O
intrahepatic B-NEG
and I-NEG
extrahepatic I-NEG
cholestasis I-NEG
. O

hepatocyte O
tight O
junctions O
(tjs) O
, O
the O
only O
intercellular O
barrier O
between O
the O
sinusoidal O
and O
the O
canalicular O
spaces O
, O
play O
a O
key O
role O
in O
bile O
formation O
. O

although O
hepatocyte O
tjs O
are O
impaired O
in O
cholestasis B-NEG
, O
attempts O
to O
localize O
the O
precise O
site O
of O
hepatocyte O
tj O
damage O
by O
freeze-fracture O
electron O
microscopy O
have O
produced O
limited O
information O
. O

recently O
, O
several O
tj-associated O
proteins O
like O
zo-1 O
and O
7h6 O
have O
been O
identified O
and O
characterized O
. O

immunolocalization O
of O
7h6 O
appears O
to O
closely O
correlate O
with O
paracellular O
permeability O
. O

we O
used O
rat O
models O
of O
intrahepatic B-NEG
cholestasis I-NEG
by O
ethinyl O
estradiol O
( O
ee O
) O
treatment O
and O
extrahepatic B-NEG
cholestasis I-NEG
by O
bile O
duct O
ligation O
( O
bdl O
) O
to O
precisely O
determine O
the O
site O
of O
tj O
damage O
. O

alterations O
in O
hepatocyte O
tjs O
were O
assessed O
by O
double-immunolabeling O
for O
7h6 O
and O
zo-1 O
using O
a O
confocal O
laser O
scanning O
microscope O
. O

in O
control O
rats O
, O
immunostaining O
for O
7h6 O
and O
zo-1 O
colocalized O
to O
outline O
bile O
canaliculi O
in O
a O
continuous O
fashion O
. O

in O
contrast O
, O
7h6 O
and O
zo-1 O
immunostaining O
was O
more O
discontinuous O
, O
outlining O
the O
bile O
canaliculi O
after O
bdl O
. O

immunostaining O
for O
7h6 O
, O
not O
zo-1 O
, O
decreased O
and O
predominantly O
appeared O
as O
discrete O
signals O
in O
the O
submembranous O
cytoplasm O
of O
periportal O
hepatocytes O
after O
bdl O
. O

after O
ee O
treatment O
, O
changes O
in O
immunostaining O
for O
7h6 O
and O
zo-1 O
were O
similar O
to O
those O
seen O
in O
periportal O
hepatocytes O
after O
bdl O
, O
but O
distributed O
more O
diffusely O
throughout O
the O
lobule O
. O

this O
study O
is O
the O
first O
to O
demonstrate O
that O
impairment O
of O
hepatocyte O
tjs O
occurs O
heterogenously O
in O
the O
liver O
lobule O
after O
bdl O
and O
suggests O
that O
bdl O
and O
ee O
treatments O
produce O
different O
lobular O
distributions O
of O
increased O
paracellular O
permeability O
. O

-DOCSTART- O

long O
term O
audiological O
evaluation O
of O
beta-thalassemic B-NEG
patients O
. O

objective O
: O
the O
objective O
of O
this O
study O
was O
to O
identify O
the O
incidence O
and O
to O
monitor O
the O
progression O
of O
hearing B-NEG
loss I-NEG
in O
children O
and O
young O
adults O
with O
beta-thalassemia B-NEG
major O
. O

methods O
: O
one O
hundred O
and O
four O
( O
104 O
) O
patients O
aged O
6-35 O
years O
( O
mean O
17,2 O
years O
) O
participated O
in O
the O
study O
. O

all O
patients O
were O
on O
a O
regular O
transfusion-chelation O
program O
maintaining O
a O
mean O
hemoglobin O
level O
of O
9.5 O
gr/dl O
. O

subjects O
were O
receiving O
desferrioxamine O
( O
dfo O
) O
chelation O
treatment O
with O
a O
mean O
daily O
dose O
of O
50-60 O
mg/kg O
, O
5-6 O
days O
a O
week O
during O
the O
first O
six O
years O
of O
the O
study O
, O
which O
was O
then O
reduced O
to O
40-50 O
mg/kg O
for O
the O
following O
eight O
years O
. O

patients O
were O
followed O
for O
8-14 O
years O
. O

results O
: O
overall O
, O
21 O
out O
of O
104 O
patients O
( O
20.2% O
) O
presented O
with O
high O
frequency O
sensorineural B-NEG
hearing I-NEG
loss I-NEG
( O
snhl B-NEG
), O
either O
unilateral O
or O
bilateral O
. O

no O
ototoxic B-NEG
factor O
, O
other O
than O
dfo O
, O
was O
present O
in O
any O
of O
the O
patients O
. O

patients O
with O
snhl B-NEG
presented O
with O
relatively O
lower O
serum O
ferritin O
levels O
than O
those O
with O
normal O
hearing O
, O
however O
, O
no O
statistically O
significant O
difference O
was O
observed O
. O

subjects O
with O
snhl B-NEG
were O
submitted O
to O
dfo O
reduction O
or O
temporary O
withdrawal O
. O

following O
intervention O
, O
7 O
out O
of O
21 O
affected O
patients O
recovered O
, O
10 O
remained O
stable O
and O
4 O
demonstrated O
aggravation O
. O

conclusion O
: O
the O
findings O
are O
indicative O
of O
dfo's O
contributing O
role O
in O
the O
development O
of O
hearing B-NEG
impairment I-NEG
. O

regular O
audiologic O
evaluation O
is O
imperative O
in O
all O
thalassemic B-NEG
patients O
so O
that O
early O
changes O
may O
be O
recognized O
and O
treatment O
may O
be O
judiciously O
adjusted O
in O
order O
to O
prevent O
or O
reverse O
hearing B-NEG
impairment I-NEG
. O

-DOCSTART- O

design O
and O
analysis O
of O
the O
hypren-trial O
: O
safety O
of O
enalapril O
and O
prazosin O
in O
the O
initial O
treatment O
phase O
of O
patients O
with O
congestive B-NEG
heart I-NEG
failure I-NEG
. O

since O
the O
introduction O
of O
angiotensin O
converting O
enzyme O
( O
ace O
) O
inhibitors O
into O
the O
adjunctive O
treatment O
of O
patients O
with O
congestive B-NEG
heart I-NEG
failure I-NEG
, O
cases O
of O
severe O
hypotension B-NEG
, O
especially O
on O
the O
first O
day O
of O
treatment O
, O
have O
occasionally O
been O
reported O
. O

to O
assess O
the O
safety O
of O
the O
ace O
inhibitor O
enalapril O
a O
multicenter O
, O
randomized O
, O
prazosin-controlled O
trial O
was O
designed O
that O
compared O
the O
incidence O
and O
severity O
of O
symptomatic O
hypotension B-NEG
on O
the O
first O
day O
of O
treatment O
. O

trial O
medication O
was O
2.5 O
mg O
enalapril O
or O
0.5 O
prazosin O
. O

subjects O
were O
1210 O
inpatients O
with O
new O
york O
heart O
association O
( O
nyha O
) O
functional O
class O
ii O
and O
iii O
. O

patients O
who O
received O
enalapril O
experienced O
clinically O
and O
statistically O
significantly O
less O
symptomatic O
hypotension B-NEG
( O
5.2% O
) O
than O
the O
patients O
who O
received O
prazosin O
(12.9%) O
. O

all O
patients O
recovered O
. O

it O
was O
concluded O
that O
treatment O
with O
enalapril O
was O
well O
tolerated O
and O
it O
is O
, O
therefore O
, O
unreasonable O
to O
restrict O
the O
initiation O
of O
treatment O
with O
enalapril O
to O
inpatients O
. O

-DOCSTART- O

antagonism O
between O
interleukin O
3 O
and O
erythropoietin O
in O
mice O
with O
azidothymidine-induced O
anemia B-NEG
and O
in O
bone O
marrow O
endothelial O
cells O
. O

azidothymidine O
( O
azt)-induced O
anemia B-NEG
in O
mice O
can O
be O
reversed O
by O
the O
administration O
of O
igf-il-3 O
( O
fusion O
protein O
of O
insulin-like O
growth O
factor O
ii O
( O
igf O
ii O
) O
and O
interleukin O
3) O
. O

although O
interleukin O
3 O
( O
il-3 O
) O
and O
erythropoietin O
( O
epo O
) O
are O
known O
to O
act O
synergistically O
on O
hematopoietic O
cell O
proliferation O
in O
vitro O
, O
injection O
of O
igf-il-3 O
and O
epo O
in O
azt-treated O
mice O
resulted O
in O
a O
reduction O
of O
red O
cells O
and O
an O
increase O
of O
plasma O
epo O
levels O
as O
compared O
to O
animals O
treated O
with O
igf-il-3 O
or O
epo O
alone O
. O

we O
tested O
the O
hypothesis O
that O
the O
antagonistic O
effect O
of O
il-3 O
and O
epo O
on O
erythroid O
cells O
may O
be O
mediated O
by O
endothelial O
cells O
. O

bovine O
liver O
erythroid O
cells O
were O
cultured O
on O
monolayers O
of O
human O
bone O
marrow O
endothelial O
cells O
previously O
treated O
with O
epo O
and O
igf-il-3 O
. O

there O
was O
a O
significant O
reduction O
of O
thymidine O
incorporation O
into O
both O
erythroid O
and O
endothelial O
cells O
in O
cultures O
pre-treated O
with O
igf-il-3 O
and O
epo O
. O

endothelial O
cell O
culture O
supernatants O
separated O
by O
ultrafiltration O
and O
ultracentrifugation O
from O
cells O
treated O
with O
epo O
and O
il-3 O
significantly O
reduced O
thymidine O
incorporation O
into O
erythroid O
cells O
as O
compared O
to O
identical O
fractions O
obtained O
from O
the O
media O
of O
cells O
cultured O
with O
epo O
alone O
. O

these O
results O
suggest O
that O
endothelial O
cells O
treated O
simultaneously O
with O
epo O
and O
il-3 O
have O
a O
negative O
effect O
on O
erythroid O
cell O
production O
. O

-DOCSTART- O

interactive O
effects O
of O
variations O
in O
[na]o O
and O
[ca]o O
on O
rat O
atrial O
spontaneous O
frequency O
. O

the O
effects O
of O
varying O
the O
extracellular O
concentrations O
of O
na O
and O
ca O
( O
[na]o O
and O
[ca]o O
) O
on O
both O
, O
the O
spontaneous O
beating O
and O
the O
negative O
chronotropic O
action O
of O
verapamil O
, O
were O
studied O
in O
the O
isolated O
rat O
atria O
. O

basal O
frequency O
( O
bf O
) O
evaluated O
by O
surface O
electrogram O
was O
223 O
+/- O
4 O
beats/min O
. O
in O
control O
krebs-ringer O
containing O
137 O
mm O
na O
and O
1.35 O
mm O
ca O
(n) O
. O

it O
decreased O
by O
16 O
+/- O
3% O
by O
lowering O
[na]o O
to O
78 O
mm O
(lna) O
, O
23 O
+/- O
2% O
by O
lowering O
simultaneously O
[na]o O
to O
78 O
mm O
and O
[ca]o O
to O
0.675 O
mm O
( O
lna+lca O
) O
and O
31 O
+/- O
5% O
by O
lowering O
[na]o O
to O
78 O
mm O
plus O
increasing O
[ca]o O
to O
3.6 O
mm O
(lna+hca) O
. O

at O
normal O
[na]o O
, O
decrease O
( O
0.675 O
mm O
) O
or O
increase O
( O
3.6 O
mm O
) O
of O
[ca]o O
did O
not O
modify O
bf O
; O
a O
reduction O
of O
ten O
times O
( O
0.135 O
mm O
of O
normal O
[ca]o O
was O
effective O
to O
reduce O
bf O
by O
40 O
+/- O
13% O
. O
all O
negative O
chronotropic O
effects O
were O
bf-dependent O
. O
dose-dependent O
bradycardia B-NEG
induced O
by O
verapamil O
was O
potentiated O
by O
lna O
, O
lca O
, O
and O
hca O
. O
independent O
but O
not O
additive O
effects O
of O
na O
and O
ca O
are O
shown O
by O
decreases O
in O
the O
values O
of O
[verapamil]o O
needed O
to O
reduce O
bf O
by O
30% O
( O
ic30 O
) O
with O
the O
following O
order O
of O
inhibitory O
potency O
: O
lna O
> O
lca O
> O
hca O
> O
n, O
resulting O
lna+hca O
similar O
to O
lna O
. O

the O
[verapamil]o O
that O
arrested O
atrial O
beating O
( O
ac O
) O
was O
also O
potentiated O
with O
the O
order O
lna O
= O
lna+lca O
= O
lna+hca O
= O
lca O
> O
hca O
= O
n. O

the O
results O
indicate O
that O
rat O
atrial O
spontaneous O
beating O
is O
more O
dependent O
on O
[na]o O
than O
on O
[ca]o O
in O
a O
range O
of O
+/- O
50% O
of O
their O
normal O
concentration O
. O

also O
the O
enhancement O
of O
verapamil O
effects O
on O
atrial O
beating O
was O
more O
pronounced O
at O
lna O
than O
at O
lca.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

sodium O
status O
influences O
chronic O
amphotericin O
b O
nephrotoxicity B-NEG
in O
rats O
. O

the O
nephrotoxic B-NEG
potential O
of O
amphotericin O
b O
(5 O
mg/kg O
per O
day O
intraperitoneally O
for O
3 O
weeks O
) O
has O
been O
investigated O
in O
salt-depleted O
, O
normal-salt O
, O
and O
salt-loaded O
rats O
. O

in O
salt-depleted O
rats O
, O
amphotericin O
b O
decreased O
creatinine O
clearance O
linearly O
with O
time O
, O
with O
an O
85% O
reduction O
by O
week O
3. O

in O
contrast O
, O
in O
normal-salt O
rats O
creatinine O
clearance O
was O
decreased O
but O
to O
a O
lesser O
extent O
at O
week O
2 O
and O
3, O
and O
in O
salt-loaded O
rats O
creatinine O
clearance O
did O
not O
change O
for O
2 O
weeks O
and O
was O
decreased O
by O
43% O
at O
week O
3. O

all O
rats O
in O
the O
sodium-depleted O
group O
had O
histopathological O
evidence O
of O
patchy O
tubular O
cytoplasmic O
degeneration O
in O
tubules O
that O
was O
not O
observed O
in O
any O
normal-salt O
or O
salt-loaded O
rat O
. O

concentrations O
of O
amphotericin O
b O
in O
plasma O
were O
not O
significantly O
different O
among O
the O
three O
groups O
at O
any O
time O
during O
the O
study O
. O

however O
, O
at O
the O
end O
of O
3 O
weeks O
, O
amphotericin O
b O
levels O
in O
the O
kidneys O
and O
liver O
were O
significantly O
higher O
in O
salt-depleted O
and O
normal-salt O
rats O
than O
those O
in O
salt-loaded O
rats O
, O
with O
plasma/kidney O
ratios O
of O
21 O
, O
14 O
, O
and O
8 O
in O
salt-depleted O
, O
normal-salt O
, O
and O
salt-loaded O
rats O
, O
respectively O
. O

in O
conclusion O
, O
reductions O
in O
creatinine O
clearance O
and O
renal O
amphotericin O
b O
accumulation O
after O
chronic O
amphotericin O
b O
administration O
were O
enhanced O
by O
salt O
depletion O
and O
attenuated O
by O
sodium O
loading O
in O
rats O
. O

-DOCSTART- O

reversible O
inferior B-NEG
colliculus I-NEG
lesion I-NEG
in O
metronidazole-induced O
encephalopathy B-NEG
: O
magnetic O
resonance O
findings O
on O
diffusion-weighted O
and O
fluid O
attenuated O
inversion O
recovery O
imaging O
. O

objective O
: O
this O
is O
to O
present O
reversible O
inferior B-NEG
colliculus I-NEG
lesions I-NEG
in O
metronidazole-induced O
encephalopathy B-NEG
, O
to O
focus O
on O
the O
diffusion-weighted O
imaging O
( O
dwi O
) O
and O
fluid O
attenuated O
inversion O
recovery O
( O
flair O
) O
imaging O
. O

materials O
and O
methods O
: O
from O
november O
2005 O
to O
september O
2007 O
, O
8 O
patients O
(5 O
men O
and O
3 O
women O
) O
were O
diagnosed O
as O
having O
metronidazole-induced O
encephalopathy B-NEG
( O
age O
range O
; O
43-78 O
years) O
. O

they O
had O
been O
taking O
metronidazole O
( O
total O
dosage O
, O
45-120 O
g; O
duration O
, O
30 O
days O
to O
2 O
months O
) O
to O
treat O
the O
infection B-NEG
in O
various O
organs O
. O

initial O
brain O
magnetic O
resonance O
imaging O
( O
mri O
) O
were O
obtained O
after O
the O
hospitalization O
, O
including O
dwi O
(8/8) O
, O
apparent O
diffusion O
coefficient O
( O
adc O
) O
map O
(4/8) O
, O
flair O
(7/8) O
, O
and O
t2-weighted O
image O
(8/8) O
. O

follow-up O
mris O
were O
performed O
on O
5 O
patients O
from O
third O
to O
14th O
days O
after O
discontinuation O
of O
metronidazole O
administration O
. O

findings O
of O
initial O
and O
follow-up O
mris O
were O
retrospectively O
evaluated O
by O
2 O
neuroradiologists O
by O
consensus O
, O
to O
analyze O
the O
presence O
of O
abnormal O
signal O
intensities O
, O
their O
locations O
, O
and O
signal O
changes O
on O
follow-up O
images O
. O

results O
: O
initial O
mris O
showed O
abnormal O
high O
signal O
intensities O
on O
dwi O
and O
flair O
( O
or O
t2-weighted O
image O
) O
at O
the O
dentate O
nucleus O
(8/8) O
, O
inferior O
colliculus O
(6/8) O
, O
corpus O
callosum O
(2/8) O
, O
pons O
(2/8) O
, O
medulla O
(1/8) O
, O
and O
bilateral O
cerebral O
white O
matter O
(1/8) O
. O

high-signal O
intensity O
lesions O
on O
dwi O
tended O
to O
show O
low O
signal O
intensity O
on O
adc O
map O
(3/4) O
, O
but O
in O
one O
patient O
, O
high O
signal O
intensity O
was O
shown O
at O
bilateral O
dentate O
nuclei O
on O
not O
only O
dwi O
but O
also O
adc O
map O
. O

all O
the O
lesions O
in O
dentate O
, O
inferior O
colliculus O
, O
pons O
, O
and O
medullas O
had O
been O
resolved O
completely O
on O
follow-up O
mris O
in O
5 O
patients O
, O
but O
in O
1 O
patient O
of O
them O
, O
corpus O
callosal B-NEG
lesion I-NEG
persisted O
. O

conclusions O
: O
reversible O
inferior B-NEG
colliculus I-NEG
lesions I-NEG
could O
be O
considered O
as O
the O
characteristic O
for O
metronidazole-induced O
encephalopathy B-NEG
, O
next O
to O
the O
dentate O
nucleus O
involvement O
. O

-DOCSTART- O

comparison O
of O
the O
respiratory O
effects O
of O
i.v O
. O
infusions O
of O
morphine O
and O
regional O
analgesia O
by O
extradural O
block O
. O

the O
incidence O
of O
postoperative O
respiratory O
apnoea B-NEG
was O
compared O
between O
five O
patients O
receiving O
a O
continuous O
i.v O
. O
infusion O
of O
morphine O
( O
mean O
73.6 O
mg O
) O
and O
five O
patients O
receiving O
a O
continuous O
extradural O
infusion O
of O
0.25% O
bupivacaine O
( O
mean O
192 O
mg O
) O
in O
the O
24-h O
period O
following O
upper O
abdominal O
surgery O
. O

monitoring O
consisted O
of O
airflow O
detection O
by O
a O
carbon O
dioxide O
analyser O
, O
chest O
wall O
movement O
detected O
by O
pneumatic O
capsules O
, O
and O
continuous O
electrocardiograph O
recorded O
with O
a O
holter O
ambulatory O
monitor O
. O

both O
obstructive B-NEG
( O
p I-NEG
less I-NEG
than I-NEG
0.05 I-NEG
) O
and I-NEG
central I-NEG
apnoea I-NEG
(p O
less O
than O
0.05 O
) O
occurred O
more O
frequently O
in O
patients O
who O
had O
a O
morphine O
infusion O
. O

there O
was O
also O
a O
higher O
incidence O
of O
tachyarrhythmias B-NEG
(p O
less O
than O
0.05 O
) O
and O
ventricular B-NEG
ectopic I-NEG
beats I-NEG
(p O
less O
than O
0.05 O
) O
in O
the O
morphine O
infusion O
group O
. O

-DOCSTART- O

magnetic O
resonance O
volumetry O
of O
the O
cerebellum O
in O
epileptic B-NEG
patients O
after O
phenytoin O
overdosages B-NEG
. O

the O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
relationship O
between O
phenytoin O
medication O
and O
cerebellar B-NEG
atrophy I-NEG
in O
patients O
who O
had O
experienced O
clinical O
intoxication O
. O

five O
females O
and O
6 O
males O
, O
21-59 O
years O
of O
age O
, O
were O
examined O
with O
a O
1.5-t O
whole-body O
system O
using O
a O
circular O
polarized O
head O
coil O
. O

conventional O
spin O
echo O
images O
were O
acquired O
in O
the O
sagittal O
and O
transverse O
orientation O
. O

in O
addition O
, O
we O
performed O
a O
high-resolution O
3d O
gradient O
echo O
, O
t1-weighted O
sequences O
at O
a O
1-mm O
slice O
thickness O
. O

the O
images O
were O
subsequently O
processed O
to O
obtain O
volumetric O
data O
for O
the O
cerebellum O
. O

cerebellar O
volume O
for O
the O
patient O
group O
ranged O
between O
67.66 O
and O
131.08 O
ml O
( O
mean O
108.9 O
ml) O
. O

in O
addition O
3d O
gradient O
echo O
data O
sets O
from O
10 O
healthy O
male O
and O
10 O
healthy O
female O
age-matched O
volunteers O
were O
used O
to O
compare O
cerebellar O
volumes O
. O

using O
linear O
regression O
we O
found O
that O
no O
correlation O
exists O
between O
seizure B-NEG
duration O
, O
elevation O
of O
phenytoin O
serum O
levels O
and O
cerebellar O
volume O
. O

however O
, O
multiple O
regression O
for O
the O
daily O
dosage O
, O
duration O
of O
phenytoin O
treatment O
and O
cerebellar O
volume O
revealed O
a O
correlation O
of O
these O
parameters O
. O

we O
conclude O
that O
phenytoin O
overdosage B-NEG
does O
not O
necessarily O
result O
in O
cerebellar B-NEG
atrophy I-NEG
and O
it O
is O
unlikely O
that O
phenytoin O
medication O
was O
the O
only O
cause O
of O
cerebellar B-NEG
atrophy I-NEG
in O
the O
remaining O
patients O
. O

quantitative O
morphometric O
studies O
of O
the O
cerebellum O
provide O
valuable O
insights O
into O
the O
pathogenesis O
of O
cerebellar B-NEG
disorders I-NEG
. O

-DOCSTART- O

evaluation O
of O
cardiac O
troponin O
i O
and O
t O
levels O
as O
markers O
of O
myocardial B-NEG
damage I-NEG
in O
doxorubicin-induced O
cardiomyopathy B-NEG
rats O
, O
and O
their O
relationship O
with O
echocardiographic O
and O
histological O
findings O
. O

background O
: O
cardiac O
troponins O
i O
( O
ctni O
) O
and O
t O
( O
ctnt O
) O
have O
been O
shown O
to O
be O
highly O
sensitive O
and O
specific O
markers O
of O
myocardial B-NEG
cell I-NEG
injury I-NEG
. O

we O
investigated O
the O
diagnostic O
value O
of O
ctni O
and O
ctnt O
for O
the O
diagnosis O
of O
myocardial B-NEG
damage I-NEG
in O
a O
rat O
model O
of O
doxorubicin O
( O
dox)-induced O
cardiomyopathy B-NEG
, O
and O
we O
examined O
the O
relationship O
between O
serial O
ctni O
and O
ctnt O
with O
the O
development O
of O
cardiac B-NEG
disorders I-NEG
monitored O
by O
echocardiography O
and O
histological O
examinations O
in O
this O
model O
. O

methods O
: O
thirty-five O
wistar O
rats O
were O
given O
1.5 O
mg/kg O
dox O
, O
i.v. O
, O
weekly O
for O
up O
to O
8 O
weeks O
for O
a O
total O
cumulative O
dose O
of O
12 O
mg/kg O
bw O
. O

ten O
rats O
received O
saline O
as O
a O
control O
group O
. O

ctni O
was O
measured O
with O
access(r O
) O
( O
ng/ml O
) O
and O
a O
research O
immunoassay O
(pg/ml) O
, O
and O
compared O
with O
ctnt O
, O
ck-mb O
mass O
and O
ck O
. O

by O
using O
transthoracic O
echocardiography O
, O
anterior O
and O
posterior O
wall O
thickness O
, O
lv O
diameters O
and O
lv O
fractional O
shortening O
( O
fs O
) O
were O
measured O
in O
all O
rats O
before O
dox O
or O
saline O
, O
and O
at O
weeks O
6 O
and O
9 O
after O
treatment O
in O
all O
surviving O
rats O
. O

histology O
was O
performed O
in O
dox-rats O
at O
6 O
and O
9 O
weeks O
after O
the O
last O
dox O
dose O
and O
in O
all O
controls O
. O

results O
: O
eighteen O
of O
the O
dox O
rats O
died O
prematurely O
of O
general O
toxicity B-NEG
during O
the O
9-week O
period O
. O

end-diastolic O
( O
ed O
) O
and O
end-systolic O
( O
es O
) O
lv O
diameters/bw O
significantly O
increased O
, O
whereas O
lv O
fs O
was O
decreased O
after O
9 O
weeks O
in O
the O
dox O
group O
(p<0.001) O
. O

these O
parameters O
remained O
unchanged O
in O
controls O
. O

histological O
evaluation O
of O
hearts O
from O
all O
rats O
given O
dox O
revealed O
significant O
slight O
degrees O
of O
perivascular O
and O
interstitial O
fibrosis B-NEG
. O

in O
7 O
of O
the O
18 O
rats O
, O
degeneration O
and O
myocyte O
vacuolisation O
were O
found O
. O

only O
five O
of O
the O
controls O
exhibited O
evidence O
of O
very O
slight O
perivascular O
fibrosis B-NEG
. O

a O
significant O
rise O
in O
ctnt O
was O
found O
in O
dox O
rats O
after O
cumulative O
doses O
of O
7.5 O
and O
12 O
mg/kg O
in O
comparison O
with O
baseline O
(p<0.05) O
. O

ctnt O
found O
in O
rats O
after O
12 O
mg/kg O
were O
significantly O
greater O
than O
that O
found O
after O
7.5 O
mg/kg O
dox O
. O

maximal O
ctni O
( O
pg/ml O
) O
and O
ctnt O
levels O
were O
significantly O
increased O
in O
dox O
rats O
compared O
with O
controls O
(p=0.006 O
, O
0.007) O
. O

ctni O
(ng/ml) O
, O
ck-mb O
mass O
and O
ck O
remained O
unchanged O
in O
dox O
rats O
compared O
with O
controls O
. O

all O
markers O
remained O
stable O
in O
controls O
. O

analysis O
of O
data O
revealed O
a O
significant O
correlation O
between O
maximal O
ctnt O
and O
ed O
and O
es O
lv O
diameters/bw O
( O
r=0.81 O
and O
0.65 O
; O
p<0.0001) O
. O

a O
significant O
relationship O
was O
observed O
between O
maximal O
ctnt O
and O
the O
extent O
of O
myocardial O
morphological O
changes O
, O
and O
between O
lv O
diameters/bw O
and O
histological O
findings O
. O

conclusions O
: O
among O
markers O
of O
ischemic B-NEG
injury I-NEG
after O
dox O
in O
rats O
, O
ctnt O
showed O
the O
greatest O
ability O
to O
detect O
myocardial B-NEG
damage I-NEG
assessed O
by O
echocardiographic O
detection O
and O
histological O
changes O
. O

although O
there O
was O
a O
discrepancy O
between O
the O
amount O
of O
ctni O
and O
ctnt O
after O
dox O
, O
probably O
due O
to O
heterogeneity O
in O
cross-reactivities O
of O
mabs O
to O
various O
ctni O
and O
ctnt O
forms O
, O
it O
is O
likely O
that O
ctnt O
in O
rats O
after O
dox O
indicates O
cell O
damage O
determined O
by O
the O
magnitude O
of O
injury O
induced O
and O
that O
ctnt O
should O
be O
a O
useful O
marker O
for O
the O
prediction O
of O
experimentally O
induced O
cardiotoxicity B-NEG
and O
possibly O
for O
cardioprotective O
experiments O
. O

-DOCSTART- O

calcineurin-inhibitor O
induced O
pain B-NEG
syndrome O
( O
cips B-NEG
): O
a O
severe O
disabling O
complication O
after O
organ O
transplantation O
. O

bone O
pain B-NEG
after O
transplantation O
is O
a O
frequent O
complication O
that O
can O
be O
caused O
by O
several O
diseases O
. O

treatment O
strategies O
depend O
on O
the O
correct O
diagnosis O
of O
the O
pain B-NEG
. O

nine O
patients O
with O
severe O
pain B-NEG
in O
their O
feet O
, O
which O
was O
registered O
after O
transplantation O
, O
were O
investigated O
. O

bone O
scans O
showed O
an O
increased O
tracer O
uptake O
of O
the O
foot O
bones O
. O

magnetic O
resonance O
imaging O
demonstrated O
bone B-NEG
marrow I-NEG
oedema I-NEG
in O
the O
painful O
bones O
. O
pain B-NEG
was O
not O
explained O
by O
other O
diseases O
causing O
foot O
pain B-NEG
, O
like O
reflex B-NEG
sympathetic I-NEG
dystrophy I-NEG
, O
polyneuropathy B-NEG
, O
morton's B-NEG
neuralgia I-NEG
, O
gout B-NEG
, O
osteoporosis B-NEG
, O
avascular B-NEG
necrosis I-NEG
, O
intermittent B-NEG
claudication I-NEG
, O
orthopaedic O
foot B-NEG
deformities I-NEG
, O
stress B-NEG
fractures I-NEG
, O
and O
hyperparathyroidism B-NEG
. O

the O
reduction O
of O
cyclosporine- O
or O
tacrolimus O
trough O
levels O
and O
the O
administration O
of O
calcium O
channel O
blockers O
led O
to O
relief O
of O
pain B-NEG
. O

the O
calcineurin-inhibitor O
induced O
pain B-NEG
syndrome O
( O
cips B-NEG
) O
is O
a O
rare O
but O
severe O
side O
effect O
of O
cyclosporine O
or O
tacrolimus O
and O
is O
accurately O
diagnosed O
by O
its O
typical O
presentation O
, O
magnetic O
resonance O
imaging O
and O
bone O
scans O
. O

incorrect O
diagnosis O
of O
the O
syndrome O
will O
lead O
to O
a O
significant O
reduction O
of O
life O
quality O
in O
patients O
suffering O
from O
cips B-NEG
. O

-DOCSTART- O

the O
haemodynamic O
effects O
of O
propofol O
in O
combination O
with O
ephedrine O
in O
elderly O
patients O
( O
asa O
groups O
3 O
and O
4) O
. O

the O
marked O
vasodilator O
and O
negative O
inotropic O
effects O
of O
propofol O
are O
disadvantages O
in O
frail O
elderly O
patients O
. O

we O
investigated O
the O
safety O
and O
efficacy O
of O
adding O
different O
doses O
of O
ephedrine O
to O
propofol O
in O
order O
to O
obtund O
the O
hypotensive B-NEG
response O
. O

the O
haemodynamic O
effects O
of O
adding O
15 O
, O
20 O
or O
25 O
mg O
of O
ephedrine O
to O
200 O
mg O
of O
propofol O
were O
compared O
to O
control O
in O
40 O
asa O
3/4 O
patients O
over O
60 O
years O
presenting O
for O
genito-urinary O
surgery O
. O

the O
addition O
of O
ephedrine O
to O
propofol O
appears O
to O
be O
an O
effective O
method O
of O
obtunding O
the O
hypotensive B-NEG
response O
to O
propofol O
at O
all O
doses O
used O
in O
this O
study O
. O

however O
, O
marked O
tachycardia B-NEG
associated O
with O
the O
use O
of O
ephedrine O
in O
combination O
with O
propofol O
occurred O
in O
the O
majority O
of O
patients O
, O
occasionally O
reaching O
high O
levels O
in O
individual O
patients O
. O

due O
to O
the O
risk O
of O
this O
tachycardia B-NEG
inducing O
myocardial B-NEG
ischemia I-NEG
, O
we O
would O
not O
recommend O
the O
use O
in O
elderly O
patients O
of O
any O
of O
the O
ephedrine/propofol/mixtures O
studied O
. O

-DOCSTART- O

neurotoxicity B-NEG
of O
halogenated O
hydroxyquinolines O
: O
clinical O
analysis O
of O
cases O
reported O
outside O
japan O
. O

an O
analysis O
is O
presented O
of O
220 O
cases O
of O
possible O
neurotoxic B-NEG
reactions O
to O
halogenated O
hydroxyquinolines O
reported O
from O
outside O
japan O
. O

in O
80 O
cases O
insufficient O
information O
was O
available O
for O
adequate O
comment O
and O
in O
29 O
a O
relationship O
to O
the O
administration O
of O
clioquinol O
could O
be O
excluded O
. O

of O
the O
remainder O
, O
a O
relationship O
to O
clioquinol O
was O
considered O
probable O
in O
42 O
and O
possible O
in O
69 O
cases O
. O

in O
six O
of O
the O
probable O
cases O
the O
neurological B-NEG
disturbance I-NEG
consisted O
of O
an O
acute O
reversible O
encephalopathy B-NEG
usually O
related O
to O
the O
ingestion O
of O
a O
high O
dose O
of O
clioquinol O
over O
a O
short O
period O
. O

the O
most O
common O
manifestation O
, O
observed O
in O
15 O
further O
cases O
, O
was O
isolated O
optic B-NEG
atrophy I-NEG
. O

this O
was O
most O
frequently O
found O
in O
children O
, O
many O
of O
whom O
had O
received O
clioquinol O
as O
treatment O
for O
acrodermatitis B-NEG
enteropathica I-NEG
. O

in O
the O
remaining O
cases O
, O
a O
combination O
of O
myelopathy B-NEG
, O
visual B-NEG
disturbance I-NEG
, O
and O
peripheral B-NEG
neuropathy I-NEG
was O
the O
most O
common O
manifestation O
. O

isolated O
myelopathy B-NEG
or O
peripheral B-NEG
neuropathy I-NEG
, O
or O
these O
manifestations O
occurring O
together O
, O
were O
infrequent O
. O

the O
onset O
of O
all O
manifestations O
( O
except O
toxic O
encephalopathy B-NEG
) O
was O
usually O
subacute O
, O
with O
subsequent O
partial O
recovery O
. O

older O
subjects O
tended O
to O
display O
more O
side O
effects O
. O

the O
full O
syndrome O
of O
subacute O
myelo-optic B-NEG
neuropathy I-NEG
was O
more O
frequent O
in O
women O
, O
but O
they O
tended O
to O
have O
taken O
greater O
quantities O
of O
the O
drug O
. O

-DOCSTART- O

epileptic B-NEG
seizures I-NEG
following O
cortical O
application O
of O
fibrin O
sealants O
containing O
tranexamic O
acid O
in O
rats O
. O

background O
: O
fibrin O
sealants O
( O
fs O
) O
derived O
from O
human O
plasma O
are O
frequently O
used O
in O
neurosurgery O
. O

in O
order O
to O
increase O
clot O
stability O
, O
fs O
typically O
contain O
aprotinin O
, O
a O
natural O
fibrinolysis O
inhibitor O
. O

recently O
, O
synthetic O
fibrinolysis O
inhibitors O
such O
as O
tranexamic O
acid O
( O
tamca O
) O
have O
been O
considered O
as O
substitutes O
for O
aprotinin O
. O

however O
, O
tamca O
has O
been O
shown O
to O
cause O
epileptic B-NEG
seizures I-NEG
. O

we O
wanted O
to O
study O
whether O
tamca O
retains O
its O
convulsive B-NEG
action O
if O
incorporated O
into O
a O
fs O
. O

method O
: O
fs O
containing O
aprotinin O
or O
different O
concentrations O
of O
tamca O
( O
0.5-47.5 O
mg/ml O
) O
were O
applied O
to O
the O
pial O
surface O
of O
the O
cortex O
of O
anaesthetized O
rats O
. O

the O
response O
of O
the O
animals O
was O
evaluated O
using O
electroencephalography O
and O
by O
monitoring O
the O
clinical O
behaviour O
during O
and O
after O
recovery O
from O
anaesthesia O
. O

findings O
: O
fs O
containing O
tamca O
caused O
paroxysmal O
brain O
activity O
which O
was O
associated O
with O
distinct O
convulsive B-NEG
behaviours O
. O

the O
degree O
of O
these O
seizures B-NEG
increased O
with O
increasing O
concentration O
of O
tamca O
. O

thus O
, O
fs O
containing O
47.5 O
mg/ml O
tamca O
evoked O
generalized B-NEG
seizures I-NEG
in O
all O
tested O
rats O
( O
n=6 O
) O
while O
the O
lowest O
concentration O
of O
tamca O
( O
0.5 O
mg/ml O
) O
only O
evoked O
brief O
episodes O
of O
jerk-correlated O
convulsive B-NEG
potentials O
in O
1 O
of O
6 O
rats O
. O

in O
contrast O
, O
fs O
containing O
aprotinin O
did O
not O
evoke O
any O
paroxysmal O
activity O
. O

interpretation O
: O
tranexamic O
acid O
retains O
its O
convulsive B-NEG
action O
within O
fs O
. O

thus O
, O
use O
of O
fs O
containing O
tamca O
for O
surgery O
within O
or O
close O
to O
the O
cns O
may O
pose O
a O
substantial O
risk O
to O
the O
patient O
. O

-DOCSTART- O

a O
diet O
promoting O
sugar B-NEG
dependency I-NEG
causes O
behavioral B-NEG
cross-sensitization I-NEG
to O
a O
low O
dose O
of O
amphetamine O
. O

previous O
research O
in O
this O
laboratory O
has O
shown O
that O
a O
diet O
of O
intermittent O
excessive O
sugar O
consumption O
produces O
a O
state O
with O
neurochemical O
and O
behavioral O
similarities O
to O
drug B-NEG
dependency I-NEG
. O

the O
present O
study O
examined O
whether O
female O
rats O
on O
various O
regimens O
of O
sugar O
access O
would O
show O
behavioral B-NEG
cross-sensitization I-NEG
to O
a O
low O
dose O
of O
amphetamine O
. O

after O
a O
30-min O
baseline O
measure O
of O
locomotor O
activity O
( O
day O
0) O
, O
animals O
were O
maintained O
on O
a O
cyclic O
diet O
of O
12-h O
deprivation O
followed O
by O
12-h O
access O
to O
10% O
sucrose O
solution O
and O
chow O
pellets O
( O
12 O
h O
access O
starting O
4 O
h O
after O
onset O
of O
the O
dark O
period O
) O
for O
21 O
days O
. O

locomotor O
activity O
was O
measured O
again O
for O
30 O
min O
at O
the O
beginning O
of O
days O
1 O
and O
21 O
of O
sugar O
access O
. O

beginning O
on O
day O
22 O
, O
all O
rats O
were O
maintained O
on O
ad O
libitum O
chow O
. O

nine O
days O
later O
locomotor O
activity O
was O
measured O
in O
response O
to O
a O
single O
low O
dose O
of O
amphetamine O
( O
0.5 O
mg/kg) O
. O

the O
animals O
that O
had O
experienced O
cyclic O
sucrose O
and O
chow O
were O
hyperactive B-NEG
in O
response O
to O
amphetamine O
compared O
with O
four O
control O
groups O
( O
ad O
libitum O
10% O
sucrose O
and O
chow O
followed O
by O
amphetamine O
injection O
, O
cyclic O
chow O
followed O
by O
amphetamine O
injection O
, O
ad O
libitum O
chow O
with O
amphetamine O
, O
or O
cyclic O
10% O
sucrose O
and O
chow O
with O
a O
saline O
injection) O
. O

these O
results O
suggest O
that O
a O
diet O
comprised O
of O
alternating O
deprivation O
and O
access O
to O
a O
sugar O
solution O
and O
chow O
produces O
bingeing O
on O
sugar O
that O
leads O
to O
a O
long O
lasting O
state O
of O
increased O
sensitivity O
to O
amphetamine O
, O
possibly O
due O
to O
a O
lasting O
alteration O
in O
the O
dopamine O
system O
. O

-DOCSTART- O

d-penicillamine-induced O
angiopathy B-NEG
in O
rats O
. O

the O
effect O
of O
high O
dose O
d-penicillamine O
treatment O
on O
aortic O
permeability O
to O
albumin O
and O
on O
the O
ultrastructure O
of O
the O
vessel O
. O

male O
sprague-dawley O
rats O
were O
treated O
with O
d-penicillamine O
( O
d-pen O
) O
500 O
mg/kg/day O
for O
10 O
or O
42 O
days O
. O

pair O
fed O
rats O
served O
as O
controls O
. O

changes O
in O
aortic O
morphology O
were O
examined O
by O
light- O
and O
transmission-electron O
microscopy O
(tem) O
. O

in O
addition O
, O
the O
endothelial O
permeability O
and O
the O
penetration O
through O
the O
aortic O
wall O
of O
albumin O
were O
studied O
10 O
minutes O
, O
24 O
and O
48 O
hours O
after O
i. O

v. O
injection O
of O
human O
serum O
131i-albumin O
(131i-hsa) O
. O

tem O
revealed O
extensive O
elastolysis O
in O
the O
arterial O
wall O
of O
d-pen-treated O
rats O
, O
consistent O
with O
an O
inhibitory O
effect O
on O
crosslink O
formation O
. O

in O
experimental O
animals O
excess O
deposition O
of O
collagen O
and O
glycoaminoglycans O
was O
observed O
in O
the O
subendothelial O
and O
medial O
layer O
of O
the O
aortic O
wall O
, O
together O
with O
prominent O
basal O
membrane O
substance O
around O
aortic O
smooth O
muscle O
cells O
. O

the O
aorta/serum-ratio O
and O
the O
radioactive O
build-up O
24 O
and O
48 O
hours O
after O
injection O
of O
131i-hsa O
was O
reduced O
in O
animals O
treated O
with O
d-pen O
for O
42 O
days O
, O
indicating O
an O
impeded O
transmural O
transport O
of O
tracer O
which O
may O
be O
caused O
by O
a O
steric O
exclusion O
effect O
of O
abundant O
hyaluronate O
. O

the O
endothelial O
ultrastructure O
was O
unaffected O
by O
d-pen O
, O
and O
no O
differences O
in O
aortic O
131i-hsa O
radioactivity O
or O
aorta/serum-ratio O
were O
recorded O
between O
experimental O
and O
control O
groups O
10 O
minutes O
after O
tracer O
injection O
, O
indicating O
that O
the O
permeability O
of O
the O
endothelial O
barrier O
to O
albumin O
remained O
unaffected O
by O
d-pen O
treatment O
. O

these O
observations O
support O
the O
hypothesis O
that O
treatment O
with O
high O
doses O
of O
d-pen O
may O
induce O
a O
fibroproliferative O
response O
in O
rat O
aorta O
, O
possibly O
by O
an O
inhibitory O
effect O
on O
the O
cross-linking O
of O
collagen O
and O
elastin O
. O

-DOCSTART- O

brain O
natriuretic O
peptide O
is O
a O
predictor O
of O
anthracycline-induced O
cardiotoxicity B-NEG
. O

anthracyclines O
are O
effective O
antineoplastic O
drugs O
, O
but O
they O
frequently O
cause O
dose-related O
cardiotoxicity B-NEG
. O

the O
cardiotoxicity B-NEG
of O
conventional O
anthracycline O
therapy O
highlights O
a O
need O
to O
search O
for O
methods O
that O
are O
highly O
sensitive O
and O
capable O
of O
predicting O
cardiac B-NEG
dysfunction I-NEG
. O

we O
measured O
the O
plasma O
level O
of O
brain O
natriuretic O
peptide O
( O
bnp O
) O
to O
determine O
whether O
bnp O
might O
serve O
as O
a O
simple O
diagnostic O
indicator O
of O
anthracycline-induced O
cardiotoxicity B-NEG
in O
patients O
with O
acute B-NEG
leukemia I-NEG
treated O
with O
a O
daunorubicin O
( O
dnr)-containing O
regimen O
. O

thirteen O
patients O
with O
acute B-NEG
leukemia I-NEG
were O
treated O
with O
a O
dnr-containing O
regimen O
. O

cardiac O
functions O
were O
evaluated O
with O
radionuclide O
angiography O
before O
chemotherapies O
. O

the O
plasma O
levels O
of O
atrial O
natriuretic O
peptide O
( O
anp O
) O
and O
bnp O
were O
measured O
at O
the O
time O
of O
radionuclide O
angiography O
. O

three O
patients O
developed O
congestive B-NEG
heart I-NEG
failure I-NEG
after O
the O
completion O
of O
chemotherapy O
. O

five O
patients O
were O
diagnosed O
as O
having O
subclinical O
heart B-NEG
failure I-NEG
after O
the O
completion O
of O
chemotherapy O
. O

the O
plasma O
levels O
of O
bnp O
in O
all O
the O
patients O
with O
clinical O
and O
subclinical O
heart B-NEG
failure I-NEG
increased O
above O
the O
normal O
limit O
( O
40 O
pg/ml O
) O
before O
the O
detection O
of O
clinical O
or O
subclinical O
heart B-NEG
failure I-NEG
by O
radionuclide O
angiography O
. O

on O
the O
other O
hand O
, O
bnp O
did O
not O
increase O
in O
the O
patients O
without O
heart B-NEG
failure I-NEG
given O
dnr O
, O
even O
at O
more O
than O
700 O
mg/m(2) O
. O

the O
plasma O
level O
of O
anp O
did O
not O
always O
increase O
in O
all O
the O
patients O
with O
clinical O
and O
subclinical O
heart B-NEG
failure I-NEG
. O

these O
preliminary O
results O
suggest O
that O
bnp O
may O
be O
useful O
as O
an O
early O
and O
sensitive O
indicator O
of O
anthracycline-induced O
cardiotoxicity B-NEG
. O

-DOCSTART- O

antibacterial O
medication O
use O
during O
pregnancy O
and O
risk O
of O
birth B-NEG
defects I-NEG
: O
national O
birth B-NEG
defects I-NEG
prevention O
study O
. O

objective O
: O
to O
estimate O
the O
association O
between O
antibacterial O
medications O
and O
selected O
birth B-NEG
defects I-NEG
. O

design O
, O
setting O
, O
and O
participants O
: O
population-based O
, O
multisite O
, O
case-control O
study O
of O
women O
who O
had O
pregnancies O
affected O
by O
1 O
of O
more O
than O
30 O
eligible O
major O
birth B-NEG
defects I-NEG
identified O
via O
birth B-NEG
defect I-NEG
surveillance O
programs O
in O
10 O
states O
(n O
= O
13 O
155 O
) O
and O
control O
women O
randomly O
selected O
from O
the O
same O
geographical O
regions O
(n O
= O
4941) O
. O

main O
exposure O
: O
reported O
maternal O
use O
of O
antibacterials O
(1 O
month O
before O
pregnancy O
through O
the O
end O
of O
the O
first O
trimester) O
. O

main O
outcome O
measure O
: O
odds O
ratios O
( O
ors O
) O
measuring O
the O
association O
between O
antibacterial O
use O
and O
selected O
birth B-NEG
defects I-NEG
adjusted O
for O
potential O
confounders O
. O

results O
: O
the O
reported O
use O
of O
antibacterials O
increased O
during O
pregnancy O
, O
peaking O
during O
the O
third O
month O
. O

sulfonamides O
were O
associated O
with O
anencephaly B-NEG
( O
adjusted O
or O
[aor] O
= O
3.4 O
; O
95% O
confidence O
interval O
[ci] O
, O
1.3-8.8) O
, O
hypoplastic B-NEG
left I-NEG
heart I-NEG
syndrome I-NEG
( O
aor O
= O
3.2 O
; O
95% O
ci O
, O
1.3-7.6) O
, O
coarctation B-NEG
of I-NEG
the I-NEG
aorta I-NEG
( O
aor O
= O
2.7 O
; O
95% O
ci O
, O
1.3-5.6) O
, O
choanal B-NEG
atresia I-NEG
( O
aor O
= O
8.0 O
; O
95% O
ci O
, O
2.7-23.5) O
, O
transverse B-NEG
limb I-NEG
deficiency I-NEG
( O
aor O
= O
2.5 O
; O
95% O
ci O
, O
1.0-5.9) O
, O
and O
diaphragmatic B-NEG
hernia I-NEG
( O
aor O
= O
2.4 O
; O
95% O
ci O
, O
1.1-5.4) O
. O

nitrofurantoins O
were O
associated O
with O
anophthalmia B-NEG
or O
microphthalmos B-NEG
( O
aor O
= O
3.7 O
; O
95% O
ci O
, O
1.1-12.2) O
, O
hypoplastic B-NEG
left I-NEG
heart I-NEG
syndrome I-NEG
( O
aor O
= O
4.2 O
; O
95% O
ci O
, O
1.9-9.1) O
, O
atrial B-NEG
septal I-NEG
defects I-NEG
( O
aor O
= O
1.9 O
; O
95% O
ci O
, O
1.1-3.4) O
, O
and O
cleft B-NEG
lip I-NEG
with O
cleft B-NEG
palate I-NEG
( O
aor O
= O
2.1 O
; O
95% O
ci O
, O
1.2-3.9) O
. O

other O
antibacterial O
agents O
that O
showed O
associations O
included O
erythromycins O
(2 O
defects) O
, O
penicillins O
(1 O
defect) O
, O
cephalosporins O
(1 O
defect) O
, O
and O
quinolones O
(1 O
defect) O
. O

conclusions O
: O
reassuringly O
, O
penicillins O
, O
erythromycins O
, O
and O
cephalosporins O
, O
although O
used O
commonly O
by O
pregnant O
women O
, O
were O
not O
associated O
with O
many O
birth B-NEG
defects I-NEG
. O

sulfonamides O
and O
nitrofurantoins O
were O
associated O
with O
several O
birth B-NEG
defects I-NEG
, O
indicating O
a O
need O
for O
additional O
scrutiny O
. O

-DOCSTART- O

incidence O
of O
neoplasms B-NEG
in O
patients O
with O
rheumatoid B-NEG
arthritis I-NEG
exposed O
to O
different O
treatment O
regimens O
. O

immunosuppressive O
drugs O
have O
been O
used O
during O
the O
last O
30 O
years O
in O
treatment O
of O
patients O
with O
severe O
rheumatoid B-NEG
arthritis I-NEG
. O

the O
drugs O
commonly O
used O
are O
cyclophosphamide O
and O
chlorambucil O
( O
alkylating O
agents) O
, O
azathioprine O
( O
purine O
analogue) O
, O
and O
methotrexate O
( O
folic O
acid O
analogue) O
. O

there O
is O
evidence O
that O
all O
four O
immunosuppressive O
drugs O
can O
reduce O
synovitis B-NEG
, O
but O
disease O
activity O
almost O
always O
recurs O
after O
therapy O
is O
stopped O
. O

since O
adverse O
reactions O
are O
frequent O
, O
less O
than O
50 O
percent O
of O
patients O
are O
able O
to O
continue O
a O
particular O
drug O
for O
more O
than O
one O
year O
. O

since O
it O
takes O
three O
to O
12 O
months O
to O
achieve O
maximal O
effects O
, O
those O
patients O
who O
are O
unable O
to O
continue O
the O
drug O
receive O
little O
benefit O
from O
it O
. O

patients O
treated O
with O
alkylating O
agents O
have O
an O
increased O
risk O
of O
development O
of O
acute B-NEG
nonlymphocytic I-NEG
leukemia I-NEG
, O
and O
both O
alkylating O
agents O
and O
azathioprine O
are O
associated O
with O
the O
development O
of O
non-hodgkin's B-NEG
lymphoma I-NEG
. O

cyclophosphamide O
therapy O
increases O
the O
risk O
of O
carcinoma B-NEG
of I-NEG
the I-NEG
bladder I-NEG
. O

there O
have O
been O
several O
long-term O
studies O
of O
patients O
with O
rheumatoid B-NEG
arthritis I-NEG
treated O
with O
azathioprine O
and O
cyclophosphamide O
and O
the O
incidence O
of O
most O
of O
the O
common O
cancers B-NEG
is O
not O
increased O
. O

data O
on O
the O
possible O
increased O
risk O
of O
malignancy B-NEG
in O
rheumatoid B-NEG
arthritis I-NEG
are O
still O
being O
collected O
, O
and O
until O
further O
information O
is O
available O
, O
the O
use O
of O
immunosuppressive O
drugs O
, O
particularly O
alkylating O
agents O
, O
in O
the O
treatment O
of O
rheumatoid B-NEG
arthritis I-NEG
should O
be O
reserved O
for O
patients O
with O
severe O
progressive O
disease O
or O
life-threatening O
complications O
. O

-DOCSTART- O

patterns O
of O
hepatic B-NEG
injury I-NEG
induced O
by O
methyldopa O
. O

twelve O
patients O
with O
liver B-NEG
disease I-NEG
related O
to O
methyldopa O
were O
seen O
between O
1967 O
and O
1977 O
. O

illness O
occurred O
within O
1--9 O
weeks O
of O
commencement O
of O
therapy O
in O
9 O
patients O
, O
the O
remaining O
3 O
patients O
having O
received O
the O
drug O
for O
13 O
months O
, O
15 O
months O
and O
7 O
years O
before O
experiencing O
symptoms O
. O
jaundice B-NEG
with O
tender O
hepatomegaly B-NEG
, O
usually O
preceded O
by O
symptoms O
of O
malaise O
, O
anorexia B-NEG
, O
nausea B-NEG
and O
vomiting B-NEG
, O
and O
associated O
with O
upper O
abdominal B-NEG
pain I-NEG
, O
was O
an O
invariable O
finding O
in O
all O
patients O
. O

biochemical O
liver O
function O
tests O
indicated O
hepatocellular O
necrosis B-NEG
and O
correlated O
with O
histopathological O
evidence O
of O
hepatic B-NEG
injury I-NEG
, O
the O
spectrum O
of O
which O
ranged O
from O
fatty B-NEG
change I-NEG
and O
focal O
hepatocellular O
necrosis B-NEG
to O
massive B-NEG
hepatic I-NEG
necrosis I-NEG
. O

most O
patients O
showed O
moderate O
to O
severe O
acute B-NEG
hepatitis I-NEG
or O
chronic B-NEG
active I-NEG
hepatitis I-NEG
with O
associated O
cholestasis B-NEG
. O

the O
drug O
was O
withdrawn O
on O
presentation O
to O
hospital O
in O
11 O
patients O
, O
with O
rapid O
clinical O
improvement O
in O
9. O

one O
patient O
died O
, O
having O
presented O
in O
hepatic B-NEG
failure I-NEG
, O
and O
another O
, O
who O
had O
been O
taking O
methyldopa O
for O
7 O
years O
, O
showed O
slower O
clinical O
and O
biochemical O
resolution O
over O
a O
period O
of O
several O
months O
. O

the O
remaining O
patient O
in O
the O
series O
developed O
fulminant B-NEG
hepatitis I-NEG
when O
the O
drug O
was O
accidentally O
recommenced O
1 O
year O
after O
a O
prior O
episode O
of O
methyldopa-induced O
hepatitis B-NEG
. O

in O
this O
latter O
patient O
, O
and O
in O
2 O
others O
, O
the O
causal O
relationship O
between O
methyldopa O
and O
hepatic B-NEG
dysfunction I-NEG
was O
proved O
with O
the O
recurrence O
of O
hepatitis B-NEG
within O
2 O
weeks O
of O
re-exposure O
to O
the O
drug O
. O

-DOCSTART- O

a O
phase O
i/ii O
study O
of O
paclitaxel O
plus O
cisplatin O
as O
first-line O
therapy O
for O
head B-NEG
and I-NEG
neck I-NEG
cancers I-NEG
: O
preliminary O
results O
. O

improved O
outcomes O
among O
patients O
with O
head B-NEG
and I-NEG
neck I-NEG
carcinomas I-NEG
require O
investigations O
of O
new O
drugs O
for O
induction O
therapy O
. O

preliminary O
results O
of O
an O
eastern O
cooperative O
oncology O
group O
study O
of O
single-agent O
paclitaxel O
(taxol O
; O
bristol-myers O
squibb O
company O
, O
princeton O
, O
nj O
) O
reported O
a O
37% O
response O
rate O
in O
patients O
with O
head B-NEG
and I-NEG
neck I-NEG
cancer I-NEG
, O
and O
the O
paclitaxel/cisplatin O
combination O
has O
been O
used O
successfully O
and O
has O
significantly O
improved O
median O
response O
duration O
in O
ovarian B-NEG
cancer I-NEG
patients O
. O

we O
initiated O
a O
phase O
i/ii O
trial O
to O
determine O
the O
response O
and O
toxicity B-NEG
of O
escalating O
paclitaxel O
doses O
combined O
with O
fixed-dose O
cisplatin O
with O
granulocyte O
colony-stimulating O
factor O
support O
in O
patients O
with O
untreated O
locally O
advanced O
inoperable O
head B-NEG
and I-NEG
neck I-NEG
carcinoma I-NEG
. O

to O
date O
, O
23 O
men O
with O
a O
median O
age O
of O
50 O
years O
and O
good O
performance O
status O
have O
entered O
the O
trial O
. O

primary O
tumor B-NEG
sites O
were O
oropharynx O
, O
10 O
patients O
; O
hypopharynx O
, O
four O
; O
larynx O
, O
two O
; O
oral O
cavity O
, O
three O
; O
unknown O
primary O
, O
two O
; O
and O
nasal O
cavity O
and O
parotid O
gland O
, O
one O
each O
. O

of O
20 O
patients O
evaluable O
for O
toxicity B-NEG
, O
four O
had O
stage O
iii O
and O
16 O
had O
stage O
iv O
disease O
. O

treatment O
, O
given O
every O
21 O
days O
for O
a O
maximum O
of O
three O
cycles O
, O
consisted O
of O
paclitaxel O
by O
3-hour O
infusion O
followed O
the O
next O
day O
by O
a O
fixed O
dose O
of O
cisplatin O
( O
75 O
mg/m2) O
. O

the O
dose O
levels O
incorporate O
escalating O
paclitaxel O
doses O
, O
and O
intrapatient O
escalations O
within O
a O
given O
dose O
level O
are O
permitted O
if O
toxicity B-NEG
permits O
. O

at O
the O
time O
of O
this O
writing O
, O
dose O
level O
4 O
(260 O
, O
270 O
, O
and O
280 O
mg/m2 O
) O
is O
being O
evaluated O
; O
three O
patients O
from O
this O
level O
are O
evaluable O
. O

with O
paclitaxel O
doses O
of O
200 O
mg/m2 O
and O
higher O
, O
granulocyte O
colony-stimulating O
factor O
5 O
micrograms/kg/d O
is O
given O
( O
days O
4 O
through O
12) O
. O

of O
18 O
patients O
evaluable O
for O
response O
, O
seven O
( O
39% O
) O
achieved O
a O
complete O
response O
and O
six O
( O
33% O
) O
achieved O
a O
partial O
response O
. O

three O
patients O
had O
no O
change O
and O
disease O
progressed O
in O
two O
. O

the O
overall O
response O
rate O
is O
72% O
. O

eleven O
responding O
patients O
had O
subsequent O
surgery/radiotherapy O
or O
radical O
radiotherapy O
. O

two O
pathologic O
complete O
responses O
were O
observed O
in O
patients O
who O
had O
achieved O
clinical O
complete O
responses O
. O
alopecia B-NEG
, O
paresthesias B-NEG
, O
and O
arthralgias B-NEG
/ O
myalgias B-NEG
have O
occurred O
frequently O
, O
but O
with O
one O
exception O
(a O
grade O
3 O
myalgia B-NEG
) O
they O
have O
been O
grade O
1 O
or O
2. O

no O
dose-limiting O
hematologic O
toxicity B-NEG
has O
been O
seen O
. O

paclitaxel/cisplatin O
is O
an O
effective O
first-line O
regimen O
for O
locoregionally O
advanced O
head B-NEG
and I-NEG
neck I-NEG
cancer I-NEG
and O
continued O
study O
is O
warranted O
. O

results O
thus O
far O
suggest O
no O
dose-response O
effect O
for O
paclitaxel O
doses O
above O
200 O
mg/m2 O
. O

-DOCSTART- O

a O
phase O
i O
study O
of O
4'-0-tetrahydropyranyladriamycin O
. O

clinical O
pharmacology O
and O
pharmacokinetics O
. O

a O
phase O
i O
study O
of O
intravenous O
( O
iv O
) O
bolus O
4'-0-tetrahydropyranyladriamycin O
( O
pirarubicin O
) O
was O
done O
in O
55 O
patients O
in O
good O
performance O
status O
with O
refractory O
tumors B-NEG
. O

twenty-six O
had O
minimal O
prior O
therapy O
( O
good O
risk) O
, O
23 O
had O
extensive O
prior O
therapy O
( O
poor O
risk) O
, O
and O
six O
had O
renal B-NEG
and/or I-NEG
hepatic I-NEG
dysfunction I-NEG
. O

a O
total O
of O
167 O
courses O
at O
doses O
of O
15 O
to O
70 O
mg/m2 O
were O
evaluable O
. O

maximum O
tolerated O
dose O
in O
good-risk O
patients O
was O
70 O
mg/m2 O
, O
and O
in O
poor-risk O
patients O
, O
60 O
mg/m2 O
. O

the O
dose-limiting O
toxic O
effect O
was O
transient O
noncumulative O
granulocytopenia B-NEG
. O

granulocyte O
nadir O
was O
on O
day O
14 O
(range O
, O
4-22) O
. O

less O
frequent O
toxic O
effects O
included O
thrombocytopenia B-NEG
, O
anemia B-NEG
, O
nausea B-NEG
, O
mild O
alopecia B-NEG
, O
phlebitis B-NEG
, O
and O
mucositis B-NEG
. O
myelosuppression B-NEG
was O
more O
in O
patients O
with O
hepatic B-NEG
dysfunction I-NEG
. O

pharmacokinetic O
analyses O
in O
21 O
patients O
revealed O
pirarubicin O
plasma O
t O
1/2 O
alpha O
( O
+/- O
se O
) O
of O
2.5 O
+/- O
0.85 O
minutes O
, O
t O
beta O
1/2 O
of O
25.6 O
+/- O
6.5 O
minutes O
, O
and O
t O
1/2 O
gamma O
of O
23.6 O
+/- O
7.6 O
hours O
. O

the O
area O
under O
the O
curve O
was O
537 O
+/- O
149 O
ng/ml O
x O
hours O
, O
volume O
of O
distribution O
( O
vd O
) O
3504 O
+/- O
644 O
l/m2 O
, O
and O
total O
clearance O
( O
clt O
) O
was O
204 O
+ O
39.3 O
l/hour/m2 O
. O

adriamycinol O
, O
doxorubicin O
, O
adriamycinone O
, O
and O
tetrahydropyranyladriamycinol O
were O
the O
metabolites O
detected O
in O
plasma O
and O
the O
amount O
of O
doxorubicin O
was O
less O
than O
or O
equal O
to O
10% O
of O
the O
total O
metabolites O
. O

urinary O
excretion O
of O
pirarubicin O
in O
the O
first O
24 O
hours O
was O
less O
than O
or O
equal O
to O
10% O
. O

activity O
was O
noted O
in O
mesothelioma B-NEG
, O
leiomyosarcoma B-NEG
, O
and O
basal B-NEG
cell I-NEG
carcinoma I-NEG
. O

the O
recommended O
starting O
dose O
for O
phase O
ii O
trials O
is O
60 O
mg/m2 O
iv O
bolus O
every O
3 O
weeks O
. O

-DOCSTART- O

differential O
effects O
of O
gamma-hexachlorocyclohexane O
( O
lindane O
) O
on O
pharmacologically-induced O
seizures B-NEG
. O

gamma-hexachlorocyclohexane O
(gamma-hch) O
, O
the O
active O
ingredient O
of O
the O
insecticide O
lindane O
, O
has O
been O
shown O
to O
decrease O
seizure B-NEG
threshold O
to O
pentylenetrazol O
( O
ptz O
) O
3 O
h O
after O
exposure O
to O
gamma-hch O
and O
conversely O
increase O
threshold O
to O
ptz-induced O
seizures B-NEG
24 O
h O
after O
exposure O
to O
gamma-hch O
( O
vohland O
et O
al O
. O
1981) O
. O

in O
this O
study O
, O
the O
severity O
of O
response O
to O
other O
seizure B-NEG
-inducing O
agents O
was O
tested O
in O
mice O
1 O
and O
24 O
h O
after O
intraperitoneal O
administration O
of O
80 O
mg/kg O
gamma-hch O
. O

one O
hour O
after O
the O
administration O
of O
gamma-hch O
, O
the O
activity O
of O
seizure B-NEG
-inducing O
agents O
was O
increased O
, O
regardless O
of O
their O
mechanism O
, O
while O
24 O
h O
after O
gamma-hch O
a O
differential O
response O
was O
observed O
. O
seizure B-NEG
activity O
due O
to O
ptz O
and O
picrotoxin O
( O
ptx O
) O
was O
significantly O
decreased O
; O
however O
, O
seizure B-NEG
activity O
due O
to O
3-mercaptopropionic O
acid O
(mpa) O
, O
bicuculline O
(bcc) O
, O
methyl O
6,7-dimethoxy-4-ethyl-b-carboline-3-carboxylate O
(dmcm) O
, O
or O
strychnine O
( O
str O
) O
was O
not O
different O
from O
control O
. O

in O
vitro O
, O
gamma-hch O
, O
pentylenetetrazol O
and O
picrotoxin O
were O
shown O
to O
inhibit O
3h-tbob O
binding O
in O
mouse O
whole O
brain O
, O
with O
ic50 O
values O
of O
4.6 O
, O
404 O
and O
9.4 O
microm O
, O
respectively O
. O

mpa O
, O
bcc O
, O
dmcm O
, O
and O
str O
showed O
no O
inhibition O
of O
3h-tbob O
( O
t-butyl O
bicyclo-orthobenzoate O
) O
binding O
at O
concentrations O
of O
100 O
micron O
. O

the O
pharmacological O
challenge O
data O
suggest O
that O
tolerance O
may O
occur O
to O
seizure B-NEG
activity O
induced O
by O
ptz O
and O
ptx O
24 O
h O
after O
gamma-hch O
, O
since O
the O
response O
to O
only O
these O
two O
seizure B-NEG
-inducing O
agents O
is O
decreased O
. O

the O
in O
vitro O
data O
suggest O
that O
the O
site O
responsible O
for O
the O
decrease O
in O
seizure B-NEG
activity O
24 O
h O
after O
gamma-hch O
may O
be O
the O
gaba-a O
receptor-linked O
chloride O
channel O
. O

-DOCSTART- O

severe O
ocular B-NEG
and I-NEG
orbital I-NEG
toxicity I-NEG
after O
intracarotid O
injection O
of O
carboplatin O
for O
recurrent O
glioblastomas B-NEG
. O

background O
: O
glioblastoma B-NEG
is O
a O
malignant B-NEG
tumor I-NEG
that O
occurs O
in O
the O
cerebrum O
during O
adulthood O
. O

with O
current O
treatment O
regimens O
including O
combined O
surgery O
, O
radiation O
and O
chemotherapy O
, O
the O
average O
life O
expectancy O
of O
the O
patients O
is O
limited O
to O
approximately O
1 O
year O
. O

therefore O
, O
patients O
with O
glioblastoma B-NEG
sometimes O
have O
intracarotid O
injection O
of O
carcinostatics O
added O
to O
the O
treatment O
regimen O
. O

generally O
, O
carboplatin O
is O
said O
to O
have O
milder O
side O
effects O
than O
cisplatin O
, O
whose O
ocular B-NEG
and I-NEG
orbital I-NEG
toxicity I-NEG
are O
well O
known O
. O

however O
, O
we O
experienced O
a O
case O
of O
severe O
ocular B-NEG
and I-NEG
orbital I-NEG
toxicity I-NEG
after O
intracarotid O
injection O
of O
carboplatin O
, O
which O
is O
infrequently O
reported O
. O

case O
: O
a O
58-year-old O
man O
received O
an O
intracarotid O
injection O
of O
carboplatin O
for O
recurrent O
glioblastomas B-NEG
in O
his O
left O
temporal O
lobe O
. O

he O
complained O
of O
pain B-NEG
and I-NEG
visual I-NEG
disturbance I-NEG
in I-NEG
the I-NEG
ipsilateral I-NEG
eye I-NEG
30 O
h O
after O
the O
injection O
. O

various O
ocular O
symptoms O
and O
findings O
caused O
by O
carboplatin O
toxicity B-NEG
were O
seen O
. O

results O
: O
he O
was O
treated O
with O
intravenous O
administration O
of O
corticosteroids O
and O
glycerin O
for O
6 O
days O
after O
the O
injection O
. O

although O
the O
intraocular O
pressure O
elevation O
caused O
by O
secondary O
acute O
angle-closure O
glaucoma B-NEG
decreased O
and O
ocular B-NEG
pain I-NEG
diminished O
, O
inexorable O
papilledema B-NEG
and O
exudative O
retinal B-NEG
detachment I-NEG
continued O
for O
3 O
weeks O
. O

finally O
, O
6 O
weeks O
later O
, O
diffuse O
chorioretinal B-NEG
atrophy I-NEG
with O
optic B-NEG
atrophy I-NEG
occurred O
and O
the O
vision O
in O
his O
left O
eye O
was O
lost O
. O

conclusion O
: O
when O
performing O
intracarotid O
injection O
of O
carboplatin O
, O
we O
must O
be O
aware O
of O
its O
potentially O
blinding O
ocular B-NEG
toxicity I-NEG
. O

it O
is O
recommended O
that O
further O
studies O
and O
investigations O
are O
undertaken O
in O
the O
effort O
to O
minimize O
such O
severe O
side O
effects O
. O

-DOCSTART- O

phase O
ii O
study O
of O
the O
amsacrine O
analogue O
ci-921 O
( O
nsc O
343499 O
) O
in O
non-small B-NEG
cell I-NEG
lung I-NEG
cancer I-NEG
. O

ci-921 O
( O
nsc O
343499 O
; O
9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] O
-n,5-dimethyl- O
4-acridinecarboxamide O
) O
is O
a O
topoisomerase O
ii O
poison O
with O
high O
experimental O
antitumour O
activity O
. O

it O
was O
administered O
by O
15 O
min O
infusion O
to O
16 O
evaluable O
patients O
with O
non-small B-NEG
cell I-NEG
lung I-NEG
cancer I-NEG
( O
nsclc B-NEG
) O
(7 O
with O
no O
prior O
treatment O
, O
9 O
patients O
in O
relapse O
following O
surgery/radiotherapy O
) O
at O
a O
dose O
( O
648 O
mg/m2 O
divided O
over O
3 O
days O
, O
repeated O
every O
3 O
weeks O
) O
determined O
by O
phase O
i O
trial O
. O

patients O
had O
a O
median O
performance O
status O
of O
1 O
(who) O
, O
and O
median O
age O
of O
61 O
years O
. O

the O
histology O
comprised O
squamous B-NEG
carcinoma I-NEG
(11) O
, O
adenocarcinoma B-NEG
(1) O
, O
mixed O
histology O
(2) O
, O
bronchio-alveolar B-NEG
carcinoma I-NEG
( O
1 O
) O
and O
large O
cell O
undifferentiated B-NEG
carcinoma I-NEG
(1) O
. O
neutropenia B-NEG
grade O
greater O
than O
or O
equal O
to O
3 O
was O
seen O
in O
15 O
patients O
, O
infections B-NEG
with O
recovery O
in O
3, O
and O
grand O
mal O
seizures B-NEG
in O
1 O
patient O
. O

grade O
less O
than O
or O
equal O
to O
2 O
nausea B-NEG
and O
vomiting B-NEG
occurred O
in O
66% O
courses O
and O
phlebitis B-NEG
in O
the O
infusion O
arm O
in O
37% O
. O

1 O
patient O
with O
squamous B-NEG
cell I-NEG
carcinoma I-NEG
achieved O
a O
partial O
response O
lasting O
5 O
months O
. O

further O
testing O
in O
this O
and O
other O
tumour B-NEG
types O
using O
multiple O
daily O
schedules O
is O
warranted O
. O

-DOCSTART- O

alpha-lipoic O
acid O
prevents O
mitochondrial B-NEG
damage I-NEG
and O
neurotoxicity B-NEG
in O
experimental O
chemotherapy O
neuropathy B-NEG
. O

the O
study O
investigates O
if O
alpha-lipoic O
acid O
is O
neuroprotective O
against O
chemotherapy O
induced O
neurotoxicity B-NEG
, O
if O
mitochondrial B-NEG
damage I-NEG
plays O
a O
critical O
role O
in O
toxic B-NEG
neurodegenerative I-NEG
cascade I-NEG
, O
and O
if O
neuroprotective O
effects O
of O
alpha-lipoic O
acid O
depend O
on O
mitochondria O
protection O
. O

we O
used O
an O
in O
vitro O
model O
of O
chemotherapy O
induced O
peripheral B-NEG
neuropathy I-NEG
that O
closely O
mimic O
the O
in O
vivo O
condition O
by O
exposing O
primary O
cultures O
of O
dorsal O
root O
ganglion O
( O
drg O
) O
sensory O
neurons O
to O
paclitaxel O
and O
cisplatin O
, O
two O
widely O
used O
and O
highly O
effective O
chemotherapeutic O
drugs O
. O

this O
approach O
allowed O
investigating O
the O
efficacy O
of O
alpha-lipoic O
acid O
in O
preventing O
axonal B-NEG
damage I-NEG
and O
apoptosis O
and O
the O
function O
and O
ultrastructural O
morphology O
of O
mitochondria O
after O
exposure O
to O
toxic O
agents O
and O
alpha-lipoic O
acid O
. O

our O
results O
demonstrate O
that O
both O
cisplatin O
and O
paclitaxel O
cause O
early O
mitochondrial B-NEG
impairment I-NEG
with O
loss O
of O
membrane O
potential O
and O
induction O
of O
autophagic O
vacuoles O
in O
neurons O
. O

alpha-lipoic O
acid O
exerts O
neuroprotective O
effects O
against O
chemotherapy O
induced O
neurotoxicity B-NEG
in O
sensory O
neurons O
: O
it O
rescues O
the O
mitochondrial B-NEG
toxicity I-NEG
and O
induces O
the O
expression O
of O
frataxin O
, O
an O
essential O
mitochondrial O
protein O
with O
anti-oxidant O
and O
chaperone O
properties O
. O

in O
conclusion O
mitochondrial B-NEG
toxicity I-NEG
is O
an O
early O
common O
event O
both O
in O
paclitaxel O
and O
cisplatin O
induced O
neurotoxicity B-NEG
. O

alpha-lipoic O
acid O
protects O
sensory O
neurons O
through O
its O
anti-oxidant O
and O
mitochondrial O
regulatory O
functions O
, O
possibly O
inducing O
the O
expression O
of O
frataxin O
. O

these O
findings O
suggest O
that O
alpha-lipoic O
acid O
might O
reduce O
the O
risk O
of O
developing O
peripheral B-NEG
nerve I-NEG
toxicity I-NEG
in O
patients O
undergoing O
chemotherapy O
and O
encourage O
further O
confirmatory O
clinical O
trials O
. O

-DOCSTART- O

optimising O
stroke B-NEG
prevention O
in O
non-valvular O
atrial B-NEG
fibrillation I-NEG
. O
atrial B-NEG
fibrillation I-NEG
is O
associated O
with O
substantial O
morbidity O
and O
mortality O
. O

pooled O
data O
from O
trials O
comparing O
antithrombotic O
treatment O
with O
placebo O
have O
shown O
that O
warfarin O
reduces O
the O
risk O
of O
stroke B-NEG
by O
62% O
, O
and O
that O
aspirin O
alone O
reduces O
the O
risk O
by O
22% O
. O

overall O
, O
in O
high-risk O
patients O
, O
warfarin O
is O
superior O
to O
aspirin O
in O
preventing O
strokes B-NEG
, O
with O
a O
relative O
risk O
reduction O
of O
36% O
. O

ximelagatran O
, O
an O
oral O
direct O
thrombin O
inhibitor O
, O
was O
found O
to O
be O
as O
efficient O
as O
vitamin O
k O
antagonist O
drugs O
in O
the O
prevention O
of O
embolic B-NEG
events I-NEG
, O
but O
has O
been O
recently O
withdrawn O
because O
of O
abnormal B-NEG
liver I-NEG
function I-NEG
tests O
. O

the O
active-w O
( O
atrial B-NEG
fibrillation I-NEG
clopidogrel O
trial O
with O
irbesartan O
for O
prevention O
of O
vascular O
events O
) O
study O
has O
demonstrated O
that O
warfarin O
is O
superior O
to O
platelet O
therapy O
( O
clopidogrel O
plus O
aspirin O
) O
in O
the O
prevention O
af O
embolic B-NEG
events I-NEG
. O

idraparinux O
, O
a O
factor O
xa O
inhibitor O
, O
is O
being O
evaluated O
in O
patients O
with O
atrial B-NEG
fibrillation I-NEG
. O

angiotensin-converting O
enzyme O
inhibitors O
and O
angiotensin O
ii O
receptor-blocking O
drugs O
hold O
promise O
in O
atrial B-NEG
fibrillation I-NEG
through O
cardiac B-NEG
remodelling I-NEG
. O

preliminary O
studies O
suggest O
that O
statins O
could O
interfere O
with O
the O
risk O
of O
recurrence O
after O
electrical O
cardioversion O
. O

finally O
, O
percutaneous O
methods O
for O
the O
exclusion O
of O
left O
atrial O
appendage O
are O
under O
investigation O
in O
high-risk O
patients O
. O

-DOCSTART- O

interaction O
of O
cyclosporin O
a O
with O
antineoplastic O
agents O
. O

a O
synergistic O
effect O
of O
etoposide O
and O
cyclosporin O
a O
was O
observed O
in O
a O
patient O
with O
acute B-NEG
t-lymphocytic I-NEG
leukemia I-NEG
in O
relapse O
. O

the O
concomitant O
administration O
of O
etoposide O
and O
cyclosporin O
a O
resulted O
in O
eradication O
of O
hitherto O
refractory O
leukemic B-NEG
infiltration I-NEG
of O
bone O
marrow O
. O

severe O
side O
effects O
in O
terms O
of O
mental O
confusion B-NEG
and O
progressive O
hyperbilirubinemia B-NEG
, O
however O
, O
point O
to O
an O
enhancement O
not O
only O
of O
antineoplastic O
effects O
but O
also O
of O
toxicity B-NEG
in O
normal O
tissues O
. O

this O
report O
demonstrates O
for O
the O
first O
time O
that O
the O
pharmacodynamic O
properties O
of O
cyclosporin O
a O
may O
not O
be O
confined O
strictly O
to O
suppression O
of O
normal O
t-cell O
functions O
. O

-DOCSTART- O

the O
hematologic O
effects O
of O
cefonicid O
and O
cefazedone O
in O
the O
dog O
: O
a O
potential O
model O
of O
cephalosporin O
hematotoxicity B-NEG
in O
man O
. O

cephalosporin O
antibiotics O
cause O
a O
variety O
of O
hematologic B-NEG
disturbances I-NEG
in O
man O
, O
the O
pathogeneses O
and O
hematopathology O
of O
which O
remain O
poorly O
characterized O
. O

there O
is O
a O
need O
for O
a O
well-defined O
animal O
model O
in O
which O
these O
blood B-NEG
dyscrasias I-NEG
can O
be O
studied O
. O

in O
four O
subacute O
toxicity B-NEG
studies O
, O
the O
intravenous O
administration O
of O
cefonicid O
or O
cefazedone O
to O
beagle O
dogs O
caused O
a O
dose-dependent O
incidence O
of O
anemia B-NEG
, O
neutropenia B-NEG
, O
and O
thrombocytopenia B-NEG
after O
1-3 O
months O
of O
treatment O
. O

a O
nonregenerative O
anemia B-NEG
was O
the O
most O
compromising O
of O
the O
cytopenias B-NEG
and O
occurred O
in O
approximately O
50% O
of O
dogs O
receiving O
400-500 O
mg/kg O
cefonicid O
or O
540-840 O
mg/kg O
cefazedone O
. O

all O
three O
cytopenias B-NEG
were O
completely O
reversible O
following O
cessation O
of O
treatment O
; O
the O
time O
required O
for O
recovery O
of O
the O
erythron O
( O
approximately O
1 O
month O
) O
was O
considerably O
longer O
than O
that O
of O
the O
granulocytes O
and O
platelets O
( O
hours O
to O
a O
few O
days) O
. O

upon O
rechallenge O
with O
either O
cephalosporin O
, O
the O
hematologic B-NEG
syndrome I-NEG
was O
reproduced O
in O
most O
dogs O
tested O
; O
cefonicid O
( O
but O
not O
cefazedone)-treated O
dogs O
showed O
a O
substantially O
reduced O
induction O
period O
( O
15 O
+/- O
5 O
days O
) O
compared O
to O
that O
of O
the O
first O
exposure O
to O
the O
drug O
( O
61 O
+/- O
24 O
days) O
. O

this O
observation O
, O
along O
with O
the O
rapid O
rate O
of O
decline O
in O
red O
cell O
mass O
parameters O
of O
affected O
dogs O
, O
suggests O
that O
a O
hemolytic B-NEG
component O
complicated O
the O
red O
cell O
production O
problem O
and O
that O
multiple O
toxicologic O
mechanisms O
contributed O
to O
the O
cytopenia B-NEG
. O

we O
conclude O
that O
the O
administration O
of O
high O
doses O
of O
cefonicid O
or O
cefazedone O
to O
dogs O
can O
induce O
hematotoxicity B-NEG
similar O
to O
the O
cephalosporin-induced O
blood B-NEG
dyscrasias I-NEG
described O
in O
man O
and O
thus O
provides O
a O
useful O
model O
for O
studying O
the O
mechanisms O
of O
these O
disorders O
. O

-DOCSTART- O

a O
pyridoxine-dependent O
behavioral B-NEG
disorder I-NEG
unmasked O
by O
isoniazid O
. O

a O
3-year-old O
girl O
had O
behavioral B-NEG
deterioration I-NEG
, O
with O
hyperkinesis B-NEG
, O
irritability B-NEG
, O
and O
sleeping B-NEG
difficulties I-NEG
after O
the O
therapeutic O
administration O
of O
isoniazid O
. O

the O
administration O
of O
pharmacologic O
doses O
of O
pyridoxine O
hydrochloride O
led O
to O
a O
disappearance O
of O
symptoms O
. O

after O
discontinuing O
isoniazid O
therapy O
a O
similar O
pattern O
of O
behavior O
was O
noted O
that O
was O
controlled O
by O
pyridoxine O
. O

a O
placebo O
had O
no O
effect O
, O
but O
niacinamide O
was O
as O
effective O
as O
pyridoxine O
. O

periodic O
withdrawal O
of O
pyridoxine O
was O
associated O
with O
return O
of O
the O
hyperkinesis B-NEG
. O

the O
level O
of O
pyridoxal O
in O
the O
blood O
was O
normal O
during O
the O
periods O
of O
relapse O
. O

metabolic O
studies O
suggested O
a O
block O
in O
the O
kynurenine O
pathway O
of O
tryptophan O
metabolism O
. O

the O
patient O
has O
been O
followed O
for O
six O
years O
and O
has O
required O
pharmacologic O
doses O
of O
pyridoxine O
to O
control O
her O
behavior O
. O

-DOCSTART- O

a O
selective O
dopamine O
d4 O
receptor O
antagonist O
, O
nra0160 O
: O
a O
preclinical O
neuropharmacological O
profile O
. O

nra0160 O
, O
5 O
- O
[2- O
( O
4- O
( O
3 O
- O
fluorobenzylidene O
) O
piperidin-1-yl O
) O
ethyl] O
- O
4 O
-(4-fluorophenyl O
) O
thiazole-2-carboxamide O
, O
has O
a O
high O
affinity O
for O
human O
cloned O
dopamine O
d4.2 O
, O
d4.4 O
and O
d4.7 O
receptors O
, O
with O
ki O
values O
of O
0.5 O
, O
0.9 O
and O
2.7 O
nm O
, O
respectively O
. O

nra0160 O
is O
over O
20,000fold O
more O
potent O
at O
the O
dopamine O
d4.2 O
receptor O
compared O
with O
the O
human O
cloned O
dopamine O
d2l O
receptor O
. O

nra0160 O
has O
negligible O
affinity O
for O
the O
human O
cloned O
dopamine O
d3 O
receptor O
( O
ki=39 O
nm) O
, O
rat O
serotonin O
( O
5-ht)2a O
receptors O
( O
ki=180 O
nm O
) O
and O
rat O
alpha1 O
adrenoceptor O
( O
ki=237 O
nm) O
. O

nra0160 O
and O
clozapine O
antagonized O
locomotor O
hyperactivity B-NEG
induced O
by O
methamphetamine O
( O
map O
) O
in O
mice O
. O

nra0160 O
and O
clozapine O
antagonized O
map-induced O
stereotyped O
behavior O
in O
mice O
, O
although O
their O
effects O
did O
not O
exceed O
50% O
inhibition O
, O
even O
at O
the O
highest O
dose O
given O
. O

nra0160 O
and O
clozapine O
significantly O
induced O
catalepsy B-NEG
in O
rats O
, O
although O
their O
effects O
did O
not O
exceed O
50% O
induction O
even O
at O
the O
highest O
dose O
given O
. O

nra0160 O
and O
clozapine O
significantly O
reversed O
the O
disruption O
of O
prepulse O
inhibition O
( O
ppi O
) O
in O
rats O
produced O
by O
apomorphine O
. O

nra0160 O
and O
clozapine O
significantly O
shortened O
the O
phencyclidine O
( O
pcp)-induced O
prolonged O
swimming O
latency O
in O
rats O
in O
a O
water O
maze O
task O
. O

these O
findings O
suggest O
that O
nra0160 O
may O
have O
unique O
antipsychotic O
activities O
without O
the O
liability O
of O
motor O
side O
effects O
typical O
of O
classical O
antipsychotics O
. O

-DOCSTART- O

prolonged O
cholestasis B-NEG
after O
troleandomycin-induced O
acute O
hepatitis B-NEG
. O

we O
report O
the O
case O
of O
a O
patient O
in O
whom O
troleandomycin-induced O
hepatitis B-NEG
was O
followed O
by O
prolonged O
anicteric O
cholestasis B-NEG
. O
jaundice B-NEG
occurred O
after O
administration O
of O
troleandomycin O
for O
7 O
days O
and O
was O
associated O
with O
hypereosinophilia B-NEG
. O
jaundice B-NEG
disappeared O
within O
3 O
months O
but O
was O
followed O
by O
prolonged O
anicteric O
cholestasis B-NEG
marked O
by O
pruritus B-NEG
and O
high O
levels O
of O
alkaline O
phosphatase O
and O
gammaglutamyltransferase O
activities O
. O

finally O
, O
pruritus B-NEG
disappeared O
within O
19 O
months O
, O
and O
liver O
tests O
returned O
to O
normal O
27 O
months O
after O
the O
onset O
of O
hepatitis B-NEG
. O

this O
observation O
demonstrates O
that O
prolonged O
cholestasis B-NEG
can O
follow O
troleandomycin-induced O
acute O
hepatitis B-NEG
. O

-DOCSTART- O

hmg O
coa O
reductase O
inhibitors O
. O

current O
clinical O
experience O
. O

lovastatin O
and O
simvastatin O
are O
the O
2 O
best-known O
members O
of O
the O
class O
of O
hypolipidaemic O
agents O
known O
as O
hmg O
coa O
reductase O
inhibitors O
. O

clinical O
experience O
with O
lovastatin O
includes O
over O
5000 O
patients O
, O
700 O
of O
whom O
have O
been O
treated O
for O
2 O
years O
or O
more O
, O
and O
experience O
with O
simvastatin O
includes O
over O
3500 O
patients O
, O
of O
whom O
350 O
have O
been O
treated O
for O
18 O
months O
or O
more O
. O

lovastatin O
has O
been O
marketed O
in O
the O
united O
states O
for O
over O
6 O
months O
. O

both O
agents O
show O
substantial O
clinical O
efficacy O
, O
with O
reductions O
in O
total O
cholesterol O
of O
over O
30% O
and O
in O
ldl-cholesterol O
of O
40% O
in O
clinical O
studies O
. O

modest O
increases O
in O
hdl-cholesterol O
levels O
of O
about O
10% O
are O
also O
reported O
. O

clinical O
tolerability O
of O
both O
agents O
has O
been O
good O
, O
with O
fewer O
than O
3% O
of O
patients O
withdrawn O
from O
treatment O
because O
of O
clinical O
adverse O
experiences O
. O

ophthalmological O
examinations O
in O
over O
1100 O
patients O
treated O
with O
one O
or O
the O
other O
agent O
have O
revealed O
no O
evidence O
of O
significant O
short O
term O
( O
up O
to O
2 O
years O
) O
cataractogenic O
potential O
. O

one O
to O
2% O
of O
patients O
have O
elevations O
of O
serum O
transaminases O
to O
greater O
than O
3 O
times O
the O
upper O
limit O
of O
normal O
. O

these O
episodes O
are O
asymptomatic O
and O
reversible O
when O
therapy O
is O
discontinued O
. O

minor O
elevations O
of O
creatine O
kinase O
levels O
are O
reported O
in O
about O
5% O
of O
patients O
. O
myopathy B-NEG
, O
associated O
in O
some O
cases O
with O
myoglobinuria B-NEG
, O
and O
in O
2 O
cases O
with O
transient O
renal B-NEG
failure I-NEG
, O
has O
been O
rarely O
reported O
with O
lovastatin O
, O
especially O
in O
patients O
concomitantly O
treated O
with O
cyclosporin O
, O
gemfibrozil O
or O
niacin O
. O

lovastatin O
and O
simvastatin O
are O
both O
effective O
and O
well-tolerated O
agents O
for O
lowering O
elevated O
levels O
of O
serum O
cholesterol O
. O

as O
wider O
use O
confirms O
their O
safety O
profile O
, O
they O
will O
gain O
increasing O
importance O
in O
the O
therapeutic O
approach O
to O
hypercholesterolaemia B-NEG
and O
its O
consequences O
. O

-DOCSTART- O

sulfasalazine-induced O
lupus B-NEG
erythematosus I-NEG
. O
pneumonitis B-NEG
, O
bilateral O
pleural B-NEG
effusions I-NEG
, O
echocardiographic O
evidence O
of O
cardiac B-NEG
tamponade I-NEG
, O
and O
positive O
autoantibodies O
developed O
in O
a O
43-year-old O
man O
, O
who O
was O
receiving O
long-term O
sulfasalazine O
therapy O
for O
chronic O
ulcerative B-NEG
colitis I-NEG
. O

after O
cessation O
of O
the O
sulfasalazine O
and O
completion O
of O
a O
six-week O
course O
of O
corticosteroids O
, O
these O
problems O
resolved O
over O
a O
period O
of O
four O
to O
six O
months O
. O

it O
is O
suggested O
that O
the O
patient O
had O
sulfasalazine-induced O
lupus B-NEG
, O
which O
manifested O
with O
serositis B-NEG
and O
pulmonary O
parenchymal O
involvement O
in O
the O
absence O
of O
joint O
symptoms O
. O

physicians O
who O
use O
sulfasalazine O
to O
treat O
patients O
with O
inflammatory B-NEG
bowel I-NEG
disease I-NEG
should O
be O
aware O
of O
the O
signs O
of O
sulfasalazine-induced O
lupus B-NEG
syndrome I-NEG
. O

-DOCSTART- O

optimization O
of O
levodopa O
therapy O
. O

while O
there O
is O
no O
single O
correct O
starting O
dose O
for O
levodopa O
therapy O
, O
many O
individuals O
can O
be O
started O
on O
either O
the O
25/100 O
or O
controlled-release O
formula O
, O
following O
the O
general O
rule O
not O
to O
attempt O
to O
titrate O
carbidopa-levodopa O
to O
the O
point O
of O
normality O
, O
which O
can O
lead O
to O
toxicity B-NEG
. O

the O
physician O
should O
also O
determine O
the O
proper O
use O
of O
any O
adjunctive O
medications O
; O
such O
combined O
therapy O
has O
become O
the O
standard O
approach O
to O
treatment O
. O

following O
the O
initial O
period O
of O
therapy O
, O
emerging O
difficulties O
require O
a O
reassessment O
of O
therapeutic O
approaches O
, O
such O
as O
dosage O
adjustment O
or O
introduction O
of O
a O
dopamine O
agonist O
. O

other O
possible O
adverse O
effects--such O
as O
gastrointestinal B-NEG
disorders I-NEG
, O
orthostatic B-NEG
hypotension I-NEG
, O
levodopa-induced O
psychosis B-NEG
, O
sleep B-NEG
disturbances I-NEG
or O
parasomnias B-NEG
, O
or O
drug O
interactions--also O
require O
carefully O
monitored O
individual O
treatment O
. O

nonpharmacologic O
concerns O
can O
help O
the O
parkinson's B-NEG
disease I-NEG
patient O
achieve O
and O
maintain O
optimal O
functioning O
, O
including O
daily O
exercise O
, O
physical O
therapy O
, O
and O
involvement O
with O
support O
groups O
. O

-DOCSTART- O

alpha O
and O
beta O
coma B-NEG
in O
drug O
intoxication O
uncomplicated O
by O
cerebral B-NEG
hypoxia I-NEG
. O

four O
patients O
who O
were O
rendered O
comatose B-NEG
or O
stuporous B-NEG
by O
drug O
intoxication O
, O
but O
who O
were O
not O
hypoxic O
, O
are O
described O
. O

three O
patients O
received O
high O
doses O
of O
chlormethiazole O
for O
alcohol O
withdrawal B-NEG
symptoms I-NEG
, O
and O
one O
took O
a O
suicidal O
overdose B-NEG
of O
nitrazepam O
. O

the O
patient O
with O
nitrazepam O
overdose B-NEG
and O
two O
of O
those O
with O
chlormethiazole O
intoxication O
conformed O
to O
the O
criteria O
of O
'alpha O
coma B-NEG
', O
showing O
non-reactive O
generalized O
or O
frontally O
predominant O
alpha O
activity O
in O
the O
eeg O
. O

the O
fourth O
patient O
who O
was O
unconscious O
after O
chlormethiazole O
administration O
exhibite O
generalized O
non-reactive O
activity O
in O
the O
slow O
beta O
range O
. O

all O
four O
recovered O
completely O
without O
neurological B-NEG
sequelae I-NEG
following O
the O
withdrawal O
of O
the O
offending O
agents O
. O

the O
similarities O
between O
the O
effects O
of O
structural O
lesions O
and O
pharmacological O
depression B-NEG
of O
the O
brain O
stem O
reticular O
formation O
are O
discussed O
. O

it O
is O
suggested O
that O
in O
both O
situations O
disturbed O
reticulo-thalamic O
interactions O
are O
important O
in O
the O
pathogenesis O
of O
alpha O
coma B-NEG
. O

it O
is O
concluded O
that O
when O
this O
electroencephalographic O
and O
behavioural O
picture O
is O
seen O
in O
drug O
intoxication O
, O
in O
the O
absence O
of O
significant O
hypoxaemia B-NEG
, O
a O
favourable O
outcome O
may O
be O
anticipated O
. O

-DOCSTART- O

omitting O
fentanyl O
reduces O
nausea B-NEG
and O
vomiting B-NEG
, O
without O
increasing O
pain B-NEG
, O
after O
sevoflurane O
for O
day O
surgery O
. O

background O
and O
objective O
: O
despite O
advantages O
of O
induction O
and O
maintenance O
of O
anaesthesia O
with O
sevoflurane O
, O
postoperative B-NEG
nausea I-NEG
and I-NEG
vomiting I-NEG
occurs O
frequently O
. O

fentanyl O
is O
a O
commonly O
used O
supplement O
that O
may O
contribute O
to O
this O
, O
although O
it O
may O
also O
improve O
analgesia O
. O

methods O
: O
this O
double-blind O
study O
examined O
the O
incidence O
and O
severity O
of O
postoperative B-NEG
nausea I-NEG
and I-NEG
vomiting I-NEG
and O
pain B-NEG
in O
the O
first O
24 O
h O
after O
sevoflurane O
anaesthesia O
in O
216 O
adult O
day O
surgery O
patients O
. O

patients O
were O
randomly O
allocated O
to O
either O
receive O
or O
not O
receive O
1 O
1 O
fentanyl O
, O
while O
a O
third O
group O
received O
dexamethasone O
in O
addition O
to O
fentanyl O
. O

results O
: O
omission O
of O
fentanyl O
did O
not O
reduce O
the O
overall O
incidence O
of O
postoperative B-NEG
nausea I-NEG
and I-NEG
vomiting I-NEG
, O
but O
did O
reduce O
the O
incidence O
of O
vomiting B-NEG
and/or O
moderate O
to O
severe O
nausea B-NEG
prior O
to O
discharge O
from O
20% O
and O
17% O
with O
fentanyl O
and O
fentanyl-dexamethasone O
, O
respectively O
, O
to O
5% O
(p O
= O
0.013) O
. O

antiemetic O
requirements O
were O
reduced O
from O
24% O
and O
31% O
to O
7% O
(p O
= O
0.0012) O
. O

dexamethasone O
had O
no O
significant O
effect O
on O
the O
incidence O
or O
severity O
of O
postoperative B-NEG
nausea I-NEG
and I-NEG
vomiting I-NEG
. O

combining O
the O
two O
fentanyl O
groups O
revealed O
further O
significant O
benefits O
from O
the O
avoidance O
of O
opioids O
, O
reducing O
postoperative B-NEG
nausea I-NEG
and I-NEG
vomiting I-NEG
and O
nausea B-NEG
prior O
to O
discharge O
from O
35% O
and O
33% O
to O
22% O
and O
19% O
(p O
= O
0.049 O
and O
p O
= O
0.035) O
, O
respectively O
, O
while O
nausea B-NEG
in O
the O
first O
24 O
h O
was O
decreased O
from O
42% O
to O
27% O
(p O
= O
0.034) O
. O
pain B-NEG
severity O
and O
analgesic O
requirements O
were O
unaffected O
by O
the O
omission O
of O
fentanyl O
. O

fentanyl O
did O
reduce O
minor O
intraoperative O
movement O
but O
had O
no O
sevoflurane-sparing O
effect O
and O
increased O
respiratory B-NEG
depression I-NEG
, O
hypotension B-NEG
and O
bradycardia B-NEG
. O

conclusion O
: O
as O
fentanyl O
exacerbated O
postoperative B-NEG
nausea I-NEG
and I-NEG
vomiting I-NEG
without O
an O
improvement O
in O
postoperative B-NEG
pain I-NEG
and O
also O
had O
adverse O
cardiorespiratory O
effects O
, O
it O
appears O
to O
be O
an O
unnecessary O
and O
possibly O
detrimental O
supplement O
to O
sevoflurane O
in O
day O
surgery O
. O

-DOCSTART- O

renal B-NEG
fanconi I-NEG
syndrome I-NEG
and O
myopathy B-NEG
after O
liver O
transplantation O
: O
drug-related O
mitochondrial B-NEG
cytopathy I-NEG
? O

advances O
in O
the O
field O
of O
transplantation O
provide O
a O
better O
quality O
of O
life O
and O
allow O
more O
favorable O
conditions O
for O
growth O
and O
development O
in O
children O
. O

however O
, O
combinations O
of O
different O
therapeutic O
regimens O
require O
consideration O
of O
potential O
adverse O
reactions O
. O

we O
describe O
a O
15-yr-old O
girl O
who O
had O
orthotopic O
liver O
transplantation O
because O
of O
wilson's B-NEG
disease I-NEG
. O

tacrolimus O
, O
mmf O
, O
and O
steroids O
were O
given O
as O
immunosuppressant O
. O

lamivudine O
was O
added O
because O
of O
de O
nova O
hepatitis B-NEG
b I-NEG
infection I-NEG
during O
her O
follow-up O
. O

three O
yr O
after O
transplantation O
she O
developed O
renal B-NEG
fanconi I-NEG
syndrome I-NEG
with O
severe O
metabolic B-NEG
acidosis I-NEG
, O
hypophosphatemia B-NEG
, O
glycosuria B-NEG
, O
and O
aminoaciduria B-NEG
. O

although O
tacrolimus O
was O
suspected O
to O
be O
the O
cause O
of O
late O
post-transplant O
renal O
acidosis B-NEG
and O
was O
replaced O
by O
sirolimus O
, O
acidosis B-NEG
, O
and O
electrolyte O
imbalance O
got O
worse O
. O

proximal O
muscle B-NEG
weakness I-NEG
has O
developed O
during O
her O
follow-up O
. O
fanconi B-NEG
syndrome I-NEG
, O
as O
well O
as O
myopathy B-NEG
, O
is O
well O
recognized O
in O
patients O
with O
mitochondrial B-NEG
disorders I-NEG
and O
caused O
by O
depletion O
of O
mtdna O
. O

we O
suggest O
that O
our O
patient's O
tubular B-NEG
dysfunction I-NEG
and O
myopathy B-NEG
may O
have O
resulted O
from O
mitochondrial B-NEG
dysfunction I-NEG
which O
is O
triggered O
by O
tacrolimus O
and O
augmented O
by O
lamivudine O
. O

-DOCSTART- O

antipsychotic-like O
profile O
of O
thioperamide O
, O
a O
selective O
h3-receptor O
antagonist O
in O
mice O
. O

experimental O
and O
clinical O
evidence O
points O
to O
a O
role O
of O
central O
histaminergic O
system O
in O
the O
pathogenesis O
of O
schizophrenia B-NEG
. O

the O
present O
study O
was O
designed O
to O
study O
the O
effect O
of O
histamine O
h(3)-receptor O
ligands O
on O
neuroleptic-induced O
catalepsy B-NEG
, O
apomorphine-induced O
climbing O
behavior O
and O
amphetamine-induced O
locomotor O
activities O
in O
mice O
. O
catalepsy B-NEG
was O
induced O
by O
haloperidol O
(2 O
mg/kg O
p.o.) O
, O
while O
apomorphine O
( O
1.5 O
mg/kg O
s.c. O
) O
and O
amphetamine O
(2 O
mg/kg O
s.c. O
) O
were O
used O
for O
studying O
climbing O
behavior O
and O
locomotor O
activities O
, O
respectively O
. O

( O
r)-alpha-methylhistamine O
( O
ramh O
) O
(5 O
microg O
i.c.v. O
) O
and O
thioperamide O
( O
thp O
) O
( O
15 O
mg/kg O
i.p.) O
, O
per O
se O
did O
not O
cause O
catalepsy B-NEG
. O

administration O
of O
thp O
(3.75 O
, O
7.5 O
and O
15 O
mg/kg O
i.p. O
) O
1 O
h O
prior O
to O
haloperidol O
resulted O
in O
a O
dose-dependent O
increase O
in O
the O
catalepsy B-NEG
times O
(p O
< O
0.05) O
. O

however O
, O
pretreatment O
with O
ramh O
significantly O
reversed O
such O
an O
effect O
of O
thp O
( O
15 O
mg/kg O
i.p.) O
. O

ramh O
per O
se O
showed O
significant O
reduction O
in O
locomotor O
time O
, O
distance O
traveled O
and O
average O
speed O
but O
thp O
( O
15 O
mg/kg O
i.p. O
) O
per O
se O
had O
no O
effect O
on O
these O
parameters O
. O

on O
amphetamine-induced O
hyperactivity B-NEG
, O
thp O
( O
3.75 O
and O
7.5 O
mg/kg O
i.p. O
) O
reduced O
locomotor O
time O
, O
distance O
traveled O
and O
average O
speed O
(p O
< O
0.05) O
. O

pretreatment O
with O
ramh O
(5 O
microg O
i.c.v. O
) O
could O
partially O
reverse O
such O
effects O
of O
thp O
( O
3.75 O
mg/kg O
i.p.) O
. O

climbing O
behavior O
induced O
by O
apomorphine O
was O
reduced O
in O
animals O
treated O
with O
thp O
. O

such O
an O
effect O
was O
, O
however O
, O
reversed O
in O
presence O
of O
ramh O
. O

thp O
exhibited O
an O
antipsychotic-like O
profile O
by O
potentiating O
haloperidol-induced O
catalepsy B-NEG
, O
reducing O
amphetamine-induced O
hyperactivity B-NEG
and O
reducing O
apomorphine-induced O
climbing O
in O
mice O
. O

such O
effects O
of O
thp O
were O
reversed O
by O
ramh O
indicating O
the O
involvement O
of O
histamine O
h(3)-receptors O
. O

findings O
suggest O
a O
potential O
for O
h(3)-receptor O
antagonists O
in O
improving O
the O
refractory O
cases O
of O
schizophrenia B-NEG
. O

-DOCSTART- O

transient O
platypnea-orthodeoxia-like B-NEG
syndrome I-NEG
induced O
by O
propafenone O
overdose B-NEG
in O
a O
young O
woman O
with O
ebstein's B-NEG
anomaly I-NEG
. O

in O
this O
report O
we O
describe O
the O
case O
of O
a O
37-year-old O
white O
woman O
with O
ebstein's B-NEG
anomaly I-NEG
, O
who O
developed O
a O
rare O
syndrome O
called O
platypnea-orthodeoxia B-NEG
, O
characterized O
by O
massive O
right-to-left O
interatrial O
shunting O
with O
transient O
profound O
hypoxia B-NEG
and O
cyanosis B-NEG
. O

this O
shunt O
of O
blood O
via O
a O
patent B-NEG
foramen I-NEG
ovale I-NEG
occurred O
in O
the O
presence O
of O
a O
normal O
pulmonary O
artery O
pressure O
, O
and O
was O
probably O
precipitated O
by O
a O
propafenone O
overdose B-NEG
. O

this O
drug O
caused O
biventricular B-NEG
dysfunction I-NEG
, O
due O
to O
its O
negative O
inotropic O
effect O
, O
and O
hypotension B-NEG
, O
due O
to O
its O
peripheral O
vasodilatory O
effect O
. O

these O
effects O
gave O
rise O
to O
an O
increase O
in O
the O
right O
atrial O
pressure O
and O
a O
decrease O
in O
the O
left O
one O
with O
a O
consequent O
stretching O
of O
the O
foramen O
ovale O
and O
the O
creation O
of O
massive O
right-to-left O
shunting O
. O

in O
our O
case O
this O
interatrial O
shunt O
was O
very O
accurately O
detected O
at O
bubble O
contrast O
echocardiography O
. O

-DOCSTART- O

a O
phase O
ii O
trial O
of O
cisplatin O
plus O
wr-2721 O
( O
amifostine O
) O
for O
metastatic O
breast B-NEG
carcinoma I-NEG
: O
an O
eastern O
cooperative O
oncology O
group O
study O
(e8188) O
. O

background O
: O
cisplatin O
has O
minimal O
antitumor O
activity O
when O
used O
as O
second- O
or O
third-line O
treatment O
of O
metastatic O
breast B-NEG
carcinoma I-NEG
. O

older O
reports O
suggest O
an O
objective O
response O
rate O
of O
8% O
when O
60-120 O
mg/m2 O
of O
cisplatin O
is O
administered O
every O
3-4 O
weeks O
. O

although O
a O
dose-response O
effect O
has O
been O
observed O
with O
cisplatin O
, O
the O
dose-limiting O
toxicities B-NEG
associated O
with O
cisplatin O
(e.g. O
, O
nephrotoxicity B-NEG
, O
ototoxicity B-NEG
, O
and O
neurotoxicity B-NEG
) O
have O
limited O
its O
use O
as O
a O
treatment O
for O
breast B-NEG
carcinoma I-NEG
. O

wr-2721 O
or O
amifostine O
initially O
was O
developed O
to O
protect O
military O
personnel O
in O
the O
event O
of O
nuclear O
war O
. O

amifostine O
subsequently O
was O
shown O
to O
protect O
normal O
tissues O
from O
the O
toxic O
effects O
of O
alkylating O
agents O
and O
cisplatin O
without O
decreasing O
the O
antitumor O
effect O
of O
the O
chemotherapy O
. O

early O
trials O
of O
cisplatin O
and O
amifostine O
also O
suggested O
that O
the O
incidence O
and O
severity O
of O
cisplatin-induced O
nephrotoxicity B-NEG
, O
ototoxicity B-NEG
, O
and O
neuropathy B-NEG
were O
reduced O
. O

methods O
: O
a O
phase O
ii O
study O
of O
the O
combination O
of O
cisplatin O
plus O
amifostine O
was O
conducted O
in O
patients O
with O
progressive O
metastatic O
breast B-NEG
carcinoma I-NEG
who O
had O
received O
one O
, O
but O
not O
more O
than O
one O
, O
chemotherapy O
regimen O
for O
metastatic O
disease O
. O

patients O
received O
amifostine O
, O
910 O
mg/m2 O
intravenously O
over O
15 O
minutes O
. O

after O
completion O
of O
the O
amifostine O
infusion O
, O
cisplatin O
120 O
mg/m2 O
was O
administered O
over O
30 O
minutes O
. O

intravenous O
hydration O
and O
mannitol O
was O
administered O
before O
and O
after O
cisplatin O
. O

treatment O
was O
administered O
every O
3 O
weeks O
until O
disease O
progression O
. O

results O
: O
forty-four O
patients O
were O
enrolled O
in O
the O
study O
of O
which O
7 O
( O
16% O
) O
were O
ineligible O
. O

a O
median O
of O
2 O
cycles O
of O
therapy O
was O
administered O
to O
the O
37 O
eligible O
patients O
. O

six O
partial O
responses O
were O
observed O
for O
an O
overall O
response O
rate O
of O
16% O
. O

most O
patients O
( O
57% O
) O
stopped O
treatment O
because O
of O
disease O
progression O
. O
neurologic B-NEG
toxicity I-NEG
was O
reported O
in O
52% O
of O
patients O
. O

seven O
different O
life-threatening O
toxicities B-NEG
were O
observed O
in O
patients O
while O
receiving O
treatment O
. O

conclusions O
: O
the O
combination O
of O
cisplatin O
and O
amifostine O
in O
this O
study O
resulted O
in O
an O
overall O
response O
rate O
of O
16% O
. O

neither O
a O
tumor B-NEG
-protective O
effect O
nor O
reduced O
toxicity B-NEG
to O
normal O
tissues O
was O
observed O
with O
the O
addition O
of O
amifostine O
to O
cisplatin O
in O
this O
trial O
. O

-DOCSTART- O

warfarin-induced O
iliopsoas O
hemorrhage B-NEG
with O
subsequent O
femoral B-NEG
nerve I-NEG
palsy I-NEG
. O

we O
present O
the O
case O
of O
a O
28-year-old O
man O
on O
chronic O
warfarin O
therapy O
who O
sustained O
a O
minor O
muscle B-NEG
tear I-NEG
and O
developed O
increasing O
pain B-NEG
and O
a O
flexure O
contracture B-NEG
of O
the O
right O
hip O
. O

surgical O
exploration O
revealed O
an O
iliopsoas O
hematoma B-NEG
and O
femoral O
nerve B-NEG
entrapment I-NEG
, O
resulting O
in O
a O
femoral B-NEG
nerve I-NEG
palsy I-NEG
and O
partial B-NEG
loss I-NEG
of I-NEG
quadriceps I-NEG
functions I-NEG
. O

anticoagulant-induced O
femoral B-NEG
nerve I-NEG
palsy I-NEG
represents O
the O
most O
common O
form O
of O
warfarin-induced O
peripheral B-NEG
neuropathy I-NEG
; O
it O
is O
characterized O
by O
severe O
pain B-NEG
in O
the O
inguinal O
region O
, O
varying O
degrees O
of O
motor B-NEG
and I-NEG
sensory I-NEG
impairment I-NEG
, O
and O
flexure O
contracture B-NEG
of O
the O
involved O
extremity O
. O

-DOCSTART- O

myasthenia B-NEG
gravis I-NEG
caused O
by O
penicillamine O
and O
chloroquine O
therapy O
for O
rheumatoid B-NEG
arthritis I-NEG
. O

we O
have O
described O
a O
unique O
patient O
who O
had O
reversible O
and O
dose-related O
myasthenia B-NEG
gravis I-NEG
after O
penicillamine O
and O
chloroquine O
therapy O
for O
rheumatoid B-NEG
arthritis I-NEG
. O

although O
acetylcholine O
receptor O
antibodies O
were O
not O
detectable O
, O
the O
time O
course O
was O
consistent O
with O
an O
autoimmune O
process O
. O

-DOCSTART- O

nephrotoxicity B-NEG
of O
combined O
cephalothin-gentamicin O
regimen O
. O

two O
patients O
developed O
acute B-NEG
tubular I-NEG
necrosis I-NEG
, O
characterized O
clinically O
by O
acute O
oliguric B-NEG
renal I-NEG
failure I-NEG
, O
while O
they O
were O
receiving O
a O
combination O
of O
cephalothin O
sodium O
and O
gentamicin O
sulfate O
therapy O
. O

patients O
who O
are O
given O
this O
drug O
regimen O
should O
be O
observed O
very O
carefully O
for O
early O
signs O
of O
nephrotoxicity B-NEG
. O

high O
doses O
of O
this O
antibiotic O
combination O
should O
be O
avoided O
especially O
in O
elderly O
patients O
. O

patients O
with O
renal B-NEG
insufficiency I-NEG
should O
not O
be O
given O
this O
regimen O
. O

-DOCSTART- O

components O
of O
lemon O
essential O
oil O
attenuate O
dementia B-NEG
induced O
by O
scopolamine O
. O

the O
anti- O
dementia B-NEG
effects O
of O
s-limonene O
and O
s-perillyl O
alcohol O
were O
observed O
using O
the O
passive O
avoidance O
test O
( O
pa O
) O
and O
the O
open O
field O
habituation O
test O
(ofh) O
. O

these O
lemon O
essential O
oils O
showed O
strong O
ability O
to O
improve O
memory B-NEG
impaired I-NEG
by O
scopolamine O
; O
however O
, O
s-perillyl O
alcohol O
relieved O
the O
deficit B-NEG
of I-NEG
associative I-NEG
memory I-NEG
in O
pa O
only O
, O
and O
did O
not O
improve O
non-associative O
memory O
significantly O
in O
ofh O
. O

analysis O
of O
neurotransmitter O
concentration O
in O
some O
brain O
regions O
on O
the O
test O
day O
showed O
that O
dopamine O
concentration O
of O
the O
vehicle/scopolamine O
group O
was O
significantly O
lower O
than O
that O
of O
the O
vehicle/vehicle O
group O
, O
but O
this O
phenomenon O
was O
reversed O
when O
s-limonene O
or O
s-perillyl O
alcohol O
were O
administered O
before O
the O
injection O
of O
scopolamine O
. O

simultaneously O
, O
we O
found O
that O
these O
two O
lemon O
essential O
oil O
components O
could O
inhibit O
acetylcholinesterase O
activity O
in O
vitro O
using O
the O
ellman O
method O
. O

-DOCSTART- O

the O
selective O
5-ht6 O
receptor O
antagonist O
ro4368554 O
restores O
memory O
performance O
in O
cholinergic O
and O
serotonergic O
models O
of O
memory B-NEG
deficiency I-NEG
in O
the O
rat O
. O

antagonists O
at O
serotonin O
type O
6 O
( O
5-ht(6) O
) O
receptors O
show O
activity O
in O
models O
of O
learning O
and O
memory O
. O

although O
the O
underlying O
mechanism(s O
) O
are O
not O
well O
understood O
, O
these O
effects O
may O
involve O
an O
increase O
in O
acetylcholine O
( O
ach O
) O
levels O
. O

the O
present O
study O
sought O
to O
characterize O
the O
cognitive-enhancing O
effects O
of O
the O
5-ht(6 O
) O
antagonist O
ro4368554 O
( O
3-benzenesulfonyl-7-(4-methyl-piperazin-1-yl)1h-indole O
) O
in O
a O
rat O
object O
recognition O
task O
employing O
a O
cholinergic O
( O
scopolamine O
pretreatment O
) O
and O
a O
serotonergic- O
( O
tryptophan O
( O
trp O
) O
depletion O
) O
deficient O
model O
, O
and O
compared O
its O
pattern O
of O
action O
with O
that O
of O
the O
acetylcholinesterase O
inhibitor O
metrifonate O
. O

initial O
testing O
in O
a O
time-dependent O
forgetting O
task O
employing O
a O
24-h O
delay O
between O
training O
and O
testing O
showed O
that O
metrifonate O
improved O
object O
recognition O
( O
at O
10 O
and O
30 O
mg/kg O
, O
p.o.) O
, O
whereas O
ro4368554 O
was O
inactive O
. O

both O
, O
ro4368554 O
(3 O
and O
10 O
mg/kg O
, O
intraperitoneally O
( O
i.p.) O
) O
and O
metrifonate O
( O
10 O
mg/kg O
, O
p.o. O
, O
respectively O
) O
reversed O
memory B-NEG
deficits I-NEG
induced O
by O
scopolamine O
and O
trp O
depletion O
( O
10 O
mg/kg O
, O
i.p. O
, O
and O
3 O
mg/kg O
, O
p.o. O
, O
respectively) O
. O

in O
conclusion O
, O
although O
ro4368554 O
did O
not O
improve O
a O
time-related O
retention O
deficit O
, O
it O
reversed O
a O
cholinergic O
and O
a O
serotonergic O
memory B-NEG
deficit I-NEG
, O
suggesting O
that O
both O
mechanisms O
may O
be O
involved O
in O
the O
facilitation O
of O
object O
memory O
by O
ro4368554 O
and O
, O
possibly O
, O
other O
5-ht(6 O
) O
receptor O
antagonists O
. O

-DOCSTART- O

lone O
atrial B-NEG
fibrillation I-NEG
associated O
with O
creatine O
monohydrate O
supplementation O
. O
atrial B-NEG
fibrillation I-NEG
in O
young O
patients O
without O
structural O
heart B-NEG
disease I-NEG
is O
rare O
. O

therefore O
, O
when O
the O
arrhythmia B-NEG
is O
present O
in O
this O
population O
, O
reversible O
causes O
must O
be O
identified O
and O
resolved O
. O
thyroid B-NEG
disorders I-NEG
, O
illicit O
drug O
or O
stimulant O
use O
, O
and O
acute B-NEG
alcohol I-NEG
intoxication I-NEG
are O
among O
these O
causes O
. O

we O
report O
the O
case O
of O
a O
30-year-old O
caucasian O
man O
who O
came O
to O
the O
emergency O
department O
in O
atrial B-NEG
fibrillation I-NEG
with O
rapid O
ventricular O
response O
. O

his O
medical O
history O
was O
unremarkable O
, O
except O
for O
minor O
fractures B-NEG
of O
the O
fingers O
and O
foot O
. O

thyroid-stimulating O
hormone O
, O
magnesium O
, O
and O
potassium O
levels O
were O
within O
normal O
limits O
, O
urine O
drug O
screen O
was O
negative O
, O
and O
alcohol O
use O
was O
denied O
. O

however O
, O
when O
the O
patient O
was O
questioned O
about O
use O
of O
herbal O
products O
and O
supplements O
, O
the O
use O
of O
creatine O
monohydrate O
was O
revealed O
. O

the O
patient O
was O
admitted O
to O
the O
hospital O
, O
anticoagulated O
with O
unfractionated O
heparin O
, O
and O
given O
intravenous O
diltiazem O
for O
rate O
control O
and O
intravenous O
amiodarone O
for O
rate O
and O
rhythm O
control O
. O

when O
discharged O
less O
than O
24 O
hours O
later O
, O
he O
was O
receiving O
metoprolol O
and O
aspirin O
, O
with O
follow-up O
plans O
for O
echocardiography O
and O
nuclear O
imaging O
to O
assess O
perfusion O
. O

exogenous O
creatine O
is O
used O
by O
athletes O
to O
theoretically O
improve O
exercise O
performance O
. O

vegetarians O
may O
also O
take O
creatine O
to O
replace O
what O
they O
are O
not O
consuming O
from O
meat O
, O
fish O
, O
and O
other O
animal O
products O
. O

previous O
anecdotal O
reports O
have O
linked O
creatine O
to O
the O
development O
of O
arrhythmia B-NEG
. O

clinicians O
must O
be O
diligent O
when O
interviewing O
patients O
about O
their O
drug O
therapy O
histories O
and O
include O
questions O
about O
their O
use O
of O
herbal O
products O
and O
dietary O
supplements O
. O

in O
addition O
, O
it O
is O
important O
to O
report O
adverse O
effects O
associated O
with O
frequently O
consumed O
supplements O
and O
herbal O
products O
to O
the O
food O
and O
drug O
administration O
and O
in O
the O
literature O
. O

-DOCSTART- O

comparison O
of O
developmental O
toxicity B-NEG
of O
selective O
and O
non-selective O
cyclooxygenase-2 O
inhibitors O
in O
crl:(wi)wubr O
wistar O
rats--dfu O
and O
piroxicam O
study O
. O

background O
: O
cyclooxygenase O
( O
cox O
) O
inhibitors O
are O
one O
of O
the O
most O
often O
ingested O
drugs O
during O
pregnancy O
. O

unlike O
general O
toxicity B-NEG
data O
, O
their O
prenatal O
toxic O
effects O
were O
not O
extensively O
studied O
before O
. O

the O
aim O
of O
the O
experiment O
was O
to O
evaluate O
the O
developmental O
toxicity B-NEG
of O
the O
non-selective O
( O
piroxicam O
) O
and O
selective O
(dfu O
; O
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl O
) O
phenyl-2(5h)-furanon O
) O
cox-2 O
inhibitors O
. O

methods O
: O
drugs O
were O
separately O
, O
orally O
once O
daily O
dosed O
to O
pregnant O
rats O
from O
day O
8 O
to O
21 O
( O
gd1=plug O
day) O
. O

doses O
were O
set O
at O
0.3 O
, O
3.0 O
and O
30.0mg/kg O
for O
piroxicam O
and O
0.2 O
, O
2.0 O
and O
20.0mg/kg O
for O
dfu O
. O

fetuses O
were O
delivered O
on O
gd O
21 O
and O
routinely O
examined O
. O

comprehensive O
clinical O
and O
developmental O
measurements O
were O
done O
. O

the O
pooled O
statistical O
analysis O
for O
ventricular B-NEG
septal I-NEG
( O
vsd I-NEG
) O
and I-NEG
midline I-NEG
( O
md I-NEG
) O
defects I-NEG
was O
performed O
for O
rat O
fetuses O
exposed O
to O
piroxicam O
, O
selective O
and O
non-selective O
cox-2 O
inhibitor O
based O
on O
present O
and O
historic O
data O
. O

results O
: O
maternal O
toxicity B-NEG
, O
intrauterine B-NEG
growth I-NEG
retardation I-NEG
, O
and O
increase B-NEG
of I-NEG
external I-NEG
and I-NEG
skeletal I-NEG
variations I-NEG
were O
found O
in O
rats O
treated O
with O
the O
highest O
dose O
of O
piroxicam O
. O

decrease O
of O
fetal O
length O
was O
the O
only O
signs O
of O
the O
dfu O
developmental O
toxicity B-NEG
observed O
in O
pups O
exposed O
to O
the O
highest O
compound O
dose O
. O

lack O
of O
teratogenicity O
was O
found O
in O
piroxicam O
and O
dfu-exposed O
groups O
. O

prenatal O
exposure O
to O
non-selective O
cox O
inhibitors O
increases O
the O
risk O
of O
vsd O
and O
md O
when O
compared O
to O
historic O
control O
but O
not O
with O
selective O
cox-2 O
inhibitors O
. O

conclusion O
: O
both O
selective O
and O
non-selective O
cox-2 O
inhibitors O
were O
toxic O
for O
rats O
fetuses O
when O
administered O
in O
the O
highest O
dose O
. O

unlike O
dfu O
, O
piroxicam O
was O
also O
highly O
toxic O
to O
the O
dams O
. O

prenatal O
exposure O
to O
selective O
cox-2 O
inhibitors O
does O
not O
increase O
the O
risk O
of O
ventricular B-NEG
septal I-NEG
and I-NEG
midline I-NEG
defects I-NEG
in O
rat O
when O
compared O
to O
non-selective O
drugs O
and O
historic O
control O
. O

-DOCSTART- O

protective O
efficacy O
of O
neuroactive O
steroids O
against O
cocaine O
kindled- O
seizures B-NEG
in O
mice O
. O

neuroactive O
steroids O
demonstrate O
pharmacological O
actions O
that O
have O
relevance O
for O
a O
host O
of O
neurological B-NEG
and I-NEG
psychiatric I-NEG
disorders I-NEG
. O

they O
offer O
protection O
against O
seizures B-NEG
in O
a O
range O
of O
models O
and O
seem O
to O
inhibit O
certain O
stages O
of O
drug B-NEG
dependence I-NEG
in O
preclinical O
assessments O
. O

the O
present O
study O
was O
designed O
to O
evaluate O
two O
endogenous O
and O
one O
synthetic O
neuroactive O
steroid O
that O
positively O
modulate O
the O
gamma-aminobutyric O
acid O
( O
gaba(a) O
) O
receptor O
against O
the O
increase O
in O
sensitivity O
to O
the O
convulsant O
effects O
of O
cocaine O
engendered O
by O
repeated O
cocaine O
administration O
( O
seizure B-NEG
kindling) O
. O

allopregnanolone O
(3alpha-hydroxy-5alpha-pregnan-20-one) O
, O
pregnanolone O
( O
3alpha-hydroxy-5beta-pregnan-20-one O
) O
and O
ganaxolone O
(a O
synthetic O
derivative O
of O
allopregnanolone O
3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one O
) O
were O
tested O
for O
their O
ability O
to O
suppress O
the O
expression O
( O
anticonvulsant O
effect O
) O
and O
development O
( O
antiepileptogenic O
effect O
) O
of O
cocaine-kindled O
seizures B-NEG
in O
male O
, O
swiss-webster O
mice O
. O

kindled O
seizures B-NEG
were O
induced O
by O
daily O
administration O
of O
60 O
mg/kg O
cocaine O
for O
5 O
days O
. O

all O
of O
these O
positive O
gaba(a O
) O
modulators O
suppressed O
the O
expression O
of O
kindled O
seizures B-NEG
, O
whereas O
only O
allopregnanolone O
and O
ganaxolone O
inhibited O
the O
development O
of O
kindling O
. O

allopregnanolone O
and O
pregnanolone O
, O
but O
not O
ganaxolone O
, O
also O
reduced O
cumulative O
lethality O
associated O
with O
kindling O
. O

these O
findings O
demonstrate O
that O
some O
neuroactive O
steroids O
attenuate O
convulsant O
and O
sensitizing O
properties O
of O
cocaine O
and O
add O
to O
a O
growing O
literature O
on O
their O
potential O
use O
in O
the O
modulation O
of O
effects O
of O
drugs O
of O
abuse O
. O

-DOCSTART- O

kidney O
function O
and O
morphology O
after O
short-term O
combination O
therapy O
with O
cyclosporine O
a, O
tacrolimus O
and O
sirolimus O
in O
the O
rat O
. O

background O
: O
sirolimus O
( O
srl O
) O
may O
supplement O
calcineurin O
inhibitors O
in O
clinical O
organ O
transplantation O
. O

these O
are O
nephrotoxic B-NEG
, O
but O
srl O
seems O
to O
act O
differently O
displaying O
only O
minor O
nephrotoxic B-NEG
effects O
, O
although O
this O
question O
is O
still O
open O
. O

in O
a O
number O
of O
treatment O
protocols O
where O
srl O
was O
combined O
with O
a O
calcineurin O
inhibitor O
indications O
of O
a O
synergistic O
nephrotoxic B-NEG
effect O
were O
described O
. O

the O
aim O
of O
this O
study O
was O
to O
examine O
further O
the O
renal O
function O
, O
including O
morphological O
analysis O
of O
the O
kidneys O
of O
male O
sprague-dawley O
rats O
treated O
with O
either O
cyclosporine O
a O
(csa) O
, O
tacrolimus O
( O
fk506 O
) O
or O
srl O
as O
monotherapies O
or O
in O
different O
combinations O
. O

methods O
: O
for O
a O
period O
of O
2 O
weeks O
, O
csa O
15 O
mg/kg/day O
( O
given O
orally) O
, O
fk506 O
3.0 O
mg/kg/day O
( O
given O
orally O
) O
or O
srl O
0.4 O
mg/kg/day O
( O
given O
intraperitoneally O
) O
was O
administered O
once O
a O
day O
as O
these O
doses O
have O
earlier O
been O
found O
to O
achieve O
a O
significant O
immunosuppressive O
effect O
in O
sprague-dawley O
rats O
. O

in O
the O
'conscious O
catheterized O
rat' O
model O
, O
the O
glomerular O
filtration O
rate O
( O
gfr O
) O
was O
measured O
as O
the O
clearance O
of O
cr(edta) O
. O

the O
morphological O
analysis O
of O
the O
kidneys O
included O
a O
semi-quantitative O
scoring O
system O
analysing O
the O
degree O
of O
striped O
fibrosis B-NEG
, O
subcapsular O
fibrosis B-NEG
and O
the O
number O
of O
basophilic O
tubules O
, O
plus O
an O
additional O
stereological O
analysis O
of O
the O
total O
grade O
of O
fibrosis B-NEG
in O
the O
cortex O
stained O
with O
sirius O
red O
. O

results O
: O
csa O
, O
fk506 O
and O
srl O
all O
significantly O
decreased O
the O
gfr O
. O

a O
further O
deterioration O
was O
seen O
when O
csa O
was O
combined O
with O
either O
fk506 O
or O
srl O
, O
whereas O
the O
gfr O
remained O
unchanged O
in O
the O
group O
treated O
with O
fk506 O
plus O
srl O
when O
compared O
with O
treatment O
with O
any O
of O
the O
single O
substances O
. O

the O
morphological O
changes O
presented O
a O
similar O
pattern O
. O

the O
semi-quantitative O
scoring O
was O
significantly O
worst O
in O
the O
group O
treated O
with O
csa O
plus O
srl O
( O
p<0.001 O
compared O
with O
controls O
) O
and O
the O
analysis O
of O
the O
total O
grade O
of O
fibrosis B-NEG
also O
showed O
the O
highest O
proportion O
in O
the O
same O
group O
and O
was O
significantly O
different O
from O
controls O
(p<0.02) O
. O

the O
fk506 O
plus O
srl O
combination O
showed O
only O
a O
marginally O
higher O
degree O
of O
fibrosis B-NEG
as O
compared O
with O
controls O
(p=0.05) O
. O

conclusion O
: O
this O
rat O
study O
demonstrated O
a O
synergistic O
nephrotoxic B-NEG
effect O
of O
csa O
plus O
srl O
, O
whereas O
fk506 O
plus O
srl O
was O
better O
tolerated O
. O

-DOCSTART- O

effect O
of O
fucoidan O
treatment O
on O
collagenase-induced O
intracerebral B-NEG
hemorrhage I-NEG
in O
rats O
. O

inflammatory O
cells O
are O
postulated O
to O
mediate O
some O
of O
the O
brain B-NEG
damage I-NEG
following O
ischemic B-NEG
stroke I-NEG
. O
intracerebral B-NEG
hemorrhage I-NEG
is O
associated O
with O
more O
inflammation B-NEG
than O
ischemic B-NEG
stroke I-NEG
. O

we O
tested O
the O
sulfated O
polysaccharide O
fucoidan O
, O
which O
has O
been O
reported O
to O
reduce O
inflammatory O
brain B-NEG
damage I-NEG
, O
in O
a O
rat O
model O
of O
intracerebral B-NEG
hemorrhage I-NEG
induced O
by O
injection O
of O
bacterial O
collagenase O
into O
the O
caudate O
nucleus O
. O

rats O
were O
treated O
with O
seven O
day O
intravenous O
infusion O
of O
fucoidan O
( O
30 O
micrograms O
h-1 O
) O
or O
vehicle O
. O

the O
hematoma B-NEG
was O
assessed O
in O
vivo O
by O
magnetic O
resonance O
imaging O
. O

motor O
behavior O
, O
passive O
avoidance O
, O
and O
skilled O
forelimb O
function O
were O
tested O
repeatedly O
for O
six O
weeks O
. O

fucoidan-treated O
rats O
exhibited O
evidence O
of O
impaired B-NEG
blood I-NEG
clotting I-NEG
and O
hemodilution B-NEG
, O
had O
larger O
hematomas B-NEG
, O
and O
tended O
to O
have O
less O
inflammation B-NEG
in O
the O
vicinity O
of O
the O
hematoma B-NEG
after O
three O
days O
. O

they O
showed O
significantly O
more O
rapid O
improvement O
of O
motor O
function O
in O
the O
first O
week O
following O
hemorrhage B-NEG
and O
better O
memory O
retention O
in O
the O
passive O
avoidance O
test O
. O

acute O
white B-NEG
matter I-NEG
edema I-NEG
and O
eventual O
neuronal B-NEG
loss I-NEG
in O
the O
striatum O
adjacent O
to O
the O
hematoma B-NEG
did O
not O
differ O
between O
the O
two O
groups O
. O

investigation O
of O
more O
specific O
anti-inflammatory O
agents O
and O
hemodiluting O
agents O
are O
warranted O
in O
intracerebral B-NEG
hemorrhage I-NEG
. O

-DOCSTART- O

paracetamol-associated O
coma B-NEG
, O
metabolic B-NEG
acidosis I-NEG
, O
renal B-NEG
and I-NEG
hepatic I-NEG
failure I-NEG
. O

a O
case O
of O
metabolic B-NEG
acidosis I-NEG
, O
acute B-NEG
renal I-NEG
failure I-NEG
and I-NEG
hepatic I-NEG
failure I-NEG
following O
paracetamol O
ingestion O
is O
presented O
. O

the O
diagnostic O
difficulty O
at O
presentation O
is O
highlighted O
. O

continuous O
arteriovenous O
haemofiltration O
proved O
a O
valuable O
means O
of O
maintaining O
fluid O
and O
electrolyte O
balance O
. O

the O
patient O
recovered O
. O

-DOCSTART- O

hepatic O
reactions O
associated O
with O
ketoconazole O
in O
the O
united O
kingdom O
. O

ketoconazole O
was O
introduced O
in O
the O
united O
kingdom O
in O
1981 O
. O

by O
november O
1984 O
the O
committee O
on O
safety O
of O
medicines O
had O
received O
82 O
reports O
of O
possible O
hepatotoxicity B-NEG
associated O
with O
the O
drug O
, O
including O
five O
deaths B-NEG
. O

an O
analysis O
of O
the O
75 O
cases O
that O
had O
been O
adequately O
followed O
up O
suggested O
that O
16 O
, O
including O
three O
deaths B-NEG
, O
were O
probably O
related O
to O
treatment O
with O
the O
drug O
. O

of O
the O
remainder O
, O
48 O
were O
possibly O
related O
to O
treatment O
, O
five O
were O
unlikely O
to O
be O
so O
, O
and O
six O
were O
unclassifiable O
. O

the O
mean O
age O
of O
patients O
in O
the O
16 O
probable O
cases O
was O
57.9 O
, O
with O
hepatotoxicity B-NEG
being O
more O
common O
in O
women O
. O

the O
average O
duration O
of O
treatment O
before O
the O
onset O
of O
jaundice B-NEG
was O
61 O
days O
. O

none O
of O
these O
well O
validated O
cases O
occurred O
within O
the O
first O
10 O
days O
after O
treatment O
. O

the O
results O
of O
serum O
liver O
function O
tests O
suggested O
hepatocellular B-NEG
injury I-NEG
in O
10 O
(63%) O
; O
the O
rest O
showed O
a O
mixed O
pattern O
. O

in O
contrast O
, O
the O
results O
of O
histological O
examination O
of O
the O
liver O
often O
showed O
evidence O
of O
cholestasis B-NEG
. O

the O
characteristics O
of O
the O
48 O
patients O
in O
the O
possible O
cases O
were O
similar O
. O

allergic O
manifestations O
such O
as O
rash B-NEG
and O
eosinophilia B-NEG
were O
rare O
. O
hepatitis B-NEG
was O
usually O
reversible O
when O
treatment O
was O
stopped O
, O
with O
the O
results O
of O
liver O
function O
tests O
returning O
to O
normal O
after O
an O
average O
of O
3.1 O
months O
. O

in O
two O
of O
the O
three O
deaths B-NEG
probably O
associated O
with O
ketoconazole O
treatment O
the O
drug O
had O
been O
continued O
after O
the O
onset O
of O
jaundice B-NEG
and O
other O
symptoms O
of O
hepatitis B-NEG
. O

clinical O
and O
biochemical O
monitoring O
at O
regular O
intervals O
for O
evidence O
of O
hepatitis B-NEG
is O
advised O
during O
long O
term O
treatment O
with O
ketoconazole O
to O
prevent O
possible O
serious O
hepatic B-NEG
injury I-NEG
. O

-DOCSTART- O

combined O
effects O
of O
prolonged O
prostaglandin O
e1-induced O
hypotension B-NEG
and O
haemodilution B-NEG
on O
human O
hepatic O
function O
. O

combined O
effects O
of O
prolonged O
prostaglandin O
e1 O
( O
pge1)-induced O
hypotension B-NEG
and O
haemodilution B-NEG
on O
hepatic O
function O
were O
studied O
in O
30 O
patients O
undergoing O
hip O
surgery O
. O

the O
patients O
were O
randomly O
allocated O
to O
one O
of O
three O
groups O
; O
those O
in O
group O
a O
(n O
= O
10 O
) O
were O
subjected O
to O
controlled O
hypotension B-NEG
alone O
, O
those O
in O
group O
b O
(n O
= O
10 O
) O
to O
haemodilution B-NEG
alone O
and O
those O
in O
group O
c O
(n O
= O
10 O
) O
to O
both O
controlled O
hypotension B-NEG
and O
haemodilution B-NEG
. O
haemodilution B-NEG
in O
groups O
b O
and O
c O
was O
produced O
by O
withdrawing O
approximately O
1000 O
ml O
of O
blood O
and O
replacing O
it O
with O
the O
same O
amount O
of O
dextran O
solution O
, O
and O
final O
haematocrit O
values O
were O
21 O
or O
22% O
. O

controlled O
hypotension B-NEG
in O
groups O
a O
and O
c O
was O
induced O
with O
pge1 O
to O
maintain O
mean O
arterial O
blood O
pressure O
at O
55 O
mmhg O
for O
180 O
min O
. O

measurements O
included O
arterial O
ketone O
body O
ratio O
(akbr O
, O
aceto-acetate/3-hydroxybutyrate O
) O
and O
clinical O
hepatic O
function O
parameters O
. O

akbr O
and O
biological O
hepatic O
function O
tests O
showed O
no O
change O
throughout O
the O
time O
course O
in O
groups O
a O
and O
b. O

in O
group O
c, O
akbr O
showed O
a O
significant O
decrease O
at O
120 O
min O
( O
-40% O
) O
and O
at O
180 O
min O
( O
-49% O
) O
after O
the O
start O
of O
hypotension B-NEG
and O
at O
60 O
min O
( O
-32% O
) O
after O
recovery O
of O
normotension O
, O
and O
sgot O
, O
sgpt O
, O
ldh O
and O
total O
bilirubin O
showed O
significant O
increases O
after O
operation O
. O

the O
results O
suggest O
that O
a O
prolonged O
combination O
of O
more O
than O
120 O
min O
of O
pge1-induced O
hypotension B-NEG
and O
moderate O
haemodilution B-NEG
would O
cause O
impairment B-NEG
of I-NEG
hepatic I-NEG
function I-NEG
. O

-DOCSTART- O

levodopa-induced O
dyskinesias B-NEG
in O
patients O
with O
parkinson's B-NEG
disease I-NEG
: O
filling O
the O
bench-to-bedside O
gap O
. O

levodopa O
is O
the O
most O
effective O
drug O
for O
the O
treatment O
of O
parkinson's B-NEG
disease I-NEG
. O

however O
, O
the O
long-term O
use O
of O
this O
dopamine O
precursor O
is O
complicated O
by O
highly O
disabling O
fluctuations O
and O
dyskinesias B-NEG
. O

although O
preclinical O
and O
clinical O
findings O
suggest O
pulsatile O
stimulation O
of O
striatal O
postsynaptic O
receptors O
as O
a O
key O
mechanism O
underlying O
levodopa-induced O
dyskinesias B-NEG
, O
their O
pathogenesis O
is O
still O
unclear O
. O

in O
recent O
years O
, O
evidence O
from O
animal O
models O
of O
parkinson's B-NEG
disease I-NEG
has O
provided O
important O
information O
to O
understand O
the O
effect O
of O
specific O
receptor O
and O
post-receptor O
molecular O
mechanisms O
underlying O
the O
development O
of O
dyskinetic B-NEG
movements I-NEG
. O

recent O
preclinical O
and O
clinical O
data O
from O
promising O
lines O
of O
research O
focus O
on O
the O
differential O
role O
of O
presynaptic O
versus O
postsynaptic O
mechanisms O
, O
dopamine O
receptor O
subtypes O
, O
ionotropic O
and O
metabotropic O
glutamate O
receptors O
, O
and O
non-dopaminergic O
neurotransmitter O
systems O
in O
the O
pathophysiology O
of O
levodopa-induced O
dyskinesias B-NEG
. O

-DOCSTART- O

prevention O
of O
seizures B-NEG
and O
reorganization O
of O
hippocampal O
functions O
by O
transplantation O
of O
bone O
marrow O
cells O
in O
the O
acute O
phase O
of O
experimental O
epilepsy B-NEG
. O

in O
this O
study O
, O
we O
investigated O
the O
therapeutic O
potential O
of O
bone O
marrow O
mononuclear O
cells O
( O
bmcs O
) O
in O
a O
model O
of O
epilepsy B-NEG
induced O
by O
pilocarpine O
in O
rats O
. O

bmcs O
obtained O
from O
green O
fluorescent O
protein O
( O
gfp O
) O
transgenic O
mice O
or O
rats O
were O
transplanted O
intravenously O
after O
induction O
of O
status B-NEG
epilepticus I-NEG
( O
se B-NEG
). O
spontaneous B-NEG
recurrent I-NEG
seizures I-NEG
( O
srs B-NEG
) O
were O
monitored O
using O
racine's O
seizure B-NEG
severity O
scale O
. O

all O
of O
the O
rats O
in O
the O
saline-treated O
epileptic B-NEG
control O
group O
developed O
srs B-NEG
, O
whereas O
none O
of O
the O
bmc-treated O
epileptic B-NEG
animals O
had O
seizures B-NEG
in O
the O
short O
term O
( O
15 O
days O
after O
transplantation) O
, O
regardless O
of O
the O
bmc O
source O
. O

over O
the O
long-term O
chronic O
phase O
( O
120 O
days O
after O
transplantation) O
, O
only O
25% O
of O
bmc-treated O
epileptic B-NEG
animals O
had O
seizures B-NEG
, O
but O
with O
a O
lower O
frequency O
and O
duration O
compared O
to O
the O
epileptic B-NEG
control O
group O
. O

the O
density O
of O
hippocampal O
neurons O
in O
the O
brains O
of O
animals O
treated O
with O
bmcs O
was O
markedly O
preserved O
. O

at O
hippocampal O
schaeffer O
collateral-ca1 O
synapses O
, O
long-term O
potentiation O
was O
preserved O
in O
bmc-transplanted O
rats O
compared O
to O
epileptic B-NEG
controls O
. O

the O
donor-derived O
gfp(+ O
) O
cells O
were O
rarely O
found O
in O
the O
brains O
of O
transplanted O
epileptic B-NEG
rats O
. O

in O
conclusion O
, O
treatment O
with O
bmcs O
can O
prevent O
the O
development O
of O
chronic O
seizures B-NEG
, O
reduce O
neuronal B-NEG
loss I-NEG
, O
and O
influence O
the O
reorganization O
of O
the O
hippocampal O
neuronal O
network O
. O

-DOCSTART- O

cardioprotective O
effect O
of O
salvianolic O
acid O
a O
on O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
. O

the O
present O
study O
was O
designed O
to O
evaluate O
the O
cardioprotective O
potential O
of O
salvianolic O
acid O
a O
on O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
in O
rats O
. O

hemodynamic O
parameters O
and O
lead O
ii O
electrocardiograph O
were O
monitored O
and O
recorded O
continuously O
. O

cardiac O
marker O
enzymes O
and O
antioxidative O
parameters O
in O
serum O
and O
heart O
tissues O
were O
measured O
. O

assay O
for O
mitochondrial O
respiratory O
function O
and O
histopathological O
examination O
of O
heart O
tissues O
were O
performed O
. O

isoproterenol-treated O
rats O
showed O
significant O
increases O
in O
the O
levels O
of O
lactate O
dehydrogenase O
, O
aspartate O
transaminase O
, O
creatine O
kinase O
and O
malondialdehyde O
and O
significant O
decreases O
in O
the O
activities O
of O
superoxide O
dismutase O
, O
catalase O
and O
glutathione O
peroxidase O
in O
serum O
and O
heart O
. O

these O
rats O
also O
showed O
declines O
in O
left O
ventricular O
systolic O
pressure O
, O
maximum O
and O
minimum O
rate O
of O
developed O
left O
ventricular O
pressure O
, O
and O
elevation O
of O
left O
ventricular O
end-diastolic O
pressure O
and O
st-segment O
. O

in O
addition O
, O
mitochondrial O
respiratory B-NEG
dysfunction I-NEG
characterized O
by O
decreased O
respiratory O
control O
ratio O
and O
adp/o O
was O
observed O
in O
isoproterenol-treated O
rats O
. O

administration O
of O
salvianolic O
acid O
a O
for O
a O
period O
of O
8 O
days O
significantly O
attenuated O
isoproterenol-induced O
cardiac B-NEG
dysfunction I-NEG
and O
myocardial B-NEG
injury I-NEG
and O
improved O
mitochondrial O
respiratory O
function O
. O

the O
protective O
role O
of O
salvianolic O
acid O
a O
against O
isoproterenol-induced O
myocardial B-NEG
damage I-NEG
was O
further O
confirmed O
by O
histopathological O
examination O
. O

the O
results O
of O
our O
study O
suggest O
that O
salvianolic O
acid O
a O
possessing O
antioxidant O
activity O
has O
a O
significant O
protective O
effect O
against O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
. O

-DOCSTART- O

acute O
effects O
of O
n-(2-propylpentanoyl)urea O
on O
hippocampal O
amino O
acid O
neurotransmitters O
in O
pilocarpine-induced O
seizure B-NEG
in O
rats O
. O

the O
present O
study O
aimed O
to O
investigate O
the O
anticonvulsant O
activity O
as O
well O
as O
the O
effects O
on O
the O
level O
of O
hippocampal O
amino O
acid O
neurotransmitters O
(glutamate O
, O
aspartate O
, O
glycine O
and O
gaba O
) O
of O
n-(2-propylpentanoyl)urea O
( O
vpu O
) O
in O
comparison O
to O
its O
parent O
compound O
, O
valproic O
acid O
(vpa) O
. O

vpu O
was O
more O
potent O
than O
vpa O
, O
exhibiting O
the O
median O
effective O
dose O
( O
ed(50) O
) O
of O
49 O
mg/kg O
in O
protecting O
rats O
against O
pilocarpine-induced O
seizure B-NEG
whereas O
the O
corresponding O
value O
for O
vpa O
was O
322 O
mg/kg O
. O

in O
vivo O
microdialysis O
demonstrated O
that O
an O
intraperitoneal O
administration O
of O
pilocarpine O
induced O
a O
pronounced O
increment O
of O
hippocampal O
glutamate O
and O
aspartate O
whereas O
no O
significant O
change O
was O
observed O
on O
the O
level O
of O
glycine O
and O
gaba O
. O

pretreatment O
with O
either O
vpu O
( O
50 O
and O
100 O
mg/kg O
) O
or O
vpa O
( O
300 O
and O
600 O
mg/kg O
) O
completely O
abolished O
pilocarpine-evoked O
increases O
in O
extracellular O
glutamate O
and O
aspartate O
. O

in O
addition O
, O
a O
statistically O
significant O
reduction O
was O
also O
observed O
on O
the O
level O
of O
gaba O
and O
glycine O
but O
less O
than O
a O
drastic O
reduction O
of O
glutamate O
and O
aspartate O
level O
. O

based O
on O
the O
finding O
that O
vpu O
and O
vpa O
could O
protect O
the O
animals O
against O
pilocarpine-induced O
seizure B-NEG
it O
is O
suggested O
that O
the O
reduction O
of O
inhibitory O
amino O
acid O
neurotransmitters O
was O
comparatively O
minor O
and O
offset O
by O
a O
pronounced O
reduction O
of O
glutamate O
and O
aspartate O
. O

therefore O
, O
like O
vpa O
, O
the O
finding O
that O
vpu O
could O
drastically O
reduce O
pilocarpine-induced O
increases O
in O
glutamate O
and O
aspartate O
should O
account O
, O
at O
least O
partly O
, O
for O
its O
anticonvulsant O
activity O
observed O
in O
pilocarpine-induced O
seizure B-NEG
in O
experimental O
animals O
. O

some O
other O
mechanism O
than O
those O
being O
reported O
herein O
should O
be O
further O
investigated O
. O

-DOCSTART- O

acute O
hepatitis B-NEG
attack O
after O
exposure O
to O
telithromycin O
. O

introduction O
: O
antibiotic-associated O
hepatotoxicity B-NEG
is O
rare O
. O

with O
widespread O
use O
of O
antimicrobial O
agents O
, O
however O
, O
hepatic B-NEG
injury I-NEG
occurs O
frequently O
, O
and O
among O
adverse B-NEG
drug I-NEG
reactions I-NEG
, O
idiosyncratic O
reactions O
are O
the O
most O
serious O
. O

case O
summary O
: O
a O
25-year-old O
male O
patient O
, O
with O
a O
height O
of O
175 O
cm O
and O
weight O
of O
72 O
kg O
presented O
to O
marmara O
university O
hospital O
emergency O
department O
, O
istanbul O
, O
turkey O
, O
with O
5 O
days' O
history O
of O
jaundice B-NEG
, O
malaise O
, O
nausea B-NEG
, O
and O
vomiting B-NEG
. O

he O
had O
been O
prescribed O
telithromycin O
400 O
mg/d O
po O
to O
treat O
an O
upper B-NEG
respiratory I-NEG
tract I-NEG
infection I-NEG
7 O
days O
prior O
. O

admission O
laboratory O
tests O
were O
as O
follows O
: O
alanine O
aminotransferase O
, O
67 O
u/l O
( O
reference O
range O
, O
10-37 O
u/l) O
; O
aspartate O
aminotransferase O
, O
98 O
u/l O
( O
10-40 O
u/l) O
; O
alkaline O
phosphatase O
, O
513 O
u/l O
( O
0-270 O
u/l) O
; O
gamma-glutamyltransferase O
, O
32 O
u/l O
( O
7-49 O
u/l) O
; O
amylase O
, O
46 O
u/l O
( O
0-220 O
u/l) O
; O
total O
bilirubin O
, O
20.1 O
mg/dl O
( O
0.2-1.0 O
mg/dl) O
; O
direct O
bilirubin O
, O
14.8 O
mg/dl O
( O
0-0.3 O
mg/dl) O
; O
and O
albumin O
, O
4.7 O
mg/dl O
( O
3.5-5.4 O
mg/dl) O
. O

no O
toxin O
, O
alcohol O
, O
or O
other O
drugs O
were O
reported O
. O

the O
patient O
had O
suffered O
a O
previous O
episode O
of O
acute O
hepatitis B-NEG
of O
unknown O
origin O
, O
that O
occurred O
after O
telithromycin O
usage O
. O

both O
incidents O
occurred O
within O
a O
year O
. O

discussion O
: O
telithromycin O
is O
the O
first O
of O
the O
ketolide O
antibacterials O
to O
receive O
us O
food O
and O
drug O
administration O
approval O
for O
clinical O
use O
. O

it O
has O
been O
associated O
with O
infrequent O
and O
usually O
reversible O
severe O
hepatic B-NEG
dysfunction I-NEG
. O

based O
on O
a O
score O
of O
8 O
on O
the O
naranjo O
adverse B-NEG
drug I-NEG
reaction I-NEG
probability O
scale O
, O
telithromycin O
was O
the O
probable O
cause O
of O
acute O
hepatitis B-NEG
in O
this O
patient O
, O
and O
pathological O
findings O
suggested O
drug-induced O
toxic B-NEG
hepatitis I-NEG
. O

recurrence O
of O
hepatitis B-NEG
attack O
might O
have O
been O
avoided O
if O
the O
initial O
incident O
had O
been O
communicated O
to O
the O
attending O
physician O
who O
prescribed O
telithromycin O
the O
second O
time O
. O

conclusion O
: O
here O
we O
report O
a O
case O
of O
acute O
hepatitis B-NEG
probably O
associated O
with O
the O
administration O
of O
telithromycin O
. O

-DOCSTART- O

spironolactone-induced O
renal B-NEG
insufficiency I-NEG
and O
hyperkalemia B-NEG
in O
patients O
with O
heart B-NEG
failure I-NEG
. O

background O
: O
a O
previous O
randomized O
controlled O
trial O
evaluating O
the O
use O
of O
spironolactone O
in O
heart B-NEG
failure I-NEG
patients O
reported O
a O
low O
risk O
of O
hyperkalemia B-NEG
( O
2% O
) O
and O
renal B-NEG
insufficiency I-NEG
(0%) O
. O

because O
treatments O
for O
heart B-NEG
failure I-NEG
have O
changed O
since O
the O
benefits O
of O
spironolactone O
were O
reported O
, O
the O
prevalence O
of O
these O
complications O
may O
differ O
in O
current O
clinical O
practice O
. O

we O
therefore O
sought O
to O
determine O
the O
prevalence O
and O
clinical O
associations O
of O
hyperkalemia B-NEG
and O
renal B-NEG
insufficiency I-NEG
in O
heart B-NEG
failure I-NEG
patients O
treated O
with O
spironolactone O
. O

methods O
: O
we O
performed O
a O
case O
control O
study O
of O
heart B-NEG
failure I-NEG
patients O
treated O
with O
spironolactone O
in O
our O
clinical O
practice O
. O

cases O
were O
patients O
who O
developed O
hyperkalemia B-NEG
( O
k(+ O
) O
>5.0 O
meq/l O
) O
or O
renal B-NEG
insufficiency I-NEG
( O
cr O
>or=2.5 O
mg/dl) O
, O
and O
they O
were O
compared O
to O
2 O
randomly O
selected O
controls O
per O
case O
. O

clinical O
characteristics O
, O
medications O
, O
and O
serum O
chemistries O
at O
baseline O
and O
follow-up O
time O
periods O
were O
compared O
. O

results O
: O
sixty-seven O
of O
926 O
patients O
( O
7.2% O
) O
required O
discontinuation O
of O
spironolactone O
due O
to O
hyperkalemia B-NEG
(n O
= O
33 O
) O
or O
renal B-NEG
failure I-NEG
(n O
= O
34) O
. O

patients O
who O
developed O
hyperkalemia B-NEG
were O
older O
and O
more O
likely O
to O
have O
diabetes B-NEG
, O
had O
higher O
baseline O
serum O
potassium O
levels O
and O
lower O
baseline O
potassium O
supplement O
doses O
, O
and O
were O
more O
likely O
to O
be O
treated O
with O
beta-blockers O
than O
controls O
(n O
= O
134) O
. O

patients O
who O
developed O
renal B-NEG
insufficiency I-NEG
had O
lower O
baseline O
body O
weight O
and O
higher O
baseline O
serum O
creatinine O
, O
required O
higher O
doses O
of O
loop O
diuretics O
, O
and O
were O
more O
likely O
to O
be O
treated O
with O
thiazide O
diuretics O
than O
controls O
. O

conclusions O
: O
spironolactone-induced O
hyperkalemia B-NEG
and O
renal B-NEG
insufficiency I-NEG
are O
more O
common O
in O
our O
clinical O
experience O
than O
reported O
previously O
. O

this O
difference O
is O
explained O
by O
patient O
comorbidities O
and O
more O
frequent O
use O
of O
beta-blockers O
. O

-DOCSTART- O

end-stage B-NEG
renal I-NEG
disease I-NEG
( O
esrd B-NEG
) O
after O
orthotopic O
liver O
transplantation O
( O
oltx O
) O
using O
calcineurin-based O
immunotherapy O
: O
risk O
of O
development O
and O
treatment O
. O

background O
: O
the O
calcineurin O
inhibitors O
cyclosporine O
and O
tacrolimus O
are O
both O
known O
to O
be O
nephrotoxic B-NEG
. O

their O
use O
in O
orthotopic O
liver O
transplantation O
( O
oltx O
) O
has O
dramatically O
improved O
success O
rates O
. O

recently O
, O
however O
, O
we O
have O
had O
an O
increase O
of O
patients O
who O
are O
presenting O
after O
oltx O
with O
end-stage B-NEG
renal I-NEG
disease I-NEG
( O
esrd B-NEG
). O

this O
retrospective O
study O
examines O
the O
incidence O
and O
treatment O
of O
esrd B-NEG
and O
chronic B-NEG
renal I-NEG
failure I-NEG
( O
crf B-NEG
) O
in O
oltx O
patients O
. O

methods O
: O
patients O
receiving O
an O
oltx O
only O
from O
june O
1985 O
through O
december O
of O
1994 O
who O
survived O
6 O
months O
postoperatively O
were O
studied O
(n=834) O
. O

our O
prospectively O
collected O
database O
was O
the O
source O
of O
information O
. O

patients O
were O
divided O
into O
three O
groups O
: O
controls O
, O
no O
crf B-NEG
or O
esrd B-NEG
, O
n=748 O
; O
crf B-NEG
, O
sustained O
serum O
creatinine O
>2.5 O
mg/dl O
, O
n=41 O
; O
and O
esrd B-NEG
, O
n=45 O
. O

groups O
were O
compared O
for O
preoperative O
laboratory O
variables O
, O
diagnosis O
, O
postoperative O
variables O
, O
survival O
, O
type O
of O
esrd B-NEG
therapy O
, O
and O
survival O
from O
onset O
of O
esrd B-NEG
. O

results O
: O
at O
13 O
years O
after O
oltx O
, O
the O
incidence O
of O
severe O
renal B-NEG
dysfunction I-NEG
was O
18.1% O
( O
crf B-NEG
8.6% O
and O
esrd B-NEG
9.5%) O
. O

compared O
with O
control O
patients O
, O
crf B-NEG
and O
esrd B-NEG
patients O
had O
higher O
preoperative O
serum O
creatinine O
levels O
, O
a O
greater O
percentage O
of O
patients O
with O
hepatorenal B-NEG
syndrome I-NEG
, O
higher O
percentage O
requirement O
for O
dialysis O
in O
the O
first O
3 O
months O
postoperatively O
, O
and O
a O
higher O
1-year O
serum O
creatinine O
. O

multivariate O
stepwise O
logistic O
regression O
analysis O
using O
preoperative O
and O
postoperative O
variables O
identified O
that O
an O
increase O
of O
serum O
creatinine O
compared O
with O
average O
at O
1 O
year O
, O
3 O
months O
, O
and O
4 O
weeks O
postoperatively O
were O
independent O
risk O
factors O
for O
the O
development O
of O
crf B-NEG
or O
esrd B-NEG
with O
odds O
ratios O
of O
2.6 O
, O
2.2 O
, O
and O
1.6 O
, O
respectively O
. O

overall O
survival O
from O
the O
time O
of O
oltx O
was O
not O
significantly O
different O
among O
groups O
, O
but O
by O
year O
13 O
, O
the O
survival O
of O
the O
patients O
who O
had O
esrd B-NEG
was O
only O
28.2% O
compared O
with O
54.6% O
in O
the O
control O
group O
. O

patients O
developing O
esrd B-NEG
had O
a O
6-year O
survival O
after O
onset O
of O
esrd B-NEG
of O
27% O
for O
the O
patients O
receiving O
hemodialysis O
versus O
71.4% O
for O
the O
patients O
developing O
esrd B-NEG
who O
subsequently O
received O
kidney O
transplants O
. O

conclusions O
: O
patients O
who O
are O
more O
than O
10 O
years O
post-oltx O
have O
crf B-NEG
and O
esrd B-NEG
at O
a O
high O
rate O
. O

the O
development O
of O
esrd B-NEG
decreases O
survival O
, O
particularly O
in O
those O
patients O
treated O
with O
dialysis O
only O
. O

patients O
who O
develop O
esrd B-NEG
have O
a O
higher O
preoperative O
and O
1-year O
serum O
creatinine O
and O
are O
more O
likely O
to O
have O
hepatorenal B-NEG
syndrome I-NEG
. O

however O
, O
an O
increase O
of O
serum O
creatinine O
at O
various O
times O
postoperatively O
is O
more O
predictive O
of O
the O
development O
of O
crf B-NEG
or O
esrd B-NEG
. O

new O
strategies O
for O
long-term O
immunosuppression O
may O
be O
needed O
to O
decrease O
this O
complication O
. O

-DOCSTART- O

effect O
of O
intravenous O
nimodipine O
on O
blood O
pressure O
and O
outcome O
after O
acute B-NEG
stroke I-NEG
. O

background O
and O
purpose O
: O
the O
intravenous O
nimodipine O
west O
european O
stroke B-NEG
trial O
( O
inwest O
) O
found O
a O
correlation O
between O
nimodipine-induced O
reduction B-NEG
in I-NEG
blood I-NEG
pressure I-NEG
( O
bp O
) O
and O
an O
unfavorable O
outcome O
in O
acute B-NEG
stroke I-NEG
. O

we O
sought O
to O
confirm O
this O
correlation O
with O
and O
without O
adjustment O
for O
prognostic O
variables O
and O
to O
investigate O
outcome O
in O
subgroups O
with O
increasing O
levels O
of O
bp B-NEG
reduction I-NEG
. O

methods O
: O
patients O
with O
a O
clinical O
diagnosis O
of O
ischemic B-NEG
stroke I-NEG
( O
within O
24 O
hours O
) O
were O
consecutively O
allocated O
to O
receive O
placebo O
(n=100) O
, O
1 O
mg/h O
( O
low-dose O
) O
nimodipine O
(n=101) O
, O
or O
2 O
mg/h O
( O
high-dose O
) O
nimodipine O
(n=94) O
. O

the O
correlation O
between O
average O
bp O
change O
during O
the O
first O
2 O
days O
and O
the O
outcome O
at O
day O
21 O
was O
analyzed O
. O

results O
: O
two O
hundred O
sixty-five O
patients O
were O
included O
in O
this O
analysis O
(n=92 O
, O
93 O
, O
and O
80 O
for O
placebo O
, O
low O
dose O
, O
and O
high O
dose O
, O
respectively) O
. O

nimodipine O
treatment O
resulted O
in O
a O
statistically O
significant O
reduction B-NEG
in I-NEG
systolic I-NEG
bp I-NEG
( O
sbp O
) O
and O
diastolic O
bp O
( O
dbp O
) O
from O
baseline O
compared O
with O
placebo O
during O
the O
first O
few O
days O
. O

in O
multivariate O
analysis O
, O
a O
significant O
correlation O
between O
dbp B-NEG
reduction I-NEG
and O
worsening O
of O
the O
neurological O
score O
was O
found O
for O
the O
high-dose O
group O
(beta=0.49 O
, O
p=0 O
. O
048) O
. O

patients O
with O
a O
dbp B-NEG
reduction I-NEG
of O
> O
or O
=20% O
in O
the O
high-dose O
group O
had O
a O
significantly O
increased O
adjusted O
or O
for O
the O
compound O
outcome O
variable O
death B-NEG
or O
dependency O
( O
barthel O
index O
<60 O
) O
(n/n=25/26 O
, O
or O
10 O
. O
16 O
, O
95% O
ci O
1.02 O
to O
101.74 O
) O
and O
death B-NEG
alone O
(n/n=9/26 O
, O
or O
4.336 O
, O
95% O
ci O
1.131 O
16.619 O
) O
compared O
with O
all O
placebo O
patients O
( O
n/n=62/92 O
and O
14/92 O
, O
respectively) O
. O

there O
was O
no O
correlation O
between O
sbp O
change O
and O
outcome O
. O

conclusions O
: O
dbp O
, O
but O
not O
sbp O
, O
reduction O
was O
associated O
with O
neurological O
worsening O
after O
the O
intravenous O
administration O
of O
high-dose O
nimodipine O
after O
acute B-NEG
stroke I-NEG
. O

for O
low-dose O
nimodipine O
, O
the O
results O
were O
not O
conclusive O
. O

these O
results O
do O
not O
confirm O
or O
exclude O
a O
neuroprotective O
property O
of O
nimodipine O
. O

-DOCSTART- O

transient B-NEG
neurologic I-NEG
symptoms I-NEG
after O
spinal O
anesthesia O
: O
a O
lower O
incidence O
with O
prilocaine O
and O
bupivacaine O
than O
with O
lidocaine O
. O

background O
: O
recent O
evidence O
suggests O
that O
transient B-NEG
neurologic I-NEG
symptoms I-NEG
( O
tnss B-NEG
) O
frequently O
follow O
lidocaine O
spinal O
anesthesia O
but O
are O
infrequent O
with O
bupivacaine O
. O

however O
, O
identification O
of O
a O
short-acting O
local O
anesthetic O
to O
substitute O
for O
lidocaine O
for O
brief O
surgical O
procedures O
remains O
an O
important O
goal O
. O

prilocaine O
is O
an O
amide O
local O
anesthetic O
with O
a O
duration O
of O
action O
similar O
to O
that O
of O
lidocaine O
. O

accordingly O
, O
the O
present O
, O
prospective O
double-blind O
study O
compares O
prilocaine O
with O
lidocaine O
and O
bupivacaine O
with O
respect O
to O
duration O
of O
action O
and O
relative O
risk O
of O
tnss B-NEG
. O

methods O
: O
ninety O
patients O
classified O
as O
american O
society O
of O
anesthesiologists O
physical O
status O
i O
or O
ii O
who O
were O
scheduled O
for O
short O
gynecologic O
procedures O
under O
spinal O
anesthesia O
were O
randomly O
allocated O
to O
receive O
2.5 O
ml O
2% O
lidocaine O
in O
7.5% O
glucose O
, O
2% O
prilocaine O
in O
7.5% O
glucose O
, O
or O
0.5% O
bupivacaine O
in O
7.5% O
glucose O
. O

all O
solutions O
were O
provided O
in O
blinded O
vials O
by O
the O
hospital O
pharmacy O
. O

details O
of O
spinal O
puncture O
, O
extension O
and O
regression O
of O
spinal O
block O
, O
and O
the O
times O
to O
reach O
discharge O
criteria O
were O
noted O
. O

in O
the O
evening O
of O
postoperative O
day O
1, O
patients O
were O
evaluated O
for O
tnss B-NEG
by O
a O
physician O
unaware O
of O
the O
drug O
administered O
and O
the O
details O
of O
the O
anesthetic O
procedure O
. O

results O
: O
nine O
of O
30 O
patients O
receiving O
lidocaine O
experienced O
tnss B-NEG
, O
1 O
of O
30 O
patients O
receiving O
prilocaine O
(p O
= O
0.03 O
) O
had O
them O
, O
and O
none O
of O
30 O
patients O
receiving O
bupivacaine O
had O
tnss B-NEG
. O

times O
to O
ambulate O
and O
to O
void O
were O
similar O
after O
lidocaine O
and O
prilocaine O
( O
150 O
vs O
. O
165 O
min O
and O
238 O
vs O
. O
253 O
min O
, O
respectively O
) O
but O
prolonged O
after O
bupivacaine O
( O
200 O
and O
299 O
min O
, O
respectively O
; O
p O
< O
0.05) O
. O

conclusions O
: O
prilocaine O
may O
be O
preferable O
to O
lidocaine O
for O
short O
surgical O
procedures O
because O
it O
has O
a O
similar O
duration O
of O
action O
but O
a O
lower O
incidence O
of O
tnss B-NEG
. O

-DOCSTART- O

the O
role O
of O
nicotine O
in O
smoking-related O
cardiovascular B-NEG
disease I-NEG
. O

nicotine O
activates O
the O
sympathetic O
nervous O
system O
and O
in O
this O
way O
could O
contribute O
to O
cardiovascular B-NEG
disease I-NEG
. O

animal O
studies O
and O
mechanistic O
studies O
indicate O
that O
nicotine O
could O
play O
a O
role O
in O
accelerating O
atherosclerosis B-NEG
, O
but O
evidence O
among O
humans O
is O
too O
inadequate O
to O
be O
definitive O
about O
such O
an O
effect O
. O

almost O
certainly O
, O
nicotine O
via O
its O
hemodynamic O
effects O
contributes O
to O
acute O
cardiovascular O
events O
, O
although O
current O
evidence O
suggests O
that O
the O
effects O
of O
nicotine O
are O
much O
less O
important O
than O
are O
the O
prothrombotic O
effects O
of O
cigarette O
smoking O
or O
the O
effects O
of O
carbon O
monoxide O
. O

nicotine O
does O
not O
appear O
to O
enhance O
thrombosis B-NEG
among O
humans O
. O

clinical O
studies O
of O
pipe O
smokers O
and O
people O
using O
transdermal O
nicotine O
support O
the O
idea O
that O
toxins O
other O
than O
nicotine O
are O
the O
most O
important O
causes O
of O
acute O
cardiovascular O
events O
. O

finally O
, O
the O
dose O
response O
for O
cardiovascular O
events O
of O
nicotine O
appears O
to O
be O
flat O
, O
suggesting O
that O
if O
nicotine O
is O
involved O
, O
adverse O
effects O
might O
be O
seen O
with O
relatively O
low-level O
cigarette O
exposures O
. O

-DOCSTART- O

seizure B-NEG
resulting O
from O
a O
venlafaxine O
overdose B-NEG
. O

objective O
: O
to O
report O
a O
case O
of O
venlafaxine O
overdose B-NEG
. O

case O
summary O
: O
a O
40-year-old O
woman O
with O
major B-NEG
depression I-NEG
took O
an O
overdose B-NEG
of O
venlafaxine O
in O
an O
apparent O
suicide O
attempt O
. O

after O
the O
ingestion O
of O
26 O
venlafaxine O
50-mg O
tablets O
, O
the O
patient O
experienced O
a O
witnessed O
generalized O
seizure B-NEG
. O

she O
was O
admitted O
to O
the O
medical O
intensive O
care O
unit O
, O
venlafaxine O
was O
discontinued O
, O
and O
no O
further O
sequelae O
were O
seen O
. O

discussion O
: O
to O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
venlafaxine O
overdose B-NEG
that O
resulted O
in O
a O
generalized O
seizure B-NEG
. O

based O
on O
nonoverdose O
pharmacokinetics O
and O
pharmacodynamics O
of O
venlafaxine O
and O
the O
potential O
risks O
of O
available O
interventions O
, O
no O
emergent O
therapy O
was O
instituted O
. O

conclusions O
: O
the O
venlafaxine O
overdose B-NEG
in O
our O
patient O
resulted O
in O
a O
single O
episode O
of O
generalized O
seizure B-NEG
but O
elicited O
no O
further O
sequelae O
. O

-DOCSTART- O

effect O
of O
nifedipine O
on O
renal O
function O
in O
liver O
transplant O
recipients O
receiving O
tacrolimus O
. O

the O
effect O
of O
nifedipine O
on O
renal O
function O
in O
liver O
transplant O
recipients O
who O
were O
receiving O
tacrolimus O
was O
evaluated O
between O
january O
1992 O
and O
january O
1996 O
. O

two O
groups O
of O
patients O
receiving O
tacrolimus O
were O
compared O
over O
a O
period O
of O
1 O
year O
, O
one O
group O
comprising O
hypertensive B-NEG
patients O
who O
were O
receiving O
nifedipine O
, O
and O
the O
other O
comprising O
nonhypertensive O
patients O
not O
receiving O
nifedipine O
. O

the O
time O
from O
transplant O
to O
baseline O
was O
similar O
in O
all O
patients O
. O

nifedipine O
significantly O
improved O
kidney O
function O
as O
indicated O
by O
a O
significant O
lowering O
of O
serum O
creatinine O
levels O
at O
6 O
and O
12 O
months O
. O

the O
observed O
positive O
impact O
of O
nifedipine O
on O
reducing O
the O
nephrotoxicity B-NEG
associated O
with O
tacrolimus O
in O
liver O
transplant O
recipients O
should O
be O
an O
important O
factor O
in O
selecting O
an O
agent O
to O
treat O
hypertension B-NEG
in O
this O
population O
. O

-DOCSTART- O

sinus B-NEG
arrest I-NEG
associated O
with O
continuous-infusion O
cimetidine O
. O

the O
administration O
of O
intermittent O
intravenous O
infusions O
of O
cimetidine O
is O
infrequently O
associated O
with O
the O
development O
of O
bradyarrhythmias B-NEG
. O

a O
40-year-old O
man O
with O
leukemia B-NEG
and O
no O
history O
of O
cardiac B-NEG
disease I-NEG
developed O
recurrent O
, O
brief O
episodes O
of O
apparent O
sinus B-NEG
arrest I-NEG
while O
receiving O
continuous-infusion O
cimetidine O
50 O
mg/hour O
. O

the O
arrhythmias B-NEG
were O
temporally O
related O
to O
cimetidine O
administration O
, O
disappeared O
after O
dechallenge O
, O
and O
did O
not O
recur O
during O
ranitidine O
treatment O
. O

this O
is O
the O
first O
reported O
case O
of O
sinus B-NEG
arrest I-NEG
associated O
with O
continuous-infusion O
cimetidine O
. O

-DOCSTART- O

composition O
of O
gall B-NEG
bladder I-NEG
stones I-NEG
associated O
with O
octreotide O
: O
response O
to O
oral O
ursodeoxycholic O
acid O
. O

octreotide O
, O
an O
effective O
treatment O
for O
acromegaly B-NEG
, O
induces O
gall B-NEG
bladder I-NEG
stones I-NEG
in O
13-60% O
of O
patients O
. O

because O
knowledge O
of O
stone O
composition O
is O
essential O
for O
studies O
of O
their O
pathogenesis O
, O
treatment O
, O
and O
prevention O
, O
this O
was O
investigated O
by O
direct O
and O
indirect O
methods O
in O
14 O
octreotide O
treated O
acromegalic B-NEG
patients O
with O
gall B-NEG
stones I-NEG
. O

chemical O
analysis O
of O
gall B-NEG
stones I-NEG
retrieved O
at O
cholecystectomy O
from O
two O
patients O
, O
showed O
that O
they O
contained O
71% O
and O
87% O
cholesterol O
by O
weight O
. O

in O
the O
remaining O
12 O
patients O
, O
localised O
computed O
tomography O
of O
the O
gall O
bladder O
showed O
that O
eight O
had O
stones O
with O
maximum O
attenuation O
scores O
of O
< O
100 O
hounsfield O
units O
( O
values O
of O
< O
100 O
hu O
predict O
cholesterol O
rich O
, O
dissolvable O
stones) O
. O

gall O
bladder O
bile O
was O
obtained O
by O
ultrasound O
guided O
, O
fine O
needle O
puncture O
from O
six O
patients O
. O

all O
six O
patients O
had O
supersaturated O
bile O
( O
mean O
( O
sem O
) O
cholesterol O
saturation O
index O
of O
1.19 O
( O
0.08 O
) O
( O
range O
1.01-1.53) O
) O
and O
all O
had O
abnormally O
rapid O
cholesterol O
microcrystal O
nucleation O
times O
(< O
4 O
days O
( O
range O
1-4)) O
, O
whilst O
in O
four O
, O
the O
bile O
contained O
cholesterol O
microcrystals O
immediately O
after O
sampling O
. O

of O
the O
12 O
patients O
considered O
for O
oral O
ursodeoxycholic O
acid O
( O
udca O
) O
treatment O
, O
two O
had O
a O
blocked O
cystic O
duct O
and O
were O
not O
started O
on O
udca O
while O
one O
was O
lost O
to O
follow O
up O
. O

after O
one O
year O
of O
treatment O
, O
five O
of O
the O
remaining O
nine O
patients O
showed O
either O
partial O
(n O
= O
3) O
or O
complete O
(n O
= O
2) O
gall B-NEG
stone I-NEG
dissolution O
, O
suggesting O
that O
their O
stones O
were O
cholesterol O
rich O
. O

this O
corresponds O
, O
by O
actuarial O
( O
life O
table O
) O
analysis O
, O
to O
a O
combined O
gall B-NEG
stone I-NEG
dissolution O
rate O
of O
58.3 O
(15.9%) O
. O

in O
conclusion O
, O
octreotide O
induced O
gall B-NEG
stones I-NEG
are O
generally O
small O
, O
multiple O
, O
and O
cholesterol O
rich O
although O
, O
in O
common O
with O
spontaneous O
gall B-NEG
stone I-NEG
disease I-NEG
, O
at O
presentation O
some O
patients O
will O
have O
a O
blocked O
cystic O
duct O
and O
some O
gall B-NEG
stones I-NEG
containing O
calcium O
. O

-DOCSTART- O

cardiovascular B-NEG
complications I-NEG
associated O
with O
terbutaline O
treatment O
for O
preterm B-NEG
labor I-NEG
. O

severe O
cardiovascular B-NEG
complications I-NEG
occurred O
in O
eight O
of O
160 O
patients O
treated O
with O
terbutaline O
for O
preterm B-NEG
labor I-NEG
. O

associated O
corticosteroid O
therapy O
and O
twin O
gestations O
appear O
to O
be O
predisposing O
factors O
. O

potential O
mechanisms O
of O
the O
pathophysiology O
are O
briefly O
discussed O
. O

-DOCSTART- O

neurologic O
effects O
of O
subarachnoid O
administration O
of O
2-chloroprocaine-ce O
, O
bupivacaine O
, O
and O
low O
ph O
normal O
saline O
in O
dogs O
. O

the O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
neurologic O
consequences O
of O
deliberate O
subarachnoid O
injection O
of O
large O
volumes O
of O
2-chloroprocaine-ce O
in O
experimental O
animals O
. O

the O
possible O
role O
of O
low O
ph O
as O
well O
as O
total O
volume O
as O
potential O
factors O
in O
causing O
neurotoxicity B-NEG
was O
evaluated O
. O

the O
65 O
dogs O
in O
the O
study O
received O
injections O
in O
the O
subarachnoid O
space O
as O
follows O
: O
6 O
to O
8 O
ml O
of O
bupivacaine O
(n O
= O
15) O
, O
2-chloroprocaine-ce O
(n O
= O
20) O
, O
low O
ph O
normal O
saline O
( O
ph O
3.0 O
) O
(n O
= O
20) O
, O
or O
normal O
saline O
(n O
= O
10) O
. O

of O
the O
20 O
animals O
that O
received O
subarachnoid O
injection O
of O
2-chloroprocaine-ce O
seven O
( O
35% O
) O
developed O
hind-limb O
paralysis B-NEG
. O

none O
of O
the O
animals O
that O
received O
bupivacaine O
, O
normal O
saline O
, O
or O
normal O
saline O
titrated O
to O
a O
ph O
3.0 O
developed O
hind-limb O
paralysis B-NEG
. O

of O
the O
15 O
spinal O
cords O
of O
the O
animals O
that O
received O
2-chloroprocaine-ce O
, O
13 O
showed O
subpial B-NEG
necrosis I-NEG
; O
the O
nerve O
roots O
and O
subarachnoid O
vessels O
were O
normal O
. O

the O
spinal O
cords O
of O
the O
animals O
that O
received O
bupivacaine O
, O
low O
ph O
normal O
saline O
( O
ph O
3.0) O
, O
or O
normal O
saline O
did O
not O
show O
abnormal O
findings O
. O

-DOCSTART- O

early O
adjuvant O
adriamycin O
in O
superficial O
bladder B-NEG
carcinoma I-NEG
. O

a O
multicenter O
study O
was O
performed O
in O
110 O
patients O
with O
superficial O
transitional O
cell O
carcinoma B-NEG
of I-NEG
the I-NEG
bladder I-NEG
. O

adriamycin O
( O
50 O
mg/50 O
ml O
) O
was O
administered O
intravesically O
within O
24 O
h O
after O
transurethral O
resection O
of O
ta-t1 O
( O
o-a O
) O
bladder B-NEG
tumors I-NEG
. O

instillation O
was O
repeated O
twice O
during O
the O
first O
week O
, O
then O
weekly O
during O
the O
first O
month O
and O
afterwards O
monthly O
for O
1 O
year O
. O

the O
tolerance O
was O
evaluated O
in O
these O
110 O
patients O
, O
and O
29 O
patients O
presented O
with O
local O
side-effects O
. O

in O
24 O
of O
these O
patients O
chemical O
cystitis B-NEG
was O
severe O
enough O
for O
them O
to O
drop O
out O
of O
the O
study O
. O

no O
systemic O
side-effects O
were O
observed O
. O

recurrence O
was O
studied O
in O
82 O
evaluable O
patients O
after O
1 O
year O
of O
follow-up O
and O
in O
72 O
patients O
followed O
for O
2-3 O
years O
( O
mean O
32 O
months) O
. O

of O
the O
82 O
patients O
studied O
after O
1 O
year O
, O
23 O
had O
primary O
and O
59 O
recurrent O
disease O
. O

of O
the O
82 O
evaluable O
patients O
, O
50 O
did O
not O
show O
any O
recurrence O
after O
1 O
year O
(61%) O
, O
while O
32 O
presented O
with O
one O
or O
more O
recurrences O
(39%) O
. O

of O
these O
recurrences O
, O
27 O
were O
t1 O
tumors B-NEG
while O
five O
progressed O
to O
more O
highly O
invasive O
lesions O
. O

in O
patients O
that O
were O
free O
of O
recurrence O
during O
the O
first O
year O
, O
80% O
remained O
tumor B-NEG
-free O
during O
the O
2- O
to O
3-year O
follow-up O
period O
. O

of O
the O
patients O
developing O
one O
or O
more O
recurrences O
during O
the O
first O
year O
, O
only O
50% O
presented O
with O
further O
recurrence O
once O
the O
instillations O
were O
stopped O
. O

the O
beneficial O
effect O
of O
adriamycin O
appears O
obvious O
and O
might O
be O
related O
to O
the O
drug O
itself O
, O
the O
early O
and O
repeated O
instillations O
after O
tur O
, O
or O
both O
. O

-DOCSTART- O

hyperkalemia B-NEG
associated O
with O
sulindac O
therapy O
. O
hyperkalemia B-NEG
has O
recently O
been O
recognized O
as O
a O
complication O
of O
nonsteroidal O
antiinflammatory O
agents O
( O
nsaid O
) O
such O
as O
indomethacin O
. O

several O
recent O
studies O
have O
stressed O
the O
renal O
sparing O
features O
of O
sulindac O
, O
owing O
to O
its O
lack O
of O
interference O
with O
renal O
prostacyclin O
synthesis O
. O

we O
describe O
4 O
patients O
in O
whom O
hyperkalemia B-NEG
ranging O
from O
6.1 O
to O
6.9 O
meq/l O
developed O
within O
3 O
to O
8 O
days O
of O
sulindac O
administration O
. O

in O
all O
of O
them O
normal O
serum O
potassium O
levels O
reached O
within O
2 O
to O
4 O
days O
of O
stopping O
sulindac O
. O

as O
no O
other O
medications O
known O
to O
effect O
serum O
potassium O
had O
been O
given O
concomitantly O
, O
this O
course O
of O
events O
is O
suggestive O
of O
a O
cause-and-effect O
relationship O
between O
sulindac O
and O
hyperkalemia B-NEG
. O

these O
observations O
indicate O
that O
initial O
hopes O
that O
sulindac O
may O
not O
be O
associated O
with O
the O
adverse O
renal O
effects O
of O
other O
nsaid O
are O
probably O
not O
justified O
. O

-DOCSTART- O

ventricular B-NEG
tachyarrhythmias I-NEG
during O
cesarean O
section O
after O
ritodrine O
therapy O
: O
interaction O
with O
anesthetics O
. O

this O
case O
illustrates O
that O
patients O
receiving O
ritodrine O
for O
preterm B-NEG
labor I-NEG
may O
risk O
interactions O
between O
the O
residual O
betamimetic O
effects O
of O
ritodrine O
and O
the O
effects O
of O
anesthetics O
during O
cesarean O
section O
. O

such O
interactions O
may O
result O
in O
serious O
cardiovascular B-NEG
complications I-NEG
even O
after O
cessation O
of O
an O
infusion O
of O
ritodrine O
. O

preoperative O
assessment O
should O
focus O
on O
cardiovascular O
status O
and O
serum O
potassium O
level O
. O

delaying O
induction O
of O
anesthesia O
should O
be O
considered O
whenever O
possible O
. O

careful O
fluid O
administration O
and O
cautious O
use O
of O
titrated O
doses O
of O
ephedrine O
are O
advised O
. O

after O
delivery O
of O
the O
infant O
, O
there O
should O
be O
no O
contraindication O
to O
the O
use O
of O
an O
alpha-adrenergic O
vasopressor O
such O
as O
phenylephrine O
to O
treat O
hypotensive B-NEG
patients O
with O
tachycardia B-NEG
. O

-DOCSTART- O

immunohistochemical O
, O
electron O
microscopic O
and O
morphometric O
studies O
of O
estrogen-induced O
rat O
prolactinomas B-NEG
after O
bromocriptine O
treatment O
. O

to O
clarify O
the O
effects O
of O
bromocriptine O
on O
prolactinoma B-NEG
cells O
in O
vivo O
, O
immunohistochemical O
, O
ultrastructural O
and O
morphometrical O
analyses O
were O
applied O
to O
estrogen-induced O
rat O
prolactinoma B-NEG
cells O
1 O
h O
and O
6 O
h O
after O
injection O
of O
bromocriptine O
(3 O
mg/kg O
of O
body O
weight) O
. O

one O
h O
after O
treatment O
, O
serum O
prolactin O
levels O
decreased O
markedly O
. O

electron O
microscopy O
disclosed O
many O
secretory O
granules O
, O
slightly O
distorted O
rough O
endoplasmic O
reticulum O
, O
and O
partially O
dilated O
golgi O
cisternae O
in O
the O
prolactinoma B-NEG
cells O
. O

morphometric O
analysis O
revealed O
that O
the O
volume O
density O
of O
secretory O
granules O
increased O
, O
while O
the O
volume O
density O
of O
cytoplasmic O
microtubules O
decreased O
. O

these O
findings O
suggest O
that O
lowered O
serum O
prolactin O
levels O
in O
the O
early O
phase O
of O
bromocriptine O
treatment O
may O
result O
from O
an O
impaired O
secretion O
of O
prolactin O
due O
to O
decreasing O
numbers O
of O
cytoplasmic O
microtubules O
. O

at O
6 O
h O
after O
injection O
, O
serum O
prolactin O
levels O
were O
still O
considerably O
lower O
than O
in O
controls O
. O

the O
prolactinoma B-NEG
cells O
at O
this O
time O
were O
well O
granulated O
, O
with O
vesiculated O
rough O
endoplasmic O
reticulum O
and O
markedly O
dilated O
golgi O
cisternae O
. O

electron O
microscopical O
immunohistochemistry O
revealed O
positive O
reaction O
products O
noted O
on O
the O
secretory O
granules O
, O
golgi O
cisternae O
, O
and O
endoplasmic O
reticulum O
of O
the O
untreated O
rat O
prolactinoma B-NEG
cells O
. O

however O
, O
only O
secretory O
granules O
showed O
the O
positive O
reaction O
products O
for O
prolactin O
6 O
h O
after O
bromocriptine O
treatment O
of O
the O
adenoma B-NEG
cells O
. O

an O
increase O
in O
the O
volume O
density O
of O
secretory O
granules O
and O
a O
decrease O
in O
the O
volume O
densities O
of O
rough O
endoplasmic O
reticulum O
and O
microtubules O
was O
determined O
by O
morphometric O
analysis O
, O
suggesting O
that O
bromocriptine O
inhibits O
protein O
synthesis O
as O
well O
as O
bringing O
about O
a O
disturbance O
of O
the O
prolactin O
secretion O
. O

-DOCSTART- O

on O
two O
paradoxical O
side-effects O
of O
prednisolone O
in O
rats O
, O
ribosomal O
rna O
biosyntheses O
, O
and O
a O
mechanism O
of O
action O
. O
liver B-NEG
enlargement I-NEG
and O
muscle B-NEG
wastage I-NEG
occurred O
in O
wistar O
rats O
following O
the O
subcutaneous O
administration O
of O
prednisolone O
. O

in O
the O
liver O
both O
the O
content O
of O
rna O
and O
the O
biosynthesis O
of O
ribosomal O
rna O
increased O
while O
both O
the O
rna O
content O
and O
ribosomal O
rna O
biosynthesis O
were O
reduced O
in O
the O
gastrocnemius O
muscle O
. O

it O
is O
suggested O
that O
the O
drug O
acted O
in O
a O
selective O
and O
tissue-specific O
manner O
to O
enhance O
ribosomal O
rna O
synthesis O
in O
the O
liver O
and O
depress O
such O
synthesis O
in O
the O
muscle O
. O

this O
view O
supports O
the O
contention O
that O
the O
liver O
and O
muscle O
are O
independent O
sites O
of O
prednisolone O
action O
. O

-DOCSTART- O

possible O
intramuscular O
midazolam-associated O
cardiorespiratory B-NEG
arrest I-NEG
and O
death B-NEG
. O

midazolam O
hydrochloride O
is O
commonly O
used O
for O
dental O
or O
endoscopic O
procedures O
. O

although O
generally O
consisted O
safe O
when O
given O
intramuscularly O
, O
intravenous O
administration O
is O
known O
to O
cause O
respiratory B-NEG
and I-NEG
cardiovascular I-NEG
depression I-NEG
. O

this O
report O
describes O
the O
first O
published O
case O
of O
cardiorespiratory B-NEG
arrest I-NEG
and O
death B-NEG
associated O
with O
intramuscular O
administration O
of O
midazolam O
. O

information O
regarding O
midazolam O
use O
is O
reviewed O
to O
provide O
recommendation O
for O
safe O
administration O
. O

-DOCSTART- O

serial O
epilepsy B-NEG
caused O
by O
levodopa/carbidopa O
administration O
in O
two O
patients O
on O
hemodialysis O
. O

two O
patients O
with O
similar O
clinical O
features O
are O
presented O
: O
both O
patients O
had O
chronic B-NEG
renal I-NEG
failure I-NEG
, O
on O
hemodialysis O
for O
many O
years O
but O
recently O
begun O
on O
a O
high-flux O
dialyzer O
; O
both O
had O
been O
receiving O
a O
carbidopa/levodopa O
preparation O
; O
and O
both O
had O
the O
onset O
of O
hallucinosis B-NEG
and O
recurrent O
seizures B-NEG
, O
which O
were O
refractory O
to O
anticonvulsants O
. O

the O
first O
patient O
died O
without O
a O
diagnosis O
; O
the O
second O
patient O
had O
a O
dramatic O
recovery O
following O
the O
administration O
of O
vitamin O
b6 O
. O

neither O
patient O
was O
considered O
to O
have O
a O
renal O
state O
sufficiently O
severe O
enough O
to O
explain O
their O
presentation O
. O

-DOCSTART- O

effect O
of O
l-alpha-glyceryl-phosphorylcholine O
on O
amnesia B-NEG
caused O
by O
scopolamine O
. O

the O
present O
study O
was O
carried O
out O
to O
test O
the O
effects O
of O
l-alpha-glycerylphosphorylcholine O
( O
l-alpha-gfc O
) O
on O
memory B-NEG
impairment I-NEG
induced O
by O
scopolamine O
in O
man O
. O

thirty-two O
healthy O
young O
volunteers O
were O
randomly O
allocated O
to O
four O
different O
groups O
. O

they O
were O
given O
a O
ten O
day O
pretreatment O
with O
either O
l-alpha-gfc O
or O
placebo O
, O
p.o. O
, O
and O
on O
the O
eleventh O
day O
either O
scopolamine O
or O
placebo O
, O
i.m O
. O

before O
and O
0.5 O
, O
1, O
2, O
3, O
and O
6 O
h O
after O
injection O
the O
subjects O
were O
given O
attention O
and O
mnemonic O
tests O
. O

the O
findings O
of O
this O
study O
indicate O
that O
the O
drug O
is O
able O
to O
antagonize O
impairment B-NEG
of I-NEG
attention I-NEG
and I-NEG
memory I-NEG
induced O
by O
scopolamine O
. O

-DOCSTART- O

seizures B-NEG
induced O
by O
the O
cocaine O
metabolite O
benzoylecgonine O
in O
rats O
. O

the O
half-life O
( O
t1/2 O
) O
of O
cocaine O
is O
relatively O
short O
, O
but O
some O
of O
the O
consequences O
of O
its O
use O
, O
such O
as O
seizures B-NEG
and O
strokes B-NEG
, O
can O
occur O
hours O
after O
exposure O
. O

this O
led O
us O
to O
hypothesize O
that O
a O
metabolite O
of O
cocaine O
may O
be O
responsible O
for O
some O
of O
those O
delayed O
sequelae O
. O

we O
evaluated O
the O
potential O
of O
the O
major O
metabolite O
of O
cocaine O
, O
benzoylecgonine O
(be) O
, O
to O
cause O
seizures B-NEG
. O

two O
separate O
equimolar O
doses O
( O
0.2 O
and O
0.4 O
mumol O
) O
of O
either O
cocaine O
or O
be O
were O
injected O
ventricularly O
in O
unanesthetized O
juvenile O
rats O
. O

treated O
rats O
were O
then O
evaluated O
for O
incidence O
, O
latency O
, O
and O
seizure B-NEG
pattern O
or O
for O
locomotor O
activity O
in O
animals O
without O
seizures B-NEG
. O

be-induced O
seizures B-NEG
occurred O
more O
frequently O
and O
had O
significantly O
longer O
latencies O
than O
those O
induced O
by O
equimolar O
amounts O
of O
cocaine O
. O

whereas O
cocaine-induced O
seizures B-NEG
were O
best O
characterized O
as O
brief O
, O
generalized O
, O
and O
tonic O
and O
resulted O
in O
death B-NEG
, O
those O
induced O
by O
be O
were O
prolonged O
, O
often O
multiple O
and O
mixed O
in O
type O
, O
and O
rarely O
resulted O
in O
death B-NEG
. O

electrical O
recordings O
from O
the O
hippocampus O
showed O
a O
rhythmic O
progression O
in O
eeg O
frequency O
and O
voltage O
with O
clinical O
seizure B-NEG
expression O
. O

be-injected O
rats O
that O
did O
not O
have O
seizures B-NEG
had O
significantly O
more O
locomotor O
activity O
than O
cocaine-injected O
animals O
without O
seizures B-NEG
. O

the O
finding O
that O
cocaine- O
and O
be-induced O
seizures B-NEG
differ O
in O
several O
respects O
suggests O
more O
than O
one O
mechanism O
for O
cocaine-induced O
seizures B-NEG
and O
emphasizes O
the O
importance O
of O
a O
cocaine O
metabolite O
, O
be O
. O

-DOCSTART- O

protection O
against O
amphetamine-induced O
neurotoxicity B-NEG
toward O
striatal O
dopamine O
neurons O
in O
rodents O
by O
ly274614 O
, O
an O
excitatory O
amino O
acid O
antagonist O
. O

ly274614 O
, O
3sr,4ars,6sr,8ars-6-[phosphonomethyl]decahydr O
oisoquinoline-3- O
carboxylic O
acid O
, O
has O
been O
described O
as O
a O
potent O
antagonist O
of O
the O
n-methyl-d-aspartate O
( O
nmda O
) O
subtype O
of O
glutamate O
receptor O
. O

here O
its O
ability O
to O
antagonize O
the O
prolonged O
depletion O
of O
dopamine O
in O
the O
striatum O
by O
amphetamine O
in O
iprindole-treated O
rats O
is O
reported O
. O

a O
single O
18.4 O
mg/kg O
( O
i.p. O
) O
dose O
of O
( O
+/-)-amphetamine O
hemisulfate O
, O
given O
to O
rats O
pretreated O
with O
iprindole O
, O
resulted O
in O
persistent O
depletion O
of O
dopamine O
in O
the O
striatum O
1 O
week O
later O
. O

this O
prolonged O
depletion O
of O
dopamine O
in O
the O
striatum O
was O
antagonized O
by O
dizocilpine O
(mk-801 O
, O
a O
non-competitive O
antagonist O
of O
nmda O
receptors O
) O
or O
by O
ly274614 O
(a O
competitive O
antagonist O
of O
nmda O
receptors) O
. O

the O
protective O
effect O
of O
ly274614 O
was O
dose-dependent O
, O
being O
maximum O
at O
10-40 O
mgkg O
(i.p.) O
. O

a O
10 O
mg/kg O
dose O
of O
ly274614 O
was O
effective O
in O
antagonizing O
the O
depletion O
of O
dopamine O
in O
the O
striatum O
, O
when O
given O
as O
long O
as O
8 O
hr O
prior O
to O
amphetamine O
but O
not O
when O
given O
24 O
hr O
prior O
to O
amphetamine O
. O

depletion O
of O
dopamine O
in O
the O
striatum O
was O
also O
antagonized O
when O
ly274614 O
was O
given O
after O
the O
injection O
of O
amphetamine O
; O
ly274614 O
protected O
when O
given O
up O
to O
4 O
hr O
after O
but O
not O
when O
given O
8 O
or O
24 O
hr O
after O
amphetamine O
. O

the O
prolonged O
depletion O
of O
dopamine O
in O
the O
striatum O
in O
mice O
, O
given O
multiple O
injections O
of O
methamphetamine O
, O
was O
also O
antagonized O
dose-dependently O
and O
completely O
by O
ly274614 O
. O

the O
data O
strengthen O
the O
evidence O
that O
the O
neurotoxic B-NEG
effect O
of O
amphetamine O
and O
related O
compounds O
toward O
nigrostriatal O
dopamine O
neurons O
involves O
nmda O
receptors O
and O
that O
ly274614 O
is O
an O
nmda O
receptor O
antagonist O
with O
long-lasting O
in O
vivo O
effects O
in O
rats O
. O

-DOCSTART- O

neonatal O
pyridoxine O
responsive O
convulsions B-NEG
due O
to O
isoniazid O
therapy O
. O

a O
17-day-old O
infant O
on O
isoniazid O
therapy O
13 O
mg/kg O
daily O
from O
birth O
because O
of O
maternal O
tuberculosis B-NEG
was O
admitted O
after O
4 O
days O
of O
clonic B-NEG
fits I-NEG
. O

no O
underlying O
infective O
or O
biochemical O
cause O
could O
be O
found O
. O

the O
fits B-NEG
ceased O
within O
4 O
hours O
of O
administering O
intramuscular O
pyridoxine O
, O
suggesting O
an O
aetiology O
of O
pyridoxine O
deficiency O
secondary O
to O
isoniazid O
medication O
. O

-DOCSTART- O

reversal O
by O
phenylephrine O
of O
the O
beneficial O
effects O
of O
intravenous O
nitroglycerin O
in O
patients O
with O
acute B-NEG
myocardial I-NEG
infarction I-NEG
. O

nitroglycerin O
has O
been O
shown O
to O
reduce O
st-segment O
elevation O
during O
acute B-NEG
myocardial I-NEG
infarction I-NEG
, O
an O
effect O
potentiated O
in O
the O
dog O
by O
agents O
that O
reverse O
nitroglycerin-induced O
hypotension B-NEG
. O

our O
study O
was O
designed O
to O
determine O
the O
effects O
of O
combined O
nitroglycerin O
and O
phenylephrine O
therapy O
. O

ten O
patients O
with O
acute O
transmural O
myocardial B-NEG
infarctions I-NEG
received O
intravenous O
nitroglycerin O
, O
sufficient O
to O
reduce O
mean O
arterial O
pressure O
from O
107 O
+/- O
6 O
to O
85 O
+/- O
6 O
mm O
hg O
(p O
less O
than O
0.001) O
, O
for O
60 O
minutes O
. O

left O
ventricular O
filling O
pressure O
decreased O
from O
19 O
+/- O
2 O
to O
11 O
+/- O
2 O
mm O
hg O
(p O
less O
than O
0.001) O
. O

sigmast O
, O
the O
sum O
of O
st-segment O
elevations O
in O
16 O
precordial O
leads O
, O
decreased O
(p O
less O
than O
0.02 O
) O
with O
intravenous O
nitroglycerin O
. O

subsequent O
addition O
of O
phenylephrine O
infusion O
, O
sufficient O
to O
re-elevate O
mean O
arterial O
pressure O
to O
106 O
+/- O
4 O
mm O
hg O
(p O
less O
than O
0.001 O
) O
for O
30 O
minutes O
, O
increased O
left O
ventricular O
filling O
pressure O
to O
17 O
+/- O
2 O
mm O
hg O
(p O
less O
than O
0.05 O
) O
and O
also O
significantly O
increased O
sigmast O
(p O
less O
than O
0.05) O
. O

our O
results O
suggest O
that O
addition O
of O
phenylephrine O
to O
nitroglycerin O
is O
not O
beneficial O
in O
the O
treatment O
of O
patients O
with O
acute B-NEG
myocardial I-NEG
infarction I-NEG
. O

-DOCSTART- O

elevation O
of O
adam10 O
, O
adam17 O
, O
mmp-2 O
and O
mmp-9 O
expression O
with O
media O
degeneration O
features O
cacl2-induced O
thoracic B-NEG
aortic I-NEG
aneurysm I-NEG
in O
a O
rat O
model O
. O

purpose O
: O
this O
study O
was O
designed O
to O
establish O
a O
rat O
model O
of O
thoracic B-NEG
aortic I-NEG
aneurysm I-NEG
( O
taa B-NEG
) O
by O
calcium O
chloride O
( O
cacl(2))-induced O
arterial B-NEG
injury I-NEG
and O
to O
explore O
the O
potential O
role O
of O
a O
disintegrin O
and O
metalloproteinase O
(adam) O
, O
matrix O
metalloproteinases O
( O
mmps O
) O
and O
their O
endogenous O
inhibitors O
( O
timps O
) O
in O
taa B-NEG
formation O
. O

methods O
: O
thoracic O
aorta O
of O
male O
sprague-dawley O
rats O
was O
exposed O
to O
0.5m O
cacl(2 O
) O
or O
normal O
saline O
(nacl) O
. O

after O
12weeks O
, O
animals O
were O
euthanized O
, O
and O
cacl(2)-treated O
, O
cacl(2)-untreated O
( O
n=12 O
) O
and O
nacl-treated O
aortic O
segments O
( O
n=12 O
) O
were O
collected O
for O
histological O
and O
molecular O
assessments O
. O

mmp-timp O
and O
adam O
mrnas O
were O
semi-quantitatively O
analyzed O
and O
protein O
expressions O
were O
determined O
by O
immunohistochemistry O
. O

results O
: O
despite O
similar O
external O
diameters O
among O
cacl(2)-treated O
, O
non-cacl(2)-treated O
and O
nacl-treated O
segments O
, O
aneurymal O
alteration O
(n=6 O
, O
50%) O
, O
media O
degeneration O
with O
regional O
disruption O
, O
fragmentation O
of O
elastic O
fiber O
, O
and O
increased O
collagen O
deposition O
(n=12 O
, O
100% O
) O
were O
demonstrated O
in O
cacl(2)-treated O
segments O
. O

mmp-2 O
, O
mmp-9 O
, O
adam-10 O
and O
adam-17 O
mrna O
levels O
were O
increased O
in O
cacl(2)-treated O
segments O
( O
all O
p<0.01) O
, O
with O
trends O
of O
elevation O
in O
cacl(2)-untreated O
segments O
, O
as O
compared O
with O
nacl-treated O
segments O
. O

immunohistochemistry O
displayed O
significantly O
increased O
expressions O
of O
mmp-2 O
, O
mmp-9 O
, O
adam-10 O
and O
adam-17 O
( O
all O
p<0.01 O
) O
in O
intima O
and O
media O
for O
cacl(2)-treated O
segments O
. O

timp O
mrna O
and O
tissue O
levels O
did O
not O
differ O
obviously O
among O
the O
three O
aortic O
segments O
. O

conclusion O
: O
this O
study O
establishes O
a O
taa B-NEG
model O
by O
periarterial O
cacl(2 O
) O
exposure O
in O
rats O
, O
and O
demonstrates O
a O
significant O
elevation O
of O
expression O
of O
mmp-2 O
, O
mmp-9 O
, O
adam10 O
and O
adam17 O
in O
the O
pathogenesis O
of O
vascular O
remodeling O
. O

-DOCSTART- O

when O
drugs O
disappear O
from O
the O
patient O
: O
elimination O
of O
intravenous O
medication O
by O
hemodiafiltration O
. O

twenty-three O
hours O
after O
heart O
transplantation O
, O
life-threatening O
acute O
right B-NEG
heart I-NEG
failure I-NEG
was O
diagnosed O
in O
a O
patient O
requiring O
continuous O
venovenous O
hemodiafiltration O
(cvvhdf) O
. O

increasing O
doses O
of O
catecholamines O
, O
sedatives O
, O
and O
muscle O
relaxants O
administered O
through O
a O
central O
venous O
catheter O
were O
ineffective O
. O

however O
, O
a O
bolus O
of O
epinephrine O
injected O
through O
an O
alternative O
catheter O
provoked O
a O
hypertensive B-NEG
crisis O
. O

thus O
, O
interference O
with O
the O
central O
venous O
infusion O
by O
the O
dialysis O
catheter O
was O
suspected O
. O

the O
catheters O
were O
changed O
, O
and O
hemodynamics O
stabilized O
at O
lower O
catecholamine O
doses O
. O

when O
the O
effects O
of O
iv O
drugs O
are O
inadequate O
in O
patients O
receiving O
cvvhdf O
, O
interference O
with O
adjacent O
catheters O
resulting O
in O
elimination O
of O
the O
drug O
by O
cvvhdf O
should O
be O
suspected O
. O

-DOCSTART- O

long-term O
glutamate O
supplementation O
failed O
to O
protect O
against O
peripheral B-NEG
neurotoxicity I-NEG
of O
paclitaxel O
. O

toxic O
peripheral B-NEG
neuropathy I-NEG
is O
still O
a O
significant O
limiting O
factor O
for O
chemotherapy O
with O
paclitaxel O
(pac) O
, O
although O
glutamate O
and O
its O
closely O
related O
amino O
acid O
glutamine O
were O
claimed O
to O
ameliorate O
pac O
neurotoxicity B-NEG
. O

this O
pilot O
trial O
aimed O
to O
evaluate O
the O
role O
of O
glutamate O
supplementation O
for O
preventing O
pac-induced O
peripheral B-NEG
neuropathy I-NEG
in O
a O
randomized O
, O
placebo-controlled O
, O
double-blinded O
clinical O
and O
electro-diagnostic O
study O
. O

forty-three O
ovarian B-NEG
cancer I-NEG
patients O
were O
available O
for O
analysis O
following O
six O
cycles O
of O
the O
same O
pac-containing O
regimen O
: O
23 O
had O
been O
supplemented O
by O
glutamate O
all O
along O
the O
treatment O
period O
, O
at O
a O
daily O
dose O
of O
three O
times O
500 O
mg O
( O
group O
g) O
, O
and O
20 O
had O
received O
a O
placebo O
( O
group O
p) O
. O

patients O
were O
evaluated O
by O
neurological O
examinations O
, O
questionnaires O
and O
sensory-motor O
nerve O
conduction O
studies O
. O

there O
was O
no O
significant O
difference O
in O
the O
frequency O
of O
signs O
or O
symptoms O
between O
the O
two O
groups O
although O
neurotoxicity B-NEG
symptoms O
presented O
mostly O
with O
lower O
scores O
of O
severity O
in O
group O
g. O

however O
, O
this O
difference O
reached O
statistical O
significance O
only O
with O
regard O
to O
reported O
pain B-NEG
sensation O
(p O
= O
0.011) O
. O

also O
the O
frequency O
of O
abnormal O
electro-diagnostic O
findings O
showed O
similarity O
between O
the O
two O
groups O
(g O
: O
7/23 O
= O
30.4% O
; O
p: O
6/20 O
= O
30%) O
. O

this O
pilot O
study O
leads O
to O
the O
conclusion O
that O
glutamate O
supplementation O
at O
the O
chosen O
regimen O
fails O
to O
protect O
against O
peripheral B-NEG
neurotoxicity I-NEG
of O
pac O
. O

-DOCSTART- O

attentional O
modulation O
of O
perceived O
pain B-NEG
intensity O
in O
capsaicin-induced O
secondary O
hyperalgesia B-NEG
. O

perceived O
pain B-NEG
intensity O
is O
modulated O
by O
attention O
. O

however O
, O
it O
is O
not O
known O
that O
how O
pain B-NEG
intensity O
ratings O
are O
affected O
by O
attention O
in O
capsaicin-induced O
secondary O
hyperalgesia B-NEG
. O

here O
we O
show O
that O
perceived O
pain B-NEG
intensity O
in O
secondary O
hyperalgesia B-NEG
is O
decreased O
when O
attention O
is O
distracted O
away O
from O
the O
painful O
pinprick O
stimulus O
with O
a O
visual O
task O
. O

furthermore O
, O
it O
was O
found O
that O
the O
magnitude O
of O
attentional O
modulation O
in O
secondary O
hyperalgesia B-NEG
is O
very O
similar O
to O
that O
of O
capsaicin-untreated O
, O
control O
condition O
. O

our O
findings O
, O
showing O
no O
interaction O
between O
capsaicin O
treatment O
and O
attentional O
modulation O
suggest O
that O
capsaicin-induced O
secondary O
hyperalgesia B-NEG
and O
attention O
might O
affect O
mechanical O
pain B-NEG
through O
independent O
mechanisms O
. O

-DOCSTART- O

testosterone-dependent O
hypertension B-NEG
and O
upregulation O
of O
intrarenal O
angiotensinogen O
in O
dahl O
salt-sensitive O
rats O
. O

blood O
pressure O
( O
bp O
) O
is O
more O
salt O
sensitive O
in O
men O
than O
in O
premenopausal O
women O
. O

in O
dahl O
salt-sensitive O
rats O
(ds) O
, O
high-salt O
( O
hs O
) O
diet O
increases O
bp O
more O
in O
males O
than O
females O
. O

in O
contrast O
to O
the O
systemic O
renin-angiotensin O
system O
, O
which O
is O
suppressed O
in O
response O
to O
hs O
in O
male O
ds O
, O
intrarenal O
angiotensinogen O
expression O
is O
increased O
, O
and O
intrarenal O
levels O
of O
ang O
ii O
are O
not O
suppressed O
. O

in O
this O
study O
, O
the O
hypothesis O
was O
tested O
that O
there O
is O
a O
sexual O
dimorphism O
in O
hs-induced O
upregulation O
of O
intrarenal O
angiotensinogen O
mediated O
by O
testosterone O
that O
also O
causes O
increases O
in O
bp O
and O
renal B-NEG
injury I-NEG
. O

on O
a O
low-salt O
( O
ls O
) O
diet O
, O
male O
ds O
had O
higher O
levels O
of O
intrarenal O
angiotensinogen O
mrna O
than O
females O
. O

hs O
diet O
for O
4 O
wk O
increased O
renal O
cortical O
angiotensinogen O
mrna O
and O
protein O
only O
in O
male O
ds O
, O
which O
was O
prevented O
by O
castration O
. O

ovariectomy O
of O
female O
ds O
had O
no O
effect O
on O
intrarenal O
angiotensinogen O
expression O
on O
either O
diet O
. O

radiotelemetric O
bp O
was O
similar O
between O
males O
and O
castrated O
rats O
on O
ls O
diet O
. O

hs O
diet O
for O
4 O
wk O
caused O
a O
progressive O
increase O
in O
bp O
, O
protein O
and O
albumin O
excretion O
, O
and O
glomerular B-NEG
sclerosis I-NEG
in O
male O
ds O
rats O
, O
which O
were O
attenuated O
by O
castration O
. O

testosterone O
replacement O
in O
castrated O
ds O
rats O
increased O
bp O
, O
renal B-NEG
injury I-NEG
, O
and O
upregulation O
of O
renal O
angiotensinogen O
associated O
with O
hs O
diet O
. O

testosterone O
contributes O
to O
the O
development O
of O
hypertension B-NEG
and O
renal B-NEG
injury I-NEG
in O
male O
ds O
rats O
on O
hs O
diet O
possibly O
through O
upregulation O
of O
the O
intrarenal O
renin-angiotensin O
system O
. O

-DOCSTART- O

prenatal O
protein O
deprivation O
alters O
dopamine-mediated O
behaviors O
and O
dopaminergic O
and O
glutamatergic O
receptor O
binding O
. O

epidemiological O
evidence O
indicates O
that O
prenatal O
nutritional O
deprivation O
may O
increase O
the O
risk O
of O
schizophrenia B-NEG
. O

the O
goal O
of O
these O
studies O
was O
to O
use O
an O
animal O
model O
to O
examine O
the O
effects O
of O
prenatal O
protein O
deprivation O
on O
behaviors O
and O
receptor O
binding O
with O
relevance O
to O
schizophrenia B-NEG
. O

we O
report O
that O
prenatally O
protein O
deprived O
( O
pd O
) O
female O
rats O
showed O
an O
increased O
stereotypic O
response O
to O
apomorphine O
and O
an O
increased O
locomotor O
response O
to O
amphetamine O
in O
adulthood O
. O

these O
differences O
were O
not O
observed O
during O
puberty O
. O

no O
changes O
in O
haloperidol-induced O
catalepsy B-NEG
or O
mk-801-induced O
locomotion O
were O
seen O
following O
pd O
. O

in O
addition O
, O
pd O
female O
rats O
showed O
increased O
( O
3)h-mk-801 O
binding O
in O
the O
striatum O
and O
hippocampus O
, O
but O
not O
in O
the O
cortex O
. O

pd O
female O
rats O
also O
showed O
increased O
( O
3)h-haloperidol O
binding O
and O
decreased O
dopamine O
transporter O
binding O
in O
striatum O
. O

no O
statistically O
significant O
changes O
in O
behavior O
or O
receptor O
binding O
were O
found O
in O
pd O
males O
with O
the O
exception O
of O
increased O
( O
3)h-mk-801 O
binding O
in O
cortex O
. O

this O
animal O
model O
may O
be O
useful O
to O
explore O
the O
mechanisms O
by O
which O
prenatal O
nutritional B-NEG
deficiency I-NEG
enhances O
risk O
for O
schizophrenia B-NEG
in O
humans O
and O
may O
also O
have O
implications O
for O
developmental O
processes O
leading O
to O
differential O
sensitivity O
to O
drugs O
of O
abuse O
. O

-DOCSTART- O

mtor O
inhibitors-induced O
proteinuria B-NEG
: O
mechanisms O
, O
significance O
, O
and O
management O
. O

massive O
urinary O
protein O
excretion O
has O
been O
observed O
after O
conversion O
from O
calcineurin O
inhibitors O
to O
mammalian O
target O
of O
rapamycin O
( O
mtor O
) O
inhibitors O
, O
especially O
sirolimus O
, O
in O
renal O
transplant O
recipients O
with O
chronic B-NEG
allograft I-NEG
nephropathy I-NEG
. O

because O
proteinuria B-NEG
is O
a O
major O
predictive O
factor O
of O
poor O
transplantation O
outcome O
, O
many O
studies O
focused O
on O
this O
adverse O
event O
during O
the O
past O
years O
. O

whether O
proteinuria B-NEG
was O
due O
to O
sirolimus O
or O
only O
a O
consequence O
of O
calcineurin O
inhibitors O
withdrawal O
remained O
unsolved O
until O
high O
range O
proteinuria B-NEG
has O
been O
observed O
during O
sirolimus O
therapy O
in O
islet O
transplantation O
and O
in O
patients O
who O
received O
sirolimus O
de O
novo O
. O

podocyte O
injury O
and O
focal O
segmental O
glomerulosclerosis B-NEG
have O
been O
related O
to O
mtor O
inhibition O
in O
some O
patients O
, O
but O
the O
pathways O
underlying O
these O
lesions O
remain O
hypothetic O
. O

we O
discuss O
herein O
the O
possible O
mechanisms O
and O
the O
significance O
of O
mtor O
blockade-induced O
proteinuria B-NEG
. O

-DOCSTART- O

hypothalamic O
prolactin O
receptor O
messenger O
ribonucleic O
acid O
levels O
, O
prolactin O
signaling O
, O
and O
hyperprolactinemic B-NEG
inhibition O
of O
pulsatile O
luteinizing O
hormone O
secretion O
are O
dependent O
on O
estradiol O
. O
hyperprolactinemia B-NEG
can O
reduce O
fertility O
and O
libido O
. O

although O
central O
prolactin O
actions O
are O
thought O
to O
contribute O
to O
this O
, O
the O
mechanisms O
are O
poorly O
understood O
. O

we O
first O
tested O
whether O
chronic O
hyperprolactinemia B-NEG
inhibited O
two O
neuroendocrine O
parameters O
necessary O
for O
female O
fertility O
: O
pulsatile O
lh O
secretion O
and O
the O
estrogen-induced O
lh O
surge O
. O

chronic O
hyperprolactinemia B-NEG
induced O
by O
the O
dopamine O
antagonist O
sulpiride O
caused O
a O
40% O
reduction O
lh O
pulse O
frequency O
in O
ovariectomized O
rats O
, O
but O
only O
in O
the O
presence O
of O
chronic O
low O
levels O
of O
estradiol O
. O

sulpiride O
did O
not O
affect O
the O
magnitude O
of O
a O
steroid-induced O
lh O
surge O
or O
the O
percentage O
of O
gnrh O
neurons O
activated O
during O
the O
surge O
. O

estradiol O
is O
known O
to O
influence O
expression O
of O
the O
long O
form O
of O
prolactin O
receptors O
( O
prl-r O
) O
and O
components O
of O
prolactin's O
signaling O
pathway O
. O

to O
test O
the O
hypothesis O
that O
estrogen O
increases O
prl-r O
expression O
and O
sensitivity O
to O
prolactin O
, O
we O
next O
demonstrated O
that O
estradiol O
greatly O
augments O
prolactin-induced O
stat5 O
activation O
. O

lastly O
, O
we O
measured O
prl-r O
and O
suppressor O
of O
cytokine O
signaling O
( O
socs-1 O
and O
-3 O
and O
cis O
, O
which O
reflect O
the O
level O
of O
prolactin O
signaling O
) O
mrnas O
in O
response O
to O
sulpiride O
and O
estradiol O
. O

sulpiride O
induced O
only O
socs-1 O
in O
the O
medial O
preoptic O
area O
, O
where O
gnrh O
neurons O
are O
regulated O
, O
but O
in O
the O
arcuate O
nucleus O
and O
choroid O
plexus O
, O
prl-r O
, O
socs-3 O
, O
and O
cis O
mrna O
levels O
were O
also O
induced O
. O

estradiol O
enhanced O
these O
effects O
on O
socs-3 O
and O
cis O
. O

interestingly O
, O
estradiol O
also O
induced O
prl-r O
, O
socs-3 O
, O
and O
cis O
mrna O
levels O
independently O
. O

these O
data O
show O
that O
gnrh O
pulse O
frequency O
is O
inhibited O
by O
chronic O
hyperprolactinemia B-NEG
in O
a O
steroid-dependent O
manner O
. O

they O
also O
provide O
evidence O
for O
estradiol-dependent O
and O
brain O
region-specific O
regulation O
of O
prl-r O
expression O
and O
signaling O
responses O
by O
prolactin O
. O

-DOCSTART- O

estrogen O
prevents O
cholesteryl O
ester O
accumulation O
in O
macrophages O
induced O
by O
the O
hiv O
protease O
inhibitor O
ritonavir O
. O

individuals O
with O
hiv O
can O
now O
live O
long O
lives O
with O
drug O
therapy O
that O
often O
includes O
protease O
inhibitors O
such O
as O
ritonavir O
. O

many O
patients O
, O
however O
, O
develop O
negative O
long-term O
side O
effects O
such O
as O
premature B-NEG
atherosclerosis I-NEG
. O

we O
have O
previously O
demonstrated O
that O
ritonavir O
treatment O
increases O
atherosclerotic B-NEG
lesion I-NEG
formation O
in O
male O
mice O
to O
a O
greater O
extent O
than O
in O
female O
mice O
. O

furthermore O
, O
peripheral O
blood O
monocytes O
isolated O
from O
ritonavir-treated O
females O
had O
less O
cholesteryl O
ester O
accumulation O
. O

in O
the O
present O
study O
, O
we O
have O
investigated O
the O
molecular O
mechanisms O
by O
which O
female O
hormones O
influence O
cholesterol O
metabolism O
in O
macrophages O
in O
response O
to O
the O
hiv O
protease O
inhibitor O
ritonavir O
. O

we O
have O
utilized O
the O
human O
monocyte O
cell O
line O
, O
thp-1 O
as O
a O
model O
to O
address O
this O
question O
. O

briefly O
, O
cells O
were O
differentiated O
for O
72 O
h O
with O
100 O
nm O
pma O
to O
obtain O
a O
macrophage-like O
phenotype O
in O
the O
presence O
or O
absence O
of O
1 O
nm O
17beta-estradiol O
(e2) O
, O
100 O
nm O
progesterone O
or O
vehicle O
( O
0.01% O
ethanol) O
. O

cells O
were O
then O
treated O
with O
30 O
ng/ml O
ritonavir O
or O
vehicle O
in O
the O
presence O
of O
aggregated O
ldl O
for O
24 O
h. O

cell O
extracts O
were O
harvested O
, O
and O
lipid O
or O
total O
rna O
was O
isolated O
. O

e2 O
decreased O
the O
accumulation O
of O
cholesteryl O
esters O
in O
macrophages O
following O
ritonavir O
treatment O
. O

ritonavir O
increased O
the O
expression O
of O
the O
scavenger O
receptor O
, O
cd36 O
mrna O
, O
responsible O
for O
the O
uptake O
of O
ldl O
. O

additionally O
, O
ritonavir O
treatment O
selectively O
increased O
the O
relative O
levels O
of O
ppargamma O
mrna O
, O
a O
transcription O
factor O
responsible O
for O
the O
regulation O
of O
cd36 O
mrna O
expression O
. O

treatment O
with O
e2 O
, O
however O
, O
failed O
to O
prevent O
these O
increases O
at O
the O
mrna O
level O
. O

e2 O
did O
, O
however O
, O
significantly O
suppress O
cd36 O
protein O
levels O
as O
measured O
by O
fluorescent O
immunocytochemistry O
. O

this O
data O
suggests O
that O
e2 O
modifies O
the O
expression O
of O
cd36 O
at O
the O
level O
of O
protein O
expression O
in O
monocyte-derived O
macrophages O
resulting O
in O
reduced O
cholesteryl O
ester O
accumulation O
following O
ritonavir O
treatment O
. O

-DOCSTART- O

upregulation O
of O
brain O
expression O
of O
p-glycoprotein O
in O
mrp2-deficient O
tr(- O
) O
rats O
resembles O
seizure B-NEG
-induced O
up-regulation O
of O
this O
drug O
efflux O
transporter O
in O
normal O
rats O
. O

purpose O
: O
the O
multidrug O
resistance O
protein O
2 O
( O
mrp2 O
) O
is O
a O
drug O
efflux O
transporter O
that O
is O
expressed O
predominantly O
at O
the O
apical O
domain O
of O
hepatocytes O
but O
seems O
also O
to O
be O
expressed O
at O
the O
apical O
membrane O
of O
brain O
capillary O
endothelial O
cells O
that O
form O
the O
blood-brain O
barrier O
(bbb) O
. O

mrp2 O
is O
absent O
in O
the O
transport-deficient O
( O
tr(-) O
) O
wistar O
rat O
mutant O
, O
so O
that O
this O
rat O
strain O
was O
very O
helpful O
in O
defining O
substrates O
of O
mrp2 O
by O
comparing O
tissue O
concentrations O
or O
functional O
activities O
of O
compounds O
in O
mrp2-deficient O
rats O
with O
those O
in O
transport-competent O
wistar O
rats O
. O

by O
using O
this O
strategy O
to O
study O
the O
involvement O
of O
mrp2 O
in O
brain O
access O
of O
antiepileptic O
drugs O
(aeds) O
, O
we O
recently O
reported O
that O
phenytoin O
is O
a O
substrate O
for O
mrp2 O
in O
the O
bbb O
. O

however O
, O
one O
drawback O
of O
such O
studies O
in O
genetically O
deficient O
rats O
is O
the O
fact O
that O
compensatory O
changes O
with O
upregulation O
of O
other O
transporters O
can O
occur O
. O

this O
prompted O
us O
to O
study O
the O
brain O
expression O
of O
p-glycoprotein O
(pgp) O
, O
a O
major O
drug O
efflux O
transporter O
in O
many O
tissues O
, O
including O
the O
bbb O
, O
in O
tr(- O
) O
rats O
compared O
with O
nonmutant O
( O
wild-type O
) O
wistar O
rats O
. O

methods O
: O
the O
expression O
of O
mrp2 O
and O
pgp O
in O
brain O
and O
liver O
sections O
of O
tr(- O
) O
rats O
and O
normal O
wistar O
rats O
was O
determined O
with O
immunohistochemistry O
, O
by O
using O
a O
novel O
, O
highly O
selective O
monoclonal O
mrp2 O
antibody O
and O
the O
monoclonal O
pgp O
antibody O
c219 O
, O
respectively O
. O

results O
: O
immunofluorescence O
staining O
with O
the O
mrp2 O
antibody O
was O
found O
to O
label O
a O
high O
number O
of O
microvessels O
throughout O
the O
brain O
in O
normal O
wistar O
rats O
, O
whereas O
such O
labeling O
was O
absent O
in O
tr(- O
) O
rats O
. O

tr(- O
) O
rats O
exhibited O
a O
significant O
up-regulation O
of O
pgp O
in O
brain O
capillary O
endothelial O
cells O
compared O
with O
wild-type O
controls O
. O

no O
such O
obvious O
upregulation O
of O
pgp O
was O
observed O
in O
liver O
sections O
. O

a O
comparable O
overexpression O
of O
pgp O
in O
the O
bbb O
was O
obtained O
after O
pilocarpine-induced O
seizures B-NEG
in O
wild-type O
wistar O
rats O
. O

experiments O
with O
systemic O
administration O
of O
the O
pgp O
substrate O
phenobarbital O
and O
the O
selective O
pgp O
inhibitor O
tariquidar O
in O
tr(- O
) O
rats O
substantiated O
that O
pgp O
is O
functional O
and O
compensates O
for O
the O
lack O
of O
mrp2 O
in O
the O
bbb O
. O

conclusions O
: O
the O
data O
on O
tr(- O
) O
rats O
indicate O
that O
pgp O
plays O
an O
important O
role O
in O
the O
compensation O
of O
mrp2 O
deficiency O
in O
the O
bbb O
. O

because O
such O
a O
compensatory O
mechanism O
most O
likely O
occurs O
to O
reduce O
injury B-NEG
to I-NEG
the I-NEG
brain I-NEG
from O
cytotoxic O
compounds O
, O
the O
present O
data O
substantiate O
the O
concept O
that O
mrp2 O
performs O
a O
protective O
role O
in O
the O
bbb O
. O

furthermore O
, O
our O
data O
suggest O
that O
tr(- O
) O
rats O
are O
an O
interesting O
tool O
to O
study O
consequences O
of O
overexpression O
of O
pgp O
in O
the O
bbb O
on O
access O
of O
drugs O
in O
the O
brain O
, O
without O
the O
need O
of O
inducing O
seizures B-NEG
or O
other O
pgp-enhancing O
events O
for O
this O
purpose O
. O

-DOCSTART- O

use O
of O
chromosome O
substitution O
strains O
to O
identify O
seizure B-NEG
susceptibility O
loci O
in O
mice O
. O
seizure B-NEG
susceptibility O
varies O
among O
inbred O
mouse O
strains O
. O

chromosome O
substitution O
strains O
(css) O
, O
in O
which O
a O
single O
chromosome O
from O
one O
inbred O
strain O
( O
donor O
) O
has O
been O
transferred O
onto O
a O
second O
strain O
( O
host O
) O
by O
repeated O
backcrossing O
, O
may O
be O
used O
to O
identify O
quantitative O
trait O
loci O
( O
qtls O
) O
that O
contribute O
to O
seizure B-NEG
susceptibility O
. O

qtls O
for O
susceptibility O
to O
pilocarpine-induced O
seizures B-NEG
, O
a O
model O
of O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
, O
have O
not O
been O
reported O
, O
and O
css O
have O
not O
previously O
been O
used O
to O
localize O
seizure B-NEG
susceptibility O
genes O
. O

we O
report O
qtls O
identified O
using O
a O
b6 O
( O
host O
) O
x O
a/j O
( O
donor O
) O
css O
panel O
to O
localize O
genes O
involved O
in O
susceptibility O
to O
pilocarpine-induced O
seizures B-NEG
. O

three O
hundred O
fifty-five O
adult O
male O
css O
mice O
, O
58 O
b6 O
, O
and O
39 O
a/j O
were O
tested O
for O
susceptibility O
to O
pilocarpine-induced O
seizures B-NEG
. O

highest O
stage O
reached O
and O
latency O
to O
each O
stage O
were O
recorded O
for O
all O
mice O
. O

b6 O
mice O
were O
resistant O
to O
seizures B-NEG
and O
slower O
to O
reach O
stages O
compared O
to O
a/j O
mice O
. O

the O
css O
for O
chromosomes O
10 O
and O
18 O
progressed O
to O
the O
most O
severe O
stages O
, O
diverging O
dramatically O
from O
the O
b6 O
phenotype O
. O

latencies O
to O
stages O
were O
also O
significantly O
shorter O
for O
css10 O
and O
css18 O
mice O
. O

css O
mapping O
suggests O
seizure B-NEG
susceptibility O
loci O
on O
mouse O
chromosomes O
10 O
and O
18 O
. O

this O
approach O
provides O
a O
framework O
for O
identifying O
potentially O
novel O
homologous O
candidate O
genes O
for O
human O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
. O

-DOCSTART- O

investigation O
of O
mitochondrial O
involvement O
in O
the O
experimental O
model O
of O
epilepsy B-NEG
induced O
by O
pilocarpine O
. O
mitochondrial B-NEG
abnormalities I-NEG
have O
been O
associated O
with O
several O
aspects O
of O
epileptogenesis O
, O
such O
as O
energy O
generation O
, O
control O
of O
cell O
death B-NEG
, O
neurotransmitter O
synthesis O
, O
and O
free O
radical O
( O
fr O
) O
production O
. O

increased O
production O
of O
frs O
may O
cause O
mtdna O
damage O
leading O
to O
decreased O
activities O
of O
oxidative O
phosphorylation O
complexes O
containing O
mtdna-encoded O
subunits O
. O

in O
this O
study O
, O
we O
investigated O
whether O
increased O
generation O
of O
fr O
during O
status B-NEG
epilepticus I-NEG
would O
be O
sufficient O
to O
provoke O
abnormalities O
in O
mtdna O
and O
in O
the O
expression O
and O
activity O
of O
cytochrome O
c O
oxidase O
(cco) O
, O
complex O
iv O
of O
the O
respiratory O
chain O
, O
in O
the O
chronic O
phase O
of O
the O
pilocarpine O
model O
of O
temporal B-NEG
lobe I-NEG
epilepsy I-NEG
. O

dna O
analysis O
revealed O
low O
amounts O
of O
a O
4.8 O
kb O
mtdna O
deletion O
but O
with O
no O
differences O
in O
frequency O
or O
quantity O
in O
the O
control O
and O
experimental O
groups O
. O

we O
did O
not O
find O
abnormalities O
in O
the O
expression O
and O
distribution O
of O
an O
mtdna-encoded O
subunit O
of O
cco O
( O
cco-i O
) O
or O
a O
relative O
decrease O
in O
cco-i O
when O
compared O
with O
nuclear-encoded O
subunits O
( O
cco-iv O
and O
sdh-fp) O
. O

no O
abnormality O
in O
cco O
activity O
was O
observed O
through O
histochemistry O
. O

although O
evidences O
of O
mitochondrial B-NEG
abnormalities I-NEG
were O
found O
in O
previously O
published O
studies O
, O
our O
results O
do O
not O
suggest O
that O
the O
frs O
, O
generated O
during O
the O
acute O
phase O
, O
determined O
important O
abnormalities O
in O
mtdna O
, O
in O
expression O
of O
cco-i O
, O
and O
in O
cco O
activity O
. O

-DOCSTART- O

causes O
of O
acute O
thrombotic B-NEG
microangiopathy I-NEG
in O
patients O
receiving O
kidney O
transplantation O
. O

objectives O
: O
thrombotic B-NEG
microangiopathy I-NEG
is O
a O
well-known O
problem O
in O
patients O
following O
renal O
transplantation O
. O

in O
postrenal O
transplantation O
, O
thrombotic B-NEG
microangiopathy I-NEG
is O
often O
a O
reflection O
of O
hemolytic B-NEG
uremic I-NEG
syndrome I-NEG
. O

we O
aimed O
to O
determine O
the O
causes O
of O
thrombotic B-NEG
microangiopathy I-NEG
in O
a O
population O
of O
renal O
transplantation O
recipients O
and O
discuss O
the O
literature O
. O

materials O
and O
methods O
: O
we O
investigated O
the O
causes O
of O
thrombotic B-NEG
microangiopathy I-NEG
during O
a O
1-year O
period O
, O
from O
june O
2003 O
to O
june O
2004 O
, O
at O
the O
king O
fahad O
national O
guard O
hospital O
in O
riyadh O
, O
saudi O
arabia O
, O
by O
reviewing O
the O
slides O
of O
all O
transplant O
biopsies O
( O
n=25 O
) O
performed O
during O
this O
interval O
. O

pre- O
and O
posttransplant O
crossmatching O
was O
done O
when O
possible O
. O

results O
: O
five O
cases O
of O
thrombotic B-NEG
microangiopathy I-NEG
were O
found O
. O

three O
of O
these O
cases O
were O
from O
the O
25 O
transplantations O
performed O
at O
king O
fahad O
national O
guard O
hospital O
, O
while O
the O
other O
2 O
transplantations O
had O
been O
performed O
abroad O
and O
were O
referred O
to O
us O
for O
follow-up O
. O

three O
cases O
were O
related O
to O
cyclosporine O
, O
and O
1 O
case O
was O
secondary O
to O
both O
cyclosporine O
and O
tacrolimus O
. O

the O
fifth O
case O
had O
features O
of O
thrombotic B-NEG
microangiopathy I-NEG
related O
to O
an O
antiphospholipid B-NEG
syndrome I-NEG
in O
a O
patient O
with O
systemic B-NEG
lupus I-NEG
erythematosus I-NEG
. O

conclusions O
: O
in O
the O
literature O
, O
the O
most-frequent O
cause O
of O
hemolytic B-NEG
uremic I-NEG
syndrome I-NEG
in O
patients O
following O
renal O
transplantation O
is O
recurrence O
of O
the O
hemolytic B-NEG
uremic I-NEG
syndrome I-NEG
. O

other O
causes O
include O
drug-related O
(cyclosporine O
, O
tacrolimus O
) O
toxicity B-NEG
, O
procoagulant O
status O
, O
and O
antibody-mediated O
rejection O
. O

we O
found O
that O
the O
most-frequent O
cause O
of O
thrombotic B-NEG
microangiopathy I-NEG
was O
drug O
related O
, O
secondary O
mainly O
to O
cyclosporine O
. O

in O
the O
current O
study O
, O
the O
frequency O
of O
thrombotic B-NEG
microangiopathy I-NEG
was O
similar O
to O
the O
percentage O
reported O
in O
the O
literature O
(20%) O
. O

-DOCSTART- O

severe O
reversible O
left B-NEG
ventricular I-NEG
systolic I-NEG
and I-NEG
diastolic I-NEG
dysfunction I-NEG
due O
to O
accidental O
iatrogenic O
epinephrine O
overdose B-NEG
. O

catecholamine-induced O
cardiomyopathy B-NEG
due O
to O
chronic O
excess O
of O
endogenous O
catecholamines O
has O
been O
recognized O
for O
decades O
as O
a O
clinical O
phenomenon O
. O

in O
contrast O
, O
reports O
of O
myocardial B-NEG
dysfunction I-NEG
due O
to O
acute O
iatrogenic O
overdose B-NEG
are O
rare O
. O

a O
35-year-old O
woman O
whose O
cervix O
uteri O
was O
inadvertently O
injected O
with O
8 O
mg O
of O
epinephrine O
developed O
myocardial B-NEG
stunning I-NEG
that O
was O
characterized O
by O
severe O
hemodynamic O
compromise O
, O
profound O
, O
albeit O
transient O
, O
left B-NEG
ventricular I-NEG
systolic I-NEG
and I-NEG
diastolic I-NEG
dysfunction I-NEG
, O
and O
only O
modestly O
elevated O
biochemical O
markers O
of O
myocardial B-NEG
necrosis I-NEG
. O

our O
case O
illustrates O
the O
serious O
consequences O
of O
medical O
errors O
that O
can O
be O
avoided O
through O
improved O
medication O
labeling O
and O
staff O
supervision O
. O

-DOCSTART- O

urinary B-NEG
bladder I-NEG
cancer I-NEG
in O
wegener's B-NEG
granulomatosis I-NEG
: O
risks O
and O
relation O
to O
cyclophosphamide O
. O

objective O
: O
to O
assess O
and O
characterise O
the O
risk O
of O
bladder B-NEG
cancer I-NEG
, O
and O
its O
relation O
to O
cyclophosphamide O
, O
in O
patients O
with O
wegener's B-NEG
granulomatosis I-NEG
. O

methods O
: O
in O
the O
population O
based O
, O
nationwide O
swedish O
inpatient O
register O
a O
cohort O
of O
1065 O
patients O
with O
wegener's B-NEG
granulomatosis I-NEG
, O
1969-95 O
, O
was O
identified O
. O

through O
linkage O
with O
the O
swedish O
cancer B-NEG
register O
, O
all O
subjects O
in O
this O
cohort O
diagnosed O
with O
bladder B-NEG
cancer I-NEG
were O
identified O
. O

nested O
within O
the O
cohort O
, O
a O
matched O
case-control O
study O
was O
performed O
to O
estimate O
the O
association O
between O
cyclophosphamide O
and O
bladder B-NEG
cancer I-NEG
using O
odds O
ratios O
( O
ors O
) O
as O
relative O
risk O
. O

in O
the O
cohort O
the O
cumulative O
risk O
of O
bladder B-NEG
cancer I-NEG
after O
wegener's B-NEG
granulomatosis I-NEG
, O
and O
the O
relative O
prevalence O
of O
a O
history O
of O
bladder B-NEG
cancer I-NEG
at O
the O
time O
of O
diagnosis O
of O
wegener's B-NEG
granulomatosis I-NEG
, O
were O
also O
estimated O
. O

results O
: O
the O
median O
cumulative O
doses O
of O
cyclophosphamide O
among O
cases O
(n O
= O
11 O
) O
and O
controls O
(n O
= O
25 O
) O
were O
113 O
g O
and O
25 O
g, O
respectively O
. O

the O
risk O
of O
bladder B-NEG
cancer I-NEG
doubled O
for O
every O
10 O
g O
increment O
in O
cyclophosphamide O
( O
or O
= O
2.0 O
, O
95% O
confidence O
interval O
( O
ci O
) O
0.8 O
to O
4.9) O
. O

treatment O
duration O
longer O
than O
1 O
year O
was O
associated O
with O
an O
eightfold O
increased O
risk O
( O
or O
= O
7.7 O
, O
95% O
ci O
0.9 O
to O
69) O
. O

the O
absolute O
risk O
for O
bladder B-NEG
cancer I-NEG
in O
the O
cohort O
reached O
10% O
16 O
years O
after O
diagnosis O
of O
wegener's B-NEG
granulomatosis I-NEG
, O
and O
a O
history O
of O
bladder B-NEG
cancer I-NEG
was O
( O
non-significantly O
) O
twice O
as O
common O
as O
expected O
at O
the O
time O
of O
diagnosis O
of O
wegener's B-NEG
granulomatosis I-NEG
. O

conclusion O
: O
the O
results O
indicate O
a O
dose-response O
relationship O
between O
cyclophosphamide O
and O
the O
risk O
of O
bladder B-NEG
cancer I-NEG
, O
high O
cumulative O
risks O
in O
the O
entire O
cohort O
, O
and O
also O
the O
possibility O
of O
risk O
factors O
operating O
even O
before O
wegener's B-NEG
granulomatosis I-NEG
. O

-DOCSTART- O

l-arginine O
transport O
in O
humans O
with O
cortisol-induced O
hypertension B-NEG
. O

a O
deficient O
l-arginine-nitric O
oxide O
system O
is O
implicated O
in O
cortisol-induced O
hypertension B-NEG
. O

we O
investigate O
whether O
abnormalities O
in O
l-arginine O
uptake O
contribute O
to O
this O
deficiency O
. O

eight O
healthy O
men O
were O
recruited O
. O

hydrocortisone O
acetate O
( O
50 O
mg O
) O
was O
given O
orally O
every O
6 O
hours O
for O
24 O
hours O
after O
a O
5-day O
fixed-salt O
diet O
( O
150 O
mmol/d) O
. O

crossover O
studies O
were O
performed O
2 O
weeks O
apart O
. O

thirty O
milliliters O
of O
blood O
was O
obtained O
for O
isolation O
of O
peripheral O
blood O
mononuclear O
cells O
after O
each O
treatment O
period O
. O

l-arginine O
uptake O
was O
assessed O
in O
mononuclear O
cells O
incubated O
with O
l-arginine O
(1 O
to O
300 O
micromol/l) O
, O
incorporating O
100 O
nmol/l O
[3h]-l-arginine O
for O
a O
period O
of O
5 O
minutes O
at O
37 O
degrees O
c. O

forearm O
[3h]-l-arginine O
extraction O
was O
calculated O
after O
infusion O
of O
[3h]-l-arginine O
into O
the O
brachial O
artery O
at O
a O
rate O
of O
100 O
nci/min O
for O
80 O
minutes O
. O

deep O
forearm O
venous O
samples O
were O
collected O
for O
determination O
of O
l-arginine O
extraction O
. O

plasma O
cortisol O
concentrations O
were O
significantly O
raised O
during O
the O
active O
phase O
( O
323+/-43 O
to O
1082+/-245 O
mmol/l O
, O
p<0.05) O
. O

systolic O
blood O
pressure O
was O
elevated O
by O
an O
average O
of O
7 O
mm O
hg O
. O

neither O
l-arginine O
transport O
into O
mononuclear O
cells O
( O
placebo O
vs O
active O
, O
26.3+/-3.6 O
vs O
29.0+/-2.1 O
pmol/10 O
000 O
cells O
per O
5 O
minutes O
, O
respectively O
, O
at O
an O
l-arginine O
concentration O
of O
300 O
micromol/l O
) O
nor O
l-arginine O
extraction O
in O
the O
forearm O
( O
at O
80 O
minutes O
, O
placebo O
vs O
active O
, O
1 O
868 O
904+/-434 O
962 O
vs O
2 O
013 O
910+/-770 O
619 O
disintegrations O
per O
minute O
) O
was O
affected O
by O
cortisol O
treatment O
; O
ie O
, O
that O
l-arginine O
uptake O
is O
not O
affected O
by O
short-term O
cortisol O
treatment O
. O

we O
conclude O
that O
cortisol-induced O
increases B-NEG
in I-NEG
blood I-NEG
pressure I-NEG
are O
not O
associated O
with O
abnormalities O
in O
the O
l-arginine O
transport O
system O
. O

-DOCSTART- O

mr O
imaging O
with O
quantitative O
diffusion O
mapping O
of O
tacrolimus-induced O
neurotoxicity B-NEG
in O
organ O
transplant O
patients O
. O

our O
objective O
was O
to O
investigate O
brain O
mr O
imaging O
findings O
and O
the O
utility O
of O
diffusion-weighted O
( O
dw O
) O
imaging O
in O
organ O
transplant O
patients O
who O
developed O
neurologic O
symptoms O
during O
tacrolimus O
therapy O
. O

brain O
mr O
studies O
, O
including O
dw O
imaging O
, O
were O
prospectively O
performed O
in O
14 O
organ O
transplant O
patients O
receiving O
tacrolimus O
who O
developed O
neurologic B-NEG
complications I-NEG
. O

in O
each O
patient O
who O
had O
abnormalities O
on O
the O
initial O
mr O
study O
, O
a O
follow-up O
mr O
study O
was O
performed O
1 O
month O
later O
. O

apparent O
diffusion O
coefficient O
( O
adc O
) O
values O
on O
the O
initial O
mr O
study O
were O
correlated O
with O
reversibility O
of O
the O
lesions O
. O

of O
the O
14 O
patients O
, O
5 O
( O
35.7% O
) O
had O
white B-NEG
matter I-NEG
abnormalities I-NEG
, O
1 O
( O
7.1% O
) O
had O
putaminal B-NEG
hemorrhage I-NEG
, O
and O
8 O
( O
57.1% O
) O
had O
normal O
findings O
on O
initial O
mr O
images O
. O

among O
the O
5 O
patients O
with O
white B-NEG
matter I-NEG
abnormalities I-NEG
, O
4 O
patients O
( O
80.0% O
) O
showed O
higher O
than O
normal O
adc O
values O
on O
initial O
mr O
images O
, O
and O
all O
showed O
complete O
resolution O
on O
follow-up O
images O
. O

the O
remaining O
1 O
patient O
( O
20.0% O
) O
showed O
lower O
than O
normal O
adc O
value O
and O
showed O
incomplete O
resolution O
with O
cortical B-NEG
laminar I-NEG
necrosis I-NEG
. O

diffusion-weighted O
imaging O
may O
be O
useful O
in O
predicting O
the O
outcomes O
of O
the O
lesions O
of O
tacrolimus-induced O
neurotoxicity B-NEG
. O

-DOCSTART- O

octreotide-induced O
hypoxemia B-NEG
and O
pulmonary B-NEG
hypertension I-NEG
in O
premature O
neonates O
. O

the O
authors O
report O
2 O
cases O
of O
premature O
neonates O
who O
had O
enterocutaneous O
fistula B-NEG
complicating O
necrotizing B-NEG
enterocolitis I-NEG
. O
pulmonary B-NEG
hypertension I-NEG
developed O
after O
administration O
of O
a O
somatostatin O
analogue O
, O
octreotide O
, O
to O
enhance O
resolution O
of O
the O
fistula B-NEG
. O

the O
authors O
discuss O
the O
mechanism O
of O
the O
occurrence O
of O
this O
complication O
and O
recommend O
caution O
of O
its O
use O
in O
high-risk O
premature O
neonates O
. O

-DOCSTART- O

sequential O
observations O
of O
exencephaly B-NEG
and O
subsequent O
morphological O
changes O
by O
mouse O
exo O
utero O
development O
system O
: O
analysis O
of O
the O
mechanism O
of O
transformation O
from O
exencephaly B-NEG
to O
anencephaly B-NEG
. O
anencephaly B-NEG
has O
been O
suggested O
to O
develop O
from O
exencephaly B-NEG
; O
however O
, O
there O
is O
little O
direct O
experimental O
evidence O
to O
support O
this O
, O
and O
the O
mechanism O
of O
transformation O
remains O
unclear O
. O

we O
examined O
this O
theory O
using O
the O
exo O
utero O
development O
system O
that O
allows O
direct O
and O
sequential O
observations O
of O
mid- O
to O
late-gestation O
mouse O
embryos O
. O

we O
observed O
the O
exencephaly B-NEG
induced O
by O
5-azacytidine O
at O
embryonic O
day O
13.5 O
(e13.5) O
, O
let O
the O
embryos O
develop O
exo O
utero O
until O
e18.5 O
, O
and O
re-observed O
the O
same O
embryos O
at O
e18.5 O
. O

we O
confirmed O
several O
cases O
of O
transformation O
from O
exencephaly B-NEG
to O
anencephaly B-NEG
. O

however O
, O
in O
many O
cases O
, O
the O
exencephalic B-NEG
brain O
tissue O
was O
preserved O
with O
more O
or O
less O
reduction O
during O
this O
period O
. O

to O
analyze O
the O
transformation O
patterns O
, O
we O
classified O
the O
exencephaly B-NEG
by O
size O
and O
shape O
of O
the O
exencephalic B-NEG
tissue O
into O
several O
types O
at O
e13.5 O
and O
e18.5 O
. O

it O
was O
found O
that O
the O
transformation O
of O
exencephalic B-NEG
tissue O
was O
not O
simply O
size-dependent O
, O
and O
all O
cases O
of O
anencephaly B-NEG
at O
e18.5 O
resulted O
from O
embryos O
with O
a O
large O
amount O
of O
exencephalic B-NEG
tissue O
at O
e13.5 O
. O

microscopic O
observation O
showed O
the O
configuration O
of O
exencephaly B-NEG
at O
e13.5 O
, O
frequent O
hemorrhaging B-NEG
and O
detachment O
of O
the O
neural O
plate O
from O
surface O
ectoderm O
in O
the O
exencephalic B-NEG
head O
at O
e15.5 O
, O
and O
multiple O
modes O
of O
reduction O
in O
the O
exencephalic B-NEG
tissue O
at O
e18.5 O
. O

from O
observations O
of O
the O
vasculature O
, O
altered O
distribution O
patterns O
of O
vessels O
were O
identified O
in O
the O
exencephalic B-NEG
head O
. O

these O
findings O
suggest O
that O
overgrowth O
of O
the O
exencephalic B-NEG
neural O
tissue O
causes O
the O
altered O
distribution O
patterns O
of O
vessels O
, O
subsequent O
peripheral O
circulatory B-NEG
failure I-NEG
and/or O
hemorrhaging B-NEG
in O
various O
parts O
of O
the O
exencephalic B-NEG
head O
, O
leading O
to O
the O
multiple O
modes O
of O
tissue O
reduction O
during O
transformation O
from O
exencephaly B-NEG
to O
anencephaly B-NEG
. O

-DOCSTART- O

acute O
cocaine-induced O
seizures B-NEG
: O
differential O
sensitivity O
of O
six O
inbred O
mouse O
strains O
. O

mature O
male O
and O
female O
mice O
from O
six O
inbred O
stains O
were O
tested O
for O
susceptibility O
to O
behavioral O
seizures B-NEG
induced O
by O
a O
single O
injection O
of O
cocaine O
. O

cocaine O
was O
injected O
ip O
over O
a O
range O
of O
doses O
( O
50-100 O
mg/kg O
) O
and O
behavior O
was O
monitored O
for O
20 O
minutes O
. O
seizure B-NEG
end O
points O
included O
latency O
to O
forelimb O
or O
hindlimb O
clonus O
, O
latency O
to O
clonic O
running O
seizure B-NEG
and O
latency O
to O
jumping O
bouncing O
seizure B-NEG
. O

a O
range O
of O
strain O
specific O
sensitivities O
was O
documented O
with O
a/j O
and O
sjl O
mice O
being O
most O
sensitive O
and O
c57bl/6j O
most O
resistant O
. O

dba/2j O
, O
balb/cbyj O
and O
nzw/lacj O
strains O
exhibited O
intermediate O
sensitivity O
. O

eeg O
recordings O
were O
made O
in O
sjl O
, O
a/j O
and O
c57bl/6j O
mice O
revealing O
a O
close O
correspondence O
between O
electrical O
activity O
and O
behavior O
. O

additionally O
, O
levels O
of O
cocaine O
determined O
in O
hippocampus O
and O
cortex O
were O
not O
different O
between O
sensitive O
and O
resistant O
strains O
. O

additional O
studies O
of O
these O
murine O
strains O
may O
be O
useful O
for O
investigating O
genetic O
influences O
on O
cocaine-induced O
seizures B-NEG
. O

-DOCSTART- O

microangiopathic B-NEG
hemolytic I-NEG
anemia I-NEG
complicating O
fk506 O
( O
tacrolimus O
) O
therapy O
. O

we O
describe O
3 O
episodes O
of O
microangiopathic B-NEG
hemolytic I-NEG
anemia I-NEG
( O
maha B-NEG
) O
in O
2 O
solid O
organ O
recipients O
under O
fk506 O
( O
tacrolimus O
) O
therapy O
. O

in O
both O
cases O
, O
discontinuation O
of O
fk506 O
and O
treatment O
with O
plasma O
exchange O
, O
fresh O
frozen O
plasma O
replacement O
, O
corticosteroids O
, O
aspirin O
, O
and O
dipyridamole O
led O
to O
resolution O
of O
maha B-NEG
. O

in O
one O
patient O
, O
reintroduction O
of O
fk506 O
led O
to O
rapid O
recurrence O
of O
maha B-NEG
. O

fk506-associated O
maha B-NEG
is O
probably O
rare O
but O
physicians O
must O
be O
aware O
of O
this O
severe O
complication O
. O

in O
our O
experience O
and O
according O
to O
the O
literature O
, O
fk506 O
does O
not O
seem O
to O
cross-react O
with O
cyclosporin O
a O
(cya) O
, O
an O
immuno-suppressive O
drug O
already O
known O
to O
induce O
maha B-NEG
. O

-DOCSTART- O

variant O
ventricular B-NEG
tachycardia I-NEG
in O
desipramine O
toxicity B-NEG
. O

we O
report O
a O
case O
of O
variant O
ventricular B-NEG
tachycardia I-NEG
induced O
by O
desipramine O
toxicity B-NEG
. O

unusual O
features O
of O
the O
arrhythmia B-NEG
are O
repetitive O
group O
beating O
, O
progressive O
shortening O
of O
the O
r-r O
interval O
, O
progressive O
widening O
of O
the O
qrs O
complex O
with O
eventual O
failure O
of O
intraventricular O
conduction O
, O
and O
changes O
in O
direction O
of O
the O
qrs O
axis O
. O

recognition O
of O
variant O
ventricular B-NEG
tachycardia I-NEG
is O
important O
because O
therapy O
differs O
from O
that O
of O
classic O
ventricular B-NEG
tachycardia I-NEG
. O

-DOCSTART- O

desipramine-induced O
delirium B-NEG
at O
subtherapeutic O
concentrations O
: O
a O
case O
report O
. O

an O
elderly O
patient O
treated O
with O
low O
dose O
desipramine O
developed O
a O
delirium B-NEG
while O
her O
plasma O
level O
was O
in O
the O
subtherapeutic O
range O
. O
delirium B-NEG
, O
which O
may O
be O
induced O
by O
tricyclic O
drug O
therapy O
in O
the O
elderly O
, O
can O
be O
caused O
by O
tricyclics O
with O
low O
anticholinergic O
potency O
. O

therapeutic O
ranges O
for O
antidepressants O
that O
have O
been O
derived O
from O
general O
adult O
population O
studies O
may O
not O
be O
appropriate O
for O
the O
elderly O
. O

further O
studies O
of O
specifically O
elderly O
patients O
are O
now O
required O
to O
establish O
safer O
and O
more O
appropriate O
guidelines O
for O
drug O
therapy O
. O

-DOCSTART- O

mouse O
strain-dependent O
effect O
of O
amantadine O
on O
motility O
and O
brain O
biogenic O
amines O
. O

the O
effect O
of O
amantadine O
hydrochloride O
, O
injected O
i.p O
. O
in O
6 O
increments O
of O
100 O
mg/kg O
each O
over O
30 O
hr O
, O
on O
mouse O
motility O
and O
whole O
brain O
content O
of O
selected O
biogenic O
amines O
and O
major O
metabolites O
was O
studied O
in O
4 O
strains O
of O
mice O
. O

these O
were O
the O
albino O
sprague-dawley O
icr O
and O
balb/c O
, O
the O
black O
c57bl/6 O
and O
the O
brown O
cdf-i O
mouse O
strains O
. O

amantadine O
treatment O
produced O
a O
biphasic O
effect O
on O
mouse O
motility O
. O

the O
initial O
dose O
of O
amantadine O
depressed B-NEG
locomotor O
activity O
in O
all O
mouse O
strains O
studied O
with O
the O
balb/c O
mice O
being O
the O
most O
sensitive O
. O

subsequent O
amantadine O
treatments O
produced O
enhancement O
of O
motility O
from O
corresponding O
control O
in O
all O
mouse O
strains O
with O
the O
balb/c O
mice O
being O
the O
least O
sensitive O
. O

the O
locomotor O
activity O
was O
decreased O
from O
corresponding O
controls O
in O
all O
strains O
studied O
, O
except O
for O
the O
icr O
mice O
, O
during O
an O
overnight O
drug-free O
period O
following O
the O
fourth O
amantadine O
treatment O
. O

readministration O
of O
amantadine O
, O
after O
a O
drug-free O
overnight O
period O
, O
increased O
motility O
from O
respective O
saline O
control O
in O
all O
strains O
with O
exception O
of O
the O
balb/c O
mice O
where O
suppression B-NEG
of I-NEG
motility I-NEG
occurred O
. O

treatment O
with O
amantadine O
did O
not O
alter O
whole O
brain O
dopamine O
levels O
but O
decreased O
the O
amounts O
of O
3,4-dihydroxyphenylacetic O
acid O
in O
the O
balb/c O
mice O
compared O
to O
saline O
control O
. O

conversely O
, O
brain O
normetanephrine O
concentration O
was O
increased O
from O
saline O
control O
by O
amantadine O
in O
the O
balb/c O
mice O
. O

the O
results O
suggest O
a O
strain-dependent O
effect O
of O
amantadine O
on O
motility O
and O
indicate O
a O
differential O
response O
to O
the O
acute O
and O
multiple O
dose O
regimens O
used O
. O

the O
balb/c O
mouse O
was O
the O
most O
sensitive O
strain O
and O
could O
serve O
as O
the O
strain O
of O
choice O
for O
evaluating O
the O
side O
effects O
of O
amantadine O
. O

the O
biochemical O
results O
of O
brain O
biogenic O
amines O
of O
balb/c O
mouse O
strain O
suggest O
a O
probable O
decrease O
of O
catecholamine O
turnover O
rate O
and/or O
metabolism O
by O
monoamine O
oxidase O
and O
a O
resulting O
increase O
in O
o-methylation O
of O
norepinephrine O
which O
may O
account O
for O
a O
behavioral B-NEG
depression I-NEG
caused O
by O
amantadine O
in O
the O
balb/c O
mice O
. O

-DOCSTART- O

no O
enhancement O
by O
phenobarbital O
of O
the O
hepatocarcinogenicity O
of O
a O
choline-devoid O
diet O
in O
the O
rat O
. O

an O
experiment O
was O
performed O
to O
test O
whether O
inclusion O
of O
phenobarbital O
in O
a O
choline-devoid O
diet O
would O
increase O
the O
hepatocarcinogenicity O
of O
the O
diet O
. O

groups O
of O
5-week O
old O
male O
fischer-344 O
rats O
were O
fed O
for O
7-25 O
months O
semipurified O
choline-devoid O
or O
choline-supplemented O
diets O
, O
containing O
or O
not O
0.06% O
phenobarbital O
. O

no O
hepatic O
preneoplastic O
nodules O
or O
hepatocellular B-NEG
carcinomas I-NEG
developed O
in O
rats O
fed O
the O
plain O
choline-supplemented O
diet O
, O
while O
one O
preneoplastic O
nodule O
and O
one O
hepatocellular B-NEG
carcinoma I-NEG
developed O
in O
two O
rats O
fed O
the O
same O
diet O
containing O
phenobarbital O
. O

the O
incidence O
of O
preneoplastic O
nodules O
and O
of O
hepatocellular B-NEG
carcinomas I-NEG
was O
10% O
and O
37% O
, O
respectively O
, O
in O
rats O
fed O
the O
plain O
choline-devoid O
diet O
, O
and O
17% O
and O
30% O
, O
in O
rats O
fed O
the O
phenobarbital-containing O
choline-devoid O
diet O
. O

the O
results O
evinced O
no O
enhancement O
of O
the O
hepatocarcinogenicity O
of O
the O
choline-devoid O
diet O
by O
phenobarbital O
. O

sporadic O
neoplastic O
lesions O
were O
observed O
in O
organs O
other O
than O
the O
liver O
of O
some O
of O
the O
animals O
, O
irrespective O
of O
the O
diet O
fed O
. O

-DOCSTART- O

effect O
of O
direct O
intracoronary O
administration O
of O
methylergonovine O
in O
patients O
with O
and O
without O
variant B-NEG
angina I-NEG
. O

the O
effects O
of O
intracoronary O
administration O
of O
methylergonovine O
were O
studied O
in O
21 O
patients O
with O
variant B-NEG
angina I-NEG
and O
22 O
patients O
with O
atypical O
chest B-NEG
pain I-NEG
and O
in O
others O
without O
angina B-NEG
pectoris I-NEG
( O
control O
group) O
. O

methylergonovine O
was O
administered O
continuously O
at O
a O
rate O
of O
10 O
micrograms/min O
up O
to O
50 O
micrograms O
. O

in O
all O
patients O
with O
variant B-NEG
angina I-NEG
, O
coronary B-NEG
spasm I-NEG
was O
provoked O
at O
a O
mean O
dose O
of O
28 O
+/- O
13 O
micrograms O
( O
mean O
+/- O
sd) O
. O

in O
the O
control O
group O
neither O
ischemic O
st O
change O
nor O
localized O
spasm B-NEG
occurred O
. O

the O
basal O
tone O
of O
the O
right O
coronary O
artery O
was O
significantly O
lower O
than O
that O
of O
the O
left O
coronary O
artery O
. O

the O
percentage O
of O
vasoconstriction O
of O
the O
right O
coronary O
artery O
was O
significantly O
higher O
than O
that O
of O
the O
left O
coronary O
artery O
. O

these O
results O
suggest O
that O
spasm B-NEG
provocation O
tests O
, O
which O
use O
an O
intracoronary O
injection O
of O
a O
relatively O
low O
dose O
of O
methylergonovine O
, O
have O
a O
high O
sensitivity O
in O
variant B-NEG
angina I-NEG
and O
the O
vasoreactivity O
of O
the O
right O
coronary O
artery O
may O
be O
greater O
than O
that O
of O
the O
other O
coronary O
arteries O
. O

-DOCSTART- O

dobutamine O
stress O
echocardiography O
: O
a O
sensitive O
indicator O
of O
diminished O
myocardial O
function O
in O
asymptomatic O
doxorubicin-treated O
long-term O
survivors O
of O
childhood O
cancer B-NEG
. O

doxorubicin O
is O
an O
effective O
anticancer O
chemotherapeutic O
agent O
known O
to O
cause O
acute O
and O
chronic O
cardiomyopathy B-NEG
. O

to O
develop O
a O
more O
sensitive O
echocardiographic O
screening O
test O
for O
cardiac B-NEG
damage I-NEG
due O
to O
doxorubicin O
, O
a O
cohort O
study O
was O
performed O
using O
dobutamine O
infusion O
to O
differentiate O
asymptomatic O
long-term O
survivors O
of O
childhood O
cancer B-NEG
treated O
with O
doxorubicin O
from O
healthy O
control O
subjects O
. O

echocardiographic O
data O
from O
the O
experimental O
group O
of O
21 O
patients O
( O
mean O
age O
16 O
+/- O
5 O
years O
) O
treated O
from O
1.6 O
to O
14.3 O
years O
( O
median O
5.3 O
) O
before O
this O
study O
with O
27 O
to O
532 O
mg/m2 O
of O
doxorubicin O
( O
mean O
196 O
) O
were O
compared O
with O
echocardiographic O
data O
from O
12 O
normal O
age-matched O
control O
subjects O
. O

graded O
dobutamine O
infusions O
of O
0.5 O
, O
2.5 O
, O
5 O
and O
10 O
micrograms/kg O
per O
min O
were O
administered O
. O

echocardiographic O
doppler O
studies O
were O
performed O
before O
infusion O
and O
after O
15 O
min O
of O
infusion O
at O
each O
rate O
. O

dobutamine O
infusion O
at O
10 O
micrograms/kg O
per O
min O
was O
discontinued O
after O
six O
studies O
secondary O
to O
a O
50% O
incidence O
rate O
of O
adverse O
symptoms O
. O

the O
most O
important O
findings O
were O
that O
compared O
with O
values O
in O
control O
subjects O
, O
end-systolic O
left O
ventricular O
posterior O
wall O
dimension O
and O
percent O
of O
left O
ventricular O
posterior O
wall O
thickening O
in O
doxorubicin-treated O
patients O
were O
decreased O
at O
baseline O
study O
and O
these O
findings O
were O
more O
clearly O
delineated O
with O
dobutamine O
stimulation O
. O

end-systolic O
left O
ventricular O
posterior O
wall O
dimension O
at O
baseline O
for O
the O
doxorubicin-treated O
group O
was O
11 O
+/- O
1.9 O
mm O
versus O
13.1 O
+/- O
1.5 O
mm O
for O
control O
subjects O
(p O
less O
than O
0.01) O
. O

end-systolic O
left O
ventricular O
posterior O
wall O
dimension O
at O
the O
5-micrograms/kg O
per O
min O
dobutamine O
infusion O
for O
the O
doxorubicin-treated O
group O
was O
14.1 O
+/- O
2.4 O
mm O
versus O
19.3 O
+/- O
2.6 O
mm O
for O
control O
subjects O
(p O
less O
than O
0.01).(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

effects O
of O
aminophylline O
on O
the O
threshold O
for O
initiating O
ventricular B-NEG
fibrillation I-NEG
during O
respiratory B-NEG
failure I-NEG
. O
cardiac B-NEG
arrhythmias I-NEG
have O
frequently O
been O
reported O
in O
association O
with O
respiratory B-NEG
failure I-NEG
. O

the O
possible O
additive O
role O
of O
pharmacologic O
agents O
in O
precipitating O
cardiac B-NEG
disturbances I-NEG
in O
patients O
with O
respiratory B-NEG
failure I-NEG
has O
only O
recently O
been O
emphasized O
. O

the O
effects O
of O
aminophylline O
on O
the O
ventricular B-NEG
fibrillation I-NEG
threshold O
during O
normal O
acid-base O
conditions O
and O
during O
respiratory B-NEG
failure I-NEG
were O
studied O
in O
anesthetized O
open O
chest O
dogs O
. O

the O
ventricular B-NEG
fibrillation I-NEG
threshold O
was O
measured O
by O
passing O
a O
gated O
train O
of O
12 O
constant O
current O
pulses O
through O
the O
ventricular O
myocardium O
during O
the O
vulnerable O
period O
of O
the O
cardiac O
cycle O
. O

during O
the O
infusion O
of O
aminophylline O
, O
the O
ventricular B-NEG
fibrillation I-NEG
threshold O
was O
reduced O
by O
30 O
to O
40 O
percent O
of O
the O
control O
when O
ph O
and O
partial O
pressures O
of O
oxygen O
( O
po2 O
) O
and O
carbon O
dioxide O
( O
co2 O
) O
were O
kept O
within O
normal O
limits O
. O

when O
respiratory B-NEG
failure I-NEG
was O
produced O
by O
hypoventilation B-NEG
( O
ph O
7.05 O
to O
7.25 O
; O
pc02 O
70 O
to O
100 O
mm O
hg O
: O
p02 O
20 O
to O
40 O
mm O
hg) O
, O
infusion O
of O
aminophylline O
resulted O
in O
an O
even O
greater O
decrease O
in O
ventricular B-NEG
fibrillation I-NEG
threshold O
to O
60 O
percent O
of O
the O
control O
level O
. O

these O
experiments O
suggest O
that O
although O
many O
factors O
may O
contribute O
to O
the O
increased O
incidence O
of O
ventricular B-NEG
arrhythmias I-NEG
in O
respiratory B-NEG
failure I-NEG
, O
pharmacologic O
agents O
, O
particularly O
aminophylline O
, O
may O
play O
a O
significant O
role O
. O

-DOCSTART- O

case O
report O
: O
acute O
unintentional O
carbachol O
intoxication O
. O

introduction O
: O
intoxications O
with O
carbachol O
, O
a O
muscarinic O
cholinergic O
receptor O
agonist O
are O
rare O
. O

we O
report O
an O
interesting O
case O
investigating O
a O
( O
near O
) O
fatal O
poisoning B-NEG
. O

methods O
: O
the O
son O
of O
an O
84-year-old O
male O
discovered O
a O
newspaper O
report O
stating O
clinical O
success O
with O
plant O
extracts O
in O
alzheimer's B-NEG
disease I-NEG
. O

the O
mode O
of O
action O
was O
said O
to O
be O
comparable O
to O
that O
of O
the O
synthetic O
compound O
'carbamylcholin' O
; O
that O
is O
, O
carbachol O
. O

he O
bought O
25 O
g O
of O
carbachol O
as O
pure O
substance O
in O
a O
pharmacy O
, O
and O
the O
father O
was O
administered O
400 O
to O
500 O
mg O
. O

carbachol O
concentrations O
in O
serum O
and O
urine O
on O
day O
1 O
and O
2 O
of O
hospital O
admission O
were O
analysed O
by O
hplc-mass O
spectrometry O
. O

results O
: O
minutes O
after O
oral O
administration O
, O
the O
patient O
developed O
nausea B-NEG
, O
sweating O
and O
hypotension B-NEG
, O
and O
finally O
collapsed O
. O
bradycardia B-NEG
, O
cholinergic O
symptoms O
and O
asystole B-NEG
occurred O
. O

initial O
cardiopulmonary O
resuscitation O
and O
immediate O
treatment O
with O
adrenaline O
(epinephrine) O
, O
atropine O
and O
furosemide O
was O
successful O
. O

on O
hospital O
admission O
, O
blood O
pressure O
of O
the O
intubated O
, O
bradyarrhythmic O
patient O
was O
100/65 O
mmhg O
. O

further O
signs O
were O
hyperhidrosis B-NEG
, O
hypersalivation B-NEG
, O
bronchorrhoea B-NEG
, O
and O
severe O
miosis B-NEG
; O
the O
electrocardiographic O
finding O
was O
atrio-ventricular B-NEG
dissociation I-NEG
. O

high O
doses O
of O
atropine O
( O
up O
to O
50 O
mg O
per O
24 O
hours) O
, O
adrenaline O
and O
dopamine O
were O
necessary O
. O

the O
patient O
was O
extubated O
1 O
week O
later O
. O

however O
, O
increased O
dyspnoea B-NEG
and O
bronchospasm B-NEG
necessitated O
reintubation O
. O
respiratory B-NEG
insufficiency I-NEG
was O
further O
worsened O
by O
proteus B-NEG
mirabilis I-NEG
infection I-NEG
and O
severe O
bronchoconstriction O
. O

one O
week O
later O
, O
the O
patient O
was O
again O
extubated O
and O
3 O
days O
later O
was O
transferred O
to O
a O
peripheral O
ward O
. O

on O
the O
next O
day O
he O
died O
, O
probably O
as O
a O
result O
of O
heart B-NEG
failure I-NEG
. O

serum O
samples O
from O
the O
first O
and O
second O
days O
contained O
3.6 O
and O
1.9 O
mg/l O
carbachol O
, O
respectively O
. O

the O
corresponding O
urine O
concentrations O
amounted O
to O
374 O
and O
554 O
mg/l O
. O

conclusion O
: O
this O
case O
started O
with O
a O
media O
report O
in O
a O
popular O
newspaper O
, O
initiated O
by O
published O
, O
peer-reviewed O
research O
on O
herbals O
, O
and O
involved O
human O
failure O
in O
a O
case O
history O
, O
medical O
examination O
and O
clinical O
treatment O
. O

for O
the O
first O
time O
, O
an O
analytical O
method O
for O
the O
determination O
of O
carbachol O
in O
plasma O
and O
urine O
has O
been O
developed O
. O

the O
analysed O
carbachol O
concentration O
exceeded O
the O
supposed O
serum O
level O
resulting O
from O
a O
therapeutic O
dose O
by O
a O
factor O
of O
130 O
to O
260 O
. O

especially O
in O
old O
patients O
, O
intensivists O
should O
consider O
intoxications O
( O
with O
cholinergics O
) O
as O
a O
cause O
of O
acute B-NEG
cardiovascular I-NEG
failure I-NEG
. O

-DOCSTART- O

crossover O
comparison O
of O
efficacy O
and O
preference O
for O
rizatriptan O
10 O
mg O
versus O
ergotamine/caffeine O
in O
migraine B-NEG
. O

rizatriptan O
is O
a O
selective O
5-ht(1b/1d O
) O
receptor O
agonist O
with O
rapid O
oral O
absorption O
and O
early O
onset O
of O
action O
in O
the O
acute O
treatment O
of O
migraine B-NEG
. O

this O
randomized O
double- O
blind O
crossover O
outpatient O
study O
assessed O
the O
preference O
for O
1 O
rizatriptan O
10 O
mg O
tablet O
to O
2 O
ergotamine O
1 O
mg/caffeine O
100 O
mg O
tablets O
in O
439 O
patients O
treating O
a O
single O
migraine B-NEG
attack O
with O
each O
therapy O
. O

of O
patients O
expressing O
a O
preference O
(89.1%) O
, O
more O
than O
twice O
as O
many O
preferred O
rizatriptan O
to O
ergotamine/caffeine O
( O
69.9 O
vs O
. O
30.1% O
, O
p O
< O
or O
= O
0.001) O
. O

faster O
relief O
of O
headache B-NEG
was O
the O
most O
important O
reason O
for O
preference O
, O
cited O
by O
67.3% O
of O
patients O
preferring O
rizatriptan O
and O
54.2% O
of O
patients O
who O
preferred O
ergotamine/caffeine O
. O

the O
co-primary O
endpoint O
of O
being O
pain B-NEG
free O
at O
2 O
h O
was O
also O
in O
favor O
of O
rizatriptan O
. O

forty-nine O
percent O
of O
patients O
were O
pain B-NEG
free O
2 O
h O
after O
rizatriptan O
, O
compared O
with O
24.3% O
treated O
with O
ergotamine/caffeine O
(p O
< O
or O
= O
0.001) O
, O
rizatriptan O
being O
superior O
within O
1 O
h O
of O
treatment O
. O
headache B-NEG
relief O
at O
2 O
h O
was O
75.9% O
for O
rizatriptan O
and O
47.3% O
for O
ergotamine/caffeine O
(p O
< O
or O
= O
0.001) O
, O
with O
rizatriptan O
being O
superior O
to O
ergotamine/caffeine O
within O
30 O
min O
of O
dosing O
. O

almost O
36% O
of O
patients O
taking O
rizatriptan O
were O
pain B-NEG
free O
at O
2 O
h O
and O
had O
no O
recurrence O
or O
need O
for O
additional O
medication O
within O
24 O
h, O
compared O
to O
20% O
of O
patients O
on O
ergotamine/caffeine O
(p O
< O
or O
= O
0.001) O
. O

rizatriptan O
was O
also O
superior O
to O
ergotamine/caffeine O
in O
the O
proportions O
of O
patients O
with O
no O
nausea B-NEG
, O
vomiting B-NEG
, O
phonophobia B-NEG
or O
photophobia B-NEG
and O
for O
patients O
with O
normal O
function O
2 O
h O
after O
drug O
intake O
(p O
< O
or O
= O
0.001) O
. O

more O
patients O
were O
(completely O
, O
very O
or O
somewhat O
) O
satisfied O
2 O
h O
after O
treatment O
with O
rizatriptan O
( O
69.8% O
) O
than O
at O
2 O
h O
after O
treatment O
with O
ergotamine/caffeine O
(38.6% O
, O
p O
< O
or O
= O
0.001) O
. O

recurrence O
rates O
were O
31.4% O
with O
rizatriptan O
and O
15.3% O
with O
ergotamine/caffeine O
. O

both O
active O
treatments O
were O
well O
tolerated O
. O

the O
most O
common O
adverse O
events O
( O
incidence O
> O
or O
= O
5% O
in O
one O
group O
) O
after O
rizatriptan O
and O
ergotamine/caffeine O
, O
respectively O
, O
were O
dizziness B-NEG
( O
6.7 O
and O
5.3%) O
, O
nausea B-NEG
( O
4.2 O
and O
8.5% O
) O
and O
somnolence B-NEG
( O
5.5 O
and O
2.3%) O
. O

-DOCSTART- O

thrombotic B-NEG
microangiopathy I-NEG
and O
renal B-NEG
failure I-NEG
associated O
with O
antineoplastic O
chemotherapy O
. O

five O
patients O
with O
carcinoma B-NEG
developed O
thrombotic B-NEG
microangiopathy I-NEG
( O
characterized O
by O
renal B-NEG
insufficiency I-NEG
, O
microangiopathic B-NEG
hemolytic I-NEG
anemia I-NEG
, O
and O
usually O
thrombocytopenia B-NEG
) O
after O
treatment O
with O
cisplatin O
, O
bleomycin O
, O
and O
a O
vinca O
alkaloid O
. O

one O
patient O
had O
thrombotic B-NEG
thrombocytopenic I-NEG
purpura I-NEG
, O
three O
the O
hemolytic-uremic B-NEG
syndrome I-NEG
, O
and O
one O
an O
apparent O
forme O
fruste O
of O
one O
of O
these O
disorders O
. O

histologic O
examination O
of O
the O
renal O
tissue O
showed O
evidence O
of O
intravascular B-NEG
coagulation I-NEG
, O
primarily O
affecting O
the O
small O
arteries O
, O
arterioles O
, O
and O
glomeruli O
. O

because O
each O
patient O
was O
tumor B-NEG
-free O
or O
had O
only O
a O
small O
tumor B-NEG
at O
the O
onset O
of O
this O
syndrome O
, O
the O
thrombotic B-NEG
microangiopathy I-NEG
may O
have O
been O
induced O
by O
chemotherapy O
. O

diagnosis O
of O
this O
potentially O
fatal O
complication O
may O
be O
delayed O
or O
missed O
if O
renal O
tissue O
or O
the O
peripheral O
blood O
smear O
is O
not O
examined O
, O
because O
renal B-NEG
failure I-NEG
may O
be O
ascribed O
to O
cisplatin O
nephrotoxicity B-NEG
and O
the O
anemia B-NEG
and O
thrombocytopenia B-NEG
to O
drug-induced O
bone B-NEG
marrow I-NEG
suppression I-NEG
. O

-DOCSTART- O

salvage O
therapy O
with O
nelarabine O
, O
etoposide O
, O
and O
cyclophosphamide O
in O
relapsed/refractory O
paediatric O
t-cell B-NEG
lymphoblastic I-NEG
leukaemia I-NEG
and I-NEG
lymphoma I-NEG
. O

a O
combination O
of O
5 O
d O
of O
nelarabine O
( O
arag O
) O
with O
5 O
d O
of O
etoposide O
( O
vp O
) O
and O
cyclophosphamide O
( O
cpm O
) O
and O
prophylactic O
intrathecal O
chemotherapy O
was O
used O
as O
salvage O
therapy O
in O
seven O
children O
with O
refractory O
or O
relapsed O
t-cell B-NEG
leukaemia I-NEG
or I-NEG
lymphoma I-NEG
. O

the O
most O
common O
side O
effects O
attributable O
to O
the O
arag O
included O
grade O
2 O
and O
3 O
sensory O
and O
motor O
neuropathy B-NEG
and O
musculoskeletal B-NEG
pain I-NEG
. O
haematological B-NEG
toxicity I-NEG
was O
greater O
for O
the O
combination O
than O
arag O
alone O
, O
although O
median O
time O
to O
neutrophil O
and O
platelet O
recovery O
was O
consistent O
with O
other O
salvage O
therapies O
. O

all O
patients O
had O
some O
response O
to O
the O
combined O
therapy O
and O
five O
of O
the O
seven O
went O
into O
complete O
remission O
after O
one O
or O
two O
courses O
of O
arag/vp/cpm O
. O

our O
experience O
supports O
the O
safety O
of O
giving O
arag O
as O
salvage O
therapy O
in O
synchrony O
with O
etoposide O
and O
cyclophosphamide O
, O
although O
neurological B-NEG
toxicity I-NEG
must O
be O
closely O
monitored O
. O

-DOCSTART- O

the O
3-week O
sulphasalazine O
syndrome O
strikes O
again O
. O

a O
34-year-old O
lady O
developed O
a O
constellation O
of O
dermatitis B-NEG
, O
fever B-NEG
, O
lymphadenopathy B-NEG
and O
hepatitis B-NEG
, O
beginning O
on O
the O
17th O
day O
of O
a O
course O
of O
oral O
sulphasalazine O
for O
sero-negative O
rheumatoid B-NEG
arthritis I-NEG
. O

cervical O
and O
inguinal O
lymph O
node O
biopsies O
showed O
the O
features O
of O
severe O
necrotising O
lymphadenitis B-NEG
, O
associated O
with O
erythrophagocytosis O
and O
prominent O
eosinophilic O
infiltrates O
, O
without O
viral O
inclusion O
bodies O
, O
suggestive O
of O
an O
adverse B-NEG
drug I-NEG
reaction I-NEG
.a O
week O
later O
, O
fulminant O
drug-induced B-NEG
hepatitis I-NEG
, O
associated O
with O
the O
presence O
of O
anti-nuclear O
autoantibodies O
( O
but O
not O
with O
other O
markers O
of O
autoimmunity B-NEG
), O
and O
accompanied O
by O
multi-organ B-NEG
failure I-NEG
and O
sepsis B-NEG
, O
supervened O
. O

she O
subsequently O
died O
some O
5 O
weeks O
after O
the O
commencement O
of O
her O
drug O
therapy.post-mortem O
examination O
showed O
evidence O
of O
massive B-NEG
hepatocellular I-NEG
necrosis I-NEG
, O
acute O
hypersensitivity O
myocarditis B-NEG
, O
focal O
acute O
tubulo-interstitial O
nephritis B-NEG
and O
extensive O
bone B-NEG
marrow I-NEG
necrosis I-NEG
, O
with O
no O
evidence O
of O
malignancy B-NEG
. O

it O
is O
thought O
that O
the O
clinico-pathological O
features O
and O
chronology O
of O
this O
case O
bore O
the O
hallmarks O
of O
the O
so-called O
3-week O
sulphasalazine O
syndrome O
, O
a O
rare O
, O
but O
often O
fatal O
, O
immunoallergic O
reaction O
to O
sulphasalazine O
. O

-DOCSTART- O

bupropion O
( O
zyban O
) O
toxicity B-NEG
. O

bupropion O
is O
a O
monocyclic O
antidepressant O
structurally O
related O
to O
amphetamine O
. O

zyban O
, O
a O
sustained-release O
formulation O
of O
bupropion O
hydrochloride O
, O
was O
recently O
released O
in O
ireland O
, O
as O
a O
smoking O
cessation O
aid O
. O

in O
the O
initial O
6 O
months O
since O
it's O
introduction O
, O
12 O
overdose B-NEG
cases O
have O
been O
reported O
to O
the O
national O
poisons O
information O
centre O
. O

8 O
patients O
developed O
symptoms O
of O
toxicity B-NEG
. O

common O
features O
included O
tachycardia B-NEG
, O
drowsiness O
, O
hallucinations B-NEG
and O
convulsions B-NEG
. O

two O
patients O
developed O
severe O
cardiac B-NEG
arrhythmias I-NEG
, O
including O
one O
patient O
who O
was O
resuscitated O
following O
a O
cardiac B-NEG
arrest I-NEG
. O

all O
patients O
recovered O
without O
sequelae O
. O

we O
report O
a O
case O
of O
a O
31 O
year O
old O
female O
who O
required O
admission O
to O
the O
intensive O
care O
unit O
for O
ventilation O
and O
full O
supportive O
therapy O
, O
following O
ingestion O
of O
13.5g O
bupropion O
. O

recurrent O
seizures B-NEG
were O
treated O
with O
diazepam O
and O
broad O
complex O
tachycardia B-NEG
was O
successfully O
treated O
with O
adenosine O
. O

zyban O
caused O
significant O
neurological B-NEG
and I-NEG
cardiovascular I-NEG
toxicity I-NEG
in O
overdose B-NEG
. O

the O
potential O
toxic O
effects O
should O
be O
considered O
when O
prescribing O
it O
as O
a O
smoking O
cessation O
aid O
. O

-DOCSTART- O

survey O
of O
complications O
of O
indocyanine O
green O
angiography O
in O
japan O
. O

purpose O
: O
we O
evaluated O
the O
safety O
of O
indocyanine O
green O
for O
use O
in O
fundus O
angiography O
. O

methods O
: O
we O
sent O
a O
questionnaire O
concerning O
complications O
of O
indocyanine O
green O
to O
32 O
institutions O
in O
japan O
, O
which O
were O
selected O
on O
the O
basis O
of O
the O
client O
list O
from O
the O
topcon O
company O
, O
which O
manufactures O
the O
indocyanine O
green O
fundus O
camera O
. O

results O
: O
ophthalmologists O
at O
15 O
institutions O
responded O
, O
reporting O
a O
total O
of O
3,774 O
indocyanine O
green O
angiograms O
performed O
on O
2,820 O
patients O
between O
june O
1984 O
and O
september O
1992 O
. O

before O
angiography O
, O
intradermal O
or O
intravenous O
indocyanine O
green O
testing O
, O
or O
both O
was O
performed O
at O
13 O
of O
15 O
institutions O
. O

for O
three O
patients O
, O
the O
decision O
was O
made O
not O
to O
proceed O
with O
angiography O
after O
positive O
preangiographic O
testing O
. O

the O
dosage O
of O
indocyanine O
green O
used O
for O
angiography O
varied O
from O
25 O
to O
75 O
mg O
, O
depending O
upon O
the O
institution O
. O

there O
were O
13 O
cases O
of O
adverse O
reactions O
(0.34%) O
, O
ten O
of O
which O
were O
mild O
reactions O
such O
as O
nausea B-NEG
, O
exanthema B-NEG
, O
urtication B-NEG
, O
itchiness B-NEG
, O
and O
urgency O
to O
defecate O
, O
and O
did O
not O
require O
treatment O
. O

also O
recorded O
were O
one O
case O
of O
pain B-NEG
of O
the O
vein O
, O
which O
required O
treatment O
, O
and O
two O
cases O
of O
hypotension B-NEG
. O

the O
two O
hypotensive B-NEG
patients O
required O
treatment O
for O
shock B-NEG
. O

conclusions O
: O
a O
comparison O
of O
frequency O
of O
adverse O
reactions O
to O
indocyanine O
green O
with O
the O
previously O
reported O
frequency O
of O
such O
reactions O
to O
fluorescein O
sodium O
indicated O
that O
indocyanine O
green O
is O
a O
safe O
as O
fluorescein O
for O
use O
in O
angiography O
. O

-DOCSTART- O

bradykinin O
receptors O
antagonists O
and O
nitric O
oxide O
synthase O
inhibitors O
in O
vincristine O
and O
streptozotocin O
induced O
hyperalgesia B-NEG
in O
chemotherapy O
and O
diabetic B-NEG
neuropathy I-NEG
rat O
model O
. O

purpose O
: O
the O
influence O
of O
an O
irreversible O
inhibitor O
of O
constitutive O
no O
synthase O
(l-noarg O
; O
1.0 O
mg/kg O
ip) O
, O
a O
relatively O
selective O
inhibitor O
of O
inducible O
no O
synthase O
(l-nil O
; O
1.0 O
mg/kg O
ip O
) O
and O
a O
relatively O
specific O
inhibitor O
of O
neuronal O
no O
synthase O
(7-ni O
; O
0.1 O
mg/kg O
ip) O
, O
on O
antihyperalgesic O
action O
of O
selective O
antagonists O
of O
b2 O
and O
b1 O
receptors O
: O
d-arg-[hyp3,thi5,d-tic7,oic8] O
bradykinin O
( O
hoe O
140 O
; O
70 O
nmol/kg O
ip O
) O
or O
des O
arg10 O
hoe O
140 O
( O
70 O
nmol/kg O
ip O
) O
respectively O
, O
in O
model O
of O
diabetic B-NEG
( O
streptozotocin-induced I-NEG
) O
and I-NEG
toxic I-NEG
( O
vincristine-induced I-NEG
) O
neuropathy I-NEG
was O
investigated O
. O

methods O
: O
the O
changes O
in O
pain B-NEG
thresholds O
were O
determined O
using O
mechanical O
stimuli--the O
modification O
of O
the O
classic O
paw O
withdrawal O
test O
described O
by O
randall-selitto O
. O

results O
: O
the O
results O
of O
this O
paper O
confirm O
that O
inhibition O
of O
bradykinin O
receptors O
and O
inducible O
no O
synthase O
but O
not O
neuronal O
no O
synthase O
activity O
reduces O
diabetic B-NEG
hyperalgesia I-NEG
. O

pretreatment O
with O
l-noarg O
and O
l-nil O
but O
not O
7-ni O
, O
significantly O
increases O
antihyperalgesic O
activity O
both O
hoe O
140 O
and O
des O
arg10 O
hoe O
140 O
. O

it O
was O
also O
shown O
that O
both O
products O
of O
inducible O
no O
synthase O
and O
neuronal O
no O
synthase O
activation O
as O
well O
as O
bradykinin O
are O
involved O
in O
hyperalgesia B-NEG
produced O
by O
vincristine O
. O

moreover O
, O
l-noarg O
and O
7-ni O
but O
not O
l-nil O
intensify O
antihyperalgesic O
activity O
of O
hoe O
140 O
or O
des-arg10hoe O
140 O
in O
toxic B-NEG
neuropathy I-NEG
. O

conclusions O
: O
results O
of O
these O
studies O
suggest O
that O
b1 O
and O
b2 O
receptors O
are O
engaged O
in O
transmission O
of O
nociceptive O
stimuli O
in O
both O
diabetic B-NEG
and I-NEG
toxic I-NEG
neuropathy I-NEG
. O

in O
streptozotocin-induced O
hyperalgesia B-NEG
, O
inducible O
no O
synthase O
participates O
in O
pronociceptive O
activity O
of O
bradykinin O
, O
whereas O
in O
vincristine-induced O
hyperalgesia B-NEG
bradykinin O
seemed O
to O
activate O
neuronal O
no O
synthase O
pathway O
. O

therefore O
, O
concomitant O
administration O
of O
small O
doses O
of O
bradykinin O
receptor O
antagonists O
and O
no O
synthase O
inhibitors O
can O
be O
effective O
in O
alleviation O
of O
neuropathic B-NEG
pain I-NEG
, O
even O
in O
hospital O
care O
. O

-DOCSTART- O

cardiac B-NEG
toxicity I-NEG
observed O
in O
association O
with O
high-dose O
cyclophosphamide-based O
chemotherapy O
for O
metastatic O
breast B-NEG
cancer I-NEG
. O

introduction O
: O
cyclophosphamide O
is O
an O
alkylating O
agent O
given O
frequently O
as O
a O
component O
of O
many O
conditioning O
regimens O
. O

in O
high O
doses O
, O
its O
nonhematological O
dose-limiting O
toxicity B-NEG
is O
cardiomyopathy B-NEG
. O

study O
design O
: O
we O
combined O
paclitaxel O
, O
melphalan O
and O
high-dose O
cyclophosphamide O
, O
thiotepa O
, O
and O
carboplatin O
in O
a O
triple O
sequential O
high-dose O
regimen O
for O
patients O
with O
metastatic O
breast B-NEG
cancer I-NEG
. O

analysis O
was O
performed O
on O
61 O
women O
with O
chemotherapy-responsive O
metastatic O
breast B-NEG
cancer I-NEG
receiving O
96-h O
infusional O
cyclophosphamide O
as O
part O
of O
a O
triple O
sequential O
high-dose O
regimen O
to O
assess O
association O
between O
presence O
of O
peritransplant O
congestive B-NEG
heart I-NEG
failure I-NEG
( O
chf B-NEG
) O
and O
the O
following O
pretreatment O
characteristics O
: O
presence O
of O
electrocardiogram O
( O
ekg O
) O
abnormalities O
, O
age O
, O
hypertension B-NEG
, O
prior O
cardiac O
history O
, O
smoking O
, O
diabetes B-NEG
mellitus I-NEG
, O
prior O
use O
of O
anthracyclines O
, O
and O
left-sided O
chest O
irradiation O
. O

results O
: O
six O
of O
61 O
women O
( O
10% O
) O
developed O
clinically O
reversible O
grade O
3 O
chf B-NEG
following O
infusional O
cyclophosphamide O
with O
a O
median O
percent O
decline O
in O
ejection O
fraction O
of O
31% O
. O

incidence O
of O
transient O
cyclophosphamide-related O
cardiac B-NEG
toxicity I-NEG
( O
10% O
) O
is O
comparable O
to O
previous O
recorded O
literature O
. O

older O
age O
was O
significantly O
correlated O
with O
the O
chf B-NEG
development O
; O
with O
median O
ages O
for O
the O
entire O
group O
and O
for O
patients O
developing O
chf B-NEG
of O
45 O
and O
59 O
, O
respectively O
. O

no O
association O
was O
found O
with O
other O
pretreatment O
characteristics O
. O

conclusions O
: O
as O
a O
result O
of O
these O
findings O
, O
oncologists O
should O
carefully O
monitor O
fluid O
balance O
in O
older O
patients O
. O

routine O
ekg O
monitoring O
during O
infusional O
cyclophosphamide O
did O
not O
predict O
chf B-NEG
development O
. O

-DOCSTART- O

inappropriate O
use O
of O
carbamazepine O
and O
vigabatrin O
in O
typical O
absence B-NEG
seizures I-NEG
. O

carbamazepine O
and O
vigabatrin O
are O
contraindicated O
in O
typical O
absence B-NEG
seizures I-NEG
. O

of O
18 O
consecutive O
referrals O
of O
children O
with O
resistant O
typical O
absences O
only O
, O
eight O
were O
erroneously O
treated O
with O
carbamazepine O
either O
as O
monotherapy O
or O
as O
an O
add-on O
. O

vigabatrin O
was O
also O
used O
in O
the O
treatment O
of O
two O
children O
. O

frequency O
of O
absences O
increased O
in O
four O
children O
treated O
with O
carbamazepine O
and O
two O
of O
these O
developed O
myoclonic B-NEG
jerks I-NEG
, O
which O
resolved O
on O
withdrawal O
of O
carbamazepine O
. O

absences O
were O
aggravated O
in O
both O
cases O
where O
vigabatrin O
was O
added O
on O
to O
concurrent O
treatment O
. O

optimal O
control O
of O
the O
absences O
was O
achieved O
with O
sodium O
valproate O
, O
lamotrigine O
, O
or O
ethosuximide O
alone O
or O
in O
combination O
. O

-DOCSTART- O

hemolytic B-NEG
anemia I-NEG
associated O
with O
the O
use O
of O
omeprazole O
. O

omeprazole O
is O
the O
first O
drug O
designed O
to O
block O
the O
final O
step O
in O
the O
acid O
secretory O
process O
within O
the O
parietal O
cell O
. O

it O
has O
been O
shown O
to O
be O
extremely O
effective O
in O
the O
treatment O
of O
peptic B-NEG
ulcer I-NEG
disease I-NEG
, O
reflux B-NEG
esophagitis I-NEG
, O
and O
the O
zollinger-ellison B-NEG
syndrome I-NEG
. O

although O
clinical O
experience O
with O
omeprazole O
is O
still O
limited O
, O
many O
controlled O
studies O
have O
established O
the O
short-term O
safety O
of O
this O
drug O
. O

we O
report O
the O
first O
case O
of O
a O
serious O
short-term O
adverse O
reaction O
with O
the O
use O
of O
omeprazole O
: O
hemolytic B-NEG
anemia I-NEG
. O

the O
patient O
developed O
weakness O
, O
lethargy B-NEG
, O
and O
shortness B-NEG
of I-NEG
breath I-NEG
2 O
days O
after O
starting O
therapy O
with O
omeprazole O
. O

two O
weeks O
after O
the O
initiation O
of O
therapy O
, O
her O
hematocrit O
had O
decreased O
from O
44.1% O
to O
20.4% O
, O
and O
she O
had O
a O
positive O
direct O
coombs O
antiglobulin O
test O
and O
an O
elevated O
indirect O
bilirubin O
. O

after O
she O
discontinued O
the O
omeprazole O
, O
her O
hemoglobin O
and O
hematocrit O
gradually O
returned O
to O
normal O
. O

the O
mechanism O
by O
which O
omeprazole O
caused O
the O
patient's O
hemolytic B-NEG
anemia I-NEG
is O
uncertain O
, O
but O
physicians O
should O
be O
alerted O
to O
this O
possible O
adverse O
effect O
. O

-DOCSTART- O

the O
use O
and O
toxicity B-NEG
of O
didanosine O
( O
ddi O
) O
in O
hiv B-NEG
antibody-positive I-NEG
individuals O
intolerant O
to O
zidovudine O
( O
azt O
) O
one O
hundred O
and O
fifty-one O
patients O
intolerant O
to O
zidovudine O
( O
azt O
) O
received O
didanosine O
( O
ddi O
) O
to O
a O
maximum O
dose O
of O
12.5 O
mg/kg/day O
. O

patient O
response O
was O
assessed O
using O
changes O
in O
cd4+ O
lymphocyte O
subset O
count O
, O
hiv O
p24 O
antigen O
, O
weight O
, O
and O
quality O
of O
life O
. O

seventy O
patients O
developed O
major O
opportunistic B-NEG
infections I-NEG
whilst O
on O
therapy O
; O
this O
was O
the O
first O
aids B-NEG
diagnosis O
in O
17 O
. O

only O
minor O
changes O
in O
cd4+ O
lymphocyte O
subset O
count O
were O
observed O
in O
aids B-NEG
patients O
, O
although O
a O
more O
significant O
rise O
occurred O
in O
those O
with O
earlier O
stages O
of O
disease O
. O

of O
those O
positive O
for O
p24 O
antigen O
at O
the O
commencement O
of O
the O
study O
67% O
showed O
a O
positive O
response O
, O
and O
this O
was O
most O
likely O
in O
those O
with O
cd4+ O
lymphocyte O
subset O
counts O
above O
100 O
mm3 O
. O

a O
positive O
weight O
response O
was O
seen O
in O
16% O
of O
patients O
. O

most O
patients O
showed O
improvement O
in O
individual O
parameters O
and O
global O
score O
of O
quality O
of O
life O
. O

adverse O
reactions O
possibly O
attributable O
to O
didanosine O
were O
common O
. O

the O
most O
common O
side-effect O
was O
diarrhoea B-NEG
, O
which O
resulted O
in O
cessation O
of O
therapy O
in O
19 O
individuals O
. O
peripheral B-NEG
neuropathy I-NEG
occurred O
in O
12 O
patients O
and O
pancreatitis B-NEG
in O
six O
. O

thirteen O
patients O
developed O
a O
raised O
serum O
amylase O
without O
abdominal B-NEG
pain I-NEG
. O

seven O
patients O
developed O
glucose B-NEG
tolerance I-NEG
curves I-NEG
characteristic O
of O
diabetes B-NEG
but O
these O
were O
mild O
, O
did O
not O
require O
treatment O
and O
returned O
to O
normal O
on O
ceasing O
didanosine O
. O

-DOCSTART- O

can O
angiogenesis O
be O
a O
target O
of O
treatment O
for O
ribavirin O
associated O
hemolytic B-NEG
anemia I-NEG
? O

background/aims O
: O
recently O
ribavirin O
has O
been O
found O
to O
inhibit O
angiogenesis O
and O
a O
number O
of O
angiogenesis O
inhibitors O
such O
as O
sunitinib O
and O
sorafenib O
have O
been O
found O
to O
cause O
acute O
hemolysis B-NEG
. O

we O
aimed O
to O
investigate O
whether O
there O
is O
a O
relation O
between O
hemoglobin O
, O
haptoglobin O
and O
angiogenesis O
soluble O
markers O
which O
are O
modifiable O
and O
can O
help O
in O
developing O
strategies O
against O
anemia B-NEG
. O

methods O
: O
fourteen O
patients O
chronically B-NEG
infected I-NEG
with I-NEG
hepatitis I-NEG
c I-NEG
virus I-NEG
were O
treated O
by O
pegylated O
interferon O
alpha O
2a O
and O
ribavirin O
. O

serum O
hemoglobin O
, O
haptoglobin O
and O
angiogenesis O
markers O
of O
vascular O
endothelial O
growth O
factor O
and O
angiopoetin-2 O
were O
investigated O
before O
and O
after O
therapy O
. O

results O
: O
we O
observed O
a O
significant O
decrease O
in O
haptoglobin O
levels O
at O
the O
end O
of O
the O
treatment O
period O
. O

hemoglobin O
levels O
also O
decreased O
but O
insignificantly O
by O
treatment O
. O

in O
contrast O
with O
the O
literature O
, O
serum O
levels O
of O
angiogenesis O
factors O
did O
not O
change O
significantly O
by O
pegylated O
interferon O
and O
ribavirin O
therapy O
. O

we O
found O
no O
correlation O
of O
angiogenesis O
soluble O
markers O
with O
either O
hemoglobin O
or O
haptoglobin O
. O

conclusion O
: O
this O
is O
the O
first O
study O
in O
the O
literature O
investigating O
a O
link O
between O
angiogenesis O
soluble O
markers O
and O
ribavirin O
induced O
anemia B-NEG
in O
patients O
with O
hepatitis B-NEG
c I-NEG
and O
we O
could O
not O
find O
any O
relation O
. O

future O
research O
with O
larger O
number O
of O
patients O
is O
needed O
to O
find O
out O
modifiable O
factors O
that O
will O
improve O
the O
safety O
of O
ribavirin O
therapy O
. O

-DOCSTART- O

cocaine O
causes O
memory B-NEG
and I-NEG
learning I-NEG
impairments I-NEG
in O
rats O
: O
involvement O
of O
nuclear O
factor O
kappa O
b O
and O
oxidative O
stress O
, O
and O
prevention O
by O
topiramate O
. O

different O
mechanisms O
have O
been O
suggested O
for O
cocaine O
toxicity B-NEG
including O
an O
increase O
in O
oxidative O
stress O
but O
the O
association O
between O
oxidative O
status O
in O
the O
brain O
and O
cocaine O
induced-behaviour O
is O
poorly O
understood O
. O

nuclear O
factor O
kappa O
b O
( O
nfkappab O
) O
is O
a O
sensor O
of O
oxidative O
stress O
and O
participates O
in O
memory O
formation O
that O
could O
be O
involved O
in O
drug O
toxicity B-NEG
and O
addiction O
mechanisms O
. O

therefore O
nfkappab O
activity O
, O
oxidative O
stress O
, O
neuronal O
nitric O
oxide O
synthase O
( O
nnos O
) O
activity O
, O
spatial O
learning O
and O
memory O
as O
well O
as O
the O
effect O
of O
topiramate O
, O
a O
previously O
proposed O
therapy O
for O
cocaine B-NEG
addiction I-NEG
, O
were O
evaluated O
in O
an O
experimental O
model O
of O
cocaine O
administration O
in O
rats O
. O

nfkappab O
activity O
was O
decreased O
in O
the O
frontal O
cortex O
of O
cocaine O
treated O
rats O
, O
as O
well O
as O
gsh O
concentration O
and O
glutathione O
peroxidase O
activity O
in O
the O
hippocampus O
, O
whereas O
nnos O
activity O
in O
the O
hippocampus O
was O
increased O
. O

memory O
retrieval O
of O
experiences O
acquired O
prior O
to O
cocaine O
administration O
was O
impaired O
and O
negatively O
correlated O
with O
nfkappab O
activity O
in O
the O
frontal O
cortex O
. O

in O
contrast O
, O
learning O
of O
new O
tasks O
was O
enhanced O
and O
correlated O
with O
the O
increase O
of O
nnos O
activity O
and O
the O
decrease O
of O
glutathione O
peroxidase O
. O

these O
results O
provide O
evidence O
for O
a O
possible O
mechanistic O
role O
of O
oxidative O
and O
nitrosative O
stress O
and O
nfkappab O
in O
the O
alterations O
induced O
by O
cocaine O
. O

topiramate O
prevented O
all O
the O
alterations O
observed O
, O
showing O
novel O
neuroprotective O
properties O
. O

-DOCSTART- O

antinociceptive O
and O
antiamnesic O
properties O
of O
the O
presynaptic O
cholinergic O
amplifier O
pg-9 O
. O

the O
antinociceptive O
effect O
of O
3 O
alpha-tropyl O
2-(p-bromophenyl)propionate O
[(+/-)-pg-9] O
( O
10-40 O
mg O
kg-1 O
s.c. O
; O
30-60 O
mg O
kg-1 O
p.o. O
; O
10-30 O
mg O
kg-1 O
i.v. O
; O
10-30 O
micrograms/mouse O
i.c.v. O
) O
was O
examined O
in O
mice O
, O
rats O
and O
guinea O
pigs O
by O
use O
of O
the O
hot-plate O
, O
abdominal-constriction O
, O
tail-flick O
and O
paw-pressure O
tests O
. O

( O
+/-)-pg-9 O
antinociception O
peaked O
15 O
min O
after O
injection O
and O
then O
slowly O
diminished O
. O

the O
antinociception O
produced O
by O
( O
+/-)-pg-9 O
was O
prevented O
by O
the O
unselective O
muscarinic O
antagonist O
atropine O
, O
the O
m1-selective O
antagonists O
pirenzepine O
and O
dicyclomine O
and O
the O
acetylcholine O
depletor O
hemicholinium-3 O
, O
but O
not O
by O
the O
opioid O
antagonist O
naloxone O
, O
the O
gamma-aminobutyric O
acidb O
antagonist O
3-aminopropyl-diethoxy-methyl-phosphinic O
acid O
, O
the O
h3 O
agonist O
r-(alpha)-methylhistamine O
, O
the O
d2 O
antagonist O
quinpirole O
, O
the O
5-hydroxytryptamine4 O
antagonist O
2-methoxy-4-amino-5-chlorobenzoic O
acid O
2-(diethylamino)ethyl O
ester O
hydrochloride O
, O
the O
5-hydroxytryptamin1a O
antagonist O
1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine O
hydrobromide O
and O
the O
polyamines O
depletor O
reserpine O
. O

based O
on O
these O
data O
, O
it O
can O
be O
postulated O
that O
( O
+/-)-pg-9 O
exerted O
an O
antinociceptive O
effect O
mediated O
by O
a O
central O
potentiation O
of O
cholinergic O
transmission O
. O

( O
+/-)-pg-9 O
( O
10-40 O
mg O
kg-1 O
i.p. O
) O
was O
able O
to O
prevent O
amnesia B-NEG
induced O
by O
scopolamine O
(1 O
mg O
kg-1 O
i.p. O
) O
and O
dicyclomine O
(2 O
mg O
kg-1 O
i.p. O
) O
in O
the O
mouse O
passive-avoidance O
test O
. O

affinity O
profiles O
of O
( O
+/-)-pg-9 O
for O
muscarinic O
receptor O
subtypes O
, O
determined O
by O
functional O
studies O
( O
rabbit O
vas O
deferens O
for O
m1 O
, O
guinea O
pig O
atrium O
for O
m2 O
, O
guinea O
pig O
ileum O
for O
m3 O
and O
immature O
guinea O
pig O
uterus O
for O
putative O
m4) O
, O
have O
shown O
an O
m4/m1 O
selectivity O
ratio O
of O
10.2 O
that O
might O
be O
responsible O
for O
the O
antinociception O
and O
the O
anti- O
amnesic B-NEG
effect O
induced O
by O
( O
+/-)-pg-9 O
through O
an O
increase O
in O
acetylcholine O
extracellular O
levels O
. O

in O
the O
antinociceptive O
and O
antiamnesic O
dose O
range O
, O
( O
+/-)-pg-9 O
did O
not O
impair O
mouse O
performance O
evaluated O
by O
the O
rota-rod O
test O
and O
animex O
apparatus O
. O

-DOCSTART- O

hyperbaric O
oxygen O
therapy O
for O
control O
of O
intractable O
cyclophosphamide-induced O
hemorrhagic B-NEG
cystitis I-NEG
. O

we O
report O
a O
case O
of O
intractable O
hemorrhagic B-NEG
cystitis I-NEG
due O
to O
cyclophosphamide O
therapy O
for O
wegener's B-NEG
granulomatosis I-NEG
. O

conservative O
treatment O
, O
including O
bladder O
irrigation O
with O
physiological O
saline O
and O
instillation O
of O
prostaglandin O
f2 O
alpha O
, O
failed O
to O
totally O
control O
hemorrhage B-NEG
. O

we O
then O
used O
hyperbaric O
oxygen O
at O
an O
absolute O
pressure O
of O
2 O
atm O
, O
5 O
days O
a O
week O
for O
8 O
consecutive O
weeks O
. O

the O
bleeding B-NEG
ceased O
completely O
by O
the O
end O
of O
treatment O
and O
the O
patient O
remained O
free O
of O
hematuria B-NEG
thereafter O
. O

no O
side O
effect O
was O
noted O
during O
the O
course O
of O
therapy O
. O

in O
future O
, O
this O
form O
of O
therapy O
can O
offer O
a O
safe O
alternative O
in O
the O
treatment O
of O
cyclophosphamide-induced O
hemorrhagic B-NEG
cystitis I-NEG
. O

-DOCSTART- O

further O
studies O
on O
effects O
of O
irrigation O
solutions O
on O
rat O
bladders O
. O

further O
studies O
on O
the O
effects O
of O
certain O
irrigating O
fluids O
on O
the O
rat O
bladder O
for O
18 O
hours O
are O
reported O
. O

the O
results O
have O
shown O
that O
the O
degradation O
product O
p-choloroaniline O
is O
not O
a O
significant O
factor O
in O
chlorhexidine-digluconate O
associated O
erosive O
cystitis B-NEG
. O

a O
high O
percentage O
of O
kanamycin-colistin O
and O
povidone-iodine O
irrigations O
were O
associated O
with O
erosive O
cystitis B-NEG
and O
suggested O
a O
possible O
complication O
with O
human O
usage O
. O

picloxydine O
irrigations O
appeared O
to O
have O
a O
lower O
incidence O
of O
erosive O
cystitis B-NEG
but O
further O
studies O
would O
have O
to O
be O
performed O
before O
it O
could O
be O
recommended O
for O
use O
in O
urological O
procedures O
. O

-DOCSTART- O

clinical O
experiences O
in O
an O
open O
and O
a O
double-blind O
trial O
. O

a O
total O
of O
sixty O
patients O
were O
trated O
with O
bromperidol O
first O
in O
open O
conditions O
( O
20 O
patients) O
, O
then O
on O
a O
double O
blind O
basis O
( O
40 O
patients O
) O
with O
haloperidol O
as O
the O
reference O
substance O
. O

the O
open O
study O
lasted O
for O
four O
weeks O
; O
the O
drug O
was O
administrated O
in O
the O
form O
of O
1 O
mg O
tablets O
. O

the O
daily O
dose O
( O
initial O
dose O
: O
1 O
mg O
; O
mean O
dose O
at O
the O
end O
of O
the O
trial O
: O
4.47 O
mg O
) O
was O
always O
administered O
in O
one O
single O
dose O
. O

nineteen O
patients O
finished O
the O
trial O
, O
and O
in O
18 O
cases O
the O
therapeutic O
result O
was O
considered O
very O
good O
to O
good O
. O

these O
results O
were O
confirmed O
by O
statistical O
analysis O
. O

nine O
patients O
exhibited O
mild O
to O
moderate O
extrapyramidal B-NEG
concomitant I-NEG
symptoms I-NEG
; O
no O
other O
side O
effects O
were O
observed O
. O

the O
results O
of O
detailed O
laboratory O
tests O
and O
evaluations O
of O
various O
quantitative O
and O
qualitative O
tolerability O
parameters O
were O
not O
indicative O
of O
toxic O
effects O
. O

in O
the O
double O
blind O
study O
with O
haloperidol O
, O
both O
substances O
were O
found O
to O
be O
highly O
effective O
in O
the O
treatment O
of O
psychotic B-NEG
syndromes I-NEG
belonging I-NEG
predominantly I-NEG
to I-NEG
the I-NEG
schizophrenia I-NEG
group I-NEG
. O

certain O
clues O
, O
including O
the O
onset O
of O
action O
, O
seem O
to O
be O
indicative O
of O
the O
superiority O
of O
bromperidol O
. O

no O
differences O
were O
observed O
with O
respect O
to O
side O
effects O
and O
general O
tolerability O
. O

-DOCSTART- O

curcumin O
ameliorates O
cognitive B-NEG
dysfunction I-NEG
and O
oxidative O
damage O
in O
phenobarbitone O
and O
carbamazepine O
administered O
rats O
. O

the O
antiepileptic O
drugs O
, O
phenobarbitone O
and O
carbamazepine O
are O
well O
known O
to O
cause O
cognitive B-NEG
impairment I-NEG
on O
chronic O
use O
. O

the O
increase O
in O
free O
radical O
generation O
has O
been O
implicated O
as O
one O
of O
the O
important O
mechanisms O
of O
cognitive B-NEG
impairment I-NEG
by O
antiepileptic O
drugs O
. O

curcumin O
has O
shown O
antioxidant O
, O
anti-inflammatory O
and O
neuro-protective O
properties O
. O

therefore O
, O
the O
present O
study O
was O
carried O
out O
to O
investigate O
the O
effect O
of O
chronic O
curcumin O
administration O
on O
phenobarbitone- O
and O
carbamazepine-induced O
cognitive B-NEG
impairment I-NEG
and O
oxidative O
stress O
in O
rats O
. O

pharmacokinetic O
interactions O
of O
curcumin O
with O
phenobarbitone O
and O
carbamazepine O
were O
also O
studied O
. O

vehicle/drugs O
were O
administered O
daily O
for O
21days O
to O
male O
wistar O
rats O
. O

passive O
avoidance O
paradigm O
and O
elevated O
plus O
maze O
test O
were O
used O
to O
assess O
cognitive O
function O
. O

at O
the O
end O
of O
study O
period O
, O
serum O
phenobarbitone O
and O
carbamazepine O
, O
whole O
brain O
malondialdehyde O
and O
reduced O
glutathione O
levels O
were O
estimated O
. O

the O
administration O
of O
phenobarbitone O
and O
carbamazepine O
for O
21days O
caused O
a O
significant O
impairment B-NEG
of I-NEG
learning I-NEG
and I-NEG
memory I-NEG
as O
well O
as O
an O
increased O
oxidative O
stress O
. O

concomitant O
curcumin O
administration O
prevented O
the O
cognitive B-NEG
impairment I-NEG
and O
decreased O
the O
increased O
oxidative O
stress O
induced O
by O
these O
antiepileptic O
drugs O
. O

curcumin O
co-administration O
did O
not O
cause O
any O
significant O
alteration O
in O
the O
serum O
concentrations O
of O
both O
phenobarbitone O
as O
well O
as O
carbamazepine O
. O

these O
results O
show O
that O
curcumin O
has O
beneficial O
effect O
in O
mitigating O
the O
deterioration B-NEG
of I-NEG
cognitive I-NEG
functions I-NEG
and O
oxidative O
damage O
in O
rats O
treated O
with O
phenobarbitone O
and O
carbamazepine O
without O
significantly O
altering O
their O
serum O
concentrations O
. O

the O
findings O
suggest O
that O
curcumin O
can O
be O
considered O
as O
a O
potential O
safe O
and O
effective O
adjuvant O
to O
phenobarbitone O
and O
carbamazepine O
therapy O
in O
preventing O
cognitive B-NEG
impairment I-NEG
associated O
with O
these O
drugs O
. O

-DOCSTART- O

pyrrolidine O
dithiocarbamate O
protects O
the O
piriform O
cortex O
in O
the O
pilocarpine O
status B-NEG
epilepticus I-NEG
model O
. O

pyrrolidine O
dithiocarbamate O
( O
pdtc O
) O
has O
a O
dual O
mechanism O
of O
action O
as O
an O
antioxidant O
and O
an O
inhibitor O
of O
the O
transcription O
factor O
kappa-beta O
. O

both O
, O
production O
of O
reactive O
oxygen O
species O
as O
well O
as O
activation O
of O
nf-kappab O
have O
been O
implicated O
in O
severe O
neuronal B-NEG
damage I-NEG
in O
different O
sub-regions O
of O
the O
hippocampus O
as O
well O
as O
in O
the O
surrounding O
cortices O
. O

the O
effect O
of O
pdtc O
on O
status B-NEG
epilepticus I-NEG
-associated O
cell O
loss O
in O
the O
hippocampus O
and O
piriform O
cortex O
was O
evaluated O
in O
the O
rat O
fractionated O
pilocarpine O
model O
. O

treatment O
with O
150 O
mg/kg O
pdtc O
before O
and O
following O
status B-NEG
epilepticus I-NEG
significantly O
increased O
the O
mortality O
rate O
to O
100% O
. O

administration O
of O
50 O
mg/kg O
pdtc O
( O
low-dose O
) O
did O
not O
exert O
major O
effects O
on O
the O
development O
of O
a O
status B-NEG
epilepticus I-NEG
or O
the O
mortality O
rate O
. O

in O
vehicle-treated O
rats O
, O
status B-NEG
epilepticus I-NEG
caused O
pronounced O
neuronal B-NEG
damage I-NEG
in O
the O
piriform O
cortex O
comprising O
both O
pyramidal O
cells O
and O
interneurons O
. O

low-dose O
pdtc O
treatment O
almost O
completely O
protected O
from O
lesions O
in O
the O
piriform O
cortex O
. O

a O
significant O
decrease O
in O
neuronal O
density O
of O
the O
hippocampal O
hilar O
formation O
was O
identified O
in O
vehicle- O
and O
pdtc-treated O
rats O
following O
status B-NEG
epilepticus I-NEG
. O

in O
conclusion O
, O
the O
nf-kappab O
inhibitor O
and O
antioxidant O
pdtc O
protected O
the O
piriform O
cortex O
, O
whereas O
it O
did O
not O
affect O
hilar O
neuronal B-NEG
loss I-NEG
. O

these O
data O
might O
indicate O
that O
the O
generation O
of O
reactive O
oxygen O
species O
and O
activation O
of O
nf-kappab O
plays O
a O
more O
central O
role O
in O
seizure B-NEG
-associated O
neuronal B-NEG
damage I-NEG
in O
the O
temporal O
cortex O
as O
compared O
to O
the O
hippocampal O
hilus O
. O

however O
, O
future O
investigations O
are O
necessary O
to O
exactly O
analyze O
the O
biochemical O
mechanisms O
by O
which O
pdtc O
exerted O
its O
beneficial O
effects O
in O
the O
piriform O
cortex O
. O

-DOCSTART- O

safety O
profile O
of O
a O
nicotine O
lozenge O
compared O
with O
that O
of O
nicotine O
gum O
in O
adult O
smokers O
with O
underlying O
medical O
conditions O
: O
a O
12-week O
, O
randomized O
, O
open-label O
study O
. O

background O
: O
nicotine O
polacrilex O
lozenges O
deliver O
25% O
to O
27% O
more O
nicotine O
compared O
with O
equivalent O
doses O
of O
nicotine O
polacrilex O
gum O
. O

the O
increased O
nicotine O
exposure O
from O
the O
lozenge O
has O
raised O
questions O
about O
the O
relative O
safety O
of O
the O
lozenge O
and O
gum O
. O

objective O
: O
the O
objective O
of O
this O
study O
was O
to O
compare O
the O
safety O
profiles O
of O
the O
4-mg O
nicotine O
lozenge O
and O
4-mg O
nicotine O
gum O
in O
smokers O
with O
selected O
label-restricted O
diseases O
. O

methods O
: O
this O
was O
a O
multicenter O
, O
randomized O
, O
open-label O
study O
in O
adult O
smokers O
with O
heart B-NEG
disease I-NEG
, O
hypertension B-NEG
not O
controlled O
by O
medication O
, O
and/or O
diabetes B-NEG
mellitus I-NEG
. O

patients O
were O
randomized O
in O
a O
1:1 O
ratio O
to O
receive O
the O
4-mg O
nicotine O
lozenge O
or O
4-mg O
nicotine O
gum O
. O

safety O
assessments O
were O
made O
at O
baseline O
and O
at O
2, O
4, O
6, O
and O
12 O
weeks O
after O
the O
start O
of O
product O
use O
. O

results O
: O
nine O
hundred O
one O
patients O
were O
randomized O
to O
treatment O
, O
447 O
who O
received O
the O
lozenge O
and O
454 O
who O
received O
the O
gum O
( O
safety O
population) O
. O

the O
majority O
were O
women O
(52.7%) O
. O

patients' O
mean O
age O
was O
53.9 O
years O
, O
their O
mean O
weight O
was O
193.9 O
pounds O
, O
and O
they O
smoked O
a O
mean O
of O
25.2 O
cigarettes O
per O
day O
at O
baseline O
. O

five O
hundred O
fifty-three O
patients O
, O
264 O
taking O
the O
lozenge O
and O
289 O
taking O
the O
gum O
, O
used O
the O
study O
product O
for O
> O
or O
=4 O
days O
per O
week O
during O
the O
first O
2 O
weeks O
( O
evaluable O
population) O
. O

the O
nicotine O
lozenge O
and O
nicotine O
gum O
were O
equally O
well O
tolerated O
, O
despite O
increased O
nicotine O
exposure O
from O
the O
lozenge O
. O

the O
incidence O
of O
adverse O
events O
in O
the O
2 O
groups O
was O
similar O
during O
the O
first O
2 O
weeks O
of O
product O
use O
( O
evaluation O
population O
: O
55.3% O
lozenge O
, O
54.7% O
gum) O
, O
as O
well O
as O
during O
the O
entire O
study O
( O
safety O
population O
: O
63.8% O
and O
58.6% O
, O
respectively) O
. O

stratification O
of O
patients O
by O
sex O
, O
age O
, O
extent O
of O
concurrent O
smoking O
, O
extent O
of O
product O
use O
, O
and O
severity O
of O
adverse O
events O
revealed O
no O
clinically O
significant O
differences O
between O
the O
lozenge O
and O
gum O
. O

the O
most O
common O
adverse O
events O
were O
nausea B-NEG
( O
17.2% O
and O
16.1% O
; O
95% O
ci O
, O
-3.7 O
to O
6.0) O
, O
hiccups B-NEG
( O
10.7% O
and O
6.6% O
; O
95% O
ci O
, O
0.5 O
to O
7.8) O
, O
and O
headache B-NEG
( O
8.7% O
and O
9.9% O
; O
95% O
cl O
, O
-5.0 O
to O
2.6) O
. O

serious O
adverse O
events O
were O
reported O
in O
11 O
and O
13 O
patients O
in O
the O
respective O
groups O
. O

fewer O
than O
6% O
of O
patients O
in O
either O
group O
were O
considered O
by O
the O
investigator O
to O
have O
a O
worsening O
of O
their O
overall O
disease O
condition O
during O
the O
study O
. O

the O
majority O
of O
patients O
( O
>60% O
) O
experienced O
no O
change O
in O
their O
disease O
status O
from O
baseline O
. O

conclusion O
: O
the O
4-mg O
nicotine O
lozenge O
and O
4-mg O
nicotine O
gum O
had O
comparable O
safety O
profiles O
in O
these O
patients O
with O
label-restricted O
medical O
conditions O
. O

-DOCSTART- O

development O
of O
levodopa-induced O
dyskinesias B-NEG
in O
parkinsonian B-NEG
monkeys O
may O
depend O
upon O
rate O
of O
symptom O
onset O
and/or O
duration O
of O
symptoms O
. O

levodopa-induced O
dyskinesias B-NEG
( O
lids B-NEG
) O
present O
a O
major O
problem O
for O
the O
long-term O
management O
of O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
patients O
. O

due O
to O
the O
interdependence O
of O
risk O
factors O
in O
clinical O
populations O
, O
it O
is O
difficult O
to O
independently O
examine O
factors O
that O
may O
influence O
the O
development O
of O
lids B-NEG
. O

using O
macaque O
monkeys O
with O
different O
types O
of O
mptp-induced O
parkinsonism B-NEG
, O
the O
current O
study O
evaluated O
the O
degree O
to O
which O
rate O
of O
symptom O
progression O
, O
symptom O
severity O
, O
and O
response O
to O
and O
duration O
of O
levodopa O
therapy O
may O
be O
involved O
in O
the O
development O
of O
lids B-NEG
. O

monkeys O
with O
acute O
( O
short-term O
) O
mptp O
exposure O
, O
rapid O
symptom O
onset O
and O
short O
symptom O
duration O
prior O
to O
initiation O
of O
levodopa O
therapy O
developed O
dyskinesia B-NEG
between O
11 O
and O
24 O
days O
of O
daily O
levodopa O
administration O
. O

in O
contrast O
, O
monkeys O
with O
long-term O
mptp O
exposure O
, O
slow O
symptom O
progression O
and/or O
long O
symptom O
duration O
prior O
to O
initiation O
of O
levodopa O
therapy O
were O
more O
resistant O
to O
developing O
lids B-NEG
(e.g. O
, O
dyskinesia B-NEG
developed O
no O
sooner O
than O
146 O
days O
of O
chronic O
levodopa O
administration) O
. O

all O
animals O
were O
similarly O
symptomatic O
at O
the O
start O
of O
levodopa O
treatment O
and O
had O
similar O
therapeutic O
responses O
to O
the O
drug O
. O

these O
data O
suggest O
distinct O
differences O
in O
the O
propensity O
to O
develop O
lids B-NEG
in O
monkeys O
with O
different O
rates O
of O
symptom O
progression O
or O
symptom O
durations O
prior O
to O
levodopa O
and O
demonstrate O
the O
value O
of O
these O
models O
for O
further O
studying O
the O
pathophysiology O
of O
lids B-NEG
. O

-DOCSTART- O

propylthiouracil-induced O
perinuclear-staining O
antineutrophil O
cytoplasmic O
autoantibody-positive O
vasculitis B-NEG
in O
conjunction O
with O
pericarditis B-NEG
. O

objective O
: O
to O
describe O
a O
case O
of O
propylthiouracil-induced O
vasculitis B-NEG
manifesting O
with O
pericarditis B-NEG
. O

methods O
: O
we O
present O
the O
first O
case O
report O
of O
a O
woman O
with O
hyperthyroidism B-NEG
treated O
with O
propylthiouracil O
in O
whom O
a O
syndrome O
of O
pericarditis B-NEG
, O
fever B-NEG
, O
and O
glomerulonephritis B-NEG
developed O
. O

serologic O
testing O
and O
immunologic O
studies O
were O
done O
, O
and O
a O
pericardial O
biopsy O
was O
performed O
. O

results O
: O
a O
25-year-old O
woman O
with O
graves' B-NEG
disease I-NEG
had O
a O
febrile B-NEG
illness I-NEG
and O
evidence O
of O
pericarditis B-NEG
, O
which O
was O
confirmed O
by O
biopsy O
. O

serologic O
evaluation O
revealed O
the O
presence O
of O
perinuclear-staining O
antineutrophil O
cytoplasmic O
autoantibodies O
( O
panca O
) O
against O
myeloperoxidase O
(mpo) O
. O

propylthiouracil O
therapy O
was O
withdrawn O
, O
and O
she O
was O
treated O
with O
a O
1-month O
course O
of O
prednisone O
, O
which O
alleviated O
her O
symptoms O
. O

a O
literature O
review O
revealed O
no O
prior O
reports O
of O
pericarditis B-NEG
in O
anti-mpo O
panca-positive O
vasculitis B-NEG
associated O
with O
propylthio- O
uracil O
therapy O
. O

conclusion O
: O
pericarditis B-NEG
may O
be O
the O
initial O
manifestation O
of O
drug-induced O
vasculitis B-NEG
attributable O
to O
propylthio- O
uracil O
therapy O
. O

-DOCSTART- O

two O
mouse O
lines O
selected O
for O
differential O
sensitivities O
to O
beta-carboline-induced O
seizures B-NEG
are O
also O
differentially O
sensitive O
to O
various O
pharmacological O
effects O
of O
other O
gaba(a O
) O
receptor O
ligands O
. O

two O
mouse O
lines O
were O
selectively O
bred O
according O
to O
their O
sensitivity O
( O
bs O
line O
) O
or O
resistance O
( O
br O
line O
) O
to O
seizures B-NEG
induced O
by O
a O
single O
i.p O
. O
injection O
of O
methyl O
beta-carboline-3-carboxylate O
(beta-ccm) O
, O
an O
inverse O
agonist O
of O
the O
gaba(a O
) O
receptor O
benzodiazepine O
site O
. O

our O
aim O
was O
to O
characterize O
both O
lines' O
sensitivities O
to O
various O
physiological O
effects O
of O
other O
ligands O
of O
the O
gaba(a O
) O
receptor O
. O

we O
measured O
diazepam-induced O
anxiolysis O
with O
the O
elevated O
plus-maze O
test O
, O
diazepam-induced O
sedation O
by O
recording O
the O
vigilance O
states O
, O
and O
picrotoxin- O
and O
pentylenetetrazol-induced O
seizures B-NEG
after O
i.p O
. O
injections O
. O

results O
presented O
here O
show O
that O
the O
differential O
sensitivities O
of O
bs O
and O
br O
lines O
to O
beta-ccm O
can O
be O
extended O
to O
diazepam O
, O
picrotoxin O
, O
and O
pentylenetetrazol O
, O
suggesting O
a O
genetic O
selection O
of O
a O
general O
sensitivity O
and O
resistance O
to O
several O
ligands O
of O
the O
gaba(a O
) O
receptor O
. O

-DOCSTART- O

analgesic O
effect O
of O
intravenous O
ketamine O
in O
cancer B-NEG
patients O
on O
morphine O
therapy O
: O
a O
randomized O
, O
controlled O
, O
double-blind O
, O
crossover O
, O
double-dose O
study O
. O
pain B-NEG
not O
responsive O
to O
morphine O
is O
often O
problematic O
. O

animal O
and O
clinical O
studies O
have O
suggested O
that O
n-methyl-d-aspartate O
( O
nmda O
) O
antagonists O
, O
such O
as O
ketamine O
, O
may O
be O
effective O
in O
improving O
opioid O
analgesia O
in O
difficult O
pain B-NEG
syndromes O
, O
such O
as O
neuropathic B-NEG
pain I-NEG
. O

a O
slow O
bolus O
of O
subhypnotic O
doses O
of O
ketamine O
( O
0.25 O
mg/kg O
or O
0.50 O
mg/kg O
) O
was O
given O
to O
10 O
cancer B-NEG
patients O
whose O
pain B-NEG
was O
unrelieved O
by O
morphine O
in O
a O
randomized O
, O
double-blind O
, O
crossover O
, O
double-dose O
study O
. O
pain B-NEG
intensity O
on O
a O
0 O
to O
10 O
numerical O
scale O
; O
nausea B-NEG
and O
vomiting B-NEG
, O
drowsiness O
, O
confusion B-NEG
, O
and O
dry B-NEG
mouth I-NEG
, O
using O
a O
scale O
from O
0 O
to O
3 O
( O
not O
at O
all O
, O
slight O
, O
a O
lot O
, O
awful) O
; O
mini-mental O
state O
examination O
( O
mmse O
) O
(0-30) O
; O
and O
arterial O
pressure O
were O
recorded O
before O
administration O
of O
drugs O
( O
t0 O
) O
and O
after O
30 O
minutes O
(t30) O
, O
60 O
minutes O
(t60) O
, O
120 O
minutes O
(t120) O
, O
and O
180 O
minutes O
(t180) O
. O

ketamine O
, O
but O
not O
saline O
solution O
, O
significantly O
reduced O
the O
pain B-NEG
intensity O
in O
almost O
all O
the O
patients O
at O
both O
doses O
. O

this O
effect O
was O
more O
relevant O
in O
patients O
treated O
with O
higher O
doses O
. O
hallucinations B-NEG
occurred O
in O
4 O
patients O
, O
and O
an O
unpleasant O
sensation O
( O
empty O
head O
) O
was O
also O
reported O
by O
2 O
patients O
. O

these O
episodes O
reversed O
after O
the O
administration O
of O
diazepam O
1 O
mg O
intravenously O
. O

significant O
increases O
in O
drowsiness O
were O
reported O
in O
patients O
treated O
with O
ketamine O
in O
both O
groups O
and O
were O
more O
marked O
with O
ketamine O
0.50 O
mg/kg O
. O

a O
significant O
difference O
in O
mmse O
was O
observed O
at O
t30 O
in O
patients O
who O
received O
0.50 O
mg/kg O
of O
ketamine O
. O

ketamine O
can O
improve O
morphine O
analgesia O
in O
difficult O
pain B-NEG
syndromes O
, O
such O
as O
neuropathic B-NEG
pain I-NEG
. O

however O
, O
the O
occurrence O
of O
central O
adverse O
effects O
should O
be O
taken O
into O
account O
, O
especially O
when O
using O
higher O
doses O
. O

this O
observation O
should O
be O
tested O
in O
studies O
of O
prolonged O
ketamine O
administration O
. O

-DOCSTART- O

endocrine O
screening O
in O
1,022 O
men O
with O
erectile B-NEG
dysfunction I-NEG
: O
clinical O
significance O
and O
cost-effective O
strategy O
. O

purpose O
: O
we O
reviewed O
the O
results O
of O
serum O
testosterone O
and O
prolactin O
determination O
in O
1,022 O
patients O
referred O
because O
of O
erectile B-NEG
dysfunction I-NEG
and O
compared O
the O
data O
with O
history O
, O
results O
of O
physical O
examination O
, O
other O
etiological O
investigations O
and O
effects O
of O
endocrine O
therapy O
to O
refine O
the O
rules O
of O
cost-effective O
endocrine O
screening O
and O
to O
pinpoint O
actual O
responsibility O
for O
hormonal O
abnormalities O
. O

materials O
and O
methods O
: O
testosterone O
and O
prolactin O
were O
determined O
by O
radioimmunoassay O
. O

every O
patient O
was O
screened O
for O
testosterone O
and O
451 O
were O
screened O
for O
prolactin O
on O
the O
basis O
of O
low B-NEG
sexual I-NEG
desire I-NEG
, O
gynecomastia B-NEG
or O
testosterone O
less O
than O
4 O
ng./ml O
. O

determination O
was O
repeated O
in O
case O
of O
abnormal O
first O
results O
. O

prolactin O
results O
were O
compared O
with O
those O
of O
a O
previous O
personal O
cohort O
of O
1,340 O
patients O
with O
erectile B-NEG
dysfunction I-NEG
and O
systematic O
prolactin O
determination O
. O

main O
clinical O
criteria O
tested O
regarding O
efficiency O
in O
hormone O
determination O
were O
low B-NEG
sexual I-NEG
desire I-NEG
, O
small O
testes O
and O
gynecomastia B-NEG
. O

endocrine O
therapy O
consisted O
of O
testosterone O
heptylate O
or O
human O
chorionic O
gonadotropin O
for O
hypogonadism B-NEG
and O
bromocriptine O
for O
hyperprolactinemia B-NEG
. O

results O
: O
testosterone O
was O
less O
than O
3 O
ng./ml O
. O
in O
107 O
patients O
but O
normal O
in O
40% O
at O
repeat O
determination O
. O

the O
prevalence O
of O
repeatedly O
low O
testosterone O
increased O
with O
age O
( O
4% O
before O
age O
50 O
years O
and O
9% O
50 O
years O
or O
older) O
. O

two O
pituitary B-NEG
tumors I-NEG
were O
discovered O
after O
testosterone O
determination O
. O

most O
of O
the O
other O
low O
testosterone O
levels O
seemed O
to O
result O
from O
nonorganic O
hypothalamic B-NEG
dysfunction I-NEG
because O
of O
normal O
serum O
luteinizing O
hormone O
and O
prolactin O
and O
to O
have O
only O
a O
small O
role O
in O
erectile B-NEG
dysfunction I-NEG
( O
definite O
improvement O
in O
only O
16 O
of O
44 O
[36%] O
after O
androgen O
therapy O
, O
normal O
morning O
or O
nocturnal O
erections O
in O
30% O
and O
definite O
vasculogenic O
contributions O
in O
42%) O
. O

determining O
testosterone O
only O
in O
cases O
of O
low B-NEG
sexual I-NEG
desire I-NEG
or O
abnormal O
physical O
examination O
would O
have O
missed O
40% O
of O
the O
cases O
with O
low O
testosterone O
, O
including O
37% O
of O
those O
subsequently O
improved O
by O
androgen O
therapy O
. O

prolactin O
exceeded O
20 O
ng./ml O
. O
in O
5 O
men O
and O
was O
normal O
in O
2 O
at O
repeat O
determination O
. O

only O
1 O
prolactinoma B-NEG
was O
discovered O
. O

these O
data O
are O
lower O
than O
those O
we O
found O
during O
the O
last O
2 O
decades O
( O
overall O
prolactin O
greater O
than O
20 O
ng./ml O
. O
in O
1.86% O
of O
1,821 O
patients O
, O
prolactinomas B-NEG
in O
7, O
0.38%) O
. O

bromocriptine O
was O
definitely O
effective O
in O
cases O
with O
prolactin O
greater O
than O
35 O
ng./ml O
. O

(8 O
of O
12 O
compared O
to O
only O
9 O
of O
22 O
cases O
with O
prolactin O
between O
20 O
and O
35 O
ng./ml.) O
. O

testosterone O
was O
low O
in O
less O
than O
50% O
of O
cases O
with O
prolactin O
greater O
than O
35 O
ng./ml O
. O

conclusions O
: O
low O
prevalences O
and O
effects O
of O
low O
testosterone O
and O
high O
prolactin O
in O
erectile B-NEG
dysfunction I-NEG
cannot O
justify O
their O
routine O
determination O
. O

however O
, O
cost-effective O
screening O
strategies O
recommended O
so O
far O
missed O
40 O
to O
50% O
of O
cases O
improved O
with O
endocrine O
therapy O
and O
the O
pituitary B-NEG
tumors I-NEG
. O

we O
now O
advocate O
that O
before O
age O
50 O
years O
testosterone O
be O
determined O
only O
in O
cases O
of O
low B-NEG
sexual I-NEG
desire I-NEG
and O
abnormal O
physical O
examination O
but O
that O
it O
be O
measured O
in O
all O
men O
older O
than O
50 O
years O
. O

prolactin O
should O
be O
determined O
only O
in O
cases O
of O
low B-NEG
sexual I-NEG
desire I-NEG
, O
gynecomastia B-NEG
and/or O
testosterone O
less O
than O
4 O
ng./ml O
. O

-DOCSTART- O

thiopentone O
pretreatment O
for O
propofol O
injection O
pain B-NEG
in O
ambulatory O
patients O
. O

this O
study O
investigated O
propofol O
injection O
pain B-NEG
in O
patients O
undergoing O
ambulatory O
anaesthesia O
. O

in O
a O
randomized O
, O
double-blind O
trial O
, O
90 O
women O
were O
allocated O
to O
receive O
one O
of O
three O
treatments O
prior O
to O
induction O
of O
anaesthesia O
with O
propofol O
. O

patients O
in O
group O
c O
received O
2 O
ml O
normal O
saline O
, O
group O
l, O
2 O
ml O
, O
lidocaine O
2% O
( O
40 O
mg O
) O
and O
group O
t, O
2 O
ml O
thiopentone O
2.5% O
( O
50 O
mg) O
. O

venous O
discomfort O
was O
assessed O
with O
a O
visual O
analogue O
scale O
( O
vas O
) O
5-15 O
sec O
after O
commencing O
propofol O
administration O
using O
an O
infusion O
pump O
( O
rate O
1000 O
micrograms.kg-1.min-1) O
. O
loss B-NEG
of I-NEG
consciousness I-NEG
occurred O
in O
60-90 O
sec O
. O

visual O
analogue O
scores O
( O
mean O
+/- O
sd O
) O
during O
induction O
were O
lower O
in O
groups O
l O
( O
3.3 O
+/- O
2.5 O
) O
and O
t O
( O
4.1 O
+/- O
2.7 O
) O
than O
in O
group O
c O
( O
5.6 O
+/- O
2.3) O
; O
p O
= O
0.0031 O
. O

the O
incidence O
of O
venous O
discomfort O
was O
lower O
in O
group O
l O
(76.6% O
; O
p O
< O
0.05 O
) O
than O
in O
group O
c O
( O
100% O
) O
but O
not O
different O
from O
group O
t O
(90%) O
. O

the O
vas O
scores O
for O
recall O
of O
pain B-NEG
in O
the O
recovery O
room O
were O
correlated O
with O
the O
vas O
scores O
during O
induction O
(r O
= O
0.7045 O
; O
p O
< O
0.0001) O
. O

recovery O
room O
discharge O
times O
were O
similar O
: O
c O
( O
75.9 O
+/- O
19.4 O
min) O
; O
l O
73.6 O
+/- O
21.6 O
min) O
; O
t O
( O
77.1 O
+/- O
18.9 O
min) O
. O

assessing O
their O
overall O
satisfaction O
, O
89.7% O
would O
choose O
propofol O
anaesthesia O
again O
. O

we O
conclude O
that O
lidocaine O
reduces O
the O
incidence O
and O
severity O
of O
propofol O
injection O
pain B-NEG
in O
ambulatory O
patients O
whereas O
thiopentone O
only O
reduces O
its O
severity O
. O

-DOCSTART- O

comparison O
of O
i.v O
. O
glycopyrrolate O
and O
atropine O
in O
the O
prevention O
of O
bradycardia B-NEG
and O
arrhythmias B-NEG
following O
repeated O
doses O
of O
suxamethonium O
in O
children O
. O

the O
effectiveness O
of O
administration O
of O
glycopyrrolate O
5 O
and O
10 O
micrograms O
kg-1 O
and O
atropine O
10 O
and O
20 O
micrograms O
kg-1 O
i.v O
. O
immediately O
before O
the O
induction O
of O
anaesthesia O
, O
to O
prevent O
arrhythmia B-NEG
and O
bradycardia B-NEG
following O
repeated O
doses O
of O
suxamethonium O
in O
children O
, O
was O
studied O
. O

a O
control O
group O
was O
included O
for O
comparison O
with O
the O
lower O
dose O
range O
of O
glycopyrrolate O
and O
atropine O
. O

a O
frequency O
of O
bradycardia B-NEG
of O
50% O
was O
noted O
in O
the O
control O
group O
, O
but O
this O
was O
not O
significantly O
different O
from O
the O
frequency O
with O
the O
active O
drugs O
. O
bradycardia B-NEG
( O
defined O
as O
a O
decrease O
in O
heart O
rate O
to O
less O
than O
50 O
beat O
min-1 O
) O
was O
prevented O
when O
the O
larger O
dose O
of O
either O
active O
drug O
was O
used O
. O

it O
is O
recommended O
that O
either O
glycopyrrolate O
10 O
micrograms O
kg-1 O
or O
atropine O
20 O
micrograms O
kg-1 O
i.v O
. O
should O
immediately O
precede O
induction O
of O
anaesthesia O
, O
in O
children O
, O
if O
the O
repeated O
administration O
of O
suxamethonium O
is O
anticipated O
. O

-DOCSTART- O

reduction O
in O
caffeine O
toxicity B-NEG
by O
acetaminophen O
. O

a O
patient O
who O
allegedly O
consumed O
100 O
tablets O
of O
an O
over-the-counter O
analgesic O
containing O
sodium O
acetylsalicylate O
, O
caffeine O
, O
and O
acetaminophen O
displayed O
no O
significant O
cns O
stimulation O
despite O
the O
presence O
of O
175 O
micrograms O
of O
caffeine O
per O
ml O
of O
serum O
. O

because O
salicylates O
have O
been O
reported O
to O
augment O
the O
stimulatory O
effects O
of O
caffeine O
on O
the O
cns O
, O
attention O
was O
focused O
on O
the O
possibility O
that O
the O
presence O
of O
acetaminophen O
( O
52 O
micrograms/ml O
) O
reduced O
the O
cns O
toxicity B-NEG
of O
caffeine O
. O

studies O
in O
dba/2j O
mice O
showed O
that O
: O
1) O
pretreatment O
with O
acetaminophen O
( O
100 O
mg/kg O
) O
increased O
the O
interval O
between O
the O
administration O
of O
caffeine O
( O
300 O
to O
450 O
mg/kg O
ip O
) O
and O
the O
onset O
of O
fatal O
convulsions B-NEG
by O
a O
factor O
of O
about O
two O
; O
and O
2) O
pretreatment O
with O
acetaminophen O
( O
75 O
mg/kg O
) O
reduced O
the O
incidence O
of O
audiogenic O
seizures B-NEG
produced O
in O
the O
presence O
of O
caffeine O
( O
12.5 O
to O
75 O
mg/kg O
ip) O
. O

the O
frequency O
of O
sound-induced O
seizures B-NEG
after O
12.5 O
or O
25 O
mg/kg O
caffeine O
was O
reduced O
from O
50 O
to O
5% O
by O
acetaminophen O
. O

in O
the O
absence O
of O
caffeine O
, O
acetaminophen O
( O
up O
to O
300 O
mg/kg O
) O
did O
not O
modify O
the O
seizures B-NEG
induced O
by O
maximal O
electroshock O
and O
did O
not O
alter O
the O
convulsant O
dose O
of O
pentylenetetrezol O
in O
mice O
( O
tests O
performed O
by O
the O
anticonvulsant O
screening O
project O
of O
nincds) O
. O

acetaminophen O
( O
up O
to O
150 O
micrograms/ml O
) O
did O
not O
retard O
the O
incorporation O
of O
radioactive O
adenosine O
into O
atp O
in O
slices O
of O
rat O
cerebral O
cortex O
. O

thus O
the O
mechanism O
by O
which O
acetaminophen O
antagonizes O
the O
actions O
of O
caffeine O
in O
the O
cns O
remains O
unknown O
. O

-DOCSTART- O

flestolol O
: O
an O
ultra-short-acting O
beta-adrenergic O
blocking O
agent O
. O

flestolol O
( O
acc-9089 O
) O
is O
a O
nonselective O
, O
competitive O
, O
ultra-short-acting O
beta-adrenergic O
blocking O
agent O
, O
without O
any O
intrinsic O
sympathomimetic O
activity O
. O

flestolol O
is O
metabolized O
by O
plasma O
esterases O
and O
has O
an O
elimination O
half-life O
of O
approximately O
6.5 O
minutes O
. O

this O
agent O
was O
well O
tolerated O
in O
healthy O
volunteers O
at O
doses O
up O
to O
100 O
micrograms/kg/min O
. O

in O
long-term O
infusion O
studies O
, O
flestolol O
was O
well O
tolerated O
at O
the O
effective O
beta-blocking O
dose O
(5 O
micrograms/kg/min O
) O
for O
up O
to O
seven O
days O
. O

flestolol O
blood O
concentrations O
increased O
linearly O
with O
increasing O
dose O
and O
good O
correlation O
exists O
between O
blood O
concentrations O
of O
flestolol O
and O
beta-adrenergic O
blockade O
. O

flestolol O
produced O
a O
dose-dependent O
attenuation O
of O
isoproterenol-induced O
tachycardia B-NEG
. O

electrophysiologic O
and O
hemodynamic O
effects O
of O
flestolol O
are O
similar O
to O
those O
of O
other O
beta O
blockers O
. O

in O
contrast O
with O
other O
beta O
blockers O
, O
flestolol-induced O
effects O
reverse O
rapidly O
( O
within O
30 O
minutes O
) O
following O
discontinuation O
because O
of O
its O
short O
half-life O
. O

flestolol O
effectively O
reduced O
heart O
rate O
in O
patients O
with O
supraventricular B-NEG
tachyarrhythmia I-NEG
. O

in O
patients O
with O
unstable B-NEG
angina I-NEG
, O
flestolol O
infusion O
was O
found O
to O
be O
safe O
and O
effective O
in O
controlling O
chest B-NEG
pain I-NEG
. O

it O
is O
concluded O
that O
flestolol O
is O
a O
potent O
, O
well-tolerated O
, O
ultra-short-acting O
beta-adrenergic O
blocking O
agent O
. O

use O
of O
flestolol O
in O
the O
critical O
care O
setting O
is O
currently O
undergoing O
investigation O
. O

-DOCSTART- O

adverse O
effect O
of O
the O
calcium O
channel O
blocker O
nitrendipine O
on O
nephrosclerosis B-NEG
in O
rats O
with O
renovascular B-NEG
hypertension I-NEG
. O

the O
effect O
of O
a O
6-week O
treatment O
with O
the O
calcium O
channel O
blocker O
nitrendipine O
or O
the O
angiotensin O
converting O
enzyme O
inhibitor O
enalapril O
on O
blood O
pressure O
, O
albuminuria B-NEG
, O
renal O
hemodynamics O
, O
and O
morphology O
of O
the O
nonclipped O
kidney O
was O
studied O
in O
rats O
with O
two-kidney O
, O
one O
clip O
renovascular B-NEG
hypertension I-NEG
. O

six O
weeks O
after O
clipping O
of O
one O
renal O
artery O
, O
hypertensive B-NEG
rats O
( O
178 O
+/- O
4 O
mm O
hg O
) O
were O
randomly O
assigned O
to O
three O
groups O
: O
untreated O
hypertensive B-NEG
controls O
(n O
= O
8) O
, O
enalapril-treated O
(n O
= O
8) O
, O
or O
nitrendipine-treated O
(n O
= O
10) O
. O

sham-operated O
rats O
served O
as O
normotensive O
controls O
( O
128 O
+/- O
3 O
mm O
hg O
, O
n O
= O
8) O
. O

after O
6 O
weeks O
of O
treatment O
, O
renal O
hemodynamics O
( O
glomerular O
filtration O
rate O
and O
renal O
plasma O
flow O
) O
were O
measured O
in O
the O
anesthetized O
rats O
. O

renal O
tissue O
was O
obtained O
for O
determination O
of O
glomerular O
size O
and O
sclerosis O
. O

enalapril O
but O
not O
nitrendipine O
reduced O
blood O
pressure O
significantly O
. O

after O
6 O
weeks O
of O
therapy O
, O
glomerular O
filtration O
rate O
was O
not O
different O
among O
the O
studied O
groups O
. O

renal O
plasma O
flow O
increased O
, O
but O
albumin O
excretion O
and O
glomerulosclerosis B-NEG
did O
not O
change O
after O
enalapril O
treatment O
. O

in O
contrast O
, O
in O
the O
nitrendipine-treated O
group O
albuminuria B-NEG
increased O
from O
12.8 O
+/- O
2 O
progressively O
to O
163 O
+/- O
55 O
compared O
with O
19.2 O
+/- O
9 O
mg/24 O
hr O
in O
the O
hypertensive B-NEG
controls O
. O

furthermore O
, O
glomerulosclerosis B-NEG
index O
was O
significantly O
increased O
in O
the O
nitrendipine-treated O
group O
compared O
with O
the O
hypertensive B-NEG
controls O
( O
0.38 O
+/- O
0.1 O
versus O
0.13 O
+/- O
0.04) O
. O

in O
addition O
, O
glomerular O
size O
was O
higher O
in O
the O
nitrendipine-treated O
group O
( O
14.9 O
+/- O
0.17 O
10(-3 O
) O
mm2 O
) O
but O
lower O
in O
the O
enalapril-treated O
group O
( O
11.5 O
+/- O
0.15 O
10(-3 O
) O
mm2 O
) O
compared O
with O
the O
hypertensive B-NEG
controls O
( O
12.1 O
+/- O
0.17 O
10(-3 O
) O
mm2).(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

treatment O
of O
tinnitus B-NEG
by O
intratympanic O
instillation O
of O
lignocaine O
( O
lidocaine O
) O
2 O
per O
cent O
through O
ventilation O
tubes O
. O
idiopathic B-NEG
subjective I-NEG
tinnitus I-NEG
( O
ist B-NEG
) O
is O
one O
of O
the O
most O
obscure O
otological O
pathologies O
. O

this O
paper O
presents O
the O
results O
of O
treating O
ist B-NEG
by O
intratympanic O
instillation O
of O
lignocaine O
( O
lidocaine O
) O
2 O
per O
cent O
through O
a O
grommet O
, O
for O
five O
weekly O
courses O
. O

fifty-two O
patients O
suffering O
from O
intractable O
tinnitus B-NEG
entered O
this O
therapeutic O
trial O
, O
but O
only O
nine O
finished O
all O
five O
courses O
. O

in O
one O
patient O
, O
the O
tinnitus B-NEG
was O
almost O
completely O
abolished O
, O
but O
in O
all O
the O
nine O
patients O
the O
decompensated O
tinnitus B-NEG
changed O
to O
a O
compensated O
one O
. O

we O
suggest O
this O
mode O
of O
treatment O
for O
patients O
that O
were O
previously O
treated O
by O
drugs O
, O
acupuncture O
and O
biofeedback O
, O
with O
disappointing O
results O
. O

patients O
should O
be O
warned O
about O
the O
side O
effects O
of O
vertigo B-NEG
and O
vomiting B-NEG
, O
which O
subsides O
gradually O
with O
every O
new O
instillation O
, O
and O
that O
the O
tinnitus B-NEG
may O
not O
disappear O
but O
will O
be O
alleviated O
, O
enabling O
them O
to O
cope O
more O
easily O
with O
the O
disease O
and O
lead O
a O
more O
normal O
life O
. O

-DOCSTART- O

perhexiline O
maleate O
and O
peripheral B-NEG
neuropathy I-NEG
. O
peripheral B-NEG
neuropathy I-NEG
has O
been O
noted O
as O
a O
complication O
of O
therapy O
with O
perhexiline O
maleate O
, O
a O
drug O
widely O
used O
in O
france O
( O
and O
in O
clinical O
trials O
in O
the O
united O
states O
) O
for O
the O
prophylactic O
treatment O
of O
angina B-NEG
pectoris I-NEG
. O

in O
24 O
patients O
with O
this O
complication O
, O
the O
marked O
slowing O
of O
motor O
nerve O
conduction O
velocity O
and O
the O
electromyographic O
changes O
imply O
mainly O
a O
demyelinating B-NEG
disorder I-NEG
. O

improvement O
was O
noted O
with O
cessation O
of O
therapy O
. O

in O
a O
few O
cases O
the O
presence O
of O
active O
denervation O
signified O
a O
poor O
prognosis O
, O
with O
only O
slight O
improvement O
. O

the O
underlying O
mechanism O
causing O
the O
neuropathy B-NEG
is O
not O
yet O
fully O
known O
, O
although O
some O
evidence O
indicates O
that O
it O
may O
be O
a O
lipid O
storage O
process O
. O

-DOCSTART- O

effect O
of O
humoral O
modulators O
of O
morphine-induced O
increase B-NEG
in I-NEG
locomotor I-NEG
activity I-NEG
of O
mice O
. O

the O
effect O
of O
humoral O
modulators O
on O
the O
morphine-induced O
increase B-NEG
in I-NEG
locomotor I-NEG
activity I-NEG
of O
mice O
was O
studied O
. O

the O
subcutaneous O
administration O
of O
10 O
mg/kg O
of O
morphine-hc1 O
produced O
a O
marked O
increase B-NEG
in I-NEG
locomotor I-NEG
activity I-NEG
in O
mice O
. O

the O
morphine-induced O
hyperactivity B-NEG
was O
potentiated O
by O
scopolamine O
and O
attenuated O
by O
physostigmine O
. O

in O
contrast O
, O
both O
methscopolamine O
and O
neostigmine O
, O
which O
do O
not O
penetrate O
the O
blood-brain O
barrier O
, O
had O
no O
effect O
on O
the O
hyperactivity B-NEG
produced O
by O
morphine O
. O

pretreatment O
of O
mice O
with O
alpha-methyltyrosine O
( O
20 O
mg/kg O
i.p. O
, O
one O
hour) O
, O
an O
inhibitor O
of O
tyrosine O
hydroxylase O
, O
significantly O
decreased O
the O
activity-increasing O
effects O
of O
morphine O
. O

on O
the O
other O
hand O
, O
pretreatment O
with O
p-chlorophenylalamine O
(3 O
x O
320 O
mg/kg O
i.p. O
, O
24 O
hr) O
, O
a O
serotonin O
depletor O
, O
caused O
no O
significant O
change O
in O
the O
hyperactivity B-NEG
. O

the O
study O
suggests O
that O
the O
activity-increasing O
effects O
of O
morphine O
are O
mediated O
by O
the O
release O
of O
catecholamines O
from O
adrenergic O
neurons O
in O
the O
brain O
. O

and O
the O
results O
are O
consistent O
with O
the O
hypothesis O
that O
morphine O
acts O
by O
retarding O
the O
release O
of O
acetylcholine O
at O
some O
central O
cholinergic O
synapses O
. O

it O
is O
also O
suggested O
from O
collected O
evidence O
that O
the O
activity-increasing O
effects O
of O
morphine O
in O
mice O
are O
mediated O
by O
mechanisms O
different O
from O
those O
which O
mediate O
the O
activity-increasing O
effects O
of O
morphine O
in O
rats O
. O

-DOCSTART- O

mechanisms O
of O
fk O
506-induced O
hypertension B-NEG
in O
the O
rat O
. O
-tacrolimus O
( O
fk O
506 O
) O
is O
a O
powerful O
, O
widely O
used O
immunosuppressant O
. O

the O
clinical O
utility O
of O
fk O
506 O
is O
complicated O
by O
substantial O
hypertension B-NEG
and O
nephrotoxicity B-NEG
. O

to O
clarify O
the O
mechanisms O
of O
fk O
506-induced O
hypertension B-NEG
, O
we O
studied O
the O
chronic O
effects O
of O
fk O
506 O
on O
the O
synthesis O
of O
endothelin-1 O
(et-1) O
, O
the O
expression O
of O
mrna O
of O
et-1 O
and O
endothelin-converting O
enzyme-1 O
(ece-1) O
, O
the O
endothelial O
nitric O
oxide O
synthase O
( O
enos O
) O
activity O
, O
and O
the O
expression O
of O
mrna O
of O
enos O
and O
c-type O
natriuretic O
peptide O
( O
cnp O
) O
in O
rat O
blood O
vessels O
. O

in O
addition O
, O
the O
effect O
of O
the O
specific O
endothelin O
type O
a O
receptor O
antagonist O
fr O
139317 O
on O
fk O
506-induced O
hypertension B-NEG
in O
rats O
was O
studied O
. O

fk O
506 O
, O
5 O
mg O
. O

kg-1 O
. O

d-1 O
given O
for O
4 O
weeks O
, O
elevated O
blood O
pressure O
from O
102+/-13 O
to O
152+/-15 O
mm O
hg O
and O
increased O
the O
synthesis O
of O
et-1 O
and O
the O
levels O
of O
et-1 O
mrna O
in O
the O
mesenteric O
artery O
( O
240% O
and O
230% O
, O
respectively) O
. O

little O
change O
was O
observed O
in O
the O
expression O
of O
ece-1 O
mrna O
and O
cnp O
mrna O
. O

fk O
506 O
decreased O
enos O
activity O
and O
the O
levels O
of O
enos O
mrna O
in O
the O
aorta O
( O
48% O
and O
55% O
, O
respectively) O
. O

the O
administration O
of O
fr O
139317 O
( O
10 O
mg O
. O
kg-1 O
. O
d-1 O
) O
prevented O
fk O
506-induced O
hypertension B-NEG
in O
rats O
. O

these O
results O
indicate O
that O
fk O
506 O
may O
increase O
blood O
pressure O
not O
only O
by O
increasing O
et-1 O
production O
but O
also O
by O
decreasing O
no O
synthesis O
in O
the O
vasculature O
. O

-DOCSTART- O

suxamethonium O
induced O
prolonged O
apnea B-NEG
in O
a O
patient O
receiving O
electroconvulsive O
therapy O
. O

suxamethonium O
causes O
prolonged O
apnea B-NEG
in O
patients O
in O
whom O
pseudocholinesterase O
enzyme O
gets O
deactivated O
by O
organophosphorus O
( O
op O
) O
poisons O
. O

here O
, O
we O
present O
a O
similar O
incident O
in O
a O
severely O
depressed B-NEG
patient O
who O
received O
electroconvulsive O
therapy O
(ect) O
. O

prolonged O
apnea B-NEG
in O
our O
case O
ensued O
because O
the O
information O
about O
suicidal O
attempt O
by O
op O
compound O
was O
concealed O
from O
the O
treating O
team O
. O

-DOCSTART- O

the O
effects O
of O
the O
adjunctive O
bupropion O
on O
male O
sexual B-NEG
dysfunction I-NEG
induced O
by O
a O
selective O
serotonin O
reuptake O
inhibitor O
: O
a O
double-blind O
placebo-controlled O
and O
randomized O
study O
. O

objective O
: O
to O
determine O
the O
safety O
and O
efficacy O
of O
adjunctive O
bupropion O
sustained-release O
( O
sr O
) O
on O
male O
sexual B-NEG
dysfunction I-NEG
( O
sd B-NEG
) O
induced O
by O
a O
selective O
serotonin O
reuptake O
inhibitor O
(ssri) O
, O
as O
sd B-NEG
is O
a O
common O
side-effect O
of O
ssris O
and O
the O
most O
effective O
treatments O
have O
yet O
to O
be O
determined O
. O

patients O
and O
methods O
: O
the O
randomized O
sample O
consisted O
of O
234 O
euthymic O
men O
who O
were O
receiving O
some O
type O
of O
ssri O
. O

the O
men O
were O
randomly O
assigned O
to O
bupropion O
sr O
( O
150 O
mg O
twice O
daily O
, O
117 O
) O
or O
placebo O
( O
twice O
daily O
, O
117 O
) O
for O
12 O
weeks O
. O

efficacy O
was O
evaluated O
using O
the O
clinical O
global O
impression-sexual O
function O
(cgi-sf O
; O
the O
primary O
outcome O
measure) O
, O
the O
international O
index O
of O
erectile O
function O
(iief) O
, O
arizona O
sexual O
experience O
scale O
(asex) O
, O
and O
erectile B-NEG
dysfunction I-NEG
inventory O
of O
treatment O
satisfaction O
( O
edits O
) O
( O
secondary O
outcome O
measures) O
. O

participants O
were O
followed O
biweekly O
during O
study O
period O
. O

results O
: O
after O
12 O
weeks O
of O
treatment O
, O
the O
mean O
( O
sd O
) O
scores O
for O
cgi-sf O
were O
significantly O
lower O
, O
i.e O
. O
better O
, O
in O
patients O
on O
bupropion O
sr O
, O
at O
2.4 O
(1.2) O
, O
than O
in O
the O
placebo O
group O
, O
at O
3.9 O
( O
1.1 O
) O
( O
p= O
0.01) O
. O

men O
who O
received O
bupropion O
had O
a O
significant O
increase O
in O
the O
total O
iief O
score O
( O
54.4% O
vs O
1.2% O
; O
p= O
0.003) O
, O
and O
in O
the O
five O
different O
domains O
of O
the O
iief O
. O

total O
asex O
scores O
were O
significantly O
lower O
, O
i.e O
. O
better O
, O
among O
men O
who O
received O
bupropion O
than O
placebo O
, O
at O
15.5 O
( O
4.3 O
) O
vs O
21.5 O
( O
4.7 O
) O
( O
p= O
0.002) O
. O

the O
edits O
scores O
were O
67.4 O
( O
10.2 O
) O
for O
the O
bupropion O
and O
36.3 O
( O
11.7 O
) O
for O
the O
placebo O
group O
( O
p= O
0.001) O
. O

the O
asex O
score O
and O
cgi-sf O
score O
were O
correlated O
( O
p= O
0.003) O
. O

in O
linear O
regression O
analyses O
the O
cgi-sf O
score O
was O
not O
affected O
significantly O
by O
the O
duration O
of O
sd B-NEG
, O
type O
of O
ssri O
used O
and O
age O
. O

conclusions O
: O
bupropion O
is O
an O
effective O
treatment O
for O
male O
sd B-NEG
induced O
by O
ssris O
. O

these O
results O
provide O
empirical O
support O
for O
conducting O
a O
further O
study O
of O
bupropion O
. O

-DOCSTART- O

lamivudine O
for O
the O
prevention O
of O
hepatitis B-NEG
b I-NEG
virus O
reactivation O
in O
hepatitis-b O
surface O
antigen O
( O
hbsag O
) O
seropositive O
cancer B-NEG
patients O
undergoing O
cytotoxic O
chemotherapy O
. O
hepatitis B-NEG
b I-NEG
virus O
( O
hbv O
) O
is O
one O
of O
the O
major O
causes O
of O
chronic O
liver B-NEG
disease I-NEG
worldwide O
. O
cancer B-NEG
patients O
who O
are O
chronic O
carriers O
of O
hbv O
have O
a O
higher O
hepatic B-NEG
complication I-NEG
rate O
while O
receiving O
cytotoxic O
chemotherapy O
( O
ct O
) O
and O
this O
has O
mainly O
been O
attributed O
to O
hbv O
reactivation O
. O

in O
this O
study O
, O
cancer B-NEG
patients O
who O
have O
solid O
and O
hematological B-NEG
malignancies I-NEG
with O
chronic O
hbv B-NEG
infection I-NEG
received O
the O
antiviral O
agent O
lamivudine O
prior O
and O
during O
ct O
compared O
with O
historical O
control O
group O
who O
did O
not O
receive O
lamivudine O
. O

the O
objectives O
were O
to O
assess O
the O
efficacy O
of O
lamivudine O
in O
reducing O
the O
incidence O
of O
hbv O
reactivation O
, O
and O
diminishing O
morbidity O
and O
mortality O
during O
ct O
. O

two O
groups O
were O
compared O
in O
this O
study O
. O

the O
prophylactic O
lamivudin O
group O
consisted O
of O
37 O
patients O
who O
received O
prophylactic O
lamivudine O
treatment O
. O

the O
historical O
controls O
consisted O
of O
50 O
consecutive O
patients O
who O
underwent O
ct O
without O
prophylactic O
lamivudine O
. O

they O
were O
followed O
up O
during O
and O
for O
8 O
weeks O
after O
ct O
. O

the O
outcomes O
were O
compared O
for O
both O
groups O
. O

of O
our O
control O
group O
( O
n= O
50) O
, O
21 O
patients O
( O
42% O
) O
were O
established O
hepatitis B-NEG
. O

twelve O
( O
24% O
) O
of O
them O
were O
evaluated O
as O
severe O
hepatitis B-NEG
. O

in O
the O
prophylactic O
lamivudine O
group O
severe O
hepatitis B-NEG
were O
observed O
only O
in O
1 O
patient O
( O
2.7% O
) O
of O
37 O
patients O
(p O
< O
0.006) O
. O

comparison O
of O
the O
mean O
alt O
values O
revealed O
significantly O
higher O
mean O
alanine O
aminotransferase O
( O
alt O
) O
values O
in O
the O
control O
group O
than O
the O
prophylactic O
lamivudine O
group O
; O
154:64 O
(p O
< O
0.32) O
. O

our O
study O
suggests O
that O
prophylactic O
lamivudine O
significantly O
decreases O
the O
incidence O
of O
hbv O
reactivation O
and O
overall O
morbidity O
in O
cancer B-NEG
patients O
during O
and O
after O
immunosuppressive O
therapy O
. O

further O
studies O
are O
needed O
to O
determine O
the O
most O
appropriate O
nucleoside O
or O
nucleotide O
analogue O
for O
antiviral O
prophylaxis O
during O
ct O
and O
the O
optimal O
duration O
of O
administration O
after O
completion O
of O
ct O
. O

-DOCSTART- O

ginsenoside O
rg1 O
restores O
the O
impairment B-NEG
of I-NEG
learning I-NEG
induced O
by O
chronic O
morphine O
administration O
in O
rats O
. O

rg1 O
, O
as O
a O
ginsenoside O
extracted O
from O
panax O
ginseng O
, O
could O
ameliorate O
spatial O
learning B-NEG
impairment I-NEG
. O

previous O
studies O
have O
demonstrated O
that O
rg1 O
might O
be O
a O
useful O
agent O
for O
the O
prevention O
and O
treatment O
of O
the O
adverse O
effects O
of O
morphine O
. O

the O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effect O
of O
rg1 O
on O
learning B-NEG
impairment I-NEG
by O
chronic O
morphine O
administration O
and O
the O
mechanism O
responsible O
for O
this O
effect O
. O

male O
rats O
were O
subcutaneously O
injected O
with O
morphine O
( O
10 O
mg/kg O
) O
twice O
a O
day O
at O
12 O
hour O
intervals O
for O
10 O
days O
, O
and O
rg1 O
( O
30 O
mg/kg O
) O
was O
intraperitoneally O
injected O
2 O
hours O
after O
the O
second O
injection O
of O
morphine O
once O
a O
day O
for O
10 O
days O
. O

spatial O
learning O
capacity O
was O
assessed O
in O
the O
morris O
water O
maze O
. O

the O
results O
showed O
that O
rats O
treated O
with O
morphine/rg1 O
decreased O
escape O
latency O
and O
increased O
the O
time O
spent O
in O
platform O
quadrant O
and O
entering O
frequency O
. O

by O
implantation O
of O
electrodes O
and O
electrophysiological O
recording O
in O
vivo O
, O
the O
results O
showed O
that O
rg1 O
restored O
the O
long-term O
potentiation O
( O
ltp O
) O
impaired O
by O
morphine O
in O
both O
freely O
moving O
and O
anaesthetised O
rats O
. O

the O
electrophysiological O
recording O
in O
vitro O
showed O
that O
rg1 O
restored O
the O
ltp O
in O
slices O
from O
the O
rats O
treated O
with O
morphine O
, O
but O
not O
changed O
ltp O
in O
the O
slices O
from O
normal O
saline- O
or O
morphine/rg1-treated O
rats O
; O
this O
restoration O
could O
be O
inhibited O
by O
n-methyl-d-aspartate O
( O
nmda O
) O
receptor O
antagonist O
mk801 O
. O

we O
conclude O
that O
rg1 O
may O
significantly O
improve O
the O
spatial O
learning O
capacity O
impaired O
by O
chonic O
morphine O
administration O
and O
restore O
the O
morphine-inhibited O
ltp O
. O

this O
effect O
is O
nmda O
receptor O
dependent O
. O

-DOCSTART- O

a O
study O
on O
the O
effect O
of O
the O
duration O
of O
subcutaneous O
heparin O
injection O
on O
bruising B-NEG
and O
pain B-NEG
. O

aim O
: O
this O
study O
was O
carried O
out O
to O
determine O
the O
effect O
of O
injection O
duration O
on O
bruising B-NEG
and O
pain B-NEG
following O
the O
administration O
of O
the O
subcutaneous O
injection O
of O
heparin O
. O

background O
: O
although O
different O
methods O
to O
prevent O
bruising B-NEG
and O
pain B-NEG
following O
the O
subcutaneous O
injection O
of O
heparin O
have O
been O
widely O
studied O
and O
described O
, O
the O
effect O
of O
injection O
duration O
on O
the O
occurrence O
of O
bruising B-NEG
and O
pain B-NEG
is O
little O
documented O
. O

design O
: O
this O
study O
was O
designed O
as O
within-subject O
, O
quasi-experimental O
research O
. O

method O
: O
the O
sample O
for O
the O
study O
consisted O
of O
50 O
patients O
to O
whom O
subcutaneous O
heparin O
was O
administered O
. O

heparin O
was O
injected O
over O
10 O
seconds O
on O
the O
right O
abdominal O
site O
and O
30 O
seconds O
on O
the O
left O
abdominal O
site O
. O

injections O
areas O
were O
assessed O
for O
the O
presence O
of O
bruising B-NEG
at O
48 O
and O
72 O
hours O
after O
each O
injection O
. O

dimensions O
of O
the O
bruising B-NEG
on O
the O
heparin O
applied O
areas O
were O
measured O
using O
transparent O
millimetric O
measuring O
paper O
. O

the O
visual O
analog O
scale O
( O
vas O
) O
was O
used O
to O
measure O
pain B-NEG
intensity O
and O
a O
stop-watch O
was O
used O
to O
time O
the O
pain B-NEG
period O
. O

data O
were O
analysed O
using O
chi-square O
test O
, O
mann-whitney O
u, O
wilcoxon O
signed O
ranks O
tests O
and O
correlation O
. O

results O
: O
the O
percentage O
of O
bruising B-NEG
occurrence O
was O
64% O
with O
the O
injection O
of O
10 O
seconds O
duration O
and O
42% O
in O
the O
30-second O
injection O
. O

it O
was O
determined O
that O
the O
size O
of O
the O
bruising B-NEG
was O
smaller O
in O
the O
30-second O
injection O
. O
pain B-NEG
intensity O
and O
pain B-NEG
period O
were O
statistically O
significantly O
lower O
for O
the O
30-second O
injection O
than O
for O
the O
10-second O
injection O
. O

conclusions O
: O
it O
was O
determined O
that O
injection O
duration O
had O
an O
effect O
on O
bruising B-NEG
and O
pain B-NEG
following O
the O
subcutaneous O
administration O
of O
heparin O
. O

this O
study O
should O
be O
repeated O
on O
a O
larger O
sample O
. O

relevance O
to O
clinical O
practice O
: O
when O
administering O
subcutaneous O
heparin O
injections O
, O
it O
is O
important O
to O
extend O
the O
duration O
of O
the O
injection O
. O

-DOCSTART- O

acute O
reserpine O
and O
subchronic O
haloperidol O
treatments O
change O
synaptosomal O
brain O
glutamate O
uptake O
and O
elicit O
orofacial B-NEG
dyskinesia I-NEG
in O
rats O
. O

reserpine- O
and O
haloperidol-induced O
orofacial B-NEG
dyskinesia I-NEG
are O
putative O
animal O
models O
of O
tardive B-NEG
dyskinesia I-NEG
( O
td B-NEG
) O
whose O
pathophysiology O
has O
been O
related O
to O
free O
radical O
generation O
and O
oxidative O
stress O
. O

in O
the O
present O
study O
, O
the O
authors O
induced O
orofacial B-NEG
dyskinesia I-NEG
by O
acute O
reserpine O
and O
subchronic O
haloperidol O
administration O
to O
rats O
. O

reserpine O
injection O
( O
one O
dose O
of O
1 O
mg/kg O
s.c. O
) O
every O
other O
day O
for O
3 O
days O
caused O
a O
significant O
increase O
in O
vacuous O
chewing O
, O
tongue O
protrusion O
and O
duration O
of O
facial O
twitching O
, O
compared O
to O
the O
control O
. O

haloperidol O
administration O
( O
one O
dose O
of O
12 O
mg/kg O
once O
a O
week O
s.c. O
) O
for O
4 O
weeks O
caused O
an O
increase O
in O
vacuous O
chewing O
, O
tongue O
protrusion O
and O
duration O
of O
facial O
twitching O
observed O
in O
four O
weekly O
evaluations O
. O

after O
the O
treatments O
and O
behavioral O
observation O
, O
glutamate O
uptake O
by O
segments O
of O
the O
brain O
was O
analyzed O
. O

a O
decreased O
glutamate O
uptake O
was O
observed O
in O
the O
subcortical O
parts O
of O
animals O
treated O
with O
reserpine O
and O
haloperidol O
, O
compared O
to O
the O
control O
. O

importantly O
, O
a O
decrease O
in O
glutamate O
uptake O
correlates O
negatively O
with O
an O
increase O
in O
the O
incidence O
of O
orofacial B-NEG
diskinesia I-NEG
. O

these O
results O
indicate O
that O
early O
changes O
in O
glutamate O
transport O
may O
be O
related O
to O
the O
development O
of O
vacuous O
chewing O
movements O
in O
rats O
. O

-DOCSTART- O

acute B-NEG
psychosis I-NEG
due O
to O
treatment O
with O
phenytoin O
in O
a O
nonepileptic O
patient O
. O

the O
development O
of O
psychosis B-NEG
related O
to O
antiepileptic O
drug O
treatment O
is O
usually O
attributed O
to O
the O
interaction O
between O
the O
epileptic B-NEG
brain O
substratum O
and O
the O
antiepileptic O
drugs O
. O

the O
case O
of O
a O
nonepileptic O
patient O
who O
developed O
psychosis B-NEG
following O
phenytoin O
treatment O
for O
trigeminal B-NEG
neuralgia I-NEG
is O
described O
. O

this O
case O
suggests O
that O
the O
psychotic B-NEG
symptoms I-NEG
that O
occur O
following O
phenytoin O
treatment O
in O
some O
epileptic B-NEG
patients O
may O
be O
the O
direct O
result O
of O
medication O
, O
unrelated O
to O
seizures B-NEG
. O

-DOCSTART- O

the O
effect O
of O
treatment O
with O
gum O
arabic O
on O
gentamicin O
nephrotoxicity B-NEG
in O
rats O
: O
a O
preliminary O
study O
. O

in O
the O
present O
work O
we O
assessed O
the O
effect O
of O
treatment O
of O
rats O
with O
gum O
arabic O
on O
acute B-NEG
renal I-NEG
failure I-NEG
induced O
by O
gentamicin O
( O
gm O
) O
nephrotoxicity B-NEG
. O

rats O
were O
treated O
with O
the O
vehicle O
(2 O
ml/kg O
of O
distilled O
water O
and O
5% O
w/v O
cellulose O
, O
10 O
days) O
, O
gum O
arabic O
(2 O
ml/kg O
of O
a O
10% O
w/v O
aqueous O
suspension O
of O
gum O
arabic O
powder O
, O
orally O
for O
10 O
days) O
, O
or O
gum O
arabic O
concomitantly O
with O
gm O
( O
80mg/kg/day O
intramuscularly O
, O
during O
the O
last O
six O
days O
of O
the O
treatment O
period) O
. O
nephrotoxicity B-NEG
was O
assessed O
by O
measuring O
the O
concentrations O
of O
creatinine O
and O
urea O
in O
the O
plasma O
and O
reduced O
glutathione O
( O
gsh O
) O
in O
the O
kidney O
cortex O
, O
and O
by O
light O
microscopic O
examination O
of O
kidney O
sections O
. O

the O
results O
indicated O
that O
concomitant O
treatment O
with O
gum O
arabic O
and O
gm O
significantly O
increased O
creatinine O
and O
urea O
by O
about O
183 O
and O
239% O
, O
respectively O
( O
compared O
to O
432 O
and O
346% O
, O
respectively O
, O
in O
rats O
treated O
with O
cellulose O
and O
gm) O
, O
and O
decreased O
that O
of O
cortical O
gsh O
by O
21% O
( O
compared O
to O
27% O
in O
the O
cellulose O
plus O
gm O
group O
) O
the O
gm-induced O
proximal O
tubular B-NEG
necrosis I-NEG
appeared O
to O
be O
slightly O
less O
severe O
in O
rats O
given O
gm O
together O
with O
gum O
arabic O
than O
in O
those O
given O
gm O
and O
cellulose O
. O

it O
could O
be O
inferred O
that O
gum O
arabic O
treatment O
has O
induced O
a O
modest O
amelioration O
of O
some O
of O
the O
histological O
and O
biochemical O
indices O
of O
gm O
nephrotoxicity B-NEG
. O

further O
work O
is O
warranted O
on O
the O
effect O
of O
the O
treatments O
on O
renal O
functional O
aspects O
in O
models O
of O
chronic B-NEG
renal I-NEG
failure I-NEG
, O
and O
on O
the O
mechanism(s O
) O
involved O
. O

-DOCSTART- O

visual B-NEG
hallucinations I-NEG
associated O
with O
zonisamide O
. O

zonisamide O
is O
a O
broad-spectrum O
antiepileptic O
drug O
used O
to O
treat O
various O
types O
of O
seizures B-NEG
. O

although O
visual B-NEG
hallucinations I-NEG
have O
not O
been O
reported O
as O
an O
adverse O
effect O
of O
this O
agent O
, O
we O
describe O
three O
patients O
who O
experienced O
complex O
visual B-NEG
hallucinations I-NEG
and O
altered O
mental O
status O
after O
zonisamide O
treatment O
was O
begun O
or O
its O
dosage O
increased O
. O

all O
three O
had O
been O
diagnosed O
earlier O
with O
epilepsy B-NEG
, O
and O
their O
electroencephalogram O
( O
eeg O
) O
findings O
were O
abnormal O
. O

during O
monitoring O
, O
visual B-NEG
hallucinations I-NEG
did O
not O
correlate O
with O
eeg O
readings O
, O
nor O
did O
video O
recording O
capture O
any O
of O
the O
described O
events O
. O

none O
of O
the O
patients O
had O
experienced O
visual B-NEG
hallucinations I-NEG
before O
this O
event O
. O

the O
only O
recent O
change O
in O
their O
treatment O
was O
the O
introduction O
or O
increased O
dosage O
of O
zonisamide O
. O

with O
either O
discontinuation O
or O
decreased O
dosage O
of O
the O
drug O
the O
symptoms O
disappeared O
and O
did O
not O
recur O
. O

further O
observations O
and O
reports O
will O
help O
clarify O
this O
adverse O
effect O
. O

until O
then O
, O
clinicians O
need O
to O
be O
aware O
of O
this O
possible O
complication O
associated O
with O
zonisamide O
. O

-DOCSTART- O

glepp1 O
receptor O
tyrosine O
phosphatase O
( O
ptpro O
) O
in O
rat O
pan O
nephrosis B-NEG
. O

a O
marker O
of O
acute O
podocyte O
injury O
. O

glomerular O
epithelial O
protein O
1 O
( O
glepp1 O
) O
is O
a O
podocyte O
receptor O
membrane O
protein O
tyrosine O
phosphatase O
located O
on O
the O
apical O
cell O
membrane O
of O
visceral O
glomerular O
epithelial O
cell O
and O
foot O
processes O
. O

this O
receptor O
plays O
a O
role O
in O
regulating O
the O
structure O
and O
function O
of O
podocyte O
foot O
process O
. O

to O
better O
understand O
the O
utility O
of O
glepp1 O
as O
a O
marker O
of O
glomerular B-NEG
injury I-NEG
, O
the O
amount O
and O
distribution O
of O
glepp1 O
protein O
and O
mrna O
were O
examined O
by O
immunohistochemistry O
, O
western O
blot O
and O
rnase O
protection O
assay O
in O
a O
model O
of O
podocyte O
injury O
in O
the O
rat O
. O

puromycin O
aminonucleoside O
nephrosis B-NEG
was O
induced O
by O
single O
intraperitoneal O
injection O
of O
puromycin O
aminonucleoside O
(pan O
, O
20 O
mg/100g O
bw) O
. O

tissues O
were O
analyzed O
at O
0, O
5, O
7, O
11 O
, O
21 O
, O
45 O
, O
80 O
and O
126 O
days O
after O
pan O
injection O
so O
as O
to O
include O
both O
the O
acute O
phase O
of O
proteinuria B-NEG
associated O
with O
foot O
process O
effacement O
( O
days O
5-11 O
) O
and O
the O
chronic O
phase O
of O
proteinuria B-NEG
associated O
with O
glomerulosclerosis B-NEG
( O
days O
45-126) O
. O

at O
day O
5, O
glepp1 O
protein O
and O
mrna O
were O
reduced O
from O
the O
normal O
range O
( O
265.2 O
+/- O
79.6 O
x O
10(6 O
) O
moles/glomerulus O
and O
100% O
) O
to O
15% O
of O
normal O
( O
41.8 O
+/- O
4.8 O
x O
10(6 O
) O
moles/glomerulus O
, O
p O
< O
0.005) O
. O

this O
occurred O
in O
association O
with O
an O
increase O
in O
urinary O
protein O
content O
from O
1.8 O
+/- O
1 O
to O
99.0 O
+/- O
61 O
mg/day O
(p O
< O
0.001) O
. O

in O
contrast O
, O
podocalyxin O
did O
not O
change O
significantly O
at O
this O
time O
. O

by O
day O
11 O
, O
glepp1 O
protein O
and O
mrna O
had O
begun O
to O
return O
towards O
baseline O
. O

by O
day O
45-126 O
, O
at O
a O
time O
when O
glomerular O
scarring O
was O
present O
, O
glepp1 O
was O
absent O
from O
glomerulosclerotic O
areas O
although O
the O
total O
glomerular O
content O
of O
glepp1 O
was O
not O
different O
from O
normal O
. O

we O
conclude O
that O
glepp1 O
expression O
, O
unlike O
podocalyxin O
, O
reflects O
podocyte O
injury O
induced O
by O
pan O
. O

glepp1 O
expression O
may O
be O
a O
useful O
marker O
of O
podocyte O
injury O
. O

-DOCSTART- O

ticlopidine-induced O
aplastic B-NEG
anemia I-NEG
: O
report O
of O
three O
chinese O
patients O
and O
review O
of O
the O
literature O
. O

in O
this O
study O
, O
three O
chinese O
patients O
with O
ticlopidine-induced O
aplastic B-NEG
anemia I-NEG
were O
reported O
and O
another O
13 O
patients O
in O
the O
english O
literature O
were O
reviewed O
. O

we O
attempted O
to O
find O
underlying O
similarities O
, O
evaluate O
the O
risk O
factors O
, O
and O
identify O
appropriate O
treatment O
for O
this O
complication O
. O

all O
but O
one O
of O
the O
patients O
were O
over O
60 O
years O
old O
, O
and O
the O
6 O
who O
died O
were O
all O
older O
than O
65 O
. O

therefore O
, O
old O
age O
may O
be O
a O
risk O
factor O
for O
developing O
this O
complication O
. O
agranulocytosis B-NEG
occurred O
3-20 O
weeks O
after O
initiation O
of O
ticlopidine O
, O
so O
frequent O
examination O
of O
white O
cell O
count O
during O
treatment O
is O
recommended O
. O

there O
seemed O
to O
be O
no O
direct O
correlation O
between O
the O
dose O
or O
duration O
used O
and O
the O
severity O
of O
bone B-NEG
marrow I-NEG
suppression I-NEG
. O

treatment O
for O
ticlopidine-induced O
aplastic B-NEG
anemia I-NEG
with O
colony-stimulating O
factors O
seemed O
to O
have O
little O
effect O
. O

the O
fact O
that O
5 O
of O
the O
6 O
patients O
who O
received O
concurrent O
calcium O
channel O
blockers O
died O
, O
should O
alert O
clinicians O
to O
be O
more O
cautious O
when O
using O
these O
two O
drugs O
simultaneously O
. O

-DOCSTART- O

facilitation O
of O
memory O
retrieval O
by O
pre-test O
morphine O
and O
its O
state O
dependency O
in O
the O
step-through O
type O
passive O
avoidance O
learning O
test O
in O
mice O
. O
amnesia B-NEG
produced O
by O
scopolamine O
and O
cycloheximide O
were O
reversed O
by O
morphine O
given O
30 O
min O
before O
the O
test O
trial O
(pre-test) O
, O
and O
pre-test O
morphine O
also O
facilitated O
the O
memory O
retrieval O
in O
the O
animals O
administered O
naloxone O
during O
the O
training O
trial O
. O

similarly O
, O
pre-test O
scopolamine O
partially O
reversed O
the O
scopolamine-induced O
amnesia B-NEG
, O
but O
not O
significantly O
; O
and O
pre-test O
cycloheximide O
failed O
to O
reverse O
the O
cycloheximide-induced O
amnesia B-NEG
. O

these O
results O
suggest O
that O
the O
facilitation O
of O
memory O
retrieval O
by O
pre-test O
morphine O
might O
be O
the O
direct O
action O
of O
morphine O
rather O
than O
a O
state O
dependent O
effect O
. O

-DOCSTART- O

test O
conditions O
influence O
the O
response O
to O
a O
drug O
challenge O
in O
rodents O
. O

these O
studies O
were O
conducted O
to O
examine O
the O
differential O
response O
to O
a O
drug O
challenge O
under O
varied O
experimental O
test O
conditions O
routinely O
employed O
to O
study O
drug-induced O
behavioral O
and O
neurophysiological O
responses O
in O
rodents O
. O

apomorphine O
, O
a O
nonselective O
dopamine O
agonist O
, O
was O
selected O
due O
to O
its O
biphasic O
behavioral O
effects O
, O
its O
ability O
to O
induce O
hypothermia B-NEG
, O
and O
to O
produce O
distinct O
changes O
to O
dopamine O
turnover O
in O
the O
rodent O
brain O
. O

from O
such O
experiments O
there O
is O
evidence O
that O
characterization O
and O
detection O
of O
apomorphine-induced O
activity O
in O
rodents O
critically O
depends O
upon O
the O
test O
conditions O
employed O
. O

in O
rats O
, O
detection O
of O
apomorphine-induced O
hyperactivity B-NEG
was O
facilitated O
by O
a O
period O
of O
acclimatization O
to O
the O
test O
conditions O
. O

moreover O
, O
test O
conditions O
can O
impact O
upon O
other O
physiological O
responses O
to O
apomorphine O
such O
as O
drug-induced O
hypothermia B-NEG
. O

in O
mice O
, O
apomorphine O
produced O
qualitatively O
different O
responses O
under O
novel O
conditions O
when O
compared O
to O
those O
behaviors O
elicited O
in O
the O
home O
test O
cage O
. O

drug-induced O
gross O
activity O
counts O
were O
increased O
in O
the O
novel O
exploratory O
box O
only O
, O
while O
measures O
of O
stereotypic O
behavior O
were O
similar O
in O
both O
. O

by O
contrast O
, O
apomorphine-induced O
locomotion O
was O
more O
prominent O
in O
the O
novel O
exploratory O
box O
. O

dopamine O
turnover O
ratios O
( O
dopac:da O
and O
hva:da O
) O
were O
found O
to O
be O
lower O
in O
those O
animals O
exposed O
to O
the O
exploratory O
box O
when O
compared O
to O
their O
home O
cage O
counterparts O
. O

however O
, O
apomorphine-induced O
reductions O
in O
striatal O
dopamine O
turnover O
were O
detected O
in O
both O
novel O
and O
home O
cage O
environments O
. O

the O
implications O
of O
these O
findings O
are O
discussed O
with O
particular O
emphasis O
upon O
conducting O
psychopharmacological O
challenge O
tests O
in O
rodents O
. O

-DOCSTART- O

famotidine-associated O
delirium B-NEG
. O

a O
series O
of O
six O
cases O
. O

famotidine O
is O
a O
histamine O
h2-receptor O
antagonist O
used O
in O
inpatient O
settings O
for O
prevention O
of O
stress O
ulcers B-NEG
and O
is O
showing O
increasing O
popularity O
because O
of O
its O
low O
cost O
. O

although O
all O
of O
the O
currently O
available O
h2-receptor O
antagonists O
have O
shown O
the O
propensity O
to O
cause O
delirium B-NEG
, O
only O
two O
previously O
reported O
cases O
have O
been O
associated O
with O
famotidine O
. O

the O
authors O
report O
on O
six O
cases O
of O
famotidine-associated O
delirium B-NEG
in O
hospitalized O
patients O
who O
cleared O
completely O
upon O
removal O
of O
famotidine O
. O

the O
pharmacokinetics O
of O
famotidine O
are O
reviewed O
, O
with O
no O
change O
in O
its O
metabolism O
in O
the O
elderly O
population O
seen O
. O

the O
implications O
of O
using O
famotidine O
in O
elderly O
persons O
are O
discussed O
. O

-DOCSTART- O

indomethacin O
induced O
hypotension B-NEG
in O
sodium O
and O
volume O
depleted O
rats O
. O

after O
a O
single O
oral O
dose O
of O
4 O
mg/kg O
indomethacin O
( O
idm O
) O
to O
sodium O
and O
volume O
depleted O
rats O
plasma O
renin O
activity O
( O
pra O
) O
and O
systolic O
blood O
pressure O
fell O
significantly O
within O
four O
hours O
. O

in O
sodium O
repleted O
animals O
indomethacin O
did O
not O
change O
systolic O
blood O
pressure O
( O
bp O
) O
although O
plasma O
renin O
activity O
was O
decreased O
. O

thus O
, O
indomethacin O
by O
inhibition O
of O
prostaglandin O
synthesis O
may O
diminish O
the O
blood O
pressure O
maintaining O
effect O
of O
the O
stimulated O
renin-angiotensin O
system O
in O
sodium O
and O
volume O
depletion O
. O

-DOCSTART- O

late-onset O
scleroderma B-NEG
renal I-NEG
crisis I-NEG
induced O
by O
tacrolimus O
and O
prednisolone O
: O
a O
case O
report O
. O
scleroderma B-NEG
renal I-NEG
crisis I-NEG
( O
src B-NEG
) O
is O
a O
rare O
complication O
of O
systemic B-NEG
sclerosis I-NEG
( O
ssc B-NEG
) O
but O
can O
be O
severe O
enough O
to O
require O
temporary O
or O
permanent O
renal O
replacement O
therapy O
. O

moderate O
to O
high O
dose O
corticosteroid O
use O
is O
recognized O
as O
a O
major O
risk O
factor O
for O
src B-NEG
. O

furthermore O
, O
there O
have O
been O
reports O
of O
thrombotic B-NEG
microangiopathy I-NEG
precipitated O
by O
cyclosporine O
in O
patients O
with O
ssc B-NEG
. O

in O
this O
article O
, O
we O
report O
a O
patient O
with O
src B-NEG
induced O
by O
tacrolimus O
and O
corticosteroids O
. O

the O
aim O
of O
this O
work O
is O
to O
call O
attention O
to O
the O
risk O
of O
tacrolimus O
use O
in O
patients O
with O
ssc B-NEG
. O

-DOCSTART- O

the O
risk O
and O
associated O
factors O
of O
methamphetamine O
psychosis B-NEG
in O
methamphetamine-dependent O
patients O
in O
malaysia O
. O

objective O
: O
the O
objective O
of O
this O
study O
was O
to O
determine O
the O
risk O
of O
lifetime O
and O
current O
methamphetamine-induced O
psychosis B-NEG
in O
patients O
with O
methamphetamine O
dependence O
. O

the O
association O
between O
psychiatric O
co-morbidity O
and O
methamphetamine-induced O
psychosis B-NEG
was O
also O
studied O
. O

methods O
: O
this O
was O
a O
cross-sectional O
study O
conducted O
concurrently O
at O
a O
teaching O
hospital O
and O
a O
drug O
rehabilitation O
center O
in O
malaysia O
. O

patients O
with O
the O
diagnosis O
of O
methamphetamine O
based O
on O
dsm-iv O
were O
interviewed O
using O
the O
mini O
international O
neuropsychiatric O
interview O
( O
m.i.n.i. O
) O
for O
methamphetamine-induced O
psychosis B-NEG
and O
other O
axis O
i O
psychiatric B-NEG
disorders I-NEG
. O

the O
information O
on O
sociodemographic O
background O
and O
drug O
use O
history O
was O
obtained O
from O
interview O
or O
medical O
records O
. O

results O
: O
of O
292 O
subjects O
, O
47.9% O
of O
the O
subjects O
had O
a O
past O
history O
of O
psychotic B-NEG
symptoms I-NEG
and O
13.0% O
of O
the O
patients O
were O
having O
current O
psychotic B-NEG
symptoms I-NEG
. O

co-morbid O
major O
depressive B-NEG
disorder I-NEG
(or=7.18 O
, O
95 O
ci=2.612-19.708) O
, O
bipolar B-NEG
disorder I-NEG
(or=13.807 O
, O
95 O
ci=5.194-36.706) O
, O
antisocial B-NEG
personality I-NEG
disorder I-NEG
(or=12.619 O
, O
95 O
ci=6.702-23.759 O
) O
and O
heavy O
methamphetamine O
uses O
were O
significantly O
associated O
with O
lifetime O
methamphetamine-induced O
psychosis B-NEG
after O
adjusted O
for O
other O
factors O
. O
major B-NEG
depressive I-NEG
disorder I-NEG
(or=2.870 O
, O
ci=1.154-7.142 O
) O
and O
antisocial B-NEG
personality I-NEG
disorder I-NEG
(or=3.299 O
, O
95 O
ci=1.375-7.914 O
) O
were O
the O
only O
factors O
associated O
with O
current O
psychosis B-NEG
. O

conclusion O
: O
there O
was O
a O
high O
risk O
of O
psychosis B-NEG
in O
patients O
with O
methamphetamine O
dependence O
. O

it O
was O
associated O
with O
co-morbid O
affective B-NEG
disorder I-NEG
, O
antisocial B-NEG
personality I-NEG
, O
and O
heavy O
methamphetamine O
use O
. O

it O
is O
recommended O
that O
all O
cases O
of O
methamphetamine O
dependence O
should O
be O
screened O
for O
psychotic B-NEG
symptoms I-NEG
. O

-DOCSTART- O

cerebellar O
sensory O
processing O
alterations O
impact O
motor O
cortical O
plasticity O
in O
parkinson's B-NEG
disease I-NEG
: O
clues O
from O
dyskinetic B-NEG
patients O
. O

the O
plasticity O
of O
primary O
motor O
cortex O
( O
m1 O
) O
in O
patients O
with O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
and O
levodopa-induced O
dyskinesias B-NEG
( O
lids B-NEG
) O
is O
severely O
impaired O
. O

we O
recently O
reported O
in O
young O
healthy O
subjects O
that O
inhibitory O
cerebellar O
stimulation O
enhanced O
the O
sensorimotor O
plasticity O
of O
m1 O
that O
was O
induced O
by O
paired O
associative O
stimulation O
(pas) O
. O

this O
study O
demonstrates O
that O
the O
deficient O
sensorimotor O
m1 O
plasticity O
in O
16 O
patients O
with O
lids B-NEG
could O
be O
reinstated O
by O
a O
single O
session O
of O
real O
inhibitory O
cerebellar O
stimulation O
but O
not O
sham O
stimulation O
. O

this O
was O
evident O
only O
when O
a O
sensory O
component O
was O
involved O
in O
the O
induction O
of O
plasticity O
, O
indicating O
that O
cerebellar O
sensory O
processing O
function O
is O
involved O
in O
the O
resurgence O
of O
m1 O
plasticity O
. O

the O
benefit O
of O
inhibitory O
cerebellar O
stimulation O
on O
lids B-NEG
is O
known O
. O

to O
explore O
whether O
this O
benefit O
is O
linked O
to O
the O
restoration O
of O
sensorimotor O
plasticity O
of O
m1 O
, O
we O
conducted O
an O
additional O
study O
looking O
at O
changes O
in O
lids B-NEG
and O
pas-induced O
plasticity O
after O
10 O
sessions O
of O
either O
bilateral O
, O
real O
inhibitory O
cerebellar O
stimulation O
or O
sham O
stimulation O
. O

only O
real O
and O
not O
sham O
stimulation O
had O
an O
antidyskinetic O
effect O
and O
it O
was O
paralleled O
by O
a O
resurgence O
in O
the O
sensorimotor O
plasticity O
of O
m1 O
. O

these O
results O
suggest O
that O
alterations O
in O
cerebellar O
sensory O
processing O
function O
, O
occurring O
secondary O
to O
abnormal O
basal O
ganglia O
signals O
reaching O
it O
, O
may O
be O
an O
important O
element O
contributing O
to O
the O
maladaptive O
sensorimotor O
plasticity O
of O
m1 O
and O
the O
emergence O
of O
abnormal B-NEG
involuntary I-NEG
movements I-NEG
. O

-DOCSTART- O

the O
function O
of O
p2x3 O
receptor O
and O
nk1 O
receptor O
antagonists O
on O
cyclophosphamide-induced O
cystitis B-NEG
in O
rats O
. O

purpose O
: O
the O
purpose O
of O
the O
study O
is O
to O
explore O
the O
function O
of O
p2x3 O
and O
nk1 O
receptors O
antagonists O
on O
cyclophosphamide O
( O
cyp)-induced O
cystitis B-NEG
in O
rats O
. O

methods O
: O
sixty O
female O
sprague-dawley O
( O
sd O
) O
rats O
were O
randomly O
divided O
into O
three O
groups O
. O

the O
rats O
in O
the O
control O
group O
were O
intraperitoneally O
( O
i.p. O
) O
injected O
with O
0.9% O
saline O
(4 O
ml/kg) O
; O
the O
rats O
in O
the O
model O
group O
were O
i.p O
. O
injected O
with O
cyp O
( O
150 O
mg/kg) O
; O
and O
the O
rats O
in O
the O
intervention O
group O
were O
i.p O
. O
injected O
with O
cyp O
with O
subsequently O
perfusion O
of O
bladder O
with O
p2x3 O
and O
nk1 O
receptors' O
antagonists O
, O
suramin O
and O
gr O
82334 O
. O

spontaneous O
pain B-NEG
behaviors O
following O
the O
administration O
of O
cyp O
were O
observed O
. O

urodynamic O
parameters O
, O
bladder O
pressure-volume O
curve O
, O
maximum O
voiding O
pressure O
(mvp) O
, O
and O
maximum O
cystometric O
capacity O
(mcc) O
, O
were O
recorded O
. O

pathological O
changes O
in O
bladder O
tissue O
were O
observed O
. O

immunofluorescence O
was O
used O
to O
detect O
the O
expression O
of O
p2x3 O
and O
nk1 O
receptors O
in O
bladder O
. O

results O
: O
cyclophosphamide O
treatment O
increased O
the O
spontaneous O
pain B-NEG
behaviors O
scores O
. O

the O
incidence O
of O
bladder O
instability O
during O
urine O
storage O
period O
of O
model O
group O
was O
significantly O
higher O
than O
intervention O
group O
( O
x(2 O
) O
= O
7.619 O
, O
p O
= O
0.007 O
) O
and O
control O
group O
( O
x(2 O
) O
= O
13.755 O
, O
p O
= O
0.000) O
. O

mcc O
in O
the O
model O
group O
was O
lower O
than O
the O
control O
and O
intervention O
groups O
(p O
< O
0.01) O
. O

histological O
changes O
evident O
in O
model O
and O
intervention O
groups O
rats' O
bladder O
included O
edema B-NEG
, O
vasodilation O
, O
and O
infiltration O
of O
inflammatory O
cells O
. O

in O
model O
group O
, O
the O
expression O
of O
p2x3 O
receptor O
increased O
in O
urothelium O
and O
suburothelium O
, O
and O
nk1 O
receptor O
increased O
in O
suburothelium O
, O
while O
the O
expression O
of O
them O
in O
intervention O
group O
was O
lower O
. O

conclusions O
: O
in O
cyp-induced O
cystitis B-NEG
, O
the O
expression O
of O
p2x3 O
and O
nk1 O
receptors O
increased O
in O
urothelium O
and/or O
suburothelium O
. O

perfusion O
of O
bladder O
with O
p2x3 O
and O
nk1 O
receptors O
antagonists O
ameliorated O
the O
bladder O
function O
. O

-DOCSTART- O

acute O
hepatitis B-NEG
associated O
with O
clopidogrel O
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

drug-induced O
hepatotoxicity B-NEG
is O
a O
common O
cause O
of O
acute O
hepatitis B-NEG
, O
and O
the O
recognition O
of O
the O
responsible O
drug O
may O
be O
difficult O
. O

we O
describe O
a O
case O
of O
clopidogrel-related O
acute O
hepatitis B-NEG
. O

the O
diagnosis O
is O
strongly O
suggested O
by O
an O
accurate O
medical O
history O
and O
liver O
biopsy O
. O

reports O
about O
cases O
of O
hepatotoxicity B-NEG
due O
to O
clopidogrel O
are O
increasing O
in O
the O
last O
few O
years O
, O
after O
the O
increased O
use O
of O
this O
drug O
. O

in O
conclusion O
, O
we O
believe O
that O
physicians O
should O
carefully O
consider O
the O
risk O
of O
drug-induced O
hepatic B-NEG
injury I-NEG
when O
clopidogrel O
is O
prescribed O
. O

-DOCSTART- O

bortezomib O
and O
dexamethasone O
as O
salvage O
therapy O
in O
patients O
with O
relapsed/refractory O
multiple B-NEG
myeloma I-NEG
: O
analysis O
of O
long-term O
clinical O
outcomes O
. O

bortezomib O
( O
bort)-dexamethasone O
( O
dex O
) O
is O
an O
effective O
therapy O
for O
relapsed/refractory O
( O
r/r O
) O
multiple B-NEG
myeloma I-NEG
( O
mm B-NEG
). O

this O
retrospective O
study O
investigated O
the O
combination O
of O
bort O
( O
1.3 O
mg/m(2 O
) O
on O
days O
1, O
4, O
8, O
and O
11 O
every O
3 O
weeks O
) O
and O
dex O
( O
20 O
mg O
on O
the O
day O
of O
and O
the O
day O
after O
bort O
) O
as O
salvage O
treatment O
in O
85 O
patients O
with O
r/r O
mm B-NEG
after O
prior O
autologous O
stem O
cell O
transplantation O
or O
conventional O
chemotherapy O
. O

the O
median O
number O
of O
prior O
lines O
of O
therapy O
was O
2. O

eighty-seven O
percent O
of O
the O
patients O
had O
received O
immunomodulatory O
drugs O
included O
in O
some O
line O
of O
therapy O
before O
bort-dex O
. O

the O
median O
number O
of O
bort-dex O
cycles O
was O
6, O
up O
to O
a O
maximum O
of O
12 O
cycles O
. O

on O
an O
intention-to-treat O
basis O
, O
55 O
% O
of O
the O
patients O
achieved O
at O
least O
partial O
response O
, O
including O
19 O
% O
cr O
and O
35 O
% O
achieved O
at O
least O
very O
good O
partial O
response O
. O

median O
durations O
of O
response O
, O
time O
to O
next O
therapy O
and O
treatment-free O
interval O
were O
8, O
11.2 O
, O
and O
5.1 O
months O
, O
respectively O
. O

the O
most O
relevant O
adverse O
event O
was O
peripheral B-NEG
neuropathy I-NEG
, O
which O
occurred O
in O
78 O
% O
of O
the O
patients O
( O
grade O
ii O
, O
38 O
%; O
grade O
iii O
, O
21 O
%) O
and O
led O
to O
treatment O
discontinuation O
in O
6 O
%. O

with O
a O
median O
follow O
up O
of O
22 O
months O
, O
median O
time O
to O
progression O
, O
progression-free O
survival O
( O
pfs O
) O
and O
overall O
survival O
( O
os O
) O
were O
8.9 O
, O
8.7 O
, O
and O
22 O
months O
, O
respectively O
. O

prolonged O
pfs O
and O
os O
were O
observed O
in O
patients O
achieving O
cr O
and O
receiving O
bort-dex O
a O
single O
line O
of O
prior O
therapy O
. O

bort-dex O
was O
an O
effective O
salvage O
treatment O
for O
mm B-NEG
patients O
, O
particularly O
for O
those O
in O
first O
relapse O
. O

-DOCSTART- O

pubertal O
exposure O
to O
bisphenol O
a O
increases O
anxiety B-NEG
-like O
behavior O
and O
decreases O
acetylcholinesterase O
activity O
of O
hippocampus O
in O
adult O
male O
mice O
. O

the O
negative O
effects O
of O
bisphenol O
a O
( O
bpa O
) O
on O
neurodevelopment O
and O
behaviors O
have O
been O
well O
established O
. O

acetylcholinesterase O
( O
ache O
) O
is O
a O
regulatory O
enzyme O
which O
is O
involved O
in O
anxiety B-NEG
-like O
behavior O
. O

this O
study O
investigated O
behavioral O
phenotypes O
and O
ache O
activity O
in O
male O
mice O
following O
bpa O
exposure O
during O
puberty O
. O

on O
postnatal O
day O
( O
pnd O
) O
35 O
, O
male O
mice O
were O
exposed O
to O
50mg O
bpa/kg O
diet O
per O
day O
for O
a O
period O
of O
35 O
days O
. O

on O
pnd71 O
, O
a O
behavioral O
assay O
was O
performed O
using O
the O
elevated O
plus O
maze O
( O
epm O
) O
and O
the O
light/dark O
test O
. O

in O
addition O
, O
ache O
activity O
was O
measured O
in O
the O
prefrontal O
cortex O
, O
hypothalamus O
, O
cerebellum O
and O
hippocampus O
. O

results O
from O
our O
behavioral O
phenotyping O
indicated O
that O
anxiety B-NEG
-like O
behavior O
was O
increased O
in O
mice O
exposed O
to O
bpa O
. O

ache O
activity O
was O
significantly O
decreased O
in O
the O
hippocampus O
of O
mice O
with O
bpa O
compared O
to O
control O
mice O
, O
whereas O
no O
difference O
was O
found O
in O
the O
prefrontal O
cortex O
, O
hypothalamus O
and O
cerebellum O
. O

our O
findings O
showed O
that O
pubertal O
bpa O
exposure O
increased O
anxiety B-NEG
-like O
behavior O
, O
which O
may O
be O
associated O
with O
decreased O
ache O
activity O
of O
the O
hippocampus O
in O
adult O
male O
mice O
. O

further O
studies O
are O
necessary O
to O
investigate O
the O
cholinergic O
signaling O
of O
the O
hippocampus O
in O
pbe O
induced O
anxiety B-NEG
-like O
behaviors O
. O

-DOCSTART- O

biochemical O
effects O
of O
solidago O
virgaurea O
extract O
on O
experimental O
cardiotoxicity B-NEG
. O
cardiovascular B-NEG
diseases I-NEG
( O
cvds B-NEG
) O
are O
the O
major O
health O
problem O
of O
advanced O
as O
well O
as O
developing O
countries O
of O
the O
world O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
the O
solidago O
virgaurea O
extract O
on O
isoproterenol-induced O
cardiotoxicity B-NEG
in O
rats O
. O

the O
subcutaneous O
injection O
of O
isoproterenol O
( O
30 O
mg/kg O
) O
into O
rats O
twice O
at O
an O
interval O
of O
24 O
h, O
for O
two O
consecutive O
days O
, O
led O
to O
a O
significant O
increase O
in O
serum O
lactate O
dehydrogenase O
, O
creatine O
phosphokinase O
, O
alanine O
transaminase O
, O
aspartate O
transaminase O
, O
and O
angiotensin-converting O
enzyme O
activities O
, O
total O
cholesterol O
, O
triglycerides O
, O
free O
serum O
fatty O
acid O
, O
cardiac O
tissue O
malondialdehyde O
(mda) O
, O
and O
nitric O
oxide O
levels O
and O
a O
significant O
decrease O
in O
levels O
of O
glutathione O
and O
superoxide O
dismutase O
in O
cardiac O
tissue O
as O
compared O
to O
the O
normal O
control O
group O
(p O
< O
0.05) O
. O

pretreatment O
with O
s. O
virgaurea O
extract O
for O
5 O
weeks O
at O
a O
dose O
of O
250 O
mg/kg O
followed O
by O
isoproterenol O
injection O
significantly O
prevented O
the O
observed O
alterations O
. O

captopril O
( O
50 O
mg/kg/day O
, O
given O
orally) O
, O
an O
inhibitor O
of O
angiotensin-converting O
enzyme O
used O
as O
a O
standard O
cardioprotective O
drug O
, O
was O
used O
as O
a O
positive O
control O
in O
this O
study O
. O

the O
data O
of O
the O
present O
study O
suggest O
that O
s. O
virgaurea O
extract O
exerts O
its O
protective O
effect O
by O
decreasing O
mda O
level O
and O
increasing O
the O
antioxidant O
status O
in O
isoproterenol-treated O
rats O
. O

the O
study O
emphasizes O
the O
beneficial O
action O
of O
s. O
virgaurea O
extract O
as O
a O
cardioprotective O
agent O
. O

-DOCSTART- O

real-world O
data O
on O
the O
efficacy O
and O
safety O
of O
lenalidomide O
and O
dexamethasone O
in O
patients O
with O
relapsed/refractory O
mu O
ltiple B-NEG
myeloma I-NEG
w I-NEG
ho O
were O
treated O
according O
to O
the O
standard O
clinical O
practice O
: O
a O
study O
of O
the O
greek O
my O
eloma B-NEG
s I-NEG
tudy O
group O
. O

lenalidomide O
and O
dexamethasone O
( O
rd O
) O
is O
a O
standard O
of O
care O
for O
relapsed/refractory O
mu O
ltiple B-NEG
myeloma I-NEG
( O
rr O
mm B-NEG
) O
, O
but O
there O
is O
limited O
published O
data O
on O
its O
efficacy O
and O
safety O
in O
the O
real O
world O
(rw) O
, O
according O
to O
the O
international O
society O
of O
pharmacoeconomics O
and O
outcomes O
research O
definition O
. O

we O
studied O
212 O
rr O
mm B-NEG
p I-NEG
atients O
who O
received O
rd O
in O
rw O
. O

objective O
response O
( O
>pr O
( O
partial O
response) O
) O
rate O
was O
77.4 O
% O
( O
complete O
response O
(cr) O
, O
20.2 O
%) O
. O

median O
time O
to O
first O
and O
best O
response O
was O
2 O
and O
5 O
months O
, O
respectively O
. O

median O
time O
to O
cr O
when O
rd O
was O
given O
as O
2nd O
or O
>2(nd)-line O
treatment O
at O
4 O
and O
11 O
months O
, O
respectively O
. O

quality O
of O
response O
was O
independent O
of O
previous O
lines O
of O
therapies O
or O
previous O
exposure O
to O
thalidomide O
or O
bortezomib O
. O

median O
duration O
of O
response O
was O
34.4 O
months O
, O
and O
it O
was O
higher O
in O
patients O
who O
received O
rd O
until O
progression O
( O
not O
reached O
versus O
19 O
months O
, O
p O
< O
0.001) O
. O

improvement O
of O
humoral O
immunity O
occurred O
in O
60 O
% O
of O
responders O
(p O
< O
0.001 O
) O
and O
in O
the O
majority O
of O
patients O
who O
achieved O
stable O
disease O
. O

adverse O
events O
were O
reported O
in O
68.9 O
% O
of O
patients O
( O
my O
elosuppression B-NEG
i I-NEG
n O
49.4 O
%) O
and O
12.7 O
% O
of O
patients O
needed O
hospitalization O
. O

pe O
ripheral B-NEG
neuropathy I-NEG
w I-NEG
as O
observed O
only O
in O
2.5 O
% O
of O
patients O
and O
de O
ep B-NEG
vein I-NEG
thrombosis I-NEG
i I-NEG
n O
5.7 O
%. O

dose O
reductions O
were O
needed O
in O
31 O
% O
of O
patients O
and O
permanent O
discontinuation O
in O
38.9 O
%. O

median O
time O
to O
treatment O
discontinuation O
was O
16.8 O
months O
. O

performance O
status O
( O
ps O
) O
and O
initial O
lenalidomide O
dose O
predicted O
for O
treatment O
discontinuation O
. O

extra-medullary O
relapses O
occurred O
in O
3.8 O
% O
of O
patients O
. O

our O
study O
confirms O
that O
rd O
is O
effective O
and O
safe O
in O
rr O
mm B-NEG
i I-NEG
n O
the O
rw O
; O
it O
produces O
durable O
responses O
especially O
in O
patients O
who O
continue O
on O
treatment O
till O
progression O
and O
improves O
humoral O
immunity O
even O
in O
patients O
with O
stable O
disease O
. O

-DOCSTART- O

the O
cytogenetic O
action O
of O
ifosfamide O
, O
mesna O
, O
and O
their O
combination O
on O
peripheral O
rabbit O
lymphocytes O
: O
an O
in O
vivo/in O
vitro O
cytogenetic O
study O
. O

ifosfamide O
( O
ifo O
) O
is O
an O
alkylating O
nitrogen O
mustard O
, O
administrated O
as O
an O
antineoplasmic O
agent O
. O

it O
is O
characterized O
by O
its O
intense O
urotoxic O
action O
, O
leading O
to O
hemorrhagic B-NEG
cystitis I-NEG
. O

this O
side O
effect O
of O
ifo O
raises O
the O
requirement O
for O
the O
co-administration O
with O
sodium O
2-sulfanylethanesulfonate O
( O
mesna O
) O
aiming O
to O
avoid O
or O
minimize O
this O
effect O
. O

ifo O
and O
mesna O
were O
administrated O
separately O
on O
rabbit's O
lymphocytes O
in O
vivo O
, O
which O
were O
later O
developed O
in O
vitro O
. O

cytogenetic O
markers O
for O
sister O
chromatid O
exchanges O
(sces) O
, O
proliferation O
rate O
index O
( O
pri O
) O
and O
mitotic O
index O
were O
recorded O
. O

mesna's O
action O
, O
in O
conjunction O
with O
ifo O
reduces O
the O
frequency O
of O
sces O
, O
in O
comparison O
with O
the O
sces O
recordings O
obtained O
when O
ifo O
is O
administered O
alone O
. O

in O
addition O
to O
this O
, O
when O
high O
concentrations O
of O
mesna O
were O
administered O
alone O
significant O
reductions O
of O
the O
pri O
were O
noted O
, O
than O
with O
ifo O
acting O
at O
the O
same O
concentration O
on O
the O
lymphocytes O
. O

mesna O
significantly O
reduces O
ifo's O
genotoxicity B-NEG
, O
while O
when O
administered O
in O
high O
concentrations O
it O
acts O
in O
an O
inhibitory O
fashion O
on O
the O
cytostatic O
action O
of O
the O
drug O
. O

-DOCSTART- O

risk O
factors O
and O
predictors O
of O
levodopa-induced O
dyskinesia B-NEG
among O
multiethnic O
malaysians O
with O
parkinson's B-NEG
disease I-NEG
. O

chronic O
pulsatile O
levodopa O
therapy O
for O
parkinson's B-NEG
disease I-NEG
( O
pd B-NEG
) O
leads O
to O
the O
development O
of O
motor O
fluctuations O
and O
dyskinesia B-NEG
. O

we O
studied O
the O
prevalence O
and O
predictors O
of O
levodopa-induced O
dyskinesia B-NEG
among O
multiethnic O
malaysian O
patients O
with O
pd B-NEG
. O

methods O
: O
this O
is O
a O
cross-sectional O
study O
involving O
95 O
patients O
with O
pd B-NEG
on O
uninterrupted O
levodopa O
therapy O
for O
at O
least O
6 O
months O
. O

the O
instrument O
used O
was O
the O
updrs O
questionnaires O
. O

the O
predictors O
of O
dyskinesia B-NEG
were O
determined O
using O
multivariate O
logistic O
regression O
analysis O
. O

results O
: O
the O
mean O
age O
was O
65.6 O
+ O
8.5 O
years O
. O

the O
mean O
onset O
age O
was O
58.5 O
+ O
9.8 O
years O
. O

the O
median O
disease O
duration O
was O
6 O
( O
7 O
) O
years O
. O
dyskinesia B-NEG
was O
present O
in O
44% O
(n O
= O
42 O
) O
with O
median O
levodopa O
therapy O
of O
3 O
years O
. O

there O
were O
64.3% O
chinese O
, O
31% O
malays O
, O
and O
3.7% O
indians O
and O
other O
ethnic O
groups O
. O

eighty-one O
percent O
of O
patients O
with O
dyskinesia B-NEG
had O
clinical O
fluctuations O
. O

patients O
with O
dyskinesia B-NEG
had O
lower O
onset O
age O
( O
p O
< O
0.001) O
, O
longer O
duration O
of O
levodopa O
therapy O
( O
p O
< O
0.001) O
, O
longer O
disease O
duration O
( O
p O
< O
0.001) O
, O
higher O
total O
daily O
levodopa O
dose O
( O
p O
< O
0.001) O
, O
and O
higher O
total O
updrs O
scores O
( O
p O
= O
0.005 O
) O
than O
patients O
without O
dyskinesia B-NEG
. O

the O
three O
significant O
predictors O
of O
dyskinesia B-NEG
were O
duration O
of O
levodopa O
therapy O
, O
onset O
age O
, O
and O
total O
daily O
levodopa O
dose O
. O

conclusions O
: O
the O
prevalence O
of O
levodopa-induced O
dyskinesia B-NEG
in O
our O
patients O
was O
44% O
. O

the O
most O
significant O
predictors O
were O
duration O
of O
levodopa O
therapy O
, O
total O
daily O
levodopa O
dose O
, O
and O
onset O
age O
. O

-DOCSTART- O

an O
unexpected O
diagnosis O
in O
a O
renal-transplant O
patient O
with O
proteinuria B-NEG
treated O
with O
everolimus O
: O
al B-NEG
amyloidosis B-NEG
. O
proteinuria B-NEG
is O
an O
expected O
complication O
in O
transplant O
patients O
treated O
with O
mammalian O
target O
of O
rapamycin O
inhibitors O
(mtor-i) O
. O

however O
, O
clinical O
suspicion O
should O
always O
be O
supported O
by O
histological O
evidence O
in O
order O
to O
investigate O
potential O
alternate O
diagnoses O
such O
as O
acute O
or O
chronic O
rejection O
, O
interstitial O
fibrosis B-NEG
and O
tubular O
atrophy B-NEG
, O
or O
recurrent O
or O
de O
novo O
glomerulopathy B-NEG
. O

in O
this O
case O
we O
report O
the O
unexpected O
diagnosis O
of O
amyloidosis B-NEG
in O
a O
renal-transplant O
patient O
with O
pre-transplant O
monoclonal O
gammapathy O
of O
undetermined O
significance O
who O
developed O
proteinuria B-NEG
after O
conversion O
from O
tacrolimus O
to O
everolimus O
. O

-DOCSTART- O

an O
investigation O
of O
the O
pattern O
of O
kidney B-NEG
injury I-NEG
in O
hiv-positive O
persons O
exposed O
to O
tenofovir O
disoproxil O
fumarate O
: O
an O
examination O
of O
a O
large O
population O
database O
( O
mhra O
database) O
. O

the O
potential O
for O
tenofovir O
to O
cause O
a O
range O
of O
kidney O
syndromes O
has O
been O
established O
from O
mechanistic O
and O
randomised O
clinical O
trials O
. O

however O
, O
the O
exact O
pattern O
of O
kidney O
involvement O
is O
still O
uncertain O
. O

we O
undertook O
a O
descriptive O
analysis O
of O
yellow O
card O
records O
of O
407 O
hiv-positive O
persons O
taking O
tenofovir O
disoproxil O
fumarate O
( O
tdf O
) O
as O
part O
of O
their O
antiretroviral O
therapy O
regimen O
and O
submitted O
to O
the O
medicines O
and O
healthcare O
products O
regulatory O
agency O
( O
mhra O
) O
with O
suspected O
kidney O
adverse O
effects O
. O

reports O
that O
satisfy O
defined O
criteria O
were O
classified O
as O
acute B-NEG
kidney I-NEG
injury I-NEG
, O
kidney B-NEG
tubular I-NEG
dysfunction I-NEG
and O
fanconi B-NEG
syndrome I-NEG
. O

of O
the O
407 O
yellow O
card O
records O
analysed O
, O
106 O
satisfied O
criteria O
for O
tdf-related O
kidney B-NEG
disease I-NEG
, O
of O
which O
53 O
( O
50% O
) O
had O
features O
of O
kidney B-NEG
tubular I-NEG
dysfunction I-NEG
, O
35 O
( O
33% O
) O
were O
found O
to O
have O
features O
of O
glomerular B-NEG
dysfunction I-NEG
and O
18 O
( O
17% O
) O
had O
fanconi B-NEG
syndrome I-NEG
. O

the O
median O
tdf O
exposure O
was O
316 O
days O
( O
interquartile O
range O
120-740) O
. O

the O
incidence O
of O
hospitalisation O
for O
tdf O
kidney O
adverse O
effects O
was O
high O
, O
particularly O
amongst O
patients O
with O
features O
of O
fanconi B-NEG
syndrome I-NEG
. O

the O
pattern O
of O
kidney O
syndromes O
in O
this O
population O
series O
mirrors O
that O
reported O
in O
randomised O
clinical O
trials O
. O

cessation O
of O
tdf O
was O
associated O
with O
complete O
restoration O
of O
kidney O
function O
in O
up O
half O
of O
the O
patients O
in O
this O
report O
. O

-DOCSTART- O

incidence O
of O
postoperative B-NEG
delirium I-NEG
is O
high O
even O
in O
a O
population O
without O
known O
risk O
factors O
. O

purpose O
: O
postoperative B-NEG
delirium I-NEG
is O
a O
recognized O
complication O
in O
populations O
at O
risk O
. O

the O
aim O
of O
this O
study O
is O
to O
assess O
the O
prevalence O
of O
early O
postoperative B-NEG
delirium I-NEG
in O
a O
population O
without O
known O
risk O
factors O
admitted O
to O
the O
icu O
for O
postoperative O
monitoring O
after O
elective O
major O
surgery O
. O

the O
secondary O
outcome O
investigated O
is O
to O
identify O
eventual O
independent O
risk O
factors O
among O
demographic O
data O
and O
anesthetic O
drugs O
used O
. O

methods O
: O
an O
observational O
, O
prospective O
study O
was O
conducted O
on O
a O
consecutive O
cohort O
of O
patients O
admitted O
to O
our O
icu O
within O
and O
for O
at O
least O
24 O
h O
after O
major O
surgical O
procedures O
. O

exclusion O
criteria O
were O
any O
preexisting O
predisposing O
factor O
for O
delirium B-NEG
or O
other O
potentially O
confounding O
neurological B-NEG
dysfunctions I-NEG
. O

patients O
were O
assessed O
daily O
using O
the O
confusion B-NEG
assessment O
method O
for O
the O
icu O
scale O
for O
3 O
days O
after O
the O
surgical O
procedure O
. O

early O
postoperative B-NEG
delirium I-NEG
incidence O
risk O
factors O
were O
then O
assessed O
through O
three O
different O
multiple O
regression O
models O
. O

results O
: O
according O
to O
the O
confusion O
assessment O
method O
for O
the O
icu O
scale O
, O
28 O
% O
of O
patients O
were O
diagnosed O
with O
early O
postoperative B-NEG
delirium I-NEG
. O

the O
use O
of O
thiopentone O
was O
significantly O
associated O
with O
an O
eight-fold-higher O
risk O
for O
delirium B-NEG
compared O
to O
propofol O
( O
57.1% O
vs O
. O
7.1% O
, O
rr O
= O
8.0 O
, O
x2 O
= O
4.256 O
; O
df O
= O
1; O
0.05 O
< O
p O
< O
0.02) O
. O

conclusion O
: O
in O
this O
study O
early O
postoperative B-NEG
delirium I-NEG
was O
found O
to O
be O
a O
very O
common O
complication O
after O
major O
surgery O
, O
even O
in O
a O
population O
without O
known O
risk O
factors O
. O

thiopentone O
was O
independently O
associated O
with O
an O
increase O
in O
its O
relative O
risk O
. O

-DOCSTART- O

a O
single O
neurotoxic B-NEG
dose O
of O
methamphetamine O
induces O
a O
long-lasting O
depressive B-NEG
-like O
behaviour O
in O
mice O
. O

methamphetamine O
( O
meth O
) O
triggers O
a O
disruption O
of O
the O
monoaminergic O
system O
and O
meth O
abuse O
leads O
to O
negative O
emotional O
states O
including O
depressive B-NEG
symptoms I-NEG
during O
drug O
withdrawal O
. O

however O
, O
it O
is O
currently O
unknown O
if O
the O
acute O
toxic O
dosage O
of O
meth O
also O
causes O
a O
long-lasting O
depressive B-NEG
phenotype O
and O
persistent O
monoaminergic O
deficits O
. O

thus O
, O
we O
now O
assessed O
the O
depressive B-NEG
-like O
behaviour O
in O
mice O
at O
early O
and O
long-term O
periods O
following O
a O
single O
high O
meth O
dose O
( O
30 O
mg/kg O
, O
i.p.) O
. O

meth O
did O
not O
alter O
the O
motor O
function O
and O
procedural O
memory O
of O
mice O
as O
assessed O
by O
swimming O
speed O
and O
escape O
latency O
to O
find O
the O
platform O
in O
a O
cued O
version O
of O
the O
water O
maze O
task O
. O

however O
, O
meth O
significantly O
increased O
the O
immobility O
time O
in O
the O
tail O
suspension O
test O
at O
3 O
and O
49 O
days O
post-administration O
. O

this O
depressive B-NEG
-like O
profile O
induced O
by O
meth O
was O
accompanied O
by O
a O
marked O
depletion O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
neurotransmission O
, O
indicated O
by O
a O
reduction O
in O
the O
levels O
of O
dopamine O
, O
dopac O
and O
hva O
, O
tyrosine O
hydroxylase O
and O
serotonin O
, O
observed O
at O
both O
3 O
and O
49 O
days O
post-administration O
. O

in O
parallel O
, O
another O
neurochemical O
feature O
of O
depression B-NEG
--astroglial O
dysfunction--was O
unaffected O
in O
the O
cortex O
and O
the O
striatal O
levels O
of O
the O
astrocytic O
protein O
marker O
, O
glial O
fibrillary O
acidic O
protein O
, O
were O
only O
transiently O
increased O
at O
3 O
days O
. O

these O
findings O
demonstrate O
for O
the O
first O
time O
that O
a O
single O
high O
dose O
of O
meth O
induces O
long-lasting O
depressive B-NEG
-like O
behaviour O
in O
mice O
associated O
with O
a O
persistent O
disruption O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
homoeostasis O
. O

-DOCSTART- O

linezolid-induced O
optic B-NEG
neuropathy I-NEG
. O

many O
systemic O
antimicrobials O
have O
been O
implicated O
to O
cause O
ocular O
adverse O
effects O
. O

this O
is O
especially O
relevant O
in O
multidrug O
therapy O
where O
more O
than O
one O
drug O
can O
cause O
a O
similar O
ocular O
adverse O
effect O
. O

we O
describe O
a O
case O
of O
progressive O
loss B-NEG
of I-NEG
vision I-NEG
associated O
with O
linezolid O
therapy O
. O

a O
45-year-old O
male O
patient O
who O
was O
on O
treatment O
with O
multiple O
second-line O
anti-tuberculous O
drugs O
including O
linezolid O
and O
ethambutol O
for O
extensively B-NEG
drug-resistant I-NEG
tuberculosis I-NEG
( O
xdr-tb B-NEG
) O
presented O
to O
us O
with O
painless O
progressive O
loss B-NEG
of I-NEG
vision I-NEG
in O
both O
eyes O
. O

color O
vision O
was O
defective O
and O
fundus O
examination O
revealed O
optic B-NEG
disc I-NEG
edema I-NEG
in O
both O
eyes O
. O

ethambutol-induced O
toxic B-NEG
optic I-NEG
neuropathy I-NEG
was O
suspected O
and O
tablet O
ethambutol O
was O
withdrawn O
. O
deterioration B-NEG
of I-NEG
vision I-NEG
occurred O
despite O
withdrawal O
of O
ethambutol O
. O

discontinuation O
of O
linezolid O
resulted O
in O
marked O
improvement O
of O
vision O
. O

our O
report O
emphasizes O
the O
need O
for O
monitoring O
of O
visual O
function O
in O
patients O
on O
long-term O
linezolid O
treatment O
. O

-DOCSTART- O

resuscitation O
with O
lipid O
, O
epinephrine O
, O
or O
both O
in O
levobupivacaine-induced O
cardiac B-NEG
toxicity I-NEG
in O
newborn O
piglets O
. O

background O
: O
the O
optimal O
dosing O
regimens O
of O
lipid O
emulsion O
, O
epinephrine O
, O
or O
both O
are O
not O
yet O
determined O
in O
neonates O
in O
cases O
of O
local O
anaesthetic O
systemic O
toxicity B-NEG
(last) O
. O

methods O
: O
newborn O
piglets O
received O
levobupivacaine O
until O
cardiovascular B-NEG
collapse I-NEG
occurred O
. O

standard O
cardiopulmonary O
resuscitation O
was O
started O
and O
electrocardiogram O
( O
ecg O
) O
was O
monitored O
for O
ventricular B-NEG
tachycardia I-NEG
, O
fibrillation B-NEG
, O
or O
qrs O
prolongation O
. O

piglets O
were O
then O
randomly O
allocated O
to O
four O
groups O
: O
control O
(saline) O
, O
intralipid( O
) O
alone O
, O
epinephrine O
alone O
, O
or O
a O
combination O
of O
intralipd O
plus O
epinephrine O
. O

resuscitation O
continued O
for O
30 O
min O
or O
until O
there O
was O
a O
return O
of O
spontaneous O
circulation O
( O
rosc O
) O
accompanied O
by O
a O
mean O
arterial O
pressure O
at O
or O
superior O
to O
the O
baseline O
pressure O
and O
normal O
sinus O
rhythm O
for O
a O
period O
of O
30 O
min O
. O

results O
: O
rosc O
was O
achieved O
in O
only O
one O
of O
the O
control O
piglets O
compared O
with O
most O
of O
the O
treated O
piglets O
. O

mortality O
was O
not O
significantly O
different O
between O
the O
three O
treatment O
groups O
, O
but O
was O
significantly O
lower O
in O
all O
the O
treatment O
groups O
compared O
with O
control O
. O

the O
number O
of O
ecg O
abnormalities O
was O
zero O
in O
the O
intralipid O
only O
group O
, O
but O
14 O
and O
17 O
, O
respectively O
, O
in O
the O
epinephrine O
and O
epinephrine O
plus O
lipid O
groups O
(p<0.05) O
. O

conclusions O
: O
lipid O
emulsion O
with O
or O
without O
epinephrine O
, O
or O
epinephrine O
alone O
were O
equally O
effective O
in O
achieving O
a O
return O
to O
spontaneous O
circulation O
in O
this O
model O
of O
last O
. O

epinephrine O
alone O
or O
in O
combination O
with O
lipid O
was O
associated O
with O
an O
increased O
number O
of O
ecg O
abnormalities O
compared O
with O
lipid O
emulsion O
alone O
. O

-DOCSTART- O

incidence O
of O
heparin-induced O
thrombocytopenia B-NEG
type I-NEG
ii I-NEG
and O
postoperative O
recovery O
of O
platelet O
count O
in O
liver O
graft O
recipients O
: O
a O
retrospective O
cohort O
analysis O
. O

background O
: O
thrombocytopenia B-NEG
in O
patients O
with O
end-stage B-NEG
liver I-NEG
disease I-NEG
is O
a O
common O
disorder O
caused O
mainly O
by O
portal B-NEG
hypertension I-NEG
, O
low O
levels O
of O
thrombopoetin O
, O
and O
endotoxemia B-NEG
. O

the O
impact O
of O
immune-mediated O
heparin-induced O
thrombocytopenia B-NEG
type I-NEG
ii I-NEG
( O
hit B-NEG
type I-NEG
ii I-NEG
) O
as O
a O
cause O
of O
thrombocytopenia B-NEG
after O
liver O
transplantation O
is O
not O
yet O
understood O
, O
with O
few O
literature O
citations O
reporting O
contradictory O
results O
. O

the O
aim O
of O
our O
study O
was O
to O
demonstrate O
the O
perioperative O
course O
of O
thrombocytopenia B-NEG
after O
liver O
transplantation O
and O
determine O
the O
occurrence O
of O
clinical O
hit B-NEG
type I-NEG
ii I-NEG
. O

method O
: O
we O
retrospectively O
evaluated O
the O
medical O
records O
of O
205 O
consecutive O
adult O
patients O
who O
underwent O
full-size O
liver O
transplantation O
between O
january O
2006 O
and O
december O
2010 O
due O
to O
end-stage B-NEG
or I-NEG
malignant I-NEG
liver I-NEG
disease I-NEG
. O

preoperative O
platelet O
count O
, O
postoperative O
course O
of O
platelets O
, O
and O
clinical O
signs O
of O
hit B-NEG
type I-NEG
ii I-NEG
were O
analyzed O
. O

results O
: O
a O
total O
of O
155 O
( O
75.6% O
) O
of O
205 O
patients O
had O
thrombocytopenia B-NEG
before O
transplantation O
, O
significantly O
influenced O
by O
model O
of O
end-stage B-NEG
liver I-NEG
disease I-NEG
score O
and O
liver B-NEG
cirrhosis I-NEG
. O

the O
platelet O
count O
exceeded O
100,000/ul O
in O
most O
of O
the O
patients O
(n O
= O
193 O
) O
at O
a O
medium O
of O
7 O
d. O

regarding O
hit B-NEG
ii I-NEG
, O
there O
were O
four O
( O
1.95% O
) O
patients O
with O
a O
background O
of O
hit B-NEG
type I-NEG
ii I-NEG
. O

conclusions O
: O
the O
incidence O
of O
hit B-NEG
in O
patients O
with O
end-stage B-NEG
hepatic I-NEG
failure I-NEG
is O
, O
with O
about O
1.95% O
, O
rare O
. O

for O
further O
reduction O
of O
hit B-NEG
type I-NEG
ii I-NEG
, O
the O
use O
of O
intravenous O
heparin O
should O
be O
avoided O
and O
the O
prophylactic O
anticoagulation O
should O
be O
performed O
with O
low-molecular-weight O
heparin O
after O
normalization O
of O
platelet O
count O
. O

-DOCSTART- O

takotsubo B-NEG
syndrome I-NEG
( O
or O
apical B-NEG
ballooning I-NEG
syndrome I-NEG
) O
secondary O
to O
zolmitriptan O
. O
takotsubo B-NEG
syndrome I-NEG
( O
ts B-NEG
), O
also O
known O
as O
broken B-NEG
heart I-NEG
syndrome I-NEG
, O
is O
characterized O
by O
left O
ventricle O
apical O
ballooning O
with O
elevated O
cardiac O
biomarkers O
and O
electrocardiographic O
changes O
suggestive O
of O
an O
acute B-NEG
coronary I-NEG
syndrome I-NEG
(ie O
, O
st-segment O
elevation O
, O
t O
wave O
inversions O
, O
and O
pathologic O
q O
waves) O
. O

we O
report O
a O
case O
of O
54-year-old O
woman O
with O
medical O
history O
of O
mitral B-NEG
valve I-NEG
prolapse I-NEG
and O
migraines B-NEG
, O
who O
was O
admitted O
to O
the O
hospital O
for O
substernal O
chest B-NEG
pain I-NEG
and O
electrocardiogram O
demonstrated O
1/2 O
mm O
st-segment O
elevation O
in O
leads O
ii O
, O
iii O
, O
avf O
, O
v5 O
, O
and O
v6 O
and O
positive O
troponin O
i. O

emergent O
coronary O
angiogram O
revealed O
normal O
coronary O
arteries O
with O
moderately O
reduced O
left O
ventricular O
ejection O
fraction O
with O
wall O
motion O
abnormalities O
consistent O
with O
ts B-NEG
. O

detailed O
history O
obtained O
retrospectively O
revealed O
that O
the O
patient O
took O
zolmitriptan O
sparingly O
only O
when O
she O
had O
migraines B-NEG
. O

but O
before O
this O
event O
, O
she O
was O
taking O
zolmitriptan O
2-3 O
times O
daily O
for O
several O
days O
because O
of O
a O
persistent O
migraine B-NEG
headache I-NEG
. O

she O
otherwise O
reported O
that O
she O
is O
quite O
active O
, O
rides O
horses O
, O
and O
does O
show O
jumping O
without O
any O
limitations O
in O
her O
physical O
activity O
. O

there O
was O
no O
evidence O
of O
any O
recent O
stress O
or O
status B-NEG
migrainosus I-NEG
. O

extensive O
literature O
search O
revealed O
multiple O
cases O
of O
coronary B-NEG
artery I-NEG
vasospasm I-NEG
secondary O
to O
zolmitriptan O
, O
but O
none O
of O
the O
cases O
were O
associated O
with O
ts B-NEG
. O

-DOCSTART- O

depression B-NEG
, O
impulsiveness B-NEG
, O
sleep O
, O
and O
memory O
in O
past O
and O
present O
polydrug O
users O
of O
3,4-methylenedioxymethamphetamine O
(mdma O
, O
ecstasy) O
. O

rationale O
: O
ecstasy O
(3,4-methylenedioxymethamphetamine O
, O
mdma O
) O
is O
a O
worldwide O
recreational O
drug O
of O
abuse O
. O

unfortunately O
, O
the O
results O
from O
human O
research O
investigating O
its O
psychological O
effects O
have O
been O
inconsistent O
. O

objectives O
: O
the O
present O
study O
aimed O
to O
be O
the O
largest O
to O
date O
in O
sample O
size O
and O
5ht-related O
behaviors O
; O
the O
first O
to O
compare O
present O
ecstasy O
users O
with O
past O
users O
after O
an O
abstinence O
of O
4 O
or O
more O
years O
, O
and O
the O
first O
to O
include O
robust O
controls O
for O
other O
recreational O
substances O
. O

methods O
: O
a O
sample O
of O
997 O
participants O
( O
52 O
% O
male O
) O
was O
recruited O
to O
four O
control O
groups O
( O
non-drug O
(nd) O
, O
alcohol/nicotine O
(an) O
, O
cannabis/alcohol/nicotine O
(can) O
, O
non-ecstasy O
polydrug O
(pd)) O
, O
and O
two O
ecstasy O
polydrug O
groups O
( O
present O
( O
mdma O
) O
and O
past O
users O
(ex-mdma) O
. O

participants O
completed O
a O
drug O
history O
questionnaire O
, O
beck O
depression B-NEG
inventory O
, O
barratt O
impulsiveness B-NEG
scale O
, O
pittsburgh O
sleep O
quality O
index O
, O
and O
wechsler O
memory O
scale-revised O
which O
, O
in O
total O
, O
provided O
13 O
psychometric O
measures O
. O

results O
: O
while O
the O
can O
and O
pd O
groups O
tended O
to O
record O
greater O
deficits O
than O
the O
non-drug O
controls O
, O
the O
mdma O
and O
ex-mdma O
groups O
recorded O
greater O
deficits O
than O
all O
the O
control O
groups O
on O
ten O
of O
the O
13 O
psychometric O
measures O
. O

strikingly O
, O
despite O
prolonged O
abstinence O
(mean O
, O
4.98 O
; O
range O
, O
4-9 O
years) O
, O
past O
ecstasy O
users O
showed O
few O
signs O
of O
recovery O
. O

compared O
with O
present O
ecstasy O
users O
, O
the O
past O
users O
showed O
no O
change O
for O
ten O
measures O
, O
increased O
impairment O
for O
two O
measures O
, O
and O
improvement O
on O
just O
one O
measure O
. O

conclusions O
: O
given O
this O
record O
of O
impaired B-NEG
memory I-NEG
and O
clinically O
significant O
levels O
of O
depression B-NEG
, O
impulsiveness B-NEG
, O
and O
sleep B-NEG
disturbance I-NEG
, O
the O
prognosis O
for O
the O
current O
generation O
of O
ecstasy O
users O
is O
a O
major O
cause O
for O
concern O
. O

-DOCSTART- O

association O
of O
common O
genetic O
variants O
of O
homer1 O
gene O
with O
levodopa O
adverse O
effects O
in O
parkinson's B-NEG
disease I-NEG
patients O
. O

levodopa O
is O
the O
most O
effective O
symptomatic O
therapy O
for O
parkinson's B-NEG
disease I-NEG
, O
but O
its O
chronic O
use O
could O
lead O
to O
chronic O
adverse O
outcomes O
, O
such O
as O
motor O
fluctuations O
, O
dyskinesia B-NEG
and O
visual B-NEG
hallucinations I-NEG
. O

homer1 O
is O
a O
protein O
with O
pivotal O
function O
in O
glutamate O
transmission O
, O
which O
has O
been O
related O
to O
the O
pathogenesis O
of O
these O
complications O
. O

this O
study O
investigates O
whether O
polymorphisms O
in O
the O
homer1 O
gene O
promoter O
region O
are O
associated O
with O
the O
occurrence O
of O
the O
chronic O
complications O
of O
levodopa O
therapy O
. O

a O
total O
of O
205 O
patients O
with O
idiopathic B-NEG
parkinson's I-NEG
disease I-NEG
were O
investigated O
. O

patients O
were O
genotyped O
for O
rs4704559 O
, O
rs10942891 O
and O
rs4704560 O
by O
allelic O
discrimination O
with O
taqman O
assays O
. O

the O
rs4704559 O
g O
allele O
was O
associated O
with O
a O
lower O
prevalence O
of O
dyskinesia B-NEG
( O
prevalence O
ratio O
(pr)=0.615 O
, O
95% O
confidence O
interval O
( O
ci O
) O
0.426-0.887 O
, O
p=0.009 O
) O
and O
visual B-NEG
hallucinations I-NEG
(pr=0.515 O
, O
95% O
ci O
0.295-0.899 O
, O
p=0.020) O
. O

our O
data O
suggest O
that O
homer1 O
rs4704559 O
g O
allele O
has O
a O
protective O
role O
for O
the O
development O
of O
levodopa O
adverse O
effects O
. O

-DOCSTART- O

crocin O
improves O
lipid O
dysregulation O
in O
subacute O
diazinon O
exposure O
through O
erk1/2 O
pathway O
in O
rat O
liver O
. O

introduction O
: O
diazinon O
yis O
one O
of O
the O
most O
broadly O
used O
organophosphorus O
insecticides O
in O
agriculture O
. O

it O
has O
been O
shown O
that O
exposure O
to O
diazinon O
may O
interfere O
with O
lipid O
metabolism O
. O

moreover O
, O
the O
hypolipidemic O
effect O
of O
crocin O
has O
been O
established O
. O

earlier O
studies O
revealed O
the O
major O
role O
of O
extracellular O
signal-regulated O
kinase O
( O
erk O
) O
pathways O
in O
low-density O
lipoprotein O
receptor O
( O
ldlr O
) O
expression O
. O

the O
aim O
of O
this O
study O
was O
to O
evaluate O
changes O
in O
the O
regulation O
of O
lipid O
metabolism O
, O
erk O
and O
ldlr O
expression O
in O
the O
liver O
of O
rats O
exposed O
to O
subacute O
diazinon O
. O

furthermore O
ameliorating O
effect O
of O
crocin O
on O
diazinon O
induced O
disturbed O
cholesterol O
homeostasis O
was O
studied O
. O

methods O
: O
24 O
rats O
were O
divided O
into O
4 O
groups O
and O
received O
following O
treatments O
for O
4 O
weeks O
; O
corn O
oil O
(control) O
, O
diazinon O
( O
15mg/kg O
per O
day O
, O
orally O
) O
and O
crocin O
( O
12.5 O
and O
25mg/kg O
per O
day O
, O
intraperitoneally O
) O
in O
combination O
with O
diazinon O
( O
15 O
mg/kg) O
. O

the O
levels O
of O
cholesterol O
, O
triglyceride O
and O
ldl O
in O
blood O
of O
rats O
were O
analyzed O
. O

moreover O
mrna O
levels O
of O
ldlr O
and O
erk1/2 O
as O
well O
as O
protein O
levels O
of O
total O
and O
activated O
forms O
of O
erk1/2 O
in O
rat O
liver O
were O
evaluated O
by O
western O
blotting O
and O
quantitative O
real O
time O
polymerase O
chain O
reaction O
analysis O
. O

results O
: O
our O
data O
showed O
that O
subacute O
exposure O
to O
diazinon O
significantly O
increased O
concentrations O
of O
cholesterol O
, O
triglyceride O
and O
ldl O
. O

moreover O
diazinon O
decreased O
erk1/2 O
protein O
phosphorylation O
and O
ldlr O
transcript O
. O

crocin O
reduced O
inhibition O
of O
erk O
activation O
and O
diazinon-induced O
hyperlipemia B-NEG
and O
increased O
levels O
of O
ldlr O
transcript O
. O

conclusions O
: O
crocin O
may O
be O
considered O
as O
a O
novel O
protective O
agent O
in O
diazinon-induced O
hyperlipemia B-NEG
through O
modulating O
of O
erk O
pathway O
and O
increase O
of O
ldlr O
expression O
. O

-DOCSTART- O

gem-p O
chemotherapy O
is O
active O
in O
the O
treatment O
of O
relapsed O
hodgkin B-NEG
lymphoma I-NEG
. O
hodgkin B-NEG
lymphoma I-NEG
( O
hl B-NEG
) O
is O
a O
relatively O
chemosensitive O
malignancy B-NEG
. O

however O
, O
for O
those O
who O
relapse O
, O
high-dose O
chemotherapy O
with O
autologous O
stem O
cell O
transplant O
is O
the O
treatment O
of O
choice O
which O
relies O
on O
adequate O
disease O
control O
with O
salvage O
chemotherapy O
. O

regimens O
commonly O
used O
often O
require O
inpatient O
administration O
and O
can O
be O
difficult O
to O
deliver O
due O
to O
toxicity B-NEG
. O

gemcitabine O
and O
cisplatin O
have O
activity O
in O
hl B-NEG
, O
non-overlapping O
toxicity B-NEG
with O
first-line O
chemotherapeutics O
, O
and O
may O
be O
delivered O
in O
an O
outpatient O
setting O
. O

in O
this O
retrospective O
single-centre O
analysis O
, O
patients O
with O
relapsed O
or O
refractory O
hl B-NEG
treated O
with O
gemcitabine O
1,000 O
mg/m(2 O
) O
day O
(d)1 O
, O
d8 O
and O
d15 O
; O
methylprednisolone O
1,000 O
mg O
d1-5 O
; O
and O
cisplatin O
100 O
mg/m(2 O
) O
d15 O
, O
every O
28 O
days O
( O
gem-p O
) O
were O
included O
. O

demographic O
, O
survival O
, O
response O
and O
toxicity B-NEG
data O
were O
recorded O
. O

forty-one O
eligible O
patients O
were O
identified O
: O
median O
age O
27 O
. O

one O
hundred O
and O
twenty-two O
cycles O
of O
gem-p O
were O
administered O
in O
total O
( O
median O
3 O
cycles O
; O
range O
1-6) O
. O

twenty O
of O
41 O
( O
48 O
%) O
patients O
received O
gem-p O
as O
second-line O
treatment O
and O
11/41 O
( O
27 O
%) O
as O
third-line O
therapy O
. O

overall O
response O
rate O
( O
orr O
) O
to O
gem-p O
in O
the O
entire O
cohort O
was O
80 O
% O
( O
complete O
response O
( O
cr O
) O
37 O
%, O
partial O
response O
44 O
%) O
with O
14/15 O
cr O
confirmed O
as O
a O
metabolic O
cr O
on O
pet O
and O
orr O
of O
85 O
% O
in O
the O
20 O
second-line O
patients O
. O

the O
most O
common O
grade O
3/4 O
toxicities B-NEG
were O
haematological O
: O
neutropenia B-NEG
54 O
% O
and O
thrombocytopenia B-NEG
51 O
%. O

median O
follow-up O
from O
the O
start O
of O
gem-p O
was O
4.5 O
years O
. O

following O
gem-p O
, O
5-year O
progression-free O
survival O
was O
46 O
% O
( O
95 O
% O
confidence O
interval O
(ci) O
, O
30-62 O
%) O
and O
5-year O
overall O
survival O
was O
59 O
% O
( O
95 O
% O
ci O
, O
43-74 O
%) O
. O

fourteen O
of O
41 O
patients O
proceeded O
directly O
to O
autologous O
transplant O
. O

gem-p O
is O
a O
salvage O
chemotherapy O
with O
relatively O
high O
response O
rates O
, O
leading O
to O
successful O
transplantation O
in O
appropriate O
patients O
, O
in O
the O
treatment O
of O
relapsed O
or O
refractory O
hl B-NEG
. O

-DOCSTART- O

basal O
functioning O
of O
the O
hypothalamic-pituitary-adrenal O
( O
hpa O
) O
axis O
and O
psychological O
distress O
in O
recreational O
ecstasy O
polydrug O
users O
. O

rationale O
: O
ecstasy O
( O
mdma O
) O
is O
a O
psychostimulant O
drug O
which O
is O
increasingly O
associated O
with O
psychobiological B-NEG
dysfunction I-NEG
. O

while O
some O
recent O
studies O
suggest O
acute O
changes O
in O
neuroendocrine O
function O
, O
less O
is O
known O
about O
long-term O
changes O
in O
hpa O
functionality O
in O
recreational O
users O
. O

objectives O
: O
the O
current O
study O
is O
the O
first O
to O
explore O
the O
effects O
of O
ecstasy-polydrug O
use O
on O
psychological O
distress O
and O
basal O
functioning O
of O
the O
hpa O
axis O
through O
assessing O
the O
secretion O
of O
cortisol O
across O
the O
diurnal O
period O
. O

method O
: O
seventy-six O
participants O
( O
21 O
nonusers O
, O
29 O
light O
ecstasy-polydrug O
users O
, O
26 O
heavy O
ecstasy-polydrug O
users O
) O
completed O
a O
substance O
use O
inventory O
and O
measures O
of O
psychological O
distress O
at O
baseline O
, O
then O
two O
consecutive O
days O
of O
cortisol O
sampling O
( O
on O
awakening O
, O
30 O
min O
post O
awakening O
, O
between O
1400 O
and O
1600 O
hours O
and O
pre O
bedtime) O
. O

on O
day O
2, O
participants O
also O
attended O
the O
laboratory O
to O
complete O
a O
20-min O
multitasking O
stressor O
. O

results O
: O
both O
user O
groups O
exhibited O
significantly O
greater O
levels O
of O
anxiety B-NEG
and O
depression B-NEG
than O
nonusers O
. O

on O
day O
1, O
all O
participants O
exhibited O
a O
typical O
cortisol O
profile O
, O
though O
light O
users O
had O
significantly O
elevated O
levels O
pre-bed O
. O

on O
day O
2, O
heavy O
users O
demonstrated O
elevated O
levels O
upon O
awakening O
and O
all O
ecstasy-polydrug O
users O
demonstrated O
elevated O
pre-bed O
levels O
compared O
to O
non-users O
. O

significant O
between O
group O
differences O
were O
also O
observed O
in O
afternoon O
cortisol O
levels O
and O
in O
overall O
cortisol O
secretion O
across O
the O
day O
. O

conclusions O
: O
the O
increases O
in O
anxiety B-NEG
and O
depression B-NEG
are O
in O
line O
with O
previous O
observations O
in O
recreational O
ecstasy-polydrug O
users O
. O

dysregulated O
diurnal O
cortisol O
may O
be O
indicative O
of O
inappropriate O
anticipation O
of O
forthcoming O
demands O
and O
hypersecretion O
may O
lead O
to O
the O
increased O
psychological O
and O
physical O
morbidity O
associated O
with O
heavy O
recreational O
use O
of O
ecstasy O
. O

-DOCSTART- O

ifosfamide O
related O
encephalopathy B-NEG
: O
the O
need O
for O
a O
timely O
eeg O
evaluation O
. O

background O
: O
ifosfamide O
is O
an O
alkylating O
agent O
useful O
in O
the O
treatment O
of O
a O
wide O
range O
of O
cancers B-NEG
including O
sarcomas B-NEG
, O
lymphoma B-NEG
, O
gynecologic B-NEG
and I-NEG
testicular I-NEG
cancers I-NEG
. O
encephalopathy B-NEG
has O
been O
reported O
in O
10-40% O
of O
patients O
receiving O
high-dose O
iv O
ifosfamide O
. O

objective O
: O
to O
highlight O
the O
role O
of O
electroencephalogram O
( O
eeg O
) O
in O
the O
early O
detection O
and O
management O
of O
ifosfamide O
related O
encephalopathy B-NEG
. O

methods O
: O
retrospective O
chart O
review O
including O
clinical O
data O
and O
eeg O
recordings O
was O
done O
on O
five O
patients O
, O
admitted O
to O
md O
anderson O
cancer B-NEG
center O
between O
years O
2009 O
and O
2012 O
, O
who O
developed O
ifosfamide O
related O
acute O
encephalopathy B-NEG
. O

results O
: O
all O
five O
patients O
experienced O
symptoms O
of O
encephalopathy B-NEG
soon O
after O
( O
within O
12 O
h-2 O
days O
) O
receiving O
ifosfamide O
. O

two O
patients O
developed O
generalized O
convulsions B-NEG
while O
one O
patient O
developed O
continuous O
non-convulsive B-NEG
status I-NEG
epilepticus I-NEG
( O
ncse B-NEG
) O
that O
required O
icu O
admission O
and O
intubation O
. O

initial O
eeg O
showed O
epileptiform O
discharges O
in O
three O
patients O
; O
run O
of O
triphasic O
waves O
in O
one O
patient O
and O
moderate O
degree O
diffuse O
generalized O
slowing O
. O

mixed O
pattern O
with O
the O
presence O
of O
both O
sharps O
and O
triphasic O
waves O
were O
also O
noted O
. O

repeat O
eegs O
within O
24_h O
of O
symptom O
onset O
showed O
marked O
improvement O
that O
was O
correlated O
with O
clinical O
improvement O
. O

conclusions O
: O
severity O
of O
ifosfamide O
related O
encephalopathy B-NEG
correlates O
with O
eeg O
changes O
. O

we O
suggest O
a O
timely O
eeg O
evaluation O
for O
patients O
receiving O
ifosfamide O
who O
develop O
features O
of O
encephalopathy B-NEG
. O

-DOCSTART- O

incidence O
of O
contrast-induced O
nephropathy B-NEG
in O
hospitalised O
patients O
with O
cancer B-NEG
. O

objectives O
: O
to O
determine O
the O
frequency O
of O
and O
possible O
factors O
related O
to O
contrast-induced O
nephropathy B-NEG
( O
cin O
) O
in O
hospitalised O
patients O
with O
cancer B-NEG
. O

methods O
: O
ninety O
adult O
patients O
were O
enrolled O
. O

patients O
with O
risk O
factors O
for O
acute B-NEG
renal I-NEG
failure I-NEG
were O
excluded O
. O

blood O
samples O
were O
examined O
the O
day O
before O
contrast-enhanced O
computed O
tomography O
( O
ct O
) O
and O
serially O
for O
3 O
days O
thereafter O
. O

cin O
was O
defined O
as O
an O
increase O
in O
serum O
creatinine O
( O
cr O
) O
of O
0.5 O
mg/dl O
or O
more O
, O
or O
elevation O
of O
cr O
to O
25 O
% O
over O
baseline O
. O

relationships O
between O
cin O
and O
possible O
risk O
factors O
were O
investigated O
. O

results O
: O
cin O
was O
detected O
in O
18/90 O
( O
20 O
%) O
patients O
. O

cin O
developed O
in O
25.5 O
% O
patients O
who O
underwent O
chemotherapy O
and O
in O
11 O
% O
patients O
who O
did O
not O
(p O
= O
0.1) O
. O

cin O
more O
frequently O
developed O
in O
patients O
who O
had O
undergone O
ct O
within O
45 O
days O
after O
the O
last O
chemotherapy O
(p O
= O
0.005) O
; O
it O
was O
also O
an O
independent O
risk O
factor O
(p O
= O
0.017) O
. O

cin O
was O
significantly O
more O
after O
treatment O
with O
bevacizumab/irinotecan O
(p O
= O
0.021 O
) O
and O
in O
patients O
with O
hypertension B-NEG
(p O
= O
0.044) O
. O

conclusions O
: O
the O
incidence O
of O
cin O
after O
ct O
in O
hospitalised O
oncological O
patients O
was O
20 O
%. O

cin O
developed O
4.5-times O
more O
frequently O
in O
patients O
with O
cancer B-NEG
who O
had O
undergone O
recent O
chemotherapy O
. O
hypertension B-NEG
and O
the O
combination O
of O
bevacizumab/irinotecan O
may O
be O
additional O
risk O
factors O
for O
cin O
development O
. O

key O
points O
: O
. O

contrast-induced O
nephropathy B-NEG
( O
cin O
) O
is O
a O
concern O
for O
oncological O
patients O
undergoing O
ct O
. O
. O

cin O
occurs O
more O
often O
when O
ct O
is O
performed O
<45 O
days O
after O
chemotherapy O
. O
. O
hypertension B-NEG
and O
treatment O
with O
bevacizumab O
appear O
to O
be O
additional O
risk O
factors O
. O

-DOCSTART- O

syndrome B-NEG
of I-NEG
inappropriate I-NEG
antidiuretic I-NEG
hormone I-NEG
secretion O
associated O
with O
desvenlafaxine O
. O

objective O
: O
to O
report O
a O
case O
of O
syndrome B-NEG
of I-NEG
inappropriate I-NEG
anti-diuretic I-NEG
hormone I-NEG
( O
siadh B-NEG
) O
secretion O
associated O
with O
desvenlafaxine O
. O

case O
summary O
: O
a O
57-year O
old O
female O
with O
hyponatraemia B-NEG
. O

her O
medications O
included O
desvenlafaxine O
, O
and O
symptoms O
included O
nausea B-NEG
, O
anxiety B-NEG
and O
confusion B-NEG
. O

the O
serum O
sodium O
at O
this O
time O
was O
120 O
mmol/l O
, O
serum O
osmolality O
was O
263 O
mosmol/kg O
, O
urine O
osmolality O
410 O
mosmol/kg O
and O
urine O
sodium O
63 O
mmol/l O
, O
consistent O
with O
a O
diagnosis O
of O
siadh B-NEG
. O

desvenlafaxine O
was O
ceased O
and O
fluid O
restriction O
implemented O
. O

after O
4 O
days O
the O
sodium O
increased O
to O
128 O
mmol/l O
and O
fluid O
restriction O
was O
relaxed O
. O

during O
her O
further O
3 O
weeks O
inpatient O
admission O
the O
serum O
sodium O
ranged O
from O
134 O
to O
137 O
mmol/l O
during O
treatment O
with O
mirtazapine O
. O

discussion O
: O
siadh B-NEG
has O
been O
widely O
reported O
with O
a O
range O
of O
antidepressants O
. O

this O
case O
report O
suggests O
that O
desvenlafaxine O
might O
cause O
clinically O
significant O
hyponatremia B-NEG
. O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
the O
potential O
for O
antidepressants O
to O
cause O
hyponatremia B-NEG
,and O
take O
appropriate O
corrective O
action O
where O
necessary O
. O

-DOCSTART- O

oxidative O
stress O
on O
cardiotoxicity B-NEG
after O
treatment O
with O
single O
and O
multiple O
doses O
of O
doxorubicin O
. O

the O
mechanism O
of O
doxorubicin O
( O
dox)-induced O
cardiotoxicity B-NEG
remains O
controversial O
. O

wistar O
rats O
(n O
= O
66 O
) O
received O
dox O
injections O
intraperitoneally O
and O
were O
randomly O
assigned O
to O
2 O
experimental O
protocols O
: O
( O
1 O
) O
rats O
were O
killed O
before O
( O
-24 O
h, O
n O
= O
8) O
and O
24 O
h O
after O
( O
+24 O
h, O
n O
= O
8) O
a O
single O
dose O
of O
dox O
(4 O
mg/kg O
body O
weight O
) O
to O
determine O
the O
dox O
acute O
effect O
and O
( O
2 O
) O
rats O
(n O
= O
58 O
) O
received O
4 O
injections O
of O
dox O
(4 O
mg/kg O
body O
weight/week O
) O
and O
were O
killed O
before O
the O
first O
injection O
( O
m0 O
) O
and O
1 O
week O
after O
each O
injection O
(m1 O
, O
m2 O
, O
m3 O
, O
and O
m4 O
) O
to O
determine O
the O
chronological O
effects O
. O

animals O
used O
at O
m0 O
(n O
= O
8) O
were O
also O
used O
at O
moment O
-24 O
h O
of O
acute O
study O
. O

cardiac O
total O
antioxidant O
performance O
(tap) O
, O
dna O
damage O
, O
and O
morphology O
analyses O
were O
carried O
out O
at O
each O
time O
point O
. O

single O
dose O
of O
dox O
was O
associated O
with O
increased O
cardiac B-NEG
disarrangement I-NEG
, O
necrosis B-NEG
, O
and O
dna O
damage O
( O
strand O
breaks O
( O
sbs O
) O
and O
oxidized O
pyrimidines O
) O
and O
decreased O
tap O
. O

the O
chronological O
study O
showed O
an O
effect O
of O
a O
cumulative O
dose O
on O
body O
weight O
(r O
= O
-0.99 O
, O
p O
= O
0.011) O
, O
necrosis B-NEG
(r O
= O
1.00 O
, O
p O
= O
0.004) O
, O
tap O
(r O
= O
0.95 O
, O
p O
= O
0.049) O
, O
and O
dna O
sbs O
(r O
= O
-0.95 O
, O
p O
= O
0.049) O
. O

dna O
sbs O
damage O
was O
negatively O
associated O
with O
tap O
(r O
= O
-0.98 O
, O
p O
= O
0.018) O
, O
and O
necrosis B-NEG
(r O
= O
-0.97 O
, O
p O
= O
0.027) O
. O

our O
results O
suggest O
that O
oxidative O
damage O
is O
associated O
with O
acute O
cardiotoxicity B-NEG
induced O
by O
a O
single O
dose O
of O
dox O
only O
. O

increased O
resistance O
to O
the O
oxidative O
stress O
is O
plausible O
for O
the O
multiple O
dose O
of O
dox O
. O

thus O
, O
different O
mechanisms O
may O
be O
involved O
in O
acute O
toxicity B-NEG
versus O
chronic O
toxicity B-NEG
. O

-DOCSTART- O

tacrolimus-related O
seizure B-NEG
after O
pediatric O
liver O
transplantation--a O
single-center O
experience O
. O

to O
identify O
the O
risk O
factors O
for O
new-onset O
seizures B-NEG
after O
pediatric O
lt O
and O
to O
assess O
their O
clinical O
implications O
and O
long-term O
prognosis O
. O

the O
clinical O
and O
laboratory O
data O
of O
27 O
consecutive O
children O
who O
underwent O
lt O
from O
january O
2007 O
to O
december O
2010 O
in O
our O
center O
were O
analyzed O
retrospectively O
. O

patients O
were O
divided O
into O
seizures B-NEG
group O
and O
a O
non- O
seizures B-NEG
group O
. O

pre-operative O
, O
intra-operative O
, O
and O
post-operative O
data O
were O
collected O
. O
seizures B-NEG
occurred O
in O
four O
children O
, O
an O
incidence O
of O
14.8% O
. O

all O
exhibited O
generalized O
tonic-clonic B-NEG
seizures I-NEG
within O
the O
first O
two O
wk O
after O
lt O
. O

univariate O
analysis O
showed O
that O
the O
risk O
factors O
associated O
with O
seizures B-NEG
after O
pediatric O
lt O
included O
gender O
, O
pediatric O
end-stage B-NEG
liver I-NEG
disease I-NEG
score O
before O
surgery O
, O
child-pugh O
score O
before O
surgery O
, O
serum O
total O
bilirubin O
after O
surgery O
, O
and O
trough O
tac O
level O
. O

multivariate O
analysis O
showed O
that O
trough O
tac O
level O
was O
the O
only O
independent O
risk O
factor O
associated O
with O
the O
seizures B-NEG
. O

all O
children O
who O
experienced O
seizures B-NEG
survived O
with O
good O
graft O
function O
and O
remained O
seizure B-NEG
-free O
without O
anti- O
epileptic B-NEG
drugs O
over O
a O
mean O
follow-up O
period O
of O
33.7 O
+ O
14.6 O
months O
. O

high O
trough O
tac O
level O
was O
the O
predominant O
factor O
that O
contributed O
to O
seizures B-NEG
in O
the O
early O
post-operative O
period O
after O
pediatric O
lt O
. O

high O
peld O
and O
child-pugh O
scores O
before O
lt O
and O
high O
post-operative O
serum O
tbil O
may O
be O
contributory O
risk O
factors O
for O
tac-related O
seizures B-NEG
. O

-DOCSTART- O

the O
flavonoid O
apigenin O
delays O
forgetting O
of O
passive O
avoidance O
conditioning O
in O
rats O
. O

the O
present O
experiments O
were O
performed O
to O
study O
the O
effect O
of O
the O
flavonoid O
apigenin O
( O
20 O
mg/kg O
intraperitoneally O
(i.p.) O
, O
1 O
h O
before O
acquisition) O
, O
on O
24 O
h O
retention O
performance O
and O
forgetting O
of O
a O
step-through O
passive O
avoidance O
task O
, O
in O
young O
male O
wistar O
rats O
. O

there O
were O
no O
differences O
between O
saline- O
and O
apigenin-treated O
groups O
in O
the O
24 O
h O
retention O
trial O
. O

furthermore O
, O
apigenin O
did O
not O
prevent O
the O
amnesia B-NEG
induced O
by O
scopolamine O
(1mg/kg O
, O
i.p. O
, O
30 O
min O
before O
the O
acquisition) O
. O

the O
saline- O
and O
apigenin-treated O
rats O
that O
did O
not O
step O
through O
into O
the O
dark O
compartment O
during O
the O
cut-off O
time O
( O
540 O
s) O
were O
retested O
weekly O
for O
up O
to O
eight O
weeks O
. O

in O
the O
saline O
treated O
group O
, O
the O
first O
significant O
decline O
in O
passive O
avoidance O
response O
was O
observed O
at O
four O
weeks O
, O
and O
complete O
memory B-NEG
loss I-NEG
was O
found O
five O
weeks O
after O
the O
acquisition O
of O
the O
passive O
avoidance O
task O
. O

at O
the O
end O
of O
the O
experimental O
period O
, O
60% O
of O
the O
animals O
treated O
with O
apigenin O
still O
did O
not O
step O
through O
. O

these O
data O
suggest O
that O
1) O
apigenin O
delays O
the O
long-term O
forgetting O
but O
did O
not O
modulate O
the O
24 O
h O
retention O
of O
fear O
memory O
and O
2) O
the O
obtained O
beneficial O
effect O
of O
apigenin O
on O
the O
passive O
avoidance O
conditioning O
is O
mediated O
by O
mechanisms O
that O
do O
not O
implicate O
its O
action O
on O
the O
muscarinic O
cholinergic O
system O
. O

-DOCSTART- O

cholecystokinin-octapeptide O
restored O
morphine-induced O
hippocampal O
long-term O
potentiation O
impairment O
in O
rats O
. O

cholecystokinin-octapeptide O
(cck-8) O
, O
which O
is O
a O
typical O
brain-gut O
peptide O
, O
exerts O
a O
wide O
range O
of O
biological O
activities O
on O
the O
central O
nervous O
system O
. O

we O
have O
previously O
reported O
that O
cck-8 O
significantly O
alleviated O
morphine-induced O
amnesia B-NEG
and O
reversed O
spine O
density O
decreases O
in O
the O
ca1 O
region O
of O
the O
hippocampus O
in O
morphine-treated O
animals O
. O

here O
, O
we O
investigated O
the O
effects O
of O
cck-8 O
on O
long-term O
potentiation O
( O
ltp O
) O
in O
the O
lateral O
perforant O
path O
( O
lpp)-granule O
cell O
synapse O
of O
rat O
dentate O
gyrus O
( O
dg O
) O
in O
acute O
saline O
or O
morphine-treated O
rats O
. O

population O
spikes O
(ps) O
, O
which O
were O
evoked O
by O
stimulation O
of O
the O
lpp O
, O
were O
recorded O
in O
the O
dg O
region O
. O

acute O
morphine O
(30mg/kg O
, O
s.c. O
) O
treatment O
significantly O
attenuated O
hippocampal O
ltp O
and O
cck-8 O
(1ug O
, O
i.c.v. O
) O
restored O
the O
amplitude O
of O
ps O
that O
was O
attenuated O
by O
morphine O
injection O
. O

furthermore O
, O
microinjection O
of O
cck-8 O
( O
0.1 O
and O
1ug O
, O
i.c.v. O
) O
also O
significantly O
augmented O
hippocampal O
ltp O
in O
saline-treated O
(1ml/kg O
, O
s.c. O
) O
rats O
. O

pre-treatment O
of O
the O
cck2 O
receptor O
antagonist O
l-365,260 O
(10ug O
, O
i.c.v O
) O
reversed O
the O
effects O
of O
cck-8 O
, O
but O
the O
cck1 O
receptor O
antagonist O
l-364,718 O
(10ug O
, O
i.c.v O
) O
did O
not O
. O

the O
present O
results O
demonstrate O
that O
cck-8 O
attenuates O
the O
effect O
of O
morphine O
on O
hippocampal O
ltp O
through O
cck2 O
receptors O
and O
suggest O
an O
ameliorative O
function O
of O
cck-8 O
on O
morphine-induced O
memory B-NEG
impairment I-NEG
. O

-DOCSTART- O

glial O
activation O
and O
post-synaptic O
neurotoxicity B-NEG
: O
the O
key O
events O
in O
streptozotocin O
( O
icv O
) O
induced O
memory B-NEG
impairment I-NEG
in O
rats O
. O

in O
the O
present O
study O
the O
role O
of O
glial O
activation O
and O
post O
synaptic O
toxicity B-NEG
in O
icv O
streptozotocin O
( O
stz O
) O
induced O
memory B-NEG
impaired I-NEG
rats O
was O
explored O
. O

in O
experiment O
set O
up O
1: O
memory B-NEG
deficit I-NEG
was O
found O
in O
morris O
water O
maze O
test O
on O
14-16 O
days O
after O
stz O
(icv O
; O
3mg/kg O
) O
administration O
. O

stz O
causes O
increased O
expression O
of O
gfap O
, O
cd11b O
and O
tnf-a O
indicating O
glial O
activation O
and O
neuroinflammation B-NEG
. O

stz O
also O
significantly O
increased O
the O
level O
of O
ros O
, O
nitrite O
, O
ca(2+ O
) O
and O
reduced O
the O
mitochondrial O
activity O
in O
synaptosomal O
preparation O
illustrating O
free O
radical O
generation O
and O
excitotoxicity B-NEG
. O

increased O
expression O
and O
activity O
of O
caspase-3 O
was O
also O
observed O
in O
stz O
treated O
rat O
which O
specify O
apoptotic O
cell O
death O
in O
hippocampus O
and O
cortex O
. O

stz O
treatment O
showed O
decrease O
expression O
of O
post O
synaptic O
markers O
camkiia O
and O
psd-95 O
, O
while O
, O
expression O
of O
pre O
synaptic O
markers O
( O
synaptophysin O
and O
snap-25 O
) O
remains O
unaltered O
indicating O
selective O
post O
synaptic O
neurotoxicity B-NEG
. O

oral O
treatment O
with O
memantine O
( O
10mg/kg O
) O
and O
ibuprofen O
( O
50 O
mg/kg O
) O
daily O
for O
13 O
days O
attenuated O
stz O
induced O
glial O
activation O
, O
apoptotic O
cell O
death O
and O
post O
synaptic O
neurotoxicity B-NEG
in O
rat O
brain O
. O

further O
, O
in O
experiment O
set O
up O
2: O
where O
memory O
function O
was O
not O
affected O
i.e O
. O

7-9 O
days O
after O
stz O
treatment O
. O

the O
level O
of O
gfap O
, O
cd11b O
, O
tnf-a O
, O
ros O
and O
nitrite O
levels O
were O
increased O
. O

on O
the O
other O
hand O
, O
apoptotic O
marker O
, O
synaptic O
markers O
, O
mitochondrial O
activity O
and O
ca(2+ O
) O
levels O
remained O
unaffected O
. O

collective O
data O
indicates O
that O
neuroinflammatory B-NEG
process O
and O
oxidative O
stress O
occurs O
earlier O
to O
apoptosis O
and O
does O
not O
affect O
memory O
function O
. O

present O
study O
clearly O
suggests O
that O
glial O
activation O
and O
post O
synaptic O
neurotoxicity B-NEG
are O
the O
key O
factors O
in O
stz O
induced O
memory B-NEG
impairment I-NEG
and O
neuronal O
cell O
death O
. O

-DOCSTART- O

comparison O
of O
effects O
of O
isotonic O
sodium O
chloride O
with O
diltiazem O
in O
prevention O
of O
contrast-induced O
nephropathy B-NEG
. O

introduction O
and O
objective O
: O
contrast-induced O
nephropathy B-NEG
( O
cin O
) O
significantly O
increases O
the O
morbidity O
and O
mortality O
of O
patients O
. O

the O
aim O
of O
this O
study O
is O
to O
investigate O
and O
compare O
the O
protective O
effects O
of O
isotonic O
sodium O
chloride O
with O
sodium O
bicarbonate O
infusion O
and O
isotonic O
sodium O
chloride O
infusion O
with O
diltiazem O
, O
a O
calcium O
channel O
blocker O
, O
in O
preventing O
cin O
. O

materials O
and O
methods O
: O
our O
study O
included O
patients O
who O
were O
administered O
30-60 O
ml O
of O
iodinated O
contrast O
agent O
for O
percutaneous O
coronary O
angiography O
(pcag) O
, O
all O
with O
creatinine O
values O
between O
1.1 O
and O
3.1 O
mg/dl O
. O

patients O
were O
divided O
into O
three O
groups O
and O
each O
group O
had O
20 O
patients O
. O

the O
first O
group O
of O
patients O
was O
administered O
isotonic O
sodium O
chloride O
; O
the O
second O
group O
was O
administered O
a O
solution O
that O
of O
5% O
dextrose O
and O
sodium O
bicarbonate O
, O
while O
the O
third O
group O
was O
administered O
isotonic O
sodium O
chloride O
before O
and O
after O
the O
contrast O
injection O
. O

the O
third O
group O
received O
an O
additional O
injection O
of O
diltiazem O
the O
day O
before O
and O
first O
2 O
days O
after O
the O
contrast O
injection O
. O

all O
of O
the O
patients' O
plasma O
blood O
urea O
nitrogen O
( O
bun O
) O
and O
creatinine O
levels O
were O
measured O
on O
the O
second O
and O
seventh O
day O
after O
the O
administration O
of O
intravenous O
contrast O
material O
. O

results O
: O
the O
basal O
creatinine O
levels O
were O
similar O
for O
all O
three O
groups O
(p O
> O
0.05) O
. O

among O
a O
total O
of O
60 O
patients O
included O
in O
the O
study O
, O
16 O
patients O
developed O
acute B-NEG
renal I-NEG
failure I-NEG
( O
arf B-NEG
) O
on O
the O
second O
day O
after O
contrast O
material O
was O
injected O
(26.6%) O
. O

the O
number O
of O
patients O
who O
developed O
arf B-NEG
on O
the O
second O
day O
after O
the O
injection O
in O
the O
first O
group O
was O
five O
(25%) O
, O
in O
the O
second O
group O
was O
six O
( O
30% O
) O
and O
the O
third O
group O
was O
five O
( O
25% O
) O
(p O
> O
0.05) O
. O

conclusion O
: O
there O
was O
no O
significant O
difference O
between O
isotonic O
sodium O
chloride O
, O
sodium O
bicarbonate O
and O
isotonic O
sodium O
chloride O
with O
diltiazem O
application O
in O
prevention O
of O
cin O
. O

-DOCSTART- O

neurocognitive O
and O
neuroradiologic O
central O
nervous O
system O
late O
effects O
in O
children O
treated O
on O
pediatric O
oncology O
group O
( O
pog O
) O
p9605 O
( O
standard O
risk O
) O
and O
p9201 O
( O
lesser O
risk O
) O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
protocols O
(accl0131) O
: O
a O
methotrexate O
consequence? O

a O
report O
from O
the O
children's O
oncology O
group O
. O

concerns O
about O
long-term O
methotrexate O
( O
mtx O
) O
neurotoxicity B-NEG
in O
the O
1990s O
led O
to O
modifications O
in O
intrathecal O
( O
it O
) O
therapy O
, O
leucovorin O
rescue O
, O
and O
frequency O
of O
systemic O
mtx O
administration O
in O
children O
with O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
. O

in O
this O
study O
, O
neurocognitive O
outcomes O
and O
neuroradiologic O
evidence O
of O
leukoencephalopathy B-NEG
were O
compared O
in O
children O
treated O
with O
intense O
central O
nervous O
system O
( O
cns)-directed O
therapy O
( O
p9605 O
) O
versus O
those O
receiving O
fewer O
cns-directed O
treatment O
days O
during O
intensive O
consolidation O
(p9201) O
. O

a O
total O
of O
66 O
children O
from O
16 O
pediatric O
oncology O
group O
institutions O
with O
standard-risk O
acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG
, O
1.00 O
to O
9.99 O
years O
at O
diagnosis O
, O
without O
evidence O
of O
cns O
leukemia B-NEG
at O
diagnosis O
were O
enrolled O
on O
accl0131 O
: O
28 O
from O
p9201 O
and O
38 O
from O
p9605 O
. O

magnetic O
resonance O
imaging O
scans O
and O
standard O
neuropsychological O
tests O
were O
performed O
>2.6 O
years O
after O
the O
end O
of O
treatment O
. O

significantly O
more O
p9605 O
patients O
developed O
leukoencephalopathy B-NEG
compared O
with O
p9201 O
patients O
(68% O
, O
95% O
confidence O
interval O
49%-83% O
vs O
. O
22% O
, O
95% O
confidence O
interval O
5%-44% O
; O
p=0.001 O
) O
identified O
as O
late O
as O
7.7 O
years O
after O
the O
end O
of O
treatment O
. O

overall O
, O
40% O
of O
patients O
scored O
<85 O
on O
either O
verbal O
or O
performance O
iq O
. O

children O
on O
both O
studies O
had O
significant O
attention B-NEG
problems I-NEG
, O
but O
p9605 O
children O
scored O
below O
average O
on O
more O
neurocognitive O
measures O
than O
those O
treated O
on O
p9201 O
(82% O
, O
14/17 O
measures O
vs O
. O
24% O
, O
4/17 O
measures) O
. O

this O
supports O
ongoing O
concerns O
about O
intensive O
mtx O
exposure O
as O
a O
major O
contributor O
to O
cns O
late O
effects O
. O

-DOCSTART- O

tranexamic O
acid O
overdosage-induced O
generalized O
seizure B-NEG
in O
renal B-NEG
failure I-NEG
. O

we O
report O
a O
45-year-old O
lady O
with O
chronic B-NEG
kidney I-NEG
disease I-NEG
stage O
4 O
due O
to O
chronic O
tubulointerstial B-NEG
disease I-NEG
. O

she O
was O
admitted O
to O
our O
center O
for O
severe O
anemia B-NEG
due O
to O
menorrhagia B-NEG
and O
deterioration B-NEG
of I-NEG
renal I-NEG
function I-NEG
. O

she O
was O
infused O
three O
units O
of O
packed O
cells O
during O
a O
session O
of O
hemodialysis O
. O

tranexamic O
acid O
( O
tna O
) O
1 O
g O
8-hourly O
was O
administered O
to O
her O
to O
control O
bleeding B-NEG
per O
vaginum O
. O

two O
hours O
after O
the O
sixth O
dose O
of O
tna O
, O
she O
had O
an O
episode O
of O
generalized O
tonic B-NEG
clonic I-NEG
convulsions I-NEG
. O

tna O
was O
discontinued O
. O

investigations O
of O
the O
patient O
revealed O
no O
biochemical O
or O
structural O
central O
nervous B-NEG
system I-NEG
abnormalities I-NEG
that O
could O
have O
provoked O
the O
convulsions B-NEG
. O

she O
did O
not O
require O
any O
further O
dialytic O
support O
. O

she O
had O
no O
further O
episodes O
of O
convulsion B-NEG
till O
dis-charge O
and O
during O
the O
two O
months O
of O
follow-up O
. O

thus O
, O
the O
precipitating O
cause O
of O
convulsions B-NEG
was O
believed O
to O
be O
an O
overdose B-NEG
of O
tna O
. O

-DOCSTART- O

pre-treatment O
of O
bupivacaine-induced O
cardiovascular B-NEG
depression I-NEG
using O
different O
lipid O
formulations O
of O
propofol O
. O

background O
: O
pre-treatment O
with O
lipid O
emulsions O
has O
been O
shown O
to O
increase O
lethal O
doses O
of O
bupivacaine O
, O
and O
the O
lipid O
content O
of O
propofol O
may O
alleviate O
bupivacaine-induced O
cardiotoxicity B-NEG
. O

the O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
propofol O
in O
intralipid O
or O
medialipid O
emulsions O
on O
bupivacaine-induced O
cardiotoxicity B-NEG
. O

methods O
: O
rats O
were O
anaesthetised O
with O
ketamine O
and O
were O
given O
0.5 O
mg/kg/min O
propofol O
in O
intralipid O
( O
group O
p) O
, O
propofol O
in O
medialipid O
( O
group O
l) O
, O
or O
saline O
( O
group O
c) O
over O
20 O
min O
. O

thereafter O
, O
2 O
mg/kg/min O
bupivacaine O
0.5% O
was O
infused O
. O

we O
recorded O
time O
to O
first O
dysrhythmia B-NEG
occurrence O
, O
respective O
times O
to O
25% O
and O
50% O
reduction O
of O
the O
heart O
rate O
( O
hr O
) O
and O
mean O
arterial O
pressure O
, O
and O
time O
to O
asystole B-NEG
and O
total O
amount O
of O
bupivacaine O
consumption O
. O

blood O
and O
tissue O
samples O
were O
collected O
following O
asystole B-NEG
. O

results O
: O
the O
time O
to O
first O
dysrhythmia B-NEG
occurrence O
, O
time O
to O
25% O
and O
50% O
reductions O
in O
hr O
, O
and O
time O
to O
asystole B-NEG
were O
longer O
in O
group O
p O
than O
the O
other O
groups O
. O

the O
cumulative O
bupivacaine O
dose O
given O
at O
those O
time O
points O
was O
higher O
in O
group O
p. O

plasma O
bupivacaine O
levels O
were O
significantly O
lower O
in O
group O
p O
than O
in O
group O
c. O

bupivacaine O
levels O
in O
the O
brain O
and O
heart O
were O
significantly O
lower O
in O
group O
p O
and O
group O
l O
than O
in O
group O
c. O

conclusion O
: O
we O
conclude O
that O
pre-treatment O
with O
propofol O
in O
intralipid O
, O
compared O
with O
propofol O
in O
medialipid O
or O
saline O
, O
delayed O
the O
onset O
of O
bupivacaine-induced O
cardiotoxic B-NEG
effects O
as O
well O
as O
reduced O
plasma O
bupivacaine O
levels O
. O

further O
studies O
are O
needed O
to O
explore O
tissue O
bupivacaine O
levels O
of O
propofol O
in O
medialipid O
and O
adapt O
these O
results O
to O
clinical O
practice O
. O

-DOCSTART- O

drug-induced B-NEG
acute I-NEG
liver I-NEG
injury I-NEG
within O
12 O
hours O
after O
fluvastatin O
therapy O
. O

although O
statins O
are O
generally O
well-tolerated O
drugs O
, O
recent O
cases O
of O
drug-induced B-NEG
liver I-NEG
injury I-NEG
associated O
with O
their O
use O
have O
been O
reported O
. O

a O
52-year-old O
chinese O
man O
reported O
with O
liver B-NEG
damage I-NEG
, O
which O
appeared O
12 O
hours O
after O
beginning O
treatment O
with O
fluvastatin O
. O

patient O
presented O
with O
complaints O
of O
increasing O
nausea B-NEG
, O
anorexia B-NEG
, O
and O
upper O
abdominal B-NEG
pain I-NEG
. O

his O
laboratory O
values O
showed O
elevated O
creatine O
kinase O
and O
transaminases O
. O

testing O
for O
autoantibodies O
was O
also O
negative O
. O

the O
liver O
biochemistries O
eventually O
normalized O
within O
3 O
weeks O
of O
stopping O
the O
fluvastatin O
. O

therefore O
, O
when O
prescribing O
statins O
, O
the O
possibility O
of O
hepatic B-NEG
damage I-NEG
should O
be O
taken O
into O
account O
. O

-DOCSTART- O

fluconazole O
associated O
agranulocytosis B-NEG
and O
thrombocytopenia B-NEG
. O

case O
: O
we O
describe O
a O
second O
case O
of O
fluconazole O
associated O
agranulocytosis B-NEG
with O
thrombocytopenia B-NEG
and O
recovery O
upon O
discontinuation O
of O
therapy O
. O

the O
patient O
began O
to O
have O
changes O
in O
white O
blood O
cells O
and O
platelets O
within O
48 O
h O
of O
administration O
of O
fluconazole O
and O
began O
to O
recover O
with O
48 O
h O
of O
discontinuation O
. O

this O
case O
highlights O
that O
drug-induced O
blood B-NEG
dyscrasias I-NEG
can O
occur O
unexpectedly O
as O
a O
result O
of O
treatment O
with O
a O
commonly O
used O
drug O
thought O
to O
be O
safe O
. O

conclusion O
: O
according O
to O
naranjo's O
algorithm O
the O
likelihood O
that O
our O
patient's O
agranulocytosis B-NEG
and O
thrombocytopenia B-NEG
occurred O
as O
a O
result O
of O
therapy O
with O
fluconazole O
is O
probable O
, O
with O
a O
total O
of O
six O
points O
. O

we O
feel O
that O
the O
weight O
of O
the O
overall O
evidence O
of O
this O
evidence O
is O
strong O
. O

in O
particular O
the O
temporal O
relationship O
of O
bone B-NEG
marrow I-NEG
suppression I-NEG
to O
the O
initiation O
of O
fluconazole O
and O
the O
abatement O
of O
symptoms O
that O
rapidly O
reversed O
immediately O
following O
discontinuation O
. O

-DOCSTART- O

two-dimensional O
speckle O
tracking O
echocardiography O
combined O
with O
high-sensitive O
cardiac O
troponin O
t O
in O
early O
detection O
and O
prediction O
of O
cardiotoxicity B-NEG
during O
epirubicine-based O
chemotherapy O
. O

aims O
: O
to O
investigate O
whether O
alterations O
of O
myocardial B-NEG
strain I-NEG
and O
high-sensitive O
cardiac O
troponin O
t O
( O
ctnt O
) O
could O
predict O
future O
cardiac B-NEG
dysfunction I-NEG
in O
patients O
after O
epirubicin O
exposure O
. O

methods O
: O
seventy-five O
patients O
with O
non-hodgkin B-NEG
lymphoma I-NEG
treated O
with O
epirubicin O
were O
studied O
. O

blood O
collection O
and O
echocardiography O
were O
performed O
at O
baseline O
, O
1 O
day O
after O
the O
third O
cycle O
, O
and O
1 O
day O
after O
completion O
of O
chemotherapy O
. O

patients O
were O
studied O
using O
echocardiography O
during O
follow-up O
. O

global O
longitudinal O
(gls) O
, O
circumferential O
(gcs) O
, O
and O
radial O
strain O
( O
grs O
) O
were O
calculated O
using O
speckle O
tracking O
echocardiography O
. O

left O
ventricular O
ejection O
fraction O
was O
analysed O
by O
real-time O
3d O
echocardiography O
. O
cardiotoxicity B-NEG
was O
defined O
as O
a O
reduction O
of O
the O
lvef O
of O
>5% O
to O
<55% O
with O
symptoms O
of O
heart B-NEG
failure I-NEG
or O
an O
asymptomatic O
reduction O
of O
the O
lvef O
of O
>10% O
to O
<55% O
. O

results O
: O
fourteen O
patients O
( O
18.67% O
) O
developed O
cardiotoxicity B-NEG
after O
treatment O
. O

gls O
( O
-18.48 O
+ O
1.72% O
vs O
. O
-15.96 O
+ O
1.6%) O
, O
gcs O
( O
-20.93 O
+ O
2.86% O
vs O
. O
-19.20 O
+ O
3.21%) O
, O
and O
grs O
( O
39.23 O
+ O
6.44% O
vs O
. O
34.98 O
+ O
6.2% O
) O
were O
markedly O
reduced O
and O
ctnt O
was O
elevated O
from O
0.0010 O
+ O
0.0020 O
to O
0.0073 O
+ O
0.0038 O
ng/ml O
(p O
all O
< O
0.01 O
) O
at O
the O
completion O
of O
chemotherapy O
compared O
with O
baseline O
values O
. O

a O
>15.9% O
decrease O
in O
gls O
[sensitivity O
, O
86% O
; O
specificity O
, O
75% O
; O
area O
under O
the O
curve O
( O
auc O
) O
= O
0.815 O
; O
p O
= O
0.001] O
and O
a O
>0.004 O
ng/ml O
elevation O
in O
ctnt O
(sensitivity O
, O
79% O
; O
specificity O
, O
64% O
; O
auc O
= O
0.757 O
; O
p O
= O
0.005 O
) O
from O
baseline O
to O
the O
third O
cycle O
of O
chemotherapy O
predicted O
later O
cardiotoxicity B-NEG
. O

the O
decrease O
in O
gls O
remained O
the O
only O
independent O
predictor O
of O
cardiotoxicity B-NEG
(p O
= O
0.000) O
. O

conclusions O
: O
gls O
combined O
with O
ctnt O
may O
provide O
a O
reliable O
and O
non-invasive O
method O
to O
predict O
cardiac B-NEG
dysfunction I-NEG
in O
patients O
receiving O
anthracycline-based O
chemotherapy O
. O

-DOCSTART- O

prevention O
of O
etomidate-induced O
myoclonus B-NEG
: O
which O
is O
superior O
: O
fentanyl O
, O
midazolam O
, O
or O
a O
combination? O

a O
retrospective O
comparative O
study O
. O

background O
: O
in O
this O
retrospective O
comparative O
study O
, O
we O
aimed O
to O
compare O
the O
effectiveness O
of O
fentanyl O
, O
midazolam O
, O
and O
a O
combination O
of O
fentanyl O
and O
midazolam O
to O
prevent O
etomidate-induced O
myoclonus B-NEG
. O

material O
and O
methods O
: O
this O
study O
was O
performed O
based O
on O
anesthesia O
records O
. O

depending O
on O
the O
drugs O
that O
would O
be O
given O
before O
the O
induction O
of O
anesthesia O
with O
etomidate O
, O
the O
patients O
were O
separated O
into O
4 O
groups O
: O
no O
pretreatment O
( O
group O
np) O
, O
fentanyl O
1 O
ug.kg-1 O
( O
group O
f) O
, O
midazolam O
0.03 O
mg.kg-1 O
( O
group O
m) O
, O
and O
midazolam O
0.015 O
mg.kg-1 O
+ O
fentanyl O
0.5 O
ug.kg-1 O
( O
group O
fm) O
. O

patients O
who O
received O
the O
same O
anesthetic O
procedure O
were O
selected O
: O
2 O
minutes O
after O
intravenous O
injections O
of O
the O
pretreatment O
drugs O
, O
anesthesia O
is O
induced O
with O
0.3 O
mg.kg-1 O
etomidate O
injected O
intravenously O
over O
a O
period O
of O
20-30 O
seconds O
. O
myoclonic B-NEG
movements I-NEG
are O
evaluated O
, O
which O
were O
observed O
and O
graded O
according O
to O
clinical O
severity O
during O
the O
2 O
minutes O
after O
etomidate O
injection O
. O

the O
severity O
of O
pain B-NEG
due O
to O
etomidate O
injection O
, O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
adverse O
effects O
were O
also O
evaluated O
. O

results O
: O
study O
results O
showed O
that O
myoclonus B-NEG
incidence O
was O
85% O
, O
40% O
, O
70% O
, O
and O
25% O
in O
group O
np O
, O
group O
f, O
group O
m, O
and O
group O
fm O
, O
respectively O
, O
and O
were O
significantly O
lower O
in O
group O
f O
and O
group O
fm O
. O

conclusions O
: O
we O
conclude O
that O
pretreatment O
with O
fentanyl O
or O
combination O
of O
fentanyl O
and O
midazolam O
was O
effective O
in O
preventing O
etomidate-induced O
myoclonus B-NEG
. O

-DOCSTART- O

cholestatic B-NEG
presentation O
of O
yellow O
phosphorus O
poisoning B-NEG
. O

yellow O
phosphorus O
, O
a O
component O
of O
certain O
pesticide O
pastes O
and O
fireworks O
, O
is O
well O
known O
to O
cause O
hepatotoxicity B-NEG
. O
poisoning B-NEG
with O
yellow O
phosphorus O
classically O
manifests O
with O
acute B-NEG
hepatitis I-NEG
leading O
to O
acute B-NEG
liver I-NEG
failure I-NEG
which O
may O
need O
liver O
transplantation O
. O

we O
present O
a O
case O
of O
yellow O
phosphorus O
poisoning B-NEG
in O
which O
a O
patient O
presented O
with O
florid O
clinical O
features O
of O
cholestasis B-NEG
highlighting O
the O
fact O
that O
cholestasis B-NEG
can O
rarely O
be O
a O
presenting O
feature O
of O
yellow O
phosphorus O
hepatotoxicity B-NEG
. O

-DOCSTART- O

vasovagal B-NEG
syncope I-NEG
and O
severe O
bradycardia B-NEG
following O
intranasal O
dexmedetomidine O
for O
pediatric O
procedural O
sedation O
. O

we O
report O
syncope B-NEG
and O
bradycardia B-NEG
in O
an O
11-year-old O
girl O
following O
administration O
of O
intranasal O
dexmedetomidine O
for O
sedation O
for O
a O
voiding O
cystourethrogram O
. O

following O
successful O
completion O
of O
vcug O
and O
a O
60-min O
recovery O
period O
, O
the O
patient's O
level O
of O
consciousness O
and O
vital O
signs O
returned O
to O
presedation O
levels O
. O

upon O
leaving O
the O
sedation O
area O
, O
the O
patient O
collapsed O
, O
with O
no O
apparent O
inciting O
event O
. O

the O
patient O
quickly O
regained O
consciousness O
and O
no O
injury O
occurred O
. O

the O
primary O
abnormality O
found O
was O
persistent O
bradycardia B-NEG
, O
and O
she O
was O
admitted O
to O
the O
hospital O
for O
telemetric O
observation O
. O

the O
bradycardia B-NEG
lasted O
~2 O
h, O
and O
further O
cardiac O
workup O
revealed O
no O
underlying O
abnormality O
. O

unanticipated O
and O
previously O
unreported O
outcomes O
may O
be O
witnessed O
as O
we O
expand O
the O
use O
of O
certain O
sedatives O
to O
alternative O
routes O
of O
administration O
. O

-DOCSTART- O

paradoxical O
severe O
agitation B-NEG
induced O
by O
add-on O
high-doses O
quetiapine O
in O
schizo-affective B-NEG
disorder I-NEG
. O

we O
report O
the O
case O
of O
a O
35-year-old O
patient O
suffering O
from O
schizo-affective B-NEG
disorder I-NEG
since O
the O
age O
of O
19 O
years O
, O
treated O
by O
a O
combination O
of O
first-generation O
antipsychotics O
, O
zuclopenthixol O
( O
100 O
mg/day O
) O
and O
lithium O
( O
1200 O
mg/day O
) O
( O
serum O
lithium=0.85 O
meq/l) O
. O

this O
patient O
had O
no O
associated O
personality B-NEG
disorder I-NEG
( O
particularly O
no O
antisocial B-NEG
disorder I-NEG
) O
and O
no O
substance B-NEG
abuse I-NEG
disorder I-NEG
. O

within O
the O
48 O
h O
following O
the O
gradual O
introduction O
of O
quetiapine O
( O
up O
to O
600 O
mg/day) O
, O
the O
patient O
presented O
severe O
agitation B-NEG
without O
an O
environmental O
explanation O
, O
contrasting O
with O
the O
absence O
of O
a O
history O
of O
aggressiveness B-NEG
or O
personality B-NEG
disorder I-NEG
. O

the O
diagnoses O
of O
manic B-NEG
shift O
and O
akathisia B-NEG
were O
dismissed O
. O

the O
withdrawal O
and O
the O
gradual O
reintroduction O
of O
quetiapine O
2 O
weeks O
later O
, O
which O
led O
to O
another O
severe O
agitation B-NEG
, O
enabled O
us O
to O
attribute O
the O
agitation B-NEG
specifically O
to O
quetiapine O
. O

-DOCSTART- O

antioxidant O
effects O
of O
bovine O
lactoferrin O
on O
dexamethasone-induced O
hypertension B-NEG
in O
rat O
. O

dexamethasone- O
( O
dex- O
) O
induced O
hypertension B-NEG
is O
associated O
with O
enhanced O
oxidative O
stress O
. O

lactoferrin O
( O
lf O
) O
is O
an O
iron-binding O
glycoprotein O
with O
antihypertensive O
properties O
. O

in O
this O
study O
, O
we O
investigated O
the O
effect O
of O
chronic O
administration O
of O
lf O
on O
oxidative O
stress O
and O
hypertension B-NEG
upon O
dex O
administration O
. O

male O
wistar O
rats O
were O
treated O
by O
dex O
( O
30 O
u O
g/kg/day O
subcutaneously O
) O
or O
saline O
for O
14 O
days O
. O

oral O
bovine O
lf O
(30 O
, O
100 O
, O
300 O
mg/kg O
) O
was O
given O
from O
day O
8 O
to O
14 O
in O
a O
reversal O
study O
. O

in O
a O
prevention O
study O
, O
rats O
received O
4 O
days O
of O
lf O
treatment O
followed O
by O
dex O
and O
continued O
during O
the O
test O
period O
. O

systolic O
blood O
pressure O
( O
sbp O
) O
was O
measured O
using O
tail-cuff O
method O
. O

thymus O
weight O
was O
used O
as O
a O
marker O
of O
glucocorticoid O
activity O
. O

plasma O
hydrogen O
peroxide O
( O
h2o2 O
) O
concentration O
and O
ferric O
reducing O
antioxidant O
power O
( O
frap O
) O
value O
were O
determined O
. O

dexamethasone O
significantly O
increased O
sbp O
and O
plasma O
h2o2 O
level O
and O
decreased O
thymus O
and O
body O
weights O
. O

lf O
lowered O
(p O
< O
0.01 O
) O
and O
dose O
dependently O
prevented O
(p O
< O
0.001 O
) O
dex-induced O
hypertension B-NEG
. O

lf O
prevented O
body O
weight B-NEG
loss I-NEG
and O
significantly O
reduced O
the O
elevated O
plasma O
h2o2 O
and O
increased O
frap O
values O
. O

chronic O
administration O
of O
lf O
strongly O
reduced O
the O
blood O
pressure O
and O
production O
of O
ros O
and O
improved O
antioxidant O
capacity O
in O
dex-induced O
hypertension B-NEG
, O
suggesting O
the O
role O
of O
inhibition O
of O
oxidative O
stress O
as O
another O
mechanism O
of O
antihypertensive O
action O
of O
lf O
. O

-DOCSTART- O

the O
association O
between O
tranexamic O
acid O
and O
convulsive B-NEG
seizures B-NEG
after O
cardiac O
surgery O
: O
a O
multivariate O
analysis O
in O
11 O
529 O
patients O
. O

because O
of O
a O
lack O
of O
contemporary O
data O
regarding O
seizures B-NEG
after O
cardiac O
surgery O
, O
we O
undertook O
a O
retrospective O
analysis O
of O
prospectively O
collected O
data O
from O
11 O
529 O
patients O
in O
whom O
cardiopulmonary O
bypass O
was O
used O
from O
january O
2004 O
to O
december O
2010 O
. O

a O
convulsive B-NEG
seizure B-NEG
was O
defined O
as O
a O
transient O
episode O
of O
disturbed O
brain O
function O
characterised O
by O
abnormal B-NEG
involuntary I-NEG
motor I-NEG
movements I-NEG
. O

multivariate O
regression O
analysis O
was O
performed O
to O
identify O
independent O
predictors O
of O
postoperative O
seizures B-NEG
. O

a O
total O
of O
100 O
( O
0.9% O
) O
patients O
developed O
postoperative O
convulsive B-NEG
seizures B-NEG
. O
generalised B-NEG
and I-NEG
focal I-NEG
seizures I-NEG
were O
identified O
in O
68 O
and O
32 O
patients O
, O
respectively O
. O

the O
median O
( O
iqr O
[range] O
) O
time O
after O
surgery O
when O
the O
seizure B-NEG
occurred O
was O
7 O
( O
6-12 O
[1-216] O
) O
h O
and O
8 O
( O
6-11 O
[4-18] O
) O
h, O
respectively O
. O

epileptiform O
findings O
on O
electroencephalography O
were O
seen O
in O
19 O
patients O
. O

independent O
predictors O
of O
postoperative O
seizures B-NEG
included O
age O
, O
female O
sex O
, O
redo O
cardiac O
surgery O
, O
calcification O
of O
ascending O
aorta O
, O
congestive B-NEG
heart I-NEG
failure I-NEG
, O
deep O
hypothermic B-NEG
circulatory O
arrest O
, O
duration O
of O
aortic O
cross-clamp O
and O
tranexamic O
acid O
. O

when O
tested O
in O
a O
multivariate O
regression O
analysis O
, O
tranexamic O
acid O
was O
a O
strong O
independent O
predictor O
of O
seizures B-NEG
( O
or O
14.3 O
, O
95% O
ci O
5.5-36.7 O
; O
p O
< O
0.001) O
. O

patients O
with O
convulsive B-NEG
seizures B-NEG
had O
2.5 O
times O
higher O
in-hospital O
mortality O
rates O
and O
twice O
the O
length O
of O
hospital O
stay O
compared O
with O
patients O
without O
convulsive B-NEG
seizures B-NEG
. O

mean O
( O
iqr O
[range] O
) O
length O
of O
stay O
in O
the O
intensive O
care O
unit O
was O
115 O
( O
49-228 O
[32-481] O
) O
h O
in O
patients O
with O
convulsive B-NEG
seizures B-NEG
compared O
with O
26 O
( O
22-69 O
[14-1080] O
) O
h O
in O
patients O
without O
seizures B-NEG
(p O
< O
0.001) O
. O
convulsive B-NEG
seizures B-NEG
are O
a O
serious O
postoperative B-NEG
complication I-NEG
after O
cardiac O
surgery O
. O

as O
tranexamic O
acid O
is O
the O
only O
modifiable O
factor O
, O
its O
administration O
, O
particularly O
in O
doses O
exceeding O
80 O
mg.kg(-1) O
, O
should O
be O
weighed O
against O
the O
risk O
of O
postoperative O
seizures B-NEG
. O

-DOCSTART- O

dysfunctional B-NEG
overnight I-NEG
memory I-NEG
consolidation O
in O
ecstasy O
users O
. O

sleep O
plays O
an O
important O
role O
in O
the O
consolidation O
and O
integration O
of O
memory O
in O
a O
process O
called O
overnight O
memory O
consolidation O
. O

previous O
studies O
indicate O
that O
ecstasy O
users O
have O
marked O
and O
persistent O
neurocognitive O
and O
sleep-related B-NEG
impairments I-NEG
. O

we O
extend O
past O
research O
by O
examining O
overnight O
memory O
consolidation O
among O
regular O
ecstasy O
users O
( O
n=12 O
) O
and O
drug O
naive O
healthy O
controls O
(n=26) O
. O

memory O
recall O
of O
word O
pairs O
was O
evaluated O
before O
and O
after O
a O
period O
of O
sleep O
, O
with O
and O
without O
interference O
prior O
to O
testing O
. O

in O
addition O
, O
we O
assessed O
neurocognitive O
performances O
across O
tasks O
of O
learning O
, O
memory O
and O
executive O
functioning O
. O

ecstasy O
users O
demonstrated O
impaired B-NEG
overnight I-NEG
memory I-NEG
consolidation O
, O
a O
finding O
that O
was O
more O
pronounced O
following O
associative O
interference O
. O

additionally O
, O
ecstasy O
users O
demonstrated O
impairments O
on O
tasks O
recruiting O
frontostriatal O
and O
hippocampal O
neural O
circuitry O
, O
in O
the O
domains O
of O
proactive O
interference O
memory O
, O
long-term O
memory O
, O
encoding O
, O
working O
memory O
and O
complex O
planning O
. O

we O
suggest O
that O
ecstasy-associated O
dysfunction O
in O
fronto-temporal O
circuitry O
may O
underlie O
overnight O
consolidation O
memory B-NEG
impairments I-NEG
in O
regular O
ecstasy O
users O
. O

-DOCSTART- O

normoammonemic O
encephalopathy B-NEG
: O
solely O
valproate O
induced O
or O
multiple O
mechanisms? O

a O
77-year-old O
woman O
presented O
with O
subacute O
onset O
progressive O
confusion B-NEG
, O
aggression B-NEG
, O
auditory B-NEG
hallucinations I-NEG
and O
delusions B-NEG
. O

in O
the O
preceding O
months O
, O
the O
patient O
had O
a O
number O
of O
admissions O
with O
transient O
unilateral O
hemiparesis B-NEG
with O
facial O
droop O
, O
and O
had O
been O
started O
on O
valproate O
for O
presumed O
hemiplegic B-NEG
migraine I-NEG
. O

valproate O
was O
withdrawn O
soon O
after O
admission O
and O
her O
cognitive O
abilities O
have O
gradually O
improved O
over O
3 O
months O
of O
follow-up O
. O

valproate O
levels O
taken O
prior O
to O
withdrawal O
were O
subtherapeutic O
and O
the O
patient O
was O
normoammonaemic O
. O

eeg O
undertaken O
during O
inpatient O
stay O
showed O
changes O
consistent O
with O
encephalopathy B-NEG
, O
and O
low O
titre O
n-methyl-d-aspartate O
( O
nmda O
) O
receptor O
antibodies O
were O
present O
in O
this O
patient O
. O

the O
possible O
aetiologies O
of O
valproate-induced O
encephalopathy B-NEG
and O
nmda O
receptor-associated O
encephalitis B-NEG
present O
a O
diagnostic O
dilemma O
. O

we O
present O
a O
putative O
combinatorial O
hypothesis O
to O
explain O
this O
patient's O
symptoms O
. O

-DOCSTART- O

cerebellar B-NEG
and I-NEG
oculomotor I-NEG
dysfunction I-NEG
induced O
by O
rapid O
infusion O
of O
pethidine O
. O

pethidine O
is O
an O
opioid O
that O
gains O
its O
popularity O
for O
the O
effective O
pain B-NEG
control O
through O
acting O
on O
the O
opioid-receptors O
. O

however O
, O
rapid O
pain B-NEG
relief O
sometimes O
brings O
about O
unfavourable O
side O
effects O
that O
largely O
limit O
its O
clinical O
utility O
. O

common O
side O
effects O
include O
nausea B-NEG
, O
vomiting B-NEG
and O
hypotension B-NEG
. O

in O
patients O
with O
impaired B-NEG
renal I-NEG
and I-NEG
liver I-NEG
function I-NEG
, O
and O
those O
who O
need O
long-term O
pain B-NEG
control O
, O
pethidine O
may O
cause O
excitatory O
central O
nervous O
system O
( O
cns O
) O
effects O
through O
its O
neurotoxic B-NEG
metabolite O
, O
norpethidine O
, O
resulting O
in O
irritability B-NEG
and O
seizure B-NEG
attack O
. O

on O
the O
contrary O
, O
though O
not O
clinically O
apparent O
, O
pethidine O
potentially O
causes O
inhibitory O
impacts O
on O
the O
cns O
and O
impairs O
normal O
cerebellar O
and O
oculomotor O
function O
in O
the O
short O
term O
. O

in O
this O
case O
report O
, O
we O
highlight O
opioid's O
inhibitory O
side O
effects O
on O
the O
cerebellar O
structure O
that O
causes O
dysmetria B-NEG
, O
dysarthria B-NEG
, O
reduced O
smooth O
pursuit O
gain O
and O
decreased O
saccadic O
velocity O
. O

-DOCSTART- O

baboon B-NEG
syndrome I-NEG
induced O
by O
ketoconazole O
. O

a O
27-year-old O
male O
patient O
presented O
with O
a O
maculopapular B-NEG
eruption I-NEG
on O
the O
flexural O
areas O
and O
buttocks O
after O
using O
oral O
ketoconazole O
. O

the O
patient O
was O
diagnosed O
with O
drug-induced O
baboon B-NEG
syndrome I-NEG
based O
on O
his O
history O
, O
which O
included O
prior O
sensitivity O
to O
topical O
ketoconazole O
, O
a O
physical O
examination O
, O
and O
histopathological O
findings O
. O
baboon B-NEG
syndrome I-NEG
is O
a O
drug- O
or O
contact O
allergen-related O
maculopapular B-NEG
eruption I-NEG
that O
typically O
involves O
the O
flexural O
and O
gluteal O
areas O
. O

to O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
ketoconazole-induced O
baboon B-NEG
syndrome I-NEG
in O
the O
english O
literature O
. O

-DOCSTART- O

a O
case O
of O
sudden B-NEG
cardiac I-NEG
death I-NEG
due O
to O
pilsicainide-induced O
torsades B-NEG
de I-NEG
pointes I-NEG
. O

an O
84-year-old O
male O
received O
oral O
pilsicainide O
, O
a O
pure O
sodium O
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
his O
paroxysmal O
atrial B-NEG
fibrillation I-NEG
to O
a O
sinus O
rhythm O
; O
the O
patient O
developed O
sudden B-NEG
cardiac I-NEG
death I-NEG
two O
days O
later O
. O

the O
holter O
electrocardiogram O
, O
which O
was O
worn O
by O
chance O
, O
revealed O
torsade B-NEG
de I-NEG
pointes I-NEG
with O
gradually O
prolonged O
qt O
intervals O
. O

this O
drug O
is O
rapidly O
absorbed O
from O
the O
gastrointestinal O
tract O
, O
and O
most O
of O
it O
is O
excreted O
from O
the O
kidney O
. O

although O
the O
patient's O
renal O
function O
was O
not O
highly O
impaired O
and O
the O
dose O
of O
pilsicainide O
was O
low O
, O
the O
plasma O
concentration O
of O
pilsicainide O
may O
have O
been O
high O
, O
which O
can O
produce O
torsades B-NEG
de I-NEG
pointes I-NEG
in O
the O
octogenarian O
. O

although O
the O
oral O
administration O
of O
class O
ic O
drugs O
, O
including O
pilsicainide O
, O
is O
effective O
to O
terminate O
atrial B-NEG
fibrillation I-NEG
, O
careful O
consideration O
must O
be O
taken O
before O
giving O
these O
drugs O
to O
octogenarians O
. O

-DOCSTART- O

all-trans O
retinoic O
acid-induced O
inflammatory O
myositis B-NEG
in O
a O
patient O
with O
acute B-NEG
promyelocytic I-NEG
leukemia I-NEG
. O

all-trans O
retinoic O
acid O
(atra) O
, O
a O
component O
of O
standard O
therapy O
for O
acute B-NEG
promyelocytic I-NEG
leukemia I-NEG
( O
apl B-NEG
), O
is O
associated O
with O
potentially O
serious O
but O
treatable O
adverse O
effects O
involving O
numerous O
organ O
systems O
, O
including O
rare O
skeletal O
muscle O
involvement O
. O

only O
a O
handful O
of O
cases O
of O
atra-induced O
myositis B-NEG
in O
children O
have O
been O
reported O
, O
and O
none O
in O
the O
radiology O
literature O
. O

we O
present O
such O
a O
case O
in O
a O
15-year-old O
boy O
with O
apl B-NEG
, O
where O
recognition O
of O
imaging O
findings O
played O
a O
crucial O
role O
in O
making O
the O
diagnosis O
and O
facilitated O
prompt O
, O
effective O
treatment O
. O

-DOCSTART- O

tolerability O
of O
lomustine O
in O
combination O
with O
cyclophosphamide O
in O
dogs O
with O
lymphoma B-NEG
. O

this O
retrospective O
study O
describes O
toxicity B-NEG
associated O
with O
a O
protocol O
of O
lomustine O
( O
ccnu O
) O
and O
cyclophosphamide O
( O
ctx O
) O
in O
dogs O
with O
lymphoma B-NEG
. O

ccnu O
was O
administered O
per O
os O
( O
po O
) O
at O
a O
targeted O
dosage O
of O
60 O
mg/m(2 O
) O
body O
surface O
area O
on O
day O
0, O
ctx O
was O
administered O
po O
at O
a O
targeted O
dosage O
of O
250 O
mg/m(2 O
) O
divided O
over O
days O
0 O
through O
4, O
and O
all O
dogs O
received O
prophylactic O
antibiotics O
. O

ninety O
treatments O
were O
given O
to O
the O
57 O
dogs O
included O
in O
the O
study O
. O
neutropenia B-NEG
was O
the O
principal O
toxic O
effect O
, O
and O
the O
overall O
frequency O
of O
grade O
4 O
neutropenia B-NEG
after O
the O
first O
treatment O
of O
ccnu/ctx O
was O
30% O
( O
95% O
confidence O
interval O
, O
19-43%) O
. O

the O
mean O
body O
weight O
of O
dogs O
with O
grade O
4 O
neutropenia B-NEG
( O
19.7 O
kg O
+ O
13.4 O
kg O
) O
was O
significantly O
less O
than O
the O
mean O
body O
weight O
of O
dogs O
that O
did O
not O
develop O
grade O
4 O
neutropenia B-NEG
( O
31.7 O
kg O
+ O
12.4 O
kg O
; O
p O
= O
.005) O
. O

one O
dog O
( O
3% O
) O
developed O
hematologic O
changes O
suggestive O
of O
hepatotoxicity B-NEG
. O

no O
dogs O
had O
evidence O
of O
either O
renal B-NEG
toxicity I-NEG
or O
hemorrhagic B-NEG
cystitis I-NEG
. O

adverse O
gastrointestinal O
effects O
were O
uncommon O
. O

on O
the O
basis O
of O
the O
findings O
reported O
herein O
, O
a O
dose O
of O
60 O
mg/m(2 O
) O
of O
ccnu O
combined O
with O
250 O
mg/m(2 O
) O
of O
ctx O
( O
divided O
over O
5 O
days O
) O
q O
4 O
wk O
is O
tolerable O
in O
tumor B-NEG
-bearing O
dogs O
. O

-DOCSTART- O

nelarabine O
neurotoxicity B-NEG
with O
concurrent O
intrathecal O
chemotherapy O
: O
case O
report O
and O
review O
of O
literature O
. O

severe O
nelarabine O
neurotoxicity B-NEG
in O
a O
patient O
who O
received O
concurrent O
intrathecal O
( O
it O
) O
chemotherapy O
is O
reported O
. O

a O
37-year-old O
caucasian O
woman O
with O
a O
history O
of O
t-cell B-NEG
lymphoblastic I-NEG
lymphoma I-NEG
was O
admitted O
for O
relapsed O
disease O
. O

she O
was O
originally O
treated O
with O
induction O
chemotherapy O
followed O
by O
an O
autologous O
transplant O
. O

she O
developed O
relapsed O
disease O
10 O
months O
later O
with O
leukemic B-NEG
involvement O
. O

she O
was O
re-induced O
with O
nelarabine O
1500 O
mg/m(2 O
) O
on O
days O
1, O
3, O
and O
5 O
with O
1 O
dose O
of O
it O
cytarabine O
100 O
mg O
on O
day O
2 O
as O
central O
nervous O
system O
( O
cns O
) O
prophylaxis O
. O

at O
the O
time O
of O
treatment O
, O
she O
was O
on O
continuous O
renal O
replacement O
therapy O
due O
to O
sequelae O
of O
tumor B-NEG
lysis I-NEG
syndrome I-NEG
( O
tls B-NEG
). O

she O
tolerated O
therapy O
well O
, O
entered O
a O
complete O
remission O
, O
and O
recovered O
her O
renal O
function O
. O

she O
received O
a O
second O
cycle O
of O
nelarabine O
without O
additional O
it O
prophylaxis O
one O
month O
later O
. O

a O
week O
after O
this O
second O
cycle O
, O
she O
noted O
numbness O
in O
her O
lower O
extremities O
. O

predominantly O
sensory O
, O
though O
also O
motor O
and O
autonomic O
, O
peripheral B-NEG
neuropathy I-NEG
started O
in O
her O
feet O
, O
ascended O
proximally O
to O
the O
mid-thoracic O
region O
, O
and O
eventually O
included O
her O
distal O
upper O
extremities O
. O

a O
magnetic O
resonance O
imaging O
( O
mri O
) O
of O
her O
spine O
demonstrated O
changes O
from O
c2 O
to O
c6 O
consistent O
with O
subacute O
combined O
degeneration O
. O

nelarabine O
was O
felt O
to O
be O
the O
cause O
of O
her O
symptoms O
. O

her O
neuropathy B-NEG
stabilized O
and O
showed O
slight O
improvement O
and O
ultimately O
received O
an O
unrelated O
, O
reduced-intensity O
allogeneic O
transplant O
while O
in O
complete O
remission O
, O
but O
relapsed O
disease O
10 O
weeks O
later O
. O

she O
is O
currently O
being O
treated O
with O
best O
supportive O
care O
. O

to O
our O
knowledge O
, O
this O
is O
the O
first O
published O
case O
report O
of O
severe O
neurotoxicity B-NEG
caused O
by O
nelarabine O
in O
a O
patient O
who O
received O
concurrent O
it O
chemotherapy O
. O

-DOCSTART- O

valproate-induced O
hyperammonemic B-NEG
encephalopathy B-NEG
in O
a O
renal O
transplanted O
patient O
. O
neurological B-NEG
complications I-NEG
after O
renal O
transplantation O
constitute O
an O
important O
cause O
of O
morbidity O
and O
mortality O
. O

their O
differential O
diagnosis O
is O
difficult O
and O
essential O
for O
subsequent O
patient's O
management O
. O

valproate-induced O
hyperammonemic B-NEG
encephalopathy B-NEG
is O
an O
uncommon O
but O
serious O
effect O
of O
valproate O
treatment O
. O

here O
, O
we O
describe O
the O
case O
of O
a O
15-year-old O
girl O
who O
was O
on O
a O
long-term O
therapy O
with O
valproate O
due O
to O
epilepsy B-NEG
and O
revealed O
impaired B-NEG
consciousness I-NEG
with O
hyperammonemia B-NEG
12 O
days O
after O
renal O
transplantation O
. O

after O
withdraw O
of O
valproate O
, O
patients' O
symptoms O
resolved O
within O
24 O
h. O

clinicians O
should O
increase O
their O
awareness O
for O
potential O
complication O
of O
valproate O
, O
especially O
in O
transplanted O
patients O
. O

-DOCSTART- O

necrotising B-NEG
fasciitis I-NEG
after O
bortezomib O
and O
dexamethasone-containing O
regimen O
in O
an O
elderly O
patient O
of O
waldenstrom B-NEG
macroglobulinaemia I-NEG
. O

bortezomib O
and O
high-dose O
dexamethasone-containing O
regimens O
are O
considered O
to O
be O
generally O
tolerable O
with O
few O
severe O
bacterial B-NEG
infections I-NEG
in O
patients O
with O
b-cell O
malignancies B-NEG
. O

however O
, O
information O
is O
limited O
concerning O
the O
safety O
of O
the O
regimen O
in O
elderly O
patients O
. O

we O
report O
a O
case O
of O
a O
76-year-old O
man O
with O
waldenstrom B-NEG
macroglobulinaemia I-NEG
who O
suffered O
necrotising B-NEG
fasciitis I-NEG
without O
neutropenia B-NEG
after O
the O
combination O
treatment O
with O
bortezomib O
, O
high-dose O
dexamethasone O
and O
rituximab O
. O

despite O
immediate O
intravenous O
antimicrobial O
therapy O
, O
he O
succumbed O
23 O
h O
after O
the O
onset O
. O

physicians O
should O
recognise O
the O
possibility O
of O
fatal O
bacterial B-NEG
infections I-NEG
related O
to O
bortezomib O
plus O
high-dose O
dexamethasone O
in O
elderly O
patients O
, O
and O
we O
believe O
this O
case O
warrants O
further O
investigation O
. O

-DOCSTART- O

an O
integrated O
characterization O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
in O
doxorubicin-induced O
cardiotoxicity B-NEG
. O

many O
efficacious O
cancer B-NEG
treatments O
cause O
significant O
cardiac O
morbidity O
, O
yet O
biomarkers O
or O
functional O
indices O
of O
early O
damage O
, O
which O
would O
allow O
monitoring O
and O
intervention O
, O
are O
lacking O
. O

in O
this O
study O
, O
we O
have O
utilized O
a O
rat O
model O
of O
progressive O
doxorubicin O
( O
dox)-induced O
cardiomyopathy B-NEG
, O
applying O
multiple O
approaches O
, O
including O
cardiac O
magnetic O
resonance O
imaging O
(mri) O
, O
to O
provide O
the O
most O
comprehensive O
characterization O
to O
date O
of O
the O
timecourse O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
underlying O
this O
toxicity B-NEG
. O

hannover O
wistar O
rats O
were O
dosed O
with O
1.25 O
mg/kg O
dox O
weekly O
for O
8 O
weeks O
followed O
by O
a O
4 O
week O
off-dosing O
recovery O
period O
. O

electron O
microscopy O
of O
the O
myocardium O
revealed O
subcellular B-NEG
degeneration I-NEG
and O
marked O
mitochondrial O
changes O
after O
a O
single O
dose O
. O

histopathological O
analysis O
revealed O
progressive O
cardiomyocyte B-NEG
degeneration I-NEG
, O
hypertrophy B-NEG
/cytomegaly O
, O
and O
extensive O
vacuolation O
after O
two O
doses O
. O

extensive O
replacement O
fibrosis B-NEG
( O
quantified O
by O
sirius O
red O
staining O
) O
developed O
during O
the O
off-dosing O
period O
. O

functional O
indices O
assessed O
by O
cardiac O
mri O
( O
including O
left O
ventricular O
ejection O
fraction O
(lvef) O
, O
cardiac O
output O
, O
and O
e/a O
ratio O
) O
declined O
progressively O
, O
reaching O
statistical O
significance O
after O
two O
doses O
and O
culminating O
in O
clinical O
lv B-NEG
dysfunction I-NEG
by O
12 O
weeks O
. O

significant O
increases O
in O
peak O
myocardial O
contrast O
enhancement O
and O
serological O
cardiac O
troponin O
i O
( O
ctni O
) O
emerged O
after O
eight O
doses O
, O
importantly O
preceding O
the O
lvef O
decline O
to O
<50% O
. O

troponin O
i O
levels O
positively O
correlated O
with O
delayed O
and O
peak O
gadolinium O
contrast O
enhancement O
, O
histopathological O
grading O
, O
and O
diastolic B-NEG
dysfunction I-NEG
. O

in O
summary O
, O
subcellular O
cardiomyocyte B-NEG
degeneration I-NEG
was O
the O
earliest O
marker O
, O
followed O
by O
progressive O
functional O
decline O
and O
histopathological O
manifestations O
. O

myocardial O
contrast O
enhancement O
and O
elevations O
in O
ctni O
occurred O
later O
. O

however O
, O
all O
indices O
predated O
clinical O
lv B-NEG
dysfunction I-NEG
and O
thus O
warrant O
further O
evaluation O
as O
predictive O
biomarkers O
. O

-DOCSTART- O

intradermal O
glutamate O
and O
capsaicin O
injections O
: O
intra- O
and O
interindividual O
variability O
of O
provoked O
hyperalgesia B-NEG
and O
allodynia B-NEG
. O

intradermal O
injections O
of O
glutamate O
and O
capsaicin O
are O
attractive O
to O
use O
in O
human O
experimental O
pain B-NEG
models O
because O
hyperalgesia B-NEG
and O
allodynia B-NEG
mimic O
isolated O
aspects O
of O
clinical O
pain B-NEG
disorders I-NEG
. O

the O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
reproducibility O
of O
these O
models O
. O

twenty O
healthy O
male O
volunteers O
( O
mean O
age O
24 O
years O
; O
range O
18-38 O
years O
) O
received O
intradermal O
injections O
of O
glutamate O
and O
capsaicin O
in O
the O
volar O
forearm O
. O

magnitudes O
of O
secondary O
pinprick O
hyperalgesia B-NEG
and O
brush-evoked O
allodynia B-NEG
were O
investigated O
using O
von O
frey O
filaments O
( O
gauges O
10 O
, O
15 O
, O
60 O
and O
100 O
g) O
and O
brush O
strokes O
. O

areas O
of O
secondary B-NEG
hyperalgesia I-NEG
and O
allodynia B-NEG
were O
quantified O
immediately O
after O
injection O
and O
after O
15 O
, O
30 O
and O
60 O
min O
. O

two O
identical O
experiments O
separated O
by O
at O
least O
7 O
days O
were O
performed O
. O

reproducibility O
across O
and O
within O
volunteers O
( O
inter- O
and O
intra-individual O
variation O
, O
respectively O
) O
was O
assessed O
using O
intraclass O
correlation O
coefficient O
( O
icc O
) O
and O
coefficient O
of O
variation O
(cv) O
. O

secondary O
pinprick O
hyperalgesia B-NEG
was O
observed O
as O
a O
marked O
increase O
in O
the O
visual O
analogue O
scale O
( O
vas O
) O
response O
to O
von O
frey O
gauges O
60 O
and O
100 O
g O
(p O
< O
0.001 O
) O
after O
glutamate O
injection O
. O

for O
capsaicin O
, O
secondary O
pinprick O
hyperalgesia B-NEG
was O
detected O
with O
all O
von O
frey O
gauges O
(p O
< O
0.001) O
. O

glutamate O
evoked O
reproducible O
vas O
response O
to O
all O
von O
frey O
gauges O
( O
icc O
> O
0.60 O
) O
and O
brush O
strokes O
( O
icc O
> O
0.83) O
. O

capsaicin O
injection O
was O
reproducible O
for O
secondary B-NEG
hyperalgesia I-NEG
( O
icc O
> O
0.70 O
) O
and O
allodynia B-NEG
( O
icc O
> O
0.71) O
. O

intra-individual O
variability O
was O
generally O
lower O
for O
the O
vas O
response O
to O
von O
frey O
and O
brush O
compared O
with O
areas O
of O
secondary B-NEG
hyperalgesia I-NEG
and O
allodynia B-NEG
. O

in O
conclusion O
, O
glutamate O
and O
capsaicin O
yield O
reproducible O
hyperalgesic B-NEG
and O
allodynic B-NEG
responses O
, O
and O
the O
present O
model O
is O
well O
suited O
for O
basic O
research O
, O
as O
well O
as O
for O
assessing O
the O
modulation O
of O
central O
phenomena O
. O

-DOCSTART- O

ocular-specific O
er O
stress O
reduction O
rescues O
glaucoma B-NEG
in O
murine O
glucocorticoid-induced O
glaucoma B-NEG
. O

administration O
of O
glucocorticoids O
induces O
ocular B-NEG
hypertension I-NEG
in O
some O
patients O
. O

if O
untreated O
, O
these O
patients O
can O
develop O
a O
secondary O
glaucoma B-NEG
that O
resembles O
primary B-NEG
open-angle I-NEG
glaucoma I-NEG
( O
poag B-NEG
). O

the O
underlying O
pathology O
of O
glucocorticoid-induced O
glaucoma B-NEG
is O
not O
fully O
understood O
, O
due O
in O
part O
to O
lack O
of O
an O
appropriate O
animal O
model O
. O

here O
, O
we O
developed O
a O
murine O
model O
of O
glucocorticoid-induced O
glaucoma B-NEG
that O
exhibits O
glaucoma B-NEG
features O
that O
are O
observed O
in O
patients O
. O

treatment O
of O
wt O
mice O
with O
topical O
ocular O
0.1% O
dexamethasone O
led O
to O
elevation O
of O
intraocular O
pressure O
(iop) O
, O
functional O
and O
structural O
loss O
of O
retinal B-NEG
ganglion I-NEG
cells O
, O
and O
axonal B-NEG
degeneration I-NEG
, O
resembling O
glucocorticoid-induced O
glaucoma B-NEG
in O
human O
patients O
. O

furthermore O
, O
dexamethasone-induced O
ocular B-NEG
hypertension I-NEG
was O
associated O
with O
chronic O
er O
stress O
of O
the O
trabecular O
meshwork O
(tm) O
. O

similar O
to O
patients O
, O
withdrawal O
of O
dexamethasone O
treatment O
reduced O
elevated O
iop O
and O
er O
stress O
in O
this O
animal O
model O
. O

dexamethasone O
induced O
the O
transcriptional O
factor O
chop O
, O
a O
marker O
for O
chronic O
er O
stress O
, O
in O
the O
anterior O
segment O
tissues O
, O
and O
chop O
deletion O
reduced O
er O
stress O
in O
these O
tissues O
and O
prevented O
dexamethasone-induced O
ocular B-NEG
hypertension I-NEG
. O

furthermore O
, O
reduction O
of O
er O
stress O
in O
the O
tm O
with O
sodium O
4-phenylbutyrate O
prevented O
dexamethasone-induced O
ocular B-NEG
hypertension I-NEG
in O
wt O
mice O
. O

our O
data O
indicate O
that O
er O
stress O
contributes O
to O
glucocorticoid-induced O
ocular B-NEG
hypertension I-NEG
and O
suggest O
that O
reducing O
er O
stress O
has O
potential O
as O
a O
therapeutic O
strategy O
for O
treating O
glucocorticoid-induced O
glaucoma B-NEG
. O

-DOCSTART- O

effects O
of O
ginsenosides O
on O
opioid-induced O
hyperalgesia B-NEG
in O
mice O
. O

opioid-induced O
hyperalgesia B-NEG
( O
oih B-NEG
) O
is O
characterized O
by O
nociceptive O
sensitization O
caused O
by O
the O
cessation O
of O
chronic O
opioid O
use O
. O
oih B-NEG
can O
limit O
the O
clinical O
use O
of O
opioid O
analgesics O
and O
complicate O
withdrawal O
from O
opioid B-NEG
addiction I-NEG
. O

in O
this O
study O
, O
we O
investigated O
the O
effects O
of O
re O
, O
rg1 O
, O
and O
rb1 O
ginsenosides O
, O
the O
bioactive O
components O
of O
ginseng O
, O
on O
oih B-NEG
. O
oih B-NEG
was O
achieved O
in O
mice O
after O
subcutaneous O
administration O
of O
morphine O
for O
7 O
consecutive O
days O
three O
times O
per O
day O
. O

during O
withdrawal O
( O
days O
8 O
and O
9) O
, O
these O
mice O
were O
administered O
re O
, O
rg1 O
, O
or O
rb1 O
intragastrically O
two O
times O
per O
day O
. O

on O
the O
test O
day O
( O
day O
10) O
, O
mice O
were O
subjected O
to O
the O
thermal O
sensitivity O
test O
and O
the O
acetic O
acid-induced O
writhing O
test O
. O

re O
( O
300 O
mg/kg O
) O
inhibited O
oih B-NEG
in O
both O
the O
thermal O
sensitivity O
test O
and O
the O
acetic O
acid-induced O
writhing O
test O
. O

however O
, O
the O
rg1 O
and O
rb1 O
ginsenosides O
failed O
to O
prevent O
oih B-NEG
in O
either O
test O
. O

furthermore O
, O
rg1 O
showed O
a O
tendency O
to O
aggravate O
oih B-NEG
in O
the O
acetic O
acid-induced O
writhing O
test O
. O

our O
data O
suggested O
that O
the O
ginsenoside O
re O
, O
but O
not O
rg1 O
or O
rb1 O
, O
may O
contribute O
toward O
reversal O
of O
oih B-NEG
. O

-DOCSTART- O

a O
comparison O
of O
severe O
hemodynamic O
disturbances O
between O
dexmedetomidine O
and O
propofol O
for O
sedation O
in O
neurocritical O
care O
patients O
. O

objective O
: O
dexmedetomidine O
and O
propofol O
are O
commonly O
used O
sedatives O
in O
neurocritical O
care O
as O
they O
allow O
for O
frequent O
neurologic O
examinations O
. O

however O
, O
both O
agents O
are O
associated O
with O
significant O
hemodynamic O
side O
effects O
. O

the O
primary O
objective O
of O
this O
study O
is O
to O
compare O
the O
prevalence O
of O
severe O
hemodynamic O
effects O
in O
neurocritical O
care O
patients O
receiving O
dexmedetomidine O
and O
propofol O
. O

design O
: O
multicenter O
, O
retrospective O
, O
propensity-matched O
cohort O
study O
. O

setting O
: O
neurocritical O
care O
units O
at O
two O
academic O
medical O
centers O
with O
dedicated O
neurocritical O
care O
teams O
and O
board-certified O
neurointensivists O
. O

patients O
: O
neurocritical O
care O
patients O
admitted O
between O
july O
2009 O
and O
september O
2012 O
were O
evaluated O
and O
then O
matched O
1:1 O
based O
on O
propensity O
scoring O
of O
baseline O
characteristics O
. O

interventions O
: O
continuous O
sedation O
with O
dexmedetomidine O
or O
propofol O
. O

measurements O
and O
main O
results O
: O
a O
total O
of O
342 O
patients O
( O
105 O
dexmedetomidine O
and O
237 O
propofol O
) O
were O
included O
in O
the O
analysis O
, O
with O
190 O
matched O
( O
95 O
in O
each O
group O
) O
by O
propensity O
score O
. O

the O
primary O
outcome O
of O
this O
study O
was O
a O
composite O
of O
severe O
hypotension B-NEG
( O
mean O
arterial O
pressure O
< O
60 O
mm O
hg O
) O
and O
bradycardia B-NEG
( O
heart O
rate O
< O
50 O
beats/min O
) O
during O
sedative O
infusion O
. O

no O
difference O
in O
the O
primary O
composite O
outcome O
in O
both O
the O
unmatched O
( O
30% O
vs O
30% O
, O
p O
= O
0.94 O
) O
or O
matched O
cohorts O
( O
28% O
vs O
34% O
, O
p O
= O
0.35 O
) O
could O
be O
found O
. O

when O
analyzed O
separately O
, O
no O
differences O
could O
be O
found O
in O
the O
prevalence O
of O
severe O
hypotension B-NEG
or O
bradycardia B-NEG
in O
either O
the O
unmatched O
or O
matched O
cohorts O
. O

conclusions O
: O
severe O
hypotension B-NEG
and O
bradycardia B-NEG
occur O
at O
similar O
prevalence O
in O
neurocritical O
care O
patients O
who O
receive O
dexmedetomidine O
or O
propofol O
. O

providers O
should O
similarly O
consider O
the O
likelihood O
of O
hypotension B-NEG
or O
bradycardia B-NEG
before O
starting O
either O
sedative O
. O

-DOCSTART- O

hydroxytyrosol O
ameliorates O
oxidative O
stress O
and O
mitochondrial B-NEG
dysfunction I-NEG
in O
doxorubicin-induced O
cardiotoxicity B-NEG
in O
rats O
with O
breast B-NEG
cancer I-NEG
. O

oxidative O
stress O
is O
involved O
in O
several O
processes O
including O
cancer B-NEG
, O
aging O
and O
cardiovascular B-NEG
disease I-NEG
, O
and O
has O
been O
shown O
to O
potentiate O
the O
therapeutic O
effect O
of O
drugs O
such O
as O
doxorubicin O
. O

doxorubicin O
causes O
significant O
cardiotoxicity B-NEG
characterized O
by O
marked O
increases O
in O
oxidative O
stress O
and O
mitochondrial B-NEG
dysfunction I-NEG
. O

herein O
, O
we O
investigate O
whether O
doxorubicin-associated O
chronic O
cardiac B-NEG
toxicity I-NEG
can O
be O
ameliorated O
with O
the O
antioxidant O
hydroxytyrosol O
in O
rats O
with O
breast B-NEG
cancer I-NEG
. O

thirty-six O
rats O
bearing O
breast B-NEG
tumors I-NEG
induced O
chemically O
were O
divided O
into O
4 O
groups O
: O
control O
, O
hydroxytyrosol O
(0.5mg/kg O
, O
5days/week) O
, O
doxorubicin O
(1mg/kg/week) O
, O
and O
doxorubicin O
plus O
hydroxytyrosol O
. O
cardiac B-NEG
disturbances I-NEG
at O
the O
cellular O
and O
mitochondrial O
level O
, O
mitochondrial O
electron O
transport O
chain O
complexes O
i-iv O
and O
apoptosis-inducing O
factor O
, O
and O
oxidative O
stress O
markers O
have O
been O
analyzed O
. O

hydroxytyrosol O
improved O
the O
cardiac B-NEG
disturbances I-NEG
enhanced O
by O
doxorubicin O
by O
significantly O
reducing O
the O
percentage O
of O
altered O
mitochondria O
and O
oxidative O
damage O
. O

these O
results O
suggest O
that O
hydroxytyrosol O
improve O
the O
mitochondrial O
electron O
transport O
chain O
. O

this O
study O
demonstrates O
that O
hydroxytyrosol O
protect O
rat O
heart B-NEG
damage I-NEG
provoked O
by O
doxorubicin O
decreasing O
oxidative O
damage O
and O
mitochondrial O
alterations O
. O

-DOCSTART- O

amiodarone-induced O
myxoedema B-NEG
coma I-NEG
. O

a O
62-year-old O
man O
was O
found O
to O
have O
bradycardia B-NEG
, O
hypothermia B-NEG
and O
respiratory B-NEG
failure I-NEG
3 O
weeks O
after O
initiation O
of O
amiodarone O
therapy O
for O
atrial B-NEG
fibrillation I-NEG
. O

thyroid-stimulating O
hormone O
was O
found O
to O
be O
168 O
uiu/ml O
(nl O
. O
0.3-5 O
uiu/ml O
) O
and O
free O
thyroxine O
( O
ft4 O
) O
was O
<0.2 O
ng/dl O
(nl O
. O
0.8-1.8 O
ng/dl) O
. O

he O
received O
intravenous O
fluids O
, O
vasopressor O
therapy O
and O
stress O
dose O
steroids O
; O
he O
was O
intubated O
and O
admitted O
to O
the O
intensive O
care O
unit O
. O

he O
received O
500 O
ug O
of O
intravenous O
levothyroxine O
in O
the O
first O
18 O
h O
of O
therapy O
, O
and O
150 O
ug O
intravenous O
daily O
thereafter O
. O

haemodynamic O
improvement O
, O
along O
with O
complete O
recovery O
of O
mental O
status O
, O
occurred O
after O
48 O
h. O

twelve O
hours O
after O
the O
initiation O
of O
therapy O
, O
ft4 O
was O
0.96 O
ng/dl O
. O

the O
patient O
was O
maintained O
on O
levothyroxine O
175 O
(g O
poorally O
daily O
. O
a O
thyroid O
ultrasound O
showed O
diffuse O
heterogeneity O
. O
the O
24 O
hour O
excretion O
of O
iodine O
was O
3657 O
( O
mcg O
( O
25-756 O
( O
mcg) O
. O

the O
only O
two O
cases O
of O
amiodarone-induced O
myxoedema B-NEG
coma I-NEG
in O
the O
literature O
report O
patient O
death O
despite O
supportive O
therapy O
and O
thyroid O
hormone O
replacement O
. O

this O
case O
represents O
the O
most O
thoroughly O
investigated O
case O
of O
amiodarone-induced O
myxoedema B-NEG
coma I-NEG
with O
a O
history O
significant O
for O
subclinical O
thyroid B-NEG
disease I-NEG
. O

-DOCSTART- O

use O
of O
argatroban O
and O
catheter-directed O
thrombolysis B-NEG
with O
alteplase O
in O
an O
oncology O
patient O
with O
heparin-induced O
thrombocytopenia B-NEG
with O
thrombosis B-NEG
. O

purpose O
: O
the O
case O
of O
an O
oncology O
patient O
who O
developed O
heparin-induced O
thrombocytopenia B-NEG
with O
thrombosis B-NEG
( O
hitt B-NEG
) O
and O
was O
treated O
with O
argatroban O
plus O
catheter-directed O
thrombolysis B-NEG
( O
cdt O
) O
with O
alteplase O
is O
presented O
. O

summary O
: O
a O
63-year-old O
caucasian O
man O
with O
renal O
amyloidosis B-NEG
undergoing O
peripheral O
blood O
stem O
cell O
collection O
for O
an O
autologous O
stem O
cell O
transplant O
developed O
extensive O
bilateral O
upper-extremity B-NEG
deep I-NEG
venous I-NEG
thrombosis I-NEG
( O
dvt B-NEG
) O
and O
pulmonary B-NEG
embolism I-NEG
secondary O
to O
heparin-induced O
thrombocytopenia B-NEG
. O

a O
continuous O
i.v O
. O
infusion O
of O
argatroban O
was O
initiated O
, O
and O
the O
patient O
was O
managed O
on O
the O
general O
medical O
floor O
. O

after O
one O
week O
of O
therapy O
, O
he O
was O
transferred O
to O
the O
intensive O
care O
unit O
with O
cardiopulmonary O
compromise O
related O
to O
superior B-NEG
vena I-NEG
cava I-NEG
( O
svc I-NEG
) O
syndrome I-NEG
. O

a O
percutaneous O
mechanical O
thrombectomy O
and O
cdt O
with O
alteplase O
were O
attempted O
, O
but O
the O
procedure O
was O
aborted O
due O
to O
epistaxis B-NEG
. O

the O
epistaxis B-NEG
resolved O
the O
next O
day O
, O
and O
the O
patient O
was O
restarted O
on O
argatroban O
. O

a O
second O
percutaneous O
mechanical O
thrombectomy O
was O
performed O
six O
days O
later O
and O
resulted O
in O
partial O
revascularization O
of O
the O
svc O
and O
central O
veins O
. O

postthrombectomy O
continuous O
cdt O
with O
alteplase O
was O
commenced O
while O
argatroban O
was O
withheld O
, O
and O
complete O
patency O
of O
the O
svc O
and O
central O
veins O
was O
achieved O
after O
three O
days O
of O
therapy O
. O

alteplase O
was O
discontinued O
, O
and O
the O
patient O
was O
reinitiated O
on O
argatroban O
; O
ultimately O
, O
he O
was O
transitioned O
to O
warfarin O
for O
long-term O
anticoagulation O
. O

although O
the O
patient O
recovered O
, O
he O
experienced O
permanent O
vision B-NEG
and I-NEG
hearing I-NEG
loss I-NEG
, O
as O
well O
as O
end-stage B-NEG
renal I-NEG
disease I-NEG
. O

conclusion O
: O
a O
63-year-old O
man O
with O
renal O
amyloidosis B-NEG
and O
svc B-NEG
syndrome I-NEG
secondary O
to O
hitt B-NEG
was O
successfully O
treated O
with O
argatroban O
and O
cdt O
with O
alteplase O
. O

-DOCSTART- O

effects O
of O
dehydroepiandrosterone O
in O
amphetamine-induced O
schizophrenia B-NEG
models O
in O
mice O
. O

objective O
: O
to O
examine O
the O
effects O
of O
dehydroepiandrosterone O
( O
dhea O
) O
on O
animal O
models O
of O
schizophrenia B-NEG
. O

methods O
: O
seventy O
swiss O
albino O
female O
mice O
( O
25-35 O
g) O
were O
divided O
into O
4 O
groups O
: O
amphetamine-free O
(control) O
, O
amphetamine O
, O
50 O
, O
and O
100 O
mg/kg O
dhea O
. O

the O
dhea O
was O
administered O
intraperitoneally O
( O
ip O
) O
for O
5 O
days O
. O

amphetamine O
(3 O
mg/kg O
ip O
) O
induced O
hyper B-NEG
locomotion O
, O
apomorphine O
( O
1.5 O
mg/kg O
subcutaneously O
[sc] O
) O
induced O
climbing O
, O
and O
haloperidol O
( O
1.5 O
mg/kg O
sc O
) O
induced O
catalepsy B-NEG
tests O
were O
used O
as O
animal O
models O
of O
schizophrenia B-NEG
. O

the O
study O
was O
conducted O
at O
the O
animal O
experiment O
laboratories O
, O
department O
of O
pharmacology O
, O
medical O
school O
, O
eskisehir O
osmangazi O
university O
, O
eskisehir O
, O
turkey O
between O
march O
and O
may O
2012 O
. O

statistical O
analysis O
was O
carried O
out O
using O
kruskal-wallis O
test O
for O
hyper B-NEG
locomotion O
, O
and O
one-way O
anova O
for O
climbing O
and O
catalepsy B-NEG
tests O
. O

results O
: O
in O
the O
amphetamine-induced O
locomotion O
test O
, O
there O
were O
significant O
increases O
in O
all O
movements O
compared O
with O
the O
amphetamine-free O
group O
. O

both O
dhea O
50 O
mg/kg O
(p<0.05) O
, O
and O
100 O
mg/kg O
( O
p<0.01 O
) O
significantly O
decreased O
all O
movements O
compared O
with O
the O
amphetamine-induced O
locomotion O
group O
. O

there O
was O
a O
significant O
difference O
between O
groups O
in O
the O
haloperidol-induced O
catalepsy B-NEG
test O
(p<0.05) O
. O

there O
was O
no O
significant O
difference O
between O
groups O
in O
terms O
of O
total O
climbing O
time O
in O
the O
apomorphine-induced O
climbing O
test O
(p>0.05) O
. O

conclusion O
: O
we O
observed O
that O
dhea O
reduced O
locomotor O
activity O
and O
increased O
catalepsy B-NEG
at O
both O
doses O
, O
while O
it O
had O
no O
effect O
on O
climbing O
behavior O
. O

we O
suggest O
that O
dhea O
displays O
typical O
neuroleptic-like O
effects O
, O
and O
may O
be O
used O
in O
the O
treatment O
of O
schizophrenia B-NEG
. O

-DOCSTART- O

availability O
of O
human O
induced O
pluripotent O
stem O
cell-derived O
cardiomyocytes O
in O
assessment O
of O
drug O
potential O
for O
qt B-NEG
prolongation I-NEG
. O

field O
potential O
duration O
( O
fpd O
) O
in O
human-induced O
pluripotent O
stem O
cell-derived O
cardiomyocytes O
(hips-cms) O
, O
which O
can O
express O
qt O
interval O
in O
an O
electrocardiogram O
, O
is O
reported O
to O
be O
a O
useful O
tool O
to O
predict O
k(+ O
) O
channel O
and O
ca(2+ O
) O
channel O
blocker O
effects O
on O
qt O
interval O
. O

however O
, O
there O
is O
no O
report O
showing O
that O
this O
technique O
can O
be O
used O
to O
predict O
multichannel O
blocker O
potential O
for O
qt B-NEG
prolongation I-NEG
. O

the O
aim O
of O
this O
study O
is O
to O
show O
that O
fpd O
from O
mea O
( O
multielectrode O
array O
) O
of O
hips-cms O
can O
detect O
qt B-NEG
prolongation I-NEG
induced O
by O
multichannel O
blockers O
. O

hips-cms O
were O
seeded O
onto O
mea O
and O
fpd O
was O
measured O
for O
2min O
every O
10min O
for O
30min O
after O
drug O
exposure O
for O
the O
vehicle O
and O
each O
drug O
concentration O
. O

ikr O
and O
iks O
blockers O
concentration-dependently O
prolonged O
corrected O
fpd O
(fpdc) O
, O
whereas O
ca(2+ O
) O
channel O
blockers O
concentration-dependently O
shortened O
fpdc O
. O

also O
, O
the O
multichannel O
blockers O
amiodarone O
, O
paroxetine O
, O
terfenadine O
and O
citalopram O
prolonged O
fpdc O
in O
a O
concentration O
dependent O
manner O
. O

finally O
, O
the O
ikr O
blockers O
, O
terfenadine O
and O
citalopram O
, O
which O
are O
reported O
to O
cause O
torsade B-NEG
de I-NEG
pointes I-NEG
( O
tdp B-NEG
) O
in O
clinical O
practice O
, O
produced O
early O
afterdepolarization O
(ead) O
. O

hips-cms O
using O
mea O
system O
and O
fpdc O
can O
predict O
the O
effects O
of O
drug O
candidates O
on O
qt O
interval O
. O

this O
study O
also O
shows O
that O
this O
assay O
can O
help O
detect O
ead O
for O
drugs O
with O
tdp B-NEG
potential O
. O

-DOCSTART- O

dermal O
developmental O
toxicity B-NEG
of O
n-phenylimide O
herbicides O
in O
rats O
. O

background O
: O
s-53482 O
and O
s-23121 O
are O
n-phenylimide O
herbicides O
and O
produced O
embryolethality B-NEG
, O
teratogenicity B-NEG
( O
mainly O
ventricular B-NEG
septal I-NEG
defects I-NEG
and O
wavy O
ribs) O
, O
and O
growth B-NEG
retardation I-NEG
in O
rats O
in O
conventional O
oral O
developmental O
toxicity B-NEG
studies O
. O

our O
objective O
in O
this O
study O
was O
to O
investigate O
whether O
the O
compounds O
induce O
developmental O
toxicity B-NEG
via O
the O
dermal O
route O
, O
which O
is O
more O
relevant O
to O
occupational O
exposure O
, O
hence O
better O
addressing O
human O
health O
risks O
. O

methods O
: O
s-53482 O
was O
administered O
dermally O
to O
rats O
at O
30 O
, O
100 O
, O
and O
300 O
mg/kg O
during O
organogenesis O
, O
and O
s-23121 O
was O
administered O
at O
200 O
, O
400 O
, O
and O
800 O
mg/kg O
( O
the O
maximum O
applicable O
dose O
level) O
. O

fetuses O
were O
obtained O
by O
a O
cesarean O
section O
and O
examined O
for O
external O
, O
visceral O
, O
and O
skeletal O
alterations O
. O

results O
: O
dermal O
exposure O
of O
rats O
to O
s-53482 O
at O
300 O
mg/kg O
produced O
patterns O
of O
developmental O
toxicity B-NEG
similar O
to O
those O
resulting O
from O
oral O
exposure O
. O
toxicity B-NEG
included O
embryolethality B-NEG
, O
teratogenicity B-NEG
, O
and O
growth B-NEG
retardation I-NEG
. O

dermal O
administration O
of O
s-23121 O
at O
800 O
mg/kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic B-NEG
death I-NEG
and O
ventricular B-NEG
septal I-NEG
defect I-NEG
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
s-23121 O
. O

conclusions O
: O
based O
on O
the O
results O
, O
s-53482 O
and O
s-23121 O
were O
teratogenic B-NEG
when O
administered O
dermally O
to O
pregnant O
rats O
as O
were O
the O
compounds O
administered O
orally O
. O

thus O
, O
investigation O
of O
the O
mechanism O
and O
its O
human O
relevancy O
become O
more O
important O
. O

-DOCSTART- O

rates O
of O
renal B-NEG
toxicity I-NEG
in O
cancer B-NEG
patients O
receiving O
cisplatin O
with O
and O
without O
mannitol O
. O

background O
: O
cisplatin O
is O
a O
widely O
used O
antineoplastic O
. O

one O
of O
the O
major O
complications O
of O
cisplatin O
use O
is O
dose-limiting O
nephrotoxicity B-NEG
. O

there O
are O
many O
strategies O
to O
prevent O
this O
toxicity B-NEG
, O
including O
the O
use O
of O
mannitol O
as O
a O
nephroprotectant O
in O
combination O
with O
hydration O
. O

objective O
: O
we O
aimed O
to O
evaluate O
the O
rates O
of O
cisplatin-induced O
nephrotoxicity B-NEG
in O
cancer B-NEG
patients O
receiving O
single-agent O
cisplatin O
with O
and O
without O
mannitol O
. O

methods O
: O
this O
single-center O
retrospective O
analysis O
was O
a O
quasi O
experiment O
created O
by O
the O
national O
mannitol O
shortage O
. O

data O
were O
collected O
on O
adult O
cancer B-NEG
patients O
receiving O
single-agent O
cisplatin O
as O
an O
outpatient O
from O
january O
2011 O
to O
september O
2012 O
. O

the O
primary O
outcome O
was O
acute B-NEG
kidney I-NEG
injury I-NEG
( O
aki B-NEG
). O

results O
: O
we O
evaluated O
143 O
patients O
who O
received O
single-agent O
cisplatin O
; O
97.2% O
of O
patients O
had O
head B-NEG
and I-NEG
neck I-NEG
cancer I-NEG
as O
their O
primary O
malignancy B-NEG
. O

patients O
who O
did O
not O
receive O
mannitol O
were O
more O
likely O
to O
develop O
nephrotoxicity B-NEG
: O
odds O
ratio O
[or] O
= O
2.646 O
( O
95% O
ci O
= O
1.008 O
, O
6.944 O
; O
p O
= O
0.048) O
. O

patients O
who O
received O
the O
100 O
mg/m(2 O
) O
dosing O
and O
patients O
who O
had O
a O
history O
of O
hypertension B-NEG
also O
had O
a O
higher O
likelihood O
of O
developing O
nephrotoxicity B-NEG
: O
or O
= O
11.494 O
( O
95% O
ci O
= O
4.149 O
, O
32.258 O
; O
p O
< O
0.0001 O
) O
and O
or O
= O
3.219 O
( O
95% O
ci O
= O
1.228 O
, O
8.439 O
; O
p O
= O
0.017) O
, O
respectively O
. O

conclusions O
: O
when O
limited O
quantities O
of O
mannitol O
are O
available O
, O
it O
should O
preferentially O
be O
given O
to O
patients O
at O
particularly O
high O
risk O
of O
nephrotoxicity B-NEG
. O

our O
analysis O
suggests O
that O
those O
patients O
receiving O
the O
dosing O
schedule O
of O
100 O
mg/m(2 O
) O
cisplatin O
every O
3 O
weeks O
and O
those O
with O
hypertension B-NEG
are O
at O
the O
greatest O
risk O
of O
nephrotoxicity B-NEG
and O
would O
benefit O
from O
the O
addition O
of O
mannitol O
. O

-DOCSTART- O

metformin O
protects O
against O
seizures B-NEG
, O
learning B-NEG
and I-NEG
memory I-NEG
impairments I-NEG
and O
oxidative O
damage O
induced O
by O
pentylenetetrazole-induced O
kindling O
in O
mice O
. O
cognitive B-NEG
impairment I-NEG
, O
the O
most O
common O
and O
severe O
comorbidity O
of O
epilepsy B-NEG
, O
greatly O
diminishes O
the O
quality O
of O
life O
. O

however O
, O
current O
therapeutic O
interventions O
for O
epilepsy B-NEG
can O
also O
cause O
untoward O
cognitive O
effects O
. O

thus O
, O
there O
is O
an O
urgent O
need O
for O
new O
kinds O
of O
agents O
targeting O
both O
seizures B-NEG
and O
cognition B-NEG
deficits I-NEG
. O

oxidative O
stress O
is O
considered O
to O
play O
an O
important O
role O
in O
epileptogenesis O
and O
cognitive B-NEG
deficits I-NEG
, O
and O
antioxidants O
have O
a O
putative O
antiepileptic O
potential O
. O

metformin O
, O
the O
most O
commonly O
prescribed O
antidiabetic O
oral O
drug O
, O
has O
antioxidant O
properties O
. O

this O
study O
was O
designed O
to O
evaluate O
the O
ameliorative O
effects O
of O
metformin O
on O
seizures B-NEG
, O
cognitive B-NEG
impairment I-NEG
and O
brain O
oxidative O
stress O
markers O
observed O
in O
pentylenetetrazole-induced O
kindling O
animals O
. O

male O
c57bl/6 O
mice O
were O
administered O
with O
subconvulsive O
dose O
of O
pentylenetetrazole O
( O
37 O
mg/kg O
, O
i.p. O
) O
every O
other O
day O
for O
14 O
injections O
. O

metformin O
was O
injected O
intraperitoneally O
in O
dose O
of O
200mg/kg O
along O
with O
alternate-day O
ptz O
. O

we O
found O
that O
metformin O
suppressed O
the O
progression O
of O
kindling O
, O
ameliorated O
the O
cognitive B-NEG
impairment I-NEG
and O
decreased O
brain O
oxidative O
stress O
. O

thus O
the O
present O
study O
concluded O
that O
metformin O
may O
be O
a O
potential O
agent O
for O
the O
treatment O
of O
epilepsy B-NEG
as O
well O
as O
a O
protective O
medicine O
against O
cognitive B-NEG
impairment I-NEG
induced O
by O
seizures B-NEG
. O

-DOCSTART- O

p53 O
inhibition O
exacerbates O
late-stage O
anthracycline O
cardiotoxicity B-NEG
. O

aims O
: O
doxorubicin O
( O
dox O
) O
is O
an O
effective O
anti- O
cancer B-NEG
therapeutic O
, O
but O
is O
associated O
with O
both O
acute O
and O
late-stage O
cardiotoxicity B-NEG
. O

children O
are O
particularly O
sensitive O
to O
dox-induced O
heart B-NEG
failure I-NEG
. O

here O
, O
the O
impact O
of O
p53 O
inhibition O
on O
acute O
vs O
. O
late-stage O
dox O
cardiotoxicity B-NEG
was O
examined O
in O
a O
juvenile O
model O
. O

methods O
and O
results O
: O
two-week-old O
mhc-cb7 O
mice O
( O
which O
express O
dominant-interfering O
p53 O
in O
cardiomyocytes O
) O
and O
their O
non-transgenic O
( O
non-txg O
) O
littermates O
received O
weekly O
dox O
injections O
for O
5 O
weeks O
( O
25 O
mg/kg O
cumulative O
dose) O
. O

one O
week O
after O
the O
last O
dox O
treatment O
( O
acute O
stage) O
, O
mhc-cb7 O
mice O
exhibited O
improved O
cardiac O
function O
and O
lower O
levels O
of O
cardiomyocyte O
apoptosis O
when O
compared O
with O
the O
non-txg O
mice O
. O

surprisingly O
, O
by O
13 O
weeks O
following O
the O
last O
dox O
treatment O
( O
late O
stage) O
, O
mhc-cb7 O
exhibited O
a O
progressive O
decrease O
in O
cardiac O
function O
and O
higher O
rates O
of O
cardiomyocyte O
apoptosis O
when O
compared O
with O
non-txg O
mice O
. O

p53 O
inhibition O
blocked O
transient O
dox-induced O
stat3 O
activation O
in O
mhc-cb7 O
mice O
, O
which O
was O
associated O
with O
enhanced O
induction O
of O
the O
dna O
repair O
proteins O
ku70 O
and O
ku80 O
. O

mice O
with O
cardiomyocyte-restricted O
deletion O
of O
stat3 O
exhibited O
worse O
cardiac O
function O
, O
higher O
levels O
of O
cardiomyocyte O
apoptosis O
, O
and O
a O
greater O
induction O
of O
ku70 O
and O
ku80 O
in O
response O
to O
dox O
treatment O
during O
the O
acute O
stage O
when O
compared O
with O
control O
animals O
. O

conclusion O
: O
these O
data O
support O
a O
model O
wherein O
a O
p53-dependent O
cardioprotective O
pathway O
, O
mediated O
via O
stat3 O
activation O
, O
mitigates O
dox-induced O
myocardial O
stress O
during O
drug O
delivery O
. O

furthermore O
, O
these O
data O
suggest O
an O
explanation O
as O
to O
how O
p53 O
inhibition O
can O
result O
in O
cardioprotection O
during O
drug O
treatment O
and O
, O
paradoxically O
, O
enhanced O
cardiotoxicity B-NEG
long O
after O
the O
cessation O
of O
drug O
treatment O
. O

-DOCSTART- O

metronidazole-induced O
encephalopathy B-NEG
: O
an O
uncommon O
scenario O
. O

metronidazole O
can O
produce O
neurological O
complications O
although O
it O
is O
not O
a O
common O
scenario O
. O

we O
present O
a O
case O
where O
a O
patient O
developed O
features O
of O
encephalopathy B-NEG
following O
prolonged O
metronidazole O
intake O
. O

magnetic O
resonance O
imaging O
( O
mri O
) O
brain O
showed O
abnormal O
signal O
intensity O
involving O
both O
dentate O
nuclei O
of O
cerebellum O
and O
splenium O
of O
corpus O
callosum O
. O

the O
diagnosis O
of O
metronidazole O
toxicity B-NEG
was O
made O
by O
the O
mri O
findings O
and O
supported O
clinically O
. O

-DOCSTART- O

aconitine-induced O
ca2+ O
overload O
causes O
arrhythmia B-NEG
and O
triggers O
apoptosis O
through O
p38 O
mapk O
signaling O
pathway O
in O
rats O
. O

aconitine O
is O
a O
major O
bioactive O
diterpenoid O
alkaloid O
with O
high O
content O
derived O
from O
herbal O
aconitum O
plants O
. O

emerging O
evidence O
indicates O
that O
voltage-dependent O
na(+ O
) O
channels O
have O
pivotal O
roles O
in O
the O
cardiotoxicity B-NEG
of O
aconitine O
. O

however O
, O
no O
reports O
are O
available O
on O
the O
role O
of O
ca(2+ O
) O
in O
aconitine O
poisoning B-NEG
. O

in O
this O
study O
, O
we O
explored O
the O
importance O
of O
pathological O
ca(2+ O
) O
signaling O
in O
aconitine O
poisoning B-NEG
in O
vitro O
and O
in O
vivo O
. O

we O
found O
that O
ca(2+ O
) O
overload O
lead O
to O
accelerated O
beating O
rhythm O
in O
adult O
rat O
ventricular O
myocytes O
and O
caused O
arrhythmia B-NEG
in O
conscious O
freely O
moving O
rats O
. O

to O
investigate O
effects O
of O
aconitine O
on O
myocardial B-NEG
injury I-NEG
, O
we O
performed O
cytotoxicity B-NEG
assay O
in O
neonatal O
rat O
ventricular O
myocytes O
(nrvms) O
, O
as O
well O
as O
measured O
lactate O
dehydrogenase O
level O
in O
the O
culture O
medium O
of O
nrvms O
and O
activities O
of O
serum O
cardiac O
enzymes O
in O
rats O
. O

the O
results O
showed O
that O
aconitine O
resulted O
in O
myocardial B-NEG
injury I-NEG
and O
reduced O
nrvms O
viability O
dose-dependently O
. O

to O
confirm O
the O
pro-apoptotic O
effects O
, O
we O
performed O
flow O
cytometric O
detection O
, O
cardiac O
histology O
, O
transmission O
electron O
microscopy O
and O
terminal O
deoxynucleotidyl O
transferase-mediated O
dutp-biotin O
nick O
end O
labeling O
assay O
. O

the O
results O
showed O
that O
aconitine O
stimulated O
apoptosis O
time-dependently O
. O

the O
expression O
analysis O
of O
ca(2+ O
) O
handling O
proteins O
demonstrated O
that O
aconitine O
promoted O
ca(2+ O
) O
overload O
through O
the O
expression O
regulation O
of O
ca(2+ O
) O
handling O
proteins O
. O

the O
expression O
analysis O
of O
apoptosis-related O
proteins O
revealed O
that O
pro-apoptotic O
protein O
expression O
was O
upregulated O
, O
and O
anti-apoptotic O
protein O
bcl-2 O
expression O
was O
downregulated O
. O

furthermore O
, O
increased O
phosphorylation O
of O
mapk O
family O
members O
, O
especially O
the O
p-p38/p38 O
ratio O
was O
found O
in O
cardiac O
tissues O
. O

hence O
, O
our O
results O
suggest O
that O
aconitine O
significantly O
aggravates O
ca(2+ O
) O
overload O
and O
causes O
arrhythmia B-NEG
and O
finally O
promotes O
apoptotic O
development O
via O
phosphorylation O
of O
p38 O
mitogen-activated O
protein O
kinase O
. O

-DOCSTART- O

chronic O
treatment O
with O
metformin O
suppresses O
toll-like O
receptor O
4 O
signaling O
and O
attenuates O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
following O
myocardial B-NEG
infarction I-NEG
. O

acute O
treatment O
with O
metformin O
has O
a O
protective O
effect O
in O
myocardial B-NEG
infarction I-NEG
by O
suppression O
of O
inflammatory O
responses O
due O
to O
activation O
of O
amp-activated O
protein O
kinase O
(ampk) O
. O

in O
the O
present O
study O
, O
the O
effect O
of O
chronic O
pre-treatment O
with O
metformin O
on O
cardiac B-NEG
dysfunction I-NEG
and O
toll-like O
receptor O
4 O
( O
tlr4 O
) O
activities O
following O
myocardial B-NEG
infarction I-NEG
and O
their O
relation O
with O
ampk O
were O
assessed O
. O

male O
wistar O
rats O
were O
randomly O
assigned O
to O
one O
of O
5 O
groups O
(n=6) O
: O
normal O
control O
and O
groups O
were O
injected O
isoproterenol O
after O
chronic O
pre-treatment O
with O
0, O
25 O
, O
50 O
, O
or O
100mg/kg O
of O
metformin O
twice O
daily O
for O
14 O
days O
. O

isoproterenol O
( O
100mg/kg O
) O
was O
injected O
subcutaneously O
on O
the O
13th O
and O
14th O
days O
to O
induce O
acute B-NEG
myocardial I-NEG
infarction I-NEG
. O

isoproterenol O
alone O
decreased O
left O
ventricular O
systolic O
pressure O
and O
myocardial O
contractility O
indexed O
as O
lvdp/dtmax O
and O
lvdp/dtmin O
. O

the O
left B-NEG
ventricular I-NEG
dysfunction I-NEG
was O
significantly O
lower O
in O
the O
groups O
treated O
with O
25 O
and O
50mg/kg O
of O
metformin O
. O

metfromin O
markedly O
lowered O
isoproterenol-induced O
elevation O
in O
the O
levels O
of O
tlr4 O
mrna O
, O
myeloid O
differentiation O
protein O
88 O
(myd88) O
, O
tumor B-NEG
necrosis B-NEG
factor-alpha O
(tnf-a) O
, O
and O
interleukin O
6 O
( O
il-6 O
) O
in O
the O
heart O
tissues O
. O

similar O
changes O
were O
also O
seen O
in O
the O
serum O
levels O
of O
tnf-a O
and O
il-6 O
. O

however O
, O
the O
lower O
doses O
of O
25 O
and O
50mg/kg O
were O
more O
effective O
than O
100mg/kg O
. O

phosphorylated O
ampka O
( O
p-ampk O
) O
in O
the O
myocardium O
was O
significantly O
elevated O
by O
25mg/kg O
of O
metformin O
, O
slightly O
by O
50mg/kg O
, O
but O
not O
by O
100mg/kg O
. O

chronic O
pre-treatment O
with O
metformin O
reduces O
post- O
myocardial B-NEG
infarction I-NEG
cardiac O
dysfunction O
and O
suppresses O
inflammatory O
responses O
, O
possibly O
through O
inhibition O
of O
tlr4 O
activities O
. O

this O
mechanism O
can O
be O
considered O
as O
a O
target O
to O
protect O
infarcted O
myocardium O
. O

-DOCSTART- O

neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
induced O
by O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
in O
a O
japanese O
patient O
with O
huntington's B-NEG
disease I-NEG
at O
the O
terminal O
stage O
of O
recurrent O
breast B-NEG
cancer I-NEG
. O

we O
herein O
describe O
the O
case O
of O
an O
81-year-old O
japanese O
woman O
with O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
that O
occurred O
36 O
days O
after O
the O
initiation O
of O
combination O
therapy O
with O
tiapride O
( O
75 O
mg/day O
) O
and O
tetrabenazine O
( O
12.5 O
mg/day O
) O
for O
huntington's B-NEG
disease I-NEG
. O

the O
patient O
had O
been O
treated O
with O
tiapride O
or O
tetrabenazine O
alone O
without O
any O
adverse O
effects O
before O
the O
administration O
of O
the O
combination O
therapy O
. O

she O
also O
had O
advanced O
breast B-NEG
cancer I-NEG
when O
the O
combination O
therapy O
was O
initiated O
. O

to O
the O
best O
of O
our O
knowledge O
, O
the O
occurrence O
of O
neuroleptic B-NEG
malignant I-NEG
syndrome I-NEG
due O
to O
combination O
therapy O
with O
tetrabenazine O
and O
tiapride O
has O
not O
been O
previously O
reported O
. O

tetrabenazine O
should O
be O
administered O
very O
carefully O
in O
combination O
with O
other O
neuroleptic O
drugs O
, O
particularly O
in O
patients O
with O
a O
worsening O
general O
condition O
. O

-DOCSTART- O

a O
metoprolol-terbinafine O
combination O
induced O
bradycardia B-NEG
. O

to O
report O
a O
sinus B-NEG
bradycardia I-NEG
induced O
by O
metoprolol O
and O
terbinafine O
drug-drug O
interaction O
and O
its O
management O
. O

a O
63 O
year-old O
caucasian O
man O
on O
metoprolol O
200 O
mg/day O
for O
stable O
coronary B-NEG
artery I-NEG
disease I-NEG
was O
prescribed O
a O
90-day O
course O
of O
oral O
terbinafine O
250 O
mg/day O
for O
onychomycosis B-NEG
. O

on O
the O
49th O
day O
of O
terbinafine O
therapy O
, O
he O
was O
brought O
to O
the O
emergency O
room O
for O
a O
decrease O
of O
his O
global O
health O
status O
, O
confusion B-NEG
and O
falls O
. O

the O
electrocardiogram O
revealed O
a O
37 O
beats/min O
sinus B-NEG
bradycardia I-NEG
. O

a O
score O
of O
7 O
on O
the O
naranjo O
adverse B-NEG
drug I-NEG
reaction I-NEG
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
patient's O
sinus B-NEG
bradycardia I-NEG
and O
the O
drug O
interaction O
between O
metoprolol O
and O
terbinafine O
. O

the O
heart O
rate O
ameliorated O
first O
with O
a O
decrease O
in O
the O
dose O
of O
metoprolol O
. O

it O
was O
subsequently O
changed O
to O
bisoprolol O
and O
the O
heart O
rate O
remained O
normal O
. O

by O
inhibiting O
the O
cytochrome O
p450 O
2d6 O
, O
terbinafine O
had O
decreased O
metoprolol's O
clearance O
, O
leading O
in O
metoprolol O
accumulation O
which O
has O
resulted O
in O
clinically O
significant O
sinus B-NEG
bradycardia I-NEG
. O

-DOCSTART- O

optochiasmatic O
and O
peripheral B-NEG
neuropathy I-NEG
due O
to O
ethambutol O
overtreatment O
. O

ethambutol O
is O
known O
to O
cause O
optic B-NEG
neuropathy I-NEG
and O
, O
more O
rarely O
, O
axonal O
polyneuropathy B-NEG
. O

we O
characterize O
the O
clinical O
, O
neurophysiological O
, O
and O
neuroimaging O
findings O
in O
a O
72-year-old O
man O
who O
developed O
visual B-NEG
loss I-NEG
and O
paresthesias B-NEG
after O
11 O
weeks O
of O
exposure O
to O
a O
supratherapeutic O
dose O
of O
ethambutol O
. O

this O
case O
demonstrates O
the O
selective O
vulnerability O
of O
the O
anterior O
visual O
pathways O
and O
peripheral O
nerves O
to O
ethambutol O
toxicity B-NEG
. O

-DOCSTART- O

testosterone O
ameliorates O
streptozotocin-induced O
memory B-NEG
impairment I-NEG
in O
male O
rats O
. O

aim O
: O
to O
study O
the O
effects O
of O
testosterone O
on O
streptozotocin O
( O
stz)-induced O
memory B-NEG
impairment I-NEG
in O
male O
rats O
. O

methods O
: O
adult O
male O
wistar O
rats O
were O
intracerebroventricularly O
( O
icv O
) O
infused O
with O
stz O
( O
750 O
ug O
) O
on O
d O
1 O
and O
d O
3, O
and O
a O
passive O
avoidance O
task O
was O
assessed O
2 O
weeks O
after O
the O
first O
injection O
of O
stz O
. O

castration O
surgery O
was O
performed O
in O
another O
group O
of O
rats O
, O
and O
the O
passive O
avoidance O
task O
was O
assessed O
4 O
weeks O
after O
the O
operation O
. O

testosterone O
(1 O
mg.kg(-1).d(-1) O
, O
sc) O
, O
the O
androgen O
receptor O
antagonist O
flutamide O
( O
10 O
mg.kg(-1).d(-1) O
, O
ip) O
, O
the O
estrogen O
receptor O
antagonist O
tamoxifen O
(1 O
mg.kg(-1).d(-1) O
, O
ip O
) O
or O
the O
aromatase O
inhibitor O
letrozole O
(4 O
mg.kg(-1).d(-1) O
, O
ip O
) O
were O
administered O
for O
6 O
d O
after O
the O
first O
injection O
of O
stz O
. O

results O
: O
stz O
administration O
and O
castration O
markedly O
decreased O
both O
stl1 O
( O
the O
short O
memory O
) O
and O
stl2 O
( O
the O
long O
memory O
) O
in O
passive O
avoidance O
tests O
. O

testosterone O
replacement O
almost O
restored O
the O
stl1 O
and O
stl2 O
in O
castrated O
rats O
, O
and O
significantly O
prolonged O
the O
stl1 O
and O
stl2 O
in O
stz-treated O
rats O
. O

administration O
of O
flutamide O
, O
letrozole O
or O
tamoxifen O
significantly O
impaired B-NEG
the I-NEG
memory I-NEG
in O
intact O
rats O
, O
and O
significantly O
attenuated O
the O
testosterone O
replacement O
in O
improving O
stz- O
and O
castration-induced O
memory B-NEG
impairment I-NEG
. O

conclusion O
: O
testosterone O
administration O
ameliorates O
stz- O
and O
castration-induced O
memory B-NEG
impairment I-NEG
in O
male O
wistar O
rats O
. O

-DOCSTART- O

behavioral O
and O
neurochemical O
studies O
in O
mice O
pretreated O
with O
garcinielliptone O
fc O
in O
pilocarpine-induced O
seizures B-NEG
. O

garcinielliptone O
fc O
( O
gfc O
) O
isolated O
from O
hexanic O
fraction O
seed O
extract O
of O
species O
platonia O
insignis O
mart O
. O

it O
is O
widely O
used O
in O
folk O
medicine O
to O
treat O
skin B-NEG
diseases I-NEG
in O
both O
humans O
and O
animals O
as O
well O
as O
the O
seed O
decoction O
has O
been O
used O
to O
treat O
diarrheas B-NEG
and O
inflammatory B-NEG
diseases I-NEG
. O

however O
, O
there O
is O
no O
research O
on O
gfc O
effects O
in O
the O
central O
nervous O
system O
of O
rodents O
. O

the O
present O
study O
aimed O
to O
evaluate O
the O
gfc O
effects O
at O
doses O
of O
25 O
, O
50 O
or O
75 O
mg/kg O
on O
seizure B-NEG
parameters O
to O
determine O
their O
anticonvulsant O
activity O
and O
its O
effects O
on O
amino O
acid O
( O
r-aminobutyric O
acid O
(gaba) O
, O
glutamine O
, O
aspartate O
and O
glutathione O
) O
levels O
as O
well O
as O
on O
acetylcholinesterase O
( O
ache O
) O
activity O
in O
mice O
hippocampus O
after O
seizures B-NEG
. O

gfc O
produced O
an O
increased O
latency O
to O
first O
seizure B-NEG
, O
at O
doses O
25mg/kg O
( O
20.12 O
+ O
2.20 O
min) O
, O
50mg/kg O
( O
20.95 O
+ O
2.21 O
min O
) O
or O
75 O
mg/kg O
( O
23.43 O
+ O
1.99 O
min O
) O
when O
compared O
with O
seized O
mice O
. O

in O
addition O
, O
gaba O
content O
of O
mice O
hippocampus O
treated O
with O
gfc75 O
plus O
p400 O
showed O
an O
increase O
of O
46.90% O
when O
compared O
with O
seized O
mice O
. O

in O
aspartate O
, O
glutamine O
and O
glutamate O
levels O
detected O
a O
decrease O
of O
5.21% O
, O
13.55% O
and O
21.80% O
, O
respectively O
in O
mice O
hippocampus O
treated O
with O
gfc75 O
plus O
p400 O
when O
compared O
with O
seized O
mice O
. O

hippocampus O
mice O
treated O
with O
gfc75 O
plus O
p400 O
showed O
an O
increase O
in O
ache O
activity O
( O
63.30% O
) O
when O
compared O
with O
seized O
mice O
. O

the O
results O
indicate O
that O
gfc O
can O
exert O
anticonvulsant O
activity O
and O
reduce O
the O
frequency O
of O
installation O
of O
pilocarpine-induced O
status B-NEG
epilepticus I-NEG
, O
as O
demonstrated O
by O
increase O
in O
latency O
to O
first O
seizure B-NEG
and O
decrease O
in O
mortality O
rate O
of O
animals O
. O

in O
conclusion O
, O
our O
data O
suggest O
that O
gfc O
may O
influence O
in O
epileptogenesis O
and O
promote O
anticonvulsant O
actions O
in O
pilocarpine O
model O
by O
modulating O
the O
gaba O
and O
glutamate O
contents O
and O
of O
ache O
activity O
in O
seized O
mice O
hippocampus O
. O

this O
compound O
may O
be O
useful O
to O
produce O
neuronal O
protection O
and O
it O
can O
be O
considered O
as O
an O
anticonvulsant O
agent O
. O

-DOCSTART- O

standard O
operating O
procedures O
for O
antibiotic O
therapy O
and O
the O
occurrence O
of O
acute B-NEG
kidney I-NEG
injury I-NEG
: O
a O
prospective O
, O
clinical O
, O
non-interventional O
, O
observational O
study O
. O

introduction O
: O
acute B-NEG
kidney I-NEG
injury I-NEG
( O
aki B-NEG
) O
occurs O
in O
7% O
of O
hospitalized O
and O
66% O
of O
intensive O
care O
unit O
( O
icu O
) O
patients O
. O

it O
increases O
mortality O
, O
hospital O
length O
of O
stay O
, O
and O
costs O
. O

the O
aim O
of O
this O
study O
was O
to O
investigate O
, O
whether O
there O
is O
an O
association O
between O
adherence O
to O
guidelines O
( O
standard O
operating O
procedures O
( O
sop) O
) O
for O
potentially O
nephrotoxic B-NEG
antibiotics O
and O
the O
occurrence O
of O
aki B-NEG
. O

methods O
: O
this O
study O
was O
carried O
out O
as O
a O
prospective O
, O
clinical O
, O
non-interventional O
, O
observational O
study O
. O

data O
collection O
was O
performed O
over O
a O
total O
of O
170 O
days O
in O
three O
icus O
at O
charite O
- O
universitaetsmedizin O
berlin O
. O

a O
total O
of O
675 O
patients O
were O
included O
; O
163 O
of O
these O
had O
therapy O
with O
vancomycin O
, O
gentamicin O
, O
or O
tobramycin O
; O
were O
>18 O
years O
; O
and O
treated O
in O
the O
icu O
for O
>24 O
hours O
. O

patients O
with O
an O
adherence O
to O
sop O
>70% O
were O
classified O
into O
the O
high O
adherence O
group O
( O
hag O
) O
and O
patients O
with O
an O
adherence O
of O
<70% O
into O
the O
low O
adherence O
group O
(lag) O
. O
aki B-NEG
was O
defined O
according O
to O
rifle O
criteria O
. O

adherence O
to O
sops O
was O
evaluated O
by O
retrospective O
expert O
audit O
. O

development O
of O
aki B-NEG
was O
compared O
between O
groups O
with O
exact O
chi2-test O
and O
multivariate O
logistic O
regression O
analysis O
( O
two-sided O
p O
<0.05) O
. O

results O
: O
lag O
consisted O
of O
75 O
patients O
( O
46% O
) O
versus O
88 O
hag O
patients O
(54%) O
. O
aki B-NEG
occurred O
significantly O
more O
often O
in O
lag O
with O
36% O
versus O
21% O
in O
hag O
(p O
= O
0.035) O
. O

basic O
characteristics O
were O
comparable O
, O
except O
an O
increased O
rate O
of O
soft O
tissue O
infections B-NEG
in O
lag O
. O

multivariate O
analysis O
revealed O
an O
odds O
ratio O
of O
2.5-fold O
for O
lag O
to O
develop O
aki B-NEG
compared O
with O
hag O
( O
95% O
confidence O
interval O
1.195 O
to O
5.124 O
, O
p O
= O
0.039) O
. O

conclusion O
: O
low O
adherence O
to O
sops O
for O
potentially O
nephrotoxic B-NEG
antibiotics O
was O
associated O
with O
a O
higher O
occurrence O
of O
aki B-NEG
. O

trial O
registration O
: O
current O
controlled O
trials O
isrctn54598675 O
. O

registered O
17 O
august O
2007 O
. O

-DOCSTART- O

rhabdomyolysis B-NEG
in O
a O
hepatitis B-NEG
c I-NEG
virus I-NEG
infected I-NEG
patient O
treated O
with O
telaprevir O
and O
simvastatin O
. O

a O
46-year O
old O
man O
with O
a O
chronic O
hepatitis B-NEG
c I-NEG
virus I-NEG
infection I-NEG
received O
triple O
therapy O
with O
ribavirin O
, O
pegylated O
interferon O
and O
telaprevir O
. O

the O
patient O
also O
received O
simvastatin O
. O

one O
month O
after O
starting O
the O
antiviral O
therapy O
, O
the O
patient O
was O
admitted O
to O
the O
hospital O
because O
he O
developed O
rhabdomyolysis B-NEG
. O

at O
admission O
simvastatin O
and O
all O
antiviral O
drugs O
were O
discontinued O
because O
toxicity B-NEG
due O
to O
a O
drug-drug O
interaction O
was O
suspected O
. O

the O
creatine O
kinase O
peaked O
at O
62,246 O
iu/l O
and O
the O
patient O
was O
treated O
with O
intravenous O
normal O
saline O
. O

the O
patient's O
renal O
function O
remained O
unaffected O
. O

fourteen O
days O
after O
hospitalization O
, O
creatine O
kinase O
level O
had O
returned O
to O
230 O
iu/l O
and O
the O
patient O
was O
discharged O
. O

telaprevir O
was O
considered O
the O
probable O
causative O
agent O
of O
an O
interaction O
with O
simvastatin O
according O
to O
the O
drug O
interaction O
probability O
scale O
. O

the O
interaction O
is O
due O
to O
inhibition O
of O
cyp3a4-mediated O
simvastatin O
clearance O
. O

simvastatin O
plasma O
concentration O
increased O
30 O
times O
in O
this O
patient O
and O
statin O
induced O
muscle B-NEG
toxicity I-NEG
is O
related O
to O
the O
concentration O
of O
the O
statin O
in O
blood O
. O

in O
conclusion O
, O
with O
this O
case O
we O
illustrate O
that O
telaprevir O
as O
well O
as O
statins O
are O
susceptible O
to O
clinical O
relevant O
drug-drug O
interactions O
. O

-DOCSTART- O

combination O
of O
bortezomib O
, O
thalidomide O
, O
and O
dexamethasone O
( O
vtd O
) O
as O
a O
consolidation O
therapy O
after O
autologous O
stem O
cell O
transplantation O
for O
symptomatic O
multiple B-NEG
myeloma I-NEG
in O
japanese O
patients O
. O

consolidation O
therapy O
for O
patients O
with O
multiple B-NEG
myeloma I-NEG
( O
mm B-NEG
) O
has O
been O
widely O
adopted O
to O
improve O
treatment O
response O
following O
autologous O
stem O
cell O
transplantation O
. O

in O
this O
study O
, O
we O
retrospectively O
analyzed O
the O
safety O
and O
efficacy O
of O
combination O
regimen O
of O
bortezomib O
, O
thalidomide O
, O
and O
dexamethasone O
( O
vtd O
) O
as O
consolidation O
therapy O
in O
24 O
japanese O
patients O
with O
newly O
diagnosed O
mm B-NEG
. O

vtd O
consisted O
of O
bortezomib O
at O
a O
dose O
of O
1.3 O
mg/m(2 O
) O
and O
dexamethasone O
at O
a O
dose O
of O
40 O
mg/day O
on O
days O
1, O
8, O
15 O
, O
and O
22 O
of O
a O
35-day O
cycle O
, O
with O
daily O
oral O
thalidomide O
at O
a O
dose O
of O
100 O
mg/day O
. O

grade O
3-4 O
neutropenia B-NEG
and O
thrombocytopenia B-NEG
were O
documented O
in O
four O
and O
three O
patients O
( O
17 O
and O
13 O
%) O
, O
respectively O
, O
but O
drug O
dose O
reduction O
due O
to O
cytopenia B-NEG
was O
not O
required O
in O
any O
case O
. O
peripheral B-NEG
neuropathy I-NEG
was O
common O
( O
63 O
%) O
, O
but O
severe O
grade O
3-4 O
peripheral B-NEG
neuropathy I-NEG
was O
not O
observed O
. O

very O
good O
partial O
response O
or O
better O
response O
( O
>vgpr O
) O
rates O
before O
and O
after O
consolidation O
therapy O
were O
54 O
and O
79 O
%, O
respectively O
. O

patients O
had O
a O
significant O
probability O
of O
improving O
from O
<vgpr O
before O
consolidation O
therapy O
to O
>vgpr O
after O
consolidation O
therapy O
(p O
= O
0.041) O
. O

the O
vtd O
regimen O
may O
be O
safe O
and O
effective O
as O
a O
consolidation O
therapy O
in O
the O
treatment O
of O
mm O
in O
japanese O
population O
. O

-DOCSTART- O

conversion O
to O
sirolimus O
ameliorates O
cyclosporine-induced O
nephropathy B-NEG
in O
the O
rat O
: O
focus O
on O
serum O
, O
urine O
, O
gene O
, O
and O
protein O
renal O
expression O
biomarkers O
. O

protocols O
of O
conversion O
from O
cyclosporin O
a O
( O
csa O
) O
to O
sirolimus O
( O
srl O
) O
have O
been O
widely O
used O
in O
immunotherapy O
after O
transplantation O
to O
prevent O
csa-induced O
nephropathy B-NEG
, O
but O
the O
molecular O
mechanisms O
underlying O
these O
protocols O
remain O
nuclear O
. O

this O
study O
aimed O
to O
identify O
the O
molecular O
pathways O
and O
putative O
biomarkers O
of O
csa-to-srl O
conversion O
in O
a O
rat O
model O
. O

four O
animal O
groups O
(n O
= O
6) O
were O
tested O
during O
9 O
weeks O
: O
control O
, O
csa O
, O
srl O
, O
and O
conversion O
( O
csa O
for O
3 O
weeks O
followed O
by O
srl O
for O
6 O
weeks) O
. O

classical O
and O
emergent O
serum O
, O
urinary O
, O
and O
kidney O
tissue O
( O
gene O
and O
protein O
expression O
) O
markers O
were O
assessed O
. O
renal B-NEG
lesions I-NEG
were O
analyzed O
in O
hematoxylin O
and O
eosin O
, O
periodic O
acid-schiff O
, O
and O
masson's O
trichrome O
stains O
. O

srl-treated O
rats O
presented O
proteinuria B-NEG
and O
ngal O
( O
serum O
and O
urinary O
) O
as O
the O
best O
markers O
of O
renal B-NEG
impairment I-NEG
. O

short O
csa O
treatment O
presented O
slight O
or O
even O
absent O
kidney B-NEG
lesions I-NEG
and O
tgf-b O
, O
nf- O
kb O
, O
mtor O
, O
pcna O
, O
tp53 O
, O
kim-1 O
, O
and O
ctgf O
as O
relevant O
gene O
and O
protein O
changes O
. O

prolonged O
csa O
exposure O
aggravated O
renal B-NEG
damage I-NEG
, O
without O
clear O
changes O
on O
the O
traditional O
markers O
, O
but O
with O
changes O
in O
serums O
tgf- O
b O
and O
il-7 O
, O
tbars O
clearance O
, O
and O
kidney O
tgf-b O
and O
mtor O
. O

conversion O
to O
srl O
prevented O
csa-induced O
renal B-NEG
damage I-NEG
evolution O
( O
absent/mild O
grade O
lesions) O
, O
while O
ngal O
( O
serum O
versus O
urine O
) O
seems O
to O
be O
a O
feasible O
biomarker O
of O
csa O
replacement O
to O
srl O
. O

-DOCSTART- O

kinin O
b2 O
receptor O
deletion O
and O
blockage O
ameliorates O
cisplatin-induced O
acute B-NEG
renal I-NEG
injury I-NEG
. O

cisplatin O
treatment O
has O
been O
adopted O
in O
some O
chemotherapies O
; O
however O
, O
this O
drug O
can O
induce O
acute B-NEG
kidney I-NEG
injury I-NEG
due O
its O
ability O
to O
negatively O
affect O
renal O
function O
, O
augment O
serum O
levels O
of O
creatinine O
and O
urea O
, O
increase O
the O
acute B-NEG
tubular I-NEG
necrosis I-NEG
score O
and O
up-regulate O
cytokines O
(e.g. O
, O
il-1b O
and O
tnf-a) O
. O

the O
kinin O
b2 O
receptor O
has O
been O
associated O
with O
the O
inflammation B-NEG
process O
, O
as O
well O
as O
the O
regulation O
of O
cytokine O
expression O
, O
and O
its O
deletion O
resulted O
in O
an O
improvement O
in O
the O
diabetic B-NEG
nephropathy I-NEG
status O
. O

to O
examine O
the O
role O
of O
the O
kinin O
b2 O
receptor O
in O
cisplatin-induced O
acute B-NEG
kidney I-NEG
injury I-NEG
, O
kinin O
b2 O
receptor O
knockout O
mice O
were O
challenged O
with O
cisplatin O
. O

additionally O
, O
wt O
mice O
were O
treated O
with O
a O
b2 O
receptor O
antagonist O
after O
cisplatin O
administration O
. O

b2 O
receptor-deficient O
mice O
were O
less O
sensitive O
to O
this O
drug O
than O
the O
wt O
mice O
, O
as O
shown O
by O
reduced O
weight B-NEG
loss I-NEG
, O
better O
preservation O
of O
kidney O
function O
, O
down O
regulation O
of O
inflammatory O
cytokines O
and O
less O
acute B-NEG
tubular I-NEG
necrosis I-NEG
. O

moreover O
, O
treatment O
with O
the O
kinin O
b2 O
receptor O
antagonist O
effectively O
reduced O
the O
levels O
of O
serum O
creatinine O
and O
blood O
urea O
after O
cisplatin O
administration O
. O

thus O
, O
our O
data O
suggest O
that O
the O
kinin O
b2 O
receptor O
is O
involved O
in O
cisplatin-induced O
acute B-NEG
kidney I-NEG
injury I-NEG
by O
mediating O
the O
necrotic B-NEG
process O
and O
the O
expression O
of O
inflammatory O
cytokines O
, O
thus O
resulting O
in O
declined O
renal O
function O
. O

these O
results O
highlight O
the O
kinin O
b2 O
receptor O
antagonist O
treatment O
in O
amelioration O
of O
nephrotoxicity B-NEG
induced O
by O
cisplatin O
therapy O
. O

-DOCSTART- O

safety O
and O
efficacy O
of O
fluocinolone O
acetonide O
intravitreal O
implant O
( O
0.59 O
mg O
) O
in O
birdshot B-NEG
retinochoroidopathy I-NEG
. O

purpose O
: O
to O
report O
the O
treatment O
outcomes O
of O
the O
fluocinolone O
acetonide O
intravitreal O
implant O
( O
0.59 O
mg O
) O
in O
patients O
with O
birdshot B-NEG
retinochoroidopathy I-NEG
whose O
disease O
is O
refractory O
or O
intolerant O
to O
conventional O
immunomodulatory O
therapy O
. O

methods O
: O
a O
retrospective O
case O
series O
involving O
11 O
birdshot B-NEG
retinochoroidopathy I-NEG
patients O
( O
11 O
eyes) O
. O

eleven O
patients O
( O
11 O
eyes O
) O
underwent O
surgery O
for O
fluocinolone O
acetonide O
implant O
( O
0.59 O
mg) O
. O

treatment O
outcomes O
of O
interest O
were O
noted O
at O
baseline O
, O
before O
fluocinolone O
acetonide O
implant O
, O
and O
then O
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
3 O
years O
, O
and O
beyond O
3 O
years O
. O

disease O
activity O
markers O
, O
including O
signs O
of O
ocular O
inflammation B-NEG
, O
evidence O
of O
retinal B-NEG
vasculitis I-NEG
, O
swedish O
interactive O
threshold O
algorithm-short O
wavelength O
automated O
perimetry O
humphrey O
visual O
field O
analysis O
, O
electroretinographic O
parameters O
, O
and O
optical O
coherence O
tomography O
were O
recorded O
. O

data O
on O
occurrence O
of O
cataract B-NEG
and O
raised B-NEG
intraocular I-NEG
pressure I-NEG
were O
collected O
in O
all O
eyes O
. O

results O
: O
intraocular O
inflammation B-NEG
was O
present O
in O
54.5 O
, O
9.9 O
, O
11.1 O
, O
and O
0% O
of O
patients O
at O
baseline O
, O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
3 O
years O
, O
and O
beyond O
3 O
years O
after O
receiving O
the O
implant O
, O
respectively O
. O

active O
vasculitis B-NEG
was O
noted O
in O
36.3% O
patients O
at O
baseline O
and O
0% O
at O
3 O
years O
of O
follow-up O
. O

more O
than O
20% O
( O
47.61-67.2% O
) O
reduction O
in O
central O
retinal O
thickness O
was O
noted O
in O
all O
patients O
with O
cystoid B-NEG
macular I-NEG
edema I-NEG
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
and O
3 O
years O
postimplant O
. O

at O
baseline O
, O
54.5% O
patients O
were O
on O
immunomodulatory O
agents O
. O

this O
percentage O
decreased O
to O
45.45 O
, O
44.4 O
, O
and O
14.28% O
at O
1 O
year O
, O
2 O
years O
, O
and O
3 O
years O
postimplant O
, O
respectively O
. O

adverse O
events O
included O
increased B-NEG
intraocular I-NEG
pressure I-NEG
( O
54.5% O
) O
and O
cataract B-NEG
formation O
(100%) O
. O

conclusion O
: O
the O
data O
suggest O
that O
fluocinolone O
acetonide O
implant O
( O
0.59 O
mg O
) O
helps O
to O
control O
inflammation B-NEG
in O
otherwise O
treatment-refractory O
cases O
of O
birdshot B-NEG
retinochoroidopathy I-NEG
. O

it O
is O
associated O
with O
significant O
side O
effects O
of O
cataract B-NEG
and O
ocular B-NEG
hypertension I-NEG
requiring O
treatment O
. O

-DOCSTART- O

optimal O
precurarizing O
dose O
of O
rocuronium O
to O
decrease O
fasciculation B-NEG
and O
myalgia B-NEG
following O
succinylcholine O
administration O
. O

background O
: O
succinylcholine O
commonly O
produces O
frequent O
adverse O
effects O
, O
including O
muscle B-NEG
fasciculation I-NEG
and O
myalgia B-NEG
. O

the O
current O
study O
identified O
the O
optimal O
dose O
of O
rocuronium O
to O
prevent O
succinylcholine-induced O
fasciculation B-NEG
and O
myalgia B-NEG
and O
evaluated O
the O
influence O
of O
rocuronium O
on O
the O
speed O
of O
onset O
produced O
by O
succinylcholine O
. O

methods O
: O
this O
randomized O
, O
double-blinded O
study O
was O
conducted O
in O
100 O
patients O
randomly O
allocated O
into O
five O
groups O
of O
20 O
patients O
each O
. O

patients O
were O
randomized O
to O
receive O
0.02 O
, O
0.03 O
, O
0.04 O
, O
0.05 O
and O
0.06 O
mg/kg O
rocuronium O
as O
a O
precurarizing O
dose O
. O

neuromuscular O
monitoring O
after O
each O
precurarizing O
dose O
was O
recorded O
from O
the O
adductor O
pollicis O
muscle O
using O
acceleromyography O
with O
train-of-four O
stimulation O
of O
the O
ulnar O
nerve O
. O

all O
patients O
received O
succinylcholine O
1.5 O
mg/kg O
at O
2 O
minutes O
after O
the O
precurarization O
, O
and O
were O
assessed O
the O
incidence O
and O
severity O
of O
fasciculations B-NEG
, O
while O
myalgia B-NEG
was O
assessed O
at O
24 O
hours O
after O
surgery O
. O

results O
: O
the O
incidence O
and O
severity O
of O
visible O
muscle B-NEG
fasciculation I-NEG
was O
significantly O
less O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
(p O
< O
0.001) O
. O

those O
of O
myalgia B-NEG
tend O
to O
decrease O
according O
to O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
, O
but O
there O
was O
no O
significance O
(p O
= O
0.072) O
. O

the O
onset O
time O
of O
succinylcholine O
was O
significantly O
longer O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium O
(p O
< O
0.001) O
. O

conclusions O
: O
precurarization O
with O
0.04 O
mg/kg O
rocuronium O
was O
the O
optimal O
dose O
considering O
the O
reduction O
in O
the O
incidence O
and O
severity O
of O
fasciculation B-NEG
and O
myalgia B-NEG
with O
acceptable O
onset O
time O
, O
and O
the O
safe O
and O
effective O
precurarization O
. O

-DOCSTART- O

absence O
of O
pkc-alpha O
attenuates O
lithium-induced O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
. O

lithium O
, O
an O
effective O
antipsychotic O
, O
induces O
nephrogenic B-NEG
diabetes I-NEG
insipidus I-NEG
( O
ndi B-NEG
) O
in O
40% O
of O
patients O
. O

the O
decreased O
capacity O
to O
concentrate O
urine O
is O
likely O
due O
to O
lithium O
acutely O
disrupting O
the O
camp O
pathway O
and O
chronically O
reducing O
urea O
transporter O
( O
ut-a1 O
) O
and O
water O
channel O
( O
aqp2 O
) O
expression O
in O
the O
inner O
medulla O
. O

targeting O
an O
alternative O
signaling O
pathway O
, O
such O
as O
pkc-mediated O
signaling O
, O
may O
be O
an O
effective O
method O
of O
treating O
lithium-induced O
polyuria B-NEG
. O

pkc-alpha O
null O
mice O
( O
pkca O
ko O
) O
and O
strain-matched O
wild O
type O
( O
wt O
) O
controls O
were O
treated O
with O
lithium O
for O
0, O
3 O
or O
5 O
days O
. O

wt O
mice O
had O
increased O
urine O
output O
and O
lowered O
urine O
osmolality O
after O
3 O
and O
5 O
days O
of O
treatment O
whereas O
pkca O
ko O
mice O
had O
no O
change O
in O
urine O
output O
or O
concentration O
. O

western O
blot O
analysis O
revealed O
that O
aqp2 O
expression O
in O
medullary O
tissues O
was O
lowered O
after O
3 O
and O
5 O
days O
in O
wt O
mice O
; O
however O
, O
aqp2 O
was O
unchanged O
in O
pkca O
ko O
. O

similar O
results O
were O
observed O
with O
ut-a1 O
expression O
. O

animals O
were O
also O
treated O
with O
lithium O
for O
6 O
weeks O
. O

lithium-treated O
wt O
mice O
had O
19-fold O
increased O
urine O
output O
whereas O
treated O
pkca O
ko O
animals O
had O
a O
4-fold O
increase O
in O
output O
. O

aqp2 O
and O
ut-a1 O
expression O
was O
lowered O
in O
6 O
week O
lithium-treated O
wt O
animals O
whereas O
in O
treated O
pkca O
ko O
mice O
, O
aqp2 O
was O
only O
reduced O
by O
2-fold O
and O
ut-a1 O
expression O
was O
unaffected O
. O

urinary O
sodium O
, O
potassium O
and O
calcium O
were O
elevated O
in O
lithium-fed O
wt O
but O
not O
in O
lithium-fed O
pkca O
ko O
mice O
. O

our O
data O
show O
that O
ablation O
of O
pkca O
preserves O
aqp2 O
and O
ut-a1 O
protein O
expression O
and O
localization O
in O
lithium-induced O
ndi B-NEG
, O
and O
prevents O
the O
development O
of O
the O
severe O
polyuria B-NEG
associated O
with O
lithium O
therapy O
. O

-DOCSTART- O

is O
dysguesia B-NEG
going O
to O
be O
a O
rare O
or O
a O
common O
side-effect O
of O
amlodipine? O

a O
very O
rare O
side-effect O
of O
amlodipine O
is O
dysguesia B-NEG
. O

a O
review O
of O
the O
literature O
produced O
only O
one O
case O
. O

we O
report O
a O
case O
about O
a O
female O
with O
essential O
hypertension B-NEG
on O
drug O
treatment O
with O
amlodipine O
developed O
loss B-NEG
of I-NEG
taste I-NEG
sensation I-NEG
. O

condition O
moderately O
improved O
on O
stoppage O
of O
the O
drug O
for O
25 O
days O
. O

we O
conclude O
that O
amlodipine O
can O
cause O
dysguesia B-NEG
. O

here O
, O
we O
describe O
the O
clinical O
presentation O
and O
review O
the O
relevant O
literature O
on O
amlodipine O
and O
dysguesia B-NEG
. O

-DOCSTART- O

rhabdomyolysis B-NEG
in O
association O
with O
simvastatin O
and O
dosage O
increment O
in O
clarithromycin O
. O

clarithromycin O
is O
the O
most O
documented O
cytochrome O
p450 O
3a4 O
( O
cyp3a4 O
) O
inhibitor O
to O
cause O
an O
adverse O
interaction O
with O
simvastatin O
. O

this O
particular O
case O
is O
of O
interest O
as O
rhabdomyolysis B-NEG
only O
occurred O
after O
an O
increase O
in O
the O
dose O
of O
clarithromycin O
. O

the O
patient O
developed O
raised O
cardiac O
biomarkers O
without O
any O
obvious O
cardiac O
issues O
, O
a O
phenomenon O
that O
has O
been O
linked O
to O
rhabdomyolysis B-NEG
previously O
. O

to O
date O
, O
there O
has O
been O
no O
reported O
effect O
of O
rhabdomyolysis B-NEG
on O
the O
structure O
and O
function O
of O
cardiac O
muscle O
. O

clinicians O
need O
to O
be O
aware O
of O
prescribing O
concomitant O
medications O
that O
increase O
the O
risk O
of O
myopathy B-NEG
or O
inhibit O
the O
cyp3a4 O
enzyme O
. O

our O
case O
suggests O
that O
troponin O
elevation O
could O
be O
associated O
with O
statin O
induced O
rhabdomyolysis B-NEG
, O
which O
may O
warrant O
further O
studies O
. O

-DOCSTART- O

characterization O
of O
a O
novel O
bche O
silent O
allele O
: O
point O
mutation O
( O
p.val204asp O
) O
causes O
loss O
of O
activity O
and O
prolonged O
apnea B-NEG
with O
suxamethonium O
. O
butyrylcholinesterase B-NEG
deficiency I-NEG
is O
characterized O
by O
prolonged O
apnea B-NEG
after O
the O
use O
of O
muscle O
relaxants O
( O
suxamethonium O
or O
mivacurium O
) O
in O
patients O
who O
have O
mutations O
in O
the O
bche O
gene O
. O

here O
, O
we O
report O
a O
case O
of O
prolonged O
neuromuscular O
block O
after O
administration O
of O
suxamethonium O
leading O
to O
the O
discovery O
of O
a O
novel O
bche O
variant O
(c.695t>a O
, O
p.val204asp) O
. O

inhibition O
studies O
, O
kinetic O
analysis O
and O
molecular O
dynamics O
were O
undertaken O
to O
understand O
how O
this O
mutation O
disrupts O
the O
catalytic O
triad O
and O
determines O
a O
silent O
phenotype O
. O

low O
activity O
of O
patient O
plasma O
butyrylcholinesterase O
with O
butyrylthiocholine O
( O
btc O
) O
and O
benzoylcholine O
, O
and O
values O
of O
dibucaine O
and O
fluoride O
numbers O
fit O
with O
heterozygous O
atypical O
silent O
genotype O
. O

electrophoretic O
analysis O
of O
plasma O
bche O
of O
the O
proband O
and O
his O
mother O
showed O
that O
patient O
has O
a O
reduced O
amount O
of O
tetrameric O
enzyme O
in O
plasma O
and O
that O
minor O
fast-moving O
bche O
components O
: O
monomer O
, O
dimer O
, O
and O
monomer-albumin O
conjugate O
are O
missing O
. O

kinetic O
analysis O
showed O
that O
the O
p.val204asp/p.asp70gly-p.ala539thr O
bche O
displays O
a O
pure O
michaelian O
behavior O
with O
btc O
as O
the O
substrate O
. O

both O
catalytic O
parameters O
km O
= O
265 O
um O
for O
btc O
, O
two O
times O
higher O
than O
that O
of O
the O
atypical O
enzyme O
, O
and O
a O
low O
vmax O
are O
consistent O
with O
the O
absence O
of O
activity O
against O
suxamethonium O
. O

molecular O
dynamic O
( O
md O
) O
simulations O
showed O
that O
the O
overall O
effect O
of O
the O
mutation O
p.val204asp O
is O
disruption O
of O
hydrogen O
bonding O
between O
gln223 O
and O
glu441 O
, O
leading O
ser198 O
and O
his438 O
to O
move O
away O
from O
each O
other O
with O
subsequent O
disruption O
of O
the O
catalytic O
triad O
functionality O
regardless O
of O
the O
type O
of O
substrate O
. O

md O
also O
showed O
that O
the O
enzyme O
volume O
is O
increased O
, O
suggesting O
a O
pre-denaturation O
state O
. O

this O
fits O
with O
the O
reduced O
concentration O
of O
p.ala204asp/p.asp70gly-p.ala539thr O
tetrameric O
enzyme O
in O
the O
plasma O
and O
non-detectable O
fast O
moving-bands O
on O
electrophoresis O
gels O
. O

-DOCSTART- O

delayed O
anemia B-NEG
after O
treatment O
with O
injectable O
artesunate O
in O
the O
democratic O
republic O
of O
the O
congo O
: O
a O
manageable O
issue O
. O

cases O
of O
delayed O
hemolytic B-NEG
anemia I-NEG
have O
been O
described O
after O
treatment O
with O
injectable O
artesunate O
, O
the O
current O
world O
health O
organization O
( O
who)-recommended O
first-line O
drug O
for O
the O
treatment O
of O
severe O
malaria B-NEG
. O

a O
total O
of O
350 O
patients O
( O
215 O
[61.4%] O
< O
5 O
years O
of O
age O
and O
135 O
[38.6%] O
> O
5 O
years O
of O
age O
) O
were O
followed-up O
after O
treatment O
with O
injectable O
artesunate O
for O
severe O
malaria B-NEG
in O
hospitals O
and O
health O
centers O
of O
the O
democratic O
republic O
of O
the O
congo O
. O

complete O
series O
of O
hemoglobin O
( O
hb O
) O
measurements O
were O
available O
for O
201 O
patients O
. O

a O
decrease O
in O
hb O
levels O
between O
2 O
and O
5 O
g/dl O
was O
detected O
in O
23 O
( O
11.4% O
) O
patients O
during O
the O
follow-up O
period O
. O

for O
five O
patients O
, O
hb O
levels O
decreased O
below O
5 O
g/dl O
during O
at O
least O
one O
follow-up O
visit O
. O

all O
cases O
of O
delayed O
anemia B-NEG
were O
clinically O
manageable O
and O
resolved O
within O
one O
month O
. O

-DOCSTART- O

regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
and O
apoptotic O
pathways O
by O
betaine O
attenuates O
isoproterenol-induced O
acute O
myocardial B-NEG
injury I-NEG
in O
rats O
. O

the O
present O
study O
was O
designed O
to O
investigate O
the O
cardioprotective O
effects O
of O
betaine O
on O
acute O
myocardial B-NEG
ischemia I-NEG
induced O
experimentally O
in O
rats O
focusing O
on O
regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
stat3 O
) O
and O
apoptotic O
pathways O
as O
the O
potential O
mechanism O
underlying O
the O
drug O
effect O
. O

male O
sprague O
dawley O
rats O
were O
treated O
with O
betaine O
(100 O
, O
200 O
, O
and O
400 O
mg/kg O
) O
orally O
for O
40 O
days O
. O

acute O
myocardial B-NEG
ischemic I-NEG
injury I-NEG
was O
induced O
in O
rats O
by O
subcutaneous O
injection O
of O
isoproterenol O
( O
85 O
mg/kg) O
, O
for O
two O
consecutive O
days O
. O

serum O
cardiac O
marker O
enzyme O
, O
histopathological O
variables O
and O
expression O
of O
protein O
levels O
were O
analyzed O
. O

oral O
administration O
of O
betaine O
( O
200 O
and O
400 O
mg/kg O
) O
significantly O
reduced O
the O
level O
of O
cardiac O
marker O
enzyme O
in O
the O
serum O
and O
prevented O
left O
ventricular B-NEG
remodeling I-NEG
. O

western O
blot O
analysis O
showed O
that O
isoproterenol-induced O
phosphorylation O
of O
stat3 O
was O
maintained O
or O
further O
enhanced O
by O
betaine O
treatment O
in O
myocardium O
. O

furthermore O
, O
betaine O
( O
200 O
and O
400 O
mg/kg O
) O
treatment O
increased O
the O
ventricular O
expression O
of O
bcl-2 O
and O
reduced O
the O
level O
of O
bax O
, O
therefore O
causing O
a O
significant O
increase O
in O
the O
ratio O
of O
bcl-2/bax O
. O

the O
protective O
role O
of O
betaine O
on O
myocardial B-NEG
damage I-NEG
was O
further O
confirmed O
by O
histopathological O
examination O
. O

in O
summary O
, O
our O
results O
showed O
that O
betaine O
pretreatment O
attenuated O
isoproterenol-induced O
acute O
myocardial B-NEG
ischemia I-NEG
via O
the O
regulation O
of O
stat3 O
and O
apoptotic O
pathways O
. O

-DOCSTART- O

quetiapine-induced O
neutropenia B-NEG
in O
a O
bipolar B-NEG
patient O
with O
hepatocellular B-NEG
carcinoma I-NEG
. O

objective O
: O
quetiapine O
is O
a O
dibenzothiazepine O
derivative O
, O
similar O
to O
clozapine O
, O
which O
has O
the O
highest O
risk O
of O
causing O
blood B-NEG
dyscrasias I-NEG
, O
especially O
neutropenia B-NEG
. O

there O
are O
some O
case O
reports O
about O
this O
side O
effect O
of O
quetiapine O
, O
but O
possible O
risk O
factors O
are O
seldom O
discussed O
and O
identified O
. O

a O
case O
of O
a O
patient O
with O
hepatocellular B-NEG
carcinoma I-NEG
that O
developed O
neutropenia B-NEG
after O
treatment O
with O
quetiapine O
is O
described O
here O
. O

case O
report O
: O
a O
62-year-old O
taiwanese O
widow O
with O
bipolar B-NEG
disorder I-NEG
was O
diagnosed O
with O
hepatocellular B-NEG
carcinoma I-NEG
at O
age O
60 O
. O

she O
developed O
leucopenia B-NEG
after O
being O
treated O
with O
quetiapine O
. O

after O
quetiapine O
was O
discontinued O
, O
her O
white O
blood O
cell O
count O
returned O
to O
normal O
. O

conclusions O
: O
although O
neutropenia B-NEG
is O
not O
a O
common O
side O
effect O
of O
quetiapine O
, O
physicians O
should O
be O
cautious O
about O
its O
presentation O
and O
associated O
risk O
factors O
. O
hepatic B-NEG
dysfunction I-NEG
may O
be O
one O
of O
the O
possible O
risk O
factors O
, O
and O
concomitant O
fever B-NEG
may O
be O
a O
diagnostic O
marker O
for O
adverse O
reaction O
to O
quetiapine O
. O

-DOCSTART- O

lateral O
antebrachial O
cutaneous O
neuropathy B-NEG
after O
steroid O
injection O
at O
lateral O
epicondyle O
. O

background O
and O
objectives O
: O
this O
report O
aimed O
to O
present O
a O
case O
of O
lateral O
antebrachial O
cutaneous O
neuropathy B-NEG
( O
lacnp O
) O
that O
occurred O
after O
a O
steroid O
injection O
in O
the O
lateral O
epicondyle O
to O
treat O
lateral B-NEG
epicondylitis I-NEG
in O
a O
40-year-old O
woman O
. O

material O
and O
method O
: O
a O
40-year-old O
woman O
presented O
with O
decreased O
sensation O
and O
paresthesia B-NEG
over O
her O
right O
lateral O
forearm O
; O
the O
paresthesia B-NEG
had O
occurred O
after O
a O
steroid O
injection O
in O
the O
right O
lateral O
epicondyle O
3 O
months O
before O
. O

her O
sensation O
of O
light O
touch O
and O
pain B-NEG
was O
diminished O
over O
the O
lateral O
side O
of O
the O
right O
forearm O
and O
wrist O
area O
. O

results O
: O
the O
sensory O
action O
potential O
amplitude O
of O
the O
right O
lateral O
antebrachial O
cutaneous O
nerve O
( O
lacn O
) O
( O
6.2 O
uv O
) O
was O
lower O
than O
that O
of O
the O
left O
( O
13.1 O
uv) O
. O

the O
difference O
of O
amplitude O
between O
both O
sides O
was O
significant O
because O
there O
was O
more O
than O
a O
50% O
reduction O
. O

she O
was O
diagnosed O
with O
right O
lacnp O
( O
mainly O
axonal O
involvement O
) O
on O
the O
basis O
of O
the O
clinical O
manifestation O
and O
the O
electrodiagnostic O
findings O
. O

her O
symptoms O
improved O
through O
physical O
therapy O
but O
persisted O
to O
some O
degree O
. O

conclusion O
: O
this O
report O
describes O
the O
case O
of O
a O
woman O
with O
lacnp O
that O
developed O
after O
a O
steroid O
injection O
for O
the O
treatment O
of O
lateral B-NEG
epicondylitis I-NEG
. O

an O
electrodiagnostic O
study O
, O
including O
a O
nerve O
conduction O
study O
of O
the O
lacn O
, O
was O
helpful O
to O
diagnose O
right O
lacnp O
and O
to O
find O
the O
passage O
of O
the O
lacn O
on O
the O
lateral O
epicondyle O
. O

-DOCSTART- O

curcumin O
prevents O
maleate-induced O
nephrotoxicity B-NEG
: O
relation O
to O
hemodynamic O
alterations O
, O
oxidative O
stress O
, O
mitochondrial O
oxygen O
consumption O
and O
activity O
of O
respiratory O
complex O
i. O

the O
potential O
protective O
effect O
of O
the O
dietary O
antioxidant O
curcumin O
( O
120 O
mg/kg/day O
for O
6 O
days O
) O
against O
the O
renal B-NEG
injury I-NEG
induced O
by O
maleate O
was O
evaluated O
. O

tubular O
proteinuria B-NEG
and O
oxidative O
stress O
were O
induced O
by O
a O
single O
injection O
of O
maleate O
( O
400 O
mg/kg O
) O
in O
rats O
. O

maleate-induced O
renal B-NEG
injury I-NEG
included O
increase O
in O
renal O
vascular O
resistance O
and O
in O
the O
urinary O
excretion O
of O
total O
protein O
, O
glucose O
, O
sodium O
, O
neutrophil O
gelatinase-associated O
lipocalin O
( O
ngal O
) O
and O
n-acetyl O
b-d-glucosaminidase O
(nag) O
, O
upregulation O
of O
kidney B-NEG
injury I-NEG
molecule O
(kim)-1 O
, O
decrease O
in O
renal O
blood O
flow O
and O
claudin-2 O
expression O
besides O
of O
necrosis B-NEG
and O
apoptosis O
of O
tubular O
cells O
on O
24 O
h. O

oxidative O
stress O
was O
determined O
by O
measuring O
the O
oxidation O
of O
lipids O
and O
proteins O
and O
diminution O
in O
renal O
nrf2 O
levels O
. O

studies O
were O
also O
conducted O
in O
renal O
epithelial O
llc-pk1 O
cells O
and O
in O
mitochondria O
isolated O
from O
kidneys O
of O
all O
the O
experimental O
groups O
. O

maleate O
induced O
cell O
damage O
and O
reactive O
oxygen O
species O
( O
ros O
) O
production O
in O
llc-pk1 O
cells O
in O
culture O
. O

in O
addition O
, O
maleate O
treatment O
reduced O
oxygen O
consumption O
in O
adp-stimulated O
mitochondria O
and O
diminished O
respiratory O
control O
index O
when O
using O
malate/glutamate O
as O
substrate O
. O

the O
activities O
of O
both O
complex O
i O
and O
aconitase O
were O
also O
diminished O
. O

all O
the O
above-described O
alterations O
were O
prevented O
by O
curcumin O
. O

it O
is O
concluded O
that O
curcumin O
is O
able O
to O
attenuate O
in O
vivo O
maleate-induced O
nephropathy B-NEG
and O
in O
vitro O
cell O
damage O
. O

the O
in O
vivo O
protection O
was O
associated O
to O
the O
prevention O
of O
oxidative O
stress O
and O
preservation O
of O
mitochondrial O
oxygen O
consumption O
and O
activity O
of O
respiratory O
complex O
i, O
and O
the O
in O
vitro O
protection O
was O
associated O
to O
the O
prevention O
of O
ros O
production O
. O

-DOCSTART- O

incidence O
of O
solid O
tumours B-NEG
among O
pesticide O
applicators O
exposed O
to O
the O
organophosphate O
insecticide O
diazinon O
in O
the O
agricultural O
health O
study O
: O
an O
updated O
analysis O
. O

objective O
: O
diazinon O
, O
a O
common O
organophosphate O
insecticide O
with O
genotoxic O
properties O
, O
was O
previously O
associated O
with O
lung B-NEG
cancer I-NEG
in O
the O
agricultural O
health O
study O
( O
ahs O
) O
cohort O
, O
but O
few O
other O
epidemiological O
studies O
have O
examined O
diazinon-associated O
cancer B-NEG
risk O
. O

we O
used O
updated O
diazinon O
exposure O
and O
cancer B-NEG
incidence O
information O
to O
evaluate O
solid O
tumour B-NEG
risk O
in O
the O
ahs O
. O

methods O
: O
male O
pesticide O
applicators O
in O
iowa O
and O
north O
carolina O
reported O
lifetime O
diazinon O
use O
at O
enrolment O
( O
1993-1997 O
) O
and O
follow-up O
(1998-2005) O
; O
cancer B-NEG
incidence O
was O
assessed O
through O
2010(north O
carolina)/2011(iowa) O
. O

among O
applicators O
with O
usage O
information O
sufficient O
to O
evaluate O
exposure-response O
patterns O
, O
we O
used O
poisson O
regression O
to O
estimate O
adjusted O
rate O
ratios O
( O
rrs O
) O
and O
95% O
ci O
for O
cancer B-NEG
sites O
with O
>10 O
exposed O
cases O
for O
both O
lifetime O
( O
lt O
) O
exposure O
days O
and O
intensity-weighted O
( O
iw O
) O
lifetime O
exposure O
days O
( O
accounting O
for O
factors O
impacting O
exposure) O
. O

results O
: O
we O
observed O
elevated O
lung B-NEG
cancer I-NEG
risks O
( O
n=283 O
) O
among O
applicators O
with O
the O
greatest O
number O
of O
lt O
(rr=1.60 O
; O
95% O
ci O
1.11 O
to O
2.31 O
; O
ptrend=0.02 O
) O
and O
iw O
days O
of O
diazinon O
use O
(rr=1.41 O
; O
95% O
ci O
0.98 O
to O
2.04 O
; O
ptrend=0.08) O
. O
kidney B-NEG
cancer I-NEG
( O
n=94 O
) O
risks O
were O
non-significantly O
elevated O
( O
rrlt O
days=1.77 O
; O
95% O
ci O
0.90 O
to O
3.51 O
; O
ptrend=0.09 O
; O
rriw O
days O
1.37 O
; O
95% O
ci O
0.64 O
to O
2.92 O
; O
ptrend=0.50) O
, O
as O
were O
risks O
for O
aggressive O
prostate B-NEG
cancer I-NEG
(n=656) O
. O

conclusions O
: O
our O
updated O
evaluation O
of O
diazinon O
provides O
additional O
evidence O
of O
an O
association O
with O
lung B-NEG
cancer I-NEG
risk O
. O

newly O
identified O
links O
to O
kidney B-NEG
cancer I-NEG
and O
associations O
with O
aggressive O
prostate B-NEG
cancer I-NEG
require O
further O
evaluation O
. O

-DOCSTART- O

associations O
of O
ozone O
and O
pm2.5 O
concentrations O
with O
parkinson's B-NEG
disease I-NEG
among O
participants O
in O
the O
agricultural O
health O
study O
. O

objective O
: O
this O
study O
describes O
associations O
of O
ozone O
and O
fine O
particulate O
matter O
with O
parkinson's B-NEG
disease I-NEG
observed O
among O
farmers O
in O
north O
carolina O
and O
iowa O
. O

methods O
: O
we O
used O
logistic O
regression O
to O
determine O
the O
associations O
of O
these O
pollutants O
with O
self-reported O
, O
doctor-diagnosed O
parkinson's B-NEG
disease I-NEG
. O

daily O
predicted O
pollutant O
concentrations O
were O
used O
to O
derive O
surrogates O
of O
long-term O
exposure O
and O
link O
them O
to O
study O
participants' O
geocoded O
addresses O
. O

results O
: O
we O
observed O
positive O
associations O
of O
parkinson's B-NEG
disease I-NEG
with O
ozone O
( O
odds O
ratio O
= O
1.39 O
; O
95% O
ci O
: O
0.98 O
to O
1.98 O
) O
and O
fine O
particulate O
matter O
( O
odds O
ratio O
= O
1.34 O
; O
95% O
ci O
: O
0.93 O
to O
1.93 O
) O
in O
north O
carolina O
but O
not O
in O
iowa O
. O

conclusions O
: O
the O
plausibility O
of O
an O
effect O
of O
ambient O
concentrations O
of O
these O
pollutants O
on O
parkinson's B-NEG
disease I-NEG
risk O
is O
supported O
by O
experimental O
data O
demonstrating O
damage O
to O
dopaminergic O
neurons O
at O
relevant O
concentrations O
. O

additional O
studies O
are O
needed O
to O
address O
uncertainties O
related O
to O
confounding O
and O
to O
examine O
temporal O
aspects O
of O
the O
associations O
we O
observed O
. O

-DOCSTART- O

low O
functional O
programming O
of O
renal O
at2r O
mediates O
the O
developmental O
origin O
of O
glomerulosclerosis B-NEG
in O
adult O
offspring O
induced O
by O
prenatal O
caffeine O
exposure O
. O

unassigned O
: O
our O
previous O
study O
has O
indicated O
that O
prenatal O
caffeine O
exposure O
( O
pce O
) O
could O
induce O
intrauterine B-NEG
growth I-NEG
retardation I-NEG
( O
iugr B-NEG
) O
of O
offspring O
. O

recent O
research O
suggested O
that O
iugr B-NEG
is O
a O
risk O
factor O
for O
glomerulosclerosis B-NEG
. O

however O
, O
whether O
pce O
could O
induce O
glomerulosclerosis B-NEG
and O
its O
underlying O
mechanisms O
remain O
unknown O
. O

this O
study O
aimed O
to O
demonstrate O
the O
induction O
to O
glomerulosclerosis B-NEG
in O
adult O
offspring O
by O
pce O
and O
its O
intrauterine O
programming O
mechanisms O
. O

a O
rat O
model O
of O
iugr B-NEG
was O
established O
by O
pce O
, O
male O
fetuses O
and O
adult O
offspring O
at O
the O
age O
of O
postnatal O
week O
24 O
were O
euthanized O
. O

the O
results O
revealed O
that O
the O
adult O
offspring O
kidneys O
in O
the O
pce O
group O
exhibited O
glomerulosclerosis B-NEG
as O
well O
as O
interstitial B-NEG
fibrosis I-NEG
, O
accompanied O
by O
elevated O
levels O
of O
serum O
creatinine O
and O
urine O
protein O
. O

renal O
angiotensin O
ii O
receptor O
type O
2 O
( O
at2r O
) O
gene O
expression O
in O
adult O
offspring O
was O
reduced O
by O
pce O
, O
whereas O
the O
renal O
angiotensin O
ii O
receptor O
type O
1a O
( O
at1ar)/at2r O
expression O
ratio O
was O
increased O
. O

the O
fetal O
kidneys O
in O
the O
pce O
group O
displayed O
an O
enlarged O
bowman's O
space O
and O
a O
shrunken O
glomerular O
tuft O
, O
accompanied O
by O
a O
reduced O
cortex O
width O
and O
an O
increase O
in O
the O
nephrogenic O
zone/cortical O
zone O
ratio O
. O

observation O
by O
electronic O
microscope O
revealed O
structural O
damage O
of O
podocytes O
; O
the O
reduced O
expression O
level O
of O
podocyte O
marker O
genes O
, O
nephrin O
and O
podocin O
, O
was O
also O
detected O
by O
q-pcr O
. O

moreover O
, O
at2r O
gene O
and O
protein O
expressions O
in O
fetal O
kidneys O
were O
inhibited O
by O
pce O
, O
associated O
with O
the O
repression O
of O
the O
gene O
expression O
of O
glial-cell-line-derived O
neurotrophic O
factor O
( O
gdnf)/tyrosine O
kinase O
receptor O
( O
c-ret O
) O
signaling O
pathway O
. O

these O
results O
demonstrated O
that O
pce O
could O
induce O
dysplasia B-NEG
of I-NEG
fetal I-NEG
kidneys I-NEG
as O
well O
as O
glomerulosclerosis B-NEG
of O
adult O
offspring O
, O
and O
the O
low O
functional O
programming O
of O
renal O
at2r O
might O
mediate O
the O
developmental O
origin O
of O
adult O
glomerulosclerosis B-NEG
. O

-DOCSTART- O

1,3-butadiene O
, O
cml B-NEG
and O
the O
t(9:22 O
) O
translocation O
: O
a O
reality O
check O
. O

unassigned O
: O
epidemiological O
studies O
of O
1,3-butadiene O
have O
suggest O
that O
exposures O
to O
humans O
are O
associated O
with O
chronic B-NEG
myeloid I-NEG
leukemia I-NEG
( O
cml B-NEG
). O
cml B-NEG
has O
a O
well-documented O
association O
with O
ionizing O
radiation O
, O
but O
reports O
of O
associations O
with O
chemical O
exposures O
have O
been O
questioned O
. O

ionizing O
radiation O
is O
capable O
of O
inducing O
the O
requisite O
cml B-NEG
-associated O
t(9:22 O
) O
translocation O
( O
philadelphia B-NEG
chromosome I-NEG
) O
in O
appropriate O
cells O
in O
vitro O
but O
, O
thus O
far O
, O
chemicals O
have O
not O
shown O
this O
capacity O
. O

we O
have O
proposed O
that O
1,3-butadiene O
metabolites O
be O
so O
tested O
as O
a O
reality O
check O
on O
the O
epidemiological O
reports O
. O

in O
order O
to O
conduct O
reliable O
testing O
in O
this O
regard O
, O
it O
is O
essential O
that O
a O
positive O
control O
for O
induction O
be O
available O
. O

we O
have O
used O
ionizing O
radiation O
to O
develop O
such O
a O
control O
. O

results O
described O
here O
demonstrate O
that O
this O
agent O
does O
in O
fact O
induce O
pathogenic O
t(9:22 O
) O
translocations O
in O
a O
human O
myeloid O
cell O
line O
in O
vitro O
, O
but O
does O
so O
at O
low O
frequencies O
. O

conditions O
that O
will O
be O
required O
for O
studies O
of O
1,3-butadiene O
are O
discussed O
. O

-DOCSTART- O

cancer B-NEG
incidence O
and O
metolachlor O
use O
in O
the O
agricultural O
health O
study O
: O
an O
update O
. O

unassigned O
: O
metolachlor O
, O
a O
widely O
used O
herbicide O
, O
is O
classified O
as O
a O
group O
c O
carcinogen O
by O
the O
u.s O
. O

environmental O
protection O
agency O
based O
on O
increased O
liver B-NEG
neoplasms I-NEG
in O
female O
rats O
. O

epidemiologic O
studies O
of O
the O
health O
effects O
of O
metolachlor O
have O
been O
limited O
. O

the O
agricultural O
health O
study O
( O
ahs O
) O
is O
a O
prospective O
cohort O
study O
including O
licensed O
private O
and O
commercial O
pesticide O
applicators O
in O
iowa O
and O
north O
carolina O
enrolled O
1993-1997 O
. O

we O
evaluated O
cancer B-NEG
incidence O
through O
2010/2011 O
( O
nc/ia O
) O
for O
49,616 O
applicators O
, O
53% O
of O
whom O
reported O
ever O
using O
metolachlor O
. O

we O
used O
poisson O
regression O
to O
evaluate O
relations O
between O
two O
metrics O
of O
metolachlor O
use O
( O
lifetime O
days O
, O
intensity-weighted O
lifetime O
days O
) O
and O
cancer B-NEG
incidence O
. O

we O
saw O
no O
association O
between O
metolachlor O
use O
and O
incidence O
of O
all O
cancers B-NEG
combined O
(n O
= O
5,701 O
with O
a O
5-year O
lag O
) O
or O
most O
site-specific O
cancers B-NEG
. O

for O
liver B-NEG
cancer I-NEG
, O
in O
analyses O
restricted O
to O
exposed O
workers O
, O
elevations O
observed O
at O
higher O
categories O
of O
use O
were O
not O
statistically O
significant O
. O

however O
, O
trends O
for O
both O
lifetime O
and O
intensity-weighted O
lifetime O
days O
of O
metolachor O
use O
were O
positive O
and O
statistically O
significant O
with O
an O
unexposed O
reference O
group O
. O

a O
similar O
pattern O
was O
observed O
for O
follicular B-NEG
cell I-NEG
lymphoma I-NEG
, O
but O
no O
other O
lymphoma B-NEG
subtypes O
. O

an O
earlier O
suggestion O
of O
increased O
lung B-NEG
cancer I-NEG
risk O
at O
high O
levels O
of O
metolachlor O
use O
in O
this O
cohort O
was O
not O
confirmed O
in O
this O
update O
. O

this O
suggestion O
of O
an O
association O
between O
metolachlor O
and O
liver B-NEG
cancer I-NEG
among O
pesticide O
applicators O
is O
a O
novel O
finding O
and O
echoes O
observation O
of O
increased O
liver B-NEG
neoplasms I-NEG
in O
some O
animal O
studies O
. O

however O
, O
our O
findings O
for O
both O
liver B-NEG
cancer I-NEG
and O
follicular O
cell O
lymphoma B-NEG
warrant O
follow-up O
to O
better O
differentiate O
effects O
of O
metolachlor O
use O
from O
other O
factors O
. O

-DOCSTART- O

mechanisms O
underlying O
latent O
disease O
risk O
associated O
with O
early-life O
arsenic O
exposure O
: O
current O
research O
trends O
and O
scientific O
gaps O
. O

background O
: O
millions O
of O
individuals O
worldwide O
, O
particularly O
those O
living O
in O
rural O
and O
developing O
areas O
, O
are O
exposed O
to O
harmful O
levels O
of O
inorganic O
arsenic O
( O
ias O
) O
in O
their O
drinking O
water O
. O

inorganic O
as O
exposure O
during O
key O
developmental O
periods O
is O
associated O
with O
a O
variety O
of O
adverse O
health O
effects O
including O
those O
that O
are O
evident O
in O
adulthood O
. O

there O
is O
considerable O
interest O
in O
identifying O
the O
molecular O
mechanisms O
that O
relate O
early-life O
ias O
exposure O
to O
the O
development O
of O
these O
latent O
diseases O
, O
particularly O
in O
relationship O
to O
cancer B-NEG
. O

objectives O
: O
this O
work O
summarizes O
research O
on O
the O
molecular O
mechanisms O
that O
underlie O
the O
increased O
risk O
of O
cancer B-NEG
development O
in O
adulthood O
that O
is O
associated O
with O
early-life O
ias O
exposure O
. O

discussion O
: O
epigenetic O
reprogramming O
that O
imparts O
functional O
changes O
in O
gene O
expression O
, O
the O
development O
of O
cancer B-NEG
stem O
cells O
, O
and O
immunomodulation O
are O
plausible O
underlying O
mechanisms O
by O
which O
early-life O
ias O
exposure O
elicits O
latent O
carcinogenic O
effects O
. O

conclusions O
: O
evidence O
is O
mounting O
that O
relates O
early-life O
ias O
exposure O
and O
cancer B-NEG
development O
later O
in O
life O
. O

future O
research O
should O
include O
animal O
studies O
that O
address O
mechanistic O
hypotheses O
and O
studies O
of O
human O
populations O
that O
integrate O
early-life O
exposure O
, O
molecular O
alterations O
, O
and O
latent O
disease O
outcomes O
. O

-DOCSTART- O

on O
the O
antiarrhythmic O
activity O
of O
one O
n-substituted O
piperazine O
derivative O
of O
trans-2-amino-3-hydroxy-1 O
, O
2, O
3, O
4-tetrahydroanaphthalene O
. O

the O
antiarrhythmic O
activity O
of O
the O
compound O
n-(trans-3-hydroxy-1,2,3,4-tetrahydro-2-naphthyl)-n-(3-oxo-3-phenyl-2-methylpropyl)-piperazine O
hydrochloride O
, O
referred O
to O
as O
p11 O
, O
is O
studied O
on O
anaesthesized O
cats O
and O
wistar O
albino O
rats O
, O
as O
well O
as O
on O
non-anaesthesized O
rabbits O
. O

four O
types O
of O
experimental O
arrhythmia B-NEG
are O
used--with O
bacl2 O
, O
with O
chloroform-adrenaline O
, O
with O
strophantine O
g O
and O
with O
aconitine O
. O

the O
compound O
p11 O
is O
introduced O
in O
doses O
of O
0.25 O
and O
0.50 O
mg/kg O
intravenously O
and O
10 O
mg/kg O
orally O
. O

the O
compound O
manifests O
antiarrhythmic O
activity O
in O
all O
models O
of O
experimental O
arrhythmia B-NEG
used O
, O
causing O
greatest O
inhibition O
on O
the O
arrhythmia B-NEG
induced O
by O
chloroform-adrenaline O
( O
in O
90 O
per O
cent O
) O
and O
with O
bacl2 O
( O
in O
84 O
per O
cent) O
. O

the O
results O
obtained O
are O
associated O
with O
the O
beta-adrenoblocking O
and O
with O
the O
membrane-stabilizing O
action O
of O
the O
compound O
. O

-DOCSTART- O

experimental O
progressive O
muscular B-NEG
dystrophy I-NEG
and O
its O
treatment O
with O
high O
doses O
anabolizing O
agents O
. O

we O
are O
still O
a O
long O
way O
from O
discovering O
an O
unequivocal O
pathogenetic O
interpretation O
of O
progressive O
muscular B-NEG
dystrophy I-NEG
in O
man O
. O

noteworthy O
efforts O
have O
been O
made O
in O
the O
experimental O
field O
; O
a O
recessive O
autosomic O
form O
found O
in O
the O
mouse O
seems O
to O
bear O
the O
closest O
resemblance O
to O
the O
human O
form O
from O
the O
genetic O
point O
of O
view O
. O
myopathy B-NEG
due O
to O
lack O
of O
vitamin O
e O
and O
myopathy B-NEG
induced O
by O
certain O
viruses O
have O
much O
in O
common O
anatomically O
and O
pathologically O
with O
the O
human O
form O
. O

the O
authors O
induced O
myodystrophy B-NEG
in O
the O
rat O
by O
giving O
it O
a O
diet O
lacking O
in O
vitamin O
e. O

the O
pharmacological O
characteristics O
of O
vitamin O
e O
and O
the O
degenerative O
changes O
brought O
about O
by O
its O
deficiency O
, O
especially O
in O
the O
muscles O
, O
are O
illustrated O
. O

it O
is O
thus O
confirmed O
that O
the O
histological O
characteristics O
of O
myopathic B-NEG
rat O
muscle O
induced O
experimentally O
are O
extraordinarily O
similar O
to O
those O
of O
human O
myopathy B-NEG
as O
confirmed O
during O
biopsies O
performed O
at O
the O
orthopaedic O
traumatological O
centre O
, O
florence O
. O

the O
encouraging O
results O
obtained O
in O
various O
authoratative O
departments O
in O
myopathic B-NEG
patients O
by O
using O
anabolizing O
steroids O
have O
encouraged O
the O
authors O
to O
investigate O
the O
beneficial O
effects O
of O
one O
anabolizing O
agent O
(dianabol O
, O
ciba O
) O
at O
high O
doses O
in O
rats O
rendered O
myopathic B-NEG
by O
a O
diet O
deficient O
in O
vitamin O
e. O

in O
this O
way O
they O
obtained O
appreciable O
changes O
in O
body O
weight O
( O
increased O
from O
50 O
to O
70 O
g O
after O
forty O
days O
at O
a O
dose O
of O
5 O
mg O
per O
day O
of O
anabolizing O
agent) O
, O
but O
most O
of O
all O
they O
found O
histological O
changes O
due O
to O
regenerative O
changes O
in O
the O
muscle O
tissue O
, O
which O
however O
maintained O
its O
myopathic B-NEG
characteristics O
in O
the O
control O
animals O
that O
were O
not O
treated O
with O
the O
anabolizing O
agent O
. O

the O
authors O
conclude O
by O
affirming O
the O
undoubted O
efficacy O
of O
the O
anabolizing O
steroids O
in O
experimental O
myopathic B-NEG
disease I-NEG
, O
but O
they O
have O
reservations O
as O
to O
the O
transfer O
of O
the O
results O
into O
the O
human O
field O
, O
where O
high O
dosage O
cannot O
be O
carried O
out O
continuously O
because O
of O
the O
effects O
of O
the O
drug O
on O
virility O
; O
because O
the O
tissue O
injury O
too O
often O
occurs O
at O
an O
irreversible O
stage O
vis-a-vis O
the O
regeneration O
of O
the O
muscle O
tissue O
; O
and O
finally O
because O
the O
dystrophic O
injurious O
agent O
is O
certainly O
not O
the O
lack O
of O
vitamin O
e O
but O
something O
as O
yet O
unknown O
. O

-DOCSTART- O

fetal O
risks O
due O
to O
warfarin O
therapy O
during O
pregnancy O
. O

two O
mothers O
with O
heart O
valve O
prosthesis O
were O
treated O
with O
warfarin O
during O
pregnancy O
. O

in O
the O
first O
case O
a O
caesarean O
section O
was O
done O
one O
week O
after O
replacement O
of O
warfarin O
with O
heparin O
. O

the O
baby O
died O
of O
cerebral B-NEG
and I-NEG
pulmonary I-NEG
hemorrhage I-NEG
. O

the O
second O
mother O
had O
a O
male O
infant O
by O
caesarean O
section O
. O

the O
baby O
showed O
warfarin-induced O
embryopathy B-NEG
with O
nasal B-NEG
hypoplasia I-NEG
and O
stippled B-NEG
epiphyses I-NEG
( O
chondrodysplasia B-NEG
punctata I-NEG
). O
nasal B-NEG
hypoplasia I-NEG
with O
or O
without O
stippled B-NEG
epiphyses I-NEG
has O
now O
been O
reported O
in O
11 O
infants O
born O
to O
mothers O
treated O
with O
warfarin O
during O
the O
first O
trimester O
, O
and O
a O
causal O
association O
is O
probable O
. O

in O
view O
of O
the O
risks O
to O
both O
mother O
and O
fetus O
in O
women O
with O
prosthetic O
cardiac O
valves O
it O
is O
recommended O
that O
therapeutic O
abortion O
be O
advised O
as O
the O
first O
alternative O
. O

-DOCSTART- O

isradipine O
treatment O
for O
hypertension B-NEG
in O
general O
practice O
in O
hong O
kong O
. O

a O
6-week O
open O
study O
of O
the O
introduction O
of O
isradipine O
treatment O
was O
conducted O
in O
general O
practice O
in O
hong O
kong O
. O

303 O
chinese O
patients O
with O
mild O
to O
moderate O
hypertension B-NEG
entered O
the O
study O
. O

side O
effects O
were O
reported O
in O
21% O
of O
patients O
and O
caused O
withdrawal O
from O
the O
study O
in O
3 O
patients O
. O

the O
main O
side-effects O
were O
headache B-NEG
, O
dizziness B-NEG
, O
palpitation B-NEG
and O
flushing B-NEG
and O
these O
were O
not O
more O
frequent O
than O
reported O
in O
other O
studies O
with O
isradipine O
or O
with O
placebo O
. O

supine O
blood O
pressure O
was O
reduced O
(p O
less O
than O
0.01 O
) O
from O
170 O
+/- O
20/102 O
+/- O
6 O
mmhg O
to O
153 O
+/- O
19/92 O
+/- O
8, O
147 O
+/- O
18/88 O
+/- O
7 O
and O
144 O
+/- O
14/87 O
+/- O
6 O
mmhg O
at O
2, O
4 O
and O
6 O
weeks O
respectively O
in O
evaluable O
patients O
. O

similar O
reductions O
occurred O
in O
standing O
blood O
pressure O
and O
there O
was O
no O
evidence O
of O
postural B-NEG
hypotension I-NEG
. O

normalization O
and O
responder O
rates O
at O
6 O
weeks O
were O
86% O
and O
69% O
respectively O
. O

dosage O
was O
increased O
from O
2.5 O
mg O
b.d O
. O
to O
5 O
mg O
b.d O
. O
at O
4 O
weeks O
in O
patients O
with O
diastolic O
blood O
pressure O
greater O
than O
90 O
mmhg O
and O
their O
further O
response O
was O
greater O
than O
those O
remaining O
on O
2.5 O
mg O
b.d O
. O

-DOCSTART- O

tachyphylaxis O
to O
systemic O
but O
not O
to O
airway O
responses O
during O
prolonged O
therapy O
with O
high O
dose O
inhaled O
salbutamol O
in O
asthmatics B-NEG
. O

high O
doses O
of O
inhaled O
salbutamol O
produce O
substantial O
improvements O
in O
airway O
response O
in O
patients O
with O
asthma B-NEG
, O
and O
are O
associated O
with O
dose-dependent O
systemic O
beta-adrenoceptor O
responses O
. O

the O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
whether O
tachyphylaxis O
occurs O
during O
prolonged O
treatment O
with O
high O
dose O
inhaled O
salbutamol O
. O

twelve O
asthmatic B-NEG
patients O
(fev1 O
, O
81 O
+/- O
4% O
predicted) O
, O
requiring O
only O
occasional O
inhaled O
beta-agonists O
as O
their O
sole O
therapy O
, O
were O
given O
a O
14-day O
treatment O
with O
high O
dose O
inhaled O
salbutamol O
(hds) O
, O
4,000 O
micrograms O
daily O
, O
low O
dose O
inhaled O
salbutamol O
(lds) O
, O
800 O
micrograms O
daily O
, O
or O
placebo O
( O
pi O
) O
by O
metered-dose O
inhaler O
in O
a O
double-blind O
, O
randomized O
crossover O
design O
. O

during O
the O
14-day O
run-in O
and O
during O
washout O
periods O
, O
inhaled O
beta-agonists O
were O
withheld O
and O
ipratropium O
bromide O
was O
substituted O
for O
rescue O
purposes O
. O

at O
the O
end O
of O
each O
14-day O
treatment O
, O
a O
dose-response O
curve O
( O
drc O
) O
was O
performed O
, O
and O
airway O
(fev1 O
, O
fef25-75 O
) O
chronotropic O
(hr) O
, O
tremor B-NEG
, O
and O
metabolic O
(k O
, O
glu O
) O
responses O
were O
measured O
at O
each O
step O
( O
from O
100 O
to O
4,000 O
micrograms) O
. O

treatment O
had O
no O
significant O
effect O
on O
baseline O
values O
. O

there O
were O
dose-dependent O
increases O
in O
fev1 O
and O
fef25-75 O
(p O
less O
than O
0.001) O
, O
and O
pretreatment O
with O
hds O
did O
not O
displace O
the O
drc O
to O
the O
right O
. O

drc O
for O
hr O
(p O
less O
than O
0.001) O
, O
k O
(p O
less O
than O
0.001) O
, O
and O
glu O
(p O
less O
than O
0.005 O
) O
were O
attenuated O
after O
treatment O
with O
hds O
compared O
with O
pi O
. O

there O
were O
also O
differences O
between O
hds O
and O
lds O
for O
hr O
(p O
less O
than O
0.001 O
) O
and O
glu O
(p O
less O
than O
0.05 O
) O
responses O
. O

frequency O
and O
severity O
of O
subjective O
adverse O
effects O
were O
also O
reduced O
after O
hds O
: O
tremor B-NEG
(p O
less O
than O
0.001) O
, O
palpitations B-NEG
(p O
less O
than O
0.001).(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

increased O
anxiogenic O
effects O
of O
caffeine O
in O
panic B-NEG
disorders I-NEG
. O

the O
effects O
of O
oral O
administration O
of O
caffeine O
( O
10 O
mg/kg O
) O
on O
behavioral O
ratings O
, O
somatic O
symptoms O
, O
blood O
pressure O
and O
plasma O
levels O
of O
3-methoxy-4-hydroxyphenethyleneglycol O
( O
mhpg O
) O
and O
cortisol O
were O
determined O
in O
17 O
healthy O
subjects O
and O
21 O
patients O
meeting O
dsm-iii O
criteria O
for O
agoraphobia B-NEG
with O
panic B-NEG
attacks I-NEG
or O
panic B-NEG
disorder I-NEG
. O

caffeine O
produced O
significantly O
greater O
increases O
in O
subject-rated O
anxiety B-NEG
, O
nervousness O
, O
fear O
, O
nausea B-NEG
, O
palpitations B-NEG
, O
restlessness B-NEG
, O
and O
tremors B-NEG
in O
the O
patients O
compared O
with O
healthy O
subjects O
. O

in O
the O
patients O
, O
but O
not O
the O
healthy O
subjects O
, O
these O
symptoms O
were O
significantly O
correlated O
with O
plasma O
caffeine O
levels O
. O

seventy-one O
percent O
of O
the O
patients O
reported O
that O
the O
behavioral O
effects O
of O
caffeine O
were O
similar O
to O
those O
experienced O
during O
panic B-NEG
attacks I-NEG
. O

caffeine O
did O
not O
alter O
plasma O
mhpg O
levels O
in O
either O
the O
healthy O
subjects O
or O
patients O
. O

caffeine O
increased O
plasma O
cortisol O
levels O
equally O
in O
the O
patient O
and O
healthy O
groups O
. O

because O
caffeine O
is O
an O
adenosine O
receptor O
antagonist O
, O
these O
results O
suggest O
that O
some O
panic B-NEG
disorder I-NEG
patients O
may O
have O
abnormalities B-NEG
in I-NEG
neuronal I-NEG
systems I-NEG
involving O
adenosine O
. O

patients O
with O
anxiety B-NEG
disorders I-NEG
may O
benefit O
by O
avoiding O
caffeine-containing O
foods O
and O
beverages O
. O

-DOCSTART- O

human O
and O
canine O
ventricular O
vasoactive O
intestinal O
polypeptide O
: O
decrease O
with O
heart B-NEG
failure I-NEG
. O

vasoactive O
intestinal O
polypeptide O
( O
vip O
) O
is O
a O
systemic O
and O
coronary O
vasodilator O
that O
may O
have O
positive O
inotropic O
properties O
. O

myocardial O
levels O
of O
vip O
were O
assayed O
before O
and O
after O
the O
development O
of O
heart B-NEG
failure I-NEG
in O
two O
canine O
models O
. O

in O
the O
first O
, O
cobalt O
cardiomyopathy B-NEG
was O
induced O
in O
eight O
dogs O
; O
vip O
( O
by O
radioimmunoassay O
) O
decreased O
from O
35 O
+/- O
11 O
pg/mg O
protein O
( O
mean O
+/- O
sd O
) O
to O
5 O
+/- O
4 O
pg/mg O
protein O
(p O
less O
than O
0.05) O
. O

in O
six O
dogs O
with O
doxorubicin-induced O
heart B-NEG
failure I-NEG
, O
vip O
decreased O
from O
31 O
+/- O
7 O
to O
11 O
+/- O
4 O
pg/mg O
protein O
(p O
less O
than O
0.05) O
. O

in O
addition O
, O
vip O
content O
of O
left O
ventricular O
muscle O
of O
resected O
failing O
hearts O
in O
10 O
patients O
receiving O
a O
heart O
transplant O
was O
compared O
with O
the O
papillary O
muscles O
in O
14 O
patients O
( O
five O
with O
rheumatic B-NEG
disease I-NEG
, O
nine O
with O
myxomatous B-NEG
degeneration I-NEG
) O
receiving O
mitral O
valve O
prostheses O
. O

the O
lowest O
myocardial O
vip O
concentration O
was O
found O
in O
the O
hearts O
of O
patients O
with O
coronary B-NEG
disease I-NEG
( O
one O
patient O
receiving O
a O
transplant O
and O
three O
receiving O
mitral O
prostheses O
) O
( O
6.3 O
+/- O
1.9 O
pg/mg O
protein) O
. O

the O
other O
patients O
undergoing O
transplantation O
had O
an O
average O
ejection O
fraction O
of O
17% O
+/- O
6% O
and O
a O
vip O
level O
of O
8.8 O
+/- O
3.9 O
pg/mg O
protein O
. O

the O
hearts O
without O
coronary B-NEG
artery I-NEG
disease I-NEG
( O
average O
ejection O
fraction O
of O
this O
group O
62% O
+/- O
10% O
) O
had O
a O
vip O
concentration O
of O
14.1 O
+/- O
7.9 O
pg/mg O
protein O
, O
and O
this O
was O
greater O
than O
in O
hearts O
of O
the O
patients O
with O
coronary B-NEG
disease I-NEG
and O
the O
hearts O
of O
patients O
receiving O
a O
transplant O
(p O
less O
than O
0.05) O
. O

myocardial O
catecholamines O
were O
also O
determined O
in O
14 O
subjects O
; O
a O
weak O
correlation O
(r O
= O
0.57 O
, O
p O
less O
than O
0.05 O
) O
between O
the O
tissue O
concentrations O
of O
vip O
and O
norepinephrine O
was O
noted.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

interstrain O
variation O
in O
acute O
toxic O
response O
to O
caffeine O
among O
inbred O
mice O
. O

acute O
toxic O
dosage-dependent O
behavioral O
effects O
of O
caffeine O
were O
compared O
in O
adult O
males O
from O
seven O
inbred O
mouse O
strains O
(a/j O
, O
balb/cj O
, O
cba/j O
, O
c3h/hej O
, O
c57bl/6j O
, O
dba/2j O
, O
swr/j) O
. O

c57bl/6j O
, O
chosen O
as O
a O
prototypic O
mouse O
strain O
, O
was O
used O
to O
determine O
behavioral O
responses O
to O
a O
broad O
range O
( O
5-500 O
mg/kg O
) O
of O
caffeine O
doses O
. O

five O
phenotypic O
characteristics--locomotor O
activity O
, O
righting O
ability O
, O
clonic B-NEG
seizure I-NEG
induction O
, O
stress-induced O
lethality O
, O
death O
without O
external O
stress--were O
scored O
at O
various O
caffeine O
doses O
in O
drug-naive O
animals O
under O
empirically O
optimized O
, O
rigidly O
constant O
experimental O
conditions O
. O

mice O
(n O
= O
12 O
for O
each O
point O
) O
received O
single O
ip O
injections O
of O
a O
fixed O
volume/g O
body O
weight O
of O
physiological O
saline O
carrier O
with O
or O
without O
caffeine O
in O
doses O
ranging O
from O
125-500 O
mg/kg O
. O

loss O
of O
righting O
ability O
was O
scored O
at O
1, O
3, O
5 O
min O
post O
dosing O
and O
at O
5 O
min O
intervals O
thereafter O
for O
20 O
min O
. O

in O
the O
same O
animals O
the O
occurrence O
of O
clonic B-NEG
seizures I-NEG
was O
scored O
as O
to O
time O
of O
onset O
and O
severity O
for O
20 O
min O
after O
drug O
administration O
. O

when O
these O
proceeded O
to O
tonic B-NEG
seizures I-NEG
, O
death O
occurred O
in O
less O
than O
20 O
min O
. O

animals O
surviving O
for O
20 O
min O
were O
immediately O
stressed O
by O
a O
swim O
test O
in O
25 O
degrees O
c O
water O
, O
and O
death-producing O
tonic B-NEG
seizures I-NEG
were O
scored O
for O
2 O
min O
. O

in O
other O
animals O
locomotor O
activity O
was O
measured O
15 O
or O
60 O
min O
after O
caffeine O
administration O
. O

by O
any O
single O
behavioral O
criterion O
or O
a O
combination O
of O
these O
criteria O
, O
marked O
differences O
in O
response O
to O
toxic O
caffeine O
doses O
were O
observed O
between O
strains O
. O

these O
results O
indicate O
that O
behavioral O
toxicity B-NEG
testing O
of O
alkylxanthines O
in O
a O
single O
mouse O
strain O
may O
be O
misleading O
and O
suggest O
that O
toxic O
responses O
of O
the O
central O
nervous O
system O
to O
this O
class O
of O
compounds O
are O
genetically O
influenced O
in O
mammals O
. O

-DOCSTART- O

invasive O
carcinoma B-NEG
of I-NEG
the I-NEG
renal I-NEG
pelvis I-NEG
following O
cyclophosphamide O
therapy O
for O
nonmalignant O
disease O
. O

a O
47-year-old O
woman O
with O
right O
hydroureteronephrosis B-NEG
due O
to O
ureterovesical O
junction O
obstruction O
had O
gross O
hematuria B-NEG
after O
being O
treated O
for O
five O
years O
wtih O
cyclophosphamide O
for O
cerebral B-NEG
vasculitis I-NEG
. O

a O
right O
nephroureterectomy O
was O
required O
for O
control O
of O
bleeding B-NEG
. O

the O
pathology O
specimen O
contained O
clinically O
occult O
invasive O
carcinoma B-NEG
of I-NEG
the I-NEG
renal I-NEG
pelvis I-NEG
. O

although O
the O
ability O
of O
cyclophosphamide O
to O
cause O
hemorrhagic B-NEG
cystitis I-NEG
and O
urine O
cytologic O
abnormalities O
indistinguishable O
from O
high O
grade O
carcinoma B-NEG
is O
well O
known O
, O
it O
is O
less O
widely O
appreciated O
that O
it O
is O
also O
associated O
with O
carcinoma B-NEG
of I-NEG
the I-NEG
urinary I-NEG
tract I-NEG
. O

twenty O
carcinomas B-NEG
of I-NEG
the I-NEG
urinary I-NEG
bladder I-NEG
and O
one O
carcinoma B-NEG
of I-NEG
the I-NEG
prostate I-NEG
have O
been O
reported O
in O
association O
with O
its O
use O
. O

the O
present O
case O
is O
the O
first O
carcinoma B-NEG
of I-NEG
the I-NEG
renal I-NEG
pelvis I-NEG
reported O
in O
association O
with O
cyclophosphamide O
treatment O
. O

it O
is O
the O
third O
urinary B-NEG
tract I-NEG
cancer I-NEG
reported O
in O
association O
with O
cyclophosphamide O
treatment O
for O
nonmalignant O
disease O
. O

the O
association O
of O
the O
tumor B-NEG
with O
preexisting O
hydroureteronephrosis B-NEG
suggests O
that O
stasis O
prolonged O
and O
intensified O
exposure O
of O
upper O
urinary O
tract O
epithelium O
to O
cyclophosphamide O
. O

patients O
who O
are O
candidates O
for O
long-term O
cyclophosphamide O
treatment O
should O
be O
routinely O
evaluated O
for O
obstructive B-NEG
uropathy I-NEG
. O

-DOCSTART- O

ascending O
dose O
tolerance O
study O
of O
intramuscular O
carbetocin O
administered O
after O
normal O
vaginal O
birth O
. O

objective O
: O
to O
determine O
the O
maximum O
tolerated O
dose O
( O
mtd O
) O
of O
carbetocin O
(a O
long-acting O
synthetic O
analogue O
of O
oxytocin) O
, O
when O
administered O
immediately O
after O
vaginal O
delivery O
at O
term O
. O

materials O
and O
methods O
: O
carbetocin O
was O
given O
as O
an O
intramuscular O
injection O
immediately O
after O
the O
birth O
of O
the O
infant O
in O
45 O
healthy O
women O
with O
normal O
singleton O
pregnancies O
who O
delivered O
vaginally O
at O
term O
. O

dosage O
groups O
of O
15 O
, O
30 O
, O
50 O
, O
75 O
, O
100 O
, O
125 O
, O
150 O
, O
175 O
or O
200 O
microg O
carbetocin O
were O
assigned O
to O
blocks O
of O
three O
women O
according O
to O
the O
continual O
reassessment O
method O
(crm) O
. O

results O
: O
all O
dosage O
groups O
consisted O
of O
three O
women O
, O
except O
those O
with O
100 O
microg O
( O
n=6 O
) O
and O
200 O
microg O
(n=18) O
. O

recorded O
were O
dose-limiting O
adverse O
events O
: O
hyper- B-NEG
or I-NEG
hypotension I-NEG
(three) O
, O
severe O
abdominal B-NEG
pain I-NEG
(0) O
, O
vomiting B-NEG
( O
0 O
) O
and O
retained B-NEG
placenta I-NEG
(four) O
. O

serious O
adverse O
events O
occurred O
in O
seven O
women O
: O
six O
cases O
with O
blood B-NEG
loss I-NEG
> O
or O
= O
1000 O
ml O
, O
four O
cases O
of O
manual O
placenta O
removal O
, O
five O
cases O
of O
additional O
oxytocics O
administration O
and O
five O
cases O
of O
blood O
transfusion O
. O

maximum O
blood B-NEG
loss I-NEG
was O
greatest O
at O
the O
upper O
and O
lower O
dose O
levels O
, O
and O
lowest O
in O
the O
70-125 O
microg O
dose O
range O
. O

four O
out O
of O
six O
cases O
with O
blood B-NEG
loss I-NEG
> O
or O
= O
1000 O
ml O
occurred O
in O
the O
200 O
microg O
group O
. O

the O
majority O
of O
additional O
administration O
of O
oxytocics O
( O
4/5 O
) O
and O
blood O
transfusion O
( O
3/5 O
) O
occurred O
in O
the O
dose O
groups O
of O
200 O
microg O
. O

all O
retained O
placentae O
were O
found O
in O
the O
group O
of O
200 O
microg O
. O

conclusion O
: O
the O
mtd O
was O
calculated O
to O
be O
at O
200 O
microg O
carbetocin O
. O

-DOCSTART- O

a O
pilot O
study O
to O
assess O
the O
safety O
of O
dobutamine O
stress O
echocardiography O
in O
the O
emergency O
department O
evaluation O
of O
cocaine-associated O
chest B-NEG
pain I-NEG
. O

study O
objective O
: O
chest B-NEG
pain I-NEG
in O
the O
setting O
of O
cocaine O
use O
poses O
a O
diagnostic O
dilemma O
. O

dobutamine O
stress O
echocardiography O
( O
dse O
) O
is O
a O
widely O
available O
and O
sensitive O
test O
for O
evaluating O
cardiac O
ischemia B-NEG
. O

because O
of O
the O
theoretical O
concern O
regarding O
administration O
of O
dobutamine O
in O
the O
setting O
of O
cocaine O
use O
, O
we O
conducted O
a O
pilot O
study O
to O
assess O
the O
safety O
of O
dse O
in O
emergency O
department O
patients O
with O
cocaine-associated O
chest B-NEG
pain I-NEG
. O

methods O
: O
a O
prospective O
case O
series O
was O
conducted O
in O
the O
intensive O
diagnostic O
and O
treatment O
unit O
in O
the O
ed O
of O
an O
urban O
tertiary-care O
teaching O
hospital O
. O

patients O
were O
eligible O
for O
dse O
if O
they O
had O
used O
cocaine O
within O
24 O
hours O
preceding O
the O
onset O
of O
chest B-NEG
pain I-NEG
and O
had O
a O
normal O
ecg O
and O
tropinin O
i O
level O
. O

patients O
exhibiting O
signs O
of O
continuing O
cocaine O
toxicity B-NEG
were O
excluded O
from O
the O
study O
. O

all O
patients O
were O
admitted O
to O
the O
hospital O
for O
serial O
testing O
after O
the O
dse O
testing O
in O
the O
intensive O
diagnostic O
and O
treatment O
unit O
. O

results O
: O
twenty-four O
patients O
were O
enrolled O
. O

two O
patients O
had O
inadequate O
resting O
images O
, O
one O
dse O
was O
terminated O
because O
of O
inferior O
hypokinesis B-NEG
, O
another O
dse O
was O
terminated O
because O
of O
a O
rate-related O
atrial O
conduction O
deficit O
, O
and O
1 O
patient O
did O
not O
reach O
the O
target O
heart O
rate O
. O

thus O
, O
19 O
patients O
completed O
a O
dse O
and O
reached O
their O
target O
heart O
rates O
. O

none O
of O
the O
patients O
experienced O
signs O
of O
exaggerated O
adrenergic O
response O
, O
which O
was O
defined O
as O
a O
systolic O
blood O
pressure O
of O
greater O
than O
200 O
mm O
hg O
or O
the O
occurrence O
of O
tachydysrhythmias B-NEG
( O
excluding O
sinus B-NEG
tachycardia I-NEG
). O

further O
suggesting O
lack O
of O
exaggerated O
adrenergic O
response O
, O
13 O
( O
65% O
) O
of O
20 O
patients O
required O
supplemental O
atropine O
to O
reach O
their O
target O
heart O
rates O
. O

conclusion O
: O
no O
exaggerated O
adrenergic O
response O
was O
detected O
when O
dobutamine O
was O
administered O
to O
patients O
with O
cocaine-related O
chest B-NEG
pain I-NEG
. O

-DOCSTART- O

amiodarone-induced O
torsade B-NEG
de I-NEG
pointes I-NEG
during O
bladder O
irrigation O
: O
an O
unusual O
presentation--a O
case O
report O
. O

the O
authors O
present O
a O
case O
of O
early O
( O
within O
4 O
days O
) O
development O
of O
torsade B-NEG
de I-NEG
pointes I-NEG
( O
tdp B-NEG
) O
associated O
with O
oral O
amiodarone O
therapy O
. O

consistent O
with O
other O
reports O
this O
case O
of O
tdp B-NEG
occurred O
in O
the O
context O
of O
multiple O
exacerbating O
factors O
including O
hypokalemia B-NEG
and O
digoxin O
excess O
. O

transient O
prolongation O
of O
the O
qt O
during O
bladder O
irrigation O
prompted O
the O
episode O
of O
tdp B-NEG
. O

it O
is O
well O
known O
that O
bradycardia B-NEG
exacerbates O
acquired O
tdp B-NEG
. O

the O
authors O
speculate O
that O
the O
increased O
vagal O
tone O
during O
bladder O
irrigation O
, O
a O
vagal O
maneuver O
, O
in O
the O
context O
of O
amiodarone O
therapy O
resulted O
in O
amiodarone-induced O
proarrhythmia B-NEG
. O

in O
the O
absence O
of O
amiodarone O
therapy O
, O
a O
second O
bladder O
irrigation O
did O
not O
induce O
tdp B-NEG
despite O
hypokalemia B-NEG
and O
hypomagnesemia B-NEG
. O

-DOCSTART- O

acute B-NEG
renal I-NEG
insufficiency I-NEG
after O
high-dose O
melphalan O
in O
patients O
with O
primary B-NEG
systemic I-NEG
amyloidosis I-NEG
during O
stem O
cell O
transplantation O
. O

background O
: O
patients O
with O
primary B-NEG
systemic I-NEG
amyloidosis I-NEG
( O
al B-NEG
) O
have O
a O
poor O
prognosis O
. O

median O
survival O
time O
from O
standard O
treatments O
is O
only O
17 O
months O
. O

high-dose O
intravenous O
melphalan O
followed O
by O
peripheral O
blood O
stem O
cell O
transplant O
( O
pbsct O
) O
appears O
to O
be O
the O
most O
promising O
therapy O
, O
but O
treatment O
mortality O
can O
be O
high O
. O

the O
authors O
have O
noted O
the O
development O
of O
acute B-NEG
renal I-NEG
insufficiency I-NEG
immediately O
after O
melphalan O
conditioning O
. O

this O
study O
was O
undertaken O
to O
further O
examine O
its O
risk O
factors O
and O
impact O
on O
posttransplant O
mortality O
. O

methods O
: O
consecutive O
al B-NEG
patients O
who O
underwent O
pbsct O
were O
studied O
retrospectively O
. O
acute B-NEG
renal I-NEG
insufficiency I-NEG
( O
ari B-NEG
) O
after O
high-dose O
melphalan O
was O
defined O
by O
a O
minimum O
increase O
of O
0.5 O
mg/dl O
( O
44 O
micromol/l O
) O
in O
the O
serum O
creatinine O
level O
that O
is O
greater O
than O
50% O
of O
baseline O
immediately O
after O
conditioning O
. O

urine O
sediment O
score O
was O
the O
sum O
of O
the O
individual O
types O
of O
sediment O
identified O
on O
urine O
microscopy O
. O

results O
: O
of O
the O
80 O
patients O
studied O
, O
ari B-NEG
developed O
in O
18.8% O
of O
the O
patients O
after O
high-dose O
melphalan O
. O

univariate O
analysis O
identified O
age O
, O
hypoalbuminemia B-NEG
, O
heavy O
proteinuria B-NEG
, O
diuretic O
use O
, O
and O
urine O
sediment O
score O
( O
>3 O
) O
as O
risk O
factors O
. O

age O
and O
urine O
sediment O
score O
remained O
independently O
significant O
risk O
factors O
in O
the O
multivariate O
analysis O
. O

patients O
who O
had O
ari B-NEG
after O
high-dose O
melphalan O
underwent O
dialysis O
more O
often O
(p O
= O
0.007) O
, O
and O
had O
a O
worse O
1-year O
survival O
(p O
= O
0.03) O
. O

conclusion O
: O
the O
timing O
of O
renal B-NEG
injury I-NEG
strongly O
suggests O
melphalan O
as O
the O
causative O
agent O
. O

ongoing O
tubular B-NEG
injury I-NEG
may O
be O
a O
prerequisite O
for O
renal B-NEG
injury I-NEG
by O
melphalan O
as O
evidenced O
by O
the O
active O
urinary O
sediment O
. O

development O
of O
ari B-NEG
adversely O
affected O
the O
outcome O
after O
pbsct O
. O

effective O
preventive O
measures O
may O
help O
decrease O
the O
treatment O
mortality O
of O
pbsct O
in O
al B-NEG
patients O
. O

-DOCSTART- O

impaired B-NEG
fear I-NEG
recognition I-NEG
in O
regular O
recreational O
cocaine O
users O
. O

introduction O
: O
the O
ability O
to O
read O
facial O
expressions O
is O
essential O
for O
normal O
human O
social O
interaction O
. O

the O
aim O
of O
the O
present O
study O
was O
to O
conduct O
the O
first O
investigation O
of O
facial O
expression O
recognition O
performance O
in O
recreational O
cocaine O
users O
. O

materials O
and O
methods O
: O
three O
groups O
, O
comprised O
of O
21 O
cocaine O
naive O
participants O
(cn) O
, O
30 O
occasional O
cocaine O
(oc) O
, O
and O
48 O
regular O
recreational O
cocaine O
( O
rc O
) O
users O
, O
were O
compared O
. O

an O
emotional O
facial O
expression O
( O
efe O
) O
task O
consisting O
of O
a O
male O
and O
female O
face O
expressing O
six O
basic O
emotions O
(happiness O
, O
surprise O
, O
sadness O
, O
anger O
, O
fear O
, O
and O
disgust O
) O
was O
administered O
. O

mean O
percent O
accuracy O
and O
latencies O
for O
correct O
responses O
across O
eight O
presentations O
of O
each O
basic O
emotion O
were O
derived O
. O

participants O
were O
also O
assessed O
with O
the O
eyes O
task O
to O
investigate O
their O
ability O
to O
recognize O
more O
complex O
emotional O
states O
and O
the O
symptom O
checklist-90-revised O
to O
measure O
psychopathology O
. O

results O
: O
there O
were O
no O
group O
differences O
in O
psychopathology O
or O
eyes O
task O
performance O
, O
but O
the O
rc O
group O
, O
who O
otherwise O
had O
similar O
illicit O
substance O
use O
histories O
to O
the O
oc O
group O
, O
exhibited O
impaired B-NEG
fear I-NEG
recognition I-NEG
accuracy O
compared O
to O
the O
oc O
and O
cn O
groups O
. O

the O
rc O
group O
also O
correctly O
identified O
anger O
, O
fear O
, O
happiness O
, O
and O
surprise O
, O
more O
slowly O
than O
cn O
, O
but O
not O
oc O
participants O
. O

the O
oc O
group O
was O
slower O
than O
cn O
when O
correctly O
identifying O
disgust O
. O

the O
selective O
deficit B-NEG
in I-NEG
fear I-NEG
recognition I-NEG
accuracy O
manifested O
by O
the O
rc O
group O
cannot O
be O
explained O
by O
the O
subacute O
effects O
of O
cocaine O
, O
or O
ecstasy O
, O
because O
recent O
and O
less O
recent O
users O
of O
these O
drugs O
within O
this O
group O
were O
similarly O
impaired O
. O

possible O
parallels O
between O
rc O
users O
and O
psychopaths B-NEG
with O
respect O
to O
impaired B-NEG
fear I-NEG
recognition I-NEG
, O
amygdala B-NEG
dysfunction I-NEG
, O
and O
etiology O
are O
discussed O
. O

-DOCSTART- O

corneal B-NEG
ulcers I-NEG
associated O
with O
aerosolized O
crack O
cocaine O
use O
. O

purpose O
: O
we O
report O
4 O
cases O
of O
corneal B-NEG
ulcers I-NEG
associated O
with O
drug B-NEG
abuse I-NEG
. O

the O
pathogenesis O
of O
these O
ulcers B-NEG
and O
management O
of O
these O
patients O
are O
also O
reviewed O
. O

methods O
: O
review O
of O
all O
cases O
of O
corneal B-NEG
ulcers I-NEG
associated O
with O
drug B-NEG
abuse I-NEG
seen O
at O
our O
institution O
from O
july O
2006 O
to O
december O
2006 O
. O

results O
: O
four O
patients O
with O
corneal B-NEG
ulcers I-NEG
associated O
with O
crack O
cocaine O
use O
were O
reviewed O
. O

all O
corneal B-NEG
ulcers I-NEG
were O
cultured O
, O
and O
the O
patients O
were O
admitted O
to O
the O
hospital O
for O
intensive O
topical O
antibiotic O
treatment O
. O

each O
patient O
received O
comprehensive O
health O
care O
, O
including O
medical O
and O
substance B-NEG
abuse I-NEG
consultations O
. O

streptococcal O
organisms O
were O
found O
in O
3 O
cases O
and O
capnocytophaga O
and O
brevibacterium O
casei O
in O
1 O
patient O
. O

the O
infections B-NEG
responded O
to O
antibiotic O
treatment O
. O

two O
patients O
needed O
a O
lateral O
tarsorrhaphy O
for O
persistent O
epithelial B-NEG
defects I-NEG
. O

conclusions O
: O
aerosolized O
crack O
cocaine O
use O
can O
be O
associated O
with O
the O
development O
of O
corneal B-NEG
ulcers I-NEG
. O
drug B-NEG
abuse I-NEG
provides O
additional O
challenges O
for O
management O
. O

not O
only O
treatment O
of O
their O
infections B-NEG
but O
also O
the O
overall O
poor O
health O
of O
the O
patients O
and O
increased O
risk O
of O
noncompliance O
need O
to O
be O
addressed O
. O

comprehensive O
care O
may O
provide O
the O
patient O
the O
opportunity O
to O
discontinue O
their O
substance B-NEG
abuse I-NEG
, O
improve O
their O
overall O
health O
, O
and O
prevent O
future O
corneal O
complications O
. O

-DOCSTART- O

levetiracetam O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
suspected O
idiopathic B-NEG
epilepsy I-NEG
. O

objective O
: O
to O
assess O
pharmacokinetics O
, O
efficacy O
, O
and O
tolerability O
of O
oral O
levetiracetam O
administered O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
poorly O
controlled O
suspected O
idiopathic B-NEG
epilepsy I-NEG
. O

design-open-label O
, O
noncomparative O
clinical O
trial O
. O

animals O
: O
12 O
cats O
suspected O
to O
have O
idiopathic B-NEG
epilepsy I-NEG
that O
was O
poorly O
controlled O
with O
phenobarbital O
or O
that O
had O
unacceptable O
adverse O
effects O
when O
treated O
with O
phenobarbital O
. O

procedures O
: O
cats O
were O
treated O
with O
levetiracetam O
( O
20 O
mg/kg O
[9.1 O
mg/lb] O
, O
po O
, O
q O
8 O
h) O
. O

after O
a O
minimum O
of O
1 O
week O
of O
treatment O
, O
serum O
levetiracetam O
concentrations O
were O
measured O
before O
and O
2, O
4, O
and O
6 O
hours O
after O
drug O
administration O
, O
and O
maximum O
and O
minimum O
serum O
concentrations O
and O
elimination O
half-life O
were O
calculated O
. O
seizure B-NEG
frequencies O
before O
and O
after O
initiation O
of O
levetiracetam O
treatment O
were O
compared O
, O
and O
adverse O
effects O
were O
recorded O
. O

results O
: O
median O
maximum O
serum O
levetiracetam O
concentration O
was O
25.5 O
microg/ml O
, O
median O
minimum O
serum O
levetiracetam O
concentration O
was O
8.3 O
microg/ml O
, O
and O
median O
elimination O
half-life O
was O
2.9 O
hours O
. O

median O
seizure B-NEG
frequency O
prior O
to O
treatment O
with O
levetiracetam O
( O
2.1 O
seizures B-NEG
/mo O
) O
was O
significantly O
higher O
than O
median O
seizure B-NEG
frequency O
after O
initiation O
of O
levetiracetam O
treatment O
( O
0.42 O
seizures B-NEG
/mo) O
, O
and O
7 O
of O
10 O
cats O
were O
classified O
as O
having O
responded O
to O
levetiracetam O
treatment O
(ie O
, O
reduction O
in O
seizure B-NEG
frequency O
of O
>or=50%) O
. O

two O
cats O
had O
transient O
lethargy B-NEG
and O
inappetence B-NEG
. O

conclusions O
and O
clinical O
relevance O
: O
results O
suggested O
that O
levetiracetam O
is O
well O
tolerated O
in O
cats O
and O
may O
be O
useful O
as O
an O
adjunct O
to O
phenobarbital O
treatment O
in O
cats O
with O
idiopathic B-NEG
epilepsy I-NEG
. O

-DOCSTART- O

bilateral O
haemorrhagic B-NEG
infarction I-NEG
of I-NEG
the I-NEG
globus I-NEG
pallidus I-NEG
after O
cocaine O
and O
alcohol O
intoxication O
. O

cocaine O
is O
a O
risk O
factor O
for O
both O
ischemic B-NEG
and I-NEG
haemorrhagic I-NEG
stroke I-NEG
. O

we O
present O
the O
case O
of O
a O
31-year-old O
man O
with O
bilateral O
ischemia B-NEG
of I-NEG
the I-NEG
globus I-NEG
pallidus I-NEG
after O
excessive O
alcohol O
and O
intranasal O
cocaine O
use O
. O

drug-related O
globus B-NEG
pallidus I-NEG
infarctions I-NEG
are O
most O
often O
associated O
with O
heroin O
. O

bilateral O
basal B-NEG
ganglia I-NEG
infarcts I-NEG
after O
the O
use O
of O
cocaine O
, O
without O
concurrent O
heroin O
use O
, O
have O
never O
been O
reported O
. O

in O
our O
patient O
, O
transient O
cardiac B-NEG
arrhythmia I-NEG
or O
respiratory B-NEG
dysfunction I-NEG
related O
to O
cocaine O
and/or O
ethanol O
use O
were O
the O
most O
likely O
causes O
of O
cerebral B-NEG
hypoperfusion I-NEG
. O

-DOCSTART- O

acute B-NEG
renal I-NEG
failure I-NEG
after O
high-dose O
methotrexate O
therapy O
in O
a O
patient O
with O
ileostomy O
. O

high-dose O
methotrexate O
( O
hd-mtx O
) O
is O
an O
important O
treatment O
for O
burkitt B-NEG
lymphoma I-NEG
, O
but O
can O
cause O
hepatic B-NEG
and I-NEG
renal I-NEG
toxicity I-NEG
when O
its O
clearance O
is O
delayed O
. O

we O
report O
a O
case O
of O
acute B-NEG
renal I-NEG
failure I-NEG
after O
hd-mtx O
therapy O
in O
a O
patient O
with O
ileostomy O
, O
the O
patient O
was O
a O
3-year-old O
boy O
who O
had O
received O
a O
living-related O
liver O
transplantation O
for O
congenital O
biliary B-NEG
atresia I-NEG
. O

at O
day O
833 O
after O
the O
transplantation O
, O
he O
was O
diagnosed O
with O
ptld B-NEG
( O
post-transplantation B-NEG
lymphoproliferative I-NEG
disorder I-NEG
, O
burkitt-type B-NEG
malignant I-NEG
lymphoma I-NEG
). O

during O
induction O
therapy O
, O
he O
suffered O
ileal O
perforation O
and O
ileostomy O
was O
performed O
. O

subsequent O
hd-mtx O
therapy O
caused O
acute B-NEG
renal I-NEG
failure I-NEG
that O
required O
continuous O
hemodialysis O
. O

we O
supposed O
that O
intravascular O
hypovolemia B-NEG
due O
to O
substantial O
drainage O
from O
the O
ileostoma O
caused O
acute B-NEG
prerenal I-NEG
failure I-NEG
. O

after O
recovery O
of O
his O
renal O
function O
, O
we O
could O
safely O
treat O
the O
patient O
with O
hd-mtx O
therapy O
by O
controlling O
drainage O
from O
ileostoma O
with O
total O
parenteral O
nutrition O
. O

-DOCSTART- O

antithrombotic O
drug O
use O
, O
cerebral B-NEG
microbleeds I-NEG
, O
and O
intracerebral B-NEG
hemorrhage I-NEG
: O
a O
systematic O
review O
of O
published O
and O
unpublished O
studies O
. O

background O
and O
purpose O
: O
cerebral B-NEG
microbleeds I-NEG
( O
mb B-NEG
) O
are O
potential O
risk O
factors O
for O
intracerebral B-NEG
hemorrhage I-NEG
( O
ich B-NEG
), O
but O
it O
is O
unclear O
if O
they O
are O
a O
contraindication O
to O
using O
antithrombotic O
drugs O
. O

insights O
could O
be O
gained O
by O
pooling O
data O
on O
mb B-NEG
frequency O
stratified O
by O
antithrombotic O
use O
in O
cohorts O
with O
ich B-NEG
and O
ischemic B-NEG
stroke I-NEG
( O
is B-NEG
)/ O
transient B-NEG
ischemic I-NEG
attack I-NEG
( O
tia B-NEG
). O

methods O
: O
we O
performed O
a O
systematic O
review O
of O
published O
and O
unpublished O
data O
from O
cohorts O
with O
stroke B-NEG
or O
tia B-NEG
to O
compare O
the O
presence O
of O
mb B-NEG
in O
: O
( O
1 O
) O
antithrombotic O
users O
vs O
nonantithrombotic O
users O
with O
ich B-NEG
; O
( O
2 O
) O
antithrombotic O
users O
vs O
nonusers O
with O
is B-NEG
/ O
tia B-NEG
; O
and O
( O
3 O
) O
ich B-NEG
vs O
ischemic B-NEG
events O
stratified O
by O
antithrombotic O
use O
. O

we O
also O
analyzed O
published O
and O
unpublished O
follow-up O
data O
to O
determine O
the O
risk O
of O
ich B-NEG
in O
antithrombotic O
users O
with O
mb B-NEG
. O

results O
: O
in O
a O
pooled O
analysis O
of O
1460 O
ich B-NEG
and O
3817 O
is B-NEG
/ O
tia B-NEG
, O
mb B-NEG
were O
more O
frequent O
in O
ich B-NEG
vs O
is B-NEG
/ O
tia B-NEG
in O
all O
treatment O
groups O
, O
but O
the O
excess O
increased O
from O
2.8 O
( O
odds O
ratio O
; O
range O
, O
2.3-3.5 O
) O
in O
nonantithrombotic O
users O
to O
5.7 O
(range O
, O
3.4-9.7 O
) O
in O
antiplatelet O
users O
and O
8.0 O
(range O
, O
3.5-17.8 O
) O
in O
warfarin O
users O
(p O
difference=0.01) O
. O

there O
was O
also O
an O
excess O
of O
mb B-NEG
in O
warfarin O
users O
vs O
nonusers O
with O
ich B-NEG
(or O
, O
2.7 O
; O
95% O
ci O
, O
1.6-4.4 O
; O
p<0.001 O
) O
but O
none O
in O
warfarin O
users O
with O
is B-NEG
/ O
tia B-NEG
(or O
, O
1.3 O
; O
95% O
ci O
, O
0.9-1.7 O
; O
p=0.33 O
; O
p O
difference=0.01) O
. O

there O
was O
a O
smaller O
excess O
of O
mb B-NEG
in O
antiplatelet O
users O
vs O
nonusers O
with O
ich B-NEG
(or O
, O
1.7 O
; O
95% O
ci O
, O
1.3-2.3 O
; O
p<0.001) O
, O
but O
findings O
were O
similar O
for O
antiplatelet O
users O
with O
is B-NEG
/ O
tia B-NEG
(or O
, O
1.4 O
; O
95% O
ci O
, O
1.2-1.7 O
; O
p<0.001 O
; O
p O
difference=0.25) O
. O

in O
pooled O
follow-up O
data O
for O
768 O
antithrombotic O
users O
, O
presence O
of O
mb B-NEG
at O
baseline O
was O
associated O
with O
a O
substantially O
increased O
risk O
of O
subsequent O
ich B-NEG
(or O
, O
12.1 O
; O
95% O
ci O
, O
3.4-42.5 O
; O
p<0.001) O
. O

conclusions O
: O
the O
excess O
of O
mb B-NEG
in O
warfarin O
users O
with O
ich B-NEG
compared O
to O
other O
groups O
suggests O
that O
mb B-NEG
increase O
the O
risk O
of O
warfarin-associated O
ich B-NEG
. O

limited O
prospective O
data O
corroborate O
these O
findings O
, O
but O
larger O
prospective O
studies O
are O
urgently O
required O
. O

-DOCSTART- O

verapamil O
stimulation O
test O
in O
hyperprolactinemia B-NEG
: O
loss O
of O
prolactin O
response O
in O
anatomic O
or O
functional O
stalk O
effect O
. O

aim O
: O
verapamil O
stimulation O
test O
was O
previously O
investigated O
as O
a O
tool O
for O
differential O
diagnosis O
of O
hyperprolactinemia B-NEG
, O
but O
with O
conflicting O
results O
. O
macroprolactinemia B-NEG
was O
never O
considered O
in O
those O
previous O
studies O
. O

here O
, O
we O
aimed O
to O
re-investigate O
the O
diagnostic O
value O
of O
verapamil O
in O
a O
population O
who O
were O
all O
screened O
for O
macroprolactinemia B-NEG
. O

prolactin O
responses O
to O
verapamil O
in O
65 O
female O
patients O
(age O
: O
29.9 O
+/- O
8.1 O
years O
) O
with O
hyperprolactinemia B-NEG
were O
tested O
in O
a O
descriptive O
, O
matched O
case-control O
study O
. O

methods O
: O
verapamil O
80 O
mg O
, O
p.o O
. O
was O
administered O
, O
and O
then O
prl O
levels O
were O
measured O
at O
8th O
and O
16th O
hours O
, O
by O
immunometric O
chemiluminescence O
. O

verapamil O
responsiveness O
was O
determined O
by O
peak O
percent O
change O
in O
basal O
prolactin O
levels O
(prl) O
. O

results O
: O
verapamil O
significantly O
increased O
prl O
levels O
in O
healthy O
controls O
(n O
. O
8, O
prl O
: O
183%) O
, O
macroprolactinoma B-NEG
(n O
. O
8, O
prl O
: O
7%) O
, O
microprolactinoma B-NEG
(n O
. O
19 O
, O
prl O
: O
21%) O
, O
macroprolactinemia B-NEG
(n O
. O
23 O
, O
prl O
: O
126%) O
, O
but O
not O
in O
pseudoprolactinoma B-NEG
(n O
. O
8, O
prl O
: O
0.8%) O
, O
and O
risperidone-induced O
hyperprolactinemia B-NEG
(n O
. O
7, O
prl O
: O
3%) O
. O

roc O
curve O
analysis O
revealed O
that O
unresponsiveness O
to O
verapamil O
defined O
as O
prl O
<7% O
, O
discriminated O
anatomical O
or O
functional O
stalk O
effect O
(sensitivity O
: O
74% O
, O
specificity O
: O
73% O
, O
auc O
: O
0.855+/-0.04 O
, O
p O
<0.001 O
, O
ci O
: O
0.768-0.942 O
) O
associated O
with O
pseudoprolactinoma B-NEG
or O
risperidone-induced O
hyperprolactinemia B-NEG
, O
respectively O
. O

conclusion O
: O
verapamil O
responsiveness O
is O
not O
a O
reliable O
finding O
for O
the O
differential O
diagnosis O
of O
hyperprolactinemia B-NEG
. O

however O
, O
verapamil O
unresponsiveness O
discriminates O
stalk O
effect O
(i.e. O
, O
anatomically O
or O
functionally O
inhibited O
dopaminergic O
tonus O
) O
from O
other O
causes O
of O
hyperprolactinemia B-NEG
with O
varying O
degrees O
of O
responsiveness O
. O

-DOCSTART- O

central O
action O
of O
narcotic O
analgesics O
. O

part O
iv O
. O

noradrenergic O
influences O
on O
the O
activity O
of O
analgesics O
in O
rats O
. O

the O
effect O
of O
clonidine O
, O
naphazoline O
and O
xylometazoline O
on O
analgesia O
induced O
by O
morphine O
, O
codeine O
, O
fentanyl O
and O
pentazocine O
, O
and O
on O
cataleptic B-NEG
effect O
of O
morphine O
, O
codine O
and O
fentanyl O
was O
studied O
in O
rats O
. O

the O
biochemical O
assays O
on O
the O
influence O
of O
four O
analgesics O
on O
the O
brain O
concentration O
and O
turnover O
of O
noradrenaline O
( O
na O
) O
were O
also O
performed O
. O

it O
was O
found O
that O
three O
drugs O
stimulating O
central O
na O
receptors O
failed O
to O
affect O
the O
analgesic O
ed50 O
of O
all O
antinociceptive O
agents O
and O
they O
enhanced O
catalepsy B-NEG
induced O
by O
morphine O
and O
fentanyl O
. O

codeine O
catalepsy B-NEG
was O
increased O
by O
clonidine O
and O
decreased O
by O
naphazoline O
and O
xylometazoline O
. O

the O
brain O
concentration O
of O
na O
was O
not O
changed O
by O
morphine O
and O
fentanyl O
, O
but O
one O
of O
the O
doses O
of O
codeine O
( O
45 O
mg/kg O
) O
slightly O
enhanced O
it O
. O

pentazocine O
dose-dependently O
decreased O
the O
brain O
level O
of O
na O
. O

the O
rate O
of O
na O
turnover O
was O
not O
altered O
by O
analgesics O
except O
for O
the O
higher O
dose O
of O
fentanyl O
( O
0.2 O
mg/kg O
) O
following O
which O
the O
disappearance O
of O
na O
from O
the O
brain O
was O
diminished O
. O

the O
results O
are O
discussed O
in O
the O
light O
of O
various O
and O
non-uniform O
data O
from O
the O
literature O
. O

it O
is O
suggested O
that O
in O
rats O
the O
brain O
na O
plays O
a O
less O
important O
function O
than O
the O
other O
monoamines O
in O
the O
behavioural O
activity O
of O
potent O
analgesics O
. O

-DOCSTART- O

modification O
by O
propranolol O
of O
cardiovascular O
effects O
of O
induced O
hypoglycaemia B-NEG
. O

the O
cardiovascular O
effects O
of O
hypoglycaemia B-NEG
, O
with O
and O
without O
beta-blockade O
, O
were O
compared O
in O
fourteen O
healthy O
men O
. O

eight O
received O
insulin O
alone O
, O
and O
eight O
, O
including O
two O
of O
the O
original O
insulin-only O
group O
, O
were O
given O
propranolol O
and O
insulin O
. O

in O
the O
insulin-group O
the O
period O
of O
hypoglycaemia B-NEG
was O
associated O
with O
an O
increase O
in O
heart-rate O
and O
a O
fall O
in O
diastolic O
blood-pressure O
. O

in O
the O
propranolol-insulin O
group O
there O
was O
a O
significant O
fall O
in O
heart-rate O
in O
most O
subjects O
and O
an O
increase O
in O
diastolic O
pressure O
. O

typical O
s-t/t O
changes O
occurred O
in O
the O
insulin-group O
but O
in O
none O
of O
the O
propranolol-insulin O
group O
. O
hypertension B-NEG
in O
diabetics B-NEG
prone O
to O
hypoglycaemia B-NEG
attacks O
should O
not O
be O
treated O
with O
beta-blockers O
because O
these O
drugs O
may O
cause O
a O
sharp O
rise O
in O
blood-pressure O
in O
such O
patients O
. O

-DOCSTART- O

prevention O
and O
treatment O
of O
endometrial B-NEG
disease I-NEG
in O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

the O
treatment O
regimens O
are O
described O
in O
74 O
patients O
with O
endometrial B-NEG
disease I-NEG
among O
850 O
climacteric O
women O
receiving O
oestrogen O
therapy O
. O

cystic O
hyperplasia B-NEG
was O
associated O
with O
unopposed O
oestrogen O
therapy O
without O
progestagen O
. O

two O
courses O
of O
21 O
days O
of O
5 O
mg O
norethisterone O
daily O
caused O
reversion O
to O
normal O
in O
all O
57 O
cases O
of O
cystic O
hyperplasia B-NEG
and O
6 O
of O
the O
8 O
cases O
of O
atypical O
hyperplasia B-NEG
. O

4 O
cases O
of O
endometrial B-NEG
carcinoma I-NEG
referred O
from O
elsewhere O
demonstrated O
the O
problems O
of O
inappropriate O
and O
unsupervised O
unopposed O
oestrogen O
therapy O
and O
the O
difficulty O
in O
distinguishing O
severe O
hyperplasia B-NEG
from O
malignancy B-NEG
. O

cyclical O
low-dose O
oestrogen O
therapy O
with O
7--13 O
days O
of O
progestagen O
does O
not O
seem O
to O
increase O
the O
risk O
of O
endometrial B-NEG
hyperplasia I-NEG
or O
carcinoma B-NEG
. O

-DOCSTART- O

pure B-NEG
red I-NEG
cell I-NEG
aplasia I-NEG
, O
toxic B-NEG
dermatitis I-NEG
and O
lymphadenopathy B-NEG
in O
a O
patient O
taking O
diphenylhydantoin O
. O

a O
patient O
taking O
diphenylhydantoin O
for O
3 O
weeks O
developed O
a O
generalized O
skin B-NEG
rash I-NEG
, O
lymphadenopathy B-NEG
and O
pure B-NEG
red I-NEG
cell I-NEG
aplasia I-NEG
. O

after O
withdrawal O
of O
the O
pharmacon O
all O
symptoms O
disappeared O
spontaneously O
. O
skin B-NEG
rash I-NEG
is O
a O
well-known O
complication O
of O
diphenylhydantoin O
treatment O
as O
is O
benign O
and O
malignant O
lymphadenopathy B-NEG
. O
pure B-NEG
red I-NEG
cell I-NEG
aplasia I-NEG
associated O
with O
diphenylhydantoin O
medication O
has O
been O
reported O
in O
3 O
patients O
. O

the O
exact O
mechanism O
by O
which O
diphenylhydantoin O
exerts O
its O
toxic O
effects O
is O
not O
known O
. O

in O
this O
patient O
the O
time O
relation O
between O
the O
ingestion O
of O
diphenylhydantoin O
and O
the O
occurrence O
of O
the O
skin B-NEG
rash I-NEG
, O
lymphadenopathy B-NEG
and O
pure B-NEG
red I-NEG
cell I-NEG
aplasia I-NEG
is O
very O
suggestive O
of O
a O
direct O
connection O
. O

-DOCSTART- O

continuous O
infusion O
tobramycin O
combined O
with O
carbenicillin O
for O
infections B-NEG
in O
cancer B-NEG
patients O
. O

the O
cure O
rate O
of O
infections B-NEG
in O
cancer B-NEG
patients O
is O
adversely O
affected O
by O
neutropenia B-NEG
( O
less O
than O
1,000/mm3) O
. O

in O
particular O
, O
patients O
with O
severe O
neutropenia B-NEG
( O
less O
than O
100/mm3 O
) O
have O
shown O
a O
poor O
response O
to O
antibiotics O
. O

to O
overcome O
the O
adverse O
effects O
of O
neutropenia B-NEG
, O
tobramycin O
was O
given O
by O
continuous O
infusion O
and O
combined O
with O
intermittent O
carbenicillin O
. O

tobramycin O
was O
given O
to O
a O
total O
daily O
dose O
of O
300 O
mg/m2 O
and O
carbenicillin O
was O
given O
at O
a O
dose O
of O
5 O
gm O
every O
four O
hours O
. O

there O
were O
125 O
infectious O
episodes O
in O
116 O
cancer B-NEG
patients O
receiving O
myelosuppressive O
chemotherapy O
. O

the O
overall O
cure O
rate O
was O
70% O
. O
pneumonia B-NEG
was O
the O
most O
common O
infection B-NEG
and O
61% O
of O
59 O
episodes O
were O
cured O
. O

gram-negative O
bacilli O
were O
the O
most O
common O
causative O
organisms O
and O
69% O
of O
these O
infections B-NEG
were O
cured O
. O

the O
most O
common O
pathogen O
was O
klebsiella O
pneumoniae B-NEG
and O
this O
, O
together O
with O
escherichia O
coli O
and O
pseudomonas O
aeruginosa O
, O
accounted O
for O
74% O
of O
all O
gram-negative B-NEG
bacillary I-NEG
infections I-NEG
. O

response O
was O
not O
influenced O
by O
the O
initial O
neutrophil O
count O
, O
with O
a O
62% O
cure O
rate O
for O
39 O
episodes O
associated O
with O
severe O
neutropenia B-NEG
. O

however O
, O
failure O
of O
the O
neutrophil O
count O
to O
increase O
during O
therapy O
adversely O
affected O
response O
. O
azotemia B-NEG
was O
the O
major O
side O
effect O
recognized O
, O
and O
it O
occurred O
in O
11% O
of O
episodes O
. O

major O
azotemia B-NEG
( O
serum O
creatinine O
greater O
than O
2.5 O
mg/dl O
or O
bun O
greater O
than O
50 O
mg/dl O
) O
occurred O
in O
only O
2% O
. O
azotemia B-NEG
was O
not O
related O
to O
duration O
of O
therapy O
or O
serum O
tobramycin O
concentration O
. O

this O
antibiotic O
regimen O
showed O
both O
therapeutic O
efficacy O
and O
acceptable O
renal B-NEG
toxicity I-NEG
for O
these O
patients O
. O

-DOCSTART- O

recurrent O
subarachnoid B-NEG
hemorrhage I-NEG
associated O
with O
aminocaproic O
acid O
therapy O
and O
acute B-NEG
renal I-NEG
artery I-NEG
thrombosis I-NEG
. O

case O
report O
. O

epsilon O
aminocaproic O
acid O
( O
eaca O
) O
has O
been O
used O
to O
prevent O
rebleeding O
in O
patients O
with O
subarachnoid B-NEG
hemorrhage I-NEG
( O
sah B-NEG
). O

although O
this O
agent O
does O
decrease O
the O
frequency O
of O
rebleeding O
, O
several O
reports O
have O
described O
thrombotic B-NEG
complications O
of O
eaca O
therapy O
. O

these O
complications O
have O
included O
clinical O
deterioration O
and O
intracranial B-NEG
vascular I-NEG
thrombosis I-NEG
in O
patients O
with O
sah B-NEG
, O
arteriolar O
and O
capillary O
fibrin O
thrombi B-NEG
in O
patients O
with O
fibrinolytic O
syndromes O
treated O
with O
eaca O
, O
or O
other O
thromboembolic B-NEG
phenomena I-NEG
. O

since O
intravascular O
fibrin O
thrombi B-NEG
are O
often O
observed O
in O
patients O
with O
fibrinolytic O
disorders O
, O
eaca O
should O
not O
be O
implicated O
in O
the O
pathogenesis O
of O
fibrin O
thrombi B-NEG
in O
patients O
with O
disseminated B-NEG
intravascular I-NEG
coagulation I-NEG
or O
other O
consumption B-NEG
coagulopathies I-NEG
. O

this O
report O
describes O
subtotal O
infarction B-NEG
of O
the O
kidney O
due O
to O
thrombosis B-NEG
of I-NEG
a I-NEG
normal I-NEG
renal I-NEG
artery I-NEG
. O

this O
occlusion O
occurred O
after O
eaca O
therapy O
in O
a O
patient O
with O
sah B-NEG
and O
histopathological O
documentation O
of O
recurrent O
sah B-NEG
. O

the O
corresponding O
clinical O
event O
was O
characterized O
by O
marked O
hypertension B-NEG
and O
abrupt O
neurological O
deterioration O
. O

-DOCSTART- O

long-term O
propranolol O
therapy O
in O
pregnancy O
: O
maternal O
and O
fetal O
outcome O
. O

propranolol O
, O
a O
beta-adrenergic O
blocking O
agent O
, O
has O
found O
an O
important O
position O
in O
the O
practice O
of O
medicine O
. O

its O
use O
in O
pregnancy O
, O
however O
, O
is O
an O
open O
question O
as O
a O
number O
of O
detrimental O
side O
effects O
have O
been O
reported O
in O
the O
fetus O
and O
neonate O
. O

ten O
patients O
and O
12 O
pregnancies O
are O
reported O
where O
chronic O
propranolol O
has O
been O
administered O
. O

five O
patients O
with O
serial O
pregnancies O
with O
and O
without O
propranolol O
therapy O
are O
also O
examined O
. O

maternal O
, O
fetal O
, O
and O
neonatal O
complications O
are O
examined O
. O

an O
attempt O
is O
made O
to O
differentiate O
drug-related O
complications O
from O
maternal O
disease--related O
complications O
. O

we O
conclude O
that O
previously O
reported O
hypoglycemia B-NEG
, O
hyperbilirubinemia B-NEG
, O
polycythemia B-NEG
, O
neonatal B-NEG
apnea I-NEG
, O
and O
bradycardia B-NEG
are O
not O
invariable O
and O
cannot O
be O
statistically O
correlated O
with O
chronic O
propranolol O
therapy O
. O
growth B-NEG
retardation I-NEG
, O
however O
, O
appears O
to O
be O
significant O
in O
both O
of O
our O
series O
. O

-DOCSTART- O

use O
of O
propranolol O
in O
the O
treatment O
of O
idiopathic B-NEG
orthostatic I-NEG
hypotension I-NEG
. O

five O
patients O
with O
idiopathic B-NEG
orthostatic I-NEG
hypotension I-NEG
who O
had O
physiologic O
and O
biochemical O
evidence O
of O
severe O
autonomic O
dysfunction O
were O
included O
in O
the O
study O
. O

they O
all O
exhibited O
markedly O
reduced O
plasma O
catecholamines O
and O
plasma O
renin O
activity O
in O
both O
recumbent O
and O
upright O
positions O
and O
had O
marked O
hypersensitivity B-NEG
to O
the O
pressor O
effects O
of O
infused O
norepinephrine O
. O

treatment O
with O
propanolol O
administered O
intravenously O
( O
1-5 O
mg O
) O
produced O
increases O
in O
supine O
and O
upright O
blood O
pressure O
in O
4 O
of O
the O
5 O
individuals O
with O
rises O
ranging O
from O
11/6 O
to O
22/11 O
mmhg O
. O

chronic O
oral O
administration O
of O
propranolol O
( O
40-160 O
mg/day O
) O
also O
elevated O
the O
blood O
pressures O
of O
these O
individuals O
with O
increases O
in O
the O
order O
of O
20-35/15-25 O
mmg O
being O
observed O
. O

in O
1 O
patient O
, O
marked O
hypertension B-NEG
was O
induced O
by O
propranolol O
and O
the O
drug O
had O
to O
be O
withdrawn O
. O

it O
otherwise O
was O
well O
tolerated O
and O
no O
important O
side O
effects O
were O
observed O
. O

treatment O
has O
been O
continued O
in O
3 O
individuals O
for O
6-13 O
months O
with O
persistence O
of O
the O
pressor O
effect O
, O
although O
there O
appears O
to O
have O
been O
some O
decrease O
in O
the O
degree O
of O
response O
with O
time O
. O

hemodynamic O
measurements O
in O
1 O
of O
the O
patients O
demonstrated O
an O
increase O
in O
total O
peripheral O
resistance O
and O
essentially O
no O
change O
in O
cardiac O
output O
following O
propranolol O
therapy O
. O

the O
studies O
suggest O
that O
propranolol O
is O
a O
useful O
drug O
in O
selected O
patients O
with O
severe O
idiopathic B-NEG
orthostatic I-NEG
hypotension I-NEG
. O

-DOCSTART- O

total O
intravenous O
anesthesia O
with O
etomidate O
. O

iii O
. O

some O
observations O
in O
adults O
. O

an O
investigation O
was O
undertaken O
to O
determine O
the O
dosage O
of O
etomidate O
required O
to O
maintain O
sleep O
in O
adults O
undergoing O
surgery O
under O
regional O
local O
anesthesia O
. O

premedication O
of O
diazepam O
10 O
mg O
and O
atropine O
0.5 O
mg O
was O
given O
, O
and O
sleep O
was O
induced O
and O
maintained O
by O
intermittent O
intravenous O
injections O
of O
etomidate O
0.1/mg/kg O
, O
given O
whenever O
the O
patient O
would O
open O
his O
eyes O
on O
request O
. O

a O
mean O
overall O
dose O
of O
etomidate O
17.4 O
microgram/kg/min O
. O
was O
required O
to O
maintain O
sleep O
, O
but O
great O
individual O
variation O
occurred O
, O
with O
older O
patients O
requiring O
less O
drug O
. O

the O
investigation O
was O
discontinued O
after O
18 O
patients O
because O
of O
the O
frequency O
and O
intensity O
of O
side-effects O
, O
particularly O
pain B-NEG
and O
myoclonia B-NEG
, O
which O
caused O
the O
technique O
to O
be O
abandoned O
in O
two O
cases O
. O

it O
is O
considered O
unlikely O
that O
etomidate O
will O
prove O
to O
be O
the O
hypnotic O
of O
choice O
for O
a O
totally O
intravenous O
anesthetic O
technique O
in O
adults O
because O
of O
the O
high O
incidence O
of O
myoclonia B-NEG
after O
prolonged O
administration O
. O

in O
several O
patients O
uncontrollable O
muscle O
movements O
persisted O
for O
many O
minutes O
after O
complete O
recovery O
of O
consciousness O
. O

-DOCSTART- O

a O
method O
for O
the O
measurement O
of O
tremor B-NEG
, O
and O
a O
comparison O
of O
the O
effects O
of O
tocolytic O
beta-mimetics O
. O

a O
method O
permitting O
measurement O
of O
finger O
tremor B-NEG
as O
a O
displacement-time O
curve O
is O
described O
, O
using O
a O
test O
system O
with O
simple O
amplitude O
calibration O
. O

the O
coordinates O
of O
the O
inversion O
points O
of O
the O
displacement-time O
curves O
were O
transferred O
through O
graphical O
input O
equipment O
to O
punched O
tape O
. O

by O
means O
of O
a O
computer O
program O
, O
periods O
and O
amplitudes O
of O
tremor B-NEG
oscillations O
were O
calculated O
and O
classified O
. O

the O
event O
frequency O
for O
each O
class O
of O
periods O
and O
amplitudes O
was O
determined O
. O

the O
actions O
of O
fenoterol-hydrobromide O
, O
ritodrin-hcl O
and O
placebo O
given O
to O
10 O
healthy O
subjects O
by O
intravenous O
infusion O
in O
a O
double-blind O
crossover O
study O
were O
tested O
by O
this O
method O
. O

at O
therapeutic O
doses O
both O
substances O
raised O
the O
mean O
tremor B-NEG
amplitude O
to O
about O
three O
times O
the O
control O
level O
. O

at O
the O
same O
time O
, O
the O
mean O
period O
within O
each O
class O
of O
amplitudes O
shortened O
by O
10--20 O
ms O
, O
whereas O
the O
mean O
periods O
calculated O
from O
all O
oscillations O
together O
did O
not O
change O
significantly O
. O

after O
the O
end O
of O
fenoterol-hydrobromide O
infusion O
, O
tremor B-NEG
amplitudes O
decreased O
significantly O
faster O
than O
those O
following O
ritodrin-hcl O
infusion O
. O

-DOCSTART- O

bilateral O
retinal B-NEG
artery I-NEG
and I-NEG
choriocapillaris I-NEG
occlusion I-NEG
following O
the O
injection O
of O
long-acting O
corticosteroid O
suspensions O
in O
combination O
with O
other O
drugs O
: O
i. O

clinical O
studies O
. O

two O
well-documented O
cases O
of O
bilateral O
retinal B-NEG
artery I-NEG
and I-NEG
choriocapillaris I-NEG
occlusions I-NEG
with O
blindness B-NEG
following O
head O
and O
neck O
soft-tissue O
injection O
with O
methylprednisolone O
acetate O
in O
combination O
with O
lidocaine O
, O
epinephrine O
, O
or O
penicillin O
are O
reported O
. O

one O
case O
had O
only O
a O
unilateral O
injection O
. O

the O
acute O
observations O
included O
hazy O
sensorium O
, O
superior O
gaze O
palsy B-NEG
, O
pupillary B-NEG
abnormalities I-NEG
, O
and O
conjunctival O
hemorrhages B-NEG
with O
edema B-NEG
. O

follow-up O
changes O
showed O
marked O
visual B-NEG
loss I-NEG
, O
constricted O
visual O
fields O
, O
optic O
nerve O
pallor O
, O
vascular O
attenuation O
, O
and O
chorioretinal B-NEG
atrophy I-NEG
. O

the O
literature O
is O
reviewed O
, O
and O
possible O
causes O
are O
discussed O
. O

-DOCSTART- O

cephalothin-induced O
immune O
hemolytic B-NEG
anemia I-NEG
. O

a O
patient O
with O
renal B-NEG
disease I-NEG
developed O
coombs-positive O
hemolytic B-NEG
anemia I-NEG
while O
receiving O
cephalothin O
therapy O
. O

an O
anti-cephalothin O
igg O
antibody O
was O
detected O
in O
the O
patient's O
serum O
and O
in O
the O
eluates O
from O
her O
erythrocytes O
. O

in O
addition O
, O
nonimmunologic O
binding O
of O
normal O
and O
patient's O
serum O
proteins O
to O
her O
own O
and O
cephalothin-coated O
normal O
red O
cells O
was O
demonstrated O
. O

skin O
tests O
and O
in O
vitro O
lymphocyte O
stimulation O
revealed O
that O
the O
patient O
was O
sensitized O
to O
cephalothin O
and O
also O
to O
ampicillin O
. O

careful O
investigation O
of O
drug-induced O
hemolytic B-NEG
anemias I-NEG
reveals O
the O
complexity O
of O
the O
immune O
mechanisms O
involved O
. O

-DOCSTART- O

kaliuretic O
effect O
of O
l-dopa O
treatment O
in O
parkinsonian B-NEG
patients O
. O
hypokalemia B-NEG
, O
sometimes O
severe O
, O
was O
observed O
in O
some O
l-dopa-treated O
parkinsonian B-NEG
patients O
. O

the O
influence O
of O
l-dopa O
on O
the O
renal O
excretion O
of O
potassium O
was O
studied O
in O
3 O
patients O
with O
hypokalemia B-NEG
and O
in O
5 O
normokalemic O
patients O
by O
determination O
of O
renal O
plasma O
flow O
, O
glomerular O
filtration O
rate O
, O
plasma O
concentration O
of O
potassium O
and O
sodium O
as O
well O
as O
urinary O
excretion O
of O
potassium O
, O
sodium O
and O
aldosterone O
. O

l-dopa O
intake O
was O
found O
to O
cause O
an O
increased O
excretion O
of O
potassium O
, O
and O
sometimes O
also O
of O
sodium O
, O
in O
the O
hypokalemic O
but O
not O
in O
the O
normokalemic O
patients O
. O

this O
effect O
on O
the O
renal O
function O
could O
be O
prohibited O
by O
the O
administration O
of O
a O
peripheral O
dopa O
decarbodylase O
inhibitor O
. O

it O
is O
not O
known O
why O
this O
effect O
occurred O
in O
some O
individuals O
but O
not O
in O
others O
, O
but O
our O
results O
indicate O
a O
correlation O
between O
aldosterone O
production O
and O
this O
renal O
effect O
of O
l-dopa O
. O

-DOCSTART- O

phenytoin O
encephalopathy B-NEG
as O
probable O
idiosyncratic O
reaction O
: O
case O
report O
. O

a O
case O
of O
phenytoin O
( O
dph O
) O
encephalopathy B-NEG
with O
increasing O
seizures B-NEG
and O
eeg O
and O
mental O
changes O
is O
described O
. O

despite O
adequate O
oral O
dosage O
of O
dph O
(5 O
mg/kg/daily O
) O
the O
plasma O
level O
was O
very O
low O
( O
2.8 O
microgramg/ml) O
. O

the O
encephalopathy B-NEG
was O
probably O
an O
idiosyncratic O
and O
not O
toxic O
or O
allergic O
reaction O
. O

in O
fact O
the O
concentration O
of O
free O
dph O
was O
normal O
, O
the O
patient O
presented O
a O
retarded O
morbilliform O
rash B-NEG
during O
dph O
treatment O
, O
the O
protidogram O
was O
normal O
, O
and O
an O
intradermic O
dph O
injection O
had O
no O
local O
effect O
. O

the O
authors O
conclude O
that O
in O
a O
patient O
starting O
dph O
treatment O
an O
unexpected O
increase O
in O
seizures B-NEG
, O
with O
eeg O
and O
mental O
changes O
occurring O
simultaneously O
, O
should O
alert O
the O
physician O
to O
the O
possible O
need O
for O
eliminating O
dph O
from O
the O
therapeutic O
regimen O
, O
even O
if O
plasma O
concentrations O
are O
low O
. O

-DOCSTART- O

effects O
of O
exercise O
on O
the O
severity O
of O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
. O

the O
effect O
of O
exercise O
on O
the O
severity O
of O
isoproterenol-induced O
myocardial B-NEG
infarction I-NEG
was O
studied O
in O
male O
rats O
. O

ninety-three O
rats O
were O
randomly O
divided O
into O
three O
groups O
. O

the O
exercise-isoproterenol O
( O
e-1 O
) O
and O
exercise O
control O
( O
ec O
) O
groups O
exercised O
daily O
for O
thirty O
days O
on O
a O
treadmill O
at O
1 O
mph O
, O
2% O
grade O
while O
animals O
of O
the O
sedentary-isoproterenol O
( O
s-i O
) O
group O
remained O
sedentary O
. O

eight O
animals O
were O
assigned O
to O
the O
sedentary O
control O
( O
sc O
) O
group O
which O
remained O
sedentary O
throughout O
the O
experimental O
period O
. O

forty-eight O
hours O
after O
the O
final O
exercise O
period O
, O
s-i O
and O
e-i O
animals O
received O
a O
single O
subcutaneous O
injection O
of O
isoproterenol O
( O
250 O
mg/kg O
body O
weight) O
. O

animals O
of O
the O
s-i O
group O
exhibited O
significantly O
( O
pp O
less O
than O
0.05 O
) O
greater O
mortality O
from O
the O
effects O
of O
isoproterenol O
than O
animals O
of O
the O
e-i O
group O
. O

serum O
cpk O
activity O
for O
e-i O
animals O
was O
significantly O
(p O
less O
than O
0.05 O
) O
greater O
than O
for O
animals O
in O
the O
s-i O
and O
ec O
groups O
twenty O
hours O
following O
isoproterenol O
injection O
. O

no O
statistically O
significant O
differences O
were O
observed O
between O
the O
two O
isoproterenol O
treated O
groups O
for O
severity O
of O
the O
induced O
lesions O
, O
changes O
in O
heart O
weight O
, O
or O
heart O
weight O
to O
body O
weight O
ratios O
. O

the O
results O
indicated O
that O
exercise O
reduced O
the O
mortality O
associated O
with O
the O
effects O
of O
large O
dosages O
of O
isoproterenol O
but O
had O
little O
on O
the O
severity O
of O
the O
infarction B-NEG
. O

-DOCSTART- O

effect O
of O
d-glucarates O
on O
basic O
antibiotic-induced O
renal B-NEG
damage I-NEG
in O
rats O
. O
dehydrated B-NEG
rats O
regularly O
develop O
acute B-NEG
renal I-NEG
failure I-NEG
following O
single O
injection O
of O
aminoglycoside O
antibiotics O
combined O
with O
dextran O
or O
of O
antibiotics O
only O
. O

oral O
administration O
of O
2,5-di-o-acetyl-d-glucaro-1,4-6,3-dilactone O
protected O
rats O
against O
renal B-NEG
failure I-NEG
induced O
by O
kanamycin-dextran O
. O

the O
protective O
effect O
was O
prevalent O
among O
d-glucarates O
, O
and O
also O
to O
other O
saccharic O
acid O
, O
hexauronic O
acids O
and O
hexaaldonic O
acids O
, O
although O
to O
a O
lesser O
degree O
, O
but O
not O
to O
a O
hexaaldose O
, O
sugar O
alcohols O
, O
substances O
inthe O
tca O
cycle O
and O
other O
acidic O
compounds O
. O

d-glucarates O
were O
effective O
against O
renal B-NEG
damage I-NEG
induced O
by O
peptide O
antibiotics O
as O
well O
as O
various O
aminoglycoside O
antibitocis O
. O

dose-responses O
were O
observed O
in O
the O
protective O
effect O
of O
d-glucarates O
. O

with O
a O
d-glucarate O
of O
a O
fixed O
size O
of O
dose O
, O
approximately O
the O
same O
degree O
of O
protection O
was O
obtained O
against O
renal B-NEG
damages I-NEG
induced O
by O
different O
basic O
antibiotics O
despite O
large O
disparities O
in O
administration O
doses O
of O
different O
antibiotics O
. O

d-glucarates O
had O
the O
ability O
to O
prevent O
renal B-NEG
damage I-NEG
but O
not O
to O
cure O
it O
. O

rats O
excreted O
acidic O
urine O
when O
they O
were O
spared O
from O
renal B-NEG
lesions I-NEG
by O
monosaccharides O
. O

the O
reduction O
effect O
of O
d-glucarates O
against O
nephrotoxicity B-NEG
of O
basic O
antibiotics O
was O
discussed O
. O

-DOCSTART- O

paraplegia B-NEG
following O
intrathecal O
methotrexate O
: O
report O
of O
a O
case O
and O
review O
of O
the O
literature O
. O

a O
patient O
who O
developed O
paraplegia B-NEG
following O
the O
intrathecal O
instillation O
of O
methotrexate O
is O
discribed O
. O

the O
ten O
previously O
reported O
cases O
of O
this O
unusual O
complication O
are O
reviewed O
. O

the O
following O
factors O
appear O
to O
predispose O
to O
the O
development O
of O
this O
complication O
: O
abnormal O
cerebrospinal O
dynamics O
related O
to O
the O
presence O
of O
central B-NEG
nervous I-NEG
system I-NEG
leukemia I-NEG
, O
and O
epidural O
cerebrospinal O
leakage O
; O
elevated O
cerebrospinal O
fluid O
methothexate O
concentration O
related O
to O
abnormal O
cerebrospinal O
fluid O
dynamics O
and O
to O
inappropriately O
high O
methotrexate O
doses O
based O
on O
body O
surface O
area O
calculations O
in O
older O
children O
and O
adults O
; O
the O
presence O
of O
neurotoxic B-NEG
preservatives O
in O
commercially O
available O
methotrexate O
preparations O
and O
diluents O
; O
and O
the O
use O
of O
methotrexate O
diluents O
of O
unphysiologic O
ph O
, O
ionic O
content O
and O
osmolarity O
. O

the O
role O
of O
methotrexate O
contaminants O
, O
local O
folate B-NEG
deficiency I-NEG
, O
and O
cranial O
irradiation O
in O
the O
pathogenesis O
of O
intrathecal O
methotrexate O
toxicity B-NEG
is O
unclear O
. O

the O
incidence O
of O
neurotoxicity B-NEG
may O
be O
reduced O
by O
employing O
lower O
doses O
of O
methotrexate O
in O
the O
presence O
of O
central B-NEG
nervous I-NEG
system I-NEG
leukemia I-NEG
, O
in O
older O
children O
and O
adults O
, O
and O
in O
the O
presence O
of O
epidural O
leakage O
. O

only O
preservative-free O
methotrexate O
in O
elliott's O
b O
solution O
at O
a O
concentration O
of O
not O
more O
than O
1 O
mg/ml O
should O
be O
used O
for O
intrathecal O
administration O
. O

periodic O
monitoring O
of O
cerebruspinal O
fluid O
methotrexate O
levels O
may O
be O
predictive O
of O
the O
development O
of O
serious O
neurotoxicity B-NEG
. O

-DOCSTART- O

centrally O
mediated O
cardiovascular O
effects O
of O
intracisternal O
application O
of O
carbachol O
in O
anesthetized O
rats O
. O

the O
pressor O
response O
to O
the O
intracisternal O
( O
i.c. O
) O
injection O
of O
carbachol O
(1 O
mug O
) O
in O
anesthetized O
rats O
was O
analyzed O
. O

this O
response O
was O
significantly O
reduced O
by O
the O
intravenous O
( O
i.v. O
) O
injection O
of O
guanethidine O
(5 O
mg) O
, O
hexamethonium O
( O
10 O
mg O
) O
or O
phentolamine O
(5 O
mg) O
, O
and O
conversely O
, O
potentiated O
by O
i.v O
. O
desmethylimipramine O
( O
0.3 O
mg) O
, O
while O
propranolol O
( O
0.5 O
mg O
) O
i.v O
. O
selectively O
inhibited O
the O
enlargement B-NEG
of I-NEG
pulse I-NEG
pressure I-NEG
and O
the O
tachycardia B-NEG
following O
i.c O
. O
carbachol O
(1 O
mug) O
. O

on O
the O
other O
hand O
, O
the O
pressor O
response O
to O
i.c O
. O
carbachol O
(1 O
mug O
) O
was O
almost O
completely O
blocked O
by O
i.c O
. O
atropine O
(3 O
mug O
) O
or O
hexamethonium O
( O
500 O
mug) O
, O
and O
significantly O
reduced O
by O
i.c O
. O
chlorpromazine O
( O
50 O
mug O
) O
but O
significantly O
potentiated O
by O
i.c O
. O
desmethylimipramine O
( O
30 O
mug) O
. O

the O
pressor O
response O
to O
i.c O
. O
carbachol O
(1 O
mug O
) O
remained O
unchanged O
after O
sectioning O
of O
the O
bilateral O
cervical O
vagal O
nerves O
but O
disappeared O
after O
sectioning O
of O
the O
spinal O
cord O
(c7-c8) O
. O

from O
the O
above O
result O
it O
is O
suggested O
that O
the O
pressor O
response O
to O
i.c O
. O
carbachol O
ortral O
and O
peripheral O
adrenergic O
mechanisms O
, O
and O
that O
the O
sympathetic O
trunk O
is O
the O
main O
pathway O
. O

-DOCSTART- O

hyperglycemic B-NEG
effect O
of O
amino O
compounds O
structurally O
related O
to O
caproate O
in O
rats O
. O

the O
chronic O
feeding O
of O
small O
amounts O
( O
0.3-3% O
of O
diet O
weight O
) O
of O
certain O
amino O
derivatives O
of O
caproate O
resulted O
in O
hyperglycemia B-NEG
, O
an O
elevated O
glucose O
tolerance O
curve O
and O
, O
occasionally O
, O
glucosuria B-NEG
. O

effective O
compounds O
included O
norleucine O
, O
norvaline O
, O
glutamate O
, O
epsilon-aminocaproate O
, O
methionine O
, O
and O
leucine O
. O

-DOCSTART- O

fatty B-NEG
liver I-NEG
induced O
by O
tetracycline O
in O
the O
rat O
. O

dose-response O
relationships O
and O
effect O
of O
sex O
. O

dose-response O
relationships O
, O
biochemical O
mechanisms O
, O
and O
sex O
differences O
in O
the O
experimental O
fatty B-NEG
liver I-NEG
induced O
by O
tetracycline O
were O
studied O
in O
the O
intact O
rat O
and O
with O
the O
isolated O
perfused O
rat O
liver O
in O
vitro O
. O

in O
the O
intact O
male O
and O
female O
rat O
, O
no O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline O
and O
hepatic O
accumulation O
of O
triglyceride O
. O

with O
provision O
of O
adequate O
oleic O
acid O
as O
a O
substrate O
for O
the O
isolated O
perfused O
liver O
, O
a O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline O
and O
both O
accumulation O
of O
triglyceride O
in O
the O
liver O
and O
depression B-NEG
of O
output O
of O
triglyceride O
by O
livers O
from O
male O
and O
female O
rats O
. O

marked O
differences O
were O
observed O
between O
female O
and O
male O
rats O
with O
regard O
to O
base O
line O
( O
control O
) O
hepatic O
concentration O
of O
triglyceride O
and O
output O
of O
triglyceride O
. O

accumulation O
of O
hepatic O
triglyceride O
, O
as O
a O
per O
cent O
of O
control O
values O
, O
in O
response O
to O
graded O
doses O
of O
tetracycline O
, O
did O
not O
differ O
significantly O
between O
male O
, O
female O
and O
pregnant O
rat O
livers O
. O

however O
, O
livers O
from O
female O
, O
and O
especially O
pregnant O
female O
rats O
, O
were O
strikingly O
resistant O
to O
the O
effects O
of O
tetracycline O
on O
depression B-NEG
of O
output O
of O
triglyceride O
under O
these O
experimental O
conditions O
. O

these O
differences O
between O
the O
sexes O
could O
not O
be O
related O
to O
altered O
disposition O
of O
tetracycline O
or O
altered O
uptake O
of O
oleic O
acid O
. O

depressed O
hepatic O
secretion O
of O
triglyceride O
accounted O
only O
for O
30 O
to O
50% O
of O
accumulated O
hepatic O
triglyceride O
, O
indicating O
that O
additional O
mechanisms O
must O
be O
involved O
in O
the O
production O
of O
the O
triglyceride-rich O
fatty B-NEG
liver I-NEG
in O
response O
to O
tetracycline O
. O

-DOCSTART- O

fatal O
myeloencephalopathy B-NEG
due O
to O
intrathecal O
vincristine O
administration O
. O

vincristine O
was O
accidentally O
given O
intrathecally O
to O
a O
child O
with O
leukaemia B-NEG
, O
producing O
sensory B-NEG
and I-NEG
motor I-NEG
dysfunction I-NEG
followed O
by O
encephalopathy B-NEG
and O
death O
. O

separate O
times O
for O
administering O
vincristine O
and O
intrathecal O
therapy O
is O
recommended O
. O

-DOCSTART- O

progesterone O
potentiation O
of O
bupivacaine O
arrhythmogenicity O
in O
pentobarbital-anesthetized O
rats O
and O
beating O
rat O
heart O
cell O
cultures O
. O

the O
effects O
of O
progesterone O
treatment O
on O
bupivacaine O
arrhythmogenicity O
in O
beating O
rat O
heart O
myocyte O
cultures O
and O
on O
anesthetized O
rats O
were O
determined O
. O

after O
determining O
the O
bupivacaine O
ad50 O
( O
the O
concentration O
of O
bupivacaine O
that O
caused O
50% O
of O
all O
beating O
rat O
heart O
myocyte O
cultures O
to O
become O
arrhythmic B-NEG
), O
we O
determined O
the O
effect O
of O
1-hour O
progesterone O
hcl O
exposure O
on O
myocyte O
contractile O
rhythm O
. O

each O
concentration O
of O
progesterone O
(6.25 O
, O
12.5 O
, O
25 O
, O
and O
50 O
micrograms/ml O
) O
caused O
a O
significant O
and O
concentration-dependent O
reduction O
in O
the O
ad50 O
for O
bupivacaine O
. O

estradiol O
treatment O
also O
increased O
the O
arrhythmogenicity O
of O
bupivacaine O
in O
myocyte O
cultures O
, O
but O
was O
only O
one O
fourth O
as O
potent O
as O
progesterone O
. O

neither O
progesterone O
nor O
estradiol O
effects O
on O
bupivacaine O
arrhythmogenicity O
were O
potentiated O
by O
epinephrine O
. O

chronic O
progesterone O
pretreatment O
(5 O
mg/kg/day O
for O
21 O
days O
) O
caused O
a O
significant O
increase O
in O
bupivacaine O
arrhythmogenicity O
in O
intact O
pentobarbital-anesthetized O
rats O
. O

there O
was O
a O
significant O
decrease O
in O
the O
time O
to O
onset O
of O
arrhythmia B-NEG
as O
compared O
with O
control O
nonprogesterone-treated O
rats O
( O
6.2 O
+/- O
1.3 O
vs O
. O
30.8 O
+/- O
2.5 O
min O
, O
mean O
+/- O
se) O
. O

the O
results O
of O
this O
study O
indicate O
that O
progesterone O
can O
potentiate O
bupivacaine O
arrhythmogenicity O
both O
in O
vivo O
and O
in O
vitro O
. O

potentiation O
of O
bupivacaine O
arrhythmia B-NEG
in O
myocyte O
cultures O
suggests O
that O
this O
effect O
is O
at O
least O
partly O
mediated O
at O
the O
myocyte O
level O
. O

-DOCSTART- O

acute B-NEG
renal I-NEG
failure I-NEG
occurring O
during O
intravenous O
desferrioxamine O
therapy O
: O
recovery O
after O
haemodialysis O
. O

a O
patient O
with O
transfusion-dependent O
thalassemia B-NEG
was O
undergoing O
home O
intravenous O
desferrioxamine O
( O
dfx O
) O
treatment O
by O
means O
of O
a O
totally O
implanted O
system O
because O
of O
his O
poor O
compliance O
with O
the O
nightly O
subcutaneous O
therapy O
. O

due O
to O
an O
accidental O
malfunctioning O
of O
the O
infusion O
pump O
, O
the O
patient O
was O
inadvertently O
administered O
a O
toxic O
dosage O
of O
the O
drug O
which O
caused O
renal B-NEG
insufficiency I-NEG
. O

given O
the O
progressive O
deterioration O
of O
the O
symptoms O
and O
of O
the O
laboratory O
values O
, O
despite O
adequate O
medical O
treatment O
, O
a O
decision O
was O
made O
to O
introduce O
haemodialytical O
therapy O
in O
order O
to O
remove O
the O
drug O
and O
therapy O
reduce O
the O
nephrotoxicity B-NEG
. O

from O
the O
results O
obtained O
, O
haemodialysis O
can O
therefore O
be O
suggested O
as O
a O
useful O
therapy O
in O
rare O
cases O
of O
progressive O
acute B-NEG
renal I-NEG
failure I-NEG
caused O
by O
desferrioxamine O
. O

-DOCSTART- O

neuroleptic-associated O
hyperprolactinemia B-NEG
. O

can O
it O
be O
treated O
with O
bromocriptine? O

six O
stable O
psychiatric O
outpatients O
with O
hyperprolactinemia B-NEG
and O
amenorrhea B-NEG
/ O
oligomenorrhea B-NEG
associated O
with O
their O
neuroleptic O
medications O
were O
treated O
with O
bromocriptine O
. O

daily O
dosages O
of O
5-10 O
mg O
corrected O
the O
hyperprolactinemia B-NEG
and O
restored O
menstruation O
in O
four O
of O
the O
six O
patients O
. O

one O
woman O
, O
however O
, O
developed O
worsened O
psychiatric B-NEG
symptoms I-NEG
while O
taking O
bromocriptine O
, O
and O
it O
was O
discontinued O
. O

thus O
, O
three O
of O
six O
patients O
had O
their O
menstrual O
irregularity O
successfully O
corrected O
with O
bromocriptine O
. O

this O
suggests O
that O
bromocriptine O
should O
be O
further O
evaluated O
as O
potential O
therapy O
for O
neuroleptic-associated O
hyperprolactinemia B-NEG
and O
amenorrhea B-NEG
/ O
galactorrhea B-NEG
. O

-DOCSTART- O

ethacrynic O
acid-induced O
convulsions B-NEG
and O
brain O
neurotransmitters O
in O
mice O
. O

intracerebroventricular O
injection O
of O
ethacrynic O
acid O
( O
50% O
convulsive B-NEG
dose O
; O
50 O
micrograms/mouse O
) O
accelerated O
the O
synthesis/turnover O
of O
5-hydroxytryptamine O
( O
5-ht O
) O
but O
suppressed O
the O
synthesis O
of O
gamma-aminobutyric O
acid O
and O
acetylcholine O
in O
mouse O
brain O
. O

these O
effects O
were O
completely O
antagonized O
by O
pretreatment O
with O
a O
glutamate/n-methyl-d-aspartate O
antagonist O
, O
aminophosphonovaleric O
acid O
. O

in O
ethacrynic O
acid-induced O
convulsions B-NEG
, O
these O
neurotransmitter O
systems O
may O
be O
differentially O
modulated O
, O
probably O
through O
activation O
of O
glutaminergic O
neurons O
in O
the O
brain O
. O

-DOCSTART- O

pharmacology O
of O
gamma-aminobutyric O
acida O
receptor O
complex O
after O
the O
in O
vivo O
administration O
of O
the O
anxioselective O
and O
anticonvulsant O
beta-carboline O
derivative O
abecarnil O
. O

in O
rodents O
, O
the O
effect O
of O
the O
beta-carboline O
derivative O
isopropyl-6- O
benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate O
(abecarrnil) O
, O
a O
new O
ligand O
for O
benzodiazepine O
receptors O
possessing O
anxiolytic O
and O
anticonvulsant O
properties O
, O
was O
evaluated O
on O
the O
function O
of O
central O
gamma-aminobutyric O
acid O
( O
gaba)a O
receptor O
complex O
, O
both O
in O
vitro O
and O
in O
vivo O
. O

added O
in O
vitro O
to O
rat O
cortical O
membrane O
preparation O
, O
abecarnil O
increased O
[3h]gaba O
binding O
, O
enhanced O
muscimol-stimulated O
36cl- O
uptake O
and O
reduced O
the O
binding O
of O
t-[35s]butylbicyclophosphorothionate O
([35s]tbps) O
. O

these O
effects O
were O
similar O
to O
those O
induced O
by O
diazepam O
, O
whereas O
the O
partial O
agonist O
ro O
16-6028 O
( O
tert-butyl-(s)-8-bromo-11,12,13,13a-tetrahydro-9-oxo-9h- O
imidazo[1,5-a]-pyrrolo-[2,1-c][1,4]benzodiazepine-1-carboxylate O
) O
showed O
very O
weak O
efficacy O
in O
these O
biochemical O
tests O
. O

after O
i.p O
. O
injection O
to O
rats O
, O
abecarnil O
and O
diazepam O
decreased O
in O
a O
time-dependent O
and O
dose-related O
( O
0.25-20 O
mg/kg O
i.p. O
) O
manner O
[35s]tbps O
binding O
measured O
ex O
vivo O
in O
the O
cerebral O
cortex O
. O

moreover O
, O
both O
drugs O
at O
the O
dose O
of O
0.5 O
mg/kg O
antagonized O
completely O
the O
convulsant O
activity O
and O
the O
increase O
of O
[35s]tbps O
binding O
induced O
by O
isoniazide O
( O
350 O
mg/kg O
s.c. O
) O
as O
well O
as O
the O
increase O
of O
[35s]tbps O
binding O
induced O
by O
foot-shock O
stress O
. O

to O
better O
correlate O
the O
biochemical O
and O
the O
pharmacological O
effects O
, O
we O
studied O
the O
action O
of O
abecarnil O
on O
[35s]tbps O
binding O
, O
exploratory O
motility O
and O
on O
isoniazid-induced O
biochemical O
and O
pharmacological O
effects O
in O
mice O
. O

in O
these O
animals O
, O
abecarnil O
produced O
a O
paralleled O
dose-dependent O
( O
0.05-1 O
mg/kg O
i.p. O
) O
reduction O
of O
both O
motor O
behavior O
and O
cortical O
[35s]tbps O
binding O
. O

moreover O
, O
0.05 O
mg/kg O
of O
this O
beta-carboline O
reduced O
markedly O
the O
increase O
of O
[35s]tbps O
binding O
and O
the O
convulsions B-NEG
induced O
by O
isoniazid O
( O
200 O
mg/kg O
s.c.).(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

recurrent O
myocardial B-NEG
infarction I-NEG
in O
a O
postpartum O
patient O
receiving O
bromocriptine O
. O
myocardial B-NEG
infarction I-NEG
in O
puerperium O
is O
infrequently O
reported O
. O
spasm B-NEG
, O
coronary O
dissection O
, O
or O
atheromatous O
etiology O
has O
been O
described O
. O

bromocriptine O
has O
been O
implicated O
in O
several O
previous O
case O
reports O
of O
myocardial B-NEG
infarction I-NEG
in O
the O
puerperium O
. O

our O
case O
( O
including O
an O
inadvertent O
rechallenge O
) O
suggests O
such O
a O
relationship O
. O

although O
generally O
regarded O
as O
safe O
, O
possible O
serious O
cardiac O
effects O
of O
bromocriptine O
should O
be O
acknowledged O
. O

-DOCSTART- O

asterixis B-NEG
induced O
by O
carbamazepine O
therapy O
. O

there O
are O
very O
few O
reports O
about O
asterixis B-NEG
as O
a O
side O
effect O
of O
treatment O
with O
psychopharmacologic O
agents O
. O

in O
this O
report O
we O
present O
four O
patients O
treated O
with O
a O
combination O
of O
different O
psychotropic O
drugs O
, O
in O
whom O
asterixis B-NEG
was O
triggered O
either O
by O
adding O
carbamazepine O
( O
cbz O
) O
to O
a O
treatment O
regimen O
, O
or O
by O
increasing O
its O
dosage O
. O

neither O
dosage O
nor O
serum O
levels O
of O
cbz O
were O
in O
a O
higher O
range O
. O

we O
consider O
asterixis B-NEG
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity B-NEG
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium O
or O
clozapine O
are O
used O
in O
combination O
with O
cbz O
. O

-DOCSTART- O

pharmacodynamics O
of O
the O
hypotensive B-NEG
effect O
of O
levodopa O
in O
parkinsonian B-NEG
patients O
. O

blood O
pressure O
effects O
of O
i.v O
. O
levodopa O
were O
examined O
in O
parkinsonian B-NEG
patients O
with O
stable O
and O
fluctuating O
responses O
to O
levodopa O
. O

the O
magnitude O
of O
the O
hypotensive B-NEG
effect O
of O
levodopa O
was O
concentration O
dependent O
and O
was O
fit O
to O
an O
emax O
model O
in O
fluctuating O
responders O
. O

stable O
responders O
demonstrated O
a O
small O
hypotensive B-NEG
response O
. O

baseline O
blood O
pressures O
were O
higher O
in O
fluctuating O
patients O
; O
a O
higher O
baseline O
blood O
pressure O
correlated O
with O
greater O
hypotensive B-NEG
effects O
. O

antiparkinsonian O
effects O
of O
levodopa O
temporally O
correlated O
with O
blood O
pressure O
changes O
. O

phenylalanine O
, O
a O
large O
neutral O
amino O
acid O
( O
lnaa O
) O
competing O
with O
levodopa O
for O
transport O
across O
the O
blood-brain O
barrier O
, O
reduced O
the O
hypotensive B-NEG
and O
antiparkinsonian O
effects O
of O
levodopa O
. O

we O
conclude O
that O
levodopa O
has O
a O
central O
hypotensive B-NEG
action O
that O
parallels O
the O
motor O
effects O
in O
fluctuating O
patients O
. O

the O
hypotensive B-NEG
effect O
appears O
to O
be O
related O
to O
the O
higher O
baseline O
blood O
pressure O
we O
observed O
in O
fluctuating O
patients O
relative O
to O
stable O
patients O
. O

-DOCSTART- O

syndrome B-NEG
of I-NEG
inappropriate I-NEG
secretion I-NEG
of I-NEG
antidiuretic I-NEG
hormone I-NEG
after O
infusional O
vincristine O
. O

a O
77-year-old O
woman O
with O
refractory O
multiple B-NEG
myeloma I-NEG
was O
treated O
with O
a O
4-day O
continuous O
intravenous O
infusion O
of O
vincristine O
and O
doxorubicin O
and O
4 O
days O
of O
oral O
dexamethasone O
. O

nine O
days O
after O
her O
second O
cycle O
she O
presented O
with O
lethargy B-NEG
and O
weakness B-NEG
associated O
with O
hyponatremia B-NEG
. O

evaluation O
revealed O
the O
syndrome B-NEG
of I-NEG
inappropriate I-NEG
secretion I-NEG
of I-NEG
antidiuretic I-NEG
hormone I-NEG
, O
which O
was O
attributed O
to O
the O
vincristine O
infusion O
. O

after O
normal O
serum O
sodium O
levels O
returned O
, O
further O
doxorubicin O
and O
dexamethasone O
chemotherapy O
without O
vincristine O
did O
not O
produce O
this O
complication O
. O

-DOCSTART- O

heart B-NEG
failure I-NEG
: O
to O
digitalise O
or O
not? O

the O
view O
against O
. O

despite O
extensive O
clinical O
experience O
the O
role O
of O
digoxin O
is O
still O
not O
well O
defined O
. O

in O
patients O
with O
atrial B-NEG
fibrillation I-NEG
digoxin O
is O
beneficial O
for O
ventricular O
rate O
control O
. O

for O
patients O
in O
sinus O
rhythm O
and O
heart B-NEG
failure I-NEG
the O
situation O
is O
less O
clear O
. O

digoxin O
has O
a O
narrow O
therapeutic:toxic O
ratio O
and O
concentrations O
are O
affected O
by O
a O
number O
of O
drugs O
. O

also O
, O
digoxin O
has O
undesirable O
effects O
such O
as O
increasing O
peripheral O
resistance O
and O
myocardial O
demands O
, O
and O
causing O
arrhythmias B-NEG
. O

there O
is O
a O
paucity O
of O
data O
from O
well-designed O
trials O
. O

the O
trials O
that O
are O
available O
are O
generally O
small O
with O
limitations O
in O
design O
and O
these O
show O
variation O
in O
patient O
benefit O
. O

more O
convincing O
evidence O
is O
required O
showing O
that O
digoxin O
improves O
symptoms O
or O
exercise O
capacity O
. O

furthermore O
, O
no O
trial O
has O
had O
sufficient O
power O
to O
evaluate O
mortality O
. O

pooled O
analysis O
of O
the O
effects O
of O
other O
inotropic O
drugs O
shows O
an O
excess O
mortality O
and O
there O
is O
a O
possibility O
that O
digoxin O
may O
increase O
mortality O
after O
myocardial B-NEG
infarction I-NEG
( O
mi B-NEG
). O

angiotensin-converting O
enzyme O
( O
ace O
) O
inhibitors O
should O
be O
used O
first O
as O
they O
are O
safer O
, O
do O
not O
require O
blood O
level O
monitoring O
, O
modify O
progression O
of O
disease O
, O
relieve O
symptoms O
, O
improve O
exercise O
tolerance O
and O
reduce O
mortality O
. O

caution O
should O
be O
exercised O
in O
using O
digoxin O
until O
large O
mortality O
trials O
are O
completed O
showing O
either O
benefit O
or O
harm O
. O

until O
then O
digoxin O
should O
be O
considered O
a O
third-line O
therapy O
. O

-DOCSTART- O

intravascular O
hemolysis B-NEG
and O
acute B-NEG
renal I-NEG
failure I-NEG
following O
intermittent O
rifampin O
therapy O
. O
renal B-NEG
failure I-NEG
is O
a O
rare O
complication O
associated O
with O
the O
use O
of O
rifampin O
. O

intravascular O
hemolysis B-NEG
leading O
to O
acute B-NEG
renal I-NEG
failure I-NEG
following O
rifampin O
therapy O
is O
extremely O
rare O
. O

two O
patients O
with O
leprosy B-NEG
who O
developed O
hemolysis B-NEG
and O
acute B-NEG
renal I-NEG
failure I-NEG
following O
rifampin O
are O
reported O
. O

-DOCSTART- O

zidovudine-induced O
hepatitis B-NEG
. O

a O
case O
of O
acute O
hepatitis B-NEG
induced O
by O
zidovudine O
in O
a O
38-year-old O
patient O
with O
aids B-NEG
is O
presented O
. O

the O
mechanism O
whereby O
the O
hepatitis B-NEG
was O
induced O
is O
not O
known O
. O

however O
, O
the O
patient O
tolerated O
well O
an O
alternative O
reverse O
transcriptase O
inhibitor O
, O
2'3' O
dideoxyinosine O
. O

physicians O
caring O
for O
patients O
with O
aids B-NEG
should O
be O
aware O
of O
this O
hitherto O
rarely O
reported O
complication O
. O

-DOCSTART- O

thoracic B-NEG
hematomyelia I-NEG
secondary O
to O
coumadin O
anticoagulant O
therapy O
: O
a O
case O
report O
. O

a O
case O
of O
thoracic B-NEG
hematomyelia I-NEG
secondary O
to O
anticoagulant O
therapy O
is O
presented O
. O

clinical O
features O
, O
similar O
to O
2 O
other O
previously O
reported O
cases O
, O
are O
discussed O
. O

a O
high O
index O
of O
suspicion O
may O
lead O
to O
a O
quick O
diagnostic O
procedure O
and O
successful O
decompressive O
surgery O
. O

-DOCSTART- O

mania B-NEG
associated O
with O
fluoxetine O
treatment O
in O
adolescents O
. O

fluoxetine O
, O
a O
selective O
serotonin O
reuptake O
inhibitor O
, O
is O
gaining O
increased O
acceptance O
in O
the O
treatment O
of O
adolescent O
depression B-NEG
. O

generally O
safe O
and O
well O
tolerated O
by O
adults O
, O
fluoxetine O
has O
been O
reported O
to O
induce O
mania B-NEG
. O

the O
cases O
of O
five O
depressed B-NEG
adolescents O
, O
14-16 O
years O
of O
age O
, O
who O
developed O
mania B-NEG
during O
pharmacotherapy O
with O
fluoxetine O
, O
are O
reported O
here O
. O

apparent O
risk O
factors O
for O
the O
development O
of O
mania B-NEG
or O
hypomania B-NEG
during O
fluoxetine O
pharmacotherapy O
in O
this O
population O
were O
the O
combination O
of O
attention-deficit B-NEG
hyperactivity I-NEG
disorder I-NEG
and O
affective O
instability O
; O
major O
depression B-NEG
with O
psychotic B-NEG
features O
; O
a O
family O
history O
of O
affective B-NEG
disorder I-NEG
, O
especially O
bipolar B-NEG
disorder I-NEG
; O
and O
a O
diagnosis O
of O
bipolar B-NEG
disorder I-NEG
. O

further O
study O
is O
needed O
to O
determine O
the O
optimal O
dosage O
and O
to O
identify O
risk O
factors O
that O
increase O
individual O
vulnerability O
to O
fluoxetine O
induced O
mania B-NEG
in O
adolescents O
. O

-DOCSTART- O

gemfibrozil-lovastatin O
therapy O
for O
primary O
hyperlipoproteinemias B-NEG
. O

the O
specific O
aim O
of O
this O
retrospective O
, O
observational O
study O
was O
to O
assess O
safety O
and O
efficacy O
of O
long-term O
( O
21 O
months/patient) O
, O
open-label O
, O
gemfibrozil-lovastatin O
treatment O
in O
80 O
patients O
with O
primary O
mixed O
hyperlipidemia B-NEG
( O
68% O
of O
whom O
had O
atherosclerotic B-NEG
vascular I-NEG
disease I-NEG
). O

because O
ideal O
lipid O
targets O
were O
not O
reached O
( O
low-density O
lipoprotein O
( O
ldl O
) O
cholesterol O
less O
than O
130 O
mg/dl O
, O
high-density O
lipoprotein O
( O
hdl O
) O
cholesterol O
greater O
than O
35 O
mg/dl O
, O
or O
total O
cholesterol/hdl O
cholesterol O
less O
than O
4.5 O
mg/dl O
) O
with O
diet O
plus O
a O
single O
drug O
, O
gemfibrozil O
( O
1.2 O
g/day)-lovastatin O
( O
primarily O
20 O
or O
40 O
mg O
) O
treatment O
was O
given O
. O

follow-up O
visits O
were O
scheduled O
with O
2-drug O
therapy O
every O
6 O
to O
8 O
weeks O
, O
an O
average O
of O
10.3 O
visits O
per O
patient O
, O
with O
741 O
batteries O
of O
6 O
liver O
function O
tests O
and O
714 O
creatine O
phosphokinase O
levels O
measured O
. O

only O
1 O
of O
the O
4,446 O
liver O
function O
tests O
(0.02%) O
, O
a O
gamma O
glutamyl O
transferase O
, O
was O
greater O
than O
or O
equal O
to O
3 O
times O
the O
upper O
normal O
limit O
. O

of O
the O
714 O
creatine O
phosphokinase O
levels O
, O
9% O
were O
high O
; O
only O
1 O
( O
0.1% O
) O
was O
greater O
than O
or O
equal O
to O
3 O
times O
the O
upper O
normal O
limit O
. O

with O
2-drug O
therapy O
, O
mean O
total O
cholesterol O
decreased O
22% O
from O
255 O
to O
200 O
mg/dl O
, O
triglyceride O
levels O
decreased O
35% O
from O
236 O
to O
154 O
mg/dl O
, O
ldl O
cholesterol O
decreased O
26% O
from O
176 O
to O
131 O
mg/dl O
, O
and O
the O
total O
cholesterol/hdl O
cholesterol O
ratio O
decreased O
24% O
from O
7.1 O
to O
5.4 O
, O
all O
p O
less O
than O
or O
equal O
to O
0.0001 O
. O
myositis B-NEG
, O
attributable O
to O
the O
drug O
combination O
and O
symptomatic O
enough O
to O
discontinue O
it O
, O
occurred O
in O
3% O
of O
patients O
, O
and O
in O
1% O
with O
concurrent O
high O
creatine O
phosphokinase O
( O
769 O
u/liter) O
; O
no O
patients O
had O
rhabdomyolysis B-NEG
or O
myoglobinuria B-NEG
.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

hepatocellular B-NEG
carcinoma I-NEG
in O
fanconi's B-NEG
anemia I-NEG
treated O
with O
androgen O
and O
corticosteroid O
. O

the O
case O
of O
an O
11-year-old O
boy O
is O
reported O
who O
was O
known O
to O
have O
fanconi's B-NEG
anemia I-NEG
for O
3 O
years O
and O
was O
treated O
with O
androgens O
, O
corticosteroids O
and O
transfusions O
. O

two O
weeks O
before O
his O
death O
he O
was O
readmitted O
because O
of O
aplastic O
crisis O
with O
septicemia B-NEG
and O
marked O
abnormalities O
in O
liver O
function O
and O
died O
of O
hemorrhagic B-NEG
bronchopneumonia I-NEG
. O

at O
autopsy O
peliosis B-NEG
and O
multiple O
hepatic B-NEG
tumors I-NEG
were O
found O
which O
histologically O
proved O
to O
be O
well-differentiated O
hepatocellular B-NEG
carcinoma I-NEG
. O

this O
case O
contributes O
to O
the O
previous O
observations O
that O
non-metastasizing O
hepatic B-NEG
neoplasms I-NEG
and O
peliosis B-NEG
can O
develop O
in O
patients O
with O
androgen- O
and O
corticosteroid-treated O
fanconi's B-NEG
anemia I-NEG
. O

-DOCSTART- O

chronic O
lesion O
of O
rostral O
ventrolateral O
medulla O
in O
spontaneously O
hypertensive B-NEG
rats O
. O

we O
studied O
the O
effects O
of O
chronic O
selective O
neuronal O
lesion O
of O
rostral O
ventrolateral O
medulla O
on O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
neurogenic O
tone O
in O
conscious O
, O
unrestrained O
spontaneously O
hypertensive B-NEG
rats O
. O

the O
lesions O
were O
placed O
via O
bilateral O
microinjections O
of O
30 O
nmol/200 O
nl O
n-methyl-d-aspartic O
acid O
. O

the O
restimulation O
of O
this O
area O
with O
n-methyl-d-aspartic O
acid O
15 O
days O
postlesion O
failed O
to O
produce O
a O
pressor O
response O
. O

one O
day O
postlesion O
, O
the O
resting O
mean O
arterial O
pressure O
was O
significantly O
decreased O
in O
lesioned O
rats O
when O
compared O
with O
sham O
rats O
( O
100 O
+/- O
7 O
versus O
173 O
+/- O
4 O
mm O
hg O
, O
p O
less O
than O
0.05) O
. O

fifteen O
days O
later O
, O
the O
lesioned O
group O
still O
showed O
values O
significantly O
lower O
than O
the O
sham O
group O
( O
150 O
+/- O
6 O
versus O
167 O
+/- O
5 O
mm O
hg O
, O
p O
less O
than O
0.05) O
. O

no O
significant O
heart O
rate O
differences O
were O
observed O
between O
the O
sham O
and O
lesioned O
groups O
. O

the O
ganglionic O
blocker O
trimethaphan O
(5 O
mg/kg O
i.v. O
) O
caused O
similar O
reductions O
in O
mean O
arterial O
pressure O
in O
both O
lesioned O
and O
sham O
groups O
. O

the O
trimethaphan-induced O
hypotension B-NEG
was O
accompanied O
by O
a O
significant O
bradycardia B-NEG
in O
lesioned O
rats O
( O
-32 O
+/- O
13 O
beats O
per O
minute O
) O
but O
a O
tachycardia B-NEG
in O
sham O
rats O
( O
+33 O
+/- O
12 O
beats O
per O
minute O
) O
1 O
day O
postlesion O
. O

therefore O
, O
rostral O
ventrolateral O
medulla O
neurons O
appear O
to O
play O
a O
significant O
role O
in O
maintaining O
hypertension B-NEG
in O
conscious O
spontaneously O
hypertensive B-NEG
rats O
. O

spinal O
or O
suprabulbar O
structures O
could O
be O
responsible O
for O
the O
gradual O
recovery O
of O
the O
hypertension B-NEG
in O
the O
lesioned O
rats O
. O

-DOCSTART- O

damage B-NEG
of I-NEG
substantia I-NEG
nigra I-NEG
pars I-NEG
reticulata I-NEG
during O
pilocarpine-induced O
status B-NEG
epilepticus I-NEG
in O
the O
rat O
: O
immunohistochemical O
study O
of O
neurons O
, O
astrocytes O
and O
serum-protein O
extravasation O
. O

the O
substantia O
nigra O
has O
a O
gating O
function O
controlling O
the O
spread O
of O
epileptic B-NEG
seizure I-NEG
activity O
. O

additionally O
, O
in O
models O
of O
prolonged B-NEG
status I-NEG
epilepticus I-NEG
the O
pars O
reticulata O
of O
substantia O
nigra O
( O
snr O
) O
suffers O
from O
a O
massive O
lesion O
which O
may O
arise O
from O
a O
massive O
metabolic B-NEG
derangement I-NEG
and O
hyperexcitation O
developing O
in O
the O
activated O
snr O
. O

in O
this O
study O
, O
status B-NEG
epilepticus I-NEG
was O
induced O
by O
systemic O
injection O
of O
pilocarpine O
in O
rats O
. O

the O
neuropathology O
of O
snr O
was O
investigated O
using O
immunohistochemical O
techniques O
with O
the O
major O
emphasis O
on O
the O
time-course O
of O
changes O
in O
neurons O
and O
astrocytes O
. O

animals O
surviving O
20 O
, O
30 O
, O
40 O
, O
60 O
min O
, O
2, O
3, O
6 O
hours O
, O
1, O
2, O
and O
3 O
days O
after O
induction O
of O
status B-NEG
epilepticus I-NEG
were O
perfusion-fixed O
, O
and O
brains O
processed O
for O
immunohistochemical O
staining O
of O
snr O
. O

nissl-staining O
and O
antibodies O
against O
the O
neuron-specific O
calcium-binding O
protein O
, O
parvalbumin O
, O
served O
to O
detect O
neuronal B-NEG
damage I-NEG
in O
snr O
. O

antibodies O
against O
the O
astroglia-specific O
cytoskeletal O
protein O
, O
glial O
fibrillary O
acidic O
protein O
(gfap) O
, O
and O
against O
the O
glial O
calcium-binding O
protein O
, O
s-100 O
protein O
, O
were O
used O
to O
assess O
the O
status O
of O
astrocytes O
. O

immunohistochemical O
staining O
for O
serum-albumin O
and O
immunoglobulins O
in O
brain O
tissue O
was O
taken O
as O
indicator O
of O
blood-brain O
barrier O
disturbances O
and O
vasogenic B-NEG
edema I-NEG
formation O
. O

immunohistochemical O
staining O
indicated O
loss O
of O
gfap-staining O
already O
at O
30 O
min O
after O
induction O
of O
seizures B-NEG
in O
an O
oval O
focus O
situated O
in O
the O
center O
of O
snr O
while O
sparing O
medial O
and O
lateral O
aspects O
. O

at O
1 O
h O
there O
was O
additional O
vacuolation O
in O
s-100 O
protein O
staining O
. O

by O
2 O
hours O
, O
parvalbumin-staining O
changed O
in O
the O
central O
snr O
indicating O
neuronal B-NEG
damage I-NEG
, O
and O
nissl-staining O
visualized O
some O
neuronal O
distortion O
. O

staining O
for O
serum-proteins O
occurred O
in O
a O
patchy O
manner O
throughout O
the O
forebrain O
during O
the O
first O
hours O
. O

by O
6 O
h, O
vasogenic B-NEG
edema I-NEG
covered O
the O
lesioned B-NEG
snr I-NEG
. O

by O
24 O
h, O
glial O
and O
neuronal O
markers O
indicated O
a O
massive O
lesion O
in O
the O
center O
of O
snr O
. O

by O
48-72 O
h, O
astrocytes O
surrounding O
the O
lesion O
increased O
in O
size O
, O
and O
polymorphic O
phagocytotic O
cells O
invaded O
the O
damaged O
area O
. O

in O
a O
further O
group O
of O
animals O
surviving O
1 O
to O
5 O
days O
, O
conventional O
paraffin-sections O
confirmed O
the O
neuronal O
and O
glial O
damage B-NEG
of I-NEG
snr I-NEG
. O

additional O
pathology O
of O
similar O
quality O
was O
found O
in O
the O
globus O
pallidus O
. O

since O
astrocytes O
were O
always O
damaged O
in O
parallel O
with O
neurons O
in O
snr O
it O
is O
proposed O
that O
the O
anatomical O
and O
functional O
interrelationship O
between O
neurons O
and O
astrocytes O
is O
particularly O
tight O
in O
snr O
. O

both O
cell O
elements O
may O
suffer O
in O
common O
from O
metabolic O
disturbance O
and O
neurotransmitter B-NEG
dysfunction I-NEG
as O
occur O
during O
massive O
status B-NEG
epilepticus I-NEG
. O

-DOCSTART- O

reduced O
cardiotoxicity B-NEG
of O
doxorubicin O
given O
in O
the O
form O
of O
n-(2-hydroxypropyl)methacrylamide O
conjugates O
: O
and O
experimental O
study O
in O
the O
rat O
. O

a O
rat O
model O
was O
used O
to O
evaluate O
the O
general O
acute O
toxicity B-NEG
and O
the O
late O
cardiotoxicity B-NEG
of O
4 O
mg/kg O
doxorubicin O
( O
dox O
) O
given O
either O
as O
free O
drug O
or O
in O
the O
form O
of O
three O
n-(2-hydroxypropyl)methacrylamide O
( O
hpma O
) O
copolymer O
conjugates O
. O

in O
these O
hpma O
copolymers O
, O
dox O
was O
covalently O
bound O
via O
peptide O
linkages O
that O
were O
either O
non-biodegradable O
( O
gly-gly O
) O
or O
degradable O
by O
lysosomal O
proteinases O
(gly-phe-leu-gly) O
. O

in O
addition O
, O
one O
biodegradable O
conjugate O
containing O
galactosamine O
was O
used O
; O
this O
residue O
was O
targeted O
to O
the O
liver O
. O

over O
the O
first O
3 O
weeks O
after O
the O
i.v O
. O
administration O
of O
free O
and O
polymer-bound O
dox O
, O
all O
animals O
showed O
a O
transient O
reduction O
in O
body O
weight O
. O

however O
, O
the O
maximal O
reduction O
in O
body O
weight O
seen O
in O
animals O
that O
received O
polymer-bound O
dox O
(4 O
mg/kg O
) O
was O
significantly O
lower O
than O
that O
observed O
in O
those O
that O
received O
free O
dox O
(4 O
mg/kg O
) O
or O
a O
mixture O
of O
the O
unmodified O
parent O
hpma O
copolymer O
and O
free O
dox O
(4 O
mg/kg O
; O
p O
less O
than O
0.01) O
. O

throughout O
the O
study O
( O
20 O
weeks) O
, O
deaths O
related O
to O
cardiotoxicity B-NEG
were O
observed O
only O
in O
animals O
that O
received O
either O
free O
dox O
or O
the O
mixture O
of O
hpma O
copolymer O
and O
free O
dox O
; O
in O
these O
cases O
, O
histological O
investigations O
revealed O
marked O
changes O
in O
the O
heart O
that O
were O
consistent O
with O
dox-induced O
cardiotoxicity B-NEG
. O

sequential O
measurements O
of O
cardiac O
output O
in O
surviving O
animals O
that O
received O
either O
free O
dox O
or O
the O
mixture O
of O
hpma O
copolymer O
and O
free O
dox O
showed O
a O
reduction O
of O
approximately O
30% O
in O
function O
beginning O
at O
the O
4th O
week O
after O
drug O
administration O
. O

the O
heart O
rate O
in O
these O
animals O
was O
approximately O
12% O
lower O
than O
that O
measured O
in O
age-matched O
control O
rats O
(p O
less O
than O
0.05) O
. O

animals O
that O
were O
given O
the O
hpma O
copolymer O
conjugates O
containing O
dox O
exhibited O
no O
significant O
change O
in O
cardiac O
output O
throughout O
the O
study O
(p O
less O
than O
0.05) O
. O

in O
addition O
, O
no O
significant O
histological O
change O
was O
observed O
in O
the O
heart O
of O
animals O
that O
received O
dox O
in O
the O
form O
of O
hpma O
copolymer O
conjugates O
and O
were O
killed O
at O
the O
end O
of O
the O
study O
. O

however O
, O
these O
animals O
had O
shown O
a O
significant O
increase O
in O
heart O
rate O
beginning O
at O
8 O
weeks O
after O
drug O
administration O
(p O
less O
than O
0.01).(abstract O
truncated O
at O
400 O
words O
) O

-DOCSTART- O

topical O
0.025% O
capsaicin O
in O
chronic O
post-herpetic B-NEG
neuralgia I-NEG
: O
efficacy O
, O
predictors O
of O
response O
and O
long-term O
course O
. O

in O
order O
to O
evaluate O
the O
efficacy O
, O
time-course O
of O
action O
and O
predictors O
of O
response O
to O
topical O
capsaicin O
, O
39 O
patients O
with O
chronic O
post-herpetic B-NEG
neuralgia I-NEG
( O
phn B-NEG
), O
median O
duration O
24 O
months O
, O
were O
treated O
with O
0.025% O
capsaicin O
cream O
for O
8 O
weeks O
. O

during O
therapy O
the O
patients O
rated O
their O
pain B-NEG
on O
a O
visual O
analogue O
scale O
( O
vas O
) O
and O
a O
verbal O
outcome O
scale O
. O

a O
follow-up O
investigation O
was O
performed O
10-12 O
months O
after O
study O
onset O
on O
the O
patients O
who O
had O
improved O
. O

nineteen O
patients O
( O
48.7% O
) O
substantially O
improved O
after O
the O
8-week O
trial O
; O
5 O
( O
12.8% O
) O
discontinued O
therapy O
due O
to O
side-effects O
such O
as O
intolerable O
capsaicin-induced O
burning O
sensations O
( O
4 O
) O
or O
mastitis B-NEG
(1) O
; O
15 O
( O
38.5% O
) O
reported O
no O
benefit O
. O

the O
decrease O
in O
vas O
ratings O
was O
significant O
after O
2 O
weeks O
of O
continuous O
application O
. O

of O
the O
responders O
72.2% O
were O
still O
improved O
at O
the O
follow-up O
; O
only O
one-third O
of O
them O
had O
continued O
application O
irregularly O
. O

treatment O
effect O
was O
not O
dependent O
on O
patient's O
age O
, O
duration O
or O
localization O
of O
phn B-NEG
( O
trigeminal O
involvement O
was O
excluded) O
, O
sensory B-NEG
disturbance I-NEG
or O
pain B-NEG
character O
. O

treatment O
response O
was O
not O
correlated O
with O
the O
incidence O
, O
time-course O
or O
severity O
of O
capsaicin-induced O
burning O
. O

if O
confirmed O
in O
controlled O
trials O
, O
the O
long-term O
results O
of O
this O
open O
, O
non-randomized O
study O
might O
indicate O
that O
the O
analgesic O
effect O
of O
capsaicin O
in O
phn B-NEG
is O
mediated O
by O
both O
interference O
with O
neuropeptide O
metabolism O
and O
morphological O
changes O
( O
perhaps O
degeneration O
) O
of O
nociceptive O
afferents O
. O

-DOCSTART- O

serotonin O
reuptake O
inhibitors O
, O
paranoia B-NEG
, O
and O
the O
ventral O
basal O
ganglia O
. O

antidepressants O
have O
previously O
been O
associated O
with O
paranoid B-NEG
reactions O
in O
psychiatric O
patients O
. O

five O
cases O
of O
paranoid B-NEG
exacerbation O
with O
the O
serotonin O
reuptake O
inhibitors O
fluoxetine O
and O
amitriptyline O
are O
reported O
here O
. O

elements O
common O
to O
these O
cases O
included O
a O
history O
of O
paranoid B-NEG
symptomatology O
and O
the O
concomitant O
occurrence O
of O
depressive B-NEG
and I-NEG
psychotic I-NEG
symptoms I-NEG
. O

complicated O
depressive B-NEG
disorders I-NEG
( O
including O
atypicality O
of O
course O
and O
symptomatology O
, O
chronicity O
, O
psychosis B-NEG
, O
bipolarity O
, O
and O
secondary O
onset O
in O
the O
course O
of O
a O
primary O
psychosis B-NEG
) O
may O
present O
particular O
vulnerability O
to O
paranoid B-NEG
exacerbations O
associated O
with O
serotonin O
reuptake O
inhibitors O
. O

although O
the O
pharmacology O
and O
neurobiology O
of O
paranoia B-NEG
remain O
cryptic O
, O
several O
mechanisms O
, O
including O
5ht3 O
receptor-mediated O
dopamine O
release O
, O
beta-noradrenergic O
receptor O
downregulation O
, O
or O
gabab O
receptor O
upregulation O
acting O
in O
the O
vicinity O
of O
the O
ventral O
basal O
ganglia O
( O
possibly O
in O
lateral O
orbitofrontal O
or O
anterior O
cingulate O
circuits) O
, O
might O
apply O
to O
this O
phenomenon O
. O

these O
cases O
call O
attention O
to O
possible O
paranoid B-NEG
exacerbations O
with O
serotonin O
reuptake O
blockers O
in O
select O
patients O
and O
raise O
neurobiological O
considerations O
regarding O
paranoia B-NEG
. O

-DOCSTART- O

five O
cases O
of O
encephalitis B-NEG
during O
treatment O
of O
loiasis B-NEG
with O
diethylcarbamazine O
. O

five O
cases O
of O
encephalitis B-NEG
following O
treatment O
with O
diethylcarbamazine O
( O
dec O
) O
were O
observed O
in O
congolese O
patients O
with O
loa O
loa O
filariasis B-NEG
. O

two O
cases O
had O
a O
fatal O
outcome O
and O
one O
resulted O
in O
severe O
sequelae O
. O

the O
notable O
fact O
was O
that O
this O
complication O
occurred O
in O
three O
patients O
hospitalized O
before O
treatment O
began O
, O
with O
whom O
particularly O
strict O
therapeutic O
precautions O
were O
taken O
, O
i.e. O
, O
initial O
dose O
less O
than O
10 O
mg O
of O
dec O
, O
very O
gradual O
dose O
increases O
, O
and O
associated O
anti-allergic O
treatment O
. O

this O
type O
of O
drug-induced O
complication O
may O
not O
be O
that O
uncommon O
in O
highly O
endemic O
regions O
. O

it O
occurs O
primarily O
, O
but O
not O
exclusively O
, O
in O
subjects O
presenting O
with O
a O
high O
microfilarial O
load O
. O

the O
relationship O
between O
the O
occurrence O
of O
encephalitis B-NEG
and O
the O
decrease O
in O
microfilaremia B-NEG
is O
evident O
. O

the O
pathophysiological O
mechanisms O
are O
discussed O
in O
the O
light O
of O
these O
observations O
and O
the O
few O
other O
comments O
on O
this O
subject O
published O
in O
the O
literature O
. O

-DOCSTART- O

delirium B-NEG
in O
an O
elderly O
woman O
possibly O
associated O
with O
administration O
of O
misoprostol O
. O

misoprostol O
has O
been O
associated O
with O
adverse O
reactions O
, O
including O
gastrointestinal O
symptoms O
, O
gynecologic O
problems O
, O
and O
headache B-NEG
. O

changes O
in O
mental O
status O
, O
however O
, O
have O
not O
been O
reported O
. O

we O
present O
a O
case O
in O
which O
an O
89-year-old O
woman O
in O
a O
long-term O
care O
facility O
became O
confused O
after O
the O
initiation O
of O
misoprostol O
therapy O
. O

the O
patient's O
change O
in O
mental O
status O
was O
first O
reported O
nine O
days O
after O
the O
initiation O
of O
therapy O
. O

her O
delirium B-NEG
significantly O
improved O
after O
misoprostol O
was O
discontinued O
and O
her O
mental O
status O
returned O
to O
normal O
within O
a O
week O
. O

because O
no O
other O
factors O
related O
to O
this O
patient O
changed O
significantly O
, O
the O
delirium B-NEG
experienced O
by O
this O
patient O
possibly O
resulted O
from O
misoprostol O
therapy O
. O

-DOCSTART- O

hepatocellular O
oxidant O
stress O
following O
intestinal O
ischemia B-NEG
- O
reperfusion B-NEG
injury I-NEG
. O

reperfusion O
of O
ischemic B-NEG
intestine O
results O
in O
acute O
liver B-NEG
dysfunction I-NEG
characterized O
by O
hepatocellular O
enzyme O
release O
into O
plasma O
, O
reduction O
in O
bile O
flow O
rate O
, O
and O
neutrophil O
sequestration O
within O
the O
liver O
. O

the O
pathophysiology O
underlying O
this O
acute O
hepatic B-NEG
injury I-NEG
is O
unknown O
. O

this O
study O
was O
undertaken O
to O
determine O
whether O
oxidants O
are O
associated O
with O
the O
hepatic B-NEG
injury I-NEG
and O
to O
determine O
the O
relative O
value O
of O
several O
indirect O
methods O
of O
assessing O
oxidant O
exposure O
in O
vivo O
. O

rats O
were O
subjected O
to O
a O
standardized O
intestinal O
ischemia B-NEG
- O
reperfusion B-NEG
injury I-NEG
. O

hepatic O
tissue O
was O
assayed O
for O
lipid O
peroxidation O
products O
and O
oxidized O
and O
reduced O
glutathione O
. O

there O
was O
no O
change O
in O
hepatic O
tissue O
total O
glutathione O
following O
intestinal O
ischemia B-NEG
- O
reperfusion B-NEG
injury I-NEG
. O

oxidized O
glutathione O
( O
gssg O
) O
increased O
significantly O
following O
30 O
and O
60 O
min O
of O
reperfusion O
. O

there O
was O
no O
increase O
in O
any O
of O
the O
products O
of O
lipid O
peroxidation O
associated O
with O
this O
injury O
. O

an O
increase O
in O
gssg O
within O
hepatic O
tissue O
during O
intestinal O
reperfusion O
suggests O
exposure O
of O
hepatocytes O
to O
an O
oxidant O
stress O
. O

the O
lack O
of O
a O
significant O
increase O
in O
products O
of O
lipid O
peroxidation O
suggests O
that O
the O
oxidant O
stress O
is O
of O
insufficient O
magnitude O
to O
result O
in O
irreversible O
injury O
to O
hepatocyte O
cell O
membranes O
. O

these O
data O
also O
suggest O
that O
the O
measurement O
of O
tissue O
gssg O
may O
be O
a O
more O
sensitive O
indicator O
of O
oxidant O
stress O
than O
measurement O
of O
products O
of O
lipid O
peroxidation O
. O

-DOCSTART- O

diphenhydramine O
prevents O
the O
haemodynamic O
changes O
of O
cimetidine O
in O
icu O
patients O
. O

cimetidine O
, O
a O
histamine O
2 O
( O
h2 O
) O
antagonist O
, O
produces O
a O
decrease O
in O
arterial O
pressure O
due O
to O
vasodilatation O
, O
especially O
in O
critically O
ill O
patients O
. O

this O
may O
be O
because O
cimetidine O
acts O
as O
a O
histamine O
agonist O
. O

we O
, O
therefore O
, O
investigated O
the O
effects O
of O
the O
histamine O
1(h1 O
) O
receptor O
antagonist O
, O
diphenhydramine O
, O
on O
the O
haemodynamic O
changes O
observed O
after O
cimetidine O
in O
icu O
patients O
. O

each O
patient O
was O
studied O
on O
two O
separate O
days O
. O

in O
a O
random O
fashion O
, O
they O
received O
cimetidine O
200 O
mg O
iv O
on O
one O
day O
, O
and O
on O
the O
other O
, O
a O
pretreatment O
of O
diphenhydramine O
40 O
mg O
iv O
with O
cimetidine O
200 O
mg O
iv O
. O

in O
the O
non-pretreatment O
group O
, O
mean O
arterial O
pressure O
( O
map O
) O
decreased O
from O
107.4 O
+/- O
8.4 O
mmhg O
to O
86.7 O
+/- O
11.4 O
mmhg O
(p O
less O
than O
0.01 O
) O
two O
minutes O
after O
cimetidine O
. O

also O
, O
systemic O
vascular O
resistance O
( O
svr O
) O
decreased O
during O
the O
eight-minute O
observation O
period O
(p O
less O
than O
0.01) O
. O

in O
contrast O
, O
in O
the O
pretreatment O
group O
, O
little O
haemodynamic O
change O
was O
seen O
. O

we O
conclude O
that O
an O
h1 O
antagonist O
may O
be O
useful O
in O
preventing O
hypotension B-NEG
caused O
by O
iv O
cimetidine O
, O
since O
the O
vasodilating O
activity O
of O
cimetidine O
is O
mediated O
, O
in O
part O
, O
through O
the O
h1 O
receptor O
. O

-DOCSTART- O

acute B-NEG
renal I-NEG
failure I-NEG
due O
to O
rifampicin O
. O

a O
23-year-old O
male O
patient O
with O
bacteriologically O
proven O
pulmonary B-NEG
tuberculosis I-NEG
was O
treated O
with O
the O
various O
regimens O
of O
antituberculosis O
drugs O
for O
nearly O
15 O
months O
. O

rifampicin O
was O
administered O
thrice O
as O
one O
of O
the O
3-4 O
drug O
regimen O
and O
each O
time O
he O
developed O
untoward O
side O
effects O
like O
nausea B-NEG
, O
vomiting B-NEG
and O
fever B-NEG
with O
chills O
and O
rigors O
. O

the O
last O
such O
episode O
was O
of O
acute O
renal O
failure O
at O
which O
stage O
the O
patient O
was O
seen O
by O
the O
authors O
of O
this O
report O
. O

the O
patient O
, O
however O
, O
made O
a O
full O
recovery O
. O

-DOCSTART- O

severe O
polyneuropathy B-NEG
and O
motor O
loss O
after O
intrathecal O
thiotepa O
combination O
chemotherapy O
: O
description O
of O
two O
cases O
. O

two O
cases O
of O
severe O
delayed O
neurologic B-NEG
toxicity I-NEG
related O
to O
the O
administration O
of O
intrathecal O
( O
it O
) O
combination O
chemotherapy O
including O
thiotepa O
( O
tspa O
) O
are O
presented O
. O

both O
cases O
developed O
axonal B-NEG
neuropathy I-NEG
with O
motor O
predominance O
in O
the O
lower O
extremities O
1 O
and O
6 O
months O
after O
it O
chemotherapy O
was O
administered O
. O
neurologic B-NEG
toxicities I-NEG
have O
been O
described O
with O
it-methotrexate O
, O
it-cytosine O
arabinoside O
and O
it-tspa O
. O

to O
our O
knowledge O
, O
however O
, O
axonal B-NEG
neuropathy I-NEG
following O
administration O
of O
these O
three O
agents O
has O
not O
been O
previously O
described O
. O

in O
spite O
of O
the O
fact O
that O
tspa O
is O
a O
useful O
it O
agent O
, O
its O
combination O
with O
mtx O
, O
ara-c O
and O
radiotherapy O
could O
cause O
severe O
neurotoxicity B-NEG
. O

this O
unexpected O
complication O
indicates O
the O
need O
for O
further O
toxicology O
research O
on O
it-tspa O
. O

-DOCSTART- O

effects O
of O
cromakalim O
and O
pinacidil O
on O
large O
epicardial O
and O
small O
coronary O
arteries O
in O
conscious O
dogs O
. O

the O
effects O
of O
i.v O
. O
bolus O
administration O
of O
cromakalim O
( O
1-10 O
micrograms/kg O
) O
and O
pinacidil O
( O
3-100 O
micrograms/kg O
) O
on O
large O
( O
circumflex O
artery O
) O
and O
small O
coronary O
arteries O
and O
on O
systemic O
hemodynamics O
were O
investigated O
in O
chronically O
instrumented O
conscious O
dogs O
and O
compared O
to O
those O
of O
nitroglycerin O
( O
0.03-10 O
micrograms/kg) O
. O

nitroglycerin O
, O
up O
to O
0.3 O
micrograms/kg O
, O
selectively O
increased O
circumflex O
artery O
diameter O
( O
cxad O
) O
without O
simultaneously O
affecting O
any O
other O
cardiac O
or O
systemic O
hemodynamic O
parameter O
. O

in O
contrast O
, O
cromakalim O
and O
pinacidil O
at O
all O
doses O
and O
nitroglycerin O
at O
doses O
higher O
than O
0.3 O
micrograms/kg O
simultaneously O
and O
dose-dependently O
increased O
cxad O
, O
coronary O
blood O
flow O
and O
heart O
rate O
and O
decreased O
coronary O
vascular O
resistance O
and O
aortic O
pressure O
. O

cromakalim O
was O
approximately O
8- O
to O
9.5-fold O
more O
potent O
than O
pinacidil O
in O
increasing O
cxad O
. O

vasodilation O
of O
large O
and O
small O
coronary O
vessels O
and O
hypotension B-NEG
induced O
by O
cromakalim O
and O
pinacidil O
were O
not O
affected O
by O
prior O
combined O
beta O
adrenergic O
and O
muscarinic O
receptors O
blockade O
but O
drug-induced O
tachycardia B-NEG
was O
abolished O
. O

when O
circumflex O
artery O
blood O
flow O
was O
maintained O
constant O
, O
the O
increases O
in O
cxad O
induced O
by O
cromakalim O
( O
10 O
micrograms/kg) O
, O
pinacidil O
( O
30 O
micrograms/kg O
) O
and O
nitroglycerin O
( O
10 O
micrograms/kg O
) O
were O
reduced O
by O
68 O
+/- O
7, O
54 O
+/- O
9 O
and O
1 O
+/- O
1% O
, O
respectively O
. O

thus O
, O
whereas O
nitroglycerin O
preferentially O
and O
flow-independently O
dilates O
large O
coronary O
arteries O
, O
cromakalim O
and O
pinacidil O
dilate O
both O
large O
and O
small O
coronary O
arteries O
and O
this O
effect O
is O
not O
dependent O
upon O
the O
simultaneous O
beta O
adrenoceptors-mediated O
rise O
in O
myocardial O
metabolic O
demand O
. O

finally O
, O
two O
mechanisms O
at O
least O
, O
direct O
vasodilation O
and O
flow O
dependency O
, O
are O
involved O
in O
the O
cromakalim- O
and O
pinacidil-induced O
increase O
in O
cxad O
. O

-DOCSTART- O

mefenamic O
acid-induced O
neutropenia B-NEG
and O
renal B-NEG
failure I-NEG
in O
elderly O
females O
with O
hypothyroidism B-NEG
. O

we O
report O
mefenamic O
acid-induced O
non-oliguric O
renal B-NEG
failure I-NEG
and O
severe O
neutropenia B-NEG
occurring O
simultaneously O
in O
two O
elderly O
females O
. O

the O
neutropenia B-NEG
was O
due O
to O
maturation O
arrest O
of O
the O
myeloid O
series O
in O
one O
patient O
. O

both O
patients O
were O
also O
hypothyroid B-NEG
, O
but O
it O
is O
not O
clear O
whether O
this O
was O
a O
predisposing O
factor O
to O
the O
development O
of O
these O
adverse O
reactions O
. O

however O
, O
it O
would O
seem O
prudent O
not O
to O
use O
mefenamic O
acid O
in O
hypothyroid B-NEG
patients O
until O
the O
hypothyroidism B-NEG
has O
been O
corrected O
. O

-DOCSTART- O

etiology O
of O
hypercalcemia B-NEG
in O
hemodialysis O
patients O
on O
calcium O
carbonate O
therapy O
. O

fourteen O
of O
39 O
dialysis O
patients O
( O
36% O
) O
became O
hypercalcemic B-NEG
after O
switching O
to O
calcium O
carbonate O
as O
their O
principal O
phosphate O
binder O
. O

in O
order O
to O
identify O
risk O
factors O
associated O
with O
the O
development O
of O
hypercalcemia B-NEG
, O
indirect O
parameters O
of O
intestinal O
calcium O
reabsorption O
and O
bone O
turnover O
rate O
in O
these O
14 O
patients O
were O
compared O
with O
results O
in O
14 O
eucalcemic O
patients O
matched O
for O
age O
, O
sex O
, O
length O
of O
time O
on O
dialysis O
, O
and O
etiology O
of O
renal B-NEG
disease I-NEG
. O

in O
addition O
to O
experiencing O
hypercalcemic B-NEG
episodes O
with O
peak O
calcium O
values O
of O
2.7 O
to O
3.8 O
mmol/l O
( O
10.7 O
to O
15.0 O
mg/dl) O
, O
patients O
in O
the O
hypercalcemic B-NEG
group O
exhibited O
a O
significant O
increase O
in O
the O
mean O
calcium O
concentration O
obtained O
during O
6 O
months O
before O
the O
switch O
, O
compared O
with O
the O
mean O
value O
obtained O
during O
the O
7 O
months O
of O
observation O
after O
the O
switch O
( O
2.4 O
+/- O
0.03 O
to O
2.5 O
+/- O
0.03 O
mmol/l O
[9.7 O
+/- O
0.2 O
to O
10.2 O
+/- O
0.1 O
mg/dl] O
, O
p O
= O
0.006) O
. O

in O
contrast O
, O
eucalcemic O
patients O
exhibited O
no O
change O
in O
mean O
calcium O
values O
over O
the O
same O
time O
period O
( O
2.3 O
+/- O
0.05 O
to O
2.3 O
+/- O
0.05 O
mmol/l O
[9.2 O
+/- O
0.2 O
to O
9.2 O
+/- O
0.2 O
mg/dl]) O
. O

caco3 O
dosage O
, O
calculated O
dietary O
calcium O
intake O
, O
and O
circulating O
levels O
of O
vitamin O
d O
metabolites O
were O
similar O
in O
both O
groups O
. O

physical O
activity O
index O
and O
predialysis O
serum O
bicarbonate O
levels O
also O
were O
similar O
in O
both O
groups O
. O

however O
, O
there O
was O
a O
significant O
difference O
in O
parameters O
reflecting O
bone O
turnover O
rates O
between O
groups.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

methyldopa-induced O
hemolytic B-NEG
anemia I-NEG
in O
a O
15 O
year O
old O
presenting O
as O
near- O
syncope B-NEG
. O

methyldopa O
is O
an O
antihypertensive O
medication O
which O
is O
available O
generically O
and O
under O
the O
trade O
name O
aldomet O
that O
is O
widely O
prescribed O
in O
the O
adult O
population O
and O
infrequently O
used O
in O
children O
. O

methyldopa O
causes O
an O
autoimmune B-NEG
hemolytic I-NEG
anemia I-NEG
in O
a O
small O
percentage O
of O
patients O
who O
take O
the O
drug O
. O

we O
report O
a O
case O
of O
methyldopa-induced O
hemolytic B-NEG
anemia I-NEG
in O
a O
15-year-old O
boy O
who O
presented O
to O
the O
emergency B-NEG
department I-NEG
with O
near- O
syncope B-NEG
. O

the O
boy O
had O
been O
treated O
with O
intravenous O
methyldopa O
during O
a O
trauma B-NEG
admission O
seven O
weeks O
prior O
to O
presentation O
. O

evaluation O
revealed O
a O
hemoglobin O
of O
three O
grams O
, O
3+ O
coombs' O
test O
with O
polyspecific O
anti-human O
globulin O
and O
monospecific O
igg O
reagents O
, O
and O
a O
warm O
reacting O
autoantibody O
. O

transfusion O
and O
corticosteroid O
therapy O
resulted O
in O
a O
complete O
recovery O
of O
the O
patient O
. O

emergency O
physicians O
treating O
children O
must O
be O
aware O
of O
this O
syndrome O
in O
order O
to O
diagnose O
and O
treat O
it O
correctly O
. O

a O
brief O
review O
of O
autoimmune O
and O
drug-induced O
hemolytic B-NEG
anemias I-NEG
is O
provided O
. O

-DOCSTART- O

the O
long-term O
safety O
of O
danazol O
in O
women O
with O
hereditary B-NEG
angioedema I-NEG
. O

although O
the O
short-term O
safety O
( O
less O
than O
or O
equal O
to O
6 O
months O
) O
of O
danazol O
has O
been O
established O
in O
a O
variety O
of O
settings O
, O
no O
information O
exists O
as O
to O
its O
long-term O
safety O
. O

we O
therefore O
investigated O
the O
long-term O
safety O
of O
danazol O
by O
performing O
a O
retrospective O
chart O
review O
of O
60 O
female O
patients O
with O
hereditary B-NEG
angioedema I-NEG
treated O
with O
danazol O
for O
a O
continuous O
period O
of O
6 O
months O
or O
longer O
. O

the O
mean O
age O
of O
the O
patients O
was O
35.2 O
years O
and O
the O
mean O
duration O
of O
therapy O
was O
59.7 O
months O
. O

virtually O
all O
patients O
experienced O
one O
or O
more O
adverse O
reactions O
. O
menstrual B-NEG
abnormalities I-NEG
(79%) O
, O
weight B-NEG
gain I-NEG
(60%) O
, O
muscle B-NEG
cramps I-NEG
/ O
myalgias B-NEG
(40%) O
, O
and O
transaminase O
elevations O
( O
40% O
) O
were O
the O
most O
common O
adverse O
reactions O
. O

the O
drug O
was O
discontinued O
due O
to O
adverse O
reactions O
in O
8 O
patients O
. O

no O
patient O
has O
died O
or O
suffered O
any O
apparent O
long-term O
sequelae O
that O
were O
directly O
attributable O
to O
the O
drug O
. O

we O
conclude O
that O
, O
despite O
a O
relatively O
high O
incidence O
of O
adverse O
reactions O
, O
danazol O
has O
proven O
to O
be O
remarkably O
safe O
over O
the O
long-term O
in O
this O
group O
of O
patients O
. O

-DOCSTART- O

patient O
tolerance O
study O
of O
topical O
chlorhexidine O
diphosphanilate O
: O
a O
new O
topical O
agent O
for O
burns B-NEG
. O

effective O
topical O
antimicrobial O
agents O
decrease O
infection B-NEG
and O
mortality O
in O
burn B-NEG
patients O
. O

chlorhexidine O
phosphanilate O
(chp) O
, O
a O
new O
broad-spectrum O
antimicrobial O
agent O
, O
has O
been O
evaluated O
as O
a O
topical O
burn B-NEG
wound O
dressing O
in O
cream O
form O
, O
but O
preliminary O
clinical O
trials O
reported O
that O
it O
was O
painful O
upon O
application O
. O

this O
study O
compared O
various O
concentrations O
of O
chp O
to O
determine O
if O
a O
tolerable O
concentration O
could O
be O
identified O
with O
retention O
of O
antimicrobial O
efficacy O
. O

twenty-nine O
burn B-NEG
patients O
, O
each O
with O
two O
similar O
burns B-NEG
which O
could O
be O
separately O
treated O
, O
were O
given O
pairs O
of O
treatments O
at O
successive O
12-h O
intervals O
over O
a O
3-day O
period O
. O

one O
burn B-NEG
site O
was O
treated O
with O
each O
of O
four O
different O
chp O
concentrations O
, O
from O
0.25 O
per O
cent O
to O
2 O
per O
cent O
, O
their O
vehicle O
, O
and O
1 O
per O
cent O
silver O
sulphadiazine O
( O
agsd O
) O
cream O
, O
an O
antimicrobial O
agent O
frequently O
used O
for O
topical O
treatment O
of O
burn B-NEG
wounds O
. O

the O
other O
site O
was O
always O
treated O
with O
agsd O
cream O
. O

there O
was O
a O
direct O
relationship O
between O
chp O
concentration O
and O
patients' O
ratings O
of O
pain B-NEG
on O
an O
analogue O
scale O
. O

the O
0.25 O
per O
cent O
chp O
cream O
was O
closest O
to O
agsd O
in O
pain B-NEG
tolerance O
; O
however O
, O
none O
of O
the O
treatments O
differed O
statistically O
from O
agsd O
or O
from O
each O
other O
. O

in O
addition O
, O
ease O
of O
application O
of O
chp O
creams O
was O
less O
satisfactory O
than O
that O
of O
agsd O
. O

it O
was O
concluded O
that O
formulations O
at O
or O
below O
0.5 O
per O
cent O
chp O
may O
prove O
acceptable O
for O
wound O
care O
, O
but O
the O
vehicle O
system O
needs O
pharmaceutical O
improvement O
to O
render O
it O
more O
tolerable O
and O
easier O
to O
use O
. O

-DOCSTART- O

dose-dependent O
neurotoxicity B-NEG
of O
high-dose O
busulfan O
in O
children O
: O
a O
clinical O
and O
pharmacological O
study O
. O

busulfan O
is O
known O
to O
be O
neurotoxic B-NEG
in O
animals O
and O
humans O
, O
but O
its O
acute O
neurotoxicity B-NEG
remains O
poorly O
characterized O
in O
children O
. O

we O
report O
here O
a O
retrospective O
study O
of O
123 O
children O
( O
median O
age O
, O
6.5 O
years O
) O
receiving O
high-dose O
busulfan O
in O
combined O
chemotherapy O
before O
bone O
marrow O
transplantation O
for O
malignant O
solid O
tumors B-NEG
, O
brain B-NEG
tumors I-NEG
excluded O
. O

busulfan O
was O
given O
p.o. O
, O
every O
6 O
hours O
for O
16 O
doses O
over O
4 O
days O
. O

two O
total O
doses O
were O
consecutively O
used O
: O
16 O
mg/kg O
, O
then O
600 O
mg/m2 O
. O

the O
dose O
calculation O
on O
the O
basis O
of O
body O
surface O
area O
results O
in O
higher O
doses O
in O
young O
children O
than O
in O
older O
patients O
( O
16 O
to O
28 O
mg/kg) O
. O

ninety-six O
patients O
were O
not O
given O
anticonvulsive O
prophylaxis O
; O
7 O
( O
7.5% O
) O
developed O
seizures B-NEG
during O
the O
4 O
days O
of O
the O
busulfan O
course O
or O
within O
24 O
h O
after O
the O
last O
dosing O
. O

when O
the O
total O
busulfan O
dose O
was O
taken O
into O
account O
, O
there O
was O
a O
significant O
difference O
in O
terms O
of O
neurotoxicity B-NEG
incidence O
among O
patients O
under O
16 O
mg/kg O
(1 O
of O
57 O
, O
1.7% O
) O
and O
patients O
under O
600 O
mg/m2 O
(6 O
of O
39 O
, O
15.4% O
) O
(p O
less O
than O
0.02) O
. O

twenty-seven O
patients O
were O
given O
a O
600-mg/m2 O
busulfan O
total O
dose O
with O
continuous O
i.v O
. O
infusion O
of O
clonazepam O
; O
none O
had O
any O
neurological B-NEG
symptoms I-NEG
. O

busulfan O
levels O
were O
measured O
by O
a O
gas O
chromatographic-mass O
spectrometry O
assay O
in O
the O
plasma O
and O
cerebrospinal O
fluid O
of O
9 O
children O
without O
central B-NEG
nervous I-NEG
system I-NEG
disease I-NEG
under O
600 O
mg/m2 O
busulfan O
with O
clonazepam:busulfan O
cerebrospinal O
fluid:plasma O
ratio O
was O
1.39 O
. O

this O
was O
significantly O
different O
(p O
less O
than O
0.02 O
) O
from O
the O
cerebrospinal O
fluid:plasma O
ratio O
previously O
defined O
in O
children O
receiving O
a O
16-mg/kg O
total O
dose O
of O
busulfan O
. O

this O
study O
shows O
that O
busulfan O
neurotoxicity B-NEG
is O
dose-dependent O
in O
children O
and O
efficiently O
prevented O
by O
clonazepam O
. O

a O
busulfan O
dose O
calculated O
on O
the O
basis O
of O
body O
surface O
area O
, O
resulting O
in O
higher O
doses O
in O
young O
children O
, O
was O
followed O
by O
increased O
neurotoxicity B-NEG
, O
close O
to O
neurotoxicity B-NEG
incidence O
observed O
in O
adults O
. O

since O
plasma O
pharmacokinetic O
studies O
showed O
a O
faster O
busulfan O
clearance O
in O
children O
than O
in O
adults O
, O
this O
new O
dose O
may O
approximate O
more O
closely O
the O
adult O
systemic O
exposure O
obtained O
after O
the O
usual O
16-mg/kg O
total O
dose O
, O
with O
potential O
inferences O
in O
terms O
of O
anticancer O
or O
myeloablative O
effects O
. O

the O
busulfan O
dose O
in O
children O
and O
infants O
undergoing O
bone O
marrow O
transplantation O
should O
be O
reconsidered O
on O
the O
basis O
of O
pharmacokinetic O
studies O
. O

-DOCSTART- O

histamine O
antagonists O
and O
d-tubocurarine-induced O
hypotension B-NEG
in O
cardiac O
surgical O
patients O
. O

hemodynamic O
effects O
and O
histamine O
release O
by O
bolus O
injection O
of O
0.35 O
mg/kg O
of O
d-tubocurarine O
were O
studied O
in O
24 O
patients O
. O

h1- O
and O
h2-histamine O
antagonists O
or O
placebo O
were O
given O
before O
dosing O
with O
d-tubocurarine O
in O
a O
randomized O
double-blind O
fashion O
to O
four O
groups O
: O
group O
1--placebo O
; O
group O
2--cimetidine O
, O
4 O
mg/kg O
, O
plus O
placebo O
; O
group O
3--chlorpheniramine O
, O
0.1 O
mg/kg O
, O
plus O
placebo O
; O
and O
group O
4--cimetidine O
plus O
chlorpheniramine O
. O

histamine O
release O
occurred O
in O
most O
patients O
, O
the O
highest O
level O
2 O
minutes O
after O
d-tubocurarine O
dosing O
. O

group O
1 O
had O
a O
moderate O
negative O
correlation O
between O
plasma O
histamine O
change O
and O
systemic O
vascular O
resistance O
(r O
= O
0.58 O
; O
p O
less O
than O
0.05 O
) O
not O
present O
in O
group O
4. O

prior O
dosing O
with O
antagonists O
partially O
prevented O
the O
fall O
in O
systemic O
vascular O
resistance O
. O

these O
data O
demonstrate O
that O
the O
hemodynamic O
changes O
associated O
with O
d-tubocurarine O
dosing O
are O
only O
partially O
explained O
by O
histamine O
release O
. O

thus O
prior O
dosing O
with O
h1- O
and O
h2-antagonists O
provides O
only O
partial O
protection O
. O

-DOCSTART- O

convulsant O
effect O
of O
lindane O
and O
regional O
brain O
concentration O
of O
gaba O
and O
dopamine O
. O

lindane O
( O
gamma-hexachlorocyclohexane O
) O
is O
an O
organochlorine O
insecticide O
with O
known O
neurotoxic B-NEG
effects O
. O

its O
mechanism O
of O
action O
is O
not O
well O
understood O
although O
it O
has O
been O
proposed O
that O
lindane O
acts O
as O
a O
non-competitive O
antagonist O
at O
the O
gamma-aminobutyric O
acid O
( O
gaba)-a O
receptor O
. O

we O
studied O
the O
effect O
of O
lindane O
( O
150 O
mg/kg O
) O
on O
the O
gabaergic O
and O
dopaminergic O
systems O
by O
measuring O
the O
concentration O
of O
gaba O
, O
dopamine O
and O
its O
metabolites O
in O
7 O
brain O
areas O
at O
the O
onset O
of O
seizures B-NEG
. O

all O
animals O
suffered O
tonic O
convulsions B-NEG
at O
18.3 O
+/- O
1.4 O
min O
after O
lindane O
administration O
. O

the O
concentration O
of O
gaba O
was O
only O
slightly O
but O
significantly O
decreased O
in O
the O
colliculi O
without O
modifications O
in O
the O
other O
areas O
. O

the O
concentration O
of O
dopamine O
was O
increased O
in O
the O
mesencephalon O
and O
that O
of O
its O
metabolite O
dopac O
was O
also O
increased O
in O
the O
mesencephalon O
and O
the O
striatum O
. O

-DOCSTART- O

unusual O
complications O
of O
antithyroid O
drug O
therapy O
: O
four O
case O
reports O
and O
review O
of O
literature O
. O

two O
cases O
of O
propylthiouracil-associated O
acute O
hepatitis B-NEG
, O
one O
case O
of O
fatal O
methimazole-associated O
hepatocellular B-NEG
necrosis I-NEG
and O
one O
case O
of O
propylthiouracil-associated O
lupus-like B-NEG
syndrome I-NEG
are O
described O
. O

the O
literature O
related O
to O
antithyroid O
drug O
side O
effects O
and O
the O
mechanisms O
for O
their O
occurrence O
are O
reviewed O
and O
the O
efficacy O
and O
complications O
of O
thyroidectomy O
and O
radioiodine O
compared O
to O
those O
of O
antithyroid O
drugs O
. O

it O
is O
concluded O
that O
in O
most O
circumstances O
131i O
is O
the O
therapy O
of O
choice O
for O
hyperthyroidism B-NEG
. O

-DOCSTART- O

anticonvulsant O
actions O
of O
mk-801 O
on O
the O
lithium-pilocarpine O
model O
of O
status B-NEG
epilepticus I-NEG
in O
rats O
. O

mk-801 O
, O
a O
noncompetitive O
n-methyl-d-aspartate O
( O
nmda O
) O
receptor O
antagonist O
, O
was O
tested O
for O
anticonvulsant O
effects O
in O
rats O
using O
two O
seizure B-NEG
models O
, O
coadministration O
of O
lithium O
and O
pilocarpine O
and O
administration O
of O
a O
high O
dose O
of O
pilocarpine O
alone O
. O

three O
major O
results O
are O
reported O
. O

first O
, O
pretreatment O
with O
mk-801 O
produced O
an O
effective O
and O
dose-dependent O
anticonvulsant O
action O
with O
the O
lithium-pilocarpine O
model O
but O
not O
with O
rats O
treated O
with O
pilocarpine O
alone O
, O
suggesting O
that O
different O
biochemical O
mechanisms O
control O
seizures B-NEG
in O
these O
two O
models O
. O

second O
, O
the O
anticonvulsant O
effect O
of O
mk-801 O
in O
the O
lithium-pilocarpine O
model O
only O
occurred O
after O
initial O
periods O
of O
seizure B-NEG
activity O
. O

this O
observation O
is O
suggested O
to O
be O
an O
in O
vivo O
demonstration O
of O
the O
conclusion O
derived O
from O
in O
vitro O
experiments O
that O
mk-801 O
binding O
requires O
agonist-induced O
opening O
of O
the O
channel O
sites O
of O
the O
nmda O
receptor O
. O

third O
, O
although O
it O
is O
relatively O
easy O
to O
block O
seizures B-NEG
induced O
by O
lithium O
and O
pilocarpine O
by O
administration O
of O
anticonvulsants O
prior O
to O
pilocarpine O
, O
it O
is O
more O
difficult O
to O
terminate O
ongoing O
status B-NEG
epilepticus I-NEG
and O
block O
the O
lethality O
of O
the O
seizures B-NEG
. O

administration O
of O
mk-801 O
30 O
or O
60 O
min O
after O
pilocarpine O
, O
i.e. O
, O
during O
status B-NEG
epilepticus I-NEG
, O
gradually O
reduced O
electrical O
and O
behavioral O
seizure B-NEG
activity O
and O
greatly O
enhanced O
the O
survival O
rate O
. O

these O
results O
suggest O
that O
activation O
of O
nmda O
receptors O
plays O
an O
important O
role O
in O
status B-NEG
epilepticus I-NEG
and O
brain B-NEG
damage I-NEG
in O
the O
lithium-pilocarpine O
model O
. O

this O
was O
further O
supported O
by O
results O
showing O
that O
nonconvulsive O
doses O
of O
nmda O
and O
pilocarpine O
were O
synergistic O
, O
resulting O
in O
status B-NEG
epilepticus I-NEG
and O
subsequent O
mortality O
. O

-DOCSTART- O

nifedipine O
induced O
bradycardia B-NEG
in O
a O
patient O
with O
autonomic B-NEG
neuropathy I-NEG
. O

an O
80 O
year O
old O
diabetic B-NEG
male O
with O
evidence O
of O
peripheral B-NEG
and I-NEG
autonomic I-NEG
neuropathy I-NEG
was O
admitted O
with O
chest B-NEG
pain I-NEG
. O

he O
was O
found O
to O
have O
atrial B-NEG
flutter I-NEG
at O
a O
ventricular O
rate O
of O
70/min O
which O
slowed O
down O
to O
30-40/min O
when O
nifedipine O
( O
60 O
mg O
) O
in O
3 O
divided O
doses O
, O
during O
which O
he O
was O
paced O
at O
a O
rate O
of O
70/min O
. O

this O
is O
inconsistent O
with O
the O
well-established O
finding O
that O
nifedipine O
induces O
tachycardia B-NEG
in O
normally O
innervated O
hearts O
. O

however O
, O
in O
hearts O
deprived O
of O
compensatory O
sympathetic O
drive O
, O
it O
may O
lead O
to O
bradycardia B-NEG
. O

-DOCSTART- O

the O
effect O
of O
haloperidol O
in O
cocaine O
and O
amphetamine O
intoxication O
. O

the O
effectiveness O
of O
haloperidol O
pretreatment O
in O
preventing O
the O
toxic O
effects O
of O
high O
doses O
of O
amphetamine O
and O
cocaine O
was O
studied O
in O
rats O
. O

in O
this O
model O
, O
toxic O
effects O
were O
induced O
by O
intraperitoneal O
( O
i.p. O
) O
injection O
of O
amphetamine O
75 O
mg/kg O
( O
100% O
death O
rate O
) O
or O
cocaine O
70 O
mg/kg O
( O
82% O
death O
rate) O
. O

haloperidol O
failed O
to O
prevent O
amphetamine-induced O
seizures B-NEG
, O
but O
did O
lower O
the O
mortality O
rate O
at O
most O
doses O
tested O
. O

haloperidol O
decreased O
the O
incidence O
of O
cocaine-induced O
seizures B-NEG
at O
the O
two O
highest O
doses O
, O
but O
the O
lowering O
of O
the O
mortality O
rate O
did O
not O
reach O
statistical O
significance O
at O
any O
dose O
. O

these O
data O
suggest O
a O
protective O
role O
for O
the O
central O
dopamine O
blocker O
haloperidol O
against O
death O
from O
high-dose O
amphetamine O
exposure O
without O
reducing O
the O
incidence O
of O
seizures B-NEG
. O

in O
contrast O
, O
haloperidol O
demonstrated O
an O
ability O
to O
reduce O
cocaine-induced O
seizures B-NEG
without O
significantly O
reducing O
mortality O
. O

-DOCSTART- O

autoradiographic O
evidence O
of O
estrogen O
binding O
sites O
in O
nuclei O
of O
diethylstilbesterol O
induced O
hamster O
renal B-NEG
carcinomas I-NEG
. O

estrogen O
binding O
sites O
were O
demonstrated O
by O
autoradiography O
in O
one O
transplantable O
and O
five O
primary O
diethylstilbesterol O
induced O
renal B-NEG
carcinomas I-NEG
in O
three O
hamsters O
. O

radiolabelling O
, O
following O
the O
in O
vivo O
injection O
of O
3h-17 O
beta O
estradiol O
, O
was O
increased O
only O
over O
the O
nuclei O
of O
tumor B-NEG
cells O
; O
stereologic O
analysis O
revealed O
a O
4.5- O
to O
6.7-times O
higher O
concentration O
of O
reduced O
silver O
grains O
over O
nuclei O
than O
cytoplasm O
of O
these O
cells O
. O

despite O
rapid O
tubular O
excretion O
of O
estradiol O
which O
peaked O
in O
less O
than O
1 O
h, O
the O
normal O
cells O
did O
not O
appear O
to O
bind O
the O
ligand O
. O

this O
is O
the O
first O
published O
report O
documenting O
the O
preferential O
in O
vivo O
binding O
of O
estrogen O
to O
nuclei O
of O
cells O
in O
estrogen O
induced O
hamster O
renal B-NEG
carcinomas I-NEG
. O

-DOCSTART- O

bradycardia B-NEG
due O
to O
biperiden O
. O

in O
a O
38-year-old O
male O
patient O
suffering O
from O
a O
severe O
postzosteric B-NEG
trigeminal B-NEG
neuralgia I-NEG
, O
intravenous O
application O
of O
10 O
mg O
biperiden O
lactate O
led O
to O
a O
long-lasting O
paradoxical O
reaction O
characterized O
by O
considerable O
bradycardia B-NEG
, O
dysarthria B-NEG
, O
and O
dysphagia B-NEG
. O

the O
heart O
rate O
was O
back O
to O
normal O
within O
12 O
hours O
upon O
administration O
of O
orciprenaline O
under O
cardiac O
monitoring O
in O
an O
intensive O
care O
unit O
. O
bradycardia B-NEG
induced O
by O
biperiden O
is O
attributed O
to O
the O
speed O
of O
injection O
and O
to O
a O
dose-related O
dual O
effect O
of O
atropine-like O
drugs O
on O
muscarine O
receptors O
. O

-DOCSTART- O

deliberate O
hypotension B-NEG
induced O
by O
labetalol O
with O
halothane O
, O
enflurane O
or O
isoflurane O
for O
middle-ear O
surgery O
. O

the O
feasibility O
of O
using O
labetalol O
, O
an O
alpha- O
and O
beta-adrenergic O
blocking O
agent O
, O
as O
a O
hypotensive B-NEG
agent O
in O
combination O
with O
inhalation O
anaesthetics O
(halothane O
, O
enflurane O
or O
isoflurane O
) O
was O
studied O
in O
23 O
adult O
patients O
undergoing O
middle-ear O
surgery O
. O

the O
mean O
arterial O
pressure O
was O
decreased O
from O
86 O
+/- O
5 O
(s.e O
. O
mean O
) O
mmhg O
to O
52 O
+/- O
1 O
mmhg O
( O
11.5 O
+/- O
0.7 O
to O
6.9 O
+/- O
0.1 O
kpa O
) O
for O
98 O
+/- O
10 O
min O
in O
the O
halothane O
( O
h O
) O
group O
, O
from O
79 O
+/- O
5 O
to O
53 O
+/- O
1 O
mmhg O
( O
10.5 O
+/- O
0.7 O
to O
7.1 O
+/- O
0.1 O
kpa O
) O
for O
129 O
+/- O
11 O
min O
in O
the O
enflurane O
( O
e O
) O
group O
, O
and O
from O
80 O
+/- O
4 O
to O
49 O
+/- O
1 O
mmhg O
( O
10.7 O
+/- O
0.5 O
to O
6.5 O
+/- O
0.1 O
kpa O
) O
for O
135 O
+/- O
15 O
min O
in O
the O
isoflurane O
( O
i O
) O
group O
. O

the O
mean O
h O
concentration O
during O
hypotension B-NEG
in O
the O
inspiratory O
gas O
was O
0.7 O
+/- O
0.1 O
vol% O
, O
the O
mean O
e O
concentration O
1.6 O
+/- O
0.2 O
vol% O
, O
and O
the O
mean O
i O
concentration O
1.0 O
+/- O
0.1 O
vol% O
. O

in O
addition O
, O
the O
patients O
received O
fentanyl O
and O
d-tubocurarine O
. O

the O
initial O
dose O
of O
labetalol O
for O
lowering O
blood O
pressure O
was O
similar O
, O
0.52-0.59 O
mg/kg O
, O
in O
all O
the O
groups O
. O

during O
hypotension B-NEG
, O
the O
heart O
rate O
was O
stable O
without O
tachy- B-NEG
or I-NEG
bradycardia I-NEG
. O

the O
operating O
conditions O
regarding O
bleeding B-NEG
were O
estimated O
in O
a O
double-blind O
manner O
, O
and O
did O
not O
differ O
significantly O
between O
the O
groups O
. O

during O
hypotension B-NEG
, O
the O
serum O
creatinine O
concentration O
rose O
significantly O
in O
all O
groups O
from O
the O
values O
before O
hypotension B-NEG
and O
returned O
postoperatively O
to O
the O
initial O
level O
in O
the O
other O
groups O
, O
except O
the O
isoflurane O
group O
. O

after O
hypotension B-NEG
there O
was O
no O
rebound O
phenomenon O
in O
either O
blood O
pressure O
or O
heart O
rate O
. O

these O
results O
indicate O
that O
labetalol O
induces O
easily O
adjustable O
hypotension B-NEG
without O
compensatory O
tachycardia B-NEG
and O
rebound O
hypertension B-NEG
. O

-DOCSTART- O

convulsion B-NEG
following O
intravenous O
fluorescein O
angiography O
. O
tonic-clonic B-NEG
seizures I-NEG
followed O
intravenous O
fluorescein O
injection O
for O
fundus O
angiography O
in O
a O
47-year-old O
male O
. O

despite O
precautions O
this O
adverse O
reaction O
recurred O
on O
re-exposure O
to O
intravenous O
fluorescein O
. O

-DOCSTART- O

pharmacology O
of O
acc-9653 O
( O
phenytoin O
prodrug) O
. O

acc-9653 O
, O
the O
disodium O
phosphate O
ester O
of O
3-hydroxymethyl-5,5-diphenylhydantoin O
, O
is O
a O
prodrug O
of O
phenytoin O
with O
advantageous O
physicochemical O
properties O
. O

acc-9653 O
is O
rapidly O
converted O
enzymatically O
to O
phenytoin O
in O
vivo O
. O

acc-9653 O
and O
phenytoin O
sodium O
have O
equivalent O
anticonvulsant O
activity O
against O
seizures B-NEG
induced O
by O
maximal O
electroshock O
( O
mes O
) O
in O
mice O
following O
i.p. O
, O
oral O
, O
or O
i.v O
. O
administration O
. O

the O
ed50 O
doses O
were O
16 O
mg/kg O
for O
i.v O
. O

acc-9653 O
and O
8 O
mg/kg O
for O
i.v O
. O
phenytoin O
sodium O
. O

acc-9653 O
and O
phenytoin O
sodium O
have O
similar O
antiarrhythmic O
activity O
against O
ouabain-induced O
ventricular B-NEG
tachycardia I-NEG
in O
anesthetized O
dogs O
. O

the O
total O
doses O
of O
acc-9653 O
or O
phenytoin O
sodium O
necessary O
to O
convert O
the O
arrhythmia B-NEG
to O
a O
normal O
sinus O
rhythm O
were O
24 O
+/- O
6 O
and O
14 O
+/- O
3 O
mg/kg O
, O
respectively O
. O

only O
phenytoin O
sodium O
displayed O
in O
vitro O
antiarrhythmic O
activity O
against O
strophanthidin-induced O
arrhythmias B-NEG
in O
guinea O
pig O
right O
atria O
. O

in O
anesthetized O
dogs O
, O
a O
high O
dose O
of O
acc-9653 O
( O
31 O
mg/kg O
) O
was O
infused O
over O
15 O
, O
20 O
, O
and O
30 O
min O
and O
the O
responses O
were O
compared O
to O
an O
equimolar O
dose O
of O
phenytoin O
sodium O
( O
21 O
mg/kg) O
. O

the O
acc-9653 O
and O
phenytoin O
sodium O
treatments O
produced O
similar O
marked O
reductions O
in O
diastolic O
blood O
pressure O
and O
contractile O
force O
(lvdp/dt) O
. O

the O
maximum O
effects O
of O
each O
treatment O
occurred O
at O
the O
time O
of O
maximum O
phenytoin O
sodium O
levels O
. O

acute O
toxicity B-NEG
studies O
of O
acc-9653 O
and O
phenytoin O
sodium O
were O
carried O
out O
in O
mice O
, O
rats O
, O
rabbits O
, O
and O
dogs O
by O
i.v. O
, O
i.m. O
, O
and O
i.p O
. O
routes O
of O
administration O
. O

the O
systemic O
toxic O
signs O
of O
both O
agents O
were O
similar O
and O
occurred O
at O
approximately O
equivalent O
doses O
. O

importantly O
, O
the O
local O
irritation O
of O
acc-9653 O
was O
markedly O
less O
than O
phenytoin O
sodium O
following O
i.m O
. O

administration.(abstract O
truncated O
at O
250 O
words O
) O

-DOCSTART- O

phenytoin O
induced O
fatal O
hepatic B-NEG
injury I-NEG
. O

a O
61 O
year O
old O
female O
developed O
fatal O
hepatic B-NEG
failure I-NEG
after O
phenytoin O
administration O
. O

a O
typical O
multisystem O
clinical O
pattern O
precedes O
the O
manifestations O
of O
hepatic B-NEG
injury I-NEG
. O

the O
hematologic O
, O
biochemical O
and O
pathologic O
features O
indicate O
a O
mixed O
hepatocellular B-NEG
damage I-NEG
due O
to O
drug B-NEG
hypersensitivity I-NEG
. O

in O
a O
patient O
receiving O
phenytoin O
who O
presents O
a O
viral-like O
illness O
, O
early O
recognition O
and O
discontinuation O
of O
the O
drug O
are O
mandatory O
. O

-DOCSTART- O

treatment O
of O
lethal O
pertussis O
vaccine O
reaction O
with O
histamine O
h1 O
antagonists O
. O

we O
studied O
mortality O
after O
pertussis B-NEG
immunization O
in O
the O
mouse O
. O

without O
treatment O
, O
73 O
of O
92 O
animals O
( O
80% O
) O
died O
after O
injection O
of O
bovine O
serum O
albumin O
( O
bsa O
) O
on O
day O
+7 O
of O
pertussis B-NEG
immunization O
. O

after O
pretreatment O
with O
3 O
mg O
of O
cyproheptadine O
, O
2 O
mg O
mianserin O
, O
or O
2 O
mg O
chlorpheniramine O
, O
only O
5 O
of O
105 O
animals O
( O
5% O
) O
died O
after O
receiving O
bsa O
on O
day O
+7 O
(p O
less O
than O
0.001) O
. O

blockade O
of O
histamine O
h1 O
receptors O
may O
reduce O
mortality O
in O
pertussis B-NEG
immunization-induced O
encephalopathy B-NEG
in O
mice O
. O

-DOCSTART- O

support O
for O
adrenaline- O
hypertension B-NEG
hypothesis O
: O
18 O
hour O
pressor O
effect O
after O
6 O
hours O
adrenaline O
infusion O
. O

in O
a O
double O
blind O
, O
crossover O
study O
6 O
h O
infusions O
of O
adrenaline O
( O
15 O
ng/kg/min O
; O
1 O
ng O
= O
5.458 O
pmol) O
, O
noradrenaline O
( O
30 O
ng/kg/min O
; O
1 O
ng O
= O
5.911 O
pmol) O
, O
and O
a O
5% O
dextrose O
solution O
( O
5.4 O
ml/h) O
, O
were O
given O
to O
ten O
healthy O
volunteers O
in O
random O
order O
2 O
weeks O
apart O
. O

by O
means O
of O
intra-arterial O
ambulatory O
monitoring O
the O
haemodynamic O
effects O
were O
followed O
for O
18 O
h O
after O
the O
infusions O
were O
stopped O
. O

adrenaline O
, O
but O
not O
noradrenaline O
, O
caused O
a O
delayed O
and O
protracted O
pressor O
effect O
. O

over O
the O
total O
postinfusion O
period O
systolic O
and O
diastolic O
arterial O
pressure O
were O
6 O
( O
sem O
2)% O
and O
7 O
(2)% O
, O
respectively O
, O
higher O
than O
after O
dextrose O
infusion O
(anova O
, O
p O
less O
than O
0.001) O
. O

thus O
, O
stress O
levels O
of O
adrenaline O
( O
230 O
pg/ml O
) O
for O
6 O
h O
cause O
a O
delayed O
and O
protracted O
pressor O
effect O
. O

these O
findings O
are O
strong O
support O
for O
the O
adrenaline- O
hypertension B-NEG
hypothesis O
in O
man O
. O

-DOCSTART- O

effect O
of O
alkylxanthines O
on O
gentamicin-induced O
acute B-NEG
renal I-NEG
failure I-NEG
in O
the O
rat O
. O

adenosine O
antagonists O
have O
been O
previously O
shown O
to O
be O
of O
benefit O
in O
some O
ischaemic B-NEG
and O
nephrotoxic B-NEG
models O
of O
acute B-NEG
renal I-NEG
failure I-NEG
( O
arf B-NEG
). O

in O
the O
present O
study O
, O
the O
effects O
of O
three O
alkylxanthines O
with O
different O
potencies O
as O
adenosine O
antagonists O
8-phenyltheophylline O
, O
theophylline O
and O
enprofylline O
, O
were O
examined O
in O
rats O
developing O
acute B-NEG
renal I-NEG
failure I-NEG
after O
4 O
daily O
injections O
of O
gentamicin O
( O
200 O
mg O
kg-1) O
. O

renal O
function O
was O
assessed O
by O
biochemical O
( O
plasma O
urea O
and O
creatinine) O
, O
functional O
( O
urine O
analysis O
and O
[3h]inulin O
and O
[14c]p-aminohippuric O
acid O
clearances O
) O
and O
morphological O
( O
degree O
of O
necrosis B-NEG
) O
indices O
. O

the O
various O
drug O
treatments O
produced O
improvements O
in O
some O
, O
but O
not O
all O
, O
measurements O
of O
renal O
function O
. O

however O
, O
any O
improvement O
produced O
by O
drug O
treatment O
was O
largely O
a O
result O
of O
a O
beneficial O
effect O
exerted O
by O
its O
vehicle O
( O
polyethylene O
glycol O
and O
naoh) O
. O

the O
lack O
of O
any O
consistent O
protective O
effect O
noted O
with O
the O
alkylxanthines O
tested O
in O
the O
present O
study O
indicates O
that O
adenosine O
plays O
little O
, O
if O
any O
, O
pathophysiological O
role O
in O
gentamicin-induced O
arf B-NEG
. O

-DOCSTART- O

adverse O
ocular O
reactions O
possibly O
associated O
with O
isotretinoin O
. O

a O
total O
of O
261 O
adverse O
ocular O
reactions O
occurred O
in O
237 O
patients O
who O
received O
isotretinoin O
, O
a O
commonly O
used O
drug O
in O
the O
treatment O
of O
severe O
cystic O
acne B-NEG
. O
blepharoconjunctivitis B-NEG
, O
subjective O
complaints O
of O
dry B-NEG
eyes I-NEG
, O
blurred B-NEG
vision I-NEG
, O
contact O
lens O
intolerance O
, O
and O
photodermatitis B-NEG
are O
reversible O
side O
effects O
. O

more O
serious O
ocular O
adverse O
reactions O
include O
papilledema B-NEG
, O
pseudotumor B-NEG
cerebri I-NEG
, O
and O
white O
or O
gray O
subepithelial O
corneal B-NEG
opacities I-NEG
; O
all O
of O
these O
are O
reversible O
if O
the O
drug O
is O
discontinued O
. O

reported O
cases O
of O
decreased O
dark O
adaptation O
are O
under O
investigation O
. O

isotretinoin O
is O
contraindicated O
in O
pregnancy O
because O
of O
the O
many O
reported O
congenital B-NEG
abnormalities I-NEG
after O
maternal O
use O
( O
including O
microphthalmos B-NEG
, O
orbital O
hypertelorism B-NEG
, O
and O
optic B-NEG
nerve I-NEG
hypoplasia I-NEG
). O

-DOCSTART- O

procaterol O
and O
terbutaline O
in O
bronchial B-NEG
asthma I-NEG
. O

a O
double-blind O
, O
placebo-controlled O
, O
cross-over O
study O
. O

procaterol O
, O
a O
new O
beta-2 O
adrenoceptor O
stimulant O
, O
was O
studied O
in O
a O
double-blind O
, O
placebo-controlled O
, O
cross-over O
trial O
in O
patients O
with O
bronchial B-NEG
asthma I-NEG
. O

oral O
procaterol O
50 O
micrograms O
b.d. O
, O
procaterol O
100 O
micrograms O
b.d. O
, O
and O
terbutaline O
5 O
mg O
t.i.d. O
, O
were O
compared O
when O
given O
randomly O
in O
1-week O
treatment O
periods O
. O

the O
best O
clinical O
effect O
was O
found O
with O
terbutaline O
. O

both O
anti- O
asthmatic B-NEG
and O
tremorgenic B-NEG
effects O
of O
procaterol O
were O
dose-related O
. O

procaterol O
appeared O
effective O
in O
the O
doses O
tested O
, O
and O
a O
twice O
daily O
regimen O
would O
appear O
to O
be O
suitable O
with O
this O
drug O
. O

-DOCSTART- O

subacute O
effects O
of O
propranolol O
and O
b O
24/76 O
on O
isoproterenol-induced O
rat O
heart B-NEG
hypertrophy I-NEG
in O
correlation O
with O
blood O
pressure O
. O

we O
compared O
the O
potential O
beta-receptor O
blocker O
, O
b O
24/76 O
i.e O
. O

1-(2,4-dichlorophenoxy)-3[2-3,4-dimethoxyphenyl)ethanolamino]-prop O
an-2-ol O
, O
which O
is O
characterized O
by O
beta O
1-adrenoceptor O
blocking O
and O
beta O
2-adrenoceptor O
stimulating O
properties O
with O
propranolol O
. O

the O
studies O
were O
performed O
using O
an O
experimental O
model O
of O
isoproterenol-induced O
heart B-NEG
hypertrophy I-NEG
in O
rats O
. O

a O
correlation O
of O
the O
blood O
pressure O
was O
neither O
found O
in O
the O
development O
nor O
in O
the O
attempt O
to O
suppress O
the O
development O
of O
heart B-NEG
hypertrophy I-NEG
with O
the O
two O
beta-receptor O
blockers O
. O

both O
beta-blockers O
influenced O
the O
development O
of O
hypertrophy B-NEG
to O
a O
different O
, O
but O
not O
reproducible O
extent O
. O

it O
was O
possible O
to O
suppress O
the O
increased O
ornithine O
decarboxylase O
activity O
with O
both O
beta-blockers O
in O
hypertrophied B-NEG
hearts I-NEG
, O
but O
there O
was O
no O
effect O
on O
the O
heart O
mass O
. O

neither O
propranolol O
nor O
b O
24/76 O
could O
stop O
the O
changes O
in O
the O
characteristic O
myosin O
isoenzyme O
pattern O
of O
the O
hypertrophied B-NEG
rat O
heart O
. O

thus O
, O
the O
investigations O
did O
not O
provide O
any O
evidence O
that O
the O
beta-receptor O
blockers O
propranolol O
and O
b O
24/76 O
have O
the O
potency O
to O
prevent O
isoproterenol O
from O
producing O
heart B-NEG
hypertrophy I-NEG
. O

-DOCSTART- O

comparison O
of O
the O
effect O
of O
oxitropium O
bromide O
and O
of O
slow-release O
theophylline O
on O
nocturnal O
asthma B-NEG
. O

the O
effects O
of O
a O
new O
inhaled O
antimuscarinic O
drug O
, O
oxitropium O
bromide O
, O
and O
of O
a O
slow-release O
theophylline O
preparation O
upon O
nocturnal O
asthma B-NEG
were O
compared O
in O
a O
placebo-controlled O
double-blind O
study O
. O

two O
samples O
were O
studied O
: O
12 O
patients O
received O
oxitropium O
at O
600 O
micrograms O
(6 O
subjects O
) O
or O
at O
400 O
micrograms O
t.i.d O
. O

(6 O
subjects O
) O
whereas O
11 O
received O
theophylline O
at O
300 O
mg O
b.i.d O
. O

morning O
dipping O
, O
assessed O
by O
the O
fall O
in O
peak O
flow O
overnight O
, O
was O
significantly O
reduced O
in O
the O
periods O
when O
either O
active O
drug O
was O
taken O
, O
whereas O
no O
difference O
was O
noticed O
during O
the O
placebo O
administration O
. O

no O
significant O
difference O
was O
noticed O
between O
results O
obtained O
with O
either O
active O
drug O
, O
as O
well O
as O
with O
either O
dosage O
of O
oxitropium O
. O

no O
subject O
reported O
side O
effects O
of O
oxitropium O
, O
as O
compared O
to O
three O
subjects O
reporting O
nausea B-NEG
, O
vomiting B-NEG
and O
tremors B-NEG
after O
theophylline O
. O

oxitropium O
proves O
to O
be O
a O
valuable O
alternative O
to O
theophylline O
in O
nocturnal O
asthma B-NEG
, O
since O
it O
is O
equally O
potent O
, O
safer O
and O
does O
not O
require O
the O
titration O
of O
dosage O
. O

-DOCSTART- O

penicillin O
anaphylaxis B-NEG
. O

a O
case O
of O
oral O
penicillin O
anaphylaxis B-NEG
is O
described O
, O
and O
the O
terminology O
, O
occurrence O
, O
clinical O
manifestations O
, O
pathogenesis O
, O
prevention O
, O
and O
treatment O
of O
anaphylaxis B-NEG
are O
reviewed O
. O

emergency O
physicians O
should O
be O
aware O
of O
oral O
penicillin O
anaphylaxis B-NEG
in O
order O
to O
prevent O
its O
occurrence O
by O
prescribing O
the O
antibiotic O
judiciously O
and O
knowledgeably O
and O
to O
offer O
optimal O
medical O
therapy O
once O
this O
life-threatening O
reaction O
has O
begun O
. O

-DOCSTART- O

reversible O
valproic O
acid-induced O
dementia B-NEG
: O
a O
case O
report O
. O

reversible O
valproic O
acid-induced O
dementia B-NEG
was O
documented O
in O
a O
21-year-old O
man O
with O
epilepsy B-NEG
who O
had O
a O
3-year O
history O
of O
insidious O
progressive O
decline O
in O
global O
cognitive O
abilities O
documented O
by O
serial O
neuropsychological O
studies O
. O

repeat O
neuropsychological O
testing O
7 O
weeks O
after O
discontinuation O
of O
the O
drug O
revealed O
dramatic O
improvement O
in O
iq O
, O
memory O
, O
naming O
, O
and O
other O
tasks O
commensurate O
with O
clinical O
recovery O
in O
his O
intellectual O
capacity O
. O

possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a O
direct O
central O
nervous O
system O
( O
cns O
) O
toxic O
effect O
of O
valproic O
acid O
; O
a O
paradoxical O
epileptogenic O
effect O
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
cns O
toxic O
effect O
mediated O
through O
valproic O
acid-induced O
hyperammonemia B-NEG
. O

-DOCSTART- O

reversal O
of O
scopolamine-induced O
amnesia B-NEG
of O
passive O
avoidance O
by O
pre- O
and O
post-training O
naloxone O
. O

in O
a O
series O
of O
five O
experiments O
, O
the O
modulating O
role O
of O
naloxone O
on O
a O
scopolamine-induced O
retention B-NEG
deficit I-NEG
in O
a O
passive O
avoidance O
paradigm O
was O
investigated O
in O
mice O
. O

scopolamine O
, O
but O
not O
methyl O
scopolamine O
(1 O
and O
3 O
mg/kg) O
, O
induced O
an O
amnesia B-NEG
as O
measured O
by O
latency O
and O
duration O
parameters O
. O

naloxone O
(0.3 O
, O
1, O
3, O
and O
10 O
mg/kg O
) O
injected O
prior O
to O
training O
attenuated O
the O
retention B-NEG
deficit I-NEG
with O
a O
peak O
of O
activity O
at O
3 O
mg/kg O
. O

the O
effect O
of O
naloxone O
could O
be O
antagonized O
with O
morphine O
(1 O
, O
3, O
and O
10 O
mg/kg) O
, O
demonstrating O
the O
opioid O
specificity O
of O
the O
naloxone O
effect O
. O

post-training O
administration O
of O
naloxone O
(3 O
mg/kg O
) O
as O
a O
single O
or O
as O
a O
split O
dose O
also O
attenuated O
the O
scopolamine-induced O
amnesia B-NEG
. O

control O
experiments O
indicated O
that O
neither O
an O
increase O
in O
pain B-NEG
sensitivity O
( O
pre-training O
naloxone O
) O
nor O
an O
induced O
aversive O
state O
( O
post-training O
naloxone O
) O
appear O
to O
be O
responsible O
for O
the O
influence O
of O
naloxone O
on O
the O
scopolamine-induced O
retention B-NEG
deficit I-NEG
. O

these O
results O
extend O
previous O
findings O
implicating O
a O
cholinergic-opioid O
interaction O
in O
memory O
processes O
. O

a O
possible O
mechanism O
for O
this O
interaction O
involving O
the O
septo-hippocampal O
cholinergic O
pathway O
is O
discussed O
. O

-DOCSTART- O

electron O
microscopic O
investigations O
of O
the O
cyclophosphamide-induced O
lesions B-NEG
of I-NEG
the I-NEG
urinary I-NEG
bladder I-NEG
of O
the O
rat O
and O
their O
prevention O
by O
mesna O
. O

fully O
developed O
cyclophosphamide-induced O
cystitis B-NEG
is O
characterized O
by O
nearly O
complete O
detachment O
of O
the O
urothelium O
, O
severe O
submucosal O
edema B-NEG
owing O
to O
damage O
to O
the O
microvascular O
bed O
and O
focal O
muscle O
necroses B-NEG
. O

the O
initial O
response O
to O
the O
primary O
attack O
by O
the O
cyclophosphamide O
metabolites O
seems O
to O
be O
fragmentation O
of O
the O
luminal O
membrane O
. O

this O
damages O
the O
cellular O
barrier O
against O
the O
hypertonic O
urine O
. O

subsequent O
breaks O
in O
the O
lateral O
cell O
membranes O
of O
the O
superficial O
cells O
and O
in O
all O
the O
plasma O
membranes O
of O
the O
intermediate O
and O
basal O
cells O
, O
intercellular O
and O
intracellular O
edema B-NEG
and O
disintegration O
of O
the O
desmosomes O
and O
hemidesmosomes O
lead O
to O
progressive O
degeneration O
and O
detachment O
of O
the O
epithelial O
cells O
with O
exposure O
and O
splitting O
of O
the O
basal O
membrane O
. O

the O
morphological O
changes O
of O
the O
endothelial O
cells O
, O
which O
become O
more O
pronounced O
in O
the O
later O
stages O
of O
the O
experiment O
, O
the O
involvement O
of O
blood O
vessels O
regardless O
of O
their O
diameter O
and O
the O
location-dependent O
extent O
of O
the O
damage O
indicate O
a O
direct O
type O
of O
damage O
which O
is O
preceded O
by O
a O
mediator-induced O
increase O
in O
permeability O
, O
the O
morphological O
correlate O
of O
which O
is O
the O
formation O
of O
gaps O
in O
the O
interendothelial O
cell O
connections O
on O
the O
venules O
. O

these O
changes O
can O
be O
effectively O
prevented O
by O
mesna O
. O

the O
only O
sign O
of O
a O
possible O
involvement O
is O
the O
increase O
in O
the O
number O
of O
specific O
granules O
with O
a O
presumed O
lysosomal O
function O
in O
the O
superficial O
cells O
. O

-DOCSTART- O

increase O
in O
intragastric O
pressure O
during O
suxamethonium-induced O
muscle B-NEG
fasciculations I-NEG
in O
children O
: O
inhibition O
by O
alfentanil O
. O

changes O
in O
intragastric O
pressure O
after O
the O
administration O
of O
suxamethonium O
1.5 O
mg O
kg-1 O
i.v O
. O
were O
studied O
in O
32 O
children O
( O
mean O
age O
6.9 O
yr O
) O
pretreated O
with O
either O
physiological O
saline O
or O
alfentanil O
50 O
micrograms O
kg-1 O
. O

anaesthesia O
was O
induced O
with O
thiopentone O
5 O
mg O
kg-1 O
. O

the O
incidence O
and O
intensity O
of O
muscle B-NEG
fasciculations I-NEG
caused O
by O
suxamethonium O
were O
significantly O
greater O
in O
the O
control O
than O
in O
the O
alfentanil O
group O
. O

the O
intragastric O
pressure O
during O
muscle B-NEG
fasciculations I-NEG
was O
significantly O
higher O
in O
the O
control O
group O
( O
16 O
+/- O
0.7 O
( O
sem O
) O
cm O
h2o O
) O
than O
in O
the O
alfentanil O
group O
( O
7.7 O
+/- O
1.5 O
( O
sem O
) O
cm O
h2o) O
. O

the O
increase O
in O
intragastric O
pressure O
was O
directly O
related O
to O
the O
intensity O
of O
muscle B-NEG
fasciculations I-NEG
( O
regression O
line O
: O
y O
= O
0.5 O
+ O
4.78x O
with O
r O
of O
0.78) O
. O

it O
is O
concluded O
that O
intragastric O
pressure O
increases O
significantly O
during O
muscle B-NEG
fasciculations I-NEG
caused O
by O
suxamethonium O
in O
healthy O
children O
. O

alfentanil O
50 O
micrograms O
kg-1 O
effectively O
inhibits O
the O
incidence O
and O
intensity O
of O
suxamethonium-induced O
muscle B-NEG
fasciculations I-NEG
; O
moreover O
, O
intragastric O
pressure O
remains O
at O
its O
control O
value O
. O

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEU
, O
stanch O
bleeding B-NEG
and O
disperse O
swelling B-NEG
, O
kill O
worms B-NEG
. O

-DOCSTART- O

investigated O
for O
use/treatment O
in O
angioedema B-NEG
. O

-DOCSTART- O

neurological B-DNP
systems I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
protective B-NEU
immunity I-NEU
, O
others O

-DOCSTART- O

swelling B-NEG
of I-NEG
carbuncle I-NEG
caused O
by O
heat B-NEG
toxin I-NEG

-DOCSTART- O

to O
dispel O
wind B-NEG
, O
to O
remove O
damp B-NEU
, O
to O
clear O
the O
stuffed B-NEG
nose I-NEG
, O
to O
relieve O
pain B-NEG
, O
and O
to O
promote O
the O
subsidence O
of O
swelling B-NEG
and O
drainage O
of O
pus B-NEG
. O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
overall O
cvd B-NEG
, O
diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
general O
skin B-DNP
health I-DNP
, O
others O
, O
reproductive B-DNP
systems I-DNP
, O
protective O
immunity B-NEU

-DOCSTART- O

acne B-NEG
vulgaris I-NEG

-DOCSTART- O

to O
clear O
heat B-NEG
and O
cool O
blood B-DNP
; O

to O
benefit O
qi O
and O
contain O
blood B-DNP
; O

to O
revitalize O
blood B-DNP
and O
desolve O
stagnation B-NEG

-DOCSTART- O

diabetes B-NEG
mellitus I-NEG

-DOCSTART- O

to O
disperse O
accumulation O
, O
disinhibit O
diaphragm B-DNP
, O
precipitate O
heat B-NEG
toxin I-NEG
. O

-DOCSTART- O

circulating O
tumor B-DNP
cells I-DNP
in O
pancreatic O
cancer O
surgery O

-DOCSTART- O

pulmonary O
aspiration O

-DOCSTART- O

this O
is O
a O
syndrome O
with O
chronic B-NEG
coughing I-NEG
and O
inflammation B-NEG
in O
urination O
. O

-DOCSTART- O

for O
the O
prophylaxis O
of O
organ B-NEG
rejection I-NEG
in O
patients O
receiving O
renal O
transplants O
. O

-DOCSTART- O

postpartum B-NEU
sexual I-NEU
function I-NEU

-DOCSTART- O

critical B-NEG
symptom I-NEG
complex I-NEG
with O
complicated O
, O
changable O
and O
serious O
conditions O
; O

disease B-NEG
due O
to O
the O
poisonous B-NEG

-DOCSTART- O

cosolidate O
bones B-DNP

-DOCSTART- O

it O
usually O
happens O
by O
the O
liver B-NEU
heat I-NEU
, O
lung B-NEU
heat I-NEU
, O
heart B-NEU
heat I-NEU
, O
insufficiency O
of O
the O
genuine O
eum O
, O
or O
infiltration O
of O
pathogenic O
wind O
to O
the O
ocular O
connection O
. O

usually O
disease B-NEG
can O
be O
divided O
by O
the O
coloration O
. O

-DOCSTART- O

diagnostic O
yield O
and O
adverse O
effects O
of O
mri-guided O
free-hand O
brain O
biopsies O
through O
a O
mini-burr O
hole O
in O
dogs O
with O
encephalitis O
. O

-DOCSTART- O

weakness B-NEG
of I-NEG
constitution I-NEG

-DOCSTART- O

to O
expel O
wind B-NEG
and O
heat B-NEU
, O
purge O
pathogenic O
fire O
and O
relax O
the O
bowels O
. O

-DOCSTART- O

gsk716155 O
, O
a O
glp-1 O
receptor O
agonist O
, O
has O
been O
shown O
to O
have O
multiple O
physiologic O
activities O
in O
the O
central O
nervous O
system O
and O
gastrointestinal O
system O
that O
could O
lower O
a1c O
. O

it O
increases O
peripheral B-NEU
glucose I-NEU
uptake I-NEU
, O
enhances O
insulin B-NEU
secretion I-NEU
, O
decreases O
glucagon B-NEU
secretion I-NEU
, O
delays O
gastric B-NEU
emptying I-NEU
, O
reduces O
food O
intake O
and O
induces O
satiety B-NEU
at O
cns O
. O

-DOCSTART- O

to O
remove O
toxic B-NEG
heat I-NEG
, O
to O
promote O
the O
drainage B-POS
of I-POS
pus I-POS
, O
and O
to O
relieve O
dysuria B-NEG
. O

-DOCSTART- O

tonify O
marrow B-DNP

-DOCSTART- O

nourish O
blood B-DNP

-DOCSTART- O

this O
is O
a O
symptom O
with O
a O
pain B-NEG
in O
a O
waist O
and O
the O
side O
. O

-DOCSTART- O

type B-NEG
1 I-NEG
diabetes I-NEG
mellitus I-NEG

-DOCSTART- O

moderate O
sinews B-DNP
and O
bones B-DNP

-DOCSTART- O

to O
quicken O
blood B-DNP
and O
nourish O
heart B-NEU
, O
constrain O
lung B-DNP
and O
astringe B-DNP
intestines O
. O

-DOCSTART- O

to O
warm O
and O
replenish O
qi O
and O
blood B-DNP
. O

-DOCSTART- O

to O
remove O
heat O
from O
the O
lung B-DNP
, O
and O
to O
relieve O
cough B-NEG
and O
dyspnea B-NEG
. O

-DOCSTART- O

roundworm B-NEG

-DOCSTART- O

difficult B-NEG
delivery I-NEG
; O

dystocia B-NEG

-DOCSTART- O

benign B-NEG
prostatic I-NEG
hyperplasia I-NEG

-DOCSTART- O

the O
complex O
binds O
to O
and O
irreversibly O
inactivates O
thrombin O
and O
other O
activated O
clotting O
factors O
, O
such O
as O
factors O
ix O
, O
x, O
xi O
, O
and O
xii O
, O
thereby O
preventing O
the O
polymerization O
of O
fibrinogen O
to O
fibrin O
and O
the O
subsequent O
formation B-NEU
of I-NEU
clots I-NEU
. O

-DOCSTART- O

stage O
ii O
adult B-NEG
t-cell I-NEG
leukemia/lymphoma I-NEG

-DOCSTART- O

heavy B-NEG
eyes I-NEG

-DOCSTART- O

regurgitation B-NEG
; O
frequent B-NEG
vomiting I-NEG

-DOCSTART- O

1 O
its O
aqueous O
infusion O
exerts O
a O
significant O
diuretic B-NEU
effect I-NEU
in O
experimental O
animals O
. O

2 O
shortening O
clotting B-NEU
time O
and O
bleeding B-NEG
time O
, O
and O
decreasing O
the O
permeability O
of O
blood O
vessels O
. O

3 O
inhibiting O
the O
growth O
of O
staphylococcus B-NEG
aureus I-NEG
and O
bacillus B-NEG
dysenteriae I-NEG
. O

-DOCSTART- O

warm O
the O
bladder B-DNP

-DOCSTART- O

investigated O
for O
use O
/ O
treatment O
in O
cardiovascular B-NEG
disorders I-NEG
and O
inflammatory B-NEG
disorders I-NEG
( O
unspecified O
) O
. O

-DOCSTART- O

invigorate O
the O
network B-DNP
vessels I-DNP

-DOCSTART- O

venomous O
snake-bite B-NEG

-DOCSTART- O

rescinnamine O
binds O
to O
and O
inhibits O
the O
angiotensin B-DNP
converting I-DNP
enzyme I-DNP
. O

rescinnamine O
competes O
with O
angiotensin O
i O
for O
binding O
at O
the O
angiotensin-converting B-DNP
enzyme I-DNP
, O
blocking O
the O
conversion O
of O
angiotensin B-DNP
i I-DNP
to O
angiotensin B-DNP
ii I-DNP
. O

inhibition O
of O
ace O
results O
in O
decreased O
plasma B-DNP
angiotensin I-DNP
ii I-DNP
. O

as O
angiotensin B-DNP
ii I-DNP
is I-DNP
a O
vasoconstrictor B-NEG
and O
a O
negative-feedback O
mediator O
for O
renin B-DNP
activity O
, O
lower O
concentrations O
result O
in O
a O
decrease O
in O
blood B-NEU
pressure I-NEU
and O
stimulation O
of O
baroreceptor O
reflex O
mechanisms O
, O
which O
leads O
to O
decreased O
vasopressor B-NEU
activity O
and O
to O
decreased O
aldosterone B-DNP
secretion O
. O

-DOCSTART- O

cold O
dysentery B-NEG

-DOCSTART- O

distension B-NEG
and O
fullness B-NEG

-DOCSTART- O

developmemt O
of O
manic B-NEG
syndrome I-NEG

-DOCSTART- O

protective B-NEU
immunity I-NEU
, O
others O
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
others O
health B-DNP
and O
immunity B-NEU
, O
metabolism B-NEU

-DOCSTART- O

its O
chief O
component O
is O
berberine O
. O

possessing O
broad-spectrum O
antibacterial B-POS
and O
antiprotozoal B-POS
effects O
. O

intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-NEG
effect O
on O
experimental O
animals O
. O

small O
dosage O
of O
berberine O
enhances O
the O
action O
of O
acetylcholine O
on O
animals' O
hearts B-DNP
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

relaxing O
the O
smooth B-DNP
muscles I-DNP
of O
blood O
vessels O
and O
stimulating O
those O
of O
uterus B-DNP
, O
urinary B-DNP
bladderl I-DNP
bronchus I-DNP
and O
gastrointestines B-DNP
. O

promoting O
bile B-NEU
secretion I-NEU
. O

berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic O
cancer B-NEG
and O
lymphoma B-NEG
. O

-DOCSTART- O

black B-POS
hair I-POS

-DOCSTART- O

promote O
the O
large B-DNP
intestine I-DNP

-DOCSTART- O

to O
dispel O
cold B-NEG
, O
eliminate O
damp B-NEU
and O
phlegm B-NEG
, O
and O
arrest O
emesis B-NEG
or O
nausea B-NEG
. O

-DOCSTART- O

phlegm B-NEG
stagnation I-NEG
in O
chest O
and O
diaphragm O
, O
glomus B-DNP
in I-DNP
chest I-DNP
, O
distention B-NEU
in I-NEU
rib-side I-NEU
, O
food B-NEG
accumulation I-NEG
, O
retching B-NEG
counterflow I-NEG
. O

-DOCSTART- O

strength B-POS
and O
power B-POS
, O
physical B-DNP
performance I-DNP
and O
fitness B-POS

-DOCSTART- O

warm B-NEG
malaria I-NEG
; O

pyrexial B-NEG
malaria I-NEG

-DOCSTART- O

to O
invigorate O
the O
function B-NEU
of I-NEU
the I-NEU
kidney I-NEU
, O
to O
alleviate O
asthma B-NEG
, O
and O
to O
relieve O
diarrhea B-NEG
. O

-DOCSTART- O

facial B-NEG
hemiparalysis I-NEG
due O
to O
wind B-NEG
stroke I-NEG

-DOCSTART- O

injury B-NEG
of I-NEG
bladder I-NEG

-DOCSTART- O

skin B-NEG
disease I-NEG
on O
palms O
. O

-DOCSTART- O

distribution O
) O
, O
energy O
supply O
and O
recovery O
, O
mental B-NEG
state I-NEG
and O
performance O
, O
man O

-DOCSTART- O

liver B-DNP
health I-DNP
, O
liver B-DNP

-DOCSTART- O

the O
mechanism O
of O
action O
and O
receptor O
for O
pck3145 O
suggests O
pck3145 O
to O
be O
a O
signal O
transduction O
inhibitor O
with O
multiple O
ways O
( O
apoptosis B-NEU
, O
anti-angiogenesis B-NEU
and O
anti-metastasis B-NEU
) O
to O
restrict O
disease B-NEG
development I-NEG
. O

-DOCSTART- O

for O
nutritional O
supplementation O
, O
also O
for O
treating O
dietary B-NEG
shortage I-NEG
or I-NEG
imbalance I-NEG
. O

-DOCSTART- O

thirst B-NEG
with O
fever B-NEG

-DOCSTART- O

esophageal B-NEG
varices I-NEG

-DOCSTART- O

adult B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG
without O
maturation O

-DOCSTART- O

diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
hemostatic B-NEU
function I-NEU

-DOCSTART- O

myocardial B-NEG
reperfusion I-NEG
injury I-NEG

-DOCSTART- O

chronic B-NEG
viral I-NEG
hepatitis I-NEG
b I-NEG
without I-NEG
delta-agent I-NEG

-DOCSTART- O

treatment O
of O
edema B-NEG
, O
oliguria B-NEG
, O
arthritis B-NEG
with O
contracture B-NEG
of O
joints O
, O
diarrhea B-NEG
due O
to O
diminished B-NEG
function I-NEG
of I-NEG
the I-NEG
spleen I-NEG
, O
lung B-NEG
abscess I-NEG
, O
appendicitis B-NEG
, O
verruca B-NEG
plana I-NEG
. O

-DOCSTART- O

recurrent O
adult B-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

untreated O
adult B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG

-DOCSTART- O

hydrochlorothiazide O
allows O
the O
blood B-DNP
vessels I-DNP
to O
relax O
and O
causes O
kidneys B-DNP
to O
remove O
more O
salt B-NEU
and I-NEU
water I-NEU
from I-NEU
the I-NEU
blood I-NEU
in O
order O
to O
reduce O
blood B-NEU
volume I-NEU
. O

valsartan O
is O
in O
a O
group O
of O
drugs O
called O
angiotensin O
ii O
receptor O
antagonists O
. O

valsartan O
keeps O
blood B-DNP
vessels I-DNP
from O
narrowing O
, O
which O
lowers O
blood B-NEU
pressure I-NEU
and O
improves O
blood B-NEU
flow I-NEU
. O

-DOCSTART- O

chronic B-NEG
kidney I-NEG
disease I-NEG

-DOCSTART- O

fluoxetine O
is O
an O
antidepressant O
belonging O
to O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
class O
, O
and O
blocks O
the O
reuptake B-NEU
of I-NEU
serotonin I-NEU
at O
the O
serotonin O
reuptake O
pump O
of O
the O
neuronal O
membrane O
, O
enhancing O
the O
actions B-NEU
of I-NEU
serotonin I-NEU
on O
5ht<sub>1a</sub> O
autoreceptors O
. O

quetiapine's O
antipsychotic O
activity O
is O
likely O
due O
to O
a O
combination O
of O
antagonism O
at O
d2 O
receptors O
in O
the O
mesolimbic O
pathway O
and O
5ht2a O
receptors O
in O
the O
frontal O
cortex O
. O

-DOCSTART- O

1 O
broad-spectrum O
antibacteric O
. O
its O
antibacterial O
components O
are O
para-hydroxyphenylacetic O
acid O
, O
salicylic O
acid O
, O
vanillic O
acid O
, O
pyromucic O
acid O
and O
hydroquinone O
. O
2 O
. O
its O
1/1800-1/1600 O
decoction O
inhibits O
the O
growth O
of O
leptospira B-NEG
. O
3 O
. O
anti-trichomonas B-POS
vaginalis I-POS
in O
vitro O
. O
4 O
. O
its O
component O
, O
senecionine O
, O
is O
anticarcinogenic O
on O
walker O
sarcoma256 O
. O

-DOCSTART- O

hepatitis B-NEG
b I-NEG
reactivation I-NEG

-DOCSTART- O

bleeding B-NEG
in O
the O
hemorrhoids O

-DOCSTART- O

to O
induce O
diaphoresis B-NEG
, O
to O
ease O
the O
mind B-DNP
, O
and O
to O
relieve O
fever B-NEG
. O

-DOCSTART- O

cough B-NEG
due O
to O
dryness B-NEG
of I-NEG
the I-NEG
lung I-NEG

-DOCSTART- O

to O
enrich O
the O
blood B-DNP
, O
to O
activate O
blood B-NEU
circulation I-NEU
, O
and O
to O
remove O
obstruction O
of O
the O
channels O
and O
collaterals O
. O

-DOCSTART- O

a O
disease O
that O
has O
watery B-NEG
and I-NEG
chronic I-NEG
defecation I-NEG

-DOCSTART- O

mental B-NEG
confusion I-NEG

-DOCSTART- O

clear O
the O
lung B-DNP

-DOCSTART- O

five O
colored O
dysentery B-NEG
; O
dysentery B-NEG
with O
multi-colored O
stools O

-DOCSTART- O

its O
solution O
may O
kill O
the O
oncomelania O
. O

-DOCSTART- O

diarrhea B-NEG
, O
dysentery B-NEG
, O
leprosy B-NEG
, O
scrotal B-NEG
wind I-NEG
, O
itchy B-NEG
skin I-NEG
. O

-DOCSTART- O

acute B-NEG
lymphoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

svere O
nodular B-NEG
acne I-NEG

-DOCSTART- O

cool O
the O
heart B-DNP

-DOCSTART- O

erysipelas B-NEG
acute I-NEG
infection I-NEG
of I-NEG
the I-NEG
skin I-NEG
characterized O
by O
sudden O
onset O
of O
local O
bright O
red O
coloration O
and O
swelling B-NEG
with O
rapid O
spreading O
. O

-DOCSTART- O

restlessness B-NEG
and O
thirst B-NEU
; O

polydipsia B-NEG

-DOCSTART- O

prostate B-NEG
cancer I-NEG

-DOCSTART- O

arthralgia B-NEG
and O
myalgia B-NEG
; O
pain B-NEG
in O
the O
muscles O
and O
bones O

-DOCSTART- O

metrorrhagia B-NEG
and O
bloody B-NEG
stool I-NEG

-DOCSTART- O

distribution O
) O
, O
absorption B-NEU
, O
endurance B-NEU
, O
body B-NEU
weight I-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
mimmuietabolic B-NEU
rate I-NEU
/ I-NEU
energy I-NEU
expenditure I-NEU
, O
motility B-NEU
, O
others O

-DOCSTART- O

neuromyelitis B-NEG
optica I-NEG
( O
nmo B-NEG
) O

-DOCSTART- O

clear O
heat B-NEU
and O
calm O
the O
fetus O

-DOCSTART- O

treatment O
of O
rheumatic B-NEG
arthritis I-NEG
with O
muscular B-NEG
contracture I-NEG
, O
aching B-NEG
of O
the O
loins O
and O
knees O
, O
inflammation B-NEG
of O
the O
throat O
, O
carbuncle B-NEG
and O
boils O
, O
traumatic B-NEG
injuries I-NEG
. O

-DOCSTART- O

for O
the O
treatment O
and O
management O
of O
congestive B-NEG
cardiac I-NEG
insufficiency I-NEG
, O
arrhythmias B-NEG
and O
heart B-NEG
failure I-NEG
. O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
mood O
, O
quality O
of O
life O
, O
endocrine B-DNP
system I-DNP
, O
activation O
, O
attention O
, O
sleep O
, O
arousal O
, O
vigilance B-NEG
, O
mental B-NEG
state I-NEG
and O
performance O

-DOCSTART- O

reinforce O
gi(qi O
) O
and O
blood B-DNP

-DOCSTART- O

treatment O
of O
attack O
of O
damp-heat B-NEG
manifested O
by O
stuffiness B-NEG
and O
fullness O
sensation O
in O
the O
abdomen B-DNP
, O
or O
causing O
acute B-NEG
dysentery I-NEG
of O
jaundice B-NEG
, O
high O
fever B-NEG
accompained O
by O
impairment B-NEG
of O
conciousness B-DNP
, O
fidgetness O
and O
insomnia B-NEG
due O
to O
exuberant O
fire O
, O
spitting B-NEG
of I-NEG
blood I-NEG
and O
epistaxis B-NEG
caused O
by O
heat B-NEU
in O
the O
blood O
, O
inflammation B-NEG
of O
the O
eye O
, O
acid B-NEG
regurgitation I-NEG
, O
toothache B-NEG
, O
diabetes B-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
, O
external O
use O
for O
eczema B-NEG
and O
other O
skin B-NEG
diseases I-NEG
with O
exudation O
, O
purulent B-POS
discharge I-POS
from O
the O
ear O
. O

rhizoma O
coptidis O
( O
processed O
with O
wine O
) O
inflammation B-NEG
of O
the O
eye O
, O
ulcers B-NEG
in O
the O
mouth O
. O

rhizoma O
coptidis O
( O
processed O
with O
ginger O
) O
stuffiness O
and O
fullness O
sensation O
in O
the O
abdomen B-DNP
with O
nausea B-NEG
and O
vomiting B-NEG
caused O
by O
damp-heat B-NEG
in O
combination O
with O
cold B-NEG
. O

-DOCSTART- O

to O
remove O
phlegm B-NEG
, O
disperse O
the O
lumps B-NEG
, O
detoxify O
and O
relieve O
swelling B-NEG
. O

-DOCSTART- O

swelling B-NEG
and O
bearing-down B-NEG
pain I-NEG
of O
unilateral O
testis O
; O
unilateral O
swelling B-NEG
of I-NEG
the I-NEG
testis I-NEG

-DOCSTART- O

warm O
the O
stomach B-DNP

-DOCSTART- O

carbuncle B-NEG
and O
cellulitis B-NEG
of O
the O
back O
; O

carbuncle B-NEG
on O
the O
back O

-DOCSTART- O

asthma B-NEG

-DOCSTART- O

acute B-NEG
adrenal I-NEG
insufficiency I-NEG

-DOCSTART- O

stop O
diarrhea B-NEG

-DOCSTART- O

breast B-NEG
cancer I-NEG

-DOCSTART- O

to O
relieve O
muscle B-DNP
; O
to O
clear O
heat B-NEU
, O
to O
accelerate O
rash B-NEG
, O
to O
stop O
cough B-NEG

-DOCSTART- O

acute O
gout B-NEG
flare O

-DOCSTART- O

hypogonadotropic B-NEG
hypogonadism I-NEG

-DOCSTART- O

parkinson B-NEG
disease I-NEG

-DOCSTART- O

to O
transform O
dampness B-NEG
and O
promote O
water B-NEU
metabolism I-NEU
. O

-DOCSTART- O

investigated O
for O
use/treatment O
in O
hepatitis B-NEG
( O
viral B-NEG
, I-NEG
b I-NEG
) O
. O

-DOCSTART- O

rhizoma O
coptidis O
( O
processed O
with O
ginger O
) O
stuffiness B-NEG
and O
fullness B-NEG
sensation O
in O
the O
abdomen O
with O
nausea B-NEG
and O
vomiting B-NEG
caused O
by O
damp-heat B-NEG
in O
combination O
with O
cold B-NEG
. O

-DOCSTART- O

loratadine O
is O
a O
second-generation O
h1 O
histamine O
antagonist O
drug O
and O
appears O
to O
suppress O
the O
release B-NEU
of I-NEU
histamine I-NEU
and I-NEU
leukotrienes I-NEU
from O
mast O
cells O
, O
and O
the O
release B-NEU
of I-NEU
leukotrienes I-NEU
from O
human O
lung O
fragments O
. O

-DOCSTART- O

having O
painful B-NEG
and I-NEG
benumbed I-NEG
joint I-NEG

-DOCSTART- O

breast B-NEG
abscess I-NEG
; O
abscess B-NEG
of I-NEG
breast I-NEG
; O
acute B-NEG
mastitis I-NEG

-DOCSTART- O

tetanus B-NEG

-DOCSTART- O

cough B-NEG
due O
to O
phlegm-damp B-NEG

-DOCSTART- O

dispel O
stasis B-NEG

-DOCSTART- O

woman O
, O
eye B-DNP
, O
mood O
, O
physical B-DNP
performance I-DNP
and O
fitness B-POS
, O
menopausal B-NEG
woman I-NEG
, O
eye B-DNP
health I-DNP
, O
lipid B-NEU
profile I-NEU
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
sleep B-NEU
, O
inflammation B-NEG
, O
other O
system B-DNP
health I-DNP
, O
memory B-DNP
, O
reproductive B-DNP
systems I-DNP
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
post O
delivery O
, O
hypersensitivity B-NEG
, O
protective B-NEU
immunity I-NEU
, O
quality B-POS
of I-POS
life I-POS
, O
eye B-DNP
health I-DNP
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
blood B-NEU
pressure I-NEU
, O
protective B-NEU
immunity I-NEU
, O
diet B-NEG
cardiovascular I-NEG
disease I-NEG
, O
endocrine B-DNP
system I-DNP
, O
neurological B-DNP
systems I-DNP
, O
liver B-DNP
, O
others O
, O
vigilance B-NEG
, O
bone B-DNP
health I-DNP
and O
osteoporosis B-NEG
, O
homocysteine B-NEU
metabolism I-NEU
, O
bone B-NEU
metabolism I-NEU
/ I-NEU
density I-NEU
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
activation B-POS
, O
attention B-POS
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
liver B-DNP
health I-DNP
, O
eldery O
, O
strength B-POS
and O
power B-POS
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
neurological B-DNP
systems I-DNP
, O
hemostatic B-NEU
function I-NEU
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
reproductive B-DNP
systems I-DNP
, O
intelligence B-POS
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
overall O
cvd B-NEG
, O
general O
woman O
, O
general O
skin B-DNP
health I-DNP
, O
strength B-POS
and O
power B-DNP
reproductive I-DNP
systems I-DNP
, O
arousal B-NEU
, O
protective B-NEU
immunity I-NEU
, O
man O
, O
sleep B-NEU

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEU
, O
soothe O
sinews O
and O
quicken O
blood B-DNP
, O
relieve O
cough B-NEG
, O
resolve O
toxin B-NEG
. O

-DOCSTART- O

temporomandibular B-NEG
joint I-NEG
dysfunction I-NEG

-DOCSTART- O

cough B-NEG
in O
phthisis B-NEG
, O
dyspnea B-NEG
in O
the O
aged O
, O
depressed B-NEG
sensation I-NEG
and O
stuffiness B-NEG
in O
the O
chest O
. O

-DOCSTART- O

declination O
of O
the O
fire O
of O
the O
vital O
gate O
dysfunction O
of O
reproduction O
due O
to O
insufficiency O
of O
the O
kidney-yang O
. O

-DOCSTART- O

unresectable O
metastasis O
originating O
in O
colonic B-NEG
cancer I-NEG
. O

-DOCSTART- O

treatment O
of O
attack O
of O
damp-heat B-NEG
manifested O
by O
stuffiness B-NEG
and O
fullness B-NEG
sensation O
in O
the O
abdomen O
, O
or O
causing O
acute O
dysentery B-NEG
of I-NEG
jaundice I-NEG
, O
high B-NEG
fever I-NEG
accompained O
by O
impairment B-NEG
of I-NEG
conciousness I-NEG
, O
fidgetness B-NEG
and O
insomnia B-NEG
due O
to O
exuberant B-NEG
fire I-NEG
, O
spitting B-NEG
of I-NEG
blood I-NEG
and O
epistaxis B-NEG
caused O
by O
heat B-NEU
in I-NEU
the I-NEU
blood I-NEU
, O
inflammation B-NEG
of O
the O
eye O
, O
acid B-NEG
regurgitation I-NEG
, O
toothache B-NEG
, O
diabetes B-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
, O
external O
use O
for O
eczema B-NEG
and O
other O
skin B-NEG
diseases I-NEG
with O
exudation B-NEG
, O
purulent B-NEG
discharge I-NEG
from O
the O
ear O
. O

-DOCSTART- O

vigilance O
, O
physical B-DNP
performance I-DNP
and O
fitness O
, O
endurance O
, O
activation O
, O
attention O
, O
energy B-DNP
supply I-DNP
and O
recovery O
, O
metabolism B-DNP
, O
sleep B-DNP
, O
memory B-DNP
, O
arousal B-DNP
, O
others O
, O
mental B-DNP
state I-DNP
and O
performance O

-DOCSTART- O

incised B-NEG
wound I-NEG

-DOCSTART- O

fetal B-NEG
irritability I-NEG
; O
threatened B-NEG
abortion I-NEG
; O
excessive O
fetal O
movements O
continuous O
moving O
of O
the O
fetus O
causing O
pain B-NEG
in I-NEG
the I-NEG
lower I-NEG
abdomen I-NEG
. O

-DOCSTART- O

blood B-NEG
stasis I-NEG
in O
the O
hypochondriac O
region O
due O
to O
traumatic B-NEG
injury I-NEG
characterised O
by O
hypochondriac B-NEG
pain I-NEG
. O

traumatic O
swelling O
pain B-NEG
, O
intercostal B-NEG
neuralgia I-NEG
, O
costal B-NEG
chrondritis I-NEG
marked O
by O
accumulation O
of O
blood B-NEG
stasis I-NEG
can O
be O
treated O
by O
the O
modified O
recipe O
. O

-DOCSTART- O

sweating O
head O
; O
perspiration B-NEG
on O
forehead O
; O
morbid O
perspiration B-NEG
on O
the O
head O

-DOCSTART- O

iss O
1018 O
signals O
through O
toll-like O
receptor O
9 O
( O
tlr9 O
) O
to O
induce O
the O
production O
of O
immunoglobulin O
by O
b O
cells O
and O
interferon O
( O
ifn O
) O
#name? O
, O
ifn-beta B-DNP
, O
interleukin-12 B-DNP
( O
il-12 B-DNP
) O
, O
and O
tumor B-DNP
necrosis I-DNP
factor I-DNP
- I-DNP
alpha I-DNP
( O
tnf-alpha B-DNP
) O
by O
plasmacytoid O
dendritic O
cells O
( O
pdc O
) O
. O

pdc O
and O
ifn-alpha O
and O
#name? O
then O
induce O
natural B-DNP
killer I-DNP
( O
nk B-DNP
) O
cell B-NEU
proliferation I-NEU
, O
nk B-NEU
cell I-NEU
production I-NEU
of O
ifn-gamma B-DNP
, O
and O
nk B-NEU
cell-mediated I-NEU
cytotoxicity I-NEU
. O

secreted O
ifns O
also O
stimulate O
bystander O
t B-NEU
cell I-NEU
activation I-NEU
and O
differentiation O
of O
naive O
cd4+ O
t O
cells O
into O
t-helper O
1 O
cells O
on O
specific O
antigen O
challenge O
. O

-DOCSTART- O

clear O
heat B-NEU
and O
dry O
dampness B-NEG

-DOCSTART- O

abscess B-NEG

-DOCSTART- O

liver B-NEG
disease I-NEG

-DOCSTART- O

affection O
by O
summer O
heat O
; O
exposure O
to O
summer O
heat O

-DOCSTART- O

to O
supplement O
blood B-DNP
, O
quicken B-NEU
blood I-NEU
, O
strengthen O
lumbus B-DNP
and O
knees B-DNP
. O

-DOCSTART- O

headache B-NEG
due O
to O
cold B-NEG
affection O

-DOCSTART- O

investigated O
for O
use/treatment O
in O
cancer/tumors B-NEG
( O
unspecified O
) O
, O
lung B-NEG
cancer I-NEG
, O
myelodysplastic B-NEG
syndrome I-NEG
, O
and O
prostate B-NEG
cancer I-NEG
. O

-DOCSTART- O

dyspnea B-NEG
and O
tachypnea B-NEG
; O

shortness B-NEG
of I-NEG
breath I-NEG

-DOCSTART- O

hyperlipidemia B-NEG

-DOCSTART- O

myelodysplastic B-NEG
syndromes I-NEG

-DOCSTART- O

white-haired B-NEU

-DOCSTART- O

night B-NEG
sweat I-NEG
and O
nocturnal B-NEU
emission I-NEU

-DOCSTART- O

insulin B-NEG
sensitivity I-NEG
and O
diabetes B-NEG
risk O
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
woman O
, O
physical O
performance O
and O
fitness O
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
absorption B-NEU
, O
others O
, O
body O
weight O
regulation O
, O
general O
woman O
, O
strength O
and O
power O
, O
digestion B-POS
, O
hypersensitivity B-NEG
, O
motility B-POS

-DOCSTART- O

promote O
the O
stomach B-DNP
and O
disperse O
food O

-DOCSTART- O

clear O
heat B-NEU
and O
relieve O
toxicity B-NEG

-DOCSTART- O

arrest O
cough B-NEG
and O
relieve O
asthms B-NEG

-DOCSTART- O

hematuria B-NEG
with I-NEG
pain I-NEG
; O
stranguria B-NEG
with I-NEG
hematuria I-NEG
; O
painful O
urination B-NEG
with I-NEG
blood I-NEG

-DOCSTART- O

wind-cold-damp B-NEG
impediment O
, O
paralysis B-NEG
, O
painful O
wound B-NEG
from O
knocks O
and O
falls O
, O
tetanus O
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
quality O
of O
life O
, O
absorption O
, O
liver B-DNP
health I-DNP
, O
motility O
, O
liver B-DNP
, O
others O

-DOCSTART- O

to O
remove O
heat B-NEU
and O
counteract O
toxicity B-NEG
, O
to O
expel O
intestinal B-NEG
worms I-NEG
, O
stanch O
bleeding B-NEG
. O

-DOCSTART- O

pain B-NEG
with O
1 O
hernia B-NEG
2 O
diseases B-NEG
of I-NEG
genitalia I-NEG
3 O
. O
severe O
pain B-NEG
in I-NEG
the I-NEG
lower I-NEG
abdomen I-NEG

-DOCSTART- O

treatment O
of O
fever B-NEG
with O
constipation B-NEG
, O
retention O
of O
the O
feces O
and O
abdominal B-NEG
pain I-NEG
, O
dysentery B-NEG
with O
inadequate O
discharge O
from O
the O
bowels B-DNP
, O
jaundice B-NEG
caused O
by O
damp-heat B-NEG
, O
haematemesis B-NEG
, O
epistaxis B-NEG
, O
inflammation B-NEG
of O
eye O
and O
swelling B-NEG
of O
the O
throat O
due O
to O
heat B-NEU
in O
the O
blood O
, O
appendicitis B-NEG
with O
abdominal B-NEG
pain I-NEG
, O
boils B-NEG
, O
sores B-NEG
and O
abscess B-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
traumatic B-NEG
injuries I-NEG
, O
hemorrhage B-NEG
from O
the O
upper B-DNP
gastrointestinal I-DNP
tract I-DNP
. O

external O
use O
for O
scalds B-NEG
and O
burns.radixet O
rhizoma O
rhei O
( O
stir-fried O
with O
wine O
) O
inflammation B-NEG
of O
the O
eye O
, O
swelling B-NEG
of O
the O
throat O
and O
painful O
swelling B-NEG
of O
the O
gums O
. O

radix O
et O
rhizoma O
rhei O
( O
prepared O
) O
boils B-NEG
, O
sores B-NEG
and O
abscess B-NEG
. O

radix O
et O
rhizoma O
rhei O
( O
carbonized O
) O
hemorrhage B-NEG
with O
blood B-NEG
stasis I-NEG
due O
to O
heat B-NEU
in O
the O
blood O
. O

-DOCSTART- O

destroy O
intestinal B-NEG
parasites I-NEG

-DOCSTART- O

a O
symptom O
that O
a O
person O
has O
tightness B-NEG
in I-NEG
the I-NEG
chest I-NEG
and O
does O
not O
feel O
hungry O
. O

-DOCSTART- O

asthma B-NEG
; O

dyspnea B-NEG
; O

abnormal O
rising O
of O
gi O
; O

upward O
gi O
dyspnea O
due O
to O
upward O
adverse O
flow O
of O
the O
lung-gi O

-DOCSTART- O

menstrual B-NEG
discomfort I-NEG
, O
feelings O
of O
heat B-NEU
, O
flushed B-NEU
face I-NEU
, O
irritability B-NEG

-DOCSTART- O

stage O
iii O
adult B-NEG
t-cell I-NEG
leukemia/lymphoma I-NEG

-DOCSTART- O

settle O
the O
pain B-NEG

-DOCSTART- O

schizophrenia B-NEG
prodrome I-NEG

-DOCSTART- O

the O
chinese O
herb O
modified O
yi O
guan O
jian O
( O
mygj O
) O
is O
an O
effective O
regimen O
that O
is O
usually O
used O
in O
outpatients O
with O
chronic B-NEG
liver I-NEG
diseases I-NEG
such O
as O
fibrosis B-NEG
and O
cirrhosis B-NEG
. O

however O
, O
the O
mechanism O
for O
the O
action O
of O
mygj O
on O
liver B-NEG
fibrosis I-NEG
is O
not O
yet O
clear O
. O

in O
this O
study O
, O
we O
found O
that O
mygj O
induced O
hepatic B-DNP
stellate I-DNP
cells I-DNP
( O
hscs B-DNP
) O
apoptosis O
concomitant O
with O
the O
downregulation O
of O
bcl-2 B-DNP
expression I-DNP
and O
slight O
elevation O
of O
bax B-DNP
level I-DNP
. O

moreover O
, O
the O
reactive O
oxygen O
species O
( O
ros O
) O
were O
generated O
in O
the O
early O
stages O
of O
mygj-induced B-NEU
hscs I-NEU
apoptosis I-NEU
to O
facilitate O
calcium O
and O
cytochrome O
c O
release O
from O
the O
mitochondria O
to O
cytosol O
. O

subsequently O
, O
caspase B-DNP
9 I-DNP
and O
caspase B-DNP
3 I-DNP
were O
activated O
. O

furthermore O
, O
the O
activation O
of O
er O
stress-associated O
caspase B-DNP
12 I-DNP
in O
hscs B-DNP
was O
also O
evaluated O
. O

together O
, O
we O
report O
the O
first O
evidence-based O
study O
to O
demonstrate O
that O
mygj O
decoction O
induces O
hscs B-DNP
apoptosis O
through O
ros O
accumulation O
and O
the O
intrinsic O
apoptosis O
pathway O
. O

these O
findings O
provide O
rationale O
for O
further O
clinical O
investigation O
of O
traditional O
chinese O
medicine O
recipes O
against O
liver B-NEG
fibrosis I-NEG
. O

-DOCSTART- O

the O
symptom O
of O
disease O
where O
the O
skin B-NEG
turns I-NEG
yellow I-NEG
because O
dampness O
and O
heat O
tangle O
together O

-DOCSTART- O

heat B-NEU
in O
the O
heart O
, O
insufficient O
yin O
in O
kidney B-DNP
, O
frightening O
and O
madness B-NEG
, O
frequent O
talk O
and O
smile O
, O
driness B-NEG
in O
the O
mouth O
, O
red B-NEG
tong I-NEG
, O
loss B-NEG
of I-NEG
blood I-NEG

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
soothe O
sinews B-DNP
and O
quicken O
network O
vessels B-DNP
. O

-DOCSTART- O

high B-NEG
fever I-NEG
due O
to O
shaking B-NEG
chills I-NEG
during O
fever B-NEG

-DOCSTART- O

1 O
nocturnal O
enuresis O
; O
bed-wetting O
2 O
incontinence O
of O
urine O

-DOCSTART- O

the O
upper O
emaciation B-NEG
; O
lung B-NEG
diabetes I-NEG

-DOCSTART- O

for O
the O
treatment O
of O
obesity B-NEG
. O

-DOCSTART- O

pain B-NEG
of O
back O
and O
vertebra O

-DOCSTART- O

nocturnal B-NEG
emission I-NEG
; O
emission B-NEU
; O
spermatorrhea B-NEG
; O
seminal B-NEG
emission I-NEG

-DOCSTART- O

investigated O
for O
use/treatment O
in O
fibromyalgia B-NEG
. O

-DOCSTART- O

this O
is O
a O
syndrome O
with O
felling B-NEG
of I-NEG
cold I-NEG
and O
a O
pain B-NEG
in I-NEG
the I-NEG
lower I-NEG
abdomen I-NEG
. O

-DOCSTART- O

hepatitis B-NEG
c I-NEG
recurrence O
after O
liver O
transplant O

-DOCSTART- O

for O
malaria B-NEG
, O
applying O
crushed O
product O
on O
neiguan O
( O
p.6 O
) O
and O
dazhui O
( O
du' O
14 O
) O
2 O
hours O
before O
the O
episode O
; O
alos O
used O
for O
dyspnea B-NEG
due O
to O
the O
retention B-NEG
of I-NEG
phlegm I-NEG
. O

-DOCSTART- O

move O
gi O
( O
qi O
) O
and O
break O
blood B-DNP

-DOCSTART- O

cosolidate O
the O
kidney B-DNP

-DOCSTART- O

anhidrosis B-NEG
and O
aversion B-NEU
to I-NEU
cold I-NEU

-DOCSTART- O

to O
move O
qi O
, O
precipitate O
qi O
, O
relieve O
pain B-NEG
, O
disperse O
distention O
, O
free O
milk O
. O

-DOCSTART- O

when O
administered O
, O
g17dt O
induces O
an O
immune B-NEU
response I-NEU
producing O
antibodies O
which O
bind O
with O
the O
peptide O
and O
also O
cross-react O
and O
neutralise O
gastrin B-DNP
17 I-DNP
thus O
inhibiting O
the O
growth B-NEU
of I-NEU
cancers I-NEU
and O
metastasis B-NEU
. O

in O
addition O
the O
product O
neutralizes O
glycine-extended B-DNP
gastrin I-DNP
17 I-DNP
which O
is O
also O
a O
stomach O
and O
pancreatic O
cancer O
growth O
factor O
. O

-DOCSTART- O

1 O
sennoside O
a O
is O
the O
component O
for O
purgation O
. O

2 O
. O
promoting O
biliary B-DNP
secretion I-DNP
and O
enhancing O
the O
amount O
of O
bilirubin B-DNP
and O
bile B-DNP
acid I-DNP
. O

3 O
. O
rhein O
and O
emodin O
exert O
bacteriostatic O
effect O
by O
inhibting O
the O
synthesis B-DNP
of I-DNP
dna I-DNP
, O
rna O
and O
protein O
in O
bacteria O
4 O
. O
emodin O
is O
a O
component O
for O
hypotensive B-NEG
5 O
. O
oral O
use O
of O
its O
extract O
reduces O
the O
raio O
of O
serum B-DNP
cholesterol I-DNP
and O
total O
phospholipid B-DNP
in O
rabbits O
with O
hypercholesterolemia B-NEG
. O
6 O
. O
chrysophanol O
, O
an O
other O
active O
component O
, O
exerts O
a O
hemostatic B-POS
effect I-POS
. O

-DOCSTART- O

glaucoma B-NEG

-DOCSTART- O

bacterial B-NEG
infections I-NEG
of O
the O
ear O

-DOCSTART- O

relieve O
toxicity B-NEG
and O
alleviate O
edema B-NEG

-DOCSTART- O

traumatic B-NEG
cataract I-NEG

-DOCSTART- O

strengthen O
tooth B-DNP

-DOCSTART- O

for O
the O
treatment O
of O
essential B-NEG
hypertension I-NEG
, O
alone O
or O
as O
an O
adjunct O
. O

also O
for O
the O
management O
of O
severe B-NEG
hypertension I-NEG
when O
the O
drug O
cannot O
be O
given O
orally O
or O
when O
blood B-NEU
pressure I-NEU
must O
be O
lowered O
immediately O
, O
congestive B-NEG
heart I-NEG
failure I-NEG
( O
in O
combination O
with O
cardiac O
glycosides O
and O
diuretics O
and O
/ O
or O
with O
isosorbide O
dinitrate O
) O
, O
and O
hypertension B-NEG
secondary I-NEG
to O
pre-eclampsia B-NEG
/ O
eclampsia B-NEG
. O

-DOCSTART- O

high-grade O
lymphoma B-NEG

-DOCSTART- O

to O
nourish O
blood B-DNP
and O
consolidate O
the O
yin O
; O

to O
pacify O
the O
liver B-DNP
and O
stop O
pain B-NEG
; O

to O
soothe O
liver O
yang O

-DOCSTART- O

this O
is O
a O
symptom O
that O
the O
body O
becomes O
haggard B-NEG
because O
of O
exhaustion B-NEG
syndrome I-NEG
. O

-DOCSTART- O

simvastatin O
competitively O
inhibits O
hmg-coa B-DNP
reductase I-DNP
, O
lowers O
plasma O
cholesterol O
and O
lipoprotein B-NEU
levels O
, O
and O
modulates O
immune B-NEU
responses I-NEU
by O
suppressing O
mhc O
ii O
on O
interferon O
gamma-stimulated O
, O
antigen-presenting O
cells O
such O
as O
human O
vascular O
endothelial O
cells O
. O

ezetimibe O
localizes O
and O
appears O
to O
act O
at O
the O
brush O
border O
of O
the O
small O
intestine O
and O
inhibits O
the O
absorption O
of O
cholesterol O
. O

atorvastatin O
competitively O
inhibits O
hepatic B-DNP
hydroxymethyl-glutaryl I-DNP
coenzyme I-DNP
a I-DNP
( O
hmg-coa B-DNP
) O
reductase O
, O
the O
enzyme O
which O
catalyzes O
the O
conversion O
of O
hmg-coa O
to O
mevalonate O
, O
a O
key O
step O
in O
cholesterol B-NEU
synthesis I-NEU
. O

-DOCSTART- O

reserpine's O
mechanism O
of O
action O
is O
through O
inhibition O
of O
the O
atp/mg2+ O
pump O
responsible O
for O
the O
sequestering O
of O
neurotransmitters B-DNP
into O
storage O
vesicles O
located O
in O
the O
presynaptic B-DNP
neuron I-DNP
. O
trichlormethiazide O
appears O
to O
block O
the O
active O
reabsorption O
of O
chloride O
and O
possibly O
sodium O
in O
the O
ascending O
loop B-DNP
of I-DNP
henle I-DNP
, O
altering O
electrolyte O
transfer O
in O
the O
proximal B-DNP
tubule I-DNP
. O

-DOCSTART- O

to O
strengthen O
spleen B-DNP
and O
benefit O
dampness B-NEU
; O

to O
kill O
worms B-NEG
and O
stop O
diarrhea B-NEG

-DOCSTART- O

allosteric O
interactions O
between O
central O
benzodiazepine O
receptors O
and O
gamma-aminobutyric O
acid O
( O
gaba O
) O
receptors O
potentiate O
the O
effects O
of O
gaba O
. O

-DOCSTART- O

nephrotic B-NEG
syndrome I-NEG

-DOCSTART- O

rikkunshito O
( O
rkt O
) O
, O
a O
japanese O
traditional O
medicine O
, O
has O
been O
shown O
to O
stimulate O
food O
intake O
in O
rats O
with O
cisplatin-induced B-NEG
anorexia I-NEG
; O
however O
, O
the O
underlying O
mechanisms O
remain O
unknown O
. O

in O
this O
study O
, O
we O
investigated O
whether O
rkt O
is O
involved O
in O
the O
degradation O
of O
peripheral B-DNP
ghrelin I-DNP
. O

rkt O
inhibited O
decreases O
in O
plasma B-NEU
ghrelin I-NEU
level I-NEU
and O
enhanced O
acyl- B-DNP
to I-DNP
desacyl-ghrelin I-DNP
( O
a/d B-DNP
) O
ratio O
in O
cisplatin-treated O
rats O
. O

several O
components O
of O
rkt O
demonstrated O
inhibitory O
activity O
against O
ghrelin B-DNP
deacylating I-DNP
enzymes I-DNP
. O

in O
addition O
, O
10-gingerol O
, O
a O
component O
of O
rkt O
, O
inhibited O
exogenous O
ghrelin B-DNP
deacylation I-DNP
. O

therefore O
, O
rkt O
may O
enhance O
plasma B-NEU
acyl I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
, O
at O
least O
in O
part O
, O
by O
inhibiting O
the O
circulating O
ghrelin B-DNP
degrading I-DNP
enzyme I-DNP
. O

-DOCSTART- O

protracted O
dysentery B-NEG
; O
chronic B-NEG
dysentery I-NEG
; O
prolonged O
dysentery B-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
absorption O
, O
lipid O
profile O
, O
dietnarelated O
cardiovascular B-NEG
disease I-NEG
, O
motility O
, O
evacuation O

-DOCSTART- O

soothe O
diaphragm B-DNP

-DOCSTART- O

spontaneous B-NEG
sweating I-NEG
( O
perspiration B-NEG
) O
frequent B-NEG
sweating I-NEG
due O
to O
lowered B-NEG
superficial I-NEG
resistance I-NEG
brought O
on O
by O
deficiency O
of O
gi O
. O

-DOCSTART- O

chronic B-NEG
ulcers I-NEG
. O
dragon's O
blood O
( O
xuejie O
) O
is O
used O
with O
frankincense O
( O
ruxiang O
) O
and O
myrrh O
( O
moyao O
) O
for O
external O
use O
. O

-DOCSTART- O

pulmonary B-NEG
arterial I-NEG
hypertension I-NEG

-DOCSTART- O

pyogenic B-NEG
infections I-NEG

-DOCSTART- O

alzheimer's B-NEG
disease I-NEG

-DOCSTART- O

childhood B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG
with O
maturation B-NEG

-DOCSTART- O

background O
_ O
aims O
: O
chemotherapy O
with O
an O
anticancer O
agent O
generally O
causes O
gastrointestinal B-NEG
tract I-NEG
disorders I-NEG
such O
as O
vomiting B-NEG
and O
anorexia B-NEG
, O
but O
the O
mechanism O
remains O
unclear O
. O

rikkunshito O
, O
a O
kampo O
preparation O
, O
is O
known O
to O
alleviate O
such O
adverse O
reactions O
. O

in O
this O
study O
, O
we O
attempted O
to O
clarify O
the O
mechanism O
. O

methods O
: O
we O
investigated O
the O
decreases O
of O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
caused O
by O
cisplatin O
, O
serotonin B-DNP
( O
5-ht B-DNP
) O
, O
5-ht O
agonists O
, O
and O
vagotomy O
as O
well O
as O
the O
decrease-suppressing O
effects O
of O
rikkunshito O
and O
5-ht O
antagonists O
. O

in O
addition O
, O
binding O
affinities O
of O
rikkunshito O
components O
were O
determined O
in O
receptor-binding O
assays O
using O
5-ht2b O
and O
5-ht2c O
receptors O
. O

results O
: O
cisplatin O
, O
5-ht B-DNP
, O
bw723c86 O
( O
5-ht2b-receptor O
agonist O
) O
, O
and O
m-chlorophenylpiperazine O
hcl O
( O
5-ht2c O
agonist O
) O
markedly O
decreased O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
levels I-NEU
, O
although O
5-ht3 O
and O
5-ht4 O
agonists O
had O
no O
effect O
. O

in O
contrast O
, O
5-ht2b O
and O
5-ht2c O
antagonists O
suppressed O
the O
cisplatin-induced O
decrease O
of O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
. O

administration O
of O
rat O
ghrelin B-NEU
improved O
the O
cisplatin-induced O
decrease O
in O
food O
intake O
. O

vagotomy O
decreased O
the O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
, O
which O
was O
decreased O
further O
by O
cisplatin O
. O

rikkunshito O
suppressed O
such O
cisplatin-induced O
decreases O
of O
plasma B-NEU
acylated- I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
. O

the O
suppressive O
effect O
of O
rikkunshito O
was O
blocked O
by O
a O
ghrelin O
antagonist O
. O

components O
of O
rikkunshito O
, O
3,3',4',5,6,7,8-heptamethoxyflavone O
, O
hesperidin O
, O
and O
iso-liquiritigenin O
showed O
a O
5-ht2b-antagonistic O
effect O
in O
vitro O
, O
and O
oral O
administration O
of O
rikkunshito O
suppressed O
the O
cisplatin-induced O
decrease O
in O
the O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
. O

conclusions O
: O
the O
cisplatin-induced O
decreases O
of O
the O
plasma B-NEU
acylated I-NEU
- I-NEU
ghrelin I-NEU
level I-NEU
and O
food O
intake O
are O
mediated O
by O
5-ht2b/2c O
receptors O
and O
suppressed O
by O
flavonoids O
in O
rikkunshito O
. O

-DOCSTART- O

qi O
vacuity O
, O
yin O
depletion O
and O
effulgent O
fire O
, O
cough B-NEG
and O
asthma B-NEG
with O
phlegm-blood B-NEG
, O
vacuity O
heat B-NEG
and O
vexation O
fatigue B-NEG
, O
diabetes B-NEG
mellitus I-NEG
due O
to O
internal O
heat B-NEG
, O
thirst B-NEU
with O
dry B-NEG
throat I-NEG
. O

-DOCSTART- O

constipation B-NEG

-DOCSTART- O

dyspnea B-NEG
due O
to O
the O
kidney B-NEG
deficiency I-NEG

-DOCSTART- O

to O
dispel O
damp B-NEU
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

glad O
and O
misten B-NEG
complexion I-NEG

-DOCSTART- O

injury B-NEG
by O
wind B-NEG
pathogen O
and O
headache B-NEG

-DOCSTART- O

possessing O
broad-spectrum O
antibacterial B-POS
and I-POS
antiprotozoal I-POS
effects I-POS
. O

-DOCSTART- O

insulin O
binds O
to O
the O
insulin O
receptor O
( O
ir O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

the O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
ir O
stimulates O
the O
tyrosine B-DNP
kinase I-DNP
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

the O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
irs O
) O
proteins O
, O
cbl B-DNP
, O
aps B-DNP
, O
shc B-DNP
and O
gab B-DNP

these O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-DNP
of I-DNP
downstream I-DNP
signaling I-DNP
molecules I-DNP
including O
pi3 B-DNP
kinase I-DNP
and O
akt B-DNP
. O

akt O
regulates O
the O
activity B-DNP
of I-DNP
glucose I-DNP
transporter I-DNP
4 I-DNP
( O
glut4 B-DNP
) O
and O
protein B-DNP
kinase I-DNP
c I-DNP
( O
pkc B-DNP
) O
which O
play O
a O
critical O
role O
in O
metabolism O
. O

-DOCSTART- O

( O
1 O
) O
cold-type B-NEG
hernia I-NEG
; O
periumbilical B-NEG
colic I-NEG
due O
to O
invasion B-NEG
of I-NEG
cold I-NEG
( O
2 O
) O
testalgia B-NEG
due O
to O
pathogenic B-NEG
cold I-NEG

-DOCSTART- O

mouth B-NEG
sore I-NEG
, O
clove B-NEG
sore I-NEG
, O
hemorrhoids B-NEG
, O
scrotal B-NEG
eczema I-NEG
, O
bleeding B-NEG
due O
to O
external B-NEG
injury I-NEG
. O

-DOCSTART- O

neuromyelitis B-NEG
optica I-NEG
( O
nmo B-NEG
) O
and O
nmo B-NEG
spectrum I-NEG
disorder I-NEG
( O
nmosd B-NEG
) O

-DOCSTART- O

it O
causes O
blood B-NEU
vessels I-NEU
to I-NEU
narrow I-NEU
, O
resulting O
in O
an O
increase O
in O
blood B-NEU
pressure I-NEU
. O

-DOCSTART- O

swelling B-NEG
of O
the O
cheek O
; O
parotitis B-NEG

-DOCSTART- O

motivation O
, O
mood O
, O
physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
endurance B-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
others O
, O
effort O
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
quicken O
blood B-DNP
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

retention B-NEG
or I-NEG
stagnancy I-NEG
of I-NEG
undigested I-NEG
food I-NEG

-DOCSTART- O

acute B-NEG
myelogenous I-NEG
leukemia I-NEG

-DOCSTART- O

hematemesis B-NEG
; O
blood B-NEG
vomiting I-NEG
; O
spitting B-NEG
blood I-NEG
; O
blood B-NEG
vomiting I-NEG

-DOCSTART- O

for O
tonifying O
blood B-DNP

-DOCSTART- O

multiple B-NEG
myeloma I-NEG
and O
plasma B-NEG
cell I-NEG
neoplasm I-NEG

-DOCSTART- O

treatment O
of O
endemic B-NEG
goiter I-NEG
, O
hyperthyroidism B-NEG
, O
whooping B-NEG
cough I-NEG
, O
cough B-NEG
of O
lung-heat O
type O
, O
thyroid B-NEG
adenoma I-NEG
, O
thyroid B-NEG
cancer I-NEG
, O
tumour B-NEG
of O
digestive O
tract O
, O
lung B-NEG
and I-NEG
mammary I-NEG
cancer I-NEG
, O
etc O
. O

-DOCSTART- O

swelling B-NEG
pain I-NEG
in O
throat O
, O
red O
eyes O
with O
gall O
, O
lung O
heat O
cough B-NEG
, O
mastitis B-NEG
, O
damp-heat B-NEG
jaundice B-NEG
, O
wind-damp B-NEG
impediment O
pain B-NEG
, O
bleeding B-NEG
due O
to O
external B-NEG
injury I-NEG
. O

-DOCSTART- O

juzentaihoto O
failed O
to O
augment O
antigen-specific O
immunity B-NEU
but O
prevented O
deterioration B-NEG
of O
patients' O
conditions O
in O
advanced O
pancreatic B-NEG
cancer I-NEG
under O
personalized O
peptide O
vaccine O
. O

-DOCSTART- O

intelligence B-POS
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
others O

-DOCSTART- O

t'aeyang B-NEG
meridian I-NEG
affected O
by O
the O
wind B-NEG
; O

invasion B-NEG
of I-NEG
wind I-NEG
pathogen I-NEG
in O
t'aeyang O
meridian O

-DOCSTART- O

de O
novo O
kidney O
transplantation O

-DOCSTART- O

asthma B-NEG
and O
cough B-NEG

-DOCSTART- O

however O
, O
like O
other O
antihypertensives O
, O
they O
all O
have O
to O
be O
self-administered O
daily O
and O
don't O
provide O
a O
good O
solution O
for O
improving O
patient O
compliance O
. O

-DOCSTART- O

jaundice B-NEG
a O
morbid O
condition O
clinically O
characterized O
by O
yellow-brown B-NEG
pigmentation I-NEG
of I-NEG
the I-NEG
skin I-NEG
and I-NEG
sclera I-NEG
and O
dark B-NEG
yellow I-NEG
colored I-NEG
urine I-NEG
, O
and O
classified O
into O
two O
types O
, O
yang B-NEG
jaundice I-NEG
and O
eum B-NEG
jaundice I-NEG
; O

one O
of O
the O
five O
types O
of O
jaundice B-NEG
. O

-DOCSTART- O

phlegm B-NEG
; O
sputum B-NEG
pathologic O
mucoid O
substances O
collected O
in O
a O
diseased O
organ O
or O
tissue O
. O

-DOCSTART- O

for O
for O
use O
with O
insulin O
for O
the O
treatment O
of O
noninsulin-dependent O
( O
type O
2 O
) O
diabetes B-NEG
mellitus I-NEG
. O

-DOCSTART- O

nourish O
eum(yin O
) O
blood B-DNP

-DOCSTART- O

pulmonary B-NEG
disease I-NEG
, I-NEG
chronic I-NEG
obstructive I-NEG

-DOCSTART- O

relief O
of O
mild O
to O
moderate O
pain B-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
evacuation B-NEU

-DOCSTART- O

cyclophosphamide's O
active O
metabolites O
aldophosphamide O
and O
phosphoramide O
mustard O
bind O
to O
dna B-DNP
, O
thereby O
inhibiting O
dna B-NEU
replication I-NEU
and O
initiating O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

treatment O
of O
headache B-NEG
, O
particularly O
pain B-NEG
in O
the O
forehead O
, O
and O
stuffed B-NEG
nose I-NEG
due O
to O
colds B-NEG
, O
sinusitis B-NEG
, O
toothache B-NEG
, O
excessive O
leukorrhea B-NEG
, O
swelling B-NEG
and O
pain B-NEG
of O
sores B-NEG
and O
wounds B-NEG
. O

-DOCSTART- O

invigorate O
the O
spleen B-DNP

-DOCSTART- O

in O
order O
to O
better O
understand O
the O
characteristics O
of O
atmospheric O
carbonaceous O
aerosol O
at O
a O
background O
site O
in O
northeast O
asia O
, O
semicontinuous O
organic O
carbon O
( O
oc O
) O
and O
elemental O
carbon O
( O
ec O
) O
, O
and O
time-resolved O
water-soluble O
organic O
carbon O
( O
wsoc O
) O
were O
measured O
by O
a O
sunset O
oc O
/ O
ec O
and O
a O
pils-toc O
( O
particle-into-liquid O
sampler O
coupled O
with O
an O
online O
total O
organic O
carbon O
) O
analyzer O
, O
respectively O
, O
at O
the O
gosan O
supersite O
on O
jeju O
island O
, O
korea O
, O
in O
the O
summer O
( O
may O
42914 O
17 O
) O
and O
fall O
( O
august O
43002 O
30 O
) O
of O
2009 O
. O

hourly O
average O
oc O
concentration O
varied O
in O
the O
range O
of O
approximately O
0.87-28.38 O
microgc O
m-3 O
, O
with O
a O
mean O
of O
4.07+/- O
2.6 O
microgc O
m-3 O
, O
while O
the O
hourly O
average O
ec O
concentration O
ranged O
approximately O
from O
0.04 O
to O
8.19 O
. O

microgc O
m-3 O
, O
with O
a O
mean O
of O
1.35 O
+/- O
0.71 O
microgc O
m-3 O
, O
from O
may O
28 O
to O
june O
17 O
, O
2009 O
. O
during O
the O
fall O
season O
, O
oc O
varied O
in O
the O
approximate O
range O
0.9-9.6 O
microgc O
m-3 O
, O
with O
a O
mean O
of O
2.3 O
+/-0.80 O
microgc O
m-3 O
, O
whereas O
ec O
ranged O
approximately O
from O
0.01 O
to O
5.4 O
microgc O
m-3 O
, O
with O
a O
mean O
of O
0.66 O
+/- O
0.38 O
microgc O
m-3 O
. O

average O
contributions O
of O
ec O
to O
tc O
and O
wsoc O
to O
oc O
were O
0.26 O
+/- O
0.097 O
and O
0.206 O
+/-7.4% O
, O
and O
0.376 O
+/- O
0.235 O
and O
0.572 O
+/- O
0.222 O
during O
summer O
and O
fall O
seasons O
, O
respectively O
. O

as O
expected O
, O
clear O
diurnal O
variation O
of O
wsoc/oc O
was O
found O
in O
summer O
, O
varying O
from O
0.22 O
during O
the O
nighttime O
up O
to O
0.72 O
during O
the O
daytime O
, O
mainly O
due O
to O
the O
photo-oxidation O
process O
. O

in O
order O
to O
investigate O
the O
effect O
of O
air O
mass O
pathway O
on O
the O
characteristics O
of O
carbonaceous O
aerosol O
, O
5-day O
back-trajectory O
analysis O
was O
conducted O
using O
the O
hysplit O
model O
. O

the O
air O
mass O
pathways O
were O
classified O
into O
four O
types O
: O
continental O
( O
cc O
) O
, O
marine O
( O
m O
) O
, O
east O
sea O
( O
es O
) O
and O
korean O
peninsula O
( O
kp O
) O
. O

the O
highest O
oc/ec O
ratio O
of O
3.63 O
was O
observed O
when O
air O
mass O
originated O
from O
the O
continental O
area O
( O
cc O
) O
. O

the O
lowest O
oc/ec O
ratio O
of O
0.79 O
was O
measured O
when O
air O
mass O
originated O
from O
the O
marine O
area O
( O
m O
) O
. O

a O
high O
oc O
concentration O
was O
occasionally O
observed O
at O
gosan O
due O
to O
local O
biomass O
burning O
activities O
. O

the O
contribution O
of O
secondary O
oc O
to O
total O
oc O
varied O
approximately O
between O
0.084 O
and O
0.322 O
and O
depended O
on O
air O
mass O
type O
. O

-DOCSTART- O

aphasia B-NEG
with O
stiffness B-NEG
of I-NEG
the I-NEG
tongue I-NEG

-DOCSTART- O

a O
disease B-NEG
with O
pain B-NEG
and O
cold B-NEG
in O
the O
joints O

-DOCSTART- O

cold B-NEG
sweating I-NEG
at O
night O

-DOCSTART- O

eti-204 O
is O
an O
affinity-enhanced O
, O
de-immunized O
antibody O
, O
which O
means O
that O
its O
ability O
to O
bind O
to O
its O
target O
pathogen O
has O
been O
strengthened O
and O
that O
elements O
that O
might O
cause O
an O
immune B-NEU
response I-NEU
have O
been O
removed O
. O

eti-204 O
targets O
and O
binds O
to O
protective O
antigen O
, O
which O
prevents O
the O
anthrax B-NEG
toxins I-NEG
from O
binding O
to O
and O
entering O
the O
cells O
in O
the O
body O
, O
thereby O
preventing O
death B-NEG
. O

-DOCSTART- O

dietnarelated O
cardiovascular B-NEG
disease I-NEG
, O
liver B-DNP
health I-DNP
, O
liver B-DNP
, O
blood B-NEU
pressure I-NEU

-DOCSTART- O

endocrine B-DNP
system I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP

-DOCSTART- O

sore B-NEG
throat I-NEG
; O
swollen B-NEG
and I-NEG
pailful I-NEG
throat I-NEG

-DOCSTART- O

g4544 O
reduces O
bone B-NEG
loss I-NEG
by O
inhibiting O
calcium B-NEU
resorption I-NEU
from I-NEU
bone I-NEU
. O

preclinical O
evidence O
suggests O
that O
the O
mechanism O
of O
g4544 O
action O
is O
multifactorial O
and O
different O
from O
other O
current O
therapies O
used O
to O
treat O
bone B-NEG
loss I-NEG
, O
such O
as O
estrogen B-DNP
or O
selective O
estrogen O
receptor O
modulators O
( O
serms O
) O
, O
calcitonin O
, O
or O
bisphosphonates O
( O
e.g O
. O
, O
zometa O
or O
fosamax O
) O
. O

g4544 O
preferentially O
accumulates O
in O
metabolically O
active O
regions O
of O
bone O
, O
inhibits O
osteoclast-mediated B-NEU
bone I-NEU
resorption I-NEU
, O
and O
favorably O
alters O
bone B-DNP
mineral I-DNP
composition I-DNP
and O
properties O
. O

-DOCSTART- O

the O
disease B-NEG
that O
liver O
and O
spleen O
become O
swollen B-NEG
and O
enlarged B-NEG

-DOCSTART- O

hyperkalemia B-NEG

-DOCSTART- O

pain B-NEG
in O
joints O
due O
to O
rheumatalgia B-NEG
, O
aching B-NEG
in O
lumbus O
and O
legs O
, O
kidney B-NEG
vacuity I-NEG
and O
edema B-NEG
, O
diabetes B-NEG
mellitus I-NEG
, O
knocks O
and O
falls O
, O
fracture O
, O
pain O
in O
stomach O
duct O
, O
blood B-NEG
ejection I-NEG
, O
spontaneous O
external B-NEG
bleeding I-NEG
, O
malaria B-NEG
, O
lacquer O
sore B-NEG
, O
medullitis B-NEG
, O
deep O
pus B-NEG
ulcer I-NEG
. O

-DOCSTART- O

treatment O
of O
taeniasis B-NEG
, O
ancylostomiasis B-NEG
, O
ascariasis B-NEG
, O
intestinal B-NEG
parasitosis I-NEG
with O
abdominal B-NEG
pain I-NEG
or O
with O
infantile B-NEG
malnutrition I-NEG
. O

-DOCSTART- O

epilepsy B-NEG
induced O
by O
frightening B-NEG
and O
mania-withdrawal B-NEG

-DOCSTART- O

adult B-NEG
acute I-NEG
megakaryoblastic I-NEG
leukemia I-NEG
( O
m7 B-NEG
) O

-DOCSTART- O

retention B-NEG
of I-NEG
the I-NEG
dead I-NEG
fetus I-NEG

-DOCSTART- O

retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
; O
dyspepsia B-NEG
retention O
of O
food O
resulting O
from O
dysfunction B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG

-DOCSTART- O

fatigue B-NEG

-DOCSTART- O

deficiency B-NEG
of O
the O
kidney O
; O

deficiency B-NEG
syndrome I-NEG
of O
the O
kidney O
the O
pathological B-NEG
changes I-NEG
due O
to O
deficiency B-NEG
of O
the O
kidney O
essence O
, O
usually O
characterized O
by O
dizziness B-NEG
, O
tinnitus B-NEG
, O
lumbago B-NEG
, O
nocturnal B-NEU
emission I-NEU
, O
impotence B-NEG
, O
lassitude B-NEG
, O
forgetfulness B-NEG
. O

-DOCSTART- O

stabilize O
pain B-NEG

-DOCSTART- O

acetaminophen O
acts O
primarily O
in O
the O
cns B-DNP
, O
by O
increasing O
the O
pain B-NEU
threshold I-NEU
by O
inhibiting O
both O
isoforms B-DNP
of I-DNP
cyclooxygenase I-DNP
, O
cox-1 B-DNP
, O
cox-2 B-DNP
, O
and O
cox-3 B-DNP
enzymes O
involved O
in O
prostaglandin B-NEU
( I-NEU
pg I-NEU
) I-NEU
synthesis I-NEU
. O

-DOCSTART- O

cholangiocarcinoma B-NEG

-DOCSTART- O

difficulty B-NEG
in I-NEG
urination I-NEG
and I-NEG
defecation I-NEG
; O
constipation B-NEG
and O
ischuria B-NEG

-DOCSTART- O

1 O
for O
cases O
attributive O
to O
deficiency B-NEG
and O
collapse O
of O
vital O
energy O
and O
downward O
flowing O
of O
essential O
substance,which O
manifest O
as O
prolonged O
discharge O
of O
rice-water O
like O
urine O
, O
pale B-NEG
complexion I-NEG
, O
fatigue B-NEG
, O
pale B-NEG
tongue I-NEG
and O
feeble B-NEU
pulse I-NEU
, O
add O
fructus O
corni O
to O
keep O
t O

-DOCSTART- O

heavy B-NEG
sensation I-NEG
of O
the O
body O

-DOCSTART- O

swelling B-NEG
and O
pain B-NEG
due O
to O
blood B-NEG
stagnation I-NEG
caused O
by O
external B-NEG
injuries I-NEG
. O

-DOCSTART- O

a O
disease O
that O
menstruation B-NEU
is O
not O
even O
due O
to O
coldness B-NEG

-DOCSTART- O

nervous B-NEG
system I-NEG
diseases I-NEG
, O
sympathetic O

-DOCSTART- O

effects O
of O
yokukansan O
, O
a O
traditional O
japanese O
medicine O
, O
on O
thiamine B-NEU
deficiency I-NEU
( O
td B-NEU
) O
- O
induced O
decrease O
of O
glutamate O
uptake O
were O
examined O
in O
cultured O
rat O
cortical O
astrocytes O
. O

yokukansan O
( O
100 O
- O
500 O
microg O
/ O
ml O
) O
ameliorated O
the O
td B-NEU
- O
induced O
decrease O
in O
glutamate O
uptake O
by O
astrocytes O
, O
implying O
that O
yokukansan O
may O
contain O
active O
herbs O
and O
compounds O
possessing O
this O
effect O
. O

among O
the O
seven O
constituent O
herbs O
of O
yokukansan O
, O
significant O
effects O
were O
found O
for O
glycyrrhiza O
. O

furthermore O
, O
glycyrrhizin O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
( O
10(-7)-10(-4)m O
) O
, O
among O
the O
eight O
components O
of O
glycyrrhiza O
, O
ameliorated O
the O
td B-NEG
- O
induced O
decrease O
of O
glutamate O
uptake O
in O
astrocytes O
in O
a O
concentration O
- O
dependent O
manner O
. O

these O
substances O
inhibited O
protein B-DNP
kinase I-DNP
c I-DNP
( O
pkc B-DNP
) O
activity O
under O
the O
in O
vitro O
conditions O
. O

these O
lines O
of O
evidence O
suggest O
that O
glycyrrhizin O
, O
a O
main O
component O
of O
glycyrrhiza O
, O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
are O
likely O
responsible O
for O
amelioration O
of O
dysfunction O
of O
glutamate O
transport O
in O
astrocytes O
. O

the O
inhibition O
of O
the O
pkc B-NEU
activity I-NEU
might O
be O
related O
to O
the O
pharmacological O
efficacy O
of O
these O
substances O
. O

-DOCSTART- O

conjunctival B-NEG
congestion I-NEG

-DOCSTART- O

urgency B-NEG
incontinence I-NEG

-DOCSTART- O

lingual B-NEG
pustule I-NEG
; O
boil B-NEG
of O
the O
tongue O

-DOCSTART- O

eczema B-NEG

-DOCSTART- O

end B-NEG
stage I-NEG
renal I-NEG
disease I-NEG

-DOCSTART- O

extinguish O
wind B-NEG
and O
stabilize O
fright B-NEG

-DOCSTART- O

lumbago B-NEG
due O
to O
the O
kidney B-NEG
deficiency I-NEG

-DOCSTART- O

forceful O
pulse O

-DOCSTART- O

treatment O
of O
weakness B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
the I-NEG
lung I-NEG
manifested O
by O
shortness B-NEG
of I-NEG
breath I-NEG
, O
cough B-NEG
, O
palpitation B-NEG
, O
anorexia B-NEG
, O
loose B-NEG
stools I-NEG
, O
diabetes B-NEG
caused O
by O
internal O
heat B-NEU
. O

-DOCSTART- O

breast B-NEG
neoplasms I-NEG

-DOCSTART- O

moisten O
the O
lung B-DNP

-DOCSTART- O

thirst B-NEG

-DOCSTART- O

lenalidomide O
inhibits O
tnf-alpha B-NEU
production I-NEU
, O
stimulates O
t B-DNP
cells I-DNP
, O
reduces O
serum O
levels O
of O
the O
cytokines O
vascular O
endothelial O
growth O
factor O
( O
vegf O
) O
and O
basic O
fibroblast O
growth O
factor O
( O
bfgf O
) O
, O
and O
inhibits O
angiogenesis B-NEG
. O

acetylsalicylic O
acid O
binds O
to O
and O
acetylates O
serine O
residues O
in O
cyclooxygenases O
, O
resulting O
in O
decreased O
synthesis B-NEU
of I-NEU
prostaglandin I-NEU
, O
platelet O
aggregation O
, O
and O
inflammation B-NEG
. O

dexamethasone O
is O
a O
glucocorticoid O
agonist O
. O

in O
addition O
to O
binding O
to O
specific O
nuclear O
steroid O
receptors O
, O
dexamethasone O
also O
interferes O
with O
nf-kb B-NEU
activation I-NEU
and O
apoptotic O
pathways O
. O

bendamustine O
acts O
as O
an O
alkylating O
agent O
causing O
intra-strand O
and O
inter-strand O
cross-links O
between O
dna O
bases O
. O

-DOCSTART- O

used O
to O
produce O
controlled B-NEG
hypotension I-NEG
during O
surgical O
procedures O
and O
in O
hypertensive B-NEG
crises I-NEG
. O

-DOCSTART- O

relieve O
fever B-NEG

-DOCSTART- O

patients O
with O
squamous B-NEG
cell I-NEG
carcinoma I-NEG
of O
the O
head O
and O
neck O
. O

-DOCSTART- O

hematuria B-NEG
; O
bloody B-NEG
urine I-NEG
without O
pain O

-DOCSTART- O

cooling O
throat B-DNP

-DOCSTART- O

to O
nourish O
blood B-DNP
, O
stanch O
bleeding B-NEG
, O
calm O
liver B-DNP
, O
moisten O
dryness B-NEG
. O

-DOCSTART- O

treatment O
of O
aching B-NEG
and O
weakness B-NEG
of O
the O
loins O
and O
knees O
, O
asthma B-NEG
and O
cough B-NEG
of O
deficiency-cold B-NEG
type O
, O
seminal O
emission O
, O
impotence B-NEG
. O

-DOCSTART- O

move O
blood B-DNP

-DOCSTART- O

this O
is O
passing B-NEG
urine I-NEG
unconsciously I-NEG
. O

-DOCSTART- O

gallbladder B-NEG
neoplasms I-NEG

-DOCSTART- O

fever B-NEG
, O
sweats B-NEU
, O
and O
hot B-NEG
flashes I-NEG

-DOCSTART- O

childhood B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG
without O
maturation B-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
absorption B-NEU
, O
motility B-NEU
, O
evacuation B-NEU
, O
protective O
immunity B-NEU

-DOCSTART- O

disliking O
wind B-NEG
syndrome I-NEG
due O
to O
external B-NEG
and I-NEG
internal I-NEG
injury I-NEG
. O

-DOCSTART- O

slight O
thirst O
and O
redness B-NEG
of I-NEG
the I-NEG
face I-NEG

-DOCSTART- O

ovarian B-NEG
cancer I-NEG

-DOCSTART- O

to O
strengthen O
the O
body B-NEU
resistance I-NEU
to O
consolidate O
the O
constitution O
, O
replenish O
qi O
, O
invigorate O
the O
spleen B-DNP
and O
tonify O
the O
spleen B-DNP
and O
tonify O
the O
kidney B-DNP
to O
relieve O
mental B-NEU
strain I-NEU
. O

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
resolve O
toxin B-NEG
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

stop O
tearing O

-DOCSTART- O

treatment O
of O
deficient O
yin O
of O
the O
liver O
and O
kidneys O
and O
hyperactivity B-NEG
of O
liver O
yang O
manifested O
as O
distension B-NEU
and O
pain B-NEG
in O
the O
head O
and O
eyes O
, O
dizziness B-NEG
and O
vertigo B-NEG
. O

red O
ochre O
( O
daizheshi O
) O
is O
used O
with O
dragon's O
bone O
( O
longgu O
) O
, O
oyster O
shell O
( O
muli O
) O
, O
white O
peony O
root O
( O
bais O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
reproductive B-DNP
systems I-DNP
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
overall O
cvd B-NEG
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
general O
skin B-DNP
health I-DNP
, O
others O

-DOCSTART- O

for O
the O
treatment O
of O
egfr-expressing O
, O
metastatic B-NEG
colorectal I-NEG
carcinoma I-NEG
that O
is O
refractory O
to O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan- O
containing O
chemotherapy O
regimens O
. O

-DOCSTART- O

12-0-tetradecanoyl-phorbol-13-acetate O
isolated O
from O
its O
croton O
oil O
is O
a O
cancerigenic B-NEG
component I-NEG
. O

-DOCSTART- O

general O
weakness B-NEG
and O
weight B-NEU
loss I-NEU

-DOCSTART- O

adult B-NEG
t I-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

epistaxis B-NEG

-DOCSTART- O

polydipsia B-NEG
due O
to O
high B-NEG
fever I-NEG

-DOCSTART- O

ipilimumab O
blocks O
the O
ctla-4 B-NEU
inhibitory I-NEU
signal I-NEU
, O
and O
allows O
the O
cytotoxic B-DNP
t I-DNP
lymphocytes I-DNP
to O
destroy O
the O
cancer B-DNP
cells I-DNP
. O

fotemustine O
alkylates O
guanine O
by O
forming O
chloroethyl O
adducts O
at O
the O
6 O
position O
of O
guanine O
, O
resulting O
in O
n1-guanine O
and O
n3-cytosine O
cross O
linkages O
, O
inhibition O
of O
dna B-NEU
synthesis I-NEU
, O
cell B-DNP
cycle I-DNP
arrest I-DNP
, O
and O
finally O
apoptosis B-NEU
. O

-DOCSTART- O

treatment O
of O
scrotal B-NEG
hernia I-NEG
with O
pain B-NEG
and O
cold B-NEG
extremities I-NEG
, O
dysmenorrhea B-NEG
with O
lower O
abdominal B-NEG
pain I-NEG
and O
cold B-NEG
sensation I-NEG
, O
distending B-NEG
pain I-NEG
in I-NEG
the I-NEG
epigastrium I-NEG
with O
anorexia B-NEG
, O
vomiting B-NEG
and O
diarrhea B-NEG
, O
hydrocele B-NEG
of O
tunica O
vaginalis O
. O

fructus O
foeniculi O
( O
processed O
with O
salt O
) O
: O
scrotal B-NEG
hernia I-NEG
with O
pain B-NEG
and O
cold B-NEG
extremities I-NEG
, O
dysmenorrhea B-NEG
with O
abdominal B-NEG
pain I-NEG
caused O
by O
cold B-NEG
. O

-DOCSTART- O

impetigo B-NEG
; O
pyoderma B-NEG

-DOCSTART- O

to O
stop O
pain B-NEG

-DOCSTART- O

general O
edema B-NEG
with O
abdominal B-NEG
distension I-NEG

-DOCSTART- O

to O
replenish O
blood B-DNP
, O
activate O
circulation B-DNP
and O
regulate O
menstruation B-NEU
. O

-DOCSTART- O

reinforce O
marrow B-DNP

-DOCSTART- O

kidney B-NEG
cancer I-NEG

-DOCSTART- O

baker's B-NEG
cyst I-NEG

-DOCSTART- O

dextromethorphan O
is O
an O
opioid-like O
drug O
that O
binds O
to O
and O
acts O
as O
antagonist O
to O
the O
nmda O
glutamatergic O
receptor O
, O
and O
targets O
the O
serotonin O
reuptake O
pump O
. O

-DOCSTART- O

to O
eliminate O
blood B-NEG
stasis I-NEG
, O
arrest O
bleeding B-NEG
, O
cause O
subsidence O
of O
swelling B-NEG
and O
alleviate O
pain B-NEG
. O

-DOCSTART- O

wind-evil O
attacked O
meridian O
, O
facial B-NEG
paralysis I-NEG
, O
muscle B-NEG
numbness I-NEG
, O
pain B-NEG
of I-NEG
tendons I-NEG
and I-NEG
bone I-NEG
. O

-DOCSTART- O

analysis O
of O
the O
constituents O
in O
the O
rat O
plasma O
after O
oral O
administration O
of O
yin O
chen O
hao O
tang O
by O
uplc/q-tof-ms/ms O
. O

-DOCSTART- O

to O
promote O
blood B-NEU
circulation I-NEU
, O
remove O
blood B-NEG
stasis I-NEG
and O
improve O
microcirculation B-NEU
. O

-DOCSTART- O

distension B-NEG
and O
pain B-NEG
of O
the O
breast O

-DOCSTART- O

astringe O
and O
stop O
bleeding B-NEG

-DOCSTART- O

to O
eliminate O
phlegm B-NEG
and O
relieve O
cough B-NEG
. O

for O
acute O
and O
chronic B-NEG
bronchitis I-NEG
. O

-DOCSTART- O

treatment O
of O
deficiency B-NEG
condition I-NEG
of I-NEG
the I-NEG
kidney I-NEG
marked O
by O
lumbago B-NEG
and O
lack B-NEG
of I-NEG
strength I-NEG
, O
threatened B-NEG
abortion I-NEG
, O
hypertension B-NEG
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
absorption B-NEU
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
motility B-NEU
, O
others O
, O
hemostatic B-NEU
function I-NEU

-DOCSTART- O

counteracting O
the O
arrhythmias B-NEG
induced O
pituitrin B-DNP
in O
rabbits. O
. O

-DOCSTART- O

treatment O
of O
hemoptysis B-NEG
, O
hematemesis B-NEG
, O
epistaxis B-NEG
, O
hematochezia B-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
traumatic B-NEG
bleeding I-NEG
, O
pricking O
pain B-NEG
in O
the O
chest O
and O
abdomen O
, O
traumatic B-NEG
swelling I-NEG
and O
pain B-NEG
. O

-DOCSTART- O

clear O
the O
liver B-DNP

-DOCSTART- O

for O
the O
treatment O
of O
the O
following O
mild-to-moderate B-NEG
infections I-NEG
caused O
by O
susceptible O
strains O
of O
microorganisms O
: O
acute B-NEG
bacterial I-NEG
exacerbations I-NEG
of I-NEG
chronic I-NEG
bronchitis I-NEG
, O
secondary B-NEG
bacterial I-NEG
infection I-NEG
of O
acute B-NEG
bronchitis I-NEG
, O
community B-NEG
- I-NEG
acquired I-NEG
pneumonia I-NEG
, O
pharyngitis B-NEG
/ O
tonsilitis B-NEG
, O
and O
uncomplicated B-NEG
skin I-NEG
and O
skin B-NEG
structure I-NEG
infections I-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
absorption B-NEU
, O
lipid O
profile O
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
motility B-NEU
, O
evacuation B-NEU

-DOCSTART- O

treatment O
of O
stagnation O
of O
qi O
in O
the O
liver B-DNP
and O
stomach B-DNP
manifested O
by O
distending O
pain B-NEG
in O
the O
chest O
and O
hypochodria B-NEG
, O
fullness B-NEG
and O
stuffiness B-NEG
sensation O
in O
the O
epigastrium O
, O
vomiting B-NEG
and O
belching B-NEG
, O
cough B-NEG
with O
copious O
expectoration B-NEG
. O

-DOCSTART- O

for O
clearing O
heat B-NEU
and O
removing O
toxic B-NEG
substances I-NEG

-DOCSTART- O

different O
poisoning B-NEG
, O

-DOCSTART- O

replenish O
essence-marrow O

-DOCSTART- O

dyspnea B-NEG
with O
coughing B-NEG

-DOCSTART- O

damp B-NEG
pi I-NEG
syndrome I-NEG
; O
arthritis B-NEG
due O
to O
dampness B-NEU
; O
damp B-NEG
impediment O
[ O
blockage B-NEG
] O

-DOCSTART- O

atrophic B-NEG
vaginitis I-NEG

-DOCSTART- O

general O
edema B-NEG
with O
abdominal B-NEG
distension I-NEG
of O
body O
and O
extremities O

-DOCSTART- O

tourette B-DNP
syndrome I-DNP

-DOCSTART- O

exogenous O
exogenous B-NEG
febrile I-NEG
disease I-NEG
; O

syndrome B-NEG
of I-NEG
t'aeyang I-NEG
meridian I-NEG
affected O
by O
the O
wind B-NEG

affection O
by O
cold B-NEG
; O

common B-NEG
cold I-NEG

-DOCSTART- O

traumatic B-NEG
brain I-NEG
injury I-NEG

-DOCSTART- O

1 O
inhibiting O
sarcoma180 B-NEG
and O
cervix B-NEG
carcinoma14 I-NEG
in O
mice O
and O
l16 O
cells O
isolated O
from O
human O
liver B-NEG
cancer I-NEG
. O
2 O
. O
promoting O
the O
adrenocortical B-DNP
function I-DNP
in O
mice O
. O
3 O
. O
promoting O
metabolism B-NEU
and O
reticuloendothelial B-DNP
function I-DNP
. O

-DOCSTART- O

tonify O
the O
kidney B-DNP

-DOCSTART- O

abdominal B-NEG
fullness I-NEG
; O
abdominal B-NEG
distension I-NEG

-DOCSTART- O

eldery O
, O
others O

-DOCSTART- O

extemal O
use O
for O
carbuncle B-NEG
, O
pyogenic B-NEG
infection I-NEG
of O
skin O
, O
ulcera B-NEG
tive I-NEG
gingivitis I-NEG
and O
dental B-NEG
caries I-NEG
. O

recently O
, O
also O
for O
carcinoma B-NEG
of I-NEG
breast I-NEG
, I-NEG
cervix I-NEG
and I-NEG
pancreas I-NEG
and O
malignant B-NEG
lymphoma I-NEG

-DOCSTART- O

methyclothiazide O
appears O
to O
block O
the O
active O
reabsorption B-NEU
of I-NEU
chloride I-NEU
and O
possibly O
sodium O
in O
the O
ascending O
loop O
of O
henle O
, O
altering O
electrolyte O
transfer O
in O
the O
proximal O
tubule O
. O

pargyline O
is O
a O
monoamine O
oxidase O
b O
( O
mao-b O
) O
inhibitor O
with O
antihypertensive O
properties O
. O

-DOCSTART- O

after O
binding O
to O
her2 O
on O
the O
tumor B-NEG
cell I-NEG
surface O
, O
trastuzumab O
induces O
an O
antibody-dependent B-NEG
cell-mediated I-NEG
cytotoxicity I-NEG
against O
tumor B-DNP
cells I-DNP
that O
overexpress O
her2 B-DNP
. O

epirubicin O
intercalates O
into O
dna O
and O
interacts O
with O
topoisomerase B-DNP
ii I-DNP
, O
thereby O
inhibiting O
dna B-NEU
replication I-NEU
and O
repair O
and O
rna O
and O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

since O
it O
is O
not O
degraded O
in O
the O
neuromuscular O
junction O
, O
the O
depolarized O
membrance O
remains O
depolarized O
and O
unresponsive O
to O
any O
other O
impulse O
, O
causing O
muscle B-NEG
paralysis I-NEG
. O

-DOCSTART- O

its O
aqueous O
infusion O
inhibits O
the O
growth B-NEG
of I-NEG
skin I-NEG
fungi I-NEG
such O
as O
trichophyton B-NEG
violaceum I-NEG
. O

-DOCSTART- O

as O
gaba B-DNP
is O
an O
inhibitory O
neurotransmitter O
, O
this O
results O
in O
increased O
inhibition O
of O
the O
ascending O
reticular B-DNP
activating I-DNP
system I-DNP
. O

-DOCSTART- O

bald B-NEG
white I-NEG
scalp I-NEG
sore I-NEG
; O
tinea B-NEG
alba I-NEG
; O
white B-NEG
ringworm I-NEG

-DOCSTART- O

regenerate O
blood B-DNP

-DOCSTART- O

to O
control O
the O
essence O
; O

to O
astringe O
the O
intestines B-DNP
and O
stop O
diarrhea B-NEG
; O

to O
decrease O
urination B-NEU

-DOCSTART- O

abdominal B-NEG
pain I-NEG
and O
tenesmus B-NEG

-DOCSTART- O

nfantile O
malnutrition B-NEG
with O
diarrhea B-NEG

-DOCSTART- O

scrofula B-NEG
; O
tuberculosis B-NEG
of I-NEG
the I-NEG
cervical I-NEG
lymphic I-NEG
node I-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
physical B-DNP
performance I-DNP
and O
fitness O
, O
absorption B-NEU
, O
strength O
and O
power O
, O
liver B-DNP
health I-DNP
, O
inflammation B-NEG
, O
liver B-DNP
, O
others O
, O
motility B-NEG

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG

-DOCSTART- O

bleeding B-NEG
due O
to O
blood B-NEU
heat I-NEU
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
knocks O
and O
falls B-NEG
, O
impediment O
pain B-NEG
in O
joints O
. O

-DOCSTART- O

to O
break O
qi O
and O
move O
phlegm B-NEG
, O
harmonize O
stomach B-DNP
and O
disperse O
accumulation B-NEG
. O

-DOCSTART- O

relieve O
clonorchiasis B-NEG
toxin I-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
mood O
, O
quality O
of O
life O
, O
inflammation B-NEG
, O
other B-DNP
system I-DNP
health I-DNP
, O
others O
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

harmonize O
blood B-DNP
vessel I-DNP

-DOCSTART- O

seasonal B-NEG
allergic I-NEG
rhinitis I-NEG

-DOCSTART- O

other O
system B-DNP
health I-DNP
, O
others O

-DOCSTART- O

bleeding B-NEG
before O
defecation B-NEU

-DOCSTART- O

dietnarelated O
cardiovascular B-NEG
disease I-NEG
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
protective B-POS
immunity I-POS
, O
overall O
cvd B-NEG
, O
others O

-DOCSTART- O

to O
relieve O
rheumatic B-NEU
conditions I-NEU
, O
to O
strengthen O
the O
tendons B-DNP
and O
bones B-DNP
, O
and O
to O
arrest O
bleeding B-NEG
. O

-DOCSTART- O

terminate O
lactation B-NEU

-DOCSTART- O

this O
is O
a O
symptom O
with O
stuffiness B-NEG
and O
hot B-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

post B-NEU
delivery I-NEU
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
woman O
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
hypersensitivity B-NEG
, O
motility B-NEU
, O
others O
, O
body B-NEU
weight I-NEU
, O
protective B-NEU
immunity I-NEU
, O
quality O
of O
life O
, O
hemostatic B-NEU
function I-NEU
, O
inflammation B-NEG

-DOCSTART- O

solid B-NEG
tumors I-NEG

-DOCSTART- O

invigorate O
blood B-DNP
and O
move O
stasis B-NEG

-DOCSTART- O

tuberculosis B-NEG

-DOCSTART- O

adult B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG
with O
t(9;11)(p22;q23 O
) O
; O
mllt3-mll O

-DOCSTART- O

to O
warm O
the O
kidney B-DNP
and O
promote O
virility B-DNP
, O
to O
reduce O
modulation O
, O
and O
to O
induce O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

thyroid B-NEG
tumor I-NEG
, O
lump B-DNP
in O
neck O
, O
slight B-NEG
yellow I-NEG
tong I-NEG
, O
heavy B-NEG
pulse I-NEG

-DOCSTART- O

loosen O
the O
chest B-DNP

-DOCSTART- O

difficulty B-NEG
in I-NEG
urination I-NEG

-DOCSTART- O

discharge O
heat B-NEU
and O
cool O
blood B-DNP

-DOCSTART- O

hypertension B-NEG

-DOCSTART- O

red-white O
dysentery B-NEG

-DOCSTART- O

heparin O
binds O
to O
antithrombin B-DNP
iii I-DNP
to O
form O
a O
heparin-antithrombin O
iii O
complex O
. O

-DOCSTART- O

trachoma B-NEG

-DOCSTART- O

for O
activating O
blood B-DNP
and O
modulating O
period O

-DOCSTART- O

urinary B-DNP
system I-DNP
health I-DNP
, O
endocrine O
& O
reproductive B-DNP
systems I-DNP
, O
reproductive B-DNP
systems I-DNP
, O
urinary B-DNP
systems I-DNP
, O
others O
, O
man O

-DOCSTART- O

deficiency B-NEG
and I-NEG
cold I-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
the I-NEG
stomach I-NEG
; O
hypofunction B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
with O
cold B-NEG
manifestations O

-DOCSTART- O

dihydroergotamine O
is O
a O
5-ht1d O
receptor O
agonists O
used O
for O
migraine B-NEG
, O
activation O
of O
5-ht1d O
receptors O
located O
on O
intracranial O
blood O
vessels O
, O
leads O
to O
vasoconstriction B-NEU
; O
activation O
of O
5-ht1d O
receptors O
on O
sensory O
nerve O
endings O
of O
the O
trigeminal B-DNP
system I-DNP
results O
in O
the O
inhibition O
of O
pro-inflammatory B-NEU
neuropeptide I-NEU
release I-NEU
. O

-DOCSTART- O

gastric B-NEG
cancer I-NEG

-DOCSTART- O

epilepsy B-NEG

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
remove O
obstruction B-NEG
from O
the O
channels O
and O
to O
remove O
heat B-NEU
from O
blood B-DNP
and O
cause O
subsidence O
of O
swelling B-NEG
. O

-DOCSTART- O

pneumonia B-NEG
, O
pyothorax B-NEG
, O
sore B-NEG
pharynx I-NEG
, O
oral B-NEG
ulcer I-NEG
, O
vesical B-NEG
calculus I-NEG
, O
swollen O
welling O
abscess B-NEG
. O

-DOCSTART- O

penis B-NEG
ulceration I-NEG

-DOCSTART- O

purge O
heat B-NEU
and O
treat O
gam B-NEG
( O
gan O
) O

-DOCSTART- O

alleviate O
edema B-NEG
and O
relieve O
toxicity B-NEG

-DOCSTART- O

liver B-DNP
health I-DNP
, O
liver B-DNP
, O
others O

-DOCSTART- O

tardive B-NEG
dyskinesia I-NEG
. O

-DOCSTART- O

hemoptysis B-NEG
; O
coughing B-NEG
up I-NEG
blood I-NEG

-DOCSTART- O

childhood B-NEG
acute I-NEG
monoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

for O
the O
treatment O
of O
chronic B-NEG
gouty I-NEG
arthritis I-NEG
when O
complicated O
by O
frequent O
, O
recurrent O
acute O
attacks O
of O
gout B-NEG
. O

-DOCSTART- O

wind-cold B-NEG
common O
cold B-NEG
, O
summerheat O
damage O
, O
vomiting B-NEG
diarrhea B-NEG
with O
abdominal B-NEG
pain I-NEG
, O
dribbling O
pain B-NEG
of I-NEG
urination I-NEG
, O
wind-damp B-NEG
impediment O
pain B-NEG
, O
cough B-NEG
and O
asthma B-NEG
, O
bronchial B-NEG
asthma I-NEG
. O

-DOCSTART- O

apical B-NEG
ballooning I-NEG
syndrome I-NEG

-DOCSTART- O

aids B-NEG
with O
tuberculosis B-NEG

-DOCSTART- O

lysophospholipids O
have O
been O
found O
to O
mediate O
the O
activity O
of O
this O
drug O
. O

-DOCSTART- O

illness B-NEG
that O
occurs O
on O
teeth O

-DOCSTART- O

obesity B-NEG

-DOCSTART- O

diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
hemostatic B-DNP
function I-DNP
, O
overall O
cvd B-NEG
, O
other O
system B-DNP
health I-DNP
, O
others O

-DOCSTART- O

to O
transform O
water O
and O
reduce O
edema B-NEG

-DOCSTART- O

treatment O
of O
deficiency B-NEG
syndrome I-NEG
of O
the O
kidney O
marked O
by O
back B-NEG
pain I-NEG
, O
tinnitus B-NEG
, O
impairment B-NEG
of I-NEG
hearing I-NEG
and O
looseness B-NEG
of I-NEG
teeth I-NEG
, O
traumatic B-NEG
injury I-NEG
, O
bone B-NEG
fracture I-NEG
, O
external O
use O
for O
alopecia B-NEG
areata I-NEG
, O
vitiligo B-NEG
. O

-DOCSTART- O

1 O
for O
cases O
with O
paralysis B-NEG
of I-NEG
lower I-NEG
limbs I-NEG
and O
feverish B-NEG
sensation I-NEG
of O
joints O
, O
which O
are O
attritbutive O
to O
deficiency O
of O
kidney-yin O
, O
omit O
menthae O
, O
ziziphi O
jujubae O
and O
add O
carapax O
trionycis O
and O
ramulus O
mori O
to O
benefit O
kidney-yin O
and O
eliminate O
asthenic B-NEG
heat I-NEG
. O

-DOCSTART- O

to O
dispel O
wind-heat B-NEG
, O
to O
promote O
eruption B-NEG
, O
and O
to O
cause O
diuresis B-NEU
. O

-DOCSTART- O

cold B-NEG
pain I-NEG
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-NEG
, O
vomiting B-NEG
nausea B-NEG
, O
diarrhea B-NEG
, O
cold B-NEG
mounting O
, O
dysmenorrhea B-NEG
, O
urethral B-NEG
stone I-NEG
, O
swelling B-NEG
pain I-NEG
of O
sore O
and O
boil O
. O

-DOCSTART- O

to O
warm O
the O
spleen B-DNP
and O
stomach B-DNP
, O
to O
regulate O
the O
adverse O
flow O
of O
the O
stomach O
qi O
, O
and O
to O
restore O
the O
kidney O
yang O
. O

-DOCSTART- O

wind-damp B-NEG
impediment O
pain B-NEG
, O
toothache B-NEG
, O
knee B-NEG
joint I-NEG
pain I-NEG
, O
scab B-NEG
and O
lichen B-NEG
, O
eczema B-NEG
, O
trichomoniasis B-NEG
, O
scalds B-NEG
, O
wound B-NEG
, O
enduring B-NEG
sores I-NEG
, O
bilharziosis B-NEG
, O
cough B-NEG
and O
asthma B-NEG
. O

-DOCSTART- O

appears O
to O
preferentially O
bind O
to O
mycobacterial B-DNP
dna I-DNP
leading O
to O
disruption B-NEU
of I-NEU
the I-NEU
cell I-NEU
cycle I-NEU
and O
eventually O
kills O
the O
bacterium B-NEG
. O

-DOCSTART- O

diabetics B-NEG
due O
to O
interior O
heat B-NEU

-DOCSTART- O

stage O
iv O
adult B-NEG
lymphoblastic I-NEG
lymphoma I-NEG

-DOCSTART- O

investigated O
for O
use O
/ O
treatment O
in O
colorectal B-NEG
cancer I-NEG
. O

-DOCSTART- O

tinnitus B-NEG

-DOCSTART- O

acute B-NEG
gastroenteritis I-NEG
in O
adult O
travelers O

-DOCSTART- O

to O
purge O
pathogenic B-NEG
fire I-NEG
and O
lessen O
virulence O
of O
any O
pathogenic O
organism O
. O

-DOCSTART- O

night B-NEG
blindness I-NEG
. O
visual B-NEG
disorder I-NEG
at O
night O
. O

-DOCSTART- O

inability B-NEG
to O
turn O
over O

-DOCSTART- O

gout B-NEG

-DOCSTART- O

to O
dispel O
wind B-NEG
, O
to O
counteract O
toxicity B-NEG
, O
to O
kill O
parasites B-NEG
, O
and O
to O
relieve O
itching B-NEG
. O

-DOCSTART- O

cholelithiasis B-NEG
, O
infection B-NEG
of O
the O
biliary O
tract O
, O
cholecystitis B-NEG
. O

-DOCSTART- O

for O
promoting O
diuresis B-NEU
and O
desolving O
inflammation B-NEG
. O

-DOCSTART- O

treatment O
of O
anorexia B-NEG
, O
lassitude B-NEG
and O
loose B-NEG
stools I-NEG
in O
deficiency O
syndrome O
of O
the O
spleen O
, O
hysteria O
in O
women O
. O

-DOCSTART- O

retention B-NEG
of I-NEG
milk I-NEG
in O
babies O
, O
profuse O
sputum B-NEG
and O
infantile B-NEG
convulsions I-NEG
. O

-DOCSTART- O

to O
break O
blood B-DNP
and O
desolve O
stagnation B-NEG
; O
to O
benefit O
qi O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
protective O
immunity B-NEU

-DOCSTART- O

carcinoma B-NEG
, I-NEG
renal I-NEG
cell I-NEG

-DOCSTART- O

bofutsushosan O
( O
bof O
) O
, O
a O
traditional O
chinese O
formulation O
( O
kampo O
formulation O
in O
japanese O
) O
, O
is O
widely O
used O
for O
patients O
with O
obesity B-NEG
and O
hyperlipidemia B-NEG
resulting O
from O
long-term O
inappropriate O
lifestyles O
. O

since O
atherosclerosis B-NEG
, O
a O
lifestyle-related B-NEG
disease I-NEG
, O
is O
accompanied O
by O
an O
abnormal O
accumulation O
of O
vascular B-DNP
smooth I-DNP
muscle I-DNP
cells I-DNP
( O
vsmcs B-DNP
) O
in O
the O
intimal O
area O
of O
the O
artery O
, O
we O
investigated O
the O
preventive O
effect O
of O
bof O
on O
intimal O
thickening O
. O

oral O
administration O
of O
bof O
extracts O
3 O
d O
before O
and O
7 O
d O
after O
balloon O
endothelial O
denudation O
dose O
dependently O
suppressed O
the O
intimal O
thickening O
and O
proliferation O
of O
vsmcs B-DNP
in O
the O
intimal O
area O
in O
rat O
carotid O
arteries O
. O

this O
model O
has O
a O
similar O
pathologic O
process O
to O
atherosclerosis B-NEG
and O
is O
considered O
to O
be O
an O
accelerated O
atherosclerosis B-NEG
model O
. O

bof O
extract O
also O
dose O
dependently O
inhibited O
the O
migration O
of O
cultured O
vsmcs B-DNP
. O

bof O
extract O
suppressed O
serum B-DNP
lipid I-DNP
levels I-DNP
, O
which O
are O
a O
major O
risk O
factor O
for O
atherosclerosis B-NEG
. O

these O
findings O
clarified O
the O
usefulness O
of O
bof O
in O
cardiovascular O
risk-reduction O
therapy O
. O

-DOCSTART- O

vomiting B-NEG
due O
to O
heat B-NEU
in O
the O
stomach O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
body B-NEU
weight I-NEU
regulation O
, O
fat B-NEU
storage I-NEU
and O
oxidation O

-DOCSTART- O

treatment O
of O
impotence B-NEG
and O
seminal O
emission O
, O
mass B-NEG
in O
the O
abdomen B-DNP
, O
scrofula B-NEG
, O
traumatic B-NEG
injuries I-NEG
, O
external O
use O
for O
carbuncles B-NEG
and O
boils O
. O

-DOCSTART- O

cystic B-NEG
fibrosis I-NEG

-DOCSTART- O

the O
anti-inflammatory B-POS
effects I-POS
of O
diclofenac O
are O
believed O
to O
be O
due O
to O
inhibition O
of O
both O
leukocyte B-NEU
migration I-NEU
and O
the O
enzyme B-DNP
cylooxygenase I-DNP
( O
cox-1 B-DNP
and O
cox-2 B-DNP
) O
, O
leading O
to O
the O
peripheral O
inhibition O
of O
prostaglandin B-NEU
synthesis I-NEU
. O

-DOCSTART- O

sr O
58611 O
has O
positive O
chronotropic O
effect O
which O
is O
mainly O
of O
peripheral O
origin O
and O
can O
be O
attributed O
to O
a O
baroreceptor-mediated O
reflex O
due O
to O
the O
beta3-adrenoceptor O
mediated O
vasodilation O
with O
an O
increase O
in O
sympathetic O
tone O
and O
a O
reduction O
in O
vagal O
tone O
to O
the O
heart O
. O

-DOCSTART- O

a O
symptom B-NEG
of I-NEG
perspiration I-NEG
. O

-DOCSTART- O

sores B-NEG
with O
swelling B-NEG

-DOCSTART- O

promote O
all O
vessels B-DNP

-DOCSTART- O

berberine O
inhibits O
the O
cellular O
growht O
of O
ascitic B-NEG
cancer I-NEG
and O
lymphoma B-NEG
. O

-DOCSTART- O

hepatitis B-NEG
b I-NEG
virus I-NEG

-DOCSTART- O

to O
activate O
blood B-NEU
circulation I-NEU
, O
eliminate O
stasis B-NEG
, O
promote O
the O
subsidence B-POS
of I-POS
swelling I-POS
and O
alleviate O
pain B-NEG
. O

-DOCSTART- O

investigated O
for O
use O
/ O
treatment O
in O
liver B-NEG
cancer I-NEG
. O

-DOCSTART- O

croton O
seed O
( O
badou O
) O
is O
used O
with O
medicated O
leaven O
( O
shenqu O
) O
, O
arisaema O
tuber O
with O
bile O
( O
dannanxing O
) O
and O
cinnabar O
( O
zhusha O
) O
in O
the O
formula O
baochi O
san O
. O

-DOCSTART- O

to O
enrich O
yin O
and O
supplement O
kidney B-DNP
, O
clear O
lung B-DNP
and O
moisten O
dryness B-NEU
, O
resolve O
toxin B-NEG
and O
disperse O
swelling B-NEG
. O

-DOCSTART- O

for O
the O
treatment O
of O
tuberculosis B-NEG
and O
tuberculosis-related O
mycobacterial B-NEG
infections I-NEG
. O

-DOCSTART- O

disperse O
accumulation B-NEU
and O
relieve O
pain B-NEG

-DOCSTART- O

childhood B-NEG
b I-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

1 O
for O
cases O
of O
apoplexy B-NEG
with O
sudden O
onset O
of O
face B-NEG
distortion I-NEG
, O
dysphasia B-NEG
, O
numbness B-NEG
of I-NEG
the I-NEG
limbs I-NEG
, O
or O
even O
hemiplegia B-NEG
, O
rigidity B-NEG
of I-NEG
the I-NEG
extremities I-NEG
, O
white B-NEG
and I-NEG
greasy I-NEG
fur I-NEG
on O
the O
tongue O
, O
floating O
and O
smooth O
pulse B-NEU
, O
which O
are O
attributive O
to O
attack O
of O
wind-phlegm B-NEG
to O
the O

-DOCSTART- O

the O
four O
limbs O
are O
swollen B-NEG
and O
they O
feel O
painful O

-DOCSTART- O

all O
kinds O
of O
pain B-NEG
due O
to O
disorder O
of O
gi O

-DOCSTART- O

to O
expel O
wind B-NEG
from O
the O
body O
surface O
, O
clear O
away O
heat B-NEU
and O
promote O
bowel B-NEU
movement I-NEU
. O

-DOCSTART- O

clear O
the O
lung B-DNP
and O
discharge O
fire B-NEU

-DOCSTART- O

close O
sores B-NEG

-DOCSTART- O

to O
arrest O
discharges O
, O
promote O
healing O
of O
wounds B-NEG
and O
tissue B-POS
regeneration I-POS
, O
and O
alleviate O
pain B-NEG
. O

-DOCSTART- O

nasal B-NEG
obstruction I-NEG
and O
the O
deep B-NEG
and I-NEG
harsh I-NEG
voice I-NEG

-DOCSTART- O

effects O
of O
hachimijiogan O
on O
dopamine O
, O
serotonin O
and O
vasoactive O
intestinal O
peptide O
in O
plasma O
and O
hypothalamus O
in O
sulpiride-induced O
hyperprolactinemic O
rats O
. O

-DOCSTART- O

investigated O
for O
use/treatment O
in O
cancer/tumors B-NEG
( O
unspecified O
) O
. O

-DOCSTART- O

intelligence O
, O
mental B-NEG
state I-NEG
and O
performance O

-DOCSTART- O

( O
1 O
) O
morbid B-NEG
leukorrhea I-NEG
; O
( O
2 O
) O
gynecological B-NEG
diseases I-NEG
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O

1)a O
disease O
due O
to O
reducing O
wind B-NEG
pathogen O
of O
the O
heart B-DNP
2) O
mental B-NEG
problem I-NEG
due O
to O
disorder O
of O
opening O
the O
heart O
by O
phlegm B-NEG
. O

-DOCSTART- O

we O
reported O
previously O
that O
cholesterol O
feeding O
induced O
an O
increase O
in O
hepatic B-NEU
secretion I-NEU
of O
vldl B-DNP
and O
a O
decrease O
in O
that O
of O
ldl B-DNP
, O
especially O
ldl-apo B-DNP
b100 I-DNP
, O
using O
monkey O
liver O
perfusion O
. O

in O
the O
present O
study O
we O
conducted O
rat O
liver O
perfusion O
using O
the O
hmg O
co O
a O
reductase O
inhibitor O
( O
cs-514 O
) O
and O
kampo O
medicine O
( O
daisaikoto O
) O
to O
elucidate O
the O
mechanism O
of O
the O
effect O
of O
dietary O
cholesterol O
on O
hepatic B-NEU
lipoprotein I-NEU
and O
apolipoprotein B-NEU
synthesis I-NEU
. O

although O
the O
secretion B-NEU
of I-NEU
vldl I-NEU
was O
increased O
by O
cholesterol O
feeding O
, O
that O
of O
ldl B-DNP
and O
especially O
of O
apo B-DNP
b100 I-DNP
of I-DNP
ldl I-DNP
were O
markedly O
decreased O
, O
and O
apo B-DNP
e I-DNP
of I-DNP
the I-DNP
ldl I-DNP
was O
increased O
as O
observed O
in O
the O
monkey O
liver O
perfusion O
experiments O
. O

the O
effect O
of O
cs-514 O
was O
clearly O
different O
from O
the O
effect O
of O
dietary B-DNP
cholesterol I-DNP
in O
spite O
of O
the O
suppression O
of O
hepatic O
cholesterogenesis O
which O
was O
comparable O
to O
that O
induced O
by O
cholesterol O
feeding O
, O
suggesting O
that O
the O
decrease O
in O
secretion B-NEU
of I-NEU
ldl-apo I-NEU
b100 I-NEU
induced O
by O
the O
dietary O
cholesterol O
is O
not O
due O
to O
suppressed O
cholesterogenesis O
. O

daisaikoto O
, O
which O
was O
added O
to O
the O
diet O
together O
with O
cholesterol B-DNP
, O
diminished O
the O
effects O
of O
dietary B-DNP
cholesterol I-DNP
on O
the O
plasma B-NEU
and I-NEU
hepatic I-NEU
cholesterol I-NEU
levels I-NEU
. O

when O
the O
liver O
treated O
with O
daisaikoto O
was O
perfused O
, O
the O
effect O
of O
dietary B-DNP
cholesterol I-DNP
on O
the O
production O
of O
lipoprotein B-DNP
and O
apolipoprotein B-DNP
was O
markedly O
diminished O
. O

this O
evidence O
indicates O
that O
the O
decrease O
in O
ldl-apo B-DNP
b100 I-DNP
and O
the O
increase O
in O
apo B-DNP
e I-DNP
were O
mediated O
by O
the O
hepatic B-NEU
cholesterol I-NEU
level I-NEU
. O

-DOCSTART- O

wind-damp B-NEG
impediment O
pain B-NEG
, O
pain B-NEG
in O
lumbus O
and O
legs O
, O
numbness B-NEG
of O
limbs O
, O
sprain O
from O
knocks O
and O
falls O
, O
sequel O
of O
poliomyelitis B-NEG
. O

-DOCSTART- O

chronic B-NEG
hepatitis I-NEG
c I-NEG

-DOCSTART- O

treatment O
of O
palpitation B-NEG
and O
insomnia B-NEG
, O
convulsion B-NEG
, O
epilepsy B-NEG
, O
nebula B-NEG
, O
skin B-NEG
ulcerations I-NEG
difficult O
to O
heal O
. O

-DOCSTART- O

this O
is O
having O
a O
lot O
of O
phlegm B-NEG
due O
to O
carbuncle B-NEG
and O
cellulites B-NEG
. O

-DOCSTART- O

deficiency O
of O
the O
yang O
of O
the O
spleen B-DNP
and O
the O
kidney B-DNP

-DOCSTART- O

blood B-NEU
activation I-NEU
and O
injury B-NEG
healing I-NEG

-DOCSTART- O

as O
an O
anthelmintic O
for O
tapeworm O
and O
hookworm O
, O
more O
effective O
than O
that O
of O
tetrachloroethylene O
. O

-DOCSTART- O

to O
dissipate O
cold B-NEG
and O
relieve O
pain B-NEG
, O
rectify O
qi O
and O
regulate O
center O
. O

-DOCSTART- O

white B-NEG
vaginal I-NEG
discharge I-NEG
; O
leukorrhea B-NEG

-DOCSTART- O

replenish O
gi O
( O
qi O
) O
and O
invigorate O
the O
spleen B-DNP

-DOCSTART- O

strengthen O
the O
teeth B-DNP

-DOCSTART- O

dry B-NEG
cough I-NEG
due O
to O
lung-heat B-NEU

-DOCSTART- O

dissipate O
stasis B-NEG

-DOCSTART- O

clear O
the O
heart B-DNP
and O
relieve O
vexation B-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
body O
weight O
regulation O
, O
woman O
, O
reproductive B-DNP
systems I-DNP
, O
diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
endocrine O
& O
reproductive B-DNP
systems I-DNP
, O
intelligence O
, O
dermatological B-DNP
systems I-DNP
health O
, O
eldery O
, O
overall O
cvd O
, O
mimmuietabolic O
rate/energy O
expenditure O
, O
general O
woman O
, O
general O
skin B-DNP
health I-DNP
, O
menopausal B-DNP
woman I-DNP
, O
others O
, O
hemostatic B-DNP
function I-DNP
, O
mental B-DNP
state I-DNP
and O
performance O
, O
man O

-DOCSTART- O

to O
eliminate O
mass B-NEG
, O
reduce O
fullness B-NEG
, O
strengthen O
spleen B-DNP
and O
regulate O
stomach B-DNP
. O

-DOCSTART- O

asthma B-NEG
, O
chronic B-NEG
bronchitis I-NEG
, O
stomachache B-NEG
, O
wind-damp B-NEG
pain I-NEG
, O
scrofula B-NEG
, O
cold B-NEG
suppurative I-NEG
sore I-NEG
, O
knocks O
and O
falls O
. O

-DOCSTART- O

this O
is O
a O
syndrome O
with O
a O
pain B-NEG
, I-NEG
bloat I-NEG
, I-NEG
and I-NEG
fullness I-NEG
in I-NEG
abdominal I-NEG
region I-NEG
. O

-DOCSTART- O

wind B-NEG
syndrome I-NEG

-DOCSTART- O

severe B-NEG
palpitation I-NEG
; O

continuous O
violent O
palpitation B-NEG

-DOCSTART- O

haemostasis B-POS

-DOCSTART- O

diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
lipid O
profile O
, O
quality O
of O
life O
, O
overall O
cvd B-NEG
, O
others O

-DOCSTART- O

saireito O
(a O
chinese O
herbal O
drug O
) O
decreases O
inhibitory O
effect O
of O
prednisolone O
and O
accelerates O
the O
recovery O
of O
rat O
hypothalamic-pituitary-adrenal O
axis O
. O

-DOCSTART- O

endometriosis B-NEG

-DOCSTART- O

cisplatin O
binds O
to O
nucleophilic O
groups O
such O
as O
gc-rich O
sites O
in O
dna O
, O
inducing O
intrastrand B-DNP
and I-DNP
interstrand I-DNP
dna I-DNP
cross-links I-DNP
, O
as O
well O
as O
dna-protein B-DNP
cross-links I-DNP
. O

-DOCSTART- O

parasite O
worms B-NEG

-DOCSTART- O

objective O
: O
the O
purpose O
of O
this O
clinical O
trial O
was O
to O
assess O
the O
efficacy O
of O
goshuyuto O
, O
a O
typical O
kampo O
formula O
, O
in O
preventing O
episodes O
of O
headache B-NEG
in O
chronic B-NEG
headache I-NEG
patients O
. O

research O
design O
and O
methods O
: O
because O
the O
treatment O
target O
of O
a O
kampo O
formula O
is O
decided O
on O
a O
basis O
different O
to O
that O
of O
western O
medicine O
, O
we O
first O
selected O
patients O
belonging O
to O
a O
subgroup O
that O
responded O
to O
goshuyuto O
before O
conducting O
the O
usual O
randomized O
controlled O
trial O
. O

during O
stage O
1, O
the O
subjects O
were O
instructed O
to O
orally O
consume O
goshuyuto O
for O
4 O
weeks O
. O

only O
those O
subjects O
judged O
as O
responders O
advanced O
to O
stage O
2, O
during O
which O
a O
double-blind O
, O
randomized O
, O
placebo-controlled O
study O
was O
conducted O
. O

the O
subjects O
consumed O
the O
same O
dose O
of O
goshuyuto O
or O
placebo O
for O
12 O
weeks O
. O

results O
: O
of O
the O
91 O
subjects O
enrolled O
in O
stage O
1, O
60 O
were O
judged O
as O
responders O
. O

of O
these O
, O
53 O
advanced O
to O
stage O
2; O
28 O
were O
assigned O
to O
the O
goshuyuto O
group O
and O
25 O
to O
the O
placebo O
group O
. O

the O
decrease O
in O
the O
number O
of O
days O
on O
which O
headache B-NEG
episodes O
occurred O
was O
greater O
in O
the O
goshuyuto O
group O
than O
in O
the O
placebo O
group O
( O
2.6 O
+/- O
3.7 O
vs O
. O
0.3 O
+/- O
4 O
days O
, O
p O
= O
0.034 O
) O
; O
no O
difference O
was O
observed O
with O
regard O
to O
the O
reduction O
in O
the O
frequency O
of O
consuming O
reliever O
medications O
( O
2.2 O
+/- O
4 O
vs O
. O
1.4 O
+/- O
8.2 O
, O
p O
= O
0.672 O
) O
. O

improvement O
in O
the O
associated O
symptoms O
was O
observed O
in O
more O
than O
0.5 O
of O
the O
subjects O
in O
the O
goshuyuto O
group O
. O

conclusion O
: O
goshuyuto O
is O
useful O
in O
preventing O
episodes O
of O
headache B-NEG
in O
chronic B-NEG
headache I-NEG
patients O
. O

responder-limited O
design O
is O
a O
candidate O
for O
evaluating O
kampo O
medicine O
. O

-DOCSTART- O

relief O
of O
mild O
to O
moderate O
pain B-NEG
of O
acte B-NEG
musculoskeletal I-NEG
disorders I-NEG
. O

-DOCSTART- O

hepatocellular B-NEG
carcinoma I-NEG

-DOCSTART- O

phlegm B-NEG
syndrome I-NEG
induced O
by O
fright O

-DOCSTART- O

fever B-NEG
with O
affection O
by O
cold B-NEG

-DOCSTART- O

septic B-NEG
shock I-NEG

-DOCSTART- O

others O

-DOCSTART- O

intravenous O
injection O
or O
oral O
administration O
of O
berberine O
exerts O
a O
hypotensive B-NEU
effect I-NEU
on O
experimental O
animals O
. O

-DOCSTART- O

lower O
the O
level B-NEU
of I-NEU
serum I-NEU
cholesterol I-NEU
and O
( O
b)-lipoprotein O
in O
experimental O
animals O
with O
hyperlipidemia. B-NEG
. O

-DOCSTART- O

chloramphenicol O
reversibly O
binds O
to O
the O
l16 B-DNP
protein I-DNP
of O
the O
50s B-DNP
subunit I-DNP
of O
bacterial O
ribosomes O
, O
thus O
inhibits O
protein B-NEU
synthesis I-NEU
. O

desoxyribonuclease O
is O
a O
biosynthetic O
form O
of O
human O
dnase B-DNP
i I-DNP
, O
which O
is O
involved O
in O
endonucleolytic O
cleavage O
of O
extracellular B-DNP
dna I-DNP
to O
5-phosphodinucleotide O
and O
5-phosphooligonucleotide O
end O
products O
. O

fibrinolysin O
attacks O
and O
inactivates O
fibrin B-DNP
molecules I-DNP
occurring O
in O
undesirable O
exudates O
on O
the O
surface O
of O
the O
human O
body O
and O
on O
human B-DNP
mucosa I-DNP
. O

-DOCSTART- O

symptoms O
of O
menopause B-NEG
. O

-DOCSTART- O

ritonavir O
inhibits O
the O
hiv B-DNP
viral I-DNP
proteinase I-DNP
enzyme I-DNP
which O
prevents O
cleavage B-NEU
of I-NEU
the I-NEU
gag-pol I-NEU
polyprotein I-NEU
, O
resulting O
in O
noninfectious O
, O
immature O
viral B-NEG
particles I-NEG
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
absorption O
, O
lipid O
profile O
, O
motility O
, O
evacuation O

-DOCSTART- O

restrain O
aconiti B-NEG
tuber I-NEG

-DOCSTART- O

( O
1 O
) O
hemorrhoids B-NEG
( O
2 O
) O
polyp B-NEG

-DOCSTART- O

used O
principally O
as O
an O
analgesic O
. O

-DOCSTART- O

acute B-NEG
arthritis I-NEG
; O
gout B-NEG

-DOCSTART- O

1 O
morellic B-NEU
acid I-NEU
, O
one O
of O
its O
components O
, O
inhibits O
ehrljch-ascites B-NEG
tumour I-NEG
and O
sarcoma180 B-NEG
. O

2 O
inhibiting O
bel-7402 B-DNP
species I-DNP
of O
hepatic B-NEG
cancer I-NEG
cells I-NEG
and O
hela B-DNP
cells I-DNP
in O
vitro O
. O

3 O
increasing O
white B-DNP
blood I-DNP
cells I-DNP
and O
promoting O
its O
phagocytosis B-NEU
during O
the O
treatment O
of O
cancer B-NEG
in O
experimental O
animals O

-DOCSTART- O

blood B-NEG
vomiting I-NEG

-DOCSTART- O

abdominal B-NEG
pain I-NEG

-DOCSTART- O

inecalcitol O
is O
an O
analogue O
of O
calcitriol O
, O
the O
naturally O
active O
metabolite O
of O
vitamin O
d O
. O

calcitriol O
and O
their O
analogues O
activate O
the O
vitamin O
d O
receptor O
( O
vdr O
) O
. O

vitamin O
d O
has O
a O
major O
role O
in O
regulating O
calcium B-NEU
absorption I-NEU
from O
the O
gut O
, O
storage O
in O
mineral O
form O
in O
the O
bones O
, O
and O
excretion B-NEU
by O
the O
kidney O
and O
effectively O
prevents O
rickets B-NEG
in O
infants O
. O

vitamin O
d O
and O
calcitriol O
can O
cause O
hypercalcemia B-NEG
at O
high O
or O
frequently O
repeated O
doses O
; O
in O
turn O
, O
hypercalcemia B-NEG
can O
cause O
kidney B-NEG
toxicity I-NEG
by O
accumulation O
of O
calcium-containing O
micro-crystals O
and O
heart B-NEG
and I-NEG
muscle I-NEG
dysfunction I-NEG
by O
impairing O
contractions O
. O

the O
mechanism O
of O
action O
is O
currently O
unknown O
, O
but O
it O
is O
proposed O
that O
inecalcitol O
exerts O
its O
superagonistic O
action O
through O
enhancing O
coactivator O
binding O
by O
the O
vdr O
. O

-DOCSTART- O

the O
steaming B-NEG
of I-NEG
bone I-NEG
and O
tidal O
fever B-NEG

-DOCSTART- O

for O
cooling O
blood B-DNP
and O
stopping O
bleeding B-NEG

-DOCSTART- O

lupus B-NEG
nephritis I-NEG

-DOCSTART- O

carpal B-NEG
tunnel I-NEG
syndrome I-NEG

-DOCSTART- O

deficiency B-NEG
and I-NEG
chills I-NEG
of I-NEG
uterus I-NEG

-DOCSTART- O

normalize O
gi O
( O
qi O
) O
and O
relieve O
pain B-NEG

-DOCSTART- O

pregnancy B-NEU
outcome O

-DOCSTART- O

the O
stagnation B-NEG
of O
gi O
a O
morbid B-NEG
condition I-NEG
due O
to O
impeded B-NEG
circulation I-NEG
of O
gi O
that O
leads O
to O
a O
local B-NEG
obstruction I-NEG
, O
manifested O
by O
distension B-NEU
or O
pain B-NEG
in O
the O
affected O
part O
. O

-DOCSTART- O

1 O
an O
active O
component O
, O
anisaldehyde O
, O
increases O
the O
effect O
of O
streptomycin B-DNP
on O
experimental O
tuberculosis B-NEG
in O
mice O
. O
accelerating O
gastrointestinal B-NEU
peristalsis I-NEU
, O
and O
promoting O
eliminating B-NEU
of I-NEU
flatus I-NEU
. O
eliminating O
phlegm B-NEG
. O

-DOCSTART- O

cough B-NEG
and O
shortness B-NEG
of I-NEG
breath I-NEG
, O
wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
itchy B-NEG
skin I-NEG
, O
innominate O
toxin B-NEG
swelling I-NEG
. O

-DOCSTART- O

huperzine O
b O
has O
been O
found O
to O
be O
an O
inhibitor O
of O
the O
enzyme B-DNP
acetylcholinesterase I-DNP
. O

this O
is O
the O
same O
mechanism O
of O
action O
of O
pharmaceutical O
drugs O
such O
as O
galantamine O
and O
donepezil O
used O
to O
treat O
alzheimer's B-NEG
disease I-NEG
. O

-DOCSTART- O

dispel O
the O
effects O
of O
alcohol O

-DOCSTART- O

progestins B-DNP
diffuse O
freely O
into O
target O
cells O
and O
bind O
to O
the O
progesterone O
receptor O
. O

once O
bound O
to O
the O
receptor O
, O
progestins B-DNP
slow O
the O
frequency O
of O
release O
of O
gonadotropin B-DNP
releasing I-DNP
hormone I-DNP
( O
gnrh B-DNP
) O
from O
the O
hypothalamus O
and O
blunt O
the O
pre-ovulatory O
lh B-DNP
surge O
. O

ethinyl O
estradiol O
is O
a O
synthetic O
derivative O
of O
the O
natural O
estrogen B-DNP
estradiol I-DNP
. O

estrogens B-DNP
increase O
the O
hepatic B-NEU
synthesis I-NEU
of I-NEU
sex I-NEU
hormone I-NEU
binding I-NEU
globulin I-NEU
, O
thyroid-binding B-DNP
globulin I-DNP
, O
and O
other O
serum B-DNP
proteins I-DNP
and O
suppress O
follicle-stimulating B-DNP
hormone I-DNP
from O
the O
anterior O
pituitary O
. O

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEU
, O
soothe O
sinews B-DNP
and O
free O
network O
vessels B-DNP
. O

-DOCSTART- O

to O
benefit O
vital O
energy O
, O
lift O
yang O
and O
activate O
vital O
energy O
. O

-DOCSTART- O

aversion B-NEG
to I-NEG
heat I-NEG
during O
fever B-NEG

-DOCSTART- O

excessive O
repair O

-DOCSTART- O

chronic B-NEG
heart I-NEG
failure I-NEG

-DOCSTART- O

heat B-NEG
sensation I-NEG
in O
the O
chest O
, O
palms O
and O
soles O

-DOCSTART- O

disharmony B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
the I-NEG
stomach I-NEG
a O
morbid B-NEG
condition I-NEG
marked O
by O
poor B-NEG
appetite I-NEG
, O
loose B-NEG
stools I-NEG
and O
other O
symptoms O
of O
indigestion B-NEG
. O

-DOCSTART- O

tinea B-NEG
favosa I-NEG
; O
mouth-corner B-NEG
ulcer I-NEG

-DOCSTART- O

pancreatic B-NEG
cancer I-NEG

-DOCSTART- O

treatment O
of O
protracted O
diarrhea B-NEG
due O
to O
hypofunction B-NEG
of O
the O
spleen O
, O
seminal B-NEU
emission I-NEU
, O
leukorrhagia B-NEG
, O
palpitation B-NEG
, O
insomnia B-NEG
. O

-DOCSTART- O

a O
symptom O
of O
pruritis B-NEG
due O
to O
smallpox B-NEG

-DOCSTART- O

move O
wind B-NEG
gi(qi O
) O

-DOCSTART- O

the O
ingredients O
of O
this O
prescription O
are O
all O
bitter O
in O
taste O
and O
cold O
in O
nature O
, O
so O
that O
the O
fire O
purging O
and O
detoxifying O
effect O
is O
very O
strong O
. O

since O
the O
bitter-cold O
drugs O
are O
liable O
to O
damage O
yin-energy O
, O
the O
prescription O
is O
only O
used O
for O
cases O
when O
the O

-DOCSTART- O

alleviate O
edema B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

obesity B-NEG
and O
obesity-related B-NEG
medical O
conditions O

-DOCSTART- O

lopinavir O
inhibits O
the O
hiv B-DNP
viral I-DNP
protease I-DNP
enzyme I-DNP
. O

-DOCSTART- O

inhibiting O
the O
excessive O
secretion B-NEU
of I-NEU
bronchi I-NEU
and I-NEU
uterus I-NEU
. O

-DOCSTART- O

this O
study O
was O
conducted O
to O
evaluate O
the O
importance O
of O
intraoperative O
smear O
examinations O
for O
the O
final O
diagnosis O
of O
intracerebral O
stereotaxic O
procedures O
. O

125 O
consecutive O
patients O
with O
suspect O
intracerebral B-NEG
lesions I-NEG
underwent O
stereotaxic O
frame-based O
biopsies O
after O
acquisition O
of O
computer O
tomographic O
and O
magnetic O
resonance O
images O
. O

after O
secondary O
image O
processing O
, O
including O
multiplanar O
visualization O
of O
the O
target O
region O
and O
target O
definition O
, O
a O
serial O
biopsy O
was O
realized O
using O
an O
aspiration O
sedan O
needle O
. O

biopsy O
taking O
was O
repeated O
as O
long O
as O
pathological O
tissue O
samples O
were O
obtained O
according O
to O
the O
visual O
impression O
of O
the O
neurosurgeon O
( O
group O
i) O
or O
to O
the O
first O
neuropathological O
result O
of O
a O
smear O
examination O
( O
group O
ii O
) O
. O

retrospective O
analysis O
of O
all O
cases O
showed O
that O
intraoperative O
microscopic O
diagnostics O
could O
improve O
the O
conditions O
for O
a O
definitive O
neuropathological O
diagnosis O
from O
0.918 O
( O
56/61 O
patients O
, O
group O
i) O
to O
0.969 O
( O
62/64 O
patients O
, O
group O
ii O
) O
( O
t>0.05 O
) O
. O

the O
number O
of O
biopsy O
specimens O
and O
the O
rate O
of O
ct-detectable O
small B-NEG
bleedings I-NEG
differed O
slightly O
between O
both O
groups O
and O
were O
higher O
in O
group O
ii O
. O

the O
duration O
of O
surgery O
and O
anaesthesia O
as O
well O
as O
the O
final O
neurological O
outcomes O
were O
comparable O
in O
both O
groups O
. O

in O
conclusion O
, O
intraoperative O
smear O
examination O
as O
a O
kind O
of O
bedside O
diagnostics O
confers O
a O
better O
diagnostic O
safety O
and O
improves O
the O
reliability O
of O
this O
minimal O
invasive O
manoeuvre O
. O

-DOCSTART- O

1 O
applicable O
to O
cases O
of O
diarrhea B-NEG
in O
summer O
time O
, O
manifested O
as O
watery B-NEG
diarrhea I-NEG
, O
abdominal B-NEG
fullness I-NEG
, O
increased O
borborygmus B-NEG
, O
nausea B-NEG
, O
feeling O
of O
oppression O
over O
the O
chest O
, O
fatigue B-NEG
, O
white O
and O
smooth O
fur O
on O
the O
tongue O
, O
soft O
and O
floating O
, O
slow B-NEU
pulse I-NEU
, O
which O
are O
attribut O

-DOCSTART- O

acute B-NEG
appendicitis I-NEG
; O
periappendicular B-NEG
abscess I-NEG
; O
intestinal B-NEG
carbuncle I-NEG
; O
intestinal B-NEG
abscess I-NEG

-DOCSTART- O

this O
is O
a O
syndrome O
after O
phlegm B-NEG
due O
to O
wind B-NEG
sidesae O
blocked O
gi O
. O

-DOCSTART- O

traumatic B-NEG
injury I-NEG
with O
ecchymosis B-NEG
, O
swelling B-NEG
and O
pain B-NEG
. O

-DOCSTART- O

treatment O
of O
headache B-NEG
and O
dizziness B-NEG
, O
costal B-NEG
and I-NEG
abdomina I-NEG
pain I-NEG
, O
spasmodic B-NEG
pain I-NEG
of O
the O
limbs O
, O
anemia B-NEG
, O
menstrual B-NEG
disorders I-NEG
, O
spontaneous O
sweating B-NEU
and O
night B-NEU
sweating I-NEU
. O

-DOCSTART- O

anhidrosis B-NEG
; O
adiaphoria B-NEG
; O
adiaphoresis B-NEG

-DOCSTART- O

pectus B-NEG
excavatum I-NEG

-DOCSTART- O

this O
is O
a O
symptom O
with O
vomiting B-NEG
because O
of O
cold-damp B-NEG
. O

-DOCSTART- O

used O
mainly O
in O
female B-NEG
infertility I-NEG
due O
to O
anovulation B-NEG
( O
e.g O
. O
due O
to O
polycystic B-NEG
ovary I-NEG
syndrome I-NEG
) O
to O
induce O
ovulation B-NEU
. O

-DOCSTART- O

to O
warm O
the O
kidney B-DNP
, O
invigorate O
yang O
, O
replenish O
the O
vital B-POS
essence I-POS
and O
reinforce O
the O
marrow B-DNP

-DOCSTART- O

plum-stone B-NEG
syndrome I-NEG
; O
globus B-NEG
hystericus I-NEG
a O
subjective O
sensation O
as O
if O
a O
plum O
pit O
is O
stuck O
in O
the O
throat O
is O
compressed O
. O

-DOCSTART- O

dimethindene O
can O
also O
be O
used O
as O
an O
adjuvant O
in O
eczema B-NEG
and O
other O
pruriginous B-NEG
dermatoses I-NEG
of O
allergic O
origin O
. O

-DOCSTART- O

clear O
heat B-NEU
and O
cool O
blood B-DNP

-DOCSTART- O

heat B-NEU
bind O
and O
accumulation O
, O
constipation B-NEG
w O
ith O
abdominal B-NEG
pain I-NEG
, O
edema B-NEG
distention I-NEG
fullness I-NEG
. O

-DOCSTART- O

this O
is O
kinds O
of O
consciousness B-NEG
disorder I-NEG
with O
a O
light O
stupor B-NEG
. O

it O
is O
sleeping O
at O
nights O
and O
days O
, O
and O
responding O
with O
opening O
an O
eye O
. O

it O
is O
cause O
by O
palsy B-NEG
. O

-DOCSTART- O

renal B-NEG
impairment I-NEG

-DOCSTART- O

three O
eum O
syndrome O
of O
cold O
attack O

-DOCSTART- O

it O
means O
not O
shiny O
hair O

-DOCSTART- O

liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
determination O
of O
arsenic O
species O
in O
dog O
plasma O
and O
its O
application O
to O
a O
pharmacokinetic O
study O
after O
oral O
administration O
of O
realgar O
and O
niu O
huang O
jie O
du O
pian O
. O

-DOCSTART- O

respiratory B-NEG
distress I-NEG

-DOCSTART- O

background O
: O
crohn's B-NEG
disease I-NEG
( O
cd B-NEG
) O
is O
a O
chronic B-NEG
inflammatory I-NEG
disease I-NEG
with O
increasing O
incidence O
in O
children O
. O

current O
medications O
have O
potentially O
serious O
side O
effects O
, O
hence O
increasing O
interest O
in O
alternative O
therapies O
. O

we O
previously O
developed O
an O
herbal O
formula O
, O
fahf-2 O
, O
based O
on O
a O
classical O
traditional O
chinese O
herbal O
formula O
wu O
mei O
wan O
that O
has O
long O
been O
used O
in O
china O
to O
treat O
colitis B-NEG
. O

we O
investigated O
fahf-2's O
potential O
anti-inflammatory B-POS
effects O
. O

methods O
: O
fahf-2 O
efficacy O
was O
tested O
in O
vivo O
in O
the O
cd45rbrag1 O
transfer O
colitis O
model O
. O

weight B-NEG
loss I-NEG
, O
colonic O
histology O
, O
and O
cytokine B-NEU
production I-NEU
from O
mesenteric B-DNP
lymph I-DNP
nodes I-DNP
were O
assessed O
. O

human O
peripheral B-DNP
blood I-DNP
mononuclear I-DNP
cells I-DNP
( O
pbmcs B-DNP
) O
and O
colonic O
biopsies O
were O
obtained O
from O
children O
newly O
diagnosed O
with O
cd O
and O
controls O
and O
cultured O
with O
or O
without O
fahf-2 O
. O

cytokine B-NEU
levels I-NEU
were O
measured O
by O
multiplex O
immunoassay O
. O

the O
effect O
of O
fahf-2 O
on O
tnf- B-DNP
- O
producing O
cells B-DNP
was O
determined O
by O
flow O
cytometry O
. O

nf-kb B-NEU
signaling I-NEU
was O
investigated O
in O
human O
lamina B-NEU
propria I-NEU
mononuclear I-NEU
cells I-NEU
upon O
fahf-2 O
treatment O
by O
in O
- O
cell O
western O
. O

results O
: O
fahf-2 O
- O
treated O
mice O
had O
decreased B-NEG
weight I-NEG
loss I-NEG
, O
improved O
histology O
, O
and O
reduced O
tnf- B-DNP
, O
il-17 B-DNP
, O
il-6 B-DNP
, O
and O
ifn-y B-DNP
production O
. O

in O
vitro O
treated O
pbmcs B-DNP
produced O
less O
tnf- B-DNP
, O
ifn-y B-DNP
, O
and O
il-12 B-DNP
. O

fahf-2 O
reduced O
the O
tnf-a B-DNP
- O
producing O
monocytes B-DNP
and O
t B-DNP
cells I-DNP
. O

-DOCSTART- O

anemia B-NEG

-DOCSTART- O

the O
heat B-NEG
syndrome I-NEG
syndrome O
due O
to O
attack O
of O
pathogenic O
heat O
or O
hyperactivity B-NEG
of O
yanggi O
, O
usually O
seen O
in O
infectious B-NEG
disease I-NEG
and O
those O
caused O
by O
abnormal O
hyperactivity I-NEG
of O
the O
body O
, O
with O
manifestation O
such O
as O
fever B-NEG
, O
fidgets B-NEG
, O
flushed B-NEG
face I-NEG
, O
congested B-NEG
eyes I-NEG
dry B-NEG
mouth I-NEG
and I-NEG
throat I-NEG
, O
red O
and O
dry B-NEG
lip I-NEG
thirst O
with O
preference O
for O
cold O
drink O
, O
constipation B-NEG
, O
scanty O
dark B-NEG
urine I-NEG
reddened B-NEG
tongue I-NEG
with O
dry B-NEG
brow I-NEG
or O
black O
coating O
, O
and O
rapid B-NEG
pulse I-NEG
. O

-DOCSTART- O

to O
lessen O
contracture B-NEG
, O
regulate O
stomach B-NEU
function I-NEU
, O
and O
dispel O
contracture B-NEG
. O

-DOCSTART- O

indicated O
as O
symptomatic O
treatment O
of O
allergic B-NEG
reactions I-NEG
: O
urticaria B-NEG
, O
allergies B-NEG
of I-NEG
the I-NEG
upper I-NEG
respiratory I-NEG
tract I-NEG
such O
as O
hey B-NEG
fever I-NEG
and O
perennial B-NEG
rhinitis I-NEG
, O
food B-NEG
and I-NEG
drug I-NEG
allergies I-NEG
; O
pruritus B-NEG
of I-NEG
various I-NEG
origins I-NEG
, O
except O
pruritus B-NEG
due O
to O
cholestasis B-NEG
; O
insect B-NEG
bites I-NEG
. O

-DOCSTART- O

healthy B-POS

-DOCSTART- O

its O
component O
oleanolic O
acid O
can O
prevent O
and O
relieve O
cyclophosphamide-induced B-NEG
leukocytopenia I-NEG
in O
mice O
. O

enhancing O
the O
anoxia B-NEU
tolerance I-NEU
of O
mice O
under O
atmospheric O
pressure O
. O

increasing O
coronary B-NEU
flow I-NEU
in O
rabbits O
in O
vitro O
. O

relaxing O
adrenaline-induced B-NEU
vasocontricyion I-NEU
in O
rabbits O
in O
vitro O
. O

lowering O
the O
level O
of O
blood B-DNP
lipid I-DNP
. O

-DOCSTART- O

join O
cutting B-NEG
wound I-NEG

-DOCSTART- O

to O
tonify O
the O
liver B-DNP
and O
the O
kidney B-DNP
, O
to O
strengthen O
the O
tendons B-DNP
and O
bones B-DNP
, O
and O
to O
prevent O
miscarrige B-NEG
. O

-DOCSTART- O

knocks B-NEG
and O
falls B-NEG
, O
stasis B-NEG
swelling I-NEG
pain I-NEG
, O
wind-damp B-NEG
impediment I-NEG
pain I-NEG
. O

-DOCSTART- O

to O
eliminate O
fluid B-NEU
and O
relieve O
edema B-NEG
( O
sthenia-syndrome B-NEG
with O
edema B-NEG
and O
ascites B-NEG
) O
. O

-DOCSTART- O

postpartum B-NEG
debility I-NEG

-DOCSTART- O

doxapram O
produces O
respiratory B-NEU
stimulation I-NEU
mediated O
through O
the O
peripheral O
carotid O
chemoreceptors O
. O

it O
is O
thought O
to O
stimulate O
the O
carotid B-DNP
body I-DNP
by O
inhibiting O
certain B-DNP
potassium I-DNP
channels I-DNP
. O

-DOCSTART- O

for O
tonifying O
weakness B-NEG
. O

-DOCSTART- O

stage O
iii O
childhood B-NEG
lymphoblastic I-NEG
lymphoma I-NEG

-DOCSTART- O

cancer B-NEG

-DOCSTART- O

burn B-NEG

-DOCSTART- O

to O
open O
orifices O
and O
arouse O
spirit O
, O
break O
phlegm B-NEG
and O
repel O
foulness O
, O
move O
qi O
and O
quicken O
blood B-DNP
, O
relieve O
pain B-NEG
. O

-DOCSTART- O

childhood B-NEG
acute I-NEG
myelomonocytic I-NEG
leukemia I-NEG

-DOCSTART- O

dribbling B-NEG
urination I-NEG
; O
dribbling B-NEG
of I-NEG
urine I-NEG

-DOCSTART- O

for O
the O
treatment O
of O
bacterial B-NEG
infections I-NEG
. O

-DOCSTART- O

for O
eliminating O
toxic B-NEG
materials I-NEG
, O
dissolving O
rottenness B-NEG
and O
growing O
new O
muscles B-DNP

-DOCSTART- O

leukorrhea B-NEG
with O
pruritis B-NEG
vulva I-NEG

-DOCSTART- O

1 O
to O
clear O
heat B-NEU
and O
toxic O
material O
. O
2 O
to O
clear O
liver-heat B-NEU
to O
treat O
eye B-NEG
disease I-NEG
. O
3 O
to O
clear O
dampness-heat B-NEG
. O

-DOCSTART- O

cardiac B-NEG
carbuncle I-NEG
has O
half O
conscious O
, O
stuffiness B-NEG
in O
the O
heart O
, O
and O
forgetting O
well O
when O
something O
occurred O
. O

-DOCSTART- O

objective O
: O
the O
aim O
of O
this O
study O
was O
to O
analyse O
the O
value O
of O
intraoperative O
micro-doppler O
in O
stereotactic O
brain O
biopsy O
( O
sbb O
) O
. O

so O
far O
, O
only O
a O
few O
studies O
have O
reported O
about O
the O
usefulness O
of O
micro-doppler O
in O
stereotactic O
brain O
biopsy O
. O

methods O
: O
between O
1998 O
and O
2003 O
, O
155 O
sbbs O
were O
performed O
in O
153 O
patients O
with O
micro-doppler O
( O
81 O
males O
, O
72 O
females O
, O
mean O
age O
: O
59 O
years O
) O
. O

all O
operations O
were O
performed O
using O
a O
zd-frame O
and O
a O
multiplanar O
computer O
tomography-guided O
trajectory O
planning O
system O
( O
leibinger O
spp O
) O
. O

a O
16 O
mhz O
micro-doppler O
probe O
( O
diameter O
1 O
mm O
, O
dwl O
) O
was O
used O
in O
all O
cases O
to O
explore O
the O
area O
of O
biopsy O
before O
the O
tissue O
probes O
were O
taken O
. O

serial O
biopsies O
( O
mean O
, O
6 O
samples O
) O
were O
taken O
with O
the O
sedan O
side-cutting O
cannula O
(n O
= O
145 O
) O
or O
the O
small O
forceps O
(n O
= O
10 O
) O
. O

we O
evaluated O
the O
number O
of O
intraoperative O
detectable O
vessel O
signals O
by O
micro-doppler O
, O
intraoperative O
bleedings B-NEG
as O
well O
as O
bleedings B-NEG
detected O
by O
postoperative O
ct O
( O
which O
was O
performed O
in O
all O
cases O
) O
. O

we O
compared O
our O
results O
according O
to O
bleeding B-NEG
- O
related O
complications O
with O
the O
data O
of O
stereotactic O
biopsy O
series O
from O
the O
recent O
literature O
. O

results O
: O
a O
conclusive O
histopathological O
diagnosis O
was O
achieved O
in O
150/153 O
patients O
( O
98 O
% O
) O
. O

a O
re-biopsy O
had O
to O
be O
undertaken O
in O
2 O
cases O
. O

in O
98 O
biopsies O
( O
63 O
% O
) O
, O
no O
vessel O
could O
be O
detected O
with O
the O
micro-doppler O
. O

in O
the O
remainder O
, O
a O
signal O
of O
arterial B-DNP
vessels I-DNP
was O
detected O
in O
22 O
( O
14 O
%) O
and O
a O
signal O
of O
venous B-DNP
vessels I-DNP
in O
35 O
cases O
( O
23 O
% O
) O
. O

detection O
of O
a O
vessel B-DNP
in O
the O
micro-doppler O
led O
to O
a O
change O
of O
the O
biopsy O
site O
in O
each O
case O
within O
the O
same O
trajectory O
. O

biopsy-related O
bleedings B-NEG
were O
detected O
in O
4 O
cases O
( O
2.6 O
% O
) O
. O

among O
these O
, O
the O
only O
bleeding B-NEG
which O
occurred O
without O
any O
signs O
of O
vessels B-DNP
in O
the O
micro-doppler O
happened O
in O
a O
case O
of O
a O
melanoma B-NEG
. O

the O
overall O
biopsy-related O
permanent O
morbidity O
was O
0.6 O
% O
(n O
= O
1 O
) O
. O

the O
biopsy-related O
mortality O
was O
0 O

conclusions O
: O
despite O
the O
overall O
high O
security O
of O
sbb O
, O
the O
use O
of O
intraoperative O
micro-doppler O
may O
lead O
to O
an O
additional O
reduction O
of O
the O
risk O
for O
a O
biopsy-related O
bleeding B-NEG
without O
enormous O
expense O
. O

-DOCSTART- O

to O
warm O
the O
spleen B-DNP
, O
stop O
vomiting B-NEG
, O
clear O
away O
summer-heat B-NEG
and O
eliminate O
dampness B-NEU
. O

-DOCSTART- O

diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
others O
, O
protective O
immunity B-NEU
, O
overall O
cvd B-NEG

-DOCSTART- O

tonify O
the O
bladder B-DNP

-DOCSTART- O

major O
red O
and O
white O
dysentery B-NEG

-DOCSTART- O

this O
is O
a O
syndrome O
of O
a O
retarded B-NEG
child I-NEU
. O

there O
are O
five O
symptoms O
including O
slow B-NEG
stand I-NEG
, I-NEG
delayed I-NEG
development I-NEG
in O
walking O
, O
retardation O
in O
hair-growing O
, O
delayed B-NEG
development I-NEG
in O
growth O
of O
teeth O
, O
and O
delayed B-NEG
development I-NEG
of O
speech O
in O
an O
infant O
. O

-DOCSTART- O

to O
arrest O
seminal B-NEU
emission I-NEU
, O
to O
restrain O
urination B-NEU
, O
and O
to O
check O
diarrhea B-NEG
. O

cturnal B-NEU
emission I-NEU
, O
spermatorrhea B-NEG
, O
enuresis B-NEG
, O
frequent B-NEG
urination I-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
excessive O
leukorrhea B-NEG
, O
protracted O
diarrhea B-NEG
, O
chronic B-NEG
dysentery I-NEG
. O

-DOCSTART- O

familial B-NEG
adenomatous I-NEG
polyposis I-NEG

-DOCSTART- O

tidal B-NEG
fever I-NEG
in O
the O
afternoon O

-DOCSTART- O

anemia B-NEG
in I-NEG
chronic I-NEG
renal I-NEG
disease I-NEG

-DOCSTART- O

convulsion B-NEG
; O

epilepsy B-NEG

-DOCSTART- O

to O
remove O
heat B-NEU
and O
counteract O
toxicity B-NEG
, O
to O
nourish O
liver B-DNP
and O
stomach B-DNP
, O
curing O
sore B-NEG
, O
to O
improve O
consciousness B-POS
, O
to O
tonify B-POS
the I-POS
body I-POS
. O

-DOCSTART- O

used O
in O
the O
treatment O
of O
kaposi's B-NEG
sarcoma I-NEG
and O
cancer B-NEG
of O
the O
lung O
, O
ovarian O
, O
and O
breast O
. O

abraxane® O
is O
specfically O
indicated O
for O
the O
treatment O
of O
metastatic B-NEG
breast I-NEG
cancer I-NEG
and O
locally O
advanced B-NEG
or I-NEG
metastatic I-NEG
non-small I-NEG
cell I-NEG
lung I-NEG
cancer I-NEG
. O

-DOCSTART- O

for O
the O
treatment O
of O
the O
signs O
and O
symptoms O
of O
idiopathic O
parkinson's B-NEG
disease I-NEG
. O

also O
used O
for O
the O
treatment O
of O
restless B-NEG
legs I-NEG
syndrome I-NEG
. O

-DOCSTART- O

hypertension B-NEG
, O
kidney B-NEG
vacuity I-NEG
lumbago I-NEG
, O
weakness B-NEG
in O
sinews O
and O
bones O
, O
stirring O
fetus O
in O
pregnancy O
. O

-DOCSTART- O

edema B-NEG
due O
to O
deficiency B-NEG
in I-NEG
the I-NEG
kidney I-NEG
, O
accompanied O
with O
heaviness O
sensation O
in O
the O
loins O
and O
knees O
and O
oliguria O
; O

retention O
of O
body O
fluid O
with O
dyspnea B-NEG
and O
cough B-NEG
. O

-DOCSTART- O

reinforce O
the O
kidney B-DNP

-DOCSTART- O

rivanicline O
is O
a O
( O
e)-metanicotine O
hemigalactarate O
. O

it O
effectively O
inhibits O
tnf- O
and O
lps-induced O
il-8 B-DNP
production O
in O
different O
cell O
types O
. O

-DOCSTART- O

the O
exact O
mechanism O
of O
action O
of O
ingenol O
mebutate O
in O
actinic B-NEG
keratosis I-NEG
is O
unknown O
. O

it O
is O
presumed O
to O
involve O
primary O
necrosis B-NEG
then O
neutrophil-mediated B-NEG
inflammation I-NEG
and O
antibody-dependent B-NEG
cell I-NEG
death I-NEG
of O
residual O
disease B-NEG
cells I-NEG
. O

additionally O
in O
early O
studies O
, O
pep005 O
was O
shown O
to O
be O
an O
effective O
activator O
of O
pkc-delta O
and O
pkc-delta O
translocation O
into O
nucleus B-DNP
and O
membranes B-DNP
. O

pep005 O
also O
downregulates O
the O
expression B-DNP
and I-DNP
activity I-DNP
of I-DNP
pkc-alpha I-DNP
. O

pep005 O
induced O
modulation O
of O
pkcs O
leads O
to O
ras B-DNP
/ O
raf B-DNP
/ O
mapk B-DNP
and O
p38 B-DNP
activation O
and O
akt B-DNP
/ O
pkb B-DNP
inhibition O
. O

-DOCSTART- O

lymphoma B-NEG

-DOCSTART- O

drug B-NEG
induced I-NEG
hepatotoxicity I-NEG

-DOCSTART- O

cholestyramine O
binds O
bile B-DNP
in O
the O
gastrointestinal O
tract O
to O
prevent O
its O
reabsorption O
. O

-DOCSTART- O

for O
dispersing O
wind-coldness B-NEG

-DOCSTART- O

regulation O
of O
qi O

-DOCSTART- O

water O
extract O
of O
samultang O
reduces O
apoptotic B-NEU
cell I-NEU
death I-NEU
by O
h(2)o(2)-induced O
oxidative B-NEG
injury I-NEG
in O
sk-n-mc O
cells O
. O

-DOCSTART- O

emtricitabine O
is O
an O
analogue O
of O
cytidine O
. O

the O
drug O
works O
by O
inhibiting O
reverse B-DNP
transcriptase I-DNP
, O
the O
enzyme O
that O
copies O
hiv B-NEG
rna I-NEG
into O
new O
viral O
dna O
. O

by O
interfering O
with O
this O
process O
, O
which O
is O
central O
to O
the O
replication O
of O
hiv B-NEG
, O
emtricitabine O
can O
help O
to O
lower O
the O
amount O
of O
hiv B-NEG
, O
or O
viral B-NEG
load I-NEG
. O

efavirenz O
falls O
in O
the O
nnrti O
class O
of O
antiretrovirals O
. O

both O
nucleoside O
and O
non-nucleoside O
rtis O
inhibit O
the O
same O
target O
, O
the O
reverse B-DNP
transcriptase I-DNP
enzyme I-DNP
, O
an O
essential O
viral B-DNP
enzyme I-DNP
which O
transcribes O
viral O
rna O
into O
dna O
. O

-DOCSTART- O

dragon's O
blood O
( O
xuejie O
) O
is O
used O
with O
frankincense O
( O
ruxiang O
) O
and O
myrrh O
( O
moyao O
) O
in O
the O
formula O
qili O
san O
. O

-DOCSTART- O

lenalidomide O
inhibits O
tnf-alpha B-NEU
production I-NEU
, O
stimulates O
t B-DNP
cells I-DNP
, O
reduces O
serum B-NEU
levels I-NEU
of I-NEU
the I-NEU
cytokines I-NEU
vascular I-NEU
endothelial I-NEU
growth I-NEU
factor I-NEU
( O
vegf B-DNP
) O
and O
basic B-DNP
fibroblast I-DNP
growth I-DNP
factor I-DNP
( O
bfgf B-DNP
) O
, O
and O
inhibits O
angiogenesis B-NEU
. O

-DOCSTART- O

constipation B-NEG
and O
difficulty B-NEG
in I-NEG
urination I-NEG

-DOCSTART- O

for O
induction O
and O
maintenance O
in O
the O
treatment O
of O
cytomegalovirus B-NEG
( O
cmv B-NEG
) O
retinitis B-NEG
in O
immunocompromised O
patients O
, O
including O
patients O
with O
acquired B-NEG
immunodeficiency I-NEG
syndrome I-NEG
( O
aids B-NEG
) O
. O

also O
used O
in O
the O
treatment O
of O
severe O
cytomegalovirus B-NEG
( O
cmv B-NEG
) O
disease B-NEG
, O
including O
cmv B-NEG
pneumonia I-NEG
, O
cmv B-NEG
gastrointestinal I-NEG
disease I-NEG
, O
and O
disseminated O
cmv B-NEG
infections I-NEG
, O
in O
immunocompromised O
patients O
. O

-DOCSTART- O

treament O
of O
edema B-NEG
or O
retained O
fluid O
with O
abdominal B-NEG
distension I-NEG
, O
oliguria B-NEG
and O
constipation B-NEG
, O
amenorrhea B-NEG
due O
to O
blood B-NEG
stasis I-NEG
, O
external O
use O
for O
ringworm B-NEG
and O
verrucous B-NEG
vegetations I-NEG
. O

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEG
, O
move O
qi O
and O
quicken O
blood B-DNP
. O

-DOCSTART- O

to O
lower O
blood B-NEU
pressure I-NEU
, O
supplement O
liver B-DNP
and O
kidney B-DNP
, O
strengthen O
sinews B-DNP
and O
bones B-DNP
, O
quiet O
fetus O
. O

-DOCSTART- O

coldness B-NEG
and O
pain B-NEG
in O
the O
lumbar O
and O
knee O
region O

-DOCSTART- O

[ O
treatment O
of O
breast B-NEG
proliferation I-NEG
disease I-NEG
with O
modified O
xiao O
yao O
san O
and O
er O
chen O
decoction O
] O
. O

-DOCSTART- O

reinforce O
bone B-DNP
marrow I-DNP

-DOCSTART- O

investigated O
for O
use/treatment O
in O
adverse O
effects O
( O
chemotherapy O
) O
and O
bone B-DNP
marrow I-DNP
transplant O
. O

-DOCSTART- O

to O
nourish O
blood B-DNP
. O

-DOCSTART- O

breech B-NEU
presentation I-NEU
in O
pregnancy O

-DOCSTART- O

effects O
of O
tokishakuyakusan O
, O
keishibukuryogan O
and O
unkeito O
on O
dna B-NEU
polymerase I-NEU
alpha I-NEU
activity I-NEU
in O
uteri O
of O
pregnant O
mare's O
serum O
gonadotropin-treated O
immature O
rats O
. O

-DOCSTART- O

endocrine B-DNP
system I-DNP
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
reproductive B-DNP
systems I-DNP
, O
others O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
digestion B-NEU
, O
energy O
/ O
food O
intake O
( O
apetite O
/ O
satiety O
) O
, O
physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
body B-NEU
fat I-NEU
deposition I-NEU
( O
total O
amount O

-DOCSTART- O

dermatitis B-NEG
, I-NEG
atopic I-NEG

-DOCSTART- O

brighten O
the O
eyes B-DNP

-DOCSTART- O

wind-damp B-NEG
impediment I-NEG
pain I-NEG
, O
swelling B-NEG
pain I-NEG
in I-NEG
throat I-NEG
, O
scrofula B-NEG
, O
mammary B-NEG
welling I-NEG
abscess I-NEG
, O
sore B-NEG
and O
boil B-NEG
, O
eczema B-NEG
, O
innominate B-NEG
toxin I-NEG
swelling I-NEG
, O
poisonous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

to O
replenish O
yin O
of O
the O
lung B-DNP
and O
stomach B-DNP
, O
remove O
heat B-NEU
from O
the O
lung O
, O
and O
promote O
fluid B-NEU
secretion I-NEU
. O

-DOCSTART- O

insubstantial O
wind B-NEG

-DOCSTART- O

pheochromocytoma B-NEG

-DOCSTART- O

to O
regulate O
qi O
, O
promote O
blood B-NEU
circulation I-NEU
and O
regulate O
menstruation B-NEU
. O

-DOCSTART- O

1 O
to O
relieve O
carbuncle B-NEG
and O
drain B-NEG
pus I-NEG
. O

for O
the O
early O
stage O
of O
carbuncle B-NEG
or O
carbuncle B-NEG
with O
unruptured O
abscess B-NEG
. O

2 O
to O
expel O
wind B-NEG
and O
kill O
parasites B-NEG
. O

for O
tinea B-NEG
infection I-NEG
and O
leprosy B-NEG
. O

-DOCSTART- O

kids O
, O
protective B-POS
immunity I-POS
, O
metabolism B-NEU

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
relieve O
pain B-NEG
, O
kill O
worms B-NEG
and O
relieve O
itch B-NEG
, O
resolve B-NEG
toxin I-NEG
and O
close O
sores B-NEG
. O

-DOCSTART- O

amenorrhea B-NEG

-DOCSTART- O

treatment O
of O
loss B-NEG
of I-NEG
consciousness I-NEG
in O
stroke B-NEG
and O
epilepsy B-NEG
, O
sore B-NEG
throat I-NEG
, O
dyspnea B-NEG
and O
cough B-NEG
with O
phlegm B-NEG
difficult O
to O
spit O
out O
, O
constipation B-NEG
, O
external O
use O
for O
subcutaneous B-NEG
pyogenic I-NEG
infections I-NEG
. O

-DOCSTART- O

in O
addition O
to O
binding O
to O
specific O
nuclear O
steroid O
receptors O
, O
dexamethasone O
also O
interferes O
with O
nf-kb B-NEU
activation I-NEU
and O
apoptotic B-DNP
pathways I-DNP
. O

-DOCSTART- O

for O
clearing O
weakness B-NEG
and O
heat B-NEU

-DOCSTART- O

warm O
the O
kidney B-DNP

-DOCSTART- O

invigorate O
blood B-NEU

-DOCSTART- O

for O
the O
treatment O
of O
moderate O
and O
severe O
hypertension B-NEG
, O
either O
alone O
or O
as O
an O
adjunct O
, O
and O
for O
the O
treatment O
of O
renal B-NEG
hypertension I-NEG
. O

-DOCSTART- O

diabetics B-NEG
; O
emaciation-thirst B-NEG

-DOCSTART- O

wind-cold B-NEG
common I-NEG
cold I-NEG
, O
headache B-NEG
, O
cough B-NEG
and O
asthma B-NEG
, O
deep-source B-NEG
nasal I-NEG
congestion I-NEG
, O
cold B-NEG
pain I-NEG
in O
stomach O
duct O
and O
abdomen O
, O
wind-cold-damp B-NEG
impediment I-NEG
, O
cold-damp B-NEG
vaginal I-NEG
discharge I-NEG
, O
dysmenorrhea B-NEG
, O
toxin B-NEG
swelling I-NEG
of I-NEG
sores I-NEG
, O
wind O
papule B-NEG
itching O
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
body B-NEU
weight I-NEU
regulation O
, O
reproductive B-DNP
systems I-DNP
, O
mood O
, O
physical B-DNP
performance I-DNP
and O
fitness O
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
endocrine B-DNP
system I-DNP
, O
endurance B-POS
, O
improvement O
of O
blood B-DNP
glucose I-DNP
levels I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
metabolism B-NEU
, O
mimmuietabolic O
rate/energy O
expenditure O
, O
strength O
and O
power O
, O
others O
, O
quality O
of O
life O
, O
protective O
immunity B-NEU
, O
body B-NEG
fat I-NEG
deposition I-NEG
( O
total O
amount O

-DOCSTART- O

emergence B-NEG
agitation I-NEG

-DOCSTART- O

spasticity B-NEG

-DOCSTART- O

to O
remove O
blood B-NEG
stasis I-NEG
, O
promote O
the O
subsidence O
of O
swelling B-NEG
, O
relieve O
pain B-NEG
and O
arrest O
bleeding B-NEG
. O

-DOCSTART- O

purging O

-DOCSTART- O

hypertrophy B-NEG
, I-NEG
left I-NEG
ventricular I-NEG

-DOCSTART- O

hemostatic O
. O

-DOCSTART- O

pain B-NEG
in O
throat O
and O
hypochondrium O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
reproductive B-DNP
systems I-DNP

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
effuse O
sweat B-NEU
, O
dissipate O
cold B-NEG
and O
dry O
damp B-NEU
. O

-DOCSTART- O

postpartum B-NEG
anemic I-NEG
faintness I-NEG
; O
faint B-NEG
after O
childbirth O

-DOCSTART- O

relaxing O
the O
smooth B-DNP
muscles I-DNP
of I-DNP
blood I-DNP
vessels I-DNP
and O
stimulating O
those O
of O
uterus B-DNP
, O
urinary B-DNP
bladder I-DNP
bronchus B-DNP
and O
gastrointestines B-DNP
. O

-DOCSTART- O

wind B-NEG
one O
of O
the O
five O
pathogenic O
factors O
, O
also O
one O
of O
the O
six O
exogenous O
pathogenic O
factors O
which O
often O
causes O
disease B-NEG
in O
association O
with O
other O
pathogenic O
agent O
. O

it O
is O
of O
yang O
nature O
and O
apt O
to O
change O
, O
resulting O
symptoms O
are O
usually O
migratory O
and O
variable O
. O

-DOCSTART- O

cardiovascular B-NEG
disorder I-NEG

-DOCSTART- O

treament O
of O
spitting B-NEG
of I-NEG
blood I-NEG
, O
epistaxis B-NEG
, O
abnormal B-NEG
uterine I-NEG
bleeding I-NEG
, O
traumatic B-NEG
bleeding I-NEG
, O
amenorrhea B-NEG
with O
blood O
stasis O
, O
arthralgia B-NEG
, O
traumatic O
swelling B-NEG
and O
pain B-NEG
. O

-DOCSTART- O

hypertension B-NEG
. O

-DOCSTART- O

diarrhea B-NEG
, O
malnutrition B-NEG

-DOCSTART- O

to O
dispel O
cold B-NEG
, O
eliminate O
damp B-NEU
and O
phlegm B-NEG
, O
and O
to O
arrest O
emesis B-NEG
or O
nausea B-NEG
. O

-DOCSTART- O

rheumatism B-NEG
numbness I-NEG
, O
damp-heat B-NEG
itchy I-NEG
sore I-NEG
, O
clove B-NEG
sore I-NEG
, O
menstruant O
morbidity O
. O

-DOCSTART- O

frequent B-NEG
urination I-NEG

-DOCSTART- O

general O
swelling B-NEG
and O
small B-NEG
amount I-NEG
urine I-NEG

-DOCSTART- O

injury B-NEG
by I-NEG
knife I-NEG

-DOCSTART- O

this O
is O
bursting O
a O
carbuncle B-NEG
and O
cellulites B-NEG
after O
decaying O
. O

it O
is O
occurred O
in O
thick O
skin O
and O
region O
which O
have O
a O
lot O
of O
glandulae B-DNP
sebaceae I-DNP
and O
follicular B-DNP
. O

-DOCSTART- O

ulceration B-NEG
in O
the O
gum O

-DOCSTART- O

to O
clear O
heat B-NEU
and O
dampness B-NEG
, O
promote O
blood B-NEU
circulation I-NEU
and O
remove O
blood B-NEG
stasis I-NEG
: O
for O
jaundice B-NEG
of O
dampness-heat B-NEG
type O
and O
abdominal B-NEG
mass I-NEG
. O
recently O
used O
for O
acute O
and O
chronic B-NEG
hepatitis I-NEG
, O
cirrhosis B-NEG
, O
cholecysitis B-NEG
, O
etc O
. O
, O
also O
for O
diarrhea B-NEG
, O
desentery B-NEG
and O
leucorrhagia B-NEG
of O
dampness-heat B-NEG
type O
, O
ough O
of O
lung-heat B-NEU
type O
, O
sorethroat B-NEG
, O
silicosis B-NEG
, O
and O
tumors B-NEG
such O
as O
lung B-NEG
cancer I-NEG
, O
nasopharyngeal B-NEG
carcinoma I-NEG
, O
chorionic B-NEG
epithelioma I-NEG
, O
tumor B-NEG
of O
the O
digestive O
tract O
, O
etc O
. O
2 O
to O
stop O
bleeding B-NEG
. O
for O
hematemesis B-NEG
, O
hemafecia B-NEG
, O
hemoptysis B-NEG
and O
epistaxis B-NEG
. O
external O
use O
for O
bleeding B-NEG
after O
trauma B-NEG
and O
after O
separation O
of O
umbilical O
cord O
in O
infants O
. O

-DOCSTART- O

wind-cold-damp B-NEG
impediment O
, O
aching B-NEG
pain I-NEG
in O
joints O
, O
arthritis B-NEG
, O
dysmenorrhea B-NEG
, O
skin B-NEG
numbness I-NEG
, O
weakness B-NEG
in O
limbs O
, O
jaundice B-NEG
, O
cough B-NEG
, O
knocks O
and O
falls O
, O
sores B-NEG
, O
zoster B-NEG
, O
scalds B-NEG
. O

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
quality O
of O
life O
, O
inflammation B-NEG
, O
protective O
immunity B-NEU
, O
others O

-DOCSTART- O

cough B-NEG
with I-NEG
blood I-NEG
due O
to O
a O
damaged B-NEG
lungs I-NEG
because O
of O
exhaustion B-NEG
syndrome I-NEG

-DOCSTART- O

muscular B-NEG
twitching I-NEG
and O
cramp B-NEG
; O

twitching B-NEG
of I-NEG
muscles I-NEG

-DOCSTART- O

a O
symptom O
that O
the O
chest B-DNP
and O
a O
middle O
part O
of O
the O
stomach B-DNP
are O
full O
and O
uncomfortable O
. O

-DOCSTART- O

leukemia B-NEG

-DOCSTART- O

nevirapine O
binds O
directly O
to O
reverse B-DNP
transcriptase I-DNP
and O
blocks O
the O
rna-dependent B-DNP
and I-DNP
dna-dependent I-DNP
dna I-DNP
polymerase I-DNP
activities O
by O
causing O
a O
disruption B-NEU
of I-NEU
the I-NEU
enzyme's I-NEU
catalytic I-NEU
site I-NEU
. O

-DOCSTART- O

diaphragmatic B-NEG
dysfunction I-NEG

-DOCSTART- O

1 O
its O
purgative O
effect O
is O
as O
three O
times O
as O
castor O
oil O
. O
2 O
. O
its O
fresh O
preparation O
may O
inhibit O
the O
progress O
of O
acute B-NEG
lymphatic I-NEG
leukemia I-NEG
, O
acute O
and O
chronic B-NEG
granulocytic I-NEG
leukemia I-NEG
and O
acute B-NEG
monocytic I-NEG
leukemia I-NEG
. O

-DOCSTART- O

hiv B-NEG
infections I-NEG

-DOCSTART- O

yokukansan O
, O
a O
traditional O
japanese O
medicine O
has O
been O
used O
to O
cure O
neuropsychological B-NEG
disorders I-NEG
. O

in O
the O
present O
study O
, O
the O
effect O
of O
yokukansan O
on O
social B-NEG
isolation I-NEG
- I-NEG
induced I-NEG
aggressive I-NEG
behavior I-NEG
was O
examined O
in O
zinc-deficient O
mice O
, O
which O
were O
fed O
a O
zinc-deficient O
diet O
and O
a O
drinking O
water O
containing O
yokukansan O
for O
2 O
weeks O
. O

in O
the O
resident-intruder O
test O
, O
the O
rate O
of O
mice O
that O
exhibited O
aggressive B-NEG
behavior I-NEG
in O
zinc-deficient O
mice O
, O
which O
was O
significantly O
higher O
than O
that O
in O
the O
control O
mice O
, O
was O
significantly O
decreased O
by O
administration O
of O
yokukansan O
. O

the O
basal O
level O
of O
serum B-DNP
glucocorticoid I-DNP
, O
which O
was O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
was O
lowered O
by O
administration O
of O
yokukansan O
. O

on O
the O
other O
hand O
, O
serum B-NEU
glucocorticoid I-NEU
levels I-NEU
after O
the O
resident-intruder O
test O
were O
almost O
the O
same O
between O
the O
control O
and O
zinc-deficient O
mice O
. O

however O
, O
administration O
of O
yokukansan O
to O
zinc-deficient O
mice O
significantly O
increased O
serum B-NEU
glucocorticoid I-NEU
level I-NEU
after O
the O
resident-intruder O
test O
and O
the O
significant O
difference O
in O
the O
rate O
of O
serum B-NEU
corticosterone I-NEU
level I-NEU
after O
the O
test O
to O
the O
basal O
level O
between O
the O
control O
and O
zinc-deficient O
mice O
was O
abolished O
. O

dietary O
zinc O
deficiency O
increases O
the O
basal O
levels B-NEU
of I-NEU
serum I-NEU
glucocorticoid I-NEU
, O
while O
may O
insufficiently O
increase O
serum B-NEU
glucocorticoid I-NEU
levels I-NEU
in O
the O
resident-intruder O
test O
. O

the O
concentrations O
of O
glutamate B-DNP
and O
gaba B-DNP
( O
y-aminobutyric B-DNP
acid I-DNP
) O
in O
the O
brain O
were O
significantly O
higher O
in O
zinc-deficient O
mice O
, O
while O
yokukansan O
ameliorated O
the O
significant O
increases O
. O

these O
results O
indicate O
that O
yokukansan O
ameliorates O
social B-NEG
isolation-induced I-NEG
aggressive I-NEG
behavior I-NEG
of O
zinc-deficient O
mice O
, O
probably O
via O
amelioration O
of O
abnormal B-NEU
glucocorticoid I-NEU
secretion I-NEU
. O

the O
ameliorative O
effect O
seems O
to O
be O
linked O
to O
the O
modification O
of O
glutamatergic B-NEU
neuron I-NEU
activity I-NEU
after O
administration O
of O
yokukansan O
. O

-DOCSTART- O

glucagon O
binds O
the O
glucagon O
receptor O
, O
a O
g O
protein-coupled O
receptor O
located O
in O
the O
plasma B-DNP
membrane I-DNP
, O
which O
then O
initiates O
a O
dual O
signaling O
pathway O
using O
both O
adenylate O
cyclase O
activation O
and O
increased O
intracellular B-DNP
calcium I-DNP
. O

adenylate O
cyclase O
manufactures O
camp O
( O
cyclic O
amp O
) O
, O
which O
activates O
protein B-DNP
kinase I-DNP
a I-DNP
( O
camp-dependent B-DNP
protein I-DNP
kinase I-DNP
) O
. O

this O
enzyme B-DNP
, O
in O
turn O
, O
activates O
phosphorylase B-DNP
kinase I-DNP
, O
which O
, O
in O
turn O
, O
phosphorylates O
glycogen B-DNP
phosphorylase I-DNP
, O
converting O
into O
the O
active O
form O
called O
phosphorylase B-DNP
a I-DNP

phosphorylase O
a O
is O
the O
enzyme O
responsible O
for O
the O
release O
of O
glucose-1-phosphate O
from O
glycogen O
polymers O
. O

this O
yields O
glucose O
molecules O
to O
be O
released O
into O
the O
blood O
. O

glucagon O
receptors O
are O
found O
in O
the O
liver B-DNP
, O
kidney B-DNP
, O
brain B-DNP
and O
pancreatic B-DNP
islet I-DNP
cells I-DNP
. O

the O
glucagon O
mediated O
signals O
lead O
to O
an O
increase O
in O
insulin B-NEU
excretion I-NEU

-DOCSTART- O

diminshing O
the O
toxicity B-NEG
of I-NEG
kanamycin I-NEG
to O
guinea-pig's B-NEG
cochlea I-NEG
. O

the O
levels O
of O
serum B-DNP
cholesterol I-DNP
and O
triglyceride B-DNP
. O

hindering O
the O
formation O
of O
arteriosclerotic B-NEG
deposits O
in O
the O
vessels O
. O

-DOCSTART- O

absorption B-NEU
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
motility B-NEU
. O

-DOCSTART- O

function O

-DOCSTART- O

convulsive B-NEG
disease I-NEG
; O
epilepsy B-NEG
induced O
by O
frightening O

-DOCSTART- O

untreated O
adult B-NEG
acute I-NEG
lymphoblastic I-NEG
leukemia I-NEG

-DOCSTART- O

prednisolone O
can O
inhibit O
leukocyte B-NEG
infiltration I-NEG
at O
the O
site O
of O
inflammation O
, O
interfere O
with O
mediators B-DNP
of I-DNP
inflammatory I-DNP
response I-DNP
, O
and O
suppress O
humoral B-NEU
immune I-NEU
responses I-NEU
. O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
reproductive B-DNP
systems I-DNP
, O
quality O
of O
life O
, O
endocrine B-DNP
system I-DNP
, O
others O
, O
memory O
, O
protective O
immunity B-NEU
, O
mental B-NEG
state I-NEG
and O
performance O

-DOCSTART- O

tinea B-NEG

-DOCSTART- O

hyperuricemia B-NEG

-DOCSTART- O

adult B-NEG
pure I-NEG
erythroid I-NEG
leukemia I-NEG

-DOCSTART- O

proellex O
selectively O
blocks O
the O
progesterone O
receptor O
thus O
avoiding O
the O
adverse O
effects O
of O
gnrh O
agonists O
associated O
with O
the O
induction O
of O
a O
low O
estrogen B-DNP
, O
menopausal-like B-DNP
state O
in O
women O
. O

-DOCSTART- O

to O
promote O
contraction O
and O
stem O
desertion O
, O
disperse O
swelling B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

distribution O
) O
, O
endurance B-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
strength B-POS
and O
power B-POS
, O
body B-NEU
weight I-NEU

-DOCSTART- O

ephedrine O
is O
a O
sympathomimetic O
amine O
- O
that O
is O
, O
its O
principal O
mechanism O
of O
action O
relies O
on O
its O
direct O
and O
indirect O
actions O
on O
the O
adrenergic B-DNP
receptor I-DNP
system I-DNP
, O
which O
is O
part O
of O
the O
sympathetic B-DNP
nervous I-DNP
system I-DNP
. O

ephedrine O
increases O
post-synaptic O
noradrenergic O
receptor O
activity O
by O
( O
weakly O
) O
directly O
activating O
post-synaptic O
receptors O
and O
receptors O
, O
but O
the O
bulk O
of O
its O
effect O
comes O
from O
the O
pre-synaptic B-DNP
neuron I-DNP
being O
unable O
to O
distinguish O
between O
real O
adrenaline B-DNP
or O
noradrenaline B-DNP
from O
ephedrine O
. O

the O
ephedrine O
, O
mixed O
with O
noradrenaline B-DNP
, O
is O
transported O
through O
the O
noradrenaline B-DNP
reuptake I-DNP
complex I-DNP
and O
packaged O
( O
along O
with O
real O
noradrenaline B-DNP
) O
into O
vesicles B-DNP
that O
reside O
at O
the O
terminal O
button O
of O
a O
nerve B-DNP
cell I-DNP
. O

ephedrine's O
action O
as O
an O
agonist O
at O
most O
major O
noradrenaline O
receptors O
and O
its O
ability O
to O
increase O
the O
release O
of O
both O
dopamine B-DNP
and O
to O
a O
lesser O
extent O
, O
serotonin B-DNP
by O
the O
same O
mechanism O
is O
presumed O
to O
have O
a O
major O
role O
in O
its O
mechanism O
of O
action O
. O

-DOCSTART- O

relieve O
toxicity B-NEG

-DOCSTART- O

prednisone O
enters O
the O
nucleus O
where O
it O
binds O
to O
and O
activates O
specific O
nuclear O
receptors O
, O
resulting O
in O
an O
altered O
gene B-NEU
expression I-NEU
and O
inhibition O
of O
proinflammatory B-NEU
cytokine I-NEU
production I-NEU
. O

-DOCSTART- O

used O
to O
numb B-NEU
the I-NEU
skin I-NEU
, O
or O
surfaces O
of O
the O
penis O
or O
vagina O
, O
in O
preparation O
for O
a O
medical O
procedure O
or O
to O
lessen O
the O
pain B-NEG
of O
inserting O
a O
medical O
instrument O
such O
as O
a O
tube O
or O
speculum O
. O

-DOCSTART- O

investigated O
for O
use/treatment O
in O
hiv B-NEG
infection I-NEG
. O

-DOCSTART- O

damp B-NEU
pi O
arthritis B-NEG
due O
to O
dampness B-NEU
. O

damp B-NEG
stroke I-NEG
; O

attack O
of O
dampness B-NEG
syndrome I-NEG
due O
to O
attack O
of O
pathogenic B-NEG
factors I-NEG
. O

-DOCSTART- O

symptoms O
associated O
with O
stagnation O
of O
liver O
qi O
, O
stagnated O
qi O
truned O
into O
fire O
, O
insufficient O
yin O
blood O

-DOCSTART- O

to O
relieve O
exterior B-NEG
syndrome I-NEG
. O

-DOCSTART- O

refers O
to O
the O
dream-disturbed O
sleep O

-DOCSTART- O

kidney B-NEG
diseases I-NEG

-DOCSTART- O

to O
tonify O
the O
spleen B-DNP
, O
to O
relieve O
diarrhea B-NEG
, O
to O
replenish O
the O
kidney B-DNP
, O
to O
arrest O
seminal B-NEU
emission I-NEU
, O
and O
to O
nourish O
the O
heart B-DNP
, O
to O
induce O
tranquillization B-NEU
. O

-DOCSTART- O

chunghyuldan O
( O
daio-orengedokuto O
in O
japanese O
) O
( O
chd O
) O
has O
been O
used O
as O
an O
antihyperlipidemic B-NEG
and O
antiischemic B-NEG
agent I-NEG
in O
korea O
. O

to O
evaluate O
in O
vitro O
the O
efficacy O
of O
chunghyuldans O
( O
chds O
) O
metabolized O
with O
and O
without O
human B-NEG
intestinal I-NEG
microflora I-NEG
against O
brain B-NEG
ischemia I-NEG
, O
we O
investigated O
its O
anti-inflammatory B-POS
effect I-POS
on O
lps-induced O
raw264.7 O
cells O
. O

both O
metabolized O
chd O
( O
mchd O
) O
and O
chd O
showed O
antioxidant B-NEU
activities I-NEU
in O
vitro O
, O
and O
inhibited O
nitric O
oxide O
( O
no O
) O
and O
prostaglandin B-DNP
e2 I-DNP
( O
pge2 B-DNP
) O
productions O
in O
lipopolysaccharide O
( O
lps)-induced O
raw264.7 O
cells O
. O

these O
also O
inhibited O
enzyme B-NEU
activities I-NEU
and O
protein B-NEU
expressions I-NEU
of O
inducible O
no B-DNP
synthase I-DNP
and O
cyclooxygenase-2 B-DNP
in O
lps-induced O
raw264.7 O
cells O
. O

mchd-inhibitory O
activity O
against O
no B-NEU
and I-NEU
pge2 I-NEU
productions I-NEU
in O
lps-induced O
raw264.7 O
cells O
was O
more O
potent O
than O
those O
of O
chd O
. O

these O
results O
suggest O
that O
chd O
may O
show O
potent O
anti-inflammatory B-POS
activity I-POS
in O
vivo O
and O
can O
improve O
brain B-NEG
ischemia I-NEG
. O

-DOCSTART- O

morbid B-NEG
leukorrhea I-NEG
; O

gynecological B-NEG
diseases I-NEG
( O
in O
a O
broad O
sense O
) O

-DOCSTART- O

insulin O
sensitivity O
and O
diabetes B-NEG
risk O
, O
body B-NEU
weight I-NEU
regulation O
, O
woman O
, O
reproductive B-DNP
systems I-DNP
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
endocrine B-DNP
system I-DNP
, O
bone B-DNP
health I-DNP
and O
osteoporosis B-NEG
, O
quality O
of O
life O
, O
menopausal B-NEG
woman O
, O
eldery O
, O
liver B-DNP
health I-DNP
, O
metabolism B-DNP
, O
mimmuietabolic O
rate/energy O
expenditure O
, O
bone B-NEU
metabolism/density B-NEU
, O
memory O
, O
liver O
, O
others O
, O
mental B-NEG
state I-NEG
and O
performance O
, O
man O

-DOCSTART- O

metrorrhagia B-NEG

-DOCSTART- O

terminate O
delivery O

-DOCSTART- O

simultaneous O
quantitative O
analyses O
of O
indole O
and O
oxindole O
alkaloids O
of O
uncaria O
hook O
in O
rat O
plasma O
and O
brain O
after O
oral O
administration O
of O
the O
traditional O
japanese O
medicine O
yokukansan O
using O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
. O

-DOCSTART- O

kampo O
( O
traditional O
japanese O
herbal O
) O
medicines O
are O
taken O
orally O
due O
to O
which O
the O
gastric B-DNP
mucosal I-DNP
immune I-DNP
system I-DNP
may O
act O
as O
one O
of O
the O
major O
targets O
for O
the O
expression O
of O
pharmacological O
activity O
. O

the O
inner O
surface O
of O
the O
intestinal O
tract O
possesses O
a O
large O
area O
of O
mucosal O
membranes O
, O
and O
the O
intestinal O
epithelial O
cells O
sit O
at O
the O
interface O
between O
a O
lumen O
and O
a O
lymphocyte O
- O
rich O
lamina O
propria O
. O

the O
cross O
talk O
that O
occurs O
between O
these O
compartments O
serves O
to O
maintain O
intestinal B-NEU
homeostasis I-NEU
, O
and O
the O
cytokine B-DNP
network I-DNP
plays O
an O
important O
role O
in O
the O
cross O
talk O
. O

in O
this O
study O
, O
the O
effect O
of O
hochuekkito O
( O
het O
) O
, O
one O
of O
kampo O
medicines O
, O
on O
cytokine B-NEU
secretion I-NEU
of O
intestinal O
epithelial O
cells O
was O
investigated O
. O

when O
murine O
normal O
colonic O
epithelial O
cell O
- O
line O
mce301 O
cells O
were O
stimulated O
with O
het O
, O
the O
contents O
of O
granulocyte B-DNP
colony I-DNP
- I-DNP
stimulating I-DNP
factor I-DNP
( O
g B-DNP
- I-DNP
csf I-DNP
) O
in O
the O
conditioned O
medium O
were O
significantly O
increased O
in O
dose O
- O
and O
time O
- O
dependent O
manners O
. O

the O
enhanced O
g B-NEU
- I-NEU
csf I-NEU
gene I-NEU
transcription I-NEU
in O
mce301 O
cells O
by O
the O
stimulation O
of O
het O
was O
observed O
by O
rt O
- O
pcr O
. O

the O
enhanced O
g B-NEU
- I-NEU
g-csf I-NEU
secretion I-NEU
by O
het O
was O
also O
observed O
in O
c3h O
/ O
hej O
mice O
- O
derived O
primary O
cultured O
colonic O
epithelial O
cells O
. O

when O
the O
het O
was O
fractionated O
, O
only O
the O
polysaccharide B-DNP
fraction I-DNP
( O
f B-DNP
- I-DNP
5 I-DNP
) O
enhanced O
the O
g B-NEU
- I-NEU
csf I-NEU
secretion I-NEU
of O
mce301 O
cells O
, O
and O
the O
activity O
of O
f B-DNP
- I-DNP
5 I-DNP
lost O
after O
the O
treatment O
of O
periodate O
that O
can O
degrade O
the O
carbohydrate O
moiety O
. O

these O
results O
suggest O
that O
het O
enhances O
secretion B-NEU
of I-NEU
g I-NEU
- I-NEU
csf I-NEU
from O
colonic O
epithelial O
cells O
and O
the O
polysaccharide O
is O
one O
of O
the O
active O
ingredients O
of O
het O
. O

the O
enhanced O
g B-NEU
- I-NEU
csf I-NEU
secretion I-NEU
by O
het O
may O
partly O
contribute O
to O
the O
clinically O
observed O
various O
pharmacological O
activities O
of O
het O
including O
immunomodulating B-NEU
activity I-NEU
. O

-DOCSTART- O

muscle B-NEG
spasticity I-NEG

-DOCSTART- O

liver O
transplantation O

-DOCSTART- O

intelligence B-POS
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
others O
, O
protective O
immunity B-NEU
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

to O
supplement O
kidney B-DNP
and O
boost O
essence O
, O
warm O
lung B-DNP
and O
settle O
asthma B-NEG
, O
moisten O
intestines B-DNP
and O
free O
stool B-NEU
. O

-DOCSTART- O

for O
ascariasis B-NEG
and O
taeniasis B-NEG
. O
for O
constipation B-NEG
due O
to O
dryness B-NEG
of O
intestine O
. O

-DOCSTART- O

to O
desolve O
phlegm B-NEG
and O
soften O
hardness O
; O
to O
revitalize O
blood B-DNP

-DOCSTART- O

loss B-NEG
of I-NEG
appetite I-NEG

-DOCSTART- O

deficiency B-NEG
of O
both O
qi O
and O
blood B-DNP
marked O
by O
pallor O
, O
shortness B-NEG
of I-NEG
breath I-NEG
, O
cardiac B-NEG
palpitation I-NEG
, O
dizziness B-NEG
, O
spontaneous B-NEG
sweating I-NEG
, O
lassitude B-NEG
and O
cold B-NEG
extremities I-NEG
, O
or O
excessive O
menstrual B-NEG
discharge I-NEG
. O

-DOCSTART- O

hgs-tr2j O
binds O
trail O
receptor O
2 O
with O
high O
affinity O
, O
induces O
apoptosis B-NEU
and O
has O
anti-tumor B-POS
activity I-POS
, O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
chemotherapy O
. O

hgs-tr2j O
mimics O
the O
activity O
of O
native O
trail O
( O
tumor O
necrosis O
factor-related O
apoptosis-inducing O
ligand O
) O
and O
, O
thus O
, O
is O
considered O
an O
agonistic O
antibody B-DNP
. O

numerous O
nonclinical O
studies O
have O
shown O
that O
cell O
lines O
derived O
from O
a O
broad O
array O
of O
solid O
and O
hematological B-NEG
human I-NEG
tumors I-NEG
, O
including O
lung O
, O
colon O
, O
breast O
, O
multiple O
myeloma B-NEG
, O
prostate O
and O
pancreas O
, O
are O
sensitive O
to O
killing O
by O
apoptosis B-NEU
( O
programmed O
cell B-NEU
death I-NEU
) O
induced O
by O
native O
trail O
or O
by O
agonistic O
antibodies O
to O
trail O
receptors O
1 O
and O
2.2-24 O
. O

-DOCSTART- O

swollen O
check O
, O
mumps B-NEG
; O
epidemic B-NEG
parotitis I-NEG

-DOCSTART- O

ischuria B-NEG
; O
dysuria B-NEG
; O
retention B-NEG
of I-NEG
urine I-NEG

-DOCSTART- O

the O
bactericidal O
action O
of O
lomefloxacin O
results O
from O
interference O
with O
the O
activity B-NEG
of I-NEG
the I-NEG
bacterial I-NEG
enzymes I-NEG
dna I-NEG
gyrase I-NEG
and O
topoisomerase B-DNP
iv I-DNP
, O
which O
are O
needed O
for O
the O
transcription O
and O
replication O
of O
bacterial O
dna O
, O
as O
a O
result O
of O
inhibition O
of O
dna B-NEU
replication I-NEU
and I-NEU
transcription I-NEU
. O

furosemide O
blocks O
the O
na-k-cl B-DNP
cotransporter I-DNP
( O
nkcc B-DNP
) O
in O
the O
luminal O
membrane O
of O
the O
thick O
ascending O
limb O
of O
the O
loop O
of O
henle O
in O
the O
kidney O
, O
by O
binding O
to O
the O
cl-binding O
site O
located O
in O
the O
cotransporter's O
transmembrane O
domain O
, O
thereby O
inhibiting O
reabsorption B-NEU
of I-NEU
sodium I-NEU
, O
chloride B-DNP
, O
potassium B-DNP
ions I-DNP
and O
water O
. O

this O
agent O
reduces O
plasma B-DNP
and O
extracellular B-NEU
fluid I-NEU
volume I-NEU
resulting O
in O
decreased O
blood B-NEU
pressure I-NEU
and O
cardiac B-NEU
output I-NEU
. O

-DOCSTART- O

ribavirin O
triphosphate O
is O
a O
potent O
competitive O
inhibitor O
of O
inosine B-DNP
monophosphate I-DNP
dehydrogenase I-DNP
, O
viral O
rna O
polymerase O
and O
mrna O
guanylyltransferase O
( O
viral O
) O
and O
can O
be O
incorporated O
into O
rna O
in O
rna O
viral O
species O
. O

sofosbuvir O
is O
a O
nucleotide O
analogue O
inhibitor O
of O
the O
hepatitis O
c O
virus O
polymerase O
which O
is O
a O
rna-dependent O
rna O
polymerase O
critical O
for O
the O
viral O
cycle O
. O

alfa O
interferons O
bind O
to O
specific O
cell-surface O
receptors O
, O
resulting O
in O
the O
transcription O
and O
translation O
of O
genes O
whose O
protein O
products O
mediate O
antiviral B-POS
, O
antiproliferative B-POS
, O
anticancer B-POS
, O
and O
immune-modulating B-NEU
effects O
. O

-DOCSTART- O

spontaneous O
external B-NEG
bleeding I-NEG
, O
hematochezia B-NEG
, O
headache B-NEG
, O
dizziness B-NEG
and O
dim B-NEG
vision I-NEG
, O
red B-NEG
eyes I-NEG
, O
night B-NEG
blindness I-NEG
, O
diabetes B-NEG
mellitus I-NEG
, O
fecal B-NEG
stoppage I-NEG
, O
hemorrhoids B-NEG
. O

-DOCSTART- O

de O
novo O
kidney O
transplant O
patients O

-DOCSTART- O

redness B-NEG

-DOCSTART- O

disperse O
wart B-NEG

-DOCSTART- O

reddish B-NEG
turbid I-NEG
urine I-NEG

-DOCSTART- O

cetuximab O
competitively O
inhibits O
epidermal O
growth O
factor O
and O
tgf B-DNP
alpha I-DNP
, O
thereby O
reducing O
their O
effects O
on O
cell B-DNP
growth I-DNP
and O
metastatic B-NEG
spread I-NEG
. O

fluorouracil O
metabolites O
incorporate O
into O
both O
rna B-DNP
and O
dna B-DNP
; O
inhibits O
synthesis B-DNP
of I-DNP
dna I-DNP
, O
incorporation O
into O
rna B-DNP
results O
in O
major O
effects O
on O
both O
rna B-DNP
processing O
and O
functions O
. O

carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
gc-rich O
sites O
in O
dna B-DNP
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
dna B-DNP
cross-links O
, O
as O
well O
as O
dna-protein B-DNP
cross-links O
. O

-DOCSTART- O

blood B-NEG
vomiting I-NEG
due O
to O
weakness B-NEG
and O
fatigue B-NEG

-DOCSTART- O

burns B-NEG
; O
fire B-NEG
burns I-NEG

-DOCSTART- O

deafness B-NEG

-DOCSTART- O

red B-NEG
face I-NEG

-DOCSTART- O

diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
overall O
cvd B-NEG

-DOCSTART- O

colonic B-NEG
cancer I-NEG
. O

-DOCSTART- O

to O
nourish O
yin O
and O
moisterize O
lung B-DNP
; O

to O
suppress O
fire O
and O
desolve O
phlegm B-NEG

-DOCSTART- O

organic O
iodine O
compounds O
attenuate O
x-rays O
as O
they O
pass O
through O
the O
body O
, O
thereby O
allowing O
the O
body O
structures O
containing O
iodine O
to O
be O
delineated O
in O
contrast O
to O
those O
structures O
that O
do O
not O
contain O
iodine O
. O

the O
degree O
of O
opacity O
produced O
by O
these O
compounds O
is O
directly O
proportional O
to O
the O
total O
amount O
( O
concentration O
and O
volume O
) O
of O
the O
iodinated O
contrast O
agent O
in O
the O
path O
of O
the O
x-rays O
. O

after O
intravascular O
administration O
, O
iodixanol O
makes O
opaque O
those O
internal O
structures O
in O
its O
path O
of O
flow O
, O
allowing O
their O
visualization O
until O
significant O
hemodilution B-NEU
and O
elimination O
occur O
. O

-DOCSTART- O

adult B-NEG
erythroleukemia I-NEG

-DOCSTART- O

treament O
of O
cough B-NEG
, O
sore B-NEG
throat I-NEG
and O
hoarseness B-NEG
of I-NEG
voice I-NEG
due O
to O
heat B-NEG
in O
the O
lung O
, O
epigastic B-NEG
pain I-NEG
due O
to O
stagnation B-NEG
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O

blood B-NEG
vaculty I-NEG
, O
menstrual B-NEG
disorder I-NEG
, O
amenorrhea B-NEG
, O
postpartum B-NEG
vacuity I-NEG
weakness I-NEG
, O
aching B-NEG
in I-NEG
lumbus I-NEG
and I-NEG
legs I-NEG
, O
fracture B-NEG
due O
to O
knocks O
and O
falls O
. O

-DOCSTART- O

to O
regulate O
the O
flow O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
, O
and O
to O
remove O
the O
retention B-NEG
of I-NEG
undigested I-NEG
food I-NEG
. O

-DOCSTART- O

mycophenolate O
stops O
t-cell B-NEU
and I-NEU
b-cell I-NEU
proliferation I-NEU
through O
selective O
inhibition O
of O
the O
de O
novo O
pathway O
of O
purine B-NEU
biosynthesis I-NEU
. O

-DOCSTART- O

organophosphate B-NEG
poisoning I-NEG

-DOCSTART- O

dimethindene O
is O
also O
indicated O
for O
pruritus B-NEG
in O
eruptive B-NEG
skin I-NEG
diseases I-NEG
such O
as O
chicken-pox B-NEG
. O

-DOCSTART- O

rifampin O
acts O
via O
the O
inhibition O
of O
dna-dependent O
rna B-DNP
polymerase I-DNP
, O
leading O
to O
a O
suppression O
of O
rna B-NEU
synthesis I-NEU
and O
cell O
death O
. O

-DOCSTART- O

proteinuria B-NEG

-DOCSTART- O

binds O
to O
the O
nicotinic O
acetycholine O
receptors O
( O
by O
virtue O
of O
its O
similarity O
to O
acetylcholine O
) O
in O
the O
motor O
endplate O
and O
blocks O
access O
to O
the O
receptors O
. O

-DOCSTART- O

rhizoma O
coptidis O
( O
processed O
with O
wine O
) O
inflammation B-NEG
of O
the O
eye O
, O
ulcers B-NEG
in O
the O
mouth O
. O

-DOCSTART- O

objectives O
mycobacterium B-NEG
avium I-NEG
subspecies I-NEG
paratuberculosis I-NEG
( O
map B-NEG
) O

-DOCSTART- O

to O
dispel O
wind B-NEG
, O
resolve O
phlegm B-NEG
and O
promote O
blood B-NEU
circulation I-NEU
to O
remove O
obstruction B-NEG
in I-NEG
the I-NEG
channels I-NEG
. O

-DOCSTART- O

to O
remove O
blood B-NEG
stasis I-NEG
and O
promote O
the O
blood B-NEU
flow I-NEU
, O
to O
stimulate O
menstrual B-NEG
discharge I-NEG
, O
and O
to O
induce O
labour O
. O

-DOCSTART- O

protracted O
diarrhea B-NEG
; O
chronic B-NEG
diarrhea I-NEG
; O
prolonged O
diarrhea B-NEG

-DOCSTART- O

tetracycline O
passively O
diffuses O
through O
porin B-DNP
channels I-DNP
in O
the O
bacterial O
membrane O
and O
reversibly O
binds O
to O
the O
30s B-DNP
ribosomal I-DNP
subunit I-DNP
, O
preventing O
binding O
of O
trna B-DNP
to O
the O
mrna-ribosome B-DNP
complex I-DNP
, O
and O
thus O
interfering O
with O
protein B-NEU
synthesis I-NEU
. O

the O
reduced O
metronidazole O
then O
covalently O
binds O
to O
dna B-DNP
, O
disrupt O
its O
helical O
structure O
, O
inhibiting O
bacterial B-NEG
nucleic I-NEG
acid I-NEG
synthesis I-NEG
and O
resulting O
in O
bacterial B-NEU
cell I-NEU
death I-NEU
. O

esomeprazole O
is O
a O
proton O
pump O
inhibitor O
that O
suppresses O
gastric B-NEU
acid I-NEU
secretion I-NEU
by O
specific O
inhibition O
of O
the O
h+/k+-atpase O
in O
the O
gastric O
parietal O
cell O
. O

-DOCSTART- O

1 O
applicable O
to O
edema B-NEG
of I-NEG
wind I-NEG
type O
attributive O
to O
attack O
of O
dampness B-NEU
and O
heat B-NEU
, O
which O
is O
manifested O
as O
general O
edema B-NEG
beginning O
from O
the O
eyelids O
, O
dyuria B-NEG
, O
fever B-NEG
, O
chilliness B-NEG
, O
white B-NEG
and I-NEG
greasy I-NEG
fur I-NEG
on O
the O
tongue O
and O
slow B-NEG
pulse I-NEG
. O
2 O
also O
applicable O
to O
urinar B-NEU

-DOCSTART- O

blood B-NEG
wind I-NEG
of O
female O

-DOCSTART- O

unblock O
blood B-DNP

-DOCSTART- O

fullness B-NEU
of O
chest O
and O
abdomen O
. O

indigestion B-NEG
caused O
by O
that O
cold O
pathogen B-NEG
of O
the O
middle-cho O
disturb O
function O
of O
stomach B-DNP
and O
spleen B-DNP
. O
feel O
tiring B-NEG
and O
heavy O
, O
pain B-NEG
in O
joint O
due O
to O
damp O
pathogen B-NEG

-DOCSTART- O

the O
hormones O
, O
t O
4 O
and O
t O
3, O
are O
tyrosine-based O
hormones O
produced O
by O
the O
thyroid O
gland O
. O

iodine O
is O
an O
important O
component O
in O
their O
synthesis O
. O

the O
major O
secreted O
form O
of O
thyroid O
hormone O
is O
t4 O
. O

t4 O
is O
converted O
t3 O
, O
the O
more O
active O
thyroid O
hormone O
, O
by O
deiodinases O
in O
peripheral O
tissues O
. O

t3 O
acts O
in O
the O
body O
to O
increase O
basal B-NEU
metabolic I-NEU
rate I-NEU
, O
alter O
protein B-NEU
synthesis I-NEU
and O
increase O
the O
body's B-NEU
sensitivity I-NEU
to O
catecholamines O
( O
such O
as O
adrenaline O
) O
. O

thyroid O
hormones O
are O
essential O
for O
proper O
development O
and O
differentiation O
of O
all O
cells O
of O
the O
human O
body O
. O

t O
4 O
and O
t O
3 O
regulate O
protein O
, O
fat O
and O
carbohydrate O
metabolism O
to O
varying O
extents O
. O

the O
most O
pronounced O
effect O
of O
the O
hormones O
is O
in O
altering O
how O
human O
cells O
use O
energetic O
compounds O
. O

the O
thyroid O
hormone O
derivatives O
bind O
to O
the O
thyroid O
hormone O
receptors O
initially O
to O
initiate O
their O
downstream O
effects O
. O

-DOCSTART- O

infantile B-NEG
malnutrition I-NEG
an O
infantile B-NEG
disease I-NEG
due O
to O
digestive B-NEG
disturbance I-NEG
or O
intestinal B-NEG
parasites I-NEG
with O
symptoms O
of O
wasting O
, O
pallor B-NEG
or O
sallowness B-NEG
, O
potbelly B-NEG
, O
and O
chronic B-NEG
diarrhea I-NEG
. O

-DOCSTART- O

hoarseness B-NEG

-DOCSTART- O

melanoma B-NEG

-DOCSTART- O

a O
diseade O
of O
chronic B-NEG
dysentery I-NEG
. O

caused O
by O
the O
central O
gi O
falling O
down O
due O
to O
deficiency B-NEG
of I-NEG
the I-NEG
spleen I-NEG
and I-NEG
stomach I-NEG
from O
chronic B-NEG
dysentery I-NEG
. O

a O
symptom O
of O
feces B-NEG
with I-NEG
pus I-NEG
and I-NEG
blood I-NEG
and O
slight O
stomach B-NEG
pain I-NEG

-DOCSTART- O

cough B-NEG
due O
to O
phlegm-damp B-NEG
due O
to O
lung-heat B-NEU

-DOCSTART- O

adult B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG
with O
t(8;21)(q22;q22 O
) O
; O
runx1-runx1t1 O

-DOCSTART- O

gastroesophageal B-NEG
reflux I-NEG
disease I-NEG

-DOCSTART- O

treatment O
of O
cough B-NEG
in O
colds O
with O
retention O
of O
phlegm B-NEG
marked O
by O
dyspnea B-NEG
, O
profuse O
expectoration B-NEG
and O
feeling O
of O
stuffiness B-NEG
in O
the O
chest O
, O
external O
use O
for O
pyogenic B-NEG
infections I-NEG
of O
the O
skin O
. O

-DOCSTART- O

dryness B-NEU
of O
mouth O

-DOCSTART- O

general O
woman O
, O
woman O
, O
menopausal B-NEG
woman I-NEG

-DOCSTART- O

chai O
hu O
( O
radix O
burpleuri O
) O
, O
a O
major O
ingredient O
in O
many O
traditional O
chinese O
medicine O
formulas O
, O
such O
as O
xiao O
yan O
wan O
, O
is O
used O
in O
the O
treatment O
of O
liver B-NEG
stagnation I-NEG
and O
spleen B-NEG
deficiency I-NEG
syndrome I-NEG
( O
lssds B-NEG
) O
. O

the O
objectives O
of O
this O
study O
were O
to O
examine O
the O
effects O
of O
xiao O
yao O
wan O
containing O
chai O
hu O
on O
the O
changes O
of O
plasma B-DNP
indices I-DNP
in O
patients O
with O
lssds B-NEG
. O

fifty-eight O
cases O
of O
lssds B-NEG
were O
randomly O
divided O
into O
two O
groups O
: O
41 O
cases O
in O
the O
experimental O
group O
were O
treated O
with O
xiao O
yao O
wan O
containing O
chai O
hu O
and O
17 O
cases O
in O
the O
control O
group O
were O
treated O
with O
zhi O
bai O
di O
huang O
wan O
for O
one O
consecutive O
month O
in O
a O
single O
blind O
design O
. O

before O
and O
after O
treatment O
, O
high O
performance O
liquid O
chromatography O
( O
hplc O
) O
was O
applied O
to O
determine O
the O
changes O
of O
plasma B-DNP
norepinephrine I-DNP
( O
ne B-DNP
) O
, O
epinephrine B-DNP
( O
e B-DNP
) O
and O
dopamine B-DNP
( O
da B-DNP
) O
. O

radioimmunoassay O
was O
performed O
to O
measure O
the O
amount O
of O
plasma B-DNP
beta-endorphin I-DNP
( O
beta-ep B-DNP
) O
, O
adrenocorticotropin B-DNP
hormone I-DNP
( O
acth B-DNP
) O
, O
estradiol B-DNP
( O
e2 B-DNP
) O
and O
testosterone B-DNP
( O
t B-DNP
) O
, O
and O
laser O
nephelometry O
was O
also O
conducted O
to O
measure O
plasma B-DNP
immunoglobulin I-DNP
a I-DNP
( O
ig B-DNP
a) I-DNP
and O
g O
( O
ig B-DNP
g I-DNP
) O
. O

compared O
to O
baseline O
levels O
, O
plasma B-DNP
beta-ep I-DNP
was O
significantly O
increased O
(p O
< O
0.01 O
) O
, O
while O
e B-DNP
and O
da B-DNP
were O
markedly O
decreased O
(p O
< O
0.01 O
) O
after O
the O
administration O
of O
xiao O
yao O
wan O
in O
the O
experimental O
group O
. O

the O
other O
indices O
did O
not O
change O
. O

this O
is O
the O
first O
evidence O
showing O
that O
the O
effect O
of O
xiao O
yao O
wan O
containing O
chai O
hu O
on O
the O
treatment O
of O
patients O
with O
lssds B-NEG
may O
be O
through O
enhancing O
plasma B-DNP
beta-ep I-DNP
and O
decreasing O
e B-DNP
and O
da B-DNP
release O
. O

we O
conclude O
that O
xiao O
yao O
wan O
containing O
chai O
hu O
regulates O
nervous B-DNP
and I-DNP
endocrine I-DNP
systems I-DNP
and O
contributes O
to O
the O
improvement O
of O
the O
clinical O
status O
of O
patients O
with O
lssds B-NEG
. O

-DOCSTART- O

reproductive B-DNP
systems I-DNP
, O
mood O
, O
physical B-DNP
performance B-DNP
and O
fitness B-POS
, O
endocrine B-DNP
system I-DNP
, O
endurance B-NEU
, O
energy O
supply O
and O
recovery B-POS
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
memory B-POS
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
quality O
of O
life O
, O
uv B-POS
protection I-POS
, O
others O
, O
man O
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
motivation O
, O
strength B-POS
and O
power B-POS
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
, O
hemostatic B-DNP
function I-DNP
, O
effort O
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
intelligence B-POS
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
overall O
cvd B-NEG
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
protective B-NEU
immunity I-NEU

-DOCSTART- O

wind B-NEG
pi I-NEG
syndrome I-NEG
; O
arthralgia B-NEG
due O
to O
wind B-NEG
arthritis I-NEG
mainly O
due O
to O
pathogenic B-NEG
wind I-NEG
, O
marked O
by O
swelling B-NEG
and O
migratory B-NEG
pain I-NEG
in O
the O
joints O
of O
the O
limbs O
. O

-DOCSTART- O

methotrexate O
anti-tumor O
activity O
is O
a O
result O
of O
the O
inhibition O
of O
folic B-DNP
acid I-DNP
reductase I-DNP
, O
leading O
to O
inhibition O
of O
dna B-NEU
synthesis I-NEU
and O
inhibition O
of O
cellular B-NEU
replication I-NEU
. O

golimumab O
inhibits O
the O
activity B-NEU
of I-NEU
the I-NEU
cytokine I-NEU
, O
tumor B-DNP
necrosis I-DNP
factor I-DNP
alpha I-DNP
. O

-DOCSTART- O

pi B-NEG
syndrome I-NEG
due O
to O
pathogenic B-NEG
wind I-NEG
, O
cold B-NEG
and O
damp B-NEU

-DOCSTART- O

to O
clear O
heat B-NEU
and O
resolve O
toxin B-NEG
, O
disinhibit O
urine B-NEU
, O
relieve O
cough B-NEG
, O
stanch O
bleeding B-NEG
. O

-DOCSTART- O

recently O
, O
also O
used O
for O
biliary B-NEG
ascariasis I-NEG
, O
biliary B-NEG
infection I-NEG
and O
cholelithiasis B-NEG
with O
abdominal B-NEG
pain I-NEG
( O
adhesive O
ascarial O
and O
paralytic B-NEG
ileus I-NEG
) O
. O

-DOCSTART- O

polysaccharide-containing O
macromolecules O
in O
a O
kampo O
( O
traditional O
japanese O
herbal O
) O
medicine O
, O
hochuekkito O
: O
dual O
active O
ingredients O
for O
modulation O
of O
immune O
functions O
on O
intestinal B-DNP
peyer's I-DNP
patches I-DNP
and O
epithelial B-DNP
cells I-DNP
. O

-DOCSTART- O

exerting O
prolong O
hypotensive B-NEU
effect I-NEU
in O
anesthetized O
animals. O
. O

-DOCSTART- O

this O
is O
a O
syndrome O
with O
palpitation B-NEG
and O
severe O
palpitation B-NEG
. O

-DOCSTART- O

for O
the O
treatment O
of O
gastroesophageal B-NEG
reflux I-NEG
disease I-NEG
( O
gerd B-NEG
) O
. O

it O
is O
also O
used O
in O
treating O
nausea B-NEG
and O
vomiting B-NEG
, O
and O
to O
increase O
gastric B-NEU
emptying I-NEU
. O

occasionally O
used O
in O
cushing's B-NEG
syndrome I-NEG
. O

-DOCSTART- O

delirium B-NEG

-DOCSTART- O

concurrent O
disease B-NEG
of O
the O
t'aeyang O
meridian O
and O
the O
soyang O
meridian O

-DOCSTART- O

bluish B-NEG
blindness I-NEG
; O
optic B-NEG
atrophy I-NEG
; O
glaucoma B-NEG

-DOCSTART- O

affection O
due O
to O
wind-heat B-NEG
; O
common O
cold B-NEG
of O
the O
wind-heat B-NEG
type O
; O
flu B-NEG
caused O
by O
wind B-NEG
and O
heat B-NEU

-DOCSTART- O

menstrual B-NEG
abdominal I-NEG
pain I-NEG

-DOCSTART- O

for O
stablizing O
period O
, O
controlling O
urine B-NEU
and O
reducing O
heavy B-NEU
blood-flow I-NEU

-DOCSTART- O

ulcerative B-NEG
gingivitis I-NEG

-DOCSTART- O

anti-inflammatory B-POS
effects O
of O
the O
chinese O
herbal O
formula O
fahf-2 O
in O
experimental O
and O
human O
ibd O
. O

-DOCSTART- O

woman O
, O
bone B-NEU
health I-NEU
and O
osteoporosis B-NEG
, O
bone B-NEU
metabolism I-NEU
/ I-NEU
density I-NEU
, O
menopausal B-NEG
woman I-NEG

-DOCSTART- O

moisten O
skin B-DNP

-DOCSTART- O

to O
relieve O
dyspnea B-NEG
and O
cough B-NEG
by O
eliminating O
cold-phlegm B-NEG
, O
to O
reduce O
modulation O
, O
and O
to O
relieve O
pain B-NEG
by O
removing O
the O
obstruction O
of O
collateral O
. O

-DOCSTART- O

secure O
the O
essence O

-DOCSTART- O

used O
for O
the O
treatment O
of O
individual O
patients O
with O
certain O
filarial B-NEG
diseases I-NEG
including O
tropical B-NEG
pulmonary I-NEG
eosinophilia I-NEG
, O
loiasis B-NEG
, O
and O
lymphatic B-NEG
filariasis I-NEG
caused O
by O
infection O
with O
wuchereria B-NEG
bancrofti I-NEG
, O
brugia B-NEG
malayi I-NEG
, O
or O
brugia B-NEG
timori I-NEG
. O

-DOCSTART- O

( O
1 O
) O
precordial B-NEG
pain I-NEG
; O
intermittent O
cardiac B-NEG
pain I-NEG
( O
2 O
) O
epigastric B-NEG
pain I-NEG

-DOCSTART- O

abdominal B-NEG
mass I-NEG

-DOCSTART- O

it O
contains O
about O
0.5 O
of O
fatty O
oil O
, O
exerting O
antitussive O
effect O
. O

-DOCSTART- O

stroke B-NEG
; O
sudden B-NEG
wind-stroke I-NEG
a O
sudden O
and O
severe O
attack O
, O
as O
of O
apoplexy B-NEG

-DOCSTART- O

genz-112638 O
, O
a O
novel O
ceramide O
analog O
given O
orally O
, O
is O
designed O
to O
inhibit O
the O
enzyme B-DNP
glucosylceramide I-DNP
synthase I-DNP
, O
which O
results O
in O
reduced O
production O
of O
glucocerebroside B-DNP
. O

this O
is O
the O
substance O
that O
builds O
up O
in O
the O
cells O
and O
tissues O
of O
people O
with O
gaucher B-NEG
disease I-NEG
. O

in O
preclinical O
studies O
, O
the O
molecule O
has O
shown O
high O
potency O
and O
specificity O
. O

-DOCSTART- O

gases B-NEG
retention I-NEG
in O
the O
lungs O

-DOCSTART- O

palonosetron O
is O
a O
selective O
serotonin O
5-ht O
3 O
receptor O
antagonist O
. O

the O
antiemetic O
activity O
of O
the O
drug O
is O
brought O
about O
through O
the O
inhibition O
of O
5-ht O
3 O
receptors O
present O
both O
centrally O
( O
medullary O
chemoreceptor O
zone O
) O
and O
peripherally O
( O
gi O
tract O
) O
. O

this O
inhibition O
of O
5-ht O
3 O
receptors O
in O
turn O
inhibits O
the O
visceral O
afferent O
stimulation O
of O
the O
vomiting O
center O
, O
likely O
indirectly O
at O
the O
level O
of O
the O
area B-DNP
postrema I-DNP
, O
as O
well O
as O
through O
direct O
inhibition O
of O
serotonin B-DNP
activity I-DNP
within O
the O
area B-DNP
postrema I-DNP
and O
the O
chemoreceptor O
trigger O
zone O
. O

alternative O
mechanisms O
appear O
to O
be O
primarily O
responsible O
for O
delayed O
nausea B-NEG
and O
vomiting B-NEG
induced O
by O
emetogenic O
chemotherapy O
, O
since O
similar O
temporal O
relationships O
between O
between O
serotonin B-DNP
and O
emesis B-NEG
beyond O
the O
first O
day O
after O
a O
dose O
have O
not O
been O
established O
, O
and O
5-ht O
3 O
receptor O
antagonists O
generally O
have O
not O
appeared O
to O
be O
effective O
alone O
in O
preventing O
or O
ameliorating O
delayed O
effects O
. O

it O
has O
been O
hypothesized O
that O
palonosetron's O
potency O
and O
long O
plasma O
half-life O
may O
contribute O
to O
its O
observed O
efficacy O
in O
preventing O
delayed O
nausea B-NEG
and O
vomiting B-NEG
caused O
by O
moderately O
emetogenic O
cancer O
chemotherapy O
. O

-DOCSTART- O

to O
dissipate O
cold B-NEG
and O
relieve O
pain B-NEG
, O
regulate O
menstruation B-NEU
. O

-DOCSTART- O

to O
nourish O
yin O
; O
to O
relieve O
fire O
; O
to O
smooth O
heart B-DNP
and O
kidney B-DNP

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU

-DOCSTART- O

tsumura O
hachimijiogan O
, O
7.5 O
g O
a O
day O
, O
was O
administered O
to O
30 O
patients O
with O
benign B-NEG
prostatic I-NEG
hypertrophy I-NEG
( O
bph B-NEG
) O
. O

clinical O
effects O
were O
estimated O
based O
on O
subjective O
symptoms O
and O
objective O
findings O
obtained O
by O
uroflowmetry O
. O

twenty O
patients O
( O
0.667 O
) O
showed O
improvement O
of O
subjective O
symptoms O
and O
14 O
patients O
( O
0.467 O
) O
showed O
good O
response O
in O
uroflowmetry O
. O

an O
improvement O
of O
overall O
clinical O
efficacy O
was O
observed O
in O
21 O
patients O
( O
0.7 O
) O
. O

these O
results O
were O
better O
than O
those O
obtained O
with O
5 O
g O
a O
day O
doses O
of O
tsumura O
hachimijiogan O
. O

no O
significant O
relation O
between O
the O
sho O
in O
chinese O
medicine O
and O
the O
clinical O
effects O
of O
hachimijiogan O
was O
detected O
. O

no O
side O
effects O
or O
abnormal O
laboratory O
data O
were O
found O
in O
any O
of O
these O
30 O
patients O
. O

-DOCSTART- O

anesthesia B-NEU
with O
use O
of O
lma O
( O
laryngeal O
mask O
airway O
) O

-DOCSTART- O

bipolar B-NEG
disorder I-NEG

-DOCSTART- O

bone O
metabolism/density B-NEU
, O
intelligence O
, O
bone B-DNP
health I-DNP
and O
osteoporosis B-NEG
, O
overall O
cvd B-NEG
, O
diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
others O
, O
mental B-NEG
state I-NEG
and O
performance O

-DOCSTART- O

1 O
applicable O
to O
summer B-NEG
fever I-NEG
in O
children O
manifested O
as O
prolonged B-NEG
fever I-NEG
, O
restlessness B-NEG
, O
thirst B-NEG
, O
fatigue B-NEG
, O
red B-NEG
tongue I-NEG
with O
little O
fur O
, O
hollow O
and O
rapid B-NEG
pulse I-NEG
, O
which O
is O
attributed O
to O
comsumption O
of O
both O
vital B-DNP
energy I-DNP
and O
body B-DNP
fluid I-DNP
by O
summer-heat O
evil O
. O
in O
this O
case O
, O

-DOCSTART- O

a O
symptom O
that O
the O
lung O
is O
blocked O
up O
caused O
by O
symptoms O
due O
to O
retention B-NEG
of I-NEG
phlegm I-NEG
. O

-DOCSTART- O

the O
functional O
group O
of O
the O
anion O
exchange O
resin O
is O
a O
quaternary O
ammonium O
group O
attached O
to O
an O
inert O
styrene-divinylbenzene O
copolymer O
. O

-DOCSTART- O

neurological B-DNP
systems I-DNP
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
mental B-NEU
state I-NEU
and I-NEU
performance I-NEU
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
memory O

-DOCSTART- O

stop O
bleeding B-NEG
; O
hemostasis B-POS

-DOCSTART- O

unblock O
blood B-DNP
vessel I-DNP

-DOCSTART- O

chlorpheniramine O
binds O
to O
the O
histamine O
h1 O
receptor O
, O
which O
blocks O
the O
action B-NEU
of I-NEU
endogenous I-NEU
histamine I-NEU
, O
which O
subsequently O
leads O
to O
temporary O
relief O
of O
the O
negative B-NEG
symptoms I-NEG
brought O
on O
by O
histamine O
. O

-DOCSTART- O

anti-inflammatory B-POS
activity I-POS
of O
gumiganghwaltang O
through O
the O
inhibition O
of O
nuclear B-NEU
factor-kappa I-NEU
b I-NEU
activation I-NEU
in O
peritoneal O
macrophages O
. O

-DOCSTART- O

1 O
to O
clear O
heat B-NEU
and O
toxic B-NEG
material I-NEG
, O
deprive O
dampness B-NEU
and O
kill O
parasites B-NEG
. O

for O
sorethroat B-NEG
, O
dysentery B-NEG
, O
trichomonas B-NEG
enteritis I-NEG
, O
toothache B-NEG
, O
stomachache B-NEG
and O
leucorrhagia B-NEU
, O
external O
use O
for O
tinea B-NEG
and O
eczema B-NEG
. O

2 O
to O
relieve O
dyspnea B-NEG
and O
cough B-NEG
. O

3 O
anticarcinogenic B-POS
. O
for O
malignant B-NEG
hydatidiform I-NEG
mole I-NEG
, O
chorionic B-NEG
epithelioma I-NEG
and O
leukemia B-NEG
. O

-DOCSTART- O

arrest O
vomiting B-NEG

-DOCSTART- O

support O
five O
viscera B-DNP

-DOCSTART- O

for O
breaking O
blood B-DNP
and O
desolving O
stasis B-NEG

-DOCSTART- O

purging O
by O
pressure O
and O
by O
removing O
liquid O

-DOCSTART- O

didanosine O
is O
converted O
to O
the O
active O
triphosphate O
form O
, O
which O
is O
incorporated O
into O
dna O
and O
inhibits O
dna B-NEU
elongation I-NEU
. O

-DOCSTART- O

hyperactivity B-NEG
of O
the O
liver-yang O
, O
hypertension B-NEG
, O
dizziness B-NEG
, O
vertigo B-NEG
, O
insomnia B-NEG
, O
amnesia B-NEG
. O

-DOCSTART- O

dissipate O
blood B-DNP

-DOCSTART- O

macular B-NEG
degeneration I-NEG

-DOCSTART- O

disease O
due O
to O
wind-dampness B-NEG
; O
rheumatism B-NEG

-DOCSTART- O

lopinavir O
inhibits O
hiv B-DNP
protease I-DNP
. O

ritonavir O
inhibits O
the O
cyp3a O
mediated O
metabolism B-NEU
of O
lopinavir O
, O
thereby O
providing O
increased O
plasma O
level O
of O
lopinavir O
. O

-DOCSTART- O

phenylpropanolamine O
acts O
directly O
on O
alpha- O
and O
, O
to O
a O
lesser O
degree O
, O
beta-adrenergic O
receptors O
in O
the O
mucosa B-DNP
of I-DNP
the I-DNP
respiratory I-DNP
tract I-DNP
. O

-DOCSTART- O

hiv B-NEG
infection I-NEG

-DOCSTART- O

headache B-NEG
due O
to O
adverse O
rising O
of O
phlegm B-NEG

-DOCSTART- O

metformin O
acts O
by O
the O
initial O
activation B-NEU
of I-NEU
amp-activated I-NEU
protein I-NEU
kinase I-NEU
( O
ampk B-DNP
) O
, O
a O
liver B-DNP
enzyme I-DNP
that O
plays O
an O
important O
role O
in O
insulin B-NEU
signaling I-NEU
, O
whole O
body B-POS
energy I-POS
balance I-POS
, O
and O
the O
metabolism B-NEU
of O
glucose O
and O
fats O
. O

rosiglitazone O
acts O
as O
a O
highly O
selective O
and O
potent O
agonist O
at O
peroxisome O
proliferator O
activated O
receptors O
( O
ppar O
) O
in O
target O
tissues O
for O
insulin B-NEU
action I-NEU
such O
as O
adipose O
tissue O
, O
skeletal O
muscle O
, O
and O
liver O
and O
enhances O
tissue B-NEU
sensitivity I-NEU
to O
insulin O
. O

-DOCSTART- O

urinary B-DNP
system I-DNP
health I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
urinary B-DNP
system I-DNP
health I-DNP
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
absorption B-NEU
, O
urinary B-DNP
systems I-DNP
, O
pregnancy B-DNP

-DOCSTART- O

stagnation O
of O
liver-qi O
, O
abnormal O
relation O
between O
spleen O
and O
stomach O
, O
sensation B-NEG
of I-NEG
fullness I-NEG
and O
obstruction B-NEG
over O
chest O
and O
diaphragm O
, O
distension B-NEG
at O
hypochondriac O
regions O
, O
stomach-ache B-NEG
, O
gastric B-NEG
upset I-NEG
, O
eructation B-NEG
, O
acid B-NEG
eructation I-NEG
, O
nausea B-NEG
and O
vomiting B-NEG
. O

-DOCSTART- O

atrophy B-NEG

-DOCSTART- O

thoracic O
surgery O

-DOCSTART- O

persistent B-NEG
asthma I-NEG

-DOCSTART- O

disperse O
wind B-NEG
and O
eliminate O
dampness B-NEU

-DOCSTART- O

stage O
iii O
adult B-NEG
lymphoblastic I-NEG
lymphoma I-NEG

-DOCSTART- O

hemoptysis B-NEG

-DOCSTART- O

the O
so O
called O
renin-angiotensin B-DNP
system I-DNP
( O
ras B-DNP
) O
is O
an O
important O
regulator O
of O
blood B-NEU
pressure I-NEU
and O
has O
already O
been O
successfully O
targeted O
by O
three O
major O
classes O
of O
antihypertensive O
drugs O
: O
by O
ace O
inhibitors O
, O
by O
arbs O
and O
by O
renin O
inhibitors O
. O
QQQQQ O
-DOCSTART- O

kidney B-NEG
failure I-NEG
, I-NEG
chronic I-NEG

-DOCSTART- O

vomiting B-NEG

-DOCSTART- O

infection B-NEG

-DOCSTART- O

zidovudine O
inhibits O
the O
activity B-NEG
of I-NEG
hiv-1 I-NEG
reverse I-NEG
transcriptase I-NEG
( O
rt B-NEG
) O
via O
dna B-NEU
chain I-NEU
termination I-NEU
after O
incorporation O
of O
the O
nucleotide O
analogue O
. O

efavirenz O
inhibits O
the O
activity B-DNP
of I-DNP
viral I-DNP
rna-directed I-DNP
dna I-DNP
polymerase I-DNP
. O

lamivudine O
is O
a O
synthetic O
nucleoside O
analogue O
and O
this O
nucleoside O
analogue O
is O
incorporated O
into O
viral O
dna O
by O
hiv B-DNP
reverse I-DNP
transcriptase I-DNP
and O
hbv B-DNP
polymerase I-DNP
, O
resulting O
in O
dna B-NEU
chain I-NEU
termination I-NEU
. O

-DOCSTART- O

as O
first O
clinical O
data O
indicate O
, O
the O
achieved O
blood B-NEU
pressure I-NEU
reduction I-NEU
was O
particularly O
pronounced O
in O
the O
early O
morning O
when O
the O
vaccine O
effect O
suppressed O
the O
naturally O
occurring O
morning O
rise O
in O
blood B-NEU
pressure I-NEU
. O

-DOCSTART- O

relax O
tension B-NEU

-DOCSTART- O

indacaterol O
works O
by O
stimulating O
adrenergic O
beta-2 O
receptors O
in O
the O
smooth O
muscle O
of O
the O
airways O
. O

tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O

-DOCSTART- O

treatment O
of O
thrist O
in O
febrile B-NEG
disease I-NEG
, O
dry B-NEG
cough I-NEG
due O
to O
heat B-NEG
in O
the O
lung O
, O
diabetes B-NEG
caused O
by O
internal O
heat B-NEU
, O
sores B-NEG
and O
abscess B-NEG
. O

-DOCSTART- O

cough B-NEG
due O
to O
phlegm B-NEG

-DOCSTART- O

invigorate O
blood B-DNP
and O
resolve O
stasis B-NEG

-DOCSTART- O

delta1-dihydrotestosterone O
binds O
to O
the O
androgen O
receptor O
, O
a O
nuclear O
receptor O
which O
binds O
the O
androgenic B-DNP
hormones I-DNP
testosterone I-DNP
and O
dihydrotestosterone B-DNP
. O

-DOCSTART- O

malignant B-NEG
furuncle I-NEG
due O
to O
scrofula B-NEG
. O

-DOCSTART- O

dry B-NEG
heat I-NEG
and O
cough B-NEG
with O
much O
expectoration B-NEG

-DOCSTART- O

swelling B-NEG
pain I-NEG
in O
joints O
, O
numbness B-NEG
in O
limbs O
, O
knocks B-NEG
and O
falls B-NEG
, O
cough B-NEG
and O
asthma B-NEG
, O
heat B-NEG
strangury I-NEG
, O
poisonous B-NEG
snake I-NEG
bite I-NEG
. O

-DOCSTART- O

to O
regulate O
the O
flow O
of O
qi O
in O
the O
liver B-DNP
, O
spleen B-DNP
and O
stomach B-DNP
, O
and O
to O
resolve O
phlegm B-NEG
. O

-DOCSTART- O

juvenile O
onset O
smallpox B-NEG
poison O

-DOCSTART- O

in O
traditional O
chinese O
medicine O
theory O
( O
tcm O
) O
, O
the O
affected O
parts O
of O
sprains B-NEG
, O
bruises B-NEG
and O
arthritis B-NEG
are O
considered O
to O
be O
under O
certain O
conditions O
of O
tcm O
concept O
. O

we O
administered O
two O
kampo O
medicines O
with O
synergistic O
effects O
to O
promote O
quick O
recovery I-POS
from O
these O
conditions O
. O

jidabokuippo O
( O
zhidapuyifang O
in O
chinese O
) O
, O
which O
means O
'decoction O
for O
contusions' B-NEG
is O
expected O
to O
remove O
these O
conditions O
. O

hachimijiogan O
( O
baweidihuangwan O
in O
chinese O
) O
, O
which O
translates O
as O
'eight-ingredient O
pill O
with O
rehmannia' O
is O
expected O
to O
restore O
presumed O
minute O
bone B-NEG
injury I-NEG
and O
regulates O
bone B-NEU
metabolism I-NEU
by O
changing O
such O
conditions O
based O
on O
tcm O
theory O
. O

we O
administered O
the O
two O
prescriptions O
to O
10 O
patients O
( O
age O
range O
: O
40-85 O
years O
; O
1 O
male O
, O
9 O
females O
) O
suffering O
from O
bruises B-NEG
, O
sprains B-NEG
, O
arthritis B-NEG
and O
spinal B-NEG
compression I-NEG
fracture I-NEG
without O
changing O
their O
routine O
intake O
of O
other O
drugs O
. O

patients O
reported O
on O
changes O
in O
the O
pain O
of O
affected O
body O
parts O
by O
using O
the O
visual O
analog O
scale O
( O
vas O
) O
before O
and O
after O
administration O
of O
kampo O
medicine O
. O

in O
almost O
all O
cases O
, O
recovery B-POS
began O
promptly O
after O
administration O
and O
the O
pain B-NEG
disappeared O
within O
approximately O
2 O
weeks O
. O

large O
doses O
for O
a O
short O
time O
brought O
about O
much O
quicker O
recovery B-POS
than O
small O
doses O
. O

administration O
of O
a O
combination O
of O
two O
kampo O
medicines O
, O
jidabokuippo O
and O
hachimijiogan O
, O
quickly O
resolved O
the O
pain B-NEG
of O
bruises B-NEG
, O
sprains B-NEG
, O
arthritis B-NEG
and O
one O
spinal B-NEG
compression I-NEG
fracture I-NEG
. O

-DOCSTART- O

epinastine O
has O
a O
multiaction O
effect O
that O
inhibits O
the O
allergic B-NEU
response I-NEU
in O
3 O
ways O
: O
1 O
stabilizes O
mast B-DNP
cells I-DNP
by O
preventing O
mast B-NEU
cell I-NEU
degranulation I-NEU
to O
control O
the O
allergic B-NEU
response I-NEU
, O
2 O
prevents O
histamine B-DNP
binding O
to O
both O
the O
h1- O
and O
h O
2-receptors O
to O
stop O
itching B-NEG
and O
provide O
lasting B-POS
protection I-POS
, O
and O
3 O
prevents O
the O
release B-NEU
of I-NEU
proinflammatory I-NEU
chemical I-NEU
mediators I-NEU
from O
the O
blood B-DNP
vessel I-DNP
to O
halt O
progression O
of O
the O
allergic B-NEU
response I-NEU
. O

-DOCSTART- O

aim O
: O
zhi O
zhu O
wan O
( O
zzw O
) O
is O
a O
classical O
chinese O
medical O
formulation O
used O
for O
the O
treatment O
of O
functional O
dyspepsia B-NEG
that O
attributed O
to O
spleen B-NEG
- I-NEG
deficiency I-NEG
syndrome I-NEG
. O

zzw O
contains O
atractylodes O
rhizome O
and O
fructus O
citrus O
immaturus O
, O
the O
later O
originates O
from O
both O
citrus O
aurantium O
l. O
( O
bzzw O
) O
and O
citrus O
sinensis O
osbeck O
( O
rzzw O
) O
. O

the O
present O
study O
is O
designed O
to O
elucidate O
disparities O
in O
the O
clinical O
efficacy O
of O
two O
zzw O
varieties O
based O
on O
the O
pharmacokinetics O
of O
naringenin O
and O
hesperetin O
. O

mehtod O
: O
after O
oral O
administration O
of O
zzws O
, O
blood O
sample O
was O
collected O
from O
healthy O
volunteers O
at O
designed O
time O
points O
. O

naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
by O
rp-hplc O
, O
pharmacokinetic O
parameters O
were O
processed O
using O
mode-independent O
methods O
with O
winnonlin O
. O

results O
: O
after O
oral O
administration O
of O
bzzw O
, O
both O
naringenin O
and O
hesperetin O
were O
detected O
in O
plasma O
, O
and O
demonstrated O
similar O
pharmacokinetic O
parameters O
. O

ka O
was O
0.384+/-0.165 O
and O
0.401+/-0.159 O
, O
t(1/2(ke))(h O
) O
was O
5.491+/-3.926 O
and O
5.824+/-3.067 O
, O
the O
auc O
( O
mg/lh O
) O
was O
34.886+/-22.199 O
and O
39.407+/-19.535 O
for O
naringenin O
and O
hesperetin O
, O
respectively O
. O

however O
, O
in O
the O
case O
of O
rzzw O
, O
only O
hesperetin O
was O
found O
in O
plasma O
, O
but O
the O
pharmacokinetic O
properties O
for O
hesperetin O
in O
rzzw O
was O
different O
from O
that O
in O
bzzw O
. O

t(max O
) O
for O
hesperetin O
in O
rzzw O
is O
about O
8.515h O
, O
and O
its O
c(max O
) O
is O
much O
larger O
than O
that O
of O
bzzw O
. O

moreover O
, O
it O
was O
eliminated O
slowly O
as O
it O
possessed O
a O
much O
larger O
auc O
value O
. O

conclusion O
: O
the O
distinct O
therapeutic O
orientations O
of O
the O
chinese O
medical O
formula O
zzws O
with O
different O
fructus O
citrus O
immaturus O
could O
be O
elucidated O
based O
on O
the O
pharmacokinetic O
parameters O
of O
constituents O
after O
oral O
administration O
. O

-DOCSTART- O

heavy B-NEG
flow I-NEG
in I-NEG
period I-NEG
due O
to O
blood B-NEG
stagnation I-NEG

-DOCSTART- O

wind B-NEG
stroke I-NEG

apoplexy B-NEG

invasion B-NEG
of I-NEG
wind I-NEG
pathogen I-NEG

wind-stroke B-NEG
syndrome I-NEG
syndrome O
due O
to O
external O
affection O
by O
the O
pathogenic B-NEG
wind I-NEG
, O
manifested O
by O
fever B-NEG
, O
headache B-NEG
, O
perspiration B-NEG
, O
slow B-DNP
and I-DNP
floating I-DNP
pulse I-DNP
. O

-DOCSTART- O

mild O
asthma B-NEG

-DOCSTART- O

woman O
, O
menopausal B-NEG
woman I-NEG

-DOCSTART- O

desire O
for O
vomiting B-NEG
; O
feel O
nauseated B-NEG
; O
nausea B-NEG

-DOCSTART- O

a O
symptom O
of O
fingers B-NEG
being I-NEG
cold I-NEG
although O
the O
temperature O
is O
not O

-DOCSTART- O

an O
illness O
in O
which O
phlegm B-NEG
formed O
on O
chest O

-DOCSTART- O

treatment O
of O
lung B-NEG
abscess I-NEG
with O
purulent B-NEG
expectoration I-NEG
, O
heat B-NEG
in I-NEG
the I-NEG
lung I-NEG
with O
cough B-NEG
and O
dyspnea B-NEG
, O
acute B-NEG
dysentery I-NEG
, O
acute B-NEG
urinary I-NEG
infection I-NEG
, O
carbuncles B-NEG
and O
sores B-NEG
. O

-DOCSTART- O

treatment O
of O
amenorrhea B-NEG
with O
mass B-NEG
in I-NEG
the I-NEG
abdomen I-NEG
, O
swelling B-NEG
of I-NEG
breast I-NEG
after O
childbirth O
, O
rubella B-NEG
red O
in O
colour O
, O
itching B-NEG
, O
acne B-NEG
. O

-DOCSTART- O

amenorrhea B-NEG
, O
concretion O
and O
conglomeration O
, O
knocks O
and O
falls O
, O
abdominal B-NEG
pain I-NEG
, O
asthma B-NEG
( O
raw O
) O
, O
blood B-NEG
ejection I-NEG
, O
hematuria B-NEG
, O
hematochezia B-NEG
, O
prolapse B-NEG
of O
rectum O
( O
scorch-fry O
) O
. O

-DOCSTART- O

acute B-NEG
mania I-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
energy O
/ O
food O
intake O
( O
apetite O
/ O
satiety O
) O
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
endocrine B-DNP
system I-DNP
, O
body B-NEU
weight I-NEU

-DOCSTART- O

be O
torn O
of O
sore O
toxic O
pathogenic O
factor O

-DOCSTART- O

a O
disease O
that O
difficult O
to O
sleep O
, O
beating O
fast O
in O
the O
chest O
, O
feel O
anxiety B-NEG
, O
sometimes O
frightening B-NEG
well O
due O
to O
cold B-NEG
of O
gallbladder B-DNP
meridian I-DNP

-DOCSTART- O

promote O
blood B-DNP
vessel I-DNP

-DOCSTART- O

urinary B-NEG
bladder I-NEG
, I-NEG
neurogenic I-NEG

-DOCSTART- O

rheumatoid B-NEG
arthritis I-NEG

-DOCSTART- O

bloodshot B-NEG
eyes I-NEG
; O
congestion B-NEG
of I-NEG
the I-NEG
eye I-NEG
; O
red B-NEG
eyes I-NEG
; O
redness B-NEG
of I-NEG
the I-NEG
eye I-NEG

-DOCSTART- O

lidocaine O
alters O
signal O
conduction O
in O
neurons O
by O
blocking O
the O
fast O
voltage O
gated O
sodium O
( O
na+ O
) O
channels O
in O
the O
neuronal O
cell O
membrane O
that O
are O
responsible O
for O
signal O
propagation O
. O

-DOCSTART- O

urinary B-NEG
tract I-NEG
stone I-NEG
marked O
by O
paroxysmal B-NEG
lumbago I-NEG
or O
pain B-NEG
in O
one O
side O
of O
the O
abdomen O
often O
radiating O
to O
pudendum O
, O
or O
accompanied O
by O
fever B-NEG
, O
hematuria B-NEG
, O
urodynia B-NEG
, O
dysuria B-NEG
, O
discontinuance B-NEG
of O
urination O
, O
yellow O
fur O
of O
the O
tongue O
and O
taut B-NEG
pulse I-NEG
. O

-DOCSTART- O

weak O
stomach O
qi O
, O
noise B-NEG
in I-NEG
stomach I-NEG
, O
diarrhea B-NEG
, O
stagnation B-NEG
of I-NEG
water I-NEG
, O
dry B-NEG
vomiting I-NEG
, O
annoyment B-NEG

-DOCSTART- O

background O
: O
the O
diagnosis O
of O
encephalitis B-NEG
is O
usually O
presumptive O
based O
on O
mri O
, O
cerebrospinal O
fluid O
analysis O
, O
or O
both O
. O

a O
definitive O
diagnosis O
based O
on O
histopathology O
, O
however O
, O
is O
required O
for O
optimizing O
treatment O
strategies O
. O

objective O
: O
to O
investigate O
the O
diagnostic O
yield O
and O
adverse O
effects O
of O
minimally O
invasive O
brain O
biopsies O
in O
dogs O
with O
encephalitis B-NEG
. O

animals O
: O
seventeen O
dogs O
with O
suspected O
encephalitis B-NEG
, O
based O
on O
mr O
imaging O
and O
cerebrospinal O
fluid O
analysis O
. O

methods O
: O
retrospective O
study O
. O

minimally O
invasive O
, O
free-hand O
brain O
biopsy O
specimens O
were O
taken O
from O
forebrain O
lesions O
through O
a O
4-mm O
burr O
hole O
using O
a O
sedan O
side-cutting O
needle O
. O

routine O
histopathological O
examination O
was O
performed O
. O

the O
adverse O
effects O
were O
assessed O
by O
mri O
evaluations O
after O
biopsy O
procedure O
( O
12/17 O
) O
and O
by O
sequential O
neurological O
examinations O
. O

results O
: O
the O
overall O
diagnostic O
yield O
with O
regard O
to O
a O
specific O
type O
of O
encephalitis B-NEG
was O
0.82 O
. O

encephalitis B-NEG
was O
evident O
in O
an O
additional O
0.12 O
, O
but O
a O
specific O
disease B-NEG
could O
not O
be O
determined O
. O

there O
were O
no O
deaths O
caused O
by O
the O
biopsy O
procedure O
itself O
, O
but O
the O
indirect O
case O
fatality O
rate O
was O
0.06 O
. O

morbidity O
was O
0.29 O
, O
including O
stupor B-NEG
, O
seizures B-NEG
, O
tetraparesis B-NEG
, O
hemiparesis B-NEG
, O
ataxia B-NEG
, O
and O
loss B-NEG
of I-NEG
conscious I-NEG
proprioception I-NEG
. O

all O
these O
signs O
resolved O
within O
3-14 O
days O
. O

conclusions O
and O
clinical O
importance O
: O
minimally O
invasive O
brain O
biopsy O
in O
dogs O
with O
suspected O
encephalitis B-NEG
leads O
to O
a O
definite O
diagnosis O
in O
the O
majority O
of O
dogs O
, O
allowing O
for O
a O
specific O
treatment O
. O

the O
advantages O
of O
a O
definite O
diagnosis O
outweigh O
potential O
case O
fatality O
rate O
and O
temporary O
neurological B-NEG
deficits I-NEG
. O

-DOCSTART- O

smallpox B-NEG

-DOCSTART- O

reducing O
signs O
and O
symptoms O
of O
crohn's B-NEG
disease I-NEG
and O
treatment O
of O
moderately O
to O
severely O
active O
rheumatoid B-NEG
arthritis I-NEG
( O
ra B-NEG
) O
. O

-DOCSTART- O

swelling B-NEG
and O
pain B-NEG
due O
to O
trauma B-NEG

-DOCSTART- O

infraumbilical B-NEG
cold I-NEG
pain I-NEG

-DOCSTART- O

injury B-NEG
due O
to O
trauma B-NEG

-DOCSTART- O

gabapentin O
interacts O
with O
cortical B-DNP
neurons I-DNP
at O
auxillary O
subunits O
of O
voltage-sensitive O
calcium O
channels O
and O
increases O
the O
synaptic B-NEU
concentration I-NEU
of I-NEU
gaba I-NEU
, O
enhances O
gaba B-NEU
responses I-NEU
at O
non-synaptic O
sites O
in O
neuronal O
tissues O
, O
and O
reduces O
the O
release O
of O
mono-amine B-DNP
neurotransmitters I-DNP
. O

duloxetine O
selectively O
prevents O
the O
reuptake B-NEU
of I-NEU
5-ht I-NEU
and I-NEU
ne I-NEU
via O
transporter O
complexes O
on O
the O
pre-synaptic B-DNP
membrane I-DNP
, O
thereby O
increasing O
the O
level O
of O
these O
neurotransmitters B-DNP
within O
the O
synaptic O
cleft O
. O

-DOCSTART- O

convulsive B-NEG
seizure I-NEG

-DOCSTART- O

metformin O
acts O
by O
the O
initial O
activation O
of O
amp-activated B-DNP
protein I-DNP
kinase I-DNP
( O
ampk B-DNP
) O
, O
a O
liver B-DNP
enzyme I-DNP
that O
plays O
an O
important O
role O
in O
insulin O
signaling O
, O
whole O
body B-NEU
energy I-NEU
balance I-NEU
, O
and O
the O
metabolism B-NEU
of I-NEU
glucose I-NEU
and O
fats B-NEG
. O

sulfonylureas O
such O
as O
glyburide O
bind O
to O
atp-sensitive B-DNP
potassium I-DNP
channels I-DNP
on O
the O
pancreatic O
cell O
surface O
, O
raising O
intracellular O
concentrations B-NEU
of I-NEU
calcium I-NEU
ions O
, O
which O
induces O
the O
secretion B-DNP
, O
or O
exocytosis B-DNP
, O
of O
insulin B-DNP
. O

-DOCSTART- O

treatment O
of O
arthralgia B-NEG
with O
weakness B-NEG
of O
the O
loins O
and O
knees O
, O
excessive B-NEG
menstrual I-NEG
flow I-NEG
, O
chronic B-NEG
phthisical I-NEG
cough I-NEG
. O

-DOCSTART- O

phlegm-retention B-NEG
syndrome I-NEG
; O
congested O
fluids O
; O
retention O
of O
phlegm B-NEG
and O
fluid O
( O
1 O
) O
morbid O
conditions O
characterized O
by O
accumulation O
of O
dampness O
as O
a O
pathological O
product O
resulting O
from O
dysfunction B-NEG
of I-NEG
the I-NEG
lung I-NEG
, I-NEG
spleen I-NEG
md I-NEG
kidney I-NEG
or O
from O
disturbance O
of O
water O
circulation O
in O
the O
passage O
of O
triple O
ch'o O
. O

the O
thicker O
dampness O
is O
called O
phlegm B-NEG
, O
while O
the O
thinner O
fluid O
. O

retention O
of O
phlegm B-NEG
and O
fluid O
can O
give O
rise O
to O
various O
diseases B-NEG
, O
one O
of O
the O
four O
kinds O
of O
fluid O
retention O
. O

( O
2 O
) O
a O
morbid O
condition O
due O
to O
fluid O
retention O
in O
the O
stomach B-DNP
and O
intestines B-DNP
. O

-DOCSTART- O

promote O
menstruation B-NEU

-DOCSTART- O

strength B-POS
and O
power B-POS
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
liver B-DNP
, O
lipid O
profile O
, O
quality O
of O
life O
, O
absorption B-NEU
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
overall O
cvd O
, O
liver B-DNP
health I-DNP
, O
diet B-NEG
related B-NEG
cardiovascular I-NEG
disease I-NEG
, O
inflammation B-NEG
, O
other B-DNP
system I-DNP
health I-DNP
, O
others O
, O
neurological B-DNP
systems I-DNP
, O
physical B-DNP
performance I-DNP
and O
fitness B-DNP
, O
protective B-NEU
immunity I-NEU
, O
hemostatic B-NEU
function I-NEU
, O
motility B-NEU

-DOCSTART- O

relaxing O
apoplexy B-NEG

-DOCSTART- O

repeated O
administration O
of O
yokukansan O
inhibits O
doi B-NEG
- I-NEG
induced I-NEG
head I-NEG
- I-NEG
twitch I-NEG
response I-NEG
and O
decreases O
expression O
of O
5 O
- O
hydroxytryptamine O
( O
5 O
- O
ht O
) O
2a O
receptors O
in O
the O
prefrontal O
cortex O
. O

-DOCSTART- O

untreated O
childhood B-NEG
myeloid I-NEG
neoplasm I-NEG

-DOCSTART- O

zuo O
jin O
wan O
( O
zjw O
) O
, O
a O
typical O
traditional O
chinese O
medicine O
( O
tcm O
) O
formula O
, O
has O
been O
identified O
to O
have O
anticancer B-POS
activity I-POS
in O
recent O
studies O
. O

in O
this O
study O
, O
we O
determined O
the O
underlying O
mechanism O
of O
zjw O
in O
the O
reversal O
effect O
of O
multidrug O
resistance O
on O
colorectal B-NEG
cancer I-NEG
in O
vitro O
and O
in O
vivo O
. O

our O
results O
showed O
that O
zjw O
significantly O
enhanced O
the O
sensitivity O
of O
chemotherapeutic O
drugs O
in O
hct116/l-ohp O
, O
sgc7901/ddp O
, O
and O
bel/fu O
mdr O
cells O
. O

moreover O
, O
combination O
of O
chemotherapy O
with O
zjw O
could O
reverse O
the O
drug O
resistance O
of O
hct116/l-ohp B-DNP
cells I-DNP
, O
increase O
the O
sensitivity O
of O
hct116/l-ohp B-DNP
cells I-DNP
to O
l-ohp O
, O
ddp O
, O
5-fu O
, O
and O
mmc O
in O
vitro O
, O
and O
inhibit O
the O
tumor B-NEG
growth I-NEG
in O
the O
colorectal O
mdr O
cancer O
xenograft O
model O
. O

icp-ms O
results O
showed O
that O
zjw O
could O
increase O
the O
concentration O
of O
chemotherapeutic O
drugs O
in O
hct116/l-ohp O
cells O
in O
a O
dose-dependent O
manner O
. O

furthermore O
, O
we O
showed O
that O
zjw O
could O
reverse O
drug O
resistance O
of O
colorectal B-NEG
cancer I-NEG
cells O
by O
decreasing O
p-gp O
level O
in O
vitro O
and O
in O
vivo O
, O
which O
has O
been O
represented O
as O
one O
of O
the O
major O
mechanisms O
that O
contribute O
to O
the O
mdr O
phenotype O
. O

our O
study O
has O
provided O
the O
first O
direct O
evidence O
that O
zjw O
plays O
an O
important O
role O
in O
reversing O
multidrug O
resistance O
of O
human B-NEG
colorectal I-NEG
cancer I-NEG
and O
may O
be O
considered O
as O
a O
useful O
target O
for O
cancer B-POS
therapy I-POS
. O

-DOCSTART- O

expel O
worm B-NEG

-DOCSTART- O

linear O
lump B-NEG
of I-NEG
scrofula I-NEG

-DOCSTART- O

woman O
, O
mood O
, O
menopausal B-DNP
woman I-DNP
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
general O
woman O
, O
general O
skin B-DNP
health I-DNP
, O
others O
, O
mental B-DNP
state I-DNP
and O
performance O

-DOCSTART- O

keishibukuryogan O
ameliorates O
glucose B-NEG
intolerance I-NEG
and O
hyperlipidemia B-NEG
in O
otsuka O
long-evans O
tokushima O
fatty O
( O
oletf O
) O
rats O
. O

-DOCSTART- O

small O
dosage O
of O
berberine O
enhances O
the O
action B-NEU
of I-NEU
acetylcholine I-NEU
on O
animals' O
hearts O
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

-DOCSTART- O

nourish O
the O
stomach B-DNP
stop O
dysentery B-NEG

-DOCSTART- O

chronic B-NEG
hepatitis I-NEG

-DOCSTART- O

deficiency B-NEG
syndrome I-NEG
after O
delivery O

-DOCSTART- O

to O
quicken O
blood B-DNP
and O
regulate O
menstruation B-NEU
, O
dissipate O
stasis B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

specifically O
, O
dalbavancin O
prevents O
incorporation O
of O
n-acetylmuramic B-DNP
acid I-DNP
( O
nam B-DNP
) O
- O
and O
n-acetylglucosamine B-DNP
( O
nag B-DNP
) O
- O
peptide O
subunits O
from O
being O
incorporated O
into O
the O
peptidoglycan O
matrix O
; O
which O
forms O
the O
major O
structural O
component O
of O
gram-positive O
cell O
walls O
. O

-DOCSTART- O

gramicidin O
d O
binds O
and O
inserts O
itself O
into O
bacterial B-DNP
membranes I-DNP
and O
results O
in O
membrane B-NEG
disruption I-NEG
and O
permeabilization O
, O
which O
leads O
to O
cell B-NEU
death I-NEU
. O

polymyxin O
b O
sulfate O
interacts O
with O
the O
lipopolysaccharide O
of O
the O
cytoplasmic O
outer O
membrane O
of O
gram-negative O
bacteria O
, O
altering O
membrane O
permeability O
and O
causing O
cell B-NEU
death I-NEU
. O

neomycin O
is O
a O
bactericidal O
aminoglycoside O
antibiotic O
that O
binds O
to O
the O
30s O
ribosome O
of O
susceptible O
organisms O
. O

binding O
interferes O
with O
mrna B-NEU
binding I-NEU
and O
acceptor B-NEU
trna I-NEU
sites I-NEU
and O
results O
in O
the O
production O
of O
non-functional O
or O
toxic B-DNP
peptides I-DNP
. O

-DOCSTART- O

to O
clear O
heat B-NEU
and O
resolve O
toxin B-NEG
, O
dispel O
wind B-NEG
and O
eliminate O
damp B-NEG
. O

-DOCSTART- O

hwansodan O
has O
been O
used O
as O
a O
prescription O
for O
senile B-NEG
and O
vascular B-NEG
dementia I-NEG
in O
oriental O
medicine O
. O

we O
investigated O
the O
neuroprotective B-POS
effects I-POS
of O
hwansodan O
water O
extract O
on O
the O
apoptotic B-NEU
death I-NEU
of O
pc12 O
cells O
by O
serum O
deprivation O
. O

hwansodan O
significantly O
rescued O
pc12 O
cells O
from O
apoptotic B-NEU
death I-NEU
by O
serum O
deprivation O
in O
a O
dose-dependent O
manner O
. O

the O
nuclear O
staining O
of O
pc12 O
cells O
clearly O
showed O
that O
hwansodan O
attenuated O
nuclear O
condensation O
and O
fragmentation O
, O
which O
represents O
typical O
neuronal O
apoptotic O
characteristics O
. O

hwansodan O
also O
prevents O
dna O
fragmentation O
and O
caspase-3-like O
protease O
activation O
in O
serum-deprived O
pc12 O
cells O
and O
induces O
the O
tyrosine O
phosphorylation O
of O
proteins O
around O
44 O
kda O
, O
which O
was O
identified O
as O
erk1 O
with O
electrophoretic O
gel O
mobility O
shift O
by O
western O
blot O
. O

in O
addition O
, O
mek O
inhibitor O
pd98059 O
and O
ras O
inactivator O
, O
alpha-hydroxyfarnesylphosphonic O
acid O
and O
mevastatin O
, O
attenuated O
the O
neuroprotective O
effects O
of O
hwansodan O
in O
serum-deprived O
pc12 O
cells O
. O

these O
results O
indicate O
that O
ras O
/ O
mek O
/ O
erk O
signaling O
pathway O
plays O
a O
role O
in O
neuroprotective B-POS
effects I-POS
of O
hwansodan O
in O
serum-deprived O
pc12 O
cells O
. O

-DOCSTART- O

neck B-NEG
bone I-NEG
problems I-NEG
and O
inflammation B-NEG

-DOCSTART- O

beginning O
stage O
of O
rash B-NEG
, O
fever B-NEG
, O
cough B-NEG
, O
alternating O
cold B-NEU
and I-NEU
hot I-NEU
feeling I-NEU

-DOCSTART- O

otitis B-NEG
media I-NEG

-DOCSTART- O

stagnation O
of O
qi O
in O
the O
liver O
and O
the O
stomach O
marked O
by O
distending O
pain I-NEG
in O
the O
epigastrium O
, O
feeling O
of O
stuffiness B-NEG
and O
fullness B-NEG
in O
the O
chest O
, O
anorexia B-NEG
, O
belching B-NEU
and O
acid B-NEG
regurgitation I-NEG
. O

-DOCSTART- O

clarithromycin O
is O
first O
metabolized O
to O
14-oh O
clarithromycin O
, O
which O
is O
active O
and O
works O
synergistically O
with O
its O
parent O
compound O
. O

-DOCSTART- O

nourish O
eum O
( O
yin O
) O
and O
reinforce O
blood B-DNP

-DOCSTART- O

this O
is O
a O
syndrome O
that O
children O
wet O
their O
pants O
regardless O
of O
time O
. O

-DOCSTART- O

affection O
due O
to O
wind-cold B-NEG
; O
common O
cold B-NEG
caused O
by O
wind B-NEG
and O
cold B-NEG

-DOCSTART- O

cool O
blood B-DNP
and O
alleviate O
edema B-NEG

-DOCSTART- O

soothe O
the O
sinews B-DNP
and O
invigorate O
the O
network B-DNP
vessels I-DNP

-DOCSTART- O

vaginal B-NEG
diseases I-NEG

-DOCSTART- O

for O
the O
treatment O
of O
documented O
ventricular B-NEG
arrhythmias I-NEG
, O
such O
as O
sustained O
ventricular B-NEG
tachycardia I-NEG
, O
that O
, O
in O
the O
judgment O
of O
the O
physician O
, O
are O
life-threatening O
. O

-DOCSTART- O

to O
stimulate O
digestion B-NEU
and O
promote O
the O
functional O
activity B-NEU
of I-NEU
the I-NEU
stomach I-NEU
; O
to O
improve O
the O
normal O
flow O
of O
qi O
and O
dissipate O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

rhigfbp-3 O
is O
a O
protein O
that O
is O
normally O
found O
in O
our O
bloodstream O
that O
has O
been O
shown O
to O
induce O
cancer O
cell O
death O
in O
a O
variety O
of O
experimental O
systems O
. O

several O
studies O
have O
demonstrated O
that O
cancer B-NEG
risk O
increases O
with O
decreasing O
levels O
of O
circulating O
igfbp-3 B-DNP
. O

igfbp-3 B-DNP
can O
induce O
cell B-NEU
cycle I-NEU
arrest I-NEU
and O
enhance O
the O
efficacy O
of O
chemotherapeutic O
agents O
. O

-DOCSTART- O

night O
fever B-NEG
and O
chilling B-NEG
in O
the O
morning O

-DOCSTART- O

overactive B-NEG
bladder I-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
mood O
, O
quality O
of O
life O
, O
absorption O
, O
motility B-POS
, O
protective B-NEU
immunity I-NEU
, O
mental B-NEG
state I-NEG
and O
performance O

-DOCSTART- O

promethazine O
hydrochloride O
selectively O
blocks O
peripheral O
h1 O
receptors O
thereby O
diminishing O
the O
effects B-NEU
of I-NEU
histamine I-NEU
on O
effector O
cells O
. O

-DOCSTART- O

urticaria B-NEG

-DOCSTART- O

wind-damp B-NEG
impediment O
pain B-NEG
, O
edema B-NEG
, O
toxin B-NEG
swelling B-NEG
of O
sores O
. O

-DOCSTART- O

measles B-NEG
papules O
with O
complicated O
pneumonia B-NEG
, O
throat B-NEG
erosion I-NEG
. O

-DOCSTART- O

nmo B-NEG
spectrum I-NEG
disorder I-NEG
( O
nmosd B-NEG
) O

-DOCSTART- O

to O
suppress O
cough B-NEG
and O
calm O
asthma B-NEG
, O
dissipate O
stasis B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

jaundice B-NEG
a O
morbid O
condition O
clinically O
characterized O
by O
yellow-brown B-NEG
pigmentation I-NEG
of I-NEG
the I-NEG
skin I-NEG
and I-NEG
sclera I-NEG
and O
dark B-NEG
yellow I-NEG
colored I-NEG
urine I-NEG
, O
and O
classified O
into O
two O
types O
, O
yang B-NEG
jaundice I-NEG
and O
eum B-NEG
jaundice I-NEG
; O

one O
of O
the O
five O
types O
of O
jaundice B-NEG
. O

-DOCSTART- O

recurrent B-NEG
fever I-NEG
by O
the O
exhaustion B-NEG
after O
healing O
from O
pyogenic B-NEG
febrile I-NEG
disease I-NEG
. O

-DOCSTART- O

type B-NEG
2 I-NEG
diabetes I-NEG
mellitus I-NEG

-DOCSTART- O

cool O
blood B-DNP
and O
relieve O
toxicity B-NEG

-DOCSTART- O

eye B-DNP
health I-DNP
, O
eye B-DNP

-DOCSTART- O

illness B-NEG

-DOCSTART- O

the O
ulcerated B-NEG
mouth I-NEG
turns O
to O
the O
aphtha B-NEG

-DOCSTART- O

to O
astringe O
intestines B-DNP
and O
check O
diarrhea B-NEG
, O
resolve O
toxin B-NEG
, O
relieve O
itch B-NEG
. O

-DOCSTART- O

exenatide O
is O
a O
functional O
analog O
of O
the O
human O
incretin O
glucagon-like O
peptide-1 O
( O
glp-1 O
) O
. O

incretins B-DNP
enhance O
glucose-dependent B-NEU
insulin I-NEU
secretion I-NEU
and O
exhibit O
other O
antihyperglycemic B-POS
actions I-POS
following O
their O
release O
into O
the O
circulation O
from O
the O
gut O
. O

the O
glp-1 B-DNP
system I-DNP
increases O
insulin B-NEU
secretion I-NEU
only O
in O
the O
presence O
of O
elevated O
plasma O
glucose O
levels O
, O
avoiding O
inappropriately O
high B-NEG
insulin I-NEG
levels I-NEG
during O
fasting O
. O

the O
drug O
also O
moderates O
peak O
serum B-NEU
glucagon I-NEU
levels I-NEU
during O
hyperglycemic O
periods O
following O
meals O
, O
but O
does O
not O
interfere O
with O
glucagon B-NEU
release I-NEU
in O
response O
to O
hypoglycemia O
. O

secondary O
effects O
of O
drug O
administration O
reduces O
the O
rate B-NEU
of I-NEU
gastric I-NEU
emptying I-NEU
and O
decreases O
food O
intake O
, O
mitigating O
the O
potential O
severity B-NEU
of I-NEU
hyperglycemic I-NEU
events I-NEU
after O
meals O
. O

-DOCSTART- O

a O
mass O
amount O
of O
phlegm B-NEG
, O
and O
dyspnea B-NEG
and O
cough B-NEG

-DOCSTART- O

relieve O
pain B-NEG

-DOCSTART- O

for O
activating O
blood B-DNP
and O
reducing O
pain B-NEG
. O

-DOCSTART- O

nausea B-NEG

-DOCSTART- O

its O
decoction O
in O
1:3000-1:200 O
concentration B-POS
inhibits O
the O
growth O
of O
influenzae B-NEG
virus I-NEG
and O
bacillus B-NEG
dysenteriae I-NEG
in O
vitr O
. O

promoting O
the O
secretion O
of O
gastric B-DNP
juice I-DNP
and O
enhancing O
the O
digestive B-POS
function I-POS
, O
also O
as O
an O
astringent B-NEU
. O

-DOCSTART- O

keishibukuryogan O
, O
one O
of O
the O
traditional O
herbal O
formulations O
, O
is O
used O
clinically O
to O
improve O
blood B-NEU
circulation I-NEU
. O

in O
this O
study O
, O
we O
examined O
the O
effects O
of O
keishibukuryogan O
on O
glucose B-NEU
and I-NEU
lipids I-NEU
metabolism I-NEU
in O
otsuka O
long-evans O
tokushima O
fatty O
( O
oletf O
) O
rats O
, O
an O
animal O
model O
of O
type B-NEG
2 I-NEG
diabetes I-NEG
. O

forty-five-week-old O
male O
oletf O
rats O
were O
divided O
into O
three O
groups O
: O
diabetic O
control O
rats O
given O
a O
standard O
chow O
; O
diabetic O
rats O
given O
keishibukuryogan O
( O
0.03 O
, O
w/w O
in O
chow O
) O
; O
diabetic O
rats O
given O
pioglitazone O
( O
0.0001 O
, O
w/w O
in O
chow O
) O
. O

oral O
administration O
of O
keishibukuryogan O
produced O
significant O
improvement O
against O
impaired B-NEG
glucose I-NEG
tolerance I-NEG
. O

on O
the O
other O
hand O
, O
fasting O
serum B-NEU
glucose I-NEU
and I-NEU
insulin I-NEU
levels I-NEU
, O
and O
the O
homeostasis B-NEU
index I-NEU
of O
insulin B-NEU
resistance I-NEU
did O
not O
change O
by O
keishibukuryogan O
treatment O
. O

against O
lipid O
parameters O
, O
keishibukuryogan O
significantly O
lowered O
serum B-NEU
total I-NEU
cholesterol I-NEU
and O
triglyceride B-NEU
levels I-NEU
, O
and O
the O
hepatic B-NEU
total I-NEU
cholesterol I-NEU
level I-NEU
. O

keishibukuryogan O
treatment O
also O
significantly O
reduced O
the O
serum B-NEU
leptin I-NEU
level I-NEU
, O
but O
it O
had O
no O
effect O
on O
the O
serum B-NEU
adiponectin I-NEU
level I-NEU
. O

additionally O
, O
keishibukuryogan O
showed O
significant O
effects O
on O
epididymal B-DNP
adipose I-DNP
tissue I-DNP
by O
decreasing O
the O
size O
of O
fat B-DNP
cells I-DNP
and O
on O
skeletal B-DNP
muscle I-DNP
by O
reducing O
tnf-alpha B-DNP
protein I-DNP
content I-DNP
. O

from O
these O
results O
, O
it O
was O
suggested O
that O
keishibukuryogan O
exerts O
beneficial O
effects O
on O
the O
features O
associated O
with O
type B-NEG
2 I-NEG
diabetes I-NEG
. O

-DOCSTART- O

to O
drain O
the O
pus B-NEG
, O
eradicate O
toxicity B-NEG
, O
eliminate O
the O
dead B-NEG
tissue I-NEG
and O
promote O
the O
growth B-NEU
of I-NEU
new I-NEU
tissue I-NEU
. O

-DOCSTART- O

macular B-NEG
edema I-NEG

-DOCSTART- O

to O
tonify O
the O
kidney B-DNP

-DOCSTART- O

imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-DNP
kinases I-DNP
( O
tk B-DNP
) O
, O
thereby O
inhibiting O
atp B-NEU
binding I-NEU
and O
preventing O
phosphorylation B-NEU
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-DNP
transduction I-DNP
pathways I-DNP
. O

temozolomide O
is O
converted O
at O
physiologic O
ph O
to O
the O
short-lived O
active O
compound O
, O
monomethyl O
triazeno O
imidazole O
carboxamide O
( O
mtic O
) O
. O

the O
cytotoxicity B-NEG
of I-NEG
mtic I-NEG
is O
due O
primarily O
to O
methylation B-NEU
of I-NEU
dna I-NEU
at O
the O
o6 O
and O
n7 O
positions O
of O
guanine O
, O
resulting O
in O
inhibition B-NEU
of I-NEU
dna I-NEU
replication I-NEU
. O

-DOCSTART- O

fracture B-NEG

-DOCSTART- O

pulmonary B-NEG
asthenia I-NEG
; O
lung B-NEG
atropy I-NEG
; O
pulmonary B-NEG
flaccidity I-NEG
syndrome I-NEG

-DOCSTART- O

toothache B-NEG

-DOCSTART- O

somnolence B-NEG

-DOCSTART- O

deficiency O
of O
yin O
of O
the O
liver B-DNP
and O
the O
kidney B-DNP
marked O
by O
tinnitus B-NEG
, O
impairment B-NEG
of I-NEG
hearing I-NEG
, O
dizziness B-NEG
and O
blurred B-NEG
vision I-NEG
. O

-DOCSTART- O

kill O
worms B-NEG

-DOCSTART- O

cool O
blood B-DNP

-DOCSTART- O

the O
low B-NEG
back I-NEG
and I-NEG
knees I-NEG
being I-NEG
aching I-NEG
and I-NEG
limp I-NEG
( O
i O
. O
e O
. O
, O
weak O
) O

-DOCSTART- O

prolapse B-NEG
of I-NEG
uterus I-NEG

-DOCSTART- O

adult B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG
with O
t(16;16)(p13.1;q22 O
) O
; O
cbfb-myh11 O

-DOCSTART- O

the O
symptomatic O
relief O
of O
cough B-NEG
. O

-DOCSTART- O

stiffness B-NEG
of O
four O
ends O

-DOCSTART- O

metabolic O
urinary O
profiling O
of O
alcohol B-NEG
hepatotoxicity I-NEG
and I-NEG
intervention I-NEG
effects O
of O
yin O
chen O
hao O
tang O
in O
rats O
using O
ultra O
- O
performance O
liquid O
chromatography O
/ O
electrospray O
ionization O
quadruple O
time O
- O
of O
- O
flight O
mass O
spectrometry O
. O

-DOCSTART- O

to O
clear O
heat B-NEU
and O
remove O
toxic B-NEG
materials I-NEG
; O
to O
tonify O
kidney B-DNP
and O
revitalize O
blood B-DNP

-DOCSTART- O

perennial B-NEG
allergic I-NEG
rhinitis I-NEG

-DOCSTART- O

deficiency O
of O
both O
gi O
( O
vital O
energy O
) O
and O
blood B-DNP

-DOCSTART- O

profuse B-NEG
nasal I-NEG
bleeding I-NEG
; O
brandy B-NEG
nose I-NEG
; O
rosacea B-NEG

-DOCSTART- O

pseudoephedrine O
relaxes O
bronchial B-DNP
smooth I-DNP
muscle I-DNP
by O
stimulating O
beta2-adrenergic O
receptors O
. O
hydrocodone O
exerts O
its O
analgesic O
activity O
by O
binding O
to O
the O
mu-receptors O
in O
the O
central B-DNP
nervous I-DNP
system I-DNP
( O
cns B-DNP
) O
, O
thereby O
mimicking O
the O
effects O
of O
endogenous O
opioids O
. O

-DOCSTART- O

pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-DNP
synthase I-DNP
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
dna B-DNP
synthesis I-DNP
. O

carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
gc-rich O
sites O
in O
dna B-DNP
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
dna B-DNP
cross-links O
, O
as O
well O
as O
dna-protein B-DNP
cross-links O
. O

by O
binding O
to O
the O
atp-binding O
site O
, O
enzastaurin O
selectively O
inhibits O
protein B-DNP
kinase I-DNP
c I-DNP
beta I-DNP
, O
which O
appears O
to O
be O
cytotoxic O
in O
cells O
with O
dna B-DNP
alterations O
or O
dna O
damage O
which O
may O
decrease O
tumor B-NEG
blood I-NEG
supply I-NEG
, O
preventing O
growth B-NEU
. O

-DOCSTART- O

this O
is O
a O
symptom O
with O
powerlessness B-NEG
in O
a O
waist O
and O
knee O
. O

-DOCSTART- O

sores B-NEG
; O
boil B-NEG
suppurative I-NEG
infection I-NEG
on O
the O
body O
surface O
. O
including O
carbuncle B-NEG
, O
furuncle B-NEG
, O
deep-rooted O
carbuncle B-NEG
, O
multiple O
abscess B-NEG
, O
scrofula B-NEG
, O
ulcer B-NEG
. O

-DOCSTART- O

known O
or O
suspected O
focal B-NEG
liver I-NEG
lesions I-NEG

-DOCSTART- O

edema B-NEG

-DOCSTART- O

to O
eliminate O
phlegm B-NEG
, O
resuscitate O
, O
tranquilize O
, O
suppress O
wind B-NEG
and O
relieve O
convulsion B-NEG
. O

-DOCSTART- O

sarcoma B-NEG

-DOCSTART- O

haemorrhage B-NEG

-DOCSTART- O

promote O
the O
small B-DNP
intestine I-DNP

-DOCSTART- O

non-small B-NEG
cell I-NEG
lung I-NEG
cancer I-NEG

-DOCSTART- O

sores B-NEG
due O
to O
swelling B-NEG
of I-NEG
carbuncle I-NEG
. O

-DOCSTART- O

sirolimus O
inhibits O
t B-NEU
lymphocyte I-NEU
activation I-NEU
and I-NEU
proliferation I-NEU
that O
occurs O
in O
response O
to O
antigenic O
and O
cytokine B-DNP
( O
interleukin B-DNP
il-2 B-DNP
, O
il-4 B-DNP
, O
and O
il-15 B-DNP
) O
stimulation O
by O
a O
mechanism O
that O
is O
distinct O
from O
that O
of O
other O
immunosuppressants O
. O

-DOCSTART- O

to O
calm O
the O
liver O
and O
suppress O
the O
asthenic B-NEG
yang O
, O
to O
promote O
the O
restoration O
of O
consciousness O
, O
decrease O
blood B-NEU
pressure I-NEU
. O

-DOCSTART- O

heartburn B-NEG

-DOCSTART- O

acute B-NEG
exacerbations I-NEG
of I-NEG
chronic I-NEG
bronchitis I-NEG

-DOCSTART- O

wind-cold B-NEG
; O

wind-cold B-NEG
pathogen I-NEG
wind B-NEG
and O
cold B-NEG
blended O
as O
a O
pathogenic O
facto O

-DOCSTART- O

to O
clear O
heat B-NEG
and O
disinhibit O
damp B-NEU
, O
cool O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

cool O
the O
blood B-DNP
and O
move O
the O
blood B-DNP

-DOCSTART- O

scabies B-NEG

-DOCSTART- O

decanoyl O
acetaldehyde O
is O
bacteriostatic O
and O
fungistatic O
. O

its O
decoction O
retards O
the O
progress O
of O
tuberculosis B-NEG
experimentally O
. O

synthetic O
product O
( O
compound O
of O
decanoyl O
acetaldehyde O
and O
nahso3 O
) O
promotes O
white B-NEU
cell I-NEU
phagocytosis I-NEU
. O

anti-inflammation B-POS
. O

quercitrin O
, O
an O
active O
component O
, O
is O
a O
strong O
diuretic O
, O
and O
exerts O
such O
effect O
in O
a O
1 O
: O
10 O
, O
0 O
solution O
. O

-DOCSTART- O

the O
antiinflammatory B-POS
effects I-POS
of O
tenoxicam O
may O
result O
from O
the O
inhibition O
of O
the O
enzyme O
cycooxygenase O
and O
the O
subsequent O
peripheral O
inhibition O
of O
prostaglandin B-DNP
synthesis I-DNP
. O
as O
prostaglandins O
sensitize O
pain B-NEG
receptors O
, O
their O
inhibition O
accounts O
for O
the O
peripheral O
analgesic O
effects O
of O
tenoxicam O
. O
antipyresis O
may O
occur O
by O
central O
action O
on O
the O
hypothalamus B-DNP
, O
resulting O
in O
peripheral O
dilation O
, O
increased O
cutaneous O
blood B-DNP
flow O
, O
and O
subsequent O
heat B-NEG
loss I-NEG
. O

-DOCSTART- O

hochuekkito O
, O
a O
kampo O
( O
traditional O
japanese O
herbal O
) O
medicine O
, O
and O
its O
polysaccharide O
portion O
stimulate O
g B-NEU
- I-NEU
csf I-NEU
secretion I-NEU
from O
intestinal O
epithelial O
cells O
. O

-DOCSTART- O

to O
remove O
heat B-NEU
and O
damp B-NEU
, O
to O
counteract O
toxicity B-NEG
, O
and O
to O
cause O
subsidence B-POS
of I-POS
swelling I-POS
. O

-DOCSTART- O

liver B-DNP
health I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
protective O
immunity B-NEU
, O
liver B-DNP

-DOCSTART- O

asthma B-NEG

-DOCSTART- O

to O
remove O
heat B-NEG
from O
the O
lung O
and O
relieve O
sore B-NEG
throat I-NEG
, O
and O
to O
regulate O
the O
flow O
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O

carotid B-NEG
artery I-NEG
stenosis I-NEG

-DOCSTART- O

hepatitis B-NEG
c I-NEG
, I-NEG
chronic I-NEG

-DOCSTART- O

taxation B-NEG
damage I-NEG
and O
sinew B-NEG
bone I-NEG
pain I-NEG
, O
impotence B-NEG
, O
stomachache B-NEG
, O
innominate B-NEG
toxin I-NEG
swelling I-NEG
, O
knife B-NEG
wound I-NEG
. O

-DOCSTART- O

dry O
phlegm B-DNP
; O
dry-phlegm B-NEG
( O
syndrome O
) O

-DOCSTART- O

dexamethasone O
is O
a O
glucocorticoid B-DNP
agonist I-DNP
. O

-DOCSTART- O

a O
disease O
like O
a O
cholera B-NEG
. O

that O
has O
a O
abdominal B-NEG
pain I-NEG
, O
vomiting B-NEG
and O
diarrhea B-NEG
caused O
by O
dirty O
and O
acute O
filthy O
gi O

-DOCSTART- O

blurred B-NEG
vision I-NEG

-DOCSTART- O

to O
dispel O
wind B-NEG
and O
free O
network B-DNP
vessels I-DNP
, O
disperse O
swelling B-NEG
and O
relieve O
pain B-NEG
, O
clear O
heat B-NEG
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

urologic B-NEG
diseases I-NEG

-DOCSTART- O

constipation B-DNP
and O
dry B-NEG
stool I-NEG

-DOCSTART- O

to O
supplement O
blood B-DNP
and O
quicken O
blood B-DNP
, O
free O
channels B-DNP
and O
quicken O
network B-DNP
vessels I-DNP
. O

-DOCSTART- O

spitting O
bloody B-NEG
pus I-NEG
; O

cough B-NEG
with O
bloody B-NEG
pus I-NEG

-DOCSTART- O

to O
relax O
the O
bowels B-NEG
, O
and O
to O
cause O
diuresis B-NEG
. O

-DOCSTART- O

muscle B-NEG
fatigue I-NEG

-DOCSTART- O

pricking B-NEG
pain I-NEG

-DOCSTART- O

1 O
hypotensive B-NEG
2 O
promoting O
phagocytosis B-NEU
of I-NEU
mononuclear I-NEU
phagocytes I-NEU
. O

sedative O
and O
diuretic O
. O

-DOCSTART- O

clindamycin O
inhibits O
bacterial B-NEG
protein I-NEG
synthesis I-NEG
by O
binding O
to O
bacterial O
50s O
ribosomal O
subunits O
. O

-DOCSTART- O

propranolol O
competes O
with O
sympathomimetic B-DNP
neurotransmitters I-DNP
such O
as O
catecholamines O
for O
binding O
at O
beta(1)-adrenergic O
receptors O
in O
the O
heart O
, O
inhibiting O
sympathetic O
stimulation O
. O

hydrochlorothiazide O
, O
a O
thiazide O
diuretic O
, O
inhibits O
water B-NEU
reabsorption I-NEU
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-DNP
symporter I-DNP
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
0.05 O
of O
total O
sodium B-NEU
reabsorption I-NEU
. O

-DOCSTART- O

menorrhagia B-NEG
; O
abnormally O
profuse B-NEG
menstruation I-NEG

-DOCSTART- O

freckles B-NEG
on O
face O

-DOCSTART- O

snake-bite B-NEG

-DOCSTART- O

to O
dispel O
wind B-NEG
, O
remove O
obstruction O
of O
the O
collaterals O
, O
and O
relieve O
spasms B-NEG
and O
convulsions B-NEG
. O

-DOCSTART- O

statin O
therapy O

-DOCSTART- O

treatment O
of O
edema B-NEG
with O
oliguria B-NEG
, O
dizziness B-NEG
and O
palpitation B-NEG
caused O
by O
retained O
fluid O
, O
diminished O
function O
of O
the O
spleen B-DNP
marked O
by O
anorexia B-NEG
, O
loose O
stools B-NEG
or O
diarrhea B-NEG
, O
restlessness B-NEG
and O
insomnia B-NEG
. O

-DOCSTART- O

acute B-NEG
otitis I-NEG
media I-NEG
in O
children O
that O
is O
caused O
by O
susceptible O
strains O
of O
haemophilus B-NEG
influenzae I-NEG
. O

-DOCSTART- O

ecchymosis B-NEG

-DOCSTART- O

lack O
of O
essence O
and O
blood B-DNP

-DOCSTART- O

treatment O
of O
cough B-NEG
, O
itching B-NEG
of O
the O
throat O
and O
profuse O
expectoration B-NEG
in I-NEG
colds I-NEG
, O
nausea B-NEG
, O
vomiting B-NEG
and O
epigastric B-NEG
distension I-NEG
caused O
by O
improper O
diet O
or O
excessive O
drinking O
. O

-DOCSTART- O

suffering B-NEG
from O
diarrhea B-NEG
and O
having O
a O
stomachache B-NEG

-DOCSTART- O

bruise B-NEG

-DOCSTART- O

dyspnea B-NEG
due O
to O
lung-heat B-NEU

-DOCSTART- O

break O
hard B-NEG
mass I-NEG
and O
dissipate O
accumulation B-NEG

-DOCSTART- O

neuropathic B-NEG
pain I-NEG

-DOCSTART- O

thicken O
the O
intestine B-DNP
and O
stomach B-DNP

-DOCSTART- O

dim B-NEU
vision I-NEU
, O
flooding B-NEG
and I-NEG
spotting I-NEG
, I-NEG
bleeding I-NEG
due O
to O
external B-NEG
injury I-NEG
, O
sore B-NEG
toxin I-NEG
and O
intractable O
lichen B-NEG
. O

-DOCSTART- O

a O
symptom O
of O
having O
muscular B-NEG
flaccidity I-NEG
due O
to O
deficiency O
of O
gi O
, O
and O
insufficiency B-NEG
of I-NEG
nourishment I-NEG
in O
organs O
due O
to O
deficiency B-NEG
of I-NEG
blood I-NEG

-DOCSTART- O

childhood B-NEG
acute I-NEG
monocytic I-NEG
leukemia I-NEG

-DOCSTART- O

to O
tonify O
qi O
and O
strengthen O
the O
spleen B-DNP
. O

to O
consolidate O
the O
chong B-DNP
channel I-DNP
and O
control O
the O
blood B-DNP
. O

-DOCSTART- O

treatment O
of O
fever B-NEG
due O
to O
deficiency B-NEG
of O
yin O
, O
consumptive O
fever B-NEG
, O
fever B-NEG
in O
infantile O
malnutrition B-NEG
. O

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
hemostatic B-DNP
function I-DNP
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG

-DOCSTART- O

neurological B-DNP
systems I-DNP
health I-DNP
, O
neurological B-DNP
systems I-DNP
health I-DNP
, O
diet O
related O
cardiovascular B-NEG
disease I-NEG
, O
memory B-DNP
, O
neurological B-DNP
systems I-DNP
, O
hemostatic B-DNP
function I-DNP
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

dental B-NEG
plaque I-NEG

-DOCSTART- O

used O
as O
an O
analgesic O
adjunct O
in O
anesthesia O
and O
as O
a O
primary O
anesthetic O
drug O
in O
procedures O
requiring O
assisted O
ventilation O
and O
in O
the O
relief O
of O
pain B-NEG
. O

-DOCSTART- O

phthisical B-NEG
cough I-NEG
due O
to O
eum O
deficiency O

-DOCSTART- O

1 O
to O
clear O
the O
lungs B-DNP
and O
tonify O
yin O
; O
2 O
to O
strengthen O
the O
stomach B-DNP
and O
promote O
the O
production B-NEU
of I-NEU
body I-NEU
fluids I-NEU

-DOCSTART- O

endurance O
, O
energy B-POS
supply I-POS
and O
recovery B-POS
, O
physical B-DNP
performance I-DNP
and O
fitness B-POS

-DOCSTART- O

relieve O
cough B-NEG

-DOCSTART- O

filgrastim O
binds O
to O
the O
g-csf O
receptor O
and O
stimulates O
the O
production B-NEU
of I-NEU
neutrophils I-NEU
in O
the O
bone O
marrow O
. O

-DOCSTART- O

to O
supplement O
qi O
and O
nourish O
yin O
, O
clear O
fire O
and O
engender O
liquid O
. O

-DOCSTART- O

weakness B-NEG
of O
the O
waist O

-DOCSTART- O

urinary B-DNP
systems I-DNP
, O
urinary B-DNP
system I-DNP
health I-DNP
, O
liver B-DNP
health I-DNP
, O
liver B-DNP

-DOCSTART- O

aversion O
to O
cold B-NEG
; O

severe B-NEG
chillness I-NEG
; O

creeping B-NEG
chills I-NEG

-DOCSTART- O

similar O
to O
zidovudine O
, O
efavirenz O
inhibits O
the O
activity B-NEU
of I-NEU
viral I-NEU
rna-directed I-NEU
dna I-NEU
polymerase I-NEU
( O
i.e O
. O
, O
reverse B-DNP
transcriptase I-DNP
) O
. O

antiviral O
activity O
of O
efavirenz O
is O
dependent O
on O
intracellular O
conversion O
to O
the O
active O
triphosphorylated O
form O
. O

the O
rate O
of O
efavirenz O
phosphorylation O
varies O
, O
depending O
on O
cell O
type O
. O

it O
is O
believed O
that O
inhibition O
of O
reverse B-DNP
transcriptase I-DNP
interferes O
with O
the O
generation B-NEU
of I-NEU
dna I-NEU
copies I-NEU
of I-NEU
viral I-NEU
rna I-NEU
, O
which O
, O
in O
turn O
, O
are O
necessary O
for O
synthesis O
of O
new O
virions O
. O

intracellular O
enzymes O
subsequently O
eliminate O
the O
hiv B-DNP
particle I-DNP
that O
previously O
had O
been O
uncoated O
, O
and O
left O
unprotected O
, O
during O
entry O
into O
the O
host O
cell O
. O

thus O
, O
reverse O
transcriptase O
inhibitors O
are O
virustatic O
and O
do O
not O
eliminate O
hiv B-DNP
from O
the O
body O
. O

even O
though O
human O
dna B-DNP
polymerase I-DNP
is O
less O
susceptible O
to O
the O
pharmacologic O
effects O
of O
triphosphorylated O
efavirenz O
, O
this O
action O
may O
nevertheless O
account O
for O
some O
of O
the O
drug's B-NEG
toxicity I-NEG
. O

-DOCSTART- O

diarrhea B-NEG
due O
to O
dysfunction B-NEG
of I-NEG
the I-NEG
spleen I-NEG

-DOCSTART- O

type B-NEG
2 I-NEG
diabetes I-NEG
mellitus I-NEG
. O

-DOCSTART- O

relieve O
heat B-NEU
and O
dissipate O
stasis B-NEG

-DOCSTART- O

diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
lipid O
profile O

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
reproductive B-DNP
systems I-DNP
, O
urinary B-DNP
system I-DNP
health I-DNP
, O
urinary B-DNP
systems I-DNP
, O
inflammation B-NEG
, O
others O

-DOCSTART- O

used O
in O
the O
treatment O
of O
relapsing O
forms O
of O
multiple B-NEG
sclerosis I-NEG
( O
ms B-NEG
) O
. O

-DOCSTART- O

yellow B-NEG
or I-NEG
reddish I-NEG
urine I-NEG
; O
dark B-NEG
urine I-NEG

-DOCSTART- O

to O
invigo O
rate O
the O
function B-NEU
of I-NEU
the I-NEU
spleen I-NEU
, O
to O
regulate O
the O
function B-NEU
of I-NEU
the I-NEU
stomach I-NEU
, O
and O
to O
promote O
the O
flow B-NEU
of I-NEU
milk I-NEU
. O

-DOCSTART- O

exciting O
the O
intestinal B-DNP
smooth I-DNP
muscles I-DNP
in O
vivo O
or O
in O
vitro O
, O
and O
relaxing O
the O
uterus B-DNP
of O
guinea-pigs O
in O
vitro O
. O

-DOCSTART- O

cool O
blood B-NEU
and O
stop O
bleeding B-NEG

-DOCSTART- O

to O
clear O
damp B-NEG
heat I-NEG
, O
resolve O
sore O
toxin B-NEG
, O
disperse O
swelling B-NEG
and O
relieve O
pain B-NEG
. O

-DOCSTART- O

intercritical O
gout B-NEG

-DOCSTART- O

adult B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG
with O
maturation O

-DOCSTART- O

postpartum B-NEG
bleeding I-NEG
, O
migraine B-NEG
. O

-DOCSTART- O

1.to O
promote O
blood B-NEU
circulation I-NEU
and O
remove O
blood B-NEG
stasis I-NEG
, O
expel O
wind B-NEG
and O
alleviate O
pain B-NEG
. O
2. O
to O
relieve O
asthma B-NEG
. O

-DOCSTART- O

this O
is O
a O
syndrome B-NEG
with I-NEG
bloat I-NEG
and I-NEG
fullness I-NEG
in I-NEG
abdominal I-NEG
region I-NEG
. O

-DOCSTART- O

to O
replenish O
the O
kidney B-DNP
and O
subdue O
hyperactivity O
of O
the O
liver B-DNP
. O

-DOCSTART- O

hydrocortisone O
binds O
to O
the O
cytosolic O
glucocorticoid O
receptor O
and O
promotes O
protein B-NEU
catabolism I-NEU
, O
gluconeogenesis B-NEU
, O
capillary B-NEU
wall I-NEU
stability I-NEU
, O
renal B-NEU
excretion I-NEU
of I-NEU
calcium I-NEU
, O
and O
suppresses O
immune B-NEU
and I-NEU
inflammatory I-NEU
responses I-NEU
. O

polymyxin O
b O
sulfate O
interacts O
with O
the O
lipopolysaccharide B-DNP
of O
the O
cytoplasmic O
outer O
membrane O
of O
gram-negative O
bacteria O
, O
altering O
membrane B-NEU
permeability I-NEU
and O
causing O
cell B-NEG
death I-NEG
. O

chloramphenicol O
reversibly O
binds O
to O
the O
l16 O
protein O
of O
the O
50s O
subunit O
of O
bacterial O
ribosomes O
, O
thus O
inhibits O
protein B-NEU
synthesis I-NEU
. O

-DOCSTART- O

warm O
the O
menses B-NEU
and O
stop O
bleeding B-NEG

-DOCSTART- O

dry B-NEG
mouth I-NEG
; O

xerostomia B-NEG
; O

dryness B-NEG
of I-NEG
mouth I-NEG

-DOCSTART- O

eye B-DNP
, O
blood B-NEU
pressure I-NEU
, O
lipid O
profile O
, O
diet B-NEG
related I-NEG
cardiovascular I-NEG
disease I-NEG
, O
inflammation B-NEG
, O
urinary B-DNP
system I-DNP
health I-DNP
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
urinary B-DNP
system I-DNP
health I-DNP
, O
absorption B-NEU
, O
uv O
protection O
, O
motility B-NEU
, O
others O
, O
urinary B-DNP
systems I-DNP
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
dermatological B-DNP
systems I-DNP
health I-DNP
, O
hemostatic B-DNP
function I-DNP
, O
insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
overall O
cvd B-NEG
, O
general O
skin B-DNP
health I-DNP
, O
eye B-DNP
health I-DNP
, O
protective B-NEU
immunity I-NEU

-DOCSTART- O

break O
blood B-DNP

-DOCSTART- O

warm O
the O
lung B-DNP

-DOCSTART- O

chronic B-NEG
fatigue I-NEG

-DOCSTART- O

headache B-NEG

-DOCSTART- O

to O
stablize O
liver B-DNP
and O
suppress O
dizziness B-NEG
; O
to O
soothe O
neck B-DNP
and O
wake-up O
brain B-DNP

-DOCSTART- O

this O
is O
a O
syndrome O
with O
a O
pain B-NEG
under O
the O
side O
. O

-DOCSTART- O

to O
boost O
essence O
, O
brighten O
eyes B-DNP
, O
cool O
blood B-DNP
and O
resolve O
toxin B-NEG
. O

-DOCSTART- O

ulcerative B-NEG
colitis I-NEG

-DOCSTART- O

reinforce O
bone B-NEG
fracture I-NEG

-DOCSTART- O

to O
induce O
subsidence O
of O
swelling B-NEG
and O
remove O
toxic B-NEG
substances O
, O
to O
cause O
purgation B-NEG
. O

-DOCSTART- O

this O
is O
a O
symptom O
that O
the O
body O
becomes O
thin O
due O
to O
exhaustion B-NEG
syndrome I-NEG
. O

-DOCSTART- O

urinary B-NEG
bladder I-NEG
diseases I-NEG

-DOCSTART- O

nourish O
gi O
( O
qi O
) O
and O
blood B-DNP

-DOCSTART- O

this O
is O
an O
external B-NEG
wound I-NEG
in I-NEG
muscle I-NEG
of I-NEG
waist I-NEG
. O

-DOCSTART- O

neurological B-DNP
systems I-DNP
, O
neurological B-DNP
systems I-DNP
health I-DNP

-DOCSTART- O

to O
benefit O
vital B-POS
energy I-POS
to O
control O
blood B-DNP
. O

-DOCSTART- O

cardiovascular B-NEG
diseases I-NEG

-DOCSTART- O

retention O
of O
moisture O
, O
dermatological B-DNP
systems I-DNP
health I-DNP

-DOCSTART- O

spinal B-NEG
cord I-NEG
problems I-NEG
, O
pain B-NEG
etc O
. O

-DOCSTART- O

sore B-NEG
throat I-NEG
due O
to O
a O
common O
cold B-NEG

-DOCSTART- O

neurocognitive B-DNP
function I-DNP
. O

-DOCSTART- O

thin B-NEG
eyebrow I-NEG

-DOCSTART- O

pain B-NEG
due O
to O
certain O
specified O
procedures O

-DOCSTART- O

insulin O
glargine O
is O
is O
a O
long-acting O
basal O
insulin O
analogue O
and O
binds O
to O
the O
insulin O
receptor O
, O
the O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
ir O
stimulates O
the O
tyrosine B-DNP
kinase I-DNP
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

insulin O
glulisine O
is O
a O
biosynthetic O
, O
rapid-acting O
human O
insulin O
analogue O
which O
differs O
from O
native O
human O
insulin O
in O
that O
the O
amino O
acid O
arginine O
at O
position O
b3 O
is O
replaced O
by O
lysine O
and O
the O
lysine O
at O
position O
b29 O
is O
replaced O
by O
glutamic O
acid O
. O

-DOCSTART- O

croup B-NEG

-DOCSTART- O

1 O
flavonoid O
glycoside O
, O
one O
of O
its O
components O
, O
increases O
coronary B-NEU
flow I-NEU
, O
reduces O
myocardial B-NEU
oxygen I-NEU
consumption I-NEU
and O
lowers O
arterial B-NEU
pressure I-NEU
. O

2 O
. O
cardiotonic O
on O
frogs' O
hearts O
in O
vitro O
; O
low O
concentration O
of O
its O
extract O
exerts O
a O
vasoconstrictive O
effect O
on O
the O
vessels O
of O
frogs' O
leg O
and O
high O
concentration O
, O
vasodilative O

3 O
. O
its O
liquid O
extract O
shortens O
clotting O
time O
and O
exerts O
hemostatic B-POS
effect I-POS
in O
rabbit O
. O

-DOCSTART- O

the O
primary O
activity O
of O
insulin O
is O
the O
regulation O
of O
glucose B-NEU
metabolism I-NEU
. O

insulin O
promotes O
glucose O
and O
amino O
acid O
uptake O
into O
muscle O
and O
adipose O
tissues O
, O
and O
other O
tissues O
except O
brain O
and O
liver O
. O

it O
also O
has O
an O
anabolic O
role O
in O
stimulating O
glycogen B-NEU
, I-NEU
fatty I-NEU
acid I-NEU
, I-NEU
and I-NEU
protein I-NEU
synthesis I-NEU
. O

insulin O
inhibits O
gluconeogenesis B-DNP
in O
the O
liver O
. O

insulin O
binds O
to O
the O
insulin O
receptor O
( O
ir O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

the O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
ir O
stimulates O
the O
tyrosine B-DNP
kinase I-DNP
activity I-DNP
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

the O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin B-DNP
receptor I-DNP
substrates I-DNP
( O
irs B-DNP
) O
proteins O
, O
cbl B-DNP
, O
aps B-DNP
, O
shc B-DNP
and O
gab B-DNP

these O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-DNP
of I-DNP
downstream I-DNP
signaling I-DNP
molecules I-DNP
including O
pi3 B-DNP
kinase I-DNP
and O
akt B-DNP
. O

akt O
regulates O
the O
activity B-DNP
of I-DNP
glucose I-DNP
transporter I-DNP
4 I-DNP
( O
glut4 B-DNP
) O
and O
protein B-DNP
kinase I-DNP
c I-DNP
( O
pkc B-DNP
) O
which O
play O
a O
critical O
role O
in O
metabolism B-DNP
and O
catabolism B-DNP
. O

-DOCSTART- O

syphilis B-NEG
; O
strawberry O
sores B-NEG
; O
syphilitic B-NEG
skin I-NEG
disease I-NEG

-DOCSTART- O

pharyngitis B-NEG
, O
excessive B-NEG
sputum I-NEG
blocking O
the O
windpipe O
, O
rapid B-NEG
breathing I-NEG
and O
even O
suffocation B-NEG
. O

-DOCSTART- O

pregnancy B-NEU

-DOCSTART- O

graft B-NEG
versus I-NEG
host I-NEG
disease I-NEG

-DOCSTART- O

advanced B-NEG
breast I-NEG
cancer I-NEG

-DOCSTART- O

quality O
of O
life O
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP
, O
mood O

-DOCSTART- O

diabetic B-NEG
neuropathy I-NEG
, O
painful O

-DOCSTART- O

abdominal B-NEG
distension I-NEG
; O
abdominal B-NEG
fullness I-NEG

-DOCSTART- O

some O
patients O
with O
major B-NEG
depressive I-NEG
disorder I-NEG
( O
mdd B-NEG
) O
do O
not O
show O
remission O
of O
their O
depressive O
symptomatology O
. O

we O
investigated O
the O
efficacy O
of O
rokumigan O
( O
tj-87 O
) O
and O
hachimijiogan O
( O
tj-7 O
) O
in O
20 O
patients O
with O
prolonged O
partial O
remitted O
mdd B-NEG
associated O
with O
fatigue B-NEG
or O
loss B-NEG
of I-NEG
energy I-NEG
. O

in O
these O
20 O
patients O
, O
tj-7 O
or O
tj-87 O
was O
added O
to O
the O
previous O
regimen O
for O
4 O
weeks O
. O

six O
patients O
were O
'much O
improved' O
, O
six O
were O
'minimally O
improved' O
( O
responders O
) O
, O
and O
eight O
showed O
'no O
change' O
( O
non-responders O
) O
, O
on O
the O
clinical O
global O
impression O
global O
improvement O
scale O
. O

all O
responders O
had O
shofuku-fujin O
( O
tenderness B-NEG
or O
weakness B-NEG
of O
the O
lower O
abdomen O
) O
. O

in O
conclusion O
, O
we O
experienced O
12 O
outpatients O
with O
prolonged O
partial O
remitted O
mdd B-NEG
with O
fatigue B-NEG
or O
loss B-NEG
of I-NEG
energy I-NEG
, O
which O
was O
successfully O
treated O
with O
tj-87 O
or O
tj-7 O
. O

-DOCSTART- O

n(omega)-nitro-l-arginine O
methyl O
ester O
( O
l-name O
) O
induces O
a O
pre-eclampsia-like B-NEG
syndrome I-NEG
in O
pregnant O
rats O
. O

we O
have O
previously O
reported O
the O
anti-hypertensive B-POS
effects I-POS
of O
several O
japanese O
traditional O
( O
kampo O
) O
medicines O
in O
this O
model O
, O
and O
one O
of O
these O
, O
tokishakuyakusan O
( O
ts O
) O
, O
also O
improved O
intrauterine B-NEG
growth I-NEG
retardation I-NEG
( O
iugr O
) O
. O

in O
the O
present O
study O
, O
we O
characterized O
the O
effect O
of O
ts O
on O
iugr O
. O

ts O
administration O
reversed O
the O
decrease O
in O
fetal O
body B-NEU
weight I-NEU
and O
fetal O
blood B-NEU
glucose I-NEU
concentration I-NEU
induced O
by O
the O
infusion O
of O
l-name O
. O

growth O
hormone O
( O
gh O
) O
levels O
in O
the O
fetal O
blood B-DNP
, O
which O
were O
decreased O
by O
l-name O
infusion O
, O
were O
also O
significantly O
elevated O
by O
ts O
; O

however O
, O
levels O
of O
gh O
releasing O
hormone O
( O
ghrh O
) O
and O
insulin-like O
growth O
factor O
i O
( O
igf-i O
) O
were O
unchanged O
and O
only O
slightly O
changed O
, O
respectively O
. O

treatment O
with O
l-name O
with O
or O
without O
ts O
had O
no O
apparent O
effect O
on O
gh O
, O
ghrh O
, O
and O
igf-i O
levels O
of O
dams O
. O

in O
an O
immunocytochemical O
study O
, O
the O
number O
of O
gh-positive O
cells O
in O
the O
fetal O
pituitary O
gland O
was O
significantly O
increased O
in O
ts-treated O
rats O
. O

these O
data O
suggest O
that O
enhanced O
proliferation O
of O
somatotrope O
cells O
of O
the O
pituitary O
gland O
and O
the O
resultant O
increase O
in O
gh O
secretion O
in O
the O
fetus O
may O
be O
involved O
in O
the O
improvement O
of O
iugr O
by O
ts O
. O

-DOCSTART- O

irregular O
chills B-NEG
and I-NEG
fever I-NEG

-DOCSTART- O

endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
urinary B-DNP
systems I-DNP
, O
reproductive B-DNP
systems I-DNP
, O
urinary B-DNP
system I-DNP
health I-DNP

-DOCSTART- O

damp-heat B-NEG
dysentery I-NEG
, O
enteritis B-NEG
and O
diarrhea B-NEG
. O

-DOCSTART- O

nourish O
the O
liver B-DNP
and O
kidney B-DNP

-DOCSTART- O

its O
alcoholic O
extract O
relaxes O
the O
spasm B-NEG
of I-NEG
smooth I-NEG
muscles I-NEG
of O
gastrointestine O
, O
gallbladder O
and O
bronchus. O
. O

-DOCSTART- O

parkinsons B-NEG
disease I-NEG

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk I-NEG
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
mood O
, O
endocrine B-DNP
& I-DNP
reproductive I-DNP
systems I-DNP
, O
endocrine B-DNP
system I-DNP
, O
intelligence B-POS
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
inflammation B-NEG
, O
others O
, O
mental B-DNP
state I-DNP
and I-DNP
performance I-DNP

-DOCSTART- O

ipilimumab O
is O
a O
fully O
human O
igg1 B-DNP
antibody I-NEG
that O
binds O
to O
ctla-4 B-DNP
( O
cytotoxic B-DNP
t I-NEG
lymphocyte-associated I-NEG
antigen I-NEG
4 I-NEG
) O
, O
a O
molecule O
on O
t-cells O
that O
is O
indicated O
for O
unresectable B-NEG
or I-NEG
metastatic I-NEG
melanoma I-NEG
. O

the O
absence O
or O
presence O
of O
ctla-4 O
can O
augment O
or O
suppress O
the O
immune B-DNP
system's I-DNP
t-cell O
response O
in O
fighting O
disease B-NEG
. O

ipilimumab O
is O
designed O
to O
block O
the O
activity O
of O
ctla-4 O
, O
thereby O
sustaining O
an O
active B-DNP
immune I-DNP
response I-DNP
in O
its O
attack O
on O
cancer B-NEG
cells I-NEG
. O

the O
proposed O
mechanism O
of O
action O
is O
indirect O
, O
and O
may O
be O
through O
t-cell O
- O
mediated O
anti-tumor B-DNP
immune I-DNP
responses I-DNP
. O

-DOCSTART- O

to O
cool O
blood B-DNP
and O
stanch O
bleeding B-NEG
, O
quicken O
blood B-DNP
and O
transform O
stasis O
. O

-DOCSTART- O

serious O
heat B-NEG
in O
lung O
and O
stomach O
, O
epidemic B-NEG
infectious I-NEG
diseases I-NEG
, O
fever B-NEG
, O
dizziness B-NEG
, O
aching B-NEG
of O
limbs O
, O
cough B-NEG
with O
copious B-NEG
phlegm I-NEG
, O
sore B-NEG
throat I-NEG
, O
epistaxis B-NEG
, O
haemoptysis B-NEG
, O
dryness B-NEG
of O
mouth O
and O
tongue O
. O

-DOCSTART- O

eliminate O
vexation B-NEG
and O
thirst B-NEU

-DOCSTART- O

corylifolinin O
( O
isobavachalcone O
) O
dilates O
coronary B-DNP
artery I-DNP
significantly O
. O

-DOCSTART- O

warm O
the O
middle O
and O
disperse O
cold B-NEG

-DOCSTART- O

mounting O
qi O
( O
hernia B-NEG
) O
, O
profuse B-NEG
menstruation I-NEG
. O

-DOCSTART- O

treament O
of O
abdomen B-NEG
pain I-NEG
due O
to O
intestinal B-NEG
worms I-NEG
, O
sores B-NEG
, O
uterine B-NEG
bleeding I-NEG
( O
drug O
carbonizing O
) O
. O

-DOCSTART- O

ascites B-NEG
; O
abdominal B-NEG
distention I-NEG
due O
to O
accumulation O
of O
liquid B-NEU

-DOCSTART- O

hydroflumethiazide O
is O
a O
thiazide O
diuretic O
that O
inhibits O
water B-NEU
reabsorption I-NEU
in O
the O
nephron O
by O
inhibiting O
the O
sodium-chloride B-DNP
symporter I-DNP
( O
slc12a3 B-DNP
) O
in O
the O
distal O
convoluted O
tubule O
, O
which O
is O
responsible O
for O
0.05 O
of O
total O
sodium B-NEU
reabsorption I-NEU
. O

normally O
, O
the O
sodium-chloride O
symporter O
transports O
sodium O
and O
chloride O
from O
the O
lumen O
into O
the O
epithelial O
cell O
lining O
the O
distal O
convoluted O
tubule O
. O

the O
energy O
for O
this O
is O
provided O
by O
a O
sodium O
gradient O
established O
by O
sodium-potassium B-NEU
atpases I-NEU
on O
the O
basolateral B-DNP
membrane I-DNP
. O

once O
sodium O
has O
entered O
the O
cell O
, O
it O
is O
transported O
out O
into O
the O
basolateral O
interstitium O
via O
the O
sodium-potassium O
atpase O
, O
causing O
an O
increase O
in O
the O
osmolarity B-NEU
of I-NEU
the I-NEU
interstitium I-NEU
, O
thereby O
establishing O
an O
osmotic B-NEU
gradient I-NEU
for O
water B-NEU
reabsorption I-NEU
. O

by O
blocking O
the O
sodium-chloride B-DNP
symporter I-DNP
, O
hydroflumethiazide O
effectively O
reduces O
the O
osmotic B-NEU
gradient I-NEU
and O
water B-NEU
reabsorption I-NEU
throughout O
the O
nephron O
. O

-DOCSTART- O

to O
cause O
diuresis B-NEU
, O
to O
invigorate O
the O
spleen B-DNP
function I-DNP
, O
and O
to O
calm O
the O
mind B-NEU
. O

-DOCSTART- O

amenorrhea B-NEG
, O
menstrual B-NEG
disorders I-NEG
, O
difficult O
labour O
, O
retention O
of O
placenta O
, O
postpartum O
abdominal B-NEG
pain I-NEG
due O
to O
blood B-NEG
stasis I-NEG
. O

-DOCSTART- O

ramipril O
is O
an O
angiotensin-converting O
enzyme O
inhibitor O
, O
used O
to O
treat O
high B-NEG
blood I-NEG
pressure I-NEG
and O
congestive B-NEG
heart I-NEG
failure I-NEG
. O

irbesartan O
, O
by O
blocking O
the O
binding O
of O
angiotensin O
ii O
to O
the O
at1 O
receptor O
, O
promotes O
vasodilation B-NEU
and O
decreases O
the O
effects B-NEU
of I-NEU
aldosterone I-NEU
. O

-DOCSTART- O

insufficiency O
of O
heart B-DNP
gi O

-DOCSTART- O

resolve O
phlegm B-NEG
and O
relieve O
cough B-NEG

-DOCSTART- O

this O
is O
insanity B-NEG
caused O
by O
hurt O
of O
mind O
due O
to O
vexation B-NEG
and O
stuffiness B-NEG
. O

-DOCSTART- O

frost B-NEG
bite I-NEG
; O
chilblain B-NEG
; O
frostbite B-NEG

-DOCSTART- O

diabetes B-NEG
mellitus I-NEG
, I-NEG
type I-NEG
2 I-NEG

-DOCSTART- O

gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
hypersensitivity B-NEG
, O
protective B-NEU
immunity I-NEU

-DOCSTART- O

in O
order O
to O
investigate O
the O
characteristic O
of O
optical O
properties O
of O
asian O
dust O
particles O
, O
the O
atmospheric O
aerosol O
vertical O
profile O
was O
measured O
with O
the O
multi-wavelength O
lidar O
system O
, O
at O
the O
gosan O
super O
site O
( O
33 O
degrees O
17'n O
, O
126 O
degrees O
10'e O
) O
in O
jeju O
island O
, O
korea O
, O
during O
the O
ace-asia O
intensive O
observation O
period O
, O
11 O
42798 O
may O
2001 O
. O

an O
air O
mass O
backward O
trajectory O
analysis O
, O
using O
hysplit-4 O
, O
was O
carried O
out O
to O
track O
the O
aerosol O
plume O
, O
with O
high O
mass O
loading O
, O
from O
the O
chinese O
desert O
regions O
during O
the O
period O
of O
asian O
dust O
storm O
events O
. O

vertical O
atmospheric O
aerosol O
profiles O
on O
three O
major O
asian O
dust O
storm O
event O
days O
, O
22 O
march O
and O
13 O
and O
26 O
april O
2001 O
, O
have O
been O
analyzed O
. O

the O
lidar-derived O
aerosol O
optical O
depth O
values O
were O
compared O
with O
those O
measured O
by O
a O
collocated O
sunphotometer O
. O

-DOCSTART- O

relieve O
spasm B-NEG

-DOCSTART- O

grepafloxacin O
exerts O
its O
antibacterial B-POS
activity I-POS
by O
inhibiting O
bacterial B-DNP
topoisomerase I-DNP
ii I-DNP
( O
dna B-DNP
gyrase I-DNP
) O
and O
topoisomerase B-DNP
iv I-DNP
, O
essential O
enzymes O
for O
duplication O
, O
transcription O
, O
and O
repair O
of O
bacterial O
dna O
. O

-DOCSTART- O

an O
active O
component O
pachyman O
promotes O
macrophage B-DNP
phagocytosis I-DNP
in O
mice O
, O
and O
enhances O
lymphocyte-blastogensis B-DNP
rate O
in O
vitro O
. O

preventing O
the O
formation O
of O
gastric B-NEG
ulcer I-NEG
under O
stress B-NEG
in O
rats O
. O

diuretic B-NEU
and O
liver-protective B-POS
. O

-DOCSTART- O

valproic O
acid O
acts O
by O
increasing O
gamma-aminobutyric B-NEU
acid I-NEU
levels I-NEU
in O
the O
brain O
or O
by O
altering O
the O
properties O
of O
voltage O
dependent O
sodium O
channels O
. O

lamotrigine O
inhibits O
voltage-sensitive O
sodium O
channels O
and/or O
calcium O
channels O
, O
thereby O
stabilizing O
neuronal B-DNP
membranes I-DNP
and O
consequently O
modulating O
presynaptic O
transmitter O
release O
of O
excitatory O
amino O
acids O
. O

-DOCSTART- O

stop O
bleeding B-NEG
and O
stabilize O
pain B-NEG

-DOCSTART- O

there O
are O
two O
isoforms O
of O
ace O
: O
the O
somatic O
isoform O
, O
which O
exists O
as O
a O
glycoprotein O
comprised O
of O
a O
single O
polypeptide O
chain O
of O
1277 O
; O
and O
the O
testicular B-DNP
isoform O
, O
which O
has O
a O
lower O
molecular O
mass O
and O
is O
thought O
to O
play O
a O
role O
in O
sperm B-POS
maturation I-POS
and O
binding O
of O
sperm B-DNP
to O
the O
oviduct O
epithelium O
. O

somatic O
ace O
has O
two O
functionally O
active O
domains O
, O
n O
and O
c, O
which O
arise O
from O
tandem O
gene B-NEU
duplication I-NEU
. O

although O
the O
two O
domains O
have O
high O
sequence O
similarity O
, O
they O
play O
distinct O
physiological O
roles O
. O

the O
c-domain O
is O
predominantly O
involved O
in O
blood B-NEU
pressure I-NEU
regulation I-NEU
while O
the O
n-domain O
plays O
a O
role O
in O
hematopoietic B-NEU
stem I-NEU
cell I-NEU
differentiation I-NEU
and I-NEU
proliferation I-NEU
. O

ace O
inhibitors O
bind O
to O
and O
inhibit O
the O
activity O
of O
both O
domains O
, O
but O
have O
much O
greater O
affinity O
for O
and O
inhibitory O
activity O
against O
the O
c-domain O
. O

enalaprilat O
, O
the O
principle O
active B-NEU
metabolite I-NEU
of O
enalapril O
, O
competes O
with O
ati O
for O
binding O
to O
ace O
and O
inhibits O
and O
enzymatic B-NEU
proteolysis I-NEU
of O
ati O
to O
atii O
. O

decreasing O
atii B-NEU
levels I-NEU
in O
the O
body O
decreases O
blood B-NEU
pressure I-NEU
by O
inhibiting O
the O
pressor B-NEU
effects I-NEU
of I-NEU
atii I-NEU
as O
described O
in O
the O
pharmacology O
section O
above O
. O

enalapril O
also O
causes O
an O
increase O
in O
plasma B-NEU
renin I-NEU
activity I-NEU
likely O
due O
to O
a O
loss O
of O
feedback O
inhibition O
mediated O
by O
atii O
on O
the O
release O
of O
renin B-DNP
and/or O
stimulation O
of O
reflex O
mechanisms O
via O
baroreceptors O
. O

enalaprilat's O
affinity O
for O
ace O
is O
approximately O
200000 O
times O
greater O
than O
that O
of O
ati O
and O
300-1000 O
times O
greater O
than O
that O
enalapril O
. O

-DOCSTART- O

have O
no B-NEG
menstruation I-NEG
due O
to O
static B-NEG
blood I-NEG
. O

-DOCSTART- O

hepatitis B-NEG
b I-NEG

-DOCSTART- O

precipitation B-NEG
of I-NEG
blood I-NEG
during O
pregnancy B-NEU

-DOCSTART- O

accumulation O
of O
pathogenic B-NEG
factors I-NEG
in O
the O
chest O
; O
accumulation O
of O
pathogens B-NEG
in O
the O
chest O
; O
knotted B-NEG
chest I-NEG
a O
syndrome O
due O
to O
accumulation O
of O
pathogenic O
heat B-NEG
or O
cold B-NEG
with O
stagnancy B-NEG
of I-NEG
fluid I-NEG
or O
phlegm B-NEG
or O
blood B-DNP
in O
the O
chest O
. O

-DOCSTART- O

to O
revitalize O
blood B-DNP
and O
desolve O
stagnation B-NEG

-DOCSTART- O

boil B-NEG
in O
the O
throat O

-DOCSTART- O

adult B-NEG
acute I-NEG
myeloid I-NEG
leukemia I-NEG
with O
minimal O
differentiation O

-DOCSTART- O

the O
resin O
is O
a O
strong O
anion O
exchange O
resin O
, O
which O
means O
that O
it O
can O
exchange O
its O
chloride O
anions O
with O
anionic B-DNP
bile I-DNP
acids I-DNP
in O
the O
gastrointestinal B-DNP
tract I-DNP
and O
bind O
them O
strongly O
in O
the O
resin O
matrix O
. O

-DOCSTART- O

constrain O
sweat B-NEU
and O
the O
intestine B-DNP

-DOCSTART- O

chronic B-NEG
cough I-NEG
due O
to O
deficiency B-NEG
of I-NEG
the I-NEG
lung I-NEG

-DOCSTART- O

croton O
seed O
( O
badou O
) O
is O
used O
with O
rhubarb O
( O
dahuang O
) O
and O
dried O
ginger O
( O
ganjiang O
) O
in O
the O
formula O
sanwu O
beiji O
wan O
. O

-DOCSTART- O

a O
traditional O
japanese O
herbal O
( O
kampo O
) O
medicine O
, O
hochuekkito O
( O
bu-zhong-yi-qi-tang O
in O
chinese O
, O
tj-41 O
) O
is O
a O
well-known O
kampo O
formula O
, O
and O
has O
been O
found O
to O
enhance O
antigen-specific B-NEU
antibody I-NEU
response I-NEU
in O
not O
only O
local O
mucosal B-DNP
immune I-DNP
system I-DNP
in O
upper O
respiratory O
tract O
, O
but O
also O
systemic B-DNP
immune I-DNP
system I-DNP
through O
upper O
respiratory B-DNP
mucosal I-DNP
immune I-DNP
system I-DNP
. O

although O
this O
immunopharmacological O
effect O
has O
been O
proposed O
to O
express O
by O
modulation O
of O
intestinal B-DNP
immune I-DNP
system I-DNP
including O
peyer's B-DNP
patches I-DNP
and O
intestinal B-DNP
epithelial I-DNP
cells I-DNP
, O
active O
ingredients O
are O
not O
known O
. O

tj-41 O
directly O
affected O
the O
production O
of O
bone B-DNP
marrow I-DNP
cell I-DNP
- O
proliferative O
growth B-DNP
factors I-DNP
from O
murine O
peyer's O
patch O
immunocompetent O
cells O
in O
vitro O
. O

among O
low O
molecular O
, O
intermediate O
size O
and O
macromolecular O
weight O
fractions O
prepared O
from O
tj-41 O
, O
only O
fraction O
containing O
macromolecular O
weight O
ingredients O
showed O
peyer's B-DNP
patch I-DNP
- O
mediated O
bone B-DNP
marrow I-DNP
cell I-DNP
- O
proliferation O
enhancing O
activity O
. O

anion-exchange O
chromatography O
and O
gel O
filtration O
gave O
17 O
subfractions O
comprising O
polysaccharides O
and O
lignins O
from O
the O
macromolecular O
weight O
fraction O
of O
tj-41 O
, O
and O
some O
of O
the O
subfractions O
showed O
significant O
enhancing O
activities O
having O
different O
degrees O
. O

some O
of O
the O
subfractions O
also O
expressed O
stimulating O
activity O
on O
g-csf B-DNP
- I-DNP
production I-DNP
from O
colonic O
epithelial O
cells O
, O
and O
statistically O
significant O
positive O
correlation O
was O
observed O
among O
enhancing O
activities O
of O
the O
subfractions O
against O
peyer's B-DNP
patch I-DNP
immunocompetent I-DNP
cells I-DNP
and O
epithelial B-DNP
cells I-DNP
. O

among O
the O
fractions O
from O
tj-41 O
oral O
administration O
of O
macromolecular O
weight O
ingredient O
fraction O
to O
mice O
succeeded O
to O
enhance O
antigen-specific B-NEU
antibody I-NEU
response I-NEU
in O
systemic B-DNP
immune I-DNP
system I-DNP
through O
upper O
respiratory B-DNP
mucosal I-DNP
immune I-DNP
system I-DNP
, O
but O
all O
the O
separated O
fractions O
failed O
to O
enhance O
the O
in O
vivo O
antibody B-NEU
response I-NEU
in O
upper O
respiratory O
tract O
. O

-DOCSTART- O

for O
the O
treatment O
of O
heparin-induced B-NEG
thrombocytopenia I-NEG

-DOCSTART- O

for O
palliative O
, O
not O
definitive O
, O
therapy O
to O
temporarily O
maintain O
the O
patency B-NEG
of I-NEG
the I-NEG
ductus I-NEG
arteriosus I-NEG
until O
corrective O
or O
palliative O
surgery O
can O
be O
performed O
in O
neonates O
who O
have O
congenital B-NEG
heart I-NEG
defects I-NEG
and O
who O
depend O
upon O
the O
patent O
ductus O
for O
survival O
. O

also O
for O
the O
treatment O
of O
erectile B-NEG
dysfunction I-NEG
due O
to O
neurogenic O
, O
vasculogenic O
, O
psychogenic O
, O
or O
mixed O
etiology O
. O

-DOCSTART- O

stop O
bleeding B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

this O
means O
urolithiasis B-NEG
made O
of O
coagulation B-NEG
of I-NEG
phlegm I-NEG
. O

-DOCSTART- O

chronic B-NEG
hepatitis I-NEG
b I-NEG
virus I-NEG
, O
pediatric O

-DOCSTART- O

invigorate O
blood B-NEU
and O
unblock O
the O
network B-DNP
vessels B-DNP

-DOCSTART- O

linezolid O
selectively O
inhibits O
bacterial B-NEU
protein I-NEU
synthesis I-NEU
through O
binding O
to O
sites O
on O
the O
bacterial O
ribosome O
and O
prevents O
the O
formation B-NEU
of I-NEU
a I-NEU
functional I-NEU
70s-initiation I-NEU
complex I-NEU
. O

isoniazid O
appears O
to O
block O
the O
synthesis B-NEU
of I-NEU
mycolic I-NEU
acids I-NEU
, O
major O
components O
of O
the O
mycobacterial O
cell O
wall O
. O

this O
agent O
is O
only O
active O
against O
actively O
growing O
mycobacteria B-NEG
because O
, O
as O
a O
pro-drug O
, O
it O
requires O
activation O
in O
susceptible O
mycobacterial O
species O
. O

rifampin O
acts O
via O
the O
inhibition O
of O
dna-dependent B-DNP
rna I-DNP
polymerase I-DNP
, O
leading O
to O
a O
suppression B-DNP
of I-DNP
rna I-DNP
synthesis I-DNP
and O
cell B-NEU
death I-NEU
. O

-DOCSTART- O

infant B-NEG
, I-NEG
large I-NEG
for I-NEG
gestational I-NEG
age I-NEG

-DOCSTART- O

prostate B-NEG
cancer I-NEG

-DOCSTART- O

may O
be O
used O
to O
treat O
primary O
, O
secondary O
or O
tertiary O
hypothyroidism B-NEG
. O
may O
also O
be O
used O
to O
suppress O
thyroid B-DNP
stimulating O
hormone O
( O
tsh O
) O
secretion O
in O
patients O
with O
simple O
( O
nontoxic O
) O
goiter B-NEG
, O
subacute O
or O
chronic O
lymphocytic B-NEG
thyroiditis I-NEG
multinodular I-NEG
goiter I-NEG
, O
and O
in O
the O
management O
of O
thyroid B-NEG
cancer I-NEG
. O
may O
be O
used O
in O
conjunction O
with O
other O
antithyroid O
agents O
to O
treat O
thyrotoxicosis B-NEG
to O
prevent O
goitrogenesis O
and O
hypothyroidism B-NEG
. O
may O
also O
be O
used O
for O
differential O
diagnosis O
of O
suspected O
mild O
hyperthyroidism B-NEG
or O
thyroid B-DNP
gland I-DNP
autonomy O
. O

-DOCSTART- O

hemicrania B-NEG
; O
migraine B-NEG
; O
megrim B-NEG

-DOCSTART- O

fetal B-NEG
leakage I-NEG

-DOCSTART- O

treatment O
of O
rheumatic B-NEG
or I-NEG
rheumatoid I-NEG
arthrits I-NEG
with O
muscular B-NEU
contracture I-NEU
and O
severe O
joint B-NEG
pain I-NEG
, O
fever B-NEG
recurring O
daily O
in O
the O
afternoon O
, O
fever B-NEG
in O
infants O
with O
malnutrition B-NEG
. O

-DOCSTART- O

shortness B-NEG
of I-NEG
breath I-NEG
short B-NEG
, I-NEG
rapid I-NEG
and I-NEG
interrupted I-NEG
breathing I-NEG
. O

-DOCSTART- O

yin O
chen O
hao O
tang O
( O
ycht O
) O
is O
one O
of O
the O
most O
frequently O
used O
prescriptions O
in O
the O
long O
history O
of O
traditional O
chinese O
medicine O
practice O
. O

the O
prescription O
contains O
three O
chinese O
herbs O
, O
namely O
artemisia O
capillaries O
thunb O
. O

( O
compositae O
) O
, O
rheum O
officinale O
baillon O
( O
polygonaceae O
) O
, O
and O
gardenia O
jasminoids O
ellis O
( O
rubiaceae O
) O
, O
and O
has O
been O
widely O
used O
to O
treat O
acute B-NEG
hepatitis I-NEG
with O
jaundice B-NEG
. O

in O
this O
study O
, O
the O
in O
vitro O
anti-hsv-1 B-POS
and I-POS
hsv-2 I-POS
activities I-POS
of O
the O
water O
extract O
of O
ycht O
were O
investigated O
. O

results O
showed O
that O
ycht O
water O
extract O
inhibited O
both O
hsv-1 B-NEG
and I-NEG
hsv-2 I-NEG
infections I-NEG
. O

however O
, O
the O
inhibition O
was O
more O
effective O
against O
hsv-2 B-NEG
than O
against O
hsv-1 B-NEG
. O

the O
ic(50 O
) O
and O
ic(90 O
) O
values O
of O
ycht O
water O
extract O
against O
hsv-1 B-NEG
infection I-NEG
were O
in O
the O
range O
of O
142.5-150.1 O
and O
191.3-393.9 O
microg/ml O
, O
and O
against O
hsv-2 B-NEG
infection I-NEG
they O
were O
in O
the O
range O
of O
19.6-29.4 O
and O
42.2-97.7 O
microg/ml O
, O
respectively O
. O

the O
water O
extract O
of O
ycht O
showed O
no O
cytotoxic O
effect O
at O
a O
concentration O
of O
500 O
microg/ml O
or O
below O
, O
and O
had O
a O
cc(50 O
) O
value O
of O
850.7+/-1.7 O
microg/ml O
. O

the O
prescription O
was O
found O
to O
diminish O
hsv-2 B-NEG
infectivity I-NEG
in O
a O
dose-dependent O
manner O
, O
and O
the O
activity O
was O
influenced O
by O
the O
incubation O
periods O
and O
the O
incubation O
temperatures O
. O

concurrent O
addition O
of O
virus O
with O
ycht O
or O
pre-treatment O
of O
the O
virus O
with O
the O
prescription O
extract O
both O
protected O
the O
cells O
from O
infection B-NEG
. O

in O
summary O
, O
the O
water O
extract O
of O
ycht O
was O
concluded O
to O
inhibit O
infections B-NEG
by O
hsv-1 B-NEG
and O
hsv-2 B-NEG
and O
this O
effect O
was O
likely O
mediated O
through O
direct O
inactivation O
of O
the O
virus B-NEG
infectivity I-NEG
. O

-DOCSTART- O

jaundice B-NEG
related O
to O
immoderate O
drinking O
; O
alcoholic B-NEG
jaundice I-NEG
one O
of O
the O
five O
types O
of O
jaundice B-NEG
. O

jaundice B-NEG
caused O
by O
endogenous O
damp-heat B-NEG
due O
to O
indulging O
in O
alcohol O
, O
manifested O
as O
yellowish O
pigmentation O
of O
the O
skin O
and O
sclera O
, O
chest B-NEG
distress I-NEG
, O
anorexia B-NEG
, O
nausea B-NEG
and O
vomiting B-NEG

-DOCSTART- O

having O
a O
yellow B-NEG
or I-NEG
reddish I-NEG
urine I-NEG
due O
to O
blocking O
the O
circulation B-NEU
of I-NEU
bile I-NEU
by O
epidemic B-NEG
toxin I-NEG
, O
fail O
to O
control O
food O
, O
and O
damp-heat B-NEG
and O
cold-damp B-NEG
blocked O
in O
the O
middle O
heater O

-DOCSTART- O

protective B-NEU
immunity I-NEU
, O
urinary B-DNP
systems I-DNP
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
urinary B-DNP
system I-DNP
health I-DNP

-DOCSTART- O

insulin B-NEU
sensitivity I-NEU
and O
diabetes B-NEG
risk O
, O
body B-NEU
weight I-NEU
regulation I-NEU
, O
improvement O
of O
blood B-NEU
glucose I-NEU
levels I-NEU
, O
body B-NEU
weight I-NEU

-DOCSTART- O

this O
paper O
was O
designed O
to O
study O
metabonomic O
characters O
of O
the O
hepatotoxicity O
induced O
by O
alcohol O
and O
the O
intervention O
effects O
of O
yin O
chen O
hao O
tang O
( O
ycht O
) O
, O
a O
classic O
traditional O
chinese O
medicine O
formula O
for O
treatment O
of O
jaundice B-NEG
and O
liver B-NEG
disorders I-NEG
in O
china O
. O

urinary O
samples O
from O
control O
, O
alcohol- O
and O
ycht-treated O
rats O
were O
analyzed O
by O
ultra-performance O
liquid O
chromatography O
/ O
electrospray O
ionization O
quadruple O
time-of-flight O
mass O
spectrometry O
( O
uplc/esi-qtof-ms O
) O
in O
positive O
ionization O
mode O
. O

the O
total O
ion O
chromatograms O
obtained O
from O
the O
control O
, O
alcohol- O
and O
ycht-treated O
rats O
were O
easily O
distinguishable O
using O
a O
multivariate O
statistical O
analysis O
method O
such O
as O
the O
principal O
components O
analysis O
( O
pca O
) O
. O

the O
greatest O
difference O
in O
metabolic O
profiling O
was O
observed O
from O
alcohol-treated O
rats O
compared O
with O
the O
control O
and O
ycht-treated O
rats O
. O

the O
positive O
ions O
m/z O
664.3126 O
( O
9 O
min O
) O
was O
elevated O
in O
urine O
of O
alcohol-treated O
rats O
, O
whereas O
, O
ions O
m/z O
155.3547 O
( O
10.96 O
min O
) O
and O
708.2932 O
( O
9.01 O
min O
) O
were O
at O
a O
lower O
concentration O
compared O
with O
that O
in O
urine O
of O
control O
rats O
, O
however O
, O
these O
ions O
did O
not O
indicate O
a O
statistical O
difference O
between O
control O
rats O
and O
ycht-treated O
rats O
. O

the O
ion O
m/z O
664.3126 O
was O
found O
to O
correspond O
to O
ceramide O
( O
d18:1/25:0 O
) O
, O
providing O
further O
support O
for O
an O
involvement O
of O
the O
sphingomyelin O
signaling O
pathway O
in O
alcohol B-NEG
hepatotoxicity I-NEG
and O
the O
intervention O
effects O
of O
ycht O
. O

-DOCSTART- O

her2-overexpressing O
breast B-NEG
cancer I-NEG

-DOCSTART- O

fenretinide O
treatment O
may O
cause O
ceramide B-NEG
to O
build O
up O
in O
tumor B-DNP
cells I-DNP
and O
is O
associated O
with O
the O
accumulation O
of O
reactive B-NEU
oxygen I-NEU
species I-NEU
, O
resulting O
in O
cell B-NEU
death I-NEU
through O
apoptosis B-NEU
and/or O
necrosis B-NEU
. O

sodium O
butyrate O
( O
nab O
) O
, O
a O
short O
chain O
fatty O
acid O
, O
is O
a O
hdac O
inhibitor O
and O
induces O
growth B-NEU
arrest I-NEU
and O
apoptosis B-NEU
in O
a O
variety O
of O
human O
cancer O
cells O
. O

-DOCSTART- O

to O
desolve O
stagnation B-NEG
; O

to O
stop O
bleeding B-NEG
; O

to O
modulate O
period O

-DOCSTART- O

for O
dispelling O
wind-dampness B-NEG
and O
dispersing O
coldness B-NEG
. O

-DOCSTART- O

this O
is O
a O
symptom O
with O
pricking B-NEG
pain I-NEG
in O
the O
chest O
and O
abdomen O
. O

-DOCSTART- O

treament O
of O
vertigo B-NEG
, O
tinnitus B-NEG
, O
weakness B-NEG
in O
the O
loins O
and O
knees O
, O
premature B-NEG
whitening I-NEG
of I-NEG
hair I-NEG
and O
impaired B-NEG
eyesight I-NEG
due O
to O
deficiency O
of O
yin O
of O
the O
liver O
and O
kidney O
. O

-DOCSTART- O

nfantile B-NEG
convulsive I-NEG
seizure I-NEG
due O
to O
fright O

-DOCSTART- O

endometrial B-NEG
cancer I-NEG

-DOCSTART- O

ureteral B-NEG
stent I-NEG
occlusion I-NEG

-DOCSTART- O

moisten O
the O
liver B-DNP

-DOCSTART- O

fever B-NEG
and O
aversion O
to O
cold B-NEG

-DOCSTART- O

intraabdominal B-NEG
infections I-NEG

-DOCSTART- O

multiple B-NEG
sclerosis I-NEG

-DOCSTART- O

investigated O
for O
use O
/ O
treatment O
in O
breast B-NEG
cancer I-NEG
, O
head B-NEG
and I-NEG
neck I-NEG
cancer I-NEG
, O
and O
lung B-NEG
cancer I-NEG
. O

-DOCSTART- O

night B-NEG
sweat I-NEG
; O
night B-NEG
sweating I-NEG
spontaneous B-NEG
sweating I-NEG
during O
asleep O
and O
no B-NEG
sweating I-NEG
while O
awake O
, O
chiefly O
caused O
by O
deficiency B-NEG
of I-NEG
vital I-NEG
essence I-NEG
and O
presence B-NEG
of I-NEG
internal I-NEG
heat I-NEG
. O

-DOCSTART- O

tiotropium O
is O
a O
muscarinic O
receptor O
antagonist O
, O
often O
referred O
to O
as O
an O
antimuscarinic O
or O
anticholinergic O
agent O
. O
although O
it O
does O
not O
display O
selectivity O
for O
specific O
muscarinic O
receptors O
, O
on O
topical O
application O
it O
acts O
mainly O
on O
m3 O
muscarinic O
receptors O
located O
in O
the O
airways O
to O
produce O
smooth O
muscle B-POS
relaxation I-POS
, O
thus O
producing O
a O
bronchodilatory B-POS
effect I-POS
. O

-DOCSTART- O

to O
remove O
heat B-NEU
from I-NEU
the I-NEU
lung I-NEU
, O
relieve O
cough B-NEG
and O
resolve O
phlegm B-NEG
. O

-DOCSTART- O

exogenous B-NEG
febrile I-NEG
disease I-NEG
of O
four O
seasons O

-DOCSTART- O

relieve O
stasis B-NEG
and O
relieve O
pain B-NEG

-DOCSTART- O

immune B-NEG
thrombocytopenic I-NEG
purpura I-NEG

-DOCSTART- O

to O
regulate O
cold B-NEU
and O
heat B-NEU
, O
regulate O
the O
functions B-NEU
of I-NEU
the I-NEU
stomach I-NEU
and O
lower O
down O
the O
adverse O
rising O
energy O
. O

-DOCSTART- O

absorption B-NEU
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-POS
, O
motility O
, O
evacuation B-NEU

-DOCSTART- O

furuncle B-NEG
; O
boil B-NEG

-DOCSTART- O

palpitation B-NEG

-DOCSTART- O

pulmonary B-NEG
carbuncle I-NEG
; O
lung B-NEG
abscess I-NEG

-DOCSTART- O

muscle B-NEG
weakness I-NEG

-DOCSTART- O

1 O
eliminating O
heat B-NEU
and O
toxic B-NEG
materials O
( O
carbuncle B-NEG
, O
erysipelas B-NEG
, O
burn B-NEG
, O
ulcer B-NEG
, O
sorethroat B-NEG
) O
, O
used O
as O
decoction O
, O
oral O
or O
external O
use O
, O
or O
gargle O
, O
also O
for O
the O
prevention O
and O
treatment O
of O
epidemic B-NEG
febrile I-NEG
diseases I-NEG
, O
such O
as O
influenza B-NEG
, O
epidemic B-NEG
meningitis I-NEG
, O
encephalitis B-NEG
, O
etc O
. O

2 O
. O
clearing O
dampness-heat B-NEG
( O
diarrhea B-NEG
, O
dysentery B-NEG
and O
leukorrhagia B-NEG
of O
dampness-heat B-NEG
type O
) O
. O

recently O
being O
used O
for O
acute O
and O
chronic B-NEG
pyelitis I-NEG
. O

3 O
to O
kill O
parasite O
( O
ancylostomoasos B-NEG
and O
filariasis B-NEG
) O
. O

-DOCSTART- O

move O
drug O
effect O

-DOCSTART- O

labetuzumab O
is O
a O
humanized O
monoclonal O
antibody O
used O
to O
treat O
cancer B-NEG
. O

retrieved O
from O
http://en.wikipedia.org/wiki/labetuzumab O

-DOCSTART- O

cough B-NEG
due O
to O
wind-cold B-NEG

-DOCSTART- O

exposure O
to O
hepatitis B-NEG
b I-NEG
virus I-NEG

-DOCSTART- O

this O
disease B-NEG
has O
a O
characteristics O
of O
gradual O
onset O
, O
plat O
form O
of O
ulceration B-NEG
, O
mild O
or O
no O
pain B-NEG
, O
no O
change O
of O
skin B-NEU
color I-NEU
or O
dark O
reddish O
or O
blackened O
color O
change O
, O
mild O
or O
no O
fever B-NEG
, O
not O
well O
subsided O
or O
healed O
, O
occasional O
lump B-NEG
formation I-NEG
, O
no O
pus B-NEG
, O
long O
duration O
of O
treatment O
, O
thin O
colourful O
discharge O
, O
chimse O
and O
weak O
mac O
. O

-DOCSTART- O

swelling B-NEG
of I-NEG
carbuncle I-NEG

-DOCSTART- O

wind-damp B-NEG
impediment O
pain B-NEG
, O
pain B-NEG
in O
stomach O
duct O
, O
wound O
swelling B-NEG
from O
knocks O
and O
falls O
, O
fracture B-NEG
, O
bleeding B-NEG
due O
to O
external O
injury B-NEG
. O

-DOCSTART- O

galactostasis B-NEG
; O
hypogalactia B-NEG
; O
scant B-NEG
breast I-NEG
; O
inadequacy B-NEG
of I-NEG
lactation I-NEG

-DOCSTART- O

absorption B-NEU
, O
gut B-DNP
health I-DNP
and O
immunity B-NEU
, O
digestion B-NEU
, O
motility O

-DOCSTART- O

1 O
applicable O
to O
cases O
of O
hypovolumic B-NEG
and I-NEG
cardiogenic I-NEG
shock I-NEG
which O
are O
attributed O
to O
exhaustion B-NEG
of O
primordial O
energy O
and O
yang-energy O
. O
2 O
also O
applicable O
to O
cases O
of O
hemorrhagic B-NEG
shock I-NEG
attributed O
to O
yang O
depletion O
. O
